PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Mannix, R; Eisenberg, M; Berry, M; Meehan, WP; Hayes, RL				Mannix, Rebekah; Eisenberg, Matthew; Berry, Mark; Meehan, William P., III; Hayes, Ronald L.			Serum Biomarkers Predict Acute Symptom Burden in Children after Concussion: A Preliminary Study	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; concussion; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; S100B; MILD; KNOWLEDGE; IMPACT; GFAP	Pediatric emergency department (ED) visits for concussion have nearly tripled in the past decade. Despite this, there are limited bedside tools available to objectively diagnose injury and prognosticate recovery. Here, we perform a preliminary evaluation of the utility of glial fibrillary acidic protein (GFAP) in predicting initial and follow-up symptom burden in children and young adults 11-21 years of age, presenting to the ED after concussion. We enrolled 13 children and young adults presenting to the ED within 24 h of concussion, and obtained initial serum samples at that time as well as follow-up samples within 24-72 h of injury. Initial GFAP levels were associated with initial and follow-up symptom burden up to 1 month after injury, whereas follow-up GFAP levels did not correlate with symptom burden. These preliminary data suggest that GFAP may offer an objective measure of injury and recovery after pediatric concussion, potentially offering clinicians a new tool in the management of this common injury.	[Mannix, Rebekah; Eisenberg, Matthew; Berry, Mark; Meehan, William P., III] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Concuss Clin, Boston, MA 02115 USA; [Mannix, Rebekah; Eisenberg, Matthew] Harvard Univ, Sch Med, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA		Mannix, R (corresponding author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	Rebekah.Mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020				Babcock L., 2013, AM ACAD PED C ORL FL; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	17	26	26	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2014	31	11					1072	1075		10.1089/neu.2013.3265			4	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AJ7RS	WOS:000337895300010	24494742				2022-02-06	
J	Maruta, J; Heaton, KJ; Mau, AL; Ghajar, J				Maruta, Jun; Heaton, Kristin J.; Mau, Alexis L.; Ghajar, Jamshid			Predictive Visual Tracking: Specificity in Mild Traumatic Brain Injury and Sleep Deprivation	MILITARY MEDICINE			English	Article							PURSUIT EYE-MOVEMENTS; SMOOTH-PURSUIT; ATTENTION; SYNCHRONIZATION	We tested whether reduced cognitive function associated with mild traumatic brain injury (mTBI) and sleep deprivation can be detected and distinguished using indices of predictive visual tracking. A circular visual tracking test was given to 13 patients with acute mTBI (recruited within 2 weeks of injury), 127 normal control subjects, and 43 healthy subjects who were fatigued by 26-hour sleep deprivation. Eye movement was monitored with video-oculography. In the mTBI-related portion of the study, visual tracking performance of acute mTBI patients was significantly worse than normal subjects (p < 0.001). In the sleep-deprivation-related portion of the study, no change was detected between the two baseline measures separated by 2 to 3 weeks, but the 26-hour sleep deprivation significantly degraded the visual tracking performance (p < 0.001). The mTBI subjects had substantially worse visual tracking than sleep-deprived subjects that could also be identified with different visual tracking indices, indicating possible different neurophysiological mechanisms. Results suggest that cognitive, impairment associated with mTBI and fatigue may be triaged with the aid of visual tracking measures.	[Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, World Trade Ctr 7, New York, NY 10007 USA; [Heaton, Kristin J.; Mau, Alexis L.] US Army, Inst Environm Med, Mil Performance Div, Natick, MA 01760 USA; [Heaton, Kristin J.; Mau, Alexis L.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; [Ghajar, Jamshid] Stanford Univ, Med Ctr, Dept Neurosurg, Stanford, CA 94305 USA		Maruta, J (corresponding author), Brain Trauma Fdn, World Trade Ctr 7, 34th Floor,250 Greenwich St, New York, NY 10007 USA.		Maruta, Jun/I-3790-2019	Maruta, Jun/0000-0002-5054-6605	CDMRPUnited States Department of Defense [W81XWH-08-2-0646]; USAMRMCU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-1-0021]; James S. McDonnell Foundation	This work was supported by CDMRP W81XWH-08-2-0646, USAMRMC W81XWH-08-1-0021, and James S. McDonnell Foundation.	Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Baumann O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007110; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Chen Y, 2002, PROG BRAIN RES, V140, P255; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Ghajar J, 2009, NEUROSCIENTIST, V15, P232, DOI 10.1177/1073858408326429; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HENN V, 1984, EXP BRAIN RES, V54, P166; Katsanis J, 1998, PSYCHOPHYSIOLOGY, V35, P64; Maruta J, 2013, BEHAV RES METHODS, V45, P289, DOI 10.3758/s13428-012-0248-3; Maruta J, 2012, PROC SPIE, V8371, DOI 10.1117/12.927790; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; Salman MS, 2006, EXP BRAIN RES, V169, P139, DOI 10.1007/s00221-005-0292-7; Suzuki Y, 1997, INVEST OPHTH VIS SCI, V38, P2103; Thomas M, 2000, J SLEEP RES, V9, P335, DOI 10.1046/j.1365-2869.2000.00225.x; VANGELDER P, 1995, VISION RES, V35, P667, DOI 10.1016/0042-6989(94)00161-E	18	26	26	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	JUN	2014	179	6					619	625		10.7205/MILMED-D-13-00420			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AN7UM	WOS:000340806500006	24902128	Bronze			2022-02-06	
J	Pang, T; Sun, LX; Wang, T; Jiang, ZZ; Liao, H; Zhang, LY				Pang, Tao; Sun, Li-xin; Wang, Tao; Jiang, Zhen-zhou; Liao, Hong; Zhang, Lu-yong			Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARy and the Akt/GSK-beta pathway	ACTA PHARMACOLOGICA SINICA			English	Article						cerebellar granule cell; nutrient deprivation; apoptosis; angiotensin II receptor blocker; telmisartan; AT(1a) receptor; Akt; GSK-3 beta; PPARy; neurotoxicity	GLYCOGEN-SYNTHASE KINASE-3; RECEPTOR-GAMMA ACTIVATION; TRAUMATIC BRAIN-INJURY; ANGIOTENSINOGEN MESSENGER-RNA; FOCAL CEREBRAL-ISCHEMIA; CELL-DEATH; INFLAMMATORY RESPONSE; PARKINSONS-DISEASE; NERVOUS-SYSTEM; DIABETIC MICE	Aim: To determine whether angiotensin II receptor blockers (ARBs) could protect central neurons against nutrient deprivation-induced apoptosis in vitro and to elucidate the underlying mechanisms. Methods: Primary rat cerebellar granule cells (CGCs) underwent B27 (a serum substitute) deprivation for 24 h to induce neurotoxicity, and cell viability was analyzed using LDH assay and WST-1 assay. DNA laddering assay and TUNEL assay were used to detect cell apoptosis. The expression of caspase-3 and Bcl-2, and the phosphorylation of Akt and GSK-3 beta were detected using Western blot analysis. AT,a mRNA expression was determined using RT-PCR analysis. Results: B27 deprivation significantly increased the apoptosis of CGCs, as demonstrated by LDH release, DNA laddering, caspase-3 activation and positive TUNEL staining. Pretreatment with 10 mu mol/L ARBs (telmisartan, candesartan or losartan) partially blocked B27 deprivation-induced apoptosis of CGCs with telmisartan being the most effective one. B27 deprivation markedly increased the expression of AT(1a) receptor in CGCs, inhibited Akt and GSK-3 beta activation, decreased Bcl-2 level, and activated caspase-3, which were reversed by pretreatment with 1 mu mol/L telmisartan. In addition, pretreatment with 10 mu mol/L PPARy agonist pioglitazone was more effective in protecting CGCs against B27 deprivation-induced apoptosis, whereas pretreatment with 20 mu mol/L PPARy antagonist GW9662 abolished all the effects of telmisartan in CGCs deprived of B27. Conclusion: ARBs, in particular telmisartan, can protect the nutrient deprivation-induced apoptosis of CGCs in vitro through activation of PPARy and the Akt/GSK-3 beta pathway.	[Pang, Tao; Sun, Li-xin; Wang, Tao; Jiang, Zhen-zhou; Liao, Hong; Zhang, Lu-yong] China Pharmaceut Univ, New Drug Screening Ctr, Nanjing 210009, Jiangsu, Peoples R China; [Pang, Tao; Liao, Hong; Zhang, Lu-yong] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China; [Pang, Tao] China Pharmaceut Univ, Minist Educ, Key Lab Drug Qual Control & Pharmacovigilance, Nanjing 210009, Jiangsu, Peoples R China		Liao, H (corresponding author), China Pharmaceut Univ, New Drug Screening Ctr, Nanjing 210009, Jiangsu, Peoples R China.	liaohong56@hotmail.com; lyzhang@cpu.edu.cn			Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK20130653, BK2010433]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [JKZD2013006]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070967, 81271338]; Specialized Research Fund for the Doctoral Program of Higher Education of ChinaSpecialized Research Fund for the Doctoral Program of Higher Education (SRFDP) [20130096110011]; China Pharmaceutical University	This study was supported by the Natural Science Foundation of Jiangsu Province (BK20130653, BK2010433), the Fundamental Research Funds for the Central Universities (JKZD2013006), the National Natural Science Foundation of China (81070967, 81271338), the Specialized Research Fund for the Doctoral Program of Higher Education of China (20130096110011) and the Initial Fund of China Pharmaceutical University to Dr Tao PANG.	AbdAlla S, 2009, J BIOL CHEM, V284, P6554, DOI 10.1074/jbc.M807746200; An JB, 2010, HYPERTENS RES, V33, P831, DOI 10.1038/hr.2010.79; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen YC, 2012, MOL NEUROBIOL, V46, P114, DOI 10.1007/s12035-012-8259-8; Chiong M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.130; Chuang DM, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00015; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; de Gasparo M, 2000, PHARMACOL REV, V52, P415; DZAU VJ, 1986, HYPERTENSION, V8, P544, DOI 10.1161/01.HYP.8.6.544; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Erbe DV, 2006, VASC PHARMACOL, V45, P154, DOI 10.1016/j.vph.2006.05.002; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Fuenzalida K, 2007, J BIOL CHEM, V282, P37006, DOI 10.1074/jbc.M700447200; Garrido-Gil P, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-38; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GYURKO R, 1993, REGUL PEPTIDES, V49, P167, DOI 10.1016/0167-0115(93)90438-E; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, J NEUROSCI, V20, P2567; Inaba S, 2009, STROKE, V40, P597, DOI 10.1161/STROKEAHA.108.519801; Iwanami J, 2010, J HYPERTENS, V28, P1730, DOI 10.1097/HJH.0b013e32833a551a; Jantas D, 2011, NEUROTOXICOLOGY, V32, P845, DOI 10.1016/j.neuro.2011.05.013; Jin N, 2005, NEUROPHARMACOLOGY, V48, P576, DOI 10.1016/j.neuropharm.2004.11.010; Jing G, 2004, BRAIN RES BULL, V62, P397, DOI 10.1016/j.brainresbull.2003.10.011; Joglar B, 2009, J NEUROCHEM, V109, P656, DOI 10.1111/j.1471-4159.2009.05999.x; Kasahara Y, 2010, BRAIN RES, V1340, P70, DOI 10.1016/j.brainres.2010.03.101; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kehoe PG, 2009, TRENDS NEUROSCI, V32, P619, DOI 10.1016/j.tins.2009.07.006; Kelly S, 2004, EXP NEUROL, V188, P378, DOI 10.1016/j.expneurol.2004.04.004; Kiaei M, 2005, EXP NEUROL, V191, P331, DOI 10.1016/j.expneurol.2004.10.007; Kiaei M, 2008, PPAR RES, V2008, DOI 10.1155/2008/418765; Koh EJ, 2013, BRIT J PHARMACOL, V169, P1404, DOI 10.1111/bph.12229; Krikov M, 2008, J HYPERTENS, V26, P544, DOI 10.1097/HJH.0b013e3282f2dac9; Kumari S, 2001, MOL BRAIN RES, V96, P157, DOI 10.1016/S0006-8993(01)03045-1; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Liang MH, 2007, J BIOL CHEM, V282, P3904, DOI 10.1074/jbc.M605178200; Liu F, 2005, J NEUROCHEM, V95, P1363, DOI 10.1111/j.1471-4159.2005.03474.x; Min LJ, 2012, HYPERTENSION, V59, P1079, DOI 10.1161/HYPERTENSIONAHA.112.192401; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Neldam S, 2010, FUTUR CARDIOL, V6, P129, DOI [10.2217/fca.09.61, 10.2217/FCA.09.61]; Pang T, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-102; Pang T, 2012, J HYPERTENS, V30, P87, DOI 10.1097/HJH.0b013e32834dde5f; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Park DS, 1997, J NEUROSCI, V17, P8975; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Rotman N, 2010, PHYSIOLOGY, V25, P176, DOI 10.1152/physiol.00018.2010; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Schelman WR, 2004, MOL BRAIN RES, V128, P20, DOI 10.1016/j.molbrainres.2004.06.001; Schrader J, 2005, STROKE, V36, P1218, DOI 10.1161/01.STR.0000166048.35740.a9; Schrader J, 2003, STROKE, V34, P1699, DOI 10.1161/01.STR.0000075777.18006.89; Seneff S, 2011, EUR J INTERN MED, V22, P134, DOI 10.1016/j.ejim.2010.12.017; Stangier J, 2000, J INT MED RES, V28, P149, DOI 10.1177/147323000002800401; Tsukuda K, 2009, HYPERTENSION, V54, P782, DOI 10.1161/HYPERTENSIONAHA.109.136879; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Wang LX, 2009, CHINESE MED J-PEKING, V122, P1380, DOI 10.3760/cma.j.issn.0366-6999.2009.12.005; Wright JW, 2008, PROG NEUROBIOL, V84, P157, DOI 10.1016/j.pneurobio.2007.10.009; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhao XR, 2006, BRAIN RES, V1073, P460, DOI 10.1016/j.brainres.2005.12.061; Zhao Y, 2006, FASEB J, V20, P1162, DOI 10.1096/fj.05-5007com; Zhu DM, 2004, NEUROTOX RES, V6, P281, DOI 10.1007/BF03033438; Zorad S, 2006, EUR J PHARMACOL, V552, P112, DOI 10.1016/j.ejphar.2006.08.062; Zuhayra M, 2011, NEUROPATH APPL NEURO, V37, P738, DOI 10.1111/j.1365-2990.2011.01169.x	66	26	28	2	16	ACTA PHARMACOLOGICA SINICA	SHANGHAI	294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	JUN	2014	35	6					727	737		10.1038/aps.2013.199			11	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Pharmacology & Pharmacy	AI9QM	WOS:000337267800003	24793312	Green Published, Bronze			2022-02-06	
J	Fu, J; Fan, HB; Guo, Z; Wang, Z; Li, XD; Li, J; Pei, GX				Fu, Jun; Fan, Hong-bin; Guo, Zheng; Wang, Zhen; Li, Xiang-dong; Li, Jing; Pei, Guo-xian			Salvianolic acid B attenuates spinal cord ischemia-reperfusion-induced neuronal injury and oxidative stress by activating the extracellular signal-regulated kinase pathway in rats	JOURNAL OF SURGICAL RESEARCH			English	Article						Salvianolic acid B; Ischemia-reperfusion injury; Neuroprotection; Oxidative stress	TRAUMATIC BRAIN-INJURY; ISCHEMIA/REPERFUSION INJURY; CORTICAL-NEURONS; MILTIORRHIZA; MECHANISMS; AKT; ERK; NEUROPROTECTION; EXTRACT; RABBITS	Background: Salvianolic acid B (SalB), the main bioactive compound isolated from the traditional Chinese medicinal herb broad Radix Salviae Miltiorrhizae exerts a spectrum of pharmacologic activities. We investigated the effects of SalB treatment in a rat model of spinal cord ischemia and reperfusion (I/R) injury and the underlying mechanism. Materials and methods: SalB was administered at 1, 10, or 50 mg/kg after spinal cord ischemia. The potential protective effects on spinal cord injury were determined by spinal cord edema, infarct volume, and motor function assessment of the hind limbs. Results: SalB treatment significantly decreased spinal cord edema and infarct volume and preserved motor function of the hind limbs in a dose-dependent manner. SalB administration ameliorated the generation of oxidative products and preserved antioxidant defense activities in the injured spinal cord at both 4 and 24 h after I/R injury. Moreover, SalB prolonged the I/R injury-induced activation of extracellular signal-regulated kinase (ERK), and blocking ERK activation with PD98059 partially prevented the neuroprotective effects of SalB. Conclusions: These findings demonstrate the neuroprotective effects of SalB in a spinal cord I/R injury model and suggest that SalB-induced neuroprotection was mediated by ERK activation. (C) 2014 Elsevier Inc. All rights reserved.	[Fu, Jun; Fan, Hong-bin; Guo, Zheng; Wang, Zhen; Li, Xiang-dong; Li, Jing; Pei, Guo-xian] Fourth Mil Med Univ, Xijing Hosp, Dept Orthopaed Oncol, Xian 710032, Shaanxi, Peoples R China		Guo, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Orthopaed Oncol, Xian 710032, Shaanxi, Peoples R China.	fmmuguozheng@163.com; fmmuwangzhen@163.com					Cao W, 2012, CHIN J INTEGR MED, V18, P316, DOI [10.1007/s11655-012-1052-8, 10.1007/s11655-011-012-1052-8]; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; de Haan P, 2001, J NEUROSURG ANESTH, V13, P3, DOI 10.1097/00008506-200101000-00002; Fan H., 2012, EVID-BASED COMPL ALT, V2012, DOI DOI 10.1155/2012/508938; Ho JHC, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-30; Hung YC, 2009, J ETHNOPHARMACOL, V124, P463, DOI 10.1016/j.jep.2009.05.020; Ji XY, 2000, ACTA PHARMACOL SIN, V21, P1089; Kam A, 2012, CURR MED CHEM, V19, P1830, DOI 10.2174/092986712800099794; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kitagawa H, 1999, NEUROSCI LETT, V274, P45, DOI 10.1016/S0304-3940(99)00676-X; Kleikers PWM, 2012, J MOL MED, V90, P1391, DOI 10.1007/s00109-012-0963-3; LIU GT, 1992, BIOCHEM PHARMACOL, V43, P147, DOI 10.1016/0006-2952(92)90271-J; Liu SP, 2010, APPL BIOCHEM BIOTECH, V162, P1206, DOI 10.1007/s12010-009-8888-1; Lu K, 2010, J NEUROCHEM, V114, P237, DOI 10.1111/j.1471-4159.2010.06747.x; Ma WY, 2005, EXPERT OPIN THER TAR, V9, P699, DOI 10.1517/14728222.9.4.699; Sawe N, 2008, J NEUROSCI RES, V86, P1659, DOI 10.1002/jnr.21604; Saxena P, 2012, J CARDIAC SURG, V27, P45, DOI 10.1111/j.1540-8191.2011.01330.x; Shioda N, 2009, INT REV NEUROBIOL, V85, P375, DOI 10.1016/S0074-7742(09)85026-5; Sun YS, 2009, J CHROMATOGR B, V877, P733, DOI 10.1016/j.jchromb.2009.02.013; SVENSSON LG, 1993, J VASC SURG, V17, P357, DOI 10.1016/0741-5214(93)90421-H; Tan DX, 2005, ENDOCRINE, V27, P149, DOI 10.1385/ENDO:27:2:149; Tang MK, 2006, BEHAV PHARMACOL, V17, P493, DOI 10.1097/00008877-200609000-00015; Wang ZS, 2013, CELL MOL NEUROBIOL, V33, P921, DOI 10.1007/s10571-013-9958-z; Wu YJ, 1998, ARTERIOSCL THROM VAS, V18, P481, DOI 10.1161/01.ATV.18.3.481; Wu YT, 2006, INT J PHARM, V326, P25, DOI 10.1016/j.ijpharm.2006.07.003; Zhang JL, 2005, BIOMED CHROMATOGR, V19, P15, DOI 10.1002/bmc.408; Zhao GR, 2008, FOOD CHEM TOXICOL, V46, P73, DOI 10.1016/j.fct.2007.06.034; Zhu JW, 2012, NEUROCHEM INT, V61, P640, DOI 10.1016/j.neuint.2012.06.021	32	26	29	2	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY	2014	188	1					222	230		10.1016/j.jss.2013.11.1118			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	AE4RS	WOS:000333971300028	24387840				2022-02-06	
J	Lu, XY; Wang, HD; Xu, JG; Ding, K; Li, T				Lu, Xin-Yu; Wang, Han-dong; Xu, Jian-Guo; Ding, Ke; Li, Tao			Pretreatment with tert-butylhydroquinone attenuates cerebral oxidative stress in mice after traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; tBHQ; Nrf2; Oxidative stress	CLOSED-HEAD INJURY; NEUROLOGICAL DEFICIT; CELL-DEATH; DAMAGE; NRF2; INHIBITION; MODEL; RATS	Background: Traumatic brain injury (TBI) is a worldwide health problem, identified as a major cause of death and disability. Increasing evidence has shown that oxidative stress plays an important role in TBI pathogenesis. The antioxidant transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2), is a known mediator in protection against TBI-induced brain damage. The objective of this study was to test whether tert-butylhydroquinone (tBHQ), a novel Nrf2 activator, can protect against TBI-induced oxidative stress. Methods: Adult male imprinting control region mice were randomly divided into three groups: (1) sham + vehicle group; (2) TBI + vehicle group; and (3) TBI + tBHQ group. Closed-head brain injury was applied using the Feeney weight-drop method. We accessed the neurologic outcome of mice at 24 h after TBI, and subsequently measured protein levels of Nrf2 and the NOX2 subunit of nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), the concentration of malondialdehyde, superoxide dismutase activity, and brain edema. Result: The NOX2 protein level was increased fivefold in the TBI + vehicle group, whereas pretreatment with tBHQ markedly attenuated the NOX2 protein expression relative to that in the TBI + vehicle group. TBI increased Nrf2 formation by 5% compared with the sham group, whereas treatment with tBHQ further upregulated the Nrf2 protein level by 12% compared with the sham group. The level of the oxidative damage marker malondialdehyde was reduced by 29% in the TBI + tBHQ group compared with the TBI + vehicle group, Moreover, pretreatment with tBHQ significantly increased the antioxidant enzyme superoxide dismutase activity. Administration of tBHQ also significantly decreased TBI-induced brain edema and neurologic deficits. Conclusions: Pretreatment with tBHQ effectively attenuated markers of cerebral oxidative stress after TBI, thus supporting the testing of tBHQ as a potential neuroprotectant and adjunct therapy for TBI patients. (C) 2014 Elsevier Inc. All rights reserved.	[Lu, Xin-Yu; Wang, Han-dong; Xu, Jian-Guo; Ding, Ke; Li, Tao] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Lu, Xin-Yu] Jiangsu Univ, Peoples Hosp, Dept Neurosurg, Zhenjiang, Jiangsu, Peoples R China		Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			Science and Technology Development Fund of Zhenjiang [SH20130037]	This study was supported by the Science and Technology Development Fund of Zhenjiang (No. SH20130037).	Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Beziaud T, 2011, CRIT CARE MED, V39, P2300, DOI 10.1097/CCM.0b013e3182227e4a; Cairns B, 2012, CURR DRUG TARGETS, V13, P199, DOI 10.2174/138945012799201676; Chapple SJ, 2012, INT J BIOCHEM CELL B, V44, P1315, DOI 10.1016/j.biocel.2012.04.021; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Ho WE, 2012, FREE RADICAL BIO MED, V53, P498, DOI 10.1016/j.freeradbiomed.2012.05.021; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Kahles T, 2012, CELL MOL LIFE SCI, V69, P2345, DOI 10.1007/s00018-012-1011-8; Kalayci M, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-75; Kandasamy R, 2013, INT J NEUROSCI, V123, P385, DOI 10.3109/00207454.2012.761983; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; Kerman M, 2012, J MOL HISTOL, V43, P49, DOI 10.1007/s10735-011-9376-9; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Lee JH, 2013, CANCER RES, V73, P785, DOI 10.1158/0008-5472.CAN-12-1994; Lo W, 2007, NEUROSCI LETT, V414, P228, DOI 10.1016/j.neulet.2006.12.055; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Nakamura Y, 2003, BIOCHEMISTRY-US, V42, P4300, DOI 10.1021/bi0340090; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Sitic S, 2008, ACTA CLIN CROAT, V47, P155; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Ye QY, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-156; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	30	26	28	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY	2014	188	1					206	212		10.1016/j.jss.2013.11.1106			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	AE4RS	WOS:000333971300026	24387843				2022-02-06	
J	Sohlberg, MM; Griffiths, GG; Fickas, S				Sohlberg, Mckay Moore; Griffiths, Gina G.; Fickas, Stephen			An Evaluation of Reading Comprehension of Expository Text in Adults With Traumatic Brain Injury	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						traumatic brain injury; cognition; reading; adults; education; assessment; dyslexia	CLOSED-HEAD-INJURY; WORKING-MEMORY; DISCOURSE; DEFICITS; ADOLESCENTS; IMPAIRMENT; MODEL; TASK	Purpose: This project was conducted to obtain information about reading problems of adults with traumatic brain injury (TBI) with mild-to-moderate cognitive impairments and to investigate how these readers respond to reading comprehension strategy prompts integrated into digital versions of text. Method: Participants from 2 groups, adults with TBI (n = 15) and matched controls (n = 15), read 4 different 500-word expository science passages linked to either a strategy prompt condition or a no-strategy prompt condition. The participants' reading comprehension was evaluated using sentence verification and free recall tasks. Results: The TBI and control groups exhibited significant differences on 2 of the 5 reading comprehension measures: paraphrase statements on a sentence verification task and communication units on a free recall task. Unexpected group differences were noted on the participants' prerequisite reading skills. For the within-group comparison, participants showed significantly higher reading comprehension scores on 2 free recall measures: words per communication unit and type-token ratio. There were no significant interactions. Conclusion: The results help to elucidate the nature of reading comprehension in adults with TBI with mild-to-moderate cognitive impairments and endorse further evaluation of reading comprehension strategies as a potential intervention option for these individuals. Future research is needed to better understand how individual	[Sohlberg, Mckay Moore; Griffiths, Gina G.; Fickas, Stephen] Univ Oregon, Eugene, OR 97403 USA		Sohlberg, MM (corresponding author), Univ Oregon, Eugene, OR 97403 USA.	mckay@uoregon.edu			Direct For Computer & Info Scie & EnginrNational Science Foundation (NSF)NSF - Directorate for Computer & Information Science & Engineering (CISE) [1013054] Funding Source: National Science Foundation		Ackerman R., 2009, NEW DIRECTIONS STUDE, V126, P5, DOI [https://doi.org/10.1002/ss.311, DOI 10.1002/SS.311]; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Berkeley S, 2010, REM SPEC EDUC, V31, P423, DOI 10.1177/0741932509355988; Biancarosa C., 2004, READING NEXT VISION; BLOOM L, 1980, J CHILD LANG, V7, P235, DOI 10.1017/S0305000900002610; Brown J, 1993, NELSON DENNY READING; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Carlisle J. F., 1989, LEARNING DISABILITY, V5, P33; Carretti B, 2005, J EXP CHILD PSYCHOL, V91, P45, DOI 10.1016/j.jecp.2005.01.005; Caspari I, 2000, J NEUROLINGUIST, V13, P15, DOI 10.1016/S0911-6044(99)00009-3; Chambers, 2018, GRAPHICAL METHODS DA; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho C, 2013, AM J SPEECH-LANG PAT, V22, pS438, DOI 10.1044/1058-0360(2013/12-0076); Conners C. K., 2000, CONNERS CONTINUOUS P; Connexions, 2009, CONN CONS; Delis D.C., 2000, CALIFORNIA VERBAL LE; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Dunn, 2007, PPVT 4 PEABODY PICTU; ERICSSON KA, 1995, PSYCHOL REV, V102, P211, DOI 10.1037/0033-295X.102.2.211; Fan XT, 2001, EDUC PSYCHOL MEAS, V61, P517, DOI 10.1177/00131640121971365; Faul M, 2010, TRAUMATIC BRAIN INJU; Ferstl EC, 2005, J CLIN EXP NEUROPSYC, V27, P367, DOI 10.1080/13803390490515784; Gajria M, 2007, J LEARN DISABIL-US, V40, P210, DOI 10.1177/00222194070400030301; Gernsbacher MA, 1997, DISCOURSE PROCESS, V23, P265, DOI 10.1080/01638539709544994; Griffiths G., 2010, OR SPEECH LANG HEAR; Griffiths G. G., 2012, ANN C INT NEUR SOC M; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guskiewicz K. M., 2003, J AM MED, V19, P2459; Hall D. E., 1986, COGNITIVE REHABILITA, V4, P6; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; HESS CW, 1984, PSYCHOL REP, V55, P51, DOI 10.2466/pr0.1984.55.1.51; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hosp, 2001, SCI STUD READ, V5, P239, DOI [10.1207/S1532799XSSR0503_3, DOI 10.1207/S1532799XSSR0503_3]; Hughes DL., 1997, GUIDE NARRATIVE LANG; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kennedy M. R., 2008, NEUROPSYCHOL REHABIL, V1, P1; Kennedy Mary R. T, 2005, Seminars in Speech and Language, V26, P242, DOI 10.1055/s-2005-922103; Kennedy MRT, 2008, NEUROREHABILITATION, V23, P511; Kim Y., 2009, SOLDIER STUDENT EASI; Kincaid J. P., 1975, 875 CHIEF NAV TECHN; KINTSCH W, 1988, PSYCHOL REV, V95, P163, DOI 10.1037/0033-295X.95.2.163; Le K, 2012, AM J SPEECH-LANG PAT, V21, pS115, DOI 10.1044/1058-0360(2012/11-0114); Lennon C., 2004, LEXILE FRAMEWORK APP; LEZAK M, 1995, NEUROLOGICAL ASSESSM; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Loban Walter, 1976, LANGUAGE DEV KINDERG; Mallery P., 2003, SPSS WINDOWS STEP ST, V4th; Mann L., 2006, THESIS U MICHIGAN AN; Manset-Williamson G, 2008, INT J SPEC EDUC, V23, P123; Mastropieri M.A., 1996, EXCEPTIONALITY, V6, P1; McNamara DS, 2004, DISCOURSE PROCESS, V38, P1, DOI 10.1207/s15326950dp3801_1; Mitchell AJ, 2010, ACTA NEUROPSYCHIATR, V22, P2, DOI 10.1111/j.1601-5215.2009.00439.x; Moran C, 2005, BRAIN INJURY, V19, P743, DOI 10.1080/02699050500110199; Moran C, 2012, LANG SPEECH HEAR SER, V43, P264, DOI 10.1044/0161-1461(2011/10-0114); Moser R. S., 2011, CLIN NEUROPSYCHOL, V1, P1; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Murnane R, 2012, FUTURE CHILD, V22, P3, DOI 10.1353/foc.2012.0013; National Center for Education Statistics, 2011, 2011455 NCES, V2011-455; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; OGLE DM, 1986, READ TEACH, V39, P564, DOI 10.1598/RT.39.6.11; Palinscar AS., 1984, COGNITION INSTRUCT, V1, P117, DOI [DOI 10.1207/S1532690XCI0102_1, 10.1207/s1532690xci0102_1]; PERFETTI C., 1985, READING ABILITY; Perfetti CA, 1996, READING COMPREHENSION DIFFICULTIES, P137; Radford A. W., 2009, 2009182 NCES US DEP; RAND Reading Study Group, 2002, READING UNDERSTANDIN; ROYER JM, 1979, J READING BEHAV, V11, P355, DOI 10.1080/10862967909547341; Rumelhart D.E., 2004, THEORETICAL MODELS P; Salmen D. J., 2004, THESIS U UTAH SALT L; Samuelsson S, 2004, J LEARN DISABIL-US, V37, P155, DOI 10.1177/00222194040370020601; Schmitter-Edgecombe M, 2005, BRAIN LANG, V94, P331, DOI 10.1016/j.bandl.2005.01.007; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg M. M., 2011, ANN C AM SPEECH LANG; Sohlberg M.M., 2011, OPTIMIZING COGNITIVE; Souvignier E, 2006, LEARN INSTR, V16, P57, DOI 10.1016/j.learninstruc.2005.12.006; Spratley A., 2010, READING DISCIPLINES; Stenner A Jackson, 2006, J Appl Meas, V7, P307; Stine-Morrow EAL, 2008, PSYCHOL AGING, V23, P131, DOI 10.1037/0882-7974.23.1.131; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; TANIELIAN T, 2008, MG720CCF RAND; Todis B, 2011, J HEAD TRAUMA REHAB, V26, P138, DOI 10.1097/HTR.0b013e3181e5a87a; TOMPKINS CA, 1994, J SPEECH HEAR RES, V37, P896, DOI 10.1044/jshr.3704.896; Verhoeven L, 2008, APPL COGNITIVE PSYCH, V22, P293, DOI 10.1002/acp.1417; Zwaan RA, 1998, PSYCHOL BULL, V123, P162, DOI 10.1037/0033-2909.123.2.162; [No title captured]	86	26	26	0	21	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY	2014	23	2					160	175		10.1044/2013_AJSLP-12-0005			16	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	AU5ZP	WOS:000345682200006	24687229				2022-02-06	
J	Sillesen, M; Johansson, PI; Rasmussen, LS; Jin, G; Jepsen, CH; Imam, A; Hwabejire, JO; Deperalta, D; Duggan, M; deMoya, M; Velmahos, GC; Alam, HB				Sillesen, Martin; Johansson, Paer I.; Rasmussen, Lars S.; Jin, Guang; Jepsen, Cecilie H.; Imam, Ayesha; Hwabejire, John O.; Deperalta, Danielle; Duggan, Michael; deMoya, Marc; Velmahos, George C.; Alam, Hasan B.			Fresh frozen plasma resuscitation attenuates platelet dysfunction compared with normal saline in a large animal model of multisystem trauma	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Trauma; brain; platelets; endothelium; swine	MASSIVE TRANSFUSION; BRAIN-INJURY; ENDOTHELIAL-CELLS; HEMORRHAGIC-SHOCK; IN-VITRO; MORTALITY; THROMBOCYTOPENIA; COAGULOPATHY; COAGULATION; INHIBITION	BACKGROUND Platelet dysfunction following trauma has been identified as an independent predictor of mortality. We hypothesized that fresh frozen plasma (FFP) resuscitation would attenuate platelet dysfunction compared with 0.9% normal saline (NS). METHODS Twelve swine were subjected to multisystem trauma (traumatic brain injury, liver injury, rib fracture, and soft tissue injury) with hemorrhagic shock (40% of estimated blood volume). Animals were left in shock (mean arterial pressure, 30-35 mm Hg) for 2 hours followed by resuscitation with three times shed volume NS (n = 6) or one times volume FFP (n = 6) and monitored for 6 hours. Platelet function was assessed by adenosine diphosphate (ADP)-induced platelet aggregation at baseline, after 2 hours of shock following resuscitation, and 6 hours after resuscitation. Fibrinogen levels and markers of platelet activation (transforming growth factor [TGF-], sP-Selectin, and CD40L) as well as endothelial injury (intercellular adhesion molecule 1 [ICAM-1], vascular cell adhesion molecule 1 [VCAM-1]) were also assayed. Thromboelastography was used to measure clotting activity. RESULTS ADP-induced platelet aggregation was significantly higher in the FFP group (46.3 U vs. 25.5 U, p < 0.01) following resuscitation. This was associated with higher fibrinogen levels (202 mg/dL vs. 80 mg/dL, p < 0.01) but lower endothelial activation (VCAM-1, 1.25 ng/mL vs. 3.87 ng/mL, p = 0.05). Other markers did not differ. After 6 hours of observation, ADP-induced platelet aggregation remained higher in the FFP group (53.8 U vs. 37.0 U, p = 0.03) as was fibrinogen levels (229 mg/dL vs. 153 mg/dL, p < 0.01). Endothelial activation was lower (ICAM-1, 21.0 ng/mL vs. 24.4 ng/mL, p = 0.05), whereas TGF- levels were higher (2,138 pg/mL vs. 1,802 pg/mL, p = 0.03) in the FFP group. Other markers did not differ. Thromboelastography revealed increased clot strength in the FFP group at both postresuscitation time points. CONCLUSION Resuscitation with FFP resulted in an immediate and sustained improvement in platelet function and clot strength compared with high-volume NS resuscitation. This was associated with an increase in fibrinogen levels and an attenuation of endothelial activation.	[Sillesen, Martin; Jepsen, Cecilie H.; Imam, Ayesha; Hwabejire, John O.; Deperalta, Danielle; Duggan, Michael; deMoya, Marc; Velmahos, George C.] Harvard Univ, Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Dept Surg,Med Sch, Boston, MA USA; [Sillesen, Martin; Rasmussen, Lars S.] Rigshosp, Copenhagen Univ Hosp, Dept Anesthesia, Copenhagen, Denmark; [Johansson, Paer I.; Jepsen, Cecilie H.] Rigshosp, Copenhagen Univ Hosp, Ctr Head & Orthoped, Copenhagen, Denmark; [Johansson, Paer I.; Jepsen, Cecilie H.] Rigshosp, Copenhagen Univ Hosp, Capital Reg Blood Bank, Copenhagen, Denmark; [Johansson, Paer I.] Univ Texas Houston, Sch Med, Dept Surg, Houston, TX USA; [Jin, Guang; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA		Alam, HB (corresponding author), Univ Michigan Hosp, Taubman Ctr 2920, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu	Johansson, Par I/P-9283-2015	Johansson, Par I/0000-0001-9778-5964; Rasmussen, Lars/0000-0002-7480-3004; Sillesen, Martin/0000-0001-9494-5475	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; Copenhagen University Hospital, Rigshospitalet (Denmark); Laerdal Foundation (Norway); Aase and Ejnar Danielsen foundation (Denmark); Olof Norlander foundation (Sweden); Maersk Foundation (Denmark); Tryg Foundation (Denmark); Lundbeck Foundation (Denmark)Lundbeckfonden; Polsky family	The study was funded by a grant from the US Army Medical Research and Materiel Command (GRANTT00521959) to H.B.A. Grants from Copenhagen University Hospital, Rigshospitalet (Denmark), The Laerdal Foundation (Norway), The Aase and Ejnar Danielsen foundation (Denmark), The Olof Norlander foundation (Sweden), and The Maersk Foundation (Denmark) supported the work done by M.S. L.S.R. has received funding from the Tryg Foundation (Denmark). P.I.J. received funding from the Lundbeck Foundation (Denmark). M.De. received funding from the Polsky family. The Multiplate machine was on unconditional loan from US Distributor Diapharma Group, Inc. (West Chester, OH) for the duration of the study, while the TEG-5000 machine was on unconditional loan from Haemonetics Corp. (Braintree, MA). These companies did not participate in study planning, execution, data analysis, or manuscript preparation.	Bochsen Louise, 2007, Thromb J, V5, P3, DOI 10.1186/1477-9560-5-3; Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; Brown JB, 2012, J TRAUMA ACUTE CARE, V73, P358, DOI 10.1097/TA.0b013e31825889ba; Brown LM, 2011, J TRAUMA, V71, pS358, DOI 10.1097/TA.0b013e318227f152; Caballo C, 2013, BLOOD TRANSFUS-ITALY, V11, P391, DOI 10.2450/2012.0034-12; Duan CJ, 2011, SHOCK, V36, P54, DOI 10.1097/SHK.0b013e318214475e; Ekseth K, 2002, ANAESTHESIA, V57, P1102, DOI 10.1046/j.1365-2044.2002.02782_1.x; Fuchs TA, 2011, BLOOD, V118, P3708, DOI 10.1182/blood-2011-01-332676; Harr JN, 2012, SURGERY, V152, P270, DOI 10.1016/j.surg.2012.05.002; Inaba K, 2013, J AM COLL SURGEONS, V216, P290, DOI 10.1016/j.jamcollsurg.2012.10.017; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Johansson PI, 2012, J THROMB HAEMOST, V10, P207, DOI 10.1111/j.1538-7836.2011.04589.x; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Kozek-Langenecker SA, 1999, KIDNEY INT, V56, P299, DOI 10.1046/j.1523-1755.1999.00518.x; Kozek-Langenecker S, 2011, CRIT CARE, V15, DOI 10.1186/cc10488; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; LANDOLFI R, 1991, BLOOD, V78, P377; Mengistu AM, 2011, ACTA ANAESTH SCAND, V55, P903, DOI 10.1111/j.1399-6576.2011.02496.x; Ostrowski SR, 2011, MED HYPOTHESES, V77, P798, DOI 10.1016/j.mehy.2011.07.040; Pati S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025171; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; Sillesen M, 2013, SURGERY, V154, P197, DOI 10.1016/j.surg.2013.04.002; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P322, DOI 10.1160/TH11-03-0175; Stissing T, 2011, CLIN APPL THROMB-HEM, V17, pE211, DOI 10.1177/1076029610397183; Thekkedath UR, 2006, AM J HEMATOL, V81, P915, DOI 10.1002/ajh.20720; Wataha K, 2013, TRANSFUSION, V53, p80S, DOI 10.1111/trf.12040; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	29	26	27	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2014	76	4					998	1007		10.1097/TA.0000000000000193			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AE7FF	WOS:000334161500021	24662863				2022-02-06	
J	Suppiej, A; Cainelli, E; Casara, G; Cappellari, A; Nosadini, M; Sartori, S				Suppiej, Agnese; Cainelli, Elisa; Casara, Giulia; Cappellari, Ambra; Nosadini, Margherita; Sartori, Stefano			Long-Term Neurocognitive Outcome and Quality of Life in Pediatric Acute Disseminated Encephalomyelitis	PEDIATRIC NEUROLOGY			English	Article						ADEM; neuropsychological; cognitive; sequelae; follow-up; impairments; multiple sclerosis	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; BACTERIAL-MENINGITIS; FOLLOW-UP; CHILDREN; AGE; PERFORMANCE; ATTENTION; DEFICITS; ONSET	BACKGROUND: Acute disseminated encephalomyelitis is an inflammatory-demyelinating disorder of the central nervous system usually with a monophasic course and a favorable neurological outcome. Long-term neurocognitive sequelae and quality of life have not yet been fully investigated. AIM: To examine neurocognitive outcome and quality of life in pediatric monophasic acute disseminated encephalomyelitis. METHODS: Of the 36 patients diagnosed with acute disseminated encephalomyelitis at our institution, six were lost to follow-up and eight relapsed (two with multiphasic forms and six with multiple sclerosis). The outcome of the 22 remaining patients was evaluated using four subscales of the Wechsler Intelligence Scales for estimation of IQ a battery of neuropsychological tests, and semistructured and PedsQL questionnaires for quality of life. The effect of age at onset, neuroradiological recovery, and time elapsed from the acute event on outcome was also investigated. RESULTS: Estimated IQ neuropsychological mean group scores, and quality of life at follow-up were within the normal range, but 23% of the patients had pathological scores in various neuropsychological functions, among which attention was the most clearly affected. The neuroradiological recovery was not correlated with the result of the neuropsychological tests. Age at onset correlated with linguistic skills, whereas the time elapsed from the acute event had a significant effect on attention tasks: scores were worse in the group of patients with a follow-up shorter than 7 years. CONCLUSION: Our results suggest that pediatric monophasic acute disseminated encephalomyelitis has a favorable neurocognitive outcome. Patients with longer follow-up had a better outcome, suggesting a neurocognitive course that is different from that of multiple sclerosis and a potential for long-term recovery of affected functions.	[Suppiej, Agnese; Cainelli, Elisa; Casara, Giulia; Cappellari, Ambra; Nosadini, Margherita; Sartori, Stefano] Univ Padua, Paediat Univ Hosp, I-35128 Padua, Italy; [Cainelli, Elisa] Univ Padua, Dept Gen Psychol, Lifespan Cognit Neurosci Lab, I-35128 Padua, Italy		Suppiej, A (corresponding author), Univ Padua, Paediat Univ Hosp, Via Giustiniani 3, I-35128 Padua, Italy.	suppiej@pediatria.unipd.it	Suppiej, Agnese/K-3424-2016; Nosadini, Margherita/AAW-4843-2020; Cainelli, Elisa/AAD-1651-2020; Sartori, Stefano/K-9498-2016	Suppiej, Agnese/0000-0001-5130-1450; Sartori, Stefano/0000-0002-0012-6848			Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2004, J PEDIATR PSYCHOL, V29, P67, DOI 10.1093/jpepsy/jsh011; Bisiacchi P.S., 2005, BATTERIA VALUTAZIONE; Cohen J., 1998, STAT POWER ANAL BEHA, V2nd; Dale RC, 2000, BRAIN, V123, P2407, DOI 10.1093/brain/123.12.2407; Deery B, 2010, DEV NEUROPSYCHOL, V35, P506, DOI 10.1080/87565641.2010.494921; Grimwood K, 2000, ARCH DIS CHILD, V83, P111, DOI 10.1136/adc.83.2.111; Hahn CD, 2003, PEDIATR NEUROL, V29, P117, DOI 10.1016/S0887-8994(03)00143-7; Holland BA, 1986, AM SOC NEURORADIOL, V7, P20; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; Jacobs RK, 2004, PEDIATR NEUROL, V31, P191, DOI 10.1016/j.pediatrneurol.2004.03.008; Jayakrishnan MP, 2010, J PEDIATR NEUROSCI, V5, P111, DOI 10.4103/1817-1745.76098; Krupp LB, 2013, MULT SCLER J, V19, P1261, DOI 10.1177/1352458513484547; Kuni BJ, 2012, DEV NEUROPSYCHOL, V37, P682, DOI 10.1080/87565641.2012.690799; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Mar S, 2010, J CHILD NEUROL, V25, P681, DOI 10.1177/0883073809343320; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; Mulhern RK, 2001, J CLIN ONCOL, V19, P472, DOI 10.1200/JCO.2001.19.2.472; Panepinto JA, 2008, J PEDIAT HEMATOL ONC, V30, P666, DOI 10.1097/MPH.0b013e31817e4a44; Picone, 2006, WISC 3 CONTRIBUTO TA; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Rostasy K, 2009, NEUROPEDIATRICS, V40, P211, DOI 10.1055/s-0030-1247518; Ruff H. A., 1996, ATTENTION EARLY DEV; Sannio Facello G, 2006, TOL TORRE LONDRA TES; Sattler JM, 1992, ASSESSMENT CHILDREN, Vthird; Stoppa E, 1997, PSICH INF ADOLESC, V64, P73; Suppiej A, 2008, PEDIATR NEUROL, V39, P12, DOI 10.1016/j.pediatrneurol.2008.03.009; Tenembaum S, 2002, NEUROLOGY, V59, P1224, DOI 10.1212/WNL.59.8.1224; Tenembaum S, 2007, NEUROLOGY, V68, pS23, DOI 10.1212/01.wnl.0000259404.51352.7f; THATCHER R, 1997, DEV PREFRONTAL CORTE; Thatcher RW, 1991, DEV NEUROPSYSCHOL, V7, P783; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yakovlev PI, 1967, REGIONAL DEV BRAIN E; Young NP, 2008, SEMIN NEUROL, V28, P84, DOI 10.1055/s-2007-1019130; Zarei M, 2003, J NEUROL NEUROSUR PS, V74, P872, DOI 10.1136/jnnp.74.7.872	36	26	27	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	APR	2014	50	4					363	367		10.1016/j.pediatrneurol.2013.12.006			5	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	AE3GY	WOS:000333866200018	24630282				2022-02-06	
J	Awai, L; Curt, A				Awai, Lea; Curt, Armin			Intralimb coordination as a sensitive indicator of motor-control impairment after spinal cord injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						spinal cord injury; human; gait; intralimb; coordination; categorization; cyclogram	GAIT ANALYSIS; TREADMILL; PATTERNS; LOCOMOTION; WALKING; PEOPLE	Background: Recovery of walking function after neurotrauma, e.g., after spinal cord injury, is routinely captured using standardized walking outcome measures of time and distance. However, these measures do not provide information on possible underlying mechanisms of recovery, nor do they tell anything about the quality of gait. Subjects with an incomplete spinal cord injury are a very heterogeneous group of people with a wide range of functional impairments. A stratification of these subjects would allow increasing sensitivity for hypothesis testing and a more targeted treatment strategy. Methods: The gait of incomplete spinal cord injured subjects was compared to healthy control subjects by analyzing kinematic data obtained by a 3-D motion capture system. Hip knee angle-angle plots (cyclograms) informed on the qualitative aspect of gait and the intralimb coordination. Features of the cyclogram, e.g., shape of the cyclogram, cycle-to-cycle consistency and its modulation due to changes in walking speed were discerned and used to stratify spinal cord injured subjects. Results: Spinal cord injured subjects were unable to modulate their cyclogram configuration when increasing speed from slow to preferred. Their gait quality remained clearly aberrant and showed even higher deviations from normal when walking at preferred speed. Qualitative categorization of spinal cord injured subjects based on their intralimb coordination was complemented by quantitative measures of cyclogram shape comparison. Discussion: Spinal cord injured subjects showed distinct distortions of intralimb coordination as well as limited modulation to changes in walking speed. The specific changes of the cyclograms revealed complementary insight in the disturbance of lower-limb control in addition to measures of time and distance and may be a useful tool for patient categorization and stratification prior to clinical trial inclusion.	[Awai, Lea; Curt, Armin] Univ Zurich, Balgrist Univ Hosp, Spinal Cord Injury Ctr, CH-8008 Zurich, Switzerland		Awai, L (corresponding author), Univ Zurich, Balgrist Univ Hosp, Spinal Cord Injury Ctr, Forchstr 340, CH-8008 Zurich, Switzerland.	lawai@paralab.balgrist.ch		Awai, Lea/0000-0002-9542-1152	European Commission's Seventh Framework Program [CP-IP 258654]; Wolf Foundation, Switzerland; Clinical Research Priority Program CRPP Neurorehab UZH; European Commission's Seventh Framework Program [NEUWalk]	We thank B. Huber for assistance with subject recruitment and kinematic data acquisition, funding: this work was supported by the European Commission's Seventh Framework Program [CP-IP 258654, NEUWalk]; the Wolf Foundation, Switzerland; the Clinical Research Priority Program CRPP Neurorehab UZH.	Abel R, 2002, SPINAL CORD, V40, P17, DOI 10.1038/sj.sc.3101239; Bachmann LC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005972; BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; Borghese NA, 1996, J PHYSIOL-LONDON, V494, P863, DOI 10.1113/jphysiol.1996.sp021539; COTES JE, 1960, ERGONOMICS, V3, P97, DOI 10.1080/00140136008930473; Courtemanche R, 1996, ARCH PHYS MED REHAB, V77, P849, DOI 10.1016/S0003-9993(96)90269-5; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Duysens J, 1998, GAIT POSTURE, V7, P131, DOI 10.1016/S0966-6362(97)00042-8; Field-Fote EC, 2002, PHYS THER, V82, P707, DOI 10.1093/ptj/82.7.707; Field-Fote EC, 2001, J REHABIL MED, V33, P177, DOI 10.1080/165019701750300645; Gil-Agudo A, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-7; Grasso R, 1998, J NEUROPHYSIOL, V80, P1868, DOI 10.1152/jn.1998.80.4.1868; Ivanenko YP, 2003, J NEUROPHYSIOL, V90, P3555, DOI 10.1152/jn.00223.2003; Krawetz P, 1996, ARCH PHYS MED REHAB, V77, P635, DOI 10.1016/S0003-9993(96)90000-3; KUHN RA, 1950, BRAIN, V73, P1, DOI 10.1093/brain/73.1.1; Lacquaniti F, 1999, NEWS PHYSIOL SCI, V14, P168, DOI 10.1152/physiologyonline.1999.14.4.168; MacLellan MJ, 2013, EXP BRAIN RES, V225, P217, DOI 10.1007/s00221-012-3364-5; Manor B, 2009, GAIT POSTURE, V30, P253, DOI 10.1016/j.gaitpost.2009.04.011; Morris M, 2005, MOVEMENT DISORD, V20, P40, DOI 10.1002/mds.20278; Morris M, 1998, MOVEMENT DISORD, V13, P61, DOI 10.1002/mds.870130115; Nakajima K, 2000, J NEUROPHYSIOL, V84, P698, DOI 10.1152/jn.2000.84.2.698; Nooijen CFJ, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-36; Pepin A, 2003, SPINAL CORD, V41, P257, DOI 10.1038/sj.sc.3101452; ROBINSON JL, 1981, PHYS THER, V61, P351, DOI 10.1093/ptj/61.3.351; SAINBURG RL, 1993, J NEUROPHYSIOL, V70, P2136, DOI 10.1152/jn.1993.70.5.2136; Tamburella F, 2013, EUR J PHYS REHAB MED, V49, P353; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45	27	26	26	2	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAR 17	2014	8								148	10.3389/fnhum.2014.00148			8	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	AC9IP	WOS:000332848200001	24672464	Green Published, gold, Green Accepted			2022-02-06	
J	Kontos, AP; Braithwaite, R; Dakan, S; Elbin, RJ				Kontos, Anthony P.; Braithwaite, Rock; Dakan, Scott; Elbin, R. J.			Computerized Neurocognitive Testing within 1 Week of Sport-Related Concussion: Meta-analytic Review and Analysis of Moderating Factors	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						ANAM; CogSport; Headminder; ImPACT; Neuropsychology; Mild traumatic brain injury	COUNSELING PSYCHOMETRIC ISSUES; IMPACT ASSESSMENT; CLINICAL UTILITY; HIGH-SCHOOL; PLAY; EPIDEMIOLOGY; PERFORMANCE; COLLEGIATE; SYMPTOMS; BIAS	The purpose of this study is to perform a meta-analysis assessing the effects of sport-related concussion as measured by computerized neurocognitive tests (NCT) 1-week post injury. Thirty-seven studies involving 3960 participants between 2000 and 2011 were included. Hedge's g provides an adjusted effect size for smaller sample sizes and was calculated for overall and cognitive task effects, and subgroup analyses were conducted for age, type of NCT, and sport. Concussions had a low negative effect (g=-0.16; p<.001) across all groups, outcomes, and time points. Code substitution (g=-0.27; p<.05), visual memory (g=-0.25; p<.05), processing speed (g=-0.18; p<.05), and memory (g=-0.21; p<.05) tasks demonstrated negative effects for concussion. Younger adolescents had lower (g=-0.29; p<.05) NCT performance than older adolescents (g=-0.01) and college aged athletes (g=-0.11). ImPACT studies (g=-0.19; p<.05) demonstrated a negative effect for concussion as did those involving contact sports (g=-0.20; p<.05). A low to moderate overall effect size of concussion on neurocognitive performance was supported. Subgroup analyses revealed different effect sizes for specific cognitive tasks, types of NCTs, age, and type of sport.	[Kontos, Anthony P.; Dakan, Scott] Univ Pittsburgh, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA USA; [Braithwaite, Rock] Humboldt State Univ, Dept Kinesiol & Recreat Adm, Arcata, CA 95521 USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Fayetteville, AR 72701 USA		Kontos, AP (corresponding author), Univ Pittsburgh, UPMC Ctr Sports Med, Dept Orthoped Surg, UPMC Sports Med Concuss Program, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu	Meijer, Anna/K-5118-2016	Kontos, Anthony/0000-0002-3749-4310			[Anonymous], 2001, REP TRENDS PART YOUT; Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Borenstein M., 2009, INTRO META ANAL; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Cohen J., 2013, STAT POWER ANAL BEHA; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Dougan B.K., 2013, J INT NEUROPSYCH SOC, P1; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field AP, 2003, PSYCHOLOGIST, V16, P642; Field AP, 2001, PSYCHOL METHODS, V6, P161, DOI 10.1037//1082-989X.6.2.161; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hedges L.V., 1985, STAT METHODS META AN; Hedges LV., 1981, J EDUC STAT, V6, P107, DOI [10.3102/10769986006002107, DOI 10.2307/1164588]; Higgins, 2005, COMPREHENSIVE META A; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hunter JE, 2000, INT J SELECT ASSESS, V8, P275, DOI 10.1111/1468-2389.00156; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Light RJ., 1984, SUMMING SCI REV RES; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P1, DOI 10.1002/0470870168; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; SHADISH WR, 1991, J CONSULT CLIN PSYCH, V59, P883, DOI 10.1037/0022-006X.59.6.883	31	26	26	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2014	20	3					324	332		10.1017/S1355617713001471			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	AM0UG	WOS:000339561800008	24521662				2022-02-06	
J	Max, JE				Max, Jeffrey E.			Neuropsychiatry of Pediatric Traumatic Brain Injury	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Pediatric traumatic brain injury; Novel psychiatric disorder; Risk factors; Treatment; Review; Brain imaging	CLOSED-HEAD-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT-HYPERACTIVITY DISORDER; 1ST 6 MONTHS; PSYCHIATRIC-DISORDERS; PERSONALITY-CHANGE; POSTCONCUSSIVE SYMPTOMS; SUBSEQUENT DEVELOPMENT; EXECUTIVE DYSFUNCTION; SPATIAL-DISTRIBUTION	Pediatric traumatic brain injury (TBI) is a major public health problem. Psychiatric disorders with onset before the injury are more common than population base rates. Novel (postinjury onset) psychiatric disorders (NPD) are also common and complicate child function after injury. Novel disorders include personality change due to TBI, secondary attention-deficit/hyperactivity disorder, other disruptive behavior disorders, and internalizing disorders. This article reviews preinjury psychiatric disorders as well as biopsychosocial risk factors and treatments for NPD.	Rady Childrens Hosp, San Diego, CA 92123 USA		Max, JE (corresponding author), Rady Childrens Hosp, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD068432, R-01 1R01HD068432-01A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD068432] Funding Source: NIH RePORTER		ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cohen ML, 2012, J PEDIATR PSYCHOL, V37, P251, DOI 10.1093/jpepsy/jsr086; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2008, J INT NEUROPSYCH SOC, V14, P673, DOI 10.1017/S1355617708080983; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs L, 2012, INT J DEV NEUROSCI, V30, P247, DOI 10.1016/j.ijdevneu.2011.07.004; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Glang A, 2007, J HEAD TRAUMA REHAB, V22, P198, DOI 10.1097/01.HTR.0000271121.42523.3a; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; HOON AH, 1992, DEV MED CHILD NEUROL, V34, P252; Jin C, 2004, CNS SPECTRUMS, V9, P217, DOI 10.1017/S1092852900009019; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Josie KL, 2008, J HEAD TRAUMA REHAB, V23, P357, DOI 10.1097/01.HTR.0000341431.29133.a8; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Kochanek PM, 2010, DEV NEUROSCI-BASEL, V32, P335, DOI 10.1159/000323016; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, EPIDEMIOLOGICAL FEAT, P22; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, NEUROCASE, V3, P119; Max JE, 1998, BRAIN INJURY, V12, P41; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P472, DOI 10.1097/00004583-199504000-00014; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; Max JE, 2010, COGNITIVE BEHAV ABNO, P647; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P187, DOI 10.1176/appi.neuropsych.12010011; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Max JE, 2012, J AM ACAD CHILD PSY, V51, P1208, DOI 10.1016/j.jaac.2012.08.026; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Ornstein TJ, 2013, J NEUROPSYCHOL, V7, P1, DOI 10.1111/j.1748-6653.2012.02027.x; Pangilinan PH, 2010, PM&R, V2, P1127, DOI 10.1016/j.pmrj.2010.07.007; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Rune V, 1970, ACTA PAEDIATR SC   S, V209, P3; Sayal K, 2000, J AM ACAD CHILD PSY, V39, P525, DOI 10.1097/00004583-200004000-00023; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Scott LK, 2009, J NEUROS-PEDIATR, V3, P484, DOI 10.3171/2009.2.PEDS08292; Senior HEJ, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-89; Sinopoli KJ, 2011, J CLIN EXP NEUROPSYC, V33, P805, DOI 10.1080/13803395.2011.562864; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2013, CHILD NEUROPSYCHOL; Wade SL, 2013, J HEAD TRAUMA REHABI; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	96	26	26	0	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	MAR	2014	37	1					125	+		10.1016/j.psc.2013.11.003			18	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	AD8UM	WOS:000333541200010	24529428	Green Accepted			2022-02-06	
J	Mohseni, S; Talving, P; Wallin, G; Ljungqvist, O; Riddez, L				Mohseni, Shahin; Talving, Peep; Wallin, Goran; Ljungqvist, Olle; Riddez, Louis			Preinjury A- blockade is protective in isolated severe traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; preinjury; -blocker; mortality	ORGAN DYSFUNCTION; UNITED-STATES; SURVIVAL; NOREPINEPHRINE; TRENDS; DEATH	BACKGROUND The purpose of this study was to investigate the effect of preinjury -blockade in patients experiencing isolated severe traumatic brain injury (TBI). We hypothesized that -blockade before TBI is associated with improved survival. METHODS The trauma registry of an urban academic trauma center was queried to identify patients with an isolated severe TBI between January 2007 and December 2011. Isolated severe TBI was defined as an intracranial injury with an Abbreviated Injury Scale (AIS) score of 3 or greater excluding all extracranial injuries AIS score of 3 or greater. Patient demographics, clinical characteristics on admission, injury profile, Injury Severity Score (ISS), AIS score, in-hospital morbidity, and -blocker exposure were abstracted for analysis. The primary outcome evaluated was in-hospital mortality stratified by preinjury -blockade exposure. RESULTS Overall, a total of 662 patients met the study criteria. Of these, 25% (n = 159) were exposed to -blockade before their traumatic insult. When comparing the demographics and injury characteristics between the groups, the sole difference was age, with the -blocked group being older (69 [12] years vs. 63 [13] years, p < 0.001). -blocked patients had a higher rate of infectious complications (30% vs. 19%, p = 0.04), with no difference in cardiac or pulmonary complications between the cohorts. Patients exposed to -blockade versus no -blockade experienced 13% and 22% mortality, respectively (p = 0.01). Stepwise logistic regression predicted the absence of -blockade exposure as a risk factor for mortality (odds ratio, 2.7; 95% confidence interval, 1.5-4.8; p = 0.002). After adjustment for significant differences between the groups, patients not exposed to -blockade experienced twofold increased risk of mortality (adjusted odds ratio, 2.2; 95% confidence interval, 1.3-3.7; p = 0.004). CONCLUSION Preinjury -blockade improves survival following isolated severe TBI. The role of prophylactic -blockade and the timing of initiation of such therapy after TBI warrant further investigations. LEVEL OF EVIDENCE Therapeutic study, level III; prognostic study, level II.	[Mohseni, Shahin; Wallin, Goran; Ljungqvist, Olle] Orebro Univ Hosp, Dept Surg, Div Acute Care Surg, Orebro, Sweden; [Talving, Peep; Riddez, Louis] Karolinska Univ Hosp, Dept Surg, Div Acute Care Surg & Trauma, Stockholm, Sweden		Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles Cty Gen Hosp LAC USC, 2051 Marengo Str,C5L100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	Talving, Peep/E-6015-2013; Talving, Peep/G-8621-2015	Talving, Peep/0000-0002-9741-2073			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; ALEXANDER RW, 1975, NATURE, V258, P437, DOI 10.1038/258437a0; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CLIFTON G L, 1989, Neurosurgical Review, V12, P465, DOI 10.1007/BF01790692; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Enderson BL, 2007, J TRAUMA, V62, P33; Gerrard P, 2012, J TRAUMA ACUTE CARE, V73, P1242, DOI 10.1097/TA.0b013e318265d234; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Kemp CD, 2008, AM SURGEON, V74, P866; KRAUS J, 1985, J NEUROSURG, V63, P537, DOI 10.3171/jns.1985.63.4.0537; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P489, DOI 10.1152/ajplegacy.1976.231.2.489; MALING HM, 1958, AM J PHYSIOL, V194, P590, DOI 10.1152/ajplegacy.1958.194.3.590; Mann NC, 2001, J TRAUMA, V50, P1111, DOI 10.1097/00005373-200106000-00022; McGwin G, 2004, J TRAUMA, V56, P1291, DOI 10.1097/01.TA.0000089354.02065.D0; MEYER JS, 1976, STROKE, V7, P158, DOI 10.1161/01.STR.7.2.158; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Poulat P, 1998, EUR J PHARMACOL, V344, P251, DOI 10.1016/S0014-2999(97)01569-0; Pryor JP, 2007, J TRAUMA, V62, P61; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Schroeppel TJ, 2010, J TRAUMA, V69, P776, DOI 10.1097/TA.0b013e3181e981b8; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	32	26	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2014	76	3					804	808		10.1097/TA.0000000000000139			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AB8YW	WOS:000332077100048	24553552				2022-02-06	
J	Sajja, VSSS; Perrine, SA; Ghoddoussi, F; Hall, CS; Galloway, MP; VandeVord, PJ				Sajja, Venkata Siva Sai Sujith; Perrine, Shane A.; Ghoddoussi, Farhad; Hall, Christina S.; Galloway, Matthew P.; VandeVord, Pamela J.			Blast neurotrauma impairs working memory and disrupts prefrontal myo-inositol levels in rats	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Working memory; Myo-inositol; Glia; Prefrontal cortex; Blast neurotrauma	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; ALZHEIMERS-DISEASE; NEUROCHEMICAL CHANGES; OXIDATIVE STRESS; CREATINE-KINASE; MR SPECTROSCOPY; ATP REGULATION; CORTEX; MODEL	Working memory, which is dependent on higher-order executive function in the prefrontal cortex, is often disrupted in patients exposed to blast overpressure. In this study, we evaluated working memory and medial prefrontal neurochemical status in a rat model of blast neurotrauma. Adult male Sprague-Dawley rats were anesthetized with 3% isoflurane and exposed to calibrated blast overpressure (17 psi, 117 kPa) while sham animals received only anesthesia. Early neurochemical effects in the prefrontal cortex included a significant decrease in betaine (trimethylglycine) and an increase in GABA at 24 h, and significant increases in glycerophosphorylcholine, phosphorylethanolamine, as well as glutamate/creatine and lactate/creatine ratios at 48 h. Seven days after blast, only myo-inositol levels were altered showing a 15% increase. Compared to controls, short-term memory in the novel object recognition task was significantly impaired in animals exposed to blast overpressure. Working memory in control animals was negatively correlated with myo-inositol levels (r = -.759, p < 0.05), an association that was absent in blast exposed animals. Increased myo-inositol may represent tardive glial scarring in the prefrontal cortex, a notion supported by GFAP changes in this region after blast overexposure as well as clinical reports of increased myo-inositol in disorders of memory. (C) 2014 Elsevier Inc All rights reserved.	[Sajja, Venkata Siva Sai Sujith; Hall, Christina S.; VandeVord, Pamela J.] Virginia Polytech & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24060 USA; [Perrine, Shane A.; Ghoddoussi, Farhad; Galloway, Matthew P.] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA; [Ghoddoussi, Farhad; Galloway, Matthew P.] Wayne State Univ, Sch Med, Dept Anesthesiol, Detroit, MI USA; [VandeVord, Pamela J.] Salem VA Med Ctr, Res & Dev Serv, Salem, VA USA		VandeVord, PJ (corresponding author), Virginia Polytech & State Univ, Sch Biomed Engn & Sci, 447 ICTAS Bldg,Stanger St, Blacksburg, VA 24060 USA.	pvord@vt.edu	Sajja, Sujith/I-5289-2019	Sajja, Sujith/0000-0002-1992-9501; Galloway, Matthew/0000-0002-7856-9606	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0207]	We would like to thank Ms. Megan Roberts in assisting with the behavioral experiments, the WSU Bioengineering Center Staff for assisting with the blast testing, especially Dr. Bin Wu and Mr. James Kopaz. This project was partially funded by the Department of Defense (Award no. W81XWH-08-2-0207).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; An SJ, 2003, J NEUROSCI RES, V71, P534, DOI 10.1002/jnr.10502; Andrade CS, 2011, EPILEPSIA, V52, P2276, DOI 10.1111/j.1528-1167.2011.03281.x; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bolanos JP, 2010, TRENDS BIOCHEM SCI, V35, P145, DOI 10.1016/j.tibs.2009.10.006; Bosco D, 2011, J CELL MOL MED, V15, P1807, DOI 10.1111/j.1582-4934.2011.01318.x; Brown JW, 2011, NEUROIMAGE, V57, P314, DOI 10.1016/j.neuroimage.2011.04.028; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cheng LL, 1997, P NATL ACAD SCI USA, V94, P6408, DOI 10.1073/pnas.94.12.6408; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Ciccarelli O., 2014, ANN NEUROL; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Di Costanzo A, 2007, EUR RADIOL, V17, P1651, DOI 10.1007/s00330-006-0546-1; Eagle AL, 2013, BEHAV BRAIN RES, V256, P591, DOI 10.1016/j.bbr.2013.09.014; Ebrahimi F, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-89; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fan YQ, 2012, INT J BIOL MACROMOL, V51, P845, DOI 10.1016/j.ijbiomac.2012.07.026; Forster DM, 2012, NMR BIOMED, V25, P52, DOI 10.1002/nbm.1712; Goldstein LE, 1996, J NEUROSCI, V16, P4787; Groenewegen HJ, 1997, J PSYCHOPHARMACOL, V11, P99, DOI 10.1177/026988119701100202; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Holtzman D, 1997, AM J PHYSIOL-CELL PH, V272, pC1567, DOI 10.1152/ajpcell.1997.272.5.C1567; Hur YS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011973; Jenkins BG, 1999, CURR OPIN NEUROL, V12, P753, DOI 10.1097/00019052-199912000-00016; KASSER TR, 1985, AM J PHYSIOL, V248, pR453, DOI 10.1152/ajpregu.1985.248.4.R453; Kekelidze T, 2001, J NEUROSCI RES, V66, P866, DOI 10.1002/jnr.10060; Kelm MK, 2010, NEUROPHARMACOLOGY, V58, P1179, DOI 10.1016/j.neuropharm.2010.02.018; Koenigs M, 2012, REV NEUROSCIENCE, V23, P253, DOI 10.1515/revneuro-2012-0036; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi E., 2012, FRONT NEUROL, V3, P11; Lassmann H, 2011, FEBS LETT, V585, P3715, DOI 10.1016/j.febslet.2011.08.004; Li ZY, 2008, J LIPID RES, V49, P1187, DOI 10.1194/jlr.R700019-JLR200; Mamelak M, 2012, J ALZHEIMERS DIS, V31, P459, DOI 10.3233/JAD-2012-120370; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Moore Gregory J, 2002, Psychopharmacol Bull, V36, P5; Nelson TJ, 2008, EUR J PHARMACOL, V585, P76, DOI 10.1016/j.ejphar.2008.01.051; Nucci-Da-Silva MP, 2009, BRAIN INJURY, V23, P707, DOI 10.1080/02699050903123351; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Paling D, 2011, J NEUROL, V258, P2113, DOI 10.1007/s00415-011-6117-7; PASSE TJ, 1995, PROG NEURO-PSYCHOPH, V19, P541, DOI 10.1016/0278-5846(95)00101-Z; Patel AB, 2005, P NATL ACAD SCI USA, V102, P5588, DOI 10.1073/pnas.0501703102; Paxinos G, 1997, RAT BRAIN STEREOTAXI; Pocernich CB, 2012, BBA-MOL BASIS DIS, V1822, P625, DOI 10.1016/j.bbadis.2011.10.003; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Rushworth MFS, 2011, NEURON, V70, P1054, DOI 10.1016/j.neuron.2011.05.014; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Saljo A., 2009, J NEUROTRAUM, V25, P1397; Schousboe A, 2003, NEUROCHEM INT, V43, P311, DOI 10.1016/S0197-0186(03)00017-2; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Song D, 2008, PSYCHOPHARMACOLOGY, V200, P187, DOI 10.1007/s00213-008-1194-8; STRANGE K, 1994, GLIA, V12, P35, DOI 10.1002/glia.440120105; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Suzuki T, 2012, EUR J NEUROSCI, V36, P3653, DOI 10.1111/j.1460-9568.2012.08280.x; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thierry AM, 2000, HIPPOCAMPUS, V10, P411, DOI 10.1002/1098-1063(2000)10:4<411::AID-HIPO7>3.0.CO;2-A; Tuinstra HM, 2013, BIOTECHNOL BIOENG, V110, P947, DOI 10.1002/bit.24750; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Vertes RP, 2006, NEUROSCIENCE, V142, P1, DOI 10.1016/j.neuroscience.2006.06.027; Wilcox CS, 2010, PHARMACOL THERAPEUT, V126, P119, DOI 10.1016/j.pharmthera.2010.01.003; Wilson M, 2013, EUR J CANCER, V49, P457, DOI 10.1016/j.ejca.2012.09.002; Yang MX, 2012, TALANTA, V88, P136, DOI 10.1016/j.talanta.2011.10.022; Yoon SJ, 2005, CLIN REHABIL, V19, P209, DOI 10.1191/0269215505cr813oa	74	26	26	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAR	2014	59						119	126		10.1016/j.mcn.2014.02.004			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AH7TP	WOS:000336338400012	24534010				2022-02-06	
J	Singh, R; Venkateshwara, G; Nair, KPS; Khan, M; Saad, R				Singh, Rajiv; Venkateshwara, Guru; Nair, Krishnan P. S.; Khan, Muhammed; Saad, Rafat			Agitation after traumatic brain injury and predictors of outcome	BRAIN INJURY			English	Article						Agitation; CT scans; neuropsychology; outcome; traumatic brain injury	CLOSED HEAD-INJURY; AGGRESSIVE-BEHAVIOR; REHABILITATION; SEQUELAE; RESTLESSNESS; VIOLENCE; SCALE	Objectives: To measure the incidence of agitation after traumatic brain injury (TBI) in an inpatient population and to identify any features associated with an adverse outcome Design: Prospective study of TBI admissions over 30 months in consecutive admissions with TBI to a regional neurorehabilitation unit. Outcome of agitation was compared to patient, injury and treatment features and any associations were sought. The presence of agitation was measured by the Agitation Behaviour Score. A good outcome for agitation was defined as a return to independent living with minimal care requirement at 6 months using an Extended Glasgow Outcome Scale (GOSE) score > 4. Results: Over 30 months, there were 146 TBI admissions, of whom 53 cases had agitation (36.3%). Achieving 100% follow-up, 27 (51%) had a good outcome. On a multivariable logistic regression analysis, a good outcome was associated with the type of lesions seen on CT scan, the severity of agitation and the duration of the behaviour. Alcohol excess and type of treatment used for the behaviour were initially significant on univariate testing but dropped out of the logistic regression model. Conclusions: Over a third of TBI admissions, developed agitation and poor functional outcome was associated with CT scan findings, severity and duration of agitation.	[Singh, Rajiv; Venkateshwara, Guru; Nair, Krishnan P. S.; Khan, Muhammed; Saad, Rafat] No Gen Hosp, Osborn Neurorehabil Unit, Sheffield S5 7AU, S Yorkshire, England		Singh, R (corresponding author), No Gen Hosp, Osborn Neurorehabil Unit, Sheffield S5 7AU, S Yorkshire, England.	rajiv.singh@sth.nhs.uk	Nair, Krishnan/AAE-3474-2020	Nair, Krishnan/0000-0002-4004-2315; singh, rajiv/0000-0002-3173-9591			Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CASSIDY JW, 1994, J HEAD TRAUMA REHAB, V9, P43, DOI 10.1097/00001199-199409000-00005; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Fleminger S, 2003, BMJ-BRIT MED J, V327, P4, DOI 10.1136/bmj.327.7405.4; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P917, DOI 10.1016/S0003-9993(97)90050-2; GALSKI T, 1994, ARCH PHYS MED REHAB, V75, P380, DOI 10.1016/0003-9993(94)90158-9; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Maryniak O, 2001, BRAIN INJURY, V15, P167, DOI 10.1080/026990501458399; Miller L., 1990, COGN REHABIL, V8, P14; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tonkonogy J M, 1991, J Neuropsychiatry Clin Neurosci, V3, P189; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	32	26	26	1	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2014	28	3					336	340		10.3109/02699052.2013.873142			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AC0RI	WOS:000332202100011	24377492				2022-02-06	
J	Young, G; Lareau, C; Pierre, B				Young, Gerald; Lareau, Craig; Pierre, Brandon			One Quintillion Ways to Have PTSD Comorbidity: Recommendations for the Disordered DSM-5	PSYCHOLOGICAL INJURY & LAW			English	Article						PTSD; Combinations; Comorbidity; DSM-5; Forensics		Galatzer-Levy and Bryant (Perspect Psychol Sci 8: 651-662, 2013) have calculated the number of ways that Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5; American Psychiatric Association, 2013) posttraumatic stress disorder (PTSD) symptoms can be combined as over 600,000. They concluded that the amount is astounding and the category is rendered amorphous. PTSD often occurs in the context of polytrauma or comorbidity. The epidemiological literature indicates that the most common comorbid conditions in cases of PTSD include major depressive disorder (MDD), chronic pain, neurocognitive disorder due to traumatic brain injury (e.g., mild), and alcohol use disorder, with premorbid personality disorder possible, as well (which we consider as exacerbated due to the traumatic incident at issue, as in borderline personality disorder). We calculated the possible symptom combinations for each of these disorders and then in comorbid combination with PTSD (e.g., PTSD with MDD, but also when all six conditions are present). The number of symptom combinations in full polytrauma involving all six conditions listed is truly astounding, over one quintillion. Also, we reviewed the range of PTSD comorbidities, which adds to the symptom heterogeneity in cases. We make recommendations to prioritize symptoms in disorders as primary (e.g., unique, marker), secondary (e.g., core essential), and tertiary (e.g., common, cross-diagnostic). The latter tertiary type of symptoms in a disorder, if any, should be kept apart in its own criterion. This approach might help make the next version of the DSM more clinically useful both to clinicians and to court.	[Young, Gerald; Pierre, Brandon] York Univ, Glendon Coll, Toronto, ON, Canada; [Lareau, Craig] Patton State Hosp, Patton, CA USA		Young, G (corresponding author), York Univ, Glendon Coll, Toronto, ON, Canada.	gyoung@glendon.yorku.ca		Young, Gerald/0000-0002-3689-6924			American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Armour C, 2013, J ANXIETY DISORD, V27, P109, DOI 10.1016/j.janxdis.2012.10.006; Berntsen D, 2012, PSYCHOL SCI, V23, P1557, DOI 10.1177/0956797612457389; Biehn TL, 2013, PSYCHOL INJ LAW, V6, P290, DOI 10.1007/s12207-013-9177-4; Blanchard EB, 2004, BEHAV RES THER, V42, P569, DOI 10.1016/S0005-7967(03)00162-1; Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552; Borsboom D, 2008, J CLIN PSYCHOL, V64, P1089, DOI 10.1002/jclp.20503; Brewin CR, 2009, J TRAUMA STRESS, V22, P366, DOI 10.1002/jts.20443; Brown TA, 2001, J ABNORM PSYCHOL, V110, P585, DOI 10.1037//0021-843X.110.4.585; Cain F, 2013, MANY STARS ARE THERE; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; Daskalakis NP, 2013, ENDOCRIN METAB CLIN, V42, P503, DOI 10.1016/j.ecl.2013.05.004; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; Dolich M. O, 2008, MOTOR VEHICLE COLLIS, P61; Duckworth M. P., 2008, MOTOR VEHICLE COLLIS, P311; Elhai JD, 2008, DEPRESS ANXIETY, V25, P737, DOI 10.1002/da.20318; Elhai JD, 2011, J ANXIETY DISORD, V25, P340, DOI 10.1016/j.janxdis.2010.10.007; Erickson DJ, 2001, J CONSULT CLIN PSYCH, V69, P41, DOI 10.1037/0022-006X.69.1.41; Forbes D, 2005, J TRAUMA STRESS, V18, P647, DOI 10.1002/jts.20073; Forbes D, 2010, J AFFECT DISORDERS, V127, P147, DOI 10.1016/j.jad.2010.05.005; Galatzer-Levy IR, 2013, PERSPECT PSYCHOL SCI, V8, P651, DOI 10.1177/1745691613504115; Galatzer-Levy IR, 2013, DEPRESS ANXIETY, V30, P489, DOI 10.1002/da.22048; Galatzer-Levy IR, 2011, J TRAUMA STRESS, V24, P557, DOI 10.1002/jts.20684; Gibbon M., 1997, USERS GUIDE STRUCTUR; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Hamanaka S, 2006, GEN HOSP PSYCHIAT, V28, P234, DOI 10.1016/j.genhosppsych.2006.02.007; Horn CAC, 2014, PSYCHONEUROENDOCRINO, V39, P88, DOI 10.1016/j.psyneuen.2013.10.003; Hruska B., 2014, TRAUMA SUBSTANCE ABU; Hruska B, 2012, PSYCHOL ADDICT BEHAV, V26, P734, DOI 10.1037/a0027584; Hruska B, 2011, PSYCHOL ADDICT BEHAV, V25, P405, DOI 10.1037/a0022439; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; Iverson G. I., 2008, MOTOR VEHICLE COLLIS, P243; Jovanovic T, 2012, NEUROPHARMACOLOGY, V62, P695, DOI 10.1016/j.neuropharm.2011.02.023; KESSLER RC, 1994, J AFFECT DISORDERS, V30, P15, DOI 10.1016/0165-0327(94)90147-3; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Kessler RC, 2011, CURR OPIN PSYCHIATR, V24, P307, DOI 10.1097/YCO.0b013e3283477b22; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90; Kramer MD., 2014, TRAUMA SUBSTANCE ABU, V2nd, P53, DOI [10.1037/14273-004, DOI 10.1037/14273-004]; Krause ED, 2008, J TRAUMA STRESS, V21, P83, DOI 10.1002/jts.20288; Lareau C. R., 2011, COPING PSYCHIAT PSYC, P610; Lockwood E., 2014, PSYCHOL INJ IN PRESS; Lynn SJ, 2012, CURR DIR PSYCHOL SCI, V21, P48, DOI 10.1177/0963721411429457; Malta LS, 2002, J NERV MENT DIS, V190, P767, DOI 10.1097/00005053-200211000-00007; Marshall RD, 2001, AM J PSYCHIAT, V158, P1467, DOI 10.1176/appi.ajp.158.9.1467; Mayou R, 2002, PSYCHOL MED, V32, P671, DOI 10.1017/S0033291702005470; McGill University Press, 2002, WHIPLASH OTHER USEFU; McNally RJ, 2012, SCIENCE, V336, P872, DOI 10.1126/science.1222069; McNally RJ, 2009, DEPRESS ANXIETY, V26, P597, DOI 10.1002/da.20586; McNally RJ, 2003, ANNU REV PSYCHOL, V54, P229, DOI 10.1146/annurev.psych.54.101601.145112; McTeague LM, 2009, BIOL PSYCHIAT, V65, P374, DOI 10.1016/j.biopsych.2008.09.023; Milad MR, 2008, J PSYCHIATR RES, V42, P515, DOI 10.1016/j.jpsychires.2008.01.017; Miller M. W., 2012, PSYCHOL TRAUMA, DOI [10.1037/a0029730, DOI 10.1037/A0029730]; Muller M., 2014, COMPREHENSI IN PRESS; Muthen B, 2000, ALCOHOL CLIN EXP RES, V24, P882, DOI 10.1111/j.1530-0277.2000.tb02070.x; Muthen L.K., 2017, MPLUS USERS GUIDE, V8th ed.; Muthen L.K., 2012, MPLUS USERS GUIDE, V7; O'Donnell M. L., 2008, MOTOR VEHICLE COLLIS, P345; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Ouimette P., 2014, TRAUMA SUBSTANCE ABU; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Panagioti M, 2013, PSYCHIAT RES, V209, P55, DOI 10.1016/j.psychres.2013.02.018; Pietrzak RH, 2013, J AFFECT DISORDERS, V148, P123, DOI 10.1016/j.jad.2012.11.003; Pietrzak RH, 2012, J PSYCHIATR RES, V46, P317, DOI 10.1016/j.jpsychires.2011.11.013; Pole N, 2007, PSYCHOL BULL, V133, P725, DOI 10.1037/0033-2909.133.5.725; Post LM, 2011, J ANXIETY DISORD, V25, P1123, DOI 10.1016/j.janxdis.2011.08.003; Reed PL, 2007, ARCH GEN PSYCHIAT, V64, P1435, DOI 10.1001/archpsyc.64.12.1435; Regier DA, 2013, AM J PSYCHIAT, V170, P59, DOI 10.1176/appi.ajp.2012.12070999; Richmond T. S., 2008, MOTOR VEHICLE COLLIS, P83; Rytwinski NK, 2013, J TRAUMA STRESS, V26, P299, DOI 10.1002/jts.21814; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Seeley JR, 2011, J ABNORM PSYCHOL, V120, P308, DOI 10.1037/a0022621; Sequeira K. A. J, 2008, MOTOR VEHICLE COLLIS, P131; Shevlin M, 2012, J ABNORM PSYCHOL, V121, P610, DOI 10.1037/a0028591; Simms LJ, 2002, J ABNORM PSYCHOL, V111, P637, DOI 10.1037//0021-843X.111.4.637; Swendsen J, 2010, ADDICTION, V105, P1117, DOI 10.1111/j.1360-0443.2010.02902.x; Tolin DF, 2006, PSYCHOL BULL, V132, P959, DOI 10.1037/0033-2909.132.6.959; Vaidyanathan U, 2011, COMPR PSYCHIAT, V52, P527, DOI 10.1016/j.comppsych.2010.10.006; van Dokkum PG, 2010, NATURE, V468, P940, DOI 10.1038/nature09578; Wolf EJ, 2012, ARCH GEN PSYCHIAT, V69, P698, DOI 10.1001/archgenpsychiatry.2011.1574; Wolf EJ, 2010, J ABNORM PSYCHOL, V119, P320, DOI 10.1037/a0019035; Yehuda R., 2004, RISK RESILIENCE POST; Yehuda R., 2005, DISASTERS MENTAL HLT, P65; Young G, 2014, INT LIBR ETH LAW NEW, V56, P1, DOI 10.1007/978-94-007-7899-3; Young G, 2011, DEVELOPMENT AND CAUSALITY: NEO-PIAGETIAN PESPECTIVES, P1, DOI 10.1007/978-1-4419-9422-6; Young G, 2006, PSYCHOLOGICAL KNOWLEDGE IN COURT: PTSD, PAIN, AND TBI, P55, DOI 10.1007/0-387-25610-5_3; Young G., 2014, CAUSALITY NORMAL ABN; Young G, 2014, PSYCHOL INJ LAW, V7, P75, DOI 10.1007/s12207-014-9187-x; Young G, 2013, PSYCHOL INJ LAW, V6, P345, DOI 10.1007/s12207-013-9181-8; Yufik T, 2010, J ABNORM PSYCHOL, V119, P764, DOI 10.1037/a0020981; Zlotnick C, 2003, J NERV MENT DIS, V191, P706, DOI 10.1097/01.nmd.0000095122.29476.ff; Zoellner LA, 2013, PSYCHOL INJ LAW, V6, P277, DOI 10.1007/s12207-013-9175-6; Zoellner LA, 2014, DEPRESS ANXIETY, V31, P97, DOI 10.1002/da.22133	96	26	26	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1938-971X	1938-9728		PSYCHOL INJ LAW	Psychol. Inj. Law	MAR	2014	7	1					61	74		10.1007/s12207-014-9186-y			14	Psychology, Clinical	Emerging Sources Citation Index (ESCI)	Psychology	VB4IO	WOS:000415475900010					2022-02-06	
J	Zeng, S; Jiang, JX; Xu, MH; Xu, LS; Shen, GJ; Zhang, AQ; Wang, XH				Zeng, Shi; Jiang, Jian-Xin; Xu, Min-Hui; Xu, Lun-Shan; Shen, Guang-Jian; Zhang, An-Qiang; Wang, Xu-Hui			Prognostic Value of Apolipoprotein E Epsilon4 Allele in Patients with Traumatic Brain Injury: A Meta-Analysis and Meta-Regression	GENETIC TESTING AND MOLECULAR BIOMARKERS			English	Article							HEAD-INJURY; E POLYMORPHISM; ALZHEIMERS-DISEASE; UNITED-STATES; E GENOTYPE; ASSOCIATION; APOE; PROTEIN; EPIDEMIOLOGY; VOLUME	Aims: Current scientific evidence suggests that the apolipoprotein E epsilon4 (APOE4) allele may be associated with a good prognosis for patients with traumatic brain injury (TBI); however, many existing studies have yielded inconclusive results. This meta-analysis aims to obtain a more precise estimation of the association between APOE4 allele and prognosis of TBI patients.Methods: A literature search of PubMed, Embase, Web of Science, Cochrane Library, CISCOM, CINAHL, Google Scholar, CNKI and CBM databases was conducted for articles published before July 1st, 2013. Crude odds ratios (OR) with 95% confidence intervals (CI) were calculated. Results: Thirteen cohort studies were included with a total of 662 TBI patients with APOE4 (+) and 1614 TBI patients with APOE4 (-). The meta-analysis results revealed that the APOE4 allele was associated with a poor prognosis in TBI patients (OR=0.68, 95% CI: 0.48-0.96, p=0.027). Subgroup analysis by ethnicity indicated that TBI patients with APOE4 (+) had a worse prognosis than those with APOE4 (-) in Asian populations (OR=0.46, 95% CI: 0.21-0.99, p=0.046), but not in Caucasian populations (OR=0.75, 95% CI: 0.53-1.08, p=0.120). A further subgroup analysis by TBI grade showed that the APOE4 allele was associated with poor prognosis in severe TBI patients (OR=0.43, 95% CI: 0.21-0.87, p=0.020). However, there was no evidence for any association between the APOE4 allele and poor prognosis in patients with other grades of TBI (all p>0.05). Conclusion: The current meta-analysis indicates that the APOE4 allele may be associated with a poor prognosis in severe TBI patients and in Asian populations. The APOE4 allele may be used as a biomarker in predicting the prognosis of TBI patients.	[Zeng, Shi; Xu, Min-Hui; Xu, Lun-Shan; Shen, Guang-Jian; Wang, Xu-Hui] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Neurosurg, Chongqing 400042, Peoples R China; [Jiang, Jian-Xin; Zhang, An-Qiang] Third Mil Med Univ, Daping Hosp, Inst Surg Res, State Key Lab Trauma Burns & Combined Injury, Chongqing 400042, Peoples R China		Jiang, JX (corresponding author), Third Mil Med Univ, Daping Hosp, Inst Surg Res, State Key Lab Trauma Burns & Combined Injury, Branch Rd 10, Chongqing 400042, Peoples R China.	tmmu_jjx@163.com; xuminhui8@163.com			army medical science and technology major projects during the 12th Five Year Plan [AWS11J008]	We would like to acknowledge the helpful comments on this article received from our reviewers. The work is funded by the army medical science and technology major projects during the 12th Five Year Plan (AWS11J008).	Bekris LM, 2010, J GERIATR PSYCH NEUR, V23, P213, DOI 10.1177/0891988710383571; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cervantes S, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2011.05.023; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Christensen DJ, 2011, J IMMUNOL, V186, P2535, DOI 10.4049/jimmunol.1002847; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cun W, 2010, J VIROL, V84, P11532, DOI 10.1128/JVI.01021-10; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; [GU Yi 顾奕], 2007, [中国神经精神疾病杂志, Chinese Journal of Nervous and Mental Diseases], V33, P385; Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008; Hauser PS, 2011, PROG LIPID RES, V50, P62, DOI 10.1016/j.plipres.2010.09.001; Ioannidis JPA, 2008, BMJ-BRIT MED J, V336, P1413, DOI 10.1136/bmj.a117; James ML, 2009, J STROKE CEREBROVASC, V18, P144, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.012; Jiang Y, 2008, ACTA NEUROCHIR SUPPL, V105, P233; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Li FQ, 2010, J PHARMACOL EXP THER, V334, P106, DOI 10.1124/jpet.110.167882; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lo TYM, 2009, CHILD NERV SYST, V25, P47, DOI 10.1007/s00381-008-0723-4; Mahley RW, 2012, NEURON, V76, P871, DOI 10.1016/j.neuron.2012.11.020; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARTINS RN, 1995, NEUROREPORT, V6, P1513, DOI 10.1097/00001756-199507310-00012; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Maysinger D, 2008, J NEUROSCI, V28, P7891, DOI 10.1523/JNEUROSCI.1461-08.2008; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Ost M, 2008, ACTA ANAESTH SCAND, V52, P1364, DOI 10.1111/j.1399-6576.2008.01675.x; Pearson-Fuhrhop KM, 2012, CURR OPIN NEUROL, V25, P682, DOI 10.1097/WCO.0b013e32835a360a; Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sun XC, 2008, CHIN J TRAUMATOL, V11, P247, DOI 10.1016/S1008-1275(08)60051-6; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takeda M, 2010, PSYCHIAT CLIN NEUROS, V64, P592, DOI 10.1111/j.1440-1819.2010.02148.x; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Xue P, 2012, PLOS ONE, V7; Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536	50	26	27	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1945-0265	1945-0257		GENET TEST MOL BIOMA	Genet. Test. Mol. Biomark.	MAR 1	2014	18	3					202	210		10.1089/gtmb.2013.0421			9	Biochemistry & Molecular Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Genetics & Heredity	AC2HL	WOS:000332320400010	24475734				2022-02-06	
J	Andruszkow, H; Deniz, E; Urner, J; Probst, C; Grun, O; Lohse, R; Frink, M; Krettek, C; Zeckey, C; Hildebrand, F				Andruszkow, Hagen; Deniz, Ezin; Urner, Julia; Probst, Christian; Gruen, Orna; Lohse, Ralf; Frink, Michael; Krettek, Christian; Zeckey, Christian; Hildebrand, Frank			Physical and psychological long-term outcome after traumatic brain injury in children and adult patients	HEALTH AND QUALITY OF LIFE OUTCOMES			English	Article						Traumatic brain injury; Long-term outcome; Morbidity; Children	RECOVERY 10 YEARS; QUALITY-OF-LIFE; YOUNG-CHILDREN; PRACTICAL SCALE; HEAD-INJURIES; HEALTH SURVEY; EVENT SCALE; PREDICTORS; ADOLESCENTS; POLYTRAUMA	Background: Several studies have indicated that younger age is associated with worse recovery after pediatric traumatic brain injury (TBI) compared to elder children. In order to verify this association between long-term outcome after moderate to severe TBI and patient's age, direct comparison between different pediatric age groups as well as an adult population was performed. Methods: This investigation represents a retrospective cohort study at a level I trauma center including patients with moderate to severe, isolated TBI with a minimum follow-up of 10 years. According to their age at time of injury, patients were divided in pre-school (0-7 years), school (8-17 years) and adult (18-65 years) patients. Physical examination and standardized questionnaire on physical and psychological aspects (Glasgow Outcome Scale, Barthel Index, Impact of Event Scale, Hospital Anxiety and Depression Scale, short form 12) were performed. Results: 135 traumatized patients were included. Physical and psychological long-term outcome was associated with injury severity but not with patients' age at time of injury. Outcome recovery measured by Glasgow Outcome Scale was demonstrated with best results for pre-school aged children (p = 0.009). According to the Hospital Anxiety and Depression Scale an increased incidence of anxiety (p = 0.010) and depression (p = 0.026) was evaluated in older patients. Conclusion: Long-term outcome perceptions after moderate to severe TBI presented in this study question current views of deteriorated recovery for the immature brain. The sustained TBI impact seemed not to reduce the child's ability to overcome the suffered impairment measured by questionnaire based psychological, physical and health related outcome scores. These results distinguish the relevance of rehabilitation and family support in the long term.	[Andruszkow, Hagen; Hildebrand, Frank] Univ Aachen, Dept Orthopaed Trauma, D-52074 Aachen, Germany; [Probst, Christian] Univ Witten Herdecke, Sch Med, Cologne Merheim Med Ctr, Dept Trauma & Orthopaed Surg,Fac Hlth, D-51109 Cologne, Germany; [Gruen, Orna; Lohse, Ralf] Hannover Re Insurance, D-30625 Hannover, Germany; [Frink, Michael] Univ Med Ctr Marburg, Dept Trauma Hand & Reconstruct Surg, D-35043 Marburg, Germany; [Andruszkow, Hagen; Deniz, Ezin; Urner, Julia; Frink, Michael; Krettek, Christian; Zeckey, Christian] Hannover Med Sch, Trauma Dept, D-30625 Hannover, Germany		Andruszkow, H (corresponding author), Univ Aachen, Dept Orthopaed Trauma, Pauwelsstr 30, D-52074 Aachen, Germany.	handruszkow@ukaachen.de	Hildebrand, Frank/J-3176-2017	Krettek, Christian/0000-0001-9807-0020	Hannover Life Re-Insurance, Hannover, Germany	Industrial support was provided by Hannover Life Re-Insurance, Hannover, Germany. Nicola Alexander Sittaro, MD and Ralf Lohse, PhD gave advice. The Trauma Department, Hannover Medical School, Hannover, Germany, has received funding from Hannover Life Re-Insurance, Hannover, Germany, during the study period. No direct or indirect financial support or other assets were transferred to the authors of this study.	Ahmadi SA, 2010, BRAIN INJURY, V24, P1539, DOI 10.3109/02699052.2010.523049; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Andruszkow H, 2013, PATIENT SAF SURG, V7, DOI 10.1186/1754-9493-7-32; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hawley CA, 2012, NEUROREHABILITATION, V30, P173, DOI 10.3233/NRE-2012-0742; Hung MC, 2014, MED CARE, V52, P63, DOI 10.1097/MLR.0000000000000010; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1975, LANCET, V1, P480; Kramer ME, 2013, J HEAD TRAUMA REHAB, V28, P361, DOI 10.1097/HTR.0b013e31824da031; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MAHONEY F I, 1965, Md State Med J, V14, P61; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Pape HC, 2006, INJURY, V37, P1197, DOI 10.1016/j.injury.2006.07.032; Probst C, 2010, J TRAUMA, V68, P706, DOI 10.1097/TA.0b013e3181a8b21c; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Sundin EC, 2003, PSYCHOSOM MED, V65, P870, DOI 10.1097/01.PSY.0000084835.46074.F0; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Zigmond AS, 1983, PSYCHIAT SCAND, V76, P361, DOI DOI 10.1111/J.1600-0447.1983.TB09716.X; ZILBERG NJ, 1982, J CONSULT CLIN PSYCH, V50, P407, DOI 10.1037/0022-006X.50.3.407; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	43	26	26	0	19	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1477-7525			HEALTH QUAL LIFE OUT	Health Qual. Life Outcomes	FEB 26	2014	12								26	10.1186/1477-7525-12-26			8	Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services	AF8IQ	WOS:000334959600001	24571742	Green Published, gold			2022-02-06	
J	Cuthbert, JP; Staniszewski, K; Hays, K; Gerber, D; Natale, A; O'Dell, D				Cuthbert, Jeffrey P.; Staniszewski, Kristi; Hays, Kaitlin; Gerber, Don; Natale, Audrey; O'Dell, Denise			Virtual reality-based therapy for the treatment of balance deficits in patients receiving inpatient rehabilitation for traumatic brain injury	BRAIN INJURY			English	Article						Balance; BBS; brain injuries; FGA; virtual reality; Wii	EXERCISE PROGRAMS; MOTOR IMPAIRMENT; OUTCOME MEASURES; STROKE; RELIABILITY; VALIDITY; SYSTEM; SCALE; GAIT	Objective: To evaluate the feasibility and safety of utilizing a commercially available virtual reality gaming system as a treatment intervention for balance training. Design: A randomized controlled trial in which assessment and analysis were blinded. Setting: An inpatient rehabilitation facility. Intervention: Interventions included balance-based physical therapy using a Nintendo Wii, as monitored by a physical therapist, and receipt of one-on-one balance-based physical therapy using standard physical therapy modalities available for use in the therapy gym. Results: Participants in the standard physical therapy group were found to have slightly higher enjoyment at mid-intervention, while those receiving the virtual reality-based balance intervention were found to have higher enjoyment at study completion. Both groups demonstrated improved static and dynamic balance over the course of the study, with no significant differences between groups. Correlational analyses suggest a relationship exists between Wii balance board game scores and BBS scores for measures taken beyond the baseline assessment. Conclusions: This study provides a modest level of evidence to support using commercially available VR gaming systems for the treatment of balance deficits in patients with a primary diagnosis of TBI receiving inpatient rehabilitation. Additional research of these types of interventions for the treatment of balance deficits is warranted.	[Cuthbert, Jeffrey P.; Staniszewski, Kristi; Hays, Kaitlin; Gerber, Don; Natale, Audrey; O'Dell, Denise] Craig Hosp, Res Dept, Englewood, CO USA		Cuthbert, JP (corresponding author), 3425 S Clarkson St, Englewood, CO 80113 USA.	jcuthbert@Craighospital.org			Craig Hospital Foundation	This work was funded by the Craig Hospital Foundation. We certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on us or on any organization with which we are associated and we certify that all financial and material support for this research are clearly identified in the title page of the manuscript.	Adamovich SV, 2009, NEUROREHABILITATION, V25, P29, DOI 10.3233/NRE-2009-0497; BERG K, 1989, Physiotherapy Canada, V41, P304; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; Bland DC, 2011, BRAIN INJURY, V25, P664, DOI 10.3109/02699052.2011.576306; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; Cameirao MS, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-48; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Cikajlo I, 2012, DISABIL REHABIL, V34, P13, DOI 10.3109/09638288.2011.583308; English CK, 2006, CLIN REHABIL, V20, P52, DOI 10.1191/0269215506cr877oa; Feld JA, 2001, NEUROREHAB NEURAL RE, V15, P239, DOI 10.1177/154596830101500312; Flynn Sheryl, 2007, J Neurol Phys Ther, V31, P180, DOI 10.1097/NPT.0b013e31815d00d5; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Hayes KW, 2003, ARTHRIT CARE RES, V49, pS28, DOI DOI 10.1002/ART.11411; Hellweg S, 2008, BRAIN INJURY, V22, P365, DOI 10.1080/02699050801998250; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; Ivers R, 2008, INJURY PREV, V14, P209, DOI 10.1136/ip.2008.019133; KENDZIERSKI D, 1991, J SPORT EXERCISE PSY, V13, P50, DOI 10.1123/jsep.13.1.50; Kim JH, 2009, AM J PHYS MED REHAB, V88, P693, DOI 10.1097/PHM.0b013e3181b33350; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4, 10.1002/14651858.CD008349.pub2]; Liston RAL, 1996, ARCH PHYS MED REHAB, V77, P425, DOI 10.1016/S0003-9993(96)90028-3; Marshall S, 2007, BRAIN INJURY, V21, P133, DOI 10.1080/02699050701201383; Moore JB, 2009, J APPL SPORT PSYCHOL, V21, pS116, DOI 10.1080/10413200802593612; Mumford N, 2010, BRAIN INJURY, V24, P780, DOI 10.3109/02699051003652807; Raedeke T, 2003, J SPORT EXERCISE PSY, V25, pS109; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Suarez H, 2011, BRAZ J OTORHINOLAR, V77, P651, DOI 10.1590/S1808-86942011000500019; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Ustinova KI, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-61; Vos-Vromans Desiree C. W. M., 2005, Physiotherapy Theory and Practice, V21, P173, DOI 10.1080/09593980500212920; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wang CY, 2011, ARCH PHYS MED REHAB, V92, P1238, DOI 10.1016/j.apmr.2011.03.014; WATSON MJ, 2001, PHYS THER REV, V6, P233; Wood-Dauphinee SL, 2002, CANADIAN J REHABILIT, V10, P35; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Yang YR, 2008, GAIT POSTURE, V28, P201, DOI 10.1016/j.gaitpost.2007.11.007; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	43	26	30	0	44	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2014	28	2					181	188		10.3109/02699052.2013.860475			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	302XR	WOS:000330638900007	24456057				2022-02-06	
J	Marquine, MJ; Iudicello, JE; Morgan, EE; Brown, GG; Letendre, SL; Ellis, RJ; Deutsch, R; Woods, SP; Grant, I; Heaton, RK				Marquine, Maria J.; Iudicello, Jennifer E.; Morgan, Erin E.; Brown, Gregory G.; Letendre, Scott L.; Ellis, Ronald J.; Deutsch, Reena; Woods, Steven Paul; Grant, Igor; Heaton, Robert K.		TMARC Grp	"Frontal systems" behaviors in comorbid human immunodeficiency virus infection and methamphetamine dependency	PSYCHIATRY RESEARCH			English	Article						Substance abuse; HIV; Apathy; Impulsive behavior; Sensation	DIAGNOSTIC INTERVIEW CIDI; HUMAN PREFRONTAL CORTEX; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; HIV-INFECTION; SENSATION SEEKING; NEUROPSYCHOLOGICAL IMPAIRMENT; RISK BEHAVIOR; SUBSTANCE USE; IMPULSIVITY	Human immunodeficiency virus (HIV) infection and methamphetamine (MA) dependence are associated with neural injury preferentially involving frontostriatal circuits. Little is known, however, about how these commonly comorbid conditions impact behavioral presentations typically associated with frontal systems dysfunction. Our sample comprised 47 HIV-uninfected/MA-nondependent; 25 HIV-uninfected/MA-dependent; 36 HIV-infected/MA-nondependent; and 28 HIV-infected/MA-dependent subjects. Participants completed self-report measures of "frontal systems" behaviors, including impulsivity/disinhibition, sensation-seeking, and apathy. They also underwent comprehensive neurocognitive and neuropsychiatric assessments that allowed for detailed characterization of neurocognitive deficits and comorbid/premorbid conditions, including lifetime Mood and Substance Use Disorders, Attention-Deficit/Hyperactivity Disorder, and Antisocial Personality Disorder. Multivariable regression models adjusting for potential confounds (i.e., demographics and comorbid/premorbid conditions) showed that MA dependence was independently associated with increased impulsivity/disinhibition, sensation-seeking and apathy, and HIV infection with greater apathy. However, we did not see synergistic/additive effects of HIV and MA on frontal systems behaviors. Global neurocognitive impairment was relatively independent of the frontal systems behaviors, which is consistent with the view that these constructs may have relatively separable biopsychosocial underpinnings. Future research should explore whether both neurocognitive impairment and frontal systems behaviors may independently contribute to everyday functioning outcomes relevant to HIV and MA. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Marquine, Maria J.; Iudicello, Jennifer E.; Morgan, Erin E.; Brown, Gregory G.; Deutsch, Reena; Woods, Steven Paul; Grant, Igor; Heaton, Robert K.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Brown, Gregory G.] Vet Adm San Diego Healthcare Syst, San Diego, CA USA; [Letendre, Scott L.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Ellis, Ronald J.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA		Heaton, RK (corresponding author), Univ Calif San Diego, HIV Neurobehav Res Program, 220 Dickinson St,Suite B MC 8231, San Diego, CA 92103 USA.	rheaton@ucsd.edu	Ellis, Ronald/K-3543-2015	Ellis, Ronald/0000-0003-4931-752X; Woods, Steven Paul/0000-0003-0776-4233	National Institute on Drug Abuse (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P50DA026306]; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [NIDA-funded Institutional Training Grant award T32DA031098]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH062512, T32MH019934, R25MH080663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS083415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P50DA026306, K23DA037793, T32DA031098] Funding Source: NIH RePORTER	The Translational Methamphetamine AIDS Research Center (TMARC) is supported by Center award P50DA026306 from the National Institute on Drug Abuse (NIDA) and is affiliated with the University of California, San Diego (UCSD) and the Sanford-Burnham Medical Research Institute (SBMRI).; Additional support for this research was provided by the NIDA-funded Institutional Training Grant award T32DA031098, Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN).	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Archibald SL, 2012, PSYCHIAT RES-NEUROIM, V202, P46, DOI 10.1016/j.pscychresns.2012.03.006; Barclay TR, 2007, HEALTH PSYCHOL, V26, P40, DOI 10.1037/0278-6133.26.1.40; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A., 2007, IOWA GAMBLING TASK P; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Blackstone K, 2013, J ADDICT MED, V7, P255, DOI 10.1097/ADM.0b013e318293653d; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Boyle PA, 2003, AM J GERIAT PSYCHIAT, V11, P214, DOI 10.1176/appi.ajgp.11.2.214; Boyle Patricia A, 2004, Curr Psychiatry Rep, V6, P20, DOI 10.1007/s11920-004-0033-9; Brecht ML, 2004, ADDICT BEHAV, V29, P89, DOI 10.1016/S0306-4603(03)00082-0; Cadet JL, 2007, NEUROTOX RES, V12, P181, DOI 10.1007/BF03033915; Carey CL, 2006, AIDS BEHAV, V10, P185, DOI 10.1007/s10461-005-9056-4; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Castellon SA, 2006, J CLIN EXP NEUROPSYC, V28, P420, DOI 10.1080/13803390590935444; Castellon SA, 1998, J NEUROPSYCH CLIN N, V10, P320, DOI 10.1176/jnp.10.3.320; Cattie JE, 2012, J NEUROPSYCH CLIN N, V24, P331, DOI 10.1176/appi.neuropsych.11080192; Chang L, 2005, AM J PSYCHIAT, V162, P361, DOI 10.1176/appi.ajp.162.2.361; Cherner M, 2005, NEUROLOGY, V64, P1343, DOI 10.1212/01.WNL.0000158328.26897.0D; Clarke D, 2006, PERS INDIV DIFFER, V40, P5, DOI 10.1016/j.paid.2005.05.008; Freeman HD, 2010, J PERS, V78, P1497, DOI 10.1111/j.1467-6494.2010.00659.x; Gonzalez R, 2005, J INT NEUROPSYCH SOC, V11, P121, DOI 10.1017/S1355617705050186; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Heaton R K, 1995, J Int Neuropsychol Soc, V1, P231; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Heaton R. K., 2004, REVISED COMPREHENSIV; Heaton RK, 2004, J INT NEUROPSYCH SOC, V10, P317, DOI 10.1017/S1355617704102130; HEATON RK, 1994, PSYCHOSOM MED, V56, P8, DOI 10.1097/00006842-199401000-00001; Heaton RK, 2002, DEMOGRAPHIC EFFECTS; Henry BL, 2010, ADDICT BEHAV, V35, P593, DOI 10.1016/j.addbeh.2010.01.013; Horn NR, 2003, NEUROPSYCHOLOGIA, V41, P1959, DOI 10.1016/S0028-3932(03)00077-0; Jernigan TL, 2005, AM J PSYCHIAT, V162, P1461, DOI 10.1176/appi.ajp.162.8.1461; KALICHMAN SC, 1994, J PERS ASSESS, V62, P385, DOI 10.1207/s15327752jpa6203_1; KALICHMAN SC, 1995, J PERS ASSESS, V65, P586, DOI 10.1207/s15327752jpa6503_16; Kalichman SC, 1996, ARCH SEX BEHAV, V25, P141, DOI 10.1007/BF02437933; Kamat R, 2012, ARCH CLIN NEUROPSYCH, V27, P520, DOI 10.1093/arclin/acs055; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Lee B, 2009, J NEUROSCI, V29, P14734, DOI 10.1523/JNEUROSCI.3765-09.2009; Leroi I, 2011, AGE AGEING, V40, P614, DOI 10.1093/ageing/afr078; Looby A, 2007, HUM PSYCHOPHARM CLIN, V22, P167, DOI 10.1002/hup.831; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Marin RS, 1997, PSYCHIAT ANN, V27, P30, DOI 10.3928/0048-5713-19970101-08; Martin EM, 2004, J INT NEUROPSYCH SOC, V10, P931, DOI 10.1017/S1355617704107054; Martin SB, 2007, NEUROPSYCHOLOGIA, V45, P2874, DOI 10.1016/j.neuropsychologia.2007.05.009; MCNAIR DM, 1980, MANUAL PROFILE MOOD; Mikami K, 2013, AM J GERIAT PSYCHIAT, V21, P848, DOI 10.1016/j.jagp.2013.03.012; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Plankey MW, 2007, JAIDS-J ACQ IMM DEF, V45, P85, DOI 10.1097/QAI.0b013e3180417c99; Purcell DW, 2005, AIDS, V19, pS37, DOI 10.1097/01.aids.0000167350.00503.db; Rabkin JG, 2000, J NEUROPSYCH CLIN N, V12, P451, DOI 10.1176/appi.neuropsych.12.4.451; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Rippeth JD, 2004, J INT NEUROPSYCH SOC, V10, P1, DOI 10.1017/S1355617704101021; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Salo R, 2013, PSYCHIAT RES-NEUROIM, V211, P234, DOI 10.1016/j.pscychresns.2012.10.003; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Scott JC, 2007, NEUROPSYCHOL REV, V17, P275, DOI 10.1007/s11065-007-9031-0; Semple SJ, 2005, J SUBST ABUSE TREAT, V29, P85, DOI 10.1016/j.jsat.2005.05.001; Tate D, 2003, AIDS PATIENT CARE ST, V17, P115, DOI 10.1089/108729103763807936; Tekin S, 2001, AM J GERIAT PSYCHIAT, V9, P81, DOI 10.1176/appi.ajgp.9.1.81; Velligan DI, 2002, PSYCHIAT RES, V113, P227, DOI 10.1016/S0165-1781(02)00264-0; Weber E, 2012, DRUG ALCOHOL DEPEN, V125, P146, DOI 10.1016/j.drugalcdep.2012.04.002; Whiteside SP, 2003, EXP CLIN PSYCHOPHARM, V11, P210, DOI 10.1037/1064-1297.11.3.210; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME; Winhusen TM, 2013, DRUG ALCOHOL DEPEN, V127, P94, DOI 10.1016/j.drugalcdep.2012.06.017; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; Zawacki TM, 2002, J NEUROPSYCH CLIN N, V14, P296, DOI 10.1176/appi.neuropsych.14.3.296; [No title captured], DOI DOI 10.1037/H0040995	69	26	26	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	JAN 30	2014	215	1					208	216		10.1016/j.psychres.2013.11.004			9	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	AA9LF	WOS:000331414300032	24290100	Green Accepted			2022-02-06	
J	Carone, DA				Carone, Dominic A.			Young Child With Severe Brain Volume Loss Easily Passes the Word Memory Test and Medical Symptom Validity Test: Implications for Mild TBI	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort; Symptom validity testing; Malingering; Word Memory Test; Medical Symptom Validity Test	TEST-PERFORMANCE; RESPONSE BIAS; TEST-SCORES; INJURY; ADOLESCENTS; FAILURE; ADULTS; TOMM	The Word Memory Test (WMT) and Medical Symptom Validity Test (MSVT) are two commonly used free-standing measures of test-taking effort. The use of any test as a measure of effort is enhanced when evidence shows that it can be easily passed by patients with severe neurological conditions. The opportunity arose to administer the WMT and MSVT to a 9-year-old girl (referred to as CJ) with severe congenital bilateral brain tissue loss (shown via a compelling brain MRI image), chronic epilepsy, an extremely low Full Scale IQ, extremely low adaptive functioning, developmental delays, numerous severe cognitive impairments, and treatment with multiple high-dose benzodiazepines. She received extensive early intervention services and numerous academic accommodations. Despite this set of problems, CJ passed the WMT and MSVT at perfect to near perfect levels. Implications for failure on these tests among patients with known or alleged mild traumatic brain injury are discussed.	[Carone, Dominic A.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA		Carone, DA (corresponding author), 505 Irving Ave,Room 2012, Syracuse, NY USA.	caroned@upstate.edu					Adams W., 2005, WIDE RANGE ASSESSMEN; An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Beery K., 2010, BEERY BUKTENICA DEV; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benton A., 1994, CONTRIBUTIONS NEUROP; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Carone D. A., 2009, APPL NEUROPSYCHOLOGY, V16; Carone D. A., APPL NEUROP IN PRESS; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Chafetz MD, 2012, CLIN NEUROPSYCHOL, V26, P1358, DOI 10.1080/13854046.2012.730674; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Delis DC., 2001, DELIS KAPLAN EXECUTI; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Donders J, 2007, BRAIN INJURY, V21, P319, DOI 10.1080/02699050701253129; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Goodrich-Hunsaker NJ, 2009, NEUROPSYCHOLOGY, V23, P529, DOI 10.1037/a0015444; Graver C.J, 2012, MIL MED, V176, P1426; Graver CJ, 2012, MIL MED, V177, pVII; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P, 2004, GREENS MED SYMPTOM V; Green P, 2012, DETECTION OF MALINGERING DURING HEAD INJURY LITIGATION, SECOND EDITION, P201, DOI 10.1007/978-1-4614-0442-2_6; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Harrison P. L., 2003, ADAPATIVE BEHAV ASSE; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Howe L, 2009, CLIN NEUROPSYCHOL, V23, P329, DOI 10.1080/13854040801945060; Kaplan E., 2001, BOSTON NAMING TEST; Kemp, 1998, NEPSY DEV NEUROPSYCH; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Larochette AC, 2012, APPL NEUROPSYCH-CHIL, V1, P38, DOI 10.1080/21622965.2012.665777; Loring DW, 2011, CLIN NEUROPSYCHOL, V25, P799, DOI 10.1080/13854046.2011.583279; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; Meyers JE, 1996, REY COMPLEX FIGURE S; Reitan RM, 2000, ARCH CLIN NEUROPSYCH, V15, P433, DOI 10.1016/S0887-6177(99)00038-4; Rienstra A, 2009, ARCH CLIN NEUROPSYCH, V24, P255, DOI 10.1093/arclin/acp035; Rienstra A, 2013, ARCH CLIN NEUROPSYCH, V28, P463, DOI 10.1093/arclin/act026; Rohling M. L., 2013, 53 ANN C AM SOC CLIN; Rohling M. L., 2011, CLIN NEUROPSYCHOL, V25, P1; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sheslow DA, 2003, WIDE RANGE ASSESSMEN; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler D., 2003, WISC 4 TECHNICAL INT; Wechsler D, 2011, WASI 2 WECHSLER ABBR; Wilkinson GaryS, 2006, WRAT4 WIDE RANGE ACH; Williamson DJ, 2012, CLIN NEUROPSYCHOL, V26, P588, DOI 10.1080/13854046.2012.670266; Willis PF, 2011, MIL MED, V176, P1426, DOI 10.7205/MILMED-D-11-00168; Woodcock R. W., 2001, WOODCOCKJOHNSON 3 TE; [No title captured]	60	26	26	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2014	28	1					146	162		10.1080/13854046.2013.861019			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AA0AF	WOS:000330756800010	24266623				2022-02-06	
J	Chen, SH; Wang, JJ; Chen, CH; Chang, HK; Lin, MT; Chang, FM; Chio, CC				Chen, Sheng-Hsien; Wang, Jhi-Joung; Chen, Chung-Hwan; Chang, Hsiu-Kang; Lin, Mao-Tsun; Chang, Fong-Ming; Chio, Chung-Ching			Umbilical Cord Blood-Derived CD34(+) Cells Improve Outcomes of Traumatic Brain Injury in Rats by Stimulating Angiogenesis and Neurogenesis	CELL TRANSPLANTATION			English	Article						Traumatic brain injury; CD34(+) cells; Apoptosis; Cytokines; Angiogenesis; Neurogenesis; Progenitor cells	MARROW STROMAL CELLS; MESENCHYMAL STEM-CELLS; INTESTINAL ISCHEMIA-REPERFUSION; HYPERBARIC-OXYGEN THERAPY; EXCITATORY AMINO-ACIDS; EXPERIMENTAL HEATSTROKE; NEUROTROPHIC FACTORS; CEREBRAL-ISCHEMIA; PROGENITOR CELLS; HEAD-INJURY	Human umbilical cord blood cells (HUCBCs) have been shown to be beneficial in reducing neurological deficits in rats with brain fluid percussion injury (FPI). This study aimed to assess the basic mechanisms underlying the neuroprotective effects of HUCBC-derived cluster of differentiation 34-positive (CD34(+)) cells. Rats were divided into three major groups: (i) sham-operated controls; (ii) FPI rats treated with phosphate-buffered saline (PBS); (iii) FPI rats treated with 0.2%, 50%, or 95% CD34(+) cells (in 5 x 10(5) cord blood lymphocytes and monocytes). Intravenous (IV) administration of 0.3 ml of PBS, 0.2% CD34(+) cells, 50% CD34(+) cells, or 95% CD34(+) cells was conducted immediately after FPI. It was found that 4 days post-FPI, CD34(+) cells could be detected in the ischemic brain tissues for 50% CD34(+) cell- or 95% CD34(+) cell-treated FPI rats, but not for the PBS-treated FPI rats or the 0.2% CD34(+) cell-treated FPI rats. CD34(+) cell (0.2%)-treated FPI rats or PBS-treated FPI rats displayed neurological and motor deficits, cerebral contusion and apoptosis [e.g., increased numbers of both TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling)-positive cells and caspase-3-positive cells], and activated inflammation (e.g., increased serum levels of tumor necrosis factor-alpha). FPI-induced neurological motor dysfunction, cerebral contusion and apoptosis, and activated inflammation could be attenuated by 50% CD34(+) or 95% CD34(+) cell therapy. In addition 50% or 95% CD34(+) cell therapy but not PBS or 0.2% CD34(+) cell therapy significantly promoted angiogenesis (e.g., increased numbers of both vasculoendothelial growth factor-positive cells and 5-bromodeoxyuridine (BrdU)-endothelial double-positive cells), neurogenesis (e.g., increased numbers of both glial cell line-derived neurotrophic factor-positive cells and BrdU/neuronal nuclei double-positive cells) in the ischemic brain after FPI, and migration of endothelial progenitor cells from the bone marrow. Our data suggest that IV administration of HUCBC-derived CD34(+) cells may improve outcomes of FPI in rats by stimulating both angiogenesis and neurogenesis.	[Chen, Sheng-Hsien] Da An Hosp Women & Children, Tainan, Taiwan; [Chen, Sheng-Hsien] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Wang, Jhi-Joung; Lin, Mao-Tsun] Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan; [Chen, Chung-Hwan] Kaohsiung Med Univ, Dept Orthoped, Kaohsiung, Taiwan; [Chang, Hsiu-Kang] Hlth Banks Biotech Co Ltd, Stem Cell Res Ctr, Taipei, Taiwan; [Chang, Fong-Ming] Natl Cheng Kung Univ, Sch Med, Dept Obstet & Gynecol, Tainan 70101, Taiwan; [Chio, Chung-Ching] Chi Mei Med Ctr, Dept Surg, Tainan 710, Taiwan		Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan.	891201@mail.chimei.org.tw	Chen, Chung-Hwan/D-4036-2009	Chen, Chung-Hwan/0000-0001-8941-4792	National Science Council of the Republic of ChinaMinistry of Science and Technology, Taiwan [NSC100-2314-B-218-001, NSC 102-2314-B-218-001-MY2, NSC99-2314-B-218-006-MY2]; Department of Health of the Republic of China (Center of Excellence for Clinical Trial and Research in Neuroscience) [DOH99-TD-B-111-003]	This study was funded in part by the National Science Council of the Republic of China (Grant Nos. NSC100-2314-B-218-001, NSC 102-2314-B-218-001-MY2, and NSC99-2314-B-218-006-MY2) and the Department of Health of the Republic of China (DOH99-TD-B-111-003, Center of Excellence for Clinical Trial and Research in Neuroscience). The authors declare no conflict of interest.	BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen SH, 2005, CRIT CARE MED, V33, P1377, DOI 10.1097/01.CCM.0000165966.28936.89; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Cheng BC, 2007, NEUROPHARMACOLOGY, V52, P297, DOI 10.1016/j.neuropharm.2006.07.033; Chio C.C., 2012, SCIENCE S, V338, P1485; Chio C.C., 2012, SCIENCE S, V338, P59; Chou YT, 2003, SHOCK, V19, P388, DOI 10.1097/00024382-200304000-00016; Dennis JE, 2002, STEM CELLS, V20, P205, DOI 10.1634/stemcells.20-3-205; DRAGO J, 1991, P NATL ACAD SCI USA, V88, P2199, DOI 10.1073/pnas.88.6.2199; Elfenbein GJ, 2004, EXP HEMATOL, V32, P327, DOI 10.1016/j.exphem.2004.01.010; Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Galvin-Parton PA, 2003, PEDIATR TRANSPLANT, V7, P83, DOI 10.1034/j.1399-3046.2003.00032.x; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Ha Y, 2001, NEUROREPORT, V12, P3523, DOI 10.1097/00001756-200111160-00030; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kuo JR, 2010, J TRAUMA, V69, P1467, DOI 10.1097/TA.0b013e3181f31b06; Kuzu MA, 2002, AM J SURG, V183, P70, DOI 10.1016/S0002-9610(01)00846-7; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li Y, 2000, J HEMATOTH STEM CELL, V9, P445, DOI 10.1089/152581600419107; Lian QZ, 2010, CIRCULATION, V121, P1113, DOI 10.1161/CIRCULATIONAHA.109.898312; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Liu WS, 2009, PEDIATR NEONATOL, V50, P208, DOI 10.1016/S1875-9572(09)60065-6; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Murasawa S, 2005, PHYSIOLOGY, V20, P36, DOI 10.1152/physiol.00033.2004; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Olanders K, 2002, SHOCK, V18, P86, DOI 10.1097/00024382-200207000-00016; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Quinones-Hinojosa A, 2006, J COMP NEUROL, V494, P415, DOI 10.1002/cne.20798; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Saporta S, 2003, J HEMATOTH STEM CELL, V12, P271, DOI 10.1089/152581603322023007; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shyu WC, 2006, J NEUROSCI, V26, P3444, DOI 10.1523/JNEUROSCI.5165-05.2006; Staimirovic D., 2000, BRAIN PATHOL, V10, P113; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Walczak P, 2004, J NEUROSCI RES, V76, P244, DOI 10.1002/jnr.20042; Wang Y, 1997, J NEUROSCI, V17, P4341; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Wu JY, 2008, J PINEAL RES, V45, P106, DOI 10.1111/j.1600-079X.2008.00567.x; Wyble CW, 1996, J SURG RES, V63, P333, DOI 10.1006/jsre.1996.0271; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yunoki M, 1998, ACT NEUR S, V71, P142; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	75	26	26	0	9	COGNIZANT COMMUNICATION CORP	PUTNAM VALLEY	18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2014	23	8					959	979		10.3727/096368913X667006			21	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine; Transplantation	AN7YB	WOS:000340815800004	23582375	Bronze			2022-02-06	
J	Choi, BY; Kim, JH; Kim, HJ; Lee, BE; Kim, IY; Sohn, M; Suh, SW				Choi, Bo Young; Kim, Jin Hee; Kim, Hyun Jung; Lee, Bo Eun; Kim, In Yeol; Sohn, Min; Suh, Sang Won			Zinc chelation reduces traumatic brain injury-induced neurogenesis in the subgranular zone of the hippocampal dentate gyrus	JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY			English	Article; Proceedings Paper	10th Meeting of the International-Society-for-Trace-Element-Research-in-Humans (ISTERH)10th International Society for Trace Element Research in Humans (ISTERH)	NOV 18-22, 2013NOV 18-22, 2013	Tokyo, JAPANTokyo, JAPAN	Int Soc Trace Element Res Humans		Traumatic brain injury; Zinc; Hippocampus; Neurogenesis; Clioquinol	HYPOGLYCEMIC NEURONAL DEATH; GENERATED GRANULE CELLS; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; CORTICAL NEUROGENESIS; CEREBRAL-ISCHEMIA; CHELATABLE ZINC; MEMORY DEFICITS; MICE; PROLIFERATION	Numerous studies have demonstrated that traumatic brain injury (TBI) increases hippocampal neurogenesis in the rodent brain. However, the mechanisms underlying increased neurogenesis after TBI remain unknown. Continuous neurogenesis occurs in the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG) in the adult brain. The mechanism that maintains active neurogenesis in the hippocampal area is not known. A high level of vesicular zinc is localized in the presynaptic terminals of the SGZ (mossy fiber). The mossy fiber of dentate granular cells contains high levels of chelatable zinc in their terminal vesicles, which can be released into the extracellular space during neuronal activity. Previously, our lab presented findings indicating that a possible correlation may exist between synaptic zinc localization and high rates of neurogenesis in this area after hypoglycemia or epilepsy. Using a weight drop animal model to mimic human TBI, we tested our hypothesis that zinc plays a key role in modulating hippocampal neurogenesis after TBI. Thus, we injected a zinc chelator, clioquinol (CQ 30 mg/kg), into the intraperitoneal space to reduce brain zinc availability twice per day for 1 week. Neuronal death was evaluated with Fluoro Jade-B and NeuN staining to determine whether CQ has neuroprotective effects after TBI. The number of degenerating neurons (FJB (+)) and live neurons (NeuN (+)) was similar in vehicle and in CQ-treated rats at 1 week after TBI. Neurogenesis was evaluated using BrdU, Ki67 and doublecortin (DCX) immunostaining 1 week after TBI. The number of BrdU, Ki67 and DCX positive cell was increased after TBI. However, the number of BrdU, Ki67 and DCX positive cells was significantly decreased by CQ treatment. The present study shows that zinc chelation did not prevent neurodegeneration but did reduce TBI-induced progenitor cell proliferation and neurogenesis. Therefore, this study suggests that zinc has an essential role for modulating hippocampal neurogenesis after TBI. (C) 2014 Elsevier GmbH. All rights reserved.	[Choi, Bo Young; Kim, Jin Hee; Kim, Hyun Jung; Lee, Bo Eun; Kim, In Yeol; Suh, Sang Won] Hallym Univ, Dept Physiol, Coll Med, Chunchon, South Korea; [Sohn, Min] Inha Univ, Dept Nursing, Inchon, South Korea		Suh, SW (corresponding author), Hallym Univ, Dept Physiol, Coll Med, Chunchon, South Korea.	swsuh@hallym.ac.kr		Choi, Bo Young/0000-0002-9579-3503; SOHN, MIN/0000-0003-4021-2051	National Research Foundation of Korea (NRF) - Korea government (MEST)Ministry of Education, Science and Technology, Republic of KoreaNational Research Foundation of KoreaKorean Government [2012R1A2A2A01040132]; Hallym University Specialization Fund [HRF-S-51]	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (2012R1A2A2A01040132) and by Hallym University Specialization Fund (HRF-S-51). The authors thank Aaron M. Hamby, University of California, Berkeley, for help with preparing the manuscript.	Aballay A, 1995, BIOCHEM J, V312, P919, DOI 10.1042/bj3120919; Adlard PA, 2010, J NEUROSCI, V30, P1631, DOI 10.1523/JNEUROSCI.5255-09.2010; Adlard Paul Anthony, 2012, Front Psychiatry, V3, P15, DOI 10.3389/fpsyt.2012.00015; APOSHIAN HV, 1995, TOXICOLOGY, V97, P23, DOI 10.1016/0300-483X(95)02965-B; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colvin RA, 2008, AM J PHYSIOL-CELL PH, V294, pC726, DOI 10.1152/ajpcell.00541.2007; DANSCHER G, 1985, J HISTOCHEM CYTOCHEM, V33, P706, DOI 10.1177/33.7.4008918; DVERGSTEN CL, 1983, BRAIN RES, V271, P217, DOI 10.1016/0006-8993(83)90284-6; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; GOLUB MS, 1994, AM J CLIN NUTR, V60, P238, DOI 10.1093/ajcn/60.2.238; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; HALAS ES, 1983, PHYSIOL BEHAV, V30, P371, DOI 10.1016/0031-9384(83)90140-3; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jo SM, 2000, BRAIN RES, V870, P163, DOI 10.1016/S0006-8993(00)02418-5; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048543; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153; MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Maret W, 2006, J TRACE ELEM MED BIO, V20, P3, DOI 10.1016/j.jtemb.2006.01.006; Markakis EA, 1999, J COMP NEUROL, V406, P449; Martel G, 2011, BEHAV BRAIN RES, V223, P233, DOI 10.1016/j.bbr.2011.04.020; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Nitzan YB, 2003, J MOL MED-JMM, V81, P637, DOI 10.1007/s00109-003-0462-7; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PRASAD AS, 1963, AM J CLIN NUTR, V12, P437, DOI 10.1093/ajcn/12.6.437; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sandstead HH, 2000, J NUTR, V130, p496S, DOI 10.1093/jn/130.2.496S; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SEKI T, 1993, J NEUROSCI, V13, P2351, DOI 10.1523/JNEUROSCI.13-06-02351.1993; Sindreu C, 2011, P NATL ACAD SCI USA, V108, P3366, DOI 10.1073/pnas.1019166108; STEWART GR, 1984, BRAIN RES, V290, P43, DOI 10.1016/0006-8993(84)90734-0; Suh SW, 2007, GLIA, V55, P1280, DOI 10.1002/glia.20440; Suh SW, 2009, J CEREBR BLOOD F MET, V29, P1579, DOI 10.1038/jcbfm.2009.80; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2005, DIABETES, V54, P500, DOI 10.2337/diabetes.54.2.500; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2003, J NEUROSCI, V23, P10681; Suh SW, 1999, J HISTOCHEM CYTOCHEM, V47, P969, DOI 10.1177/002215549904700715; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	59	26	26	0	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0946-672X			J TRACE ELEM MED BIO	J. Trace Elem. Med. Biol.		2014	28	4			SI		474	481		10.1016/j.jtemb.2014.07.007			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AX8AW	WOS:000347133800024	25200616				2022-02-06	
J	Douglas-Escobar, MV; Heaton, SC; Bennett, J; Young, LJ; Glushakova, O; Xu, XH; Barbeau, DY; Rossignol, C; Miller, C; Crow, AMO; Hayes, RL; Weiss, MD				Douglas-Escobar, Martha V.; Heaton, Shelley C.; Bennett, Jeffrey; Young, Linda J.; Glushakova, Olena; Xu, Xiaohui; Barbeau, Daphna Yasova; Rossignol, Candice; Miller, Cindy; Crow, Alissa M. Old; Hayes, Ronald L.; Weiss, Michael D.			UCH-L1 and GFAP serum levels in neonates with hypoxic-ischemic encephalopathy: a single center pilot study	FRONTIERS IN NEUROLOGY			English	Article						biomarkers; HIE; UCH-L1; GFAP	TRAUMATIC BRAIN-INJURY; C-TERMINAL HYDROLASE-L1; WHOLE-BODY HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; PERINATAL ASPHYXIA; BIOMARKERS; BLOOD; ELECTROENCEPHALOGRAM; PREDICTION; OUTCOMES	Objective: We examined two potential biomarkers of brain damage in hypoxic ischemic encephalopathy (HIE) neonates: glial fibrillary acidic protein (GFAP; a marker of gliosis) and ubiquitin C-terminal hydrolase L1 (UCH-L1; a marker of neuronal injury). We hypothesized that the biomarkers would be measurable in cord blood of healthy neonates and could serve as a normative reference for brain injury in HIE infants. We further hypothesized that higher levels would be detected in serum samples of HIE neonates and would correlate with brain damage on magnetic resonance imaging (MRI) and later developmental outcomes.? Study Design: Serum UCH-L1 and GFAP concentrations from HIE neonates (n=16) were compared to controls (n=11). The relationship between biomarker concentrations of HIE neonates and brain damage (MRI) and developmental outcomes (Bayley-III) was examined using Pearson correlation coefficients and a mixed model design. Result: Both biomarkers were detectable in cord blood from control subjects. UCH-L1 concentrations were higher in HIE neonates (p < 0.001), and associated with cortical injury (p < 0.055) and later motor and cognitive developmental outcomes (p < 0.05). The temporal change in GFAP concentrations during (from birth to 96 h of age) predicted motor developmental outcomes (p < 0.05) and injury to the basal ganglia and white matter. Conclusion: Ubiquitin C-terminal hydrolase L1 and GFAP should be explored further as promising serum biomarkers of brain damage and later neurodevelopmental outcomes in neonates with HIE.	[Douglas-Escobar, Martha V.; Barbeau, Daphna Yasova; Rossignol, Candice; Miller, Cindy; Weiss, Michael D.] Univ Florida, Dept Pediat, Gainesville, FL USA; [Douglas-Escobar, Martha V.] Univ Calif San Francisco, Dept Pediat, 505 Parnassus Ave,Moffitt Room M 680, San Francisco, CA 94143 USA; [Heaton, Shelley C.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Bennett, Jeffrey; Crow, Alissa M. Old] Univ Florida, Dept Radiol, Gainesville, FL 32610 USA; [Young, Linda J.] Univ Florida, Dept Stat, Gainesville, FL 32611 USA; [Glushakova, Olena; Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Xu, Xiaohui] Univ Florida, Dept Biostat, Gainesville, FL USA		Douglas-Escobar, MV (corresponding author), Univ Calif San Francisco, Dept Pediat, 505 Parnassus Ave,Moffitt Room M 680, San Francisco, CA 94143 USA.	martha.douglas-escobar@ucsf.edu	Glushakova, Olena/AAY-1130-2021; Xu, Xiaohui/H-5397-2019	Glushakova, Olena/0000-0002-2109-3651; Xu, Xiaohui/0000-0001-7269-4089; Young, Linda/0000-0002-3541-4313			Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Barkovich AJ, 1998, AM J NEURORADIOL, V19, P143; Bayley N., 2006, BAYLEY SCALES INFANT; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Boichot C, 2006, RADIOLOGY, V239, P839, DOI 10.1148/radiol.2393050027; Bonifacio SL, 2011, NAT REV NEUROL, V7, P485, DOI 10.1038/nrneurol.2011.119; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Chalak LF, 2014, J PEDIATR-US, V164, P468, DOI 10.1016/j.jpeds.2013.10.067; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Day INM, 2010, PROG NEUROBIOL, V90, P327, DOI 10.1016/j.pneurobio.2009.10.020; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Douglas-Escobar M, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00185; Douglas-Escobar Martha, 2012, Front Neurol, V3, P144, DOI 10.3389/fneur.2012.00144; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Ennen CS, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.025; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; Garfinkle J, 2013, EUR J PAEDIATR NEURO, V17, P492, DOI 10.1016/j.ejpn.2013.03.006; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; Gunn AJ, 2008, J PEDIATR-US, V152, P55, DOI 10.1016/j.jpeds.2007.06.003; Jouvet P, 1999, AM J NEURORADIOL, V20, P1343; Kumar A, 2008, PEDIATRICS, V122, pE722, DOI 10.1542/peds.2008-0269; Leijser LM, 2007, NEUROPEDIATRICS, V38, P219, DOI 10.1055/s-2007-992815; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Low JA, 1997, AM J OBSTET GYNECOL, V177, P1391, DOI 10.1016/S0002-9378(97)70080-2; MACDONALD HM, 1980, J PEDIATR-US, V96, P898, DOI 10.1016/S0022-3476(80)80574-9; Massaro AN, 2013, PEDIATR CRIT CARE ME, V14, P310, DOI 10.1097/PCC.0b013e3182720642; Mondello S, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-85; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; ROBERTSON CMT, 1989, J PEDIATR-US, V114, P753, DOI 10.1016/S0022-3476(89)80132-5; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Tagin MA, 2012, ARCH PEDIAT ADOL MED, V166, P558, DOI 10.1001/archpediatrics.2011.1772; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Thoresen M, 2010, PEDIATRICS, V126, pE131, DOI 10.1542/peds.2009-2938; van Laerhoven H, 2013, PEDIATRICS, V131, P88, DOI 10.1542/peds.2012-1297; Vannucci R.C, 1997, NEONATAL PERINATAL M, P856; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873	43	26	30	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								273	10.3389/fneur.2014.00273			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QW	WOS:000209629300256	25566179	gold, Green Published			2022-02-06	
J	Escribano, BM; Colin-Gonzalez, AL; Santamaria, A; Tunez, I				Escribano, Begona M.; Colin-Gonzalez, Ana L.; Santamaria, Abel; Tunez, Isaac			The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Huntington's disease; melatonin; multiple sclerosis; neurodegeneration; neuroprotection; oxidative stress; stroke	NITRIC-OXIDE SYNTHASE; ERYTHROID 2-RELATED FACTOR-2; CONCUSSIVE BRAIN-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; FREQUENCY ELECTROMAGNETIC-FIELDS; ACID-INDUCED NEUROTOXICITY; COLLAGEN-INDUCED ARTHRITIS; MESSENGER-RNA EXPRESSION; PINEAL HORMONE MELATONIN; TRANSGENIC MOUSE MODEL	Melatonin is produced and released by the pineal gland in a circadian rhythm. This neurohormone has proven to be an antioxidant and anti-inflammatory molecule able to reduce or mitigate cell damage associated with oxidative stress and inflammation, and this phenomenon underlies neurodegenerative disorders. These facts have drawn attention to this indole, triggering interest in evaluating its changes and in its relationship to the processes indicated, and analyzing its role in the mechanisms involved at the onset and development of neurodegenerative diseases, as well as its therapeutic potential. Multiple sclerosis, the most common cause of non-traumatic disability in young adults, is a chronic neuroinflammatory disease, characterized by demyelination, inflammation, and neuronal and oxidative damage. In its early diagnosis, it often requires a differential screening with other neurodegenerative diseases with similar symptoms, such as Huntington's disease, an autosomal dominant disorder. The onset of both diseases occurs in the second or third decade of life. On the other hand, cerebral ischemia is a major cause of human disability all over the world. Although a cerebral stroke can occur as the result of different damaging insults, severe ischemia produces the death of neuronal cells within minutes. Changes in melatonin levels have been observed in these processes (Huntington's disease, multiple sclerosis and cerebral ischemia) as part of their pathogenic features. This review aims to update and discuss the role played by melatonin during neurodegenerative processes, specifically in multiple sclerosis, Huntington's disease, and cerebral ischemia, and its possible therapeutic use. We also provide readers with an update on the many neuroprotective mechanisms exerted by this neurohormone in the Central Nervous System.	[Escribano, Begona M.] Univ Cordoba, Fac Vet Med, Dept Cell Biol Physiol & Immunol, E-14071 Cordoba, Spain; [Colin-Gonzalez, Ana L.; Santamaria, Abel] Natl Inst Neurol & Neurosurg Manuel Velasco Suare, Excitatory Aminoacids Lab, Mexico City, DF, Mexico; [Tunez, Isaac] Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Inst Res Biomed Cordoba IMIBIC, Dept Biochem & Mol Biol,Fac Med, Cordoba 14004, Spain		Tunez, I (corresponding author), Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Inst Res Biomed Cordoba IMIBIC, Dept Biochem & Mol Biol,Fac Med, Ave Menendez Pidal S-N, Cordoba 14004, Spain.	fm2tufii@uco.es		Escribano Duran, Begona/0000-0002-0966-0641			Acuna-Castroviejo D, 2003, ADV EXP MED BIOL, V527, P549; Ahmad A, 2011, BIOL TRACE ELEM RES, V139, P81, DOI 10.1007/s12011-010-8643-z; Akpmar Z, 2008, PSYCHIAT RES, V161, P253, DOI 10.1016/j.psychres.2007.11.022; Al-Ghoul WM, 1998, NEUROREPORT, V9, P4063, DOI 10.1097/00001756-199812210-00011; Alders J, 2009, J NEUROPSYCH CLIN N, V21, P226, DOI 10.1176/appi.neuropsych.21.2.226; Alexiuk NAM, 2007, J NEURAL TRANSM, V114, P549, DOI 10.1007/s00702-006-0582-7; Alonso-Alconada D, 2012, HISTOL HISTOPATHOL, V27, P771, DOI 10.14670/HH-27.771; Anderson G, 2011, EUR J NEUROL, V18, P680, DOI 10.1111/j.1468-1331.2010.03257.x; Arendt J., 1995, MELATONIN MAMMALIAN; Arnulf I, 2008, ARCH NEUROL-CHICAGO, V65, P482, DOI 10.1001/archneur.65.4.482; Asayama Kentaro, 2003, Journal of Nippon Medical School, V70, P334; Aziz NA, 2009, J NEUROL, V256, P1961, DOI 10.1007/s00415-009-5196-1; Back T, 1998, CELL MOL NEUROBIOL, V18, P621, DOI 10.1023/A:1020265701407; Bahamonde C, 2014, EUR J PHARMACOL, V730, P26, DOI 10.1016/j.ejphar.2014.02.020; Balduini W, 2012, J MATERN-FETAL NEO M, V25, P119, DOI 10.3109/14767058.2012.663232; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; Beal MF, 2011, AMINO ACIDS, V40, P1305, DOI 10.1007/s00726-011-0851-0; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Behan WMH, 1999, BRIT J PHARMACOL, V128, P1754, DOI 10.1038/sj.bjp.0702940; Benitez-King G, 2006, J PINEAL RES, V40, P1, DOI 10.1111/j.1600-079X.2005.00282.x; Benitez-King G, 2010, EUR J PHARMACOL, V644, P24, DOI 10.1016/j.ejphar.2010.06.057; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; Bilici D, 2002, PHARMACOL RES, V46, P133, DOI 10.1016/S1043-6618(02)00089-0; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Braunwald E, 2008, HARRISONS PRINCIPLES, VII, P2611; Brown EN, 1997, AM J PHYSIOL-ENDOC M, V272, pE506, DOI 10.1152/ajpendo.1997.272.3.E506; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; CAINE ED, 1986, ARCH NEUROL-CHICAGO, V43, P249, DOI 10.1001/archneur.1986.00520030039009; Calabresi PA, 2004, AM FAM PHYSICIAN, V70, P1935; Carampin P, 2003, J PINEAL RES, V34, P134, DOI 10.1034/j.1600-079X.2003.00020.x; Cardinali DP, 2013, HORM BEHAV, V63, P322, DOI 10.1016/j.yhbeh.2012.02.020; Cardinali DP, 2002, NEUROENDOCRINOL LETT, V23, P20; Carpentieri A, 2012, PHARMACOL RES, V65, P437, DOI 10.1016/j.phrs.2012.01.003; Carrillo-Vico A, 2005, J PINEAL RES, V39, P400, DOI 10.1111/j.1600-079X.2005.00265.x; Carrillo-Vico A, 2005, J CLIN ENDOCR METAB, V90, P992, DOI 10.1210/jc.2004-1429; Carrillo-Vico A, 2005, ENDOCRINE, V27, P189, DOI 10.1385/ENDO:27:2:189; Chahbouni M, 2010, J PINEAL RES, V48, P282, DOI 10.1111/j.1600-079X.2010.00752.x; Chang CF, 2012, J PINEAL RES, V52, P312, DOI 10.1111/j.1600-079X.2011.00945.x; Chen HY, 2009, J PINEAL RES, V47, P260, DOI 10.1111/j.1600-079X.2009.00709.x; Chern CM, 2012, FREE RADICAL BIO MED, V52, P1634, DOI 10.1016/j.freeradbiomed.2012.01.030; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOI DW, 1987, J NEUROSCI, V7, P357; Comai S, 2013, J PSYCHIATR NEUROSCI, V38; Constantinescu CS, 1997, PATHOBIOLOGY, V65, P190, DOI 10.1159/000164122; CONSTANTINESCU CS, 1995, MED HYPOTHESES, V45, P455, DOI 10.1016/0306-9877(95)90220-1; Costa EJX, 1997, FEBS LETT, V416, P103, DOI 10.1016/S0014-5793(97)01178-2; Costantino G, 1998, EUR J PHARMACOL, V363, P57, DOI 10.1016/S0014-2999(98)00673-6; Coto-Montes A, 2012, MOL CELL ENDOCRINOL, V361, P12, DOI 10.1016/j.mce.2012.04.009; Cree BAC, 2007, CURRENT DIAGNOSIS TR; Crespo E, 1999, FASEB J, V13, P1537, DOI 10.1096/fasebj.13.12.1537; Crespo I, 2010, J PINEAL RES, V49, P193, DOI 10.1111/j.1600-079X.2010.00787.x; Cuesta M, 2014, NEUROBIOL DIS, V63, P85, DOI 10.1016/j.nbd.2013.11.008; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; Dai J, 2002, J PINEAL RES, V32, P112, DOI 10.1034/j.1600-079x.2002.1844.x; Dardiotis E, 2013, NEUROSCI LETT, V548, P170, DOI 10.1016/j.neulet.2013.05.058; Das A, 2013, J PINEAL RES, V54, P58, DOI 10.1111/j.1600-079X.2012.01022.x; de Lago E, 2006, EUR NEUROPSYCHOPHARM, V16, P7, DOI 10.1016/j.euroneuro.2005.06.001; Deigner HP, 2000, EXPERT OPIN INV DRUG, V9, P747, DOI 10.1517/13543784.9.4.747; DELGOBBO V, 1989, INT J IMMUNOPHARMACO, V11, P567, DOI 10.1016/0192-0561(89)90187-2; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dominguez-Rodriguez A, 2007, CONTEMP CLIN TRIALS, V28, P532, DOI 10.1016/j.cct.2006.10.007; Dong WG, 2010, J PINEAL RES, V48, P117, DOI 10.1111/j.1600-079X.2009.00734.x; Dringen R, 2005, ANTIOXID REDOX SIGN, V7, P1223, DOI 10.1089/ars.2005.7.1223; Dubocovich M. L., 2000, IUPHAR COMPENDIUM RE, P270; Dwivedi S, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/294501; Ekmekcioglu C, 2006, BIOMED PHARMACOTHER, V60, P97, DOI 10.1016/j.biopha.2006.01.002; El-Shenawy SM, 2002, PHARMACOL RES, V46, P235, DOI 10.1016/S1043-6618(02)00094-4; Escames G, 2006, J PINEAL RES, V40, P71, DOI 10.1111/j.1600-079X.2005.00281.x; Escames G, 2003, FASEB J, V17, P932, DOI 10.1096/fj.02-0692fje; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Feng YM, 2013, AUTOPHAGY, V9, P1395, DOI 10.4161/auto.25468; Fu JL, 2013, J PINEAL RES, V55, P364, DOI 10.1111/jpi.12079; Galano A, 2011, J PINEAL RES, V51, P1, DOI 10.1111/j.1600-079X.2011.00916.x; Garcia-Navarro A, 2007, J PINEAL RES, V43, P195, DOI 10.1111/j.1600-079X.2007.00463.x; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Girish KS, 2013, BIOCHEM BIOPH RES CO, V438, P198, DOI 10.1016/j.bbrc.2013.07.053; Godson C, 1997, ENDOCRINOLOGY, V138, P397, DOI 10.1210/endo.138.1.4824; Goffredo D, 2005, PHARMACOL RES, V52, P140, DOI 10.1016/j.phrs.2005.01.006; Goldenberg Marvin M, 2012, P T, V37, P175; Gong XM, 2008, MED HYPOTHESES, V71, P580, DOI 10.1016/j.mehy.2008.04.026; Goodman AOG, 2011, CURR NEUROL NEUROSCI, V11, P211, DOI 10.1007/s11910-010-0163-x; Gupta M, 2004, EPILEPSY BEHAV, V5, P316, DOI 10.1016/j.yebeh.2004.01.012; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hamdi A, 1998, LIFE SCI, V63, P2115, DOI 10.1016/S0024-3205(99)80008-3; Han F, 2011, J PINEAL RES, V50, P281, DOI 10.1111/j.1600-079X.2010.00838.x; HANSSON I, 1990, J NEUROIMMUNOL, V27, P79, DOI 10.1016/0165-5728(90)90139-E; HANSSON I, 1992, J NEUROIMMUNOL, V39, P23, DOI 10.1016/0165-5728(92)90171-G; Hardeland R, 2003, J PINEAL RES, V34, P233, DOI 10.1034/j.1600-079X.2003.00040.x; Hardeland Rudiger, 2005, Nutr Metab (Lond), V2, P22, DOI 10.1186/1743-7075-2-22; Hardeland R, 2010, CURR NEUROPHARMACOL, V8, P168, DOI 10.2174/157015910792246244; He HW, 2010, CURR NEUROPHARMACOL, V8, P211, DOI 10.2174/157015910792246137; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Hersch SM, 2006, NEUROLOGY, V66, P250, DOI 10.1212/01.wnl.0000194318.74946.b6; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hutter CDD, 1996, MED HYPOTHESES, V46, P67; Hyson HC, 2010, MOVEMENT DISORD, V25, P1924, DOI 10.1002/mds.22408; Jacob S, 2002, J PINEAL RES, V33, P186, DOI 10.1034/j.1600-079X.2002.02943.x; Jang JW, 2012, J NEUROL SCI, V323, P221, DOI 10.1016/j.jns.2012.09.021; Jarzynka MJ, 2009, J PINEAL RES, V46, P161, DOI 10.1111/j.1600-079X.2008.00644.x; Jiang HK, 1998, J FORMOS MED ASSOC, V97, P830; Jimenez-Rubio G, 2012, NEUROSCI LETT, V511, P47, DOI 10.1016/j.neulet.2012.01.040; Johri A, 2012, BBA-MOL BASIS DIS, V1822, P664, DOI 10.1016/j.bbadis.2011.11.014; Jung KH, 2010, J PINEAL RES, V48, P239, DOI 10.1111/j.1600-079X.2010.00748.x; Jung KH, 2009, J PINEAL RES, V47, P173, DOI 10.1111/j.1600-079X.2009.00698.x; Kang J C, 2001, J Vet Sci, V2, P85; Karasek M, 2003, J PINEAL RES, V34, P294, DOI 10.1034/j.1600-079X.2003.00046.x; Karasek M, 2006, FRONTIERS CHRONOBIOL, P1; Karasek Michal, 1999, Neuro Endocrinol Lett, V20, P179; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kaur C, 2008, CURR MED CHEM, V15, P3068, DOI 10.2174/092986708786848640; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kieseier BC, 2009, PHARMACOL RES, V60, P207, DOI 10.1016/j.phrs.2009.03.016; Kilic E, 2005, J PINEAL RES, V39, P151, DOI 10.1111/j.1600-079X.2005.00228.x; Kilic E, 2004, J PINEAL RES, V36, P171, DOI 10.1046/j.1600-079X.2003.00115.x; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; Kilic U, 2013, NEUROSCIENCE, V237, P268, DOI 10.1016/j.neuroscience.2013.01.059; Kilic U, 2012, J PINEAL RES, V52, P228, DOI 10.1111/j.1600-079X.2011.00932.x; Kitkhuandee A, 2013, J STROKE CEREBROVASC, VS1052-3057, P00015; Koh PO, 2008, J PINEAL RES, V44, P101, DOI 10.1111/j.1600-079X.2007.00495.x; Koh PO, 2012, J PINEAL RES, V53, P358, DOI 10.1111/j.1600-079X.2012.01005.x; Korkmaz A, 2008, J PINEAL RES, V44, P41, DOI 10.1111/j.1600-079X.2007.00509.x; Korkmaz A, 2012, GENE, V503, P1, DOI 10.1016/j.gene.2012.04.040; Kotini A, 2007, Eura Medicophys, V43, P345; Krokosz A, 2013, ADV MED SCI-POLAND, V58, P134, DOI 10.2478/v10039-012-0067-x; Lahiri DK, 2004, J PINEAL RES, V36, P217, DOI 10.1111/j.1600-079X.2004.00120.x; Lahiri DK, 2004, J PINEAL RES, V36, P224, DOI 10.1111/j.1600-079X.2004.00121.x; LANE EA, 1985, J CLIN ENDOCR METAB, V61, P1214, DOI 10.1210/jcem-61-6-1214; Laothong U, 2010, J PINEAL RES, V49, P271, DOI 10.1111/j.1600-079X.2010.00792.x; Lassmann H, 2007, BRAIN PATHOL, V17, P210, DOI 10.1111/j.1750-3639.2007.00064.x; Lassmann H, 2012, NAT REV NEUROL, V8, P647, DOI 10.1038/nrneurol.2012.168; Lee CH, 2010, J NEUROSCI RES, V88, P2630, DOI 10.1002/jnr.22430; Lee EJ, 2004, J PINEAL RES, V36, P33, DOI 10.1046/j.1600-079X.2003.00093.x; Lee MY, 2007, J PINEAL RES, V42, P297, DOI 10.1111/j.1600-079X.2007.00420.x; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; LERNER AB, 1959, J AM CHEM SOC, V81, P6084, DOI 10.1021/ja01531a060; LERNER AB, 1958, J AM CHEM SOC, V80, P2587, DOI 10.1021/ja01543a060; Letechipia-Vallejo G, 2007, J PINEAL RES, V42, P139, DOI 10.1111/j.1600-079X.2006.00395.x; Li XJ, 1997, ACTA PHARMACOL SIN, V18, P394; Lin CH, 2008, J PINEAL RES, V44, P205, DOI 10.1111/j.1600-079X.2007.00510.x; Lin HW, 2009, NEUROPSYCH DIS TREAT, V5, P157; Liu Y, 2012, J PINEAL RES, V52, P47, DOI 10.1111/j.1600-079X.2011.00917.x; Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10-154450; Ma YX, 2013, J HISTOCHEM CYTOCHEM, V61, P591, DOI 10.1369/0022155413492159; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; Maharaj DS, 2005, J PHARM PHARMACOL, V57, P877, DOI 10.1211/0022357056424; Mahlberg R, 2006, PSYCHONEUROENDOCRINO, V31, P634, DOI 10.1016/j.psyneuen.2006.01.009; Maldonado MD, 2010, PHARMACOL RES, V62, P282, DOI 10.1016/j.phrs.2009.11.014; Maldonado MD, 2006, NEUROENDOCRINOL LETT, V27, P601; Marshall KA, 1996, FREE RADICAL BIO MED, V21, P307, DOI 10.1016/0891-5849(96)00046-9; Martin M, 2000, FASEB J, V14, P1677; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; Mazzucchelli C, 1996, MOL BRAIN RES, V39, P117, DOI 10.1016/0169-328X(96)00017-4; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; Medina FJ, 2010, CURR MED CHEM, V17, P2482, DOI 10.2174/092986710791556078; Melamud L, 2012, J NEUROL SCI, V314, P37, DOI 10.1016/j.jns.2011.11.003; Melen-Mucha G, 1998, ANTICANCER RES, V18, P3615; Medeiros CAM, 2007, J NEUROL, V254, P459, DOI 10.1007/s00415-006-0390-x; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; Micale V, 2007, PHARMACOL RES, V56, P382, DOI 10.1016/j.phrs.2007.09.008; Miller Elzbieta, 2011, Pol Merkur Lekarski, V31, P150; Miller E, 2013, J NEUROIMMUNOL, V257, P97, DOI 10.1016/j.jneuroim.2013.02.012; MISHIMA K, 1994, ACTA PSYCHIAT SCAND, V89, P1, DOI 10.1111/j.1600-0447.1994.tb01477.x; Montilla P, 2003, J PHYSIOL BIOCHEM, V59, P263, DOI 10.1007/BF03179883; Montilla P, 1997, J PHYSIOL BIOCHEM, V53, P301; Morandi B, 2008, PHARMACOL RES, V57, P1, DOI 10.1016/j.phrs.2007.11.003; Mrowicka Malgorzata, 2010, Wiad Lek, V63, P3; Mu SH, 2011, NEUROCHEM INT, V59, P224, DOI 10.1016/j.neuint.2011.05.009; Musshoff U, 2002, HIPPOCAMPUS, V12, P165, DOI 10.1002/hipo.1105; Nair SM, 2011, J PINEAL RES, V51, P313, DOI 10.1111/j.1600-079X.2011.00891.x; Nam E, 2005, BRAIN RES, V1046, P90, DOI 10.1016/j.brainres.2005.03.053; Natarajan R, 2012, J NEUROIMMUNOL, V250, P106, DOI 10.1016/j.jneuroim.2012.05.014; National Pediatric MS Center, GUID NURS; Negi G, 2011, J PINEAL RES, V50, P124, DOI 10.1111/j.1600-079X.2010.00821.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Onuki J, 2005, J PINEAL RES, V38, P107, DOI 10.1111/j.1600-079X.2004.00180.x; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Ozyener F, 2012, RESTOR NEUROL NEUROS, V30, P435, DOI 10.3233/RNN-2012-120217; Padillo FJ, 2010, J PINEAL RES, V49, P264, DOI 10.1111/j.1600-079X.2010.00791.x; Pajovic SB, 2003, PHYSIOL RES, V52, P189; Pandi-Perumal SR, 2006, FEBS J, V273, P2813, DOI 10.1111/j.1742-4658.2006.05322.x; Pandi-Perumal SR, 2012, PHYS CHEM B, V116, P7291; Paparrigopoulos T, 2001, J AFFECT DISORDERS, V65, P307, DOI 10.1016/S0165-0327(00)00270-6; Paradies G, 2010, J PINEAL RES, V48, P297, DOI 10.1111/j.1600-079X.2010.00759.x; Park OK, 2010, J NEUROL SCI, V294, P7, DOI 10.1016/j.jns.2010.04.013; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924, DOI 10.1152/ajpheart.2000.279.3.H924; Persinger MA, 2006, MED HYPOTHESES, V66, P811, DOI 10.1016/j.mehy.2005.09.044; Petit L, 1999, BIOCHEM PHARMACOL, V58, P633, DOI 10.1016/S0006-2952(99)00134-3; Petrosillo G, 2008, REJUV RES, V11, P935, DOI 10.1089/rej.2008.0772; Petrosillo G, 2009, FREE RADICAL BIO MED, V47, P969, DOI 10.1016/j.freeradbiomed.2009.06.032; PEYSER CE, 1995, AM J PSYCHIAT, V152, P1771; PIOLI C, 1993, INT J IMMUNOPHARMACO, V15, P463, DOI 10.1016/0192-0561(93)90060-C; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Poluektov M G, 2012, Zh Nevrol Psikhiatr Im S S Korsakova, V112, P26; Pozo D, 2004, J PINEAL RES, V37, P48, DOI 10.1111/j.1600-079X.2004.00135.x; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; POZO D, 1994, LIFE SCI, V55, pPL455, DOI 10.1016/0024-3205(94)00532-X; Prieto-Gomez B, 2008, NEUROSCI LETT, V448, P56, DOI 10.1016/j.neulet.2008.10.041; Provinciali M, 1996, MECH AGEING DEV, V90, P1, DOI 10.1016/0047-6374(96)01746-0; Ramaswamy S, 2007, ILAR J, V48, P356, DOI 10.1093/ilar.48.4.356; Ramaswamy S, 2007, CELL TRANSPLANT, V16, P301, DOI 10.3727/000000007783464687; Ramirez-Rodriguez G, 2011, J PINEAL RES, V50, P29, DOI 10.1111/j.1600-079X.2010.00802.x; Ranen NG, 1996, MOVEMENT DISORD, V11, P549, DOI 10.1002/mds.870110510; Reiter RJ, 1999, ANN NY ACAD SCI, V890, P471, DOI 10.1111/j.1749-6632.1999.tb08028.x; Reiter RJ, 2000, BIOL SIGNAL RECEPT, V9, P160; REITER RJ, 1993, BRAZ J MED BIOL RES, V26, P1141; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; Reiter RJ, 2002, MECH AGEING DEV, V123, P1007, DOI 10.1016/S0047-6374(01)00384-0; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; Reiter RJ, 2007, MELATONIN PRESENT FU, P261; Reiter RJ, 2007, ACTA BIOCHIM POL, V54, P1; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; Ressmeyer AR, 2003, REDOX REP, V8, P205, DOI 10.1179/135100003225002709; Ritzenthaler T, 2009, J PINEAL RES, V46, P349, DOI 10.1111/j.1600-079X.2009.00670.x; Rodriguez C, 2013, INT J MOL SCI, V14, P6597, DOI 10.3390/ijms14046597; Rodriguez-Martinez E, 2000, BRAIN RES, V858, P436, DOI 10.1016/S0006-8993(99)02474-9; Roos RAC, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-40; Rostami A, 2013, J NEUROL SCI, V333, P76, DOI 10.1016/j.jns.2013.03.002; Sainz RM, 2003, CELL MOL LIFE SCI, V60, P1407, DOI 10.1007/s00018-003-2319-1; Sanchez-Barcelo EJ, 2005, J PINEAL RES, V38, P217, DOI 10.1111/j.1600-079X.2004.00207.x; Sanchez-Hidalgo M, 2007, AM J PHYSIOL-REG I, V292, pR2208, DOI 10.1152/ajpregu.00013.2007; Sanchez-Lopez F, 2012, NEUROL RES, V34, P721, DOI 10.1179/1743132812Y.0000000073; Sandyk R, 1993, Int J Neurosci, V72, P141; SANDYK R, 1993, INT J NEUROSCI, V72, P95, DOI 10.3109/00207459308991626; SANDYK R, 1992, INT J NEUROSCI, V67, P173, DOI 10.3109/00207459208994783; SANDYK R, 1993, INT J NEUROSCI, V71, P173, DOI 10.3109/00207459309000602; SANDYK R, 1992, INT J NEUROSCI, V62, P65; Sandyk R, 1994, Int J Neurosci, V74, P95; Sandyk R, 1995, INT J NEUROSCI, V83, P1; SANDYK R, 1993, INT J NEUROSCI, V68, P227, DOI 10.3109/00207459308994278; SANDYK R, 1994, INT J NEUROSCI, V75, P213, DOI 10.3109/00207459408986305; SANDYK R, 1991, INT J NEUROSCI, V61, P61, DOI 10.3109/00207459108986271; Sariahmetoglu M, 2003, PHARMACOL RES, V48, P361, DOI 10.1016/S1043-6618(03)00177-4; Sarlak G, 2013, J PHARMACOL SCI, V123, P9, DOI 10.1254/jphs.13R01SR; Savina TA, 2006, B EXP BIOL MED+, V142, P601, DOI 10.1007/s10517-006-0429-0; Shamir E, 2001, ARCH GEN PSYCHIAT, V58, P1049, DOI 10.1001/archpsyc.58.11.1049; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Silva SO, 2004, J NEUROIMMUNOL, V156, P146, DOI 10.1016/j.jneuroim.2004.07.015; Silva SO, 2005, J PINEAL RES, V39, P302, DOI 10.1111/j.1600-079X.2005.00247.x; SLAUGENHAUPT SA, 1995, GENOMICS, V27, P355, DOI 10.1006/geno.1995.1056; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Sofic E, 2005, J NEURAL TRANSM, V112, P349, DOI 10.1007/s00702-004-0270-4; Spiro DB, 2012, J PEDIATR HEALTH CAR, V26, P399, DOI 10.1016/j.pedhc.2011.02.006; Spokoini R, 2010, MOL ENDOCRINOL, V24, P1136, DOI 10.1210/me.2009-0466; Srinivasan V, 2006, Behav Brain Funct, V2, P15, DOI 10.1186/1744-9081-2-15; Srinivasan V, 2005, NEUROTOX RES, V7, P293, DOI 10.1007/BF03033887; Stefulj J, 2001, J PINEAL RES, V30, P243, DOI 10.1034/j.1600-079X.2001.300408.x; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; SUGDEN D, 1989, EXPERIENTIA, V45, P922, DOI 10.1007/BF01953049; Sunami E, 2012, INTERNAL MED, V51, P1187, DOI 10.2169/internalmedicine.51.6699; Tai SH, 2010, J PINEAL RES, V49, P332, DOI 10.1111/j.1600-079X.2010.00797.x; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tan DX, 2005, J PINEAL RES, V39, P185, DOI 10.1111/j.1600-079X.2005.00234.x; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tan DX, 2003, EXPERT OPIN THER PAT, V13, P593; Tang Y, 2014, CELL TRANSPLANT; Tapias V, 2010, J NEUROSCI RES, V88, P420, DOI 10.1002/jnr.22201; Tapias V, 2009, J NEUROSCI RES, V87, P3002, DOI 10.1002/jnr.22123; Tardito D, 2012, EUR NEUROPSYCHOPHARM, V22, pS482, DOI 10.1016/j.euroneuro.2012.06.016; Tasset I, 2012, NEUROSCIENCE, V209, P54, DOI 10.1016/j.neuroscience.2012.02.034; Tasset I, 2011, NUTR NEUROSCI, V14, P106, DOI 10.1179/1476830511Y.0000000005; Tasset I, 2009, J PHYSIOL BIOCHEM, V65, P291, DOI 10.1007/BF03180581; Tasset I, 2009, REV NEUROLOGIA, V49, P424, DOI 10.33588/rn.4908.2009192; Tasset I, 2013, BRAIN STIMUL, V6, P84, DOI 10.1016/j.brs.2012.03.015; Tasset I, 2012, REV NEUROLOGIA, V54, P449, DOI 10.33588/rn.5408.2011672; Tasset I, 2012, CLIN BIOCHEM, V45, P440, DOI 10.1016/j.clinbiochem.2012.01.023; Tasset I, 2012, J NEUROL SCI, V315, P133, DOI 10.1016/j.jns.2011.12.014; Tasset I, 2011, PROG NEURO-PSYCHOPH, V35, P1944, DOI 10.1016/j.pnpbp.2011.09.005; Tasset I, 2010, NEUROSIGNALS, V18, P24, DOI 10.1159/000243650; Taylor N, 1997, BRIT J PSYCHIAT, V171, P393, DOI 10.1192/bjp.171.4.393c; Tripathi DN, 2010, J PINEAL RES, V48, P324, DOI 10.1111/j.1600-079X.2010.00756.x; Tunez I, 2006, J NEUROCHEM, V97, P619, DOI 10.1111/j.1471-4159.2006.03724.x; Tunez I, 2004, J PINEAL RES, V37, P252, DOI 10.1111/j.1600-079X.2004.00163.x; Tunez I, 2009, REV NEUROLOGIA, V48, P430, DOI 10.33588/rn.4808.2008678; Tunez I, 2007, MELATONIN PRESENT FU, P315; Tunez I, 2006, NEUROSCI RES, V56, P91, DOI 10.1016/j.neures.2006.05.012; Tunez I, 2011, J MED CHEM, V54, P5602, DOI 10.1021/jm200605a; Tunez I, 2010, MOLECULES, V15, P878, DOI 10.3390/molecules15020878; van Horssen J, 2011, BBA-MOL BASIS DIS, V1812, P141, DOI 10.1016/j.bbadis.2010.06.011; van Wamelen DJ, 2013, SLEEP, V36, P117, DOI 10.5665/sleep.2314; Venero JL, 2002, J PINEAL RES, V32, P6, DOI 10.1034/j.1600-079x.2002.10813.x; Videnovic A, 2009, PARKINSONISM RELAT D, V15, P471, DOI 10.1016/j.parkreldis.2008.10.002; Vijayalaxmi, 2002, J CLIN ONCOL, V20, P2575, DOI 10.1200/JCO.2002.11.004; Villapol S, 2011, PEDIATR RES, V69, P51, DOI 10.1203/PDR.0b013e3181fcb40b; VOORDOUW BCG, 1992, J CLIN ENDOCR METAB, V74, P108, DOI 10.1210/jc.74.1.108; WALDHAUSER F, 1984, NEUROENDOCRINOLOGY, V39, P307, DOI 10.1159/000123997; Wang X, 2011, J NEUROSCI, V31, P14496, DOI 10.1523/JNEUROSCI.3059-11.2011; Wang X, 2009, CNS NEUROSCI THER, V15, P345, DOI 10.1111/j.1755-5949.2009.00105.x; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; Weil ZM, 2009, NEUROBIOL DIS, V36, P352, DOI 10.1016/j.nbd.2009.07.032; Weishaupt JH, 2006, J PINEAL RES, V41, P313, DOI 10.1111/j.1600-079X.2006.00377.x; Wilhelm EA, 2013, EUR J PHARMACOL, V701, P65, DOI 10.1016/j.ejphar.2013.01.007; Winczyk K, 2002, TUMOR BIOL, V23, P298, DOI 10.1159/000068569; Winczyk K, 2001, J PINEAL RES, V31, P179, DOI 10.1034/j.1600-079x.2001.310213.x; Witherick J, 2011, AUTOIMMUN DIS, V2011, DOI 10.4061/2011/164608; Wu YH, 2005, J PINEAL RES, V38, P145, DOI 10.1111/j.1600-079X.2004.00196.x; Yang SH, 2011, CURR TOP BEHAV NEURO, V7, P61, DOI 10.1007/7854_2010_105; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang HW, 1999, CHEM RES TOXICOL, V12, P526, DOI 10.1021/tx980243t; Zhang L, 2013, BEHAV BRAIN RES, V256, P72, DOI 10.1016/j.bbr.2013.07.051; Zhang YC, 2004, ACTA PHARMACOL SIN, V25, P447; Zhou JN, 2003, J PINEAL RES, V34, P11, DOI 10.1034/j.1600-079X.2003.01897.x; ZIMMERMAN RA, 1982, RADIOLOGY, V142, P659, DOI 10.1148/radiology.142.3.7063680; Zipp F, 2006, TRENDS NEUROSCI, V29, P518, DOI 10.1016/j.tins.2006.07.006; Zuccato C, 2005, PHARMACOL RES, V52, P133, DOI 10.1016/j.phrs.2005.01.001	315	26	28	0	9	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2014	13	6					1096	1119		10.2174/1871527313666140806160400			24	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	AP1YW	WOS:000341869400023	25106623				2022-02-06	
J	Habib, P; Dang, J; Slowik, A; Victor, M; Beyer, C				Habib, Pardes; Dang, Jon; Slowik, Alexander; Victor, Marion; Beyer, Cordian			Hypoxia-Induced Gene Expression of Aquaporin-4, Cyclooxygenase-2 and Hypoxia-Inducible Factor 1 alpha in Rat Cortical Astroglia Is Inhibited by 17 beta-Estradiol and Progesterone	NEUROENDOCRINOLOGY			English	Article						Hypoxia; Astroglia; Estrogen; Progesterone; Aquaporin;4; Cyclooxygenase-2	ESTROGEN-RECEPTOR-ALPHA; GONADAL-STEROID HORMONES; TRAUMATIC BRAIN-INJURY; NEUROINFLAMMATORY PROCESSES; INFLAMMATORY RESPONSES; CEREBRAL-ISCHEMIA; GLT-1 EXPRESSION; SEX STEROIDS; ASTROCYTES; CELLS	17 beta-Estradiol (E-2) and progesterone (P) are neuroprotective in acute brain injury by attenuating neuropathophysiological processes and regulating local glial function. Besides controlling brain-intrinsic immune responses, astrocytes are cellular targets for sex steroids in health and disease and typically resist to hypoxic damage. In this in vitro study, we aimed at uncovering astroglia-specific reactions to sublethal hypoxic conditions and astroglia-specific effects of both sex steroid hormones on these parameters. Short-term hypoxia for 3 h increased reactive oxygen species production, but had no influence on cell viability of cerebral cortical rat astroglia. Astrocytes expressed classical estrogen receptors (ER), progesterone receptor (PR), and a set of nonclassical steroid hormone receptors. Hypoxia specifically induced ERa and PR isoform A gene expression. Oxygen deprivation increased gene expression of aquaporin-4 (AQP4), hypoxiainducible factor la (Hifi a), and cyclooxygenase-2 (COX2). The application of E2 and P selectively prevented this induction. Effects on protein levels of these genes appeared to be delayed. These data show that astrocytes change their receptivity for sex steroid hormones by switching steroid hormone receptor expression and that E2 and P modify or antagonize proinflannmatory COX2 synthesis, edema-promoting AQP4 expression, and the Hif1 a increase. In vivo studies have to address whether these cell responses contribute to steroid-mediated neuroprotection in stroke. (C) 2014 S. Ka rger AG, Basel	[Habib, Pardes; Dang, Jon; Slowik, Alexander; Victor, Marion; Beyer, Cordian] Rhein Westfal TH Aachen, Inst Neuroanat, DE-52074 Aachen, Germany		Beyer, C (corresponding author), Rhein Westfal TH Aachen, Inst Neuroanat, DE-52074 Aachen, Germany.	cbeyer@ukaachen.de		Dr. Slowik, Alexander/0000-0001-9907-2263			Arevalo MA, 2013, HORM BEHAV, V63, P216, DOI 10.1016/j.yhbeh.2012.02.021; Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; Arnold S, 2009, J NEUROCHEM, V110, P1, DOI 10.1111/j.1471-4159.2009.06133.x; Bajramovic JJ, 2011, CNS NEUROL DISORD-DR, V10, P4; Baker AE, 2004, ENDOCRINOLOGY, V145, P5021, DOI 10.1210/en.2004-0619; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Bustin SA, 2005, J MOL ENDOCRINOL, V34, P597, DOI 10.1677/jme.1.01755; Charlier TD, 2005, REV NEUROSCIENCE, V16, P339; Coomber B, 2010, BRAIN RES, V1361, P124, DOI 10.1016/j.brainres.2010.09.037; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; Dhandapani KM, 2007, EXP GERONTOL, V42, P70, DOI 10.1016/j.exger.2006.06.032; Freeman RS, 2005, CNS NEUROL DISORD-DR, V4, P85, DOI 10.2174/1568007053005154; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gunnarson E, 2009, P NATL ACAD SCI USA, V106, P1602, DOI 10.1073/pnas.0812708106; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Habib P, 2014, J MOL NEUROSCI, V52, P277, DOI 10.1007/s12031-013-0137-y; Habib P, 2013, J STEROID BIOCHEM, V138, P195, DOI 10.1016/j.jsbmb.2013.06.003; Han EH, 2010, TOXICOL LETT, V198, P331, DOI 10.1016/j.toxlet.2010.07.015; Hara K, 1998, NEUROSCI LETT, V256, P53, DOI 10.1016/S0304-3940(98)00755-1; Hardy DB, 2008, MOL ENDOCRINOL, V22, P1812, DOI 10.1210/me.2007-0443; Johann S, 2008, J MOL NEUROSCI, V34, P177, DOI 10.1007/s12031-007-9028-4; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Jung-Testas I, 1998, J STEROID BIOCHEM, V65, P243, DOI 10.1016/S0960-0760(97)00191-X; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; Kipp M, 2012, J NEUROENDOCRINOL, V24, P62, DOI 10.1111/j.1365-2826.2011.02163.x; Kipp M, 2009, FRONT NEUROENDOCRIN, V30, P188, DOI 10.1016/j.yfrne.2009.04.004; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lee E, 2012, J BIOL CHEM, V287, P26817, DOI 10.1074/jbc.M112.341867; Leung YK, 2006, P NATL ACAD SCI USA, V103, P13162, DOI 10.1073/pnas.0605676103; Liu W, 2011, LIFE SCI, V89, P141, DOI 10.1016/j.lfs.2011.05.011; Loram LC, 2012, PSYCHONEUROENDOCRINO, V37, P1688, DOI 10.1016/j.psyneuen.2012.02.018; Maier O, 2013, NEUROCHEM INT, V62, P1029, DOI 10.1016/j.neuint.2013.03.008; Meffre D, 2013, NEUROSCIENCE, V231, P111, DOI 10.1016/j.neuroscience.2012.11.039; Mor G, 1999, J NEUROBIOL, V40, P484, DOI 10.1002/(SICI)1097-4695(19990915)40:4<484::AID-NEU6>3.0.CO;2-C; Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Patani N, 2014, MOL CELL ENDOCRINOL, V382, P683, DOI 10.1016/j.mce.2013.09.038; Pawlak J, 2005, MOL BRAIN RES, V138, P1, DOI 10.1016/j.molbrainres.2004.10.043; Pawlak J, 2005, GLIA, V50, P270, DOI 10.1002/glia.20162; Rutkowsky JM, 2011, AM J PHYSIOL-CELL PH, V301, pC204, DOI 10.1152/ajpcell.00399.2010; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shin JA, 2011, BBA-MOL BASIS DIS, V1812, P1154, DOI 10.1016/j.bbadis.2011.05.004; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Sohrabji F, 2013, NEUROCHEM INT, V63, P291, DOI 10.1016/j.neuint.2013.06.013; Spence RD, 2011, P NATL ACAD SCI USA, V108, P8867, DOI 10.1073/pnas.1103833108; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stirone C, 2003, AM J PHYSIOL-ENDOC M, V284, pE184, DOI 10.1152/ajpendo.00165.2002; Strauss KI, 2010, CRIT CARE MED, V38, P723, DOI 10.1097/CCM.0b013e3181bc80b9; Su C, 2012, ENDOCRINOLOGY, V153, P4389, DOI 10.1210/en.2011-2177; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; Thomas P, 2008, FRONT NEUROENDOCRIN, V29, P292, DOI 10.1016/j.yfrne.2008.01.001; Tichauer J, 2007, NEUROIMMUNOMODULAT, V14, P168, DOI 10.1159/000110642; Ulbrich C, 2012, J STEROID BIOCHEM, V131, P10, DOI 10.1016/j.jsbmb.2012.01.007; Wagner DC, 2013, ACTA NEUROBIOL EXP, V73, P79; Yang M, 2009, BRAIN RES, V1290, P121, DOI 10.1016/j.brainres.2009.07.018; Yeh SH, 2011, BRAIN PATHOL, V21, P249, DOI 10.1111/j.1750-3639.2010.00443.x; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zuloaga KL, 2012, STEROIDS, V77, P835, DOI 10.1016/j.steroids.2012.04.013	59	26	27	1	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0028-3835	1423-0194		NEUROENDOCRINOLOGY	Neuroendocrinology		2014	99	3-4					156	167		10.1159/000362279			12	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	AR5RB	WOS:000343640100002	24685982				2022-02-06	
J	Henden, PL; Sondergaard, S; Rydenhag, B; Reinsfelt, B; Ricksten, SE; Aring;neman, A				Henden, Pia Lowhagen; Sondergaard, Soren; Rydenhag, Bertil; Reinsfelt, Bjorn; Ricksten, Sven-Erik; Aneman, Anders			Can Baroreflex Sensitivity and Heart Rate Variability Predict Late Neurological Outcome in Patients With Traumatic Brain Injury?	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						traumatic brain injury; baroreflex sensitivity; heart rate variability; autonomic dysfunction; neurointensive care	INTRACRANIAL HYPERTENSION; PRESSURE VARIABILITY; SPECTRAL-ANALYSIS; BLOOD-PRESSURE; NERVE ACTIVITY; LUND CONCEPT; PROPOFOL; ANESTHESIA; INDUCTION; DEATH	Background:Previous studies have suggested that depressed heart rate variability (HRV) and baroreflex sensitivity (BRS) are associated with early mortality and morbidity in patients with acute brain injuries of various etiologies. The aim of the present study was to assess changes in HRV and BRS in isolated traumatic brain injury (TBI), with the hypothesis that measurement of autonomic nervous system dysfunction can provide prognostic information on late neurological outcome.Materials and Methods:Nineteen patients with TBI, requiring mechanical ventilation, sedation and analgesia, and with arterial and intracranial pressure monitoring for at least 1 week, were included. Physiological and treatment variables were collected and power spectral analyses of HRV and BRS analyses in time domain were performed daily. HRV in the high-frequency (HF) and low-frequency (LF) domains, as well as LF/HF ratio and total power, were investigated. The power of these variables to predict poor (Glasgow Outcome Scale Extended [GOSE] score <5), late (1 y) neurological outcome was assessed.Results:Total power, LF, HF, and BRS were all significantly depressed in patients with GOSE score <5. This difference could not be explained by a more severe brain injury at admission or more extensive use of sedative or analgesic drugs. The autonomic variables predicted the late neurological outcome with areas under the receiver-operating curves between 0.78 and 0.83 (sensitivity: 0.63 to 0.88 and specificity: 0.73 to 0.82).Conclusions:HRV and BRS measures in TBI patients during intensive care treatment, including sedative, analgesic, and vasoactive drugs, may identify patients with poor late neurological outcome.	[Henden, Pia Lowhagen; Sondergaard, Soren; Reinsfelt, Bjorn; Ricksten, Sven-Erik] Univ Gothenburg, Dept Anaesthesiol & Intens Care Med, Sahlgrenska Acad, Gothenburg, Sweden; [Rydenhag, Bertil] Univ Gothenburg, Dept Neurosurg, Sahlgrenska Acad, Gothenburg, Sweden; [Rydenhag, Bertil] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; [Aneman, Anders] Univ New S Wales, Intens Care Unit, Liverpool Hosp, South Western Sydney Local Hlth Dist, Sydney, NSW, Australia		Henden, PL (corresponding author), Sahlgrens Univ Hosp, Dept Anaesthesiol & Intens Care Med, S-41345 Gothenburg, Sweden.	pia.lowhagen@vgregion.se		Aneman, Anders/0000-0003-2096-5304; Lowhagen Henden, Pia/0000-0002-0466-319X	Swedish State Support for Clinical Research [ALFGBG-75870]; Gothenburg Medical Society; Health and Medical Care Executive Board of Vastra Gotaland Region (FoU)	Supported by Swedish State Support for Clinical Research (ALFGBG-75870), The Gothenburg Medical Society, and The Health and Medical Care Executive Board of Vastra Gotaland Region (FoU).	Aono H, 2001, ACTA MED OKAYAMA, V55, P197; Baillard C, 2002, CRIT CARE MED, V30, P306, DOI 10.1097/00003246-200202000-00007; Boudreau P, 2012, CHRONOBIOL INT, V29, P757, DOI 10.3109/07420528.2012.674592; BROWN TE, 1993, J APPL PHYSIOL, V75, P2310, DOI 10.1152/jappl.1993.75.5.2310; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Camm AJ, 1996, EUR HEART J, V17, P354; Conci F, 2001, J NEUROL NEUROSUR PS, V71, P621, DOI 10.1136/jnnp.71.5.621; GALLETLY DC, 1994, BRIT J ANAESTH, V72, P219, DOI 10.1093/bja/72.2.219; Gang Yi, 2002, Curr Opin Crit Care, V8, P371, DOI 10.1097/00075198-200210000-00002; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Grande PO, 2011, J NEUROSURG ANESTH, V23, P358, DOI 10.1097/01.ana.0000405612.20356.84; Guo Yi-Fang, 2002, Card Electrophysiol Rev, V6, P267, DOI 10.1023/A:1016337210738; Haji-Michael PG, 2000, CRIT CARE MED, V28, P2578, DOI 10.1097/00003246-200007000-00066; HOWELL SJ, 1995, BRIT J ANAESTH, V74, P168, DOI 10.1093/bja/74.2.168; Hsueh C W, 1998, Zhonghua Yi Xue Za Zhi (Taipei), V61, P199; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Kahraman S, 2010, J NEUROSURG ANESTH, V22, P296, DOI 10.1097/ANA.0b013e3181e25fc3; Korach M, 2001, CRIT CARE MED, V29, P1380, DOI 10.1097/00003246-200107000-00013; La Rovere MT, 2008, ANN NONINVAS ELECTRO, V13, P191, DOI 10.1111/j.1542-474X.2008.00219.x; LATSON TW, 1992, J CLIN ANESTH, V4, P265, DOI 10.1016/0952-8180(92)90127-M; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; Marthol H, 2010, CLIN AUTON RES, V20, P363, DOI 10.1007/s10286-010-0072-8; MARTY J, 1986, ANESTH ANALG, V65, P113; Mazzeo AT, 2011, ACTA ANAESTH SCAND, V55, P797, DOI 10.1111/j.1399-6576.2011.02466.x; Mendez GD, 2013, J CLIN MONIT COMPUT, V27, P417, DOI 10.1007/s10877-012-9426-1; Modesti PA, 2004, HEART, V90, P30, DOI 10.1136/heart.90.1.30; Mowery NT, 2008, J TRAUMA, V65, P621, DOI 10.1097/TA.0b013e3181837980; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Okada Y, 2012, HYPERTENSION, V59, P98, DOI 10.1161/HYPERTENSIONAHA.111.176560; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; Riordan WP, 2009, J SURG RES, V156, P283, DOI 10.1016/j.jss.2009.03.086; Riznyk L, 2005, PHARMACOL REP, V57, P128; Sato M, 2005, BRIT J ANAESTH, V94, P577, DOI 10.1093/bja/aei092; SELLGREN J, 1994, ANESTHESIOLOGY, V80, P534, DOI 10.1097/00000542-199403000-00009; Stein PK, 2008, CRIT CARE MED, V36, P1025, DOI 10.1097/CCM.0B013E318164EC6D; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tsuchiya S, 2006, EUR J ANAESTH, V23, P454, DOI 10.1017/S0265021506000159; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Zickmann B, 1996, J CARDIOTHOR VASC AN, V10, P609, DOI 10.1016/S1053-0770(96)80138-8; Ziegler D, 2001, CLIN AUTON RES, V11, P369, DOI 10.1007/BF02292769	43	26	26	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2014	26	1					50	59		10.1097/ANA.0b013e3182a47b62			10	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	275CW	WOS:000328654300010	24064714				2022-02-06	
J	Menn, SJ; Yang, R; Lankford, A				Menn, Stuart J.; Yang, Ronghua; Lankford, Alan			Armodafinil for the Treatment of Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury: A 12-Week, Randomized, Double-Blind Study followed by a 12-Month Open-Label Extension	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						traumatic brain injury; excessive sleepiness; armodafinil	SHIFT WORK DISORDER; GLOBAL IMPRESSION SCALE; DAYTIME SLEEPINESS; LATENCY TEST; EFFICACY; TOLERABILITY; DISTURBANCES; WAKEFULNESS; PREVALENCE; NARCOLEPSY	Objective: To evaluate the efficacy and tolerability of armodafinil in patients with excessive sleepiness following mild or moderate closed traumatic brain injury (TBI). Design: Randomized, placebo-controlled, double-blind trial followed by open-label extension. Setting: 40 US centers. Patients: Adults with closed TBI (N = 117), Glasgow Coma Scale score > 8 at time of injury; baseline Epworth Sleepiness Scale (ESS) >= 10; sleep latency < 8 minutes on multiple sleep latency test (MSLT); and Clinical Global Impression-Severity of Illness (CGI-S) score >= 4 for excessive sleepiness. Intervention: Patients received armodafinil (50, 150, or 250 mg/day) or placebo for 12 weeks followed by an optional 12-month open-label extension. Measurements and Results: Outcomes included MSLT, ESS, Clinical Global Impression-Change (CGI-C), TBI-Work Instability Scale (TBI-WIS), CGI-S, and tolerability. The study was terminated early due to low enrollment. Patients receiving 250 mg armodafinil showed significant improvement in sleep latency from baseline to final visit versus placebo (+7.2 minutes vs. +2.4 minutes; p = 0.0010). CGI-C ratings were much/very much improved in approximately 50% of patients receiving 150 and 250 mg armodafinil, compared to 38% on placebo. ESS and TBI-WIS scores were not significantly different between groups. In the open-label extension (N = 49), patients demonstrated gradual improvement in ESS, TBI-WIS, and CGI-S scores up to 48 weeks post-baseline. Armodafinil was generally well tolerated, with headache the most common adverse event in both double-blind and open-label portions. Conclusions: Armodafinil 250 mg significantly improved sleep latency in patients with excessive sleepiness associated with mild or moderate TBI. Efficacy and tolerability of armodafinil were sustained throughout the open-label extension.	[Menn, Stuart J.] Pacific Sleep Med Serv, Palm Springs, CA USA; [Yang, Ronghua] Teva Pharmaceut Ind Ltd, Frazer, PA USA; [Lankford, Alan] Sleep Disorders Ctr Georgia, Atlanta, GA USA		Menn, SJ (corresponding author), 5 Dominion Court, Palm Springs, CA 92270 USA.	stuartjmenn@cs.com			Teva Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries	The authors thank Craig Q. Earl, Ph. D., formerly of Cephalon, Inc, for his contribution to the study design and Sarah Mizne, PharmD, and David Christiansen, Ph. D., of MedVal Scientific Information Services, LLC, for professional medical writing and editorial support. This manuscript was prepared according to the International Society for Medical Publication Professionals' Good Publication Practice for Communicating Company-Sponsored Medical Research: the GPP2 Guidelines. Funding for this study and to support the preparation of this manuscript was provided by Teva Pharmaceutical Industries Ltd.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, SLEEP MED CLIN, V7, P609, DOI 10.1016/j.jsmc.2012.08.002; Black JE, 2010, J CLIN SLEEP MED, V6, P458; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Czeisler CA, 2009, MAYO CLIN PROC, V84, P958, DOI 10.1016/S0025-6196(11)60666-6; Erman MK, 2011, J OCCUP ENVIRON MED, V53, P1460, DOI 10.1097/JOM.0b013e318237a17e; Faul M, 2010, TRAUMATIC BRAIN INJU; Forkmann T, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-83; Gilworth G, 2006, BRAIN INJURY, V20, P835, DOI 10.1080/02699050600832221; Greenwald B, 2011, PM&R, V3, P480, DOI 10.1016/j.pmrj.2011.04.010; Guy W., 1976, ECDEU ASSESSMENT MAN, P217; Harsh J, 2014, CURR MED RES OPIN, V30, P945, DOI 10.1185/03007995.2014.884490; Harsh JR, 2006, CURR MED RES OPIN, V22, P761, DOI 10.1185/030079906X100050; Heres S, 2014, PROG NEURO-PSYCHOPH, V48, P207, DOI 10.1016/j.pnpbp.2013.09.015; Hirshkowitz M, 2007, RESP MED, V101, P616, DOI 10.1016/j.rmed.2006.06.007; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Jiang Qin, 2009, Ann Gen Psychiatry, V8, P4, DOI 10.1186/1744-859X-8-4; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; Kadouri A, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-7; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ohayon MM, 2008, SLEEP MED REV, V12, P129, DOI 10.1016/j.smrv.2008.01.001; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Roth T, 2006, CLIN THER, V28, P689, DOI 10.1016/j.clinthera.2006.05.013; Schwartz JRL, 2010, J CLIN SLEEP MED, V6, P450; Sheng P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081802; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249	40	26	26	0	2	AMER ACAD SLEEP MEDICINE	DARIEN	2510 N FRONTAGE RD, DARIEN, IL 60561 USA	1550-9389	1550-9397		J CLIN SLEEP MED	J. Clin. Sleep Med.		2014	10	11					1181	1191		10.5664/jcsm.4196			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AT8XT	WOS:000345213100004	25325609	Green Published, Bronze			2022-02-06	
J	Yeates, KO; Bigler, ED; Abildskov, T; Dennis, M; Gerhardt, CA; Vannatta, K; Rubin, KH; Stancin, T; Taylor, HG				Yeates, Keith Owen; Bigler, Erin D.; Abildskov, Tracy; Dennis, Maureen; Gerhardt, Cynthia A.; Vannatta, Kathryn; Rubin, Kenneth H.; Stancin, Terry; Taylor, H. Gerry			Social Competence in Pediatric Traumatic Brain Injury: From Brain to Behavior	CLINICAL PSYCHOLOGICAL SCIENCE			English	Article						social cognition; brain; social behavior	NATURALISTIC OBSERVATIONS; CHILDREN; TRAJECTORIES; CHILDHOOD; NEUROSCIENCE; WITHDRAWAL; OUTCOMES; MIND	This study examined the associations among brain volumes, theory of mind (ToM), peer relationships, and psychosocial adjustment in children with traumatic brain injury (TBI). Participants included 8-to 13-year-old children, 82 with TBI and 61 with orthopedic injuries (OIs). Children completed three measures of ToM. Classmates provided ratings of participants' peer relationships, acceptance, and friendships. Parents rated children's psychosocial adjustment. MRI was used to determine brain volumes. Brain volumes were associated with ToM, which in turn was associated with peer rejection/victimization. Peer rejection/victimization in the classroom was associated with peer acceptance, friendship, social withdrawal, and general psychopathology. Brain volumes, ToM, peer relationships, and social adjustment show significant links among children with TBI and those with OI. The findings support a multilevel model of social competence in childhood TBI.	[Yeates, Keith Owen; Gerhardt, Cynthia A.; Vannatta, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen; Gerhardt, Cynthia A.; Vannatta, Kathryn] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA; [Bigler, Erin D.; Abildskov, Tracy] Brigham Young Univ, Dept Psychol Sci & Neurosci Ctr, Provo, UT 84602 USA; [Dennis, Maureen] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON, Canada; [Dennis, Maureen] Univ Toronto, Dept Psychol, Toronto, ON, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Rubin, Kenneth H.] Univ Maryland, Dept Human Dev, Baltimore, MD 21201 USA; [Stancin, Terry; Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Stancin, Terry] Metro Hlth Med Ctr, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Rubin, Kenneth H/M-5276-2018; Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Rubin, Kenneth H/0000-0002-2608-2484; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5 R01 HD048946]	The preparation of this article was supported in part by Grant 5 R01 HD048946 from the National Institute of Child Health and Human Development to K. O. Yeates.	Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; ASHER SR, 1979, DEV PSYCHOL, V15, P443, DOI 10.1037/0012-1649.15.4.443; Beauchamp, 2012, DEV SOCIAL NEUROSCIE, P23; Bendfeldt K, 2012, HUM BRAIN MAPP, V33, P1225, DOI 10.1002/hbm.21279; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Booth-LaForce C, 2012, J CLIN CHILD ADOLESC, V41, P138, DOI 10.1080/15374416.2012.651995; Bowker JCW, 2006, MERRILL PALMER QUART, V52, P671, DOI 10.1353/mpq.2006.0000; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Bukowski W.M., 1989, PEER RELATIONS CHILD, P15; Cornish K, 2005, BRAIN COGNITION, V57, P53, DOI 10.1016/j.bandc.2004.08.020; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P338, DOI 10.1017/S1355617712001440; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Faul M, 2010, TRAUMATIC BRAIN INJU; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; Harrison P.L., 2003, ABAS 2 ADAPTIVE BEHA, V2nd ed.; Hawkins DL, 2001, SOC DEV, V10, P512; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Howard I, 2005, ETHNIC DIS, V15, pS51; HUBBARD JA, 1994, MERRILL PALMER QUART, V40, P1; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Laursen B., 2007, CHILD DEV, V71, P107; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Martinez W, 2011, J PEDIATR PSYCHOL, V36, P878, DOI 10.1093/jpepsy/jsr035; MASTEN AS, 1985, DEV PSYCHOL, V21, P523, DOI 10.1037/0012-1649.21.3.523; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Oh W, 2008, J ABNORM CHILD PSYCH, V36, P553, DOI 10.1007/s10802-007-9199-z; PEPLER DJ, 1995, DEV PSYCHOL, V31, P548, DOI 10.1037/0012-1649.31.4.548; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS, V2; Riva D., CEREBELLUM IN PRESS; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Rubin K.H., 1992, HDB SOCIAL DEV, P283, DOI [10.1007/978-1-4899-0694-6_12, DOI 10.1007/978-1-4899-0694-6]; Rubin KH, 2006, J ABNORM CHILD PSYCH, V34, P143, DOI 10.1007/s10802-005-9017-4; Rubin KH., 2006, HDB CHILD PSYCHOL, P571, DOI DOI 10.1002/9780470147658.CHPSY0310; Schnack HG, 2010, HUM BRAIN MAPP, V31, P1967, DOI 10.1002/hbm.20991; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Sokolov AA, 2012, NEUROIMAGE, V59, P2824, DOI 10.1016/j.neuroimage.2011.08.039; Tate DF, 2011, J INT NEUROPSYCH SOC, V17, P308, DOI 10.1017/S1355617710001670; TEASDALE G, 1974, LANCET, V2, P81; Yeates K. O., 2010, PEDIAT NEUROPSYCHOLO, P112; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Zaki J, 2009, ANN NY ACAD SCI, V1167, P16, DOI 10.1111/j.1749-6632.2009.04601.x; Ziegler G, 2012, HUM BRAIN MAPP, V33, P2377, DOI 10.1002/hbm.21374	52	26	26	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2167-7026	2167-7034		CLIN PSYCHOL SCI	Clin. Psychol. Sci.	JAN	2014	2	1					97	107		10.1177/2167702613499734			11	Psychology, Clinical; Psychiatry; Psychology	Emerging Sources Citation Index (ESCI)	Psychology; Psychiatry	V9Y6L	WOS:000409451800010					2022-02-06	
J	Hill, BD; Rohling, ML; Boettcher, AC; Meyers, JE				Hill, Benjamin D.; Rohling, Martin L.; Boettcher, Anneliese C.; Meyers, John E.			Cognitive Intra-Individual Variability Has a Positive Association with Traumatic Brain Injury Severity and Suboptimal Effort	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Intra-individual variability; Traumatic brain injury; Dispersion; Performance validity	REACTION-TIME; PERFORMANCE; CONSISTENCY; ATTENTION; INCONSISTENCY; VALIDATION; DISPERSION; FATIGUE; SCORES	This study examined intra-individual variability in a large sample (n 629) of individuals with a history of mild traumatic brain injury (mTBI) or TBI referred for neuropsychological evaluation. Variability was assessed using the overall test battery mean standard deviation (OTBM SD). We found a negative linear relation between OTBM and OTBM SD (r .672) in this sample with a history of neurologic pathology, indicating that the variability is inversely related to cognitive performance and contrary to what is observed in most normative data. Analyses revealed main effects for OTBM and OTBM SD across three TBI severity groups: loss of consciousness (LOC) 1 h, LOC 1 h6 days, and LOC 6 days. These effects were found for both a valid performance group (no failed embedded validity measures; n 504) and an invalid performance group (failed one or more embedded validity measures; n 125). These findings support that cognitive intra-individual variability is increased uniquely by both neuropathology and suboptimal effort, there is a doseresponse relationship between neuropathology and cognitive variability, and intra-individual variability may have utility as a clinical index of both.	[Hill, Benjamin D.; Rohling, Martin L.; Boettcher, Anneliese C.] Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA; [Meyers, John E.] Meyers Neuropsychol Serv, Mililani, HI USA		Hill, BD (corresponding author), Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA.	bdhill@southalabama.edu		Hill, Benjamin/0000-0002-5797-5082			Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bielak AAM, 2010, NEUROPSYCHOLOGY, V24, P731, DOI 10.1037/a0019802; Bielak AAM, 2010, PSYCHOL AGING, V25, P575, DOI 10.1037/a0019503; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; Brooks BL, 2009, CAN PSYCHOL, V50, P196, DOI 10.1037/a0016066; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Demakis GJ, 1999, ARCH CLIN NEUROPSYCH, V14, P401, DOI 10.1016/S0887-6177(98)00039-0; Duchek JM, 2009, NEUROPSYCHOLOGY, V23, P746, DOI 10.1037/a0016583; Fuentes K, 2001, CLIN NEUROPSYCHOL, V15, P210, DOI 10.1076/clin.15.2.210.1896; Green P., 2003, GREENS WORD MEMORY T; Gunner JH, 2012, ARCH CLIN NEUROPSYCH, V27, P1, DOI 10.1093/arclin/acr089; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hamsher K., 1989, MULTILINGUAL APHASIA; HERTZOG C, 1992, BRAIN LANG, V42, P248, DOI 10.1016/0093-934X(92)90100-S; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Hilborn JV, 2009, J CLIN EXP NEUROPSYC, V31, P412, DOI 10.1080/13803390802232659; Hultsch DF, 2002, J GERONTOL B-PSYCHOL, V57, pP101, DOI 10.1093/geronb/57.2.P101; Kozel JJ, 1998, ARCH CLIN NEUROPSYCH, V13, P327, DOI 10.1016/S0887-6177(97)00036-X; MacDonald SWS, 2008, PSYCHOL AGING, V23, P595, DOI 10.1037/0882-7974.23.3.595; MacDonald SWS, 2003, PSYCHOL AGING, V18, P510, DOI 10.1037/0882-7974.18.3.510; Meyers J, 2000, TELEPHONY, V239, P7; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P79, DOI 10.1016/S0887-6177(00)00105-0; Meyers JE., 1995, REY COMPLEX FIGURE T; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Morgan EE, 2011, NEUROPSYCHOLOGY, V25, P645, DOI 10.1037/a0023792; Nesselroade JR, 2001, EUR PSYCHOL, V6, P187, DOI 10.1027//1016-9040.6.3.187; Pilgrim B M, 1999, Appl Neuropsychol, V6, P243, DOI 10.1207/s15324826an0604_7; Ram N, 2005, PSYCHOL AGING, V20, P623, DOI 10.1037/0882-7974.20.4.623; Reitan R, 1985, HALSTEAD REITAN NEUR; Reitan RM, 1997, CLIN NEUROPSYCHOL, V11, P69, DOI 10.1080/13854049708407031; Roberts M A, 1994, Appl Neuropsychol, V1, P45, DOI 10.1207/s15324826an0101&2_9; Schinka J.A., 1994, PSYCHOL ASSESSMENT, V6, P364, DOI [https://doi.org/10.1037/1040-3590.6.4.364, DOI 10.1037/1040-3590.6.4.364]; Schretlen DJ, 2003, J INT NEUROPSYCH SOC, V9, P864, DOI 10.1017/S1355617703960061; Sosnoff JJ, 2007, NEUROPSYCHOLOGY, V21, P796, DOI 10.1037/0894-4105.21.6.796; Spreen O., 1998, COMPENDIUM NEUROPSYC, P2; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Strauss E, 1999, CLIN NEUROPSYCHOL, V13, P420, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT420; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Tombaugh T.N., 1996, TEST MEMORY MALINGER; WARD LC, 1990, J CLIN PSYCHOL, V46, P436, DOI 10.1002/1097-4679(199007)46:4<436::AID-JCLP2270460411>3.0.CO;2-M	45	26	27	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2013	28	7					640	648		10.1093/arclin/act045			9	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	243AS	WOS:000326289300002	23832096	Green Published			2022-02-06	
J	Macciocchi, SN; Seel, RT; Thompson, N				Macciocchi, Stephen N.; Seel, Ronald T.; Thompson, Nicole			The Impact of Mild Traumatic Brain Injury on Cognitive Functioning Following Co-occurring Spinal Cord Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Assessment; Forensic neuropsychology; Rehabilitation	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; SPORTS-RELATED CONCUSSION; CLOSED HEAD-INJURY; METAANALYSIS; RECOVERY; ELDERS; SCORES	Meta-analytic studies have shown that mild traumatic brain injury (MTBI) has relatively negligible effects on cognitive functioning at 90 or more days post-injury. Few studies have prospectively examined the effects of MTBI in acute physical trauma populations. This prospective, cohort study compared the cognitive performance of persons who sustained a spinal cord injury (SCI) and a co-occurring MTBI (N 53) to persons who sustained an SCI alone (N 64) between 26 and 76 days (mean 46) post-injury. The presence of MTBI was determined based on acute medical record review using a standardized algorithm. Primary outcome measures were seven neuropsychological tests that evaluated visual, verbal, and working memory, perceptual reasoning, and processing speed that controlled for potential upper extremity impairment. Persons who sustained SCI with or without MTBI had lower than expected performance across all neuropsychological tests, on average about 1 SD below the mean. Analysis of covariance indicated that persons with MTBI did not evidence greater impairment on any neuropsychological test. The aggregated effect size (Cohens d) was 0.16. The strongest predictors of neuropsychological test scores were education, race, history of learning problems, and days from injury to rehabilitation admission. MTBI did not predict performance on any neuropsychological test. These findings are consistent with other controlled studies that indicate a single MTBI has negligible long-term impacts on cognition.	[Macciocchi, Stephen N.; Seel, Ronald T.; Thompson, Nicole] Shepherd Ctr, Atlanta, GA 30309 USA; [Macciocchi, Stephen N.] Univ Georgia, Athens, GA 30602 USA		Macciocchi, SN (corresponding author), Shepherd Ctr, 2020 Peachtree Rd NW, Atlanta, GA 30309 USA.	stephen_macciocchi@shepherd.org			National Institute of Disability and Rehabilitation Research [H113G03004]	Funding for this study was provided by National Institute of Disability and Rehabilitation Research: H113G03004.	Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benedict, 2001, HOPKINS VERBAL LEARN; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Dotson VM, 2008, CLIN NEUROPSYCHOL, V22, P989, DOI 10.1080/13854040701679017; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein MF, 2003, CLIN NEUROPSYCHOL, V17, P561, DOI 10.1076/clin.17.4.561.27937; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Manly JJ, 2005, J GERIATR PSYCH NEUR, V18, P213, DOI 10.1177/0891988705281868; Manly JJ, 2002, J INT NEUROPSYCH SOC, V8, P341, DOI 10.1017/S1355617702813157; Mapou R. L., 2008, ADULT LEARNING DISAB; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sipski ML, 2006, AM J PHYS MED REHAB, V85, P310, DOI 10.1097/01.phm.0000202105.87011.bf; Smith A, 1995, SYMBOL DIGIT MODALIT; Trahan DE, 1988, CONTINUOUS VISUAL ME; Wechsler D., 1997, ADM SCORING MANUAL W; Wetzel L., 2000, SHORT CATEGORY TEST	32	26	28	0	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2013	28	7					684	691		10.1093/arclin/act049			8	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	243AS	WOS:000326289300006	24055885	Green Published, Bronze			2022-02-06	
J	Okuma, Y; Wang, FF; Toyoshima, A; Kameda, M; Hishikawa, T; Tokunaga, K; Sugiu, K; Liu, KY; Haruma, J; Nishibori, M; Yasuhara, T; Date, I				Okuma, Yu; Wang, Feifei; Toyoshima, Atsuhiko; Kameda, Masahiro; Hishikawa, Tomohito; Tokunaga, Koji; Sugiu, Kenji; Liu, Keyue; Haruma, Jun; Nishibori, Masahiro; Yasuhara, Takao; Date, Isao			Mannitol enhances therapeutic effects of intra-arterial transplantation of mesenchymal stem cells into the brain after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Mesenchymal stem cells; Hypertonic solution	BONE-MARROW; RATS; PRESSURE; DELIVERY; BARRIER; STROKE	Traumatic brain injury (TBI) sustained in a traffic accident or a fall is a major cause of death that affects a broad range of ages. The aim of this study was to investigate the therapeutic effects of intra-arterial transplantation of mesenchymal stem cells (MSCs) combined with hypertonic glycerol (25%) or mannitol (25%) in a TBI model of rats. TBI models were produced with a fluid percussion device. At 24 h after TBI, MSCs (1 x 10(6) cells/100 mu l) with glycerol or mannitol were administered via the right internal carotid artery. Rats were evaluated behaviorally and immunohistochemically, and hyperpermeability of the blood-brain barrier (BBB) induced by hypertonic solutions was explored. Compared to PBS or glycerol, the administration of mannitol resulted in increased BBB disruption. The mannitol-treated rats showed significant improvement in motor function. Intra-arterial transplantation of MSCs caused no thromboembolic ischemia. Immunohistochemically, more MSCs were observed in the injured brain tissues of mannitol-treated rats than in glycerol or PBS-treated rats at 24 h after transplantation. Intra-arterial transplantation of MSCs combined with mannitol is an effective treatment in a TBI model of rats. This technique might be used for patients with diseases of the central nervous system including TBI. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Okuma, Yu; Wang, Feifei; Toyoshima, Atsuhiko; Kameda, Masahiro; Hishikawa, Tomohito; Tokunaga, Koji; Sugiu, Kenji; Haruma, Jun; Yasuhara, Takao; Date, Isao] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan; [Okuma, Yu; Liu, Keyue; Haruma, Jun; Nishibori, Masahiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Okayama, Japan; [Wang, Feifei] Kochi Univ, Sch Med, Ctr Innovat & Translat Med, Kochi 7838505, Japan		Wang, FF (corresponding author), Kochi Univ, Sch Med, Ctr Innovat & Translat Med, Nanko Ku, Oko Cho, Kochi 7838505, Japan.	f-wang@kochi-u.ac.jp		Okuma, Yu/0000-0003-4769-8111	Ministry of Education, Culture, Sports, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24390061] Funding Source: KAKEN	The authors thank Ms. Masako Arao and Ms. Natsuki Uemori for their assistance. This work was supported in part by Grants-in-Aid for Scientific Research and Health Science Research Grants for Research on Brain Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Armin SS, 2008, ACTA NEUROCHIR SUPPL, V104, P421; Borlongan CV, 2012, CURR PHARM DESIGN, V18, P3670; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; COSOLO WC, 1989, AM J PHYSIOL, V256, pR443, DOI 10.1152/ajpregu.1989.256.2.R443; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; Lee HS, 2003, STEM CELLS, V21, P190, DOI 10.1634/stemcells.21-2-190; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; MCGRAW CP, 1983, NEUROSURGERY, V13, P269, DOI 10.1227/00006123-198309000-00009; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Scalfani MT, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.10.008; Schierhout G., 2000, COCHRANE DB SYST REV, V2; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Seyfried DM, 2008, BRAIN RES, V1224, P12, DOI 10.1016/j.brainres.2008.05.080; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Wang FF, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-52; WISE BL, 1961, ARCH NEUROL-CHICAGO, V4, P200, DOI 10.1001/archneur.1961.00450080082009; Yasuhara T, 2010, J CELL MOL MED, V14, P914, DOI 10.1111/j.1582-4934.2008.00671.x	22	26	27	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 25	2013	554						156	161		10.1016/j.neulet.2013.08.058			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	261ON	WOS:000327674600030	24016413				2022-02-06	
J	Fins, JJ				Fins, Joseph J.			Disorders of Consciousness and Disordered Care: Families, Caregivers, and Narratives of Necessity	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Affordable Care Act; Brain injury; Disability and civil rights; Disorders of consciousness; Family narratives; Neuroethics; Rehabilitation; Vegetative State	TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; PLACEBO-CONTROLLED TRIAL; MEDICAL ASPECTS; RECOVERY; COMA; OPPORTUNITIES; STIMULATION; RESPONSES; ACCESS	By their nature, care decisions for patients with severe disorders of consciousness must involve surrogates. Patients, so impaired, have lost their decision-making capacity and the ability to direct their own care. Surrogates-family members, friends, or other intimates-must step in and make decisions about ongoing care or its withdrawal. This article shares the narrative experiences of these surrogate decision makers as they encounter the American health care system and accompany patients from injury through rehabilitation. Through their perspectives, the article considers challenges to ongoing care and rehabilitation that are a function of a prevailing medical infrastructure and reimbursement framework better suited to patients with acute care needs. Specific attention is paid to the ethical challenges posed by reimbursement strategies such as "medical necessity" as well as those proposed for the Affordable Care Act. The argument concludes that when it comes to care for a disorder related to consciousness, its provision is not discretionary, and its receipt is not an entitlement but a civil right. (c) 2013 by the American Congress of Rehabilitation Medicine	[Fins, Joseph J.] Weill Cornell Med Coll, Div Med Eth, New York, NY USA; [Fins, Joseph J.] Rockefeller Univ, New York, NY 10021 USA		Fins, JJ (corresponding author), Rockefeller Univ, Weill Cornell Med Coll, Div Med Eth, 435 East 70th St,Ste 4-J, New York, NY 10021 USA.	jjfins@med.cornell.edu		Fins, Joseph/0000-0002-7221-0053	Investigator Award in Health Policy Research from the Robert Wood Johnson Foundation; Buster Foundation; Jerold B. Katz Foundation	Supported by an Investigator Award in Health Policy Research from the Robert Wood Johnson Foundation, and grants from the Buster and Jerold B. Katz Foundations.	[Anonymous], 1994, N ENGL J MED, V330, P1499; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Berkowitz SA, 2011, NEW ENGL J MED, V364, DOI 10.1056/NEJMp1100076; Berube J, 2006, MOHONK REPORT REPORT; Brody H., 2009, STORIES SICKNESS; Carusone P., 2011, COMMUNICATION; Connors S, 2012, BRAIN INJURY ASS AM; Fins J, 2010, T AM CLIN CLIMAT ASS, V122, P336; Fins J. J., 2011, TRANSFORMING HLTH CA, P21; Fins JJ, 1999, J PAIN SYMPTOM MANAG, V17, P6, DOI 10.1016/S0885-3924(98)00109-2; Fins JJ, 2004, ARCH NEUROL-CHICAGO, V61, P1354, DOI 10.1001/archneur.61.9.1354; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Fins JJ, 2005, HASTINGS CENT REP, V35, P22, DOI 10.2307/3527759; FINS JJ, 2010, LAW NEUROSCIENCE CUR, V13, P367, DOI DOI 10.1093/ACPROF:OSO/9780199599844.003.0018; Fins JJ, 2006, PALLIATIVE ETHIC CAR; Fins JJ., 2007, PLUM POSNERS DIAGNOS; Fins Joseph J, 2006, Palliat Support Care, V4, P169; Fins JJ, 2007, NEUROLOGY, V68, P304, DOI 10.1212/01.wnl.0000252376.43779.96; Fins Joseph J, 2012, Virtual Mentor, V14, P221, DOI 10.1001/virtualmentor.2012.14.3.stas1-1203; Fins JJ, 2011, SOC RES, V78, P731; Fins JJ, 2012, ARCH NEUROL-CHICAGO, V69, P158, DOI 10.1001/archneurol.2011.1211; Fins JJ, 2009, PROG BRAIN RES, V177, P371, DOI 10.1016/S0079-6123(09)17726-9; Fins JJ, 2009, CAMB Q HEALTHC ETHIC, V18, P7, DOI 10.1017/S0963180108090038; Fins JJ, 2009, ANN NY ACAD SCI, V1157, P131, DOI 10.1111/j.1749-6632.2009.04473.x; Giacino J, 2012, NEUROMODULATION, V15, P339, DOI 10.1111/j.1525-1403.2012.00458.x; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Granger CV, 2009, AM J PHYS MED REHAB, V88, P755, DOI 10.1097/PHM.0b013e3181aa71a8; Kastor JA, 2011, NEW ENGL J MED, V364, DOI 10.1056/NEJMp1013221; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; Luft HS, 2010, NEW ENGL J MED, V363, P1389, DOI 10.1056/NEJMp1009380; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Nolan JP, 2010, CURR OPIN CRIT CARE, V16, P216, DOI 10.1097/MCC.0b013e3283383dca; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Pascrell B., 2011, COMMUNICATION; Relyea-Chew A, 2009, ARCH PHYS MED REHAB, V90, P413, DOI 10.1016/j.apmr.2008.07.031; Rossetti AO, 2012, NEUROLOGY, V78, P796, DOI 10.1212/WNL.0b013e318249f6bb; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2012, PRINCIPLES PRACTICE, P1724; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; the Multi-Society Task Force on PVS, 1994, N ENGL J MED, V330, P1572; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wijdicks EFM, 2007, NEUROLOGY, V68, P1092, DOI 10.1212/01.wnl.0000259401.36220.1a	49	26	28	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1934	1939		10.1016/j.apmr.2012.12.028			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	231TU	WOS:000325442100011	23770277				2022-02-06	
J	Volman, V; Ng, LJ				Volman, Vladislav; Ng, Laurel J.			Computer Modeling of Mild Axonal Injury: Implications for Axonal Signal Transmission	NEURAL COMPUTATION			English	Article							TRAUMATIC BRAIN-INJURY; POTASSIUM-ION ACCUMULATION; SPINAL-CORD AXONS; MYELINATED NERVE; WHITE-MATTER; HEAD-INJURY; CONDUCTION DEFICITS; CORPUS-CALLOSUM; SODIUM-CHANNELS; IN-VIVO	Diffusion imaging and postmortem studies of patients with mild traumatic brain injury (mTBI) of the concussive type are consistent with the observations of diffuse axonal injury to the white matter axons. Mechanical trauma to axons affects the properties of tetrodotoxin-sensitive sodium channels at the nodes of Ranvier, leading to axonal degeneration through intra-axonal accumulation of calcium ions and activation of calcium proteases; however, the immediate implications of axonal trauma regarding axonal functionality and their relevance to transient impairment of function as observed in concussion remain elusive. A biophysically realistic computational model of a myelinated axon was developed to investigate how mTBI could immediately affect axonal function. Traumatized axons showed alterations in signal propagation properties that nonlinearly depended on the level of trauma; subthreshold traumatized axons had decreased spike propagation time, whereas suprathreshold traumatized axons exhibited a slowdown of spike propagation and spike propagation failure. Trauma had consistently reduced axonal spike amplitude. The susceptibility of an axon to trauma could be modulated by the function of an ATP-dependent sodium-potassium pump. The results suggest a mechanism by which concussive mTBI could lead to the immediate impairment of signal propagation through the axon and the emerging dysfunctional neuronal information exchange.	[Volman, Vladislav; Ng, Laurel J.] L3 Appl Technol Simulat Engn & Testing, San Diego, CA 92121 USA; [Volman, Vladislav] Salk Inst Biol Studies, Computat Neurobiol Lab, La Jolla, CA 92037 USA; [Volman, Vladislav] Univ Calif San Diego, Ctr Theoret Biol Phys, La Jolla, CA 92093 USA		Volman, V (corresponding author), L3 Appl Technol Simulat Engn & Testing, San Diego, CA 92121 USA.	Vladislav.Volman@l-3com.com; Laurel.Ng@l-3com.com					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADELMAN WJ, 1973, J MEMBRANE BIOL, V13, P387, DOI 10.1007/BF01868237; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bazhenov M, 2004, J NEUROPHYSIOL, V92, P1116, DOI 10.1152/jn.00529.2003; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Boucher PA, 2012, J COMPUT NEUROSCI, V33, P301, DOI 10.1007/s10827-012-0387-7; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CHIU SY, 1979, J PHYSIOL-LONDON, V292, P149, DOI 10.1113/jphysiol.1979.sp012843; Choo A. M., 2011, SOC NEUR M, V159, pAA32; Coggan JS, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/065002; Coggan JS, 2010, P NATL ACAD SCI USA, V107, P20602, DOI 10.1073/pnas.1013798107; Destexhe A, 1994, J Comput Neurosci, V1, P195, DOI 10.1007/BF00961734; FRANKENHAEUSER B, 1964, J PHYSIOL-LONDON, V171, P302, DOI 10.1113/jphysiol.1964.sp007378; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; HEINEMANN U, 1977, EXP BRAIN RES, V27, P237; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hille B., 2001, IONS CHANNELS EXCITA; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; Huff TB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017176; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jensen MS, 1997, J NEUROPHYSIOL, V77, P1224, DOI 10.1152/jn.1997.77.3.1224; JONAS P, 1989, P NATL ACAD SCI USA, V86, P7238, DOI 10.1073/pnas.86.18.7238; Kager H, 2000, J NEUROPHYSIOL, V84, P495, DOI 10.1152/jn.2000.84.1.495; Krishnan GP, 2011, J NEUROSCI, V31, P8870, DOI 10.1523/JNEUROSCI.6200-10.2011; Leao RM, 2005, J NEUROSCI, V25, P3724, DOI 10.1523/JNEUROSCI.3983-04.2005; Li JM, 2007, J BIOMECH, V40, P569, DOI 10.1016/j.jbiomech.2006.02.009; Lopreore CL, 2008, BIOPHYS J, V95, P2624, DOI 10.1529/biophysj.108.132167; Lundborg G, 1973, J Bone Joint Surg Br, V55, P390; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MORAN N, 1980, BIOPHYS J, V32, P939, DOI 10.1016/S0006-3495(80)85028-4; OGATA K, 1986, J HAND SURG-BRIT EUR, V11B, P10, DOI 10.1016/0266-7681(86)90003-3; Patel TP, 2012, ANN BIOMED ENG, V40, P23, DOI 10.1007/s10439-011-0390-6; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rickett T, 2011, J MED SYST, V35, P787, DOI 10.1007/s10916-010-9468-1; RINGO JL, 1994, CEREB CORTEX, V4, P331, DOI 10.1093/cercor/4.4.331; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572, DOI 10.1152/jn.1996.76.3.1572; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Singh A, 2009, J NEUROTRAUM, V26, P627, DOI 10.1089/neu.2008.0621; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sun WJ, 2012, J NEUROTRAUM, V29, P611, DOI 10.1089/neu.2011.2086; Sun WJ, 2010, J NEUROPHYSIOL, V103, P469, DOI 10.1152/jn.00154.2009; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Wang JA, 2009, AM J PHYSIOL-CELL PH, V297, pC823, DOI 10.1152/ajpcell.00505.2008; WAXMAN SG, 1985, SCIENCE, V228, P1502, DOI 10.1126/science.2409596; WAXMAN SG, 1977, PROG NEUROBIOL, V8, P297, DOI 10.1016/0301-0082(77)90009-0; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yu N., 2012, PLOS COMPUT BIOL, V8; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009	61	26	26	0	20	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0899-7667	1530-888X		NEURAL COMPUT	Neural Comput.	OCT	2013	25	10					2646	2681		10.1162/NECO_a_00491			36	Computer Science, Artificial Intelligence; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Neurosciences & Neurology	210HW	WOS:000323822800004	23777525				2022-02-06	
J	Brockman, EC; Bayir, H; Blasiole, B; Shein, SL; Fink, EL; Dixon, CE; Clark, RSB; Vagni, VA; Ma, L; Hsia, CJC; Tisherman, SA; Kochanek, PM				Brockman, Erik C.; Bayir, Huelya; Blasiole, Brian; Shein, Steven L.; Fink, Ericka L.; Dixon, C. Edward; Clark, Robert S. B.; Vagni, Vincent A.; Ma, Li; Hsia, Carleton J. C.; Tisherman, Samuel A.; Kochanek, Patrick M.			Polynitroxylated-pegylated hemoglobin attenuates fluid requirements and brain edema in combined traumatic brain injury plus hemorrhagic shock in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood substitute; cerebral edema; hemoglobin blood oxygen carrier; intracranial pressure; nitroxide; resuscitation	CEREBRAL-BLOOD-FLOW; INTRACRANIAL-PRESSURE; OXYGEN DELIVERY; RESUSCITATION; HYPOTENSION; CONSEQUENCES; SUBSTITUTES; EXPRESSION; ALBUMIN; DAMAGE	Polynitroxylated-pegylated hemoglobin (PNPH), a bovine hemoglobin decorated with nitroxide and polyethylene glycol moieties, showed neuroprotection vs. lactated Ringer's (LR) in experimental traumatic brain injury plus hemorrhagic shock (TBI+HS). Hypothesis: Resuscitation with PNPH will reduce intracranial pressure (ICP) and brain edema and improve cerebral perfusion pressure (CPP) vs. LR in experimental TBI+HS. C57/BL6 mice (n = 20) underwent controlled cortical impact followed by severe HS to mean arterial pressure (MAP) of 25 to 27 mm Hg for 35 minutes. Mice (n = 10/group) were then resuscitated with a 20 mL/kg bolus of 4% PNPH or LR followed by 10 mL/kg boluses targeting MAP>70 mm Hg for 90 minutes. Shed blood was then reinfused. Intracranial pressure was monitored. Mice were killed and % brain water (%BW) was measured (wet/dry weight). Mice resuscitated with PNPH vs. LR required less fluid (26.0 +/- 0.0 vs. 167.0 +/- 10.7 mL/kg, P<0.001) and had a higher MAP (79.4 +/- 0.40 vs. 59.7 +/- 0.83mmHg, P<0.001). The PNPH-treated mice required only 20 mL/kg while LR-resuscitated mice required multiple boluses. The PNPH-treated mice had a lower peak ICP (14.5 +/- 0.97 vs. 19.7 +/- 1.12mmHg, P = 0.002), higher CPP during resuscitation (69.2 +/- 0.46 vs. 45.5 +/- 0.68mmHg, P<0.001), and lower % BW vs. LR (80.3 +/- 0.12 vs. 80.9 +/- 0.12%, P = 0.003). After TBI+HS, resuscitation with PNPH lowers fluid requirements, improves ICP and CPP, and reduces brain edema vs. LR, supporting its development.	[Brockman, Erik C.; Bayir, Huelya; Shein, Steven L.; Fink, Ericka L.; Clark, Robert S. B.; Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Brockman, Erik C.; Bayir, Huelya; Blasiole, Brian; Shein, Steven L.; Fink, Ericka L.; Dixon, C. Edward; Clark, Robert S. B.; Vagni, Vincent A.; Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Brockman, Erik C.; Bayir, Huelya; Shein, Steven L.; Fink, Ericka L.; Clark, Robert S. B.; Kochanek, Patrick M.] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Bayir, Huelya] Univ Pittsburgh, Sch Med, Pittsburgh Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA; [Blasiole, Brian] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Ma, Li] Georgia So Univ, Dept Phys, Statesboro, GA 30460 USA; [Hsia, Carleton J. C.] SynZyme Technol LLC, Irvine, CA USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Tisherman, Samuel A./AAK-9377-2020; Fink, Ericka/AAU-9792-2021; Kochanek, Patrick M/D-2371-2015; Shein, Steven/I-7763-2019	Tisherman, Samuel A./0000-0003-3810-3729; Kochanek, Patrick M/0000-0002-2627-913X; Shein, Steven/0000-0003-3382-5159; Fink, Ericka/0000-0002-3683-4571	 [U44 NS070324];  [T32 HD040686];  [K12 HD047349]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD047349, T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U44NS070324] Funding Source: NIH RePORTER	This study was supported by U44 NS070324, T32 HD040686, and K12 HD047349.	Alayash AI, 1999, NAT BIOTECHNOL, V17, P545, DOI 10.1038/9849; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Buehler PW, 2004, TRANSFUSION, V44, P1516, DOI 10.1111/j.1537-2995.2004.04081.x; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Burhop K, 2004, ARTIF CELL BLOOD SUB, V32, P353, DOI 10.1081/LABB-200027429; Chesnut R M, 1995, New Horiz, V3, P366; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; DeAngeles DA, 1997, J TRAUMA, V42, P406, DOI 10.1097/00005373-199703000-00007; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Foley LM, 2013, J CEREBR BLOOD F MET, V33, P129, DOI 10.1038/jcbfm.2012.145; GRAHAM DI, 1971, LANCET, V1, P265; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hsia Carleton Jen Chang, 2012, Artif Organs, V36, P215, DOI 10.1111/j.1525-1594.2011.01307.x; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jungner M, 2010, ANESTHESIOLOGY, V112, P1194, DOI 10.1097/ALN.0b013e3181d94d6e; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Morrison CA, 2011, J TRAUMA, V70, P652, DOI 10.1097/TA.0b013e31820e77ea; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Natanson C, 2008, JAMA-J AM MED ASSOC, V299, P2304, DOI 10.1001/jama.299.19.jrv80007; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Okayama N, 1999, FREE RADICAL RES, V31, P53, DOI 10.1080/10715769900300591; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; Reid TJ, 2003, TRANSFUSION, V43, P280, DOI 10.1046/j.1537-2995.2003.00314.x; Resta TC, 2002, J APPL PHYSIOL, V93, P1327, DOI 10.1152/japplphysiol.00175.2002; RICHES AC, 1973, J PHYSIOL-LONDON, V228, P279, DOI 10.1113/jphysiol.1973.sp010086; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Saetzler RK, 1999, FREE RADICAL BIO MED, V27, P1, DOI 10.1016/S0891-5849(99)00037-4; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Stoyanovsky DA, 2010, BIOCHEM BIOPH RES CO, V399, P139, DOI 10.1016/j.bbrc.2010.07.030; Wills BA, 2004, J INFECT DIS, V190, P810, DOI 10.1086/422754	40	26	26	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2013	33	9					1457	1464		10.1038/jcbfm.2013.104			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	214IQ	WOS:000324126400018	23801241	Green Published, Bronze			2022-02-06	
J	Holmes, AK; Rauch, PK; Cozza, SJ				Holmes, Allison K.; Rauch, Paula K.; Cozza, Stephen J.			When a Parent Is Injured or Killed in Combat	FUTURE OF CHILDREN			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; BEREAVED CHILDREN; PROVIDER PERSPECTIVES; VIETNAM VETERANS; SERVICE MEMBERS; WAR VETERANS; ADJUSTMENT; SOLDIERS	When a service member is injured or dies in a combat zone, the consequences for his or her family can be profound and long-lasting. Visible, physical battlefield injuries often require families to adapt to long and stressful rounds of treatment and rehabilitation, and they can leave the service member with permanent disabilities that mean new roles for everyone in the family. Invisible injuries, both physical and psychological, including traumatic brain injury and combat-related stress disorders, are often not diagnosed until many months after a service member returns from war (if they are diagnosed at all-many sufferers never seek treatment). They can alter a service member's behavior and personality in ways that make parenting difficult and reverberate throughout the family. And a parent's death in combat not only brings immediate grief but can also mean that survivors lose their very identity as a military family when they must move away from their supportive military community. Sifting through the evidence on both military and civilian families, Allison Holmes, Paula Rauch, and Stephen Cozza analyze, in turn, how visible injuries, traumatic brain injuries, stress disorders, and death affect parents' mental health, parenting capacity, and family organization; they also discuss the community resources that can help families in each situation. They note that most current services focus on the needs of injured service members rather than those of their families. Through seven concrete recommendations, they call for a greater emphasis on family-focused care that supports resilience and positive adaptation for all members of military families who are struggling with a service member's injury or death.	[Holmes, Allison K.; Cozza, Stephen J.] Uniformed Serv Univ Hlth Sci, Ctr Study Traumat Stress, Bethesda, MD 20814 USA; [Rauch, Paula K.] Massachusetts Gen Hosp Home Base Team, Boston, MA USA; [Rauch, Paula K.] Harvard Univ, Med School, Cambridge, MA 02138 USA; [Cozza, Stephen J.] US Army, Adelphi, MD USA		Holmes, AK (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Study Traumat Stress, Bethesda, MD 20814 USA.						ARMISTEAD L, 1995, CLIN PSYCHOL REV, V15, P409, DOI 10.1016/0272-7358(95)00023-I; Bachar E, 1997, J NERV MENT DIS, V185, P402, DOI 10.1097/00005053-199706000-00007; Ben Arzi N, 2000, BRAIN INJURY, V14, P725; Brown J, 1998, CHILD ABUSE NEGLECT, V22, P1065, DOI 10.1016/S0145-2134(98)00087-8; Butera-Prinzi F, 2004, BRAIN INJURY, V18, P83, DOI 10.1080/0269905031000118500; Charles N, 2007, NEUROREHABILITATION, V22, P61; Chwastiak LA, 2010, PSYCHOSOM MED, V72, P817, DOI 10.1097/PSY.0b013e3181eb33e9; COHEN JA, 2002, TRAUMA VIOLENCE ABUS, V3, P307, DOI DOI 10.1177/1524838002237332; Cozza S., 2011, CLIN WORK TRAUMATIZE, P139; Cozza S. J., 2011, ANN M INT SOC TRAUM; Cozza SJ, 2011, RISK AND RESILIENCE IN U S MILITARY FAMILIES, P259, DOI 10.1007/978-1-4419-7064-0_13; Cozza SJ, 2010, J TRAUMA STRESS, V23, P112, DOI 10.1002/jts.20488; Cozza Stephen J., 2009, P WORKGROUP INTERVEN; Cozza Stephen J., 2011, CARING VETERANS DEPL, V172, P171; Davidson AC, 2001, AUST NZ J PSYCHIAT, V35, P345, DOI 10.1046/j.1440-1614.2001.00897.x; Defense and Veterans Brain Injury Center, DOD WORLDW TBI; Dekel R, 2005, ANXIETY STRESS COPIN, V18, P71, DOI 10.1080/10615800412336427; del Valle L E, 1996, P R Health Sci J, V15, P101; Department of Defense, 2010, REP IMP DEPL MEMB AR; Diareme S, 2006, EUR CHILD ADOLES PSY, V15, P309, DOI 10.1007/s00787-006-0534-7; Fischer, CASUALTY STAT; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gewirtz AH, 2010, J CONSULT CLIN PSYCH, V78, P599, DOI 10.1037/a0020571; Gorman LA, 2010, PSYCHIAT QUART, V81, P1, DOI 10.1007/s11126-009-9116-4; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Hakman M, 2009, CHILD ABUSE NEGLECT, V33, P461, DOI 10.1016/j.chiabu.2008.08.003; Halcomb Elizabeth, 2005, Contemp Nurse, V19, P232; Harrington-LaMorie Jill, GRIEF BEREAVEMENT CO; Herzog JR, 2011, CHILD ADOLESC SOC WO, V28, P459, DOI 10.1007/s10560-011-0243-z; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iraq Coalition Casualty Count, IR COAL CAS COUNT; Johnson JG, 2009, DEATH STUD, V33, P691, DOI 10.1080/07481180903070392; Jones KD, 2010, J COUNS DEV, V88, P372, DOI 10.1002/j.1556-6678.2010.tb00036.x; Kalter N, 2002, OMEGA-J DEATH DYING, V46, P15; Keeley D, 2000, BRIT MED J, V321, P462, DOI 10.1136/bmj.321.7259.462; Kelley AM, 2012, J PSYCHIATR RES, V46, P582, DOI 10.1016/j.jpsychires.2012.01.017; Kieffer-Kristensen R, 2011, BRAIN INJURY, V25, P752, DOI 10.3109/02699052.2011.579933; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kotchick BA, 1997, BEHAV MODIF, V21, P409, DOI 10.1177/01454455970214002; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Lehman Douglas H., COMBAT OPERATIONAL B, P543; Lin KK, 2004, J CLIN CHILD ADOLESC, V33, P673, DOI 10.1207/s15374424jccp3304_3; MacDermid Shelley M., 2008, UNDERSTANDIG PROMOTI; MacDonald C, 1999, J TRAUMA STRESS, V12, P701, DOI 10.1023/A:1024729520686; Masten AS., 2009, EDUC CAN, V49; Monson CM, 2009, CLIN PSYCHOL REV, V29, P707, DOI 10.1016/j.cpr.2009.09.002; Muriel Anna C, 2003, J Support Oncol, V1, P143; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; Pine DS, 2002, BIOL PSYCHIAT, V51, P519, DOI 10.1016/S0006-3223(01)01352-X; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; President's Commission on Care for America's Returning Wounded Warriors, 2007, SERV SUPP SIMPL REP; Pynoos RS., 1992, BEREAVE CARE, V11, P2, DOI [DOI 10.1080/02682629208657280, 10.1080/02682629208657280]; RAND Center for Military Health Policy Research, 2008, INV WOUNDS MENT HLTH; Raveis VH, 1999, J YOUTH ADOLESCENCE, V28, P165, DOI 10.1023/A:1021697230387; Regehr C, 2005, FAM RELAT, V54, P423, DOI 10.1111/j.1741-3729.2005.00328.x; Renshaw KD, 2011, J FAM PSYCHOL, V25, P461, DOI 10.1037/a0023994; Resnik LJ, 2007, J REHABIL RES DEV, V44, P991, DOI 10.1682/JRRD.2007.05.0071; Riggs DS, 1998, J TRAUMA STRESS, V11, P87, DOI 10.1023/A:1024409200155; Ruscio AM, 2002, J TRAUMA STRESS, V15, P351, DOI 10.1023/A:1020125006371; Sandler I, 2001, AM J COMMUN PSYCHOL, V29, P19, DOI 10.1023/A:1005237110505; Sayers SL, 2009, J CLIN PSYCHIAT, V70, P163, DOI 10.4088/JCP.07m03863; Schaeffer CM, 2005, J FAM VIOLENCE, V20, P123, DOI 10.1007/s10896-005-3175-6; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Silverman PR, 2002, OMEGA-J DEATH DYING, V46, P335, DOI 10.2190/AC8P-7CAY-LF55-YXKR; Tanielian, INVISIBLE WOUNDS, pxxii; Tanielian Terri, 2008, INVISIBLE WOUNDS WAR, pXXI; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tremblay GC, 1998, CLIN PSYCHOL-SCI PR, V5, P424, DOI 10.1111/j.1468-2850.1998.tb00165.x; URBACH JR, 1991, PSYCHOSOMATICS, V32, P24, DOI 10.1016/S0033-3182(91)72108-7; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Visser-Meily A, 2005, STROKE, V36, P2436, DOI 10.1161/01.STR.0000185681.33790.0a; Visser-Meily A, 2005, J REHABIL MED, V37, P236, DOI 10.1080/16501970510025990; Wadsworth SM, 2011, ANN AM ACAD POLIT SS, V638, P163, DOI 10.1177/0002716211416445; Weaver FM, 2009, ARCH PHYS MED REHAB, V90, P517, DOI 10.1016/j.apmr.2008.09.560; Weinstein Edwin A., 1995, WAR PSYCHIAT, P353; Willerton E, 2011, J FAM PSYCHOL, V25, P521, DOI 10.1037/a0024511; Wolchik SA, 2006, J ABNORM CHILD PSYCH, V34, P221, DOI 10.1007/s10802-005-9016-5; Worden J. William, 2009, GRIEF COUNSELING GRI, P231; Worden JW, 1996, OMEGA-J DEATH DYING, V33, P91, DOI 10.2190/P77L-F6F6-5W06-NHBX; Zeber John E, 2010, Ment Health Fam Med, V7, P135	82	26	26	0	15	PRINCETON UNIV	PRINCETON	277 WALLACE HALL, PRINCETON, NJ 08544 USA	1054-8289	1550-1558		FUTURE CHILD	Future Child.	FAL	2013	23	2					143	162		10.1353/foc.2013.0017			20	Family Studies; Health Policy & Services; Social Sciences, Interdisciplinary	Social Science Citation Index (SSCI)	Family Studies; Health Care Sciences & Services; Social Sciences - Other Topics	230FR	WOS:000325322600008	25518696				2022-02-06	
J	Jamora, CW; Schroeder, SC; Ruff, RM				Jamora, Christina Weyer; Schroeder, Sara C.; Ruff, Ronald M.			Pain and mild traumatic brain injury: The implications of pain severity on emotional and cognitive functioning	BRAIN INJURY			English	Article						Chronic pain; cognition; mild traumatic brain injury; neuropsychological assessement; pain; postconcussional disorder; Ruff neurobehavioural inventory	ATTENTION; DEPRESSION; COMPLAINTS; HEALTH; IMPACT	Primary objective: The aim of this study was to examine the effect of high chronic pain on (a) neuropsychological test performance and (b) self-reported emotional complaints in persons suffering from Postconcussional Disorders (PCD) after a mild traumatic brain injury (TBI). Research design: A two-group comparative research design was employed. Methods and procedure: An outpatient sample of 66 patients with mild TBI and PCD using the Ruff Neurobehavioural Inventory (RNBI) and a neuropsychological test battery. Main outcomes and results: According to ANOVAs, no significant between-group differences were found on neuropsychological test performances; however, the high pain group had significantly more emotional residuals; particularly elevated on the RNBI were the Anger and Aggression, Anxiety, Depression and Paranoia and Suspicion sub-scales. Furthermore, an ANOVA found participants of the high pain group reporting significantly higher impairments on the RNBI Cognitive, Physical and Quality-of-Life composite scores and several RNBI sub-scales compared to their pre-morbid functioning. Conclusions: High chronic pain exacerbates the emotional aspect of PCD and, therefore, should be given special observance in treatment settings.	[Jamora, Christina Weyer] San Francisco Clin Neurosci, San Francisco, CA USA; [Jamora, Christina Weyer; Ruff, Ronald M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Schroeder, Sara C.] Univ Zurich, Zurich, Switzerland		Jamora, CW (corresponding author), 909 Hyde St,Suite 620, San Francisco, CA 94109 USA.	cyweyer@aol.com			RNBI	Dr Ruff receives royalties for the RNBI. All other authors had no conflicts of interest.	American Congress of Rehabilitation Medicine, 2003, J HEAD TRAUMA REHAB, V8, P86; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Benton AL, 1994, MULTILINGUAL APHASIA; Boone K., 2002, DOT COUNTING TEST; Brown SC, 2002, PAIN, V96, P279, DOI 10.1016/S0304-3959(01)00457-2; Buffington ALH, 2005, PAIN, V113, P172, DOI 10.1016/j.pain.2004.10.006; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Demyttenaere K, 2007, PAIN, V129, P332, DOI 10.1016/j.pain.2007.01.022; Eccleston C, 1999, PSYCHOL BULL, V125, P356, DOI 10.1037/0033-2909.125.3.356; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; Eccleston C, 1997, PAIN, V72, P209, DOI 10.1016/S0304-3959(97)00030-4; Edwards CL, 2001, PAIN, V94, P133, DOI 10.1016/S0304-3959(01)00408-0; FISHBAIN DA, 1986, PAIN, V26, P181, DOI 10.1016/0304-3959(86)90074-6; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; Hart Robert P, 2003, Curr Pain Headache Rep, V7, P116, DOI 10.1007/s11916-003-0021-5; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Jensen MP, 2001, J CONSULT CLIN PSYCH, V69, P655, DOI 10.1037/0022-006X.69.4.655; Johansson SH, 2008, BRAIN INJURY, V22, P999, DOI 10.1080/02699050802530573; Klein TA, 2007, NEUROIMAGE, V34, P1774, DOI 10.1016/j.neuroimage.2006.11.014; Kouneiher F, 2009, NAT NEUROSCI, V12, P939, DOI 10.1038/nn.2321; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Matthews CG., 1964, INSTRUCTION MANUAL A; Meyers JE., 1995, REY COMPLEX FIGURE T; Moriarty O, 2011, PROG NEUROBIOL, V93, P385, DOI 10.1016/j.pneurobio.2011.01.002; Mueller J., 2007, NEUROPSYCHIATRIC PRO; Murray RF, 2007, SPINAL CORD, V45, P429, DOI 10.1038/sj.sc.3102022; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Okifuji A, 1999, J PSYCHOSOM RES, V47, P1, DOI 10.1016/S0022-3999(99)00006-9; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Reitan R, 1969, MANUAL ADM NEUROPSYC; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Riley JL, 2002, PAIN, V100, P291, DOI 10.1016/S0304-3959(02)00306-8; Robbins TW, 1996, PHILOS T ROY SOC B, V351, P1463, DOI 10.1098/rstb.1996.0131; Ruff R. M., 2003, RUFF NEUROBEHAVIORAL; Ruff R. M., 1999, RUFF LIGHT TRAIL LEA; Ruff R. M, 1996, RUFF FIGURAL FLUENCY; RUFF RM, 1996, RUFF 2 7 SELECTIVE A; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Vernon-Wilkinson R, 1993, ARCH CLIN NEUROPSYCH, V8, P211; Wechsler D, 1997, WECHSLER MEMORY SCAL; Wechsler D., 2000, WECHSLER ADULT INTEL	51	26	26	2	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2013	27	10					1134	1140		10.3109/02699052.2013.804196			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	204KW	WOS:000323365200005	23895398				2022-02-06	
J	Williams, GP; Schache, AG; Morris, ME				Williams, Gavin P.; Schache, Anthony G.; Morris, Meg E.			Mobility After Traumatic Brain Injury: Relationships With Ankle Joint Power Generation and Motor Skill Level	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; mobility limitation; motor skills; muscle spasticity; muscle strength; outcome assessment; postural balance; rehabilitation	ASSESSMENT-TOOL; CEREBRAL-PALSY; TARDIEU SCALE; GAIT ANALYSIS; DEFICITS; CHILDREN; RECOVERY; RELIABILITY; MANAGEMENT; SPASTICITY	Background: Reduced balance, spasticity, contractures, muscle weakness, and motor skill levels may all contribute to mobility limitations after traumatic brain injury (TBI), yet the key physical impairments that contribute to mobility limitations remain unclear. Objective: The aim of this study was to determine which physical impairments best predict mobility performance after a period of 6 months of rehabilitation. Participants: Participants with TBI were selected if they were receiving therapy for mobility limitations but were able to walk without physical assistance. Outcome Measures: The clinical assessment included measures of balance, spasticity, and contracture, and 3-dimensional quantitative gait analysis was used to quantify joint power generation and motor skill level on 31 adults with severe TBI. Mobility outcome was quantified with the high-level mobility assessment tool. Results: Two variables, ankle joint power generation during the push-off phase of gait and motor skill level, explained 66.5% of the variability in mobility outcome. Balance, strength, and mobility performance, all improved significantly over the 6 months of rehabilitation. Only 2 participants had contractures, which affected mobility. Balance disorders were prevalent and improved with rehabilitation, yet they contributed to only a limited extent to the level of recovery in mobility. Conclusion: Ankle joint power generation at push-off was the strongest predictor of mobility outcome after 6 months of rehabilitation in ambulant people with TBI.	[Williams, Gavin P.] Epworth Med Fdn, Physiotherapy Dept, Melbourne, Vic 3121, Australia; [Williams, Gavin P.; Morris, Meg E.] Univ Melbourne, Sch Physiotherapy, Melbourne, Vic, Australia; [Schache, Anthony G.] Univ Melbourne, Dept Mech Engn, Melbourne, Vic, Australia		Williams, GP (corresponding author), Epworth Med Fdn, Physiotherapy Dept, Melbourne, Vic 3121, Australia.	gavin.williams@epworth.org.au	Schache, Anthony G/F-4482-2016	Schache, Anthony G/0000-0002-1041-5213; Morris, Meg/0000-0002-0114-4175; Williams, Gavin/0000-0003-2758-7473	Victorian Neurotrauma Initiative	This project was funded by the Victorian Neurotrauma Initiative.	Baker R, 2009, GAIT POSTURE, V30, P265, DOI 10.1016/j.gaitpost.2009.05.020; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BERG K, 1989, Physiotherapy Canada, V41, P304; Beynon S, 2010, GAIT POSTURE, V32, P129, DOI 10.1016/j.gaitpost.2010.01.010; Bode RK, 2002, ARCH PHYS MED REHAB, V83, P100, DOI 10.1053/apmr.2002.26073; Boyd RN, 1999, EUR J NEUROL, V6, pS23, DOI 10.1111/j.1468-1331.1999.tb00031.x; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Dumas Helene M., 2002, Physical & Occupational Therapy in Pediatrics, V22, P73, DOI 10.1300/J006v22n03_06; Dumas HM, 2004, PHYS THER, V84, P232, DOI 10.1093/ptj/84.3.232; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; Dvir Z, 1997, CLIN REHABIL, V11, P36, DOI 10.1177/026921559701100106; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; Esquenazi A, 2004, J HEAD TRAUMA REHAB, V19, P109, DOI 10.1097/00001199-200403000-00004; Fock J, 2004, BRAIN INJURY, V18, P57, DOI 10.1080/0269905031000149498; Gracies JM, 2010, ARCH PHYS MED REHAB, V91, P421, DOI 10.1016/j.apmr.2009.11.017; Harrington ME, 2007, J BIOMECH, V40, P595, DOI 10.1016/j.jbiomech.2006.02.003; Haugh AB, 2006, DISABIL REHABIL, V28, P899, DOI 10.1080/09638280500404305; Hillier SL, 1997, BRAIN INJURY, V11, P661; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Keenan M A, 1988, Orthop Rev, V17, P1185; Keenan MA, 1999, NEUROREHABILITATION, V12, P119; KEENAN MAE, 1988, CLIN ORTHOP RELAT R, P221; Kisner C., 2007, THERAPEUTIC EXERCISE; MacAvoy MC, 2007, J HAND SURG-AM, V32A, P149, DOI 10.1016/j.jhsa.2006.10.020; MANN RA, 1980, AM J SPORT MED, V8, P345, DOI 10.1177/036354658000800510; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P153, DOI 10.1097/HTR.0b013e3181e773cf; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; McFadyen BJ, 2009, ARCH PHYS MED REHAB, V90, P1596, DOI 10.1016/j.apmr.2009.03.010; McGinley JL, 2003, PHYS THER, V83, P146, DOI 10.1093/ptj/83.2.146; Mulroy SJ, 1997, J ORTHOP SPORT PHYS, V26, P192, DOI 10.2519/jospt.1997.26.4.192; Novacheck TF, 1998, GAIT POSTURE, V7, P77, DOI 10.1016/S0966-6362(97)00038-6; Nussbaumer S, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-194; Nuttin B, 1999, NEUROMODULATION, V2, P120, DOI 10.1046/j.1525-1403.1999.00120.x; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Paulis WD, 2011, GAIT POSTURE, V33, P185, DOI 10.1016/j.gaitpost.2010.10.094; Perry J, 1999, J HEAD TRAUMA REHAB, V14, P116, DOI 10.1097/00001199-199904000-00003; Pohl M, 2002, ARCH PHYS MED REHAB, V83, P784, DOI 10.1053/apmr.2002.32821; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Reavenall S, 2010, INT J THER REHABIL, V17, P360, DOI 10.12968/ijtr.2010.17.7.48893; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Schache AG, 2007, GAIT POSTURE, V25, P440, DOI 10.1016/j.gaitpost.2006.05.018; Sullivan P., 2007, 15 INT C WORLD CONF; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; Toro B, 2003, ARCH PHYS MED REHAB, V84, P1878, DOI 10.1016/S0003-9993(03)00482-9; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams G, 2010, J HEAD TRAUMA REHAB, V25, P366, DOI 10.1097/HTR.0b013e3181cd3600; Williams G, 2010, NEUROREHAB NEURAL RE, V24, P550, DOI 10.1177/1545968309357925; Williams GP, 2011, PHYSIOTHER CAN, V63, P58, DOI 10.3138/ptc.2009-53; Williams GP, 2009, BRAIN INJURY, V23, P307, DOI 10.1080/02699050902774170; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711; Winter D.A., 1991, BIOMECHANICS MOTOR C	55	26	26	1	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2013	28	5					371	378		10.1097/HTR.0b013e31824a1d40			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	298ZU	WOS:000330364600083	22613943				2022-02-06	
J	Zandi, M; Hoseini, SRS				Zandi, Mohammad; Hoseini, Seyed Rohallah Seyed			The relationship between head injury and facial trauma: a case-control study	ORAL AND MAXILLOFACIAL SURGERY-HEIDELBERG			English	Article						Maxillofacial trauma; Facial fracture; Head injury; Risk factor; Neurologic injury		Introduction In spite of anatomic proximity of the facial skeleton and cranium, there is paucity of information in the literature regarding the relationship between head injuries and facial trauma. The objective of our investigation was to evaluate the pattern of head injuries in patients with maxillofacial trauma, and to study their relationship. Material and methods We evaluated 2,692 patients with maxillofacial trauma admitted to the Besat hospital, Hamedan, Iran between 2007 and 2010. Patients with associated head injury (302 cases; study group) were compared with those without head injury (2,390 cases; control group). Results In our cohort, the rate of head injuries associated with facial bone fractures was 23.3 %. The most common associated head injury was concussion, followed by cerebral contusion and skull fractures. In the unadjusted analysis, motorcycle and car accidents were significantly more frequent in the study group, while stumbling, sports injuries, and work-related injuries were significantly more common in the control group (p<0.001). Except for Lefort III fractures which was not significantly different between groups, all facial fractures occurred more frequently in the study group (p<0.001). Logistic regression analysis demonstrated that motorcycle accidents (211-fold), car accidents (139fold), violence (69-fold), falls (66-fold), frontal sinus fractures (84.5-fold), and Lefort II fractures (27-fold) were the strongest predictors of head injuries. Discussion Present study revealed that fracture of facial bones, especially bones that are in anatomic proximity to the cranium and need a high magnitude of trauma energy to be fractured, was marker for an increased risk of head injuries.	[Zandi, Mohammad; Hoseini, Seyed Rohallah Seyed] Hamedan Univ Med Sci, Dept Oral & Maxillofacial Surg, Shahid Fahmideh St, Hamadan, Iran; [Zandi, Mohammad] Hamedan Univ Med Sci, Dent Res Ctr, Hamadan, Iran		Zandi, M (corresponding author), Hamedan Univ Med Sci, Dept Oral & Maxillofacial Surg, Shahid Fahmideh St, Hamadan, Iran.	zandi88m@yahoo.com; rohallahseyedhoseini@yahoo.com	Zandi, Mohammad/L-1368-2018	Zandi, Mohammad/0000-0003-1238-186X	Dental Research Center, Hamedan University of Medical Sciences, Hamedan, Iran	This study was supported by Dental Research Center, Hamedan University of Medical Sciences, Hamedan, Iran.	Al Ahmed HE, 2004, ORAL SURG ORAL MED O, V98, P166, DOI 10.1016/j.tripleo.2004.01.020; Al-Khateeb T, 2007, J ORAL MAXIL SURG, V65, P1094, DOI 10.1016/j.joms.2006.09.013; Bakardjiev A, 2007, J CRANIO MAXILL SURG, V35, P147, DOI 10.1016/j.jcms.2007.01.005; CHANG CJ, 1994, J TRAUMA, V37, P807, DOI 10.1097/00005373-199411000-00017; Clayton JL, 2012, INJURY, V43, P431, DOI 10.1016/j.injury.2011.06.022; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; Erol BE, 2004, J CRANIO MAXILL SURG, V32, P308, DOI 10.1016/j.jcms.2004.04.006; Brasileiro BF, 2006, ORAL SURG ORAL MED O, V102, P28, DOI 10.1016/j.tripleo.2005.07.023; Gassner R, 2003, J CRANIO MAXILL SURG, V31, P51, DOI 10.1016/S1010-5182(02)00168-3; Hackl W, 2001, ORAL SURG ORAL MED O, V92, P370, DOI 10.1067/moe.2001.116894; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAUG RH, 1994, J ORAL MAXIL SURG, V52, P729, DOI 10.1016/0278-2391(94)90488-X; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; HAYTER JP, 1991, BRIT J ORAL MAX SURG, V29, P370, DOI 10.1016/0266-4356(91)90003-N; Hohlrieder M, 2004, INT J ORAL MAX SURG, V33, P389, DOI 10.1016/j.ijom.2003.10.011; Hung YC, 2004, J ORAL MAXIL SURG, V62, P938, DOI 10.1016/j.joms.2004.01.018; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; Kloss F, 2008, J CRANIO MAXILL SURG, V36, P372, DOI 10.1016/j.jcms.2007.12.002; Lee JH, 2010, J CRANIO MAXILL SURG, V38, P192, DOI 10.1016/j.jcms.2009.06.002; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D; Martin RCG, 2002, AM SURGEON, V68, P477; Moncrieff NJ, 2004, J CRANIOFAC SURG, V15, P686, DOI 10.1097/00001665-200407000-00030; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Rajendra Prasad B, 2009, J Emerg Trauma Shock, V2, P89, DOI 10.4103/0974-2700.50742	25	26	26	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1865-1550	1865-1569		ORAL MAXILLOFAC SURG	Oral Maxillofac. Surg.-Heidelb.	SEP	2013	17	3					201	207		10.1007/s10006-012-0368-z			7	Dentistry, Oral Surgery & Medicine	Emerging Sources Citation Index (ESCI)	Dentistry, Oral Surgery & Medicine	V3K9N	WOS:000218350200007	23100036				2022-02-06	
J	Hein, M; Zoremba, N; Bleilevens, C; Bruells, C; Rossaint, R; Roehl, AB				Hein, Marc; Zoremba, Norbert; Bleilevens, Chistian; Bruells, Christian; Rossaint, Rolf; Roehl, Anna B.			Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model	BMC NEUROLOGY			English	Article						Experimental stroke; Postconditioning; Levosimendan; Cerebral reperfusion injury	ACUTE ISCHEMIC-STROKE; POTASSIUM CHANNEL; BRAIN-DAMAGE; SPINAL-CORD; EXPRESSION; RECOVERY; NEUROPROTECTION; HEMORRHAGE; INFARCTION; INHIBITION	Background: Neuroprotective strategies in ischemic stroke are an important challenge in clinical and experimental research as an adjunct to reperfusion therapy that may reduce neurologic injury and improve outcome. The neuroprotective properties of levosimendan in traumatic brain injury in vitro, transient global brain ischemia and focal spinal cord ischemia suggest the potential for similar effects in transient brain ischemia. Methods: Transient brain ischemia was induced for 60 min by intraluminal occlusion of the middle cerebral artery in 40 male Wistar rats under general anesthesia with s-ketamine and xylazine and with continuous monitoring of their blood pressure and cerebral perfusion. Five minutes before inducing reperfusion, a levosimendan bolus (24 mu g kg (-1)) was administered over a 20 minute period. Infarct size, brain swelling, neurological function and the expression of inflammatory markers were quantified 24 hours after reperfusion. Results: Although levosimendan limited the infarct size and brain swelling by 40% and 53%, respectively, no effect on neurological outcome or mortality could be demonstrated. Upregulation of tumor necrosis factor a and intercellular adhesion molecule 1 was significantly impeded. Cerebral blood flow during reperfusion was significantly reduced as a consequence of sustained autoregulation. Conclusions: Levosimendan demonstrated significant neuroprotective properties in a rat model of transient brain ischemia by reducing reperfusion injury.	[Hein, Marc; Zoremba, Norbert; Bleilevens, Chistian; Bruells, Christian; Rossaint, Rolf; Roehl, Anna B.] RWTH Aachen Univ Hosp, Dept Anesthesiol, D-52074 Aachen, Germany		Hein, M (corresponding author), RWTH Aachen Univ Hosp, Dept Anesthesiol, Pauwelstr 30, D-52074 Aachen, Germany.	mhein@ukaachen.de	Bleilevens, Christian/AAG-8034-2020	Bleilevens, Christian/0000-0002-2104-1843	Medical Faculty RWTH Aachen [10/2010]	This work was supported by the Medical Faculty RWTH Aachen (START grant number 10/2010). We would like to specifically thank Renate Nadenau and Christian Beckers (Department of Anaesthesiology) for their help in our laboratory.	Armstead WM, 2011, J NEUROTRAUM, V28, P105, DOI 10.1089/neu.2010.1581; Bleilevens C, 2013, EXP BRAIN RES, V224, P155, DOI 10.1007/s00221-012-3296-0; Cengiz SL, 2010, BRAIN INJURY, V24, P877, DOI 10.3109/02699051003789260; Choi SK, 2011, J KOREAN NEUROSURG S, V49, P1, DOI 10.3340/jkns.2011.49.1.1; Das B, 2007, VASC PHARMACOL, V47, P248, DOI 10.1016/j.vph.2007.06.008; David HN, 2003, J CEREBR BLOOD F MET, V23, P1168, DOI 10.1097/01.WCB.0000087342.31689.18; Bravo MD, 2011, NEONATOLOGY, V99, P217, DOI 10.1159/000314955; Denes A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-164; Dittmar M, 2003, STROKE, V34, P2252, DOI 10.1161/01.STR.0000083625.54851.9A; Domoki F, 1999, STROKE, V30, P2713, DOI 10.1161/01.STR.30.12.2713; Durukan A, 2007, PHARMACOL BIOCHEM BE, V87, P179, DOI 10.1016/j.pbb.2007.04.015; Encarnacion A, 2011, J NEUROSCI METH, V196, P247, DOI 10.1016/j.jneumeth.2011.01.010; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Haelewyn B, 2008, EXP NEUROL, V213, P238, DOI 10.1016/j.expneurol.2008.05.012; Hein M, 2009, ACTA ANAESTH SCAND, V53, P941, DOI 10.1111/j.1399-6576.2009.01994.x; Institute for Laboratory Animal Resources, 1996, GUIDE CARE USE LAB A; Kang SW, 2011, BRAIN RES, V1371, P121, DOI 10.1016/j.brainres.2010.11.057; Katircioglu SF, 2008, J CARDIAC SURG, V23, P44, DOI 10.1111/j.1540-8191.2007.00486.x; Kramer M, 2010, J NEUROSCI METH, V187, P84, DOI 10.1016/j.jneumeth.2009.12.020; Lafci B, 2008, EUR SURG RES, V41, P1, DOI 10.1159/000121394; Mayanagi K, 2007, BRAIN RES, V1168, P106, DOI 10.1016/j.brainres.2007.06.071; Munakata H, 2010, PERFUSION-UK, V25, P159, DOI 10.1177/0267659110370068; Nogueira RG, 2009, AM J NEURORADIOL, V30, P859, DOI 10.3174/ajnr.A1604; Robin E, 2011, BRAIN RES, V1375, P137, DOI 10.1016/j.brainres.2010.12.054; Roehl AB, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-81; Roehl AB, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-97; Ryang YM, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-113; Segreti JA, 2008, J PHARMACOL EXP THER, V325, P331, DOI 10.1124/jpet.107.132530; Sheng SP, 2012, ANESTHESIOLOGY, V117, P1262, DOI 10.1097/ALN.0b013e3182746b81; Shuaib A, 2011, LANCET NEUROL, V10, P909, DOI 10.1016/S1474-4422(11)70195-8; Strom JO, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-41; Sutherland BA, 2012, INT J STROKE, V7, P407, DOI 10.1111/j.1747-4949.2012.00770.x; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; Ulbrich C, 2012, J STEROID BIOCHEM, V131, P10, DOI 10.1016/j.jsbmb.2012.01.007; Vemuganti R, 2004, STROKE, V35, P179, DOI 10.1161/01.STR.0000106479.53235.3E; Xu XH, 2006, LIFE SCI, V78, P704, DOI 10.1016/j.lfs.2005.05.080; Yoshimura S, 2008, ANN NEUROL, V64, P547, DOI 10.1002/ana.21459; Zhu HL, 2008, NEUROSCIENCE, V157, P884, DOI 10.1016/j.neuroscience.2008.09.033	39	26	31	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	AUG 12	2013	13								106	10.1186/1471-2377-13-106			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	200NI	WOS:000323075400001	23937651	Green Published, gold			2022-02-06	
J	Amick, MM; Clark, A; Fortier, CB; Esterman, M; Rasmusson, AM; Kenna, A; Milberg, WP; McGlinchey, R				Amick, Melissa M.; Clark, Alexandra; Fortier, Catherine B.; Esterman, Michael; Rasmusson, Ann M.; Kenna, Alexandra; Milberg, William P.; McGlinchey, Regina			PTSD Modifies Performance on a Task of Affective Executive Control among Deployed OEF/OIF Veterans with Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Post-traumatic stress disorder; Attention; Brain injury; Military; Cognition; Deployment	POSTTRAUMATIC-STRESS-DISORDER; LARGE-SAMPLE; HEAD-INJURY; ATTENTION; IRAQ; INFORMATION; AFGHANISTAN; INHIBITION; MILITARY; EMOTION	Individuals with post-traumatic stress disorder (PTSD) show a cognitive bias for threatening information, reflecting dysregulated executive control for affective stimuli. This study examined whether comorbid mild Traumatic Brain Injury (mTBI) with PTSD exacerbates this bias. A computer-administered Affective Go/No-Go task measured reaction times (RTs) and errors of omission and commission to words with a non-combat-related positive or negative valence in 72 deployed United States service members from the wars in Iraq and Afghanistan. Incidents of military-related mTBI were measured with the Boston Assessment of Traumatic Brain Injury-Lifetime. PTSD symptoms were measured with the Clinician-Administered PTSD Scale. Participants were divided into those with (mTBI+, n = 34) and without a history of military-related mTBI (mTBI-, n = 38). Valence of the target stimuli differentially impacted errors of commission and decision bias (criterion) in the mTBI+ and mTBI- groups. Specifically, within the mTBI+ group, increasing severity of PTSD symptoms was associated with an increasingly liberal response pattern (defined as more commission errors to negative distractors and greater hit rate for positive stimuli) in the positive compared to the negative blocks. This association was not observed in the mTBI- group. This study underscores the importance of considering the impact of a military-related mTBI and PTSD severity upon affective executive control.	[Amick, Melissa M.; Clark, Alexandra; Fortier, Catherine B.; Esterman, Michael; Rasmusson, Ann M.; Kenna, Alexandra; Milberg, William P.; McGlinchey, Regina] VA Boston Healthcare Syst, Translat Res Ctr Traumat Brain Injury & Stress Di, Boston, MA 02130 USA; [Amick, Melissa M.; Esterman, Michael; Rasmusson, Ann M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Fortier, Catherine B.; Milberg, William P.; McGlinchey, Regina] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Milberg, William P.; McGlinchey, Regina] VA Boston Healthcare Syst, Ctr Geriatr Res Educ & Clin, Boston, MA USA		Amick, MM (corresponding author), VA Boston Healthcare Syst 182 JP, Translat Res Ctr Traumat Brain Injury & Stress Di, 150 South Huntington Ave, Boston, MA 02130 USA.	melissa.amick@va.gov	Fortier, Catherine/AAS-2163-2021	Fortier, Catherine/0000-0002-8953-9904; Milberg, William/0000-0002-6078-7066; Rasmusson, Ann/0000-0002-3488-9042; Esterman, Michael/0000-0002-9000-3920	RR&D TBI Center of Excellence at VA Boston Healthcare System, The Translational Research Center for TBI and Stress Disorders; VA Rehabilitation Research and Development Center [B6796-C]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG034258] Funding Source: NIH RePORTER	This work was supported by the RR&D TBI Center of Excellence at VA Boston Healthcare System, The Translational Research Center for TBI and Stress Disorders. We thank all of the individuals who participated in this study. We thank Dr. Gheorghe Doros for his advisement in our statistical approach. We are grateful to all members of the Human Characterization Core of TRACTS: Marge Alhquist, BS, Brad Brummett, PhD, Racheal Dayton, BS, Andrea Levine, MA, Kathleen Moriarty, BS, Lindsay Morra, BA, Roxanne Moyer, BS, Erica Scioli, PhD, Jonathan Venne, BS, Ruby Ward, BA, David Zade PhD for their expert assessment skills. We would also like to thank Walter Musto for his extraordinary recruitment efforts and Joe Degutis, PhD, Jennifer Vasterling, PhD, and Mieke Verfaellie PhD, for valuable feedback in the interpretation of our results. These findings were presented in part at the annual meetings of the International Neuropsychological Society, 2011, the International Trauma and Stress Society, 2011, the Federal Interagency Conference on TBI, 2011, and the American Psychological Association, 2012. The authors report no conflicts of interest. This research was supported by a VA Rehabilitation Research and Development Center Grant B6796-C awarded to Dr. Regina McGlinchey.	Amir N, 2009, J CONSULT CLIN PSYCH, V77, P961, DOI 10.1037/a0016685; Atkinson MP, 2009, MANAGE SCI, V55, P1454, DOI 10.1287/mnsc.1090.1042; Aupperle RL, 2012, ARCH GEN PSYCHIAT, V69, P360, DOI 10.1001/archgenpsychiatry.2011.1539; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; BLAKE DD, 1993, BEHAV THER, V18, P187; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; Calhoun PS, 2010, PSYCHIAT RES, V178, P330, DOI 10.1016/j.psychres.2009.11.009; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; Cisler JM, 2010, J PSYCHOPATHOL BEHAV, V32, P68, DOI 10.1007/s10862-009-9161-1; Constans JI, 2004, J ABNORM PSYCHOL, V113, P315, DOI 10.1037/0021-843X.113.2.315; CONSTANS JI, 2005, NEUROPSYCHOLOGY PTSD, P00105; Crawford MA, 2007, J INT NEUROPSYCH SOC, V13, P178, DOI 10.1017/S135561770707021X; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; DeGutis J, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.044.2009; DeGutis JM, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00060; Eldar S, 2010, PSYCHOL MED, V40, P667, DOI 10.1017/S0033291709990766; Esterman M., 2012, CEREBRAL CORTEX; Falconer E, 2008, J PSYCHIATR NEUROSCI, V33, P413; Fortier C.B., 2013, J HEAD TRAUMA REHABI; Green P., 2003, GREENS MED SYMPTOM V; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hayes JP, 2009, PSYCHIAT RES-NEUROIM, V172, P7, DOI 10.1016/j.pscychresns.2008.05.005; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kimble MO, 2010, J ANXIETY DISORD, V24, P293, DOI 10.1016/j.janxdis.2009.12.006; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Pineles SL, 2009, BEHAV RES THER, V47, P1050, DOI 10.1016/j.brat.2009.08.001; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; ROBBINS TW, 1994, DEMENTIA, V5, P266, DOI 10.1159/000106735; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; THRASHER SM, 1994, BEHAV RES THER, V32, P247, DOI 10.1016/0005-7967(94)90119-8; Van Zomeren AH, 1984, ATTENTIONAL DEFICITS; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Walilko T, 2009, J TRAUMA, V67, P1311, DOI 10.1097/TA.0b013e31819adc36	58	26	27	0	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	AUG	2013	19	7					792	801		10.1017/S1355617713000544			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	186CI	WOS:000322018900006	23823533	Green Accepted			2022-02-06	
J	Silverberg, ND; Lange, RT; Millis, SR; Rose, A; Hopp, G; Leach, S; Iverson, GL				Silverberg, Noah D.; Lange, Rael T.; Millis, Scott R.; Rose, Alice; Hopp, Grace; Leach, Suzanne; Iverson, Grant L.			Post-Concussion Symptom Reporting after Multiple Mild Traumatic Brain Injuries	JOURNAL OF NEUROTRAUMA			English	Article						concussion; cumulative effects; head trauma; mild traumatic brain injury; post-concussion syndrome	SPORT-RELATED CONCUSSION; POSTCONCUSSION-LIKE SYMPTOMS; COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; NEUROCOGNITIVE PERFORMANCE; TEMPORAL WINDOW; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; HISTORY; VULNERABILITY	The relationship between previous mild traumatic brain injury/ injuries (MTBI) and recovery from a subsequent MTBI may be complex. The present study investigated three factors hypothesized to influence this relation: (1) the number of prior MTBIs, (2) the interval between MTBIs, and (3) the certainty level of previous MTBIs. The study design was retrospective cross-sectional. Participants (N = 105) were evaluated at a concussion clinic on average 1 month after sustaining an MTBI, defined by World Health Organization diagnostic criteria. Approximately half the sample had at least one previous MTBI. Subgroups with 0, 1, or 2 + previous MTBIs did not differ in levels of current post-concussion symptom reporting on the British Columbia Post-Concussion Symptom Inventory. Time since the most recent previous MTBI was significantly associated with current post-concussion symptom reporting. This relation was best characterized as logarithmic; i.e., the impact of previous MTBI(s) lessens exponentially as time elapses to a subsequent MTBI. Defining previous MTBIs with a higher certainty level (i.e., probable versus possible) was not consistently associated with greater post-concussion symptom reporting. In conclusion, participants with multiple MTBIs did not report more post-concussion symptoms than those with no history of MTBI. Previous MTBI(s), however, were associated with increased symptom reporting from a subsequent MTBI to the extent they occurred closer in time. Having one or two previous remote MTBIs was not associated with worse outcome from subsequent MTBI in this sample.	[Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Dept Med, GF Strong Rehab Ctr, Vancouver, BC V5Z 2G9, Canada; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, North Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 2G9, Canada; [Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Rose, Alice] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Hopp, Grace] Independent Practice, Port Coquitlam, BC, Canada; [Leach, Suzanne] Simon Fraser Univ, Ctr Students Disabil, Burnaby, BC V5A 1S6, Canada; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA		Silverberg, ND (corresponding author), Univ British Columbia, Div Phys Med & Rehabil, Dept Med, GF Strong Rehab Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Iverson, Grant/0000-0001-7348-9570			Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Edmed S, 2012, PSYCHIAT RES, V200, P41, DOI 10.1016/j.psychres.2012.05.022; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Gardner A, 2010, EVOLUTION, V64, P25, DOI 10.1111/j.1558-5646.2009.00842.x; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harris AW, 2012, CLIN J SPORT MED, V22, P91, DOI 10.1097/JSM.0b013e31823776cb; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/316575; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kirsch NL, 2010, ARCH PHYS MED REHAB, V91, P35, DOI 10.1016/j.apmr.2009.09.019; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	57	26	26	1	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2013	30	16					1398	1404		10.1089/neu.2012.2827			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	199JB	WOS:000322989500003	23458451				2022-02-06	
J	Sumpter, RE; Dorris, L; Kelly, T; McMillan, TM				Sumpter, Ruth E.; Dorris, Liam; Kelly, Thomas; McMillan, Thomas M.			Pediatric Sleep Difficulties after Moderate-Severe Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						TBI; Head injury; Child; Pediatric; Dyssomnias; Actigraphy	SELF-REPORT; CHILDREN; ADOLESCENTS; DISTURBANCES; QUESTIONNAIRE; ACTIGRAPHY; ATTENTION; MILD	The objective of this study is to systematically investigate sleep following moderate-severe pediatric traumatic brain injury (TBI). School-aged children with moderate-severe TBI identified via hospital records were invited to participate, along with a school-age sibling. Subjective reports and objective actigraphy correlates of sleep were recorded: Children's Sleep Habits Questionnaire (CSHQ), Sleep Self-Report questionnaire (SSR), and 5-night actigraphy. TBI participants (n = 15) and their siblings (n = 15) participated. Significantly more sleep problems were parent-reported (CSHQ: p = 0.003; d = 1.57), self-reported (SSR: p = 0.003; d = 1.40), and actigraph-recorded in the TBI group (sleep efficiency: p = 0.003; d = 1.23; sleep latency: p = 0.018; d = 0.94). There was no evidence of circadian rhythm disorders, and daytime napping was not prevalent. Moderate-severe pediatric TBI was associated with sleep inefficiency in the form of sleep onset and maintenance problems. This preliminary study indicates that clinicians should be aware of sleep difficulties following pediatric TBI, and their potential associations with cognitive and behavioral problems in a group already at educational and psychosocial risk.	[Sumpter, Ruth E.; McMillan, Thomas M.] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Dorris, Liam] Natl Hlth Serv Greater Glasgow & Clyde, Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow, Lanark, Scotland; [Kelly, Thomas] Newcastle & Tyne Natl Hlth Serv Trust, Newcastle Gen Hosp, Reg Neurosci Ctr, Newcastle, England		Dorris, L (corresponding author), Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow G3 8SJ, Lanark, Scotland.	liam.dorris@ggc.scot.nhs.uk	Dorris, Liam/AAK-2273-2021	Dorris, Liam/0000-0002-9502-3154	NHS Research and Development	This research was completed in part fulfillment of a Masters degree in Clinical Neuropsychology. The authors thank Dr. David Young for consultation on statistical analyses. The research was sponsored by NHS Research and Development, but received no grant from any funding agency. There are no conflicts of interest. The authors thank all the children and young people and families who took part.	Acebo C, 1999, SLEEP, V22, P95, DOI 10.1093/sleep/22.1.95; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P845, DOI 10.1093/jpepsy/jsm003; Beebe DW, 2012, CHILD NEUROPSYCHOL, V18, P313, DOI 10.1080/09297049.2011.602014; Beebe DW, 2010, J ADOLESCENT HEALTH, V47, P523, DOI 10.1016/j.jadohealth.2010.03.005; Blunden SL, 2006, SLEEP MED REV, V10, P109, DOI 10.1016/j.smrv.2005.11.003; Dewald JF, 2010, SLEEP MED REV, V14, P179, DOI 10.1016/j.smrv.2009.10.004; Dorris L, 2008, DEV NEUROREHABIL, V11, P95, DOI 10.1080/17518420701860149; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Lewandowski AS, 2011, J PEDIATR PSYCHOL, V36, P780, DOI 10.1093/jpepsy/jsq119; Meltzer LJ, 2012, SLEEP MED REV, V16, P463, DOI 10.1016/j.smrv.2011.10.002; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Owens JA, 2000, SLEEP, V23, P1043; Owens JA, 2000, ARCH PEDIAT ADOL MED, V154, P549, DOI 10.1001/archpedi.154.6.549; Ponsford J. L., 1999, J HEAD TRAUMA REHAB, V14, P25; Sadeh A, 2011, SLEEP MED REV, V15, P259, DOI 10.1016/j.smrv.2010.10.001; Sambuco M, 2008, BRAIN INJURY, V22, P7, DOI 10.1080/02699050701822022; TEASDALE G, 1974, LANCET, V2, P81; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-1	24	26	26	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	AUG	2013	19	7					829	834		10.1017/S1355617713000465			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	186CI	WOS:000322018900010	23601180				2022-02-06	
J	Dizdar, D; Tiftik, T; Kara, M; Tunc, H; Ersoz, M; Akkus, S				Dizdar, Dilek; Tiftik, Tulay; Kara, Murat; Tunc, Hakan; Ersoz, Murat; Akkus, Selami			Risk factors for developing heterotopic ossification in patients with traumatic brain injury	BRAIN INJURY			English	Article						Heterotopic ossification; traumatic brain injury; functional ambulation category; severity of injury	SPINAL-CORD INJURY; URINARY-INCONTINENCE; BONE-FORMATION; REHABILITATION; TONE	Objective: To evaluate the possible risk factors of heterotopic ossification (HO) in traumatic brain injury (TBI) patients. Methods: A total of 151 patients with TBI were included. Demographical variables, laboratory investigations and risk factors for HO including spasticity, walking ability (using Functional Ambulation Category (FAC)), pressure ulcer, neurogenic bladder and systemic infection were recorded. Results: Fifty-six patients (37.1%) had HO. Time since injury and serum ALP and ESR levels were significantly higher in HO patients than in non-HO patients. Hip (73.2%) and knee (44.6%) were the most commonly involved joints. This study has detected significant associations between FAC scores (FAC 0-1-2 vs. FAC 3-4-5, p<0.001), degree of spasticity (p=0.01), pressure ulcer (Absent/Grade 1 vs. Grade 2, 3 and 4, p=0.001), presence of neurogenic bladder (p<0.001) and systemic infection (p=0.002) with the development of HO. According to the final logistical regression analysis, only lower FAC score was independently associated with HO development (p=0.006). Conclusion: As lower scores of FAC is an independent risk factor for HO formation and is related to the severity and consequences of injury, ambulation and regular/cautious mobilization of the joints are of paramount importance in the early period of the rehabilitation in TBI patients.	[Dizdar, Dilek; Tiftik, Tulay; Kara, Murat; Tunc, Hakan; Ersoz, Murat; Akkus, Selami] Ankara Phys Med & Rehabil Educ & Res Hosp, Ankara, Turkey		Tiftik, T (corresponding author), Ankara Fizik Tedavi Egitim & Arastirma Hastanesi, Ankara, Turkey.	drttiftik@gmail.com					BRAVOPAYNO P, 1992, PARAPLEGIA, V30, P740, DOI 10.1038/sc.1992.142; BUSCHBACHER R, 1992, CRIT REV PHYS MED RE, V4, P199; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; da Paz AC, 2007, MED HYPOTHESES, V68, P67, DOI 10.1016/j.mehy.2006.06.035; Daud O, 1993, Disabil Rehabil, V15, P114; Ersoz M, 2011, TURK FIZ TIP REHAB D, V57, P80, DOI 10.4274/tftr.57.16; Flin C., 2002, Annales de Readaptation et de Medecine Physique, V45, P517, DOI 10.1016/S0168-6054(02)00305-7; GARLAND DE, 1988, CLIN ORTHOP RELAT R, P86; Garland DE., 1995, TRAUMATIC BRAIN INJU, P119; Gebuhr P, 1996, ACTA ORTHOP SCAND, V67, P29, DOI 10.3109/17453679608995604; Greenwood R, 1993, NEUROLOGICAL REHABIL, P206; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Jacobsen S, 1995, Ugeskr Laeger, V157, P5385; Krimchansky BZ, 1999, BRAIN INJURY, V13, P899; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; MIELANTS H, 1975, ACTA ORTHOP SCAND, V46, P190, DOI 10.3109/17453677508989207; Moiyadi AV, 2007, NEUROREHABILITATION, V22, P93; Oostra K, 1996, BRAIN INJURY, V10, P459, DOI 10.1080/026990596124313; ORZEL JA, 1985, J NUCL MED, V26, P125; Rosenthal M, 1999, CONTEMP PSYCHOL, V44, P63; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539; Stohrer M, 2009, EUR UROL, V56, P81, DOI 10.1016/j.eururo.2009.04.028; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; van Kampen PJ, 2011, J HEAD TRAUMA REHAB, V26, P384, DOI 10.1097/HTR.0b013e3181f78a59; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; WADE DT, 1985, Q J MED, V56, P601; YOUNGSON HA, 1994, BRAIN INJURY, V8, P23, DOI 10.3109/02699059409150956	32	26	31	0	11	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					807	811		10.3109/02699052.2013.775490			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200006	23730889				2022-02-06	
J	Nilsson, M; Hagglund, M; Ekstrand, J; Walden, M				Nilsson, Michael; Hagglund, Martin; Ekstrand, Jan; Walden, Markus			Head and Neck Injuries in Professional Soccer	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; football; injury incidence; risk factor	FOOTBALL PLAYERS; ELITE FOOTBALL; CONCUSSION; DEFINITIONS; STATEMENT; RETURN	Objective: To investigate the rate of and risk factors for head and neck injury in male soccer. Design: Prospective cohort study. Setting: Professional soccer. Participants: Twenty-six European teams between 2001/2002 and 2009/2010. Assessment of Risk Factors: Simple and multiple risk factor analyses were evaluated using Cox regression for player-related variables and logistic regression for match-related variables. Main Outcome Measures: Injury rate (number of time loss injuries per 1000 hours). Results: A total of 136 head and neck injuries were recorded (2.2% of all injuries). The head and neck injury rate was 0.17 (0.06 concussions) per 1000 hours. There was a 20-fold higher rate of head and neck injury during match play compared with training (rate ratio [RR], 20.2; 95% confidence interval [CI], 13.3-30.6) and a 78-fold higher rate of concussions (RR, 78.5; 95% CI, 24.4-252.5). Mean layoff for concussion was 10.5 days, but 27% of the concussed players returned to play within 5 days. Defender was the only significant player-related risk factor for head and neck injuries in the multiple analysis (RR, 1.8; 95% CI, 1.0-3.1), whereas no significant variables were identified for concussions. Conclusions: Head and neck injuries were relatively uncommon in professional soccer. Defender was the playing position most at risk. More than one-quarter of the concussed players returned to play before what is recommended in the consensus statements by the major sports governing bodies.	[Nilsson, Michael; Hagglund, Martin; Ekstrand, Jan; Walden, Markus] Football Res Grp, Linkoping, Sweden; [Nilsson, Michael] Angelholm Hosp, Dept Rehabil Ctr, S-26281 Angelholm, Sweden; [Hagglund, Martin] Linkoping Univ, Div Physiotherapy, Dept Med & Hlth Sci, Linkoping, Sweden; [Ekstrand, Jan; Walden, Markus] Linkoping Univ, Div Community Med, Dept Med & Hlth Sci, Linkoping, Sweden		Nilsson, M (corresponding author), Angelholm Hosp, Dept Rehabil Ctr, S-26281 Angelholm, Sweden.	michael.nilsson@skane.se	NILSSON, MICHAEL/ABE-7821-2020	NILSSON, MICHAEL/0000-0002-8826-1621	Union of European Football Associations; Swedish National Centre for Research in Sports; Praktikertjanst AB	Grants were obtained from the Union of European Football Associations, Swedish National Centre for Research in Sports, and Praktikertjanst AB.	Al-Kashmiri A, 2006, TRAUMA, V8, P189, DOI 10.1177/1460408606071144; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2010, J SPORT SCI MED, V9, P418; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2006.034579; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Hagglund M, 2009, SCAND J MED SCI SPOR, V19, P819, DOI 10.1111/j.1600-0838.2008.00861.x; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; LINDENFELD TN, 1994, AM J SPORT MED, V22, P364, DOI 10.1177/036354659402200312; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, P76; Orchard J., 1993, SPORTS HEALTH, V11, P39; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Price J, 2012, BRIT J SPORT MED, V46, P1000, DOI 10.1136/bjsports-2011-090687; Walden M, 2005, SCAND J MED SCI SPOR, V15, P118, DOI 10.1111/j.1600-0838.2004.00393.x; Walden M, 2011, KNEE SURG SPORT TR A, V19, P11, DOI 10.1007/s00167-010-1170-9	26	26	26	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2013	23	4					255	260		10.1097/JSM.0b013e31827ee6f8			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	299AM	WOS:000330366700002	23348605				2022-02-06	
J	Oyetunji, TA; Jackson, HT; Obirieze, AC; Moore, D; Branche, MJ; Greene, WR; Cornwell, EE; Siram, SM				Oyetunji, Tolulope A.; Jackson, Hope T.; Obirieze, Augustine C.; Moore, Danier; Branche, Marc J.; Greene, Wendy R.; Cornwell, Edward E., III; Siram, Suryanarayana M.			Associated Injuries in Traumatic Sternal Fractures: A Review of the National Trauma Data Bank	AMERICAN SURGEON			English	Article; Proceedings Paper	Annual Scientific Meeting and Postgraduate Course Program of the Southeastern-Surgical-Congress	FEB 09-13, 2013	Jacksonville, FL	SE Surg Congress			RETROSPECTIVE ANALYSIS; CHEST TRAUMA; MANAGEMENT	Sternal fractures occur infrequently with blunt force trauma. The demographics and epidemiology of associated injuries have not been well characterized from a national trauma database. The National Trauma Data Bank was queried for patients with closed sternal fractures. The demographics were analyzed by age, gender, mechanism and indicators of anatomic and physiologic injuries. Types of commonly associated injuries were also determined. A total of 23,985 records were analyzed. Males accounted for 68.3 per cent and whites 70.9 per cent. Motor vehicle crash was the leading mechanism. More than 56 per cent had severe injuries based on Injury Severity Score (greater than 15) and 17 per cent with Glasgow Coma Score 8 or less. Crude mortality was 7.9 per cent. The majority (57.8%) and approximately one-third (33.7%) of the patients had rib fractures and lung contusions, respectively, 22.0 per cent with closed pneumothorax, 21.6 per cent had a closed thoracic vertebra fracture, 16.9 per cent with lumbar spine fracture, 3.9 per cent with concussion, and blunt cardiac injury in 3.6 per cent. Sternal fractures are usually associated with severe blunt trauma. Lung contusion remains the leading associated injury followed by vertebral spine fractures. Cardiac injuries are less frequent and vascular injuries less so. Mechanism of injury and presence of sternal fractures should alert providers to these potential associated injuries.	[Oyetunji, Tolulope A.; Obirieze, Augustine C.; Moore, Danier; Branche, Marc J.; Greene, Wendy R.; Cornwell, Edward E., III; Siram, Suryanarayana M.] Howard Univ, Coll Med, Dept Surg, Washington, DC 20060 USA; [Jackson, Hope T.] George Washington Univ, Sch Med & Hlth Sci, Dept Surg, Washington, DC 20052 USA		Oyetunji, TA (corresponding author), Howard Univ, Coll Med, Dept Surg, 2041 Georgia Ave NW, Washington, DC 20060 USA.	toyetunji@howard.edu		Oyetunji, Tolulope/0000-0003-3039-7195			Athanassiadi K, 2002, WORLD J SURG, V26, P1243, DOI 10.1007/s00268-002-6511-5; BROOKES JG, 1993, J TRAUMA, V35, P46, DOI 10.1097/00005373-199307000-00008; Chiu WC, 1997, AM J EMERG MED, V15, P252, DOI 10.1016/S0735-6757(97)90007-3; Clancy K, 2012, J TRAUMA ACUTE CARE, V73, pS301, DOI 10.1097/TA.0b013e318270193a; Hankins J R, 1973, Am Surg, V39, P309; HILLS MW, 1993, J TRAUMA, V35, P55, DOI 10.1097/00005373-199307000-00009; Knobloch K, 2006, ANN THORAC SURG, V82, P444, DOI 10.1016/j.athoracsur.2006.03.046; Kulshrestha P, 2004, J TRAUMA, V57, P576, DOI 10.1097/01.TA.0000091107.00699.C7; National Highway Traffic Safety Administration, 2011, 2011 MOT VEH CRASH O; OTREMSKI I, 1990, INJURY, V21, P81, DOI 10.1016/0020-1383(90)90059-4; Rashid MA, 2001, EUR J SURG, V167, P243; Recinos G, 2009, AM SURGEON, V75, P401; RICHARDSON JD, 1975, J TRAUMA, V15, P156, DOI 10.1097/00005373-197502000-00009; Sadaba JR, 2000, ANN ROY COLL SURG, V82, P162; Shott RM, 1987, ANN SURG, V206, P200; Tyburski JG, 1999, J TRAUMA, V46, P833, DOI 10.1097/00005373-199905000-00011; Velissaris T, 2003, INJURY, V34, P924, DOI 10.1016/S0020-1383(02)00415-1; von Garrel T, 2004, J TRAUMA, V57, P837, DOI 10.1097/01.TA.0000091112.02703.D8; Wiener Y, 2001, AM J EMERG MED, V19, P403, DOI 10.1053/ajem.2001.24463; Yiadom MYMAB, 2008, J EMERG MED, V35, P199, DOI 10.1016/j.jemermed.2008.05.014	20	26	27	0	1	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	JUL	2013	79	7					702	705					4	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	AI6ED	WOS:000336962600014	23816003				2022-02-06	
J	Suffoletto, B; Wagner, AK; Arenth, PM; Calabria, J; Kingsley, E; Kristan, J; Callaway, CW				Suffoletto, Brian; Wagner, Amy K.; Arenth, Patricia M.; Calabria, Jaclyn; Kingsley, Evan; Kristan, Jeffrey; Callaway, Clifton W.			Mobile Phone Text Messaging to Assess Symptoms After Mild Traumatic Brain Injury and Provide Self-Care Support: A Pilot Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; mild; mobile phone; postconcussive symptoms	HEAD-INJURY; SCREENING SCALE; RAPID SCREEN; ADULTS; QUESTIONNAIRE; DEPRESSION; SEVERITY; ALCOHOL; ANXIETY; TRIAL	Purpose: To examine whether patients with mild traumatic brain injury (mTBI) receiving text messaging based education and behavioral support had fewer and less severe postconcussive symptoms than those not receiving text-message support. Our secondary objective was to determine the feasibility of using text messaging to assess daily symptoms and provide support to patients with mTBI. Design: Randomized controlled trial with 14-day follow-up. Participants: Convenience sample of 43 adult emergency department patients with mTBI. Intervention: Fourteen days of timed SMS (short-message service) symptom assessments (9 AM: headaches; 1 PM: difficulty concentrating; 5 PM: irritability or anxiety) with self-care support messages. Main Measures: SMS symptom reports, Rivermead Postconcussion Symptoms Questionnaire. Results: Compared with the control group, intervention participants trended to lower odds of reporting headaches (odds ratio [OR] = 0.38; 95% confidence interval [CI]: 0.07-1.99), concentration difficulty (OR = 0.32; 95% CI: 0.04-2.24), and irritability or anxiety (OR = 0.33; 95% CI: 0.05-2.35). There were also trends of lower mean scores for headaches (0.99 vs 1.19; P = .5), difficulty concentrating (0.88 vs 1.23; P = .2), and irritability/anxiety (1.00 vs 1.62; P = .06). There were high response rate to SMS symptom assessments and high satisfaction with the intervention. Conclusion: Those receiving the text messaging based education and support had fewer and less severe postconcussive symptoms than the controls but none of the differences reached statistical significance. Further evaluation of more robust mobile interventions and larger sample of participants are still needed.	[Suffoletto, Brian; Calabria, Jaclyn; Kingsley, Evan; Kristan, Jeffrey; Callaway, Clifton W.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA; [Wagner, Amy K.; Arenth, Patricia M.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA		Suffoletto, B (corresponding author), Univ Pittsburgh, Dept Emergency Med, Iroquois Bldg,Ste 400A,3600 Forbes Ave, Pittsburgh, PA 15261 USA.	suffbp@upmc.edu		Callaway, Clifton/0000-0002-3309-1573			Azulay J, 2013, J HEAD TRAUMA REHAB, V28, P323, DOI 10.1097/HTR.0b013e318250ebda; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; De Monte VE, 2010, J CLIN EXP NEUROPSYC, V32, P28, DOI 10.1080/13803390902806519; DeSalvo KB, 2006, QUAL LIFE RES, V15, P191, DOI 10.1007/s11136-005-0887-2; Humeniuk R, 2008, ADDICTION, V103, P1039, DOI 10.1111/j.1360-0443.2007.02114.x; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kimerling R, 2006, J GEN INTERN MED, V21, P65, DOI 10.1111/j.1525-1497.2005.00292.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kroenke K, 2009, PSYCHOSOMATICS, V50, P613, DOI 10.1176/appi.psy.50.6.613; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Snell DL, 2010, BRAIN INJURY, V24, P1595, DOI 10.3109/02699052.2010.523048; Suffoletto B, 2012, ACAD EMERG MED, V19, P949, DOI 10.1111/j.1553-2712.2012.01411.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Wei J, 2011, J TELEMED TELECARE, V17, P41, DOI 10.1258/jtt.2010.100322	26	26	26	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					302	312		10.1097/HTR.0b013e3182847468			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900008	23474882				2022-02-06	
J	Arya, SK; Pui, TS; Wong, CC; Kumar, S; Rahman, ARA				Arya, Sunil K.; Pui, Tze Sian; Wong, Chee Chung; Kumar, Sai; Rahman, Abdur Rub Abdur			Effects of the Electrode Size and Modification Protocol on a Label-Free Electrochemical Biosensor	LANGMUIR			English	Article							TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; SELF-ASSEMBLED MONOLAYERS; IMPEDANCE SPECTROSCOPY; SERUM; IMMUNOSENSOR; BIOMARKER; GFAP; APTASENSOR; HUMANS	In the present work, the effect of a surface modification protocol along with the electrode size has been investigated for developing an efficient, label-free electrochemical biosensing method for diagnosis of traumatic brain injury (TBI) biomarkers. A microdisk electrode array (MDEA) and a macroelectrode with a comb structure (MECS) were modified with an anti-GFAP (GFAP = glial fibrillary acidic protein) antibody using two protocols for optimum and label-free detection of GEAP, a promising acute-phase TBI biomarker. For the MDEA, an array of six microdisks with a 100 mu m diameter and, for the MECS, a 3.2 mm x 5.5 mm electrode 5 mu m wide With 10 mu m spaced Comb fingers were modified using an optimized protocol for dithiobis(succinimidyl propionate) (DSP) self-assembled monolayer formation. Anti-GFAP was covalently bound, and the remaining free DSP, groups were blocked using ethanol amine (Ea). Sensors, were exposed to solutions with different GFAP concentrations, and a label-free electrochemical,1:impedance spectroscopy (EIS) technique was used to determine the concentration. EIS results confirmed that both types of Ea/anti-GFAP/DSP/Au electrodes modified with an optimized DSP-based protocol can accurately detect GFAP in the range of 1 pg mL(-1) to 100 ng mL(-1) with a detection limit of 1 pg mL(-1) However, the cross-use of the MDEA protocol on the MECS and vice versa resulted in very low sensitivity or poor signal resolution, underscoring the importance of proper Matching oldie electrode size and type and the surface modification protocol.	[Arya, Sunil K.; Pui, Tze Sian; Wong, Chee Chung; Rahman, Abdur Rub Abdur] ASTAR, Inst Microelect, Bioelect Programme, Singapore 117685, Singapore; [Kumar, Sai] SFC Fluid LLC, Enterprise Ctr, Fayetteville, AR 72701 USA		Arya, SK (corresponding author), ASTAR, Inst Microelect, Bioelect Programme, 11 Sci Pk Rd,Singapore Sci Pk 2, Singapore 117685, Singapore.	sunilarya333@gmail.com		Pui, Tze Sian/0000-0003-1056-9826	A*STAR (Agency for Science, Technology and Research), SingaporeAgency for Science Technology & Research (ASTAR) [IME/12-330041]	This work was supported by the A*STAR (Agency for Science, Technology and Research), Singapore, Grant IME/12-330041.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arya SK, 2007, ANAL BIOCHEM, V363, P210, DOI 10.1016/j.ab.2007.01.029; Arya SK, 2013, BIOSENS BIOELECTRON, V41, P446, DOI 10.1016/j.bios.2012.09.006; Arya SK, 2012, ANAL CHIM ACTA, V737, P1, DOI 10.1016/j.aca.2012.05.048; Arya SK, 2012, LAB CHIP, V12, P2362, DOI 10.1039/c2lc21174b; Arya SK, 2010, BIOSENS BIOELECTRON, V25, P2296, DOI 10.1016/j.bios.2010.03.016; Arya SK, 2009, BIOSENS BIOELECTRON, V24, P2810, DOI 10.1016/j.bios.2009.02.008; Bai HY, 2013, BIOSENS BIOELECTRON, V42, P17, DOI 10.1016/j.bios.2012.10.063; Ennen CS, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.025; Fan LF, 2013, BIOSENS BIOELECTRON, V43, P12, DOI 10.1016/j.bios.2012.11.033; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Mendes RK, 2008, J ELECTROANAL CHEM, V612, P164, DOI 10.1016/j.jelechem.2007.09.033; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Niu LM, 2013, SENSOR ACTUAT B-CHEM, V178, P10, DOI 10.1016/j.snb.2012.12.015; North SH, 2012, ANNU REV ANAL CHEM, V5, P35, DOI 10.1146/annurev-anchem-062011-143105; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Pandey CM, 2011, SENSOR ACTUAT B-CHEM, V151, P333, DOI 10.1016/j.snb.2010.07.046; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Park MK, 2012, SENSOR ACTUAT B-CHEM, V171, P323, DOI 10.1016/j.snb.2012.04.017; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pui TS, 2013, SENSOR ACTUAT B-CHEM, V181, P494, DOI 10.1016/j.snb.2013.02.019; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Singh A, 2010, BIOSENS BIOELECTRON, V26, P131, DOI 10.1016/j.bios.2010.05.024; Solanki PR, 2007, SENSOR ACTUAT B-CHEM, V123, P829, DOI 10.1016/j.snb.2006.10.046; Szymanska I, 2007, BIOSENS BIOELECTRON, V22, P1955, DOI 10.1016/j.bios.2006.08.025; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vasudev A, 2013, BIOSENS BIOELECTRON, V39, P300, DOI 10.1016/j.bios.2012.06.012; Venkatasubbarao S, 2011, PROC SPIE, V8029, DOI 10.1117/12.886661; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	37	26	26	0	54	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0743-7463			LANGMUIR	Langmuir	JUN 4	2013	29	22					6770	6777		10.1021/la401109r			8	Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Materials Science	160DK	WOS:000320097000032	23651210				2022-02-06	
J	Kokjohn, TA; Maarouf, CL; Daugs, ID; Hunter, JM; Whiteside, CM; Malek-Ahmadi, M; Rodriguez, E; Kalback, W; Jacobson, SA; Sabbagh, MN; Beach, TG; Roher, AE				Kokjohn, Tyler A.; Maarouf, Chera L.; Daugs, Ian D.; Hunter, Jesse M.; Whiteside, Charisse M.; Malek-Ahmadi, Michael; Rodriguez, Emma; Kalback, Walter; Jacobson, Sandra A.; Sabbagh, Marwan N.; Beach, Thomas G.; Roher, Alex E.			Neurochemical Profile of Dementia Pugilistica	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; immunoblots; neurodegenerative disorders; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; AMYLOID-BETA-PROTEIN; SPORADIC ALZHEIMERS-DISEASE; REPETITIVE HEAD-INJURY; DIFFUSE AXONAL INJURY; A-BETA; NEUROTROPHIC FACTOR; NEURITE OUTGROWTH; ALPHA-SYNUCLEIN	Dementia pugilistica (DP), a suite of neuropathological and cognitive function declines after chronic traumatic brain injury (TBI), is present in approximately 20% of retired boxers. Epidemiological studies indicate TBI is a risk factor for neuro-degenerative disorders including Alzheimer disease (AD) and Parkinson disease (PD). Some biochemical alterations observed in AD and PD may be recapitulated in DP and other TBI persons. In this report, we investigate long-term biochemical changes in the brains of former boxers with neuropathologically confirmed DP. Our experiments revealed biochemical and cellular alterations in DP that are complementary to and extend information already provided by histological methods. ELISA and one-dimensional and two dimensional Western blot techniques revealed differential expression of select molecules between three patients with DP and three age-matched non-demented control (NDC) persons without a history of TBI. Structural changes such as disturbances in the expression and processing of glial fibrillary acidic protein, tau, and alpha-synuclein were evident. The levels of the A beta-degrading enzyme neprilysin were reduced in the patients with DP. Amyloid-beta levels were elevated in the DP participant with the concomitant diagnosis of AD. In addition, the levels of brain-derived neurotrophic factor and the axonal transport proteins kinesin and dynein were substantially decreased in DP relative to NDC participants. Traumatic brain injury is a risk factor for dementia development, and our findings are consistent with permanent structural and functional damage in the cerebral cortex and white matter of boxers. Understanding the precise threshold of damage needed for the induction of pathology in DP and TBI is vital.	[Kokjohn, Tyler A.; Maarouf, Chera L.; Daugs, Ian D.; Hunter, Jesse M.; Whiteside, Charisse M.; Rodriguez, Emma; Kalback, Walter; Roher, Alex E.] Banner Sun Hlth Res Inst, Longtine Ctr Neurodegenerat Biochem, Sun City, AZ 85351 USA; [Kokjohn, Tyler A.] Midwestern Univ, Sch Med, Dept Microbiol, Glendale, AZ USA; [Malek-Ahmadi, Michael; Jacobson, Sandra A.; Sabbagh, Marwan N.] Banner Sun Hlth Res Inst, Cleo Roberts Ctr Clin Res, Sun City, AZ 85351 USA; [Rodriguez, Emma] Natl Inst Cardiol, Mexico City, DF, Mexico; [Beach, Thomas G.] Banner Sun Hlth Res Inst, Civin Lab Neuropathol, Sun City, AZ 85351 USA		Roher, AE (corresponding author), Banner Sun Hlth Res Inst, Longtine Ctr Neurodegenerat Biochem, 10515 W Santa Fe Dr, Sun City, AZ 85351 USA.	alex.roher@bannerhealth.com	Malek-Ahmadi, Michael/AAT-1052-2020	Malek-Ahmadi, Michael/0000-0001-9901-3650; Rodriguez, Emma/0000-0002-5509-5321	The National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG019795, P30 AG19610]; State of Arizona Alzheimer's Disease Research Consortium; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U24 NS0702026]; Arizona Department of Health Services [211002]; Arizona Biomedical Research Commission [4001, 011, 05-901, 1001]; Michael J. Fox Foundation for Parkinson's Research; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019795, P30AG013846, P50AG005134, P30AG019610] Funding Source: NIH RePORTER	This study was supported by The National Institute on Aging (R01 AG019795), by the State of Arizona Alzheimer's Disease Research Consortium. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS0702026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium), and the Michael J. Fox Foundation for Parkinson's Research. We would like to kindly acknowledge Dr. Ann McKee from the Department of Veterans Affairs and National Institute of Aging Boston University Alzheimer's Disease Center (P30 AG13846) for aid in facilitating the provision of DP brain tissues of cases #1 and #2 and for critical review of the manuscript. We also appreciate the Neuropathology Core of the Massachusetts Alzheimer Disease Research Center (P50 AG005134) and Ms. Karlotta Fitch of the Massachusetts Neuropathology Service, Massachusetts General Hospital, for providing DP brain tissue of case #3. We are in debt to Dr. Dean C. Luehrs for critical review of the manuscript.	AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; Anderson RM, 1998, AM J FOREN MED PATH, V19, P1, DOI 10.1097/00000433-199803000-00001; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bartzokis G, 2011, NEUROBIOL AGING, V32, P1341, DOI 10.1016/j.neurobiolaging.2009.08.007; Beach TG, 2008, CELL TISSUE BANK, V9, P229, DOI 10.1007/s10561-008-9067-2; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Bishop GM, 2004, BRAIN PATHOL, V14, P448; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; Breydo L, 2012, BBA-MOL BASIS DIS, V1822, P261, DOI 10.1016/j.bbadis.2011.10.002; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Castejon O. J., 2004, Journal of Submicroscopic Cytology and Pathology, V36, P285; Castejon OJ, 1998, J SUBMICR CYTOL PATH, V30, P145; CASTEJON OJ, 1985, J SUBMICR CYTOL PATH, V17, P703; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chuang JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033120; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Crawford F, 1997, ANN NY ACAD SCI, V826, P35, DOI 10.1111/j.1749-6632.1997.tb48459.x; Cullen KM, 2006, NEUROBIOL AGING, V27, P1786, DOI 10.1016/j.neurobiolaging.2005.10.016; Davidson YS, 2011, ACTA NEUROPATHOL, V122, P703, DOI 10.1007/s00401-011-0879-y; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Goux WJ, 2001, J ALZHEIMERS DIS, V3, P455, DOI 10.3233/JAD-2001-3504; GOUX WJ, 1995, FEBS LETT, V366, P81, DOI 10.1016/0014-5793(95)00486-S; GOWING E, 1994, J BIOL CHEM, V269, P10987; Graham DI, 1996, ACT NEUR S, V66, P96; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; GUALTIERI T, 1991, Brain Injury, V5, P219, DOI 10.3109/02699059109008093; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; He XS, 2010, ACTA NEUROL BELG, V110, P49; Hersh LB, 2008, CURR ALZHEIMER RES, V5, P225, DOI 10.2174/156720508783954703; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Hirokawa N, 2010, NEURON, V68, P610, DOI 10.1016/j.neuron.2010.09.039; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hol EM, 2003, MOL PSYCHIATR, V8, P786, DOI 10.1038/sj.mp.4001379; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; INAGAKI M, 1994, BRAIN PATHOL, V4, P239, DOI 10.1111/j.1750-3639.1994.tb00839.x; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Johnson VE, 2012, EXP NEUROL; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Johnston H, 2011, BIOCHEM SOC T, V39, P886, DOI 10.1042/BST0390886; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kalback W, 2004, NEUROL RES, V26, P525, DOI 10.1179/016164104225017668; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kokjohn TA, 2012, ALZHEIMERS DEMENT, V8, P574, DOI 10.1016/j.jalz.2011.05.2429; Korolainen MA, 2005, NEUROBIOL DIS, V20, P858, DOI 10.1016/j.nbd.2005.05.021; KUCHNA I, 1991, Neuropatologia Polska, V29, P103; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Liao MC, 2010, J BIOL CHEM, V285, P35590, DOI 10.1074/jbc.M110.169599; Liao MC, 2009, J BIOL CHEM, V284, P28917, DOI 10.1074/jbc.M109.050856; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Maarouf CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027291; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Martin L, 2011, NEUROCHEM INT, V58, P458, DOI 10.1016/j.neuint.2010.12.023; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouser PE, 2006, AM J PATHOL, V168, P936, DOI 10.2353/ajpath.2006.050798; Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Paris D, 2003, NEUROL RES, V25, P642, DOI 10.1179/016164103101201940; Paris Daniel, 2004, Angiogenesis, V7, P75, DOI 10.1023/B:AGEN.0000037335.17717.bf; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Porchet R, 2003, PROTEOMICS, V3, P1476, DOI 10.1002/pmic.200300456; Rauramaa T, 2011, J NEURAL TRANSM, V118, P683, DOI 10.1007/s00702-010-0574-5; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Robinson SR, 2002, NEUROBIOL AGING, V23, P1051, DOI 10.1016/S0197-4580(01)00342-6; Roher AE, 2003, ARTERIOSCL THROM VAS, V23, P2055, DOI 10.1161/01.ATV.0000095973.42032.44; Roher AE, 2002, BIOCHEMISTRY-US, V41, P11080, DOI 10.1021/bi026173d; RUDGE JS, 1990, J NEUROSCI, V10, P3594; Sabbagh MN, 2010, CURR ALZHEIMER RES, V7, P280, DOI 10.2174/156720510791162340; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schenker M, 2001, J BONE JOINT SURG BR, V83B, P916, DOI 10.1302/0301-620X.83B6.10725; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100107-01, 10.3928/02793695-20100108-02]; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SPARKMAN DR, 1991, BIOCHEM BIOPH RES CO, V181, P771, DOI 10.1016/0006-291X(91)91257-D; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stone J, 2008, MED HYPOTHESES, V71, P347, DOI 10.1016/j.mehy.2008.04.007; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thal DR, 2005, ACTA NEUROPATHOL, V110, P459, DOI 10.1007/s00401-005-1053-1; Thomas SN, 2012, ACTA NEUROPATHOL, V123, P105, DOI 10.1007/s00401-011-0893-0; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; VanPaesschen W, 1997, J NEUROL NEUROSUR PS, V63, P513, DOI 10.1136/jnnp.63.4.513; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Wu CW, 2004, NEUROBIOL DIS, V17, P367, DOI 10.1016/j.nbd.2004.08.014; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518; Zurek J, 2011, J TRAUMA, V71, P854, DOI 10.1097/TA.0b013e3182140c8c	127	26	26	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					981	997		10.1089/neu.2012.2699			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300009	23268705	Green Published			2022-02-06	
J	Yeo, SS; Jang, SH				Yeo, Sang Seok; Jang, Sung Ho			NEURAL REORGANIZATION FOLLOWING BILATERAL INJURY OF THE FORNIX CRUS IN A PATIENT WITH TRAUMATIC BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						head trauma; fornix; memory; diffusion tensor imaging; brain plasticity	DIFFUSE AXONAL INJURY; INFERIOR LONGITUDINAL FASCICULUS; MINI-MENTAL-STATE; TENSOR TRACTOGRAPHY; FIBER TRACTOGRAPHY; MEMORY IMPAIRMENT; STROKE PATIENTS; MOTOR RECOVERY	Objective: We report on a patient who appeared to demonstrate neural reorganization after head trauma resulting in bilateral injury of the fornix emus. Case report: A 58-year-old male patient and 8 control subjects were recruited. The patient had undergone head trauma as the result of a car accident and had lost consciousness for 30 min. Brain magnetic resonance imaging, performed 3 years after the head trauma, showed no evidence of abnormality. Results: Discontinuation of both crus in the proximal region was observed on diffusion tensor tractography of the fornix. In the right fornix, an abnormal neural tract originating from the right crus passed through the splenium of the corpus callosum to connect with the right inferior longitudinal fasciculus. By contrast, in the left fornix, another abnormal neural tract originating from the left column passed through the left inferior longitudinal fasciculus and the splenium of the corpus callosum. None of these abnormal neural tracts was observed in normal subjects. Conclusion: We presume that the abnormal neural tracts of the fornix observed in this patient were the result of neural reorganization triggered by bilateral injury of the fornix crus. The results of this study suggest a mechanism for recovery of the injured fornix following head trauma.	[Yeo, Sang Seok; Jang, Sung Ho] Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, Taegu 705717, South Korea		Jang, SH (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net			National Research Foundation of Korea (NRF)National Research Foundation of Korea; Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of Korea [2012R1A1A4A01001873]	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A4A01001873).	Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; Ashtari M, 2012, DEV MED CHILD NEUROL, V54, P6, DOI 10.1111/j.1469-8749.2011.04122.x; Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Chang MC, 2010, NEUROREHABILITATION, V26, P347, DOI 10.3233/NRE-2010-0572; Concha L, 2005, AM J NEURORADIOL, V26, P2267; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Han C, 2008, ARCH GERONTOL GERIAT, V47, P302, DOI 10.1016/j.archger.2007.08.012; Hong JH, 2010, J REHABIL MED, V42, P979, DOI 10.2340/16501977-0603; Hong JH, 2010, EUR NEUROL, V63, P252, DOI 10.1159/000277477; Jang SH, 2011, NEUROREHABILITATION, V28, P345, DOI 10.3233/NRE-2011-0662; Jang SH, 2011, J REHABIL MED, V43, P268, DOI 10.2340/16501977-0654; Jang SH, 2009, ARCH NEUROL-CHICAGO, V66, P1424, DOI 10.1001/archneurol.2009.242; Lee SK, 2005, RADIOGRAPHICS, V25, P53, DOI 10.1148/rg.251045085; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Parker GJM, 2005, PHILOS T R SOC B, V360, P893, DOI 10.1098/rstb.2005.1639; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; TUCKER DM, 1988, CORTEX, V24, P465, DOI 10.1016/S0010-9452(88)80010-8; TUSA RJ, 1985, ANN NEUROL, V18, P583, DOI 10.1002/ana.410180512; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wechsler D, 1981, WECHSLER ADULT INTEL; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; Williams JM., 1991, MAS MEMORY ASSESSMEN; Wolk David A, 2010, Continuum (Minneap Minn), V16, P15, DOI 10.1212/01.CON.0000368257.30791.3a; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165; Yamada K, 2009, P NATL ACAD SCI USA, V106, pE14, DOI 10.1073/pnas.0812352106	28	26	27	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	JUN	2013	45	6					595	598		10.2340/16501977-1145			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	172UI	WOS:000321030000013	23588891	gold, Green Submitted			2022-02-06	
J	Xie, K; Kuang, H; Tsien, JZ				Xie, Kun; Kuang, Hui; Tsien, Joe Z.			Mild Blast Events Alter Anxiety, Memory, and Neural Activity Patterns in the Anterior Cingulate Cortex	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; BRAIN-INJURY; ENHANCEMENT; SURVIVORS; DEFICITS; COMBAT; TRAUMA; IMPACT; MODEL	There is a general interest in understanding of whether and how exposure to emotionally traumatizing events can alter memory function and anxiety behaviors. Here we have developed a novel laboratory-version of mild blast exposure comprised of high decibel bomb explosion sound coupled with strong air blast to mice. This model allows us to isolate the effects of emotionally fearful components from those of traumatic brain injury or bodily injury typical associated with bomb blasts. We demonstrate that this mild blast exposure is capable of impairing object recognition memory, increasing anxiety in elevated O-maze test, and resulting contextual generalization. Our in vivo neural ensemble recording reveal that such mild blast exposures produced diverse firing changes in the anterior cingulate cortex, a region processing emotional memory and inhibitory control. Moreover, we show that these real-time neural ensemble patterns underwent post-event reverberations, indicating rapid consolidation of those fearful experiences. Identification of blast-induced neural activity changes in the frontal brain may allow us to better understand how mild blast experiences result in abnormal changes in memory functions and excessive fear generalization related to post-traumatic stress disorder.	[Xie, Kun; Kuang, Hui; Tsien, Joe Z.] Georgia Regents Univ, Med Coll Georgia, Brain & Behav Discovery Inst, Augusta, GA USA; [Xie, Kun; Kuang, Hui; Tsien, Joe Z.] Georgia Regents Univ, Med Coll Georgia, Dept Neurol, Augusta, GA USA		Tsien, JZ (corresponding author), Georgia Regents Univ, Med Coll Georgia, Brain & Behav Discovery Inst, Augusta, GA USA.	jtsien@gru.edu	Xie, Kun/L-9926-2013; Kuang, Hui/I-1006-2013; Kilic, Cengiz/I-9145-2013	Kuang, Hui/0000-0002-7806-2864; 	US Army Research Office [W911NF-09-1-0112]; Yunnan Province Department of Science and Technology [2012BA009]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS079774-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079774] Funding Source: NIH RePORTER	This work was supported by grants from US Army Research Office (W911NF-09-1-0112), Yunnan Province Department of Science and Technology (Grant # 2012BA009), and National Institutes of Health (NS079774-01A1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Cao XH, 2008, NEURON, V60, P353, DOI 10.1016/j.neuron.2008.08.027; Cesur R, 2013, J HEALTH ECON, V32, P51, DOI 10.1016/j.jhealeco.2012.09.001; Chen GF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008256; Eren-Kocak E, 2009, ACTA PSYCHIAT SCAND, V119, P35, DOI 10.1111/j.1600-0447.2008.01281.x; Fani N, 2012, BIOL PSYCHOL, V90, P134, DOI 10.1016/j.biopsycho.2012.03.001; Golub Y, 2009, BEHAV BRAIN RES, V205, P544, DOI 10.1016/j.bbr.2009.08.019; Jovanovic N, 2010, CROAT MED J, V51, P131, DOI 10.3325/cmj.2010.51.131; Jovanovic T, 2012, NEUROPHARMACOLOGY, V62, P695, DOI 10.1016/j.neuropharm.2011.02.023; Jovanovic T, 2010, DEPRESS ANXIETY, V27, P244, DOI 10.1002/da.20663; Lin LN, 2006, TRENDS NEUROSCI, V29, P48, DOI 10.1016/j.tins.2005.11.004; Lin LN, 2005, P NATL ACAD SCI USA, V102, P6125, DOI 10.1073/pnas.0408233102; Lin LN, 2006, J NEUROSCI METH, V155, P28, DOI 10.1016/j.jneumeth.2005.12.032; MACGREGOR AJ, 2012, INJURY; Miller MM, 2006, ANN NY ACAD SCI, V1071, P294, DOI 10.1196/annals.1364.023; Mumby DG, 1996, BEHAV NEUROSCI, V110, P266, DOI 10.1037/0735-7044.110.2.266; Osan R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000404; Quinn JJ, 2008, LEARN MEMORY, V15, P368, DOI 10.1101/lm.813608; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Rau V, 2005, NEUROSCI BIOBEHAV R, V29, P1207, DOI 10.1016/j.neubiorev.2005.04.010; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Siegmund A, 2007, J PSYCHIATR RES, V41, P848, DOI 10.1016/j.jpsychires.2006.07.017; Solomon Z, 2001, J CLIN PSYCHIAT, V62, P11; SQUIRE LR, 1987, MEMORY BRAIN, pR12; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; van Wingen GA, 2012, P NATL ACAD SCI USA, V109, P15508, DOI 10.1073/pnas.1206330109; Wang DV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017047; Yehuda R, 2004, J CLIN PSYCHIAT, V65, P29	29	26	26	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2013	8	5							e64907	10.1371/journal.pone.0064907			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	156DC	WOS:000319799900129	23741416	Green Published, Green Submitted, gold			2022-02-06	
J	Bennett, RE; Esparza, TJ; Lewis, HA; Kim, E; Mac Donald, CL; Sullivan, PM; Brody, DL				Bennett, Rachel E.; Esparza, Thomas J.; Lewis, Hal A.; Kim, Eddie; Mac Donald, Christine L.; Sullivan, Patrick M.; Brody, David L.			Human Apolipoprotein E4 Worsens Acute Axonal Pathology but Not Amyloid-beta Immunoreactivity After Traumatic Brain Injury in 3xTG-AD Mice	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Apolipoprotein E; Axon injury; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; HEAD-INJURY; MOUSE MODEL; PROTEIN DEPOSITION; TYPE-4 ALLELE; E-GENOTYPE; A-BETA; PRECURSOR; TAU	Apolipoprotein E4 (APOE4) genotype is a risk factor for poor outcome after traumatic brain injury (TBI), particularly in young patients, but the underlying mechanisms are not known. By analogy to effects of APOE4 on the risk of Alzheimer disease (AD), the APOE genotype may influence beta-amyloid (A beta) and tau deposition after TBI. To test this hypothesis, we crossed 3xTG-AD transgenic mice carrying 3 human familial AD mutations (PS1(M146V), tau(P301L), and APP(SWE)) to human ApoE2-, ApoE3-, and ApoE4-targeted replacement mice. Six- to 8-month-old 3xTG-ApoE mice were assayed by quantitative immunohistochemistry for amyloid precursor protein (APP), A beta(1-40) (A beta 40), A beta(1-42) (A beta 42), total human tau, and phosphoserine 199 (pS199) tau at 24 hours after moderate controlled cortical impact. There were increased numbers of APP-immunoreactive axonal varicosities in 3xTG-ApoE4 mice versus the other genotypes. This finding was repeated in a separate cohort of ApoE4-targeted replacement mice without human transgenes compared with ApoE3 and ApoE2 mice. There were no differences between genotypes in the extent of intra-axonal A beta 40 and A beta 42; none of the mice had extracellular A beta deposition. Regardless of injury status, 3xTG-ApoE4 mice had more total human tau accumulation in both somatodendritic and intra-axonal compartments than other genotypes. These results suggest that the APOE4 genotype may have a primary effect on the severity of axonal injury in acute TBI.	[Bennett, Rachel E.; Esparza, Thomas J.; Lewis, Hal A.; Kim, Eddie; Mac Donald, Christine L.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Sullivan, Patrick M.] Duke Univ, Dept Med, Div Geriatr, VAMC,Geriatr Res Educ Clin Ctr, Durham, NC USA; [Kim, Eddie] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Brody, David L.] Hope Ctr Neurol Disorders, St Louis, MO USA		Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Bennett, Rachel/AAU-6949-2020	Bennett, Rachel/0000-0001-9640-0575	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065069, K08-NS049237, F31-NS076047]; Burroughs Wellcome FundBurroughs Wellcome Fund; Thrasher Research Fund; Health South Research Grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237, R01NS065069, F31NS076047] Funding Source: NIH RePORTER	This work was funded by NIH NS065069 (David Brody), NIH K08-NS049237 (David Brody), NIH F31-NS076047 (Rachel Bennett), the Burroughs Wellcome Fund (David Brody), the Thrasher Research Fund (David Brody), and a Health South Research Grant (David Brody).	Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Bien-Ly N, 2012, J NEUROSCI, V32, P4803, DOI 10.1523/JNEUROSCI.0033-12.2012; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Guo QX, 2012, CELL RES, V22, P78, DOI 10.1038/cr.2011.116; Hartman RE, 2002, J NEUROSCI, V22, P10083; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ohkubo N, 2002, FASEB J, V16, P295, DOI 10.1096/fj.02-0434fje; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Tesseur I, 2000, AM J PATHOL, V157, P1495, DOI 10.1016/S0002-9440(10)64788-8; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Ye SM, 2005, P NATL ACAD SCI USA, V102, P18700, DOI 10.1073/pnas.0508693102	53	26	27	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2013	72	5					396	403		10.1097/NEN.0b013e31828e24ab			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	133RS	WOS:000318158000003	23584199	Green Accepted, Bronze			2022-02-06	
J	Park, E; Eisen, R; Kinio, A; Baker, AJ				Park, Eugene; Eisen, Rebecca; Kinio, Anna; Baker, Andrew J.			Electrophysiological white matter dysfunction and association with neurobehavioral deficits following low-level primary blast trauma	NEUROBIOLOGY OF DISEASE			English	Article						Primary blast; Mild traumatic brain injury; White matter injury; AlphaII-spectrin; Blast injury; Electrophysiology	DEPENDENT SODIUM-CHANNELS; FLUID PERCUSSION INJURY; AXONAL INITIAL SEGMENT; DIFFUSE BRAIN-INJURY; ANKYRIN-G; MILITARY PERSONNEL; CORPUS-CALLOSUM; SERVICE MEMBERS; MOUSE MODEL; ADULT-RAT	There is strong evidence that primary blast injuries can cause neuropathological alterations in the brain. Clinical findings from war veterans indicating evidence of diffuse axonal injury have been corroborated by numerous primary blast models in animals. However, the effect of a subclinical blast (blast with no obvious sign of external trauma or lung injury) as a contributing factor to the neurological symptoms and neuropathology is less clear. Our group recently developed a model of low-level primary blast and characterized aberrant expression of white matter cytoskeletal proteins in the cortex and hippocampus following a subclinical wave shock exposure. Here we examined the susceptibility of the corpus callosum following subclinical blast. We also demonstrate that white matter dysfunction is associated with neurobehavioral deficits associated with anxiety and stress in rats. Anesthetized male Sprague-Dawley rats (similar to 300 g) were exposed to a primary blast (approx. 28 kPa), below the threshold required to induce pulmonary trauma. Rats were evaluated on three behavioral outcome measures; the rotarod, the light/dark box and open field anxiety test. We used Western blotting to examine expression and degradation of axonally expressed cell-spectrin, NF200 and voltage-gated sodium channels (VGSC) in the corpus callosum. Acute slice preparations were used for electrophysiological analysis of evoked compound action potentials (CAPs) in the corpus callosum. There was evidence of alpha II-spectrin degradation in the corpus callosum at 48 h post-injury detectable up to 14 days post-injury, as well as increased heavy neurofilament expression. A reduction in VGSC expression was observed at 48 h post-blast as well as a reduction in the interaction between ankyrin G and intact all-spectrin. Blast exposed rats had significantly lower rotarod latency times relative to sham rats (p = 0.002). Increased anxiety-related and stress-related behavior were observed in blast rats relative to sham animals as indicated by the increased frequency of fecal droppings (p = 0.029) and reduced exploratory activity (p = 0.036) in the open-field test. Blast rats had fewer transitions and time spent in lit sections of the light/dark box. Electrophysiological recordings from the corpus callosum indicated greater deficits in unmyelinated fibers of the corpus callosum relative to myelinated fibers characterized by reduced CAP amplitude response at 14 days post-injury. Analysis of the relationship between stimulation distance to evoked response indicated an underlying abnormality in N1 myelinated fibers at close stimulation distances. Collectively, our results indicate that subclinical blast exposure can result in persistent neurological changes in cerebral white matter occurring in parallel with detectable neurobehavioral deficits. (C) 2012 Elsevier Inc. All rights reserved.	[Park, Eugene; Eisen, Rebecca; Kinio, Anna; Baker, Andrew J.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Baker, Andrew J.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, Dept Surg, Toronto, ON, Canada		Park, E (corresponding author), St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	parke@smh.ca; bakera@smh.ca					Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Brachet A, 2010, J CELL BIOL, V191, P383, DOI 10.1083/jcb.201003042; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Crawford DK, 2009, NEUROSCIENCE, V164, P1407, DOI 10.1016/j.neuroscience.2009.09.069; Cullen DK, 2011, J NEUROTRAUM, V28, P2307, DOI [10.1089/neu.2010.1718, 10.1089/neu.2011.1718]; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; GENTSCH C, 1981, PHYSIOL BEHAV, V27, P183, DOI 10.1016/0031-9384(81)90320-6; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hu H, 2010, NEUROSCIENCE, V169, P171, DOI 10.1016/j.neuroscience.2010.04.057; IBRAHIM M, 1995, J NEUROL SCI, V133, P119, DOI 10.1016/0022-510X(95)00174-Z; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rubtsov AM, 2000, FEBS LETT, V482, P1, DOI 10.1016/S0014-5793(00)01924-4; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Shea TB, 2008, EUR J NEUROSCI, V27, P1893, DOI 10.1111/j.1460-9568.2008.06165.x; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	48	26	26	1	18	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	APR	2013	52				SI		150	159		10.1016/j.nbd.2012.12.002			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	096UL	WOS:000315430000015	23238347				2022-02-06	
J	Wong, GKC; Ngai, K; Lam, SW; Wong, A; Mok, V; Poon, WS				Wong, George Kwok Chu; Ngai, Karine; Lam, Sandy Wai; Wong, Adrian; Mok, Vincent; Poon, Wai Sang			Validity of the Montreal Cognitive Assessment for traumatic brain injury patients with intracranial haemorrhage	BRAIN INJURY			English	Article						Cognitive assessment; mini-mental state examination; Montreal cognitive assessment; traumatic brain injury; intracranial haemorrhage	SCALE; IMPAIRMENT; PREVALENCE; VALIDATION; DEFICITS; DISEASE; UTILITY; MOCA	Background and primary objective: In recent years, the Montreal Cognitive Assessment (MoCA) has been developed to assess patients with ischemic stroke. However, it has not been validated for use on traumatic brain injury patients with intracranial haemorrhage (tICH). The aim was to evaluate the psychometric properties of the MoCA (MoCA) in such patients. Research design and method: A cross-sectional observational study was carried out on 40 controls and 48 tICH patients recruited in Hong Kong. Concurrent validity was assessed by a comprehensive battery of neuropsychological tests and the Mini-Mental State Examination (MMSE). Criterion validity was assessed by the differentiation of tICH patients from controls. Main outcome and results: In tICH patients, cognitive z-scores (beta = 0.579; p < 0.001) and MMSE (beta = 0.366, p = 0.012) significantly correlated with performance in the MoCA after adjustment for age, gender and total score for the Geriatric Depressive Scale. For the differentiation of tICH patients from controls, analysis of receiver operating characteristics curves in the MoCA revealed an optimal balance of sensitivity and specificity at 25/26 with an area under the curve of 0.704 (p = 0.001). MoCA is applicable to and significantly correlated with excellent neurological outcomes in tICH patients. Conclusions: MoCA is a useful and psychometrically valid tool for the assessment of gross cognitive function in tICH patients.	[Wong, George Kwok Chu; Ngai, Karine; Lam, Sandy Wai; Poon, Wai Sang] Chinese Univ Hong Kong, Prince Wales Hosp, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China; [Wong, Adrian; Mok, Vincent] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China		Wong, GKC (corresponding author), Prince Wales Hosp, Dept Surg, 4-F Clin Sci Bldg,1 Ngan Shing St, Shatin, Hong Kong, Peoples R China.	georgewong@surgery.cuhk.edu.hk	Wong, George KC/A-6378-2011; Poon, Wai Sang/F-1558-2011; Wong, Adrian/K-4859-2014; Wong, George Kwok Chu/L-4344-2016; Mok, Vincent/N-6421-2015	Wong, George KC/0000-0002-6078-2548; Wong, Adrian/0000-0002-7859-3956; Mok, Vincent/0000-0002-8102-8835	Chinese University of Hong KongChinese University of Hong Kong	This study was supported by the Neurosurgery Research and Training Fund of the Chinese University of Hong Kong. The funding source had no role in the study design, collection, analysis or interpretation of data, manuscript preparation or decision for submission. The authors report no conflicts of interest.	Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Chung WS., 1994, J HONG KONG COLL PSY, V4, P25, DOI DOI 10.12809/HKMJ154737; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Lee JY, 2008, J GERIATR PSYCH NEUR, V21, P104, DOI 10.1177/0891988708316855; Lim PPJ, 2000, INT J GERIATR PSYCH, V15, P824, DOI 10.1002/1099-1166(200009)15:9<824::AID-GPS207>3.0.CO;2-C; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Pallant J.F., 2007, SPSS SURVIVAL MANUAL; Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888; Rose, 1982, CLIN GERONTOLOGIST, V1, P37, DOI [10.1300/J018v01n01_06, DOI 10.1300/J018V01N01_06]; Smith T, 2007, CAN J PSYCHIAT, V52, P329, DOI 10.1177/070674370705200508; Tang WK, 2005, J GERIATR PSYCH NEUR, V18, P3, DOI 10.1177/0891988704269814; Wen Hong-Bo, 2008, Zhonghua Nei Ke Za Zhi, V47, P36; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wong A, 2009, DEMENT GERIATR COGN, V28, P81, DOI 10.1159/000232589; Wong GKC, 2012, ACTA NEUROCHIR, V154, P105, DOI 10.1007/s00701-011-1198-8; Wong GKC, 2011, HONG KONG J OCCUP TH, V21, P27, DOI 10.1016/j.hkjot.2011.05.004; Zadikoff C, 2008, MOVEMENT DISORD, V23, P297, DOI 10.1002/mds.21837; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	20	26	31	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2013	27	4					394	398		10.3109/02699052.2012.750746			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	117LG	WOS:000316954300003	23473067				2022-02-06	
J	Cockshell, SJ; Mathias, JL				Cockshell, Susan J.; Mathias, Jane L.			Cognitive Deficits in Chronic Fatigue Syndrome and Their Relationship to Psychological Status, Symptomatology, and Everyday Functioning	NEUROPSYCHOLOGY			English	Article						chronic fatigue syndrome; cognitive problems; depression; symptoms; everyday functioning	MONOZYGOTIC TWINS DISCORDANT; TRAUMATIC BRAIN-INJURY; SLEEP QUALITY INDEX; NEUROPSYCHOLOGICAL IMPAIRMENT; PROCESSING SPEED; DSM-IV; PERSONALITY; DEPRESSION; PERFORMANCE; COMPLAINTS	Objective: To examine cognitive deficits in people with chronic fatigue syndrome (CFS) and their relationship to psychological status, CFS symptoms, and everyday functioning. Method: The current study compared the cognitive performance (reaction time, attention, memory, motor functioning, verbal abilities, and visuospatial abilities) of a sample with CFS (n = 50) with that of a sample of healthy controls (n = 50), all of whom had demonstrated high levels of effort and an intention to perform well, and examined the extent to which psychological status, CFS symptoms, and everyday functioning were related to cognitive performance. Results: The CFS group showed impaired information processing speed (reaction time), relative to the controls, but comparable performance on tests of attention, memory, motor functioning, verbal ability, and visuospatial ability. Moreover, information processing speed was not related to psychiatric status, depression, anxiety, the number or severity of CFS symptoms, fatigue, sleep quality, or everyday functioning. Conclusion: A slowing in information processing speed appears to be the main cognitive deficit seen in persons with CFS whose performance on effort tests is not compromised. Importantly, this slowing does not appear to be the consequence of other CFS-related variables, such as depression and fatigue, or motor speed.	[Cockshell, Susan J.; Mathias, Jane L.] Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia		Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594			ABBEY SE, 1991, REV INFECT DIS, V13, pS73; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Ayotte BJ, 2009, INT J GERIATR PSYCH, V24, P1010, DOI 10.1002/gps.2213; Ball N, 2004, J PSYCHOSOM RES, V56, P207, DOI 10.1016/S0022-3999(03)00598-1; Beaver KM, 2012, PSYCHIAT QUART, V83, P145, DOI 10.1007/s11126-011-9190-2; Binder LM, 2004, J CLIN EXP NEUROPSYC, V26, P369, DOI 10.1080/13803390490510095; Busichio K, 2004, J INT NEUROPSYCH SOC, V10, P278, DOI 10.1017/S1355617704102178; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cassimjee N, 2010, S AFR J PSYCHOL, V40, P125, DOI 10.1177/008124631004000202; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; Christodoulou C, 1998, J NEUROL NEUROSUR PS, V64, P431, DOI 10.1136/jnnp.64.4.431; Clark K., 2006, MYALGIC ENCEPHALOPAT; Claypoole KH, 2007, NEUROPSYCHOLOGY, V21, P507, DOI 10.1037/0894-4105.21.4.507; Cockshell SJ, 2010, PSYCHOL MED, V40, P1253, DOI 10.1017/S0033291709992054; Cockshell SJ, 2012, J CLIN EXP NEUROPSYC, V34, P679, DOI 10.1080/13803395.2012.668176; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 2013, STAT POWER ANAL BEHA; Courjaret J, 2009, J PSYCHOSOM RES, V66, P13, DOI 10.1016/j.jpsychores.2008.07.001; Deary V, 2010, PSYCHOL HEALTH, V25, P465, DOI 10.1080/08870440802403863; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; DELUCA J, 1995, J NEUROL NEUROSUR PS, V58, P38, DOI 10.1136/jnnp.58.1.38; DeLuca J, 2004, REHABIL PSYCHOL, V49, P62, DOI 10.1037/0090-5550.49.1.62; DeLuca J, 2004, J INT NEUROPSYCH SOC, V10, P101; DeLuca J, 1997, J PSYCHIAT RES, V31, P83, DOI 10.1016/S0022-3956(96)00052-0; DeLuca J, 1997, J NEUROL NEUROSUR PS, V62, P151, DOI 10.1136/jnnp.62.2.151; Duits A, 2008, J NEUROL NEUROSUR PS, V79, P143, DOI 10.1136/jnnp.2007.114595; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Fiedler N, 1996, PSYCHOSOM MED, V58, P38, DOI 10.1097/00006842-199601000-00007; Fossey M, 2004, J BEHAV MED, V27, P581, DOI 10.1007/s10865-004-0004-y; Fuentes K, 2001, CLIN NEUROPSYCHOL, V15, P210, DOI 10.1076/clin.15.2.210.1896; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fuller-Thomson E, 2008, FAM PRACT, V25, P414, DOI 10.1093/fampra/cmn064; GRAFMAN J, 1993, J NEUROL NEUROSUR PS, V56, P684, DOI 10.1136/jnnp.56.6.684; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Harvey SB, 2008, PSYCHOL MED, V38, P933, DOI 10.1017/S0033291707001900; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henderson M, 2005, J PSYCHOSOM RES, V59, P181, DOI 10.1016/j.jpsychores.2004.04.374; Henderson M, 2004, J PSYCHOSOM RES, V56, P251, DOI 10.1016/S0022-3999(03)00571-3; Jason L. A., 2003, HDB CHRONIC FATIGUE, P417; Jason LA, 1999, ARCH INTERN MED, V159, P2129, DOI 10.1001/archinte.159.18.2129; Johnson S K, 1997, Appl Neuropsychol, V4, P145, DOI 10.1207/s15324826an0403_1; JOHNSON SK, 1994, CLIN INFECT DIS, V18, pS84, DOI 10.1093/clinids/18.Supplement_1.S84; Kane RL, 1997, NEUROPSY NEUROPSY BE, V10, P25; KRUPP LB, 1994, ARCH NEUROL-CHICAGO, V51, P705, DOI 10.1001/archneur.1994.00540190089021; Le Bon O, 2000, Sleep Res Online, V3, P43; Magee CA, 2008, SLEEP BIOL RHYTHMS, V6, P222, DOI 10.1111/j.1479-8425.2008.00371.x; Mahurin RK, 2004, NEUROPSYCHOLOGY, V18, P232, DOI 10.1037/0894-4105.18.2.232; Marshall PS, 1997, PSYCHOSOM MED, V59, P58, DOI 10.1097/00006842-199701000-00008; Metzger FA, 2002, ANN BEHAV MED, V24, P106, DOI 10.1207/S15324796ABM2402_07; Michiels V, 1998, J INT NEUROPSYCH SOC, V4, P456, DOI 10.1017/S135561779845505X; Michiels V, 2001, ACTA PSYCHIAT SCAND, V103, P84, DOI 10.1034/j.1600-0447.2001.00017.x; Morriss RK, 1998, J ROY SOC MED, V91, P365, DOI 10.1177/014107689809100706; MossMorris R, 1996, J NEUROL NEUROSUR PS, V60, P474, DOI 10.1136/jnnp.60.5.474; Nater UM, 2010, PSYCHOTHER PSYCHOSOM, V79, P312, DOI 10.1159/000319312; Porter RJ, 2007, AUST NZ J PSYCHIAT, V41, P115, DOI 10.1080/00048670601109881; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Short K, 2002, J PSYCHOSOM RES, V52, P475, DOI 10.1016/S0022-3999(02)00290-8; Smith A, 1996, HUM PSYCHOPHARM CLIN, V11, P161, DOI 10.1002/(SICI)1099-1077(199605)11:3<161::AID-HUP784>3.0.CO;2-5; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Sullivan KA, 2012, BRAIN INJURY, V26, P1098, DOI 10.3109/02699052.2012.666367; Thomas Marie, 2009, Open Neurol J, V3, P13, DOI 10.2174/1874205X00903010013; Tiersky L A, 2001, Appl Neuropsychol, V8, P41, DOI 10.1207/S15324826AN0801_6; Tiersky LA, 2000, MIL PSYCHOL, V12, P233, DOI 10.1207/S15327876MP1204_01; Tiersky LA, 2003, J NERV MENT DIS, V191, P324, DOI 10.1097/00005053-200305000-00008; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; Tiersky LA, 1998, CLIN NEUROPSYCHOL, V12, P503, DOI 10.1076/clin.12.4.503.7237; Unger ER, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-6; van der Werf SP, 2000, NEUROPSY NEUROPSY BE, V13, P199; van der Werf SP, 2002, NEUROPSY NEUROPSY BE, V15, P2; van Geelen SM, 2007, CLIN PSYCHOL REV, V27, P885, DOI 10.1016/j.cpr.2007.01.010; Vercoulen JHMM, 1998, J CLIN EXP NEUROPSYC, V20, P144, DOI 10.1076/jcen.20.2.144.1160; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Wagner David L., 2005, P8; Ware J., 2001, SF 36 PHYS MENTAL HL; Wearden A, 1997, PSYCHOL MED, V27, P81, DOI 10.1017/S0033291796004035; Western SL, 1996, ARCH CLIN NEUROPSYCH, V11, P557, DOI 10.1016/0887-6177(95)00043-7; Wolfson, 1993, HALSTEAD REITAN NEUR; Wood B, 1999, J PSYCHOSOM RES, V47, P385, DOI 10.1016/S0022-3999(99)00025-2; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	81	26	29	0	27	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2013	27	2					230	242		10.1037/a0032084			13	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	111NT	WOS:000316528700010	23527651				2022-02-06	
J	Evans, CT; St Andre, JR; Pape, TLB; Steiner, ML; Stroupe, KT; Hogan, TP; Weaver, FM; Smith, BM				Evans, Charlesnika T.; St Andre, Justin R.; Pape, Theresa L. -B.; Steiner, Monica L.; Stroupe, Kevin T.; Hogan, Timothy P.; Weaver, Frances M.; Smith, Bridget M.			An Evaluation of the Veterans Affairs Traumatic Brain Injury Screening Process Among Operation Enduring Freedom and/or Operation Iraqi Freedom Veterans	PM&R			English	Article							POSTTRAUMATIC-STRESS-DISORDER; AFGHANISTAN; SYMPTOMS; HEALTH; CARE	Objective: To describe the early results of the U.S. Department of Veterans Affairs (VA) screening program for traumatic brain injury (TBI) and to identify patient and facility characteristics associated with receiving a TBI screen and results of the screening. Design: National retrdspective cohort study. Setting: VA Medical facilities. Patients: A total of 170,681 Operation Enduring Freedom and/or Operation Iraqi Freedom (OEF/OIF) Veterans who sought care at VA medical facilities from April 2007 to September 30, 2008. Methods: Data were abstracted from VA administrative and operational databases, including patient demographics, facility characteristics, and outcomes. Main Outcome Measurements: The main outcomes were receipt of and results of the TBI screen. Results: The majority of veterans eligible received the TBI screen (91.6%). Screening rates varied by patient and facility characteristics. In all, 25% of screened veterans had probable TBI exposure, in which the majority. of the exposures were blasts (85.0%). The rate of a positive TBI screen was 20.5% for the screened cohort. Male gender, service in the army, multiple deployments, and mental health diagnoses in the previous year were associated with a positive screen. Conclusions: TBI screening rates are high in VA; concomitant mental health diagnoses were highly prevalent in individuals with positive TBI screens. These data indicate that there will be a significant need for long-term health care services for veterans with TBI symptomatology. PM R 2013;5:210-220	[Evans, Charlesnika T.] Edward Hines Jr Vet Affairs VA Hosp, Dept VA, Ctr Management Complex Chron Care, Hines, IL 60141 USA; [Evans, Charlesnika T.] Spinal Cord Injury Qual Enhancement Res Initiat S, Dept VA, Hines, IL USA; [Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA; [St Andre, Justin R.; Pape, Theresa L. -B.; Stroupe, Kevin T.; Hogan, Timothy P.; Weaver, Frances M.; Smith, Bridget M.] Hines VA Hosp, Ctr Management Complex Chron Care, Dept VA, Hines, IL USA; [St Andre, Justin R.; Hogan, Timothy P.; Weaver, Frances M.; Smith, Bridget M.] SCI QUERI, Dept VA, Hines, IL USA; [St Andre, Justin R.] Hlth Res & Educ Trust, Chicago, IL USA; [Pape, Theresa L. -B.; Steiner, Monica L.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept VA, Hines, IL 60141 USA; [Pape, Theresa L. -B.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Stroupe, Kevin T.; Weaver, Frances M.; Smith, Bridget M.] Loyola Univ Chicago, Stritch Sch Med, Program Hlth Serv Res, Maywood, IL USA; [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA; [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, eHlth QUERI, Natl eHlth QUERI Coordinating Ctr, Bedford, MA USA; [Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA		Evans, CT (corresponding author), Edward Hines Jr Vet Affairs VA Hosp, Dept VA, Ctr Management Complex Chron Care, 5000 S 5th Ave, Hines, IL 60141 USA.	Charlesnika.Evans@va.gov	Weaver, Frances/S-1540-2019	Bender Pape, Theresa/0000-0001-7738-5963			Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bergquist T, 2009, BRAIN INJURY, V23, P790, DOI 10.1080/02699050903196688; Bergquist TF, 2010, TELEMED J E-HEALTH, V16, P417, DOI 10.1089/tmj.2009.0118; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Brennan DM, 2004, TELEMED J E-HEALTH, V10, P147, DOI 10.1089/1530562041641237; Carey K, 2000, HEALTH ECON, V9, P435, DOI 10.1002/1099-1050(200007)9:5<435::AID-HEC523>3.0.CO;2-Z; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; HINES EJ, 2003, VIREC RES USER GUIDE; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Maguen S, 2012, J PSYCHIATR RES, V46, P311, DOI 10.1016/j.jpsychires.2011.11.007; Nemeroff CB, 2006, J PSYCHIATR RES, V40, P1, DOI 10.1016/j.jpsychires.2005.07.005; Sayer NA, 2011, J HEAD TRAUMA REHAB, V26, P454, DOI 10.1097/HTR.0b013e3181ff393c; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Stroupe KT, 2010, J REHABIL RES DEV, V47, P781, DOI 10.1682/JRRD.2009.08.0122; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587	21	26	26	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482			PM&R	PM&R	MAR	2013	5	3					210	220		10.1016/j.pmrj.2012.12.004			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	110HN	WOS:000316433300008	23375630				2022-02-06	
J	Matuseviciene, G; Borg, J; Stalnacke, BM; Ulfarsson, T; de Boussard, C				Matuseviciene, Giedre; Borg, Jorgen; Stalnacke, Britt-Marie; Ulfarsson, Trandur; de Boussard, Catharina			Early intervention for patients at risk for persisting disability after mild traumatic brain injury: A randomized, controlled study	BRAIN INJURY			English	Article						Mild brain injury; intervention; traumatic brain injury; concussion	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; ROUTINE FOLLOW-UP; POSTCONCUSSION SYNDROME; CONTROLLED-TRIAL; DEPRESSION; PREDICTION; QUESTIONNAIRE; MODERATE; IMPACT	Study objective: To investigate the effect of an early intervention visit in addition to written information and treatment as usual for patients with an estimated high risk for persisting disability after a mild traumatic brain injury (MTBI). Research design: Randomized controlled trial. Methods: One hundred and seventy-three patients, aged 15-70 years with a Glasgow Coma Scale of 14-15 were included. All received written information about MTBI. Ninety-seven patients who reported three or more symptoms according to the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) at 10 days after the injury were considered as high-risk patients and were randomized to either early visit to a doctor or to treatment as usual (TAU); all patients including the 76 low-risk patients were followed-up at 3 months. Completion rate was 83%. Outcome measures included RPQ and the Hospital Anxiety and Depression Scale. Results: RPQ symptoms decreased significantly in both randomized groups, but were not significantly different in the groups at 3 months. At 3 months, anxiety and depression scores did not differ between groups. Conclusions: An early intervention, offered to patients with an estimated high risk for persisting disability, had no additional effect on symptom level at 3 months after MTBI as compared to TAU.	[Matuseviciene, Giedre; Borg, Jorgen; de Boussard, Catharina] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden; [Stalnacke, Britt-Marie] Umea Univ, Dept Community Med & Rehabil, Umea, Sweden; [Ulfarsson, Trandur] Sahlgrens Univ Hosp, Dept Rehabil Med, Gothenburg, Sweden		Matuseviciene, G (corresponding author), Danderyds Sjukhus AB, Dept Rehabil Med, S-18288 Stockholm, Sweden.	giedre.matuseviciene@ds.se		Borg, Jorgen/0000-0002-2372-7478	AFA insurance [060083]	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This study was supported by grants from AFA insurance, No 060083. The funders had no input to the study design or analysis.	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lannsjo M, 2012, EUROPEAN J NEUROLOGY; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; World Health Organization, 1992, ICD 10 CLASSIFICATIO; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	26	26	2	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2013	27	3					318	324		10.3109/02699052.2012.750740			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	096OG	WOS:000315413400009	23438351				2022-02-06	
J	Sears, JM; Blanar, L; Bowman, SM; Adams, D; Silverstein, BA				Sears, Jeanne M.; Blanar, Laura; Bowman, Stephen M.; Adams, Darrin; Silverstein, Barbara A.			Predicting Work-Related Disability and Medical Cost Outcomes: Estimating Injury Severity Scores from Workers' Compensation Data	JOURNAL OF OCCUPATIONAL REHABILITATION			English	Article						Injury severity; Trauma severity indices; ICDPIC; Occupational injuries; Workers' compensation; Work disability	REGISTRY INTERNATIONAL CLASSIFICATION; STATE TRAUMA REGISTRY; SYSTEM ICD-9 CODES; 9TH REVISION ICD-9; OCCUPATIONAL INJURY; UNITED-STATES; IMPROVES ACCURACY; DISJOINTED NATURE; WASHINGTON-STATE; SCORING SYSTEM	Purpose Acute work-related trauma is a leading cause of death and disability among US workers. The research objectives were to assess: (1) the feasibility of estimating Abbreviated Injury Scale-based injury severity scores (ISS) from ICD-9-CM codes available in workers' compensation (WC) medical billing data, (2) whether ISS predicts work-related disability and medical cost outcomes, (3) whether ISS adds value over other injury severity proxies, and (4) whether the utility of ISS differs for an all-injury sample compared with three specific injury samples (amputations, extremity fractures, traumatic brain injury). Methods ISS was estimated from ICD-9-CM codes using Stata's user-written -icdpic- program for 208,522 compensable nonfatal WC claims for workers injured in Washington State from 1998 to 2008. The Akaike Information Criterion and R-2 were used to compare severity measures. Competing risks survival analysis was used to evaluate work disability outcomes. Adjusted total medical costs were modeled using linear regression. Results Work disability and medical costs increased monotonically with injury severity. For a subset of 4,301 claims linked to the Washington State Trauma Registry (WTR), there was moderate agreement between WC-based ISS and WTR-based ISS. Including ISS together with an early hospitalization indicator resulted in the most informative models; however, early hospitalization is a more downstream measure. Conclusions ISS was significantly associated with work disability and medical cost outcomes for work-related injuries. Injury severity should be considered as a potential confounder for occupational injury intervention, program evaluation, or outcome studies, and can be estimated using existing software when ICD-9-CM codes are available.	[Sears, Jeanne M.; Blanar, Laura] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA; [Bowman, Stephen M.] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD 21218 USA; [Adams, Darrin; Silverstein, Barbara A.] Washington State Dept Labor & Ind, Olympia, WA 98504 USA; [Silverstein, Barbara A.] Univ Washington, Sch Publ Hlth, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA		Sears, JM (corresponding author), Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Box 354809, Seattle, WA 98195 USA.	jeannes@u.washington.edu	Bowman, Stephen/AAF-2154-2019		NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [R03OH009883] Funding Source: NIH RePORTER; NIOSH CDC HHS [1R03OH009883, R03 OH009883] Funding Source: Medline		Alexander BH, 1999, AM J IND MED, V36, P317, DOI 10.1002/(SICI)1097-0274(199908)36:2<317::AID-AJIM11>3.3.CO;2-I; [Anonymous], STAT SE UI WIND; [Anonymous], 2011, NAT TRAUM DAT STAND; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Augenstein JS, 1997, J TRAUMA, V43, P256; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barth P, 2008, 0825 UPJ I DEP LAB I; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Butterfield PG, 1998, AM J IND MED, V34, P559, DOI 10.1002/(SICI)1097-0274(199812)34:6<559::AID-AJIM3>3.3.CO;2-V; Campbell DA, 1996, J HAND SURG-BRIT EUR, V21B, P295, DOI 10.1016/S0266-7681(05)80187-1; Campbell Kevin M, 2008, Health Informatics J, V14, P5, DOI 10.1177/1460458208088855; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHEADLE A, 1994, AM J PUBLIC HEALTH, V84, P190, DOI 10.2105/AJPH.84.2.190; Clark DE, 2010, ICDPIC STATA MODULE; Cleves M., 2010, INTRO SURVIVAL ANAL, V3rd ed; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Cryer C, 2010, INJURY PREV, V16, P254, DOI 10.1136/ip.2009.023903; Dasinger LK, 1999, AM J IND MED, V35, P619, DOI 10.1002/(SICI)1097-0274(199906)35:6<619::AID-AJIM9>3.0.CO;2-I; Di Bartolomeo S, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-17; DiRusso SCM, 2004, J TRAUMA, V57, P486; Faul M, 2010, TRAUMATIC BRAIN INJU; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Forst LS, 1999, J OCCUP ENVIRON MED, V41, P514, DOI 10.1097/00043764-199906000-00019; Friedman LS, 2008, J OCCUP ENVIRON MED, V50, P350, DOI 10.1097/JOM.0b013e3181617324; Gillen M, 1999, AAOHN J, V47, P65; GLANCY KE, 1992, J TRAUMA, V33, P602, DOI 10.1097/00005373-199210000-00017; Harwood PJ, 2006, J TRAUMA, V60, P334, DOI 10.1097/01.ta.0000197148.86271.13; Hepp U, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-53; Husberg BJ, 1998, AM J IND MED, V34, P493, DOI 10.1002/(SICI)1097-0274(199811)34:5&lt;493::AID-AJIM10&gt;3.0.CO;2-X; Kilgo PD, 2004, J TRAUMA, V57, P479, DOI 10.1097/01.TA.0000141024.96440.7C; Krause N, 2001, AM J IND MED, V40, P464, DOI 10.1002/ajim.1116; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leigh JP, 2011, MILBANK Q, V89, P728, DOI 10.1111/j.1468-0009.2011.00648.x; Leigh JP, 1997, ARCH INTERN MED, V157, P1557, DOI 10.1001/archinte.157.14.1557; Lin MR, 2009, ARCH PHYS MED REHAB, V90, P1716, DOI 10.1016/j.apmr.2009.04.006; Lumley T, 2002, ANNU REV PUBL HEALTH, V23, P151, DOI 10.1146/annurev.publhealth.23.100901.140546; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Mann NC, 2006, ACAD EMERG MED, V13, P946, DOI 10.1197/j.aem.2006.04.019; Miller TR, 1995, ACCIDENT ANAL PREV, V27, P741, DOI 10.1016/0001-4575(95)00022-4; MITCHELL CS, 1993, ACCIDENT ANAL PREV, V25, P453, DOI 10.1016/0001-4575(93)90074-7; National Center for Health Statistics (NCHS) Expert Group on Injury Severity Measurement, 2004, DISC DOC INJ SEV MEA; National Institute for Occupational Safety and Health, WORKPL SAF HLTH TOP; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Osler TM, 1997, J TRAUMA, V43, P253, DOI 10.1097/00005373-199708000-00008; Pintilie M, 2006, STAT PRACTICE; Pransky G, 2001, AM J IND MED, V40, P295, DOI 10.1002/ajim.1104; Schnyder U, 2003, AM J PSYCHIAT, V160, P2025, DOI 10.1176/appi.ajp.160.11.2025; Sears JM, 2012, J OCCUP ENVIRON MED, V54, P356, DOI 10.1097/JOM.0b013e3182444fe7; Sears JM, 2011, J OCCUP ENVIRON MED, V53, P1243, DOI 10.1097/JOM.0b013e31822cff63; Shaw WS, 2001, DISABIL REHABIL, V23, P815; Soberg HL, 2011, J TRAUMA, V71, P425, DOI 10.1097/TA.0b013e3181eff54f; Soderstrom CA, 1997, J TRAUMA, V43, P925; State of Washington, EMPL OCC COV; State of Washington Office of Financial Management, COUNT POP DENS LESS; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; STIPDA: Injury Surveillance Workgroup 5, 2007, STIPDA INJ SURV WORK; Tiesman HM, 2011, AM J PREV MED, V41, P61, DOI 10.1016/j.amepre.2011.03.007; TOBIASEN J, 1982, ANN EMERG MED, V11, P260, DOI 10.1016/S0196-0644(82)80096-6; Toien K, 2011, INJURY	59	26	26	0	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1053-0487			J OCCUP REHABIL	J. Occup. Rehabil.	MAR	2013	23	1					19	31		10.1007/s10926-012-9377-x			13	Rehabilitation; Social Issues	Social Science Citation Index (SSCI)	Rehabilitation; Social Issues	083ZI	WOS:000314505200003	22736281				2022-02-06	
J	Wood, RL; Doughty, C				Wood, Rodger Ll.; Doughty, Caitriona			Alexithymia and Avoidance Coping Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alexithymia; avoidant behavior; coping styles; psychological distress; traumatic brain injury	DEPRESSION INVENTORY-II; SOCIAL SUPPORT; STRATEGIES; STRESS; SCALE; RELIABILITY; SENSITIVITY; RESPONSES; VALIDITY; AMNESIA	Background: Individuals who develop maladaptive coping styles after traumatic brain injury (TBI) usually experience difficulty expressing their emotional state, increasing the risk of psychological distress. Difficulties expressing emotion and identifying feelings are features of alexithymia, which is prevalent following TBI. Objective: To examine the relations among coping styles, alexithymia, and psychological distress following TBI. Participants: Seventy-one patients with TBI drawn from a head injury clinic population and 54 demographically matched healthy controls. Main Measures: Toronto Alexithymia Scale-20, Estonian COPE-D Inventory, Beck Depression Inventory-II, and Beck Anxiety Inventory. Results: The participants with TBI exhibited significantly higher rates of alexithymia and psychological distress and lower levels of task-oriented coping than healthy controls. Levels of avoidance coping and psychological distress were significantly higher in a subgroup of TBI patients with alexithymia than in a nonalexithymic TBI subsample. There were significant relations among alexithymia, avoidance coping, and levels of psychological distress. Regression analysis revealed that difficulty identifying feelings was a significant predictor for psychological distress. Conclusion: Early screening for alexithymia following TBI might identify those most at risk of developing maladaptive coping mechanisms. This could assist in developing early rehabilitation interventions to reduce vulnerability to later psychological distress.	[Wood, Rodger Ll.; Doughty, Caitriona] Swansea Univ, Dept Psychol, Sch Human & Hlth Sci, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales		Wood, RL (corresponding author), Swansea Univ, Dept Psychol, Sch Human & Hlth Sci, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk					American Psychiatric Association, 2000, HDB PSYCHIAT MEASURE, V1st; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Bagby RM, 2007, J PERS ASSESS, V89, P258, DOI 10.1080/00223890701629771; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Besharat MA, 2010, PROCD SOC BEHV, V5, P614, DOI 10.1016/j.sbspro.2010.07.152; BONANNO GA, 1995, J PERS SOC PSYCHOL, V69, P975, DOI 10.1037/0022-3514.69.5.975; Bouteyre E, 2007, STRESS HEALTH, V9, P3, DOI 10.3109/02699052.2014.919538; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Cohen J., 2013, STAT POWER ANAL BEHA; COMPAS BE, 1988, J CONSULT CLIN PSYCH, V56, P405, DOI 10.1037/0022-006X.56.3.405; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2006, BRAIN COGNITION, V60, P214; De Berardis D, 2008, PROG NEURO-PSYCHOPH, V32, P1982, DOI 10.1016/j.pnpbp.2008.09.022; Di Schiena R, 2011, PERS INDIV DIFFER, V50, P10, DOI 10.1016/j.paid.2010.07.037; Finset A, 2000, BRAIN INJURY, V14, P887; FUKUNISHI I, 1995, PSYCHOL REP, V76, P1299, DOI 10.2466/pr0.1995.76.3c.1299; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; HIGGINS JE, 1995, EUR J PERSONALITY, V9, P253, DOI 10.1002/per.2410090403; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Kallasmaa T, 2000, PERS INDIV DIFFER, V29, P881, DOI 10.1016/S0191-8869(99)00240-8; Kim D., 2005, EDUC PSYCHOL MEAS, V65, P742, DOI DOI 10.1177/0013164405278557; KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Krpan KM, 2011, J INT NEUROPSYCH SOC, V17, P248, DOI 10.1017/S1355617710001499; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Motan I, 2007, TURK PSIKIYATR DERG, V18, P333; Mueller J, 2006, COMPR PSYCHIAT, V47, P489, DOI 10.1016/j.comppsych.2006.03.001; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Parker JDA, 1998, COMPR PSYCHIAT, V39, P91, DOI 10.1016/S0010-440X(98)90084-0; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sprinkle SD, 2002, J COUNS PSYCHOL, V49, P381, DOI 10.1037//0022-0167.49.3.381; Taylor G. J., 1997, DISORDERS AFFECT REG; TAYLOR GJ, 1992, PSYCHOTHER PSYCHOSOM, V57, P34, DOI 10.1159/000288571; TEASDALE G, 1974, LANCET, V2, P81; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; VINGERHOETS AJJM, 1995, PSYCHOTHER PSYCHOSOM, V64, P32, DOI 10.1159/000288988; WechslerD, 2001, WECHSLER TEST ADULT; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Windle M, 1996, J ABNORM PSYCHOL, V105, P551, DOI 10.1037/0021-843X.105.4.551; Wolters G, 2010, NEUROPSYCHOL REHABIL, V20, P587, DOI 10.1080/09602011003683836; Wood RLL, 2010, J INT NEUROPSYCH SOC, V16, P1108, DOI 10.1017/S1355617710001013; Wood RLL, 2009, BRAIN INJURY, V23, P649, DOI 10.1080/02699050902970786; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518	51	26	26	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2013	28	2					98	105		10.1097/HTR.0b013e3182426029			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	105HU	WOS:000316058300003	22495103				2022-02-06	
J	Mahmood, A; Wu, HT; Qu, CS; Xiong, Y; Chopp, M				Mahmood, Asim; Wu, Hongtao; Qu, Changsheng; Xiong, Ye; Chopp, Michael			Effects of treating traumatic brain injury with collagen scaffolds and human bone marrow stromal cells on sprouting of corticospinal tract axons into the denervated side of the spinal cord	JOURNAL OF NEUROSURGERY			English	Article						human bone marrow stromal cell; collagen scaffolds; traumatic brain injury; axonal sprouting; basic science; rat	MESENCHYMAL STEM-CELLS; ADULT-RATS; HEAD-INJURY; TRANSPLANTATION; STROKE; TISSUE; REGENERATION; RECOVERY; MOTOR; INCREASES	Object. This study was designed to investigate how transplantation into injured brain of human bone marrow stromal cells (hMSCs) impregnated in collagen scaffolds affects axonal sprouting in the spinal cord after traumatic brain injury (TBI) in rats. Also investigated was the relationship of axonal sprouting to sensorimotor functional recovery after treatment. Methods. Adult male Wistar rats (n = 24) underwent a controlled cortical impact injury and were divided into three equal groups (8 rats/group). The two treatment groups received either hMSCs (3 x 106) alone or hMSC (3 x 106) impregnated collagen scaffolds transplanted into the lesion cavity. In the control group, saline was injected into the lesion cavity. All treatments were performed 7 days after TBI. On Day 21 after TBI, a 10% solution of biotinylated dextran amine (10,000 MW) was stereotactically injected into the contralateral motor cortex to label the corticospinal tract (CST) originating from this area. Sensorimotor function was tested using the modified neurological severity score (mNSS) and foot-fault tests performed on Days 1, 7, 14, 21, 28, and 35 after TBI. Spatial learning was tested with Morris water maze test on Days 31-35 after TBI. All rats were sacrificed on Day 35 after TBI, and brain and spinal cord (cervical and lumbar) sections were stained inununohistochemically for histological analysis. Results. Few biotinylated dextran amine labeled CST fibers crossing over the midline were found in the contralateral spinal cord transverse sections at both cervical and lumbar levels in saline-treated (control) rats. However, hMSC-alone treatment significantly increased axonal sprouting from the intact CST into the denervated side of the gray matter of both cervical and lumbar levels of the spinal cord (p < 0.05). Also, this axonal sprouting was significantly more in the scaffold+hMSC group compared with the hMSC-alone group (p < 0.05). Sensorimotor functional analysis showed significant improvement of mNSS (p < 0.05) and foot-fault tests (p < 0.05) in hMSC-alone and scaffold+hMSC-treated rats compared with controls (p < 0.05). Functiohal improvement, however, was Significantly greater in the scaffold+hMSC group compared with the hMSC-alone group (p < 0.05). Morris water maze testing also showed significant improvement in spatial learning in scaffold+hMSC and hMSC-alone groups compared with the control group (p < 0.05), with rats in the scaffold+hMSC group performing significantly better than those in the hMSC-alone group (p < 0.05). Pearson correlation data showed significant correlation between the number of crossing CST fibers detected and sensorimotor recovery (p < 0.05). Conclusions. Axonal plasticity plays an important role in neurorestoration after TBI. Transplanting hMSCs with scaffolds enhances the effect of hMSCs on axonal sprouting of CST fibers from the contralateral intact cortex into the denervated side of spinal cord after TBI. This enhanced axonal regeneration may at least partially contribute to the therapeutic benefits of treating TBI with hMSCs. (http://thejns.org/doi/abs/10.3171/2012.11.JNS12753)	[Mahmood, Asim; Wu, Hongtao; Qu, Changsheng; Xiong, Ye] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA		Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neurou.hfh.edu		Xiong, Ye/0000-0001-9770-6031			Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; Bancroft GN, 2002, P NATL ACAD SCI USA, V99, P12600, DOI 10.1073/pnas.202296599; BENFEY M, 1982, NATURE, V296, P150, DOI 10.1038/296150a0; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; COLTON CK, 1995, CELL TRANSPLANT, V4, P415, DOI 10.1016/0963-6897(95)00025-S; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Di Giovanni S, 2009, EXPERT OPIN THER TAR, V13, P1387, DOI 10.1517/14728220903307517; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Li CM, 2006, BIOMATERIALS, V27, P3115, DOI 10.1016/j.biomaterials.2006.01.022; Liu ZW, 2008, STROKE, V39, P2571, DOI 10.1161/STROKEAHA.107.511659; Liu ZW, 2010, J CEREBR BLOOD F MET, V30, P1288, DOI 10.1038/jcbfm.2010.8; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Martin I, 2001, J BIOMED MATER RES, V55, P229, DOI 10.1002/1097-4636(200105)55:2<229::AID-JBM1009>3.3.CO;2-H; Mathias SD, 1997, STROKE, V28, P1888, DOI 10.1161/01.STR.28.10.1888; Meinel L, 2005, BONE, V37, P688, DOI 10.1016/j.bone.2005.06.010; Meinel L, 2004, ANN BIOMED ENG, V32, P112, DOI 10.1023/B:ABME.0000007796.48329.b4; Meinel L, 2004, BIOTECHNOL BIOENG, V88, P379, DOI 10.1002/bit.20252; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Navarro X, 2009, INT REV NEUROBIOL, V87, P483, DOI 10.1016/S0074-7742(09)87027-X; Netz J, 1997, BRAIN, V120, P1579, DOI 10.1093/brain/120.9.1579; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Qu CS, 2011, BRAIN RES, V1371, P129, DOI 10.1016/j.brainres.2010.10.088; Reddi AH, 2000, BIOCHEM SOC T, V28, P345, DOI 10.1042/0300-5127:0280345; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Shen LH, 2008, GLIA, V56, P1747, DOI 10.1002/glia.20722; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Sun F, 2010, CURR OPIN NEUROBIOL, V20, P510, DOI 10.1016/j.conb.2010.03.013; Teng FYH, 2006, J NEUROCHEM, V96, P1501, DOI 10.1111/j.1471-4159.2006.03663.x; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	54	26	31	0	16	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2013	118	2					381	389		10.3171/2012.11.JNS12753			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	076DY	WOS:000313937900023	23198801				2022-02-06	
J	Schroeder, RW; Buddin, WH; Hargrave, DD; VonDran, EJ; Campbell, EB; Brockman, CJ; Heinrichs, RJ; Baade, LE				Schroeder, R. W.; Buddin, W. H., Jr.; Hargrave, D. D.; VonDran, E. J.; Campbell, E. B.; Brockman, C. J.; Heinrichs, R. J.; Baade, L. E.			Efficacy of Test of Memory Malingering Trial 1, Trial 2, the Retention Trial, and the Albany Consistency Index in a Criterion Group Forensic Neuropsychological Sample	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Test of Memory Malingering; TOMM; Albany consistency index; Forensic neuropsychology; Validity	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TESTS; CLASSIFICATION ACCURACY; CHRONIC PAIN; SCALE-III; TOMM; PERFORMANCE; EXAGGERATION; VALIDATION; DEPRESSION	The Test of Memory Malingering is one of the most popular and heavily researched validity tests available for use in neuropsychological evaluations. Recent research has suggested, however, that the original indices and cutoffs may require modifications to increase sensitivity rates. Some of these modifications lack cross-validation and no study has examined all indices in a single sample. This study compares Trial 1, Trial 2, the Retention Trial, and the newly created Albany Consistency Index in a criterion group forensic neuropsychological sample. Findings lend support for the newly created indices and cutoff scores. Implications and cautionary statements are provided and discussed.	[Schroeder, R. W.; Buddin, W. H., Jr.; Hargrave, D. D.; VonDran, E. J.; Campbell, E. B.; Brockman, C. J.; Heinrichs, R. J.; Baade, L. E.] Univ Kansas, Sch Med, Dept Psychiat & Behav Sci, Wichita, KS 67206 USA		Schroeder, RW (corresponding author), Univ Kansas, Sch Med, Dept Psychiat & Behav Sci, Wichita, KS 67206 USA.	ryan.w.schroeder.psyd@hotmail.com					Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Committee on Mild Traumatic Brain Injury American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Frederick R. I., 1997, VALIDITY INDICATOR P; Green P., 2003, GREENS WORD MEMORY T; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Gunner JH, 2012, ARCH CLIN NEUROPSYCH, V27, P1, DOI 10.1093/arclin/acr089; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Iverson GL, 2007, CLIN NEUROPSYCHOL, V21, P532, DOI 10.1080/13854040600611392; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Pearson, 2009, ADV CLIN SOL WAIS 4; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schroeder RW, 2012, CLIN NEUROPSYCHOL, V26, P129, DOI 10.1080/13854046.2011.639314; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; TOMBAUGH TN, 2003, J FORENSIC NEUROPSYC, V2, P69, DOI DOI 10.1300/J151V02N03_04; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wechsler D., 2008, WECHSLER ADULT INTEL	37	26	26	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2013	28	1					21	29		10.1093/arclin/acs094			9	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	073EP	WOS:000313726600003	23079153	Bronze			2022-02-06	
J	Aligene, K; Lin, E				Aligene, Kathy; Lin, Emerald			Vestibular and balance treatment of the concussed athlete	NEUROREHABILITATION			English	Article						Vestibular and balance dysfunction; concussion; concussed athlete and treatment; vestibular rehabilitation therapy	TRAUMATIC BRAIN-INJURY; REHABILITATION; MANAGEMENT; COLLEGIATE; DIZZINESS; STATEMENT; THERAPY; SPORT; MRI	OBJECTIVES: The purpose of this chapter is to provide an update on the clinical management of vestibular and balance dysfunction in a concussed athlete with a focus on diagnosis, initial work-up, and initial and continuing management. Although much is still unknown about the etiology of vestibular and balance dysfunction in a concussed athlete, we briefly review current theories about neural pathophysiology to help link proposed treatment methodologies. INTRODUCTION: The treatment and management of vestibular and balance dysfunction in concussed athletes requires a multidisciplinary approach and is based on continuous reassessment of the presenting symptoms. The clinical challenge toward managing persistent symptoms of the post-concussive athlete is discerning whether a set of symptoms match diagnostic testing and whether further neurological work up is necessary. Because there are no discrete time boundaries to make such judgment calls, we offer a guide to help with the difficult clinical decisions necessary to treat the post-concussive athlete. METHODS: Literature search was performed using the following keywords: Vestibular and balance dysfunction, concussion, concussed athlete and treatment, vestibular rehabilitation therapy. Original research studies, literature reviews, and clinical guidelines were reviewed between 1997 and 2012, with the majority of articles dating beyond 2004. Although we acknowledge that post-concussive states lie within a continuum, we decided to divide treatment and management into three stages: time after initial impact, recovery, and prolonged recovery. RESULTS: In post-concussive athletes, impairments in balance may exist as a result of transmitted force to peripheral and central neural substrates that integrate sensory information and coordinate motor function. Corroborative information, clinical examination, neuropsychological testing, and continual reassessment are means to determine severity of dysfunction and track clinical course and resolution of symptoms. Persistence of symptoms beyond initial impact may require medication trials or adjustments that are tailored to the patient's medical history and/or neurocognitive rehabilitative techniques such as vestibular rehabilitation therapy to prevent progression of neurologic sequelae. Prolonged recovery of more than six months may require neurological consultation. CONCLUSION: Concussion management and treatment of vestibular and balance impairments in athletes should be assessed in a stepwise manner, from initial impact to resolution of symptoms. If symptoms are prolonged, impaired neuronal mechanisms or irreversible cerebral damage may underlie persistent symptoms and cognitive deficits seen in neurocognitive testing. Management protocols are currently focused on individualized assessment of neurocognitive assessment and comprehensive symptomatic evaluation (Reddy et al., 2008). It is widely accepted that neurocognitive and resolution of concussion-induced symptoms must be resolved prior to returning to sport or play and therefore, the athlete should be reassessed and treated until symptoms resolved.	[Aligene, Kathy] Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA; [Lin, Emerald] Kessler Inst, W Orange, NJ USA		Aligene, K (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.	kathy_a@yahoo.com					Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Black FO, 2000, AM J OTOL, V21, P543; Blume HK, 2011, PHYS MED REH CLIN N, V22, P665, DOI 10.1016/j.pmr.2011.08.007; Brown KE, 2006, ARCH PHYS MED REHAB, V87, P76, DOI 10.1016/j.apmr.2005.08.003; Crooks C. Y., 2007, TRAUMATIC BRAIN INJU; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Friedman Jules M, 2004, Med Health R I, V87, P296; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hall CD, 2009, OTOLARYNG CLIN N AM, V42, P161, DOI 10.1016/j.otc.2008.09.006; Han BI, 2011, J CLIN NEUROL, V7, P184, DOI 10.3988/jcn.2011.7.4.184; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Levin H., 2012, J NEUROTRAUMA; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Ma R, 2012, J BONE JOINT SURG AM, V94A, P1618, DOI 10.2106/JBJS.K.01127; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Maskell F, 2006, BRAIN INJURY, V20, P293, DOI 10.1080/02699050500488041; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P., 2009, PM&R, V1, P406; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Reddy CC, 2011, PM&R, V3, pS396, DOI 10.1016/j.pmrj.2011.07.012; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sabini RC, 2010, PHYSICIAN SPORTSMED, V38, P139, DOI 10.3810/psm.2010.04.1771; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shrier I, 2012, CLIN J SPORT MED, V22, P211, DOI 10.1097/JSM.0b013e31824cc5f9; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Yeo SS, 2012, NEUROREHABILITATION, V31, P143, DOI 10.3233/NRE-2012-0783	40	26	27	0	20	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	3					543	553		10.3233/NRE-130876			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	135DM	WOS:000318266200012	23648608				2022-02-06	
J	Bigler, ED; Yeates, KO; Dennis, M; Gerhardt, CA; Rubin, KH; Stancin, T; Taylor, HG; Vannatta, K				Bigler, Erin D.; Yeates, Keith Owen; Dennis, Maureen; Gerhardt, Cynthia A.; Rubin, Kenneth H.; Stancin, Terry; Taylor, H. Gerry; Vannatta, Kathryn			Neuroimaging and social behavior in children after traumatic brain injury: Findings from the Social Outcomes of Brain Injury in Kids (SOBIK) study	NEUROREHABILITATION			English	Article						Traumatic brain injury; social brain; neuroimaging; theory of mind; frontotemporolimbic damage	MIND; NEUROSCIENCE; ADOLESCENTS; COGNITION; AMYGDALA; BELIEFS; EMOTION; TRUTH; TBI	BACKGROUND: Neuroimaging studies identified either focal and/or non-specific frontotemporolimbic damage resulting from mild-complicated to severe traumatic brain injury (TBI) in a subset of 12 children 8-12 years of age who were part of the Social Outcomes of Brain Injury in Kids (SOBIK) study. The influence of identifiable damage on social behavior was examined. METHODS: Magnetic resonance imaging was obtained on average 2.5 years post injury wherein cases with distinct abnormalities were selected. Various direct, performance-based measures of cognitive-social-emotional functioning were obtained along with data regarding peer relations and friendships in the classroom. RESULTS: Overall, children with TBI were impaired on tasks of social-emotional processing compared to children with orthopedic injury (OI). Ten of the 12 children with TBI had multiple areas of impaired social-emotional functioning in comparison to OI controls. With regards to friendships, four of the nine children with TBI who had classroom data had no mutual friends, four also received low peer acceptance ratings, and two were perceived by peers as having high levels of rejection/victimization in the classroom. CONCLUSIONS: Children with frontotemporolimbic or diffuse damage demonstrated variable social outcomes from their TBI. Results are discussed in terms of the heterogeneity of TBI-related abnormalities and their relationship to social behavior.	[Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; [Yeates, Keith Owen; Gerhardt, Cynthia A.; Vannatta, Kathryn] Nationwide Childrens Hosp, Res Inst, Dept Pediat, Columbus, OH USA; [Yeates, Keith Owen; Gerhardt, Cynthia A.; Vannatta, Kathryn] Ohio State Univ, Columbus, OH 43210 USA; [Dennis, Maureen] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Rubin, Kenneth H.] Univ Maryland, Dept Human Dev, College Pk, MD 20742 USA; [Stancin, Terry; Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, MetroHlth Med Ctr, Cleveland, OH 44106 USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol Sci, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu	Vannatta, Kathryn/E-4237-2011; Yeates, Keith/AAJ-4223-2020; Gerhardt, Cynthia/E-3109-2011; Stancin, Terry/L-7993-2019; Rubin, Kenneth H/M-5276-2018	Rubin, Kenneth H/0000-0002-2608-2484; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5 R01 HD048946]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	The preparation of this paper was supported in part by grant 5 R01 HD048946 from the National Institute of Child Health and Human Development. The assitance in manuscript preparation of Jo ANN Petrie, Ph.D. and Tracy J. Abildskov is gratefully acknowledged.	Adolphs R, 2010, ANN NY ACAD SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Anderson V., 2012, DISABIL REHABIL; Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; ASHER SR, 1979, DEV PSYCHOL, V15, P443, DOI 10.1037/0012-1649.15.4.443; Bava S, 2010, NEUROPSYCHOL REV, V20, P398, DOI 10.1007/s11065-010-9146-6; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Bukowski W., 1989, PEER RELATIONSHIPS C; Burnett S, 2011, NEUROSCI BIOBEHAV R, V35, P1654, DOI 10.1016/j.neubiorev.2010.10.011; Cacioppo JT, 2011, ANN NY ACAD SCI, V1224, P162, DOI 10.1111/j.1749-6632.2010.05858.x; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M., J INT NEUROPSYCHOL S, V19, P338; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Ewing-Cobbs L., 2011, INT J DEV NEUROSCI; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; Gerhardt CA, 2012, J PEDIATR PSYCHOL, V37, P209, DOI 10.1093/jpepsy/jsr082; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hanten G, 2011, NEUROPSYCHOLOGIA, V49, P486, DOI 10.1016/j.neuropsychologia.2010.12.007; Heatherton TF, 2011, ANNU REV PSYCHOL, V62, P363, DOI 10.1146/annurev.psych.121208.131616; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; JAKOBSON R, 1960, STYLE LANGUAGE; Jernigan TL, 2011, PROG BRAIN RES, V189, P77, DOI 10.1016/B978-0-444-53884-0.00019-1; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Mars RB, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00189; MASTEN AS, 1985, DEV PSYCHOL, V21, P523, DOI 10.1037/0012-1649.21.3.523; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Ochsner KN, 2008, BIOL PSYCHIAT, V64, P48, DOI 10.1016/j.biopsych.2008.04.024; Oitzl MS, 2010, NEUROSCI BIOBEHAV R, V34, P853, DOI 10.1016/j.neubiorev.2009.07.006; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Rosema S., 2012, J NEUROTRAUMA; Ross KA, 2011, BRAIN INJURY, V25, P1206, DOI 10.3109/02699052.2011.609519; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shaw P, 2005, J COGNITIVE NEUROSCI, V17, P1410, DOI 10.1162/0898929054985491; Stiles J, 2010, NEUROPSYCHOL REV, V20, P327, DOI 10.1007/s11065-010-9148-4; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Yeates K. O., J INT NEUROPSYCHOL S, V19, P518; Yeates K. O., 2013, J INT NEURO IN PRESS; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Ziv I, 2011, COGN NEUROPSYCHIATRY, V16, P71, DOI 10.1080/13546805.2010.492693	49	26	26	0	26	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	4					707	720		10.3233/NRE-130896			14	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	184QF	WOS:000321907100003	23867398				2022-02-06	
J	Demange, L; Abdellah, FN; Lozach, O; Ferandin, Y; Gresh, N; Meijer, L; Galons, H				Demange, Luc; Abdellah, Fatma Nait; Lozach, Olivier; Ferandin, Yoan; Gresh, Nohad; Meijer, Laurent; Galons, Herve			Potent inhibitors of CDK5 derived from roscovitine: Synthesis, biological evaluation and molecular modelling	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						CDK5; Kinase; Roscovitine; Buchwald-Hartwig amination	CYCLIN-DEPENDENT KINASE-5; PROTEIN-KINASE; CELL-CYCLE; PHOSPHORYLATION; DEREGULATION; SPECIFICITY; TOXICITY; PURINES; DYRK1A; FAMILY	Cyclin dependent kinase 5 (CDK5) is a serine/threonine kinase belonging to the cyclin dependent kinase (CDK) family. CDK5 is involved in numerous neuronal diseases (including Alzheimer's or Parkinson's diseases, stroke, traumatic brain injury), pain signaling and cell migration. In the present Letter, we describe syntheses and biological evaluations of new 2,6,9-trisubstituted purines, structurally related to roscovitine, a promising CDK inhibitor currently in clinical trials (CDK1/Cyclin B, IC50 = 350 nM; CDK5/p25, IC50 = 200 nM). These new molecules were synthesized using an original Buchwald-Hartwig catalytic procedure; several compounds (3j, 3k, 3l, 3e, 4k, 6b, 6c) displayed potent kinase inhibitory potencies against CDK5 (IC50 values ranging from 17 to 50 nM) and showed significant cell death inducing activities (IC50 values ranging from 2 to 9 mu M on SH-SY5Y). The docking of the inhibitors into the ATP binding domain of the CDK5 catalytic site highlighted the discriminatory effect of a hydrogen bond involving the CDK5 Lys-89. In addition, the calculated final energy balances for complexation measured for several inhibitors is consistent with the ranking of the IC50 values. Lastly, we observed that several compounds exhibit submicromolar activities against DYRK1A (dual specificity, tyrosine phosphorylation regulated kinase 1A), a kinase involved in Down syndrome and Alzheimer's disease (3g, 3h, 4m; IC50 values ranging from 300 to 400 nM). (C) 2012 Elsevier Ltd. All rights reserved.	[Demange, Luc; Abdellah, Fatma Nait; Gresh, Nohad] Univ Paris 05, UFR Biomed St Peres, CNRS, LCBPT,UMR 8601, F-75270 Paris 06, France; [Lozach, Olivier; Ferandin, Yoan; Meijer, Laurent] CNRS, Biol Stn, USR3151, Prot Phosphorylat & Human Dis Grp, F-29680 Roscoff, Bretagne, France; [Meijer, Laurent; Galons, Herve] Ctr Perharidy, Hotel Rech, ManRos Therapeut, F-29680 Roscoff, France; [Galons, Herve] Univ Paris 05, Lab Pharmacochim, F-75006 Paris, France		Demange, L (corresponding author), Univ Paris 05, UFR Biomed St Peres, CNRS, LCBPT,UMR 8601, 45 Rue St Peres, F-75270 Paris 06, France.	luc.demange@parisdescartes.fr; meijer@manros-therapeutics.com	MEIJER, Laurent/ABE-7465-2021	, laurent/0000-0003-3511-4916; , Demange/0000-0002-2976-8916; Olivier, Lozach/0000-0003-0568-4387	'Canceropole Grand-Ouest' Grant; 'Institut National du Cancer' (INCa "Cancer Detection d'innovations"); 'Association France-Alzheimer Finistere'; 'Ligue Nationale contre le Cancer (Grand-Ouest)'	This research was supported by Grants from the 'Canceropole Grand-Ouest' Grant (L. M.), the 'Institut National du Cancer' (INCa "Cancer Detection d'innovations 2006") (L. M.), the 'Association France-Alzheimer Finistere' (L. M.) and the 'Ligue Nationale contre le Cancer (Grand-Ouest)' (L.M.).	Abbas T, 2006, CELL CYCLE, V5, P1123, DOI 10.4161/cc.5.10.2819; Anne SL, 2007, J NEUROSCI, V27, P7318, DOI 10.1523/JNEUROSCI.1831-07.2007; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Becker W, 2011, FEBS J, V278, P246, DOI 10.1111/j.1742-4658.2010.07956.x; Borgne Annie, 2003, Prog Cell Cycle Res, V5, P453; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Carassou P, 2012, B CANCER, V99, P163, DOI 10.1684/bdc.2011.1383; Cheung ZH, 2012, TRENDS CELL BIOL, V22, P169, DOI 10.1016/j.tcb.2011.11.003; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cruz JC, 2004, TRENDS MOL MED, V10, P452, DOI 10.1016/j.molmed.2004.07.001; Cruz JC, 2006, J NEUROSCI, V26, P10536, DOI 10.1523/JNEUROSCI.3133-06.2006; Demange L., 2012, MED CHEM RES; Demange L, 2008, HETEROCYCLES, V75, P1735; Dhariwala FA, 2008, CELL MOL NEUROBIOL, V28, P351, DOI 10.1007/s10571-007-9242-1; Garriga J, 2004, GENE, V337, P15, DOI 10.1016/j.gene.2004.05.007; Heathcore D. A., 2010, J MED CHEM, V53, P85082; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Ko J, 2001, J NEUROSCI, V21, P6758; Laha JK, 2011, BIOORG MED CHEM LETT, V21, P2098, DOI 10.1016/j.bmcl.2011.01.140; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee M. H., 1907, CELL MOL LIFE SCI, V2001, P58; Legraverend M, 2006, BIOORGAN MED CHEM, V14, P3987, DOI 10.1016/j.bmc.2005.12.060; LEW J, 1992, J BIOL CHEM, V267, P13383; Lolli G, 2005, CELL CYCLE, V4, P572, DOI 10.4161/cc.4.4.1607; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Malumbres M, 2009, NAT CELL BIOL, V11, P1275, DOI 10.1038/ncb1109-1275; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Meijer L, 2006, MONOGRAPHS ENZYME IN, V2, P187; Meijer L, 2006, B CANCER, V93, P41; Menn B., 2010, PLOS ONE, P5; Neagoie C, 2012, EUR J MED CHEM, V49, P379, DOI 10.1016/j.ejmech.2012.01.040; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Oumata N, 2008, J MED CHEM, V51, P5229, DOI 10.1021/jm800109e; Pareek TK, 2006, CELL CYCLE, V5, P585, DOI 10.4161/cc.5.6.2578; Popowycz F, 2009, J MED CHEM, V52, P655, DOI 10.1021/jm801340z; Sadleir KR, 2012, J BIOL CHEM, V287, P7224, DOI 10.1074/jbc.M111.333914; Shiradkar M, 2011, EUR J MED CHEM, V46, P2066, DOI 10.1016/j.ejmech.2011.02.059; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Utreras E, 2009, J BIOL CHEM, V284, P2275, DOI 10.1074/jbc.M805052200; Wang D, 2012, BIOORG MED CHEM LETT, V22, P168, DOI 10.1016/j.bmcl.2011.11.043; Wegiel J, 2011, FEBS J, V278, P236, DOI 10.1111/j.1742-4658.2010.07955.x; Wei FY, 2005, NAT MED, V11, P1104, DOI 10.1038/nm1299; Wong ASL, 2011, NAT CELL BIOL, V13, P568, DOI 10.1038/ncb2217	44	26	27	3	48	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	JAN 1	2013	23	1					125	131		10.1016/j.bmcl.2012.10.141			7	Chemistry, Medicinal; Chemistry, Organic	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Pharmacology & Pharmacy; Chemistry	053JO	WOS:000312267700020	23218601				2022-02-06	
J	Dolle, JP; Morrison, B; Schloss, RS; Yarmush, ML				Dolle, Jean-Pierre; Morrison, Barclay, III; Schloss, Rene S.; Yarmush, Martin L.			An organotypic uniaxial strain model using microfluidics	LAB ON A CHIP			English	Article							TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL SLICE CULTURES; DIFFUSE AXONAL INJURY; IN-VITRO MODEL; DYNAMIC STRETCH INJURY; HEAD-INJURY; MECHANICAL STRETCH; SODIUM-CHANNELS; NEURAL TRAUMA; OPTIC-NERVE	Traumatic brain injuries are the leading cause of disability each year in the US. The most common and devastating consequence is the stretching of axons caused by shear deformation that occurs during rotational acceleration of the brain during injury. The injury effects on axonal molecular and functional events are not fully characterized. We have developed a strain injury model that maintains the three dimensional cell architecture and neuronal networks found in vivo with the ability to visualize individual axons and their response to a mechanical injury. The advantage of this model is that it can apply uniaxial strains to axons that make functional connections between two organotypic slices and injury responses can be observed in real-time and over long term. This uniaxial strain model was designed to be capable of applying an array of mechanical strains at various rates of strain, thus replicating a range of modes of axonal injury. Long term culture, preservation of slice and cell orientation, and slice-slice connection on the device was demonstrated. The device has the ability to strain either individual axons or bundles of axons through the control of microchannel dimensions. The fidelity of the model was verified by observing characteristic responses to various strain injuries which included axonal beading, delayed elastic effects and breakdown in microtubules. Microtubule breakdown was shown to be dependent on the degree of the applied strain field, where maximal breakdown was observed at peak strain and minimal breakdown is observed at low strain. This strain injury model could be a powerful tool in assessing strain injury effects on functional axonal connections.	[Dolle, Jean-Pierre; Schloss, Rene S.; Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA; [Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Yarmush, Martin L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA		Yarmush, ML (corresponding author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.	jpdolle@rutgers.edu; bm2119@columbia.edu; schloss@soemail.rutgers.edu; yarmush@rci.rutgers.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Yarmush, Martin/0000-0003-4986-8444	New Jersey Commission for Brain Injury Research [BIR-1.08.016]; National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [NIH P41 EB002503]; National Institute of General Medical Sciences (Rutgers-UMDNJ Biotechnology Training Program) [T32 GM 008339]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008339] Funding Source: NIH RePORTER	This work was supported by grants from the New Jersey Commission for Brain Injury Research (BIR-1.08.016), the National Institute of Biomedical Imaging and Bioengineering (NIH P41 EB002503), and the National Institute of General Medical Sciences (Rutgers-UMDNJ Biotechnology Training Program: T32 GM 008339).	Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Berdichevsky Y, 2010, LAB CHIP, V10, P999, DOI 10.1039/b922365g; Berdichevsky Y, 2009, J NEUROSCI METH, V178, P59, DOI 10.1016/j.jneumeth.2008.11.016; Bottlang M, 2007, J NEUROTRAUM, V24, P1068, DOI 10.1089/neu.2006.3772; BUCHS PA, 1993, DEV BRAIN RES, V71, P81, DOI 10.1016/0165-3806(93)90108-M; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Choi KM, 2003, J AM CHEM SOC, V125, P4060, DOI 10.1021/ja029973k; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Del Turco Domenico, 2007, V399, P55, DOI 10.1007/978-1-59745-504-6_5; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fischer Y, 1999, J PHYSIOL-LONDON, V519, P405, DOI 10.1111/j.1469-7793.1999.0405m.x; GAHWILER BH, 1984, EXPERIENTIA, V40, P235, DOI 10.1007/BF01947561; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Kawalec M, 2011, NEUROCHEM RES, V36, P2091, DOI 10.1007/s11064-011-0568-1; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Mata A, 2005, BIOMED MICRODEVICES, V7, P281, DOI 10.1007/s10544-005-6070-2; Meaney D.F., 1990, INT C BIOM IMP LYON, P215; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Molnar Z, 1999, EXP NEUROL, V156, P363, DOI 10.1006/exnr.1999.7032; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Sia SK, 2003, ELECTROPHORESIS, V24, P3563, DOI 10.1002/elps.200305584; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STRICH SJ, 1961, LANCET, V2, P443; Sundstrom L, 2005, DRUG DISCOV TODAY, V10, P993, DOI 10.1016/S1359-6446(05)03502-6; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; WYSS JM, 1980, ANAT EMBRYOL, V158, P303, DOI 10.1007/BF00301819; Yu Z, 2009, J NEUROTRAUM, V26, P1135, DOI 10.1089/neu.2008.0810	49	26	27	0	41	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1473-0197	1473-0189		LAB CHIP	Lab Chip		2013	13	3					432	442		10.1039/c2lc41063j			11	Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry, Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics; Instruments & Instrumentation	062UE	WOS:000312947300015	23233120	Green Accepted			2022-02-06	
J	Farhad, K; Khan, HMR; Ji, AB; Yacoub, HA; Qureshi, AI; Souayah, N				Farhad, Khosro; Khan, Hafiz M. R.; Ji, Andrew B.; Yacoub, Hussam A.; Qureshi, Adnan I.; Souayah, Nizar			Trends in Outcomes and Hospitalization Costs for Traumatic Brain Injury in Adult Patients in the United States	JOURNAL OF NEUROTRAUMA			English	Article						death rates; hospitalization charges; ICDMAP-90; mechanical ventilation; TBI	NEUROLOGICAL INTENSIVE-CARE; CHILDREN; SYSTEM	Several new therapeutic strategies have been introduced for the management of adult traumatic brain injury (TBI) over the last decade, such as the development of management pathways and specialized TBI units and improved treatment of cerebral perfusion. The purpose of this study is to compare TBI-related hospitalization outcomes in the United States between two time periods, 1993-1994 and 2006-2007. We determined the rates of occurrence, in-hospital outcomes, and mean hospital charges for patients hospitalized with adult TBI in 1993-1994 using the nationally representative all-payer Nationwide Inpatient Survey (NIS) database, and compared these outcomes with homologous data from 2006-2007. The incidence of TBI admissions was reduced by 35% in 2006-2007 compared with 1993-1994; (22/100,000 versus 34/100,000 population; p<0.0001). The mean length of hospitalization (mean +/- SD, in days) was significantly lower in 2006-2007 than in 1993-1994 (2.5 +/- 2.4 days versus 2.7 +/- 2.6 days; p<0.0001). In-hospital mortality increased significantly in 2006-2007 compared with 1993-1994 (0.8% versus 0.4%, p<0.0001). Average hospitalization charges were significantly higher in 2006-2007 compared with 19993-1994 ($21,460 +/-$21,212 versus $5,142 +/-$4,625; p<0.0001), even after adjusting for inflation. In both time periods, most hospitalized adult TBI patients were graded as mild (98.2% in 1993-1994 versus 98.0% in 2006-2007; p=0.20). There was a significant increase in average hospitalization charges and death rates in all TBI severity subgroups in 2006-2007 compared with 1993-1994. The decline in rate of hospitalization between the two time periods was predominantly related to the decline in the number of admissions of patients with mild TBI. Although the number of TBI admissions was reduced, a significant increase in average hospitalization charges and in-hospital mortality rate was observed in 2006-2007 compared with 1993-1994.	[Farhad, Khosro; Ji, Andrew B.; Yacoub, Hussam A.; Souayah, Nizar] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol, Newark, NJ 07101 USA; [Khan, Hafiz M. R.] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Biostat, Miami, FL 33199 USA; [Qureshi, Adnan I.] Univ Minnesota, Zeenat Qureshi Stroke Res Ctr, Minneapolis, MN USA		Souayah, N (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol, 90 Bergen St,DOC 8100, Newark, NJ 07101 USA.	souayani@umdnj.edu	Souayah, Nizar/B-5556-2017	Souayah, Nizar/0000-0003-3873-3448; Qureshi, Adnan/0000-0003-4962-540X			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Brener I, 2004, J HEAD TRAUMA REHAB, V19, P405, DOI 10.1097/00001199-200409000-00005; Bulger EM, 2007, ANN EMERG MED, V49, P293, DOI 10.1016/j.annemergmed.2006.06.038; Chumney ECG, 2004, PHARMACOECONOMICS, V22, P1209, DOI 10.2165/00019053-200422180-00005; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Conner KA, 2010, J SAFETY RES, V41, P17, DOI 10.1016/j.jsr.2009.10.005; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Ferrando J, 2000, Inj Prev, V6, P184, DOI 10.1136/ip.6.3.184; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mayer SA, 2006, NEUROCRIT CARE, V5, P159, DOI 10.1385/NCC:5:2:159; Mayer SA, 2006, NEUROCRIT CARE, V5, P82, DOI 10.1385/NCC:5:2:82; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Simpson L, 2005, AMBUL PEDIATR, V5, P6, DOI 10.1367/A04-119R.1; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tiesman H, 2007, J NEUROTRAUM, V24, P1189, DOI 10.1089/neu.2006.0196; Tsang KK, 2011, BR J ORAL MAXILLOFAC, V50, P298	24	26	26	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					84	90		10.1089/neu.2011.2283			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000003	22978433				2022-02-06	
J	Gu, L; Li, J; Feng, DF; Cheng, ET; Li, DC; Yang, XQ; Wang, BC				Gu, Lei; Li, Jia; Feng, Dong-Fu; Cheng, Er-Tao; Li, Dao-Chang; Yang, Xian-Qing; Wang, Bo-Cheng			Detection of white matter lesions in the acute stage of diffuse axonal injury predicts long-term cognitive impairments: A clinical diffusion tensor imaging study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Diffuse axonal injury; diffusion tensor imaging; cognitive impairment; working memory; attention	TRAUMATIC BRAIN-INJURY; CORPUS-CALLOSUM; HEAD-INJURY; ACUTE MILD; MODERATE; MEMORY; INTEGRITY; METRICS; ADULTS; MODEL	BACKGROUND: White matter disruption is known to contribute to neurocognitive deficits after diffuse axonal injury (DAI). This study evaluated the relationship between white matter integrity using diffusion tensor imaging in the early stage and cognitions in the chronic stage. METHODS: Diffusion tensor imaging was performed in 15 patients with DAI within 7 days of injury and in 15 patients in the control group. Fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) were calculated within regions of interest, including the posterior limb of the internal capsule, uncinate fasciculus (UF), anterior corona radiate (ACR), superior longitudinal fasciculus (SLF), inferior longitudinal fasciculus (ILF), genu of the corpus callosum, body of the corpus callosum, and splenium of the corpus callosum and cingulum bundle (CB). The patients with DAI and the patients in the control group also underwent neuropsychological testing during the chronic stage after DAI. RESULTS: The region-of-interest analysis showed significantly reduced FA and AD values in all nine regions within 7 days of injury as well as increased MD values in the corpus callosum among patients in the DAI group. The patients demonstrated significantly poorer performance on the working memory tests and attention test. In patients, working memory function was positively correlated with the AD value in the UF and with the FA value in the CB, UF, SLF, and ILF. Working memory function was inversely correlated with the RD value in the CB, SLF, and ILF and with the MD value in the SLF and ILF. In addition, the attention function demonstrated a positive correlation with the RD value in the ACR, SLF, and ILF and with the MD value in the ACR, SLF, and ILF. In addition, attention was inversely correlated with the FA values for the posterior limb of the internal capsule, ACR, SLF, and ILF. CONCLUSION: The results indicated that the presence of white matter changes during the early stage of DAI may be helpful for predicting cognitive dysfunction over the long term. (J Trauma Acute Care Surg. 2013;74: 242-247. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Gu, Lei; Li, Jia; Feng, Dong-Fu; Cheng, Er-Tao] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 3, Dept Neurosurg, Shanghai 200030, Peoples R China; [Gu, Lei; Li, Dao-Chang; Yang, Xian-Qing] Luan Tradit Chinese Med Hosp, Dept Neurosurg, Luan, Anhui, Peoples R China; [Feng, Dong-Fu] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 201900, Peoples R China; [Wang, Bo-Cheng] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 3, Dept Radiol, Shanghai 200030, Peoples R China		Feng, DF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, 280 Mo He Rd, Shanghai 201900, Peoples R China.	feng_df@yahoo.com			Research Foundation of Shanghai Health Bureau [2010167]; Shanghai Committee of Science and TechnologyShanghai Science & Technology Committee [114119a8300]	This study was supported by the Research Foundation of Shanghai Health Bureau (grant no. 2010167) and the Shanghai Committee of Science and Technology (grant no. 114119a8300)	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Chang MC, 2010, NEUROREHABILITATION, V26, P347, DOI 10.3233/NRE-2010-0572; Delis D, 2000, CALIFORNIA VERBAL LE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hammes J., 1971, STROOP KLEUR WOORDTE; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Li XY, 2010, NEUROSCIENCE, V169, P357, DOI 10.1016/j.neuroscience.2010.04.075; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; STRICH SJ, 1961, LANCET, V2, P443; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wechsler D, 1985, WECHSLER ADULT INTEL; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	36	26	27	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2013	74	1					242	247		10.1097/TA.0b013e3182684fe8			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	071VI	WOS:000313623300056	23064612				2022-02-06	
J	Huang, YH; Lee, TC; Yang, KY; Liao, CC				Huang, Yu-Hua; Lee, Tao-Chen; Yang, Ka-Yen; Liao, Chen-Chieh			Is timing of cranioplasty following posttraumatic craniectomy related to neurological outcome?	INTERNATIONAL JOURNAL OF SURGERY			English	Article						Cranioplasty; Decompressive craniectomy; Timing; Outcomes; Complications	TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; SITE INFECTIONS; RECOVERY; MULTICENTER; EFFICACY; SURGERY; AGE	Background: With the use of decompressive craniectomy for traumatic brain injury (TBI) come a corresponding number of cranioplasties. TBI causes dynamic processes to commence or change during the period from injury to recovery; hence, the role of the timing of surgical intervention should be emphasized. Aims: We attempt to identify the relationship between the timing of cranioplasty and neurological outcomes following posttraumatic craniectomy. Methods: In this 3-year retrospective study, 105 patients undergoing decompressive craniectomies and subsequent cranioplasties for TBI were enrolled. We documented the patients' demographic information, including Glasgow Coma Scale (GCS) at admission for trauma. The follow-up period was terminated by death or a minimum of 6 months after TBI. Glasgow Outcome Scale (GOS) at the end of follow-up was used as an outcome measure. Unfavorable outcome was defined as a GOS score of 1-3. Results: The 105 patients included 71 male and 34 female subjects. The mean age was 41.94 +/- 19.73 years. Neurological assessment showed that admission GCS was 8.50 +/- 3.15, on average. The mean time interval between cranioplasty and craniectomy was 78.84 +/- 49.04 days (range, 13-245 days). Univariate logistic regression analysis showed that the association between the timing of cranioplasty and unfavorable outcomes was not statistically significant (odds ratio = 1.005, confidence interval 0.997-1.013; p = 0.195). Conclusion: The timing of cranioplasty following posttraumatic craniectomy was not related to the neurological outcomes of TBI. Despite the limitations of the retrospective design, the analyses provide preliminary information to elucidate the question. (C) 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.	[Huang, Yu-Hua; Lee, Tao-Chen; Yang, Ka-Yen; Liao, Chen-Chieh] Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung, Taiwan; [Huang, Yu-Hua; Lee, Tao-Chen; Yang, Ka-Yen; Liao, Chen-Chieh] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Huang, Yu-Hua] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan		Huang, YH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, 123 Ta Pei Rd, Kaohsiung, Taiwan.	newlupin2001@yahoo.com.tw					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sancisi E, 2009, BRAIN INJURY, V23, P163, DOI 10.1080/02699050802660446; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Stelling H, 2011, BRIT J NEUROSURG, V25, P407, DOI 10.3109/02688697.2011.566385; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Tahir MZ, 2013, BRIT J NEUROSURG; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	25	26	31	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1743-9191	1743-9159		INT J SURG	Int. J. Surg.		2013	11	9					886	890		10.1016/j.ijsu.2013.07.013			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	252AS	WOS:000326977200029	23933129				2022-02-06	
J	McGrath, N; Dinn, WM; Collins, MW; Lovell, MR; Elbin, RJ; Kontos, AP				McGrath, Neal; Dinn, Wayne M.; Collins, Michael W.; Lovell, Mark R.; Elbin, R. J.; Kontos, Anthony P.			Post-exertion neurocognitive test failure among student-athletes following concussion	BRAIN INJURY			English	Article						Sports concussion; ImPACT; neuropsychological testing; post-concussive symptoms	TEST-RETEST RELIABILITY; INTERNATIONAL-CONFERENCE; FOOTBALL PLAYERS; SPORT; STATEMENT; IMPACT; PERFORMANCE; MANAGEMENT; SYMPTOMS; RISK	Objective: The purpose of the present study was to examine post-exertion (PE) neurocognitive performance among student-athletes following concussion who were asymptomatic and returned to baseline normal neurocognitive test levels at rest. This study examined the neurocognitive performance of a sub-set of student-athletes who 'failed' to perform at baseline levels of neurocognitive function, i.e. exhibited downward reliable change index (RCI) alterations following a moderate exertional protocol during recovery from concussion. Method: A retrospective records review was carried out of Immediate Post-concussion Assessment and Cognitive Testing (ImPACT) and neuropsychological consultation data among athletes with sports-related concussion from a network of 22 schools and one junior hockey programme. Results: Fifty-four student-athletes met inclusion criteria and participated in the study. A total of 27.7% of concussed student-athletes who were symptom-free and returned to baseline on ImPACT at rest (i.e. no longer demonstrated performance deficits on neurocognitive tests) exhibited cognitive decline following moderate physical exertion. The PE cognitive changes were not simply general performance effects, but significant changes in memory ability in the presence of intact processing speed functions. The PE-Pass and PE-Fail groups did not, however, differ on post-concussive symptoms or concussion history. Conclusions: Clinicians' return-to-play evaluation protocols should include post-exertional computerized neurocognitive testing.	[McGrath, Neal; Dinn, Wayne M.] Sports Concuss New England, Brookline, MA 02446 USA; [Dinn, Wayne M.] Fatih Univ, Dept Psychol, Istanbul, Turkey; [Collins, Michael W.; Lovell, Mark R.; Elbin, R. J.; Kontos, Anthony P.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA USA		McGrath, N (corresponding author), Sports Concuss New England, 1368 Beacon St,Suite 116, Brookline, MA 02446 USA.	dr.neal@sportsconcussion.net		Kontos, Anthony/0000-0002-3749-4310			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Covassin T, 2007, BRIT J SPORT MED, V41, P370, DOI 10.1136/bjsm.2006.032334; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Lambourne K, 2010, BRAIN RES, V1341, P12, DOI 10.1016/j.brainres.2010.03.091; Lovell M. R., 2006, SPORTS NEUROPSYCHOLO, P193; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	21	26	26	0	65	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2013	27	1					103	113		10.3109/02699052.2012.729282			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	059IY	WOS:000312699300011	23252441				2022-02-06	
J	Zemek, R; Osmond, MH; Barrowman, N				Zemek, Roger; Osmond, Martin H.; Barrowman, Nick		Pediat Emergency Res Canada PERC	Predicting and preventing postconcussive problems in paediatrics (5P) study: protocol for a prospective multicentre clinical prediction rule derivation study in children with concussion	BMJ OPEN			English	Article							TRAUMATIC BRAIN-INJURY; STATES EMERGENCY-DEPARTMENTS; SPORTS-RELATED CONCUSSION; HEAD-INJURY; EARLY INTERVENTION; SYMPTOMS; IMPACT; EPIDEMIOLOGY; IMPAIRMENT; MANAGEMENT	Introduction: Persistent postconcussive symptoms (PCSs) is the persistence of somatic, cognitive, physical, psychological and/or behavioural changes lasting more than 1 month following concussion. Persistent concussion impacts the quality of life through impaired cognition, memory and attention affecting school performance, mood and social engagement. No large epidemiological studies have determined the true prevalence of persistent concussion symptoms. Validated, easy-to-use prognosticators do not exist for clinicians to identify children at highest risk. The goal of Predicting and Preventing Postconcussive Problems in Pediatrics study is to derive a clinical prediction rule for the development of persistent postconcussion symptoms in children and adolescents presenting to emergency department following acute head injury. Methods and analysis: This study is a prospective, multicentre cohort study across nine academic Canadian paediatric emergency departments. We will recruit the largest prospective epidemiological cohort of children with concussion. Eligible children will be followed using Post-Concussion Symptom Inventory, a validated tool in children as young as 5 years. Patients will follow-up at 1, 2, 4, 8 and 12 weeks postinjury. The main outcome will be the presence/absence of PCSs defined as three or more persistent concussion symptoms 1 month following the injury. 1792 patients provide adequate power to derive a clinical decision rule using multivariate analyses to find predictor variables sensitive for detecting cases of persistent postconcussion symptoms. Ethics and dissemination: Results of this large prospective study will enable clinicians to identify children at highest risk, optimise treatment and provide families with realistic and appropriate anticipatory guidance. Ethics has been obtained through the Children's Hospital of Eastern Ontario Research Ethics Board. Results will be disseminated at international conferences and in four manuscripts to peer-reviewed journals.	[Zemek, Roger; Osmond, Martin H.] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; [Zemek, Roger; Osmond, Martin H.] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Zemek, Roger; Osmond, Martin H.; Barrowman, Nick] Childrens Hosp Eastern Ontario Res Inst, Ottawa, ON, Canada		Zemek, R (corresponding author), Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada.	rzemek@cheo.on.ca	Meijer, Anna/K-5118-2016; Zemek, Roger/H-1039-2018; Barrowman, Nick/AAL-3166-2020; Mikrogianakis, Angelo/AAW-5929-2021; Freedman, Stephen/H-9102-2012; Barlow, Karen/C-1323-2014; Richer, Lawrence/D-3622-2009	Barrowman, Nick/0000-0002-4704-9595; Mikrogianakis, Angelo/0000-0002-8854-0620; Freedman, Stephen/0000-0003-2319-6192; Craig, William/0000-0002-4804-194X; Osmond, Martin/0000-0001-8275-8381; Barlow, Karen/0000-0003-2612-8507; Richer, Lawrence/0000-0002-6897-8668; Gravel, Jocelyn/0000-0001-5901-4990	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MOP:126197]; Canadian Institute of Health Research (CIHR) mild Traumatic Brain Injury Team Grant [TM1:127047]	This study is supported by a Canadian Institute of Health Research (CIHR) Operating Grant (MOP: # 126197) as well as by a Canadian Institute of Health Research (CIHR) mild Traumatic Brain Injury Team Grant (TM1: #127047).	Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; [Anonymous], DYN; [Anonymous], GROOV PEGB TEST; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bouwmeester W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001221; Breiman L., 1983, CLASSIFICATION REGRE; Burton LJ, 1997, PEDIATR EMERG CARE, V13, P1, DOI 10.1097/00006565-199702000-00001; Callahan JM, 2010, J PEDIATR-US, V157, P873, DOI 10.1016/j.jpeds.2010.08.039; Carroll L J, 2011, CONCUSSION CRISIS AN; Conners C.K., 2004, CONNERS CONTINUOUS P; Conners CK, 2008, CONNERS, V3rd; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Delis DC., 1994, CALIFORNIA VERBAL LE; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Fleiss J.L., 1981, STAT METHODS RATES P; Forsyth R, 2012, CAN MED ASSOC J, V184, P1257, DOI 10.1503/cmaj.111045; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA IP, 2000, BEHAV RATING INVENTO; Gioia GA, 2009, TOP LANG DISORD, V29, P266, DOI 10.1097/TLD.0b013e3181b5322b; Goodman R, 1999, J CHILD PSYCHOL PSYC, V40, P791, DOI 10.1111/1469-7610.00494; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Junpeng M., 2011, COCHRANE DB SYST REV, V1; Kelsall D, 2012, CAN MED ASSOC J, V184, P189, DOI 10.1503/cmaj.112129; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Maguire JL, 2011, PEDIATRICS, V128, pE666, DOI 10.1542/peds.2011-0043; Marchie A, 2003, CAN MED ASSOC J, V169, P124; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Center for Injury Prevention and Control, 2010, TRAUMATIC BRAIN INJU; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Osterrieth PA, 1994, ARCH PSYCHOL, V30, P286; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Rivara FP, 2012, ARCH PEDIAT ADOL MED, V166, P666, DOI 10.1001/archpediatrics.2011.1602; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Sen AP, 2010, NEUROTHERAPEUTICS, V7, P91, DOI 10.1016/j.nurt.2009.10.014; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Sullivan LM, 2004, STAT MED, V23, P1631, DOI 10.1002/sim.1742; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; Vincent, 2008, J INT NEUROPSYCH SOC, V1, P204; Wechsler D, 2004, WECHSLER INTELLIGENC, Vfourth; Wechsler D., 2001, WECHSLER INDIVIDUAL; Wechsler D, 2011, WASI 2 WECHSLER ABBR; Wechsler D., 2008, WECHSLER ADULT INTEL; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zafonte R, 2011, JAMA-J AM MED ASSOC, V306, P79, DOI 10.1001/jama.2011.819; Zemek R, ACAD EMERG MED; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	72	26	26	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2013	3	8							e003550	10.1136/bmjopen-2013-003550			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	301VX	WOS:000330561300065	23906960	gold, Green Published			2022-02-06	
J	Luukkainen, S; Riala, K; Laukkanen, M; Hakko, H; Rasanen, P				Luukkainen, Saku; Riala, Kaisa; Laukkanen, Matti; Hakko, Helina; Rasanen, Pirkko			Association of traumatic brain injury with criminality in adolescent psychiatric inpatients from Northern Finland	PSYCHIATRY RESEARCH			English	Article						Adolescent; Criminality; Substance-related disorders; Conduct disorder	JUVENILE-DELINQUENCY; SUBSTANCE USE; BIRTH COHORT; DISORDERS; CHILDHOOD; SYMPTOMS; LIFETIME; BEHAVIOR; CHILDREN; SMOKING	The association of traumatic brain injuries (TBI) with criminality, substance-related disorders and conduct disorders has mainly been studied in adult populations. In our study we examine the association in an adolescent population. We used a population-based clinical sample of 508 psychiatric inpatient adolescents from Northern Finland. The prevalences of TBI and criminality were 26 (5.1%) and 85 (16.7%), respectively. The information on TBI was acquired from the Finnish Hospital Discharge Register and on criminality from the Legal Register Center. DSM-IV diagnoses were obtained by interviewing the subjects using the semi-structured Schedule for Affective Disorder and Schizophrenia for School-Age Children, Present and Lifetime (K-SADS-PL). Adolescents with TBI had significantly more often committed crimes compared to adolescents without TBI (53.8% vs. 14.7%, respectively). Prevalences of both violent crimes (42.9% vs. 9.1%) and non-violent crimes (29.4% vs. 6.8%) were also higher in the TBI group. TBI during childhood and adolescence increased the risk of any criminality 6.8-fold (95% 3.0-15.2), conduct disorder 5.7-fold (95% 2.1-15.4) and concomitant criminality and conduct disorder 18.7-fold (95% 4.3-80.1). Our results suggest that clinicians working with mentally ill adolescents who have experienced head injuries should be aware of the increased risk for delinquency and violent tendencies occurring later in the adolescents' lives. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Luukkainen, Saku; Rasanen, Pirkko] Univ Oulu, Dept Psychiat, Oulu 90014, Finland; [Riala, Kaisa; Laukkanen, Matti; Hakko, Helina] Oulu Univ Hosp, Dept Psychiat, Oys 90029, Finland; [Riala, Kaisa] Univ Helsinki, Cent Hosp, Dept Adolescent Psychiat, Huch Helsinki 00029, Finland		Hakko, H (corresponding author), Oulu Univ Hosp, Dept Psychiat, POB 26, Oys 90029, Finland.	helina.hakko@oulu.fi					Bauer SM, 2011, PSYCHIAT RES, V185, P193, DOI 10.1016/j.psychres.2010.04.052; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI [10.1089/neu.2008.0849, 10.1089/neu.2008-0849]; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Hartgers C., 1995, EUR ADDICT RES, V1, P208, DOI DOI 10.1159/000259089; Hux D, 1998, BRAIN INJURY, V12, P667; Ilomaki R, 2008, EUR PSYCHIAT, V23, P85, DOI 10.1016/j.eurpsy.2007.10.009; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Keskimaki I, 1991, INT J HLTH SCI, V2, P15; Laukkanen M, 2008, J ADDICT DIS, V27, P69, DOI 10.1080/10550880802324853; Luukkonen AH, 2011, FORENSIC SCI INT, V207, P106, DOI 10.1016/j.forsciint.2010.09.012; Maniadaki Katerina, 2008, Crim Behav Ment Health, V18, P207, DOI 10.1002/cbm.698; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Najman JM, 2010, J ADOLESCENT HEALTH, V46, P538, DOI 10.1016/j.jadohealth.2009.12.001; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; RANTAKALLIO P, 1992, ARCH DIS CHILD, V67, P1459, DOI 10.1136/adc.67.12.1459; Schroeder RD, 2010, SOCIOL INQ, V80, P579, DOI 10.1111/j.1475-682X.2010.00351.x; Stoddard SA, 2011, PEDIATRICS, V127, P1074, DOI 10.1542/peds.2010-2453; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613	22	26	26	0	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	DEC 30	2012	200	2-3					767	772		10.1016/j.psychres.2012.04.018			6	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	073TF	WOS:000313764700109	22560660				2022-02-06	
J	Pontifex, MB; Broglio, SP; Drollette, ES; Scudder, MR; Johnson, CR; O'Connor, PM; Hillman, CH				Pontifex, Matthew B.; Broglio, Steven P.; Drollette, Eric S.; Scudder, Mark R.; Johnson, Chris R.; O'Connor, Phillip M.; Hillman, Charles H.			The Relation of Mild Traumatic Brain Injury to Chronic Lapses of Attention	RESEARCH QUARTERLY FOR EXERCISE AND SPORT			English	Article						cognitive control; concussion; sustained attention; vigilance	EXECUTIVE FUNCTIONS; PROFESSIONAL FOOTBALL; SUSTAINED ATTENTION; CONCUSSION; SENSITIVITY; PERFORMANCE; MEMORY; HIPPOCAMPUS; DYSFUNCTION; INHIBITION	We assessed the extent to which failures in sustained attention were associated with chronic mild traumatic brain injury (mTBI) deficits in cognitive control among college-age young adults with and without a history of sport-related concussion. Participants completed the ImPACT computer-based assessment and a modified flanker task. Results indicated that a history of mTBI, relative to healthy controls, was associated with inferior overall flanker task performance with a greater number of omission errors and more frequent sequentially occurring omission errors. Accordingly, these findings suggest that failures in the ability to maintain attentional vigilance may, in part, underlie mTBI-related cognition deficits.	[Pontifex, Matthew B.] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [Drollette, Eric S.; Scudder, Mark R.; Johnson, Chris R.; O'Connor, Phillip M.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA		Pontifex, MB (corresponding author), Michigan State Univ, Dept Kinesiol, 27P IM Sports Circle, E Lansing, MI 48824 USA.	pontifex@msu.edu	Hillman, Charles/AAD-4828-2019	Pontifex, Matthew/0000-0001-9819-9625; Hillman, Charles/0000-0002-3722-5612	Mary Jane Neer Fund for Disability Research; University of Illinois Research Board; University of Illinois predoctoral fellowship through the NICHD Developmental Psychobiology and Neurobiology Training Grant [2 T32 HD007333]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007333] Funding Source: NIH RePORTER	This research was supported by grants from the Mary Jane Neer Fund for Disability Research, the University of Illinois Research Board, and a University of Illinois predoctoral fellowship through the NICHD Developmental Psychobiology and Neurobiology Training Grant (2 T32 HD007333) awarded to the first author. No conflicting financial interests exist. At the time of this study, the first author was with the University of Illinois at Urbana-Champaign. Please address correspondence concerning this article to Matthew B. Pontifex, Department of Kinesiology, 27P IM Sports Circle, Michigan State University, East Lansing, MI 488241049.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brocki KC, 2004, DEV NEUROPSYCHOL, V26, P571, DOI 10.1207/s15326942dn2602_3; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Caggiano DM, 2004, PSYCHON B REV, V11, P932, DOI 10.3758/BF03196724; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; Diamond A, 2006, LIFESPAN COGNITION M, P70; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; ERIKSEN CW, 1979, PERCEPT PSYCHOPHYS, V25, P249, DOI 10.3758/BF03198804; FISK AD, 1981, HUM FACTORS, V23, P737, DOI 10.1177/001872088102300610; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kaufman A.S., 1990, KAUFMAN BRIEF INTELL; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Meyer DE, 1997, PSYCHOL REV, V104, P3, DOI 10.1037/0033-295X.104.1.3; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Motulsky H., 1995, INTUITIVE BIOSTATIST; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Parasuraman R, 1998, ATTENTIVE BRAIN, P221; PARASURAMAN R, 1979, SCIENCE, V205, P924, DOI 10.1126/science.472714; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Piland SG, 2010, J ATHL TRAINING, V45, P273, DOI 10.4085/1062-6050-45.3.273; Pontifex MB, 2007, CLIN NEUROPHYSIOL, V118, P570, DOI 10.1016/j.clinph.2006.09.029; Pontifex MB, 2009, MED SCI SPORT EXER, V41, P927, DOI 10.1249/MSS.0b013e3181907d69; Spencer KM, 1999, PSYCHOPHYSIOLOGY, V36, P364, DOI 10.1017/S0048577299970749; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Temple JG, 2000, HUM FACTORS, V42, P183, DOI 10.1518/001872000779656480; Warm JS, 2008, HUM FACTORS, V50, P433, DOI 10.1518/001872008X312152	45	26	26	0	30	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0270-1367	2168-3824		RES Q EXERCISE SPORT	Res. Q. Exerc. Sport	DEC	2012	83	4					553	559					7	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Psychology; Sport Sciences	062NB	WOS:000312925400009	23367818				2022-02-06	
J	Van Houtven, CH; Friedemann-Sanchez, G; Clothier, B; Levison, D; Taylor, BC; Jensen, AC; Phelan, SM; Griffin, JM				Van Houtven, Courtney Harold; Friedemann-Sanchez, Greta; Clothier, Barbara; Levison, Deborah; Taylor, Brent C.; Jensen, Agnes C.; Phelan, Sean M.; Griffin, Joan M.			Is Policy Well-Targeted to Remedy Financial Strain among Caregivers of Severely Injured US Service Members?	INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING			English	Article							TRAUMATIC BRAIN-INJURY; INFORMAL CARE; REHABILITATION; WORK; WAR; PARTICIPATION; EMPLOYMENT; VETERANS; BURDEN; IMPACT	US. military service members have sustained severe injuries since the start of the wars in Iraq and Afghanistan. This paper aims to determine the factors associated with financial strain of their caregivers and establish whether recent federal legislation targets caregivers experiencing financial strain. In our national survey, 62.3% of caregivers depleted assets and/or accumulated debt, and 41% of working caregivers left the labor force. If a severely injured veteran needed intensive help, the primary caregiver faced odds 4.63 times higher of leaving the labor force, and used $27,576 more in assets and/or accumulated debt compared to caregivers of veterans needing little or no assistance.	[Van Houtven, Courtney Harold] Vet Adm Med Ctr, Ctr Hlth Serv Res Primary Care, Dept Vet Affairs VA Med Ctr, Durham, NC 27705 USA; [Van Houtven, Courtney Harold] Duke Univ, Med Ctr, Durham, NC 27706 USA; [Friedemann-Sanchez, Greta; Levison, Deborah] Univ Minnesota, Hubert H Humphrey Sch Publ Affairs, Minneapolis, MN 55455 USA; [Clothier, Barbara; Taylor, Brent C.; Jensen, Agnes C.; Griffin, Joan M.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Taylor, Brent C.; Griffin, Joan M.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Taylor, Brent C.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA; [Phelan, Sean M.] Univ Minnesota, Med Sch, Dept Family Med & Community Hlth, Minneapolis, MN 55455 USA		Van Houtven, CH (corresponding author), 508 Fulton St 558-152, Durham, NC 27705 USA.	courtney.vanhoutven@duke.edu	Taylor, Brent C/A-8069-2009	Taylor, Brent C/0000-0002-2140-8377; Friedemann-Sanchez, Greta/0000-0002-0493-7218; Van Houtven, Courtney/0000-0002-0783-1611	Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health Administration Office of Research and Development; Health Services Research and Development Service, VA [SDR 07-044]; VA HSR&D Career Development Award [MRP 05-311]	Courtney Harold Van Houtven, Ph.D., is a research scientist at the Center for Health Services Research in Primary Care, Department of Veterans Affairs (VA) Medical Center, Durham, N. C., and an associate professor in general internal medicine at the Duke University Medical Center. Greta Friedemann-Sanchez, Ph.D., is an assistant professor at the Hubert H Humphrey School of Public Affairs, University of Minnesota. Barbara Clothier, M.S., M.A., is a statistician at the Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System. Deborah Levison, Ph.D., is a professor at the Hubert H. Humphrey School of Public Affairs, University of Minnesota. Brent C. Taylor, Ph.D., is a core investigator at the Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System, an assistant professor at the University of Minnesota Medical School, and an adjunct assistant professor at the University of Minnesota School of Public Health. Joan M. Griffin, Ph.D., is a core investigator at the Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System, and an associate professor at the University of Minnesota Medical School. Agnes C Jensen, is a research coordinator at the Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System. Sean M. Phelan, Ph.D., M.P.H., is an assistant professor in the Department of Family Medicine and Community Health, University of Minnesota Medical School. This research was supported by the Department of Veterans Affairs, Veterans Health Administration Office of Research and Development, and a grant from the Health Services Research and Development Service, VA (SDR 07-044: Griffin, PI). Dr. Van Houtven was funded by a VA HSR&D Career Development Award (MRP 05-311). Address correspondence to Dr. Van Houtven at 508 Fulton Street (558/152), Durham, NC 27705. Email: courtney.vanhoutven@duke.edu	Arno PS, 1999, HEALTH AFFAIR, V18, P182, DOI 10.1377/hlthaff.18.2.182; Bolin K, 2008, J HEALTH ECON, V27, P718, DOI 10.1016/j.jhealeco.2007.10.004; Carlson KF, 2012, J HEAD TRAUMA REHAB, V27, P14, DOI 10.1097/HTR.0b013e318236bd86; Carmichael F, 2003, J HEALTH ECON, V22, P781, DOI 10.1016/S0167-6296(03)00044-4; Deb P., 2012, AM SOC HLTH EC C MIN; Deere CD, 2006, FEM ECON, V12, P1, DOI 10.1080/13545700500508056; Dillman DA., 2007, MAIL INTERNET SURVEY; Einhorn C., 2011, NY TIMES, pA12; ETTNER SL, 1995, DEMOGRAPHY, V32, P63, DOI 10.2307/2061897; Feinberg LF, 2004, GERONTOLOGIST, V44, P760, DOI 10.1093/geront/44.6.760; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Griffin JM, 2012, J HEAD TRAUMA REHAB, V27, P3, DOI 10.1097/HTR.0b013e3182274260; Grunfeld E, 2004, CAN MED ASSOC J, V170, P1795, DOI 10.1503/cmaj.1031205; Hayman JA, 2001, J CLIN ONCOL, V19, P3219, DOI 10.1200/JCO.2001.19.13.3219; Heitmueller A, 2007, J HEALTH ECON, V26, P536, DOI 10.1016/j.jhealeco.2006.10.005; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Johnson RW, 2006, INQUIRY-J HEALTH CAR, V43, P195, DOI 10.5034/inquiryjrnl_43.3.195; Jones A., 2000, HDB HLTH EC A, V1A; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Keating, 1999, J FAMILY EC ISSUES, V20, P301, DOI [10.1023/A:1022909510229, DOI 10.1023/A:1022909510229]; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lilly MB, 2007, MILBANK Q, V85, P641, DOI 10.1111/j.1468-0009.2007.00504.x; Longo CJ, 2006, SUPPORT CARE CANCER, V14, P1077, DOI 10.1007/s00520-006-0088-8; McGarry K., 2003, HLTH CARE ISSUES US; Mincer J., 1974, MARRIAGE FAMILY HUMA; Moore MJ, 2001, J GERONTOL B-PSYCHOL, V56, pS219, DOI 10.1093/geronb/56.4.S219; Naihua D., 1984, J BUS ECON STAT, V3, P283, DOI [10.1080/07350015.1984.10509396, DOI 10.1080/07350015.1984.10509396]; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SCHARLACH AE, 1989, GERONTOLOGIST, V29, P382, DOI 10.1093/geront/29.3.382; Timmermans S, 2007, SOC SCI MED, V65, P1351, DOI 10.1016/j.socscimed.2007.05.027; Van Houtven CH, 2013, J HEALTH ECON, V32, P240, DOI 10.1016/j.jhealeco.2012.10.006; WOLF DA, 1994, J HUM RESOUR, V29, P1259, DOI 10.2307/146140; Wright J, 2000, FIM TM	33	26	26	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0046-9580	1945-7243		INQUIRY-J HEALTH CAR	Inquiry-J. Health Care Organ. Provis. Financ.	WIN	2012	49	4					339	351		10.5034/inquiryjrnl_49.04.01			13	Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services	092MZ	WOS:000315128000008	23469677				2022-02-06	
J	Wu, HT; Mahmood, A; Qu, CS; Xiong, Y; Chopp, M				Wu, Hongtao; Mahmood, Asim; Qu, Changsheng; Xiong, Ye; Chopp, Michael			Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons	BRAIN RESEARCH			English	Article						Axonal injury; Glycogen synthase kinase 3 beta; Neurite outgrowth; Simvastatin; Traumatic brain injury	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; REDUCTASE INHIBITORS; ADULT CNS; REGENERATION; LITHIUM; STROKE; DAMAGE; GROWTH; MODEL	The beneficial effects of simvastatin on experimental traumatic brain injury (TBI) have been demonstrated in previous studies. In this study, we investigated the effects of simvastatin on axonal injury and neurite outgrowth after experimental TBI and explored the underlying mechanisms. Wistar rats were subjected to controlled cortical impact or sham surgery. Saline or simvastatin was administered for 14 days. A modified neurological severity score (mNSS) test was performed to evaluate functional recovery. Immunohistochemistry studies using synaptophysin, neurofilament H (NF-H) and amyloid-beta precursor protein (APP) were performed to examine synaptogenesis and axonal injury. Primary cortical neurons (PCNs) were subjected to oxygen glucose deprivation (OGD) followed by various treatments. Western blot analysis was utilized to assess the activation of phosphatidylinositol-3 kinase (PI-3 K)/Akt/mammalian target of rapamycin (mTOR) and glycogen synthase kinase 3 beta (GSK-3 beta)/adenomatous polyposis coli (APC) pathways. Simvastatin decreased the density of APP-positive profiles and increased the density of NF-H-positive profiles. Simvastatin reduced mNSS, which was correlated with the increase of axonal density. Simvastatin treatment stimulated the neurite outgrowth of PCNs after OGD, which was attenuated by LY294002 and enhanced by lithium chloride (LiCl). Simvastatin activated Akt and mTOR, inactivated GSK-3 beta and dephosphorylated APC in the injured PCNs. Our data suggest that simvastatin reduces axonal injury, enhances neurite outgrowth and promotes neurological functional recovery after experimental TBI. The beneficial effects of simvastatin on neurite outgrowth may be mediated through manipulation of the PI-3 K/Akt/mTOR and PI-3 K/GSK-3 beta/APC pathways. (C) 2012 Elsevier B.V. All rights reserved.	[Wu, Hongtao; Mahmood, Asim; Qu, Changsheng; Xiong, Ye] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA		Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, E&R Bldg 3072,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS052280-01A1, R01AG037506]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088656, R01NS052280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG037506] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) grants R01NS052280-01A1 (A.M.), and R01AG037506 (M.C.)	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Barth AIM, 2008, SEMIN CELL DEV BIOL, V19, P245, DOI 10.1016/j.semcdb.2008.02.003; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; Chauhan NB, 2010, BRAIN RES, V1360, P177, DOI 10.1016/j.brainres.2010.09.010; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; Culmsee C, 2003, J NEUROSCI, V23, P8586; Di Giovanni S, 2009, EXPERT OPIN THER TAR, V13, P1387, DOI 10.1517/14728220903307517; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; Goold RG, 2004, BIOCHEM SOC T, V32, P809, DOI 10.1042/BST0320809; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; Kavanova M, 2005, ANN BOT-LONDON, V95, P457, DOI 10.1093/aob/mci054; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lee JK, 2009, J NEUROSCI, V29, P8649, DOI 10.1523/JNEUROSCI.1864-09.2009; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lucas FR, 1998, J CELL SCI, V111, P1351; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Max X, 2008, CELL, V133, P303, DOI 10.1016/j.cell.2008.02.031; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Povlishock J T, 2000, Clin Neurosurg, V46, P113; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Qiu J, 2005, J NEUROSCI, V25, P1645, DOI 10.1523/JNEUROSCI.3269-04.2005; Read DE, 2009, CELL MOL LIFE SCI, V66, P2975, DOI 10.1007/s00018-009-0057-8; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; SAHEKI A, 1994, PHARMACEUT RES, V11, P305, DOI 10.1023/A:1018975928974; SALTHOUSE TN, 1964, STAIN TECHNOL, V39, P123; SatoSuzuki I, 1996, NEUROSCI LETT, V220, P21, DOI 10.1016/S0304-3940(96)13221-3; Shehadah A, 2010, J NEUROL SCI, V294, P107, DOI 10.1016/j.jns.2010.03.020; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sun F, 2010, CURR OPIN NEUROBIOL, V20, P510, DOI 10.1016/j.conb.2010.03.013; Teng FYH, 2006, J NEUROCHEM, V96, P1501, DOI 10.1111/j.1471-4159.2006.03663.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; von Bohlen und Halbach O, 1998, J NEUROSCI METH, V81, P169, DOI 10.1016/S0165-0270(98)00026-0; Votin V, 2005, J CELL SCI, V118, P5699, DOI 10.1242/jcs.02679; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wu HT, 2011, NEUROSURGERY, V68, P1363, DOI 10.1227/NEU.0b013e31820c06b9; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	58	26	26	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 27	2012	1486						121	130		10.1016/j.brainres.2012.09.039			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	049KX	WOS:000311983000012	23026078	Green Accepted			2022-02-06	
J	Stippler, M; Ortiz, V; Adelson, PD; Chang, YF; Tyler-Kabara, EC; Wisniewski, SR; Fink, EL; Kochanek, PM; Brown, SD; Bell, MJ				Stippler, Martina; Ortiz, Veronica; Adelson, P. David; Chang, Yue-Fang; Tyler-Kabara, Elizabeth C.; Wisniewski, Stephen R.; Fink, Ericka L.; Kochanek, Patrick M.; Brown, S. Danielle; Bell, Michael J.			Brain tissue oxygen monitoring after severe traumatic brain injury in children: relationship to outcome and association with other clinical parameters Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						intracranial pressure; cerebral perfusion pressure; Glasgow Outcome Scale; temperature; trauma; partial pressure oxygen	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; LENGTH-OF-STAY; INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; TENSION; METABOLISM; HYPERTHERMIA; TEMPERATURE; EXPERIENCE	Object. Minimizing secondary brain injuries after traumatic brain injury (TBI) in children is critical to maximizing neurological outcome. Brain tissue oxygenation monitoring (as measured by interstitial partial pressure of O-2 [PbO2]) is a new tool that may aid in guiding therapies, yet experience in children is limited. This study aims to describe the authors' experience of PbO2 monitoring after TBI. It was hypothesized that PbO2 thresholds could be established that were associated with favorable neurological outcome, and it was determined whether any relationships between PbO2 and other important clinical variables existed. Methods. Forty-six children with severe TBI (Glasgow Coma Scale score <= 8 after resuscitation) who underwent PbO2 and brain temperature monitoring between September 2004 and June 2008 were studied. All patients received standard neurocritical care, and 24 were concurrently enrolled in a trial of therapeutic early hypothermia (n = 12/group). The PbO2 was measured in the uninjured frontal cortex. Hourly recordings and calculated daily means of various variables including PbO2, intracranial pressure (ICP), cerebral perfusion pressure (CPP), mean arterial blood pressure, partial pressure of arterial O-2, and fraction of inspired O-2 were compared using several statistical approaches. Glasgow Outcome Scale scores were determined at 6 months after injury. Results. The mean patient age was 9.4 years (range 0.1-16.5 years; 13 girls) and 8554 hours of monitoring were analyzed (PbO2 range 0.0-97.2 mm Hg). A PbO2 of 30 mm Hg was associated with the highest sensitivity/specificity for favorable neurological outcome at 6 months after TBI, yet CPP was the only factor that was independently associated with favorable outcome. Surprisingly, instances of preserved PbO2 with altered ICP and CPP were observed in some children with unfavorable outcomes. Conclusions. Monitoring of PbO2 demonstrated complex interactions with clinical variables reflecting intracranial dynamics using this protocol. A higher threshold than reported in studies in adults was suggested as a potential therapeutic target, but this threshold was not associated with improved outcomes. Additional studies to assess the utility of PbO2 monitoring after TBI in children are needed. (http://thejns.org/doi/abs/10.3171/2012.8.PEDS12165)	[Fink, Ericka L.; Kochanek, Patrick M.; Bell, Michael J.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Stippler, Martina; Ortiz, Veronica; Adelson, P. David; Chang, Yue-Fang; Tyler-Kabara, Elizabeth C.; Brown, S. Danielle; Bell, Michael J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Fink, Ericka L.; Kochanek, Patrick M.; Bell, Michael J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Adelson, P. David; Brown, S. Danielle] Phoenix Childrens Hosp, Dept Neurosurg, Phoenix, AZ USA; [Stippler, Martina] Univ New Mexico, Dept Neurol Surg, Albuquerque, NM 87131 USA		Bell, MJ (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	bellmj4@upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015; Tyler-Kabara, Elizabeth/H-4930-2013; Fink, Ericka/AAU-9792-2021	Kochanek, Patrick M/0000-0002-2627-913X; Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Fink, Ericka/0000-0002-3683-4571; Wisniewski, Stephen/0000-0002-3877-9860	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS38448, NS052478, NS30318, HD040686]; Office of the Dean of the University of Pittsburgh School of Medicine; Integra Life Sciences	This work was supported in part by NIH grants NS38448, NS052478, NS30318, and HD040686, and a grant from the Office of the Dean of the University of Pittsburgh School of Medicine. Dr. Adelson received clinical or research support for this study from Integra Life Sciences, and serves as a consultant to Traumatec.	Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Badiatia N, 2009, CURR OPIN CRIT CARE, V15, P79, DOI 10.1097/MCC.0b013e32832922e9; Bratton SL, 2008, J NEUROTRAUM, V25, P276; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Figaji AA, 2009, CHILD NERV SYST, V25, P1335, DOI 10.1007/s00381-009-0821-y; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Hardman J M, 1979, Adv Neurol, V22, P15; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Jia Jun, 2005, Chin J Traumatol, V8, P138; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Spiotta AM, 2008, NEUROSURGERY, V62, P864, DOI 10.1227/01.neu.0000316900.63124.ce; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Stocchetti N, 2005, J NEUROL NEUROSUR PS, V76, P1135, DOI 10.1136/jnnp.2004.041269; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Zhang Sai, 2002, Chin J Traumatol, V5, P43	40	26	26	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	NOV	2012	10	5					383	391		10.3171/2012.8.PEDS12165			9	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	027UZ	WOS:000310380600005	22978637				2022-02-06	
J	Rathore, FA; Gosney, JE; Reinhardt, JD; Haig, AJ; Li, JN; DeLisa, JA				Rathore, Farooq A.; Gosney, James E.; Reinhardt, Jan D.; Haig, Andrew J.; Li, Jianan; DeLisa, Joel A.			Medical Rehabilitation After Natural Disasters: Why, When, and How?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Amputation; Disability evaluation; Disasters; Occupational therapy; Outcome assessment; Rehabilitation; Spinal cord injuries	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; 2005 PAKISTAN EARTHQUAKE; QUALITY-OF-LIFE; WENCHUAN EARTHQUAKE; HEALTH; MANAGEMENT; OCTOBER; HAITI; EPIDEMIOLOGY	Rathore FA, Gosney JE, Reinhardt JD, Haig AJ, Li J, DeLisa JA. Medical rehabilitation after natural disasters: why, when, and how? Arch Phys Med Rehabil 2012;93:1875-81. Natural disasters can cause significant numbers of severe, disabling injuries, resulting in a public health emergency and requiring foreign assistance. However, since medical rehabilitation services are often poorly developed in disaster-affected regions and not highly prioritized by responding teams, physical and rehabilitation medicine (PRM) has historically been underemphasized in global disaster planning and response. Recent development of the specialties of "disaster medicine" and "disaster rehabilitation" has raised awareness of the critical importance of rehabilitation intervention during the immediate postdisaster emergency response. The World Health Organization Liaison Sub-Committee on Rehabilitation Disaster Relief of the International Society of Physical and Rehabilitation Medicine has authored this report to assess the role of emergency rehabilitation intervention after natural disasters based on current scientific evidence and subject matter expert accounts. Major disabling injury types are identified, and spinal cord injury, limb amputation, and traumatic brain injury are used as case studies to exemplify the challenges to effective management of disabling injuries after disasters. Evidence on the effectiveness of disaster rehabilitation interventions is presented. The authors then summarize the current state of disaster-related research, as well as lessons learned from PRM emergency rehabilitation response in recent disasters. Resulting recommendations for greater integration of PRM services into the immediate emergency disaster response are provided. This report aims to stimulate development of research and practice in the emerging discipline of disaster rehabilitation within organizations that provide medical rehabilitation services during the postdisaster emergency response.	[Rathore, Farooq A.] Armed Forces Inst Rehabil Med, Spinal Rehabil Unit, Rawalpindi 46000, Pakistan; [Rathore, Farooq A.; Gosney, James E.; Reinhardt, Jan D.; Haig, Andrew J.; Li, Jianan; DeLisa, Joel A.] Rehabil Disaster Relief Comm, Int Soc Phys & Rehabil Med, Geneva, Switzerland; [Rathore, Farooq A.] World Assoc Disaster & Emergency Med, Madison, WI USA; [Reinhardt, Jan D.] Swiss Parapleg Res, Nottwil, Switzerland; [Reinhardt, Jan D.] Univ Lucerne, Dept Hlth Sci & Hlth Policy, Luzern, Switzerland; [Haig, Andrew J.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Rathore, Farooq A.; Gosney, James E.; Haig, Andrew J.] Int Rehabil Forum Emergency Rehabil Work Grp, Ann Arbor, MI USA; [Li, Jianan] Nanjing Med Univ, Dept Rehab Med, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [DeLisa, Joel A.] Univ Hosp, Newark, NJ USA; [DeLisa, Joel A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA		Rathore, FA (corresponding author), Armed Forces Inst Rehabil Med, Spinal Rehabil Unit, Abid Majeed Rd, Rawalpindi 46000, Pakistan.	farooqrathore@gmail.com	Haig, Andrew/B-5206-2013; Rathore, Farooq Azam/B-8232-2008	Rathore, Farooq Azam/0000-0002-4759-0453			Ahrari M N, 2006, Electromyogr Clin Neurophysiol, V46, P59; Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; [Anonymous], 1980, WHO CHRON, V34, P96; Anonymous, 2011, Morbidity and Mortality Weekly Report, V59, P1673; [Anonymous], 2010, WORLD CONFEDERAT APR, P1; Athukorala P.C., 2005, ASIAN EC PAPERS, V4, P1, DOI DOI 10.1162/ASEP.2005.4.1.1; Bai XD, 2009, CHIN J TRAUMATOL, V12, P122, DOI 10.3760/cma.j.issn.1008-1275.2009.02.012; Bathla BS, 2005, ARCH PHYS MED REHAB, V86, pE31; Bhatti SH, 2008, JCPSP-J COLL PHYSICI, V18, P22, DOI 01.2008/JCPSP.2226; Brandeau ML, 2009, MED DECIS MAKING, V29, P438, DOI 10.1177/0272989X09340346; Bremer Rannveig, 2003, Prehosp Disaster Med, V18, P372; Butt BA, 2010, DISASTER MED PUBLIC, V4, P8, DOI 10.1017/S1935789300002317; Chen Jin, 2009, J Evid Based Med, V2, P270, DOI 10.1111/j.1756-5391.2009.01053.x; Chiou-Tan FY, 2007, AM J PHYS MED REHAB, V86, P762, DOI 10.1097/PHM.0b013e31813e61cc; Dai ZY, 2010, ULUS TRAVMA ACIL CER, V16, P503; Farfel A, 2011, EUR J PEDIATR, V170, P519, DOI 10.1007/s00431-011-1423-8; Gosney J, 2011, J REHABIL MED, V43, P965, DOI 10.2340/16501977-0890; Haig AJ, 2009, ARCH PHYS MED REHAB, V90, P2074, DOI 10.1016/j.apmr.2009.05.025; Haig AJ, 2009, J REHABIL MED, V41, P401, DOI 10.2340/16501977-0367; He HC, 2011, HONG KONG J EMERG ME, V18, P324; Hu XR, 2012, J REHABIL MED, V44, P200, DOI 10.2340/16501977-0944; IASC and Global Health Cluster, 2012, COORD REG PROV FOR M; IDNDR (International Decade for Natural Disaster Reduction), 1994, YOK STRAT PLAN ACT S; Iezzoni LI, 2010, ANN INTERN MED, V152, P812, DOI 10.7326/0003-4819-152-12-201006150-00234; IRIN Global, 2012, HAIT EM SHEDS LIGHT; KILLIAN LM, 2002, METHODS DISASTER RES, P21; Knowlton LM, 2011, PREHOSP DISASTER MED, V26, P438, DOI 10.1017/S1049023X12000076; Krogh K, 2009, SPINAL CORD, V47, P230, DOI 10.1038/sc.2008.102; Landry MD, 2010, DISABIL REHABIL, V32, P1616, DOI 10.3109/09638288.2010.500345; LECHAT MF, 1979, B WORLD HEALTH ORGAN, V57, P11; Li Yuanfeng, 2009, J Evid Based Med, V2, P258, DOI 10.1111/j.1756-5391.2009.01045.x; Mallick M, 2010, East Mediterr Health J, V16 Suppl, pS98; Mateen FJ, 2010, ANN NEUROL, V68, P282, DOI 10.1002/ana.22135; Mulvey JM, 2008, INJURY, V39, P554, DOI 10.1016/j.injury.2007.07.025; Nixon SA, 2010, PHYSIOTHER CAN, V62, P167, DOI 10.3138/physio.62.3.167; Officer A, 2011, WORLD REPORT DISABIL, P21; Pang Hee-Nee, 2011, J Orthop Surg (Hong Kong), V19, P3; Phalkey R, 2011, GLOBAL HEALTH ACTION, V4, DOI [10.3402/gha.v4i0.7191, 10.3402/gha.v4i0.7196]; Rathore FA, 2008, ARCH PHYS MED REHAB, V89, P579, DOI 10.1016/j.apmr.2007.09.027; Rathore FA, 2011, DISASTER MED PUBLIC, V5, P174, DOI 10.1001/dmp.2011.66; Rathore MFA, 2008, SPINAL CORD, V46, P461, DOI 10.1038/sj.sc.3102162; Rathore MFA, 2007, SPINAL CORD, V45, P658, DOI 10.1038/sj.sc.3102023; Rauch A, 2011, J REHABIL MED, V43, P969, DOI 10.2340/16501977-0896; Redmond AD, 2011, LANCET, V377, P1054, DOI 10.1016/S0140-6736(11)60319-X; Reinhardt JD, 2011, GLOBAL HEALTH ACTION, V4, DOI 10.3402/gha.v4i0.7191; Roy N, 2006, PREHOSP DISASTER MED, V21, P310, DOI 10.1017/S1049023X00003939; Sami F, 2009, PREHOSP DISASTER MED, V24, P535, DOI 10.1017/S1049023X00007470; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sphere Project, 2012, SPHER HDB HUM CHART; Stier-Jarmer M, 2011, J REHABIL MED, V43, P113, DOI [10.2340/16501977-0617, 10.2340/16501977-0659]; Stucki G, 2009, J REHABIL MED, V41, P843, DOI 10.2340/16501977-0431; The Johanniter International Assistance, 2012, HAIT LONG TERM ASS I; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Twisk J, 2009, J CLIN EPIDEMIOL, V62, P953, DOI 10.1016/j.jclinepi.2008.10.003; Uddin MT, 2008, J REHABIL MED S46, P24; Umer Masood, 2006, J Pak Med Assoc, V56, P370; Wade D T, 1988, Int Disabil Stud, V10, P64; WHO Department of Injuries and Violence Prevention, 2012, DIS DIS REH; World Confederation for Physical Therapy, 2012, DAT BAS EXP; Zhang Lei, 2009, Injury, V40, P84, DOI 10.1016/j.injury.2008.08.045; Zhang X, 2012, J REHABIL MED, V44, P206, DOI 10.2340/16501977-0945; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941; [No title captured]	63	26	28	0	27	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2012	93	10					1875	1881		10.1016/j.apmr.2012.05.018			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	018FP	WOS:000309645800028	22676904				2022-02-06	
J	Edlow, BL; Wu, O				Edlow, Brian L.; Wu, Ona			Advanced Neuroimaging in Traumatic Brain Injury	SEMINARS IN NEUROLOGY			English	Article						traumatic brain injury (TBI); susceptibility-weighted imaging (SWI); diffusion tensor imaging (DTI); high angular resolution diffusion imaging (HARDI); functional MRI (fMRI); traumatic axonal injury (TAI)	DIFFUSE AXONAL INJURY; DEFAULT-MODE NETWORK; AMYLOID PRECURSOR PROTEIN; MINIMALLY CONSCIOUS STATE; WHITE-MATTER INTEGRITY; COMMON DATA ELEMENTS; RESTING-STATE; VEGETATIVE STATE; HEAD-INJURY; FUNCTIONAL CONNECTIVITY	Advances in structural and functional neuroimaging have occurred at a rapid pace over the past two decades. Novel techniques for measuring cerebral blood flow, metabolism, white matter connectivity, and neural network activation have great potential to improve the accuracy of diagnosis and prognosis for patients with traumatic brain injury (TB!), while also providing biomarkers to guide the development of new therapies. Several of these advanced imaging modalities are currently being implemented into clinical practice, whereas others require further development and validation. Ultimately, for advanced neuroimaging techniques to reach their full potential and improve clinical care for the many civilians and military personnel affected by TB!, it is critical for clinicians to understand the applications and methodological limitations of each technique. In this review, we examine recent advances in structural and functional neuroimaging and the potential applications of these techniques to the clinical care of patients with TBI. We also discuss pitfalls and confounders that should be considered when interpreting data from each technique. Finally, given the vast amounts of advanced imaging data that will soon be available to clinicians, we discuss strategies for optimizing data integration, visualization, and interpretation.	[Edlow, Brian L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Edlow, Brian L.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; [Edlow, Brian L.; Wu, Ona] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Wu, Ona] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA		Edlow, BL (corresponding author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St Lunder 650, Boston, MA 02114 USA.	bedlow@partners.org		Wu, Ona/0000-0002-5509-9461	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R25NS065743, P41RR14075]; Center for Integration of Medicine & Innovative Technology (Boston, MA); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR014075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25NS065743] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (R25NS065743 and P41RR14075) and the Center for Integration of Medicine & Innovative Technology (Boston, MA).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Alexander DC., 2011, DIFFUSION MRI THEORY, P451; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, J HEAD TRAUMA REHABI; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Betz J, 2012, J NEUROTRAUM, V29, P1292, DOI 10.1089/neu.2011.2215; Binder JR, 1999, J COGNITIVE NEUROSCI, V11, P80, DOI 10.1162/089892999563265; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Boly M, 2008, ANN NY ACAD SCI, V1129, P119, DOI 10.1196/annals.1417.015; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Catani M, 2005, ANN NEUROL, V57, P8, DOI 10.1002/ana.20319; Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004; Chen YF, 2011, J MAGN RESON IMAGING, V33, P940, DOI 10.1002/jmri.22345; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Clark CA, 2000, MAGN RESON MED, V44, P852, DOI 10.1002/1522-2594(200012)44:6<852::AID-MRM5>3.0.CO;2-A; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Cordonnier C, 2007, BRAIN, V130, P1988, DOI 10.1093/brain/awl387; Cordonnier C, 2009, STROKE, V40, P94, DOI 10.1161/STROKEAHA.108.526996; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dai WY, 2008, MAGN RESON MED, V60, P1488, DOI 10.1002/mrm.21790; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Detre JA, 2002, CLIN NEUROPHYSIOL, V113, P621, DOI 10.1016/S1388-2457(02)00038-X; Dubroff JG, 2008, SEMIN NEUROL, V28, P548, DOI 10.1055/s-0028-1083698; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Edlow BL, 2012, J NEUROPATH EXP NEUR, V71, P531, DOI 10.1097/NEN.0b013e3182588293; Edlow BL, 2010, NEUROLOGY, V75, pE69, DOI 10.1212/WNL.0b013e3181f962d7; Faul M, 2010, TRAUMATIC BRAIN INJU; Fernandez-Espejo D, 2008, BRAIN INJURY, V22, P882, DOI 10.1080/02699050802403573; Fernandez-Seara MA, 2008, MAGN RESON MED, V59, P1467, DOI 10.1002/mrm.21633; Fins JJ, 2009, PROG BRAIN RES, V177, P371, DOI 10.1016/S0079-6123(09)17726-9; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Frank LR, 2001, MAGN RESON MED, V45, P935, DOI 10.1002/mrm.1125; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Fukunaga M, 2006, MAGN RESON IMAGING, V24, P979, DOI 10.1016/j.mri.2006.04.018; Gandy S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004274; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GREENBERG JH, 1981, SCIENCE, V212, P678, DOI 10.1126/science.6971492; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Gregoire SM, 2009, NEUROLOGY, V73, P1759, DOI 10.1212/WNL.0b013e3181c34a7d; Greicius MD, 2008, HUM BRAIN MAPP, V29, P839, DOI 10.1002/hbm.20537; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hagmann P, 2005, THESIS U LAUSANNE LA, P1; Hansen B, 2011, NEUROIMAGE, V57, P1458, DOI 10.1016/j.neuroimage.2011.04.052; Helle M, 2010, MAGN RESON MED, V64, P777, DOI 10.1002/mrm.22451; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hess CP, 2007, NEUROIMAG CLIN N AM, V17, P407, DOI 10.1016/j.nic.2007.07.002; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Janke AL, 2001, MAGNET RESON MED, V46, P661, DOI 10.1002/mrm.1243; Jansons KM, 2003, LECT NOTES COMPUT SC, V2732, P672; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Jo HJ, 2010, NEUROIMAGE, V52, P571, DOI 10.1016/j.neuroimage.2010.04.246; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jones DK, 1999, MAGN RESON MED, V42, P37, DOI 10.1002/(SICI)1522-2594(199907)42:1<37::AID-MRM7>3.0.CO;2-O; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Kammond ME, 2009, ISMRM 17 SCI M EXH A; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kelly JP, 1997, NEUROLOGY, V48, P581; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kim J, 2012, PSYCHOPHARMACOLOGY, V222, P47, DOI 10.1007/s00213-011-2622-8; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Leergaard TB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008595; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu AA, 2011, NEUROLOGY, V77, P1518, DOI 10.1212/WNL.0b013e318233b229; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Melhem ER, 2000, AM J NEURORADIOL, V21, P1813; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Muccio CF, 2009, BRAIN INJURY, V23, P466, DOI 10.1080/02699050902841912; Mulkern RV, 2009, MAGN RESON IMAGING, V27, P1151, DOI 10.1016/j.mri.2009.05.003; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Newsome MR, 2010, NEUROPSYCHOLOGY, V24, P139, DOI 10.1037/a0017432; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Palacios EM, 2012, CORTEX; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pieper S, 2004, IEEE INT S BIOMED IM, V1, P632, DOI DOI 10.1109/ISBI.2004.1398617; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Reese TG, 2009, J MAGN RESON IMAGING, V29, P517, DOI 10.1002/jmri.21497; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; REIVICH M, 1979, CIRC RES, V44, P127, DOI 10.1161/01.RES.44.1.127; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Rizzo J, MILITARY SURG MRIS W; Ropper A, 2011, NEW ENGL J MED, V364, P2156, DOI 10.1056/NEJMe1102187; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ropper AH, 2010, NEW ENGL J MED, V362, P648, DOI 10.1056/NEJMe0909667; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Salat D, 1997, NEUROBIOL AGING, V18, P191, DOI 10.1016/S0197-4580(97)00014-6; Salat DH, 2005, NEUROBIOL AGING, V26, P1215, DOI 10.1016/j.neurobiolaging.2004.09.017; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Setsompop K, 2012, MAGN RESON MED, V67, P1210, DOI 10.1002/mrm.23097; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shin SS, 2012, J NEUROSURG, V116, P1062, DOI 10.3171/2012.1.JNS111282; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Silva S, 2010, NEUROLOGY, V74, P313, DOI 10.1212/WNL.0b013e3181cbcd96; Singh KD, 2008, NEUROIMAGE, V41, P100, DOI 10.1016/j.neuroimage.2008.01.051; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith K, 2012, NATURE, V484, P24, DOI 10.1038/484024a; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Sporns O., 2011, NETWORKS BRAIN; STEJSKAL EO, 1965, J CHEM PHYS, V43, P3597, DOI 10.1063/1.1696526; Steriade M, 1996, SCIENCE, V272, P225, DOI 10.1126/science.272.5259.225; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Talairach J., 1988, COPLANAR STEREOTAXIC; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tanielian TL, 2008, INVISIBLE WOUNDS WAR, pxliii; Tensaouti F, 2011, J MAGN RESON IMAGING, V34, P165, DOI 10.1002/jmri.22584; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Tournier JD, 2011, DIFFUSION MRI, P465; Tuch DS, 2003, NEURON, V40, P885, DOI 10.1016/S0896-6273(03)00758-X; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Vincent JL, 2006, J NEUROPHYSIOL, V96, P3517, DOI 10.1152/jn.00048.2006; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wada T, 2012, AJNR AM J NEURORADIO; Walcott BP, 2011, NEW ENGL J MED, V365, P860, DOI 10.1056/NEJMc1107891; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang JY, 2012, NEUROIMAGE, V60, P1127, DOI 10.1016/j.neuroimage.2011.12.062; Wang R, TRACKVIS; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wedeen VJ, 2012, SCIENCE, V335, P1628, DOI 10.1126/science.1215280; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wong EC, 2006, MAGN RESON MED, V55, P1334, DOI 10.1002/mrm.20906; Worsley K.J., 2001, FUNCTIONAL MRI INTRO; Wu WC, 2007, MAGN RESON MED, V58, P1020, DOI 10.1002/mrm.21403; Wu WC, 2009, IEEE T MED IMAGING, V28, P703, DOI 10.1109/TMI.2008.2012020; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Xu V, 2008, SEMIN NEUROL, V28, P407, DOI 10.1055/s-0028-1083685; Yan CG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005743; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Yoshiura T, 2001, MAGNET RESON MED, V45, P734, DOI 10.1002/mrm.1100; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008; Zaharchuk G, 2007, AM J NEURORADIOL, V28, P1850, DOI 10.3174/ajnr.A0831; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zoroya G, US TODAY	262	26	27	2	35	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	SEP	2012	32	4					374	400		10.1055/s-0032-1331810			27	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	077AD	WOS:000313999400008	23361483	Green Accepted			2022-02-06	
J	Holmes, MW; Goodacre, S; Stevenson, MD; Pandor, A; Pickering, A				Holmes, M. W.; Goodacre, S.; Stevenson, M. D.; Pandor, A.; Pickering, A.			The cost-effectiveness of diagnostic management strategies for adults with minor head injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Minor head injuries; Cost-effectiveness; Diagnostic management strategies; Quality adjusted life-years; Economic modelling	TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; MILD	Study objective: To estimate the cost-effectiveness of diagnostic management strategies for adults with minor head injury. Methods: A mathematical model was constructed to evaluate the incremental costs and effectiveness (Quality Adjusted Life years Gained, QALYs) of ten diagnostic management strategies for adults with minor head injuries. Secondary analyses were undertaken to determine the cost-effectiveness of hospital admission compared to discharge home and to explore the cost-effectiveness of strategies when no responsible adult was available to observe the patient after discharge. Results: The apparent optimal strategy was based on the high and medium risk Canadian CT Head Rule (CCHRhm), although the costs and outcomes associated with each strategy were broadly similar. Hospital admission for patients with non-neurosurgical injury on CT dominated discharge home, whilst hospital admission for clinically normal patients with a normal CT was not cost-effective compared to discharge home with or without a responsible adult at 39 pound and 2.5 pound million per QALY, respectively. A selective CT strategy with discharge home if the CT scan was normal remained optimal compared to not investigating or CT scanning all patients when there was no responsible adult available to observe them after discharge. Conclusion: Our economic analysis confirms that the recent extension of access to CT scanning for minor head injury is appropriate. Liberal use of CT scanning based on a high sensitivity decision rule is not only effective but also cost-saving. The cost of CT scanning is very small compared to the estimated cost of caring for patients with brain injury worsened by delayed treatment. It is recommended therefore that all hospitals receiving patients with minor head injury should have unrestricted access to CT scanning for use in conjunction with evidence based guidelines. Provisionally the CCHRhm decision rule appears to be the best strategy although there is considerable uncertainty around the optimal decision rule. However, the CCHRhm rule appears to be the most widely validated and it therefore seems appropriate to conclude that the CCHRhm rule has the best evidence to support its use. (C) 2011 Elsevier Ltd. All rights reserved.	[Holmes, M. W.; Goodacre, S.; Stevenson, M. D.; Pandor, A.; Pickering, A.] Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England		Holmes, MW (corresponding author), Univ Sheffield, Sch Hlth & Related Res, 30 Regent St, Sheffield S1 4DA, S Yorkshire, England.	m.w.holmes@shef.ac.uk	Pandor, Abdullah/E-4643-2010	Pandor, Abdullah/0000-0003-2552-5260	National Institute for Health ResearchNational Institute for Health Research (NIHR) [07/37/08] Funding Source: researchfish; Department of HealthEuropean Commission [07/37/08, HTA/07/37/08] Funding Source: Medline		af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; Beecham J, 2009, BRAIN INJURY, V23, P30, DOI 10.1080/02699050802590338; CANTOR SB, 1994, MED DECIS MAKING, V14, P259, DOI 10.1177/0272989X9401400308; Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985; Curtis L, 2009, UNIT COSTS HLTH SOCI; Department of Health, 2010, NAT SCHED REF COSTS; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; Garside R, 2007, HEALTH TECHNOL ASSES, V11, P1; Goodacre S, 2008, EMERG MED J, V25, P556, DOI 10.1136/emj.2007.055723; Harnan SE, 2011, J TRAUMA, V71, P245, DOI 10.1097/TA.0b013e31820d090f; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Multi -Society Task Force on PVS, 1995, NEW ENGL J MED, V333, P130; National Health Service, HLTH RES GROUP VERS; National Institute for Health and Care Excellence (NICE), 2008, GUID METH TECHN APPR; National Radiological Protection Board (NRPB), 2001, XRAYS SAF AR THEY; NICE, 2007, HEAD INJ TRIAG ASS I; Office for National Statistics (ONS), 2008, UK INT LIF TABL 1980; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stein SC, 2008, PEDIATR NEUROSURG, V44, P448, DOI 10.1159/000172967; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Swann I, 1999, TRAUMA, V1, P143	30	26	27	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2012	43	9					1423	1431		10.1016/j.injury.2011.07.017			9	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	977MK	WOS:000306666100016	21835403				2022-02-06	
J	Alessandri, B; Schwandt, E; Kamada, Y; Nagata, M; Heimann, A; Kempski, O				Alessandri, Beat; Schwandt, Eike; Kamada, Yoshitaka; Nagata, Momoko; Heimann, Axel; Kempski, Oliver			The Neuroprotective Effect of Lactate Is Not Due to Improved Glutamate Uptake after Controlled Cortical Impact in Rats	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; lactic acid; neuroprotection; rat	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; HIPPOCAMPAL SLICE PREPARATION; SMALL-VOLUME RESUSCITATION; HUMAN HEAD-INJURY; IN-VITRO; EXTRACELLULAR LACTATE; NEUROLOGICAL STATUS; COGNITIVE DEFICITS; 5-PERCENT DEXTROSE	For many years lactate was considered to be a waste product of glycolysis. Data are accumulating that suggest that lactate is an important energy substrate for neurons during activation. In severe traumatic brain injury (TBI) glutamate release and ischemic cerebral blood flow (CBF) are major factors for a mismatch between energy demand and supply and for neuronal cell death. Although ATP and behavior could be improved by lactate treatment after TBI, no histological correlate nor any linkage to better astrocytic glutamate uptake or CBF as possible mechanisms have been described. We subjected male rats to a controlled cortical impact (CCI; 5 m/sec, 2.5 mm). To study the effects of lactate treatment on lesion volume, glutamate release, and CBF, animals were infused with either NaCl or 100 mM lactate for up to 3 h. The role of endogenous lactate was investigated by inhibiting transport with alpha-cyano-4-hydroxy-cinnamic acid (4-CIN; 90 mg/kg). Lactate treatment 15 min post-CCI reduced lesion volume from 21.1 +/- 2.8 mm(3) to 12.1 +/- 1.9 mm(3) at day 2 after CCI. Contusion produced a significant three- to fourfold increase of glutamate in microdialysates, but there was no significant difference between treatments that began 30 min before CCI. In this experiment lesion volume was significantly reduced by lactate at day 7 post-CCI (23.7 +/- 4 to 9.3 +/- 1-2 mm(3)). CBF increased immediately after CCI and dropped thereafter below baseline in all animals. Lactate infusion 15 min post-CCI elevated CBF for 20 min in 7 of 10 animals, whereas 7 of 8 NaCl-treated animals showed a further CBF decline. Neuroprotection was achieved by lactate treatment following contusion injury, whereas blocking of endogenous lactate transport exerted no adverse effects. Neuroprotection was not achieved by improved glutamate uptake into astrocytes, but was supported by augmented CBF following CCI. Due to its neuroprotective property, lactate might be a beneficial pharmacological treatment for TBI patients.	[Alessandri, Beat; Schwandt, Eike; Kamada, Yoshitaka; Nagata, Momoko; Heimann, Axel; Kempski, Oliver] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Neurosurg Pathophysiol, D-55101 Mainz, Germany		Alessandri, B (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Neurosurg Pathophysiol, Langenbeckstr 1, D-55101 Mainz, Germany.	beat.alessandri@unimedizin-mainz.de		Heimann, Axel/0000-0003-2510-3228			Alessandri B, 2006, BRAIN RES, V1111, P196, DOI 10.1016/j.brainres.2006.06.105; Alessandri B, 1998, PROG BRAIN RES, V116, P303, DOI 10.1016/S0079-6123(08)60445-8; Alessandri B, 2009, FUTUR NEUROL, V4, P209, DOI 10.2217/14796708.4.2.209; Bermueller C, 2006, J NEUROL SCI, V241, P73, DOI 10.1016/j.jns.2005.10.016; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Erlichman JS, 2008, J NEUROSCI, V28, P4888, DOI 10.1523/JNEUROSCI.5430-07.2008; FELDMAN Z, 1995, J NEUROSURG, V83, P1060, DOI 10.3171/jns.1995.83.6.1060; FELLOWS LK, 1993, J NEUROCHEM, V60, P1258, DOI 10.1111/j.1471-4159.1993.tb03285.x; Fray AE, 1996, J PHYSIOL-LONDON, V496, P49, DOI 10.1113/jphysiol.1996.sp021664; Friedrich DH, 2000, ACTA NEUROCHIR SUPPL, V76, P257; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Groussard C, 2000, J APPL PHYSIOL, V89, P169, DOI 10.1152/jappl.2000.89.1.169; Gurevich B, 1997, ANESTH ANALG, V84, P554, DOI 10.1097/00000539-199703000-00016; Hashimoto T, 2008, MED SCI SPORT EXER, V40, P486, DOI [10.1249/mss.0b013e31815fcb04, 10.1249/MSS.0b013e31815fcb04]; Hill J, 2010, J NEUROTRAUM, V27, P1439, DOI 10.1089/neu.2010.1328; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hu YB, 1997, J NEUROCHEM, V69, P1484; Ido Y, 2004, P NATL ACAD SCI USA, V101, P653, DOI 10.1073/pnas.0307458100; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1998, ACT NEUR S, V71, P114; Larrabee MG, 1996, J NEUROCHEM, V67, P1726; LARRABEE MG, 1995, J NEUROCHEM, V64, P1734; Laughton JD, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-35; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Lin JY, 2002, LIFE SCI, V71, P803, DOI 10.1016/S0024-3205(02)01738-1; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Meierhans R, 2012, MINERVA ANESTESIOL, V78, P185; Melena J, 2003, BRAIN RES, V989, P128, DOI 10.1016/S0006-8993(03)03375-4; Melo JRT, 2010, ACTA NEUROCHIR, V152, P1559, DOI 10.1007/s00701-010-0680-z; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Mintun MA, 2004, P NATL ACAD SCI USA, V101, P659, DOI 10.1073/pnas.0307457100; O'Brien J, 2007, NEUROCHEM RES, V32, P597, DOI 10.1007/s11064-006-9132-9; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pecha T, 2011, ANESTH ANALG, V113, P336, DOI 10.1213/ANE.0b013e31821d3dde; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; SCHURR A, 1989, J NEUROSCI METH, V28, P7, DOI 10.1016/0165-0270(89)90004-6; Schurr A, 2001, BRAIN RES, V895, P268, DOI 10.1016/S0006-8993(01)02082-0; Schurr A, 1997, J NEUROCHEM, V69, P423; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Serres S, 2003, NMR BIOMED, V16, P430, DOI 10.1002/nbm.838; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; Soehle M, 2000, ACTA NEUROCHIR SUPPL, V76, P181; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Stover JF, 2002, INTENS CARE MED, V28, P1491, DOI 10.1007/s00134-002-1431-2; Stover JF, 1997, EUR J CLIN INVEST, V27, P1038, DOI 10.1046/j.1365-2362.1997.2250774.x; Thomale UW, 2004, J NEUROTRAUM, V21, P1737; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435	66	26	27	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2181	2191		10.1089/neu.2011.2067			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900006	22888957				2022-02-06	
J	Veremeyko, T; Starossom, SC; Weiner, HL; Ponomarev, ED				Veremeyko, Tatiana; Starossom, Sarah-Christine; Weiner, Howard L.; Ponomarev, Eugene D.			Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Immunology; Issue 65; Neuroscience; Genetics; microglia; macrophages; microRNA; brain; mouse; real-time PCR; neuroinflammation	MACROPHAGES	Microglia are cells of the myeloid lineage that reside in the central nervous system (CNS) (1). These cells play an important role in pathologies of many diseases associated with neuroinflammation such as multiple sclerosis (MS) (2). Microglia in a normal CNS express macrophage marker CD11b and exhibit a resting phenotype by expressing low levels of activation markers such as CD45. During pathological events in the CNS, microglia become activated as determined by upregulation of CD45 and other markers3. The factors that affect microglia phenotype and functions in the CNS are not well studied. MicroRNAs (miRNAs) are a growing family of conserved molecules(similar to 22 nucleotides long) that are involved in many normal physiological processes such as cell growth and differentiation(4) and pathologies such as inflammation(5). MiRNAs downregulate the expression of certain target genes by binding complementary sequences of their mRNAs and play an important role in the activation of innate immune cells including macrophages(6) and microglia(7). In order to investigate miRNA-mediated pathways that define the microglial phenotype, biological function, and to distinguish microglia from other types of macrophages, it is important to quantitatively assess the expression of particular microRNAs in distinct subsets of CNS-resident microglia. Common methods for measuring the expression of miRNAs in the CNS include quantitative PCR from whole neuronal tissue and in situ hybridization. However, quantitative PCR from whole tissue homogenate does not allow the assessment of the expression of miRNA in microglia, which represent only 5-15% of the cells of neuronal tissue. Hybridization in situ allows the assessment of the expression of microRNA in specific cell types in the tissue sections, but this method is not entirely quantitative. In this report we describe a quantitative and sensitive method for the detection of miRNA by real-time PCR in microglia isolated from normal CNS or during neuroinflammation using experimental autoimmune encephalomyelitis (EAE), a mouse model for MS. The described method will be useful to measure the level of expression of microRNAs in microglia in normal CNS or during neuroinflammation associated with various pathologies including MS, stroke, traumatic injury, Alzheimer's disease and brain tumors.	[Veremeyko, Tatiana; Starossom, Sarah-Christine; Weiner, Howard L.; Ponomarev, Eugene D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02138 USA		Ponomarev, ED (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02138 USA.	eponomarev@rics.bwh.harvard.edu	Ponomarev, Eugene D./K-1546-2013	Ponomarev, Eugene D./0000-0002-0871-8522; Starossom, Sarah/0000-0001-7935-9910	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS071039-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071039] Funding Source: NIH RePORTER	The work was supported by the NIH R01 NS071039-01A1 research grant.	Basu Sreemanti, 2010, J Vis Exp, DOI 10.3791/1546; Caffarelli E, 2011, FRONT BIOSCI-LANDMRK, V16, P2682, DOI 10.2741/3880; Cardona AE, 2006, NAT PROTOC, V1, P1947, DOI 10.1038/nprot.2006.327; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gordon R, 2011, J NEUROSCI METH, V194, P287, DOI 10.1016/j.jneumeth.2010.11.001; Graeber M.B., 2011, FEBS LETT; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; McCoy C.E., 2010, FRONT BIOSCI, V17, P2161; Moltzahn F, 2011, JOVE-J VIS EXP, DOI 10.3791/2552; Perruisseau-Carrier C, 2011, MOL NEUROBIOL, V43, P215, DOI 10.1007/s12035-011-8179-z; Ponomarev ED, 2005, J NEUROSCI RES, V81, P374, DOI 10.1002/jnr.20488; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011	13	26	26	1	4	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	JUL	2012		65							e4097	10.3791/4097			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V36PJ	WOS:000209223200038	22872097	Green Published			2022-02-06	
J	Spaethling, J; Le, L; Meaney, DF				Spaethling, Jennifer; Le, Linda; Meaney, David F.			NMDA receptor mediated phosphorylation of GluR1 subunits contributes to the appearance of calcium-permeable AMPA receptors after mechanical stretch injury	NEUROBIOLOGY OF DISEASE			English	Article						Calcium permeable AMPA receptor; Traumatic brain injury; Glutamate receptor phosphorylation; Intracellular signaling; Synaptic NMDAR; Extrasynaptic NDMAR	GLUTAMATE RECEPTORS; EXCITATORY SYNAPSES; SYNAPTIC PLASTICITY; TRAUMATIC INJURY; NITRIC-OXIDE; IN-VITRO; BRAIN; HIPPOCAMPUS; ACTIVATION; NEURONS	Alterations in neuronal cytosolic calcium is a key mediator of the traumatic brain injury (TBI) pathobiology, but less is known of the role and source of calcium in shaping early changes in synaptic receptors and neural circuits after TBI. In this study, we examined the calcium source and potential phosphorylation events leading to insertion of calcium-permeable AMPARs (CP-AMPARs) after in vitro traumatic brain injury, a receptor subtype that influences neural circuit dynamics for hours to days following injury. We found that both synaptic and NR2B-containing NMDARs contribute significantly to the calcium influx following stretch injury. Moreover, an early and sustained phosphorylation of the S-831 site of the GluR1 subunit appeared after mechanical injury, and this phosphorylation was blocked with the inhibition of either synaptic NMDARs or NR2B-containing NMDARs. In comparison, mechanical injury led to no significant change in the S-845 phosphorylation of the GluR1 subunit. Although no change in S-845 phosphorylation appeared in injured cultures, we observed that inhibition of NR2B-containing NMDARs significantly increased S-845 phosphorylation 1 h after injury while blockade of synaptic NMDARs did not change S-845 phosphorylation at any time point following injury. These findings show that a broad class of NMDARs are activated in parallel and that targeting either subpopulation will reverse some of the consequences of mechanical injury, providing distinct paths to treat the effects of mechanical injury on neural circuits after TBI. (C) 2012 Elsevier Inc. All rights reserved.	[Spaethling, Jennifer; Meaney, David F.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Le, Linda] Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Meaney, DF (corresponding author), Univ Penn, Dept Pharmacol, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu		Meaney, David/0000-0002-0954-4122	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [41699]; Commonwealth of Pennsylvania; NS [35712]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER	Funding was provided by: NICHD 41699, NS 35712, and from the Commonwealth of Pennsylvania.	Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bengtson CP, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-11; Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cheriyan J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016495; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Fu XZ, 2004, NEUROSCI RES, V48, P85, DOI 10.1016/j.neures.2003.09.009; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; GLAUM SR, 1990, P NATL ACAD SCI USA, V87, P3454, DOI 10.1073/pnas.87.9.3454; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Hall BJ, 2007, J NEUROSCI, V27, P13446, DOI 10.1523/JNEUROSCI.3793-07.2007; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; He KW, 2009, P NATL ACAD SCI USA, V106, P20033, DOI 10.1073/pnas.0910338106; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Jin SX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011732; Kumar SS, 2002, J NEUROSCI, V22, P3005, DOI 10.1523/JNEUROSCI.22-08-03005.2002; Lee HK, 2006, PHARMACOL THERAPEUT, V112, P810, DOI 10.1016/j.pharmthera.2006.06.003; Lin YC, 2002, J NEUROSCI RES, V67, P484, DOI 10.1002/jnr.10077; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Mauceri D, 2004, J BIOL CHEM, V279, P23813, DOI 10.1074/jbc.M402796200; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Nikandrova YA, 2010, J BIOL CHEM, V285, P923, DOI 10.1074/jbc.M109.033985; Oh MC, 2006, J BIOL CHEM, V281, P752, DOI 10.1074/jbc.M509677200; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Papadia S, 2007, NEUROSCIENTIST, V13, P572, DOI 10.1177/1073858407305833; PELLEGRINIGIAMPIETRO DE, 1991, P NATL ACAD SCI USA, V88, P4157, DOI 10.1073/pnas.88.10.4157; Rakhade SN, 2008, J NEUROSCI, V28, P7979, DOI 10.1523/JNEUROSCI.1734-08.2008; Rameau GA, 2007, J NEUROSCI, V27, P3445, DOI 10.1523/JNEUROSCI.4799-06.2007; Serulle Y, 2007, NEURON, V56, P670, DOI 10.1016/j.neuron.2007.09.016; Sheng M, 2007, ANNU REV BIOCHEM, V76, P823, DOI 10.1146/annurev.biochem.76.060805.160029; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Wang HS, 2007, J BIOL CHEM, V282, P1507, DOI 10.1074/jbc.M607291200; Wang HG, 2005, NEURON, V45, P389, DOI 10.1016/j.neuron.2005.01.011; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willoughby D, 2007, PHYSIOL REV, V87, P965, DOI 10.1152/physrev.00049.2006; Wojda U, 2008, IUBMB LIFE, V60, P575, DOI 10.1002/iub.91; Xu J, 2009, J NEUROSCI, V29, P9330, DOI 10.1523/JNEUROSCI.2212-09.2009; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	54	26	29	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2012	46	3					646	654		10.1016/j.nbd.2012.03.003			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	950DK	WOS:000304629300014	22426393	Green Accepted			2022-02-06	
J	Ziu, M; Savage, JG; Jimenez, DF				Ziu, Mateo; Savage, Jennifer Gentry; Jimenez, David F.			Diagnosis and treatment of cerebrospinal fluid rhinorrhea following accidental traumatic anterior skull base fractures	NEUROSURGICAL FOCUS			English	Article						craniomaxillofacial trauma; head trauma; cerebrospinal fluid rhinorrhea; meningitis; dural repair; endoscopic surgery; skull base fracture	BETA-TRACE-PROTEIN; TRANSNASAL ENDOSCOPIC REPAIR; MAGNETIC-RESONANCE CISTERNOGRAPHY; PROSTAGLANDIN-D SYNTHASE; ANTIBIOTIC-PROPHYLAXIS; MR CISTERNOGRAPHY; GADOPENTETATE DIMEGLUMINE; INTRATHECAL FLUORESCEIN; BACTERIAL-MENINGITIS; CSF RHINORRHEA	Cerebrospinal fluid rhinorrhea is a serious and potentially fatal condition because of an increased risk of meningitis and brain abscess. Approximately 80% of all cases occur in patients with head injuries and craniofacial fractures. Despite technical advances in the diagnosis and management of CSF rhinorrhea caused by craniofacial injury through the introduction of MRI and endoscopic extracranial surgical approaches, difficulties remain. The authors review here the pathophysiology, diagnosis, and management of CSF rhinorrhea relevant exclusively to traumatic anterior skull base injuries and attempt to identify areas in which further work is needed. (http://thejns.org/doi/abs/10.3171/2012.4.FOCUS1244)	[Ziu, Mateo; Savage, Jennifer Gentry; Jimenez, David F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, San Antonio, TX 78229 USA		Ziu, M (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, 7703 Floyd Curl Dr,MC 7843, San Antonio, TX 78229 USA.	ziu@uthscsa.edu	Ziu, Mateo/AAR-4991-2020	Ziu, Mateo/0000-0002-3671-2638			Anand Vijay K., 1995, Rhinology (Utrecht), V33, P212; [Anonymous], 2001, J TRAUMA, V51, pS29; [Anonymous], 1942, Proc R Soc Med, V35, P805; Araujo Filho Bernardo Cunha, 2005, Braz J Otorhinolaryngol, V71, P472; Arrer E, 2002, CLIN CHEM, V48, P939; Aydin K, 2004, NEURORADIOLOGY, V46, P75, DOI 10.1007/s00234-003-1004-2; Aydin K, 2008, NEUROSURGERY, V62, P584, DOI 10.1227/01.neu.0000317306.39203.24; Bachmann G, 2002, NEUROSURGERY, V50, P571, DOI 10.1097/00006123-200203000-00027; Bachmann G, 2000, ANN OTO RHINOL LARYN, V109, P1099, DOI 10.1177/000348940010901202; Banks CA, 2009, OTOLARYNG HEAD NECK, V140, P826, DOI 10.1016/j.otohns.2008.12.060; Bell RB, 2004, J ORAL MAXIL SURG, V62, P676, DOI 10.1016/j.joms.2003.08.032; Bernal-Sprekelsen M, 2005, RHINOLOGY, V43, P277; Bhalodiya NH, 2009, INDIAN J OTOLARYNGOL, V61, P120, DOI 10.1007/s12070-009-0049-x; Bibas AG, 2000, BRIT J NEUROSURG, V14, P49; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Briggs RJS, 2004, J CLIN NEUROSCI, V11, P597, DOI 10.1016/j.jocn.2003.09.011; Brodie HA, 1997, AM J OTOL, V18, P188; BROWN EM, 1994, LANCET, V344, P1547; BULLOCK R, 1990, BRIT MED J, V300, P1576, DOI 10.1136/bmj.300.6739.1576; Burns JA, 1996, LARYNGOSCOPE, V106, P1080, DOI 10.1097/00005537-199609000-00007; Cairns H., 1937, J LARYNG, V52, P589, DOI 10.1017/S0022215100043991; Campbell EH, 1928, ANN OTO RHINOL LARYN, V37, P865; Casiano RR, 1999, OTOLARYNG HEAD NECK, V121, P745, DOI 10.1053/hn.1999.v121.a98754; Cassano M, 2009, RHINOLOGY, V47, P362, DOI 10.4193/Rhin08.175; Castelnuovo P, 2001, AM J RHINOL, V15, P333, DOI 10.1177/194589240101500509; Castillo L., 1999, Rhinology (Utrecht), V37, P33; Chin GY, 2003, LARYNGOSCOPE, V113, P136, DOI 10.1097/00005537-200301000-00025; Choi D, 1996, BRIT J NEUROSURG, V10, P571, DOI 10.1080/02688699646880; Cukurova I, 2008, ACTA NEUROCHIR, V150, P897, DOI 10.1007/s00701-008-0005-7; Dagi FT, 2006, SCHMIDEK SWEET OPERA, V1, P130; Dalgic A, 2007, J NEUROL SCI, V24, P280; Dandy WE, 1926, ARCH SURG-CHICAGO, V12, P949, DOI 10.1001/archsurg.1926.01130050003001; Dandy WE, 1944, ARCH SURG-CHICAGO, V49, P75, DOI 10.1001/archsurg.1944.01230020080001; Darakchiev Borimir J, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P404, DOI 10.1097/01.moo.0000134442.22229.2c; DICHIRO G, 1985, RADIOLOGY, V157, P373, DOI 10.1148/radiology.157.2.4048444; DODSON EE, 1994, OTOLARYNG HEAD NECK, V111, P600, DOI 10.1016/S0194-5998(94)70527-5; DOHLMAN G, 1948, Acta Otolaryngol Suppl, V67, P20; Eftekhar B, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-2; El Gammal T, 1998, AM J NEURORADIOL, V19, P627; ELGAMMAL T, 1994, AM J NEURORADIOL, V15, P1647; ELJAMEL M S, 1990, British Journal of Neurosurgery, V4, P381, DOI 10.3109/02688699008992759; ELJAMEL M S M, 1990, British Journal of Neurosurgery, V4, P479, DOI 10.3109/02688699008993796; Eljamel MS, 1998, SURG NEUROL, V50, P387; ELJAMEL MS, 1994, BRIT J NEUROSURG, V8, P433, DOI 10.3109/02688699408995111; ELJAMEL MS, 1993, BRIT J NEUROSURG, V7, P501, DOI 10.3109/02688699308995072; FELGENHAUER K, 1987, KLIN WOCHENSCHR, V65, P764, DOI 10.1007/BF01743251; Friedman JA, 2001, WORLD J SURG, V25, P1062, DOI 10.1007/s00268-001-0059-7; Gendeh BS, 2005, J LARYNGOL OTOL, V119, P866, DOI 10.1258/002221505774783421; Goel G, 2007, J NEUROTRAUM, V24, P1570, DOI 10.1089/neu.2007.0326; Greig JR, 2002, BRIT MED J, V325, P1037; HAND WL, 1970, ANN INTERN MED, V73, P862, DOI 10.7326/0003-4819-73-5-862; Hao SP, 1996, LARYNGOSCOPE, V106, P501; HEALY CE, 1969, CLIN PEDIATR, V8, P239, DOI 10.1177/000992286900800413; Hegazy HM, 2000, LARYNGOSCOPE, V110, P1166, DOI 10.1097/00005537-200007000-00019; HIRSCH O, 1952, AMA ARCH OTOLARYNGOL, V56, P1; Hughes RGM, 1997, J LARYNGOL OTOL, V111, P125, DOI 10.1017/S0022215100136643; Husain M, 2003, SKULL BASE-INTERD AP, V13, P73; Keerl R, 2004, LARYNGOSCOPE, V114, P266, DOI 10.1097/00005537-200402000-00016; Kerr JT, 2005, OTOLARYNG CLIN N AM, V38, P597, DOI 10.1016/j.otc.2005.03.011; KIRSCH AP, 1967, J PEDIATR-US, V71, P718, DOI 10.1016/S0022-3476(67)80210-5; Kirtane MV, 2005, OTOLARYNG HEAD NECK, V132, P208, DOI 10.1016/j.otohns.2004.09.004; Klotch D W, 1998, J Craniomaxillofac Trauma, V4, P30; KOSOY J, 1972, ARCHIV OTOLARYNGOL, V95, P255; Landeiro JA, 2004, MINIM INVAS NEUROSUR, V47, P173, DOI 10.1055/s-2004-818451; Lanza DC, 1996, LARYNGOSCOPE, V106, P1119, DOI 10.1097/00005537-199609000-00015; LAUN A, 1982, ACTA NEUROCHIR, V60, P215, DOI 10.1007/BF01406308; Lee TJ, 2004, LARYNGOSCOPE, V114, P1475, DOI 10.1097/00005537-200408000-00029; LEECH PJ, 1973, LANCET, V1, P1013; Lewin W, 1964, Clin Neurosurg, V12, P237; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; Lindstrom DR, 2004, LARYNGOSCOPE, V114, P969, DOI 10.1097/00005537-200406000-00003; Locatelli D, 2006, NEUROSURGERY, V58, P246, DOI 10.1227/01.NEU.0000193924.65297.3F; Luckett WH, 1913, SURG GYNECOL OBSTET, V17, P237; Lund VJ, 2002, AM J RHINOL, V16, P17, DOI 10.1177/194589240201600104; Lund VJ, 2000, J LARYNGOL OTOL, V114, P988; Madhusudan G, 2006, PLAST RECONSTR SURG, V117, P2382, DOI 10.1097/01.prs.0000218794.28670.07; Mao VH, 2000, OTOLARYNG HEAD NECK, V122, P56, DOI 10.1016/S0194-5998(00)70144-6; Marks SC, 1998, AM J RHINOL, V12, P417, DOI 10.2500/105065898780707900; Marshall AH, 2001, BRIT J NEUROSURG, V15, P8; Martin Timothy J, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P35, DOI 10.1097/MOO.0b013e3280123fce; MATTOX DE, 1990, LARYNGOSCOPE, V100, P857; McMains KC, 2004, LARYNGOSCOPE, V114, P1833, DOI 10.1097/00005537-200410000-00029; Meco C, 2004, LARYNGOSCOPE, V114, P991, DOI 10.1097/00005537-200406000-00007; Meco C, 2003, OTOLARYNG HEAD NECK, V129, P508, DOI 10.1016/S0194-5998(03)01448-7; Meco C, 2007, AM J RHINOL, V21, P729, DOI 10.2500/ajr.2007.21.3105; Melegos DN, 1996, CLIN CHEM, V42, P1984; MEURMAN OH, 1979, ACTA OTO-LARYNGOL, V87, P366, DOI 10.3109/00016487909126434; MINCY JE, 1966, J TRAUM, V6, P618, DOI 10.1097/00005373-196609000-00007; MOSELEY JI, 1978, J NEUROSURG, V48, P765, DOI 10.3171/jns.1978.48.5.0765; Nachtigal D, 1999, J OTOLARYNGOL, V28, P129; OMMAYA AK, 1964, NEUROLOGY, V14, P106, DOI 10.1212/WNL.14.2.106; PAPPAS DG, 1993, CLIN INFECT DIS, V17, P364, DOI 10.1093/clinids/17.3.364; Presutti L, 2009, ACTA OTORHINOLARYNGO, V29, P191; PRICE DJE, 1970, LANCET, V2, P1213; Ratilal B, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004884.pub2; Ray DE, 1998, AM J NEURORADIOL, V19, P1455; Ray DE, 1996, AM J NEURORADIOL, V17, P365; Reiber H, 2003, ACTA NEUROL SCAND, V108, P359, DOI 10.1034/j.1600-0404.2003.00173.x; Rocchi G, 2005, SURG NEUROL, V63, P559, DOI 10.1016/j.surneu.2004.07.047; Sakas DE, 1998, J NEUROSURG, V88, P471, DOI 10.3171/jns.1998.88.3.0471; Schick B, 1997, SKULL BASE SURG, V7, P77, DOI 10.1055/s-2008-1058612; Schlosser RJ, 2004, LARYNGOSCOPE, V114, P255, DOI 10.1097/00005537-200402000-00015; Schnabel C, 2004, CLIN CHEM, V50, P661, DOI 10.1373/clinchem.2003.024158; Scholsem M, 2008, NEUROSURGERY, V62, P463, DOI [10.1227/01.NEU.0000297037.51609.07, 10.1227/01.neu.0000316014.97926.82, 10.1227/01.neu.0000325884.05871.aa]; Schroeder MC, 1944, ARCH OTOLARYNGOL, V40, P206; Senior BA, 2001, AM J RHINOL, V15, P15, DOI 10.2500/105065801781329428; Sethi D. S., 1996, Annals Academy of Medicine Singapore, V25, P724; Silva LRF, 2006, MINIM INVAS NEUROSUR, V49, P88, DOI 10.1055/s-2006-932188; Tali ET, 2002, INVEST RADIOL, V37, P152; TOS M, 1973, ACTA OTO-LARYNGOL, V75, P353, DOI 10.3109/00016487309139745; Tosun F, 2005, MINIM INVAS NEUROSUR, V48, P355, DOI 10.1055/s-2005-915636; Tumani H, 1998, ANN NEUROL, V44, P882, DOI 10.1002/ana.410440606; Tumani H, 1998, NEUROSCI LETT, V242, P5, DOI 10.1016/S0304-3940(98)00021-4; VRABEC DP, 1964, ARCHIV OTOLARYNGOL, V80, P218, DOI 10.1001/archotol.80.2.218; Warnecke A, 2004, ARCH OTOLARYNGOL, V130, P1178, DOI 10.1001/archotol.130.10.1178; WIGAND M E, 1981, Rhinology (Utrecht), V19, P7; Wolf G, 1997, LARYNGO RHINO OTOL, V76, P588; Yilmazlar S, 2006, NEUROSURG REV, V29, P64, DOI 10.1007/s10143-005-0396-3; Zapalac JS, 2002, OTOLARYNG HEAD NECK, V126, P669, DOI 10.1067/mhn.2002.125755; Zeng QY, 1999, AM J ROENTGENOL, V173, P1109, DOI 10.2214/ajr.173.4.10511188; Zweig JL, 2000, OTOLARYNG HEAD NECK, V123, P195, DOI 10.1067/mhn.2000.107452	122	26	28	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	JUN	2012	32	6							E3	10.3171/2012.4.FOCUS1244			17	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	954DQ	WOS:000304927100005	22655692				2022-02-06	
J	Bartsch, AJ; Benzel, EC; Miele, VJ; Morr, DR; Prakash, V				Bartsch, Adam J.; Benzel, Edward C.; Miele, Vincent J.; Morr, Douglas R.; Prakash, Vikas			Boxing and mixed martial arts: preliminary traumatic neuromechanical injury risk analyses from laboratory impact dosage data	JOURNAL OF NEUROSURGERY			English	Article						concussion; traumatic brain injury; boxing; mixed martial arts; injury risk; severity index; rotation	PROFESSIONAL FOOTBALL; SOCCER HEADGEAR; BRAIN-INJURY; GAME IMPACTS; CONCUSSION; PERFORMANCE; HELMETS; RECONSTRUCTION; ACCELERATION; BIOMECHANICS	Object. In spite of ample literature pointing to rotational and combined impact dosage being key contributors to head and neck injury, boxing and mixed martial arts (MMA) padding is still designed to primarily reduce cranium linear acceleration. The objects of this study were to quantify preliminary linear and rotational head impact dosage for selected boxing and MMA padding in response to hook punches; compute theoretical skull, brain, and neck injury risk metrics; and statistically compare the protective effect of various glove and head padding conditions. Methods. An instrumented Hybrid III 50th percentile anthropomorphic test device (ATD) was struck in 54 pendulum impacts replicating hook punches at low (27-29 J) and high (54-58 J) energy. Five padding combinations were examined: unpadded (control), MMA glove-unpadded head, boxing glove unpadded head, unpadded pendulum-boxing headgear, and boxing glove-boxing headgear. A total of 17 injury risk parameters were measured or calculated. Results. All padding conditions reduced linear impact dosage. Other parameters significantly decreased, significantly increased, or were unaffected depending on padding condition. Of real-world conditions (MMA glove-bare head, boxing glove-bare head, and boxing glove-headgear), the boxing glove-headgear condition showed the most meaningful reduction in most of the parameters. In equivalent impacts, the MMA glove-bare head condition induced higher rotational dosage than the boxing glove-bare head condition. Finite element analysis indicated a risk of brain strain injury in spite of significant reduction of linear impact dosage. Conclusions. In the replicated hook punch impacts, all padding conditions reduced linear but not rotational impact dosage. Head and neck dosage theoretically accumulates fastest in MMA and boxing bouts without use of protective headgear. The boxing glove-headgear condition provided the best overall reduction in impact dosage. More work is needed to develop improved protective padding to minimize linear and rotational impact dosage and develop next-generation standards for head and neck injury risk. (http://thejns.org/doi/abs/10.3171/2011.12.JNS111478)	[Bartsch, Adam J.; Benzel, Edward C.] Cleveland Clin, Spine Res Lab, Cleveland, OH 44113 USA; [Benzel, Edward C.; Miele, Vincent J.] Cleveland Clin, Dept Neurol Surg, Neurol Inst, Cleveland, OH 44113 USA; [Bartsch, Adam J.; Benzel, Edward C.; Prakash, Vikas] Case Western Reserve Univ, Cleveland Traumat Neuromech Consortium, Cleveland, OH 44106 USA; [Prakash, Vikas] Case Western Reserve Univ, Dept Mech Engn, Cleveland, OH 44106 USA; [Morr, Douglas R.] Sci Expert Anal SEA Ltd, Columbus, OH USA; [Miele, Vincent J.] United Hosp Ctr Neurosurg & Spine Ctr, Clarksburg, WV USA		Bartsch, AJ (corresponding author), Cleveland Clin, Spine Res Lab, Luth2-C,1730 W 25th St, Cleveland, OH 44113 USA.	bartsca@ccf.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AR050959]; Cleveland Clinic Center for Spine Health; Ohio Third Frontier; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [T32AR050959] Funding Source: NIH RePORTER	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. They acknowledge assistance for the study from the National Institutes of Health Ruth L. Kirchstein T32 Training Grant AR050959, Cleveland Clinic Center for Spine Health, and Ohio Third Frontier. SEA, Ltd. provided use of the testing facility, impactor, instrumentation, data acquisition equipment, and Hybrid III ATD.	American Society for Testing and Materials, 2002, STAND TEST METH EQ P; Bandak FA, SIMON SIMULATED INJU; Broglio SP, 2003, J ATHL TRAINING, V38, P220; Casson IR, 2009, PHYS MED REH CLIN N, V20, P195, DOI 10.1016/j.pmr.2008.10.006; Caswell SV, 2002, J ATHL TRAINING, V37, P164; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Finan JD, 2008, TRAFFIC INJ PREV, V9, P483, DOI 10.1080/15389580802272427; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Gadd CW, 1966, P 10 STAPP CAR CRASH, V10, P164; Gilchrist A, 1996, ACCIDENT ANAL PREV, V28, P525, DOI 10.1016/0001-4575(96)00030-9; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hrysomallis C, 2004, J SCI MED SPORT, V7, P156, DOI 10.1016/S1440-2440(04)80005-7; Knouse CL, 2003, J ATHL TRAINING, V38, P330; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; McElhaney James H, 2005, Stapp Car Crash J, V49, pv; McIntosh A, 2004, BRIT J SPORT MED, V38, P46, DOI 10.1136/bjsm.2002.003103; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Newman JA, PROPOSED NEW BIOMECH; NOCSAE, STAND TEST METH EQ U; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; SAE (Society of Automotive Engineers), 1995, J2111 SAE; SMITH PK, 1986, J HUM MOVEMENT STUD, V12, P153; Smith TA, 1973, P INT RES COUNC BIOM, V1, P271; Snell Memorial Foundation, STAND PROT HEADG US; Society of Automotive Engineer (SAE), 1994, J1733 SAE; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Thibault LE, 1990, ANN PROC ASS ADV AUT, V34, P337; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	41	26	26	3	50	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2012	116	5					1070	1080		10.3171/2011.12.JNS111478			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	929TO	WOS:000303088800023	22313361				2022-02-06	
J	Ibrahim, NG; Wood, J; Margulies, SS; Christian, CW				Ibrahim, Nicole G.; Wood, Joanne; Margulies, Susan S.; Christian, Cindy W.			Influence of age and fall type on head injuries in infants and toddlers	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Falls; Brain injury; Mechanism; Age	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; POPULATION; MECHANISMS; HEIGHTS	Age-based differences in fall type and neuroanatomy in infants and toddlers may affect clinical presentations and injury patterns. Objective: Our goal is to understand the influence of fall type and age on injuries to help guide clinical evaluation. Design/Setting/Participants: Retrospectively, 285 children 0-48 months with accidental head injury from a fall and brain imaging between 2000 and 2006 were categorized by age (infan <= 1 year and toddler = 1-4 years) and fall type: low (<= 3 ft), intermediate (> 3 and < 10 ft), high height falls (>= 10 ft) and stair falls. Outcome Measures: Clinical manifestations were noted and head injuries separated into primary (bleeding) and secondary (hypoxia, edema). The influence of age and fall type on head injuries sustained was evaluated. Results: Injury patterns in children < 4 years varied with age. Despite similar injury severity scores, infants sustained more skull fractures than toddlers (71% vs. 39%). Of children with skull fractures, 11% had no evidence of scalp/facial soft tissue swelling. Of the patients with primary intracranial injury, 30% had no skull fracture and 8% had neither skull fracture nor cranial soft tissue injury. Low height falls resulted in primary intracranial injury without soft tissue or skull injury in infants (6%) and toddlers (16%). Conclusions: Within a given fall type, age-related differences in injuries exist between infants and toddlers. When interpreting a fall history, clinicians must consider the fall type and influence of age on resulting injury. For young children, intracranial injury is not always accompanied by external manifestations of their injury. (C) 2011 ISDN. Published by Elsevier Ltd. All rights reserved.	[Ibrahim, Nicole G.; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Wood, Joanne; Christian, Cindy W.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA		Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.	nicole.ibrahim@fda.hhs.gov; woodjo@email.chop.edu; margulie@seas.upenn.edu; Christian@email.chop.edu			NSF through the Center for Child Injury Prevention Studies (CChIPS); NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NIH RO1NS 39679]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER	We acknowledge Dr. Michael Nance for the use of the Trauma Registry Database at CHOP. This work was funded by NSF through the Center for Child Injury Prevention Studies (CChIPS) and NINDS (NIH RO1NS 39679).	Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; CDC, 2004, 21 CDC, V52; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; Chang LT, 2007, J TRAUMA, V63, P70, DOI 10.1097/01.ta.0000219142.15584.b8; CHIAVIELLO CT, 1994, PEDIATRICS, V94, P679; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Hennrikus WL, 2003, CLIN ORTHOP RELAT R, P148, DOI 10.1097/01.blo.0000043059.62337.97; Holsti M, 2005, PEDIATR EMERG CARE, V21, P639, DOI 10.1097/01.pec.0000181426.25342.a9; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Johnson K, 2005, CLIN RADIOL, V60, P464, DOI 10.1016/j.crad.2004.09.013; Kim K A, 2000, Neurosurg Focus, V8, pe3; Lallier M, 1999, J PEDIATR SURG, V34, P1060, DOI 10.1016/S0022-3468(99)90564-X; LEHMAN D, 1993, PEDIATRICS, V92, P121; Murray JA, 2000, AM SURGEON, V66, P863; Park SH, 2004, YONSEI MED J, V45, P229, DOI 10.3349/ymj.2004.45.2.229; Pickett W, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e365; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Spady DW, 2004, PEDIATRICS, V113, P522, DOI 10.1542/peds.113.3.522; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Wang MY, 2001, J PEDIATR SURG, V36, P1528, DOI 10.1053/jpsu.2001.27037	21	26	27	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		201	206		10.1016/j.ijdevneu.2011.10.007			6	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800005	22079853	Green Accepted, Green Published			2022-02-06	
J	Riera, A; Chen, L				Riera, Antonio; Chen, Lei			Ultrasound Evaluation of Skull Fractures in Children A Feasibility Study	PEDIATRIC EMERGENCY CARE			English	Article						ultrasound; head injuries; fractures; computed tomography	MINOR HEAD TRAUMA; BEDSIDE ULTRASOUND; INTRACRANIAL INJURY; X-RAY; DIAGNOSIS; ULTRASONOGRAPHY; INSTRUMENT; REDUCTION; RISK	Objective: The objective of this study was to investigate feasibility and evaluate test characteristics of bedside ultrasound for the detection of skull fractures in children with closed head injury (CHI). Methods: This was a prospective, observational study conducted in a pediatric emergency department of an urban tertiary care children's hospital. A convenience sample of children younger than 18 years were enrolled if they presented with an acute CHI, and a computed tomography (CT) scan was performed. Ultrasound was performed by pediatric emergency medicine physicians with at least 1 month of training in bedside ultrasound. Ultrasound interpretation as either positive or negative for the presence of skull fracture was compared with attending radiologist CT scan dictation. Test characteristics (sensitivity, specificity, and positive and negative predictive values) were calculated. Results: Forty-six patients were enrolled. The median age was 2 years (range, 2 months to 17 years). Eleven patients (24%) were diagnosed with skull fractures on CT scan. Bedside ultrasound had a sensitivity of 82% (95% confidence interval [CI], 48%-97%), specificity of 94% (95% CI, 79%-99%), positive predictive value of 82% (95% CI, 48%-97%), and negative predictive value of 94% (95% CI, 79%-99%). Conclusions: Bedside ultrasonography can be used by pediatric emergency medicine physicians to detect skull fractures in children with acute CHI. Larger studies are needed to validate these findings. Future studies should investigate the role of this modality as an adjunct to clinical decision rules to reduce unnecessary CT scans in the evaluation of acute CHI in children.	[Riera, Antonio; Chen, Lei] Yale Univ, Sch Med, New Haven, CT 06511 USA		Riera, A (corresponding author), Yale Univ, Sch Med, 100 York St,Suite 1F, New Haven, CT 06511 USA.	Antonio.riera@yale.edu			CTSAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS); National Center for Research Resources, National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2 RR024138]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024138] Funding Source: NIH RePORTER	This study was supported in part by CTSA, grant KL2 RR024138 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research.	Arnholz D, 1998, J TRAUMA, V45, P172, DOI 10.1097/00005373-199807000-00039; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brody AS, 2007, PEDIATRICS, V120, P677, DOI 10.1542/peds.2007-1910; Chen L, 2007, PEDIATR EMERG CARE, V23, P528, DOI 10.1097/PEC.0b013e318128f85d; Cho KH, 2010, KOREAN J RADIOL, V11, P84, DOI 10.3348/kjr.2010.11.1.84; CRADY SK, 1993, ANN EMERG MED, V22, P1125, DOI 10.1016/S0196-0644(05)80976-X; Cross KP, 2010, ACAD EMERG MED, V17, P687, DOI 10.1111/j.1553-2712.2010.00788.x; Decarie JC, 1999, CHILD NERV SYST, V15, P740, DOI 10.1007/s003810050463; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Levy JA, 2008, CURR OPIN PEDIATR, V20, P235, DOI 10.1097/MOP.0b013e3282ff1317; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Patel DD, 2009, PEDIATR EMERG CARE, V25, P221, DOI 10.1097/PEC.0b013e31819e34f7; Quayle KS, 1999, PEDIATR CLIN N AM, V46, P1189, DOI 10.1016/S0031-3955(05)70182-6; Quayle KS, 1999, PEDIATR CLIN N AM, V46, pvii; Ramirez-Schrempp D, 2011, PEDIATR EMERG CARE, V27, P312, DOI 10.1097/PEC.0b013e3182131579; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Steiner S, 1996, ROFO-FORTSCHR RONTG, V165, P353, DOI 10.1055/s-2007-1015768; Sun BC, 2007, ANN EMERG MED, V49, P325, DOI 10.1016/j.annemergmed.2006.08.032; Trenchs V, 2009, EUR J EMERG MED, V16, P150, DOI 10.1097/MEJ.0b013e328321b7b5; Weinberg ER, 2010, INJURY, V41, P862, DOI 10.1016/j.injury.2010.04.020	26	26	26	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	MAY	2012	28	5					420	425		10.1097/PEC.0b013e318252da3b			6	Emergency Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	937RT	WOS:000303676700004	22531195				2022-02-06	
J	Bornstein, N; Poon, WS				Bornstein, N.; Poon, W. S.			ACCELERATED RECOVERY FROM ACUTE BRAIN INJURIES: CLINICAL EFFICACY OF NEUROTROPHIC TREATMENT IN STROKE AND TRAUMATIC BRAIN INJURIES	DRUGS OF TODAY			English	Article							ACUTE ISCHEMIC-STROKE; ENHANCES FUNCTIONAL RECOVERY; RANDOMIZED CONTROLLED-TRIAL; FOCAL CEREBRAL INFARCTION; DOUBLE-BLIND; CEREBROLYSIN; RATS; MODERATE; IMMUNOREACTIVITY; THROMBOLYSIS	Stroke is one of the most devastating vascular diseases in the world as it is responsible for almost five million deaths per year. Almost 90% of all strokes are ischemic and mainly due to atherosclerosis, cardiac embolism and small-vessel disease. Intracerebral or subarachnoid hemorrhage can lead to hemorrhagic stroke, which usually has the poorest prognosis. Cerebrolysin is a peptide preparation which mimics the action of a neurotrophic factor, protecting stroke-injured neurons and promoting neuroplasticity and neuro genesis. Cerebrolysin has been widely studied as a therapeutic tool for both ischemic and hemorrhagic stroke, as well as traumatic brain injury. In ischemic stroke, Cerebrolysin given as an adjuvant therapy to antiplatelet and rheologically active medication resulted in accelerated improvement in global, neurological and motor functions, cognitive performance and activities of daily living. Cerebrolysin was also safe and well tolerated when administered in patients suffering from hemorrhagic stroke. Traumatic brain injury leads to transient or chronic impairments in physical, cognitive, emotional and behavioral functions. This is associated with deficits in the recognition of basic emotions, the capacity to interpret the mental states of others, and executive functioning. Pilot clinical studies with adjuvant Cerebrolysin in the acute and postacute phases of the injury have shown faster recovery, which translates into an earlier onset of rehabilitation and shortened hospitalization time.	[Bornstein, N.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurol, Tel Aviv Med Sch, IL-64239 Tel Aviv, Israel; [Poon, W. S.] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China		Bornstein, N (corresponding author), Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurol, Tel Aviv Med Sch, 6 Weizman St, IL-64239 Tel Aviv, Israel.	natanb@tasmc.health.gov.il	Poon, Wai Sang/F-1558-2011		EVER Neuro Pharma	The production of this supplement of Drugs of Today was sponsored by EVER Neuro Pharma, the manufacturer of Cerebrolysin. The authors have not received any payments for the writing of this article.	Abdelaziz O., 2007, PAN ARAB J NEUROSURG, V11, P51; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Alvarez XA, 2003, INT CLIN PSYCHOPHARM, V18, P271, DOI 10.1097/07.yic.0000085765.24936.9a; [Anonymous], 1993, INV HLTH; Alvarez XA, 2008, J NEURAL TRANSM, V115, P683, DOI 10.1007/s00702-008-0024-9; Bajenaru O, 2010, J Med Life, V3, P137; Bogousslavsky J, 1999, CEREBROVASC DIS, V9, P1; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Butcher K, 2003, STROKE, V34, P2159, DOI 10.1161/01.STR.0000086529.83878.A2; Clark WM, 2001, NEUROLOGY, V57, P1595, DOI 10.1212/WNL.57.9.1595; Conte V., 2003, EUR J TRAUMA, V7, P335; Daniels J.P., 2006, J FAM PRACTICE, V5, P5; Davis S, 2006, INT J CLIN PRACT, V60, P399, DOI 10.1111/j.1368-5031.2006.00873.x; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Feim Z., 1992, CHINESE J NERVOUS ME, V18, P6; Frey W., 2002, TREATMENT STROKE INT, P1; Golden Z, 2003, INT J NEUROSCI, V113, P733, DOI 10.1080/00207450390200044; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hacke W, 1999, NEUROLOGY, V53, pS3; Haffner Z, 2001, CEREBROVASC DIS, V11, P76; Haffner Z., 1999, 31 INT DAN S NEUR SC; Haninec P, 2004, EXP BRAIN RES, V159, P425, DOI 10.1007/s00221-004-1969-z; Hartbauer M, 2001, J NEURAL TRANSM, V108, P581, DOI 10.1007/s007020170058; He J, 2002, CHINESE J CLIN PRACT, V4, P71; Heiss WD, 2012, STROKE, V43, P630, DOI 10.1161/STROKEAHA.111.628537; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Herrschaft H., 1998, WIRKSAMKEIT CEREBROL; Hong Z, 2009, INT J STROKE, V4, P406, DOI 10.1111/j.1747-4949.2009.00340.x; Hong Z, 2005, CHINESE J GERIATRIC, V7, P331; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Konig P, 2006, J NEUROL NEUROCHIR P, V7, P12; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Ladurner G, 2005, J NEURAL TRANSM, V112, P415, DOI 10.1007/s00702-004-0248-2; Lang W., 2009, PROSPECTIVE RANDOMIZ; Lin SZ, 1999, STROKE, V30, P126, DOI 10.1161/01.STR.30.1.126; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Martinez Vila W., 2001, CEREBROVASC DIS, V11, P60; Maximova MY, 2009, ZH NEVROL PSIKHIATR, V109, P20; Muresanu D.F., 1999, CEREBROLYSIN THERAPE; Payne KA, 2002, PHARMACOECONOMICS, V20, P813, DOI 10.2165/00019053-200220120-00002; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Reinprecht I, 1999, HISTOCHEM J, V31, P394; Ren J, 2007, RESTOR NEUROL NEUROS, V25, P25; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Sacco RL, 2001, JAMA-J AM MED ASSOC, V285, P1719, DOI 10.1001/jama.285.13.1719; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; Shamalov NA, 2010, ZH NEVROL PSIKHIATR, V110, P34; Shi Y-M, 1990, CHINESE J NERVOUS ME, V16, P228; Skvortsova VI, 2004, ZH NEVROPATOL PSIKH, P51; SOSIN DM, 1991, BRAIN INJURY, V10, P47, DOI DOI 10.1080/026990596124719; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Windholz E, 2000, HISTOCHEM J, V32, P79, DOI 10.1023/A:1004053809591; Wong GKC, 2005, ACTA NEUROCHIR SUPPL, V95, P59; Zhang CL, 2010, J NEUROSCI RES, V88, P3275, DOI 10.1002/jnr.22495; Zhou D, 1993, ZHONG HUA CHUANG SHA, V9, P289	56	26	29	1	20	PROUS SCIENCE, SAU-THOMSON REUTERS	BARCELONA	398 PROVENCA, 08025 BARCELONA, SPAIN	1699-3993	1699-4019		DRUG TODAY	Drugs Today	APR	2012	48			A			43	61		10.1358/dot.2012.48(Suppl.A).1739723			19	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	959GW	WOS:000305301900004	22514794				2022-02-06	
J	Cha, SM; Shin, HD; Kim, KC; Han, SC				Cha, Soo Min; Shin, Hyun Dae; Kim, Kyung Cheon; Han, Sun Cheol			Percutaneous reduction and leverage fixation using K-wires in paediatric angulated radial neck fractures	INTERNATIONAL ORTHOPAEDICS			English	Article							CLOSED REDUCTION; CHILDREN; OSTEOSYNTHESIS; HEAD	We evaluated the usefulness of percutaneous reduction and leverage fixation using K-wires in children with radial neck fractures. Between 2006 and 2008, we evaluated 13 paediatric patients with radial neck fractures who had been observed for at least two years and underwent percutaneous reduction and leverage fixation using K-wires. We measured radial angulation and radial translation using preoperative, postoperative and final follow-up radiographs, and we clinically investigated range of motion and carrying angle according to Steele's grading system. Excellent clinical results were achieved in 11 (84.6%) patients, good results in one (7.6%) and fair results in one (7.6%). There were no poor results. The patient in whom fair results were achieved also had an olecranon fracture, which was treated conservatively. Complications such as nonunion, infection, iatrogenic nerve injury and periarticular ossification were minimal. Radioulnar synostosis was absent between the radial neck fracture and the greenstick fracture of the olecranon. Growth arrest in the proximal radial epiphysis was also absent. Percutaneous reduction and leverage fixation using K-wires in children with radial neck fractures is a recommended surgical treatment that can achieve recovery of normal radial angulation and elbow motion.	[Cha, Soo Min; Shin, Hyun Dae; Kim, Kyung Cheon; Han, Sun Cheol] Chungnam Natl Univ Hosp, Taejon, South Korea		Shin, HD (corresponding author), Chungnam Natl Univ Hosp, Taejon, South Korea.	csm9827@hanmail.net; hyunsd@cnu.ac.kr		Cha, Soo Min/0000-0003-1663-406X; Shin, Hyun Dae/0000-0003-4290-1125			Angelov A., 1981, 9 INT S TOP PROBL OR, P192; BERNSTEIN SM, 1993, J PEDIATR ORTHOPED, V13, P85, DOI 10.1097/01241398-199301000-00017; Eberl R, 2010, EUR J PEDIATR SURG, V20, P250, DOI 10.1055/s-0030-1249104; FERAY C, 1969, PRESSE MED, V77, P2155; GonzalezHerranz P, 1997, J PEDIATR ORTHOPED, V17, P325, DOI 10.1097/00004694-199705000-00011; JONES E R L, 1971, Journal of Bone and Joint Surgery British Volume, V53, P429; JUDET J, 1962, Ann Chir, V16, P1377; KAPANDJI A, 1987, Annales de Chirurgie de la Main, V6, P57, DOI 10.1016/S0753-9053(87)80011-X; KAUFMAN B, 1989, J BONE JOINT SURG BR, V71, P66, DOI 10.1302/0301-620X.71B1.2915009; Klitscher D, 2009, J PEDIATR ORTHOPED, V29, P698, DOI 10.1097/BPO.0b013e3181b76895; Metaizeau JP, 2005, INJURY, V36, pA75, DOI 10.1016/j.injury.2004.12.016; METAIZEAU JP, 1980, REV CHIR ORTHOP, V66, P47; METAIZEAU JP, 1993, J PEDIATR ORTHOPED, V13, P355, DOI 10.1097/01241398-199305000-00015; O'Brien P I, 1965, Clin Orthop Relat Res, V41, P51; PESUDO JV, 1982, CLIN ORTHOP RELAT R, P215; Schmittenbecher PP, 2005, J PEDIATR ORTHOPED, V25, P45; STEELE JA, 1992, J BONE JOINT SURG BR, V74, P760, DOI 10.1302/0301-620X.74B5.1527130; STEINBERG EL, 1988, J PEDIATR ORTHOPED, V8, P35, DOI 10.1097/01241398-198801000-00009; Tollet P, 1997, Acta Orthop Belg, V63, P245; Ugutmen E, 2010, J PEDIATR ORTHOP B, V19, P289, DOI 10.1097/BPB.0b013e32833918a0; Vocke AK, 1998, J PEDIATR ORTHOP B, V7, P217, DOI 10.1097/01202412-199807000-00007; [No title captured]	22	26	31	0	4	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0341-2695	1432-5195		INT ORTHOP	Int. Orthop.	APR	2012	36	4					803	809		10.1007/s00264-011-1387-3			7	Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics	917JP	WOS:000302171000018	22038445	Green Published			2022-02-06	
J	Gaur, V; Kumar, A				Gaur, Vaibhav; Kumar, Anil			Effect of nonselective and selective COX-2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury	DRUG AND CHEMICAL TOXICOLOGY			English	Article						Glutathione system; inflammation; memory; mitochondrial dysfunction; stroke	TRAUMATIC BRAIN-INJURY; MESSENGER-RNA; RAT-BRAIN; STROKE; INFLAMMATION; INVOLVEMENT; EXPRESSION; NEURONS; PATHOPHYSIOLOGY; HYPOPERFUSION	Involvement of the glutathione system is well established in stroke-induced memory dysfunction. The aim of the present study was to investigate the effects of celecoxib (a selective cyclooxygenase-2 [COX-2] inhibitor), nimesulide (a preferential COX-2 inhibitor), and ibuprofen (a nonselective COX-2 inhibitor) against bilateral common carotid artery occlusion (BCCAO)-induced memory dysfunction. BCCAO for 30 minutews, followed by 24-hour reperfusion, significantly delayed transfer latency in the plus-maze performance task and shortened fall-off time in the hanging-wire experimental test. Besides significant alterations in glutathione defense (i.e., glutathione S-transferase and redox ratio), increased acetylcholinesterase activity and proinflammatory marker (tumor necrosis factor alpha TNF-alpha) in the hippocampus was seen. Seven days of treatment with celecoxib (3 and 10 mg/kg, p.o.), nimesulide (10 mg/kg, p.o.), and ibuprofen (30 mg/kg, p.o.) significantly improved behavioral alterations and glutathione defense and attenuated acetylcholinesterase activity and TNF-alpha levels, as compared to the control (i.e., ischemic reperfusion) group. The present study highlights the neuroprotective effect of celecoxib and nimesulide against ischemia reperfusion injury-induced memory dysfunction, neuroinflammation, and oxidative damage.	[Gaur, Vaibhav; Kumar, Anil] Panjab Univ, Div Pharmacol, Univ Inst Pharmaceut Sci, UGC Ctr Adv Study, Chandigarh 160014, India		Kumar, A (corresponding author), Panjab Univ, Div Pharmacol, Univ Inst Pharmaceut Sci, UGC Ctr Adv Study, Chandigarh 160014, India.	kumaruips@yahoo.com	KUMAR, ANIL -/D-7471-2011; Gaur, Vaibhav/AAE-1706-2019	KUMAR, ANIL -/0000-0002-9506-6197; 	University Grant Commission (U.G.C.), New DelhiUniversity Grants Commission, India; U.G.C.University Grants Commission, India	The authors gratefully acknowledge the financial support of the University Grant Commission (U.G.C.), New Delhi, for carrying out this work. The Research Fellowship in Science for Meritorious Students (to V. G.) of the U.G.C. is gratefully acknowledged.	Aggarwal A, 2010, LIFE SCI, V86, P928, DOI 10.1016/j.lfs.2010.04.011; Aronowski J, 1999, J CEREBR BLOOD F MET, V19, P652, DOI 10.1097/00004647-199906000-00008; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Back T, 1998, CELL MOL NEUROBIOL, V18, P621, DOI 10.1023/A:1020265701407; Candelario-Jalil Eduardo, 2003, BMC Pharmacol, V3, P7, DOI 10.1186/1471-2210-3-7; Chen C, 2002, J NEUROPHYSIOL, V87, P2851, DOI 10.1152/jn.2002.87.6.2851; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; Cruz R, 2003, REV NEUROLOGIA, V36, P877, DOI 10.33588/rn.3609.2002395; Cruz-Aguado R, 2001, BRAIN RES BULL, V55, P327, DOI 10.1016/S0361-9230(01)00484-1; Degi R, 1998, Neurobiology (Bp), V6, P467; DeGraba TJ, 1998, NEUROLOGY, V51, pS62, DOI 10.1212/WNL.51.3_Suppl_3.S62; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; GARCIA JH, 1995, AM J PATHOL, V147, P1477; Gaur Vaibhav, 2011, Inflammopharmacology, V19, P205, DOI 10.1007/s10787-010-0068-y; Gaur V, 2010, PHARMACOL REP, V62, P635, DOI 10.1016/S1734-1140(10)70321-2; Gaur V, 2010, BRAIN RES, V1353, P204, DOI 10.1016/j.brainres.2010.07.004; Gaur V, 2010, BRAIN RES BULL, V82, P57, DOI 10.1016/j.brainresbull.2010.01.010; Gaur V, 2009, EUR J PHARMACOL, V616, P147, DOI 10.1016/j.ejphar.2009.06.056; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Jingtao Jiang, 1999, Medical Electron Microscopy, V32, P175, DOI 10.1007/s007950050025; Kaufmann AM, 1999, STROKE, V30, P93, DOI 10.1161/01.STR.30.1.93; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; KULKARNI SK, 1999, HDB EXPT PHARM, P117; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Linnik MD, 1993, STROKE, V24, p[2002, 2008], DOI 10.1161/01.STR.24.12.20028248983; Mabuchi N, 2000, J CARDIOVASC PHARM, V36, pS87, DOI 10.1097/00005344-200000006-00019; Maher P, 2005, AGEING RES REV, V4, P288, DOI 10.1016/j.arr.2005.02.005; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Nogawa S, 1997, J NEUROSCI, V17, P2746; Pantoni L, 1998, ARTERIOSCL THROM VAS, V18, P503, DOI 10.1161/01.ATV.18.4.503; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; Phillis JW, 2006, BRAIN RES REV, V52, P201, DOI 10.1016/j.brainresrev.2006.02.002; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; Reyes AE, 1997, BIOCHEM BIOPH RES CO, V232, P652, DOI 10.1006/bbrc.1997.6357; Schmidt-Kastner R, 2001, MOL BRAIN RES, V92, P157, DOI 10.1016/S0169-328X(01)00157-7; Siesjo BK, 2008, J NEUROSURG, V108, P616, DOI 10.3171/JNS/2008/108/3/0616; Teather LA, 2002, LEARN MEMORY, V9, P41, DOI 10.1101/lm.43602; Yan B, 2004, PHARMACOL BIOCHEM BE, V78, P319, DOI 10.1016/j.pbb.2004.04.010; Yanpallewar S, 2005, LIFE SCI, V76, P1325, DOI 10.1016/j.lfs.2004.06.029; Yanpallewar SU, 2004, PHARMACOL BIOCHEM BE, V79, P155, DOI 10.1016/j.pbb.2004.07.008; ZAHLER WL, 1968, J BIOL CHEM, V243, P716	50	26	29	0	8	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0148-0545			DRUG CHEM TOXICOL	Drug Chem. Toxicol.	APR	2012	35	2					218	224		10.3109/01480545.2011.589850			7	Chemistry, Multidisciplinary; Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Pharmacology & Pharmacy; Toxicology	894UG	WOS:000300451900014	21995864				2022-02-06	
J	Gupta, A; Taly, AB				Gupta, Anupam; Taly, Arun B.			Functional outcome following rehabilitation in chronic severe traumatic brain injury patients: A prospective study	ANNALS OF INDIAN ACADEMY OF NEUROLOGY			English	Article						Functional outcome; inpatient rehabilitation; severe traumatic brain injury	COGNITIVE REHABILITATION; EPIDEMIOLOGY; POPULATION; RECOVERY; TBI	Objective: The objective was to assess functional outcome of rehabilitation in chronic severe traumatic brain injury (TBI) in-patients. Setting: The study was performed at university tertiary research hospital. Study Design: A prospective cross-sectional study Materials and Methods: Forty patients (34 men) with mean age of 30.1 years (range 6--60, SD 10.8), severe TBI (Glasgow coma scale 3--8, duration of coma > 6 hours, post-traumatic amnesia > 1 day postinjury) were admitted in rehabilitation unit minimum 3 months (mean 7.74.6 months, range 3--22 months) following injury falling in Glasgow outcome scale (GOS) of 3. Functional recovery was assessed using the Barthel Index (BI) score and disability rating scores (DRS). Data Analysis: Paired Students t-test was used for the assessment of functional recovery using mean BI scores at admission and discharge. The Wilcoxon nonparametric test was used for the assessment of functional recovery by comparing admission and discharge DRS scores. Results: Mean duration of stay was 30.8 days (range 18--91, SD15.6). Significant functional recovery observed in patients comparing BI and DRS scores at admission and discharge (mean BI admission 50.525.4, range 0--85 vs. mean discharge BI score 61.125.3, range 0--95, P < 0.001, mean DRS admission score 7.574.1, range 2.5--21.0 vs. mean discharge DRS score 6.364.3, range 1.0-21.0, P < 0.001). Conclusion: Patients with severe TBI continue to show functional recovery even in chronic phase with rehabilitation. They are left with significant residual physical and cognitive deficits and would require long-term care and assistance from care givers for the daily activities, as suggested by the mean DRS score at discharge.	[Gupta, Anupam; Taly, Arun B.] Natl Inst Mental Hlth & Neurosci, Dept Psychiat & Neurol Rehabil, Neurol Rehabil Div, Bangalore 560029, Karnataka, India		Gupta, A (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Psychiat & Neurol Rehabil, Neurol Rehabil Div, Bangalore 560029, Karnataka, India.	drgupta159@yahoo.co.in	Taly, Arun/AAV-3517-2021				Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Avesani R, 2011, EUR J PHYS REHAB MED, V47, P203; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cullen NK, 2011, BRAIN INJURY, V25, P35, DOI 10.3109/02699052.2010.531691; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gururaj G, 2008, NATL MED J INDIA, V21, P14; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Hoffmann B, 2002, ACT NEUR S, V79, P33; Huang SJ, 2010, BRAIN INJURY, V24, P1606, DOI 10.3109/02699052.2010.523056; Krug E., 1999, INJURY LEADING CAUSE; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Rao S. L., 2004, NIMHANS NEUROPSYCHOL; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Singh RB, 2005, ACTA CARDIOL, V60, P611, DOI 10.2143/AC.60.6.2004933; Stalp M, 2002, J TRAUMA, V52, P1160, DOI 10.1097/00005373-200206000-00023; Svestkova O, 2010, DISABIL REHABIL, V32, pS68, DOI 10.3109/09638288.2010.511690; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Turner-Stokes L, 2005, COCHRANE DB SYST REV, V20; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; von Wild KRH, 2008, ACT NEUR S, V101, P55; Weninger P, 2008, J TRAUMA, V65, P799, DOI 10.1097/TA.0b013e3181820dae; Wertheimer JC, 2008, ARCH PHYS MED REHAB, V89, P1983, DOI 10.1016/j.apmr.2008.04.010; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	30	26	26	0	6	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0972-2327	1998-3549		ANN INDIAN ACAD NEUR	Ann. Indian Acad. Neurol.	APR-JUN	2012	15	2					120	124		10.4103/0972-2327.94995			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	932YV	WOS:000303327300010	22566725	Green Published, gold			2022-02-06	
J	Page, JL; Macpherson, AK; Middaugh-Bonney, T; Tator, CH				Page, Jessica L.; Macpherson, Alison K.; Middaugh-Bonney, Tara; Tator, Charles H.			Prevalence of helmet use by users of bicycles, push scooters, inline skates and skateboards in Toronto and the surrounding area in the absence of comprehensive legislation: an observational study	INJURY PREVENTION			English	Article								Background Legislation in the province of Ontario, Canada, mandates users under the age of 18 to wear a helmet when they ride a bicycle, and legislation has been shown to significantly increase rates of bicycle helmet use. Legislation does not exist in Ontario for older bicyclists or for users of other non-motorised modes of transportation, and there are no current data available regarding rates of helmet use in these categories. This study was designed to determine the prevalence of helmet use among users of bicycles, skateboards, push scooters and inline skates in Toronto, Ontario, and the surrounding area. Further analysis was performed to examine factors associated with helmet use. Methods We performed a cross-sectional, observational study. Three trained, stationary observers captured 6038 users of bicycles (5783), skateboards (77), inline skates (165) and push scooters (13) in the summer of 2009. Observations were separated into three time periods capturing commuters, midday users and recreational users. A general linear model was used to assess the factors associated with helmet use among bicyclists. Results Helmets were worn by 48.9% of all users observed and 50.0% of all bicyclists. Among bicyclists, females were more likely to wear helmets than males (prevalence ratio 1.27, 95% CI 1.17 to 1.36), while children were significantly more likely to wear helmets than adults (prevalence ratio 1.17, 95% CI 1.37 to 2.15). Significant behavioural variation was observed among users during the three observation periods (p<0.001), with commuters being the most likely to wear a helmet. Conclusion In the absence of comprehensive legislation encompassing all ages of users, only half of users of non-motorised, wheeled transportation devices are choosing to wear a helmet to protect against traumatic brain injury. Implementation of evidence-based strategies to increase helmet use, such as the introduction of legislation encompassing all ages and all equipment, is required.	[Tator, Charles H.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Page, Jessica L.] Univ Toronto, Fac Med, Toronto, ON, Canada; [Macpherson, Alison K.; Middaugh-Bonney, Tara] York Univ, Sch Kinesiol & Hlth Sci, Toronto, ON M3J 2R7, Canada		Tator, CH (corresponding author), Toronto Western Hosp, 12th Floor Rm 423,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	charles.tator@uhn.on.ca			Ontario Neurotrauma Foundation	This study was made possible by a summer scholarship for JL Page from the Ontario Neurotrauma Foundation. Thank you to Ajay Nadar for his assistance with data collection. Thanks to Dr Marieke Gardner for permitting inclusion of data from her 2006 study.	Adams J, 2001, Inj Prev, V7, P89, DOI 10.1136/ip.7.2.89; Beirness D J, 2001, Inj Prev, V7, P51, DOI 10.1136/ip.7.1.51; Dennis J, 2010, INJURY PREV, V16, P219, DOI 10.1136/ip.2009.025353; Gaines BA, 2004, J TRAUMA, V57, P111, DOI 10.1097/01.TA.0000082156.67895.C8; Hagel BE, 2006, INJURY PREV, V12, P262, DOI 10.1136/ip.2006.012112; Jacobsen PL, 2015, INJURY PREV, V21, P271, DOI 10.1136/ip.9.3.205rep; Khambalia A, 2005, PEDIATRICS, V116, P939, DOI 10.1542/peds.2005-0518; Macpherson A K, 2001, Inj Prev, V7, P228, DOI 10.1136/ip.7.3.228; Macpherson AK, 2006, INJURY PREV, V12, P231, DOI 10.1136/ip.2005.011379; Macpherson A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005401.pub3; Rivara F P, 1999, Inj Prev, V5, P194; ROBINSON DL, 2006, BMJ-BRIT MED J, V332, P722; Saleh F, 2008, CATASTROPHIC INJURIE, P371; SMARTRISK, 2009, EC BURD INJ CAN, P24; Tator CH, 2008, CATASTROPHIC INJURIE, P79; Thompson DC., 1999, COCHRANE DB SYST REV, V308, DOI 10.1002/14651858.CD001855; Wesson DE, 2008, PEDIATRICS, V122, P605, DOI 10.1542/peds.2007-1776	17	26	26	1	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	APR	2012	18	2					94	97		10.1136/injuryprev-2011-040029			4	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	916RD	WOS:000302120000006	21873306				2022-02-06	
J	Glover, LE; Tajiri, N; Lau, T; Kaneko, Y; van Loveren, H; Borlongan, CV				Glover, Loren E.; Tajiri, Naoki; Lau, Tsz; Kaneko, Yuji; van Loveren, Harry; Borlongan, Cesario V.			Immediate, but Not Delayed, Microsurgical Skull Reconstruction Exacerbates Brain Damage in Experimental Traumatic Brain Injury Model	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; DECOMPRESSIVE CRANIECTOMY; EARLY CRANIOPLASTY; MICE; AQUAPORIN-4; COMPLICATIONS; EXPRESSION; MANAGEMENT; EDEMA; DEATH	Moderate to severe traumatic brain injury (TBI) often results in malformations to the skull. Aesthetic surgical maneuvers may offer normalized skull structure, but inconsistent surgical closure of the skull area accompanies TBI. We examined whether wound closure by replacement of skull flap and bone wax would allow aesthetic reconstruction of the TBI-induced skull damage without causing any detrimental effects to the cortical tissue. Adult male Sprague-Dawley rats were subjected to TBI using the controlled cortical impact (CCI) injury model. Immediately after the TBI surgery, animals were randomly assigned to skull flap replacement with or without bone wax or no bone reconstruction, then were euthanized at five days post-TBI for pathological analyses. The skull reconstruction provided normalized gross bone architecture, but 2,3,5-triphenyltetrazolium chloride and hematoxylin and eosin staining results revealed larger cortical damage in these animals compared to those that underwent no surgical maneuver at all. Brain swelling accompanied TBI, especially the severe model, that could have relieved the intracranial pressure in those animals with no skull reconstruction. In contrast, the immediate skull reconstruction produced an upregulation of the edema marker aquaporin-4 staining, which likely prevented the therapeutic benefits of brain swelling and resulted in larger cortical infarcts. Interestingly, TBI animals introduced to a delay in skull reconstruction (i.e., 2 days post-TBI) showed significantly reduced edema and infarcts compared to those exposed to immediate skull reconstruction. That immediate, but not delayed, skull reconstruction may exacerbate TBI-induced cortical tissue damage warrants a careful consideration of aesthetic repair of the skull in TBI.	[Glover, Loren E.; Tajiri, Naoki; Lau, Tsz; Kaneko, Yuji; van Loveren, Harry; Borlongan, Cesario V.] Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA		Glover, LE (corresponding author), Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Tajiri, Naoki/K-1230-2012; Borlongan, Cesar/I-5696-2012	Tajiri, Naoki/0000-0003-2189-662X; Borlongan, Cesar/0000-0002-2966-9782	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS071956-01]; James and Esther King Foundation; SanBio Inc.; Celgene Cellular TherapeuticsBristol-Myers SquibbCelgene Corporation; KM Pharmaceutical Consulting; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER	CVB is supported by the National Institutes of Health, the National Institute of Neurological Disorders and Stroke 1R01NS071956-01, the James and Esther King Foundation for Biomedical Research Program, SanBio Inc., Celgene Cellular Therapeutics, KM Pharmaceutical Consulting, and NeuralStem Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amorini AM, 2003, ACT NEUR S, V86, P261; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022; Bolkvadze T, 2011, J NEUROTRAUMA; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Dumont TM, 2010, J NEUROTRAUM, V27, P1233, DOI 10.1089/neu.2009.1216; Faul M, 2010, TRAUMATIC BRAIN INJU; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Ho KM, 2011, CRITICAL CARE MED; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Huang X, 2010, INT J MED SCI, V7, P385; Lethaus B, J NEUROTRAUMA; Lukaszewicz AC, 2011, CURR OPIN ANESTHESIO, V24, P138, DOI 10.1097/ACO.0b013e32834458af; Lund-Johansen M, 2011, WORLD NEUROSURG, V75, P454, DOI 10.1016/j.wneu.2011.01.020; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Minardi J, 2009, MT SINAI J MED, V76, P138, DOI 10.1002/msj.20105; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Petersen K, 2011, J TRAUMA, V71, pS264, DOI 10.1097/TA.0b013e318227ad9a; Piero C, 2009, J CRANIOFAC SURG, V20, P498, DOI 10.1097/SCS.0b013e31819b9e14; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; SCHIETROMA M, 1992, Annali Italiani di Chirurgia, V63, P163; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Thavarajah D, 2011, BRIT J NEUROSURGERY, P1; Tourdias T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-143; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Walberer M, 2008, AGGRAVATION INFARCT; Walcott BP, 2011, NEUROTHERAPEUTICS, P1; Wang P, 2011, GENET MOL RES, V10, P2165, DOI 10.4238/vol10-3gmr1212; Wurm G, 2004, SURG NEUROL, V62, P510, DOI 10.1016/j.surneu.2004.01.025; Xia CF, 2006, HYPERTENSION, V47, P752, DOI 10.1161/01.HYP.0000214867.35632.0e; Yanagawa Y, 2000, NEUROL MED-CHIR, V40, P133, DOI 10.2176/nmc.40.133; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu GL, 2004, BRAIN RES, V1015, P50, DOI 10.1016/j.brainres.2004.04.055; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7; Zweckberger K, 2011, NEUROSCIENCE LETT	53	26	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2012	7	3							e33646	10.1371/journal.pone.0033646			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	932RV	WOS:000303309100080	22438975	gold, Green Submitted, Green Published			2022-02-06	
J	Lusardi, TA; Lytle, NK; Szybala, C; Boison, D				Lusardi, Theresa A.; Lytle, Nikki K.; Szybala, Cory; Boison, Detlev			Caffeine prevents acute mortality after TBI in rats without increased morbidity	EXPERIMENTAL NEUROLOGY			English	Article						FPI; Caffeine; Traumatic brain injury; Apnea; EEG; Neuroprotection	TRAUMATIC BRAIN-INJURY; SUDDEN UNEXPECTED DEATH; FLUID PERCUSSION INJURY; ADENOSINE KINASE; POSTTRAUMATIC EPILEPSY; HEAD-INJURY; RECEPTORS; EPILEPTOGENESIS; OVEREXPRESSION; MODEL	Severe traumatic brain injury (TBI) is associated with a high incidence of acute mortality followed by chronic alteration of homeostatic network activity that includes the emergence of posttraumatic seizures. We hypothesized that acute and chronic outcome after severe TBI critically depends on disrupted bioenergetic network homeostasis, which is governed by the availability of the brain's endogenous neuroprotectant adenosine. We used a rat lateral fluid percussion injury (FPI) model of severe TBI with an acute mortality rate of 46.7%. A subset of rats was treated with 25 mg/kg caffeine intraperitoneally within 1 min of the injury. We assessed neuromotor function at 24 h and 4 weeks, and video-EEG activity and histology at 4 weeks following injury. We first demonstrate that acute mortality is related to prolonged apnea and that a single acute injection of the adenosine receptor antagonist caffeine can completely prevent TBI-induced mortality when given immediately following the TBI. Second, we demonstrate that neuromotor function is not affected by caffeine treatment at either 24 h or 4 weeks following injury. Third, we demonstrate development of epileptiform EEG bursts as early as 4 weeks post-injury that are significantly reduced in duration in the rats that received caffeine. Our data demonstrate that acute treatment with caffeine can prevent lethal apnea following fluid percussion injury, with no negative influence on motor function or histological outcome. Further, we show epileptiform bursting is reduced after caffeine treatment, suggesting a potential role in the modulation of epilepsy development after severe injury. (C) 2011 Elsevier Inc. All rights reserved.	[Lusardi, Theresa A.; Lytle, Nikki K.; Szybala, Cory; Boison, Detlev] Legacy Res Inst, Robert Stone Dow Neurobiol Labs, Portland, OR 97232 USA		Boison, D (corresponding author), 1225 NE 2nd Ave, Portland, OR 97232 USA.	DBoison@DowNeurobiology.org	Boison, Detlev/ABE-6302-2020	Boison, Detlev/0000-0002-7740-5781; Lusardi, Theresa/0000-0003-0699-5662	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS057475, NS061844]; CURE Foundation; USAMRMCU.S. Army Medical Research & Materiel Command (USAMRMC) [05154001]; Telemedicine & Advanced Technology Research Center (TATRC) [W81XWH-10-1-0757]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061844, R21NS057475] Funding Source: NIH RePORTER	We thank Dr. Asia Pitkanen and her laboratory for their generous assistance in establishing the FPI model in our lab. This research and development project/program was conducted by the RS Dow Neurobiology Labs, and is made possible by grants from the National Institute of Neurological Disorders and Stroke (NS057475 and NS061844), the CURE Foundation in collaboration with the USAMRMC (05154001), and a cooperative agreement that was awarded and administered by the U.S. Army Medical Research & Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC), under Contract Number: W81XWH-10-1-0757. The TATRC Contracting Officer's Representative (COR) is Dr. Brenda Bart-Knauer (Brenda.Bart-Knauer@TATRC.ORG) and the TATRC Project Officer is Cheryll Quinn (Cheryll.Quirin@TATRC.ORG). The views, opinions and findings contained in this research are those of the company and do not necessarily reflect the views of the Department of Defense and should not be construed as an official DOD/Army policy unless so designated by other documentation. No official endorsement should be made. We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. None of the authors has any conflicts of interest to disclose.	Al Moutaery K, 2003, NEUROSURGERY, V53, P704, DOI 10.1227/01.NEU.0000079487.66013.6F; Barone JJ, 1996, FOOD CHEM TOXICOL, V34, P119, DOI 10.1016/0278-6915(95)00093-3; BARRACO RA, 1990, BRAIN RES, V507, P234, DOI 10.1016/0006-8993(90)90277-I; Basheer R, 2004, PROG NEUROBIOL, V73, P379, DOI 10.1016/j.pneurobio.2004.06.004; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Boison D, 2002, P NATL ACAD SCI USA, V99, P6985, DOI 10.1073/pnas.092642899; Boison D, 2010, HDB EXP PHARM, V200, P251; Boison D, 2008, PROG NEUROBIOL, V84, P249, DOI 10.1016/j.pneurobio.2007.12.002; Boison D, 2008, CURR OPIN PHARMACOL, V8, P2, DOI 10.1016/j.coph.2007.09.002; Boison D, 2011, EXPERT OPIN DRUG DIS, V6, P713, DOI 10.1517/17460441.2011.575777; BONATI M, 1985, DRUG METAB REV, V15, P1355, DOI 10.3109/03602538409029964; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Cotter G, 2008, J CARD FAIL, V14, P631, DOI 10.1016/j.cardfail.2008.08.010; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; DRAGUNOW M, 1986, NEUROSCI BIOBEHAV R, V10, P229, DOI 10.1016/0149-7634(86)90010-2; DRAGUNOW M, 1988, TRENDS PHARMACOL SCI, V9, P193, DOI 10.1016/0165-6147(88)90079-X; DUNWIDDIE TV, 1980, EPILEPSIA, V21, P541, DOI 10.1111/j.1528-1157.1980.tb04305.x; DURING MJ, 1992, ANN NEUROL, V32, P618, DOI 10.1002/ana.410320504; Elmenhorst D, 2009, BRAIN RES, V1258, P53, DOI 10.1016/j.brainres.2008.12.056; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Fredholm BB, 2005, INT REV NEUROBIOL, V63, P191, DOI 10.1016/S0074-7742(05)63007-3; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Fredholm BB, 1999, PHARMACOL REV, V51, P83; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Gouder N, 2004, J NEUROSCI, V24, P692, DOI 10.1523/JNEUROSCI.4781-03.2004; Hasko G, 2005, TRENDS PHARMACOL SCI, V26, P511, DOI 10.1016/j.tips.2005.08.004; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Hirsch LJ, 2010, ANN NEUROL, V68, P773, DOI 10.1002/ana.22242; Jacobson KA, 1996, TRENDS PHARMACOL SCI, V17, P108, DOI 10.1016/0165-6147(96)10002-X; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; McCarley RW, 2007, SLEEP MED, V8, P302, DOI 10.1016/j.sleep.2007.03.005; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nantwi KD, 2009, RESP PHYSIOL NEUROBI, V169, P102, DOI 10.1016/j.resp.2009.07.014; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Pignataro G, 2008, J CEREBR BLOOD F MET, V28, P17, DOI 10.1038/sj.jcbfm.9600499; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Ribeiro JA, 2005, CNS NEUROL DISORD-DR, V4, P325, DOI 10.2174/1568007054546090; Ribeiro JA, 2003, DRUG NEWS PERSPECT, V16, P80, DOI 10.1358/dnp.2003.16.2.740246; Roth T., 2000, PRINCIPLES NEURAL SC, P948; RUNOLD M, 1989, J APPL PHYSIOL, V67, P541, DOI 10.1152/jappl.1989.67.2.541; Sachse KT, 2008, J CEREBR BLOOD F MET, V28, P395, DOI 10.1038/sj.jcbfm.9600539; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schmidt B, 2007, NEW ENGL J MED, V357, P1893, DOI 10.1056/NEJMoa073679; Shen HY, 2010, EPILEPSIA, V51, P465, DOI 10.1111/j.1528-1167.2009.02248.x; Stewart TH, 2010, J NEUROPHYSIOL, V104, P3345, DOI 10.1152/jn.00398.2010; Svenningsson P, 1999, J NEUROSCI, V19, P4011; TSENG CJ, 1988, HYPERTENSION, V11, P191, DOI 10.1161/01.HYP.11.2.191; Weber JT, 2002, J NEUROTRAUM, V19, P1433, DOI 10.1089/089771502320914660; Yee BK, 2007, EUR J NEUROSCI, V26, P3237, DOI 10.1111/j.1460-9568.2007.05897.x	57	26	30	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2012	234	1					161	168		10.1016/j.expneurol.2011.12.026			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	910DN	WOS:000301617500018	22226594	Green Accepted			2022-02-06	
J	Haines, B; Li, PA				Haines, Bryan; Li, P. Andy			Overexpression of Mitochondrial Uncoupling Protein 2 Inhibits Inflammatory Cytokines and Activates Cell Survival Factors after Cerebral Ischemia	PLOS ONE			English	Article							OXYGEN-GLUCOSE DEPRIVATION; NECROSIS-FACTOR-ALPHA; BROWN ADIPOSE-TISSUE; BRAIN-INJURY; OXIDATIVE STRESS; ARTERY OCCLUSION; TRANSGENIC MICE; FOCAL ISCHEMIA; RAT-BRAIN; STROKE	Mitochondria play a critical role in cell survival and death after cerebral ischemia. Uncoupling proteins (UCPs) are inner mitochondrial membrane proteins that disperse the mitochondrial proton gradient by translocating H+ across the inner membrane in order to stabilize the inner mitochondrial membrane potential (Delta psi(m)) and reduce the formation of reactive oxygen species. Previous studies have demonstrated that mice transgenically overexpressing UCP2 (UCP2 Tg) in the brain are protected from cerebral ischemia, traumatic brain injury and epileptic challenges. This study seeks to clarify the mechanisms responsible for neuroprotection after transient focal ischemia. Our hypothesis is that UCP2 is neuroprotective by suppressing innate inflammation and regulating cell cycle mediators. PCR gene arrays and protein arrays were used to determine mechanisms of damage and protection after transient focal ischemia. Our results showed that ischemia increased the expression of inflammatory genes and suppressed the expression of anti-apoptotic and cell cycle genes. Overexpression of UCP2 blunted the ischemia-induced increase in IL-6 and decrease in Bcl2. Further, UCP2 increased the expression of cell cycle genes and protein levels of phospho-AKT, PKC and MEK after ischemia. It is concluded that the neuroprotective effects of UCP2 against ischemic brain injury are associated with inhibition of pro-inflammatory cytokines and activation of cell survival factors.	[Haines, Bryan] Buck Inst Res Aging, Novato, CA 94945 USA; [Li, P. Andy] N Carolina Cent Univ, Dept Pharmaceut Sci, BRITE, Durham, NC USA		Haines, B (corresponding author), Buck Inst Res Aging, Novato, CA 94945 USA.	pli@nccu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DK075476-06]; Golden Leaf Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK075476] Funding Source: NIH RePORTER	Work was funded by the National Institutes of Health R01DK075476-06. The BRITE program is partially funded by the Golden Leaf Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acalovschi D, 2003, STROKE, V34, P1864, DOI 10.1161/01.STR.0000079815.38626.44; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Choi K, 2009, CURR NEUROVASC RES, V6, P213, DOI 10.2174/156720209789630375; Chung H, 2007, ENDOCRINOLOGY, V148, P148, DOI 10.1210/en.2006-0991; Clark CB, 2009, FREE RADICAL BIO MED, V47, P1440, DOI 10.1016/j.freeradbiomed.2009.08.012; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Dang S, 2011, NEUROL RES, V33, P520, DOI 10.1179/016164111X13007856084287; Dhodda VK, 2004, J NEUROCHEM, V89, P73, DOI 10.1111/j.1471-4159.2004.02316.x; Ding XL, 2000, AM J PATHOL, V157, P1983, DOI 10.1016/S0002-9440(10)64837-7; Elzer JG, J CEREB BLOOD FLOW M, V30, P935; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Gao QL, 2006, MOL THER, V13, P928, DOI 10.1016/j.ymthe.2005.12.009; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Horvath TL, 2003, INT J OBESITY, V27, P433, DOI 10.1038/sj.ijo.0802257; Iijima T, 2003, BRAIN RES, V993, P140, DOI 10.1016/j.brainres.2003.09.041; Ishibashi N, 2002, J IMMUNOL, V168, P1926, DOI 10.4049/jimmunol.168.4.1926; Jezek P, 2002, INT J BIOCHEM CELL B, V34, P1190, DOI 10.1016/S1357-2725(02)00061-4; Kaya D, 2005, J CEREBR BLOOD F MET, V25, P1111, DOI 10.1038/sj.jcbfm.9600109; Kim HS, 2007, DIABETES RES CLIN PR, V77, pS46, DOI 10.1016/j.diabres.2007.01.032; Lengacher S, 2004, J CEREBR BLOOD F MET, V24, P780, DOI 10.1097/01.WCB.0000122743.72175.52; Li PA, 1998, BRAIN RES, V804, P36, DOI 10.1016/S0006-8993(98)00651-9; Li Y, 1997, J CEREBR BLOOD F MET, V17, P846, DOI 10.1097/00004647-199708000-00003; Liu XQ, 2009, ACTA PHARMACOL SIN, V30, P1071, DOI 10.1038/aps.2009.105; Liu Yajun, 2009, BMC Physiology, V9, P17, DOI 10.1186/1472-6793-9-17; Lu D, 1997, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V13, P224; Macdonald K, 1999, CIRC RES, V84, P820; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mehta SL, 2009, J CEREBR BLOOD F MET, V29, P1069, DOI 10.1038/jcbfm.2009.4; Minami M, 2006, J PHARMACOL SCI, V100, P461, DOI 10.1254/jphs.CRJ06005X; Mori M, 2004, CELL DEATH DIFFER, V11, P1223, DOI 10.1038/sj.cdd.4401483; Nakagomi T, 1996, NEUROL RES, V18, P559; Nakase T, 2007, NEUROPATHOLOGY, V27, P442, DOI 10.1111/j.1440-1789.2007.00815.x; NICHOLLS DG, 1977, EUR J BIOCHEM, V75, P601, DOI 10.1111/j.1432-1033.1977.tb11560.x; Ouyang YB, 2004, CELL CALCIUM, V36, P303, DOI 10.1016/j.ceca.2004.02.015; Ouyang YB, 2006, CELL STRESS CHAPERON, V11, P180, DOI 10.1379/CSC-182R.1; Palgrave CJ, 2011, J VIROL, V85, P6008, DOI 10.1128/JVI.00331-11; Pignataro G, 2008, J CEREBR BLOOD F MET, V28, P232, DOI 10.1038/sj.jcbfm.9600559; Rousset S, 2006, CYTOKINE, V35, P135, DOI 10.1016/j.cyto.2006.07.012; Sawe N, 2008, J NEUROSCI RES, V86, P1659, DOI 10.1002/jnr.21604; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Teshima Y, 2003, CIRC RES, V93, P192, DOI 10.1161/01.RES.0000085581.60197.4D; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3574, DOI 10.2174/138161208786848739; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yoshitomi H, 1999, BIOCHEM J, V340, P397, DOI 10.1042/0264-6021:3400397; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhao H, 2009, J CEREBR BLOOD F MET, V29, P873, DOI 10.1038/jcbfm.2009.13	52	26	30	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2012	7	2							e31739	10.1371/journal.pone.0031739			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	925CF	WOS:000302737400046	22348126	Green Submitted, Green Published, gold			2022-02-06	
J	Foreman, B; Hirsch, LJ				Foreman, Brandon; Hirsch, Lawrence J.			Epilepsy Emergencies: Diagnosis and Management	NEUROLOGIC CLINICS			English	Article						Epilepsy; Seizures; Status epilepticus; Coma; Intensive care unit; Nonconvulsive seizures; Critical care	REFRACTORY STATUS EPILEPTICUS; NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; CONVULSIVE STATUS EPILEPTICUS; ADD-ON TREATMENT; ACUTE SYMPTOMATIC SEIZURE; INTENSIVE-CARE-UNIT; CRITICALLY-ILL; CONTINUOUS EEG; INTRAVENOUS LEVETIRACETAM	Seizures and status epilepticus are epilepsy emergencies with high morbidity and mortality. Early treatment is crucial, and the identification of an underlying etiology informs both continued treatment and prognosis. Many patients have underdiagnosed nonconvulsive seizures or nonconvulsive status epilepticus, particularly the comatose or critically ill. Timely EEG can be useful for diagnosis, management, optimizing treatment response, and determining prognosis in these patients. Refractory conditions can be quite complicated with limited evidence-based guidance, but treatment should not be restricted by nihilism even in the most prolonged cases, especially if there is not widespread irreversible brain injury.	[Hirsch, Lawrence J.] Yale Univ, Sch Med, Div Epilepsy & EEG, New Haven, CT 06520 USA; [Foreman, Brandon] Columbia Univ, Med Ctr, Neurol Inst New York, Comprehens Epilepsy Ctr, New York, NY 10032 USA		Hirsch, LJ (corresponding author), Yale Univ, Sch Med, Div Epilepsy & EEG, POB 208018, New Haven, CT 06520 USA.	Lawrence.Hirsch@yale.edu		Hirsch, Lawrence/0000-0002-6333-832X; Foreman, Brandon/0000-0002-5418-674X	UCB-PharmaUCB Pharma SA; LundbeckLundbeck Corporation; GlaxoSmithKlineGlaxoSmithKline; Upsher-Smith; PfizerPfizer; EisaiEisai Co Ltd	Dr Hirsch has received lecture fees from UCB-Pharma, Lundbeck, and GlaxoSmithKline; consulting fees from Lundbeck and Upsher-Smith; research funding from Lundbeck, Pfizer, Upsher-Smith, Eisai, and UCB-Pharma; and receives royalties from authoring chapters in UpToDate: Neurology as well as from coauthoring Atlas of EEG in Critical Care (Wiley, 2010). There are no disclosures related to stock ownership or options, or expert testimony. Dr Foreman has nothing to disclose.	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abou Khaled KJ, 2008, NEUROL CLIN, V26, P385, DOI 10.1016/j.ncl.2008.03.017; Agarwal P, 2007, SEIZURE-EUR J EPILEP, V16, P527, DOI 10.1016/j.seizure.2007.04.012; Aiguabella M, 2011, SEIZURE-EUR J EPILEP, V20, P60, DOI 10.1016/j.seizure.2010.10.009; Alldredge BK, 2001, NEW ENGL J MED, V345, P631, DOI 10.1056/NEJMoa002141; AMINOFF MJ, 1980, AM J MED, V69, P657, DOI 10.1016/0002-9343(80)90415-5; ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; Arif H, 2008, SEMIN NEUROL, V28, P342, DOI 10.1055/s-2008-1079339; BAUER LA, 1982, NEUROLOGY, V32, P570, DOI 10.1212/WNL.32.5.570; Beach RL, 2008, INT REV NEUROBIOL, V83, P259, DOI 10.1016/S0074-7742(08)00015-9; Berning S, 2009, J NEUROL, V256, P1634, DOI 10.1007/s00415-009-5166-7; Bleck TP, 2010, EPILEPSY CURR, V10, P31, DOI 10.1111/j.1535-7511.2009.01345.x; BOGGS JG, 1993, EPILEPSY RES, V14, P87, DOI 10.1016/0920-1211(93)90077-K; Borris DJ, 2000, EPILEPSY RES, V42, P117, DOI 10.1016/S0920-1211(00)00175-3; Brenner RP, 2002, EPILEPSIA, V43, P103, DOI 10.1046/j.1528-1157.43.s.3.9.x; Burneo JG, 2001, EPILEPSIA, V42, P1156, DOI 10.1046/j.1528-1157.2001.12901.x; Camilo O, 2004, STROKE, V35, P1769, DOI 10.1161/01.STR.0000130989.17100.96; Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X; Chin RFM, 2004, EUR J NEUROL, V11, P800, DOI 10.1111/j.1468-1331.2004.00943.x; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Chu K, 2008, EPILEPSIA, V49, P1723, DOI 10.1111/j.1528-1167.2008.01644.x; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2003, J NEUROL SCI, V211, P37, DOI 10.1016/S0022-510X(03)00036-4; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; Claassen J, 2001, NEUROLOGY, V57, P1036, DOI 10.1212/WNL.57.6.1036; Claassen J, 2002, NEUROLOGY, V58, P139, DOI 10.1212/WNL.58.1.139; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2011, ATLAS VIDEO EEG MONI, P473; Cooper AD, 2009, ARCH NEUROL-CHICAGO, V66, P1505, DOI 10.1001/archneurol.2009.273; Corry JJ, 2008, NEUROCRIT CARE, V9, P189, DOI 10.1007/s12028-008-9092-9; Costello Daniel J, 2007, J Intensive Care Med, V22, P319, DOI 10.1177/0885066607307506; Costello DJ, 2006, ARCH NEUROL-CHICAGO, V63, P895, DOI 10.1001/archneur.63.6.895; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; Delanty N, 2001, SEIZURE-EUR J EPILEP, V10, P116, DOI 10.1053/seiz.2000.0482; DeLorenzo RJ, 1999, EPILEPSIA, V40, P164, DOI 10.1111/j.1528-1157.1999.tb02070.x; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; DeLorenzo RJ, 1996, NEUROLOGY, V46, P1029, DOI 10.1212/WNL.46.4.1029; Dennis LJ, 2002, NEUROSURGERY, V51, P1136, DOI 10.1097/00006123-200211000-00006; DeToledo JC, 2000, DRUG SAFETY, V22, P459, DOI 10.2165/00002018-200022060-00004; DODSON WE, 1993, JAMA-J AM MED ASSOC, V270, P854; Drislane FW, 2008, J CLIN NEUROPHYSIOL, V25, P181, DOI 10.1097/WNP.0b013e31817be70e; Drislane FW, 2009, EPILEPSIA, V50, P1566, DOI 10.1111/j.1528-1167.2008.01993.x; Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x; Eue S, 2009, EPILEPSY BEHAV, V15, P467, DOI 10.1016/j.yebeh.2009.05.020; Fattouch J, 2010, ACTA NEUROL SCAND, V121, P418, DOI 10.1111/j.1600-0404.2010.01351.x; Fisher A, 2004, EPILEPSIA, V45, P1300, DOI 10.1111/j.0013-9580.2004.26404.x; Fisher R, 2010, EPILEPSIA, V51, P899, DOI 10.1111/j.1528-1167.2010.02536.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Foreman B, 2011, CONTROLLED STUDY 202; Fountain NB, 2001, J CLIN NEUROPHYSIOL, V18, P345, DOI 10.1097/00004691-200107000-00006; FOUNTAIN NB, 1995, J CLIN NEUROPHYSIOL, V12, P326; Fountain NB, 2000, EPILEPSIA, V41, pS23, DOI 10.1111/j.1528-1157.2000.tb01521.x; Fugate JE, 2010, ANESTH ANALG, V111, P1520, DOI 10.1213/ANE.0b013e3181f6da34; Gouveia TLF, 2011, EPILEPSY BEHAV, V20, P1, DOI 10.1016/j.yebeh.2010.10.001; Gastaut H, 1983, Adv Neurol, V34, P15; Greenaway C, 2011, EPILEPSIA, V52, P258, DOI 10.1111/j.1528-1167.2010.02751.x; Hamani C, 2008, EPILEPSY RES, V78, P117, DOI 10.1016/j.eplepsyres.2007.09.010; Hamer HM, 2000, NEUROLOGY, V54, P230, DOI 10.1212/WNL.54.1.230; Hauser WA, 2008, EPILEPSIA, V49, P8, DOI 10.1111/j.1528-1167.2008.01443.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Hesdorffer DC, 2009, EPILEPSIA, V50, P1102, DOI 10.1111/j.1528-1167.2008.01945.x; Hesdorffer DC, 1998, ANN NEUROL, V44, P908, DOI 10.1002/ana.410440609; Hesdorffer DC, 1998, NEUROLOGY, V50, P735, DOI 10.1212/WNL.50.3.735; Hirsch Lawrence J, 2002, Curr Neurol Neurosci Rep, V2, P345, DOI 10.1007/s11910-002-0010-9; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Holtkamp M, 2005, ARCH NEUROL-CHICAGO, V62, P1428, DOI 10.1001/archneur.62.9.1428; Holtkamp M, 2005, J NEUROL NEUROSUR PS, V76, P534, DOI 10.1136/jnnp.2004.041947; Jaitly R, 1997, J CLIN NEUROPHYSIOL, V14, P326, DOI 10.1097/00004691-199707000-00005; Jambroszyk M, 2011, EPILEPSIA, V52, P284, DOI 10.1111/j.1528-1167.2010.02886.x; Jenssen S, 2006, EPILEPSIA, V47, P1499, DOI 10.1111/j.1528-1167.2006.00622.x; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jordan KG, 2006, EPILEPSIA, V47, P41, DOI 10.1111/j.1528-1167.2006.00659.x; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Kamel H, 2010, NEUROCRIT CARE, V12, P204, DOI 10.1007/s12028-009-9288-7; Kapur J, 2000, EPILEPSIA, V41, pS86, DOI 10.1111/j.1528-1157.2000.tb01563.x; Kellinghaus C, 2011, ACTA NEUROL SCAND, V123, P137, DOI 10.1111/j.1600-0404.2010.01423.x; Kilbride RD, 2009, ARCH NEUROL-CHICAGO, V66, P723, DOI 10.1001/archneurol.2009.100; Knake S, 2008, J NEUROL NEUROSUR PS, V79, P588, DOI 10.1136/jnnp.2007.130260; Koubeissi MZ, 2011, ACTA NEUROL SCAND, V123, P142, DOI 10.1111/j.1600-0404.2010.01430.x; Koubeissi M, 2007, NEUROLOGY, V69, P886, DOI 10.1212/01.wnl.0000269791.96189.70; Krishnamurthy KB, 1996, EPILEPSIA, V37, P863, DOI 10.1111/j.1528-1157.1996.tb00039.x; Krsek P, 2004, EPILEPSY BEHAV, V5, P180, DOI 10.1016/j.yebeh.2003.11.032; Legriel S, 2008, NEUROCRIT CARE, V9, P118, DOI 10.1007/s12028-008-9107-6; LEPPIK IE, 1983, JAMA-J AM MED ASSOC, V249, P1452, DOI 10.1001/jama.249.11.1452; Lhatoo SD, 2007, EPILEPSIA, V48, P61, DOI 10.1111/j.1528-1167.2007.01353.x; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; Loescher W, 2007, EPILEPSIA, V48, P74, DOI 10.1111/j.1528-1167.2007.01357.x; Logroscino G, 1997, EPILEPSIA, V38, P1344, DOI 10.1111/j.1528-1157.1997.tb00073.x; Lowenstein DH, 1999, EPILEPSIA, V40, P120, DOI 10.1111/j.1528-1157.1999.tb02000.x; LOWENSTEIN DH, 1993, NEUROLOGY, V43, P483, DOI 10.1212/WNL.43.3_Part_1.483; Ma XP, 2001, EPILEPSY RES, V46, P33, DOI 10.1016/S0920-1211(01)00252-2; Manno EM, 2005, ANN NEUROL, V58, P954, DOI 10.1002/ana.20677; Martin BS, 2008, EPILEPSIA, V49, P248, DOI 10.1111/j.1528-1167.2007.01384.x; Martindale JL, 2011, EMERG MED CLIN N AM, V29, P15, DOI 10.1016/j.emc.2010.08.002; Mayer SA, 2002, ARCH NEUROL-CHICAGO, V59, P205, DOI 10.1001/archneur.59.2.205; Mazarati AM, 1998, BRAIN RES, V814, P179, DOI 10.1016/S0006-8993(98)01080-4; McIntyre J, 2005, LANCET, V366, P205, DOI 10.1016/S0140-6736(05)66909-7; Meador K, 2008, EPILEPSY RES, V81, P1, DOI 10.1016/j.eplepsyres.2008.04.022; Meierkord H, 2010, EUR J NEUROL, V17, P348, DOI 10.1111/j.1468-1331.2009.02917.x; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V29, P82, DOI 10.1001/archneur.1973.00490260026003; Miranda M, 2010, EPILEPSY BEHAV, V19, P539, DOI 10.1016/j.yebeh.2010.07.025; Mirsattari SM, 2004, ARCH NEUROL-CHICAGO, V61, P1254, DOI 10.1001/archneur.61.8.1254; Misra UK, 2006, NEUROLOGY, V67, P340, DOI 10.1212/01.wnl.0000224880.35053.26; Muayqil T, 2007, EPILEPTIC DISORD, V9, P43; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Nei M, 1999, EPILEPSIA, V40, P157, DOI 10.1111/j.1528-1157.1999.tb02069.x; Nocero M, 2011, NEUROLOGY S, V76, pA1; Novy J, 2010, EPILEPSIA, V51, P2207, DOI 10.1111/j.1528-1167.2010.02646.x; Novy J, 2010, EPILEPSIA, V51, P251, DOI 10.1111/j.1528-1167.2009.02323.x; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Ono S, 1997, INTERNAL MED, V36, P59, DOI 10.2169/internalmedicine.36.59; Orta DS, 2009, ARCH NEUROL-CHICAGO, V66, P985, DOI 10.1001/archneurol.2009.137; Pallin DJ, 2008, INT J EMERG MED, V1, P97, DOI 10.1007/s12245-008-0024-4; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; PASCUAL J, 1992, J NEUROL NEUROSUR PS, V55, P49, DOI 10.1136/jnnp.55.1.49; Pellock JM, 2004, EPILEPSY BEHAV, V5, P192, DOI 10.1016/j.yebeh.2003.12.012; Penberthy LT, 2005, SEIZURE-EUR J EPILEP, V14, P46, DOI 10.1016/j.seizure.2004.06.001; Prasad K, 2005, COCHRANE DB SYST REV, V4; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Robakis TK, 2006, NEUROCRIT CARE, V4, P35, DOI 10.1385/NCC:4:1:035; Rossetti AO, 2011, NEUROCRIT CARE, V14, P4, DOI 10.1007/s12028-010-9445-z; Rossetti AO, 2005, ARCH NEUROL-CHICAGO, V62, P1698, DOI 10.1001/archneur.62.11.1698; Rossetti AO, 2004, EPILEPSIA, V45, P757, DOI 10.1111/j.0013-9580.2004.01904.x; Sander JW, 2003, ACTA NEUROL SCAND, V108, P16, DOI 10.1034/j.1600-0404.108.s180.3.x; Schmitt FC, 2006, NEUROBIOL DIS, V23, P689, DOI 10.1016/j.nbd.2006.05.008; Schmitt FC, 2010, EPILEPSY BEHAV, V17, P565, DOI 10.1016/j.yebeh.2010.01.166; Seow SC, 2008, EUR J NEUROL, V15, pE46, DOI 10.1111/j.1468-1331.2008.02125.x; Shneker BF, 2003, NEUROLOGY, V61, P1066, DOI 10.1212/01.WNL.0000082653.40257.0B; Silbergleit R, 2000, DOUBLE BLIND RANDOMI; Sinha S, 2000, NEUROLOGY, V55, P722, DOI 10.1212/WNL.55.5.722; Sisodiya SM, 2003, EPILEPSIA, V44, P261, DOI 10.1046/j.1528-1157.2003.42802.x; THEODORE WH, 1994, NEUROLOGY, V44, P1403, DOI 10.1212/WNL.44.8.1403; Tomson T, 2006, NEUROLOGY, V66, P354; Towne AR, 2003, NEUROLOGY, V60, P332, DOI 10.1212/01.WNL.0000042783.86439.27; TOWNE AR, 1994, EPILEPSIA, V35, P27, DOI 10.1111/j.1528-1157.1994.tb02908.x; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Ubogu EE, 2003, EPILEPSY BEHAV, V4, P70, DOI 10.1016/S1525-5050(02)00643-1; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vignatelli L, 2008, J NEUROL, V255, P197, DOI 10.1007/s00415-008-0635-y; Visser NA, 2011, J NEUROL, V258, P218, DOI 10.1007/s00415-010-5721-2; Walker LA, 1997, ACAD EMERG MED, V4, P918; Walker M, 2005, EPILEPTIC DISORD, V7, P253; Wasterlain CG, 2002, EPILEPSIA, V43, P20, DOI 10.1046/j.1528-1157.43.s.5.1.x; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; Waterhouse EJ, 1999, EPILEPSIA, V40, P752, DOI 10.1111/j.1528-1157.1999.tb00774.x; Wijdicks EFM, 1996, NEUROLOGY, V47, P1523, DOI 10.1212/WNL.47.6.1523; Williams AJ, 2004, J PHARMACOL EXP THER, V311, P220, DOI 10.1124/jpet.104.069146; Willmore LJ, 1998, NEUROLOGY, V51, pS34, DOI 10.1212/WNL.51.5_Suppl_4.S34; Wusthoff CJ, 2010, EPILEPSIA, V51, P1083, DOI 10.1111/j.1528-1167.2009.02388.x; Young GB, 1996, NEUROLOGY, V47, P83; Zeller JA, 1999, EPILEPSIA, V40, P186, DOI 10.1111/j.1528-1157.1999.tb02073.x	160	26	28	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	FEB	2012	30	1					11	+		10.1016/j.ncl.2011.09.005			32	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	894ZC	WOS:000300465000003	22284053				2022-02-06	
J	Harris, JE; Colantonio, A; Bushnik, T; Constantinidou, F; Dawson, D; Goldin-Lauretta, Y; Swaine, B; Warren, J				Harris, Jocelyn E.; Colantonio, Angela; Bushnik, Tamara; Constantinidou, Fofi; Dawson, Deirdre; Goldin-Lauretta, Yelena; Swaine, Bonnie; Warren, Jane			Advancing the health and quality-of-life of girls and women after traumatic brain injury: Workshop summary and recommendations	BRAIN INJURY			English	Article						Traumatic brain injury; gender; quality-of-life; advocacy; health; outcome	GENDER-DIFFERENCES; SEX-DIFFERENCES; MODERATE; OUTCOMES; TBI; HOSPITALIZATIONS; EPIDEMIOLOGY; SYMPTOMS; IMPACT	Purpose: To disseminate findings from an international workshop regarding priority issues for girls' and women's health and quality-of-life after sustaining a traumatic brain injury (TBI). Methods: A workshop was held prior to the American Congress of Rehabilitation Medicine Conference 2010. The purpose of the workshop was to highlight the unique health issues experienced by women after a TBI, to identify research, education and policy gaps and to develop strategies to promote women's health. Presentations by researchers and consumers as well as large group discussions formed the basis of the recommendations. Results: Twenty researchers, clinicians, consumers and community agency personnel attended from five countries. Significant gaps in service provision in the community were identified as were unique issues for the short-and long-term effects on maturation and ageing, reproductive and sexual health, mental health and life satisfaction. The workshop led to the development of an international task force and recommendations for future directions. Conclusion: Women and girls experience unique outcomes after a TBI. The workshop identified research, policy, education and service priorities for the promotion of health and quality-of-life within this population.	[Colantonio, Angela; Dawson, Deirdre] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5G 1V7, Canada; [Harris, Jocelyn E.] McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada; [Colantonio, Angela] Toronto Rehabil Inst, Toronto, ON, Canada; [Bushnik, Tamara] Rusk Inst, New York, NY USA; [Bushnik, Tamara] NYU, Langone Med Ctr, New York, NY USA; [Constantinidou, Fofi] Univ Cypress, Toronto, ON, Canada; [Dawson, Deirdre] Baycrest, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; [Goldin-Lauretta, Yelena] Mt Sinai Sch Med, New York, NY USA; [Swaine, Bonnie] Univ Montreal, Fac Med, Ecole Readaptat, Programme Physiotherapie, Montreal, PQ H3C 3J7, Canada; [Swaine, Bonnie] Ctr Rech Interdisciplinaire Readaptat, Montreal, PQ, Canada; [Warren, Jane] Brain Injury Assoc Canada, Ottawa, ON, Canada; [Warren, Jane] DAWN Canada, Halifax, NS, Canada		Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Sci & Occupat Therapy, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Dawson, Deirdre R/I-8882-2014; Harris, Jocelyn Ellen/ABE-7420-2021	Dawson, Deirdre R/0000-0001-7517-6121; Harris, Jocelyn Ellen/0000-0002-3293-1833; Constantinidou, Fofi/0000-0002-7928-8363; Colantonio, Angela/0000-0003-2094-4765; Bushnik, Tamara/0000-0003-3328-257X	Corinne Kagan; Ontario Neurotrauma Foundation; American Congress of Rehabilitation Medicine; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR) [200603MOP]; Ontario Ministry of Health and Long Term Care to the Toronto Rehabilitation Institute; Toronto Rehabilitation Institute Foundation	Special thanks to Marilyn Spivack who inspired the idea of a task force and future directions. We recognize the support of Corinne Kagan at the workshop and the Ontario Neurotrauma Foundation for funding subsequent knowledge mobilization activities. We thank Alana Officer who began the workshop with a global perspective on women with disability. We also acknowledge support from the American Congress of Rehabilitation Medicine, including staff support; Harry Zarins and the Brain Injury Association of Canada; and Bonnie Brayton and the DisAbled Women's Network (DAWNRAFH) Canada. We thank all those who assisted at the workshop including Sara Salehi and Sandra Sokoloff for her support with workshop development and manuscript preparation. We thank all the workshop participants and the women with lived experience of traumatic brain injury who contributed to the workshop. Lastly, we acknowledge the contributions of the late Dr Jane Gillette and dedicate this article to her.; Funding for this study for AC, JEH, BRW, DD, DV, HL, KKY and PK was obtained from a Canadian Institutes for Health Research Meetings, Planning and Dissemination Grant: Gender, Sex and Health (201006MHG). Funding for JEH was obtained by a CIHR Fellowship Award and a Strategic Training Fellowship in Health Care, Technology and Place (FRN: STP 53911). Additional funding for AC was obtained from the Canadian Institutes for Health Research (200603MOP). We recognize a grant from the Ontario Ministry of Health and Long Term Care to the Toronto Rehabilitation Institute and the support of the Toronto Rehabilitation Institute Foundation. The authors report no conflicts of interest.	Adamo MA, 2009, J NEUROSURG-PEDIATR, V4, P414, DOI 10.3171/2009.6.PEDS0939; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bernabeu M, 2009, NEUROREHAB NEURAL RE, V23, P464, DOI 10.1177/1545968308328725; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Bushnik T, 2008, ARCH PHYS MED REHAB, V89, P894, DOI 10.1016/j.apmr.2008.03.001; Casteel C, 2008, INJURY PREV, V14, P87, DOI 10.1136/ip.2007.016451; Colantonio A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-102; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Colantonio A, 2010, J WOMENS HEALTH, V19, P1109, DOI 10.1089/jwh.2009.1740; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Goldin-Lauretta Y, 2010, ANN C AM C REH MED 2; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Noggle CA, 2010, APPL NEUROPSYCHOL, V17, P110, DOI 10.1080/09084281003708977; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; Rosen DB, 2006, ANN NY ACAD SCI, V1087, P170, DOI 10.1196/annals.1385.002; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; Semrud-Clikeman M, 2010, APPL NEUROPSYCHOL, V17, P116, DOI 10.1080/09084281003708985; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Srinivasan L, 2009, BRAIN INJURY, V23, P639, DOI 10.1080/02699050902970778; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tate D G, 2001, Phys Med Rehabil Clin N Am, V12, P23	27	26	26	1	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2012	26	2					177	182		10.3109/02699052.2011.635361			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	897NP	WOS:000300658200006	22360523	Green Submitted			2022-02-06	
J	Zhang, X; Lu, XM; Huang, LF; Ye, H				Zhang, Xin; Lu, Xiao-Min; Huang, Li-Fa; Ye, Hui			Copeptin is associated with one-year mortality and functional outcome in patients with acute spontaneous basal ganglia hemorrhage	PEPTIDES			English	Article						Copeptin; Intracerebral hemorrhage; Early neurological deterioration; 1-Year outcome	TRAUMATIC BRAIN-INJURY; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; VASOPRESSIN PRECURSOR; STABLE PEPTIDE; ANTIDIURETIC-HORMONE; PROGNOSTIC MARKER; CEREBRAL-ISCHEMIA; HEART-FAILURE; V-2 RECEPTORS; STROKE	High plasma copeptin levels have been found to be associated with short-term poor outcome after intracerebral hemorrhage (ICH). We furthermore evaluate the relation of plasma copeptin levels to long-term outcome and early neurological deterioration after ICH. Fifty healthy controls and 89 patients with acute spontaneous basal ganglia hemorrhage were recruited in this study. Plasma copeptin concentrations on admission measured by enzyme-linked immunosorbent assay were considerably high in patients than healthy controls. A multivariate analysis identified plasma copeptin level as an independent predictor for 1-year mortality, 1-year unfavorable outcome (modified Rankin Scale score > 2) and early neurological deterioration. A receiver operating characteristic curve showed that the predictive value of plasma copeptin concentration was similar to that of National Institutes of Health Stroke Scale scores for long-term poor outcome and early neurological deterioration. However, copeptin did not obviously improve the predictive values of National Institutes of Health Stroke Scale scores. Thus, increased plasma copeptin level is an independent prognostic marker of 1-year mortality, 1-year unfavorable outcome and early neurological deterioration after ICH. (C) 2012 Elsevier Inc. All rights reserved.	[Zhang, Xin; Huang, Li-Fa; Ye, Hui] Tradit Chinese Med Hosp Zhejiang Prov, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China; [Lu, Xiao-Min] First Hangzhou Municipal Peoples Hosp, Wushan Branch, Dept Surg, Hangzhou 310002, Zhejiang, Peoples R China		Zhang, X (corresponding author), Tradit Chinese Med Hosp Zhejiang Prov, Dept Neurosurg, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.	changzhouzhangxin@163.com					Barat C, 2004, BIOCHEMISTRY-US, V43, P8191, DOI 10.1021/bi0400094; Boer G. J., 1987, VASOPRESSIN PRINCIPL, P175; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Darzy KH, 2010, CLIN CHEM, V56, P1190, DOI 10.1373/clinchem.2009.141689; de Bree FM, 1998, CELL MOL NEUROBIOL, V18, P173, DOI 10.1023/A:1022564803093; Delgado P, 2007, NEUROLOGIA, V22, P448; Dong XQ, 2011, J TRAUMA, V71, P1194, DOI 10.1097/TA.0b013e31821283f2; Dong XQ, 2011, PEPTIDES, V32, P253, DOI 10.1016/j.peptides.2010.11.021; HOLWERDA DA, 1972, EUR J BIOCHEM, V28, P334, DOI 10.1111/j.1432-1033.1972.tb01918.x; Katan M, 2011, NEUROLOGY, V76, P563, DOI 10.1212/WNL.0b013e31820b75e6; Katan M, 2008, NEUROENDOCRINOL LETT, V29, P341; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Molnar AH, 2008, ACTA NEUROCHIR, V150, P265, DOI 10.1007/s00701-007-1400-1; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Morgenthaler NG, 2007, SHOCK, V28, P219, DOI 10.1097/SHK.0b013e318033e5da; Ranger GS, 2002, INT J CLIN PRACT, V56, P777; Robertson GL, 2001, ENDOCRIN METAB CLIN, V30, P671, DOI 10.1016/S0889-8529(05)70207-3; Robertson GL, 2001, ENDOCRIN METAB CLIN, V30, pvii; Sacco RL, 2006, NAT CLIN PRACT NEURO, V2, P577, DOI 10.1038/ncpneuro0345; SMYTH DG, 1979, BIOCHEM BIOPH RES CO, V87, P1006, DOI 10.1016/S0006-291X(79)80007-8; Stoiser B, 2006, EUR J CLIN INVEST, V36, P771, DOI 10.1111/j.1365-2362.2006.01724.x; Struck J, 2005, PEPTIDES, V26, P2500, DOI 10.1016/j.peptides.2005.04.019; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Urwyler SA, 2010, STROKE, V41, P1564, DOI 10.1161/STROKEAHA.110.584649; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Voors AA, 2009, EUR HEART J, V30, P1187, DOI 10.1093/eurheartj/ehp098; Xu Miao, 2007, Chin J Traumatol, V10, P90; Yu GF, 2012, PEPTIDES, V33, P164, DOI 10.1016/j.peptides.2011.11.017; Zhu XD, 2011, CRIT CARE, V15, DOI 10.1186/cc10575; Zweifel C, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-34	32	26	26	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0196-9781	1873-5169		PEPTIDES	Peptides	FEB	2012	33	2					336	341		10.1016/j.peptides.2012.01.011			6	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	913IP	WOS:000301871200020	22286033				2022-02-06	
J	Crawford, F; Crynen, G; Reed, J; Mouzon, B; Bishop, A; Katz, B; Ferguson, S; Phillips, J; Ganapathi, V; Mathura, V; Roses, A; Mullan, M				Crawford, Fiona; Crynen, Gogce; Reed, Jon; Mouzon, Benoit; Bishop, Alex; Katz, Benjamin; Ferguson, Scott; Phillips, John; Ganapathi, Vani; Mathura, Venkatarajan; Roses, Allen; Mullan, Michael			Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model	JOURNAL OF NEUROTRAUMA			English	Article						APOE; biomarkers; proteomics; TBI	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; APOLIPOPROTEIN-E; INTRACEREBRAL HEMORRHAGE; ALZHEIMERS-DISEASE; SUBARACHNOID HEMORRHAGE; TRANSGENIC MICE; PROTEINS; EXPRESSION; SERUM	The current lack of diagnostic and prognostic biomarkers for traumatic brain injury (TBI) confounds treatment and management of patients and is of increasing concern as the TBI population grows. We have generated plasma proteomic profiles from mice receiving TBI by controlled cortical impact at either 1.3 mm or 1.8 mm depth, comparing these against those of sham injured-animals to identify plasma biomarkers specific to mild or severe TBI at 24 hours, 1 month, or 3 months post-injury. To identify possible prognostic biomarkers, we used apolipoprotein E (APOE)3 and APOE4 transgenic mice, which demonstrate relatively favorable and unfavorable outcomes respectively, following TBI. Using a quantitative proteomics approach (isobaric tagging for relative and absolute quantitation - iTRAQ) we have identified proteins that are significantly modulated as a function of TBI and also in response to the TBI*APOE genotype interaction, the latter representing potential prognostic biomarkers. These preliminary data clearly demonstrate plasma protein changes that are not only injury dependent but also interaction dependent. Importantly, these results demonstrate the presence of TBI-dependent and interaction-dependent plasma proteins at a 3-month time point, which is a considerable time post-injury in the mouse model, and will potentially be of significance for combat veterans receiving assessment at extended periods post-injury. Furthermore, our identification of clusters of functionally related proteins indicates disturbance of particular biological modules, which potentially increases their value beyond that of solitary biomarkers.	[Crawford, Fiona; Crynen, Gogce; Reed, Jon; Mouzon, Benoit; Bishop, Alex; Katz, Benjamin; Ferguson, Scott; Phillips, John; Ganapathi, Vani; Mathura, Venkatarajan; Mullan, Michael] Roskamp Inst, Sarasota, FL 34243 USA; [Crawford, Fiona; Reed, Jon; Mouzon, Benoit; Ferguson, Scott; Mathura, Venkatarajan; Mullan, Michael] James A Haley Vet Adm, Tampa, FL 33612 USA; [Roses, Allen] Duke Univ, R David Thomas Execut Training Ctr, Durham, NC 27706 USA		Crawford, F (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	fcrawford@rfdn.org		Mullan, Michael/0000-0002-1473-7527; Crynen, Gogce/0000-0001-6066-9900	Department of DefenseUnited States Department of Defense [W81XWH-07-1-0700]; Roskamp Foundation	This research was funded by a Department of Defense award (W81XWH-07-1-0700) to Dr. Fiona Crawford and by the Roskamp Foundation. The authors thank James Evans for his assistance in data review and manuscript preparation.	Abildayeva K, 2008, J LIPID RES, V49, P856, DOI 10.1194/jlr.M700518-JLR200; ABRAHAM CR, 1993, BRAIN RES, V621, P222, DOI 10.1016/0006-8993(93)90110-9; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bantscheff M, 2008, MOL CELL PROTEOMICS, V7, P1702, DOI 10.1074/mcp.M800029-MCP200; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Buttini M, 1999, J NEUROSCI, V19, P4867; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Deshpande AA, 1997, ARCH PHYS MED REHAB, V78, P350, DOI 10.1016/S0003-9993(97)90224-0; Dzietko M, 2008, ANN NEUROL, V64, P664, DOI 10.1002/ana.21516; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Fu Q, 2005, PROTEOMICS, V5, P2656, DOI 10.1002/pmic.200402048; Gilar M, 2005, ANAL CHEM, V77, P6426, DOI 10.1021/ac050923i; Gros-Louis F, 2007, NAT GENET, V39, P80, DOI 10.1038/ng1927; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Hausmann R, 2001, INT J LEGAL MED, V114, P338, DOI 10.1007/s004140000199; Hill EG, 2008, J PROTEOME RES, V7, P3091, DOI 10.1021/pr070520u; Iwata A, 2005, J NEUROSCI RES, V82, P103, DOI 10.1002/jnr.20607; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kato K, 2001, J BIOL CHEM, V276, P14562, DOI 10.1074/jbc.M010725200; Kay A, 2003, STROKE, V34, pE240, DOI 10.1161/01.STR.0000100157.88508.2F; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Keep RF, 2008, ACT NEUR S, V105, P73; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kramer AH, 2009, NEUROCRIT CARE, V10, P157, DOI 10.1007/s12028-008-9171-y; Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Papassotiropoulos A, 2005, J CLIN PSYCHIAT, V66, P940, DOI 10.4088/JCP.v66n0720; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; Serra-Grabulosa JM, 2003, NEUROGENETICS, V4, P141, DOI 10.1007/s10048-002-0142-8; Shao J, 2006, ACTA NEUROCHIR SUPPL, V96, P183; SLEMMON JR, 1988, J NEUROSCI, V8, P4603; Thambisetty M, 2010, ARCH GEN PSYCHIAT, V67, P739, DOI 10.1001/archgenpsychiatry.2010.78; Urban S, 2006, GENE DEV, V20, P3054, DOI 10.1101/gad.1488606; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; WONG CG, 1983, J LIPID RES, V24, P666; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; Yao DL, 1999, BRAIN RES, V818, P140, DOI 10.1016/S0006-8993(98)01118-4	54	26	28	1	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					246	260		10.1089/neu.2011.1789			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300005	21895520				2022-02-06	
J	Kincses, ZT; Szabo, N; Valalik, I; Kopniczky, Z; Dezsi, L; Klivenyi, P; Jenkinson, M; Kiraly, A; Babos, M; Voros, E; Barzo, P; Vecsei, L				Kincses, Zsigmond Tamas; Szabo, Nikoletta; Valalik, Istvan; Kopniczky, Zsolt; Dezsi, Livia; Klivenyi, Peter; Jenkinson, Mark; Kiraly, Andras; Babos, Magor; Voeroes, Erika; Barzo, Pal; Vecsei, Laszlo			Target Identification for Stereotactic Thalamotomy Using Diffusion Tractography	PLOS ONE			English	Article							DEEP BRAIN-STIMULATION; ESSENTIAL TREMOR; PARKINSONS-DISEASE; THALAMIC-STIMULATION; MULTIPLE-SCLEROSIS; VIM THALAMOTOMY; HIGH-RESOLUTION; NUCLEUS; SEGMENTATION; VALIDATION	Background: Stereotactic targets for thalamotomy are usually derived from population-based coordinates. Individual anatomy is used only to scale the coordinates based on the location of some internal guide points. While on conventional MR imaging the thalamic nuclei are indistinguishable, recently it has become possible to identify individual thalamic nuclei using different connectivity profiles, as defined by MR diffusion tractography. Methodology and Principal Findings: Here we investigated the inter-individual variation of the location of target nuclei for thalamotomy: the putative ventralis oralis posterior (Vop) and the ventral intermedius (Vim) nucleus as defined by probabilistic tractography. We showed that the mean inter-individual distance of the peak Vop location is 7.33 mm and 7.42 mm for Vim. The mean overlap between individual Vop nuclei was 40.2% and it was 31.8% for Vim nuclei. As a proof of concept, we also present a patient who underwent Vop thalamotomy for untreatable tremor caused by traumatic brain injury and another patient who underwent Vim thalamotomy for essential tremor. The probabilistic tractography indicated that the successful tremor control was achieved with lesions in the Vop and Vim respectively. Conclusions: Our data call attention to the need for a better appreciation of the individual anatomy when planning stereotactic functional neurosurgery.	[Kincses, Zsigmond Tamas; Szabo, Nikoletta; Dezsi, Livia; Klivenyi, Peter; Kiraly, Andras; Vecsei, Laszlo] Univ Szeged, Albert Szent Gyorgy Clin Ctr, Dept Neurol, Szeged, Hungary; [Kincses, Zsigmond Tamas] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Valalik, Istvan] St Johns Hosp, Dept Neurosurg, Budapest, Hungary; [Kopniczky, Zsolt; Barzo, Pal] Univ Szeged, Albert Szent Gyorgy Clin Ctr, Dept Neurosurg, Szeged, Hungary; [Jenkinson, Mark] Univ Oxford, John Radcliffe Hosp, FMRIB Ctr, Dept Clin Neurol, Oxford OX3 9DU, England; [Babos, Magor] Euromed Diagnost Hungary Ltd, Szeged, Hungary; [Voeroes, Erika] Univ Szeged, Albert Szent Gyorgy Clin Ctr, Dept Radiol, Szeged, Hungary		Kincses, ZT (corresponding author), Univ Szeged, Albert Szent Gyorgy Clin Ctr, Dept Neurol, Szeged, Hungary.	kincsesz@nepsy.szote.u-szeged.hu	Vecsei, Laszlo/ABA-6137-2021; Kincses, Zsigmond Tamas/N-4849-2015; Kopniczky, Zsolt/G-7771-2012; Jenkinson, Mark/AAC-8861-2019; Vecsei, Laszlo/B-2066-2010; Kincses, Zsigmond Tamas/A-6507-2012	Kincses, Zsigmond Tamas/0000-0002-1442-4475; Jenkinson, Mark/0000-0001-6043-0166; Vecsei, Laszlo/0000-0001-8037-3672; Kincses, Zsigmond Tamas/0000-0002-1442-4475; Klivenyi, Peter/0000-0002-5389-3266; Szabo, Nikoletta/0000-0003-1656-5121; Kiraly, Andras/0000-0003-3729-3911	Medical Research Council (ETT)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [026-04]; Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged; Hungarian Academy of SciencesHungarian Academy of Sciences; International Research Center (FNUSA-ICRC) [CZ.1.05/1.1.00/02.0123]; European Regional Development FundEuropean Commission; Creating the Center of Excellence at the University of Szeged [TAMOP-4.2.1/B-09/1/KONV-2010-0005]	Dr. Laszlo Vecsei was supported by the Medical Research Council (ETT 026-04) and the "Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged.". Dr. Zsigmond Tamas Kincses was supported by the Bolyai Scholarship Programme of the Hungarian Academy of Sciences and by the project International Research Center (FNUSA-ICRC, no. CZ.1.05/1.1.00/02.0123) from the European Regional Development Fund. Dr. Vecsei, Dr. Kincses, Dr. Szabo and Dr. Klivenyi were supported by "TAMOP-4.2.1/B-09/1/KONV-2010-0005 - Creating the Center of Excellence at the University of Szeged'' grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alusi SH, 2001, BRAIN, V124, P1576, DOI 10.1093/brain/124.8.1576; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344; Bittar RG, 2005, J CLIN NEUROSCI, V12, P638, DOI 10.1016/j.jocn.2004.09.008; Blomstedt P, 2007, BRIT J NEUROSURG, V21, P504, DOI 10.1080/02688690701552278; Broggi G, 2006, ACTA NEUROCHIR SUPPL, V99, P13, DOI 10.1007/978-3-211-35205-2_2; BROGGI G, 1993, MOVEMENT DISORD, V8, P206, DOI 10.1002/mds.870080217; Chen H, 2010, CHINESE MED J-PEKING, V123, P695, DOI 10.3760/cma.j.issn.0366-6999.2010.06.011; Critchley GR, 1998, BRIT J NEUROSURG, V12, P559, DOI 10.1080/02688699844439; Crum WR, 2006, IEEE T MED IMAGING, V25, P1451, DOI 10.1109/TMI.2006.880587; Deoni SCL, 2005, HUM BRAIN MAPP, V25, P353, DOI 10.1002/hbm.20117; Deoni SCL, 2007, NEUROIMAGE, V34, P117, DOI 10.1016/j.neuroimage.2006.09.016; Dormont D, 1997, AM J NEURORADIOL, V18, P1093; Flora ED, 2010, MOVEMENT DISORD, V25, P1550, DOI 10.1002/mds.23195; Foote KD, 2006, NEUROSURGERY, V58, P280, DOI 10.1227/01.NEU.0000192692.95455.FD; Franzini A, 2011, J NEURAL TRANSM; Gallay MN, 2008, BRAIN STRUCT FUNCT, V212, P443, DOI 10.1007/s00429-007-0170-0; GUIOT G, 1968, NEUROCHIRURGIE, V14, P553; Hamani C, 2006, NEUROSURGERY, V58, P146, DOI 10.1227/01.NEU.0000192166.62017.C1; Hassler R, 1954, NERVENARZT, V25, P441; Hooper AK, 2008, STEREOT FUNCT NEUROS, V86, P147, DOI 10.1159/000120426; Hyam JA, 2011, NEUROSURGERY; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; Kim MC, 2002, J NEUROL NEUROSUR PS, V73, P453, DOI 10.1136/jnnp.73.4.453; Macchi G, 1997, J NEUROSURG, V86, P670, DOI 10.3171/jns.1997.86.4.0670; Molnar GF, 2005, J NEUROPHYSIOL, V93, P3094, DOI 10.1152/jn.00881.2004; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; Muthusamy KA, 2007, J NEUROSURG, V107, P814, DOI 10.3171/JNS-07/10/0814; NARABAYASHI H, 1980, APPL NEUROPHYSIOL, V43, P222; Nowinski WL, 2005, STEREOT FUNCT NEUROS, V83, P190, DOI 10.1159/000091082; Nowinski WL, 2002, STEREOT FUNCT NEUROS, V79, P1, DOI 10.1159/000069499; Pahwa R, 2006, J NEUROSURG, V104, P506, DOI 10.3171/jns.2006.104.4.506; Sanborn MR, 2009, STEREOT FUNCT NEUROS, V87, P128, DOI 10.1159/000207201; Sedrak M, 2011, NEUROSURGERY; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Traynor C, 2010, NEUROIMAGE; Yamada K, 2010, AM J NEURORADIOL, V31, P732, DOI 10.3174/ajnr.A1870; Zesiewicz TA, 2005, NEUROLOGY, V64, P2008, DOI 10.1212/01.WNL.0000163769.28552.CD	42	26	26	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2012	7	1							e29969	10.1371/journal.pone.0029969			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	902VE	WOS:000301070200062	22238685	Green Published, Green Submitted, gold			2022-02-06	
J	Brittain, JM; Pan, R; You, HT; Brustovetsky, T; Brustovetsky, N; Zamponi, GW; Lee, WH; Khanna, R				Brittain, Joel M.; Pan, Rui; You, Haitao; Brustovetsky, Tatiana; Brustovetsky, Nickolay; Zamponi, Gerald W.; Lee, Wei-Hua; Khanna, Rajesh			Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model	CHANNELS			English	Article						N-methylD-aspartate receptor; CRMP-2; peptide; focal cerebral ischemia; MCAO model	TRAUMATIC BRAIN-INJURY; RESPONSE MEDIATOR PROTEIN-2; CALCIUM-CHANNEL ANTAGONIST; NMDA RECEPTOR SUBUNITS; GENE-EXPRESSION; NEUROPROTECTION; GLUTAMATE; TRANSIENT; STROKE; HIPPOCAMPUS	Collapsin response mediator protein 2 (CRMP-2), traditionally viewed as an axon/dendrite specification and axonal growth protein, has emerged as nidus in regulation of both pre- and post-synaptic Ca2+ channels. Building on our discovery of the interaction and regulation of Ca2+ channels by CRMP-2, we recently identified a short sequence in CRMP-2 which, when appended to the transduction domain of HIV TAT protein, suppressed acute, inflammatory and neuropathic pain in vivo by functionally uncoupling CRMP-2 from the Ca2+ channel. Remarkably, we also found that this region attenuated Ca2+ influx via N-methylD-Aspartate receptors (NMDARs) and reduced neuronal death in a moderate controlled cortical impact model of traumatic brain injury (TBI). Here, we sought to extend these findings by examining additional neuroprotective effects of this peptide (TAT-CBD3) and exploring the biochemical mechanisms by which TAT-CBD3 targets NMDARs. We observed that an intraperitoneal injection of TAT-CBD3 peptide significantly reduced infarct volume in an animal model of focal cerebral ischemia. Neuroprotection was observed when TAT-CBD3 peptide was given either prior to or after occlusion but just prior to reperfusion. Surprisingly, a direct biochemical complex was not resolvable between the NMDAR subunit NR2B and CRMP-2. Intracellular application of TAT-CBD3 failed to inhibit NMDAR current. NR2B interactions with the post synaptic density protein 95 (PSD-95) remained intact and were not disrupted by TAT-CBD3. Peptide tiling of intracellular regions of NR2B revealed two 15-mer sequences, in the carboxyl-terminus of NR2B, that may confer binding between NR2B and CRMP-2 which supports CRMP-2's role in excitotoxicity and neuroprotection.	[Brittain, Joel M.; Brustovetsky, Nickolay; Lee, Wei-Hua; Khanna, Rajesh] Indiana Univ, Sch Med, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN 46204 USA; [Pan, Rui] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pediat, Wuhan 430074, Hubei, Peoples R China; [You, Haitao; Zamponi, Gerald W.] Univ Calgary, Hotchkiss Brain Inst, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Brustovetsky, Tatiana; Brustovetsky, Nickolay; Khanna, Rajesh] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Brustovetsky, Tatiana; Brustovetsky, Nickolay; Khanna, Rajesh] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Lee, Wei-Hua] Indiana Univ, Sch Med, Indiana Spinal Cord & Brain Injury Res Grp, Indianapolis, IN USA; [Khanna, Rajesh] Sophia Therapeut LLC, Indianapolis, IN USA		Khanna, R (corresponding author), Indiana Univ, Sch Med, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN 46204 USA.	khanna5@iupui.edu		Khanna, Rajesh/0000-0002-9066-2969; Zamponi, Gerald/0000-0002-0644-9066	Indiana Clinical and Translational Sciences Institute; National Institutes of Health, National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR025761]; Indiana State Department of Health [A70-9-079138]; Indiana University Biomedical Committee [2286501]; National Scientist Development from the American Heart AssociationAmerican Heart Association [SDG5280023]; Elwert Award in Medicine; Larry Kays Medical Neuroscience fellowship; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078008] Funding Source: NIH RePORTER	The authors would like to acknowledge Sarah Wilson, Dr May Khanna and colleagues at the Stark Neurosciences Research Institute (SNRI) for comments on the manuscript. The peptide blot was synthesized at the SNRI core facility by Dr Andy Hudmon with assistance from Nicole Ashpole. This work was supported, in part, by grants from the Indiana Clinical and Translational Sciences Institute funded, in part by a Project Development Team Grant Number (RR025761) from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award, the Indiana State Department of Health-Spinal Cord and Brain Injury Fund (A70-9-079138 to R. K.), the Indiana University Biomedical Committee-Research Support Funds (2286501 to R. K.), a National Scientist Development from the American Heart Association (SDG5280023 to R. K.), and the Elwert Award in Medicine to R.K. J. M. B. is the recipient of a Larry Kays Medical Neuroscience fellowship. R. K. is a majority shareholder of Sophia Therapeutics L.L.C.	Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Al-Hallaq RA, 2007, J NEUROSCI, V27, P8334, DOI 10.1523/JNEUROSCI.2155-07.2007; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bordet T, 2009, NEUROTHERAPEUTICS, V6, P648, DOI 10.1016/j.nurt.2009.07.001; Bordi F, 1997, EXP NEUROL, V145, P425, DOI 10.1006/exnr.1997.6442; Bowersox SS, 1997, BRAIN RES, V747, P343; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Brustovetsky T, 2009, CELL CALCIUM, V46, P18, DOI 10.1016/j.ceca.2009.03.017; Bu XN, 2011, J NEUROCHEM, V117, P346, DOI 10.1111/j.1471-4159.2011.07209.x; Chi XX, 2009, J CELL SCI, V122, P4351, DOI 10.1242/jcs.053280; Chung MA, 2005, NEUROREPORT, V16, P1647, DOI 10.1097/01.wnr.0000176520.49841.e6; DAWSON DA, 1994, BRIT J PHARMACOL, V113, P247, DOI 10.1111/j.1476-5381.1994.tb16201.x; Derugin N, 1998, NEUROSCI RES, V32, P349, DOI 10.1016/S0168-0102(98)00096-0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Hensley K, 2011, MOL NEUROBIOL, V43, P180, DOI 10.1007/s12035-011-8166-4; Hou ST, 2009, J NEUROCHEM, V111, P870, DOI 10.1111/j.1471-4159.2009.06375.x; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Indraswari F, 2009, NEUROCHEM INT, V55, P235, DOI 10.1016/j.neuint.2009.03.005; Kloda A, 2007, CHANNELS, V1, P334, DOI 10.4161/chan.5044; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Martel MA, 2009, CHANNELS, V3, P12, DOI 10.4161/chan.3.1.7864; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Niethammer M, 1996, J NEUROSCI, V16, P2157; Orgogozo JM, 2002, STROKE, V33, P1834, DOI 10.1161/01.STR.0000020094.08790.49; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Perez-Pinzon MA, 1997, J NEUROL SCI, V153, P25, DOI 10.1016/S0022-510X(97)00196-2; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Ryan TJ, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-6; SAUTER A, 1995, J PHARMACOL EXP THER, V274, P1008; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Takahara A, 2004, BIOL PHARM BULL, V27, P1388, DOI 10.1248/bpb.27.1388; Touma E, 2007, EUR J NEUROSCI, V26, P3368, DOI 10.1111/j.1460-9568.2007.05943.x; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; Villmann C, 2007, NEUROSCIENTIST, V13, P594, DOI 10.1177/1073858406296259; Wang Yuying, 2010, Commun Integr Biol, V3, P172; Wilson SM, 2011, CHANNELS, V5, P447, DOI 10.4161/chan.5.5.17363; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078	42	26	27	0	10	LANDES BIOSCIENCE	AUSTIN	1806 RIO GRANDE ST, AUSTIN, TX 78702 USA	1933-6950			CHANNELS	Channels	JAN-FEB	2012	6	1					52	59		10.4161/chan.18919			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	953XG	WOS:000304906500007	22373559	Green Published, Green Submitted, gold			2022-02-06	
J	Egede, LE; Dismuke, C; Echols, C				Egede, Leonard E.; Dismuke, Clara; Echols, Carrae			Racial/Ethnic Disparities in Mortality Risk Among US Veterans With Traumatic Brain Injury	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							HEALTH-CARE-SYSTEM; RACIAL DISPARITIES; ETHNIC DISPARITIES; FUNCTIONAL OUTCOMES; ADMINISTRATIVE DATA; REHABILITATION; RACE; MODERATE; COHORT	Objectives. We examined the association of race/ethnicity with mortality risk in a national cohort of US veterans clinically diagnosed with traumatic brain injury. Methods. Between January 1, 2006 and December 31, 2006, we obtained data from a national cohort study of 7885 non-Hispanic White, 1748 Non-Hispanic Black, 314 Hispanic, and 4743 other or missing race/ethnicity veterans clinically diagnosed with traumatic brain injury in Veterans Affairs medical centers and community-based outpatient clinics. Results. Overall mortality at 48 months was 6.7% in Hispanic, 2.9% in non-Hispanic White, and 2.7% in non-Hispanic Black veterans. Compared with non-Hispanic White, Hispanic ethnicity was positively associated with a higher mortality risk (hazard ratio [HR]=2.33; 95% confidence interval [CI]=1.49, 3.64) in the race/ethnicity-only adjusted model. After adjusting for sociodemographic characteristics and comorbidities, Hispanic ethnicity continued to be positively associated (HR=1.61; 95% CI=1.00, 2.58) with a higher mortality risk relative to non-Hispanic White ethnicity. Conclusions. Hispanic ethnicity is positively associated with higher mortality risk among veterans clinically diagnosed with traumatic brain injury. More research is needed to understand the reasons for this disparity. (Am J Public Health. 2011;102:S266-S271. doi:10.2105/AJPH.2011.300176)	[Egede, Leonard E.; Dismuke, Clara] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA; [Egede, Leonard E.; Dismuke, Clara; Echols, Carrae] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC USA		Egede, LE (corresponding author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA.	egedel@musc.edu			Veterans Health Administration Health Services Research and Development (HSRD) [REA 08-261]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K24DK093699] Funding Source: NIH RePORTER	This study was funded by the Veterans Health Administration Health Services Research and Development (HSR&D) program (grant REA 08-261).	[Anonymous], 2008, SAS STAT VERS 9 1 3; [Anonymous], 1980, INT CLASS DIS 9 REV; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Arthur M, 2008, MED CARE, V46, P192, DOI 10.1097/MLR.0b013e31815b9d8e; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Catalano D, 2006, NEUROREHABILITATION, V21, P279; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; Deswal A, 2004, J AM COLL CARDIOL, V43, P778, DOI 10.1016/j.jacc.2003.10.033; Ellis C, 2009, ETHNIC DIS, V19, P161; Fischer HUS, 2010, MILITARY CASUALTY ST; Frei CR, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-143; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Helmer Drew, 2008, Prim Care Diabetes, V2, P73, DOI 10.1016/j.pcd.2008.02.004; Jha AK, 2001, JAMA-J AM MED ASSOC, V285, P297, DOI 10.1001/jama.285.3.297; Lynch CP, 2010, J GEN INTERN MED, V25, P1051, DOI 10.1007/s11606-010-1405-y; Mapppsy LKR, 2008, DIABETES CARE, V31, P880, DOI 10.2337/dc07-2215; Marrero MZ, 2002, CLIN PSYCHOL REV, V22, P463, DOI 10.1016/S0272-7358(01)00109-X; Martin CA, 2010, AM J SURG, V199, P210, DOI 10.1016/j.amjsurg.2009.05.001; McGinnis KA, 2003, AM J PUBLIC HEALTH, V93, P1728, DOI 10.2105/AJPH.93.10.1728; Pappadis MR, 2010, J HEAD TRAUMA REHABI; Proctor A, 2008, NEUROREHABILITATION, V23, P529; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Saha S, 2008, J GEN INTERN MED, V23, P654, DOI 10.1007/s11606-008-0521-4; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Sorani MD, 2009, J TRAUMA, V67, P75, DOI 10.1097/TA.0b013e31818234e8; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Volpp KG, 2007, HEALTH SERV RES, V42, P1613, DOI 10.1111/j.1475-6773.2006.00688.x; Wolinsky FD, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-131; Young BA, 2003, DIABETES CARE, V26, P2392, DOI 10.2337/diacare.26.8.2392	34	26	26	0	2	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health		2012	102			2			S266	S271		10.2105/AJPH.2011.300176			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	928FV	WOS:000302969500021	21852658	Green Published			2022-02-06	
J	French, LM; Lange, RT; Iverson, GL; Ivins, B; Marshall, K; Schwab, K				French, Louis M.; Lange, Rael T.; Iverson, Grant L.; Ivins, Brian; Marshall, Katherine; Schwab, Karen			Influence of Bodily Injuries on Symptom Reporting Following Uncomplicated Mild Traumatic Brain Injury in US Military Service Members	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						bodily injuries; mild traumatic brain injury; postconcussion symptoms; PTSD	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSION SYNDROME; POST-CONCUSSION SYNDROME; CHRONIC PAIN; DEPRESSION; SOLDIERS; BLAST; IRAQ; REHABILITATION; AFGHANISTAN	Objective: To examine the relations among bodily injuries, traumatic stress, and postconcussion symptoms in a sample of combat-injured US service members who sustained a mild traumatic brain injury. Participants: One hundred and thirty-seven service members evaluated and treated at Walter Reed Army Medical Center following medical evacuation from the combat theater of Operation Enduring Freedom and Operation Iraqi Freedom. All had sustained an uncomplicated mild traumatic brain injury and concurrent bodily injuries. Procedure: Participants completed 2 symptom checklists within 3 months of injury. Severity of bodily injuries was quantified with a modified version of the Injury Severity Score that excluded intracranial injuries (ISS(mod)). Participants were classified into 4 ISS(mod) groups: minor (n = 17), moderate (n = 48), serious (n = 40), severe/critical (n = 32). Main outcome measures: Neurobehavioral Symptom Inventory (NBSI) and the Posttraumatic Stress Disorder Checklist-Civilian version (PCLC). Results: There was a significant negative association between ISSmod scores and the NBSI and PCLC total scores. There were significant main effects across the 4 groups for the NBSI and PCLC total scores. The highest NBSI and PCLC scores were consistently found in the ISSmod minor group, followed by the moderate, serious, and severe/critical groups. Conclusions: While it might be expected that greater comorbid physical injuries would be associated with greater symptom burden, in this study as the severity of bodily injuries increased, symptom burden decreased. Hypothesized explanations include: underreporting of symptoms; increased peer support; disruption of fear conditioning due to acute morphine use; or delayed expression of symptoms.	[French, Louis M.; Lange, Rael T.; Iverson, Grant L.; Ivins, Brian; Marshall, Katherine; Schwab, Karen] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA		Lange, RT (corresponding author), Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Bldg 1,Room B207,6900 Georgia Ave NW, Washington, DC 20307 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	Iverson, Grant/0000-0001-7348-9570; french, louis/0000-0002-9451-0604			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2009, BIOL PSYCHIAT, V65, P438, DOI 10.1016/j.biopsych.2008.10.032; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Guez M, 2005, J CLIN EXP NEUROPSYC, V27, P151, DOI 10.1080/13803390490515487; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Helmer DA, 2009, PAIN MED, V10, P1174, DOI 10.1111/j.1526-4637.2009.00723.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; IVERSON GL, 2001, J FORENSIC NEUROPSYC, V2, P19, DOI DOI 10.1300/J151v02n01_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JAMISON RN, 1988, INT J PSYCHIAT MED, V18, P183; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Managment of Concussion/nTBI Working Group, 2009, VA DOD CLIN PRACT GU; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Melcer T, 2010, MIL MED, V175, P147, DOI 10.7205/MILMED-D-09-00120; Mental Health Advisory Team V, 2011, OP IR FREED 06 08 IR; Messinger SD, 2009, DISABIL REHABIL, V31, P2130, DOI [10.3109/09638280902943223a, 10.3109/09638280902943223]; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pasquina PF, 2008, J REHABIL RES DEV, V45, P953, DOI 10.1682/JRRD.2007.10.0163; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Quale AJ, 2009, INJURY, V40, P498, DOI 10.1016/j.injury.2008.11.006; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; WARDEN DL, 2005, TXB TRAUMATIC BRAIN, P231; World Health Organization, 2004, ICD 10 INT STAT CLAS	50	26	26	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					63	74		10.1097/HTR.0b013e3182248344			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400007	21897286				2022-02-06	
J	Grujicic, M; Arakere, A; Pandurangan, B; Grujicic, A; Littlestone, A; Barsoum, R				Grujicic, M.; Arakere, A.; Pandurangan, B.; Grujicic, A.; Littlestone, A.; Barsoum, R.			Computational investigation of shock-mitigation efficacy of polyurea when used in a combat helmet A core sample analysis	MULTIDISCIPLINE MODELING IN MATERIALS AND STRUCTURES			English	Article						Polyurea; Shock mitigation; Combat helmet; Force; Strength of materials		Purpose - Polyurea falls into a category of elastomeric co-polymers in which, due to the presence of strong hydrogen bonding, the microstructure is of a heterogeneous nature and consists of a compliant/soft matrix and stiff/hard nanometer size hard domains. Recent investigations have shown that the use of polyurea as an external or internal coating/lining had substantially improved ballistic-penetration resistance of metallic structures. The present work aims to use computational methods and tools in order to assess the shock-mitigation ability of polyurea when used in the construction of different components (suspension-pads, internal lining and external coating) of a combat helmet. Design/methodology/approach - Shock-mitigation capability of combat helmets has become an important functional requirement as shock-ingress into the intra-cranial cavity is known to be one of the main causes of traumatic brain injury (TBI). To assess the shock mitigation capability of polyurea, a combined Eulerian/Lagrangian fluid/solid transient non-linear dynamics computational analysis of an air/helmet/head core sample is carried out and the temporal evolution of the axial stress and particle velocities (for different polyurea augmented helmet designs) are monitored. Findings - The results obtained show that improvements in the shock-mitigation performance of the helmet are obtained only in the case when polyurea is used as a helmet internal lining and that these improvements are relatively small. In addition, polyurea is found to slightly outperform conventional helmet foam, but only under relatively strong (greater than five atm) blastwave peak overpressures. Originality/value - The present approach studies the effect of internal linings and external coatings on combat helmet blast mitigation performance.	[Grujicic, M.; Arakere, A.; Grujicic, A.] Clemson Univ, Clemson, SC 29634 USA; [Pandurangan, B.] Corvid Technol, Mooresville, NC USA; [Littlestone, A.] Naval Surface Warfare Ctr, Carderock Div, West Bethesda, MD 20817 USA; [Barsoum, R.] Off Naval Res, Arlington, VA 22101 USA		Grujicic, M (corresponding author), Clemson Univ, Clemson, SC 29634 USA.	gmica@clemson.edu					ABAQUS Version 6. 10 EF1, 2010, US DOC; Amini MR, 2010, MECH MATER, V42, P615, DOI 10.1016/j.mechmat.2009.09.009; Amirkhizi AV, 2006, PHILOS MAG, V86, P5847, DOI 10.1080/14786430600833198; [Anonymous], 2007, US DOC; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cooper PW., 1996, EXPLOSIVES ENG; Cuitino A., 1992, ENG COMPUT-GERMANY, V9, P437, DOI DOI 10.1108/EB023876>; Davison L, 2008, FUNDAMENTALS SHOCKWA; Grujicic M, 2010, MULTIDISCIP MODEL MA, V6, P335, DOI 10.1108/15736101011080097; Grujicic M, 2011, P I MECH ENG L-J MAT, V225, P182, DOI 10.1177/0954420711401959; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Grujicic M, 2011, MAT SCI ENG A-STRUCT, V528, P3799, DOI 10.1016/j.msea.2011.01.081; Grujicic M, 2010, MAT SCI ENG A-STRUCT, V527, P7741, DOI 10.1016/j.msea.2010.08.042; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Grujicic M, 2009, MATER DESIGN, V30, P4273, DOI 10.1016/j.matdes.2009.04.028; Grujicic M., 2010, J MATER ENG PERFORM, V21, P2; Grujicic M, 2011, J MATER SCI, V46, P1767, DOI 10.1007/s10853-010-4998-y; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hyde D., 1988, 58551 TM US ARM ENG; Moore DF, 2008, ANN NEUROL, V64, pS30; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Wallsten S. J., 2005, 0519 SOC SCI RES NET; Walsh S. M., 2005, ARLTR3700; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	27	26	27	0	0	EMERALD GROUP PUBLISHING LTD	BINGLEY	HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND	1573-6105	1573-6113		MULTIDISCIP MODEL MA	Multidiscip. Model. Mater. Struct.		2012	8	3					297	+		10.1108/15736101211269122			37	Materials Science, Multidisciplinary; Mechanics	Emerging Sources Citation Index (ESCI)	Materials Science; Mechanics	V1U7Y	WOS:000217254100002					2022-02-06	
J	Hockel, K; Scholler, K; Trabold, R; Nussberger, J; Plesnila, N				Hockel, Konstantin; Schoeller, Karsten; Trabold, Raimund; Nussberger, Juerg; Plesnila, Nikolaus			Vasopressin V-1a Receptors Mediate Posthemorrhagic Systemic Hypertension Thereby Determining Rebleeding Rate and Outcome After Experimental Subarachnoid Hemorrhage	STROKE			English	Article						antidiuretic hormone (ADH); arginine vasopressin (AVP); brain edema; Cushing response; experimental; rat; subarachnoid hemorrhage; V1(a) receptors	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; ARGININE-VASOPRESSIN; V-2 RECEPTORS; PLASMA; EDEMA; MODEL; MECHANISMS; ISCHEMIA; HORMONE	Background and Purpose-Arginine vasopressin V-1 receptors have been suggested to be involved in the pathophysiology of acute brain injury. Therefore, we aimed to determine the role of arginine vasopressin V-1 receptors after experimental subarachnoid hemorrhage (SAH). Methods-Sprague-Dawley rats subjected to SAH by endovascular puncture received either vehicle or a V1 receptor antagonist intravenously from 1 minute before until 3 hours after SAH. Intracranial pressure, cerebral blood flow, and mean arterial blood pressure were monitored until 60 minutes after SAH. Brain water content was quantified 24 hours after SAH and neurological function and mortality were assessed daily for 7 days after hemorrhage. Results-In control rats, SAH induced high intracranial pressure, a brief increase in plasma arginine vasopressin, a subsequent increase in systemic blood pressure (Cushing response), a high rebleeding rate (30%), severe neurological deficits, and a 7-day mortality rate of 50%. V1 receptor antagonist-treated animals exhibited a far less pronounced Cushing response, a less severe increase of intracranial pressure, did not exhibit rebleedings, had less severe brain edema formation and neurological deficits, and a mortality rate of only 20% (all P<0.05 versus vehicle). Conclusions-Inhibition of arginine vasopressin V-1a receptors reduces the severity of SAH and prevents rebleedings by blunting the posthemorrhagic hypertonic response (Cushing reflex), thereby reducing mortality and secondary brain damage after experimental SAH. Because the severity of the initial bleeding and rebleedings are major factors contributing to an unfavorable outcome after SAH, inhibition of V-1a receptors may represent a novel strategy to treat SAH. (Stroke. 2012;43:227-232.)	[Plesnila, Nikolaus] Univ Munich, Inst Stroke & Dementia Res, Med Ctr, Munich, Germany; [Schoeller, Karsten; Trabold, Raimund] Univ Munich, Med Ctr Grosshadern, Dept Neurosurg, Munich, Germany; [Hockel, Konstantin; Schoeller, Karsten; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Inst Surg Res, Munich, Germany; [Nussberger, Juerg] CHU Vaudois, Div Angiol & Hypertens, CH-1011 Lausanne, Switzerland; Univ Lausanne, Lausanne, Switzerland; [Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dublin 2, Ireland		Plesnila, N (corresponding author), Univ Munich, Inst Stroke & Dementia Res, Med Ctr, Munich, Germany.	plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019		Friedrich Baur Foundation	The current study was partly funded by a grant from the Friedrich Baur Foundation.	BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Chen EP, 1996, CRIT CARE MED, V24, P1352, DOI 10.1097/00003246-199608000-00014; Claassen J, 2004, CRIT CARE MED, V32, P832, DOI 10.1097/01.CCM.0000114830.48833.8A; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; ISOTANI E, 1994, STROKE, V25, P2198, DOI 10.1161/01.STR.25.11.2198; JOYNT RJ, 1981, ANN NEUROL, V9, P182, DOI 10.1002/ana.410090212; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P303; Kleindienst A, 2004, ACTA NEUROL SCAND, V109, P361, DOI 10.1046/j.1600-0404.2003.00245.x; Kozniewska E, 2006, J PHYSIOL PHARMACOL, V57, P145; LIU XF, 1991, CHINESE MED J-PEKING, V104, P480; MANNING M, 1987, NATURE, V329, P839, DOI 10.1038/329839a0; MATHER HM, 1981, J NEUROL NEUROSUR PS, V44, P216, DOI 10.1136/jnnp.44.3.216; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Ostrowski RP, 2006, NEUROL RES, V28, P399, DOI 10.1179/016164106X115008; SCHALLER MD, 1987, AM J CARDIOL, V60, P1178, DOI 10.1016/0002-9149(87)90416-4; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Tribollet E, 1998, PROG BRAIN RES, V119, P45; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Xu M, 2007, CHIN J TRAUMATOL, V10, P90; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4	26	26	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	JAN	2012	43	1					227	U432		10.1161/STROKEAHA.111.626168			10	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	866LY	WOS:000298383600056	21998059	Bronze			2022-02-06	
J	Kurowski, B; Martin, LJ; Wade, SL				Kurowski, Brad; Martin, Lisa J.; Wade, Shari L.			Genetics and outcomes after traumatic brain injury (TBI): What do we know about pediatric TBI?	JOURNAL OF PEDIATRIC REHABILITATION MEDICINE			English	Article						Brain injuries; child; genes; genetic polymorphism; epidemiology; pediatric; humans		Human genetic association studies in individuals with traumatic brain injury (TBI) have increased rapidly over the past few years. Recently, several review articles evaluated the association of genetics with outcomes after TBI. However, almost all of the articles discussed in these reviews focused on adult TBI. The primary objective of this review is to gain a better understanding of which genes and/or genetic polymorphisms have been evaluated in pediatric TBI. Our initial search identified 113 articles. After review of these articles only 5 genetic association studies specific to pediatric TBI were identified. All five of these studies evaluated the apolipoprotein (APOE) gene. The study design and methods of these identified papers will be discussed. An additional search was then performed to evaluate genes beyond APOE that have been evaluated in adult TBI; findings from these studies are highlighted. Larger genetic studies will need to be performed in the future to better elucidate the association of APOE and other genes with outcomes after TBI in children. There is great potential to utilized genetic information to inform prognosis and management after TBI in children; however, we have much work ahead of us to reach the goal of individualized management.	[Kurowski, Brad; Wade, Shari L.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Phys Med & Rehabil,Dept Pediat, Cincinnati, OH USA; [Martin, Lisa J.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Coll Med, Div Human Genet,Dept Pediat, Cincinnati, OH USA		Kurowski, B (corresponding author), Cincinnati Childrens Hosp Med Ctr, MLC 4009,3333 Burnet Ave, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org	Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946	Rehabilitation Medicine Scientist Training Program (RMSTP) [7K12 HD001097-14]; National Institute of MentalHealth (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5R01MH073764-03]; National Institute on Disability and Rehabilitation Research, Department of Education [H133B090010]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	Support from this work was provided through the Rehabilitation Medicine Scientist Training Program (RMSTP) 7K12 HD001097-14, the National Institute of MentalHealth (NIMH) 5R01MH073764-03, and H133B090010 from the National Institute on Disability and Rehabilitation Research, Department of Education.	Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Anderson GD, 2009, EPILEPSY BEHAV, V16, P501, DOI 10.1016/j.yebeh.2009.08.025; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Ariza M, 2006, J NEUROPSYCH CLIN N, V18, P39, DOI 10.1176/appi.neuropsych.18.1.39; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Brichtova E, 2008, CHILD NERV SYST, V24, P349, DOI 10.1007/s00381-007-0459-6; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Chiang MF, 2003, ACTA NEUROCHIR WIEN, V145, P53; Chuang PY, 2010, J NEUROTRAUM, V27, P999, DOI 10.1089/neu.2009.1129; Dalla Libera AL, 2011, BRAIN INJURY, V25, P365, DOI 10.3109/02699052.2011.556107; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Faul M, 2010, TRAUMATIC BRAIN INJU; Fowke Jay H, 2009, J Prev Med Public Health, V42, P343, DOI 10.3961/jpmph.2009.42.6.343; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Han SD, 2009, J HEAD TRAUMA REHAB, V24, P57, DOI 10.1097/HTR.0b013e3181957055; Harding DR, 2004, PEDIATRICS, V114, P941, DOI 10.1542/peds.2003-0494-F; Henskens LHG, 2005, STROKE, V36, P1869, DOI 10.1161/01.STR.0000177867.39769.cb; Hiekikanen H, 2007, BRAIN INJURY, V21, P1307, DOI 10.1080/02699050701739549; Hiekkanen H, 2009, BRAIN INJURY, V23, P396, DOI 10.1080/02699050902926259; Hoh NZ, 2010, J NEUROTRAUM, V27, P1413, DOI 10.1089/neu.2009.1256; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Jiang Y, 2008, ACTA NEUROCHIR SUPPL, V105, P233; Jiang Y, 2007, J NEUROTRAUM, V24, P1802, DOI 10.1089/neu.2007.0299; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Johnson VE, 2006, CLIN NEUROPATHOL, V25, P255; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Kerr ME, 2003, CRIT CARE MED, V31, P2371, DOI 10.1097/01.CCM.0000080484.72004.C4; Kohane IS, 2011, NAT REV GENET, V12, P417, DOI 10.1038/nrg2999; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Krupa Mariusz, 2003, Neurol Neurochir Pol, V37, P1223; Kurowski B, 2012, AM J PHYS MED REHAB, V91, P285; Lanctot KL, 2010, BRAIN INJURY, V24, P959, DOI 10.3109/02699051003789229; Lawford BR, 2003, EUR NEUROPSYCHOPHARM, V13, P313, DOI 10.1016/S0924-977X(02)00152-9; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Lo TYM, 2009, CHILD NERV SYST, V25, P47, DOI 10.1007/s00381-008-0723-4; Luukinen H, 2008, ACTA NEUROL SCAND, V118, P153, DOI 10.1111/j.1600-0404.2008.00994.x; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Martinez-Lucas P, 2005, INTENS CARE MED, V31, P1168, DOI 10.1007/s00134-005-2715-0; Mauri M, 2006, FUNCT NEUROL, V21, P223; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2010, PM&R, V2, pS241, DOI 10.1016/j.pmrj.2010.10.005; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McDonagh DL, 2010, ANESTHESIOLOGY, V112, P852, DOI 10.1097/ALN.0b013e3181d31fd7; Miller MA, 2010, BRAIN INJURY, V24, P1468, DOI 10.3109/02699052.2010.520299; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Noe E, 2010, BRAIN INJURY, V24, P886, DOI 10.3109/02699051003724952; Olivecrona M, 2010, J NEUROSURG, V112, P1113, DOI 10.3171/2009.8.JNS09636; Ost M, 2008, ACTA ANAESTH SCAND, V52, P1364, DOI 10.1111/j.1399-6576.2008.01675.x; Plomin R, 2009, J CHILD PSYCHOL PSYC, V50, P63, DOI 10.1111/j.1469-7610.2008.01978.x; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Quinn TJ, 2004, NEUROPATH APPL NEURO, V30, P569, DOI 10.1111/j.1365-2990.2004.00581.x; Qureischie H, 2009, J NEURAL TRANSM, V116, P467, DOI 10.1007/s00702-008-0180-y; Rao R, 2008, NEUROL SCI, V29, pS144, DOI 10.1007/s10072-008-0907-4; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Romeiro RR, 2007, NEUROSCI LETT, V426, P133, DOI 10.1016/j.neulet.2007.09.004; Sarnaik AA, 2010, J NEUROTRAUM, V27, P465, DOI 10.1089/neu.2009.1171; Shadli RM, 2011, BRAIN INJURY, V25, P596, DOI 10.3109/02699052.2011.572947; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Stover PJ, 2010, CURR OPIN LIPIDOL, V21, P136, DOI 10.1097/MOL.0b013e3283377395; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Tang J, 2003, SURG NEUROL, V60, P391, DOI 10.1016/S0090-3019(03)00323-9; Tanriverdi F, 2008, J NEUROTRAUM, V25, P1071, DOI 10.1089/neu.2007.0456; Tanriverdi T, 2006, SURG NEUROL, V65, P7, DOI 10.1016/j.surneu.2005.05.024; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Tierney RT, 2010, CLIN J SPORT MED, V20, P464, DOI 10.1097/JSM.0b013e3181fc0a81; Uzan M, 2005, ACTA NEUROCHIR, V147, P715, DOI 10.1007/s00701-005-0529-z; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Yu W, 2010, BIOINFORMATICS, V26, P145, DOI 10.1093/bioinformatics/btp618; Yu W, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-205; Yu W, 2008, EUR J HUM GENET, V16, P1155, DOI 10.1038/ejhg.2008.95; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	96	26	26	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1874-5393	1875-8894		J PEDIATR REHAB MED	J. Pediatr. Rehab. Med.		2012	5	3					217	231		10.3233/PRM-2012-0214			15	Pediatrics	Emerging Sources Citation Index (ESCI)	Pediatrics	VG7KI	WOS:000448278200010	23023254	Green Accepted			2022-02-06	
J	Landon, J; Shepherd, D; Stuart, S; Theadom, A; Freundlich, S				Landon, Jason; Shepherd, Daniel; Stuart, Stacey; Theadom, Alice; Freundlich, Simone			Hearing every footstep: Noise sensitivity in individuals following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Noise sensitivity; Traumatic brain injury; Post-concussive syndrome; Rehabilitation	HEAD-INJURY; PEOPLE; SELF; EXPERIENCE; DISABILITY; SYMPTOMS	Noise sensitivity is an important and under-researched symptom that can result from traumatic brain injury (TBI). Interpretative phenomenological analysis (IPA) was used to analyse the experiences of noise sensitivity of six individuals with TBI. The results revealed four major themes through which participants described a process of having to find information for themselves to understand what they were experiencing and their changed relationship with sounds. The participants also described feeling overwhelmed as they struggled to cope with the changes to their lives and being able to plan and take some control over their lives. The findings are of importance for both health professionals involved in rehabilitation and individuals recovering from TBI.	[Landon, Jason; Shepherd, Daniel; Stuart, Stacey; Theadom, Alice; Freundlich, Simone] Auckland Univ Technol, Dept Psychol, Auckland 1020, New Zealand		Landon, J (corresponding author), Auckland Univ Technol, Dept Psychol, Private Bag 92006, Auckland 1020, New Zealand.	Jason.landon@aut.ac.nz	Landon, Jason/AAD-3951-2019	Theadom, Alice/0000-0003-0351-6216; Landon, Jason/0000-0002-3595-7430; Shepherd, Daniel/0000-0001-7089-7130			ANDERSON EA, 1987, J CONSULT CLIN PSYCH, V55, P513, DOI 10.1037/0022-006X.55.4.513; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; COHEN F, 1973, PSYCHOSOM MED, V35, P375, DOI 10.1097/00006842-197309000-00002; Dang-Vu TT, 2010, CURR BIOL, V20, pR626, DOI 10.1016/j.cub.2010.06.032; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Gelech JM, 2011, QUAL HEALTH RES, V21, P62, DOI 10.1177/1049732310377454; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Howes H, 2005, PSYCHOL HEALTH, V20, P129, DOI 10.1080/0887044042000272903; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; JOB RFS, 1988, J ACOUST SOC AM, V83, P991, DOI 10.1121/1.396524; JOHNSTON M, 1980, PSYCHOL MED, V10, P145, DOI 10.1017/S0033291700039684; Johnston Marie, 1993, Annals of Behavioral Medicine, V15, P245; Jumisko Eija, 2005, J Neurosci Nurs, V37, P42; Jumisko E, 2009, J CLIN NURS, V18, P2273, DOI 10.1111/j.1365-2702.2008.02738.x; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lazarus RS, 1987, EUR J PERSONAL, V1, P141, DOI [10.1002/per.2410010304, DOI 10.1002/PER.2410010304]; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Miedema HME, 1999, J ACOUST SOC AM, V105, P3336, DOI 10.1121/1.424662; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; O'Callaghan C, 2006, NEUROPSYCHOL REHABIL, V16, P579, DOI 10.1080/09602010500368834; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Paterson J., 2002, REHABIL NURS, V27, P13, DOI DOI 10.1002/J.2048-7940.2002.TB01973.X; Patton M.Q., 1990, QUALITATIVE EVALUATI; Pryor J, 2004, DISABIL REHABIL, V26, P974, DOI 10.1080/09638280410001702397; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Shotton L, 2007, BRAIN INJURY, V21, P857, DOI 10.1080/02699050701481621; Smith J.A., 2003, QUALITATIVE PSYCHOL; SMITH JA, 1999, QUALITATIVE HLTH PSY; STANSFELD SA, 1992, PSYCHOL MED, P1, DOI 10.1017/S0033291716002336; Street RL, 2009, PATIENT EDUC COUNS, V74, P295, DOI 10.1016/j.pec.2008.11.015; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; YOUNG L, 1985, BRIT J CLIN PSYCHOL, V24, P303, DOI 10.1111/j.2044-8260.1985.tb00664.x	38	26	27	0	8	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	3					391	407		10.1080/09602011.2011.652496			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	936BV	WOS:000303566800004	22292864				2022-02-06	
J	Maguen, S; Lau, KM; Madden, E; Seal, K				Maguen, Shira; Lau, Karen M.; Madden, Erin; Seal, Karen			Relationship of screen-based symptoms for mild traumatic brain injury and mental health problems in Iraq and Afghanistan veterans: Distinct or overlapping symptoms?	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						depression; factor analysis; hypervigilance; insomnia; mental health; OIF/OEF; posttraumatic stress disorder; screen; traumatic brain injury; veteran	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; PRIMARY-CARE; PTSD SCREEN; VALIDITY	This study used factor analytic techniques to differentiate distinct from overlapping screen-based symptoms of traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), and depression in Iraq and Afghanistan veterans. These symptoms were derived from screen results of 1,549 veterans undergoing Department of Veterans Affairs postdeployment screening between April 2007 and January 2010. Veterans with positive TBI screens were approximately twice as likely to also screen positive for depression and PTSD (adjusted relative risks = 1.9 and 2.1, respectively). Irritability was a shared symptom between TBI and PTSD, and emotional numbing was a shared symptom between PTSD and depression. Symptoms unique to TBI included dizziness, headaches, memory problems, and light sensitivity. Four separate constructs emerged: TBI, PTSD, depression, and a fourth construct consisting of hypervigilance and sleep problems. These findings illuminate areas of overlap between TBI and common postdeployment mental health problems. Discriminating symptoms of TBI from mental health problems may facilitate diagnosis, triage to specialty care, and targeted symptom management. The emergence of a fourth factor consisting of sleep problems and hypervigilance highlights the need to attend to specific symptoms in the postdeployment screening process.	[Maguen, Shira; Lau, Karen M.; Madden, Erin; Seal, Karen] San Francisco Dept Vet Affairs VA Med Ctr, San Francisco, CA USA; [Maguen, Shira; Seal, Karen] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Maguen, Shira; Seal, Karen] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA USA		Maguen, S (corresponding author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA.	Shira.Maguen@va.gov			Department of Defense Psychological Health and Traumatic Brain Injury Research Program; VA Health Sciences Research and Development Service Career Development Award	This material was based on work supported by the Department of Defense Psychological Health and Traumatic Brain Injury Research Program and a VA Health Sciences Research and Development Service Career Development Award to Dr. Maguen.	Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588; Browne, 1993, TESTING STRUCTURAL E, DOI [10.1177/0049124192021002005, DOI 10.1177/0049124192021002005]; Calhoun PS, 2010, PSYCHIAT RES, V178, P330, DOI 10.1016/j.psychres.2009.11.009; Elbogen EB, 2010, AM J PSYCHIAT, V167, P1051, DOI 10.1176/appi.ajp.2010.09050739; FISCHER H, 2010, RS22452 C RES SERV; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Jaycox, 2008, INVISIBLE WOUNDS WAR; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; *MANP DAT CTR CON, 2009, OEF IF ROST; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Prins A, 2004, PRIMARY CARE PSYCHIA, V9, P151, DOI 10.1185/135525703125002360; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; TUCKER LR, 1973, PSYCHOMETRIKA, V38, P1, DOI 10.1007/bf02291170; *US GOV ACC OFF, 2008, GAO08276; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004	27	26	26	0	3	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					1115	1125		10.1682/JRRD.2011.02.0015			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	149EZ	WOS:000319303100013	23341283	Bronze			2022-02-06	
J	Vallat-Azouvi, C; Pradat-Diehl, P; Azouvi, P				Vallat-Azouvi, Claire; Pradat-Diehl, Pascale; Azouvi, Philippe			The Working Memory Questionnaire: A scale to assess everyday life problems related to deficits of working memory in brain injured patients	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Working memory; Ecological assessment; Stroke; Traumatic brain injury	EXECUTIVE FUNCTION; PRACTICAL SCALE; HEAD-INJURY; REHABILITATION; DYSFUNCTION; DAMAGE; COMA	The objective of the present study was to develop a scale designed to assess the consequences of working memory deficits in everyday life. The Working Memory Questionnaire (WMQ) is a self-administered scale, addressing three dimensions of working memory: short-term storage, attention, and executive control. The normative sample included 313 healthy participants. The patient group included 69 brain injured patients, who were compared to a subsample of 69 matched healthy controls. The questionnaire was found to have a good internal consistency, both in healthy participants and in patients with brain injury (Cronbach's alpha = .89 and .94, respectively). In healthy participants, significant effects of age (p<.0001) and education (p<.01) were found, due to more complaints in participants aged 60 or more and (unexpectedly) in those aged below 30, and for less educated participants, below high school level. The WMQ was found to have the sensitivity to discriminate patients from matched controls, in the three domains (p<.0001). A good concurrent validity was found with the Cognitive Failure Questionnaire and the Rating Scale of Attentional Behaviour (Spearman's Rho = .90 and .81, respectively, both ps<.0001). In addition, the total complaint score significantly correlated with neuropsychological measures of working memory (visual spans and short-term memory with interference) and with global intellectual efficiency (Raven's Matrices) but not with digit spans. Further studies are needed to measure the internal structure of the scale, and to compare self-and proxy-ratings.	[Vallat-Azouvi, Claire] Hop Raymond Poincare, Antenne UEROS, SAMSAH 92, UGECAM, F-92380 Garches, France; [Vallat-Azouvi, Claire; Pradat-Diehl, Pascale; Azouvi, Philippe] UPMC, ER 6, Paris, France; [Pradat-Diehl, Pascale] Salpetriere Hosp, AP HP, Dept Phys Med & Rehabil, Paris, France; [Azouvi, Philippe] Hop Raymond Poincare, AP HP, Dept Phys Med & Rehabil, Garches, France; [Azouvi, Philippe] Univ Versailles St Quentin, EA 4497, St Quentin en Yvelines, France		Vallat-Azouvi, C (corresponding author), Hop Raymond Poincare, Antenne UEROS, SAMSAH 92, UGECAM, F-92380 Garches, France.	claire.vallat@rpc.aphp.fr			FTC (France Traumatisme Cranien); SOFMER (the French society of Physical Medicine and Rehabilitation)	This work was supported by a grant from FTC (France Traumatisme Cranien) and SOFMER (the French society of Physical Medicine and Rehabilitation) attributed to the first author. We are grateful to the students who contributed to data collection. We thank Johanna Robertson, PhD, for translating the Working Memory Questionnaire into English.	Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Baddeley A.D., 1986, WORKING MEMORY; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Best JR, 2010, CHILD DEV, V81, P1641, DOI 10.1111/j.1467-8624.2010.01499.x; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cazalis F, 2001, J INT NEUROPSYCH SOC, V7, P795, DOI 10.1017/S1355617701777028; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Couillet J, 2010, NEUROPSYCHOL REHABIL, V20, P321, DOI 10.1080/09602010903467746; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Godefroy O, 2010, ANN NEUROL, V68, P855, DOI 10.1002/ana.22117; JENNETT B, 1975, LANCET, V1, P480; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; TEASDALE G, 1974, LANCET, V2, P81; Vallat C, 2005, BRAIN INJURY, V19, P1157, DOI 10.1080/02699050500110595; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Vallat-Azouvi C, 2009, BRAIN INJURY, V23, P585, DOI 10.1080/02699050902970711; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012	29	26	26	2	21	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	4					634	649		10.1080/09602011.2012.681110			16	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	995SC	WOS:000308031600009	22537095				2022-02-06	
J	Voelbel, GT; Genova, HM; Chiaravalotti, ND; Hoptman, MJ				Voelbel, Gerald T.; Genova, Helen M.; Chiaravalotti, Nancy D.; Hoptman, Matthew J.			Diffusion tensor imaging of traumatic brain injury review: Implications for neurorehabilitation	NEUROREHABILITATION			English	Article						Traumatic brain injury; diffusion tensor imaging; neurorehabilitation	WHITE-MATTER ABNORMALITIES; AXONAL INJURY; CORPUS-CALLOSUM; MILD; INTEGRITY; MODERATE; PLASTICITY; DYSFUNCTION	Diffusion tensor imaging (DTI) has widely been used to investigate the microstructural damage of white matter tracts that occur in individuals with traumatic brain injury (TBI). In the current review, we discuss the white matter regions which are commonly affected in adults with TBI. We also describe the current literature that has utilized DTI to investigate the relationship between microstructural integrity with neuropsychological performance and clinical outcome measures. Finally, a model is presented of the potential utilization of DTI as a biomarker of efficacy in neurorehabilitation for individuals with TBI.	[Voelbel, Gerald T.] NYU, Steinhardt Sch Educ Culture & Human Dev, Dept Occupat Therapy, New York, NY 10012 USA; [Voelbel, Gerald T.] NYU, Langone Med Ctr, Rusk Inst Rehabil Med, New York, NY 10012 USA; [Genova, Helen M.; Chiaravalotti, Nancy D.] Kessler Fdn Res Ctr, Neuropsychol & Neurosci Lab, W Orange, NJ USA; [Genova, Helen M.; Chiaravalotti, Nancy D.] UMDNJ New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [Hoptman, Matthew J.] Nathan S Kline Inst Psychiat Res, Schizophrenia Res Ctr, Orangeburg, NY 10962 USA; [Hoptman, Matthew J.] NYU, Sch Med, Dept Psychiat, New York, NY 10012 USA; [Hoptman, Matthew J.] CUNY City Coll, Dept Psychol, New York, NY 10031 USA		Voelbel, GT (corresponding author), NYU, Steinhardt Sch Educ Culture & Human Dev, Dept Occupat Therapy, 35 W 4th St,11th Floor, New York, NY 10012 USA.	gv23@nyu.edu	Hoptman, Matthew J./N-1035-2014	Hoptman, Matthew J./0000-0003-4485-6102; Chiaravalloti, Nancy/0000-0003-2943-7567			Alexopoulos GS, 2008, AM J PSYCHIAT, V165, P238, DOI 10.1176/appi.ajp.2007.07050744; Ardekani BA, 2003, NEUROREPORT, V14, P2025, DOI 10.1097/00001756-200311140-00004; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bennett IJ, 2010, HUM BRAIN MAPP, V31, P378, DOI 10.1002/hbm.20872; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CDC, 1999, TRAUM BRAIN INJ US R; Christidi F, 2011, J NEUROTRAUM, V28, P711, DOI 10.1089/neu.2010.1644; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Driemeyer J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002669; Engvig A, 2012, HUM BRAIN MAPP, V33, P2390, DOI 10.1002/hbm.21370; Faul M., 2010, TRAUM BRAIN INJURY U; Fu M, 2012, NATURE, V483, P92, DOI 10.1038/nature10844; Ge YL, 2005, ANN NY ACAD SCI, V1064, P202, DOI 10.1196/annals.1340.039; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kay T., J HEAD TRAUMA REHABI, V8, P86; Keller TA, 2009, NEURON, V64, P624, DOI 10.1016/j.neuron.2009.10.018; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee B, 2010, NEUROIMAGE, V52, P9, DOI 10.1016/j.neuroimage.2010.04.014; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lovden M, 2010, NEUROPSYCHOLOGIA, V48, P3878, DOI 10.1016/j.neuropsychologia.2010.08.026; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mateer CA, 2000, NEUROPSYCHOLOGICAL M, P3; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Matthews PM, 2013, J ALZHEIMERS DIS, V33, pS163, DOI 10.3233/JAD-2012-129012; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oechslin MS, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.076.2009; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Penner IK, 2006, J PHYSIOL-PARIS, V99, P455, DOI 10.1016/j.jphysparis.2006.03.008; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pfefferbaum A, 2005, NEUROIMAGE, V26, P891, DOI 10.1016/j.neuroimage.2005.02.034; Rogalski E, 2012, NEUROPSYCHOLOGIA, V50, P1759, DOI 10.1016/j.neuropsychologia.2012.03.033; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schlaug G, 2009, ANN NY ACAD SCI, V1169, P385, DOI 10.1111/j.1749-6632.2009.04587.x; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tana M G, 2010, Comput Intell Neurosci, P329213, DOI 10.1155/2010/329213; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	67	26	26	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2012	31	3					281	293		10.3233/NRE-2012-0796			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	028QC	WOS:000310436200005	23093455				2022-02-06	
J	Willeumier, K; Taylor, DV; Amen, DG				Willeumier, K.; Taylor, D. V.; Amen, D. G.			Elevated body mass in National Football League players linked to cognitive impairment and decreased prefrontal cortex and temporal pole activity	TRANSLATIONAL PSYCHIATRY			English	Article						body mass index (BMI); cognition; prefrontal cortex; single photon computed tomography (SPECT); temporal pole; waist-to-height ratio (WHtR)	PROFESSIONAL FOOTBALL; LATE-LIFE; INDEX; ASSOCIATION; PREVALENCE; OVERWEIGHT; OBESITY; PERFORMANCE; BMI	Obesity is a risk factor for neurodegenerative disease and has been shown to adversely affect cognitive function. Professional athletes who participate in sports, which expose them to repetitive concussions, may be at heightened risk for cognitive impairment. Here, we investigated the effects of body mass as measured by waist-to-height ratio (WHtR) on regional cerebral blood flow using single-photon emission computed tomography imaging in 38 healthy weight (WHtR mean 49.34 +/- 2.8; age 58 +/- 9.6) and 38 overweight (WHtR mean 58.7 +/- 4.7; age 58 +/- 13.3) retired National Football League football players. After matching for age and position, we used a two sample t-test to determine the differences in blood flow in healthy versus overweight subjects. Statistical parametric mapping revealed a higher WHtR ratio is associated with decreased blood flow in Brodmann areas 8, 9 and 10, brain regions involved in attention, reasoning and executive function (P < 0.05, family-wise error) along with deficits in the temporal pole. Moreover, overweight athletes had significant decrease in attention (P = 0.01326), general cognitive proficiency (P = 0.012; Microcog: Assessment of Cognitive Functioning) and memory (P = 0.005; Mild Cognitive Impairment Screen). The association between elevated WHtR percentage and decreased blood flow in the prefrontal cortex and temporal pole may be correlated with the decreased performance on tests of attention and memory. These findings suggest that a weight management program may be critical to the health of athletes who have been exposed to mild brain trauma during their careers. Translational Psychiatry (2012) 2, e68; doi:10.1038/tp.2011.67; published online 17 January 2012	[Willeumier, K.; Taylor, D. V.; Amen, D. G.] Amen Clin, Newport Beach, CA 92660 USA		Amen, DG (corresponding author), Amen Clin, 4019 Westerly Pl,Suite 100, Newport Beach, CA 92660 USA.	docamen@amenclinic.com		Willeumier, Kristen/0000-0002-1229-8516			Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Boeka AG, 2008, ARCH CLIN NEUROPSYCH, V23, P467, DOI 10.1016/j.acn.2008.03.003; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Gazdzinski S, 2008, ANN NEUROL, V63, P652, DOI 10.1002/ana.21377; Gunstad J, 2007, COMPR PSYCHIAT, V48, P57, DOI 10.1016/j.comppsych.2006.05.001; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harp JB, 2005, JAMA-J AM MED ASSOC, V293, P1061, DOI 10.1001/jama.293.9.1061-b; Kaiser GE, 2008, J STRENGTH COND RES, V22, P243, DOI 10.1519/JSC.0b013e31815f5d97; Laurson KR, 2007, JAMA-J AM MED ASSOC, V297, P363, DOI 10.1001/jama.297.4.363; Malina RM, 2007, J PEDIATR-US, V151, P378, DOI 10.1016/j.jpeds.2007.03.044; Mathews EM, 2008, J AM COLL HEALTH, V57, P33, DOI 10.3200/JACH.57.1.33-38; Medical Care Corporation, 2007, MILD COGN IMP SCREEN; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Trenkle DL, 2007, J ALZHEIMERS DIS, V11, P323; Tucker AM, 2009, JAMA-J AM MED ASSOC, V301, P2111, DOI 10.1001/jama.2009.716; Walther K, 2010, HUM BRAIN MAPP, V31, P1052, DOI 10.1002/hbm.20916; Wang GJ, 2008, OBESITY, V16, pS88, DOI 10.1038/oby.2008.469; Willeumier KC, 2011, OBESITY, V19, P1095, DOI 10.1038/oby.2011.16	27	26	26	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	JAN	2012	2								e68	10.1038/tp.2011.67			6	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Psychiatry	971PZ	WOS:000306217600004	22832730	gold, Green Published			2022-02-06	
J	Hong, SQ; Zhang, HT; You, J; Zhang, MY; Cai, YQ; Jiang, XD; Xu, RX				Hong, Sun-Quan; Zhang, Hong-Tian; You, Jian; Zhang, Mao-Ying; Cai, Ying-Qian; Jiang, Xiao-Dan; Xu, Ru-Xiang			Comparison of Transdifferentiated and Untransdifferentiated Human Umbilical Mesenchymal Stem Cells in Rats after Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Cognitive function; Human umbilical mesenchymal stem cells; Neurotrophic factor; Transdifferentiation; Transplantation; Traumatic brain injury	MARROW STROMAL CELLS; SPINAL-CORD-INJURY; NEUROTROPHIC FACTORS; PROGENITOR CELLS; TRANSPLANTATION; THERAPY; STROKE; MODEL; IMPLANTATION; RECOVERY	Transdifferentiated and untransdifferentiated mesenchymal stem cells (MSCs) have shown therapeutic benefits in central nervous system (CNS) injury. However, it is unclear which would be more appropriate for transplantation. To address this question, we transplanted untransdifferentiated human umbilical mesenchymal stem cells (HUMSCs) and transdifferentiated HUMSCs (HUMSC-derived neurospheres, HUMSC-NSs) into a rat model of traumatic brain injury. Cognitive function, cell survival and differentiation, brain tissue morphology and neurotrophin expression were compared between groups. Significant improvements in cognitive function and brain tissue morphology were seen in the HUMSCs group compared with HUMSC-NSs group, which was accompanied by increased neurotrophin expression. Moreover, only few grafted cells survived in both the HUMSCs and HUMSC-NSs groups, with very few of the cells differentiating into neural-like cells. These findings indicate that HUMSCs are more appropriate for transplantation and their therapeutic benefits may be associated with neuroprotection rather than cell replacement.	[Hong, Sun-Quan; You, Jian; Zhang, Mao-Ying; Cai, Ying-Qian; Jiang, Xiao-Dan; Xu, Ru-Xiang] So Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou 510282, Guangdong, Peoples R China; [Hong, Sun-Quan; You, Jian; Zhang, Mao-Ying; Cai, Ying-Qian; Jiang, Xiao-Dan; Xu, Ru-Xiang] So Med Univ, Inst Neurosurg, Key Lab Brain Funct Repair & Regenerat Guangdong, Guangzhou 510282, Guangdong, Peoples R China; [Hong, Sun-Quan; Zhang, Hong-Tian; Xu, Ru-Xiang] Mil Gen Hosp Beijing PLA, Dept Neurosurg, Beijing 100700, Peoples R China		Jiang, XD (corresponding author), So Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou 510282, Guangdong, Peoples R China.	jxd_neuroscience@163.com; xuruxiang_neuron@126.com			Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [U0632008, 30772232, 30801184]; Foundation for Key Sci-Tech Research Projects of Guangdong [2008A030201019, 2007-05/06-70052]	The authors acknowledge Health & Biotech Company (Guangzhou, Guangdong, China) for them kindly present human umbilical mesenchymal stem cells. This work was supported by Natural Science Foundation of China (NSFC) (No. U0632008, 30772232, 30801184) and Foundation for Key Sci-Tech Research Projects of Guangdong (No. 2008A030201019, 2007-05/06-70052).	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Bath KG, 2006, COGN AFFECT BEHAV NE, V6, P79, DOI 10.3758/CABN.6.1.79; Boyce VS, 2007, J NEUROPHYSIOL, V98, P1988, DOI 10.1152/jn.00391.2007; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005-0053; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gogel S, 2011, GENE THER, V18, P1, DOI 10.1038/gt.2010.130; Hains BC, 2004, EXP NEUROL, V188, P365, DOI 10.1016/j.expneurol.2004.04.001; Hayase M, 2009, J CEREBR BLOOD F MET, V29, P1409, DOI 10.1038/jcbfm.2009.62; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Lee MW, 2007, BIOCHEM BIOPH RES CO, V358, P637, DOI 10.1016/j.bbrc.2007.04.181; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; PAXINOS G, 2005, RAT BRAIN STEREOTAXI, P98; Pisati F, 2007, CELL TRANSPLANT, V16, P41, DOI 10.3727/000000007783464443; Shang AJ, 2011, BRAIN RES, V1391, P102, DOI 10.1016/j.brainres.2011.03.019; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Vaquero J, 2009, HISTOL HISTOPATHOL, V24, P107, DOI 10.14670/HH-24.107; Walker PA, 2010, REGEN MED, V5, P65, DOI 10.2217/RME.09.73; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Weiss ML, 2006, STEM CELLS, V24, P781, DOI 10.1634/stemcells.2005-0330; Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336; Zhang HT, 2009, NEUROSCI LETT, V458, P116, DOI 10.1016/j.neulet.2009.04.045; Zhang L, 2009, NEUROCHEM RES, V34, P2030, DOI 10.1007/s11064-009-9992-x; Zhang W, 2010, BRAIN RES, V1359, P256, DOI 10.1016/j.brainres.2010.08.072; Zurita M, 2008, NEUROSCI RES, V60, P275, DOI 10.1016/j.neures.2007.11.006	28	26	28	0	17	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	DEC	2011	36	12					2391	2400		10.1007/s11064-011-0567-2			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	841MN	WOS:000296516500024	21877237				2022-02-06	
J	Itoh, T; Imano, M; Nishida, S; Tsubaki, M; Hashimoto, S; Ito, A; Satou, T				Itoh, Tatsuki; Imano, Motohiro; Nishida, Shozo; Tsubaki, Masahiro; Hashimoto, Shigeo; Ito, Akihiko; Satou, Takao			(-)-Epigallocatechin-3-gallate Protects Against Neuronal Cell Death and Improves Cerebral Function After Traumatic Brain Injury in Rats	NEUROMOLECULAR MEDICINE			English	Article						Epigallocatechin; Traumatic brain injury; Neuroprotection; Apoptosis; Oxidative stress	CENTRAL-NERVOUS-SYSTEM; GREEN TEA POLYPHENOL; NEURAL STEM-CELLS; OXYGEN RADICALS; ISCHEMIA; DAMAGE; PROLIFERATION; ACTIVATION; RECEPTOR; GERBILS	A major component of green tea, a widely consumed beverage, is (-)-epigallocatechin gallate (EGCG), which has strong antioxidant properties. Our previous study has indicated that free radical production following rat traumatic brain injury (TBI) induces neural degeneration. In this study, we investigated the effects of EGCG on cerebral function and morphology following TBI. Six-week-old male Wistar rats that had access to normal drinking water, or water containing 0.1% (w/v) EGCG ad libitum, received TBI with a pneumatic controlled injury device at 10 weeks of age. Immunohistochemistry and lipid peroxidation studies revealed that at 1, 3 and 7 days post-TBI, the number of 8-hydroxy-2'-deoxyguanosine-, 4-hydroxy-2-nonenal-and single-stranded DNA (ssDNA)-positive cells, and the levels of malondialdehyde (MDA) around the damaged area after TBI, significantly decreased in the EGCG treatment group compared with the water group (P < 0.05). Most ssDNA-positive cells in the water group co-localized with neuronal cells. However, in the EGCG treatment group, few ssDNA-positive cells co-localized with neurons. In addition, there was a significant increase in the number of surviving neuronal cells and an improvement in cerebral dysfunction after TBI in the EGCG treatment group compared with the water group (P < 0.05). These results indicate that consumption of water containing EGCG pre- and post-TBI inhibits free radical-induced neuronal degeneration and apoptotic cell death around the damaged area, resulting in the improvement of cerebral function following TBI. In summary, consumption of green tea may be an effective therapy for TBI patients.	[Itoh, Tatsuki; Ito, Akihiko; Satou, Takao] Kinki Univ, Dept Pathol, Fac Med, Osakasayama City, Osaka 5898511, Japan; [Imano, Motohiro] Kinki Univ, Dept Surg, Fac Med, Osaka, Japan; [Nishida, Shozo; Tsubaki, Masahiro] Kinki Univ, Fac Pharmaceut Sci, Osaka 577, Japan; [Hashimoto, Shigeo] PL Hosp, Dept Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ, Div Sports Med, Inst Life Sci, Osaka, Japan; [Satou, Takao] Kinki Univ Hosp, Div Hosp Pathol, Fac Med, Osaka, Japan		Itoh, T (corresponding author), Kinki Univ, Dept Pathol, Fac Med, 377-2 Ohno Higashi, Osakasayama City, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp			 [21500803]	This work was supported by the Grant-in-Aid for Scientific Research (21500803). The authors thank Mari Yachi for technical assistance.	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; CHAN PH, 1985, PROG BRAIN RES, V63, P227; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hong JT, 2000, BRAIN RES BULL, V53, P743, DOI 10.1016/S0361-9230(00)00348-8; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Itoh T, 2009, NEUROTOX RES, V16, P378, DOI 10.1007/s12640-009-9081-6; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; Jang S, 2010, BRAIN RES, V1313, P25, DOI 10.1016/j.brainres.2009.12.012; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Lee EJ, 2005, J PINEAL RES, V38, P42, DOI 10.1111/j.1600-079X.2004.00173.x; Lee H, 2004, J NEUROSCI RES, V77, P892, DOI 10.1002/jnr.20193; Lee SY, 2003, BRAIN RES BULL, V61, P399, DOI 10.1016/S0361-9230(03)00139-4; Loren DJ, 2005, PEDIATR RES, V57, P858, DOI 10.1203/01.PDR.0000157722.07810.15; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Park JW, 2009, J NEUROSCI RES, V87, P567, DOI 10.1002/jnr.21847; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Sakurai M, 2003, J VASC SURG, V37, P446, DOI 10.1067/mva.2003.100; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Wang XY, 2001, BIOL NEONATE, V79, P172; Weinreb O, 2009, GENES NUTR, V4, P283, DOI 10.1007/s12263-009-0143-4; Weissman L, 2007, NEUROSCIENCE, V145, P1318, DOI 10.1016/j.neuroscience.2006.08.061; Won MH, 2001, NEUROSCI LETT, V301, P139, DOI 10.1016/S0304-3940(01)01625-1; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Yu JX, 2010, FEBS LETT, V584, P2921, DOI 10.1016/j.febslet.2010.05.011	32	26	30	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1535-1084			NEUROMOL MED	Neuromol. Med.	DEC	2011	13	4					300	309		10.1007/s12017-011-8162-x			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893KS	WOS:000300355400007	22038400				2022-02-06	
J	Kelley, BG; Mermelstein, PG				Kelley, Brooke G.; Mermelstein, Paul G.			Progesterone blocks multiple routes of ion flux	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Neuroprotection; Steroid; Striatum; Side effects	TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; CALCIUM-CHANNEL BLOCKERS; POTASSIUM CHANNELS; PARKINSONS-DISEASE; NIFEDIPINE; INHIBITION; PHARMACOKINETICS; PHARMACODYNAMICS; NEUROPROTECTION	The administration of progesterone as a neuroprotective agent following traumatic brain injury has recently entered phase III clinical trials. Previous work has demonstrated that therapeutic concentrations of progesterone decrease excitotoxicity through direct inhibition of voltage-gated calcium channels, an action independent of the nuclear progesterone receptor. Here we report using cultured rat striatal neurons that these same concentrations of progesterone also block voltage-gated potassium channels, sodium channels and GABA(A) currents. The actions of progesterone act at the surface membrane of neurons in a steroid specific, voltage-independent, concentration-dependent manner. Notably, these broad actions of progesterone on ion channel and neurotransmitter receptor function mirror those of dihydropyridines, and indicate potential shared mechanisms of action, the prospective of additional therapeutic applications, and possibly, untoward effects. (C) 2011 Elsevier Inc. All rights reserved.	[Kelley, Brooke G.; Mermelstein, Paul G.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA		Mermelstein, PG (corresponding author), Univ Minnesota, Dept Neurosci, 6-145 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	pmerm@umn.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS41302, NS062158]; IRACDA [GM074628]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K12GM074628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS062158, R01NS041302] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health NS41302 (PGM), Core Funding NS062158, and an IRACDA Post-Doctoral Fellowship GM074628 (BGK). We thank Dr. John Meitzen for his comments on this manuscript.	Ahmad M, 2009, TROP J PHARM RES, V8, P385; ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; Anderson L, 2009, REPROD SCI, V16, P1052, DOI 10.1177/1933719109340926; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Becker C, 2008, NEUROLOGY, V70, P1438, DOI 10.1212/01.wnl.0000303818.38960.44; *BHR PHARM, 2010, LLC EFF SAF STUD INT; BIELEFELDT K, 1996, AM J PHYSIOL, V271, P370; Borna S, 2008, AUST NZ J OBSTET GYN, V48, P58, DOI 10.1111/j.1479-828X.2007.00803.x; Chien SC, 2004, BIOPHARM DRUG DISPOS, V25, P77, DOI 10.1002/bdd.386; Das P, 2004, NEUROSCIENCE, V124, P195, DOI 10.1016/j.neuroscience.2003.12.005; Ehring GR, 1998, J EXP MED, V188, P1593, DOI 10.1084/jem.188.9.1593; Gellersen B, 2009, HUM REPROD UPDATE, V15, P119, DOI 10.1093/humupd/dmn044; GELMERS HJ, 1985, AM J CARDIOL, V55, P139; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Goodnick PJ, 2000, BIPOLAR DISORD, V2, P165, DOI 10.1034/j.1399-5618.2000.020303.x; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; HOFFMAN SW, 2008, Patent No. 7915244; HURD C, 1988, BIOCHEMISTRY-US, V27, P3618, DOI 10.1021/bi00410a014; Ilijic E, 2011, NEUROBIOL DIS, V43, P364, DOI 10.1016/j.nbd.2011.04.007; Judge SIV, 2006, J REHABIL RES DEV, V43, P111, DOI 10.1682/JRRD.2004.09.0116; KHAN A, 1991, BRIT J CLIN PHARMACO, V32, P519, DOI 10.1111/j.1365-2125.1991.tb03943.x; King JF, 2003, COCHRANE DB SYST REV, V1; Kittaka M, 1997, J NEUROSURG, V87, P731, DOI 10.3171/jns.1997.87.5.0731; LANCEL M, 1996, AM J PHYSIOL, V271, P763; Luoma JI, 2011, STEROIDS, V76, P845, DOI 10.1016/j.steroids.2011.02.013; Lyell DJ, 2008, OBSTET GYNECOL, V112, P1221, DOI 10.1097/AOG.0b013e31818d8386; Mermelstein PG, 2000, J NEUROSCI, V20, P266, DOI 10.1523/JNEUROSCI.20-01-00266.2000; MYERS MG, 1994, J HYPERTENS, V12, pS73; Pedrinelli R, 2001, J HUM HYPERTENS, V15, P455, DOI 10.1038/sj.jhh.1001201; PUTNAM CD, 1991, BIOL REPROD, V45, P266, DOI 10.1095/biolreprod45.2.266; RENWICK AG, 1988, BRIT J CLIN PHARMACO, V25, P701, DOI 10.1111/j.1365-2125.1988.tb05256.x; Ritz B, 2010, ANN NEUROL, V67, P600, DOI 10.1002/ana.21937; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; ROBERTSON DRC, 1988, BRIT J CLIN PHARMACO, V25, P297, DOI 10.1111/j.1365-2125.1988.tb03307.x; Rosendorff Clive, 2007, J Clin Hypertens (Greenwich), V9, P790; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Selye H, 1942, ENDOCRINOLOGY, V30, P437, DOI 10.1210/endo-30-3-437; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Wang Y, 2008, MED HYPOTHESES, V71, P546, DOI 10.1016/j.mehy.2008.05.021; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; WRIGHT DW, 2005, J CLIN PHARMACOL, V45, P460; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YATANI A, 1985, CIRC RES, V56, P868, DOI 10.1161/01.RES.56.6.868; Zhang ML, 2002, J PHARM PHARMACOL, V54, P1667, DOI 10.1211/002235702405; Zhang X, 1997, J PHARMACOL EXP THER, V281, P1247; Zhang XL, 2009, NEUROSCIENCE, V161, P184, DOI 10.1016/j.neuroscience.2009.03.012	47	26	28	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431			MOL CELL NEUROSCI	Mol. Cell. Neurosci.	OCT	2011	48	2					137	141		10.1016/j.mcn.2011.07.002			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	822CF	WOS:000295020600003	21782024	Green Accepted			2022-02-06	
J	Lewis, MD; Bailes, J				Lewis, Michael D.; Bailes, Julian			Neuroprotection for the Warrior: Dietary Supplementation With Omega-3 Fatty Acids	MILITARY MEDICINE			English	Article							POLYUNSATURATED FATTY-ACIDS; CHRONIC TRAUMATIC ENCEPHALOPATHY; NATIONAL-FOOTBALL-LEAGUE; CARDIOVASCULAR RISK-FACTORS; RANDOMIZED CONTROLLED-TRIAL; DOSE DOCOSAHEXAENOIC ACID; NUTRITION SUPPORT THERAPY; CRITICAL-CARE MEDICINE; ILL PATIENT SOCIETY; SPINAL-CORD-INJURY	Nutrition has traditionally involved in supplying energy and hydration. An emerging concept developed by the authors is the concept of using omega-3 fatty acids (n-3 FAs) to increase the resilience of the brain. The n-3 FAs have numerous proven benefits including support of cardiovascular and psychiatric health. Docosahexaenoic acid in particular, is found in high concentrations in the brain. N-3 FAs provide benefits by exerting a protective mechanism at the cellular and neuronal levels including the modulation of inflammatory cascade following traumatic brain injury. Promising research and evolving clinical experience now indicate that n-3 FA is useful and effective for recovery following traumatic brain injury. More exciting is that new laboratory research shows the beneficial effects extend to when n-3 FA is given before injury. Given the safety profile, availability, and affordability of n-3 FA, Generally Recognized As Safe amounts of eicosapentaenoic acid and docosahexaenoic acid (up to 3,000 mg daily) should be considered for the athlete and soldier, not only for its general health benefits, but particularly also for those at risk or high exposure to brain impacts. A comprehensive, coordinated research program to evaluate the multiple uses of n-3 FA should be a high priority for the Department of Defense.	[Lewis, Michael D.] Def & Vet Brain Injury Ctr, Rockville, MD 20812 USA; [Bailes, Julian] W Virginia Univ, Dept Neurosurg, Morgantown, WV 26506 USA		Lewis, MD (corresponding author), Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Rockville, MD 20812 USA.						Agren JJ, 1997, PROSTAG LEUKOTR ESS, V57, P419, DOI 10.1016/S0952-3278(97)90421-X; Agren JJ, 1996, EUR J CLIN NUTR, V50, P765; Antalis CJ, 2006, PROSTAG LEUKOTR ESS, V75, P299, DOI 10.1016/j.plefa.2006.07.004; Appleton KM, 2010, AM J CLIN NUTR, V91, P757, DOI 10.3945/ajcn.2009.28313; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; BAIRATI I, 1992, CIRCULATION, V85, P950, DOI 10.1161/01.CIR.85.3.950; Bays HE, 2007, AM J CARDIOL, V99, p35C, DOI 10.1016/j.amjcard.2006.11.020; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Becker DJ, 2008, MAYO CLIN PROC, V83, P758, DOI 10.4065/83.7.758; BEHAN PO, 1990, ACTA NEUROL SCAND, V82, P209, DOI 10.1111/j.1600-0404.1990.tb04490.x; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; BLONK MC, 1990, AM J CLIN NUTR, V52, P120, DOI 10.1093/ajcn/52.1.120; Buydens-Branchey L, 2008, PROG NEURO-PSYCHOPH, V32, P568, DOI 10.1016/j.pnpbp.2007.10.020; Buydens-Branchey L, 2006, J CLIN PSYCHOPHARM, V26, P661, DOI 10.1097/01.jcp.0000246214.49271.f1; Calabresi L, 2000, ATHEROSCLEROSIS, V148, P387, DOI 10.1016/S0021-9150(99)00267-1; Calder P.C., 2010, J LIPID NUTR, V19, P233; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cao DH, 2004, PHARMACOL BIOCHEM BE, V79, P651, DOI 10.1016/j.pbb.2004.09.016; COBIAC L, 1991, AM J CLIN NUTR, V53, P1210, DOI 10.1093/ajcn/53.5.1210; Colangelo LA, 2009, NUTRITION, V25, P1011, DOI 10.1016/j.nut.2008.12.008; Conquer JA, 1998, J LIPID RES, V39, P286; De Vriese SR, 2004, PROSTAG LEUKOTR ESS, V71, P13, DOI 10.1016/j.plefa.2003.12.002; DECATERINA R, 1990, CIRCULATION, V82, P428, DOI 10.1161/01.CIR.82.2.428; Deuster PA, 2009, MIL MED, V174, P671, DOI 10.7205/MILMED-D-04-4508; Devore EE, 2009, AM J CLIN NUTR, V90, P170, DOI 10.3945/ajcn.2008.27037; DYERBERG J, 1979, LANCET, V2, P433, DOI 10.1016/S0140-6736(79)91490-9; Ferretti A, 1998, J NUTR BIOCHEM, V9, P88, DOI 10.1016/S0955-2863(97)00172-1; Freeman MP, 2007, J CLIN PSYCHIAT, V68, P338; Freund-Levi Y, 2008, INT J GERIATR PSYCH, V23, P161, DOI 10.1002/gps.1857; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hallahan B, 2007, BRIT J PSYCHIAT, V190, P118, DOI 10.1192/bjp.bp.106.022707; HARKER LA, 1993, CIRCULATION, V87, P1017, DOI 10.1161/01.CIR.87.3.1017; Harris WS, 2008, CURR ATHEROSCLER REP, V10, P503, DOI 10.1007/s11883-008-0078-z; Heller AR, 2006, CRIT CARE MED, V34, P972, DOI 10.1097/01.CCM.0000206309.83570.45; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Heude B, 2003, AM J CLIN NUTR, V77, P803, DOI 10.1093/ajcn/77.4.803; Hibbeln Joseph R., 2009, V99, P17, DOI 10.1159/000192992; Hibbeln JR, 1998, LANCET, V351, P1213, DOI 10.1016/S0140-6736(05)79168-6; HIRAYAMA T, 1990, LIFE STYLE MORTALITY; Hogyes E, 2003, NEUROSCIENCE, V119, P999, DOI 10.1016/S0306-4522(03)00198-2; Huan MM, 2004, BIOL PSYCHIAT, V56, P490, DOI 10.1016/j.biopsych.2004.06.028; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Huffman DM, 2004, EUR J APPL PHYSIOL, V92, P584, DOI 10.1007/s00421-004-1069-6; Iribarren C, 2004, EUR J CLIN NUTR, V58, P24, DOI 10.1038/sj.ejcn.1601739; Jonas W.B., 2010, MIL MED, V175, P6, DOI [DOI 10.7205/MILMED-D-10-00280, 10.7205/MILMED-D-10-00280]; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Kaul N, 2008, J AM COLL NUTR, V27, P51, DOI 10.1080/07315724.2008.10719674; Keller D.D., 2007, J CLIN LIPIDOL, V1, P151; Kelley DS, 2007, AM J CLIN NUTR, V86, P324, DOI 10.1093/ajcn/86.2.324; Kim HY, 2010, PROSTAG LEUKOTR ESS, V82, P165, DOI 10.1016/j.plefa.2010.02.025; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Knapp HR, 1997, AM J CLIN NUTR, V65, P1687; KREMER JM, 1987, ANN INTERN MED, V106, P497, DOI 10.7326/0003-4819-106-4-497; LEAF A, 1994, CIRCULATION, V90, P2248, DOI 10.1161/01.CIR.90.5.2248; LEWIS M, 2011, J CLIN PSYC IN PRESS; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lin PY, 2007, J CLIN PSYCHIAT, V68, P1056, DOI 10.4088/JCP.v68n0712; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; Maes M, 1996, J AFFECT DISORDERS, V38, P35, DOI 10.1016/0165-0327(95)00092-5; Marchioli R, 2001, LIPIDS, V36, pS119, DOI 10.1007/s11745-001-0694-8; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McNamara RK, 2007, BIOL PSYCHIAT, V62, P17, DOI 10.1016/j.biopsych.2006.08.026; Merched AJ, 2008, FASEB J, V22, P3595, DOI 10.1096/fj.08-112201; Micallef MA, 2009, ATHEROSCLEROSIS, V204, P476, DOI 10.1016/j.atherosclerosis.2008.09.020; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Monahan KD, 2004, HYPERTENSION, V44, P732, DOI 10.1161/01.HYP.0000145292.38579.f4; Montain SJ, 2010, MIL MED, V175, P65, DOI DOI 10.7205/MILMED-D-10-00127; Mori TA, 2006, CURR OPIN CLIN NUTR, V9, P95, DOI 10.1097/01.mco.0000214566.67439.58; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P940, DOI 10.1001/archneur.60.7.940; Mozaffarian D, 2005, CIRCULATION, V112, P1945, DOI 10.1161/CIRCULATIONAHA.105.556886; Mullen M, 2010, MIL MED, V175, DOI DOI 10.7205/MILMED-D-10-00246; Nelson GJ, 1997, LIPIDS, V32, P1129, DOI 10.1007/s11745-997-0145-6; Nelson GJ, 1997, LIPIDS, V32, P1137, DOI 10.1007/s11745-997-0146-5; Nestel P, 2002, AM J CLIN NUTR, V76, P326, DOI 10.1093/ajcn/76.2.326; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Pauwels EKJ, 2009, DRUG NEWS PERSPECT, V22, P205, DOI 10.1358/dnp.2009.22.4.1367709; PHILLIPSON BE, 1985, NEW ENGL J MED, V312, P1210, DOI 10.1056/NEJM198505093121902; Roberts L, 2008, J AM COLL SURGEONS, V207, P276, DOI 10.1016/j.jamcollsurg.2008.02.015; ROGERS S, 1987, ATHEROSCLEROSIS, V63, P137, DOI 10.1016/0021-9150(87)90113-4; Ross BM, 2009, PROSTAG LEUKOTR ESS, V81, P309, DOI 10.1016/j.plefa.2009.10.004; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sanders TAB, 2006, BRIT J NUTR, V95, P525, DOI 10.1079/BJN20051658; Schaefer EJ, 2006, ARCH NEUROL-CHICAGO, V63, P1545, DOI 10.1001/archneur.63.11.1545; Singer P, 2004, PROSTAG LEUKOTR ESS, V71, P153, DOI 10.1016/j.plefa.2004.03.003; Stark KD, 2004, AM J CLIN NUTR, V79, P765; Sublette ME, 2006, AM J PSYCHIAT, V163, P1100, DOI 10.1176/appi.ajp.163.6.1100; Tanskanen A, 2001, ARCH GEN PSYCHIAT, V58, P512, DOI 10.1001/archpsyc.58.5.512; Tartibian B, 2009, CLIN J SPORT MED, V19, P115, DOI 10.1097/JSM.0b013e31819b51b3; Theobald HE, 2007, J NUTR, V137, P973, DOI 10.1093/jn/137.4.973; Theobald HE, 2004, AM J CLIN NUTR, V79, P558; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van Gelder BM, 2007, AM J CLIN NUTR, V85, P1142, DOI 10.1093/ajcn/85.4.1142; Vanschoonbeek K, 2004, ARTERIOSCL THROM VAS, V24, P1734, DOI 10.1161/01.ATV.0000137119.28893.0b; von Schacky C, 2009, PROSTAG LEUKOTR ESS, V81, P193, DOI 10.1016/j.plefa.2009.05.009; Walser B, 2008, EUR J APPL PHYSIOL, V104, P455, DOI 10.1007/s00421-008-0791-x; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang X, 2003, NEUROREPORT, V14, P2457, DOI 10.1097/00001756-200312190-00033; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wurtman RJ, 2009, J NUTR HEALTH AGING, V13, P189, DOI 10.1007/s12603-009-0056-3; Yates A, 2009, SPORTS HEALTH, V1, P21, DOI 10.1177/1941738108326978; Youdim KA, 2000, INT J DEV NEUROSCI, V18, P383, DOI 10.1016/S0736-5748(00)00013-7	116	26	26	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	OCT	2011	176	10					1120	1127		10.7205/MILMED-D-10-00466			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831EK	WOS:000295711300009	22128646	Bronze			2022-02-06	
J	Exo, J; Kochanek, PM; Adelson, PD; Greene, S; Clark, RSB; Bayir, H; Wisniewski, SR; Bell, MJ				Exo, Jennifer; Kochanek, Patrick M.; Adelson, P. David; Greene, Stephanie; Clark, Robert S. B.; Bayir, Huelya; Wisniewski, Stephen R.; Bell, Michael J.			Intracranial pressure-monitoring systems in children with traumatic brain injury: Combining therapeutic and diagnostic tools	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cerebrospinal fluid diversion; children; external ventricular drain; intracranial monitoring; pediatric neurotrauma database; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; TISSUE PRESSURE; FIBEROPTIC DEVICE; SURVIVAL; LESIONS	Objective: To compare the correlation of intracranial pressure (ICP) measurement and time to detection of ICP crises (defined as ICP >= 20 mm Hg for >= 5 mins) between an intraparenchymal (IP) monitor and external ventricular drain (EVD) in children for whom continuous cerebrospinal fluid diversion was used as a therapy for severe traumatic brain injury. Setting: Academic, pediatric intensive care unit. Design: Retrospective review of a prospectively collected pediatric neurotrauma database. Patients: Children with severe traumatic brain injury (Glasgow Coma Scale score of <= 8) who underwent ICP monitoring with both IP and EVD techniques were studied. In cohort 1 (n = 58), hourly ICP measurements were extracted from the medical record; in cohort 2 (n = 4), ICP measurements were collected every minute by an automated data-collection system. Measurements and Main Results: The mean absolute difference in ICP (vertical bar ICP vertical bar) and intraclass correlation coefficients were calculated. Timing to detection of ICP crises was analyzed. Data were expressed as mean +/- SEM. For cohort 1, 7,387 hrs of data were analyzed; 399 hrs (23,940 mins) were analyzed for cohort 2. In cohort 1, the. ICP. was 3.10 +/- 0.04 mm Hg (intraclass correlation coefficients = 0.98, p < .001). The. vertical bar ICP vertical bar in cohort 2 was 3.30 +/- 0.05 mm Hg (intraclass correlation coefficients = 0.98, p < .001). In cohort 2, a total of 75 ICP crises were observed. Fifty- five (73%) were detected first by the IP monitor, of which 35 were not identified by the EVD monitor. Time between IP and EVD detection of a crisis was 12.60 +/- 2.34 mins. Conclusion: EVD and IP measurements of ICP were highly correlated, although intermittent EVD ICP measurements may fail to identify ICP events when continuously draining cerebrospinal fluid. In institutions that use continuous cerebrospinal fluid diversion as a therapy, a two-monitor system may be valuable for accomplishing monitoring and therapeutic goals. (Pediatr Crit Care Med 2011; 12:560-565)	[Exo, Jennifer; Kochanek, Patrick M.; Clark, Robert S. B.; Bayir, Huelya; Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Greene, Stephanie; Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Sch Med, Dept Epidemiol & Biostat, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.; Clark, Robert S. B.; Bayir, Huelya; Bell, Michael J.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA; [Adelson, P. David] Phoenix Childrens Hosp, Dept Neurol Surg, Phoenix, AZ USA		Exo, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	exojl@upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Greene, Stephanie/0000-0002-5858-4032; Wisniewski, Stephen/0000-0002-3877-9860	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD040686, NS30318, HD08003, NS052478]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD008003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318, U01NS052478] Funding Source: NIH RePORTER	This work was supported in part by NIH 5T32HD040686 (JLE), NS30318 (PMK), HD08003 (MJB, RSBC), and NS052478 (MJB, PDA).	ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Caruselli G, 1992, J Neurosurg Sci, V36, P219; CHAMBERS IR, 1993, NEUROSURGERY, V33, P866; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; GAMBARDELLA G, 1993, CHILD NERV SYST, V9, P470, DOI 10.1007/BF00393552; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Kerr M E, 2001, Neurosurg Focus, V11, pE1; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; PIEK J, 1987, ACTA NEUROCHIR, V87, P144, DOI 10.1007/BF01476066; PIEK J, 1990, INTENS CARE MED, V16, P184, DOI 10.1007/BF01724800; Qureshi AI, 2002, CRIT CARE MED, V30, P435, DOI 10.1097/00003246-200202000-00028; ROSENWASSER RH, 1989, J NEUROSURG, V71, P503, DOI 10.3171/jns.1989.71.4.0503; Salim A, 2008, AM SURGEON, V74, P1088; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; Shapiro S, 1996, SURG NEUROL, V45, P278, DOI 10.1016/0090-3019(95)00359-2; Shore PM, 2004, J NEUROTRAUM, V21, P1113	25	26	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2011	12	5					560	565		10.1097/PCC.0b013e3181e8b3ee			6	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	816KP	WOS:000294598400019	20625341	Green Accepted			2022-02-06	
J	Lv, LQ; Hou, LJ; Yu, MK; Qi, XQ; Chen, HR; Chen, JX; Hu, GH; Luo, C; Lu, YC				Lv, Li-Quan; Hou, Li-Jun; Yu, Ming-Kun; Qi, Xiang-Qian; Chen, Huai-Rui; Chen, Ju-Xiang; Hu, Guo-Han; Luo, Chun; Lu, Yi-Cheng			Risk Factors Related to Dysautonomia After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Dysautonomia; Traumatic brain injury; Incidence; Risk factors	SEVERE HEAD-INJURY; DIENCEPHALIC SEIZURES; SYMPATHETIC STORMS	Background: Dysautonomia after severe traumatic brain injury (TBI) is a clinical syndrome affecting a subgroup of survivors and is characterized by episodes of autonomic dysregulation and muscle overactivity. The purpose of this study was to determine the incidence of dysautonomia after severe TBI in an intensive care unit setting and analyze the risk factors for developing dysautonomia. Methods: A consecutive series of 101 patients with severe TBI admitted in a major trauma hospital during a 2-year period were prospectively observed to determine the effects of age, sex, mode of injury, hypertension history, admission systolic blood pressure, fracture, lung injury, admission Glasgow Coma Scale (GCS) score, injury severity score, emergency craniotomy, sedation or analgesia, diffuse axonal injury (DAI), magnetic resonance imaging (MRI) scales, and hydrocephalus on the development of dysautonomia. Risk factors for dysautonomia were evaluated by using logistic regression analysis. Results: Seventy-nine of the 101 patients met inclusion criteria, and dysautonomia was observed in 16 (20.3%) of these patients. Univariate analysis revealed significant correlations between the occurrence of dysautonomia and patient age, admission GCS score, DAI, MRI scales, and hydrocephalus. Sex, mode of injury, hypertension history, admission systolic blood pressure, fracture, lung injury, injury severity score, sedation or analgesia, and emergency craniotomy did not influence the development of dysautonomia. Multivariate logistic regression revealed that patient age and DAI were two independent predictors of dysautonomia. There was no independent association between dysautonomia and admission GCS score, MRI scales, or hydrocephalus. Conclusions: Dysautonomia frequently occurs in patients with severe TBI. A younger age and DAI could be risk factors for facilitating the development of dysautonomia.	[Lv, Li-Quan; Hou, Li-Jun; Yu, Ming-Kun; Qi, Xiang-Qian; Chen, Huai-Rui; Chen, Ju-Xiang; Hu, Guo-Han; Luo, Chun; Lu, Yi-Cheng] Second Mil Med Univ, Dept Neurosurg, Shanghai Inst Neurosurg, Shanghai Changzheng Hosp, Shanghai 200003, Peoples R China		Hou, LJ (corresponding author), Second Mil Med Univ, Dept Neurosurg, Shanghai Inst Neurosurg, Shanghai Changzheng Hosp, 415 Feng Yang Rd, Shanghai 200003, Peoples R China.	neuro_hlj@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30600635]	Supported by the National Natural Science Foundation of China (30600635).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Goh KYC, 1999, PEDIATR NEUROL, V21, P742, DOI 10.1016/S0887-8994(99)00069-7; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KISHNER S, POSTHEAD INJURY AUTO; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022	25	26	29	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2011	71	3					538	542		10.1097/TA.0b013e31820ebee1			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	818MX	WOS:000294756900008	21427610				2022-02-06	
J	Shahlaie, K; Keachie, K; Hutchins, IM; Rudisill, N; Madden, LK; Smith, KA; Ko, KA; Latchaw, RE; Muizelaar, JP				Shahlaie, Kiarash; Keachie, Krista; Hutchins, Irene M.; Rudisill, Nancy; Madden, Lori K.; Smith, Karen A.; Ko, Karen A.; Latchaw, Richard E.; Muizelaar, J. Paul			Risk factors for posttraumatic vasospasm Clinical article	JOURNAL OF NEUROSURGERY			English	Article						fever; inflammation; intracranial hemorrhage; traumatic brain injury; vasospasm; vascular disorders	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; INTRACRANIAL ARTERIAL SPASM; SUBARACHNOID HEMORRHAGE; TIME-COURSE; CT-SCAN; TEMPERATURE; VELOCITIES; FEVER	Object. Posttraumatic vasospasm (PTV) is an underrecognized cause of ischemic damage after severe traumatic brain injury (TBI) that independently predicts poor outcome. There are, however, no guidelines for PTV screening and management, partly due to limited understanding of its pathogenesis and risk factors. Methods. A database review of 46 consecutive cases of severe TBI in pediatric and adult patients was conducted to identify risk factors for the development of PTV. Univariate analysis was performed to identify potential risk factors for PTV, which were subsequently analyzed using a multivariate logistic regression model to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Results. Fever on admission was an independent risk factor for development of PTV (OR 22.2, 95% CI 1.9-256.8), and patients with hypothermia on admission did not develop clinically significant vasospasm during their hospital stay. The presence of small parenchymal contusions was also an independent risk factor for PTV (OR 7.8, 95% CI 0.9-69.5), whereas the presence of subarachnoid hemorrhage or other patterns of intracranial injury were not. Other variables, such as age, sex, ethnicity, degree of TBI severity, or admission laboratory values, were not independent predictors for the development of clinically significant PTV. Conclusions. Independent risk factors for PTV include parenchymal contusions and fever. These results suggest that diffuse mechanical injury and activation of inflammatory pathways may be underlying mechanisms for the development of PTV, and that a subset of patients with these risk factors may be an appropriate population for aggressive screening. Further studies are needed to determine if treatments targeting fever and inflammation may be effective in reducing the incidence of vasospasm following severe TBI. (DOI: 10.3171/2011.5.JNS101667)	[Shahlaie, Kiarash; Keachie, Krista; Hutchins, Irene M.; Rudisill, Nancy; Madden, Lori K.; Smith, Karen A.; Ko, Karen A.; Muizelaar, J. Paul] Univ Calif Davis, Dept Neurol Surg, Sch Med, Sacramento, CA 95817 USA; [Latchaw, Richard E.] Univ Calif Davis, Dept Radiol, Sch Med, Sacramento, CA 95817 USA		Shahlaie, K (corresponding author), Univ Calif Davis, Dept Neurol Surg, Sch Med, 4860 Y St,Suite 3740, Sacramento, CA 95817 USA.	kiarash.shahlaie@ucdmc.ucdavis.edu	Madden, Lori K/K-3749-2012	Madden, Lori K/0000-0001-9179-4202			Armin SS, 2008, ACTA NEUROCHIR SUPPL, V104, P421; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ARSENI C, 1971, ACTA NEUROCHIR, V24, P25, DOI 10.1007/BF01403138; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; Bakshi A, 1998, NATL MED J INDIA, V11, P220; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHAN KH, 1992, NEUROSURGERY, V30, P697; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; CORK RC, 1983, ANESTH ANALG, V62, P211; Dhar R, 2008, NEUROCRIT CARE, V8, P253, DOI 10.1007/s12028-007-9020-4; Echlin FA, 1942, ARCH NEURO PSYCHIATR, V47, P77, DOI 10.1001/archneurpsyc.1942.02290010087007; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31; Ferrara-Love R, 1991, J Post Anesth Nurs, V6, P161; Fountas KN, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS08311; FULBROOK P, 1993, J ADV NURS, V18, P1451, DOI 10.1046/j.1365-2648.1993.18091451.x; Geffroy A, 2004, INTENS CARE MED, V30, P785, DOI 10.1007/s00134-004-2280-y; GROLIMUND P, 1988, LANCET, V1, P1173; Hadani M, 1997, J NEUROTRAUM, V14, P629, DOI 10.1089/neu.1997.14.629; HAMER J, 1976, NEUROCHIRURGIA, V19, P185; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; Kim GH, 2008, J NEUROSURG, V109, P38, DOI 10.3171/JNS/2008/109/7/0038; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; KORDESTANI RK, 1995, NEUROSURG CLIN N AM, V6, P657; Lee DJ, 2008, NEUROSURGERY, V63, P1004, DOI 10.1227/01.NEU.0000327685.90800.F7; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LEWIN W, 1968, BRIT J SURG, V55, P321, DOI 10.1002/bjs.1800550502; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; McGirt MJ, 2006, J NEUROSURG, V105, P671, DOI 10.3171/jns.2006.105.5.671; McGirt MJ, 2003, J NEUROSURG, V98, P1222, DOI 10.3171/jns.2003.98.6.1222; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604; Rabinstein AA, 2007, J NEUROL NEUROSUR PS, V78, P1278, DOI 10.1136/jnnp.2006.112730; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; ROUSSEAUX P, 1980, SURG NEUROL, V14, P459; Rozsa L, 1989, Radiol Diagn (Berl), V30, P151; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; Schoch B, 2007, NEUROSURGERY, V60, P828, DOI 10.1227/01.NEU.0000255440.21495.80; Seo W, 2009, WORLDV EVID-BASED NU, V6, P36, DOI 10.1111/j.1741-6787.2008.00139.x; Shahlaie K, 2009, NEUROCRIT CARE, V10, P61, DOI 10.1007/s12028-008-9138-z; Shahlaie K, 2009, J NEUROTRAUM, V26, pA91; Soustiel JF, 2004, SURG NEUROL, V62, P201, DOI 10.1016/j.surneu.2003.10.037; Soustiel JF, 2002, ACTA NEUROCHIR, V144, P137, DOI 10.1007/s007010200016; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; SYMON L, 1967, J NEUROL NEUROSUR PS, V30, P497, DOI 10.1136/jnnp.30.6.497; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Tseng MY, 2006, NEUROSURG FOCUS, V21, pE10, DOI DOI 10.3171/F0C.2006.21.3.10; Vajramani GV, 1999, BRIT J NEUROSURG, V13, P468, DOI 10.1080/02688699943277; Vath A, 2002, ACT NEUR S, V81, P307; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WEIR B, 1989, NEUROSURGERY, V25, P161, DOI 10.1227/00006123-198908000-00002; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; Zubkov AY, 1999, J NEUROTRAUM, V16, P763, DOI 10.1089/neu.1999.16.763; Zubkov ZY, 2000, SURG NEUROL, V53, P126	71	26	31	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2011	115	3					602	611		10.3171/2011.5.JNS101667			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	816FG	WOS:000294583500025	21663415				2022-02-06	
J	Vender, J; Waller, J; Dhandapani, K; McDonnell, D				Vender, John; Waller, Jennifer; Dhandapani, Krishnan; McDonnell, Dennis			AN EVALUATION AND COMPARISON OF INTRAVENTRICULAR, INTRAPARENCHYMAL, AND FLUID-COUPLED TECHNIQUES FOR INTRACRANIAL PRESSURE MONITORING IN PATIENTS WITH SEVERE TRAUMATIC BRAIN INJURY	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						traumatic brain injury; intracranial pressure monitoring; intraparenchymal; intraventricular; fluid-coupled	CEREBRAL PERFUSION-PRESSURE; CLINICAL-EVALUATION; CODMAN MICROSENSOR; ICP SIGNALS; OXYGEN	Objective. Intracranial pressure measurements have become one of the mainstays of traumatic brain injury management. Various technologies exist to monitor intracranial pressure from a variety of locations. Transducers are usually placed to assess pressure in the brain parenchyma and the intraventricular fluid, which are the two most widely accepted compartmental monitoring sites. The individual reliability and inter-reliability of these devices with and without cerebrospinal fluid diversion is not clear. The predictive capability of monitors in both of these sites to local, regional, and global changes also needs further clarification. The technique of monitoring intraventricular pressure with a fluid-coupled transducer system is also reviewed. There has been little investigation into the relationship among pressure measurements obtained from these two sources using these three techniques. Methods. Eleven consecutive patients with severe, closed traumatic brain injury not requiring intracranial mass lesion evacuation were admitted into this prospective study. Each patient underwent placement of a parenchymal and intraventricular pressure monitor. The ventricular catheter tubing was also connected to a sensor for fluid-coupled measurement. Pressure from all three sources was measured hourly with and without ventricular drainage. Results. Statistically significant correlation within each monitoring site was seen. No monitoring location was more predictive of global pressure changes or more responsive to pressure changes related to patient stimulation. However, the intraventricular pressure measurements were not reliable in the presence of cerebrospinal fluid drainage whereas the parenchymal measurements remained unaffected. Conclusion. Intraparenchymal pressure monitoring provides equivalent, statistically similar pressure measurements when compared to intraventricular monitors in all care and clinical settings. This is particularly valuable when uninterrupted cerebrospinal fluid drainage is desirable.	[Vender, John; Dhandapani, Krishnan; McDonnell, Dennis] Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA; [Waller, Jennifer] Med Coll Georgia, Dept Biostat, Augusta, GA 30912 USA		Vender, J (corresponding author), Med Coll Georgia, Dept Neurosurg, BI 3088,1120 15th St, Augusta, GA 30912 USA.	jvender@mail.mcg.edu		Dhandapani, Krishnan/0000-0001-7044-1117	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065172] Funding Source: Medline		Brain Trauma Foundation, 2000, MAN PROGN SEV TRAU 1; Brean A, 2006, J Clin Monit Comput, V20, P411, DOI 10.1007/s10877-006-9047-7; BRUDER N, 1995, INTENS CARE MED, V21, P850, DOI 10.1007/BF01700971; Chambers IR, 2001, J NEUROL NEUROSUR PS, V71, P383, DOI 10.1136/jnnp.71.3.383; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Eide PK, 2008, MED ENG PHYS, V30, P34, DOI 10.1016/j.medengphy.2007.01.005; Eide PK, 2006, MED ENG PHYS, V28, P542, DOI 10.1016/j.medengphy.2005.09.003; Fernandes HM, 1998, ACT NEUR S, V71, P44; Huschak G, 2009, J NEUROSURG ANESTH, V21, P155, DOI 10.1097/ANA.0b013e31818f2eac; Isa Ruwaida, 2003, Neurosurg Focus, V15, pE1; Khan SH, 1998, ACT NEUR S, V71, P50; Maas AI, 2008, J TRAUMA, V65, P966, DOI 10.1097/TA.0b013e318184ee7b; Munch EC, 2001, CRIT CARE MED, V29, P976; Murad A, 2008, ACT NEUR S, V102, P89, DOI 10.1007/978-3-211-85578-2_18; Poca MA, 2002, J NEUROTRAUM, V19, P439, DOI 10.1089/08977150252932398; Schneider GH, 1998, ACT NEUR S, V71, P62; Signorini DF, 1998, BRIT J NEUROSURG, V12, P223; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7	21	26	28	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	AUG	2011	25	4					231	236		10.1007/s10877-011-9300-6			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	872NJ	WOS:000298816100003	21938526				2022-02-06	
J	Garcia, AN; Shah, MA; Dixon, CE; Wagner, AK; Kline, AE				Garcia, Alexandra N.; Shah, Mansi A.; Dixon, C. Edward; Wagner, Amy K.; Kline, Anthony E.			Biologic and Plastic Effects of Experimental Traumatic Brain Injury Treatment Paradigms and Their Relevance to Clinical Rehabilitation	PM&R			English	Article							CONTROLLED CORTICAL IMPACT; FACTOR MESSENGER-RNA; RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; BAY X 3702; ENVIRONMENTAL ENRICHMENT; COGNITIVE DEFICITS; HEAD-INJURY; CHOLINE-ACETYLTRANSFERASE; NEUROBEHAVIORAL RECOVERY; CEREBRAL METABOLISM	Neuroplastic changes, whether induced by traumatic brain injury (TBI) or therapeutic interventions, alter neurobehavioral outcome. Here we present several treatment strategies that have been evaluated by using experimental TBI models and discuss potential mechanisms of action (ie, plasticity) and how such changes affect function. PM R 2011;3:S18-S27	[Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Neural Basis Cognit, Dept Phys Med & Rehabil,Ctr Neurosci,Dept Psychol, Pittsburgh, PA 15213 USA; [Garcia, Alexandra N.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA; [Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol Surg, Dept Phys Med & Rehabil,Ctr Neurosci, Pittsburgh, PA 15213 USA		Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Neural Basis Cognit, Dept Phys Med & Rehabil,Ctr Neurosci,Dept Psychol, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD046700-04, R01 HD069620, R01 HD046700] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS060005-04, R01 NS060005-03, R01 NS060005] Funding Source: Medline		Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Baxter MG, 1999, CURR OPIN NEUROBIOL, V9, P178, DOI 10.1016/S0959-4388(99)80024-5; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Buytaert KA, 2001, BRAIN RES, V894, P121, DOI 10.1016/S0006-8993(01)01987-4; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chandler M C, 1988, Brain Inj, V2, P309; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Clark WM, 1997, NEUROLOGY, V49, P671, DOI 10.1212/WNL.49.3.671; CRISMON ML, 1988, CLIN NEUROPHARMACOL, V11, P462, DOI 10.1097/00002826-198810000-00007; Darrah SH, 2011, J NEUROTRAUM, V28, P43, DOI 10.1089/neu.2010.1521; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donat CK, 2008, BRAIN RES, V1246, P167, DOI 10.1016/j.brainres.2008.09.059; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Dossett LA, 2008, J TRAUMA, V64, P580, DOI 10.1097/TA.0b013e31816543dd; Dossett LA, 2008, SURG INFECT, V9, P41, DOI 10.1089/sur.2007.037; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faul M, 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; Finger S, 2004, ARCH NEUROL-CHICAGO, V61, P283, DOI 10.1001/archneur.61.2.283; Gibbs RB, 2010, ENDOCR REV, V31, P224, DOI 10.1210/er.2009-0036; Gillespie LN, 2003, CLIN EXP PHARMACOL P, V30, P724, DOI 10.1046/j.1440-1681.2003.03909.x; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hernandez TD, 2006, J NEUROTRAUM, V23, P1211, DOI 10.1089/neu.2006.23.1211; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Hovda DA, 1996, J CEREBR BLOOD F MET, V16, P134, DOI 10.1097/00004647-199601000-00016; HOVDA DA, 1985, P W PHARMACOL SOC, V28, P209; Hughes S, 2005, BRAIN INJURY, V19, P1197, DOI 10.1080/02699050500309296; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kleim JA, 2002, NEUROBIOL LEARN MEM, V77, P63, DOI 10.1006/nlme.2000.4004; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; KumeKick J, 1996, BRAIN RES, V738, P8, DOI 10.1016/0006-8993(96)00744-5; Lanari A, 2006, MECH AGEING DEV, V127, P158, DOI 10.1016/j.mad.2005.09.016; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Leon-Carrion J, 2000, NEUROREHABILITATION, V14, P33; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Lu B, 1997, REV NEUROSCIENCE, V8, P1; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Matter AM, 2011, NEUROREHABIL NEURAL; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McEwen BS, 2010, ANN NY ACAD SCI, V1204, pE38, DOI 10.1111/j.1749-6632.2010.05568.x; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; MEYER JS, 1993, NEUROL RES, V15, P362; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Montanez S, 2000, BRAIN RES, V860, P29, DOI 10.1016/S0006-8993(00)01951-X; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mufson Elliott J, 2008, Expert Rev Neurother, V8, P1703, DOI 10.1586/14737175.8.11.1703; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; PULASKI KH, 1994, AM J OCCUP THER, V48, P263, DOI 10.5014/ajot.48.3.263; Queen SA, 1997, BRAIN RES, V777, P42, DOI 10.1016/S0006-8993(97)00717-8; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Roloff EV, 1999, CELL MOL LIFE SCI, V55, P601, DOI 10.1007/s000180050318; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schneider WN, 1999, BRAIN INJURY, V13, P863; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DE, 1999, P NATL ACAD SCI USA, V96, P10893, DOI 10.1073/pnas.96.19.10893; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Spencer JL, 2008, FRONT NEUROENDOCRIN, V29, P219, DOI 10.1016/j.yfrne.2007.08.006; Spratt DI, 2008, AM J PHYSIOL-ENDOC M, V295, pE63, DOI 10.1152/ajpendo.00472.2007; Spratt DI, 2006, AM J PHYSIOL-ENDOC M, V291, pE631, DOI 10.1152/ajpendo.00467.2005; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; Turner CA, 2003, PHYSIOL BEHAV, V80, P259, DOI 10.1016/j.physbeh.2003.07.008; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; VONMONAKOW C, 1969, MOODS STATES MIND, P27; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Whyte J, 2008, AM J PHYS MED REHAB, V87, P85, DOI 10.1097/PHM.0b013e3181619609; Widenfalk J, 1999, NEUROSCI RES, V34, P125, DOI 10.1016/S0168-0102(99)00051-6; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wu TS, 2005, J EMERG MED, V28, P289, DOI 10.1016/j.jemermed.2004.11.016; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zhao CS, 2005, BEHAV BRAIN RES, V158, P211, DOI 10.1016/j.bbr.2004.09.001; Zhao LR, 2000, NEUROSCIENCE, V97, P177, DOI 10.1016/S0306-4522(00)00023-3; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	150	26	26	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JUN	2011	3	6		S			S18	S27		10.1016/j.pmrj.2011.03.017			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	961BB	WOS:000305437800004	21703575	Green Accepted			2022-02-06	
J	Pandya, JD; Sullivan, PG; Pettigrew, LC				Pandya, Jignesh D.; Sullivan, Patrick G.; Pettigrew, L. Creed			Focal cerebral ischemia and mitochondrial dysfunction in the TNF alpha-transgenic rat	BRAIN RESEARCH			English	Article						Calcium homeostasis; Brain ischemia; Transgenic rat; Tumor necrosis factor alpha; Mitochondrial bioenergetics; Mitochondrial permeability; transition pore; Reactive oxygen species	TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; METHYL-D-ASPARTATE; PERMEABILITY TRANSITION; REACTIVE OXYGEN; CELL-DEATH; SYNAPTIC MITOCHONDRIA; HYPOXIA-ISCHEMIA; FREE-RADICALS; CYTOKINES	Post-ischemic neurodegeneration may be accelerated by a cytokine-receptor mediated apoptotic pathway, as shown in a transgenic rat overexpressing tumor necrosis factor-alpha (TNF alpha) in brain. To further investigate the mechanism of ischemic cellular injury in this animal, we tested the hypothesis that increased synthesis of TNF alpha augments neuronal death by promoting mitochondrial dysfunction, calcium dysregulation, and oxidative stress. Adult male TNF alpha-transgenic (TNF alpha-Tg) and non-transgenic (non-Tg) littermates underwent reversible middle cerebral artery occlusion (MCAO) for 1 hour followed by 1 hour of reperfusion. Cortical mitochondria were isolated from injured (ipsilateral) and uninjured (contralateral) hemispheres of ischemic rats or from pooled hemispheres of control animals. ATP synthesis was attenuated in non-ischemic TNF alpha-Tg rats, demonstrated by reduction of state III and respiratory control ratio, increased production of reactive oxygen species, and earlier formation of the calcium-induced membrane permeability transition pore. After MCAO, mitochondrial dysfunction was augmented more significantly in ischemic TNF alpha-Tg brain mitochondria than in non-Tg rats. These results show that mitochondrial dysfunction may be caused by increased brain levels of TNF alpha without physiological stress but will be exacerbated after MCAO. We conclude that ischemic stress and synthesis of inflammatory cytokines synergistically augment mitochondrial dysfunction to promote neuronal death. Published by Elsevier B.V.	[Pettigrew, L. Creed] Univ Kentucky, Med Ctr, Univ Kentucky Stroke Program, Dept Neurol, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Pettigrew, L. Creed] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Pettigrew, L. Creed] Vet Adm VA Med Ctr, Lexington, KY USA		Pettigrew, LC (corresponding author), Univ Kentucky, Med Ctr, Univ Kentucky Stroke Program, Dept Neurol, 101 Sanders Brown Bldg,800 S Limestone St, Lexington, KY 40536 USA.	cpetti@uky.edu		Pettigrew, Luther Creed/0000-0001-7878-5803	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01s N5048191, NS047375, P30 NS051220]; Medical Research Service, Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191, P30NS051220] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS grants awarded to the University of Kentucky (R01s N5048191 [PGS] and NS047375 [LCP]; P30 NS051220) and a Merit Review Award from the Medical Research Service, Department of Veterans Affairs (LCP). We thank Susan D. Craddock for her expert technical assistance. Sherry Chandler Williams, ELS, edited the manuscript and prepared the figures.	Ali MH, 1999, AM J PHYSIOL-LUNG C, V277, pL1057, DOI 10.1152/ajplung.1999.277.5.L1057; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Clarkson AN, 2007, NEUROSCIENCE, V144, P547, DOI 10.1016/j.neuroscience.2006.09.040; Dave KR, 2001, J CEREBR BLOOD F MET, V21, P1401, DOI 10.1097/00004647-200112000-00004; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Ginsburg I, 1998, MED HYPOTHESES, V51, P337, DOI 10.1016/S0306-9877(98)90059-7; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lacerda L, 2006, LIFE SCI, V79, P2194, DOI 10.1016/j.lfs.2006.07.020; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; LIU Y, 1994, J CEREBR BLOOD F MET, V14, P348, DOI 10.1038/jcbfm.1994.43; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Montaner J, 2003, J CEREBR BLOOD F MET, V23, P1403, DOI 10.1097/01.WCB.0000100044.07481.97; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; PETITO CK, 1984, J NEUROPATH EXP NEUR, V43, P141, DOI 10.1097/00005072-198403000-00004; Pettigrew LC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-47; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Puka-Sundvall M, 2000, DEV BRAIN RES, V125, P43, DOI 10.1016/S0165-3806(00)00111-5; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Shakibaei M, 2005, ANTIOXID REDOX SIGN, V7, P482, DOI 10.1089/ars.2005.7.482; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tomimoto H, 1996, ACTA NEUROPATHOL, V92, P281, DOI 10.1007/s004010050519; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Zaremba J, 2001, BIOMED PHARMACOTHER, V55, P258, DOI 10.1016/S0753-3322(01)00058-0	42	26	28	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 12	2011	1384						151	160		10.1016/j.brainres.2011.01.102			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	750JT	WOS:000289543100017	21300036	Green Accepted			2022-02-06	
J	Luostarinen, T; Niiya, T; Schramko, A; Rosenberg, P; Niemi, T				Luostarinen, Teemu; Niiya, Tomohisa; Schramko, Alexey; Rosenberg, Per; Niemi, Tomi			Comparison of Hypertonic Saline and Mannitol on Whole Blood Coagulation In Vitro Assessed by Thromboelastometry	NEUROCRITICAL CARE			English	Article						Hypertonic saline; Mannitol; Coagulation; Traumatic brain injury; Craniotomy; Neurosurgery	INTRACRANIAL HYPERTENSION; 20-PERCENT MANNITOL; 7.5-PERCENT SALINE; BRAIN RELAXATION; RESUSCITATION; PRESSURE	Hypertonic saline (HS) is an alternative to mannitol for decreasing intracranial pressure in traumatic brain injury and before craniotomy. Both HS and mannitol may interfere with blood coagulation but their influence on coagulation has not been compared in controlled situations. Therefore, we evaluated different strengths of HS and 15% mannitol on blood coagulation in vitro. Citrated fresh whole blood, withdrawn from 10 volunteers, was diluted with 0.9%, 2.5%, or 3.5% HS or 15% mannitol to make 10 vol.% and 20 vol.% hemodilution in vitro. The diluted blood and undiluted control samples were analyzed with thromboelastometry (ROTEMA (R)) using two activators, tissue thromboplastin without (ExTEM(A (R))) or with cytochalasin (FibTEM(A (R))). In the FibTEM(A (R)) analysis, maximum clot firmness (MCF) was stronger in the 2.5% HS group than in the mannitol group after both dilutions (P < 0.05). In the ExTEM(A (R)) analysis, clot formation time (CFT) was more delayed in the mannitol group than in the 0.9%, 2.5%, or 3.5% HS groups in 20 vol.% hemodilution (P < 0.05). MCF was weaker in the mannitol group than in the other groups after 20 vol.% dilution (P < 0.05). MCF was also weaker in the 3.5% than in the 0.9% saline group after 20 vol.% dilution (P < 0.05). Blood coagulation is disturbed more by 15% mannitol than by equiosmolar 2.5% saline. This disturbance seems to be attributed to overall clot formation and strength but also to pure fibrin clot firmness. This saline solution might be more favorable than mannitol before craniotomy in patients with a high risk of bleeding.	[Luostarinen, Teemu; Schramko, Alexey; Rosenberg, Per; Niemi, Tomi] Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, Toolo Hosp, Helsinki 00029, Finland; [Niiya, Tomohisa] Sapporo Med Univ, Dept Anesthesiol, Sapporo, Hokkaido, Japan		Luostarinen, T (corresponding author), Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, Toolo Hosp, POB 266, Helsinki 00029, Finland.	teemu.luostarinen@hus.fi					Bischof D, 2010, MINERVA ANESTESIOL, V76, P131; Brummel-Ziedins K, 2006, J TRAUMA, V61, P1350, DOI 10.1097/01.ta.0000235525.64176.01; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; da Silva JC, 2010, NEUROL RES, V32, P139, DOI 10.1179/174313209X405119; De Vivo P, 2001, Minerva Anestesiol, V67, P603; Erard AC, 2003, ANN FR ANESTH, V22, P18, DOI 10.1016/S0750-7658(02)00004-7; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; GRUZ J, 2001, NEUROSURGERY, V49, P864; Keyrouz SG, 2008, NEUROCRIT CARE, V9, P204, DOI 10.1007/s12028-008-9118-3; Krausz Michael M, 2006, World J Emerg Surg, V1, P14, DOI 10.1186/1749-7922-1-14; Lindroos AC, 2010, J NEUROSURG ANESTH, V22, P16, DOI 10.1097/ANA.0b013e3181bd4ede; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Niemi TT, 2005, ACTA ANAESTH SCAND, V49, P373, DOI 10.1111/j.1399-6576.2005.00619.x; Perez-Perez AJ, 2002, AM J NEPHROL, V22, P573, DOI 10.1159/000065279; REED RL, 1991, J TRAUMA, V31, P8, DOI 10.1097/00005373-199101000-00002; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Rozet I, 2007, ANESTHESIOLOGY, V107, P697, DOI 10.1097/01.anes.0000286980.92759.94; Tan TS, 2002, ANAESTHESIA, V57, P644, DOI 10.1046/j.1365-2044.2002.02603.x; Tsai SF, 2010, CLIN NEPHROL, V74, P70; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Watters JM, 2006, J TRAUMA, V61, P75, DOI 10.1097/01.ta.0000222723.54559.47; Wilder DM, 2002, THROMB RES, V107, P255, DOI 10.1016/S0049-3848(02)00335-3; Wu CT, 2010, ANESTH ANALG, V110, P903, DOI 10.1213/ANE.0b013e3181cb3f8b	26	26	27	1	13	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2011	14	2					238	243		10.1007/s12028-010-9475-6			6	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	738SY	WOS:000288663800014	21369792				2022-02-06	
J	Preece, MHW; Horswill, MS; Geffen, GM				Preece, Megan H. W.; Horswill, Mark S.; Geffen, Gina M.			Assessment of drivers' ability to anticipate traffic hazards after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							ACCIDENT RATE; RETURN; CONCUSSION; IDENTIFY; REDUCE; COMA	Objectives The aim of this study was to examine the effect of traumatic brain injury (TBI) on drivers' ability to anticipate traffic hazards. Slower anticipation of hazards has been associated with higher crash rates, but this driving skill has never been assessed after TBI. Methods The anticipatory ability of 31 drivers with TBI and 24 age-matched uninjured controls was assessed with a validated drivers' Hazard Perception Test. The Hazard Perception Test displayed videos of genuine traffic scenes filmed from the driver's perspective, and participants had to respond as soon as they anticipated a traffic hazard in a scene. The primary dependent measure was mean response latency. Results Participants with TBI were significantly slower to anticipate traffic hazards than controls (p<0.001). Within the TBI group, while hazard perception response times were significantly related to duration of post-traumatic amnesia (Spearman rho=0.63; p<0.001), they were not significantly related to Glasgow Coma Scale scores (r=-0.19; p=0.33). Also, participants with a complicated mild TBI were significantly faster in anticipating traffic conflicts than participants with moderate to severe TBI (p=0.04). Conclusions Individuals with TBI were slower to anticipate traffic hazards than age-matched uninjured controls. This finding signifies the need for hazard perception testing and training as part of driving rehabilitation after TBI.	[Preece, Megan H. W.; Horswill, Mark S.; Geffen, Gina M.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia		Preece, MHW (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.	m.preece@psy.uq.edu.au	Horswill, Mark/J-9029-2019; Preece, Megan/A-7186-2013	Horswill, Mark/0000-0002-0286-6292; Preece, Megan/0000-0003-4852-8712			Babor T.F., 2001, AUDIT THE ALCOHOL US; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Darby P, 2009, SAFETY SCI, V47, P436, DOI 10.1016/j.ssci.2008.05.004; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Fisk GD, 1998, BRAIN INJURY, V12, P683; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Horswill MS, 2010, PSYCHOL AGING, V25, P464, DOI 10.1037/a0017306; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lovibond SH., 1995, MANUAL DEPRESSION AN, V2nd; Lundqvist A, 2007, BRAIN INJURY, V21, P1109, DOI 10.1080/02699050701651660; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Milleville-Pennel I, 2010, BRAIN INJURY, V24, P678, DOI 10.3109/02699051003692159; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; Novack TA, 2010, BRAIN INJURY, V24, P464, DOI 10.3109/02699051003601713; PARKER D, 1995, ERGONOMICS, V38, P1036, DOI 10.1080/00140139508925170; Pelz D.C., 1974, ACCIDENT ANAL PREV, V6, P45, DOI [10.1016/0001-4575(74)90015-3., DOI 10.1016/0001-4575(74)90015-3]; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; Poulsen AA, 2010, AUST NZ J PSYCHIAT, V44, P528, DOI 10.3109/00048671003596048; Pradhan AK, 2009, ERGONOMICS, V52, P657, DOI 10.1080/00140130802550232; Preece MHW, 2010, NEUROPSYCHOLOGY, V24, P493, DOI 10.1037/a0018903; Rapport LJ, 2008, ARCH PHYS MED REHAB, V89, P922, DOI 10.1016/j.apmr.2008.01.009; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schanke AK, 2008, J REHABIL MED, V40, P733, DOI 10.2340/16501977-0256; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith SS, 2009, ACCIDENT ANAL PREV, V41, P729, DOI 10.1016/j.aap.2009.03.016; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Wechsler D, 1981, WESCHLER ADULT INTEL; Wells P., 2008, 81 DEP TRANSP; Wilson B., 1999, BEHAVIOURAL INATTENT BEHAV INATTENTION TE; Yudofsky S.C., 2005, TXB TRAUMATIC BRAIN, P27	40	26	27	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2011	82	4					447	451		10.1136/jnnp.2010.215228			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	734ZY	WOS:000288384100022	20884679				2022-02-06	
J	Eastman, CL; Verley, DR; Fender, JS; Stewart, TH; Nov, E; Curia, G; D'Ambrosio, R				Eastman, Clifford L.; Verley, Derek R.; Fender, Jason S.; Stewart, Tessandra H.; Nov, Eytan; Curia, Giulia; D'Ambrosio, Raimondo			Antiepileptic and Antiepileptogenic Performance of Carisbamate after Head Injury in the Rat: Blind and Randomized Studies	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							SPONTANEOUS MOTOR SEIZURES; KAINATE-INDUCED EPILEPSY; FLUID PERCUSSION INJURY; TEMPORAL-LOBE EPILEPSY; PARTIAL-ONSET SEIZURES; INTERNATIONAL-BUREAU; REFRACTORY EPILEPSY; PILOCARPINE MODEL; ANIMAL-MODELS; DRUGS	Carisbamate (CRS) exhibits broad acute anticonvulsant activity in conventional anticonvulsant screens, genetic models of absence epilepsy and audiogenic seizures, and chronic spontaneous motor seizures arising after chemoconvulsant-induced status epilepticus. In add-on phase III trials with pharmacoresistant patients CRS induced <30% average decreases in partial-onset seizure frequency. We assessed the antiepileptogenic and antiepileptic performance of subchronic CRS administration on posttraumatic epilepsy (PTE) induced by rostral parasaggital fluid percussion injury (rpFPI), which closely replicates human contusive closed head injury. Studies were blind and randomized, and treatment effects were assessed on the basis of sensitive electrocorticography (ECoG) recordings. Antiepileptogenic effects were assessed in independent groups of control and CRS-treated rats, at 1 and 3 months postinjury, after completion of a 2-week prophylactic treatment initiated 15 min after injury. The antiepileptic effects of 1-week CRS treatments were assessed in repeated measures experiments at 1 and 4 months postinjury. The studies were powered to detect similar to 50 and similar to 40% decreases in epilepsy incidence and frequency of seizures, respectively. Drug/vehicle treatment, ECoG analysis, and [CRS](plasma) determination all were performed blind. We detected no antiepileptogenic and an equivocal transient antiepileptic effects of CRS despite [CRS](plasma) comparable with or higher than levels attained in previous preclinical and clinical studies. These findings contrast with previous preclinical data demonstrating large efficacy of CRS, but agree with the average effect of CRS seen in clinical trials. The data support the use of rpFPI-induced PTE in the adolescent rat as a model of pharmacoresistant epilepsy for preclinical development.	[Eastman, Clifford L.; Verley, Derek R.; Fender, Jason S.; Nov, Eytan; Curia, Giulia; D'Ambrosio, Raimondo] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo] Univ Washington, Sch Med, Reg Epilepsy Ctr, Seattle, WA 98104 USA; [Stewart, Tessandra H.] Univ Washington, Sch Med, Grad Program Neurobiol & Behav, Seattle, WA 98104 USA		D'Ambrosio, R (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurosurg, Box 359915,325 9th Ave, Seattle, WA 98104 USA.	raid@u.washington.edu	Verley, Derek/J-4550-2015; Curia, Giulia/A-8863-2008	Verley, Derek/0000-0002-2670-6568; Curia, Giulia/0000-0002-8472-350X	Johnson and Johnson Pharmaceutical Research and Development, LLCJohnson & JohnsonJohnson & Johnson USA; National Institutes of Health National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS053928]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053928] Funding Source: NIH RePORTER	This work was supported by Johnson and Johnson Pharmaceutical Research and Development, LLC, and the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant NS053928] (to R. D.).	Andre V, 2007, EPILEPSIA, V48, P41, DOI 10.1111/j.1528-1167.2007.01288.x; Beghi E, 2005, EPILEPSIA, V46, P1698, DOI 10.1111/j.1528-1167.2005.00273_1.x; Callaghan BC, 2007, ANN NEUROL, V62, P382, DOI 10.1002/ana.21166; Crossley NA, 2008, STROKE, V39, P929, DOI 10.1161/STROKEAHA.107.498725; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P90, DOI 10.1111/j.1535-7511.2010.01367.x; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140-6736(06)68477-8; Eastman CL, 2010, EXP NEUROL, V224, P369, DOI 10.1016/j.expneurol.2010.04.013; Faught E, 2008, NEUROLOGY, V71, P1586, DOI 10.1212/01.wnl.0000334751.89859.7f; Fisher RS, 2008, EPILEPSIA, V49, P7, DOI 10.1111/j.1528-1167.2008.01921.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Francois J, 2008, EPILEPSIA, V49, P393, DOI 10.1111/j.1528-1167.2007.01278.x; French JA, 2007, EPILEPSIA, V48, P3, DOI 10.1111/j.1528-1167.2007.00992.x; Glien M, 2002, EPILEPSIA, V43, P350, DOI 10.1046/j.1528-1157.2002.18101.x; Grabenstatter HL, 2008, EPILEPSIA, V49, P1787, DOI 10.1111/j.1528-1167.2008.01657.x; Grabenstatter HL, 2005, EPILEPSIA, V46, P8, DOI 10.1111/j.0013-9580.2005.13404.x; Hitiris N, 2007, EPILEPSY RES, V75, P192, DOI 10.1016/j.eplepsyres.2007.06.003; JUULJENSEN P, 1986, INTRACTABLE EPILEPSY, P5; Klein BD, 2007, EPILEPSIA, V48, P367; Kwan P, 2003, NEUROLOGY, V60, pS2, DOI 10.1212/WNL.60.11_suppl_4.S2; Loscher W, 2007, EPILEPSIA, V48, P1245, DOI 10.1111/j.1528-1167.2007.01093.x; Loscher W, 2004, EPILEPSY RES, V60, P77, DOI 10.1016/j.eplepsyres.2004.06.004; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; LOSCHER W, 1995, EPILEPSIA, V36, P929, DOI 10.1111/j.1528-1157.1995.tb01637.x; Lu Y, 2009, CNS DRUGS, V23, P351, DOI 10.2165/00023210-200923040-00006; Mamidi RNVS, 2007, DRUG METAB DISPOS, V35, P566, DOI 10.1124/dmd.106.012336; Mattson RH, 1996, NEUROLOGY, V47, P68, DOI 10.1212/WNL.47.1.68; Meldrum B, 2002, EPILEPSY RES, V50, P33, DOI 10.1016/S0920-1211(02)00066-9; Novak GP, 2007, NEUROTHERAPEUTICS, V4, P106, DOI 10.1016/j.nurt.2006.11.016; Philip M, 2009, STROKE, V40, P577, DOI 10.1161/STROKEAHA.108.524330; Rogawski MA, 2006, EPILEPSY RES, V69, P273, DOI 10.1016/j.eplepsyres.2006.02.004; Schmidt D, 2002, EPILEPSY RES, V50, P71, DOI 10.1016/S0920-1211(02)00070-0; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Sperling MR, 2010, EPILEPSIA, V51, P333, DOI 10.1111/j.1528-1167.2009.02318.x; Stables James P., 2002, Epilepsia, V43, P1410, DOI 10.1046/j.1528-1157.2002.06702.x; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; White HS, 2006, EPILEPSIA, V47, P200; White HS, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s7.10.x; White HS, 2002, NEUROLOGY, V59, pS7, DOI 10.1212/WNL.59.9_suppl_5.S7	43	26	26	0	7	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	MAR	2011	336	3					779	790		10.1124/jpet.110.175133			12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	723AI	WOS:000287477200021	21123672	Green Published			2022-02-06	
J	Eckner, JT; Lipps, DB; Kim, H; Richardson, JK; Ashton-Miller, JA				Eckner, James T.; Lipps, David B.; Kim, Hogene; Richardson, James K.; Ashton-Miller, James A.			Can a Clinical Test of Reaction Time Predict a Functional Head-Protective Response?	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CLINICAL ASSESSMENT; GENDER; INJURY AVOIDANCE; SPORT CONCUSSION	STABILITY FOLLOWING CONCUSSION; SPORT-RELATED CONCUSSION; BRAIN-INJURY; INTERNATIONAL-CONFERENCE; GAIT; VULNERABILITY; STATEMENT; ATTENTION; PLAYERS; IMPACT	ECKNER, J. T., D. B. LIPPS, H. KIM, J. K. RICHARDSON, and J. A. ASHTON-MILLER. Can a Clinical Test of Reaction Time Predict a Functional Head-Protective Response? Med. Sci. Sports Exerc., Vol. 43, No. 3, pp. 382-387, 2011. Purpose: Reaction time is commonly prolonged after a sport-related concussion. Besides being a marker for injury, a rapid reaction time is necessary for protective maneuvers that can reduce the frequency and severity of additional head impacts. The purpose of this study was to determine whether a clinical test of simple visuomotor reaction time predicted the time taken to raise the hands to protect the head from a rapidly approaching ball. Methods: Twenty-six healthy adult participants recruited from campus and community recreation and exercise facilities completed two experimental protocols during a single session: a manual visuomotor simple reaction time test (RT(clin)) and a sport-related head-protective response (RT(sprt)). RT(clin) measured the time required to catch a thin vertically oriented device on its release by the tester and was calculated from the distance the device fell before being arrested. RT(sprt) measured the time required to raise the hands from waist level to block a foam tennis ball fired toward the subject's face from an air cannon and was determined using an optoelectronic camera system. A correlation coefficient was calculated between RT(clin) and RT(sprt), with linear regression used to assess for effect modification by other covariates. Results: A strong positive correlation was found between RT(clin) and RT(sprt) (r = 0.725, P < 0.001) independent of age, gender, height, or weight. Conclusions: RT(clin) is predictive of a functional sport-related head-protective response. To our knowledge, this is the first demonstration of a clinical test predicting the ability to protect the head in a simulated sport environment. This correlation with a functional head-protective response is a relevant consideration for the potential use of RT(clin) as part of a multifaceted concussion assessment program.	[Eckner, James T.; Richardson, James K.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; [Lipps, David B.; Kim, Hogene; Ashton-Miller, James A.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48108 USA; [Ashton-Miller, James A.] Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48108 USA		Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower Pkwy, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu	Lipps, David/C-3964-2014; Lipps, David/A-7080-2013; Ashton-Miller, James A/C-2949-2011	Lipps, David/0000-0003-1140-9891; 	Foundation for PMR; U-M Bone and Joint Injury Prevention and Rehabilitation Center; National Defense Science and Engineering; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD078502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024824, R01AG026569] Funding Source: NIH RePORTER	The authors thank the assistance of Trina DeMott, P. T., for her help in screening the subjects and with the experiment, and Nick LeCursi, C. P. O., for making the custom sabot. The authors thank the financial support of a new investigator research grant from the Foundation for PM&R (J. T. E.), a pilot grant from the U-M Bone and Joint Injury Prevention and Rehabilitation Center (J. K. R. and J. T. E.), and a National Defense Science and Engineering Graduate fellowship (D. B. L.).	Brown AM, 2008, MED SCI SPORT EXER, V40, P1142, DOI 10.1249/MSS.0b013e31816770e1; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dane S, 2003, INT J NEUROSCI, V113, P923, DOI 10.1080/00207450390220367; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Eckner JT, 2010, NEUROLOGY, V74, pA202; Eckner JT, 2009, PERCEPT MOTOR SKILL, V108, P717, DOI 10.2466/PMS.108.3.717-720; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Goodman D, 2001, BRIT J SPORT MED, V35, P371; Grindel Scott H, 2006, Curr Sports Med Rep, V5, P9; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell M., 2001, BRIT J SPORT MED, V35, P373; Lovell M, 2008, NEUROL CLIN, V26, P45, DOI 10.1016/j.ncl.2007.12.001; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	32	26	26	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	MAR	2011	43	3					382	387		10.1249/MSS.0b013e3181f1cc51			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	722OL	WOS:000287443200002	20689458	Green Accepted			2022-02-06	
J	Gehring, K; Aaronson, NK; Gundy, CM; Taphoorn, MJB; Sitskoorn, MM				Gehring, Karin; Aaronson, Neil K.; Gundy, Chad M.; Taphoorn, Martin J. B.; Sitskoorn, Margriet M.			Predictors of Neuropsychological Improvement Following Cognitive Rehabilitation in Patients with Gliomas	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Neuropsychological rehabilitation; Brain tumor; Prediction; Individual change; Reliable change; Cognitive impairment	TRAUMATIC BRAIN-INJURY; LOW-GRADE GLIOMA; RECOVERY; TUMORS; AGE; RESERVE; DAMAGE	This study investigated the specific patient factors that predict responsiveness to a cognitive rehabilitation program. The program has previously been demonstrated to be successful at the group level in patients with gliomas, but it is unclear which patient characteristics optimized the effect of the intervention at the individual level. Four categories of possible predictors of improvement were selected for evaluation: sociodemographic and clinical variables, self-reported cognitive symptoms, and objective neuropsychological test performance. Hierarchical logistic regression analyses were conducted, beginning with the most accessible (sociodemographic) variables and ending with the most difficult (baseline neuropsychological) to identify in clinical practice. Nearly 60% of the participants of the intervention were classified as reliably improved. Reliable improvement was predicted by age (p = .003) and education (p = .011). Additional results suggested that younger patients were more likely to benefit specifically from the cognitive rehabilitation program (p = .001), and that higher education was also associated with improvement in the control group (p = .024). The findings are discussed in light of brain reserve theory. A practical implication is that cognitive rehabilitation programs should take the patients' age into account and, if possible, adapt programs to increase the likelihood of improvement among older participants. (JINS, 2011, 17, 256-266)	[Gehring, Karin; Sitskoorn, Margriet M.] Tilburg Univ, Fac Social & Behav Sci, CoRPS, NL-5000 LE Tilburg, Netherlands; [Aaronson, Neil K.] Univ Amsterdam, Dept Clin Psychol, NL-1012 WX Amsterdam, Netherlands; [Taphoorn, Martin J. B.] Med Ctr Haaglanden, Dept Neurol, The Hague, Netherlands; [Taphoorn, Martin J. B.] VU Univ Med Ctr Amsterdam, Dept Neurol, Amsterdam, Netherlands		Gehring, K (corresponding author), Tilburg Univ, Fac Social & Behav Sci, CoRPS, Prisma Bldg,Room P 512,POB 90153, NL-5000 LE Tilburg, Netherlands.	k.gehring@uvt.nl	Gehring, Karin/N-6341-2014; Aaronson, Neil/AAV-8194-2021	Gehring, Karin/0000-0002-6989-1855; 	Dutch Cancer SocietyKWF Kankerbestrijding [UU2003-2783]; Health Insurers Innovation Foundation [504]	We thank Gerard Maassen for his advice on the use of the Reliable Change Index, Wobbe P. Zijlstra for his statistical advice, and Ruth E. Nieuwenhuis-Mark for editing an earlier version of this draft of this manuscript. This study was supported by the Dutch Cancer Society (UU2003-2783) and Health Insurers Innovation Foundation (file 504). There are no conflicts of interest.	ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; BRAND N, 1987, PSYCHOL MED, V17, P145, DOI 10.1017/S0033291700013040; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks J O 3rd, 1999, Int Psychogeriatr, V11, P75; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Charlton RA, 2006, NEUROLOGY, V66, P217, DOI 10.1212/01.wnl.0000194256.15247.83; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Correa DD, 2008, J NEURO-ONCOL, V86, P321, DOI 10.1007/s11060-007-9474-4; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Evans C, 1998, EVID BAS MENT HLTH, V1, P70, DOI DOI 10.1136/EBMH.1.3.70; Field A., 2009, DISCOVERING STAT USI, V3rd ed; Fiszdon JM, 2005, J NERV MENT DIS, V193, P602, DOI 10.1097/01.nmd.0000177790.23311.ba; Fratiglioni L, 2007, J ALZHEIMERS DIS, V12, P11; GEHRING K, DESCRIPTION IN PRESS; Gehring K., 2004, HANDLEIDING C CAR MA; Gehring K, 2009, J CLIN ONCOL, V27, P3712, DOI 10.1200/JCO.2008.20.5765; Gordon BA, 2008, PSYCHOPHYSIOLOGY, V45, P825, DOI 10.1111/j.1469-8986.2008.00676.x; GRAFMAN J, 1986, J NEUROSCI, V6, P301; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Hammes J. G. W., 1971, STROOP KLEUR WOORD T; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jolles J., 1995, MAASTRICHT AGING STU; Klein M, 2001, J CLIN ONCOL, V19, P4037, DOI 10.1200/JCO.2001.19.20.4037; L?ders H., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; Laack NN, 2005, INT J RADIAT ONCOL, V63, P1175, DOI 10.1016/j.ijrobp.2005.04.016; Langbaum JBS, 2009, J GERONTOL B-PSYCHOL, V64, P14, DOI 10.1093/geronb/gbn026; Lidstone V, 2003, PALLIATIVE MED, V17, P588, DOI 10.1191/0269216303pm814oa; Luteijn F., 1983, HANDLEIDING GRONINGE; Maassen GH, 2009, J CLIN EXP NEUROPSYC, V31, P339, DOI 10.1080/13803390802169059; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Medalia A, 2005, SCHIZOPHRENIA BULL, V31, P942, DOI 10.1093/schbul/sbi045; Meyers CA, 2006, J CLIN ONCOL, V24, P1305, DOI 10.1200/JCO.2005.04.6086; MEYERS CA, 2005, TXB NEUROONCOLOGY, P101; Mukand JA, 2001, AM J PHYS MED REHAB, V80, P346, DOI 10.1097/00002060-200105000-00005; NEELY AS, 1995, J GERONTOL B-PSYCHOL, V50, pP134, DOI 10.1093/geronb/50B.3.P134; Ponds RWHM, 1999, COGNITIVE FAILURE QU; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Schiff D, 2007, NEUROLOGY, V69, P1366, DOI 10.1212/01.wnl.0000277271.47601.a1; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Stewart AL, 1992, MEASURING FUNCTIONIN; Strangman GE, 2008, ARCH PHYS MED REHAB, V89, P974, DOI 10.1016/j.apmr.2008.02.011; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; van Boxtel MPJ, 1998, J GERONTOL A-BIOL, V53, pM147; VERHAEGHEN P, 1992, HDB HULPVERLENERS CU; YESAVAGE JA, 1990, PSYCHOL AGING, V5, P133, DOI 10.1037/0882-7974.5.1.133; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	49	26	26	0	16	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2011	17	2					256	266		10.1017/S1355617710001530			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	738DY	WOS:000288620900006	21205412	Green Submitted			2022-02-06	
J	Pascual, JL; Georgoff, P; Maloney-Wilensky, E; Sims, C; Sarani, B; Stiefel, MF; LeRoux, PD; Schwab, CW				Pascual, Jose L.; Georgoff, Patrick; Maloney-Wilensky, Eileen; Sims, Carrie; Sarani, Babak; Stiefel, Michael F.; LeRoux, Peter D.; Schwab, C. William			Reduced Brain Tissue Oxygen in Traumatic Brain Injury: Are Most Commonly Used Interventions Successful?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Brain tissue oxygenation; Traumatic brain injury; Treatment interventions; PbtO(2)-guided management; Clinical practice guidelines	SEVERE HEAD-INJURIES; CEREBRAL-BLOOD-FLOW; INTRACRANIAL-PRESSURE; AGGRESSIVE TREATMENT; HYPEROXIA; METABOLISM; MANAGEMENT; THERAPY; TENSION; HYPERTENSION	Background: Brain tissue oxygenation (PbtO(2))-guided management facilitates treatment of reduced PbtO(2) episodes potentially conferring survival and outcome advantages in severe traumatic brain injury (TBI). To date, the nature and effectiveness of commonly used interventions in correcting compromised PbtO(2) in TBI remains unclear. We sought to identify the most common interventions used in episodes of compromised PbtO(2) and to analyze which were effective. Methods: A retrospective 7-year review of consecutive severe TBI patients with a PbtO(2) monitor was conducted in a Level I trauma center's intensive care unit or neurosurgical registry. Episodes of compromised PbtO(2) (defined as < 20 mm Hg for 0.25-4 hours) were identified, and clinical interventions conducted during these episodes were analyzed. Response to treatment was gauged on how rapidly (Delta T) PbtO(2) normalized (> 20 mm Hg) and how great the PbtO(2) increase was (Delta PbtO(2)). Intracranial pressure (Delta ICP) and cerebral perfusion pressure (Delta CPP) also were examined for these episodes. Results: Six hundred twenty-five episodes of reduced PbtO(2) were identified in 92 patients. Patient characteristics were: age 41.2 years, 77.2% men, and Injury Severity Score and head or neck Abbreviated Injury Scale score of 34.0 +/- 9.2 and 4.9 +/- 0.4, respectively. Five interventions: narcotics or sedation, pressors, repositioning, FIO2/PEEP increases, and combined sedation or narcotics + pressors were the most commonly used strategies. Increasing the number of interventions resulted in worsening the time to PbtO(2) correction. Triple combinations resulted in the lowest Delta ICP and dual combinations in the highest Delta CPP (p < 0.05). Conclusion: Clinicians use a limited number of interventions when correcting compromised PbtO(2). Using strategies employing many interventions administered closely together may be less effective in correcting PbO2, ICP, and CPP deficits. Some PbtO(2) deficits may be self-limited.	[Pascual, Jose L.] Univ Penn, Sch Med, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, Philadelphia, PA 19104 USA; [Maloney-Wilensky, Eileen; Stiefel, Michael F.; LeRoux, Peter D.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		Pascual, JL (corresponding author), Univ Penn, Sch Med, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.	jose.pascual@uphs.upenn.edu		Sarani, Babak/0000-0001-6247-3004			Adamides AA, 2009, ACTA NEUROCHIR, V151, P1399, DOI 10.1007/s00701-009-0398-y; Bardt TF, 1998, ACT NEUR S, V71, P153; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS65; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Fletcher JJ, 2010, NEUROCRIT CARE, V13, P47, DOI 10.1007/s12028-010-9345-2; Fluckiger C, 2010, ACTA NEUROCHIR, V152, P627, DOI 10.1007/s00701-009-0579-8; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gremmelt A, 1995, ANAESTHESIST, V44, pS559; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Longhi L, 2002, ACT NEUR S, V81, P315; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh J A, 2005, Crit Care Resusc, V7, P200; NANGUNOORI RMW, 2010, LAS VEG NEV NAT NEUR; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Pascual JL, 2008, AM SURGEON, V74, P253; Pfister D, 2008, EUR J ANAESTH, V25, P98, DOI 10.1017/S0265021507003407; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Sabsovich I, 2007, AM J CRIT CARE, V16, P82, DOI 10.4037/ajcc2007.16.1.82; Schmittner MD, 2007, J NEUROSURG ANESTH, V19, P257, DOI 10.1097/ANA.0b013e31811f3feb; SCHMOKER JD, 1992, J TRAUMA, V33, P476, DOI 10.1097/00005373-199209000-00024; Senft C, 2009, NEUROL RES, V31, P1012, DOI 10.1179/174313209X409034; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2007, J TRAUMA, V63, P1155, DOI 10.1097/TA.0b013e31815965e3; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; Wilensky Eileen Maloney, 2005, J Neurosci Nurs, V37, P278; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	59	26	29	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2011	70	3					535	545		10.1097/TA.0b013e31820b59de			11	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	732PU	WOS:000288201200009	21610340				2022-02-06	
J	Pielmaier, L; Walder, B; Rebetez, MML; Maercker, A				Pielmaier, Laura; Walder, Bernhard; Rebetez, Marie My Lien; Maercker, Andreas			Post-traumatic stress symptoms in relatives in the first weeks after severe traumatic brain injury	BRAIN INJURY			English	Article						Head injury; trauma; distress; family	INTENSIVE-CARE-UNIT; FAMILY-MEMBERS; EVENT SCALE; DISORDER; RISK; IMPACT; CAREGIVERS; ADULTS; EPIDEMIOLOGY; SATISFACTION	Introduction: Severe traumatic brain injury (STBI) can cause psychological stress in proxies in the long-term. This study assessed post-traumatic stress (PTS) symptoms in proxies of survivors of STBI in the short-term and investigated stress-associated factors. Methods: Prospective cross-sectional study, conducted at three Swiss trauma centres over 1 year. Patient and proxy demographics, trauma data including Glasgow Coma Scale (GCS) and management data were collected. The proxies' PTS symptoms were assessed by applying the Impact of Event Scale Revised (IES-R), once in the first month after the accident (median: 11 days). Results: Sixty-nine proxies were included; 52 proxies were female (77.8%). Mean IES-R sum score for intrusions was 13.38 (SD = 7.26), for avoidance 8.91 (SD = 5.94), and for hyperarousal 9.07 (SD = 6.75). Clinically significant PTS symptoms were observed in 36 proxies (52.2%); mean IES-R sum scores were significantly higher in women. IES-R sub-scale values were inversely related with GCS at the scene of the accident and on hospital admission. Conclusions: More than half of proxies had clinically significant PTS symptoms shortly after their relative's accident. More severe PTS symptoms were found in women and in proxies of patients with poorer initial GCS scores. Further research into risk groups in the short- and long-term and the long-term impact on patients of PTS syndrome in proxies is warranted.	[Pielmaier, Laura; Maercker, Andreas] Univ Zurich, Inst Psychol, Dept Psychopathol & Clin Intervent, CH-8050 Zurich, Switzerland; [Walder, Bernhard; Rebetez, Marie My Lien] Univ Hosp Geneva, Div Anaesthesiol, Geneva, Switzerland		Pielmaier, L (corresponding author), Univ Zurich, Inst Psychol, Dept Psychopathol & Clin Intervent, Binzmuhlestr 14,Box 17, CH-8050 Zurich, Switzerland.	l.pielmaier@psychologie.uzh.ch	Maercker, Andreas/D-2814-2017	Maercker, Andreas/0000-0001-6925-3266			American Association for the Advancement for Automotive Medicine, 2001, ABBR INJ SCAL 1990 R; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Anderson WG, 2008, J GEN INTERN MED, V23, P1871, DOI 10.1007/s11606-008-0770-2; Auerbach SM, 2005, AM J CRIT CARE, V14, P202, DOI 10.4037/ajcc2005.14.3.202; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brewin CR, 2005, J TRAUMA STRESS, V18, P53, DOI 10.1002/jts.20007; Brunet A, 2003, CAN J PSYCHIAT, V48, P56, DOI 10.1177/070674370304800111; Bunzel B, 2007, J HEART LUNG TRANSPL, V26, P384, DOI 10.1016/j.healun.2007.01.025; Chui WYY, 2007, J CLIN NURS, V16, P372, DOI 10.1111/j.1365-2702.2005.01461.x; Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010; Dew MA, 2004, PSYCHOL MED, V34, P1065, DOI 10.1017/S0033291703001387; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jones C, 2004, INTENS CARE MED, V30, P456, DOI 10.1007/s00134-003-2149-5; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Maercker A, 1998, DIAGNOSTICA, V44, P130; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McAdam JL, 2010, CRIT CARE MED, V38, P1078, DOI 10.1097/CCM.0b013e3181cf6d94; McAdam JL, 2009, AM J CRIT CARE, V18, P200, DOI 10.4037/ajcc2009252; Noble AJ, 2008, J NEUROSURG, V109, P1027, DOI 10.3171/JNS.2008.109.12.1027; Olff M, 2007, PSYCHOL BULL, V133, P183, DOI 10.1037/0033-2909.133.2.183; OLSON CL, 1976, PSYCHOL BULL, V83, P579, DOI 10.1037/0033-2909.83.4.579; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Paparrigopoulos T, 2006, J PSYCHOSOM RES, V61, P719, DOI 10.1016/j.jpsychores.2006.05.013; Schlechtriemen T., 2005, NOTF RETT, V8, P96, DOI DOI 10.1007/S10049-005-0718-6; TEASDALE G, 1974, LANCET, V2, P81; Tolin DF, 2006, PSYCHOL BULL, V132, P959, DOI 10.1037/0033-2909.132.6.959; *U HOSP GEN, 2010, PAT REL ENDP BRAIN I; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; von Elm E, 2008, SWISS MED WKLY, V138, P327, DOI 2008/23/smw-12025; Weiss M, 2001, ANAESTHESIST, V50, P150, DOI 10.1007/s001010170030; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Wilson JP, 1996, ASSESSING PSYCHOL TR, P399	37	26	26	0	10	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2011	25	3					259	265		10.3109/02699052.2010.542429			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	734UP	WOS:000288365400001	21280978				2022-02-06	
J	Attar, A; Ayten, M; Ozdemir, M; Ozgencil, E; Bozkurt, M; Kaptanoglu, E; Beksac, M; Kanpolat, Y				Attar, Ayhan; Ayten, Murat; Ozdemir, Mevci; Ozgencil, Enver; Bozkurt, Melih; Kaptanoglu, Erkan; Beksac, Meral; Kanpolat, Yucel			An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells	CYTOTHERAPY			English	Article						mononuclear cell; regeneration; spinal cord; trauma	MESENCHYMAL STEM-CELLS; REGENERATION; RECOVERY; BRAIN; STRATEGIES; ETIOLOGY	Background aims. Spinal cord injury is common among young subjects involved in motor vehicle accidents. Mechanisms and attempts to reverse post-traumatic pathophysiologic consequences are still being investigated. Unfortunately no effective and well-established treatment modality has been developed so far. The regeneration capability of the human nervous system following an injury is highly limited. Methods. The study involved four patients (two male, two female) who had suffered spinal cord injury as a result of various types of trauma. On neurologic examination, all the patients were determined to be in American Spinal Injury Association (ASIA) grade A. All patients were treated with decompression, stabilization and fusion for vertebral trauma anteriorly, as well as intralesional implantation of cellular bone marrow concentrates using a posterior approach 1 month after the first operation. The patients were then treated and followed-up in the physical rehabilitation clinic. Results. At the end of the post-operative 1-year follow-up, two of the patients were classified as ASIA C while one was classified as ASIA B. One patient showed no neurologic change; none of the patients suffered from any complications or adverse effects as a result of intralesional application of bone marrow cells. Conclusions. The results of this experimental study show the potential contribution of intralesional implantation of bone marrow to neuronal regeneration in the injured spinal cord, with neuronal changes. In light of the results of this experimental study, the potential for regenerative treatment in injuries of the human spinal cord is no longer a speculation but an observation.	[Ozdemir, Mevci] Ergani Publ Hosp, Dept Neurosurg, TR-21950 Diyarbakir, Turkey; [Attar, Ayhan] Ankara Univ, Dept Neurosurg, Sch Med, TR-06100 Ankara, Turkey; [Ayten, Murat] Trabzon Publ Hosp, Dept Neurosurg, Trabzon, Turkey; [Ozgencil, Enver] Ankara Univ, Sch Med, Dept Anesthesiol, TR-06100 Ankara, Turkey; [Bozkurt, Melih; Kaptanoglu, Erkan] Ankara Numune Hosp, Dept Neurosurg, Ankara, Turkey; [Beksac, Meral] Ankara Univ, Sch Med, Dept Hematol, TR-06100 Ankara, Turkey; [Kanpolat, Yucel] Turkish Acad Sci, Ankara, Turkey		Ozdemir, M (corresponding author), Ergani Publ Hosp, Dept Neurosurg, TR-21950 Diyarbakir, Turkey.	drmevci@hotmail.com	bozkurt, melih/D-2848-2009; Beksac, Meral/D-6411-2013; Ozdemir, Mevci/Y-8197-2019; Ozgencil, Enver Gungor/L-7819-2018	Beksac, Meral/0000-0003-1797-8657; bozkurt, melih/0000-0001-7433-081X			Ahn H, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E15; Attar A, 2005, SURG NEUROL, V64, P28, DOI 10.1016/j.surneu.2005.07.057; Bergmark BA, 2008, SPINAL CORD, V46, P684, DOI 10.1038/sc.2008.15; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Bregman BS, 2002, PROG BRAIN RES, V137, P257; Cardenas DD, 2004, ARCH PHYS MED REHAB, V85, P1757, DOI 10.1016/j.apmr.2004.03.016; CARTER RE, 1977, TEX MED, V73, P61; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chu K, 2003, NEUROSCI LETT, V343, P129, DOI 10.1016/S0304-3940(03)00174-5; Copray JCVM, 2003, ACTA NEUROCHIR, V145, P425, DOI 10.1007/s00701-003-0062-x; Coskun K, 2000, ACTA NEUROCHIR, V142, P1143, DOI 10.1007/s007010070043; Furlan JC, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E13; Kaptanoglu E, 2005, ACTA NEUROCHIR, V147, P405, DOI 10.1007/s00701-004-0447-5; Lima C, 2006, J SPINAL CORD MED, V29, P191, DOI 10.1080/10790268.2006.11753874; Phinney DG, 2005, CURR PHARM DESIGN, V11, P1255, DOI 10.2174/1381612053507495; Satake K, 2004, SPINE, V29, P1971, DOI 10.1097/01.brs.0000138273.02820.0a; Schultz SS, 2005, CURR DRUG TARGETS, V6, P63, DOI 10.2174/1389450053345046; Tator CH, 2005, J NEUROSURG-SPINE, V2, P1, DOI 10.3171/spi.2005.2.1.0001; Tator CH, 2002, INJURY PREV, V8, pIV33, DOI 10.1136/ip.8.suppl_4.iv33; Tsai EC, 2005, CURR PHARM DESIGN, V11, P1211, DOI 10.2174/1381612053507404; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Yuceer N, 2002, NEUROSURG REV, V25, P184, DOI 10.1007/s10143-001-0193-6; Ziv Y, 2006, P NATL ACAD SCI USA, V103, P13174, DOI 10.1073/pnas.0603747103	23	26	26	1	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy	JAN	2011	13	1					54	60		10.3109/14653249.2010.510506			7	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	693SX	WOS:000285246800006	20735163				2022-02-06	
J	Hansson, MJ; Morota, S; Chen, L; Matsuyama, N; Suzuki, Y; Nakajima, S; Tanoue, T; Omi, A; Shibasaki, F; Shimazu, M; Ikeda, Y; Uchino, H; Elmer, E				Hansson, Magnus J.; Morota, Saori; Chen, Li; Matsuyama, Nagahisa; Suzuki, Yoshiaki; Nakajima, Satoshi; Tanoue, Tadashi; Omi, Akibumi; Shibasaki, Futoshi; Shimazu, Motohide; Ikeda, Yukio; Uchino, Hiroyuki; Elmer, Eskil			Cyclophilin D-Sensitive Mitochondrial Permeability Transition in Adult Human Brain and Liver Mitochondria	JOURNAL OF NEUROTRAUMA			English	Article						ischemia; oxidative stress; mitochondria; traumatic brain injury; traumatic spinal cord injury	CA-2&-INDUCED MEMBRANE TRANSITION; CYCLOSPORINE-A; CYTOCHROME-C; HEART-MITOCHONDRIA; FOREBRAIN ISCHEMIA; PHOSPHATE CARRIER; NEURONAL DEATH; MOUSE MODEL; CELL-DEATH; PORE	The mitochondrial permeability transition (mPT) is considered to be a major cause of cell death under a variety of pathophysiological conditions of the central nervous system (CNS) and other organs. Pharmacological inhibition or genetic knockout of the matrix protein cyclophilin D (CypD) prevents mPT and cell degeneration in several models of brain injury. If these findings in animal models are translatable to human disease, pharmacological inhibition of mPT offers a promising therapeutic target. The objective of this study was to validate the presence of a CypD-sensitive mPT in adult human brain and liver mitochondria. In order to perform functional characterization of human mitochondria, fresh tissue samples were obtained during hemorrhage or tumor surgery and mitochondria were rapidly isolated. Mitochondrial calcium retention capacity, a quantitative assay for mPT, was significantly increased by the CypD inhibitor cyclosporin A in both human brain and liver mitochondria, whereas thiol-reactive compounds and oxidants sensitized mitochondria to calcium-induced mPT. Brain mitochondria underwent swelling upon calcium overload, which was reversible upon calcium removal. To further explore mPT of human mitochondria, liver mitochondria were demonstrated to exhibit several classical features of the mPT phenomenon, such as calcium-induced loss of membrane potential and respiratory coupling, as well as release of the pro-apoptotic protein cytochrome c. We concluded that adult viable human brain and liver mitochondria possess an active CypD-sensitive mPT. Our findings support the rationale of CypD and mPT inhibition as pharmacological targets in acute and chronic neurodegeneration.	[Hansson, Magnus J.; Morota, Saori; Elmer, Eskil] Lund Univ, Dept Clin Sci, Expt Brain Res Lab, Mitochondrial Pathophysiol Unit, SE-22184 Lund, Sweden; [Hansson, Magnus J.] Skane Univ Hosp, Dept Clin Physiol, Lund, Sweden; [Elmer, Eskil] Skane Univ Hosp, Dept Clin Neurophysiol, Lund, Sweden; [Chen, Li; Shibasaki, Futoshi] Tokyo Metropolitan Inst Med Sci, Dept Mol Cell Physiol, Tokyo 113, Japan; [Matsuyama, Nagahisa] Tokyo Med Univ, Dept Pathol, Tokyo, Japan; [Suzuki, Yoshiaki; Shimazu, Motohide] Tokyo Med Univ, Dept Surg, Tokyo, Japan; [Uchino, Hiroyuki] Tokyo Med Univ, Dept Anesthesiol, Tokyo, Japan; [Nakajima, Satoshi; Ikeda, Yukio] Tokyo Med Univ, Hachioji Med Ctr, Dept Neurosurg, Tokyo, Japan; [Tanoue, Tadashi] Kumamoto Reg Med Ctr, Dept Anesthesiol, Kumamoto, Japan; [Omi, Akibumi] Kosei Chuoh Hosp, Dept Anesthesiol, Tokyo, Japan		Hansson, MJ (corresponding author), Lund Univ, Dept Clin Sci, Expt Brain Res Lab, Mitochondrial Pathophysiol Unit, SE-22184 Lund, Sweden.	magnus.hansson@med.lu.se	Elmer, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Elmer, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638	Swedish Research CouncilSwedish Research CouncilEuropean Commission [2008-2634]; Japanese Ministry of Health, Labour and WelfareMinistry of Health, Labour and Welfare, Japan [18591724]; Foundation of the Swedish National Board of Health and Welfare; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22249016] Funding Source: KAKEN	This study was supported by the Swedish Research Council (reference no. 2008-2634), by the Japanese Ministry of Health, Labour and Welfare grant no. 18591724, and the Foundation of the Swedish National Board of Health and Welfare. The authors are grateful to Hitoshi Miura, Takashi Ogata, Hiroshi Nishioka, Tetsuo Ishizaki, Tomohiro Nomura, Mamoru Murakami, Shingo Ohno, Hiroyuki Jinbo, and Hitoshi Izawa for support in obtaining tissue samples. D-MeAla<SUP>3</SUP>EtVal<SUP>4</SUP>-cyclosporin (Debio-025) was kindly provided by Debiophami S.A.	Alcala S, 2008, ONCOGENE, V27, P44, DOI 10.1038/sj.onc.1210600; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Baines CP, 2010, ANNU REV PHYSIOL, V72, P61, DOI 10.1146/annurev-physiol-021909-135929; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Cook AM, 2009, EXPERT OPIN DRUG SAF, V8, P411, DOI 10.1517/14740330903066742; CROMPTON M, 1988, BIOCHEM J, V255, P357; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Eliseev RA, 2007, NEUROBIOL AGING, V28, P1532, DOI 10.1016/j.neurobiolaging.2006.06.022; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Halestrap AP, 2009, BBA-BIOENERGETICS, V1787, P1402, DOI 10.1016/j.bbabio.2008.12.017; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hansson MJ, 2008, FREE RADICAL BIO MED, V45, P284, DOI 10.1016/j.freeradbiomed.2008.04.021; Hansson MJ, 2010, J BIOL CHEM, V285, P741, DOI 10.1074/jbc.M109.017731; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Karlsson J, 2004, J NEUROSURG, V101, P128, DOI 10.3171/jns.2004.101.1.0128; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Kirkinezos IG, 2004, J NEUROCHEM, V88, P821, DOI 10.1046/j.1471-4159.2003.02181.x; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuznetsov AV, 2004, AM J PHYSIOL-HEART C, V286, pH1633, DOI 10.1152/ajpheart.00701.2003; Leung AWC, 2008, J BIOL CHEM, V283, P26312, DOI 10.1074/jbc.M805235200; Liu RR, 2009, J BIOL CHEM, V284, P36109, DOI 10.1074/jbc.M109.055301; Mansson R, 2010, HEPATOLOGY, V51, P347, DOI 10.1002/hep.23465; Martin LJ, 2009, EXP NEUROL, V218, P333, DOI 10.1016/j.expneurol.2009.02.015; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mazzeo AT, 2008, ACTA NEUROCHIR, V150, P1019, DOI 10.1007/s00701-008-0021-7; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Mewton N, 2010, J AM COLL CARDIOL, V55, P1200, DOI 10.1016/j.jacc.2009.10.052; Millay DP, 2008, NAT MED, V14, P442, DOI 10.1038/nm1736; Morota S, 2009, EXP NEUROL, V218, P353, DOI 10.1016/j.expneurol.2009.03.036; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicholls DG, 2009, BBA-BIOENERGETICS, V1787, P1416, DOI 10.1016/j.bbabio.2009.03.010; PETITO CK, 1984, J CEREBR BLOOD F MET, V4, P194, DOI 10.1038/jcbfm.1984.28; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Piot C, 2008, NEW ENGL J MED, V359, P473, DOI 10.1056/NEJMoa071142; Russmann S, 2009, CURR MED CHEM, V16, P3041, DOI 10.2174/092986709788803097; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Shalbuyeva N, 2006, J BIOL CHEM, V281, P37547, DOI 10.1074/jbc.M607263200; Sims NR, 2008, NAT PROTOC, V3, P1228, DOI 10.1038/nprot.2008.105; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; ZAIDAN E, 1994, J NEUROCHEM, V63, P1812; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	66	26	27	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					143	153		10.1089/neu.2010.1613			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800014	21121808	Green Submitted, Green Published, Bronze			2022-02-06	
J	Kamps, M; Bisschops, LA; van der Hoeven, JG; Hoedemaekers, CWE				Kamps, Marlijn; Bisschops, Laurens A.; van der Hoeven, Johannes G.; Hoedemaekers, Cornelia W. E.			Hypothermia does not increase the risk of infection: a case control study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; VENTILATOR-ASSOCIATED PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL; TERM MILD HYPOTHERMIA; C-REACTIVE PROTEIN; DIGESTIVE-TRACT; SELECTIVE DECONTAMINATION; INTENSIVE-CARE; DOUBLE-BLIND; SERUM PROCALCITONIN	Introduction: Hypothermia may improve outcome in patients after traumatic brain injury, especially when hypothermia is maintained for more than 48 hours. In the acute phase, patients with severe brain injury are more vulnerable to infections. Prolonged hypothermic treatment may further enhance the risk of infection. Selective decontamination of the digestive tract (SDD) reduces the risk of respiratory tract infections. The aim of this study was to investigate the incidence of infections in patients treated with hypothermia and normothermia while receiving SDD. Methods: In this retrospective case control study 35 patients treated with prolonged hypothermia (cases) were identified and 169 patients with severe brain injury were included (controls). Propensity score matching was performed to correct for differences in baseline characteristics and clinical parameters. Primary outcome was the incidence of infection. The secondary endpoints were the micro-organisms found in the surveillance cultures and infection. In addition, a number of clinical characteristics were assessed. Results: The demographic and clinical data indicated that the cases and controls were well matched. The overall risk of infection during ICU stay was 20% in the hypothermia groups versus 34.4% in the normothermia group (P = 0.388). Pneumonia was diagnosed in 11.4% of patients in both groups (P = 1.000). The incidence of meningitis, wound infection, bacteremia, and urinary tract infection was low and comparable between the groups. SDD surveillance cultures indicated a higher colonization with gram-negative bacteria in the rectal samples of the hypothermia patients. Conclusions: Hypothermia does not increase the risk of infection in patients treated with SDD.	[Kamps, Marlijn; Bisschops, Laurens A.; van der Hoeven, Johannes G.; Hoedemaekers, Cornelia W. E.] Radboud Univ Nijmegen, Dept Intens Care, Med Ctr, NL-6500 HB Nijmegen, Netherlands		Hoedemaekers, CWE (corresponding author), Radboud Univ Nijmegen, Dept Intens Care, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	C.Hoedemaekers@ic.umcn.nl	Hoedemaekers, C.W.E./L-4375-2015; van der Hoeven, J.G./H-8048-2014				Bergmans DCJJ, 2001, AM J RESP CRIT CARE, V164, P382, DOI 10.1164/ajrccm.164.3.2005003; BIGGAR WD, 1986, J APPL PHYSIOL, V60, P1186, DOI 10.1152/jappl.1986.60.4.1186; BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; Chan EY, 2007, BMJ-BRIT MED J, V334, P889, DOI 10.1136/bmj.39136.528160.BE; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Diestel A, 2008, CRYOBIOLOGY, V57, P216, DOI 10.1016/j.cryobiol.2008.08.005; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; Fagerli J, 1996, W V Med J, V92, P265; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kox M, 2008, NEUROLOGY, V70, P480, DOI 10.1212/01.wnl.0000279479.69502.3e; Lingnau W, 1998, J HOSP INFECT, V39, P195, DOI 10.1016/S0195-6701(98)90258-4; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; O'Connor E, 2004, ANAESTH INTENS CARE, V32, P465, DOI 10.1177/0310057X0403200402; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Schuetz P, 2010, EUR J CLIN INVEST, V40, P376, DOI 10.1111/j.1365-2362.2010.02259.x; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014	26	26	29	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	1							R48	10.1186/cc10012			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742RJ	WOS:000288961900048	21291523	Green Published, gold			2022-02-06	
J	Lewis, MW; Babbage, DR; Leathem, JM				Lewis, Mark W.; Babbage, Duncan R.; Leathem, Janet M.			Assessing executive performance during cognitive rehabilitation	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Executive functioning; Neuropsychological assessment; Ecological validity; Cognitive rehabilitation	TRAUMATIC BRAIN INJURY; ECOLOGICAL VALIDITY; INTERNATIONAL CLASSIFICATION; OUTCOME MEASURES; HEALTH; EVERYDAY; DYSFUNCTION; DISABILITY; TESTS; PREDICTION	Executive functioning influences a host of other cognitive processes and people who attend neuropsychological services are more likely to display executive dysfunction than any other cognitive deficit (Stuss Levine, 2002). Impairment in executive functioning disrupts a person's ability to effectively employ their intact areas of functioning, and undermines effective self-management of other areas of dysfunction, hampering attempts to employ compensatory strategies. Therefore, assessment of a person's executive functioning is a high priority as part of a comprehensive neurorehabilitation plan. Guided by the International Classification of Functioning, Disability, and Health model (ICF model; Peterson, 2005), we suggest that an important development in the field is moving to formal assessment of executive performance in functional contexts, in addition to more traditional assessment of executive impairment. We outline a number of existing studies in this area, review current measures that can provide clinicians with useful information on these issues, and discuss how this research could be further advanced.	[Babbage, Duncan R.] Massey Univ, Sch Psychol, Wellington 6140, New Zealand		Babbage, DR (corresponding author), Massey Univ, Sch Psychol, POB 756, Wellington 6140, New Zealand.	D.R.Babbage@massey.ac.nz		Babbage, Duncan/0000-0002-9259-9246			ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; Baguena N., 2006, Annales de Readaptation et de Medecine Physique, V49, P234, DOI 10.1016/j.annrmp.2006.02.007; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; BAUM C, 1993, AM J OCCUP THER, V47, P431, DOI 10.5014/ajot.47.5.431; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BETTCHER BM, 2008, 36 ANN INT NEUR SOC; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; BURGESS PW, 1996, BEHAV AASSESSMENT DY; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COMALLI PE, 1962, J GENET PSYCHOL, V100, P47, DOI 10.1080/00221325.1962.10533572; Crowe K. M., 2005, PSYCHIAT PSYCHOL LAW, V12, P56, DOI [10.1375/pplt.2005.12.1.56, DOI 10.1375/PPLT.2005.12.1.56, http://dx.doi.org/10.1375/pplt.2005.12.1.56]; Delis DC., 2001, DELIS KAPLAN EXECUTI; Fisher AG, 2001, ASSESSMENT MOTOR PRO, VI; Fisher AG, 2001, ASSESSMENT MOTOR PRO, V2; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA IP, 2000, BEHAV RATING INVENTO; Gioia GA, 2010, STUD NEUROPSYCHOL NE, P179; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Josman N, 2001, SCAND J OCCUP THER, V8, P193, DOI DOI 10.1080/110381201317166559; Kertesz A, 1997, CAN J NEUROL SCI, V24, P29, DOI 10.1017/S0317167100021053; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Kottorp A, 2003, J INTELL DISABIL RES, V47, P597, DOI 10.1046/j.1365-2788.2003.00475.x; Lamberts KF, 2010, J CLIN EXP NEUROPSYC, V32, P56, DOI 10.1080/13803390902806550; LEWIS MW, 2009, C AUSTR FAC REH MED; LEWIS MW, 2008, J INT NEUROPSYCH SOC, V14, P186; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Long, 1996, ECOLOGICAL VALIDITY, P15; LONG CJ, 1996, ECOLOGICAL VALIDITY, P1; MAHONEY F I, 1965, Md State Med J, V14, P61; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; MCCUE M, 1998, HUMAN BRAIN FUNCT, P113; McLellan D.L., 1991, CLIN NEUROLOGY, V1, P768; MCPHEETERS HL, 1984, COMMUNITY MENT HLT J, V20, P44; Mitchell M, 2008, J CLIN EXP NEUROPSYC, V30, P683, DOI 10.1080/13803390701679893; NEISTADT ME, 1992, OCCUP THER J RES, V12, P242, DOI 10.1177/153944929201200404; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Oddy M, 1999, NEUROPSYCHOL REHABIL, V9, P373, DOI 10.1080/096020199389446; Odhuba RA, 2005, BRIT J CLIN PSYCHOL, V44, P269, DOI 10.1348/014466505X29431; Peterson DB, 2005, REHABIL PSYCHOL, V50, P105, DOI 10.1037/0090-5550.50.2.105; PIOTROWSKI C, 1989, PROF PSYCHOL-RES PR, V20, P423; Rabin LA, 2007, CLIN NEUROPSYCHOL, V21, P727, DOI 10.1080/13854040600888776; Ready RE, 2001, CLIN NEUROPSYCHOL, V15, P314, DOI 10.1076/clin.15.3.314.10269; Reed GM, 2005, REHABIL PSYCHOL, V50, P122, DOI 10.1037/0090-5550.50.2.122; Sbordone RJ, 1999, STUD NEUROPSYCHOL DE, P227; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; Semkovska M, 2004, SCHIZOPHR RES, V69, P289, DOI 10.1016/j.schres.2003.07.005; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Skinner A, 2006, CLIN REHABIL, V20, P609, DOI 10.1191/0269215506cr981oa; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Spinella M, 2005, INT J NEUROSCI, V115, P649, DOI 10.1080/00207450590524304; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Turner-Stokes L, 2002, DISABIL REHABIL, V24, P383, DOI 10.1080/096382801101550; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Van der Elst W, 2008, ARCH CLIN NEUROPSYCH, V23, P787, DOI 10.1016/j.acn.2008.09.002; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; Wechsler, 1997, WECHSLER ADULT INTEL; Wilson B. A., 1996, ECOLOGICAL VALIDITY, P413; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014; World Health Organization, 2007, INT CLASS FUNCT DIS	77	26	27	0	19	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	2					145	163	PII 932225604	10.1080/09602011.2010.543867			19	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	733NZ	WOS:000288270700001	21229458				2022-02-06	
J	Smerbeck, AM; Parrish, J; Yeh, EA; Hoogs, M; Krupp, LB; Weinstock-Guttman, B; Benedict, RHB				Smerbeck, A. M.; Parrish, J.; Yeh, E. A.; Hoogs, M.; Krupp, Lauren B.; Weinstock-Guttman, B.; Benedict, R. H. B.			Regression-Based Pediatric Norms for the Brief Visuospatial Memory Test - Revised and the Symbol Digit Modalities Test	CLINICAL NEUROPSYCHOLOGIST			English	Article						Brief Visuospatial Memory Test - Revised; BVMTR; Symbol Digit Modalities Test; SDMT; Multiple sclerosis; Psychometrics; Multiple regression; Normative data	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; COGNITIVE FUNCTION; MINIMAL ASSESSMENT; ALCOHOL; VALIDITY; CHILDREN	The Brief Visuospatial Memory Test - Revised (BVMTR) and the Symbol Digit Modalities Test (SDMT) oral-only administration are known to be sensitive to cerebral disease in adult samples, but pediatric norms are not available. A demographically balanced sample of healthy control children (N = 92) ages 6-17 was tested with the BVMTR and SDMT. Multiple regression analysis (MRA) was used to develop demographically controlled normative equations. This analysis provided equations that were then used to construct demographically adjusted z-scores for the BVMTR Trial 1, Trial 2, Trial 3, Total Learning, and Delayed Recall indices, as well as the SDMT total correct score. To demonstrate the utility of this approach, a comparison group of children with acute disseminated encephalomyelitis (ADEM) or multiple sclerosis (MS) were also assessed. We find that these visual processing tests discriminate neurological patients from controls. As the tests are validated in adult multiple sclerosis, they are likely to be useful in monitoring pediatric onset multiple sclerosis patients as they transition into adulthood.	[Smerbeck, A. M.; Parrish, J.; Yeh, E. A.; Hoogs, M.; Weinstock-Guttman, B.; Benedict, R. H. B.] SUNY Buffalo, Dept Neurol, Buffalo, NY 14260 USA; [Smerbeck, A. M.; Parrish, J.; Yeh, E. A.; Hoogs, M.; Weinstock-Guttman, B.; Benedict, R. H. B.] Buffalo Gen Hosp, Jacobs Neurol Inst, Buffalo, NY 14203 USA; [Krupp, Lauren B.] SUNY Stony Brook, Med Ctr, Natl Pediat MS Ctr, Stony Brook, NY 11794 USA		Benedict, RHB (corresponding author), Buffalo Gen Hosp, Jacobs Neurol Inst, 100 High St, Buffalo, NY 14203 USA.	benedict@buffalo.edu		krupp, lauren/0000-0001-7003-807X			Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 2008, MULT SCLER J, V14, P940, DOI 10.1177/1352458508090923; Benedict RHB, 2006, J INT NEUROPSYCH SOC, V12, P549, DOI 10.1017/S1355617706060723; Benedict RHB, 2005, J INT NEUROPSYCH SOC, V11, P727, DOI 10.1017/S1355617705050782; Benedict RHB, 2002, CLIN NEUROPSYCHOL, V16, P381, DOI 10.1076/clin.16.3.381.13859; Burden MJ, 2005, ALCOHOL CLIN EXP RES, V29, P1473, DOI 10.1097/01.alc.0000175036.34076.a0; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; Dalen K, 2009, NEUROPEDIATRICS, V40, P162, DOI 10.1055/s-0029-1243176; Delis D.C., 2000, CALIFORNIA VERBAL LE; Deloire MSA, 2006, MULT SCLER J, V12, P445, DOI 10.1191/1352458506ms1289oa; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Drake AS, 2010, MULT SCLER J, V16, P228, DOI 10.1177/1352458509354552; Lajiness-O'Neill R, 2010, APPL NEUROPSYCHOL, V17, P83, DOI 10.1080/09084281003708837; Manji S, 2009, DEV NEUROREHABIL, V12, P239, DOI 10.1080/17518420902980118; Parmenter BA, 2007, MULT SCLER J, V13, P52, DOI 10.1177/1352458506070750; Parmenter BA, 2010, J INT NEUROPSYCH SOC, V16, P6, DOI 10.1017/S1355617709990750; Rao SM., 1991, MANUAL BRIEF REPEATA; Smith A., 1982, SYMBOL DIGIT MODALIT	18	26	26	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	3					402	412	PII 934543196	10.1080/13854046.2011.554445			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	751RU	WOS:000289636100005	21391150				2022-02-06	
B	Soekadar, SR; Birbaumer, N; Cohen, LG		Kansaku, K; Cohen, LG		Soekadar, Surjo R.; Birbaumer, Niels; Cohen, Leonardo G.			Brain-Computer Interfaces in the Rehabilitation of Stroke and Neurotrauma	SYSTEMS NEUROSCIENCE AND REHABILITATION			English	Article; Book Chapter							TRANSCRANIAL MAGNETIC STIMULATION; EVENT-RELATED DESYNCHRONIZATION; PRIMARY MOTOR CORTEX; NONINVASIVE CORTICAL STIMULATION; CONTROLLED-TRIAL; ELECTROCORTICOGRAPHIC SIGNALS; MACHINE INTERFACES; SKILL ACQUISITION; MOVEMENT; HAND	Paralysis after stroke or neurotrauma is among the leading causes of long term disability in adults. The development of brain-computer interface (BCI) systems that allow online classification of electric or metabolic brain activity and their translation into control signals of external devices or computers have led to two major approaches in tackling the problem of paralysis. While assistive Bel systems strive for continuous high-dimensional control of robotic devices or functional electric stimulation (FES) of paralyzed muscles to substitute for lost motor functions in a 'daily life environment (e.g. Velliste et al. 2008 [1]; Hochberg et al. 2006 [2]; Pfurtscheller et al. 2000 [3]), restorative BCI systems aim at normalization of neurophysiologic activity that might facilitate motor recovery (e.g. Birbaumer et al. 2007, 2009 [4, 5]; Daly et al. 2008 [6]). In order to make assistive BCI systems work in daily life, high BCI communication speed is necessary, an issue that by now can only be achieved by invasive recordings of brain activity (e.g. via multi-unit arrays, MUA, or electrocorticogram, ECoG). Restorative BCI systems, in contrast, were developed as training tools based on non-invasive methods such as electro- or magnetoencephalography (EEG/MEG). More recently developed approaches use real-time functional magnetic resonance imaging (rtfMRI) or near-infrared spectroscopy (NIRS). Here, we provide an overview of the current state in the development and application of assistive and restorative BCI and introduce novel approaches to improve BCI control with brain stimulation such as transcranial direct current stimulation (tDCS). The outlook of using BCI in rehabilitation of stroke and neurotrauma is discussed.	[Soekadar, Surjo R.; Cohen, Leonardo G.] NINDS, Human Cort Physiol & Stroke Neurorehabil Sect, NIH, Bethesda, MD 20892 USA; [Soekadar, Surjo R.; Birbaumer, Niels] Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Tubingen, Germany; [Birbaumer, Niels] Osped san Camillo, IRCCS, Venice, Italy		Cohen, LG (corresponding author), NINDS, Human Cort Physiol & Stroke Neurorehabil Sect, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	cohenl@ninds.nih.gov	Soekadar, Surjo/AAA-3801-2020	Soekadar, Surjo/0000-0003-1280-5538			Ang KK, 2010, IEEE ENG MED BIO, P5549, DOI 10.1109/IEMBS.2010.5626782; Antal A, 2004, EUR J NEUROSCI, V19, P2888, DOI 10.1111/j.1460-9568.2004.03367.x; Ball T, 2009, NEUROIMAGE, V46, P708, DOI 10.1016/j.neuroimage.2009.02.028; Berger H, 1929, ARCH PSYCHIAT NERVEN, V87, P527, DOI 10.1007/BF01797193; Birbaumer N, 2003, IEEE T NEUR SYS REH, V11, P120, DOI 10.1109/TNSRE.2003.814439; Birbaumer N, 1999, NATURE, V398, P297, DOI 10.1038/18581; BIRBAUMER N, 1986, CEREBRAL PSYCHOPHYSI; Birbaumer N, 2007, J PHYSIOL-LONDON, V579, P621, DOI 10.1113/jphysiol.2006.125633; Birbaumer N, 2006, PSYCHOPHYSIOLOGY, V43, P517, DOI 10.1111/j.1469-8986.2006.00456.x; Birbaumer N, 2009, INT REV NEUROBIOL, V86, P107, DOI 10.1016/S0074-7742(09)86008-X; Blankertz B, 2007, NEUROIMAGE, V37, P539, DOI 10.1016/j.neuroimage.2007.01.051; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Bradberry TJ, 2010, J NEUROSCI, V30, P3432, DOI 10.1523/JNEUROSCI.6107-09.2010; Broetz D, 2010, NEUROREHAB NEURAL RE, V24, P674, DOI 10.1177/1545968310368683; BUCH ER, 2010, ANATOMICAL PARIETO F; Buch E, 2008, STROKE, V39, P910, DOI 10.1161/STROKEAHA.107.505313; Calautti C, 2007, NEUROIMAGE, V34, P322, DOI 10.1016/j.neuroimage.2006.08.026; Caria A, 2007, NEUROIMAGE, V35, P1238, DOI 10.1016/j.neuroimage.2007.01.018; Caria A, 2011, PSYCHOPHYSIOLOGY, V48, P578, DOI 10.1111/j.1469-8986.2010.01117.x; Carmena JM, 2003, PLOS BIOL, V1, P193, DOI 10.1371/journal.pbio.0000042; Chao Zenas C, 2010, Front Neuroeng, V3, P3, DOI 10.3389/fneng.2010.00003; Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012; Conforto AB, 2002, ANN NEUROL, V51, P122, DOI 10.1002/ana.10070; Daly JJ, 2008, LANCET NEUROL, V7, P1032, DOI 10.1016/S1474-4422(08)70223-0; Daly JJ, 2009, J NEUROL PHYS THER, V33, P203, DOI 10.1097/NPT.0b013e3181c1fc0b; deCharms RC, 2005, P NATL ACAD SCI USA, V102, P18626, DOI 10.1073/pnas.0505210102; Dickey AS, 2009, J NEUROPHYSIOL, V102, P1331, DOI 10.1152/jn.90920.2008; Diwakar M, 2011, NEUROIMAGE, V54, P253, DOI 10.1016/j.neuroimage.2010.07.023; Donoghue JP, 2007, J PHYSIOL-LONDON, V579, P603, DOI 10.1113/jphysiol.2006.127209; DUM RP, 1991, J NEUROSCI, V11, P667; Duque J, 2005, NEUROIMAGE, V28, P940, DOI 10.1016/j.neuroimage.2005.06.033; Elbert T., 1984, SELF REGULATION BRAI; FARWELL LA, 1988, ELECTROEN CLIN NEURO, V70, P510, DOI 10.1016/0013-4694(88)90149-6; FETZ EE, 1969, SCIENCE, V163, P955, DOI 10.1126/science.163.3870.955; Floel A, 2004, ANN NEUROL, V56, P206, DOI 10.1002/ana.20170; Fountas KN, 2007, STEREOT FUNCT NEUROS, V85, P264, DOI 10.1159/000107358; Freeman WJ, 2000, J NEUROSCI METH, V95, P111, DOI 10.1016/S0165-0270(99)00160-0; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Fuchs T, 2003, APPL PSYCHOPHYS BIOF, V28, P1, DOI 10.1023/A:1022353731579; Fulton JF, 1935, BRAIN, V58, P311, DOI 10.1093/brain/58.2.311; GASTAUT H, 1952, Mars Med, V89, P296; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Grefkes C, 2008, ANN NEUROL, V63, P236, DOI 10.1002/ana.21228; Harris-Love ML, 2007, J NEUROPHYSIOL, V97, P2511, DOI 10.1152/jn.01331.2006; Hesse S, 2007, RESTOR NEUROL NEUROS, V25, P9; Hinterberger T, 2005, EUR J NEUROSCI, V21, P3169, DOI 10.1111/j.1460-9568.2005.04092.x; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; HOWE RC, 1972, ELECTROEN CLIN NEURO, V32, P681, DOI 10.1016/0013-4694(72)90104-6; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Kennard MA, 1934, BRAIN, V57, P69, DOI 10.1093/brain/57.1.69; Khedr EM, 2005, NEUROLOGY, V65, P466, DOI 10.1212/01.wnl.0000173067.84247.36; Kim YH, 2006, STROKE, V37, P1471, DOI 10.1161/01.STR.0000221233.55497.51; Kotchoubey B, 2001, EPILEPSIA, V42, P406, DOI 10.1046/j.1528-1157.2001.22200.x; Kubler A, 2005, NEUROLOGY, V64, P1775, DOI 10.1212/01.WNL.0000158616.43002.6D; Kubler A, 2001, PSYCHOL BULL, V127, P358, DOI 10.1037//0033-2909.127.3.358; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Lebedev MA, 2006, TRENDS NEUROSCI, V29, P536, DOI 10.1016/j.tins.2006.07.004; Lefaucheur Jean-Pascal, 2004, Suppl Clin Neurophysiol, V57, P737; Lenhardt A, 2008, IEEE T NEUR SYS REH, V16, P121, DOI 10.1109/TNSRE.2007.912816; Leocani L, 2001, CLIN NEUROPHYSIOL, V112, P923, DOI 10.1016/S1388-2457(01)00530-2; Leuthardt EC, 2004, J NEURAL ENG, V1, P63, DOI 10.1088/1741-2560/1/2/001; Liu KPY, 2009, STROKE, V40, P2222, DOI 10.1161/STROKEAHA.108.540997; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Lotze M, 1999, NAT NEUROSCI, V2, P501, DOI 10.1038/9145; Luft AR, 2004, JAMA-J AM MED ASSOC, V292, P1853, DOI 10.1001/jama.292.15.1853; Malouin F, 2004, NEUROREHAB NEURAL RE, V18, P66, DOI 10.1177/0888439004266304; Mansur CG, 2005, NEUROLOGY, V64, P1802, DOI 10.1212/01.WNL.0000161839.38079.92; McFarland DJ, 2008, J NEURAL ENG, V5, P101, DOI 10.1088/1741-2560/5/2/001; Mellinger J, 2007, NEUROIMAGE, V36, P581, DOI 10.1016/j.neuroimage.2007.03.019; Miniussi C, 2005, CLIN NEUROPHYSIOL, V116, P1062, DOI 10.1016/j.clinph.2005.01.002; Murase N, 2004, ANN NEUROL, V55, P400, DOI 10.1002/ana.10848; Nagaoka T, 2010, ADV EXP MED BIOL, V662, P497, DOI 10.1007/978-1-4419-1241-1_72; Nicolelis MAL, 2003, NAT REV NEUROSCI, V4, P417, DOI 10.1038/nrn1105; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Page SJ, 2007, STROKE, V38, P1293, DOI 10.1161/01.STR.0000260205.67348.2b; PENFIELD W, 1951, AMA ARCH NEUROL PSY, V66, P289, DOI 10.1001/archneurpsyc.1951.02320090038004; Perelmouter J, 2000, IEEE T REHABIL ENG, V8, P227, DOI 10.1109/86.847824; Pfurtscheller G, 2000, NEUROSCI LETT, V292, P211, DOI 10.1016/S0304-3940(00)01471-3; Pfurtscheller G, 2003, NEUROSCI LETT, V351, P33, DOI 10.1016/S0304-3940(03)00947-9; PFURTSCHELLER G, 1992, J CLIN NEUROPHYSIOL, V9, P120, DOI 10.1097/00004691-199201000-00013; Pfurtscheller G, 1996, INT J PSYCHOPHYSIOL, V24, P39, DOI 10.1016/S0167-8760(96)00066-9; PFURTSCHELLER G, 1979, ELECTROEN CLIN NEURO, V46, P138, DOI 10.1016/0013-4694(79)90063-4; PFURTSCHELLER G, 2004, CLIN NEUROPHYSIOL, V57, P583; Platz T, 2002, RESTOR NEUROL NEUROS, V20, P21; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Rousche PJ, 1998, J NEUROSCI METH, V82, P1, DOI 10.1016/S0165-0270(98)00031-4; Schalk G, 2008, J NEURAL ENG, V5, P75, DOI 10.1088/1741-2560/5/1/008; Scheidtmann K, 2004, RESTOR NEUROL NEUROS, V22, P393; Scherberger H, 2005, NEURON, V46, P347, DOI 10.1016/j.neuron.2005.03.004; SEIFERT AR, 1975, BIOL PSYCHOL, V3, P157, DOI 10.1016/0301-0511(75)90033-2; Serruya MD, 2002, NATURE, V416, P141, DOI 10.1038/416141a; Sitaram R, 2009, NEURAL NETWORKS, V22, P1320, DOI 10.1016/j.neunet.2009.05.009; Skinner F., 1953, SCI HUMAN BEHAV; Staba RJ, 2002, J NEUROPHYSIOL, V88, P1743, DOI 10.1152/jn.2002.88.4.1743; Strehl U, 2006, PEDIATRICS, V118, pE1530, DOI 10.1542/peds.2005-2478; Takeuchi N, 2005, STROKE, V36, P2681, DOI 10.1161/01.STR.0000189658.51972.34; Takeuchi N, 2008, J REHABIL MED, V40, P298, DOI 10.2340/16501977-0181; Taub E, 2006, Eura Medicophys, V42, P241; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Theodore William H., 2003, Epilepsy Curr, V3, P191, DOI 10.1046/j.1535-7597.2003.03607.x; Vargas-Irwin CE, 2010, J NEUROSCI, V30, P9659, DOI 10.1523/JNEUROSCI.5443-09.2010; Velliste M, 2008, NATURE, V453, P1098, DOI 10.1038/nature06996; Waldert S, 2008, J NEUROSCI, V28, P1000, DOI 10.1523/JNEUROSCI.5171-07.2008; Ward NS, 2004, ARCH NEUROL-CHICAGO, V61, P1844, DOI 10.1001/archneur.61.12.1844; Weiskopf N, 2003, NEUROIMAGE, V19, P577, DOI 10.1016/S1053-8119(03)00145-9; Wilhelm B, 2006, NEUROLOGY, V67, P534, DOI 10.1212/01.wnl.0000228226.86382.5f; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Wolpaw JR, 2007, J PHYSIOL-LONDON, V579, P613, DOI 10.1113/jphysiol.2006.125948; Wolpaw JR, 2000, IEEE T REHABIL ENG, V8, P164, DOI 10.1109/TRE.2000.847807; Wolpaw JR, 2004, P NATL ACAD SCI USA, V101, P17849, DOI 10.1073/pnas.0403504101; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3; World Health Organization, 2003, WORLD HLTH REP SHAP; Yoo SS, 2004, NEUROREPORT, V15, P1591, DOI 10.1097/01.wnr.0000133296.39160.fe	117	26	26	0	5	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES			978-4-431-53998-8				2011							3	18		10.1007/978-4-431-54008-3_1	10.1007/978-4-431-54008-3		16	Neurosciences; Rehabilitation	Book Citation Index – Science (BKCI-S)	Neurosciences & Neurology; Rehabilitation	BWO16	WOS:000294371300001					2022-02-06	
J	Wallace, SE; Hux, K; Beukelman, DR				Wallace, Sarah E.; Hux, Karen; Beukelman, David R.			Navigation of a Dynamic Screen AAC Interface by Survivors of Severe Traumatic Brain Injury	AUGMENTATIVE AND ALTERNATIVE COMMUNICATION			English	Article							SYSTEMS; SYMBOLS; ADULTS; DISCOURSE; APHASIA	The researchers examined the effect of cognitive flexibility, image contextualization, and prompt type on accuracy and speed when adults with severe traumatic brain injury (TBI) navigated dynamic screen augmentative and alternative communication (AAC) interfaces. Eighteen participants formed two groups based on cognitive flexibility status. Given matching informative versus uninformative prompts and three image contextualization conditions, participants located words on 3-level AAC systems. ANOVA computations revealed differences between groups and between prompt types for navigation accuracy; differences occurred among image conditions and between prompt types for navigation speed. Analyses using responses from participants with cognitive flexibility challenges revealed inter-subject variability regarding error types. Overall, findings suggest cognitive flexibility may predict who may and may not need explicit training to master AAC device navigation.</.	[Wallace, Sarah E.] Duquesne Univ, Dept Speech Language Pathol, Pittsburgh, PA 15282 USA; [Hux, Karen; Beukelman, David R.] Univ Nebraska, Barkley Mem Ctr Special Educ & Commun Disorders, Lincoln, NE USA		Wallace, SE (corresponding author), Duquesne Univ, Dept Speech Language Pathol, 410 Fisher Hall,600 Forbes Ave, Pittsburgh, PA 15282 USA.	wallaces@duq.edu	Hux, Karen/AAQ-2078-2020	Wallace, Sarah E./0000-0003-4085-9250			American Speech-Language-Hearing Association (ASHA), 2005, ASHA S, V25, P1; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; BLOOMBERG K, 1990, J SPEECH HEAR RES, V33, P717, DOI 10.1044/jshr.3304.717; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Burke R, 2004, BRAIN INJURY, V18, P497, DOI 10.1080/02699050310001645784; Callaghan TC, 1999, CHILD DEV, V70, P1314, DOI 10.1111/1467-8624.00096; Campbell L, 2002, ADV SPEECH LANG PATH, V4, P89; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Demasco P, 1994, Assist Technol, V6, P10; Dietz A., 2006, PERSPECTIVES AUGMENT, V15, P13, DOI 10.1044/aac15.1.13; Doyle M, 2000, AUG ALTER COMMUN SER, P271; Fager S, 2006, AUGMENT ALTERN COMM, V22, P37, DOI 10.1080/07434610500243990; FAGER S, 2007, AUGMENTATIVE COMMUNI, P317; Fried-Oken M., 1992, J HEAD TRAUMA REHAB, V9, DOI [DOI 10.1097/00001199-199209000-00008, 10.1097/00001199-199209000-00008]; Hagen C., 2000, TBI REH MAN CAR ENV; HELMESTABROOKS N, 2001, CLQT COGNITIVE LINGU; Heuer S, 2007, APHASIOLOGY, V21, P883, DOI 10.1080/02687030600695194; Hux K, 2003, ASSISTING SURVIVORS OF TRAUMATIC BRAIN INJURY, P93; HUX K, 1993, J MED SPEECH-LANG PA, V1, P121; Hux K., 2008, J MED SPEECH LANGUAG, V16, P83; Kertesz A., 2007, WAB R W APHASIA BATT; Lacy S, 1996, JOURNALISM MASS COMM, V73, P963, DOI 10.1177/107769909607300414; Ladtkow Margaret, 1993, Seminars in Speech and Language, V14, P61, DOI 10.1055/s-2008-1064159; Larkins Brigette, 2007, Seminars in Speech and Language, V28, P334, DOI 10.1055/s-2007-986530; LIGHT J, 1991, AUGMENT ALTERN COMM, V7, P186, DOI DOI 10.1080/07434619112331275893; Light J, 2007, AUGMENT ALTERN COMM, V23, P204, DOI 10.1080/07434610701553635; LLOYD LL, 1984, J MENT DEFIC RES, V28, P3; McKelvey ML, 2010, AM J SPEECH-LANG PAT, V19, P22, DOI 10.1044/1058-0360(2009/08-0021); MCNAUGHTON S, 1993, TOP LANG DISORD, V13, P58, DOI 10.1097/00011363-199302000-00007; MIRENDA P, 1989, AUGMENTATIVE ALTERNA, V5, P3, DOI DOI 10.1080/07434618912331274916; MIZUKO M, 1989, J SPEECH HEAR DISORD, V54, P627, DOI 10.1044/jshd.5404.627; Rowland C., 2003, COMMUNICATIVE COMPET, P241; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Sohlberg M., 2001, COGNITIVE REHABILITA; THOMAS K, 2007, TEX SPEECH LANG HEAR; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME; [No title captured]	40	26	26	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0743-4618	1477-3848		AUGMENT ALTERN COMM	Augment. Altern. Commun.	DEC	2010	26	4					242	254		10.3109/07434618.2010.521895			13	Audiology & Speech-Language Pathology; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Rehabilitation	684GO	WOS:000284538600004	20979429				2022-02-06	
J	Altman, IM; Swick, S; Parrot, D; Malec, JF				Altman, Irwin M.; Swick, Shannon; Parrot, Devan; Malec, James F.			Effectiveness of Community-Based Rehabilitation After Traumatic Brain Injury for 489 Program Completers Compared With Those Precipitously Discharged	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Rehabilitation	PORTLAND ADAPTABILITY INVENTORY; RANDOMIZED CONTROLLED-TRIAL; POSTACUTE REHABILITATION; COGNITIVE REHABILITATION; PARTICIPATION; OUTCOMES; IMPACT	Objective: To evaluate outcomes of home- and community-based postacute brain injury rehabilitation (PABIR). Design: Retrospective analysis of program evaluation data for treatment completers and noncompleters. Setting: Home- and community-based PABIR conducted in 7 geographically distinct U.S. cities. Participants: Patients (N=489) with traumatic brain injury who completed the prescribed course of rehabilitation (completed-course-of-treatment [CCT] group) compared with 114 who were discharged precipitously before program completion (precipitous-discharge [PD] group). Intervention: PABIR delivered in home and community settings by certified professional staff on an individualized basis. Main Outcome Measures: Mayo-Portland Adaptability Inventory (MPAI-4) completed by means of professional consensus on admission and at discharge; MPAI-4 Participation Index at 3- and 12-month follow-up through telephone contact. Results: Analysis of covariance (CCT vs PD group as between-subjects variable, admission MPAI-4 score as covariate) showed significant differences between groups at discharge on the full MPAI-4 (F=82.25; P<.001), Ability Index (F=50.24; P<.001), Adjustment Index (F=81.20; P<.001), and Participation Index (F=59.48; P<.001). A large portion of the sample was lost to follow-up; however, available data showed that group differences remained statistically significant at follow-up. Conclusions: Results provided evidence of the effectiveness of home- and community-based PABIR and that treatment effects were maintained at follow-up.	[Parrot, Devan; Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN 46254 USA; [Malec, James F.] Indiana Univ Sch Med, Indianapolis, IN USA; [Altman, Irwin M.] Gentiva Rehab Walls, Phoenix, AZ USA; [Swick, Shannon] Gentiva Rehab Walls, Marshall, MI USA		Malec, JF (corresponding author), Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46254 USA.	jmalec@rhin.com					Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cohen J., 2013, STAT POWER ANAL BEHA; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Constantinidou F, 2005, J HEAD TRAUMA REHAB, V20, P143, DOI 10.1097/00001199-200503000-00003; Field A., 2017, DISCOVERING STAT USI, V5th; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; Lezak, 2008, MANUAL MAYO PORTLAND; Malec J., 2003, J INT NEUROPSYCH SOC, V9, P533; Malec J. F., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Malec JF, 2009, NEUROPSYCHOL REHABIL, V19, P790, DOI 10.1080/09602010903031203; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Pace GM, 1999, BRAIN INJURY, V13, P535; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624	25	26	26	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2010	91	11					1697	1704		10.1016/j.apmr.2010.08.001			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	681UQ	WOS:000284346400010	21044714				2022-02-06	
J	Norwood, KW; DeBoer, MD; Gurka, MJ; Kuperminc, MN; Rogol, AD; Blackman, JA; Wamstad, JB; Buck, ML; Patrick, PD				Norwood, Kenneth W.; DeBoer, Mark D.; Gurka, Matthew J.; Kuperminc, Michelle N.; Rogol, Alan D.; Blackman, James A.; Wamstad, Julia B.; Buck, Marcia L.; Patrick, Peter D.			Traumatic Brain Injury in Children and Adolescents: Surveillance for Pituitary Dysfunction	CLINICAL PEDIATRICS			English	Article						Growth hormone; traumatic brain injury; pituitary; pediatric	GROWTH-HORMONE; BODY-COMPOSITION; GH REPLACEMENT; LONG-TERM; HIGH-RISK; HYPOPITUITARISM; DEFICIENCY; SURVIVORS; MASS	Background. Children who sustain traumatic brain injury (TBI) are at risk for developing hypopituitarism, of which growth hormone deficiency (GHD) is the most common manifestation. Objective. To determine the prevalence of GHD and associated features following TBI among children and adolescents. Study design. A total of 32 children and adolescents were recruited from a pediatric TBI clinic. Participants were diagnosed with GHD based on insufficient growth hormone release during both spontaneous overnight testing and following arginine/glucagon administration. Results. GHD was diagnosed in 5/32 participants (16%). Those with GHD exhibited more rapid weight gain following injury than those without GHD and had lower levels of free thyroxine and follicle-stimulating hormone. Males with GHD had lower testosterone levels. Conclusions. GHD following TBI is common in children and adolescents, underscoring the importance of assessing for GHD, including evaluating height and weight velocities after TBI. Children and adolescents with GHD may further exhibit absence or intermediate function for other pituitary hormones.	[Norwood, Kenneth W.; DeBoer, Mark D.; Gurka, Matthew J.; Kuperminc, Michelle N.; Rogol, Alan D.; Blackman, James A.; Wamstad, Julia B.; Buck, Marcia L.; Patrick, Peter D.] Univ Virginia, Charlottesville, VA USA; [Rogol, Alan D.] James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA		Patrick, PD (corresponding author), POB 800386, Charlottesville, VA 22908 USA.	pdp2n@virginia.edu	Rogol, A.D./H-5871-2019	Rogol, A.D./0000-0002-7526-3142	Commonwealth Neurotrauma Initiative Trust [07-302]; General Clinical Research Center, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00847, HD060739-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD060739] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000847] Funding Source: NIH RePORTER	This study was funded by Commonwealth Neurotrauma Initiative Trust Fund, administered by VA Dept. of Rehabilitative Services, Grant #07-302; General Clinical Research Center Grant M01 RR00847 (to UVA) NIH HD060739-01 (MDD).	Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; [Anonymous], 2000, J CLIN ENDOCR METAB, V85, P3990, DOI [DOI 10.1210/jcem.85.11.6984, https://doi.org/10.1210/jcem.85.11.6984]; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Boot AM, 1997, J CLIN ENDOCR METAB, V82, P2423, DOI 10.1210/jc.82.8.2423; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Gleeson H, 2007, CLIN ENDOCRINOL, V66, P466, DOI 10.1111/j.1365-2265.2007.02753.x; Hulthen L, 2001, J CLIN ENDOCR METAB, V86, P4765, DOI 10.1210/jc.86.10.4765; Juul A, 2002, HORM RES, V58, P233, DOI 10.1159/000066265; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEE YJ, 1994, RAPID COMMUN MASS SP, V8, P571, DOI 10.1002/rcm.1290080714; Lustig Robert H, 2008, Pediatr Endocrinol Rev, V6, P220; Monson JP, 2003, EUR J ENDOCRINOL, V148, pS9, DOI 10.1530/eje.0.148S009; Moon RJ, 2009, ARCH DIS CHILD, V94, P699, DOI 10.1136/adc.2008.145235; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Poomthavorn P, 2008, ARCH DIS CHILD, V93, P133, DOI 10.1136/adc.2007.121137; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Roemmich JN, 2005, METABOLISM, V54, P1374, DOI 10.1016/j.metabol.2005.04.029; Roemmich JN, 2001, METABOLISM, V50, P537, DOI 10.1053/meta.2001.22510; Rose SR, 1996, J CLIN ENDOCR METAB, V81, P1063, DOI 10.1210/jc.81.3.1063; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476	30	26	26	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	NOV	2010	49	11					1044	1049		10.1177/0009922810376234			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	662OA	WOS:000282815700006	20724335	Green Accepted			2022-02-06	
J	Schwartzkroin, PA; Wenzel, HJ; Lyeth, BG; Poon, CC; DeLance, A; Van, KC; Campos, L; Nguyen, DV				Schwartzkroin, Philip A.; Wenzel, H. Juergen; Lyeth, Bruce G.; Poon, Carrie C.; DeLance, Arthur; Van, Ken C.; Campos, Luis; Nguyen, Danh V.			Does ketogenic diet alter seizure sensitivity and cell loss following fluid percussion injury?	EPILEPSY RESEARCH			English	Article						Animal model; Diet; Posttraumatic; epilepsy; Histology; Seizure threshold; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; EKER RAT MODEL; EPILEPTOGENESIS; MECHANISMS; SCLEROSIS; EPILEPSY; BEHAVIOR; DEATH; MICE	Traumatic brain injury (TBI) frequently leads to epilepsy. The process of epileptogenesis the development of that seizure state is still poorly understood, and effective antiepileptogenic treatments have yet to be identified. The ketogenic diet (KD) has been shown to be effective as an antiepileptic therapy, but has not been extensively tested for its efficacy in preventing the development of the seizure state, and certainly not within the context of TBI-induced epileptogenesis. We have used a rat model of TBI - fluid percussion injury (FPI) to test the hypothesis that KD treatment is antiepileptogenic and protects the brain from neuronal cell loss following TBI. Rats fed a KD had a higher seizure threshold (longer latency to fiurothyl-induced seizure activity) than rats fed a standard diet (SD); this effect was seen when KD was in place at the time of seizure testing (3 and 6 weeks following FPI), but was absent when KD had been replaced by SD at time of testing. FPI caused significant hippocampal cell loss in both KD-fed and SD-fed rats; the degree of cell loss appeared to be reduced by KD treatment before FPI but not after FPI. These results are consistent with prior demonstrations that KD raises seizure threshold, but do not provide support for the hypothesis that KD administered for a limited time directly before or after FPI alters later seizure sensitivity; that is, within the limits of this model and protocol, there is no evidence for KD-induced antiepileptogenesis. (C) 2010 Elsevier B.V. All rights reserved.	[Schwartzkroin, Philip A.; Wenzel, H. Juergen; Lyeth, Bruce G.; Poon, Carrie C.; DeLance, Arthur; Van, Ken C.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95618 USA; [Campos, Luis; Nguyen, Danh V.] Univ Calif Davis, Div Biostat, Davis, CA 95616 USA		Schwartzkroin, PA (corresponding author), Univ Calif Davis, Dept Neurol Surg, Med Neurosci Bldg,1515 Newton Court,Rm 612G, Davis, CA 95618 USA.	paschwartzkroin@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024146]; Citizens United for Research in Epilepsy in conjunction with the Department of Defense; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024146] Funding Source: NIH RePORTER	This study was supported by a grant from Citizens United for Research in Epilepsy in conjunction with the Department of Defense (PAS) and grant UL1 RR024146 from the National Center for Research Resources (DVN).	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Bough KJ, 2003, EPILEPSIA, V44, P752, DOI 10.1046/j.1528-1157.2003.55502.x; Bough KJ, 2007, EPILEPSIA, V48, P43, DOI 10.1111/j.1528-1167.2007.00915.x; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M, 2010, TRAUMATIC BRAIN INJU; Freeman J, 2006, EPILEPSY RES, V68, P145, DOI 10.1016/j.eplepsyres.2005.10.003; Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P129; Hansen SL, 2009, NEUROCHEM INT, V54, P199, DOI 10.1016/j.neuint.2008.10.012; Hori A, 1997, EPILEPSIA, V38, P750, DOI 10.1111/j.1528-1157.1997.tb01461.x; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Kossoff EH, 2008, EPILEPSIA, V49, P316, DOI 10.1111/j.1528-1167.2007.01256.x; Kossoff EH, 2009, NEUROTHERAPEUTICS, V6, P406, DOI 10.1016/j.nurt.2009.01.005; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKhann GM, 2003, NEUROSCIENCE, V122, P551, DOI 10.1016/S0306-4522(03)00562-1; Muller-Schwarze AB, 1999, NEUROREPORT, V10, P1517, DOI 10.1097/00001756-199905140-00023; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Puchowicz MA, 2008, J CEREBR BLOOD F MET, V28, P1907, DOI 10.1038/jcbfm.2008.79; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; SALAZAR AM, 1999, MISSILE WOUNDS HEAD, V2, P281; Samoilova M, 2010, J NEUROCHEM, V113, P826, DOI 10.1111/j.1471-4159.2010.06645.x; Sankar Raman, 2004, Epilepsy Curr, V4, P91, DOI 10.1111/j.1535-7597.2004.43002.x; Schwartzkroin PA, 1999, EPILEPSY RES, V37, P171, DOI 10.1016/S0920-1211(99)00069-8; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sutula TP, 2001, NEUROLOGY, V57, P169, DOI 10.1212/WNL.57.2.169; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Todorova MT, 2000, EPILEPSIA, V41, P933, DOI 10.1111/j.1528-1157.2000.tb00275.x; Tschuluun N, 2007, EPILEPSY RES, V73, P53, DOI 10.1016/j.eplepsyres.2006.08.003; Wenzel HJ, 2007, EPILEPSIA, V48, P2023, DOI 10.1111/j.1528-1167.2007.01189.x; Wenzel HJ, 2004, ACTA NEUROPATHOL, V108, P97, DOI 10.1007/s00401-004-0865-8; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Zhao XR, 2008, J NEUROTRAUM, V25, P1195, DOI 10.1089/neu.2008.0635; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29	44	26	26	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	NOV	2010	92	1					74	84		10.1016/j.eplepsyres.2010.08.009			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	684CB	WOS:000284523500007	20863664				2022-02-06	
J	Cook, NL; Vink, R; Helps, SC; Manavis, J; van den Heuvel, C				Cook, Naomi L.; Vink, Robert; Helps, Stephen C.; Manavis, Jim; van den Heuvel, Corinna			Transient Receptor Potential Melastatin 2 Expression is Increased Following Experimental Traumatic Brain Injury in Rats	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Real-time PCR; Reference genes; Transient receptor potential melastatin 2; mRNA quantification; Immunohistochemistry	HYDROGEN-PEROXIDE; CALCIUM INFLUX; OXIDATIVE STRESS; CATION CURRENTS; TRPM2 CHANNELS; PCR DATA; LTRPC2; MODEL; SUSCEPTIBILITY; VARIANT	Traumatic brain injury (TBI) elicits a sequence of complex biochemical changes including oxidative stress, oedema, inflammation and excitotoxicity. These factors contribute to the high morbidity and mortality following TBI, although their underlying molecular mechanisms remain poorly understood. Transient receptor potential melastatin 2 (TRPM2) is a non-selective cation channel, highly expressed in the brain and immune cells. Recent studies have implicated TRPM2 channels in processes involving oxidative stress, inflammation and cell death. However, no studies have investigated the role of TRPM2 in TBI pathophysiology. In the present study, we have characterised TRPM2 mRNA and protein expression following experimental TBI. Adult male Sprague Dawley rats were injured using the impact-acceleration model of diffuse TBI with survival times between 5 and 5 days. Real-time RT-PCR (including reference gene validation studies) and semi-quantitative immunohistochemistry were used to quantify TRPM2 mRNA and protein levels, respectively, following TBI. Significant increases in TRPM2 mRNA and protein expression were observed in the cerebral cortex and hippocampus of injured animals, suggesting that TRPM2 may contribute to TBI injury processes such as oxidative stress, inflammation and neuronal death. Further characterisation of how TRPM2 may contribute to TBI pathophysiology is warranted.	[van den Heuvel, Corinna] Univ Adelaide, Discipline Anat & Pathol, Sch Med Sci, Adelaide, SA 5005, Australia; [Cook, Naomi L.; Vink, Robert; Helps, Stephen C.; Manavis, Jim; van den Heuvel, Corinna] Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia		van den Heuvel, C (corresponding author), Univ Adelaide, Discipline Anat & Pathol, Sch Med Sci, Adelaide, SA 5005, Australia.	corinna.vandenheuvel@adelaide.edu.au	Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019; Cook, Naomi L/P-1223-2019; Cook, Naomi L/B-2536-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Cook, Naomi L/0000-0002-1830-2432; Cook, Naomi L/0000-0002-1830-2432; , Corinna/0000-0003-0664-8935	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia	Naomi Cook is a grateful recipient of a postgraduate scholarship from the National Health and Medical Research Council of Australia.	Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cappelli K, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-49; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Cook NL, 2009, J NEUROSCI RES, V87, P34, DOI 10.1002/jnr.21846; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022; DONKIN JJ, 2009, J CEREB BLOOD F 0513, P1; Fleig A, 2004, TRENDS PHARMACOL SCI, V25, P633, DOI 10.1016/j.tips.2004.10.004; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fonfria E, 2006, J RECEPT SIG TRANSD, V26, P179, DOI 10.1080/10799890600637522; Fonfria E, 2005, J NEUROCHEM, V95, P715, DOI 10.1111/j.1471-4159.2005.03396.x; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Heiner I, 2006, BIOCHEM J, V398, P225, DOI 10.1042/BJ20060183; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Hermosura MC, 2008, P NATL ACAD SCI USA, V105, P18029, DOI 10.1073/pnas.0808218105; Kaneko S, 2006, J PHARMACOL SCI, V101, P66, DOI 10.1254/jphs.FP0060128; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Kuhn FJP, 2005, PFLUG ARCH EUR J PHY, V451, P212, DOI 10.1007/s00424-005-1446-y; Lange I, 2008, CELL CALCIUM, V44, P604, DOI 10.1016/j.ceca.2008.05.001; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Olah ME, 2009, J PHYSIOL-LONDON, V587, P965, DOI 10.1113/jphysiol.2008.162289; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Perez R, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-79; Perraud AL, 2004, MOL IMMUNOL, V41, P657, DOI 10.1016/j.molimm.2004.04.013; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Roth P, 2000, Crit Care Nurs Q, V23, P14; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Starkus J, 2007, J GEN PHYSIOL, V130, P427, DOI 10.1085/jgp.200709836; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Xu C, 2009, BIPOLAR DISORD, V11, P1, DOI 10.1111/j.1399-5618.2008.00655.x; Yamamoto S, 2008, NAT MED, V14, P738, DOI 10.1038/nm1758; Yang XR, 2006, AM J PHYSIOL-LUNG C, V290, pL1267, DOI 10.1152/ajplung.00515.2005; Zhang W, 2003, J BIOL CHEM, V278, P16222, DOI 10.1074/jbc.M300298200	48	26	26	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	OCT	2010	42	2					192	199		10.1007/s12031-010-9347-8			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	636BL	WOS:000280702700009	20309649				2022-02-06	
J	Spinos, P; Sakellaropoulos, G; Georgiopoulos, M; Stavridi, K; Apostolopoulou, K; Ellul, J; Constantoyannis, C				Spinos, Panagiotis; Sakellaropoulos, George; Georgiopoulos, Miltiadis; Stavridi, Kleio; Apostolopoulou, Katerina; Ellul, John; Constantoyannis, Constantine			Postconcussion Syndrome After Mild Traumatic Brain Injury in Western Greece	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injury; Trauma; Mild head injury; Concussion; MTBI; Rehabilitation; Headache	MINOR HEAD-INJURY; SYMPTOM EXPECTATION; CONCUSSION; CRITERIA; RECOVERY; DISORDER; CANADA; RETURN; WORK	Background: The prevalence of postconcussion syndrome (PCS) in the first weeks after mild traumatic brain injury varies from 40% to 80%. However, as many as 50% of patients report symptoms for up to 3 months and 10% to 15% for more than a year. The objective of this study is to analyze the characteristics and estimate the prevalence of PCS in an adult Greek population. Methods: This prospective study was performed in the University Hospital of Patras in Western Greece. Patients with mild traumatic brain injury (n = 539) were randomly recruited on admission between May 2006 and May 2008. Overall, 223 patients (223 of 539, 41.5%) met the Colorado Medical Society guidelines for concussion; 141 men (63%) and 82 women (37%) with a median age of 30 years (range, 18.5-57.5 years) were included in the study. Patient follow-up consisted of telephone interviews at 1 month, 3 months, and 6 months postinjury, when they were asked about experiencing common postconcussion symptoms (International Classification of Diseases-10th revision criteria). Results: The rate of PCS at 1 month, 3 months, and 6 months postinjury was estimated to be 10.3%, 6%, and 0.9%, respectively. The syndrome was more frequent among women (17%) and individuals with bleeding diathesis (26%) compared with men (6.4%) and patients without clotting disorders (8.5%), respectively. In addition, higher rates of PCS affected patients who sustained assaults compared with other types of accidents. Conclusions: The prevalence of PCS was remarkably higher in previous studies. Cultural differences regarding symptom expectation and the lack of compensation might explain the low rate of chronic symptoms in Greeks.	[Spinos, Panagiotis; Georgiopoulos, Miltiadis; Stavridi, Kleio; Apostolopoulou, Katerina; Constantoyannis, Constantine] Patras Med Sch, Dept Neurosurg, Patras 26500, Greece; [Sakellaropoulos, George] Patras Med Sch, Dept Med Phys, Patras 26500, Greece; [Ellul, John] Patras Med Sch, Dept Neurol, Patras 26500, Greece		Constantoyannis, C (corresponding author), Patras Med Sch, Dept Neurosurg, Patras 26500, Greece.	cconst@med.upatras.gr	Sakellaropoulos, George/E-4756-2011; Georgiopoulos, Miltiadis/AAF-9126-2020	Georgiopoulos, Miltiadis/0000-0001-8656-1412; Sakellaropoulos, George/0000-0001-6275-0841; Constantoyannis, Constantine/0000-0003-3030-8439			Alves W., 1992, PHYS MED REHABIL STA, V6, P21; *AM AC NEUR QUAL S, 1997, PRACT PAR MAN CONC S; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BARTH JT, 1989, MILD HEAD INJURY, P142; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CASEY R, 1986, PEDIATRICS, V78, P497; *COL MED SOC SPORT, 1991, GUID MAN CONC SPORTS; Cook J. B, 1969, LATE EFFECTS HEAD IN, P408; Corrigan John D., 2003, American Journal of Obstetrics and Gynecology, V188, pS71, DOI 10.1067/mob.2003.404; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Evans RW, 1999, TXB CLIN NEUROLOGY, P1039; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P254, DOI 10.1016/S0303-8467(01)00161-5; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GREENBERG SM, 2001, HDB NEUROSURGERY, P627; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KRAUS JF, 1989, MILD HEAD INJURY, P8; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NARAYAN RK, 2005, PRINCIPLES NEUROSURG, P302; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Schutze M, 2008, Versicherungsmedizin, V60, P78; Solomon S, 2001, MED CLIN N AM, V85, P987, DOI 10.1016/S0025-7125(05)70355-2; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; World Health Organization, 1993, ICD 10 CLASS MENT BE; World Health Organization, 1992, ICD 10 CLASSIFICATIO; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	48	26	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2010	69	4					789	793		10.1097/TA.0b013e3181edea67			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	664KP	WOS:000282959100024	20938266				2022-02-06	
J	Senathi-Raja, D; Ponsford, J; Schonberger, M				Senathi-Raja, Dawn; Ponsford, Jennie; Schoenberger, Michael			The Association of Age and Time Postinjury With Long-Term Emotional Outcome Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aging; anxiety; brain injuries; depression; emotional stress; neuropsychology; traumatic brain injury	CLOSED-HEAD INJURY; ADULT LIFE-SPAN; DEPRESSION SCALE; HOSPITAL ANXIETY; AXIS-I; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; RISK; OLD; REHABILITATION	Objective: To examine the effect of age and time postinjury on emotional distress, 5 to 22 years following traumatic brain injury (TBI). Participants: One hundred twelve participants with mild to very severe TBI, aged 16 to 81 years at the time of injury, and 112 healthy controls matched for current age, gender, education, and estimated IQ. Main outcome measure: The Hospital Anxiety and Depression Scale (HADS). Results: The difference in HADS scores between participants with TBI and controls did not vary according to the separate variables of age at injury or time postinjury. There was an interaction between age at injury and time postinjury whereby the youngest group demonstrated higher HADS scores with longer time postinjury, whereas the older groups displayed lower HADS scores with longer time postinjury, relative to controls. Conclusions: Long-term emotional outcome following TBI is related to the combined influence of age and time postinjury. Higher levels of emotional distress, evident at longer time postinjury in younger individuals, are particularly concerning and warrant attention from clinicians.	[Senathi-Raja, Dawn; Ponsford, Jennie; Schoenberger, Michael] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia		Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au					Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; *AUSTR BUR STAT, 1997, 43260 AUSTR BUR STAT; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Blazer DG, 2000, AM J PSYCHIAT, V157, P1915, DOI 10.1176/appi.ajp.157.12.1915; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Carstensen LL, 2000, J PERS SOC PSYCHOL, V79, P644, DOI 10.1037//0022-3514.79.4.644; Christensen H, 1999, PSYCHOL MED, V29, P325, DOI 10.1017/S0033291798008150; Cohen J., 2013, STAT POWER ANAL BEHA; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorm AF, 2005, PSYCHOL MED, V35, P1253, DOI 10.1017/S0033291705004976; Jorm AF, 2000, PSYCHOL MED, V30, P11, DOI 10.1017/S0033291799001452; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraaij V, 2001, AGING MENT HEALTH, V5, P84, DOI 10.1080/13607860020020681; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rapoport MJ, 2001, BRAIN INJURY, V15, P857, DOI 10.1080/02699050110065303; Roberts RE, 1997, AM J PSYCHIAT, V154, P1384; Rothermund K, 2003, PSYCHOL AGING, V18, P80, DOI 10.1037/0882-7974.18.1.80; SCHONBERGER M, PSYCHIAT RE IN PRESS; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SENATHIRAJA DR, NEUROPSYCHO IN PRESS; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; WechslerD, 2001, WECHSLER TEST ADULT; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; WHELANGOODINSON R, J HEAD TRAU IN PRESS; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	46	26	26	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2010	25	5					330	338		10.1097/HTR.0b013e3181ccc893			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	649JR	WOS:000281765400005	20118790				2022-02-06	
J	Souter, M; Van Norman, G				Souter, Michael; Van Norman, Gail			Ethical controversies at end of life after traumatic brain injury: Defining death and organ donation	CRITICAL CARE MEDICINE			English	Article						ethics; end of life; brain death; controlled donation after cardiac death; donation after cardiac death; double effect; cardiac arrest; organ transplantation; death; declaring death	VEGETATIVE STATE	Death is more than a mere biological occurrence. It has important legal, medical, and social ramifications that make it imperative that those who are responsible for determination of death be accurate and above suspicion. The medical and legal definitions of death have evolved to include consideration of such concepts as loss of integration of the whole organism, loss of autonomy, and loss of personhood. Development of the concept of brain death coincided with advances in medical technology that facilitated artificial ventilation and organ transplantation. More recently, the process of "timed" death with subsequent organ donation (controlled donation after cardiac death transplantation) has raised controversial questions having to do with the limits of treatments that facilitate organ transplant but might hasten death, and the duration of cardiac arrest necessary for declaration of death and the commencement of organ procurement. In this review, we discuss the background and ethical ramifications of the concepts of brain death, and of controversies involved in controlled donation after cardiac death organ transplantation. (Crit Care Med 2010; 38[Suppl.]:S502-S509)	[Souter, Michael] Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pain Med & Neurosurg, Seattle, WA 98104 USA; [Van Norman, Gail] Univ Washington, Dept Anesthesiol & Pain Management, Seattle, WA 98104 USA		Souter, M (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pain Med & Neurosurg, 325 9Th Ave, Seattle, WA 98104 USA.		Souter, Michael/ABE-1890-2020				Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; [Anonymous], 1995, Neurology, V45, P1012; BARTLETT E, 1988, HUMAN DEATH DESTRUCT, P199; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Bernat JL., 2008, ETHICAL ISSUES NEURO; Cushing H, 1902, AM J MED SCI, V124, P375, DOI 10.1097/00000441-190209000-00001; Doig CJ, 2003, CAN J ANAESTH, V50, P1069, DOI 10.1007/BF03018376; GILDER SSB, 1968, BRIT MED J, V3, P493, DOI 10.1136/bmj.3.5616.493; Goldenberg F, 2009, CRIT CARE MED, V37, pA395; Greer DM, 2008, NEUROLOGY, V70, P284, DOI 10.1212/01.wnl.0000296278.59487.c2; Hawryluck LA, 2000, J PALLIATIVE CARE, V16, pS24, DOI 10.1177/082585970001601S06; Institute of Medicine, 1997, NON HEART BEAT ORG T; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Joffe Ari R, 2007, Philos Ethics Humanit Med, V2, P28, DOI 10.1186/1747-5341-2-28; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Kootstra G, 1997, TRANSPLANTATION, V63, P917, DOI 10.1097/00007890-199704150-00001; KOOTSTRA G, 1995, TRANSPLANT P, V27, P2893; Korein J, 1978, Ann N Y Acad Sci, V315, P1, DOI 10.1111/j.1749-6632.1978.tb50324.x; Kothari S, 2008, ARCH PHYS MED REHAB, V89, pS27, DOI 10.1016/j.apmr.2007.12.014; Lock, 2002, TWICE DEAD ORGAN TRA; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Machado C, 2005, NEUROLOGY, V64, P1938, DOI 10.1212/01.WNL.0000163515.09793.CB; Machado C, 1994, J Neurosurg Sci, V38, P209; Machado C, 2007, J MED ETHICS, V33, P197, DOI 10.1136/jme.2006.016931; Mandell MS, 2006, CRIT CARE MED, V34, P2952, DOI 10.1097/01.CCM.0000247718.27324.65; Marini AM, 2001, ANN NY ACAD SCI, V939, P238; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Menikoff J, 2002, ISSUES LAW MED, V18, P3; MOLLARET P., 1959, REV NEUROL [PARIS], V101, P3; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; PALLIS C, 1998, MED LEG J, V51, P1538; Plum F., 1982, DIAGNOSIS STUPOR COM, V3rd; PUCCETTI R, 1976, MONIST, V59, P249, DOI 10.5840/monist197659227; SADLER AM, 1968, J AMER MED ASSOC, V206, P2501, DOI 10.1001/jama.1968.03150110049007; SANZ ABR, 2005, ORGANS TISSUES, V3, P151; Siminoff Laura A, 2003, Prog Transplant, V13, P218; SPELLMAN B, 1995, I ETHICS J, V5, P323; Truog RD, 2007, J LAW MED ETHICS, V35, P273, DOI 10.1111/j.1748-720X.2007.00136.x; Turgeon A, 2009, CRIT CARE MED, V37, pA314; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143; Van Norman GA, 1999, ANESTHESIOLOGY, V91, P275, DOI 10.1097/00000542-199907000-00036; VEATCH RM, 1989, DYING BIOLOGICAL REV; Viruses and renal disease, 1968, JAMA, V204, P539; WERTHEIMER P, 1959, PRESSE MED, V67, P87; Whetstine LM, 2007, CRIT CARE, V11, DOI 10.1186/cc5690; Wijdicks EFM, 2006, NEUROLOGY, V66, P1300, DOI 10.1212/01.wnl.0000210497.62202.e9; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; WUDICKS EFM, 2003, NEUROLOGY, V61, P970; Yamamoto T, 2005, ACTA NEUROCHIR SUPPL, V93, P101; Youngner SJ, 1999, HASTINGS CENT REP, V29, P14, DOI 10.2307/3527866; 1968, BRAIN DEATH, V205, P337; 2007, 134 ANN SESS TAC WA; 1977, JAMA, V237, P982	53	26	27	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2010	38	9		S			S502	S509		10.1097/CCM.0b013e3181ec5354			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647FB	WOS:000281602100012	20724884				2022-02-06	
J	Al-Qattan, MM				Al-Qattan, M. M.			Nonunion and Avascular Necrosis Following Phalangeal Neck Fractures in Children	JOURNAL OF HAND SURGERY-AMERICAN VOLUME			English	Article						Children; complications; phalangeal neck fractures	PROXIMAL PHALANX; MALUNION	Purpose To investigate the characteristics of nonunion and avascular necrosis following phalangeal neck fracture in children. Methods A cohort of all pediatric phalangeal neck fractures complicated by nonunion, with or without avascular necrosis of the phalangeal head, over the last 10 years was reviewed retrospectively. The following data were documented: age, gender, fracture site, mechanism of injury, fracture type, presence of digital ischemia, initial management, and outcome. Results Our database of phalangeal neck fractures in children over the last 10 years included 215 fractured digits. Of these, 4 developed nonunion (group A) and 8 developed nonunion with avascular necrosis (group B). All patients in group A were young children (mean age, 2.5 y) with fractured thumbs, initially managed by closed reduction and splinting. The fractures redisplaced and failed to unite, resulting in instability that was later treated by bone grafting and stabilization with a K-wire. Patients in group B were older children (mean age, 5.6 y) and 7 of 8 had finger fractures. All 8 patients presented with stiffness of the affected joint, and no further surgery was performed. Conclusions When nonunion occurs following pediatric phalangeal neck fractures, it usually affects the thumb and presents with thumb instability, and bone grafting is often required to achieve union. In contrast, avascular necrosis following phalangeal neck fractures usually affects the little finger and presents with stiffness, and hence, further surgery is not often required short term, although the long-term result after skeletal maturity is unknown. (J Hand Surg 2010;35A:1269-1274. (C) 2010 Published by Elsevier Inc. on behalf of the American Society for Surgery of the Hand.)	[Al-Qattan, M. M.] King Saud Univ, Dept Surg, Riyadh, Saudi Arabia		Al-Qattan, MM (corresponding author), POB 18097, Riyadh 11415, Saudi Arabia.	moqattan@hotmail.com					Al-Qattan MM, 2006, J HAND SURG-BRIT EUR, V31B, P484, DOI 10.1016/j.jhsb.2006.06.005; Al-Qattan MM, 2009, J HAND SURG-EUR VOL, V34E, P104, DOI 10.1177/1753193408091430; Al-Qattan MM, 2001, J HAND SURG-BRIT EUR, V26, P112, DOI 10.1054/jhsb.2000.0506; Al-Qattan MM, 2004, INJURY, V35, P1207, DOI 10.1016/j.injury.2003.09.042; Al-Qattan MM, 2004, INJURY, V35, P1185, DOI 10.1016/j.injury.2003.09.043; Al-Qattan MM, 1999, J HAND SURG-BRIT EUR, V24B, P693, DOI 10.1054/jhsb.1999.0260; Al-Qattan MM, 2000, HAND CLIN, V16, P535; BARTNIKAS R, 1979, ENG DIELECTRICS, V1, P134; BARTON NJ, 1984, J BONE JOINT SURG BR, V66, P159, DOI 10.1302/0301-620X.66B2.6707048; Cornwall R, 2004, J HAND SURG-AM, V29A, P458, DOI 10.1016/j.jhsa.2004.01.008; DIXON GL, 1972, CLIN ORTHOP RELAT R, P151; Hennrikus WL, 2003, J BONE JOINT SURG BR, V85B, P273, DOI 10.1302/0301-620X.85B2.13167; LEONARD MH, 1970, CLIN ORTHOP RELAT R, P160; MINTZER CM, 1994, J HAND SURG-BRIT EUR, V19B, P594, DOI 10.1016/0266-7681(94)90122-8; NEWINGTON DP, 1995, J HAND SURG-BRIT EUR, V20B, P353, DOI 10.1016/S0266-7681(05)80093-2; SIMMONS BP, 1987, J HAND SURG-AM, V12A, P1079, DOI 10.1016/S0363-5023(87)80117-X; Waters PM, 2004, J HAND SURG-AM, V29A, P707, DOI 10.1016/j.jhsa.2004.03.007	17	26	26	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0363-5023			J HAND SURG-AM	J. Hand Surg.-Am. Vol.	AUG	2010	35A	8					1269	1274		10.1016/j.jhsa.2010.03.038			6	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	637MS	WOS:000280822800007	20684927				2022-02-06	
J	Krause, JS; Saunders, LL; Newman, S				Krause, James S.; Saunders, Lee L.; Newman, Susan			Posttraumatic Stress Disorder and Spinal Cord Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Depression; Factor analysis, statistical; Rehabilitation; Spinal cord injuries; Stress disorders, post-traumatic	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; EVENT SCALE; DEPRESSION; PREVALENCE; DISTRESS; VETERANS; ALCOHOL; IMPACT; LOCUS	Objectives: To identify the prevalence of posttraumatic stress disorder (PTSD) after spinal cord injury (SCI) in a sample averaging over 2 decades postinjury at assessment. Related objectives are to confirm the factor structure, compare subscales with those reported in a nonclinical sample, and identify the relationship of PTSD with depression. Design: Survey. Setting: A medical university in the Southeastern United States. Participants: Participants were initially identified through specialty hospitals in the Midwest and Southeastern United States. A cohort of adults (N=927) with traumatic SCI of at least 1 year duration at enrollment in 2002 to 2003 and a minimum of 7 years at the time of assessment completed the study materials. Interventions: Not applicable. Main Outcomes Measures: PTSD was measured by the Purdue Posttraumatic Stress Disorder Scale-Revised, and depression was measured by the Patient Health Questionnaire 9-item. Results: PTSD was reported by less than 10% of the participants. Item endorsement decreased as a function of years postinjury, primarily because of low rates of endorsement among those 21 or more years postinjury. Confirmatory factor analysis did not result in an acceptable fit for subscales, item sets, or factors previously reported in the literature. Participants scored higher than a nonclinical sample (reported in the literature) on the arousal and avoidance subscales but lower on the re-experiencing subscale. Item endorsements were lower for the first set of items that relate directly to the SCI itself, with the highest item endorsement for "have difficulty remembering important aspects of event." PTSD rarely occurred in the absence of a depressive disorder. Conclusions: PTSD does not appear to be highly prevalent in long-term SCI survivors, and endorsement of items related to re-experiencing and even recalling the injury are rare. Because SCI often is accompanied by mild traumatic brain injury, difficulty recalling the event may have an organic rather than psychologic component.	[Krause, James S.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA		Krause, JS (corresponding author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Suite 117,MSC 700, Charleston, SC 29425 USA.	krause@musc.edu			Department of Education, National Institute of Disability and Rehabilitation Research [H133G060126]	Supported by the Department of Education, National Institute of Disability and Rehabilitation Research (grant no. H133G060126). The contents of this publication do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government.	Agar E, 2006, BEHAV COGN PSYCHOTH, V34, P437, DOI 10.1017/S1352465806002943; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Browne, 1993, TESTING STRUCTURAL E, DOI [10.1177/0049124192021002005, DOI 10.1177/0049124192021002005]; Chung MC, 2007, PSYCHIAT RES, V152, P253, DOI 10.1016/j.psychres.2004.09.013; Chung MC, 2006, J AFFECT DISORDERS, V93, P229, DOI 10.1016/j.jad.2006.02.021; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Garrison A, 2004, J SPINAL CORD MED, V27, P111, DOI 10.1080/10790268.2004.11753740; Goldman RL, 2008, REHABIL PSYCHOL, V53, P162, DOI 10.1037/0090-5550.53.2.162; Hartsough D. M., 1988, SCREENING SCALE ESTI; Hatcher MB, 2009, BRIT J HEALTH PSYCH, V14, P541, DOI 10.1348/135910708X373445; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; Jurisic B, 2009, CRISIS, V30, P34, DOI 10.1027/0227-5910.30.1.34; Kennedy P, 2003, BRIT J CLIN PSYCHOL, V42, P41, DOI 10.1348/014466503762842002; Kennedy P, 2001, SPINAL CORD, V39, P1, DOI 10.1038/sj.sc.3101100; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kulka RA, 1990, TRAUMA VIETNAM WAR G; Lauterbach D., 1996, ASSESSMENT, V3, P17, DOI DOI 10.1177/107319119600300102; Lude P, 2005, SPINAL CORD, V43, P102, DOI 10.1038/sj.sc.3101688; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Martz E, 2005, REHABIL PSYCHOL, V50, P149, DOI 10.1037/0090-5550.50.2.149; MCFALL ME, 1991, PSYCHOSOCIAL PROCESS, V4, P88; Migliorini C, 2008, AUST NZ J PSYCHIAT, V42, P309, DOI 10.1080/00048670801886080; National Spinal Cord Injury Statistical Center (NSCISC), 2009, ANN STAT REP; Nielsen MS, 2003, SPINAL CORD, V41, P296, DOI 10.1038/sj.sc.3101427; Nielsen MS, 2003, REHABIL PSYCHOL, V48, P289, DOI 10.1037/0090-5550.48.4.289; Orsillo S.M., 2001, PRACTITIONERS GUIDE, P255, DOI DOI 10.1007/0-306-47628-2_20; Radnitz C.L., 2000, INT J REHABILITATION, V5, P195, DOI [10.1023/A:1012903406285, DOI 10.1023/A:1012903406285]; Radnitz CL, 2000, J ANXIETY DISORD, V14, P313, DOI 10.1016/S0887-6185(00)00025-6; Radnitz CL, 1998, J TRAUMA STRESS, V11, P505, DOI 10.1023/A:1024404729251; Tate DG, 2004, ARCH PHYS MED REHAB, V85, P1837, DOI 10.1016/j.apmr.2004.02.022; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; *US DEP VET AFF, 2009, NAT CTR PTSD CLIN AD; *US DEP VET AFF, 2010, PTSD CHECKL; Wilson JP, 1996, ASSESSING PSYCHOL TR, P399	38	26	27	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2010	91	8					1182	1187		10.1016/j.apmr.2010.05.012			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	642BT	WOS:000281178900005	20684898				2022-02-06	
J	Hung, CJ; Yao, CL; Cheng, FC; Wu, ML; Wang, TH; Hwang, SM				Hung, Chi-Jen; Yao, Chao-Ling; Cheng, Fu-Chou; Wu, Mei-Ling; Wang, Tzu-Hao; Hwang, Shiaw-Min			Establishment of immortalized mesenchymal stromal cells with red fluorescence protein expression for in vivo transplantation and tracing in the rat model with traumatic brain injury	CYTOTHERAPY			English	Article						mesenchymal stromal cells; non-viral transfection; red fluorescent protein; telomerase reverse transcriptase; traumatic brain injury	HUMAN BONE-MARROW; STEM-CELLS; GENE-THERAPY; LIFE-SPAN; EX-VIVO; TELOMERASE; TISSUE; PROLIFERATION; KINETICS	Background aims. Human mesenchymal stromal cells (hMSC) play a crucial role in tissue engineering and regenerative medicine, and have important clinical potential for cell therapy. However, many hMSC studies have been restricted by limited cell numbers and difficult detection in vivo. To expand the lifespan, hMSC are usually immortalized by virus-mediated gene transfer. However, these genetically modified cells easily lose critical phenotypes and stable genotypes because of insertional mutagenesis. Methods. We used a non-viral transfection method to establish human telomerase reverse transcriptase-immortalized cord blood hMSC (hTERT-cbMSC). We also established red fluorescent protein (RFP)-expressing hTERT-cbMSC (hTERT/RFP-cbMSC) by the same non-viral transfection method, and these cells were injected into a rat model with traumatic brain injury for in vivo detection analysis. Results. The hTERT-cbMSC could grow more than 200 population doublings with a stable doubling time and maintained differentiation capacities. hTERT/RFP-cbMSC could proliferate efficiently within 2 weeks at the injury location and could be detected easily under a fluorescent microscope. Importantly, both hTERT-cbMSC and hTERT/RFP-cbMSC showed no chromosomal abnormalities by karyotype analysis and no tumor formation in severe combined immunodeficient (SCID) mice by transplantation assay. Conclusions. We have developed immortalized cbMSC with hTERT expression and RFP expression, which will be useful tools for stem cell research and translational study.	[Hung, Chi-Jen; Yao, Chao-Ling; Wu, Mei-Ling; Hwang, Shiaw-Min] Food Ind Res & Dev Inst, Bioresource Collect & Res Ctr, Hsinchu 30062, Taiwan; [Yao, Chao-Ling] Yuan Ze Univ, Dept Chem Engn & Mat Sci, Chungli, Taiwan; [Cheng, Fu-Chou] Vet Gen Hosp, Dept Med Res, Taichung, Taiwan; [Wang, Tzu-Hao] Chang Gung Mem Hosp, Genom Med Res Core Lab, Tao Yuan, Taiwan		Hwang, SM (corresponding author), Food Ind Res & Dev Inst, Bioresource Collect & Res Ctr, 331 Shih Pin Rd, Hsinchu 30062, Taiwan.	hsm@firdi.org.tw					Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059; Aluigi M, 2006, STEM CELLS, V24, P454, DOI 10.1634/stemcells.2005-0198; Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301-472X(00)00160-0; Bhakta S, 2006, CARDIOVASC REVASCULA, V7, P19, DOI 10.1016/j.carrev.2005.10.008; Bleiziffer O, 2007, J CELL MOL MED, V11, P206, DOI 10.1111/j.1582-4934.2007.00027.x; Blesch A, 2004, METHODS, V33, P164, DOI 10.1016/j.ymeth.2003.11.005; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bocker W, 2008, J CELL MOL MED, V12, P1347, DOI [10.1111/j.1582-4934.2008.0299.x, 10.1111/j.1582-4934.2008.00299.x]; Bokhoven M, 2009, J VIROL, V83, P283, DOI 10.1128/JVI.01865-08; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; Burns JS, 2005, CANCER RES, V65, P3126, DOI 10.1158/0008-5472.CAN-04-2218; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Chang YJ, 2006, STEM CELLS, V24, P679, DOI 10.1634/stemcells.2004-0308; Check E, 2002, NATURE, V420, P116, DOI 10.1038/420116a; Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; Gao X, 2007, AAPS J, V9, pE92, DOI 10.1208/aapsj0901009; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hill JM, 2003, CIRCULATION, V108, P1009, DOI 10.1161/01.CIR.0000084537.66419.7A; Huang GP, 2008, J CELL BIOCHEM, V103, P1256, DOI 10.1002/jcb.21502; Huang Q, 2007, MECH AGEING DEV, V128, P25, DOI 10.1016/j.mad.2006.11.006; in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood-2003-04-1291; Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Sobajima S, 2008, SPINE J, V8, P888, DOI 10.1016/j.spinee.2007.09.011; Terai M, 2005, MOL BIOL CELL, V16, P1491, DOI 10.1091/mbc.e04-07-0652; Thomas M, 2003, APPL MICROBIOL BIOT, V62, P27, DOI 10.1007/s00253-003-1321-8; Williams JT, 1999, AM SURGEON, V65, P22; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	39	26	27	0	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy	JUL	2010	12	4					455	465		10.3109/14653240903555827			11	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	631EO	WOS:000280329600003	20230225				2022-02-06	
J	Chauhan, NB; Gatto, R; Chauhan, MB				Chauhan, Neelima B.; Gatto, Rodolfo; Chauhan, Mihirsinh B.			Neuroanatomical correlation of behavioral deficits in the CCI model of TBI	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury; Controlled cortical impact injury; DeOlmos Silver Stain; Diffuse axonal injury; Morris water maze	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; AGED GARLIC EXTRACT; COGNITIVE DEFICITS; SILVER TECHNIQUE; MOTOR; RATS; BLOOD; MICE; DEXAMETHASONE	Traumatic brain injury (TBI) is the leading cause of death and disability both in combat and civilian situations with limited treatment options including surgical removal of hematoma, ventricular drainage and use of hyperosmotic agents that restrict secondary injury following TBI. Availability of appropriate model system with full-range characterization of anatomical and behavioral components correlative with brain injury provides a pre-clinical platform to test candidate therapies for clinical translation. Modeling of TBI using controlled cortical impact injury (CCI) is largely considered to be close to clinical TBI and hence CCI models have been widely used in pre-clinical TBI research. Most studies reported so far using CCI models were presented with a limited behavioral characterization and lacked its correlation with the signature histopathology of TBI. Current investigation validated a detailed sensomotor and cognitive behavioral characterization correlative with diffuse axonal injury-the signature histopathology of TBI, in the CCI mouse model of TBI. Present study offers a comprehensively characterized model of TBI that can be used to investigate cellular and molecular mechanisms underlying TBI and to test candidate therapies in developing novel and effective treatments for TBI. Published by Elsevier B.V.	[Chauhan, Neelima B.; Gatto, Rodolfo] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA; [Chauhan, Neelima B.] Univ Illinois, Dept Pediat, Chicago, IL 60680 USA; [Chauhan, Neelima B.] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60680 USA; [Chauhan, Mihirsinh B.] Med Univ Lublin, PL-20059 Lublin, Poland		Chauhan, NB (corresponding author), Jesse Brown VA Med Ctr, R&D 151,820 S Damen Ave, Chicago, IL 60612 USA.	Neelima.Chauhan2@va.gov; Rodolfo.Gatto@va.gov; mchauhan99@gmail.com	Gatto, Rodolfo Gabriel/R-7155-2018	Gatto, Rodolfo Gabriel/0000-0003-2170-6662	Department of Veterans Affairs (VA, Chauhan NB)US Department of Veterans Affairs [B6285R]; Westside Institute for Science and Education; Department of Pediatrics; Department of Anatomy & Cell Biology, University of Illinois at Chicago; Veterans AffairsUS Department of Veterans Affairs [I01RX000880] Funding Source: NIH RePORTER	This work has been supported by the Department of Veterans Affairs (VA MERIT grant #B6285R, Chauhan NB). Authors wish to thank support provided by the Westside Institute for Science and Education, and by the Department of Pediatrics, Department of Anatomy & Cell Biology, University of Illinois at Chicago.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chauhan NB, 1999, INT J DEV NEUROSCI, V17, P255, DOI 10.1016/S0736-5748(99)00003-9; Chauhan NB, 2006, J ETHNOPHARMACOL, V108, P385, DOI 10.1016/j.jep.2006.05.030; Chauhan NB, 2007, PHYTOTHER RES, V21, P629, DOI 10.1002/ptr.2122; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Conti AC, 1998, J NEUROSCI, V18, P5663; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donat CK, 2007, BRAIN INJURY, V21, P1031, DOI 10.1080/02699050701630359; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hartl R, 1997, ACT NEUR S, V70, P240; Imaki J, 2009, NEUROSCI LETT, V454, P143, DOI 10.1016/j.neulet.2009.03.001; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Lema PP, 2004, J VET PHARMACOL THER, V27, P321, DOI 10.1111/j.1365-2885.2004.00597.x; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P1, DOI 10.1016/j.proghi.2008.10.002; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Petit-Demouliere B, 2009, BEHAV BRAIN RES, V204, P200, DOI 10.1016/j.bbr.2009.06.006; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; RICHARDSON RM, 2009, J NEUROSURG, V110, P1; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Tanaka K, 2009, NEUROSCI LETT, V462, P235, DOI 10.1016/j.neulet.2009.07.024; Tenkova Tatyana I., 2007, V399, P31, DOI 10.1007/978-1-59745-504-6_3; Vachon P, 2003, CAN J VET RES, V67, P157; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yakhnitsa V, 2006, NEUROSCIENCE, V143, P615, DOI 10.1016/j.neuroscience.2006.08.006; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	56	26	27	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUN 30	2010	190	1					1	9		10.1016/j.jneumeth.2010.04.004			9	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	625IN	WOS:000279888800001	20385166				2022-02-06	
J	Lescot, T; Fulla-Oller, L; Palmier, B; Po, C; Beziaud, T; Puybasset, L; Plotkine, M; Gillet, B; Meric, P; Marchand-Leroux, C				Lescot, Thomas; Fulla-Oller, Laurence; Palmier, Bruno; Po, Christelle; Beziaud, Tiphaine; Puybasset, Louis; Plotkine, Michel; Gillet, Brigitte; Meric, Philippe; Marchand-Leroux, Catherine			Effect of Acute Poly(ADP-Ribose) Polymerase Inhibition by 3-AB on Blood-Brain Barrier Permeability and Edema Formation after Focal Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; matrix metalloproteinase; nuclear magnetic resonance; poly(ADP-ribose) polymerase; traumatic brain injury		Recent evidence supports a crucial role for matrix metalloproteinase-9 (MMP-9) in blood-brain barrier (BBB) disruption and vasogenic edema formation after traumatic brain injury (TBI). Although the exact causes of MMP-9 upregulation after TBI are not fully understood, several arguments suggest a contribution of the enzyme poly(ADP-ribose) polymerase (PARP) in the neuroinflammatory response leading to MMP-9 activation. The objectives of this study were to evaluate the effect of PARP inhibition by 3-aminobenzamide (3-AB) (1) on MMP-9 upregulation and BBB integrity, (2) on edema formation as assessed by magnetic resonance imaging (MRI), (3) on neuron survival as assessed by H-1 magnetic resonance spectroscopy (H-1-MRS), and (4) on neurological deficits at the acute phase of TBI. Western blots and zymograms showed blunting of MMP-9 upregulation 6 h after TBI. BBB permeability was decreased at the same time point in 3-AB-treated rats compared to vehicle-treated rats. Cerebral MRI showed less "free" water in 3-AB-treated than in vehicle-treated rats 6 h after TBI. MRI findings 24 h after TBI indicated predominant cytotoxic edema, and at this time point no significant differences were found between 3-AB-and vehicle-treated rats with regard to MMP-9 upregulation, BBB permeability, or MRI changes. At both 6 and 24 h, neurological function was better in the 3-AB-treated than in the vehicle-treated rats. These data suggest that PARP inhibition by 3-AB protected the BBB against hyperpermeability induced by MMP-9 upregulation, thereby decreasing vasogenic edema formation 6 h after TBI. Furthermore, our data confirm the neuroprotective effect of 3-AB at the very acute phase of TBI.	[Lescot, Thomas; Palmier, Bruno; Beziaud, Tiphaine; Plotkine, Michel; Marchand-Leroux, Catherine] Univ Paris 05, Equipe Rech Pharmacol Circulat Cerebrale EA 2510, Fac Sci Pharmaceut & Biol, F-75006 Paris, France; [Lescot, Thomas; Fulla-Oller, Laurence; Puybasset, Louis] Grp Hosp Pitie Salpetriere, AP HP, Dept Anesthesie Reanimat, F-75634 Paris, France; [Lescot, Thomas; Fulla-Oller, Laurence; Puybasset, Louis] Univ Paris 06, Paris, France; [Fulla-Oller, Laurence; Po, Christelle; Gillet, Brigitte; Meric, Philippe] CNRS, Inst Chim Subst Nat, Lab Resonance Magnet Nucl Biol, Gif Sur Yvette, France		Lescot, T (corresponding author), Univ Paris 05, Equipe Rech Pharmacol Circulat Cerebrale EA 2510, Fac Sci Pharmaceut & Biol, 4 Ave Observ, F-75006 Paris, France.	thomas.lescot@psl.aphp.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Po, Chrystelle/0000-0001-9785-9572	nonprofit organization Fondation des Gueules Cassees	The authors are very grateful to Dr. Antoinette Wolfe for helping to prepare the manuscript. This work was supported by the nonprofit organization Fondation des Gueules Cassees (grants to T.L. and L.F.O.).	Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BEDERSON JB, 1986, J NEUROSURG, V64, P795, DOI 10.3171/jns.1986.64.5.0795; Besson VC, 2005, BRAIN RES, V1041, P149, DOI 10.1016/j.brainres.2005.01.096; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Couturier JY, 2003, EXP NEUROL, V184, P973, DOI 10.1016/S0014-4886(03)00367-4; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GUIMARAES AR, 1995, NEUROSCIENCE, V69, P1095, DOI 10.1016/0306-4522(95)00300-8; Haddad M, 2008, EUR J PHARMACOL, V588, P52, DOI 10.1016/j.ejphar.2008.04.013; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kawai N, 2003, J NEUROTRAUM, V20, P649, DOI 10.1089/089771503322144563; Koh SH, 2005, TOXICOLOGY, V214, P131, DOI 10.1016/j.tox.2005.06.023; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; LEBIHAN D, 1988, MAGNET RESON MED, V7, P346, DOI 10.1002/mrm.1910070312; Lenzser G, 2007, J CEREBR BLOOD F MET, V27, P1318, DOI 10.1038/sj.jcbfm.9600437; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; Naressi A, 2001, COMPUT BIOL MED, V31, P269, DOI 10.1016/S0010-4825(01)00006-3; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SKAPER SD, 2003, ANN NY ACAD SCI, P217; SKAPER SD, 2003, ANN NY ACAD SCI, P287; Thompson WRE, 2005, ORAL ONCOL, V1, P75, DOI 10.1016/S1744-7895(05)80156-7; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; WANG J, 2005, BRAIN PT, V7, P1622; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008	38	26	30	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1069	1079		10.1089/neu.2009.1188			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300010	20380552				2022-02-06	
J	Di Russo, F; Spinelli, D				Di Russo, Francesco; Spinelli, Donatella			Sport is not always healthy: Executive brain dysfunction in professional boxers	PSYCHOPHYSIOLOGY			English	Article						Brain trauma; ERPs; Executive control; Sport; Boxing	RESPONSE SELECTION; AMATEUR BOXERS; INJURY; P300; TASK; DISCRIMINATION; CONCUSSION; DEFICITS; CORTEX; DAMAGE	We measured ERPs of professional boxers in a Go/No-Go task, comparing them to fencers and non-athletes. Results showed that fencing improved attention and motor response control, but boxing did not. More strikingly, in boxers, as in brain trauma patients, the P3 component was delayed and reduced. The P3 delay of boxers was correlated with the amount of performed sport exercise. Furthermore, in terms of behavior, boxers showed increased intra-individual variability and switch cost. Results were consistent with the hypothesis of specific impairment at the level of response inhibition processing. We suggest that this impairment is derived from the cumulative effect of blows to the head. The changes found in boxers suggest that ERPs and reaction times may be a tool for early detection of specific brain dysfunction.	[Di Russo, Francesco] Univ Rome Foro Italico, Dept Educ Sci Motor Act & Sport, I-00194 Rome, Italy; IRCCS, Santa Lucia Fdn, Neuropsychol Lab, Rome, Italy		Di Russo, F (corresponding author), Univ Rome Foro Italico, Dept Educ Sci Motor Act & Sport, Largo Lauro De Bosis 15, I-00194 Rome, Italy.	francesco.dirusso@iusm.it	Di Russo, Francesco/N-6686-2015	Di Russo, Francesco/0000-0002-3127-9433; SPINELLI, Donatella/0000-0002-4890-6931	MIURMinistry of Education, Universities and Research (MIUR) [PRIN 2007]	Support was provided by PRIN 2007 MIUR grant. Thanks to M. Di Sera. no for his contributions to subject recruitment.	Aron AR, 2004, BRAIN, V127, P1561, DOI 10.1093/brain/awh169; Bekker EM, 2005, COGNITIVE BRAIN RES, V22, P221, DOI 10.1016/j.cogbrainres.2004.08.011; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BRETON F, 1991, BIOL PSYCHOL, V3, P57; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Di Russo F, 2005, MED SCI SPORT EXER, V37, P1586, DOI 10.1249/01.mss.0000177458.71676.0d; Di Russo F, 2006, NEUROSCI LETT, V408, P113, DOI 10.1016/j.neulet.2006.08.085; Dias EC, 2003, CEREB CORTEX, V13, P701, DOI 10.1093/cercor/13.7.701; Dien J, 2004, PSYCHOPHYSIOLOGY, V41, P665, DOI 10.1111/j.1469-8986.2004.00193.x; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Fallgatter AJ, 1999, INT J PSYCHOPHYSIOL, V32, P233, DOI 10.1016/S0167-8760(99)00018-5; Gajewski PD, 2008, BRAIN RES, V1189, P127, DOI 10.1016/j.brainres.2007.10.076; Giugni E, 2005, AM J NEURORADIOL, V26, P1140; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; HAENEL S, 2008, IMAGING AM SOC NEURO, V29, P88; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Loosemore M, 2007, BMJ-BRIT MED J, V335, P809, DOI 10.1136/bmj.39342.690220.55; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P334, DOI 10.1111/j.1469-8986.1996.tb01058.x; RAYLE C, 2006, J NEUROSCI, V4, P186; RITTER W, 1982, SCIENCE, V218, P909, DOI 10.1126/science.7134983; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rossini PM, 2007, PROG NEUROBIOL, V83, P375, DOI 10.1016/j.pneurobio.2007.07.010; Rushworth MFS, 2001, J NEUROSCI, V21, P5262, DOI 10.1523/JNEUROSCI.21-14-05262.2001; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Verleger R, 2005, J PSYCHOPHYSIOL, V19, P165, DOI 10.1027/0269-8803.19.3.165; Vogel EK, 2000, PSYCHOPHYSIOLOGY, V37, P190, DOI 10.1017/S0048577200981265; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110	33	26	27	0	16	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0048-5772			PSYCHOPHYSIOLOGY	Psychophysiology	MAY	2010	47	3					425	434		10.1111/j.1469-8986.2009.00950.x			10	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	579VY	WOS:000276406100004	20030763	Green Published			2022-02-06	
J	Ringl, H; Schernthaner, RE; Schueller, G; Balassy, C; Kienzl, D; Botosaneanu, A; Weber, M; Czerny, C; Hajdu, S; Mang, T; Herold, CJ; Schima, W				Ringl, Helmut; Schernthaner, Ruediger E.; Schueller, Gerd; Balassy, Csilla; Kienzl, Daniela; Botosaneanu, Ana; Weber, Michael; Czerny, Christian; Hajdu, Stefan; Mang, Thomas; Herold, Christian J.; Schima, Wolfgang			The Skull Unfolded: A Cranial CT Visualization Algorithm for Fast and Easy Detection of Skull Fractures	RADIOLOGY			English	Article							COMPUTED-TOMOGRAPHY; BRAIN-INJURY; 3D CT; BASE; TRAUMA; CRANIOSYNOSTOSIS; RECONSTRUCTION; POPULATION; DIAGNOSIS; RADIOLOGY	Purpose: To retrospectively assess the rate of detection of skull fractures at cranial computed tomography (CT) achieved with the use of curved maximum intensity projections (MIPs) compared with that achieved by reading transverse sections only. Materials and Methods: The institutional review board approved this research and waived informed consent. A curved thin (3-mm) MIP of the skull cap and a curved thick (50-mm) MIP of the skull base were obtained from the cranial CT data in 200 consecutive patients with head trauma. Four radiologists (two residents without experience in cranial CT and two consultants) independently evaluated all cases. Each radiologist reported findings in 100 patients by using transverse sections only and findings in the other 100 patients by using the unfolded view. The radiologists were blinded to patient names, and patient and group orders were randomized. The results were compared with a standard of reference established by two experts from all prior reading results, all reconstructions, and high-spatial-resolution multiplanar reformats. Logistic regression with repeated measurements was used for statistical analysis. Results: The experts found 63 fractures in 30 patients. When transverse sections only were used, the mean patient-based fracture detection rate was 43% (13 of 30) for inexperienced and 70% (21 of 30) for experienced readers; with curved MIPs, the rates were 80% (24 of 30) and 87% (26 of 30), respectively. Overall sensitivity was higher with curved MIPs (P < .001); specificity was higher with transverse sections (P < .001). Conclusion: Curved MIPs enable a significantly higher fracture detection rate than transverse sections. They also considerably close the experience gap in fracture detection rate between residents and experts. (C) RSNA, 2010	[Ringl, Helmut; Schernthaner, Ruediger E.; Schueller, Gerd; Balassy, Csilla; Kienzl, Daniela; Botosaneanu, Ana; Weber, Michael; Czerny, Christian; Mang, Thomas; Herold, Christian J.; Schima, Wolfgang] Med Univ Vienna, Dept Radiol, A-1090 Vienna, Austria; [Hajdu, Stefan] Med Univ Vienna, Dept Trauma Surg, A-1090 Vienna, Austria		Ringl, H (corresponding author), Med Univ Vienna, Dept Radiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	helmut.ringl@meduniwien.ac.at	Schernthaner, Rudiger/AAG-4584-2021; Weber, Michael/L-9836-2016	Weber, Michael/0000-0002-8507-2219; /0000-0002-1194-1346			ALI QM, 1994, NEURORADIOLOGY, V36, P622, DOI 10.1007/BF00600424; Alkadhi H, 2004, J COMPUT ASSIST TOMO, V28, P378, DOI 10.1097/00004728-200405000-00013; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Chen AR, 2006, WIND STRUCT, V9, P59, DOI 10.12989/was.2006.9.1.059; Chen Jian-yu, 2006, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V28, P16; de Boussard CN, 2006, J TRAUMA, V61, P577, DOI 10.1097/01.ta.0000224901.67930.ce; Fatterpekar GM, 2006, RADIOGRAPHICS, V26, pS117, DOI 10.1148/rg.26si065502; FISHMAN EK, 1991, RADIOLOGY, V181, P321, DOI 10.1148/radiology.181.2.1789832; FISHMAN EK, 1993, RADIOGRAPHICS, V13, P463, DOI 10.1148/radiographics.13.2.8460231; GRODD W, 1987, RADIOLOGE, V27, P502; KLEINBAUM DG, 2002, LOGISTIC REGRESSION, P327; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Medina LS, 2000, AM J NEURORADIOL, V21, P1951; *NIH CLIN EXC, 2007, 56 NICE NIH CLIN EXC; Philipp MO, 2003, EUR J RADIOL, V48, P33, DOI 10.1016/S0720-048X(03)00197-9; Remmler D, 2000, ANN PLAS SURG, V44, P553, DOI 10.1097/00000637-200044050-00015; Rieker O, 1998, ROFO-FORTSCHR RONTG, V169, P490, DOI 10.1055/s-2007-1015325; Ringl H, 2009, EUR RADIOL, V19, P2416, DOI 10.1007/s00330-009-1435-1; Rodt T, 2006, DENTOMAXILLOFAC RAD, V35, P227, DOI 10.1259/dmfr/22989395; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Samii M, 2002, NEUROL RES, V24, P147, DOI 10.1179/016164102101199693; VANNIER MW, 1994, AM J NEURORADIOL, V15, P1861; Xu Y M, 1999, Shanghai Kou Qiang Yi Xue, V8, P153	24	26	26	0	3	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	MAY	2010	255	2					553	562		10.1148/radiol.10091096			10	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	587FU	WOS:000276976200029	20332373	Bronze			2022-02-06	
J	Rohlwink, UK; Figaji, AA				Rohlwink, Ursula K.; Figaji, Anthony A.			Methods of monitoring brain oxygenation	CHILDS NERVOUS SYSTEM			English	Article						Brain oxygen; Jugular venous saturation; Near-infrared spectroscopy; Brain tissue oxygen tension; Children; Traumatic brain injury	NEAR-INFRARED SPECTROSCOPY; SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; TISSUE OXYGEN; BLOOD-FLOW; INTRACRANIAL-PRESSURE; ANEURYSM SURGERY; SUBARACHNOID HEMORRHAGE; REGIONAL OXYGENATION; CARBON-DIOXIDE	Posttraumatic brain ischemia or hypoxia is a major potential cause of secondary injury that may lead to poor outcome. Avoidance, or amelioration, of this secondary injury depends on early diagnosis and intervention before permanent injury occurs. However, tools to monitor brain oxygenation continuously in the neuro-intensive care unit have been lacking. In recent times, methods of monitoring aspects of brain oxygenation continuously by the bedside have been evaluated in several experimental and clinical series and are potentially changing the way we manage head-injured patients. These monitors have the potential to alert the clinician to possible secondary injury and enable intervention, help interpret pathophysiological changes (e.g., hyperemia causing raised intracranial pressure), monitor interventions (e.g., hyperventilation for increased intracranial pressure), and prognosticate. This review focuses on jugular venous saturation, brain tissue oxygen tension, and near-infrared spectroscopy as practical methods that may have an important role in managing patients with brain injury, with a particular focus on the available evidence in children. However, to use these monitors effectively and to understand the studies in which these monitors are employed, it is important for the clinician to appreciate the technical characteristics of each monitor, as well as respective strengths and limitations of each. It is equally important that the clinician understands relevant aspects of brain oxygen physiology and head trauma pathophysiology to enable correct interpretation of the monitored data and therefore to direct an appropriate therapeutic response that is likely to benefit, not harm, the patient.	[Figaji, Anthony A.] Red Cross Childrens Hosp, ZA-7700 Cape Town, South Africa; [Rohlwink, Ursula K.; Figaji, Anthony A.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Neurosurg, ZA-7925 Cape Town, South Africa		Figaji, AA (corresponding author), Red Cross Childrens Hosp, 617 ICH Bldg,Klipfontein Rd, ZA-7700 Cape Town, South Africa.	Anthony.Figaji@uct.ac.za	Rohlwink, Ursula/AAE-2513-2020; Viani, Rafael/V-1196-2018; Rohlwink, Ursula Karin/U-8917-2019	Rohlwink, Ursula Karin/0000-0002-4469-4935; Figaji, Anthony/0000-0002-3357-6490	National Research Foundation [GUN 2072790]; Integra Foundation	This work was supported in part by a grant from the South Africa-Swedish Links Program/National Research Foundation (GUN 2072790). Dr. Figaji also received a grant from the Integra Foundation for the study of cerebral perfusion pressure thresholds in children.	Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 1998, ACT NEUR S, V71, P250; Al-Rawi PG, 2000, ZBL NEUROCHIR, V61, P74, DOI 10.1055/s-2000-8263; Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Al-Rawi PG, 2006, STROKE, V37, P2720, DOI 10.1161/01.STR.0000244807.99073.ae; Alten Jeffrey, 2005, Pediatr Crit Care Med, V6, P480, DOI 10.1097/01.PCC.0000162450.62812.AE; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bruzzone P, 1998, ACT NEUR S, V71, P111; Buchner K, 2000, ZBL NEUROCHIR, V61, P69, DOI 10.1055/s-2000-8262; Chieregato A, 2003, J NEUROL NEUROSUR PS, V74, P784, DOI 10.1136/jnnp.74.6.784; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183, DOI 10.1152/jappl.1967.23.2.183; Gatto R, 2006, J NEUROSCI METH, V157, P274, DOI 10.1016/j.jneumeth.2006.04.013; Gelabert-Gonzalez M, 2002, ACTA NEUROCHIR, V144, P863, DOI 10.1007/s00701-002-0975-9; Gomersall CD, 1997, CRIT CARE MED, V25, P1252, DOI 10.1097/00003246-199707000-00031; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; Holzschuh M, 1997, NEUROL RES, V19, P246, DOI 10.1080/01616412.1997.11740807; Huchzermeyer C, 2008, J NEUROSCI, V28, P1153, DOI 10.1523/JNEUROSCI.4105-07.2008; Hull Rachel, 2009, Open Neuroimag J, V3, P26; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Jodicke A, 2003, J NEUROSURG, V98, P515, DOI 10.3171/jns.2003.98.3.0515; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kakihana Y, 2002, EUR J CARDIO-THORAC, V21, P434, DOI 10.1016/S1010-7940(01)01139-3; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kett-White R, 2002, J NEUROSURG, V96, P1013, DOI 10.3171/jns.2002.96.6.1013; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Knirsch W, 2008, ACTA ANAESTH SCAND, V52, P1370, DOI 10.1111/j.1399-6576.2008.01703.x; Kurth CD, 2009, ANESTH ANALG, V108, P1268, DOI 10.1213/ane.0b013e318196ac8e; Lang EW, 2007, NEUROSURG REV, V30, P99, DOI 10.1007/s10143-006-0062-4; Latronico N, 2000, NEUROSURGERY, V46, P1131, DOI 10.1097/00006123-200005000-00021; LENIGERFOLLERT E, 1975, PFLUG ARCH EUR J PHY, V359, P81, DOI 10.1007/BF00581279; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; Macmillan CSA, 2000, INTENS CARE MED, V26, P1028, DOI 10.1007/s001340051315; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; Marion DW, 2000, J TRAUMA, V48, P1032; Marshall RS, 2004, CURR OPIN NEUROL, V17, P705, DOI 10.1097/00019052-200412000-00010; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nemoto EM, 2000, ANESTHESIOLOGY, V92, P1847, DOI 10.1097/00000542-200006000-00057; Nemoto EM, 2000, CRIT CARE MED, V28, P1052, DOI 10.1097/00003246-200004000-00023; Nievas MCY, 2005, SURG NEUROL, V64, P362, DOI 10.1016/j.surneu.2005.02.008; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Perez Augusto, 2003, Pediatr Crit Care Med, V4, P33; Poca MA, 2007, J NEUROSURG, V106, P530, DOI 10.3171/jns.2007.106.4.530; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Rolfe P, 2000, ANNU REV BIOMED ENG, V2, P715, DOI 10.1146/annurev.bioeng.2.1.715; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Salim A, 2008, AM SURGEON, V74, P1088; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Schneider GH, 1998, ACT NEUR S, V71, P62; Schwarz G, 1996, J NEUROSURG ANESTH, V8, P189, DOI 10.1097/00008506-199607000-00001; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Siesjo BK, 2008, J NEUROSURG, V108, P616, DOI 10.3171/JNS/2008/108/3/0616; Smith M, 2009, ANESTH ANALG, V108, P1055, DOI 10.1213/ane.0b013e31819a0301; Springett RJ, 2003, ADV EXP MED BIOL, V530, P555; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stocchetti N, 2004, ANESTH ANALG, V99, P230, DOI 10.1213/01.ane.0000130393.08355.d4; Stocchetti N, 1998, ACT NEUR S, V71, P162; Subbaswamy A, 2009, NEUROCRIT CARE, V10, P129, DOI 10.1007/s12028-008-9122-7; Thavasothy M, 2002, ANAESTHESIA, V57, P999, DOI 10.1046/j.1365-2044.2002.02826.x; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Vavilala MS, 2007, PEDIATR CRIT CARE ME, V8, P192, DOI 10.1097/01.PCC.0000257105.56861.7A; Wartenberg KE, 2007, CRIT CARE CLIN, V23, P507, DOI 10.1016/j.ccc.2007.06.002; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017	85	26	26	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	APR	2010	26	4					453	464		10.1007/s00381-009-1033-1			12	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	568QI	WOS:000275537100007	19937250				2022-02-06	
J	Wang, HC; Duan, ZX; Wu, FF; Xie, L; Zhang, H; Ma, YB				Wang, Hong-Cai; Duan, Zhi-Xin; Wu, Fang-Fang; Xie, Le; Zhang, Hong; Ma, Yan-Bin			A New Rat Model for Diffuse Axonal Injury Using a Combination of Linear Acceleration and Angular Acceleration	JOURNAL OF NEUROTRAUMA			English	Article						animal model; beta-amyloid precursor protein; diffuse axonal injury; injury mechanism; traumatic brain injury	TRAUMATIC BRAIN-INJURY; INTRAAXONAL NEUROFILAMENT COMPACTION; COLLEGIATE FOOTBALL PLAYERS; HEAD IMPACT; WHITE-MATTER; BIOMECHANICS; HIPPOCAMPUS; CONCUSSION; PATHOBIOLOGY; AXOTOMY	Diffuse axonal injury (DAI) is a frequent form of traumatic brain injury, and is usually associated with long-lasting neurological impairments. A new experimental model was developed in the present study to induce DAI in rats by combining low linear and angular accelerations. In most clinical scenarios, DAI is caused by these two forms of acceleration in combination. In the injury-producing facility described here, the rat rotated instantly after it had sustained the impact that produced linear acceleration. Rats rotated rapidly 90 degrees in the coronal plane at a peak angular acceleration of 137 +/- 12 krad/sec(2) with a duration of 33.7 +/- 1.2 msec. The linear acceleration was applied to the rat's head by dropping a 450 g weight from a height of 0.9 m. Rats exposed to the combined accelerations took significantly longer to regain consciousness (11.9 +/- 3.6 min) than control rats (p < 0.01) or rats subjected to purely angular or linear acceleration (p < 0.01). Although macroscopic damage was observed in all brain-injured animals, axonal damage and hemorrhagic tissue tears were only noted in the animals sustaining the combined accelerations. All rats survived the purely linear or angular acceleration, whereas the mortality rate reached 21.7% following the combined accelerations. These results show that this model is capable of reproducing the major histological and neurological changes that are associated with DAI, and that the combination of low linear and angular accelerations can produce non-linear and synergistic effects to induce moderate/severe DAI.	[Wang, Hong-Cai; Duan, Zhi-Xin; Wu, Fang-Fang; Zhang, Hong; Ma, Yan-Bin] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp Affiliated 3, Dept Neurosurg, Shanghai 201900, Peoples R China; [Xie, Le] Shanghai Jiao Tong Univ, Natl & Mould Engn Res Ctr, Shanghai 201900, Peoples R China		Ma, YB (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp Affiliated 3, Dept Neurosurg, Shanghai 201900, Peoples R China.	mybxj@yahoo.com.cn			Shanghai Education Committee [06BZ042]; Shanghai Municipal Health Bureau [2008115]; Shanghai Jiao Tong University [YG2009MS14]	We acknowledge Yuying Chen, Zhuying Guo, and Dong Yang for excellent technical support. This work is supported by grants from Shanghai Education Committee (no. 06BZ042), Shanghai Municipal Health Bureau (no. 2008115), and Shanghai Jiao Tong University Medicine and Engineering Cross Fund (no. YG2009MS14).	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Clark RSB, 1997, J NEUROSCI, V17, P9172; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Dusart I, 2005, BRAIN RES REV, V49, P300, DOI 10.1016/j.brainresrev.2004.11.007; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; KILBOURNE M, 2009, J NEUROTRAUM, V26, P1; King A. I., 2003, IRCOBI C LISB PORT; Liu PH, 2006, J NEUROTRAUM, V23, P1857, DOI 10.1089/neu.2006.23.1857; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MCLEAN AJ, 1995, J NEUROTRAUM, V12, P621, DOI 10.1089/neu.1995.12.621; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SMITH M, 2003, TRAUMA, V5, P227; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; UENO K, 1995, J BIOMECH ENG-T ASME, V117, P319, DOI 10.1115/1.2794187; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Vorst MV, 2007, J TRAUMA, V62, P199, DOI 10.1097/01.ta.0000238665.09611.4b; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Yoganandan N, 2009, J TRAUMA, V66, P309, DOI 10.1097/TA.0b013e3181692104; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	60	26	29	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2010	27	4					707	719		10.1089/neu.2009.1071			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	584CG	WOS:000276727000005	20039778				2022-02-06	
J	Scheid, R; von Cramon, DY				Scheid, Rainer; von Cramon, D. Yves			Clinical Findings in the Chronic Phase of Traumatic Brain Injury	DEUTSCHES ARZTEBLATT INTERNATIONAL			English	Article							DIFFUSE AXONAL INJURY; BLUNT HEAD-INJURY; FOCAL LESIONS; POSTTRAUMATIC SEIZURES; RISK-FACTORS; EPILEPSY; SEQUELAE; ADULTS; MRI; REHABILITATION	Background: There are many unresolved issues in the diagnosis and treatment of persons with traumatic brain injury (TBI) in its post-acute and chronic phases. This article deals with two problems of clinical importance: (i) the interrelationships between structural brain damage, brain function, and clinical outcome, and (ii) post-traumatic epilepsy. Methods: Exploratory, retrospective analysis of clinical, neuroradiological (MRI), and neuropsychological data of all patients with TBI who were treated in a cognitive neurology outpatient clinic of a German university hospital over a period of 12 years (n=320). Results: 156 patients (48.8%) had brain contusions, 83 of them (25.9%) as the sole neuroradiological abnormality. Traumatic micro-hemorrhages were seen in 148 patients (46.2%) and were the sole neuroradiological abnormality in 79 of them (24.7%). 49 patients (15.3%) had no structural brain lesion. There was no obvious correlation between the neuroradiological findings and the clinical outcome, as measured either by a general outcome parameter such as the extended Glasgow Outcome Scale (GOSE) or by neuropsychological testing. 47 patients (14.7%) had post-traumatic epilepsy; its occurrence was positively correlated with the presence of brain contusions, but not with an isolated diagnosis of diffuse axonal injury (DAI). Conclusion: A comparison of the findings of neuroradiological studies and neuropsychological tests among patients in the chronic phase of traumatic brain injury does not reveal any simple relationship between structural and functional brain abnormalities. Diffuse axonal injury is often present in combination with other findings, and it may well be the only structural abnormality in many cases; therefore, all symptomatic patients should undergo MRI of the brain. Patients with isolated DAI seem to be less prone to post-traumatic epilepsy than those with brain contusions.	[Scheid, Rainer; von Cramon, D. Yves] Max Planck Inst Kognit & Neurowissensch, D-04103 Leipzig, Germany; [Scheid, Rainer; von Cramon, D. Yves] Univ Klinikum, Tagesklin Kognit Neurol, Leipzig, Germany; [von Cramon, D. Yves] Max Planck Inst Neurol Res, D-50931 Cologne, Germany		Scheid, R (corresponding author), Max Planck Inst Kognit & Neurowissensch, Stephanstr 1A, D-04103 Leipzig, Germany.	scheid@cbs.mpg.de					Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bigler ED, 2007, BRAIN INJURY MED PRI, P201; Brodie MJ, 2000, LANCET, V356, P323, DOI 10.1016/S0140-6736(00)02515-0; BROWN AW, 2008, ARCH PHYS MED REH S1, V89; Burgess P, 1996, BEHAV ASSESSMENT DYS; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Delis DC, 1987, CALIFORNIA VERBAL LE; Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140-6736(06)68477-8; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Harting C, 2000, WECHSLER GEDACHTNIS; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; JENNETT B, 1975, EPILEPSY NONMISSILE; Kamikubo Takeshi, 2003, No To Shinkei, V55, P669; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KIRALY M, 2007, THESCIENTIFICWORLDJO, V12, P1768; Koponen S, 2006, PSYCHIAT RES-NEUROIM, V146, P263, DOI 10.1016/j.pscychresns.2005.05.015; Kothari S, 2008, ARCH PHYS MED REHAB, V89, pS27, DOI 10.1016/j.apmr.2007.12.014; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lehrl S., 1991, MEHRFACHWAHL WORTSCH; MCALLISTER TW, 2007, BRAIN INJURY MED PRI, P835; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; RICKELS E, 2006, SCHADEL HIM VERLET Z; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Scheid R, 2006, NEUROLOGIST, V12, P255, DOI 10.1097/01.nrl.0000243977.17242.ab; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Werhahn KJ, 2009, DTSCH ARZTEBL INT, V106, P135, DOI 10.3238/arztebl.2009.0135; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; WOLFRAM H, 1986, PSYCHOL LEISTUNGSTES; YABLON SA, 2007, BRAIN INJURY MED PRI, P835; Zimmermann P., 1993, TESTBATTERIE AUFMERK; 2006, GESUNDHEITSBERICHT D; [No title captured]	49	26	26	1	2	DEUTSCHER AERZTE-VERLAG GMBH	COLOGNE	DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY	1866-0452			DTSCH ARZTEBL INT	Dtsch. Arztebl. Int.	MAR 26	2010	107	12					199	U9		10.3238/arztebl.2010.0199			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575ZJ	WOS:000276112500001	20386669	Green Submitted, Green Published			2022-02-06	
J	Ferguson, A; Duffield, G; Worrall, L				Ferguson, Alison; Duffield, Gemma; Worrall, Linda			Legal decision-making by people with aphasia: critical incidents for speech pathologists	INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS			English	Article						aphasia; speech-language therapy; practice	CLINICAL-PRACTICE; MENTAL-CAPACITY; COMPETENCE	Aims: The research presented in this paper aimed to identify the main issues for speech pathologists when decision-making capacity for legal and related matters arose for their clients with aphasia, and to describe qualitatively the nature of these issues and the practices of the speech pathologists in these situations. Methods: & Procedures: The methodology was informed by the qualitative research paradigm and made use of the semi-structured interview methods developed for the Critical Incident Technique. Nine speech pathologists, with a range of clinical experience between three and 27 years, were interviewed by telephone, with verbatim notes being taken on-line by the interviewer. The speech pathologists described a total of 21 clients (15 male, six female) with acquired neurological communication disorders (including cerebral vascular accident, traumatic brain injury, and tumour) whose care had raised critical incidents for the speech pathologist in relation to legal and related matters. These verbatim notes were qualitatively analysed using NVivo qualitative analysis software. Outcomes & Results: The main incidents related to legal decisions (for example, power of attorney, will-making), as well as decisions involving consent for medical treatment, discharge, accommodation, and business/financial decisions. In all but one of the incidents recounted, the issues centred on a situation of conflict between the person with aphasia and their family, friends or with the multidisciplinary team. The roles taken by the speech pathologists ranged from those expected within a speech pathology scope of practice, such as that of assessor and consultant, to those which arguably present dilemmas and conflict of interest, for example, interpreter, advocate. The assessment practices involved some standardized testing, but this was stressed by all participants to be of lesser importance than informal observations of function. Speech pathologists emphasized the importance of multiple observations, and multimodal means of communication. Conclusions: & Implications: The findings indicate that speech pathologists are currently playing an active role when questions arise regarding capacity for legal and related decision-making by people with aphasia. At the same time, the findings support the need for further research to develop guidelines for practice and to build educational experiences for students and novice clinicians to assist them when they engage with the complex case management issues in this area.	[Ferguson, Alison; Duffield, Gemma] Univ Newcastle, Sch Humanities & Social Sci, Callaghan, NSW 2308, Australia; [Worrall, Linda] Univ Queensland, Sch Speech Pathol & Audiol, St Lucia, Qld, Australia		Ferguson, A (corresponding author), Univ Newcastle, Sch Humanities & Social Sci, 1st Floor,McMullin Bldg, Callaghan, NSW 2308, Australia.	Alison.Ferguson@newcastle.edu.au	Worrall, Linda/D-2579-2010	Worrall, Linda/0000-0002-3283-7038			Bellhouse J, 2001, ADV PSYCHIAT TREATME, V7, P294; BRAZIER M, 1991, PROTECTING VULNERABL, P34; Carney T, 1997, ADULT GUARDIANSHIP E; CARNEY T, 1986, HUMAN RIGHTS COMMISS, V2; Cherry N.L., 2005, HIGH ED RES DEV, V24, P309, DOI [DOI 10.1080/07294360500284649, 10.1080/07294360500284649]; Claremont R., 2005, COLLABORATIVE CONFLI; Collier B., 2005, MENTAL CAPACITY POWE; COOK G, 1985, AM J FORENSIC PSYCH, V3, P10; Critchley M., 1970, APHASIOLOGY, P288; Damico JS, 2003, AM J SPEECH-LANG PAT, V12, P131, DOI 10.1044/1058-0360(2003/060); Davidson B, 2003, APHASIOLOGY, V17, P243, DOI 10.1080/729255457; Denzin N., 2001, QUAL RES, V1, P23, DOI [DOI 10.1177/146879410100100102, 10.1177/146879410100100102]; Elman R. J., 2005, APHASIA RELATED NEUR, P39; Elman RJ, 2000, APHASIOLOGY, V14, P455, DOI 10.1080/026870300401234; Enderby P, 1994, Med Leg J, V62 ( Pt 2), P70; Ferguson A, 2003, APHASIOLOGY, V17, P965, DOI 10.1080/02687030344000337; FERGUSON A, 2008, STROK 2008 C COMB M; FERGUSON A, 2004, 26 WORLD C INT ASS L; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Ganzini Linda, 2004, J Am Med Dir Assoc, V5, P263; Gardner G., 2001, QUALITATIVE RES, V1, P185; Grisso T, 1998, ASSESSMENT DECISION; Hayes S., 2000, HAYES ABILITY SCREEN; Helm-Estabrooks N, 2002, J COMMUN DISORD, V35, P171, DOI 10.1016/S0021-9924(02)00063-1; HERSH D, 2000, RES REFLECT RENEW, P126; Horner Jennifer, 2003, Seminars in Speech and Language, V24, P263; HUER MB, 2006, ASHA LEADER, V6, P28; Kagan A, 1995, CLIN APHASIOL, V23, P65; Keatinge Diana, 2002, Nurs Health Sci, V4, P33, DOI 10.1046/j.1442-2018.2002.00099.x; Kemppainen JK, 2000, J ADV NURS, V32, P1264, DOI 10.1046/j.1365-2648.2000.01597.x; KERRIDGE I, 2005, ETHICS LAW HLTH PROF; Law Society of New South Wales, 2003, LAW SOC J, V41, P50; Morse JM, 1995, QUALITATIVE RES METH; Mullaly E, 2007, AUST PSYCHOL, V42, P178, DOI 10.1080/00050060601187142; Munoz K., 2005, HEALTH EDUC J, V64, P5, DOI [10.1177/001789690506400102, DOI 10.1177/001789690506400102]; Nicholson TRJ, 2008, BRIT MED J, V336, P322, DOI 10.1136/bmj.39457.485347.80; Parry J., 2007, MENTAL DISABILITY LA; Pound C., 2000, APHASIA THERAPIES LI; PRUTTING CA, 1982, J SPEECH HEAR DISORD, V47, P123, DOI 10.1044/jshd.4702.123; Reid D, 2001, DISABIL SOC, V16, P377, DOI 10.1080/09687590120045941; Richards, 2000, NVIVO QUALITATIVE PR; Richards L., 2000, USING NVIVO QUALITAT; Silverman FH., 1992, LEGAL ETHICAL CONSID; Simmons-Mackie N., 2001, LANGUAGE INTERVENTIO, V235, P279; Sinding C, 2003, QUAL RES, V3, P95; SPAR JE, 1992, AM J PSYCHIAT, V149, P169; Strang D., 2000, WHO CAN DECIDE 6 STE; STREET A, 2001, PRACTICE KNOWLEDGE E, P207; Sturges JE., 2004, QUAL RES, V4, P107, DOI [DOI 10.1177/1468794104041110, 10.1177/1468794104041110]; Sullivan K, 2004, NEUROPSYCHOL REV, V14, P131, DOI 10.1023/B:NERV.0000048180.86543.39; UDELL R, 1980, ARCH PHYS MED REHAB, V61, P374; *UK LAW COMM, 1995, 231 UK LAW COMM, V2008; Verma S, 1997, INT J LAW PSYCHIAT, V20, P35, DOI 10.1016/S0160-2527(96)00021-0; Wagner Lynne C. Brady, 2003, Seminars in Speech and Language, V24, P275; WEBSTER EJ, 1982, CLIN APH C P MIN, P64; Wong JG, 1999, PSYCHOL MED, V29, P437, DOI 10.1017/S0033291798008113; WORRALL L, 2007, AM SPEECH LANG HEAR	57	26	26	0	14	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1368-2822			INT J LANG COMM DIS	Int. J. Lang. Commun. Disord.	MAR	2010	45	2					244	258		10.3109/13682820902936714			15	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	560CH	WOS:000274879000009	22748035				2022-02-06	
J	Newsome, MR; Scheibel, RS; Hanten, G; Chu, Z; Steinberg, JL; Hunter, JV; Lu, HZ; Vasquez, AC; Li, XQ; Lin, XD; Cook, L; Levin, HS				Newsome, Mary R.; Scheibel, Randall S.; Hanten, Gerri; Chu, Z.; Steinberg, Joel L.; Hunter, Jill V.; Lu, Hanzhang; Vasquez, Ana C.; Li, Xiaoqi; Lin, Xiaodi; Cook, Lori; Levin, Harvey S.			Brain Activation While Thinking About the Self From Another Person's Perspective After Traumatic Brain Injury in Adolescents	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; fMRI; social cognition; adolescents	CLOSED-HEAD-INJURY; EMOTION RECOGNITION; EXECUTIVE FUNCTION; CHILDREN; MIND; CHILDHOOD; MEMORY; TERM; IMPAIRMENTS; AWARENESS	Deficits in self awareness and taking the perspective of others are often observed following traumatic brain injury (TBI). Nine adolescents (ages 12-19 years) who had sustained moderate to severe TBI after an average interval of 2.6 years and nine typically developing (TD) adolescents underwent functional MRI (fMRI) while performing a perspective taking task (D'Argembeau et al., 2007). Participants made trait attributions either from their own perspective or from that of the significant other. The groups did not differ in reaction time or on a consistency criterion. When thinking of the self from a third-person perspective, adolescents with TBI demonstrated greater activation in posterior brain regions implicated in social cognition, the left lingual gyrus (BA 18) and posterior cingulate (BA 31), extending into neighboring regions not generally associated with social cognition, that is, cuneus (BA 31) and parahippocampal gyros, relative to TD adolescents. We postulate that adolescents with moderate to severe TBI recruited alternative neural pathways during perspective-taking because traumatic axonal injury disrupted their fronto-parietal networks mediating social cognition.	[Newsome, Mary R.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Chu, Z.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Chu, Z.; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Steinberg, Joel L.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX USA; [Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX USA; [Cook, Lori] Univ Texas Dallas, Ctr BrainHlth, Richardson, TX 75083 USA		Newsome, MR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	mnewsome@bcm.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS021889-20, R01 NS021889-28, R01 NS021889-27, R01 NS021889-19, R01 NS021889-21A1S1, R01 NS021889-24, R01 NS021889-24S1, R01 NS021889-21A1, R01 NS021889-22, R01 NS021889, R01 NS021889-26A1, R01 NS021889-17S1, R01 NS021889-18, R01 NS021889-23S1A1, NS021889, R01 NS021889-25, R01 NS021889-17, R01 NS021889-23, R01 NS021889-18S1, R01 NS021889-17S2] Funding Source: Medline		Allen P, 2008, J COGNITIVE NEUROSCI, V20, P1656, DOI 10.1162/jocn.2008.20107; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Bohnert AM, 2007, J ABNORM CHILD PSYCH, V35, P1021, DOI 10.1007/s10802-007-9152-1; BRETT M, 1999, MNI BRAIN TALAIRACH; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; D'Argembeau A, 2005, NEUROIMAGE, V25, P616, DOI 10.1016/j.neuroimage.2004.11.048; D'Argembeau A, 2007, J COGNITIVE NEUROSCI, V19, P935, DOI 10.1162/jocn.2007.19.6.935; DAMON W, 1982, CHILD DEV, V53, P841, DOI 10.1111/j.1467-8624.1982.tb01347.x; Damon W, 1988, SELF UNDERSTANDING C; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Eliassen JC, 2008, EPILEPSY BEHAV, V13, P463, DOI 10.1016/j.yebeh.2008.06.011; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V2, P823; Grizenko N, 2000, AM J ORTHOPSYCHIAT, V70, P501, DOI 10.1037/h0087662; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Haldane M, 2008, J PSYCHOPHARMACOL, V22, P138, DOI 10.1177/0269881107082955; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Leonard B, 2009, NEUROIMAGE, V45, P572, DOI 10.1016/j.neuroimage.2008.11.017; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Macdonald S, 2005, BRAIN INJURY, V19, P895, DOI 10.1080/02699050400004294; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; MUSCARA F, 2008, NEUROPSYCHOLOGICAL R, V1; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parker J., 2006, DEV PSYCHOPATHOL RIS, V2, P419, DOI DOI 10.1002/9780470939383.CH12; Perfetti B, 2009, HUM BRAIN MAPP, V30, P497, DOI 10.1002/hbm.20519; Pfeifer JH, 2007, J COGNITIVE NEUROSCI, V19, P1323, DOI 10.1162/jocn.2007.19.8.1323; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Ruby P, 2004, J COGNITIVE NEUROSCI, V16, P988, DOI 10.1162/0898929041502661; Ruby P, 2001, NAT NEUROSCI, V4, P546, DOI 10.1038/87510; Scarmeas N, 2003, NEUROIMAGE, V19, P1215, DOI 10.1016/S1053-8119(03)00074-0; Schmitz TW, 2007, NEUROSCI BIOBEHAV R, V31, P585, DOI 10.1016/j.neubiorev.2006.12.003; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Wechsler D., 2011, WECHSLER ABBREVIATED; Weiderholt J.L., 2001, GRAY ORAL READING TE, V4th; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WILSON M, 1988, BEHAV RES METH INSTR, V20, P6, DOI 10.3758/BF03202594; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; YEATES KO, 1990, CLIN PSYCHOL REV, V10, P567, DOI 10.1016/0272-7358(90)90097-T	63	26	26	1	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2010	24	2					139	147		10.1037/a0017432			9	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	567XV	WOS:000275483100001	20230107	Green Accepted			2022-02-06	
J	Saval, A; Chiodo, AE				Saval, April; Chiodo, Anthony E.			Intrathecal Baclofen for Spasticity Management: A Comparative Analysis of Spasticity of Spinal vs Cortical Origin	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injuries; Multiple sclerosis; Cerebral palsy; Stroke; Brain injury, traumatic; Baclofen, intrathecal; Botulinum toxin type A; Phenol; Spasticity, cortical, spinal; Intrathecal pump	HYPERTONIA; THERAPY; IMPROVEMENT; TOLERANCE; INFUSION; PUMP	Background/Objective: To examine the differences in intrathecal baclofen management of individuals with spasticity of cortical vs spinal etiologies. Design: Retrospective chart review of 57 individuals with the diagnoses of severe cortical and spinal spasticity requiring an intrathecal baclofen pump. Methods: Parameters evaluated included daily dosage of medication required, flex vs simple continuous delivery modes, dosing changes, need for other local spasticity treatment, and catheter complications. Results: There were no statistically significant differences between individuals with cortical spasticity and spinal spasticity when comparing daily dosage, number of contacts, and mode of delivery. At 6 months, there was a statistically significant difference in dosing between individuals with multiple sclerosis and those without. Within groups, there was a significant difference in average daily dosing over 3 years. A significant difference was found comparing the use of botulinum toxin type A for upper extremity spasticity within the cortical group. Nine individuals had catheter complications. Conclusions: Cortical and spinal spasticity appear to parallel each other with no significant differences in daily dosing, dosing changes, and mode of delivery of intrathecal baclofen. This did not hold true at all time points for the multiple sclerosis subgroup. The significant difference noted within groups for daily dosing over the first 3 years challenges the notion of stable dosing over time. Focal injections of Botox/phenol in the upper extremities are an important adjunct therapy for patients with cortical spasticity, even after the placement of an intrathecal baclofen pump. Our complication rate was slightly lower than that reported in the literature.	[Saval, April; Chiodo, Anthony E.] Univ Michigan, Med Ctr, Dept Phys Med & Rehabil, SCI Program, Ann Arbor, MI 48108 USA		Chiodo, AE (corresponding author), Univ Michigan, Med Ctr, Dept Phys Med & Rehabil, SCI Program, 325 E Eisenhower Pkwy, Ann Arbor, MI 48108 USA.	tchiodo@med.umich.edu					AKMAN MN, 1993, PARAPLEGIA, V31, P516, DOI 10.1038/sc.1993.84; Albright AL, 2003, J NEUROSURG, V98, P291, DOI 10.3171/jns.2003.98.2.0291; Azouvi P, 1996, ARCH PHYS MED REHAB, V77, P35, DOI 10.1016/S0003-9993(96)90217-8; Ben Smail D, 2006, MULT SCLER, V12, P101, DOI 10.1191/1352458506ms1232sr; Boviatsis EJ, 2005, CLIN NEUROL NEUROSUR, V107, P289, DOI 10.1016/j.clineuro.2004.09.007; BROWN P, 1994, J NEUROL NEUROSUR PS, V57, P773, DOI 10.1136/jnnp.57.7.773; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Francisco G E, 2001, Top Stroke Rehabil, V8, P36; Francisco GE, 2005, BRAIN INJURY, V19, P359, DOI 10.1080/02699050400003999; Francisco GE, 2006, TOP STROKE REHABIL, V13, P74, DOI 10.1310/tsr1304-74; Hsieh Joseph C, 2006, Neurosurg Focus, V21, pe5; Ivanhoe CB, 2006, ARCH PHYS MED REHAB, V87, P1509, DOI 10.1016/j.apmr.2006.08.323; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; KNUTSSON E, 1974, J NEUROL SCI, V23, P473, DOI 10.1016/0022-510X(74)90163-4; Korenkov AI, 2002, NEUROSURG REV, V25, P228, DOI 10.1007/s10143-002-0221-1; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; Nielsen JF, 2002, CLIN NEUROL NEUROSUR, V104, P142, DOI 10.1016/S0303-8467(02)00009-4; Ordia JI, 2002, NEUROMODULATION, V5, P16, DOI 10.1046/j.1525-1403.2002._2004.x; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Rawlins Patrice Korth, 2004, J Neurosci Nurs, V36, P322; Ridley B, 2006, REHABIL NURS, V31, P158, DOI 10.1002/j.2048-7940.2006.tb00381.x; Schiess M, 2006, NEUROLOGY, V66, pA324; Vender John R, 2006, Neurosurg Focus, V21, pe6; Wahlquist G I, 1987, Nurse Pract, V12, P27; Zahavi A, 2004, J NEUROL NEUROSUR PS, V75, P1553, DOI 10.1136/jnnp.2003.014282	28	26	28	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	FEB	2010	33	1					16	21		10.1080/10790268.2010.11689670			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	586IP	WOS:000276900700004	20397440	Green Published			2022-02-06	
J	Sivan, M; Neumann, V; Kent, R; Stroud, A; Bhakta, BB				Sivan, Manoj; Neumann, Vera; Kent, Ruth; Stroud, Amanda; Bhakta, Bipinchandra B.			Pharmacotherapy for treatment of attention deficits after non-progressive acquired brain injury. A systematic review	CLINICAL REHABILITATION			English	Article							DOUBLE-BLIND; SUSTAINED ATTENTION; METHYLPHENIDATE TREATMENT; CONTROLLED-TRIAL; PLACEBO; AMANTADINE; NEGLECT; RECOVERY; DONEPEZIL; SYMPTOMS	Objective: To systematically review the effectiveness of medications used to improve attention in people with non-progressive acquired brain injury. Design: A systematic review. Methods: MEDLINE, EMBASE, CINALH, PUBMED and PsychINFO databases were used to identify studies published between 1987 and 2008 meeting the following criteria: studies with subjects older than 18 years; diagnosis of new onset or previous acquired brain injury; medication given to improve attention and use of outcome to measure attention. Studies involving subjects in low arousal states or with neurogenerative conditions were excluded. The studies were categorized into three evidence levels: I - Randomized controlled trials; II - Prospective studies, controlled trials with methodological limitations; and III - Retrospective studies, clinical case series. Results: Forty-seven articles were identified on initial search. Twenty-six met the pre-specified criteria. Five articles were assessed as meeting the level I evidence criteria, 12 were level II studies and 9 were level III studies. Methylphenidate can improve information processing speed but not all attention aspects in some people after traumatic brain injury. There is weak evidence for use of dopamine agonists to improve neglect/inattention after stroke. There is little evidence on the frequency of adverse effects and long-term functional benefits. Conclusion: Although there is lack of robust evidence to recommend the routine use of medication to improve attention after traumatic brain injury and stroke, the existing evidence indicates potential for benefit in some patents and therefore further research is warranted.	[Sivan, Manoj] Univ Leeds, Acad Dept Rehabil Med, Leeds Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; [Sivan, Manoj; Neumann, Vera; Bhakta, Bipinchandra B.] Leeds Teaching Hosp NHS Trust, Dept Rehabil Med, Leeds, W Yorkshire, England; [Kent, Ruth] Mid Yorkshire NHS Trust, Dept Neurol Rehabil, Leeds, W Yorkshire, England; [Stroud, Amanda] Leeds Teaching Hosp NHS Trust, Dept Neuropsychol, Leeds, W Yorkshire, England		Sivan, M (corresponding author), Univ Leeds, Acad Dept Rehabil Med, Leeds Gen Infirm, Level D,Martin Wing, Leeds LS1 3EX, W Yorkshire, England.	M.Sivan@leeds.ac.uk		Sivan, Manoj/0000-0002-0334-2968			Bellgrove MA, 2004, NEUROREPORT, V15, P1065, DOI 10.1097/00001756-200404290-00027; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Buxbaum LJ, 2007, AM J PHYS MED REHAB, V86, P527, DOI 10.1097/PHM.0b013e31806e3392; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; Flanagan SR, 2003, J NEUROL PHYS THER, V3, P129; FLEET WS, 1987, NEUROLOGY, V37, P1765, DOI 10.1212/WNL.37.11.1765; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Hjaltason H, 1996, NEUROPSYCHOLOGIA, V34, P1229, DOI 10.1016/0028-3932(96)00044-9; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Khateb A, 2005, EUR NEUROL, V54, P39, DOI 10.1159/000087718; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Michel J A, 2006, Eura Medicophys, V42, P59; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Mukand JA, 2001, ARCH PHYS MED REHAB, V82, P1279, DOI 10.1053/apmr.2001.25149; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Pierce SR, 2002, ARCH PHYS MED REHAB, V83, P256, DOI 10.1053/apmr.2002.27333; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Posner MI., 2004, COGNITIVE NEUROSCIEN, P71; Raz Amir, 2004, Anatomical Record Part B:The New Anatomist, V281, P21, DOI 10.1002/ar.b.20035; Schneider WN, 1999, BRAIN INJURY, V13, P863; Sohlberg M., 2001, COGNITIVE REHABILITA; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2008, AM J PHYS MED REHAB, V87, P85, DOI 10.1097/PHM.0b013e3181619609; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	36	26	27	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	FEB	2010	24	2					110	121		10.1177/0269215509343234			12	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	548MY	WOS:000273968700002	20103574				2022-02-06	
J	Thaler, S; Fiedorowicz, M; Rejdak, R; Choragiewicz, TJ; Sulejczak, D; Stopa, P; Zarnowski, T; Zrenner, E; Grieb, P; Schuettauf, F				Thaler, Sebastian; Fiedorowicz, Michal; Rejdak, Robert; Choragiewicz, Tomasz J.; Sulejczak, Dorota; Stopa, Piotr; Zarnowski, Tomasz; Zrenner, Eberhart; Grieb, Pawel; Schuettauf, Frank			Neuroprotective effects of tempol on retinal ganglion cells in a partial optic nerve crush rat model with and without iron load	EXPERIMENTAL EYE RESEARCH			English	Article						optic nerve crush; neuroprotection; tempol; oxidative stress; peroxynitrite; superoxide dismutase; retinal ganglion cells	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; NITROXIDE TEMPOL; NITRIC-OXIDE; INDUCED NEUROTOXICITY; INDUCED APOPTOSIS; DEATH; INHIBITION; SURVIVAL; DAMAGE	Iron overload can contribute to oxidative stress in many tissues. We studied the effects of pretreatment with iron dextran on RGC loss in a calibrated partial optic nerve crush (PONC) model in rats, along with the protection offered by tempol (4-hydroxy-2,2,6,6-tetramethylpiperidinyl-1-oxyl, a membrane-permeable superoxide dismutase mimetic and free-radical scavenger), in the same experimental paradigm. A total of 40 rats in 6 groups of 5-8 animals each underwent PONC in one eye and sham crush in the other. Animals were pretreated with a single iron dextran load 24 h prior to PONC, and treated with tempol 6 h before and then once daily after PONC. Control animals were treated with PBS. RGC were retrogradely labeled with a fluorescent marker; all data are expressed in percent of the RGC count in the respective sham-treated eye. Immunohistochemistry was performed to visualize 3-nitrotyrosine, a marker of nitroxidative stress. PONC without iron pretreatment resulted in the survival of only 31.4% of labeled RGC after 7 days. Even fewer RGC (12.7%) survived after PONC with iron pretreatment. However, tempo] in doses of 20 mg/kg of body weight (BW) significantly attenuated this effect when given as described above; in the group without iron pretreatment the number of surviving RGC doubled from 31.4% to 62.1%. In the group with iron pretreatment the survival rate of RGC increased even more pronouncedly, from 12.7% without tempol to 46.2% with tempol. Tempol in doses of I mg/kg BW and 5 mg/kg BW showed no significant rescue of RGC. Immunostaining showed nitrotyrosine-positive RGCs in PONC but not in sham-treated eyes and an increase in positive cells after iron load. Tempol treatment reduced nitrotyrosine staining in both the iron and non-iron groups. Our results demonstrate that PONC results in significantly greater RGC damage when iron pretreatment is performed, and that the compound tempol may provide additional protection for RGC in cases of neuronal damage both with and without prior iron treatment. (C) 2009 Elsevier Ltd. All rights reserved.	[Thaler, Sebastian] Univ Tubingen, Ctr Ophthalmol, Div Expt Ophthalmol, D-72076 Tubingen, Germany; [Fiedorowicz, Michal; Rejdak, Robert; Sulejczak, Dorota; Grieb, Pawel] Polish Acad Sci, Med Res Ctr, Warsaw, Poland; [Rejdak, Robert; Choragiewicz, Tomasz J.; Stopa, Piotr; Zarnowski, Tomasz] Med Univ, Tadeusz Krwawicz Chair Ophthalmol, Lublin, Poland; [Rejdak, Robert; Choragiewicz, Tomasz J.; Stopa, Piotr; Zarnowski, Tomasz] Med Univ, Eye Hosp 1, Lublin, Poland		Thaler, S (corresponding author), Univ Tubingen, Ctr Ophthalmol, Div Expt Ophthalmol, Rontgenweg 11, D-72076 Tubingen, Germany.	sebastian.thaler@uni-tuebingen.de	Fiedorowicz, Michal/O-9779-2019; Zarnowski, Tomasz/AAM-6460-2020; Grieb, Pawel/AAT-8173-2021; Fiedorowicz, Michal/L-1538-2018	Fiedorowicz, Michal/0000-0001-5755-3608; Fiedorowicz, Michal/0000-0001-5755-3608; Zarnowski, Tomasz/0000-0002-6978-7417; Grieb, Pawel/0000-0002-6983-7947; Sulejczak, Dorota/0000-0002-1697-8164	EVI-GENORETEuropean Commission [LSHG-Cr2005-512036]	Supported by the integrated project EVI-GENORET (LSHG-Cr2005-512036). The authors thank Francois Paquet-Durand for valuable comments and Sylvia Bolz and Sandra Bernhard-Kurz for excellent technical assistance. M. Fiedorowicz and T. Choragiewicz received support from the Kerstan Foundation in the form of a research fellowship.	Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; BarPeled O, 1996, P NATL ACAD SCI USA, V93, P8530, DOI 10.1073/pnas.93.16.8530; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Bostanci MO, 2008, NEUROTOXICOLOGY, V29, P130, DOI 10.1016/j.neuro.2007.10.003; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Davalos A, 2000, NEUROLOGY, V54, P1568, DOI 10.1212/WNL.54.8.1568; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Farkas RH, 2004, INVEST OPHTH VIS SCI, V45, P1410, DOI 10.1167/iovs.03-0872; Gariboldi MB, 2006, FREE RADICAL BIO MED, V40, P1409, DOI 10.1016/j.freeradbiomed.2005.12.011; Geiger LK, 2002, NEUROSCIENCE, V109, P635, DOI 10.1016/S0306-4522(01)00493-6; Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776; He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004; Ke Y, 2003, LANCET NEUROL, V2, P246, DOI 10.1016/S1474-4422(03)00353-3; Kikuchi M, 2000, J NEUROSCI, V20, P5037; Koeberle PD, 1999, EXP NEUROL, V158, P366, DOI 10.1006/exnr.1999.7113; Levkovitch-Verbin H, 2000, INVEST OPHTH VIS SCI, V41, P4169; Lipman T, 2006, EUR J PHARMACOL, V549, P50, DOI 10.1016/j.ejphar.2006.08.022; Liu Q, 2007, INVEST OPHTH VIS SCI, V48, P4580, DOI 10.1167/iovs.07-0170; Maher P, 2005, INVEST OPHTH VIS SCI, V46, P749, DOI 10.1167/iovs.04-0883; Manabe S, 2003, INVEST OPHTH VIS SCI, V44, P385, DOI 10.1167/iovs.02-0187; Martin LJ, 2003, J NEUROCHEM, V85, P234, DOI 10.1046/j.1471-4159.2003.01659.x; MEHLHORN RJ, 1992, FREE RADICAL RES COM, V17, P157, DOI 10.3109/10715769209068163; Mehta SH, 2004, AM J PHYSIOL-REG I, V286, pR283, DOI 10.1152/ajpregu.00446.2002; Millan M, 2007, STROKE, V38, P90, DOI 10.1161/01.STR.0000251798.25803.e0; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; Monti E, 2001, J CELL BIOCHEM, V82, P271, DOI 10.1002/jcb.1160; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; Ravizza R, 2004, INT J ONCOL, V25, P1817; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Samuni AM, 2003, P NATL ACAD SCI USA, V100, P5390, DOI 10.1073/pnas.0930078100; Schuettauf F, 2000, INVEST OPHTH VIS SCI, V41, P4313; Schuettauf F, 2005, GRAEF ARCH CLIN EXP, V243, P1036, DOI 10.1007/s00417-005-1152-7; Schuettauf F, 2002, VISION RES, V42, P2333, DOI 10.1016/S0042-6989(02)00188-8; Schuettauf F, 2006, EXP EYE RES, V83, P1128, DOI 10.1016/j.exer.2006.05.021; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Souza JM, 2008, FREE RADICAL BIO MED, V45, P357, DOI 10.1016/j.freeradbiomed.2008.04.010; Swanson KI, 2005, INVEST OPHTH VIS SCI, V46, P3737, DOI 10.1167/iovs.05-0155; Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1864, DOI 10.1167/iovs.06-1065; Tezel G, 2004, INVEST OPHTH VIS SCI, V45, P4049, DOI 10.1167/iovs.04-0490; Thaler S, 2006, MOL VIS, V12, P100; Vaz SM, 2008, P NATL ACAD SCI USA, V105, P8191, DOI 10.1073/pnas.0708211105; Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Zhou XJ, 2000, LAB INVEST, V80, P1905, DOI 10.1038/labinvest.3780200	48	26	27	0	4	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0014-4835	1096-0007		EXP EYE RES	Exp. Eye Res.	FEB	2010	90	2					254	260		10.1016/j.exer.2009.10.013			7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	557AG	WOS:000274639100010	19883642				2022-02-06	
J	Hart, T; Dijkers, M; Whyte, J; Braden, C; Trott, CT; Fraser, R				Hart, Tessa; Dijkers, Marcel; Whyte, John; Braden, Cynthia; Trott, Charlotte; Fraser, Robert			Vocational interventions and supports following job placement for persons with traumatic brain injury	JOURNAL OF VOCATIONAL REHABILITATION			English	Article						Traumatic brain injury; vocational rehabilitation; treatment definition	TREATMENT DEFINITION; MODEL SYSTEMS; REHABILITATION; EMPLOYMENT; WORK; RETURN; INDIVIDUALS; SATISFACTION; POPULATION; DISABILITY	Previous research on vocational rehabilitation after traumatic brain injury (TBI) has suggested that coaching and other services provided following job placement are particularly important for successful work re-entry in this population. Methods of defining and measuring these services are needed to estimate more precisely their effects on vocational outcomes. In this study we developed a measure of the type, amount, and location of post-placement interventions that could be completed by treaters in "real time". Treatment was measured prospectively for 6 months after job placement for 65 people with moderate to severe TBI treated at 5 TBI Model System centers. Centers were found to differ substantially in the amount and location of treatment provided following job placement; centers providing more intensive treatment and treatment at the workplace also served more severely impaired clients at a longer interval after injury. Within centers, participants' cognitive speed and emotional distress predicted certain aspects of amount and type of treatment provided. Three-fourths of the sample were still working at the placement job after 6 months. Due to the confounding between case mix and treatment variables, unique effects of treatments on outcomes could not be determined.	[Hart, Tessa; Whyte, John] Moss Rehabil Res Inst, 60 Township Line Rd,2nd Floor West, Elkins Pk, PA 19027 USA; [Dijkers, Marcel] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Braden, Cynthia] Craig Hosp, Dept Res, Englewood, CO 80113 USA; [Trott, Charlotte] JFK Johnson Rehabil Inst, Dept Cognit Rehabil, Edison, NJ 08820 USA; [Fraser, Robert] Univ Washington, Sch Med, Dept Rehabil Med, Dept Neurol & Neurol Surg, Seattle, WA 98195 USA		Hart, T (corresponding author), Moss Rehabil Res Inst, 60 Township Line Rd,2nd Floor West, Elkins Pk, PA 19027 USA.	thart@einstein.edu		Dijkers, Marcel/0000-0002-8362-5596; Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133A020505, H133A070040, H133A020501, H133A020508, H133A020518, H133A070033]	This work was supported by Grants #H133A020505, H133A070040, H133A020501, H133A020508, H133A020518, and H133A070033 from the National Institute on Disability and Rehabilitation Research, U.S. Department of Education. We thank Caron Morita, Rebecca Hardin, Aaron Scrol, Joyce Leverenz, Eileen McLaughlin, Clare Morey, Rosanne Sevinsky, Jean Tyler, Jennifer Cotter, and the staff of the TBI Model System National Data and Statistical Center for assistance in data collection and management. Mark Sherer, Mark Hirsch, and Eugene Komaroff provided helpful input at various stages of project and manuscript development. Megan Bartlett assisted with manuscript preparation.	BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Delis D.C., 2000, CALIFORNIA VERBAL LE; Derogatis L.R., 2000, BRIEF SYMPTOM INVENT; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Fadyl JK, 2009, J HEAD TRAUMA REHAB, V24, P195, DOI 10.1097/HTR.0b013e3181a0d458; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P467, DOI 10.1097/00001199-200611000-00002; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Malec JF, 2005, REHABILITATION TRAUM, P176; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Smith A., 1991, SYMBOL DIGIT MODALIT; Spector P.E., 1994, JOB SATISFACTION SUR; SykesHorn W, 1997, ARCH PHYS MED REHAB, V78, P1327, DOI 10.1016/S0003-9993(97)90305-1; Vaccaro M, 2007, DISABIL REHABIL-ASSI, V2, P85, DOI 10.1080/17483100601167586; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Wehman P, 1999, REHABILITATION ADULT, P326; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Whyte J., 2004, REHABILITATION MED P, P1677; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson K, 2004, DISABIL REHABIL, V26, P145, DOI 10.1080/09638280310001636428; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	43	26	26	0	0	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1052-2263	1878-6316		J VOCAT REHABIL	J. Vocat. Rehabil.		2010	32	3					135	150		10.3233/JVR-2010-0505			16	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V71YQ	WOS:000211609900001					2022-02-06	
J	Jersey, SL; Baril, RT; McCarty, RD; Millhouse, CM				Jersey, Sean L.; Baril, Robert T.; McCarty, Richmond D.; Millhouse, Christina M.			Severe Neurological Decompression Sickness in a U-2 Pilot	AVIATION SPACE AND ENVIRONMENTAL MEDICINE			English	Article						U-2; case report; altitude; decompression sickness; neurological symptoms; traumatic brain injury; magnetic resonance imaging	PREVALENCE; LESIONS	Severe neurological decompression sickness (DCS) has been a rare entity in the U.S. Air Force, including the U-2 community. In over 50 yr of operation, few U-2 pilots reported severe neurological DCS in flight despite the extreme altitudes at which they operate. This article describes a near-fatal case of neurological DCS that occurred during a combat mission. The injury left the pilot with permanent cognitive deficits that correlated with focal lesions present on magnetic resonance imaging of his brain. To our knowledge, the images presented herein are the first to show radiological evidence of brain injury induced by altitude DCS. Though only a single case, the objective and clinical findings in the case pilot are similar to results documented in divers suffering DCS with central nervous system injury and victims of traumatic brain injury. DCS will remain a potentially serious threat to current and future air and space operations.	[Jersey, Sean L.; Millhouse, Christina M.] 99th Reconnaissance Squadron, Beale AFB, CA USA; [Baril, Robert T.] USAF, David Grant Med Ctr, Radiol Residence Program, Travis AFB, CA USA; [McCarty, Richmond D.] N Mississippi Med Ctr, Family Med Residency Program, Tupelo, MS USA		Jersey, SL (corresponding author), 9th AMDS SGOAF, 15301 Warren Shingle Rd, Beale AFB, CA 95903 USA.	sean.jersey@beale.af.mil					Balldin UI, 2004, AVIAT SPACE ENVIR MD, V75, P969; Bendrick GA, 1996, AVIAT SPACE ENVIR MD, V67, P199; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Erdem I, 2009, AVIAT SPACE ENVIR MD, V80, P2, DOI 10.3357/ASEM.2234.2009; Gronning M, 2005, UNDERSEA HYPERBAR M, V32, P397; Koch AE, 2008, UNDERSEA HYPERBAR M, V35, P197; Krause KM, 2000, AVIAT SPACE ENVIR MD, V71, P115; Moon RE, 1997, AVIAT SPACE ENVIR MD, V68, P234; Pickard BJ, 2003, AVIAT SPACE ENVIR MD, V74, P357; Pilmanis AA, 2004, AVIAT SPACE ENVIR MD, V75, P749; Ryles MT, 1996, AVIAT SPACE ENVIR MD, V67, P983; Webb JT, 2005, AVIAT SPACE ENVIR MD, V76, P547; WEIEN RW, 1990, AVIAT SPACE ENVIR MD, V61, P833; WIRJOSEMITO SA, 1989, AVIAT SPACE ENVIR MD, V60, P256	14	26	29	2	4	AEROSPACE MEDICAL ASSOC	ALEXANDRIA	320 S HENRY ST, ALEXANDRIA, VA 22314-3579 USA	0095-6562			AVIAT SPACE ENVIR MD	Aviat. Space Environ. Med.	JAN	2010	81	1					64	68		10.3357/ASEM.2303.2010			5	Public, Environmental & Occupational Health; Medicine, General & Internal; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; General & Internal Medicine; Sport Sciences	539QB	WOS:000273270900011	20058739				2022-02-06	
J	Lew, HL; Amick, MM; Kraft, M; Stein, MB; Cifu, DX				Lew, Henry L.; Amick, Melissa M.; Kraft, Malissa; Stein, Murray B.; Cifu, David X.			Potential driving issues in combat returnees	NEUROREHABILITATION			English	Article						Traumatic brain injury; post traumatic stress disorder; motor vehicle crashes; deployment; evasive driving skills; veterans	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSIAN-GULF-WAR; NEUROCOGNITIVE PERFORMANCE; POSTCONCUSSIVE SYMPTOMS; US VETERANS; CONCUSSION; IRAQ; MORTALITY; SOLDIERS	The driving abilities of service members returning from Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) have not been well reported and are an important aspect of their return to normal life. This article reviews the unique risk factors for unsafe driving in this cohort. In particular, the cognitive and psychological symptoms of mild traumatic brain injury and postraumatic stress disorder, two of the most common diagnoses affecting these returning warriors, are specified, and their possible association with impaired driving is examined. The potential negative impact of the "battlemind driving tactics" (i.e., evasive driving skills) acquired by these service members as part of their military tours is also highlighted. The article concludes with comments about the functional consequences of impaired driving in this population, including limits to participation in rehabilitation and community reintegration, as well as recognition of the need for further research in this area.	[Lew, Henry L.] VA Boston Hlth Care Syst, PM& R Serv, Polytrauma & TBI Res Ctr, Boston, MA 02130 USA; [Lew, Henry L.] DVBIC, Richmond, VA USA; [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; [Stein, Murray B.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Cifu, David X.] Hunter Holmes McGuire VA Healthcare Syst, PM&R Serv, Richmond, VA USA		Lew, HL (corresponding author), VA Boston Hlth Care Syst, PM& R Serv, Polytrauma & TBI Res Ctr, 150 S Huntington Ave, Boston, MA 02130 USA.	Henry.Lew@VA.gov		Cifu, David/0000-0003-1600-9387			*AM PSYCH ASS, 2000, DIAGN MAN PSYCH DIS; Amick MM, 2007, ARCH CLIN NEUROPSYCH, V22, P957, DOI 10.1016/j.acn.2007.07.004; [Anonymous], 1987, JAMA, V257, P790; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bell NS, 2000, MIL MED, V165, P762; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; *DEP VET AFF, 2008, DEADL TOLL POSTD CAR; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fear NT, 2008, AM J PREV MED, V35, P230, DOI 10.1016/j.amepre.2008.05.027; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hooper TI, 2005, AM J IND MED, V48, P118, DOI 10.1002/ajim.20190; JONES BH, 1999, MILITARY MED S, V164; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; Kang HK, 2001, AM J EPIDEMIOL, V154, P399, DOI 10.1093/aje/154.5.399; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Krull MAR, 2004, MIL MED, V169, P926, DOI 10.7205/MILMED.169.11.926; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P963, DOI 10.1682/JRRD.2006.12.0169; Lew HL, 2009, J HEAD TRAUMA REHAB, V24, P51, DOI 10.1097/HTR.0b013e3181956fe3; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lincoln Andrew E, 2006, Traffic Inj Prev, V7, P31, DOI 10.1080/15389580500412028; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ott BR, 2008, NEUROLOGY, V70, P1171, DOI 10.1212/01.wnl.0000294469.27156.30; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; *PDHRA, 2006, BATTL TRAIN CONT TRA; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; Sivak M, 1996, J SAFETY RES, V27, P225, DOI 10.1016/S0022-4375(96)00027-8; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tavris DR, 2001, ACCIDENT ANAL PREV, V33, P167, DOI 10.1016/S0001-4575(00)00027-0; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Uc EY, 2008, CURR NEUROL NEUROSCI, V8, P377, DOI 10.1007/s11910-008-0059-1; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	50	26	26	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	26	3					271	278		10.3233/NRE-2010-0562			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	603OQ	WOS:000278218300010	20448316				2022-02-06	
J	Riley, GA; Dennis, RK; Powell, T				Riley, Gerard A.; Dennis, Rebecca K.; Powell, Theresa			Evaluation of coping resources and self-esteem as moderators of the relationship between threat appraisals and avoidance of activities after traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Threat; Avoidance; Self-esteem; Coping behaviour	PANIC DISORDER; PROTECTION; EFFICACY; STRESS	It is not uncommon for people after a traumatic brain injury (TBI) to develop anxieties about possible negative outcomes (i.e., threat appraisals) in relation to participating in valued activities. Some respond to this anxiety by avoiding the activities, but others maintain their participation. The present study investigated two factors that may help explain this variation across individuals in their response to threat appraisals - self-esteem and the evaluation of coping resources. Forty-one individuals with a TBI completed the Avoidance and Threat Appraisals Questionnaire, the Rosenberg Self-Esteem Scale and the Coping Resources Questionnaire. The study's hypotheses were supported: Those low in self-esteem, and those with a negative evaluation of their ability to cope with the TBI, were significantly more likely to respond to threat appraisals with avoidance. Those whose injury was more recent and those whose injury was the result of an assault were also more likely to respond with avoidance. The theoretical and therapeutic implications of these results are discussed.	[Riley, Gerard A.; Dennis, Rebecca K.; Powell, Theresa] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England		Riley, GA (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.	G.A.Riley@bham.ac.uk	Riley, Gerard/A-4328-2008; Riley, Gerard Anthony/J-1646-2012; riley, gerard/AAP-1439-2020	Riley, Gerard Anthony/0000-0002-1167-8023; Powell, Theresa/0000-0002-3351-9453			American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bandura A., 1997, SELF EFFICACY EXERCI; BAUMEISTER RF, 1989, J PERS, V57, P547, DOI 10.1111/j.1467-6494.1989.tb02384.x; Beck A., 1985, ANXIETY DISORDERS PH; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Casey LM, 2004, CLIN PSYCHOL REV, V24, P529, DOI 10.1016/j.cpr.2004.01.005; Casey LM, 2004, J ANXIETY DISORD, V18, P325, DOI 10.1016/S0887-6185(02)00257-8; CLARK DM, 1986, BEHAV RES THER, V24, P461, DOI 10.1016/0005-7967(86)90011-2; Cooper-Evans S, 2008, NEUROPSYCHOL REHABIL, V18, P607, DOI 10.1080/09602010801948516; Ellis-Hill CS, 2000, CLIN REHABIL, V14, P279, DOI 10.1191/026921500671231410; Fidell L.S., 2001, USING MULTIVARIATE S; FOLKMAN S, 1984, J PERS SOC PSYCHOL, V46, P839, DOI 10.1037/0022-3514.46.4.839; Folkman S., 1984, STRESS; Goldstein K, 1942, EFFECTS BRAIN INJURY; Heimpel SA, 2006, J PERS, V74, P1293, DOI 10.1111/j.1467-6494.2006.00410.x; HIBBARD MR, 2007, COGNTIVE BEHAV STRAT, P151; HODGSON J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAVETZ S, 1995, BRAIN INJURY, V9, P131, DOI 10.3109/02699059509008186; Lazarus R.S., 1999, STRESS EMOTION NEW S; Leary MR, 2003, HANDBOOK OF SELF AND IDENTITY, P401; Man DWK, 2003, BRAIN INJURY, V17, P775, DOI 10.1080/0269905031000088577; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Riley GA, 2004, BRAIN INJURY, V18, P871, DOI 10.1080/02699050410001671829; TICE DM, 1991, J PERS SOC PSYCHOL, V60, P711, DOI 10.1037/0022-3514.60.5.711; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Vickery CD, 2008, REHABIL PSYCHOL, V53, P101, DOI 10.1037/0090-5550.53.1.101; White KS, 2006, BEHAV RES THER, V44, P147, DOI 10.1016/j.brat.2005.07.009; WOOD JV, 1994, J PERS SOC PSYCHOL, V67, P713, DOI 10.1037/0022-3514.67.4.713; Wright S., 1995, MEASURES HLTH PSYCHO	36	26	26	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	6					869	882	PII 924820493	10.1080/09602011.2010.503041			14	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	684GB	WOS:000284537300005	20665337				2022-02-06	
J	Rohling, ML; Demakis, GJ				Rohling, Martin L.; Demakis, George J.			Bowden, shores, mathias (2006): failure to replicate or just failure to notice. Does effort still account for more variance in neuropsychological test scores than tbi severity?	CLINICAL NEUROPSYCHOLOGIST			English	Article						Word Memory test; Symptom validity tests; Neuropsychological assessment; Traumatic brain injury; Suboptimal effort	TRAUMATIC BRAIN-INJURY; WORD MEMORY TEST; HEAD-INJURY; PERFORMANCE; CLAIMANTS	Several studies have reported that traumatic brain injury (TBI) has a smaller effect on neuropsychological test scores, in contrast to the large effect of poor effort on test performance. Consequently, many authors have concluded that effort needs to be measured routinely and that it is necessary to control for poor effort when measuring the effects of brain disease or injury on performance. Recently, however, Bowden, Shores, and Mathias (2006) have challenged these notions. They argued that the Immediate Recognition subtest of the Word Memory Test (Green Flaro, 2003), an effort measure, is another verbal memory test rather than a measure of cognitive effort. In this study we re-examine the data from Bowden et al. (2006) and Green, Rohling, Lees-Haley, and Allen (2001) to identify differences between the two studies that might account for their contradictory conclusions. In both sets of data, reanalysis showed that effort explains approximately five times more of the variance in composite neuropsychological test scores than TBI severity. Importantly, scores on the Word Memory Test-Immediate Recognition (WMT-IR) were not correlated with measures of TBI severity, and were not found to correlate with major variables known to be measuring ability (e.g., years of education). These findings challenge the conclusions offered by Bowden and colleagues (2006).	[Rohling, Martin L.] Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA; [Demakis, George J.] Univ N Carolina, Charlotte, NC 28223 USA		Rohling, ML (corresponding author), Univ S Alabama, Dept Psychol, 331 Life Sci Bldg, Mobile, AL 36688 USA.	mrohling@usouthal.edu					Allen L., 1997, CARB 97 MANUAL COMPU; Bianchini KJ, 2003, CLIN NEUROPSYCHOL, V17, P574, DOI 10.1076/clin.17.4.574.27946; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Carless SA, 2000, EDUC PSYCHOL MEAS, V60, P592, DOI 10.1177/00131640021970745; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97; GREEN P, 2003, STORY RECALL TEST; Green P., 2003, WORD MEMORY TEST MAN; Heaton R. K., 2004, REVISED COMPREHENSIV; Jackson D.N., 1998, MULTIDIMENSIONAL APT; Meyers JE., 1995, REY COMPLEX FIGURE T; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MILLIS SR, 1999, WORKSH S MILL UNPUB; PANIAK C, 2008, NEUROPSYCHOLOGY MALI, P101; Rohling Martin L, 2002, CNS Spectr, V7, P387; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Shores EA, 2000, AUST PSYCHOL, V35, P41, DOI 10.1080/00050060008257467; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	29	26	26	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	1					119	136	PII 918004709	10.1080/13854040903307243			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535MK	WOS:000272972300010	20029718				2022-02-06	
J	Salisbury, E; Sonnet, C; Heggeness, M; Davis, AR; Olmsted-Davis, E				Salisbury, Elizabeth; Sonnet, Corinne; Heggeness, Michael; Davis, Alan R.; Olmsted-Davis, Elizabeth			Heterotopic Ossification Has Some Nerve	CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION			English	Article						heterotopic ossification; peripheral nervous system; BMP2; neurogenic inflammation; sensory; sympathetic	GENE-RELATED PEPTIDE; BONE MORPHOGENETIC PROTEINS; MATRIX GLA PROTEIN; VANILLOID RECEPTOR TRPV1; SMOOTH-MUSCLE-CELLS; SUBSTANCE-P; STEM-CELLS; IN-VITRO; VASCULAR CALCIFICATION; OSTEOBLAST PRECURSORS	Heterotopic ossification, defined as the formation of bone in abnormal anatomic locations, can be clinically insignificant or devastating and debilitating, depending on the site and duration of new bone formation. There are many causes of heterotopic ossification (HO), including soft tissue trauma, central nervous system injury, vasculopathies, arthropathies, and inheritance. One of the least understood components of HO is the interaction of the peripheral nervous system with the induction of this process. Recent work has shown that, upon traumatic injury, a cascade of events termed neurogenic inflammation is initiated, which involves the release of neuropeptides, such as substance P and calcitonin gene related peptide. Release of these peptides ultimately leads to the recruitment of activated platelets, mast cells, and neutrophils to the injury site. These cells appear to be involved with both remodeling of the nerve, as well as potentially recruiting additional cells from the bone marrow to the injury site. Further, sensory neurons stimulated at the injury site relay local information to the brain, which can then redirect neuroendocrine signaling in the hypothalamus towards repair of the injured site. While numerous studies have highlighted the important role of nerve-derived signals, both central and peripheral, in the regulation of normal bone remodeling of the skeleton,(1) this review focuses on the role of the local, peripheral nerves in the formation of heterotopic bone. We concentrate on the manner in which local changes in bone morphogenetic protein (BMP) expression contribute to a cascade of events within the peripheral nerves, both sensory and sympathetic, in the immediate area of HO formation.	[Salisbury, Elizabeth; Sonnet, Corinne; Davis, Alan R.; Olmsted-Davis, Elizabeth] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Heggeness, Michael; Davis, Alan R.; Olmsted-Davis, Elizabeth] Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA; [Davis, Alan R.; Olmsted-Davis, Elizabeth] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA		Olmsted-Davis, E (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 1 Baylor Plaza,BCM505, Houston, TX 77030 USA.	edavis@bcm.edu		Olmsted-Davis, Elizabeth/0000-0001-9457-1848; Salisbury, Elizabeth/0000-0003-3607-2367	Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [W911NF-09-1-0040)]; Department of DefenseUnited States Department of Defense [W81XWH-07-0281, W81XWH-07-1-0214, W81XWH-08-1-0489, W81XWH-07-1-025]; National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [NIH RO1EB005173-01]; Kirschtein-National Research Service Award [T-32 HL092332-08]; American Heart AssociationAmerican Heart Association [AHA 10815339F]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL096360, T32HL092332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB005173] Funding Source: NIH RePORTER	We thank the following agencies for their support: Defense Advanced Research Projects Agency (W911NF-09-1-0040), Department of Defense (W81XWH-07-0281, W81XWH-07-1-0214, W81XWH-08-1-0489, W81XWH-07-1-025), the National Institute of Biomedical Imaging and Bioengineering (NIH RO1EB005173-01), the Kirschtein-National Research Service Award (T-32 HL092332-08), and the American Heart Association (AHA 10815339F).	ADARNEYKO I, 2009, CELL, V139, P366; AOKI M, 1994, INT ORTHOP, V18, P317; Apel PJ, 2009, J BONE JOINT SURG AM, V91A, P2886, DOI 10.2106/JBJS.H.01878; ARO H, 1985, CLIN ORTHOP RELAT R, P292; ARO H, 1985, ACTA ORTHOP SCAND, V56, P233, DOI 10.3109/17453678508993002; Azzolina A, 2003, BBA-MOL CELL RES, V1643, P75, DOI 10.1016/j.bbamcr.2003.09.003; Beiner JM, 2002, CLIN ORTHOP RELAT R, pS110, DOI 10.1097/01.blo.0000037969.69509.2c; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blasius AL, 2009, P NATL ACAD SCI USA, V106, P2706, DOI 10.1073/pnas.0813208106; Bobryshev YV, 2005, J PATHOL, V205, P641, DOI 10.1002/path.1743; Bournat Juan C, 2010, Curr Opin Endocrinol Diabetes Obes, V17, P446, DOI 10.1097/MED.0b013e32833c3026; Bucelli RC, 2008, J PHARMACOL EXP THER, V324, P1172, DOI 10.1124/jpet.107.132795; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Clever JL, 2010, AM J PHYSIOL-CELL PH, V298, pC1087, DOI 10.1152/ajpcell.00388.2009; Dilling CF, 2010, J BONE MINER RES, V25, P1147, DOI 10.1359/jbmr.091031; Dominici M, 2004, P NATL ACAD SCI USA, V101, P11761, DOI 10.1073/pnas.0404626101; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 2010, J CELL BIOL, V191, P7, DOI 10.1083/jcb.201006123; El-Maadawy S, 2003, CONNECT TISSUE RES, V44, P272, DOI 10.1080/03008200390181762; Elefteriou F, 2005, CELL MOL LIFE SCI, V62, P2339, DOI 10.1007/s00018-005-5175-3; FANN MJ, 1994, J NEUROCHEM, V63, P2074; Flanagan Thomas C., 2003, European Cells & Materials, V6, P28; Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792; Fouletier-Dilling CM, 2007, HUM GENE THER, V18, P733, DOI 10.1089/hum.2006.190; Gannon FH, 2001, HUM PATHOL, V32, P842, DOI 10.1053/hupa.2001.26464; Geppetti P., 1996, NEUROGENIC INFLAMMAT; Goolsby J, 2003, P NATL ACAD SCI USA, V100, P14926, DOI 10.1073/pnas.2434383100; Graham GJ, 2004, BLOOD, V104, P1058, DOI 10.1182/blood-2003-11-3979; Hruska KA, 2005, CIRC RES, V97, P105, DOI 10.1161/01.RES.00000175571.53833.6c; Hwang SJ, 2005, BRAIN RES, V1047, P261, DOI 10.1016/j.brainres.2005.04.036; JOHNSON D, 1988, BRAIN RES, V444, P195, DOI 10.1016/0006-8993(88)90929-8; Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041; Khairatkar-Joshi N, 2009, TRENDS MOL MED, V15, P14, DOI 10.1016/j.molmed.2008.11.004; Kitterman JA, 2005, PEDIATRICS, V116, pE654, DOI 10.1542/peds.2005-0469; Kleij Hanneke Pm van der, 2005, Allergy Asthma Clin Immunol, V1, P65, DOI 10.1186/1710-1492-1-2-65; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; Li L, 2007, J ORTHOP RES, V25, P1204, DOI 10.1002/jor.20406; Li JA, 2010, J ORTHOP RES, V28, P1643, DOI 10.1002/jor.21169; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010; Mendez-Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685; Mendez-Ferrer S, 2010, ANN NY ACAD SCI, V1192, P139, DOI 10.1111/j.1749-6632.2010.05390.x; Morikawa Y, 2009, DEVELOPMENT, V136, P3575, DOI 10.1242/dev.038133; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; NORDSLETTEN L, 1994, ACTA ORTHOP SCAND, V65, P299, DOI 10.3109/17453679408995457; Offley SC, 2005, J BONE MINER RES, V20, P257, DOI 10.1359/JBMR.041108; Olmsted-Davis EA, 2003, P NATL ACAD SCI USA, V100, P15877, DOI 10.1073/pnas.2632959100; Olmsted-Davis EA, 2002, HUM GENE THER, V13, P1337, DOI 10.1089/104303402760128568; Olmsted-Davis E, 2007, AM J PATHOL, V170, P620, DOI 10.2353/ajpath.2007.060692; Onuoha GN, 2001, PEPTIDES, V22, P1107, DOI 10.1016/S0196-9781(01)00434-X; Parrinello S, 2010, CELL, V143, P145, DOI 10.1016/j.cell.2010.08.039; Richardson JD, 2002, J PHARMACOL EXP THER, V302, P839, DOI 10.1124/jpet.102.032797; Ringvall M, 2008, J ALLERGY CLIN IMMUN, V121, P1020, DOI 10.1016/j.jaci.2007.11.031; Salari Sharif P., 2010, INFLAMM ALLERGY 0603; Schaible HG, 2005, RHEUM DIS CLIN N AM, V31, P77, DOI 10.1016/j.rdc.2004.09.004; Schneider C, 1999, NEURON, V24, P861, DOI 10.1016/S0896-6273(00)81033-8; Shafer J, 2007, TISSUE ENG, V13, P2011, DOI 10.1089/ten.2006.0063; Shah AJ, 1996, BLOOD, V87, P3563, DOI 10.1182/blood.V87.9.3563.bloodjournal8793563; Shih C, 1997, CLIN ORTHOP RELAT R, P335; Shih C, 1997, PEPTIDES, V18, P323, DOI 10.1016/S0196-9781(96)00280-X; Shih CC, 2001, BLOOD, V98, P2412, DOI 10.1182/blood.V98.8.2412; Shore EM, 2010, NAT REV RHEUMATOL, V6, P518, DOI 10.1038/nrrheum.2010.122; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Speer MY, 2009, CIRC RES, V104, P733, DOI 10.1161/CIRCRESAHA.108.183053; Starinsky-Elbaz S, 2009, MOL CELL NEUROSCI, V42, P278, DOI 10.1016/j.mcn.2009.07.014; Sucosky P, 2009, ARTERIOSCL THROM VAS, V29, P254, DOI 10.1161/ATVBAHA.108.176347; Sviderskaya EV, 1998, GENETICS, V148, P381; Szallasi A, 2007, NAT REV DRUG DISCOV, V6, P357, DOI 10.1038/nrd2280; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Takeda S, 2008, BONE, V42, P837, DOI 10.1016/j.bone.2008.01.005; Tsujii M, 2009, CLIN ORTHOP RELAT R, V467, P3183, DOI 10.1007/s11999-009-1009-1; Turner CH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.268pt3; WALLENGREN J, 1987, EUR J PHARMACOL, V143, P267, DOI 10.1016/0014-2999(87)90542-5; Yao Y, 2007, J BIOL CHEM, V282, P30131, DOI 10.1074/jbc.M704297200; Yao YC, 2010, CIRC RES, V107, P485, DOI 10.1161/CIRCRESAHA.110.219071	76	26	28	0	5	BEGELL HOUSE INC	DANBURY	50 NORTH ST, DANBURY, CT 06810 USA	1045-4403	2162-6502		CRIT REV EUKAR GENE	Crit. Rev. Eukaryot. Gene Expr.		2010	20	4					313	324		10.1615/CritRevEukarGeneExpr.v20.i4.30			12	Biotechnology & Applied Microbiology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity	737OJ	WOS:000288577800003	21395504	Green Accepted			2022-02-06	
J	Snell, DL; Siegert, RJ; Hay-Smith, EJC; Surgenor, LJ				Snell, Deborah L.; Siegert, Richard J.; Hay-Smith, E. Jean C.; Surgenor, Lois J.			An examination of the factor structure of the Revised Illness Perception Questionnaire modified for adults with mild traumatic brain injury	BRAIN INJURY			English	Article						Mild traumatic brain injury; Revised Illness Perception Questionnaire; factor analysis; illness beliefs	CONFIRMATORY FACTOR-ANALYSIS; PAIN PATIENTS; PRIMARY-CARE; IPQ-R; HEAD; OUTCOMES; BELIEFS; DEPRESSION; RECOVERY; VERSION	Objective: Factors influencing outcome after mild traumatic brain injury (MTBI) remain poorly understood. In other health conditions patient illness perceptions have been associated with outcome and have provided targets for effective interventions. These have not been systematically explored in MTBI and identifying reliable and valid measures of illness perceptions in MTBI is a first step before such concepts can be explored in clinical and research settings. Method: This study investigated the factor structure and internal consistency reliability of the Illness Perceptions Questionnaire-Revised (IPQ-R) modified for MTBI in a sample of 147 adults recruited within 3 months of injury. Results: The results demonstrated a close replication of the original factor structure although there were notable exceptions likely to be specific to MTBI and potentially other acutely injured populations. Final scales showed good internal consistency although factors relating to causal attribution were less so. Conclusion: The IPQ-R (MTBI) provides an acceptable measure of key components of injury perceptions after MTBI. Minor refinements appear required if this measure is to make a contribution to research and clinical practice in injury-based populations such as MTBI.	[Snell, Deborah L.] Burwood Hosp, Brain Injury Rehabil Serv, Concuss Clin, Canterbury Dist Hlth Board, Christchurch, New Zealand; [Snell, Deborah L.; Hay-Smith, E. Jean C.] Univ Otago Wellington, Rehabil Teaching & Res Unit, Wellington, New Zealand; [Siegert, Richard J.] Kings Coll London, Sch Med, Dept Palliat Care Policy & Rehabil, Cicely Saunders Inst, London WC2R 2LS, England; [Surgenor, Lois J.] Univ Otago, Dept Psychol Med, Christchurch, New Zealand		Snell, DL (corresponding author), Burwood Hosp, Brain Injury Rehabil Serv, Concuss Clin, Canterbury Dist Hlth Board, Private Bag 4708, Christchurch, New Zealand.	deborah.snell@cdhb.govt.nz	Siegert, Richard J./K-2030-2019	Siegert, Richard/0000-0002-3074-0929	Neurological Foundation of New Zealand [0728-SPG]	This research has been support by a Small Project Grant from the Neurological Foundation of New Zealand (Grant no: 0728-SPG).	Alexander Hamish, 2007, N Z Med J, V120, pU2420; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borg Jorgen, 2004, Journal of Rehabilitation Medicine Supplement, P76; Cabassa LJ, 2008, CULT DIVERS ETHN MIN, V14, P377, DOI 10.1037/a0012820; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen SL, 2008, J ADV NURS, V64, P524, DOI 10.1111/j.1365-2648.2008.04808.x; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Figueiras MJ, 2007, PSYCHOL HEALTH, V22, P143, DOI 10.1080/14768320600774462; Foster NE, 2008, PAIN, V136, P177, DOI 10.1016/j.pain.2007.12.007; French DP, 2008, PSYCHOL HEALTH, V23, P5, DOI 10.1080/08870440701616714; French DP, 2006, J PSYCHOSOM RES, V61, P757, DOI 10.1016/j.jpsychores.2006.07.029; Frostholm L, 2007, J PSYCHOSOM RES, V62, P129, DOI 10.1016/j.jpsychores.2006.09.003; Hagger MS, 2005, PSYCHOL HEALTH, V20, P161, DOI 10.1080/0887044042000334724; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hobro N, 2004, PAIN, V108, P276, DOI 10.1016/j.pain.2003.12.027; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Leventhal H, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P19; Llewellyn CD, 2007, J PSYCHOSOM RES, V63, P17, DOI 10.1016/j.jpsychores.2007.01.013; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; PETRIE K, 1995, J PSYCHOSOM RES, V39, P31, DOI 10.1016/0022-3999(94)00071-C; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Saltapidas H, 2008, BRAIN IMPAIR, V9, P1, DOI 10.1375/brim.9.1.1; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Skinner EA, 1996, J PERS SOC PSYCHOL, V71, P549, DOI 10.1037/0022-3514.71.3.549; Snell Deborah, 2006, N Z Med J, V119, pU1902; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Stuifbergen AK, 2006, WOMEN HEALTH ISS, V16, P353, DOI 10.1016/j.whi.2006.05.003; Surgenor LJ, 2003, EUR EAT DISORD REV, V11, P291, DOI 10.1002/erv.499; TEASDALE G, 1974, LANCET, V2, P81; Van Ittersum MW, 2009, PATIENT EDUC COUNS, V74, P53, DOI 10.1016/j.pec.2008.07.041; Watson R, 2006, J ADV NURS, V55, P330, DOI 10.1111/j.1365-2648.2006.03915.x; Weinman J, 1996, PSYCHOL HEALTH, V11, P431, DOI 10.1080/08870449608400270; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wittkowski Anja, 2008, Psychol Health Med, V13, P346, DOI 10.1080/13548500701487697	44	26	26	1	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	13-14					1595	1605		10.3109/02699052.2010.523048			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	691QV	WOS:000285096800009	20973627				2022-02-06	
J	Babikian, T; Tong, KA; Galloway, NR; Freier-Randall, MC; Obenaus, A; Ashwal, S				Babikian, Talin; Tong, Karen A.; Galloway, Nicholas R.; Freier-Randall, Mary-Catherin; Obenaus, Andre; Ashwal, Stephen			Diffusion-Weighted Imaging Predicts Cognition in Pediatric Brain Injury	PEDIATRIC NEUROLOGY			English	Article							IMPROVES OUTCOME PREDICTION; CLOSED-HEAD INJURY; WHITE-MATTER; AXONAL INJURY; MR; COEFFICIENT; CHILDREN; SPECTROSCOPY; SEVERITY; IMAGES	Apparent diffusion coefficient maps from diffusion-weighted imaging predict gross neurologic outcome in adults with traumatic brain injury. Few studies in children have been reported, and none have used apparent diffusion coefficient maps to predict long-term (>1 year) neurocognitive outcomes. In this study, pooled regional and total brain diffusion coefficients were used to predict long-term outcomes in 17 pediatric brain injury patients. Apparent diffusion coefficient values were grouped into peripheral and deep gray and white matter, posterior fossa, and total brain. Regions of interest excluded areas that appeared abnormal on T-2-weighted images. Apparent diffusion coefficient values from peripheral regions were inversely correlated with cognitive functioning. No significant correlations were apparent between the cognitive scores and apparent diffusion coefficient values for deep tissue or the posterior fossa. Regression analyses suggested that combined peripheral gray and white matter apparent diffusion coefficients explained 42% of the variance in the combined neurocognitive index. Peripheral gray diffusion coefficients alone explained an additional 20% of variance after accounting for clinical variables. These results suggest that obtaining apparent diffusion coefficient values, specifically from peripheral brain regions, may predict long-term outcome after pediatric brain injury. Discrepancies in the literature on this topic, as well as possible explanations, including sampling and clinical considerations, are discussed. (C) 2009 by Elsevier Inc. All rights reserved.	[Babikian, Talin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Tong, Karen A.; Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA USA; [Galloway, Nicholas R.; Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Radiat Med, Loma Linda, CA USA; [Freier-Randall, Mary-Catherin] Loma Linda Univ, Sch Med, Dept Psychol, Loma Linda, CA USA; [Freier-Randall, Mary-Catherin; Obenaus, Andre; Ashwal, Stephen] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA USA		Babikian, T (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,Room C8-746, Los Angeles, CA 90024 USA.	tbabikian@mednet.ucla.edu					Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GILLES EE, 1999, PEDIAT NEUROLOGY PRI, P898; GIZA C, 2006, PEDIAT NEUROLOGY PRI, P1401; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Mukherjee P, 2001, RADIOLOGY, V221, P349, DOI 10.1148/radiol.2212001702; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1080/028418501127346990; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Obenaus A, 2008, NEUROPHARMACOLOGY, V55, P271, DOI 10.1016/j.neuropharm.2008.06.010; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schneider JFL, 2004, NEURORADIOLOGY, V46, P258, DOI 10.1007/s00234-003-1154-2; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Ulug AM, 2002, DEVELOPMENTAL SCI, V5, P286, DOI 10.1111/1467-7687.t01-1-00005; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zheng H, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-5	37	26	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	DEC	2009	41	6					406	412		10.1016/j.pediatrneurol.2009.06.002			7	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	525PA	WOS:000272227200003	19931161				2022-02-06	
J	Curtis, KL; Greve, KW; Bianchini, KJ				Curtis, Kelly L.; Greve, Kevin W.; Bianchini, Kevin J.			The Wechsler Adult Intelligence Scale-III and Malingering in Traumatic Brain Injury Classification Accuracy in Known Groups	ASSESSMENT			English	Article						Wechsler Adult Intelligence Scale; malingering; traumatic brain injury; effort; classification accuracy; known groups	CARD SORTING TEST; HEAD-INJURY; WAIS-III; NEUROCOGNITIVE DYSFUNCTION; PERFORMANCE PATTERNS; LIKELIHOOD RATIOS; INCOMPLETE EFFORT; DIGIT SPAN; INDICATORS; SEVERITY	A known-groups design was used to determine the classification accuracy of Wechsler Adult Intelligence Scale-III (WAIS-III) variables in detecting malingered neurocognitive dysfunction (MND) in traumatic brain injury (TBI). TBI patients were classified into the following groups: (a) mild TBI not-MND (n = 26), (b) mild TBI MND (n = 31), and (c) moderate/severe (M/S) TBI not-MND (n = 26). A sample of 80 general clinical patients was used for comparison. Verbal IQ, Verbal Comprehension Index, and Working Memory Index detected approximately 25% of malingerers with a false positive (FP) error rate of approximately 5% in the mild TBI group. Comparable FP rates were obtained in M/S TBI. FP rates for Performance IQ, Perceptual Organization Index, and Processing Speed Index were acceptable in mild TBI but too high in M/S TBI. Previously studied specialized indicators (Vocabulary minus Digit Span and the Mittenberg formula) failed to differentiate malingerers from nonmalingerers. The clinical application of these findings is discussed.	[Greve, Kevin W.] Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Jefferson, AR USA		Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Axelrod B. N., 1999, J FORENSIC NEUROPSYC, V1, P15; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BINDER LM, 1993, PORTLAND DIGIT RECOG; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Demakis GJ, 2004, APPL NEUROPSYCHOL, V11, P222; Demakis GJ, 2001, PSYCHOL ASSESSMENT, V13, P240, DOI 10.1037//1040-3590.13.2.240; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 2001, NEUROREHABILITATION, V16, P237; Green P, 1998, ARCH CLIN NEUROPSYCH, V13, P138; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, APPL NEUROPSYCHOL, V15, P161, DOI 10.1080/09084280802324085; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Johnstone L, 2003, BRIT J CLIN PSYCHOL, V42, P303, DOI 10.1348/01446650360703401; Kaemmer, 1989, MMPI 2 MANUAL ADM SC; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Larrabee G.J., 2007, ASSESSMENT MALINGERE, P14; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LARRABEE GJ, 2007, EVALUATION MALINGERI, P334; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Lemeshow S, 2000, APPL LOGISTIC REGRES; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Miller LJ, 2004, CLIN NEUROPSYCHOL, V18, P327, DOI 10.1080/13854040490501592; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WECHSLER D, 1997, WAIS III SCORING ASS; WILLIAMS RW, 1999, AM J FORENSIC PSYCH, V17, P35	64	26	26	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	DEC	2009	16	4					401	414		10.1177/1073191109338161			14	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	519QC	WOS:000271781100008	19797328				2022-02-06	
J	Mogensen, J; Mala, H				Mogensen, Jesper; Mala, Hana			Post-traumatic functional recovery and reorganization in animal models: A theoretical and methodological challenge	SCANDINAVIAN JOURNAL OF PSYCHOLOGY			English	Article						Functional recovery; functional localization; brain injury; post-traumatic reorganization; animal models; neural plasticity; cognitive plasticity; experimental methodology; challenges	FORNIX AND/OR ABLATION; SPATIAL DELAYED ALTERNATION; HUMAN CEREBRAL-CORTEX; PREFRONTAL CORTEX; BRAIN-DAMAGE; WATER MAZE; CONCEPT-IDENTIFICATION; TRANSECTED RATS; LESIONS; REHABILITATION	Studies addressing cerebral functional localization face methodological and theoretical problems. Lesion experiments expect that when a functionally specialized structure is missing, its function can be deduced from the resulting impairments. Mostly, however, initial impairments are partially or fully eliminated through functional recovery. Apparently, such a recovery contradicts the notion of functional localization. In order to understand the mechanisms of recovery, improved methodology and a new theoretical framework are required. Insights into the mechanisms of recovery can be achieved by using "challenge" techniques, where functionally recovered individuals are exposed to organic and behavioral challenges, e.g. pharmacological manipulations or additional lesions, as well as modified test situations. Using such methods, a number of principles of functional recovery have emerged. We evaluate some of the available theories of post-traumatic recovery against these principles and find that none of them can account for the principles. Finally, we present a new conceptual framework - the Reorganization of Elementary Functions (REF) model. This model reconceptualizes the term "function", suggests mechanisms of post-traumatic reorganizations, and resolves the contradiction between localization and functional recovery.	[Mogensen, Jesper; Mala, Hana] Univ Copenhagen, Dept Psychol, Unit Cognit Neurosci, DK-1353 Copenhagen K, Denmark		Mogensen, J (corresponding author), Univ Copenhagen, Dept Psychol, Unit Cognit Neurosci, Oester Farimagsgade 2 A, DK-1353 Copenhagen K, Denmark.	jesper.mogensen@psy.ku.dk		Rytter, Hana Mala/0000-0002-2910-372X; Mogensen, Jesper/0000-0003-1959-581X			BOURNE LE, 1959, PSYCHOL REV, V66, P278, DOI 10.1037/h0041365; BOWER G, 1963, J EXP PSYCHOL, V66, P409, DOI 10.1037/h0044972; Bressler SL, 2006, INT J PSYCHOPHYSIOL, V60, P139, DOI 10.1016/j.ijpsycho.2005.12.008; Buller D. J., 2000, BRAIN MIND, V1, P307, DOI [10.1023/A:1011573226794, DOI 10.1023/A:1011573226794]; Butefisch CM, 2004, NEUROSCIENTIST, V10, P163, DOI 10.1177/1073858403262152; Coltheart M., 2001, HDB COGNITIVE NEUROP, P3; deBruin JPC, 1997, BEHAV BRAIN RES, V85, P47, DOI 10.1016/S0166-4328(96)00163-5; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; DIVAC I, 1985, BRAIN PLASTICITY LEA, P205; DUNNETT SB, 1982, SCAND J PSYCHOL, P104; Elbert T, 2004, NEUROSCIENTIST, V10, P129, DOI 10.1177/1073858403262111; Fodor J.A., 1983, MODULARITY MIND; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Krechevsky I, 1933, J COMP PSYCHOL, V16, P99, DOI 10.1037/h0072223; Krechevsky I, 1932, PSYCHOL REV, V39, P516, DOI 10.1037/h0073500; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; LEVERE ND, 1982, PHYSIOL PSYCHOL, V10, P165; LEVERE TE, 1975, PSYCHOL REV, V82, P344; LEVINE M, 1963, PSYCHOL REV, V70, P254, DOI 10.1037/h0045543; LEVINE M, 1970, PSYCHOL BULL, V74, P397, DOI 10.1037/h0032951; Marr D., 1982, VISION COMPUTATIONAL, P428; Mogensen J, 2005, BRAIN RES BULL, V65, P41, DOI 10.1016/j.brainresbull.2004.11.010; Mogensen J, 2004, PHARMACOL BIOCHEM BE, V77, P381, DOI 10.1016/j.pbb.2003.11.017; Mogensen J, 2004, BRAIN RES BULL, V63, P217, DOI 10.1016/j.brainresbull.2004.02.008; Mogensen J, 2003, PHARMACOL BIOCHEM BE, V75, P381, DOI 10.1016/S0091-3057(03)00107-2; MOGENSEN J, 1987, ACTA NEUROBIOL EXP, V47, P45; Mogensen J, 2002, NEUROBIOL LEARN MEM, V78, P139, DOI 10.1006/nlme.2001.4055; MOGENSEN J, 2003, HOMEOSTASIS HLTH DIS, V42, P97; Mogensen J., 2003, HDB LAB ANIMAL SCI, VII, P95; Mogensen J, 2007, BRAIN RES BULL, V73, P86, DOI 10.1016/j.brainresbull.2007.02.006; Monakow C, 1914, LOKALISATION GROSSHI; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nieto-Escamez FA, 2002, BEHAV BRAIN RES, V134, P93, DOI 10.1016/S0166-4328(01)00458-2; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; OLTON DS, 1978, CIBA F S, V58, P327; PANKSEPP J, 2000, EVOLUTION COGNITION, V6, P108, DOI DOI 10.1146/ANNUREV.AN.18.100189.0; Racine RJ, 1965, PSYCHON SCI, V3, P285; Ramachandran V., 1998, PHANTOMS BRAIN PROBI; RESTLE F, 1962, PSYCHOL REV, V69, P329, DOI 10.1037/h0044672; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; ROSNER BS, 1970, ANNU REV PSYCHOL, V21, P555, DOI 10.1146/annurev.ps.21.020170.003011; Rumelhart DE., 1986, PARALLEL DISTRIBUTED, P318, DOI 10.7551/mitpress/5236.001.0001; Selnes OA., 2001, HDB COGNITIVE NEUROP, P23; STEIN DG, 1997, BRAIN REPAIR; Teasell R, 2006, CAN J NEUROL SCI, V33, P357, DOI 10.1017/S0317167100005308; Trabasso T., 1968, ATTENTION LEARNING T; Werbos P. J., 1994, ROOTS BACKPROPAGATIO; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; WORTWEIN G, 1994, BEHAV BRAIN RES, V63, P127, DOI 10.1016/0166-4328(94)90083-3; WORTWEIN G, 1995, INT J NEUROSCI, V82, P71, DOI 10.3109/00207459508994291	50	26	26	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0036-5564	1467-9450		SCAND J PSYCHOL	Scand. J. Psychol.	DEC	2009	50	6					561	573		10.1111/j.1467-9450.2009.00781.x			13	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	522CR	WOS:000271975800006	19930255	Bronze			2022-02-06	
J	Li, H; Lu, GP; Shi, W; Zheng, S				Li, Hao; Lu, Guoping; Shi, Wei; Zheng, Shan			Protective Effect of Moderate Hypothermia on Severe Traumatic Brain Injury in Children	JOURNAL OF NEUROTRAUMA			English	Article						children; moderate hypothermia; traumatic brain injury	PERINATAL ASPHYXIA; MILD HYPOTHERMIA; NEWBORN-INFANTS; INTRACRANIAL HYPERTENSION; CEREBRAL HYPOTHERMIA; HEAD-INJURY; PHASE-II; DAMAGE; THERAPY; PIGLETS	This study investigated the safety and neuroprotective effect of moderate hypothermia in children with severe traumatic brain injury (TBI). Twenty-two children suffering from TBI were randomly divided into groups treated with moderate hypothermia (intracranial temperature of 34.5 +/- 0.2 degrees C, maintained for 72 h, n = 12) or normothermia (intracranial temperature of 38.0 +/- 0.5, n =10). The cerebrospinal fluid levels of neuron-specific enolase (NSE), S-100, brain-specific creatine kinase (CK-BB), and intracranial pressure (ICP) levels were used to assess the protective effects. The variations in pH and electrolyte balance were also examined. The results indicated that the peak ICP level in the normothermia group (26.30 +/- 1.08 mm Hg) was reached 48 h after TBI. The ICP level in the moderate hypothermia group was lower than in the control group at every time point examined (p < 0.01). Furthermore, at 24, 48, and 72 h, the NSE, S-100, and CK-BB levels in the moderate hypothermia group were also lower than that of the normothermia group (p < 0.01). In the moderate hypothermia group, the pH and electrolyte balance at the end of the monitoring period were normal, but the heart rates were lower (p < 0.05). There were a total of three deaths (13.6%) in this study: one in the moderate hypothermia group (8.3%) and two in the normothermia group (20%). In conclusion, moderate hypothermia provided neuronal protection for children with severe TBI, and maintaining the intracranial temperature at 34.5 degrees C for 72 h was safe in this clinical setting.	[Li, Hao; Shi, Wei; Zheng, Shan] Fudan Univ, Childrens Hosp, Dept Pediat Surg, Shanghai 200032, Peoples R China; [Lu, Guoping] Fudan Univ, Childrens Hosp, PICU, Shanghai 200032, Peoples R China; [Lu, Guoping] Neurochirurg Univ Klinikum Schleswig Holstein, Campus Kiel, Germany		Zheng, S (corresponding author), Fudan Univ, Childrens Hosp, Dept Pediat Surg, Shanghai 200032, Peoples R China.	lihao7272@163.com					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; ADELSON PD, 2003, PEDIATR CRIT CARE ME, V2, pS75; Amess PN, 1998, BIOL NEONATE, V73, P40, DOI 10.1159/000013958; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Compagnoni G, 2002, BIOL NEONATE, V82, P222, DOI 10.1159/000065890; Gruszkiewicz J, 1973, Surg Neurol, V1, P197; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; Gunn AJ, 1998, EARLY HUM DEV, V53, P19, DOI 10.1016/S0378-3782(98)00033-4; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Haaland K, 1997, PEDIATR RES, V41, P505, DOI 10.1203/00006450-199704000-00009; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; HEISTAD DD, 1973, J APPL PHYSIOL, V35, P581, DOI 10.1152/jappl.1973.35.5.581; HENDRICK E, 1963, CLIN NEUROSURG, V11, P46; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jia Jun, 2005, Chin J Traumatol, V8, P138; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Liu XM, 2006, AM J RESP CELL MOL, V34, P56, DOI 10.1165/rcmb.2005-0189OC; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Simbruner G, 1999, INTENS CARE MED, V25, P1111, DOI 10.1007/s001340051020; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Thoresen M, 1996, PEDIATR RES, V40, P738, DOI 10.1203/00006450-199611000-00014; WANG X, 1999, CHIN J PEDIAT, V37, P670; Williams GD, 1997, PEDIATR RES, V42, P700, DOI 10.1203/00006450-199711000-00024; ZHOU W, 2001, CHIN J PEDIAT, V39, P198	29	26	28	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1905	1909		10.1089/neu.2008.0828			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600005	19469686				2022-02-06	
J	Shields, BJ; Fernandez, SA; Smith, GA				Shields, Brenda J.; Fernandez, Soledad A.; Smith, Gary A.			Epidemiology of Cheerleading Stunt-Related Injuries in the United States	JOURNAL OF ATHLETIC TRAINING			English	Article						injury surveillance; athletic injuries; collegiate athletes; high school athletes; youth athletes; recreational athletes	HIGH-SCHOOL; HEAD-INJURY; CONCUSSIONS; PREVENTION; SPORTS; RISK	Context. Cheerleading-related injuries are on the rise. To date, no epidemiologic studies of cheerleading stunt-related injuries have been published. Objective: To describe and compare cheerleading stunt-related injuries by type of cheerleading team (All Star, college, high school, middle school, or recreation league) and event (practice, pep rally, athletic event, or cheerleading competition). Design: Prospective injury surveillance study. Setting: Participant exposure and injury data were collected from US cheerleading teams via the Cheerleading RIO (Reporting Information Online) surveillance tool. Patients or Other Participants: Athletes from enrolled cheerleading teams who participated in official, organized cheerleading practices, pep rallies, athletic events, or cheerleading competitions. Main Outcome Measure(s): The numbers, types, and rates of cheerleading stunt-related injuries during a 1-year period (2006-2007) are reported. Results: Stunt-related injuries accounted for 60% (338/567) of the injuries sustained by US cheerleaders who participated in the study and 96% (22/23) of the concussions and closed head injuries (CHIs) reported during the study. Collegiate cheerleaders were more likely to sustain a concussion or CHI than were cheerleaders on other types of teams (P = .02, odds ratio = 3.10, 95% confidence interval = 1.20, 8.06). Most injuries occurred while the cheerleader was spotting or basing another cheerleader (34%, 115/338), and these injuries comprised 32% (51/161) of all stunt-related strains and sprains. Four cheerleaders (1.2%, 4/335) were admitted to the hospital, and 9 cheerleaders (2.7%, 9/335) required surgery. Conclusions: Cheerleading stunts pose an increased risk for injury, especially in terms of sustaining a concussion or CHI. Spotters and bases were most likely to be injured during the performance of cheerleading stunts and were at risk for sustaining strain and sprain injuries. The ankle, lower back, and wrist were the sites most likely to be reinjured while performing cheerleading stunts.	[Shields, Brenda J.] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Smith, Gary A.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA		Shields, BJ (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	brenda.shields@nationwidechildrens.org			Research Institute at Nationwide Children's HospitalOhio State University	Funding for this study was provided by the Research Institute at Nationwide Children's Hospital. Debbie Bracewell, Lisa Thompson, and Steve Wedge helped to categorize the cheerleading maneuvers.	*AM ASS CHEERL COA, 2007 2008 AACCA COLL; Boden BP, 2003, AM J SPORT MED, V31, P881, DOI 10.1177/03635465030310062501; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cobb Sarah, 2004, J Sch Nurs, V20, P262; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giannone L., 2006, AM ASS CHEERLEADING, P1; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hutchinson MR, 1997, PHYSICIAN SPORTSMED, V25, P83, DOI 10.3810/psm.1997.09.1508; Jacobson BH, 2004, J ORTHOP SPORT PHYS, V34, P261, DOI 10.2519/jospt.2004.34.5.261; Kushner DS, 2001, AM FAM PHYSICIAN, V64, P1007; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Marshall SW, 2007, J ATHL TRAINING, V42, P234; MUELLER FO, 24 NAT CTR CAT SPORT; *NAT ATHL TRAIN AS, SEC SCH OFF STAT; National Athletic Trainers, REC GUID APPR MED CO; National Athletic Trainers Association, 2004, APPR MED CAR SEC SCH; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; Schulz MR, 2004, AM J SPORT MED, V32, P396, DOI 10.1177/0363546503261715; Shields BJ, 2006, PEDIATRICS, V117, P122, DOI 10.1542/peds.2005-1139; Shields BJ, 2009, J ATHL TRAINING, V44, P567, DOI 10.4085/1062-6050-44.6.567	23	26	27	6	28	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	NOV-DEC	2009	44	6					586	594		10.4085/1062-6050-44.6.586			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	522OU	WOS:000272008400004	19911084	Bronze, Green Published			2022-02-06	
J	Shafieian, M; Darvish, KK; Stone, JR				Shafieian, Mehdi; Darvish, Kurosh K.; Stone, James R.			Changes to the viscoelastic properties of brain tissue after traumatic axonal injury	JOURNAL OF BIOMECHANICS			English	Article						Traumatic brain injury; Traumatic axonal injury; Brain biomechanics; Viscoelastic; Properties of brain tissue; Indentation test; Finite element analysis; Damage function	BIOMECHANICS; DEFORMATION; MODEL; TESTS; RAT	While it has been shown that repetitive mild brain injuries can cause cumulative damage to the brain, changes to the mechanical properties of brain tissue at large deformations were also noted in the literature. The goal of this study was to show that the viscoelastic properties of brain tissue significantly change after traumatic axonal injury (TAI). An impact acceleration model was used to create TAI in the rat brainstem which was quantified with an immunohistochemistry technique at the ponto-medullary junction (PmJ) and pyramidal decussation (PDx). The viscoelastic properties at these two points with and without preconditioning were characterized using an indentation technique combined with finite element analysis and a comparison was made between injured and uninjured specimens, which revealed statistically significant reduction in the instantaneous elastic force at PDx where the brain tissue sustained a significantly higher level of injury. The result of this study can be used to characterize a damage function for the brain tissue undergoing large deformation. (C) 2009 Elsevier Ltd. All rights reserved	[Shafieian, Mehdi; Darvish, Kurosh K.] Temple Univ, Dept Mech Engn, Philadelphia, PA 19122 USA; [Stone, James R.] Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22908 USA		Darvish, KK (corresponding author), Temple Univ, Dept Mech Engn, 1947 N 12th St, Philadelphia, PA 19122 USA.	kdarvish@temple.edu	Shafieian, Mehdi/S-9091-2017	Shafieian, Mehdi/0000-0001-8533-0241; Darvish, Kurosh/0000-0002-6674-266X	Southern Consortium for Injury Biomechanics [DTNH22-01-H-07551]	The authors wish to acknowledge the help of Dr. Jeff Crandall and Dr. David Okonkwo, and also David McDaniel, Jamie Wagner and Prachi Sanghavi for their assistance in conducting the experiments at the Center for Applied Biomechanics and the Department of Neurosurgery at the University of Virginia. The support for this study was provided by the Southern Consortium for Injury Biomechanics under Grant no. DTNH22-01-H-07551.	Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; FALLENSTEIN GT, 1969, 69BHF6 ASME; Fung Y. C., 1993, BIOMECHANICS MECH PR; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; HAYES WC, 1972, J BIOMECH, V5, P541, DOI 10.1016/0021-9290(72)90010-3; LJUNG C, 1975, J BIOMECH, V8, P263, DOI 10.1016/0021-9290(75)90078-0; Macosko CW, 1994, RHEOLOGY PRINCIPLES; Maikos JT, 2008, J NEUROTRAUM, V25, P795, DOI 10.1089/neu.2007.0423; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MELVIN, 2002, ACCIDENTAL INJURIES, P277; MERTZ, 2002, ACCIDENTAL INJURIES, P72; MONTGOMERY, 2004, DESIGN ANAL EXPT; Motulsky H.J., 2007, PRISM 5 STAT GUIDE; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Simo JC, 1998, COMPUTATIONAL INELAS; Sneddon IN, 1965, INT J ENG SCI, V3, P47, DOI [DOI 10.1016/0020-7225(65)90019-4, 10.1016/0020-7225(65)90019-4]; STAINAKER, 1969, THESIS W VIRGINIA U; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P79; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Yang KH, 2003, INT J VEHICLE DES, V32, P116, DOI 10.1504/IJVD.2003.003240	29	26	27	0	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	SEP 18	2009	42	13					2136	2142		10.1016/j.jbiomech.2009.05.041			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	502RO	WOS:000270478000019	19698945				2022-02-06	
J	Englander, J; Bushnik, T; Wright, JM; Jamison, L; Duong, TT				Englander, Jeffrey; Bushnik, Tamara; Wright, Jerry M.; Jamison, Laura; Duong, Thao T.			Mortality in Late Post-Traumatic Seizures	JOURNAL OF NEUROTRAUMA			English	Article						epilepsy; rehabilitation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; EPILEPSY; POPULATION; COHORT; RISK; PREVALENCE; DEATH; LIFE	The objective of this study was to examine the mortality rates in individuals with traumatic brain injury (TBI) who were classified as having experienced late post-traumatic seizures (LPTS) in the first 2 years post-TBI compared to those who were seizure-free (non-LPTS). Participants were a pooled sample (n = 508) from two studies which enrolled individuals with TBI who were injured between March 31, 1992 and December 20, 1999. The first sample was made up of individuals enrolled in a study of risk factors for LPTS development; the second sample was composed of individuals enrolled in the TBI National Database from a single rehabilitation center. Seventy-one (14%) participants had LPTS, of which 27% had died at 8-15 years post-injury, as compared to 10% of non-LPTS participants. Individuals with LPTS died at a younger age (54.1 versus 67.7 years; p = 0.01), but there were no statistically significant differences in either time from date of injury to death or highest GCS score in the first 24 h. Causes of death were variable and not specifically related to epilepsy. Of those with LPTS, risk factors for death include advanced age at time of injury and presence of subdural hematoma. The higher mortality rate and death at younger age with variable causes in TBI individuals with LPTS warrant close medical evaluation and monitoring of these individuals, particularly accessibility and compliance with ongoing general medical care, and education of primary care colleagues of the unique needs of this at-risk population.	[Bushnik, Tamara; Wright, Jerry M.; Jamison, Laura] Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; [Englander, Jeffrey; Duong, Thao T.] Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA		Bushnik, T (corresponding author), Santa Clara Valley Med Ctr, Rehabil Res Ctr, 751 S Bascom Ave, San Jose, CA 95128 USA.	tamara@tbi-sci.org		Bushnik, Tamara/0000-0003-3328-257X	This work was supported by the U. S. Department of Education, Office of Special Education and Rehabilitative Services; National Institute on Disability and Rehabilitation Research [H133A020524]	This work was supported by the U. S. Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research ( grant no. H133A020524).	AISKAINEN I, 1999, EPILEPSIA, V40, P584; Annegers JF, 1999, SEIZURE-EUR J EPILEP, V8, P347, DOI 10.1053/seiz.1999.0306; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Baguley I, 2000, BRAIN INJURY, V14, P505; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; COURJON J, 1970, EPILEPSIA, V11, P29, DOI 10.1111/j.1528-1157.1970.tb03863.x; DASILVA AM, 1990, ACT NEUR S, V50, P48; De Santis A, 1979, J Neurosurg Sci, V23, P207; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; JENNETT B, 1973, SCOT MED J, V18, P8, DOI 10.1177/003693307301800103; JENNETT WB, 1975, EPILEPSY NONMISSILE; Kobau R, 2007, EPILEPSIA, V48, P1904, DOI 10.1111/j.1528-1167.2007.01161.x; Kollevold T, 1979, J Oslo City Hosp, V29, P35; Langan Y, 2002, J NEUROL NEUROSUR PS, V73, P751, DOI 10.1136/jnnp.73.6.751; Lhatoo SD, 2005, EPILEPSIA, V46, P36, DOI 10.1111/j.1528-1167.2005.00406.x; Nilsson L, 1997, EPILEPSIA, V38, P1062, DOI 10.1111/j.1528-1157.1997.tb01194.x; Nilsson L, 2003, EPILEPSIA, V44, P575, DOI 10.1046/j.1528-1157.2003.03302.x; Roberts A.V., 1979, SEVERE ACCIDENTAL HE, P140; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1987, ADV EPILEPTOL, V16, P627; Shackleton DP, 1999, J NEUROL NEUROSUR PS, V66, P636, DOI 10.1136/jnnp.66.5.636; Shackleton DP, 2002, EPILEPSIA, V43, P445, DOI 10.1046/j.1528-1157.2002.10301.x; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Strauss D, 1999, J INSUR MED, V31, P104; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; Wiebe S, 1999, CAN J NEUROL SCI, V26, P263, DOI 10.1017/S0317167100000354; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594	37	26	26	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1471	1477		10.1089/neu.2008.0729			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200004	19508123	Green Published			2022-02-06	
J	Nagy, D; Marosi, M; Kis, Z; Farkas, T; Rakos, G; Vecsei, L; Teichberg, VI; Toldi, J				Nagy, David; Marosi, Mate; Kis, Zsolt; Farkas, Tamas; Rakos, Gabriella; Vecsei, Laszlo; Teichberg, Vivian I.; Toldi, Jozsef			Oxaloacetate Decreases the Infarct Size and Attenuates the Reduction in Evoked Responses after Photothrombotic Focal Ischemia in the Rat Cortex	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Glutamate excitotoxicity; Evoked potentials; Photothrombotic lesion; Neuroprotection	GLUTAMATE NEUROTOXICITY; CEREBROSPINAL-FLUID; HEME DEGRADATION; MOTOR CORTEX; BRAIN-INJURY; AMINO-ACIDS; IN-VITRO; MODEL; POTENTIALS; NEUROPROTECTION	A traumatic brain injury or a focal brain lesion is followed by acute excitotoxicity caused by the presence of abnormally high glutamate (Glu) levels in the cerebrospinal and interstitial fluids. It has recently been demonstrated that this excess Glu in the brain can be eliminated into the blood following the intravenous administration of oxaloacetate (OxAc), which, by scavenging the blood Glu, induces an enhanced and neuroprotective brain-to-blood Glu efflux. In this study, we subjected rats to a photothrombotic lesion and treated them after the illumination with a single 30-min-long administration of OxAc (1.2 mg/100 g, i.v.). Following induction of the lesion, we measured the infarct size and the amplitudes of the somatosensory evoked potentials (SEPs) as recorded from the skull surface. The photothrombotic lesion resulted in appreciably decreased amplitudes of the evoked potentials, but OxAc administration significantly attenuated this reduction, and also the infarct size assessed histologically. We suggest that the neuroprotective effects of OxAc are due to its blood Glu-scavenging activity, which, by increasing the brain-to-blood Glu efflux, reduces the excess Glu responsible for the anatomical and functional correlates of the ischemia, as evaluated by electrophysiological evoked potential (EP) measurements.	[Nagy, David; Marosi, Mate; Kis, Zsolt; Farkas, Tamas; Rakos, Gabriella; Toldi, Jozsef] Univ Szeged, Dept Physiol Anat & Neurosci, H-6726 Szeged, Hungary; [Vecsei, Laszlo] Univ Szeged, Dept Neurol, H-6701 Szeged, Hungary; [Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel		Toldi, J (corresponding author), Univ Szeged, Dept Physiol Anat & Neurosci, Kozep Fasor 52, H-6726 Szeged, Hungary.	david.nagy01@gmail.com; marosi.mate@gmail.com; zskis@bio.u-szeged.hu; tfarkas@bio.u-szeged.hu; rakosgabi@gmail.com; vecsei@nepsy.szote.u-szeged.hu; vivian.teichberg@weizmann.ac.il; toldi@bio.u-szeged.hu	Vecsei, Laszlo/ABA-6137-2021; Vecsei, Laszlo/B-2066-2010; Kis, Zsolt/A-4583-2009; Farkas, Tamas/B-7193-2008; Nagy, David/C-7775-2011; Toldi, Jozsef/M-4858-2018	Vecsei, Laszlo/0000-0001-8037-3672; Kis, Zsolt/0000-0002-6896-5883; Toldi, Jozsef/0000-0001-7355-0503	National Bureau of Research and DevelopmentNational Office for Research and Technology [NKTH RET 08/2004]; OTKAOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [K75628]; TeT [SK-26/200]; Weizmann Institute Nella; Leon Benoziyo Center for Neurological Diseases;  [GVOP-3.2.1-2004-04-0357/3.0]	This work was supported by the National Bureau of Research and Development (NKTH RET 08/2004), OTKA K75628, TeT SK-26/200, and GVOP-3.2.1-2004-04-0357/3.0. T. F. is a Bolyai Fellow of the Hungarian Academy of Sciences. V. I. T has received support from the Weizmann Institute Nella and Leon Benoziyo Center for Neurological Diseases.	Back T, 2004, J NEUROL, V251, P388, DOI 10.1007/s00415-004-0399-y; BAIK MW, 1990, ELECTROEN CLIN NEURO, V75, P433, DOI 10.1016/0013-4694(90)90088-2; Bordi F, 1997, EXP NEUROL, V145, P425, DOI 10.1006/exnr.1997.6442; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOI DW, 1994, PROG BRAIN RES, V100, P47; Damjanac M, 2007, BRAIN RES, V1128, P40, DOI 10.1016/j.brainres.2006.05.050; Ebisu T, 2001, MAGN RESON IMAGING, V19, P153, DOI 10.1016/S0730-725X(01)00233-8; Farkas T, 2000, EUR J NEUROSCI, V12, P2190, DOI 10.1046/j.1460-9568.2000.00096.x; Farkas T, 2003, NEUROSCI LETT, V342, P49, DOI 10.1016/S0304-3940(03)00230-1; GIROTTI A W, 1985, Journal of Free Radicals in Biology and Medicine, V1, P395, DOI 10.1016/0748-5514(85)90152-7; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; HAMMOUDA AERMA, 1995, CYTOMETRY, V20, P19, DOI 10.1002/cyto.990200105; Hodgkins PS, 1999, J NEUROCHEM, V72, P643, DOI 10.1046/j.1471-4159.1999.0720643.x; Kharlamov A, 1996, BRAIN RES, V734, P1; LADDS A, 1988, ELECTROEN CLIN NEURO, V71, P233, DOI 10.1016/0168-5597(88)90008-1; LIU XG, 1992, ELECTROEN CLIN NEURO, V85, P209, DOI 10.1016/0168-5597(92)90134-W; LYE RH, 1987, J NEUROSCI METH, V22, P133, DOI 10.1016/0165-0270(87)90007-0; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MINAMIDE H, 1994, SURG NEUROL, V42, P138, DOI 10.1016/0090-3019(94)90375-1; Molchanova S, 2004, NEUROCHEM RES, V29, P1519, DOI 10.1023/B:NERE.0000029564.98905.5c; MULLER TB, 1995, STROKE, V26, P1453, DOI 10.1161/01.STR.26.8.1453; Nagababu E, 2004, ANTIOXID REDOX SIGN, V6, P967, DOI 10.1089/1523086042259823; Nagababu E, 1998, BIOCHEM BIOPH RES CO, V247, P592, DOI 10.1006/bbrc.1998.8846; Nistico R, 2008, BRIT J PHARMACOL, V153, P1022, DOI 10.1038/sj.bjp.0707587; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2; Scheller D, 2000, AMINO ACIDS, V19, P571, DOI 10.1007/s007260070007; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; Spreux-Varoquaux O, 2002, J NEUROL SCI, V193, P73, DOI 10.1016/S0022-510X(01)00661-X; Stieg PE, 1999, EUR J PHARMACOL, V375, P115, DOI 10.1016/S0014-2999(99)00214-9; STONE TW, 1993, PHARMACOL REV, V45, P309; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Toldi J, 1999, NEUROREPORT, V10, P2143, DOI 10.1097/00001756-199907130-00027; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185, DOI 10.1152/jappl.1991.71.4.1185; Umemura K, 1997, BRAIN RES, V773, P61, DOI 10.1016/S0006-8993(97)00894-9; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Wright A, 2003, FREE RADICAL BIO MED, V34, P637, DOI 10.1016/S0891-5849(02)01361-8; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	43	26	26	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	SEP	2009	29	6-7					827	835		10.1007/s10571-009-9364-8			9	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	476YI	WOS:000268482300008	19259807				2022-02-06	
J	Xiong, Y; Chopp, M; Lee, CP				Xiong, Ye; Chopp, Michael; Lee, Chuan-Pu			Erythropoietin improves brain mitochondrial function in rats after traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						Erythropoietin; mitochondrion; rat; traumatic brain injury	CELL-DEATH; ENHANCES NEUROGENESIS; DYSFUNCTION; APOPTOSIS; RECEPTOR; DAMAGE; MECHANISMS; EXPRESSION; BCL-X(L); RECOVERY	Mitochondria play a central role in cellular energetics, calcium homeostasis and apoptosis. Our previous study demonstrates traumatic brain injury induces brain mitochondrial dysfunction after injury. Preservation and/or restoration of mitochondrial function may be one of the strategies for neuroprotection. Erythropoietin, a hormone for erythropoiesis, also provides tissue protection against traumatic brain injury and stroke. The present study was undertaken to evaluate the effect of erythropoietin on traumatic brain injury-induced brain mitochondrial dysfunction. Traumatic brain injury decreased rates of respiration at the active state ( state 3), increased that at the resting state ( state 4) and consequently decreased respiratory control index (state 3/state 4 ratio) and the efficiency of ATP synthesis ( the amount of ADP phosphorylated by inorganic phosphate divided by the amount of oxygen consumed during state 3 respiration). Erythropoietin administered intraperitoneally 30 minutes post-injury at 1000 U/kg partially improved mitochondrial function at day 1 post-injury. However, erythropoietin-induced improvement was not sustained at day 7 post-injury. Erythropoietin at 2000 or 5000 U/kg restored states 3 and 4 examined at day 1 post-injury to the sham levels. Consequently, the energy coupling capacities, such as respiratory control index and/or the efficiency of ATP synthesis, were also improved. The beneficial effect of erythropoietin at these doses persisted for at least 7 days post-injury. The beneficial effect of erythropoietin on brain mitochondrial function was observed with a wide therapeutic window from 5 minutes to 6 hours post-injury. Our data, for the first time, demonstrate that erythropoietin treatment restores brain mitochondrial function after traumatic brain injury, which will enhance cellular energy generation and reduce oxidative stress, strongly supporting erythropoietin as a promising agent for the therapeutic treatment of traumatic brain injury. [Neurol Res 2009; 31: 496-502]	[Xiong, Ye; Lee, Chuan-Pu] Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; [Xiong, Ye] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA		Lee, CP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	cplee@med.wayne.edu		Xiong, Ye/0000-0001-9770-6031	Johnson and Johnson Pharmaceutical Research and DevelopmentJohnson & JohnsonJohnson & Johnson USA	This study was supported in part by funds from Johnson and Johnson Pharmaceutical Research and Development. We would like to express our sincere thanks to Dr Donna Mildvan and Dr Francis Farrell for their advice and helpful discussion.	Bahcekapili N, 2007, LIFE SCI, V80, P1245, DOI 10.1016/j.lfs.2006.12.014; Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chong ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F; Chtistophe M, 2006, CURR PHARM DESIGN, V12, P739, DOI 10.2174/138161206775474242; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Genc K, 2006, PHYSIOL RES, V55, P33; Genc S, 2004, RESTOR NEUROL NEUROS, V22, P105; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; Kumral A, 2006, BIOL NEONATE, V89, P205, DOI 10.1159/000089951; Lee C. P., 1993, V2, P41; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Liu J, 2006, GLIA, V53, P360, DOI 10.1002/glia.20289; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Mikati MA, 2007, EPILEPSIA, V48, P175, DOI 10.1111/j.1528-1167.2006.00900.x; Miro O, 2002, AM J KIDNEY DIS, V39, P1025, DOI 10.1053/ajkd.2002.32776; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Orrenius S, 2004, TOXICOL LETT, V149, P19, DOI 10.1016/j.toxlet.2003.12.017; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Radad K, 2006, NEUROCHEM INT, V49, P379, DOI 10.1016/j.neuint.2006.02.003; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang F, 2006, J NEUROSCI RES, V83, P1241, DOI 10.1002/jnr.20816; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036	49	26	27	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2009	31	5					496	502		10.1179/174313208X353703			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	468LF	WOS:000267819200009	19099671				2022-02-06	
J	Briones, TL; Rogozinska, M; Woods, J				Briones, Teresita L.; Rogozinska, Magdalena; Woods, Julie			RETRACTED: Environmental Experience Modulates Ischemia-Induced Amyloidogenesis and Enhances Functional Recovery (Retracted article. See vol. 32, pg. 863, 2015)	JOURNAL OF NEUROTRAUMA			English	Article; Retracted Publication						A beta oligomers; beta-secretase amyloid cleaving enzyme (BACE); enriched environment; learning and memory; water maze	AMYLOID PRECURSOR PROTEIN; ENRICHMENT IMPROVES COGNITION; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; BETA PEPTIDE; SYNAPTIC PLASTICITY; HIPPOCAMPAL REGION; LEARNING-CAPACITY; DENDRITIC GROWTH; GENE-EXPRESSION	In this study, we examined whether ischemia-induced amyloidogenesis could be modulated by environmental "experience,'' and whether this modulation is associated with improved cognitive functioning. Rats were subjected to either global ischemia or sham surgery and then were randomly assigned to either enriched environment housing (EE) or socially paired housing (controls). After 14 days of differential environmental housing, the rats were tested in the water maze. Our results show decreased C-terminal fragments of the beta-amyloid precursor protein (beta APP) and decreased amyloid beta (A beta) load in the ischemic EE rats compared to the ischemic control animals. In addition, A beta oligomerization was significantly decreased in the ischemic EE animals compared to the ischemic control rats. Further, significantly increased levels of neprilysin, but not insulin-degrading enzyme, amyloid-degrading enzymes, were seen in the ischemic EE rats compared to the ischemic control animals. Behavioral analyses showed that ischemic EE rats performed significantly better on the memory task compared to the ischemic control group. These results suggest that use of multi-sensory environmental enrichment following cerebral ischemia may reduce the accumulation of A beta peptide in the more pathologic oligomeric form, and consequently may enhance functional recovery.	[Briones, Teresita L.; Rogozinska, Magdalena; Woods, Julie] Univ Illinois, Chicago, IL 60612 USA		Briones, TL (corresponding author), Univ Illinois, 845 S Damen Ave,Room 750,M-C 802, Chicago, IL 60612 USA.	tbriones@uic.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NINRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [RO1 NR007666]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR007666] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health, NINR grant no. RO1 NR007666. We are grateful for the assistance of Maggie Wadowska in animal handling and tissue imaging. We would also like to thank Mai Nguyen for assistance in the analysis of behavioral data.	Abramov AY, 2003, J NEUROSCI, V23, P5088; Apelt J, 1997, INT J DEV NEUROSCI, V15, P95, DOI 10.1016/S0736-5748(96)00073-1; Arendash GW, 2004, NEUROREPORT, V15, P1751, DOI 10.1097/01.wnr.0000137183.68847.4e; Badan I, 2004, EUR J NEUROSCI, V19, P2270, DOI 10.1111/j.0953-816X.2004.03323.x; BANATI RB, 1995, J CEREBR BLOOD F MET, V15, P647, DOI 10.1038/jcbfm.1995.80; BHATIA P, 1994, ANAL BIOCHEM, V216, P223, DOI 10.1006/abio.1994.1028; Bouet V, 2007, EXP NEUROL, V203, P555, DOI 10.1016/j.expneurol.2006.09.006; BOWES MP, 1994, EXP NEUROL, V129, P112, DOI 10.1006/exnr.1994.1152; Briones T L, 2000, Biol Res Nurs, V1, P299, DOI 10.1177/109980040000100406; Briones Teresita L, 2005, Biol Res Nurs, V6, P167, DOI 10.1177/1099800404271328; Briones TL, 2006, BEHAV BRAIN RES, V171, P17, DOI 10.1016/j.bbr.2006.03.011; Briones TL, 2006, EXP NEUROL, V198, P530, DOI 10.1016/j.expneurol.2005.12.032; Briones TL, 2006, BEHAV BRAIN RES, V168, P261, DOI 10.1016/j.bbr.2005.11.015; Briones TL, 2004, BRAIN RES, V1018, P130, DOI 10.1016/j.brainres.2004.06.001; Briones TL, 2004, BRAIN RES, V997, P137, DOI 10.1016/j.brainres.2003.10.030; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Costa DA, 2007, NEUROBIOL AGING, V28, P831, DOI 10.1016/j.neurobiolaging.2006.04.009; Davidson CM, 2000, BRAIN RES, V859, P96, DOI 10.1016/S0006-8993(00)01937-5; ESCORIHUELA RM, 1995, NEUROBIOL LEARN MEM, V64, P49, DOI 10.1006/nlme.1995.1043; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Fu WM, 2002, J NEUROSCI, V22, P10710; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Huber G, 1997, NEUROSCIENCE, V80, P313, DOI 10.1016/S0306-4522(97)00120-6; Ishimaru H, 1996, NEUROREPORT, V7, P3063, DOI 10.1097/00001756-199611250-00054; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Jankowsky JL, 2003, J NEUROPATH EXP NEUR, V62, P1220, DOI 10.1093/jnen/62.12.1220; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KALARIA RN, 1993, ANN NY ACAD SCI, V695, P190, DOI 10.1111/j.1749-6632.1993.tb23050.x; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; Kim HS, 1998, NEUROREPORT, V9, P533; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Kobayashi S, 2002, J NEUROSCI RES, V70, P340, DOI 10.1002/jnr.10442; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Marr RA, 2003, J NEUROSCI, V23, P1992; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Mouri A, 2006, BEHAV BRAIN RES, V168, P83, DOI 10.1016/j.bbr.2005.10.014; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; Paganelli RA, 2004, J NEUROSCI METH, V132, P9, DOI 10.1016/j.jneumeth.2003.08.012; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Perry G, 2002, FREE RADICAL BIO MED, V33, P1475, DOI 10.1016/S0891-5849(02)01113-9; Pham TM, 1999, NEUROSCIENCE, V94, P279, DOI 10.1016/S0306-4522(99)00316-4; Pluta R, 2002, ANN NY ACAD SCI, V977, P102, DOI 10.1111/j.1749-6632.2002.tb04803.x; Popa-Wagner A, 1998, STROKE, V29, P2196, DOI 10.1161/01.STR.29.10.2196; Puurunen K, 2001, EXP NEUROL, V167, P348, DOI 10.1006/exnr.2000.7563; Puurunen K, 1997, STROKE, V28, P623, DOI 10.1161/01.STR.28.3.623; Qiao XX, 2001, EUR J NEUROSCI, V14, P474, DOI 10.1046/j.0953-816x.2001.01666.x; Schrijver NCA, 2004, BEHAV BRAIN RES, V152, P307, DOI 10.1016/j.bbr.2003.10.016; SELKOE DJ, 1997, ANN NY ACAD SCI, V777, P57; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wahl AS, 2009, NEUROSCIENCE, V158, P344, DOI 10.1016/j.neuroscience.2008.06.018; Wang J, 2003, NEUROBIOL DIS, V14, P318, DOI 10.1016/j.nbd.2003.08.009; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; WEST RW, 1972, BEHAV BIOL, V7, P279, DOI 10.1016/S0091-6773(72)80207-4; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Yi JS, 2007, NEUROBIOL DIS, V26, P94, DOI 10.1016/j.nbd.2006.12.007	69	26	27	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					613	625		10.1089/neu.2008.0707			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300012	19271963	Green Published			2022-02-06	
J	Tan, AA; Quigley, A; Smith, DC; Hoane, MR				Tan, Arlene A.; Quigley, Andrea; Smith, Douglas C.; Hoane, Michael R.			Strain Differences in Response to Traumatic Brain Injury in Long-Evans Compared to Sprague-Dawley Rats	JOURNAL OF NEUROTRAUMA			English	Article						beam walk; fluid percussion injury; loss of consciousness; Morris water maze; recovery of function; strain differences; traumatic brain injury	FLUID PERCUSSION INJURY; MORRIS WATER MAZE; GENETIC-DIFFERENCES; SPATIAL NAVIGATION; MOTOR CORTEX; DARK-AGOUTI; ALBINO-RATS; RECOVERY; WISTAR; PERFORMANCE	The selected strain of rodent used in experimental models of traumatic brain injury is typically dependent upon the experimental questions asked and the familiarity of the investigator with a specific rodent strain. This archival study compares the injury responsiveness and recovery profiles of two popular outbred strains, the Long-Evans (LE) and the Sprague-Dawley (SD), after brain injury induced by lateral fluid percussion injury (LFPI). General findings include a significantly longer duration of unconsciousness in LE rats, but similar durations of apnea. Both strains displayed the same level of initial FPI-induced behavioral deficits, followed by a more rapid rate of functional recovery in SD rats. Cortical volume loss was not significantly different, but close inspection of the data suggests the possibility that LE rats may be more susceptible to damage in the hemisphere contralateral to the injury site than are SD rats. It is hoped that the information provided here encourages greater attention to the subtle differences and similarities between strains in future pre-clinical efficacy studies of traumatic brain injury.	[Tan, Arlene A.; Quigley, Andrea; Smith, Douglas C.; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Brain & Cognit Sci Program, Carbondale, IL 62901 USA		Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Brain & Cognit Sci Program, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	The authors would like to thank Bryan McConomy, Keith Gregory, Mustafa Aladin, and Nicholas Kuypers for their assistance in data collection. Thanks also to Jason Beare and Nicholas Kaufmann for their assistance in lesion analysis. Special thanks to Dr. Douglas C. Smith for the use of laboratory facilities. Funding for this project was provided by National Institute of Neurological Disorders and Stroke grant NS045647 to M. R. H.	ANDREWS JS, 1995, PHYSIOL BEHAV, V57, P785, DOI 10.1016/0031-9384(94)00336-X; Bardutzky J, 2005, STROKE, V36, P2000, DOI 10.1161/01.STR.0000177486.85508.4d; CARR MM, 1992, ANN PLAS SURG, V28, P538; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; de Bruin NMWJ, 2000, NEUROSCI RES, V38, P165, DOI 10.1016/S0168-0102(00)00154-1; DELAHUNTY TM, 1995, NEUROCHEM RES, V20, P405; DIANA G, 1994, NEUROSCI LETT, V171, P113, DOI 10.1016/0304-3940(94)90618-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DRAGER UC, 1985, P NATL ACAD SCI USA, V82, P6716, DOI 10.1073/pnas.82.19.6716; Faraday MM, 2002, PHYSIOL BEHAV, V75, P507, DOI 10.1016/S0031-9384(02)00645-5; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Ferguson SA, 2004, PHARMACOL BIOCHEM BE, V77, P583, DOI 10.1016/j.pbb.2003.12.014; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Gleason TC, 1999, NEUROPEPTIDES, V33, P265, DOI 10.1054/npep.1999.0044; Grant S, 2001, VISUAL NEUROSCI, V18, P245, DOI 10.1017/S095252380118209X; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Harker KT, 2004, NEUROSCI BIOBEHAV R, V28, P485, DOI 10.1016/j.neubiorev.2004.06.005; Harker KT, 2002, BEHAV BRAIN RES, V134, P467; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; INOUE M, 1990, PHYSIOL BEHAV, V48, P199, DOI 10.1016/0031-9384(90)90285-C; Kearns DN, 2006, BEHAV BRAIN RES, V169, P193, DOI 10.1016/j.bbr.2006.01.005; Kosten TA, 2002, PSYCHONEUROENDOCRINO, V27, P35, DOI 10.1016/S0306-4530(01)00035-X; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; LINDNER MD, 1988, BEHAV NEUROSCI, V102, P621, DOI 10.1037/0735-7044.102.5.621; LUND RD, 1965, SCIENCE, V149, P1506, DOI 10.1126/science.149.3691.1506; Ma S, 2004, NEUROSCIENCE, V124, P963, DOI 10.1016/j.neuroscience.2003.12.028; MAYOMICHELSON L, 1993, BRAIN RES BULL, V31, P345, DOI 10.1016/0361-9230(93)90226-2; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meyerson BJ, 2006, BEHAV BRAIN RES, V168, P100, DOI 10.1016/j.bbr.2005.10.020; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nikkhah G, 1998, BEHAV BRAIN RES, V92, P85, DOI 10.1016/S0166-4328(97)00128-9; Oliff HS, 1996, BRAIN RES, V731, P208, DOI 10.1016/0006-8993(96)00582-3; Pardon MC, 2002, NEUROSCIENCE, V115, P229, DOI 10.1016/S0306-4522(02)00364-0; Paulson PE, 2005, EXP NEUROL, V196, P413, DOI 10.1016/j.expneurol.2005.08.015; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Prusky GT, 2002, BEHAV BRAIN RES, V136, P339, DOI 10.1016/S0166-4328(02)00126-2; Schallert T, 2005, BEHAV LAB RAT, P129; SHERIDAN CL, 1965, J COMP PHYSIOL PSYCH, V59, P292, DOI 10.1037/h0021816; SISSON DF, 1991, PHARMACOL BIOCHEM BE, V39, P665, DOI 10.1016/0091-3057(91)90144-Q; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Takaba H, 2004, CELL MOL NEUROBIOL, V24, P589, DOI 10.1023/B:CEMN.0000036400.55503.5e; TONKISS J, 1992, DEV PSYCHOBIOL, V25, P567, DOI 10.1002/dev.420250804; Toth E, 1996, NEUROBIOL LEARN MEM, V66, P230, DOI 10.1006/nlme.1996.0063; Vales K, 2006, NEUROSCI RES, V55, P383, DOI 10.1016/j.neures.2006.04.007; van Lier H, 2003, PHYSIOL BEHAV, V78, P91, DOI 10.1016/S0031-9384(02)00893-4; vanderStaay FJ, 1996, PHYSIOL BEHAV, V60, P97; Vorhees CV, 1999, PHARMACOGENETICS, V9, P171; Walberer M, 2006, LAB ANIM-UK, V40, P1, DOI 10.1258/002367706775404426; Whishaw IQ, 2003, BEHAV BRAIN RES, V145, P221, DOI 10.1016/S0166-4328(03)00143-8; Wyss JM, 2000, NEUROBIOL AGING, V21, P671, DOI 10.1016/S0197-4580(00)00132-9; Xu XJ, 2001, PAIN, V89, P135, DOI 10.1016/S0304-3959(00)00356-0; Zamudio S, 2005, BRAIN RES BULL, V65, P339, DOI 10.1016/j.brainresbull.2005.01.009	59	26	26	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					539	548		10.1089/neu.2008.0611			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300006	19216636	Green Accepted, Green Published			2022-02-06	
J	Evans, B; Gervais, JT; Heard, K; Valley, M; Lowenstein, SR				Evans, Bruce; Gervais, Jack T.; Heard, Kennon; Valley, Morgan; Lowenstein, Steven R.			Ski patrollers: Reluctant role models for helmet use	INTERNATIONAL JOURNAL OF INJURY CONTROL AND SAFETY PROMOTION			English	Article						traumatic brain injury; helmets; ski patrollers; skiing; snowboarding	RISK COMPENSATION; HEAD-INJURIES; SNOWBOARDERS	Ski helmets reduce the risk of traumatic brain injury (TBI), but usage rates are low. Ski patrollers could serve as role models for helmet use, but little is known about their practices and beliefs. A written survey was distributed to ski patrollers attending continuing education conferences. The questions addressed included helmet use rates, prior TBI experiences, perceptions of helmet risks and benefits and willingness to serve as safety role models for the public. To assess predictors of helmet use, odds ratios (OR) were calculated, after adjusting for skiing experience. Ninety-three ski patrollers participated and the main outcome was self-reported helmet use of 100% while patrolling. Helmet use was 23% (95% CI 15-32%). Common reasons for non-use included impaired hearing (35%) and discomfort (29%). Most patrollers believed helmets prevent injuries (90%; 95% CI 84-96%) and that they are safety role models (92%; 95% CI 86-98%). However, many believed helmets encourage recklessness (39%; 95% CI 29-49%) and increase injury risks (16%; 95% CI 7-25%). Three factors predicted 100% helmet use: perceived protection from exposure (OR = 9.68; 95% CI 3.14-29.82) or cold (OR = 5.68; 95% CI 1.27-25.42); and belief that role modelling is an advantage of helmets (OR = 4.06; 95% CI 1.29-12.83). Patrollers who believed helmets encourage recklessness were eight times less likely to wear helmets (OR = 0.13; 95% CI 0.03-0.58). Ski patrollers know helmets reduce serious injury and believe they are role models for the public, but most do not wear helmets regularly. To increase helmet use, manufacturers should address hearing-and comfort-related factors. Education programmes should address the belief that helmets encourage recklessness and stress role modelling as a professional responsibility.	[Evans, Bruce; Heard, Kennon; Valley, Morgan; Lowenstein, Steven R.] Univ Colorado Denver, Dept Surg, Sch Med, Div Emergency Med, Aurora, CO 80045 USA; [Lowenstein, Steven R.] Univ Colorado Denver, Dept Med, Sch Med, Aurora, CO 80045 USA; [Lowenstein, Steven R.] Univ Colorado Denver, Dept Prevent Med Biometr, Sch Med, Aurora, CO 80045 USA; [Evans, Bruce; Heard, Kennon; Valley, Morgan] Univ Colorado Denver, Colorado Emergency Med Res Ctr, Sch Med, Aurora, CO 80045 USA		Lowenstein, SR (corresponding author), Univ Colorado Denver, Dept Surg, Sch Med, Div Emergency Med, Leprino Off Bldg,7th Floor 12401 E 17th Ave,B215, Aurora, CO 80045 USA.	Steven.Lowenstein@ucdenver.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K08 DA020573, K08 DA020573-03, DA 020573] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 811509] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K08DA020573] Funding Source: NIH RePORTER		BROOKE J, 1998, NY TIMES        0107; Consumer Product Safety Commission, 1999, SKIING HELM EV POT R; Hagel B, 2005, ACCIDENT ANAL PREV, V37, P103, DOI 10.1016/j.aap.2004.04.003; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hedlund J, 2000, Inj Prev, V6, P82, DOI 10.1136/ip.6.2.82; Henrich J, 2001, EVOL HUM BEHAV, V22, P165, DOI 10.1016/S1090-5138(00)00071-4; JANOFSKY M, 2002, NY TIMES        0331; KENWORTHY T, 1998, WASHINGTON POST 0101; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; Macnab AJ, 2002, INJURY PREV, V8, P324, DOI 10.1136/ip.8.4.324; MCCLELLAN D, 2002, COLORADO SKI AREAS C; *NAT SKI AR ASS, 2007, NAT DEM SURV; *NAT SKI AR ASS, 2008, EV NAT SAF AW WEEK; *NAT SKI AR ASS, 2007, FACTS SKIING SNOWB S; PENNINGTON B, 2007, NY TIMES        0126; Richerson P.J., 2005, NOT GENES ALONE CULT; Scott MD, 2007, INJURY PREV, V13, P173, DOI 10.1136/ip.2006.014142; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; *UT DEP HLTH, 2004, UT DEP HLTH OFF FREE; *VT SNOW SPORTS RE, 2007, PHAT PROT YOUR HEAD; Xiang H, 2004, INJURY PREV, V10, P99, DOI 10.1136/ip.2003.004655; Xiang HY, 2003, INJURY, V34, P892, DOI 10.1016/S0020-1383(03)00055-X	23	26	26	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1745-7300	1745-7319		INT J INJ CONTROL SA	Int. J. Inj. Control Saf. Promot.		2009	16	1					9	14		10.1080/17457300902732045			6	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	618ZB	WOS:000279394500002	19225971	Green Submitted, Green Accepted			2022-02-06	
J	Gontkovsky, ST; Russum, P; Stokic, DS				Gontkovsky, Samuel T.; Russum, Paula; Stokic, Dobrivoje S.			Comparison of the CIQ and chart short form in assessing community integration in individuals with chronic spinal cord injury: A pilot study	NEUROREHABILITATION			English	Article						Community integration; Community Integration Questionnaire; Craig Handicap Assessment and Reporting Technique Short Form; spinal cord injuries	TRAUMATIC BRAIN-INJURY; CRAIG HANDICAP ASSESSMENT; REPORTING TECHNIQUE; LIFE SATISFACTION; QUESTIONNAIRE; IMPAIRMENT; VALIDATION; DISABILITY	Objective: To examine the validity of the Community Integration Questionnaire (CIQ) in measuring community integration in persons with chronic spinal cord injury (SCI) through its comparison with the Craig Handicap Assessment and Reporting Technique Short Form (CHART-SF). Design: Correlational analysis. Setting: Tertiary care rehabilitation hospital. Participants: Twenty-eight individuals with chronic SCI who completed the CIQ and CHART-SF during annual follow-up evaluation. Main outcome measures: The CIQ quantifies community integration based on subscales of Home Integration, Social Integration, and Productive Activity. The CHART-SF provides scores of community integration according to subscales of Physical Independence, Cognitive Independence, Mobility, Occupation, Social Integration, and Economic Self-Sufficiency. Results: CIQ Home Integration was significantly correlated with CHART-SF Physical Independence, Cognitive Independence, Mobility, Occupation, and Social Integration (r's= 0.47-0.57). CIQ Social Integration was significantly correlated with CHART-SF Cognitive Independence, Mobility, Occupation, and Social Integration (r's = 0.43-0.77). CIQ Productive Activity was significantly correlated only with CHART-SF Mobility and Occupation (r's = 0.39-0.41). Conclusions: The CIQ may serve as a valid measure for examining community integration in persons with chronic SCI and may be particularly appealing given its relative brevity/simplicity in administration and scoring.	[Gontkovsky, Samuel T.; Russum, Paula; Stokic, Dobrivoje S.] Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, Jackson, MS USA; [Gontkovsky, Samuel T.] Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA		Gontkovsky, ST (corresponding author), Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, Jackson, MS USA.	sgontkovsky@hotmail.com		Stokic, Dobrivoje/0000-0002-1891-5730			Anderson CJ, 2003, DEV MED CHILD NEUROL, V45, P129, DOI 10.1017/S0012162203000239; BRUININKS RH, 1992, RES DEV DISABIL, V13, P463, DOI 10.1016/0891-4222(92)90003-O; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Dijkers M., 1998, TOP SPINAL CORD INJ, V4, P1, DOI DOI 10.1310/BJJA-2018-45KL-0VTL; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; Forcheimer M., 1998, TOP SPINAL CORD INJ, V4, P42; Hall K., 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Kurylo M, 2001, REHABIL PSYCHOL, V46, P247, DOI 10.1037/0090-5550.46.3.247; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McGrew K. S., 1994, CHALLENGES SERVICE S, P65; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Mellick D., 2000, CRAIG HANDICAP ASSES; Morris J, 1986, J HEAD TRAUMA REHAB, V1, P31; Rintala DH, 1998, TOP SPINAL CORD INJ, V4, P1; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SEGAL ME, 1995, AM J PHYS MED REHAB, V74, P276, DOI 10.1097/00002060-199507000-00004; VOGEL LC, 2002, J SPINAL CORD MED, V25, P1006; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	26	26	26	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2009	24	2					185	192		10.3233/NRE-2009-0467			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	436OF	WOS:000265422900009	19339757				2022-02-06	
J	Kurowski, B; Wade, SL; Cecil, KM; Walz, NC; Yuan, WH; Rajagopal, A; Holland, SK				Kurowski, Brad; Wade, Shari L.; Cecil, Kim M.; Walz, Nicolay C.; Yuan, Weihong; Rajagopal, Akila; Holland, Scott K.			Correlation of diffusion tensor imaging with executive function measures after early childhood traumatic brain injury	JOURNAL OF PEDIATRIC REHABILITATION MEDICINE			English	Article						Brain injuries; child; diffusion magnetic resonance imaging; neuropsychology	WHITE-MATTER INJURY; AXONAL INJURY; MODERATE; CHILDREN; DTI	Objective: Examine relationships of diffusion tensor imaging (DTI) fractional anisotropy (FA) to executive function (EF) and attention measures following early childhood (3-7 years) traumatic brain injury (TBI). Design: Exploratory correlation and comparison study. Setting: Children's hospital outpatient facilities. Participants: 9 children with a history of TBI (age = 7.89 +/- 1.00 years; Glasgow Coma Scale (GCS) = 10.11 +/- 4.68) were compared to 12 children with OI (age = 7.51 +/- 0.95). All children were at least 12 months post injury at time of evaluation. Main Outcome Measures: FA in various regions of interest (ROI), EF and attention measures. Results: FA values primarily in the frontal white matter tracks correlated with EF measures. Separate tasks of inhibition and switching correlated significantly with FA in bilateral frontal lobes. Tasks combining both inhibition and switching correlated significantly with FA values in the left frontal lobe. Tasks of attention negatively correlated with FA values in the right frontal white matter and the superior longitudinal fasciculus. Conclusions: Associations between late measurement of FA and EF measures following early childhood TBI suggest that persistent white matter changes, especially in the frontal white matter, may provide an index of EF deficits.	[Kurowski, Brad; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat Rehabil Med, Cincinnati, OH 45229 USA; [Cecil, Kim M.; Yuan, Weihong; Rajagopal, Akila; Holland, Scott K.] Cincinnati Childrens Hosp Med Ctr, Dept Radiol, Cincinnati, OH 45229 USA; [Wade, Shari L.; Cecil, Kim M.; Walz, Nicolay C.; Holland, Scott K.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.; Cecil, Kim M.; Walz, Nicolay C.; Yuan, Weihong; Rajagopal, Akila; Holland, Scott K.] Univ Cincinnati, Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA		Kurowski, B (corresponding author), Univ Cincinnati, Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.; Kurowski, B (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org		Cecil, Kim/0000-0001-8233-5485	NIH from the National Council on Medical Rehabilitation Research in the National Institute of Child Health and Human Development [RO1-HD044279]; Institutional Clinical and Translational Science Award, NIH/NCRR [1UL1RR026314]; NIH grant from the US National Institute of Child Health and Human Development [RO1-HD38578]; Association of Volunteers of the Convalescent Hospital for Children, Cincinnati Children's Hospital Medical Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD044279, R01HD038578] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR026314] Funding Source: NIH RePORTER	This work was supported in part by 1) NIH grant RO1-HD044279 from the National Council on Medical Rehabilitation Research in the National Institute of Child Health and Human Development; 2) Institutional Clinical and Translational Science Award, NIH/NCRR Grant Number 1UL1RR026314 (The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH); and 3) NIH grant RO1-HD38578 from the US National Institute of Child Health and Human Development. Funding for the fMRI scans was provided by the Association of Volunteers of the Convalescent Hospital for Children, Cincinnati Children's Hospital Medical Center.	Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; [Anonymous], TRAUMATIC BRAIN INJU, V2009; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; Espy KA, 2006, PSYCHOL ASSESSMENT, V18, P373, DOI 10.1037/1040-3590.18.4.373; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Gioia GA IP, 2000, BEHAV RATING INVENTO; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jurado MB, 2007, NEUROPSYCHOL REV, V17, P213, DOI 10.1007/s11065-007-9040-z; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lowry R., VASSARSTATS WEB SITE, V2009; Manly T., 1999, TEST EVERYDAY ATTENT; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakagawa H, 1998, AM J NEURORADIOL, V19, P1129; PFEFFERBAUM A, 1994, ARCH NEUROL-CHICAGO, V51, P874, DOI 10.1001/archneur.1994.00540210046012; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	33	26	26	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1874-5393	1875-8894		J PEDIATR REHAB MED	J. Pediatr. Rehab. Med.		2009	2	4					273	283		10.3233/PRM-2009-0093			11	Pediatrics	Emerging Sources Citation Index (ESCI)	Pediatrics	GY1ER	WOS:000448267700004	21234279	Green Accepted			2022-02-06	
J	Levin, HS; Hanten, G; Li, XQ				Levin, Harvey S.; Hanten, Gerri; Li, Xiaoqi			The relation of cognitive control to social outcome after paediatric TBI: Implications for intervention	DEVELOPMENTAL NEUROREHABILITATION			English	Article						Paediatric TBI; rehabilitation; intervention; cognition; cognitive control; social outcome; social cognition	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; WORKING-MEMORY; SHORT-TERM; CHILDREN; CHILDHOOD; ADJUSTMENT; SKILLS; CONSEQUENCES; ADOLESCENTS	Hypothesis: This study postulated cognitive control is related to social outcome in children with traumatic brain injury (TBI) and orthopaedic injury (OI). Procedure and design: This study analysed 12-month, post-injury, cross-sectional data from 52 children (7-17 years) with moderate-to-severe TBI and 41 children with OI. Cognitive control was measured with the Sternberg Task (memory) and the Flanker Task (resistance to interference). Relations to social outcome (Vineland Adaptive Behavioural Scales-Socialization and Communications domains) were measured. Results: Reaction time (RT) on the Sternberg task was related to social outcome, with stronger relations in children of lower SES. Flanker baseline and interference RTs were related to social outcome, with the relation for interference RT more robust in children with lower SES. Conclusions: Cognitive control is related to social outcome. Further, it is suggested that cognitive training may have positive effects on social function through improved efficiency of social information processing.	[Levin, Harvey S.; Hanten, Gerri; Li, Xiaoqi] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA		Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin 1144, Houston, TX 77030 USA.	hlevin@bcm.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by Grant Number R01NS021889 from the National Institute of Neurological Disorders and Stroke. The authors wish to acknowledge the contributions of Kimberly Orsten and Stacey Martin for editing, proof-reading and all-around helpfulness during the preparation of this manuscript.	Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BERNDT TJ, 1982, CHILD DEV, V53, P1447, DOI 10.1111/j.1467-8624.1982.tb03466.x; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Borkowski J. G., 1996, ATTENTION MEMORY EXE, P235; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Burnett S, 2009, J COGNITIVE NEUROSCI, V21, P1736, DOI 10.1162/jocn.2009.21121; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Cheeran B, 2009, NEUROREHAB NEURAL RE, V23, P97, DOI 10.1177/1545968308326636; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; Damon W., 1983, SOCIAL PERSONALITY D; Deaton A, 1994, ED DIMENSIONS ACQUIR, P257; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Gioia GA IP, 2000, BEHAV RATING INVENTO; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Graham S., 1996, ATTENTION MEMORY EXE, P349; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; HANTEN G, 2008, COGNITIVE NEUROREHAB, P487; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Happaney K, 2004, BRAIN COGNITION, V55, P1, DOI 10.1016/j.bandc.2004.01.001; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Krasnegor N.A., 1996, ATTENTION MEMORY EXE, P263; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Larson R., 1984, BEING ADOLESCENT CON; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; March JS, 1997, J AM ACAD CHILD PSY, V36, P554, DOI 10.1097/00004583-199704000-00019; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MUSCARA F, 2009, NEUROPSYCHOL REHABIL, V33, P623; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Oswald H., 1994, SOCIAL NETWORKS SOCI, P171; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; Paus T, 2005, TRENDS COGN SCI, V9, P60, DOI 10.1016/j.tics.2004.12.008; Pennington B., 1996, ATTENTION MEMORY EXE, P327; PETERSEN AC, 1986, BEHAV THER, V17, P480, DOI 10.1016/S0005-7894(86)80090-9; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Rosso IM, 2004, ANN NY ACAD SCI, V1021, P355, DOI 10.1196/annals.1308.045; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Stiles J, 2000, DEV NEUROPSYCHOL, V18, P237, DOI 10.1207/S15326942DN1802_5; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; WALKER HM, 1994, TOP LANG DISORD, V14, P70, DOI 10.1097/00011363-199405000-00007; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; YEATES KO, 1991, MERRILL PALMER QUART, V37, P369; [No title captured]	69	26	26	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1751-8423	1751-8431		DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	5					320	329		10.3109/17518420903087673			10	Clinical Neurology; Pediatrics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FS	WOS:000207788500007	20477561				2022-02-06	
J	Lew, HL; Rosen, PN; Thomander, D; Poole, JH				Lew, Henry L.; Rosen, Peter N.; Thomander, Darryl; Poole, John H.			The Potential Utility of Driving Simulators in the Cognitive Rehabilitation of Combat-Returnees With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive assessment; cognitive rehabilitation; cognitive training; driving simulator; transfer of training	VIRTUAL-REALITY; PERFORMANCE; IMPAIRMENT; OUTCOMES; DRIVERS; DAMAGE; RISK	A large number of Operation Enduring Freedom/Operation Iraqi Freedom returnees are seeking DOD and VA rehabilitative care for war-related traumatic brain injury (TBI). This article reviews evidence on the utility of driving simulators as tools for assessment and training in TBI rehabilitation. Traditionally, cognitive rehabilitation has been shown to improve specific cognitive skills. However, there are few studies and only weak evidence to show that these gains transfer to everyday activities. Theoretically, modern driving simulators may be useful in cognitive rehabilitation because they can systematically present realistic and interesting tasks that approximate driving activities, while automatically monitoring performance. The use of simulation technology for patients with TBI provides cognitive stimulation in an ecologically compatible setting, without the risks associated with a corresponding real-world experience. The utility, limitations, and future directions for the use of driving simulator in the rehabilitation of patients with war-related TBI are discussed.	[Lew, Henry L.] Vet Affairs Boston Hlth Care Syst, PM&R Serv, Boston, MA 02130 USA; [Rosen, Peter N.] Univ Calif San Diego, Sharp Mem Hosp, Rehabil Ctr, Driving Performance Lab,Sharp Rees Stealy Med Grp, San Diego, CA 92103 USA; [Rosen, Peter N.] Univ Calif San Diego, Dept Family & Prevent Med, Div Hlth Care Sci, San Diego, CA 92103 USA; [Thomander, Darryl] Vet Affairs Palo Alto Hlth Care Syst, Polytrauma Transit Rehabil Program, Palo Alto, CA USA; [Poole, John H.] Vet Affairs Palo Alto Hlth Care Syst, Def & Vet Brain Injury Ctr, Polytrauma Network Site, Palo Alto, CA USA		Lew, HL (corresponding author), Vet Affairs Boston Hlth Care Syst, PM&R Serv, 150 S Huntington Ave, Boston, MA 02130 USA.	henry.lew@va.gov					Akinwuntan AE, 2005, NEUROLOGY, V65, P843, DOI 10.1212/01.wnl.0000171749.71919.fa; ALLEN RW, 1999, 34 ANN M HUM FACT SO; Ball K, 1997, ALZ DIS ASSOC DIS, V11, P42, DOI 10.1097/00002093-199706001-00010; Bieliauskas LA, 2005, BRAIN INJURY, V19, P221, DOI 10.1080/02699050400017213; Brookhuis KA, 2003, ERGONOMICS, V46, P433, DOI 10.1080/001401302/1000039556; Brooks N, 2005, BRAIN INJURY, V19, P165, DOI 10.1080/02699050410001720004; Cappa SF, 2005, EUR J NEUROL, V12, P665; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Coleman Bryer R, 2005, DRIVER REHABILITATIO, P165; Freund B, 2002, J AM GERIATR SOC, V50, P1309, DOI 10.1046/j.1532-5415.2002.50325.x; Freund B, 2006, J AM GERIATR SOC, V54, P1943, DOI 10.1111/j.1532-5415.2006.00966.x; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; Geusgens CAV, 2007, J REHABIL MED, V39, P425, DOI 10.2340/16501977-0092; Johansson BB, 2003, J REHABIL MED, V35, P11, DOI 10.1080/16501960310010089; Kerkhoff G, 2000, J NEUROL NEUROSUR PS, V68, P691, DOI 10.1136/jnnp.68.6.691; Lee HC, 2003, J SAFETY RES, V34, P453, DOI 10.1016/j.jsr.2003.09.007; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; LEW HL, 2003, DRIVING ISSUES TRAUM; Lynch B, 2002, J HEAD TRAUMA REHAB, V17, P446, DOI 10.1097/00001199-200210000-00006; MALIA K, 2004, RECOMMENDATIONS PRAC; Marcotte TD, 2004, NEUROLOGY, V63, P1417, DOI 10.1212/01.WNL.0000141920.33580.5D; MARCOTTE TD, 2004, ADV TANSP STUD   NOV; Michel J A, 2006, Eura Medicophys, V42, P59; Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; Rizzo M, 2001, ALZ DIS ASSOC DIS, V15, P10, DOI 10.1097/00002093-200101000-00002; Rizzo M, 2004, ARCH OPHTHALMOL-CHIC, V122, P641, DOI 10.1001/archopht.122.4.641; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; ROSEN PN, 2004, ADV TANSP STUD   NOV; ROSEN PN, 2005, DRIV SIM US GROUPS 3; STEIN AC, 1992, ERG SOC AUSTR 28 ANN; STERN EB, 2004, ADV TRANSPORTATION S, P67; Stern EB, 2006, DRIVER REHABILITATIO, P26; WACHTEL J, 1995, TR NEWS, V179, P26; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X; Zoltan B, 2007, VISION PERCEPTION CO, P1	49	26	26	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2009	24	1					51	56		10.1097/HTR.0b013e3181956fe3			6	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	427GT	WOS:000264768500008	19158596				2022-02-06	
J	Ma, M; Matthews, BT; Lampe, JW; Meaney, DF; Shofer, FS; Neumar, RW				Ma, Marek; Matthews, Brian T.; Lampe, Joshua W.; Meaney, David F.; Shofer, Frances S.; Neumar, Robert W.			Immediate short-duration hypothermia provides long-term protection in an in vivo model of traumatic axonal injury	EXPERIMENTAL NEUROLOGY			English	Article						Diffuse axonal injury; Trauma; Optic nerve; Brain injury; Hypothermia	POSTTRAUMATIC HYPOTHERMIA; OPTIC-NERVE; MODERATE HYPOTHERMIA; CYTOSKELETAL CHANGES; CALPAIN ACTIVATION; BRAIN-INJURY; DAMAGE; PROTEIN	A prospective, multicenter, randomized trial did not demonstrate improved Outcomes in severe traumatic brain injured patients treated with mild hypothermia [Clifton, G.L., Miller, E.R., Choi, S.C., Levin, H.S., McCauley, S., Smith, K.R., Jr., Muizelaar, J.P., Wagner, F.C., Jr., Marion, D.W., Luerssen, T.G., Chesnut, R.M., Schwartz, M., 2001, Lack of effect of induction of hypothermia after acute brain injury. N. EngI.J. Med. 344, 556-563.]. However, the mean time to target temperature was over 8 h and patient inclusion was based on Glasgow Coma Scale score so brain pathology was likely diverse. There remains significant interest in the benefits of hypothermia after traumatic brain injury (TBI) and, in particular, traumatic axonal injury (TAI). which is believed to significantly contribute to morbidity and mortality of TBI patients. The long-term beneficial effect of mild hypothermia on TAI has not been established. To address this issue, we developed an in vivo rat optic nerve stretch model of TAL Adult male Sprague-Dawley rats underwent unilateral optic nerve stretch at 6, 7 or 8 mm piston displacement. The increased number of axonal swellings and bulbs immunopositive for non-phosphorylated neurofilament (SMI-32) seen four days after injury was statistically significant after 8 mm displacement. Ultrastructural analysis 2 weeks after 8 mm displacement revealed a 45.0% decrease (p<0.0001) in myelinated axonal density in the optic nerve core. There was loss of axons regardless of axon size, Immediate post-injury hypothermia (32 degrees C) for 3 h reduced axonal degeneration ill the core (p = 0.027). There was no differential protection based oil axon size. These results Support further clinical investigation of temporally optimized therapeutic hypothermia after traumatic brain injury. (C) 2008 Elsevier Inc. All rights reserved.	[Ma, Marek; Matthews, Brian T.; Lampe, Joshua W.; Shofer, Frances S.; Neumar, Robert W.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Ma, Marek; Matthews, Brian T.; Lampe, Joshua W.; Neumar, Robert W.] Univ Penn, Ctr Resuscitat Sci, Philadelphia, PA 19104 USA; [Shofer, Frances S.] Univ Penn, Sch Vet Med, Dept Clin Studies, Philadelphia, PA 19104 USA		Ma, M (corresponding author), Univ Penn, Dept Emergency Med, 3400 Spruce St,Ground Ravdin, Philadelphia, PA 19104 USA.	mamarek@uphs.upen.edu		Meaney, David/0000-0002-0954-4122; Lampe, Joshua/0000-0001-6036-535X	Research Supported by National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055880]; Society of Academic Emergency Medicine institutional Research Grant (RWN); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS055880] Funding Source: NIH RePORTER	Research Supported by National Institutes of Health grant NS055880 (MM) and the Society of Academic Emergency Medicine institutional Research Grant (RWN).	Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2003, J BIOMECH ENG-T ASME, V125, P798, DOI 10.1115/1.1632627; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 2000, J NEUROSCI, V20, P2825; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hirano Asao, 1995, P49; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Meaney DF, 2003, BIOMECH MODEL MECHAN, V1, P279, DOI 10.1007/s10237-002-0020-1; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; SUGIMOTO T, 1984, EXP BRAIN RES, V54, P266; Sun Xiaochuan, 2002, Chin J Traumatol, V5, P355	37	26	33	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2009	215	1					119	127		10.1016/j.expneurol.2008.09.024			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	394QM	WOS:000262462300015	18977220	Green Accepted			2022-02-06	
J	Schwarz, L; Penna, S; Novack, T				Schwarz, Lauren; Penna, Suzanne; Novack, Thomas			Factors contributing to performance on the Rey Complex Figure Test in individuals with traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						Traumatic brain injury; Rey Complex Figure Test; Executive function	MEMORY; IMPACT; SCALE	When examining visual memory test results one must be aware of other variables that impact performance, particularly in individuals with traumatic brain injury who have broad cognitive deficits. The present investigation sought to determine the extent to which executive functioning, as operationally defined as perceptual organization, planning, and mental flexibility, impacted Rey Complex Figure Test (RCFT) performance. Results indicated that executive functioning measures accounted for between 11% and 16% of the variance in RCFT scores. ANCOVAs revealed that the relationship between degree of executive impairment and RCFT memory trials were non-significant when performance on the copy trial was controlled for. Furthermore, speed of processing and word reading were significantly related to RCFT performance. The predicted relationship with fine motor functioning was not supported. Implications and future research directions are discussed.	[Schwarz, Lauren] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL USA; [Penna, Suzanne; Novack, Thomas] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA		Schwarz, L (corresponding author), 9324 Fredr Court, St Louis, MO 63144 USA.	larallo79@aol.com			National Institute on Disability and Rehabilitation Research, U. S. Department of EducationUS Department of Education [H133A020509]	Supported by the National Institute on Disability and Rehabilitation Research, U. S. Department of Education (grant no. H133A020509).	Ashton VL, 2005, J CLIN EXP NEUROPSYC, V27, P55, DOI 10.1080/138033990513636; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P139, DOI 10.1076/1385-4046(200002)14:1;1-8;FT139; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Millis SR, 1999, J CLIN EXP NEUROPSYC, V21, P87, DOI 10.1076/jcen.21.1.87.937; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Shum DHK, 2000, J CLIN EXP NEUROPSYC, V22, P25, DOI 10.1076/1380-3395(200002)22:1;1-8;FT025; Temple RO, 2006, CLIN NEUROPSYCHOL, V20, P480, DOI 10.1080/13854040590967540; Westervelt H, 2000, ARCH CLIN NEUROPSYCH, V15, P684, DOI 10.1016/S0887-6177(00)80060-8; [No title captured]; [No title captured]	13	26	26	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	2					255	267	PII 908190130	10.1080/13854040802220034			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	399LS	WOS:000262802000004	19172529				2022-02-06	
J	Srinivasan, L; Roberts, B; Bushnik, T; Englander, J; Spain, DA; Steinberg, GK; Ren, L; Sandel, ME; Al-Lawati, Z; Teraoka, J; Hoffman, AR; Katznelson, L				Srinivasan, Lakshmi; Roberts, Brian; Bushnik, Tamara; Englander, Jeffrey; Spain, David A.; Steinberg, Gary K.; Ren, Li; Sandel, M. Elizabeth; Al-Lawati, Zahraa; Teraoka, Jeffrey; Hoffman, Andrew R.; Katznelson, Laurence			The impact of hypopituitarism on function and performance in subjects with recent history of traumatic brain injury and aneurysmal subarachnoid haemorrhage	BRAIN INJURY			English	Article						Traumatic brain injury; hypopituitarism; growth hormone deficiency; Quality of Life; subarachnoid haemorrhage	GROWTH-HORMONE DEFICIENCY; QUALITY-OF-LIFE; ANTERIOR-PITUITARY FUNCTION; NEUROENDOCRINE DYSFUNCTION; LONG-TERM; HIGH-RISK; PREVALENCE; ADULTS; INSUFFICIENCY; ASSOCIATION	Primary objective: To correlate deficient pituitary function with life satisfaction and functional performance in subjects with a recent history of traumatic brain injury (TBI) and subarachnoid haemorrhage (SAH). Research design: Cross-sectional study. Methods and procedures: Eighteen subjects with TBI and 16 subjects with SAH underwent pituitary hormonal and functional assessments 5-12 months following the event. Adrenal reserve was assessed with a 1 mcg cosyntropin stimulation test and growth hormone deficiency (GHD) was diagnosed by insufficient GH response to GHRH-Arginine stimulation. Assessments of life satisfaction and performance-function included the Satisfaction with Life Scale (SWLS), Craig Handicap Assessment and Reporting Technique (CHART) and the Mayo Portland Adaptability Inventory-4 (MPAI-4). Results: Hypopituitarism was present in 20 (58.8%) subjects, including 50% with adrenal insufficiency. Hypothyroidism correlated with worse performance on SWLS and CHART measures. GHD was associated with poorer performance on CHART and MPAI-4 scale. Conclusions: In this series of subjects with history of TBI and SAH, hypothyroidism and GHD were associated with diminished life satisfaction and performance-function on multiple assessments. Further studies are necessary to determine the appropriate testing of adrenal reserve in this population and to determine the benefit of pituitary hormone replacement therapy on function following brain injury.	[Srinivasan, Lakshmi; Roberts, Brian; Ren, Li; Al-Lawati, Zahraa; Hoffman, Andrew R.; Katznelson, Laurence] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Bushnik, Tamara; Englander, Jeffrey] Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; [Spain, David A.] Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA; [Steinberg, Gary K.; Katznelson, Laurence] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA; [Sandel, M. Elizabeth] Kaiser Fdn, Rehabil Ctr, Vallejo, CA USA; [Teraoka, Jeffrey] Stanford Univ, Dept Rehabil Med, Sch Med, Stanford, CA 94305 USA; [Teraoka, Jeffrey] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA		Katznelson, L (corresponding author), 875 Blake Wilbur Dr, Stanford, CA 94305 USA.	lkatznelson@stanford.edu		Katznelson, Laurence/0000-0001-8115-5714; Bushnik, Tamara/0000-0003-3328-257X	Human Health Service grant [M01-RR00070]; General Clinical Research CentersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Rehabilitation Research and Development Service of the Department of Veterans AffairsUS Department of Veterans Affairs; GenentechRoche HoldingGenentech; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000070] Funding Source: NIH RePORTER	The investigation was supported by Human Health Service grant M01-RR00070, General Clinical Research Centers, National Center for Research Resources, National Institutes of Health, the Rehabilitation Research and Development Service of the Department of Veterans Affairs and fellowship stipend award from Genentech.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Alexander GM, 1998, HORM BEHAV, V33, P85, DOI 10.1006/hbeh.1998.1439; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Burmeister LA, 2001, THYROID, V11, P1177, DOI 10.1089/10507250152741037; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Corrigan J., 2000, SATISFACTION LIFE SC; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Kreitschmann-Andermahr I, 2007, CLIN ENDOCRINOL, V66, P833, DOI 10.1111/j.1365-2265.2007.02821.x; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Lieberman SA, 1996, J PEDIATR-US, V128, pS58, DOI 10.1016/S0022-3476(96)70013-6; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Malec J., 2005, MAYO PORTLAND ADAPTA; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Mellick D., 2000, CRAIG HANDICAP ASSES; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Wright J, 2000, FIM TM; Wright J, 2000, DISABILITY RATING SC	45	26	26	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					639	648	PII 912683898	10.1080/02699050902970778			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600008	19557567				2022-02-06	
J	Chaumet, G; Quera-Salva, MA; MacLeod, A; Hartley, S; Taillard, J; Sagaspe, P; Mazaux, JM; Azouvi, P; Joseph, PA; Guilleminault, C; Bioulac, B; Leger, D; Philip, P				Chaumet, G.; Quera-Salva, M. -A.; MacLeod, A.; Hartley, S.; Taillard, J.; Sagaspe, P.; Mazaux, J. -M.; Azouvi, P.; Joseph, P. -A.; Guilleminault, C.; Bioulac, B.; Leger, D.; Philip, P.			Is there a link between alertness and fatigue in patients with traumatic brain injury?	NEUROLOGY			English	Article							HEAD-INJURY; DAYTIME SLEEPINESS; ATTENTION; ADULTS; PERFORMANCE; PREVALENCE; OUTCOMES; RETURN; SCALE; TIME	Objectives: Many patients with traumatic brain injury (TBI) report chronic fatigue, and previous studies showed a potential relationship between sleepiness and fatigue in these patients. Our study first looked at the impact of objective and subjective sleepiness on fatigue in patients with TBI. We then investigated how fatigue could affect driving performance in these patients. Methods: Nocturnal polysomnography, the Fatigue Severity Scale (FSS), the Epworth Sleepiness Scale (ESS), and five 40-minute maintenance of wakefulness tests (MWT) were collected in 36 patients with TBI. Fitness to drive was assessed in a subsample of 22 patients compared to 22 matched controls during an hour simulated driving session. Results: In patients with TBI, FSS, ESS, and mean MWT scores (+/- SD) were 27 +/- 10, 8 +/- 4, and 35 +/- 7 minutes vs 15 +/- 2.5, 5 +/- 3, and 37 +/- 5 minutes in controls. Patients with TBI reported more chronic fatigue (W = 99, p < 0.001) than controls, and, unlike in controls, the level of chronic fatigue was correlated to their MWT scores. Patients' driving performances were worse than the controls' (W = 79, p < 0.001). The best predictive factors of driving performance were fatigue scores and body mass index (multiple R = 0.458, 41.8% of explained variance). Conclusion: In patients with TBI, chronic fatigue is significantly related to subjective and objective levels of alertness, even though these levels are not highly pathologic. This might suggest that a small level of sleepiness (i.e., MWT scores between 33 and 39 minutes) worsens fatigue in these patients. Chronic fatigue and body mass index could predict driving simulator performance in patients with TBI. Neurology (R) 2008; 71: 1609-1613	[Chaumet, G.] Univ Bordeaux 2, Dept Psychol, F-33076 Bordeaux, France; [Chaumet, G.; Taillard, J.; Sagaspe, P.; Bioulac, B.; Philip, P.] CNRS, GENPPHASS, UMR 5227, Bordeaux, France; [Quera-Salva, M. -A.; Hartley, S.] Garches Univ, Sch Med, Neurol Rehabil Dept, Garches, France; [MacLeod, A.; Taillard, J.; Philip, P.] Univ Hosp Pellegrin, Sleep Clin, Bordeaux, France; [Sagaspe, P.] INRETS, Arcueil, France; [Mazaux, J. -M.; Joseph, P. -A.] Univ Bordeaux, Sch Med, Ctr Neurol Rehabil Dept, Bordeaux, France; [Azouvi, P.; Leger, D.] Univ Hosp Hotel Dieu, Sleep Clin, Paris, France; [Guilleminault, C.] Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA		Philip, P (corresponding author), Univ Bordeaux 2, CHU Pellegrin GENPPHASS, CNRS, UMR 5227, Pl Amelie Raba Leon, F-33076 Bordeaux, France.	pr.philip@free.fr	Taillard, Jacques/H-5063-2018; PHILIP, Pierre/AAS-8889-2020	Taillard, Jacques/0000-0001-9067-8189; PHILIP, Pierre/0000-0003-3267-634X; SAGASPE, Patricia/0000-0003-2845-1199; Hartley, Sarah/0000-0003-3028-4430	French Ministry of Health; Conseil Regional d'AquitaineRegion Nouvelle-Aquitaine	Supported by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC). G. C. was funded by a grant of Conseil Regional d'Aquitaine.	Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Barkley RA, 2007, J SAFETY RES, V38, P113, DOI 10.1016/j.jsr.2006.09.004; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Doghramji K, 1997, ELECTROEN CLIN NEURO, V103, P554, DOI 10.1016/S0013-4694(97)00010-2; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fisk GD, 2002, J HEAD TRAUMA REHAB, V17, P16, DOI 10.1097/00001199-200202000-00004; Fisk GD, 1998, BRAIN INJURY, V12, P683; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hillier SL, 1997, BRAIN INJURY, V11, P661; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; MARSHALL LF, 1991, J NEUROSURG, P75; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Newby G, 1999, BRIT J GEN PRACT, V49, P301; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; STOOHS RA, 1994, SLEEP, V17, P619; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Young T, 2004, JAMA-J AM MED ASSOC, V291, P2013, DOI 10.1001/jama.291.16.2013; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	36	26	27	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 11	2008	71	20					1609	1613		10.1212/01.wnl.0000334753.49193.48			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	370XF	WOS:000260795700009	19001250				2022-02-06	
J	Shafi, S; Gentilello, LM				Shafi, Shahid; Gentilello, Larry M.			Ethnic Disparities in Initial Management of Trauma Patients in a Nationwide Sample of Emergency Department Visits	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	2nd Annual Academic Surgical Congress of the Association-for-Academic-Surgery	FEB 09-12, 2007	Phoenix, AZ	Assoc Acad Surg, Soc Univ Surg			ACUTE MYOCARDIAL-INFARCTION; RACIAL DISPARITIES; UNITED-STATES; HEALTH-CARE; RACE; TRANSPLANTATION	Hypothesis: Ethnic disparities in functional outcomes after traumatic brain injuries have been demonstrated previously. However, it is not clear if these disparities are due to differential access to initial diagnostic and treatment modalities or disproportionate care at poorly funded inner-city emergency departments (EDs). We hypothesized that initial assessment of injured patients in EDs is affected by patient ethnicity. Design: Retrospective database analysis. Setting: Data were obtained from the National Hospital Ambulatory Medical Care Survey ED component for 2003, which includes a national probability sample survey of ED visits. Patients: All injury-related initial ED visits of patients 15 years and older were included. Patients were divided into 3 groups: non-Hispanic white (n = 6106), African American (n = 1406), and Hispanic (n = 1051). Main Outcome Measures: The intensity of ED assessment and management and patient disposition from EDs were compared in the 3 groups. Results: Compared with non-Hispanic white patients, minority patients were slightly younger and less likely to be insured but were similar in sex, mechanism of injury, and injury severity. There were no clinically significant differences between non-Hispanic white patients and the 2 minority groups in ED assessment, diagnostic and treatment modalities, and ED disposition. There were no systematic differences by region of the country, ownership of the hospitals, or insurance status of the patients. Conclusion: The initial assessment and management of injured patients from ethnic/racial minorities was similar to that of non-Hispanic white patients in a nationwide representative sample of ED visits. Other causes of ethnic disparities in outcomes after injuries should be sought.	[Shafi, Shahid; Gentilello, Larry M.] Univ Texas SW Med Sch, Div Burns Trauma & Crit Care, Dept Surg, Dallas, TX 75390 USA		Shafi, S (corresponding author), Univ Texas SW Med Sch, Div Burns Trauma & Crit Care, Dept Surg, 5323 Harry Hines Blvd,Mail Stop 9158, Dallas, TX 75390 USA.	shahid.shafi@utsouthwestern.edu					*AG HEALTHC RES QU, 2005, NAT HEALTHC DISP REP, P90; *AM COLL SURG, 2004, ATLS ADV TRAUM SUPP; BAMHART JM, 2003, ARCH INTERN MED, V163, P461; Barnato AE, 2005, MED CARE, V43, P308, DOI 10.1097/01.mlr.0000156848.62086.06; Bertoni AG, 2005, J NATL MED ASSOC, V97, P317; COLLINS KS, 1999, MINORITY HLTH CHARTB; Delano BG, 1997, ASAIO J, V43, pM861; Fiscella K, 2002, MED CARE, V40, P52, DOI 10.1097/00005650-200201000-00007; Flattery Maureen P, 2004, J Cult Divers, V11, P25; Kokoska ER, 2007, J SURG RES, V137, P83, DOI 10.1016/j.jss.2006.06.020; Lucas FL, 2006, ANN SURG, V243, P281, DOI 10.1097/01.sla.0000197560.92456.32; Mochari Heidi, 2006, Prev Cardiol, V9, P8, DOI 10.1111/j.1520-037X.2005.3703.x; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; Reid AE, 2004, LIVER TRANSPLANT, V10, P834, DOI 10.1002/lt.20174; Satcher D, 2000, J NATL MED ASSOC, V92, P315; SHAFI S, 2007, RACIAL DISPARITIES L; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; STAUDENMAYER KL, 2007, ETHNIC DISPARITIES L; Weinick RM, 2000, MED CARE RES REV, V57, P36, DOI 10.1177/107755800773743592; Werner RM, 2005, CIRCULATION, V111, P1257, DOI 10.1161/01.CIR.0000157729.59754.09	20	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	NOV	2008	143	11					1057	1061		10.1001/archsurg.143.11.1057			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	384JN	WOS:000261741200006	19015463	Bronze			2022-02-06	
J	Vukovic, M; Vuksanovic, J; Vukovic, I				Vukovic, Mile; Vuksanovic, Jasmina; Vukovic, Irena			Comparison of the recovery patterns of language and cognitive functions in patients with post-traumatic language processing deficits and in patients with aphasia following a stroke	JOURNAL OF COMMUNICATION DISORDERS			English	Article							CLOSED HEAD-INJURY; CONDUCTION APHASIA; VERBAL IMPAIRMENT; MEMORY; REHABILITATION; INTELLIGENCE; PERFORMANCE; REPETITION; APRAXIA; TRAUMA	In this study we investigated the recovery patterns of language and cognitive functions in patients with post-traumatic language processing deficits and in patients with aphasia following a stroke. The correlation of specific language functions and cognitive functions was analyzed in the acute phase and 6 months later. Significant recovery of the tested functions was observed in both groups. However, in patients with post-traumatic language processing deficits the degree of recovery of most language functions and some cognitive functions was higher. A significantly greater correlation was revealed within language and cognitive functions, as well as between language functions and other aspects of cognition in patients with post-traumatic language processing deficits than in patients with aphasia following a stroke. Our results show that patients with post-traumatic language processing deficits have a different recovery pattern and a different pattern of correlation between language and cognitive functions compared to patients with aphasia following a stroke. Learning outcomes: (1) Better understanding of the differences in recovery of language and cognitive functions in patients who have suffered strokes and those who have experienced traumatic brain injury. (2) Better understanding of the relationship between language and cognitive functions in patients with post-traumatic language processing deficits and in patients with aphasia following a stroke. (3) Better understanding of the factors influencing recovery. (c) 2008 Elsevier Inc. All rights reserved.	[Vukovic, Mile] Univ Belgrade, Fac Special Educ & Rehabil, Belgrade 11000, Serbia; [Vuksanovic, Jasmina] Hlth Ctr Zemun, Belgrade 11000, Serbia; [Vukovic, Irena] Univ Belgrade, Ctr Multidisciplinary Studies, Belgrade 11000, Serbia		Vukovic, M (corresponding author), Univ Belgrade, Fac Special Educ & Rehabil, Belgrade 11000, Serbia.	mvukovic@yubc.net		Vukovic, Irena/0000-0001-8288-4222; Vukovic, Mile/0000-0003-3750-7991			Archibald Z. M., 1967, CORTEX, V3, P275; Baldo JV, 2005, BRAIN LANG, V92, P240, DOI 10.1016/j.bandl.2004.06.103; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Bartha L, 2004, BRAIN LANG, V88, P83, DOI 10.1016/S0093-934X(03)00281-5; Bartha L, 2003, BRAIN LANG, V85, P93, DOI 10.1016/S0093-934X(02)00502-3; BASSO A, 1981, BRAIN, V104, P721, DOI 10.1093/brain/104.4.721; BASSO A, 1979, ARCH NEUROL-CHICAGO, V36, P190, DOI 10.1001/archneur.1979.00500400044005; BASSO A, 1973, BRAIN, V96, P715, DOI 10.1093/brain/96.4.715; BASSO A, 1982, CORTEX, V18, P469, DOI 10.1016/S0010-9452(82)80044-0; Basso A, 2003, APHASIA ITS THERAPY; Berndt R. S., 1990, NEUROPSYCHOLOGICAL I, P115; BOROD JC, 1982, CORTEX, V18, P199, DOI 10.1016/S0010-9452(82)80003-8; Bryan J, 2000, J CLIN EXP NEUROPSYC, V22, P40, DOI 10.1076/1380-3395(200002)22:1;1-8;FT040; BUTFIELD E, 1946, J NEUROL NEUROSUR PS, V9, P75, DOI 10.1136/jnnp.9.2.75; Cappa S.F., 1998, HDB NEUROLINGUISTICS, P535; CARAMAZZA A, 1981, BRAIN LANG, V14, P235, DOI 10.1016/0093-934X(81)90078-X; Caspari I, 1998, BRAIN COGNITION, V37, P205, DOI 10.1006/brcg.1997.0970; Goodglass H, 1983, ASSESSMENT APHASIA R; Granacher RP., 2003, TRAUMATIC BRAIN INJU; Hagan C., 1982, COGNITIVE REHABILITA, P131; HAGAN C, 1984, LANGUAGE DISORDERS A; HAMSHER K, 1991, ACQUIRED APHASIA, P339; Hartley L. L, 1995, COGNITIVE COMMUNICAT; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Helm-Estabrooks N, 2002, J COMMUN DISORD, V35, P171, DOI 10.1016/S0021-9924(02)00063-1; HJELMQUIST EKE, 1989, SCAND J PSYCHOL, V30, P243, DOI 10.1111/j.1467-9450.1989.tb01087.x; HULME C, 1991, J MEM LANG, V30, P685, DOI 10.1016/0749-596X(91)90032-F; Kaplan E, 1983, BOSTON NAMING TEST; KERTESZ A, 1977, BRAIN, V100, P1, DOI 10.1093/brain/100.1.1; KERTESZ A, 1975, BRAIN LANG, V2, P385; KOHLMEYER K, 1976, RECOVERY APHASICS; Laska AC, 2001, J INTERN MED, V249, P413, DOI 10.1046/j.1365-2796.2001.00812.x; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1976, NEUROPSYCHOLOGICAL A; Luria A.R., 1970, TRAUMATIC APHASIA; MARKS M, 1957, NEUROLOGY, V7, P837, DOI 10.1212/WNL.7.12.837; MARSHALL RC, 1982, FOLIA PHONIATR, V34, P305, DOI 10.1159/000265671; Martin N, 2004, BRAIN LANG, V89, P464, DOI 10.1016/j.bandl.2003.12.004; Martin N, 1997, COGNITIVE NEUROPSYCH, V14, P641; Martin N, 1996, BRAIN LANG, V52, P83, DOI 10.1006/brln.1996.0005; Osterrieth PA, 1994, ARCH PSYCHOL, V30, P286; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Raven J. C., 1960, GUIDE STANDARD PROGR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rothi Leslie J. Gonzalez, 1997, P91; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1991, ACQUIRED APHASIA; Sohlberg M., 2001, COGNITIVE REHABILITA; Spreen O., 2003, ASSESSMENT APHASIA; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; VIGNOLO LA, 1964, CORTEX, V1, P344, DOI DOI 10.1016/S0010-9452(64)80008-3; Vukovic M, 1998, TRAUMATIC APHASIA; [No title captured]	55	26	32	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924			J COMMUN DISORD	J. Commun. Disord.	NOV-DEC	2008	41	6					531	552		10.1016/j.jcomdis.2008.04.001			22	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	349MO	WOS:000259285100005	18571195				2022-02-06	
J	Russeler, J; Brett, A; Klaue, U; Sailer, M; Munte, TF				Ruesseler, Jascha; Brett, Alexandra; Klaue, Ulrike; Sailer, Michael; Muente, Thomas F.			The effect of coaching on the simulated malingering of memory impairment	BMC NEUROLOGY			English	Article							SYMPTOM VALIDITY TESTS; VERBAL-LEARNING TEST; FORENSIC NEUROPSYCHOLOGY; EXPANDED VERSION; HEAD-INJURY; EXAGGERATION; PERFORMANCE; VALIDATION; ATTORNEYS; DEFICITS/	Background: Detecting malingering or exaggeration of impairments in brain function after traumatic brain injury is of increasing importance in neuropsychological assessment. Lawyers involved in brain injury litigation cases routinely coach their clients how to approach neuropsychological testing to their advantage. Thus, it is important to know how robust assessment methods are with respect to symptom malingering or exaggeration. Methods: The influence of different coaching methods on the simulated malingering of memory impairments is investigated in neurologically healthy participants using the Short-Term-Memory Test from the Bremer Symptom-Validierung (STM-BSV). Cut-offs were derived from patients with mild to severe traumatic brain injury. For comparison purposes, the German adaptation of the Rey Auditory Verbal Learning Test (AVLT), and the Rey 15 Items Test (FIT) were additionally administered. Four groups of neurologically healthy subjects were instructed to (1) perform as best as they can, (2) simulate brain injury, (3) simulate brain injury and received additional information about the sequelae of head trauma, (4) simulate brain injury and received additional information on how to avoid detection. Furthermore, a group of patients with mild to severe closed head injury performed the tests with best effort. Results: The nave simulator and the symptom coached groups were the easiest to detect, whereas the symptom plus test coached group was the hardest to detect. The AVLT and the FIT were not suited to detect simulators (sensitivities from 0% to 50.8% at 75% specificity) whereas the STM-BSV detected simulators with 67% - 88% sensitivity at a specificity of 73%. However, the STM-BSV was not robust to coaching. Conclusion: The present investigation shows that symptom validity testing as implemented in the BSV-STM is one clinically useful element in the detection of memory malingering. However, clinicians have to be aware that coaching influences performance in the test.	[Ruesseler, Jascha; Brett, Alexandra; Klaue, Ulrike; Muente, Thomas F.] Otto von Guericke Univ, Dept Psychol 2, Neuropsychol Unit, Magdeburg, Germany; [Ruesseler, Jascha; Muente, Thomas F.] Ctr Behav Brain Sci, Magdeburg, Germany; [Klaue, Ulrike; Sailer, Michael] Median Klin NRZ, Magdeburg, Germany; [Sailer, Michael] Otto von Guericke Univ, Klin Neurol 2, Magdeburg, Germany; [Ruesseler, Jascha] Inst Psychol 2, Abt Neuropsychol, D-39016 Magdeburg, Germany		Russeler, J (corresponding author), Otto von Guericke Univ, Dept Psychol 2, Neuropsychol Unit, Magdeburg, Germany.	jascha.ruesseler@nat.uni-magdeburg.de; alexandra.brett@ovgu.de; ulrike.klaue@web.de; michael.sailer@med.ovgu.de; thomas.muente@med.ovgu.de	Munte, Thomas/C-2077-2014	Russeler, Jascha/0000-0002-5053-5914	Research of JR and TFM; German Research Foundation (DFG)German Research Foundation (DFG)	We thank Susanne Ploetz, Maria Zinke, and Kerstin Patzwald for help in data acquisition and the Median Klinik NRZ Magdeburg for support in assessing the patients. Research of JR and TFM is financially supported by various grants from the German Research Foundation (DFG).	Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; Bauer L, 2006, ARCH CLIN NEUROPSYCH, V21, P121, DOI 10.1016/j.acn.2005.06.010; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; BOONE KB, 2007, ASSESSMENT MALINGERE, P27; Brennan AM, 2006, APPL NEUROPSYCHOL, V13, P1, DOI 10.1207/s15324826an1301_1; BRICKENKAMP R, 2002, TEST D2; Essig SM, 2001, ARCH CLIN NEUROPSYCH, V16, P271, DOI 10.1016/S0887-6177(99)00065-7; Glassmire DM, 2003, J CLIN EXP NEUROPSYC, V25, P465, DOI 10.1076/jcen.25.4.465.13875; Gouvier W. D., 1988, ARCH CLIN NEUROPSYCH, V3, P331; Green P., 2003, GREENS WORD MEMORY T; Haines ME, 2001, CLIN NEUROPSYCHOL, V15, P171, DOI 10.1076/clin.15.2.171.1891; Heilbronner RL, 2004, CLIN NEUROPSYCHOL, V18, P312, DOI 10.1080/13854040490501574; HEILBRUN K, 1990, BEHAV SCI LAW, V0008, P00045, DOI DOI 10.1002/BSL.2370080106; Helmstaedter C., 2001, VERBALER LERN MERKFA; Heubrock D., 2000, TESTBATTERIE FORENSI; Hilsabeck RC, 2001, ARCH CLIN NEUROPSYCH, V16, P669, DOI 10.1016/S0887-6177(00)00077-9; Jager A. O., 1997, BERLINER INTELLIGENZ; Langeluddecke PM, 2005, J CLIN EXP NEUROPSYC, V27, P576, DOI 10.1080/13803390490918372; Larrabee G.J., 2007, ASSESSMENT MALINGERE, P14; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P80; Lynch W, 2004, J HEAD TRAUMA REHAB, V19, P277, DOI 10.1097/00001199-200405000-00008; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Suhr J, 2004, J CLIN EXP NEUROPSYC, V26, P416, DOI 10.1080/13803390490510121; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr J.A., 2007, ASSESSMENT MALINGERE, P131; Suhr J.A., 2007, ASSESSMENT MALINGERE, P287; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; WETTER MW, 1995, PROF PSYCHOL-RES PR, V26, P474, DOI 10.1037/0735-7028.26.5.474; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Zimmermann P, 2002, TESTBATTERIE AUFMERK	41	26	26	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	OCT 7	2008	8								37	10.1186/1471-2377-8-37			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	363GU	WOS:000260256600001	18838010	gold, Green Published			2022-02-06	
J	Hartley, CE; Varma, M; Fischer, JP; Riccardi, R; Strauss, JA; Shah, S; Zhang, S; Yang, ZJ				Hartley, Chad E.; Varma, Madhu; Fischer, John P.; Riccardi, Richard; Strauss, Judith A.; Shah, Sejal; Zhang, Shengle; Yang, Zhong-Jin			Neuroprotective effects of erythropoietin on acute metabolic and pathological changes in experimentally induced neurotrauma	JOURNAL OF NEUROSURGERY			English	Article						erythropoietin; microdialysis; neuroprotection; rat; traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; IN-VIVO EVIDENCE; CEREBRAL-ISCHEMIA; CEREBROSPINAL-FLUID; NEURONAL APOPTOSIS; ENDOTHELIAL-CELLS; PROTECTS NEURONS; BRAIN-INJURY; RECEPTOR; LACTATE	Object. Head trauma is a dynamic process characterized by a cascade of metabolic and molecular events. Erythropoietin (EPO) has been shown to have neuroprotective effects in animal models Of traumatic brain injury (TBI). Acute in vivo mechanisms and pathological changes associated with EPO following TBI are unknown. In this study the authors compare acute metabolic and pathological changes following TBI with and without systemically administered EPO. Methods. Right frontal lobe microdialysis cannulae and right parietal lobe percussion hubs were inserted into 16 Sprague-Dawley rats. After a 4- to 5-day recovery. TBI was induced via a DragonFly fluid-percussion device at 2.5-2.8 atm. Rats were randomized into 2 groups. which received 5000 U/kg EPO or normal saline intraperitoneally 30 minutes after TBI. Microdialysis samples for glucose, lactate, pyruvate. and glutamate were obtained every 25 minutes for 10 hours. Rats were killed, their brains processed for light microscopy, and sections stained with H & E. Results. Erythropoietin administered 30 Minutes after TBI directly affects acute brain metabolism. Brains treated with EPO maintain hi-her levels Of glucose 4-10 hours after TBI (p < 0.01). lower levels of lactate 6-10 hours after TBI (p < 0.01). and lower levels of pyruvate 7.5-10 hours after TBI (1) < 0.01) compared with saline-treated controls. Erythropoietin maintains aerobic metabolism after TBI. Systemic EPO administration reduces acute TBI-induced lesion volume (1) < 0.05). Conclusions. Following TBI, neuron use initially increases, with subsequent depletion of extracellular glucose, resulting in increased levels of extracellular lactate and pyruvate. This energy requirement can result in cell death due to increased metabolic demands. These data Suggest that the neuroprotective effect of EPO may be partially due to improved energy metabolism in the acute phase in this rat model of TBI.	[Hartley, Chad E.; Fischer, John P.] SUNY, Upstate Med Univ, Dept Neurosurg, Syracuse, NY 13210 USA; [Varma, Madhu; Riccardi, Richard; Yang, Zhong-Jin] SUNY, Upstate Med Univ, Dept Anesthesiol, Syracuse, NY 13210 USA; [Strauss, Judith A.] SUNY, Upstate Med Univ, Dept Orthoped, Syracuse, NY 13210 USA; [Shah, Sejal; Zhang, Shengle] SUNY, Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA		Hartley, CE (corresponding author), SUNY, Upstate Med Univ, Dept Neurosurg, 750 E Adams St, Syracuse, NY 13210 USA.	chadhartley@centura.org			Departments of Anesthesiology and Neurosurgery, Upstate Medical University, State University of New York	Support was provided for Dr. Hartley by the Departments of Anesthesiology and Neurosurgery, Upstate Medical University, State University of New York.	Alafaci C, 2000, EUR J PHARMACOL, V406, P219, DOI 10.1016/S0014-2999(00)00691-9; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Banerjee D, 2000, KIDNEY INT, V57, P1895, DOI 10.1046/j.1523-1755.2000.00039.x; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; BUEMI M, 1993, NEPHRON, V65, P440, DOI 10.1159/000187526; Buemi M, 2000, EUR J PHARMACOL, V392, P31, DOI 10.1016/S0014-2999(00)00081-9; Buemi M, 2000, NEPHROL DIAL TRANSPL, V15, P422, DOI 10.1093/ndt/15.3.422; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cheetham JC, 1998, NAT STRUCT BIOL, V5, P861, DOI 10.1038/2302; Chin K, 2000, MOL BRAIN RES, V81, P29, DOI 10.1016/S0169-328X(00)00157-1; COMBS DJ, 1990, STROKE, V21, P936, DOI 10.1161/01.STR.21.6.936; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2002, J NEUROSURG, V96, P565, DOI 10.3171/jns.2002.96.3.0565; Grasso G, 2001, J Neurosurg Sci, V45, P7; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Howard C.V., 1998, UNBIASED STEREOLOGY, V1; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1994, J BIOL CHEM, V269, P19488; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Murr R, 1996, ACTA NEUROCHIR, V138, P928, DOI 10.1007/BF01411281; Nagai A, 2001, J NEUROPATH EXP NEUR, V60, P386, DOI 10.1093/jnen/60.4.386; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Reeker W, 2000, CAN J ANAESTH, V47, P572, DOI 10.1007/BF03018950; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	50	26	27	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					708	714		10.3171/JNS/2008/109/10/0708			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100017	18826359				2022-02-06	
J	Sharp, HM; Hillenbrand, K				Sharp, Helen M.; Hillenbrand, Kathryn			Speech and Language Development and Disorders in Children	PEDIATRIC CLINICS OF NORTH AMERICA			English	Article						Child language; Developmental disabilities; Articulation; Apraxia; Cleft palate; Autism; Speech-languate evaluation; Speech therapy	AUTISM SPECTRUM DISORDERS; TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; PALATE; IDENTIFICATION; VOCALIZATIONS; DISABILITIES; IMPAIRMENT; MANAGEMENT; CHILDHOOD	Language disorders are identified when a person has difficulty with expressive language, receptive language, or pragmatic language. Speech disorders are identified when a person's voice, fluency, or articulation call attention to the speaker because his or her speech is sufficiently different from the norm. Speech and language development should be consistent with a child's overall development and can be tracked using typical milestone markers. Differential diagnosis is critical to designing appropriate intervention, which should be tailored to the parents' goals along with the child's clinical and educational needs. Early identification and intervention assist in educational planning and are often associated with better long-term outcomes. Any speech-language therapy plan should be designed with measurable goals and consistent monitoring of progress toward those goals.	[Sharp, Helen M.; Hillenbrand, Kathryn] Western Michigan Univ, Dept Speech Pathol & Audiol, Kalamazoo, MI 49008 USA		Sharp, HM (corresponding author), Western Michigan Univ, Dept Speech Pathol & Audiol, 1903 W Michigan Ave,MS 5355, Kalamazoo, MI 49008 USA.	helen.sharp@wmich.edu					*AM AC PED, 2007, AUT ALARM; *AM SPEECH LANG HE, WHAT IS LANG WHAT IS; *AM SPEECH LANG HE, 2008, PRINC SPEECH LANG PA; American Speech-Language-Hearing Association, 2008, ROL RESP SPEECH LANG; American Speech-Language-Hearing Association, NAT OUTC MEAS SYST N; American Speech-Language-Hearing Association, 2007, CHILDH APR SPEECH; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Arvedson Joan C, 2000, Lang Speech Hear Serv Sch, V31, P28, DOI 10.1044/0161-1461.3101.28; BAUMANWAENGLER J, 2003, ARTICULATORY PHONOLO; Bernthal JE, 2004, ARTICULATION PHONOLO; CATTS HW, 1993, J SPEECH HEAR RES, V36, P948, DOI 10.1044/jshr.3605.948; Clark HM, 2003, AM J SPEECH-LANG PAT, V12, P400, DOI 10.1044/1058-0360(2003/086); Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Frederickson MS, 2006, CLEFT PALATE-CRAN J, V43, P179, DOI 10.1597/04-086.1; Geren Joy, 2005, Seminars in Speech and Language, V26, P44, DOI 10.1055/s-2005-864215; GLENNEN S, 2002, LANGUAGE DEV INT ADO; Greenspan SI, 2008, PEDIATRICS, V121, P828, DOI 10.1542/peds.2007-3833; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Hall PK, 2000, LANG SPEECH HEAR SER, V31, P179, DOI 10.1044/0161-1461.3102.179; Henry J, 2007, LANG SPEECH HEAR SER, V38, P99, DOI 10.1044/0161-1461(2007/010); Johnson CP, 2007, PEDIATRICS, V120, P1183, DOI 10.1542/peds.2007-2361; Jones KL, 1997, SMITHS RECOGNIZABLE; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Krakow Rena A., 2005, Seminars in Speech and Language, V26, P33, DOI 10.1055/s-2005-864214; Kuhl PK, 1996, J ACOUST SOC AM, V100, P2425, DOI 10.1121/1.417951; Light J, 2007, AUGMENT ALTERN COMM, V23, P204, DOI 10.1080/07434610701553635; Luinge MR, 2006, J SPEECH LANG HEAR R, V49, P923, DOI 10.1044/1092-4388(2006/067); MCWILLIAMS BJ, 1991, CLEFT PALATE-CRAN J, V28, P247, DOI 10.1597/1545-1569(1991)028<0247:SCOTPH>2.3.CO;2; Millar DC, 2006, J SPEECH LANG HEAR R, V49, P248, DOI 10.1044/1092-4388(2006/021); Morris H, 2003, CLEFT PALATE-CRAN J, V40, P460, DOI 10.1597/1545-1569(2003)040<0460:PPALSO>2.0.CO;2; Myers SM, 2007, PEDIATRICS, V120, P1162, DOI 10.1542/peds.2007-2362; Nelson N. W., 2004, WRITING LAB APPROACH; OLLER DK, 1985, J SPEECH HEAR RES, V28, P47, DOI 10.1044/jshr.2801.47; OWENS RE, 2006, HUMAN COMMUNICATION; PRATHER EM, 1975, J SPEECH HEAR DISORD, V40, P179, DOI 10.1044/jshd.4002.179; RAMIG PR, 2006, HUMAN COMMUNICATION; RICHMAN LC, 1988, CLEFT PALATE J, V25, P21; SCHIFFMYERS NB, 1992, LANG SPEECH HEAR SER, V23, P28; Sebastian-Galles N, 2007, DEVELOPMENTAL SCI, V10, P713, DOI 10.1111/j.1467-7687.2007.00649.x; SMITH BL, 1983, J SPEECH HEAR DISORD, V48, P114, DOI 10.1044/jshd.4802.114; Stoel-Gammon C., 1987, LANG SPEECH HEAR SER, V18, P323, DOI DOI 10.1044/0161-1461.1804.323; SWANSON LA, 1992, J SPEECH HEAR RES, V35, P617, DOI 10.1044/jshr.3503.617; Szatmari P, 2003, J CHILD PSYCHOL PSYC, V44, P520, DOI 10.1111/1469-7610.00141; Thomas JA, 1997, CLIN PEDIATR, V36, P253, DOI 10.1177/000992289703600502; TOMBLIN JB, 1989, J SPEECH HEAR DISORD, V54, P287, DOI 10.1044/jshd.5402.287; Tomblin JB, 1998, J SPEECH LANG HEAR R, V41, P188, DOI 10.1044/jslhr.4101.188; Tomblin JB, 1997, J SPEECH LANG HEAR R, V40, P1245, DOI 10.1044/jslhr.4006.1245; Yairi E, 1996, J SPEECH HEAR RES, V39, P771, DOI 10.1044/jshr.3904.771; Yairi E., 1997, NATURE TREATMENT STU; [No title captured]	50	26	27	4	45	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0031-3955	1557-8240		PEDIATR CLIN N AM	Pediatr. Clin. N. Am.	OCT	2008	55	5					1159	+		10.1016/j.pcl.2008.07.007			16	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	368WY	WOS:000260654800008	18929058				2022-02-06	
J	Fisk, JE; Montgomery, C				Fisk, J. E.; Montgomery, C.			Real-world memory and executive processes in cannabis users and non-users	JOURNAL OF PSYCHOPHARMACOLOGY			English	Article						separable executive processes; everyday memory; prospective memory; cognitive failures; cannabis	COGNITIVE FAILURES QUESTIONNAIRE; TRAUMATIC BRAIN-INJURY; EVERYDAY MEMORY; RECREATIONAL USE; WORKING-MEMORY; MARIJUANA USE; ECSTASY MDMA; DEFICITS; IMPAIRMENT; ATTENTION	The relationships between executive processes, associative learning and different aspects of real world memory functioning were explored in a sample of cannabis users and nonusers. Measures of executive component processes, associative learning, everyday memory, prospective memory, and cognitive failures were administered. Relative to nonusers, cannabis users were found to be impaired in several aspects of real world memory functioning. No other group differences were apparent. The absence of cannabis related deficits in those executive component processes and aspects of learning that are believed to support real world memory processes is surprising given that cannabis related deficits were obtained in real world memory. The present results are discussed within the context of neuroimaging evidence which suggests that cannabis users may exhibit different patterns of neural activation when performing executive tasks while not always exhibiting deficits on these tasks.	[Fisk, J. E.] Univ Cent Lancashire, Dept Psychol, Preston PR1 2HE, Lancs, England; [Montgomery, C.] Liverpool John Moores Univ, Sch Psychol, Liverpool L3 5UX, Merseyside, England		Fisk, JE (corresponding author), Univ Cent Lancashire, Dept Psychol, Preston PR1 2HE, Lancs, England.	jfisk@uclan.ac.uk	Aviles, Jose Manuel Reales/G-3929-2011; Ballesteros, Soledad/F-5561-2015; Montgomery, Catharine/B-6096-2014	Aviles, Jose Manuel Reales/0000-0003-3340-8873; Ballesteros, Soledad/0000-0002-8391-9615; Montgomery, Catharine/0000-0003-2805-5807			Andersson M, 2005, J NEUROSCI, V25, P8432, DOI 10.1523/JNEUROSCI.1289-05.2005; BLOCK RI, 1993, PSYCHOPHARMACOLOGY, V110, P219, DOI 10.1007/BF02246977; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Collette F, 2006, NEUROSCIENCE, V139, P209, DOI 10.1016/j.neuroscience.2005.05.035; Cornish IM, 2000, BRIT J PSYCHOL, V91, P427, DOI 10.1348/000712600161916; Croft RJ, 2001, PSYCHOPHARMACOLOGY, V153, P373, DOI 10.1007/s002130000591; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Efklides A, 2002, EUR J PSYCHOL ASSESS, V18, P63, DOI 10.1027//1015-5759.18.1.63; FEHR KA, 1976, SCIENCE, V192, P1249, DOI 10.1126/science.1273591; Fisk JE, 2004, J CLIN EXP NEUROPSYC, V26, P874, DOI 10.1080/13803390490510680; GOLDSTEIN LH, 1992, CORTEX, V28, P189, DOI 10.1016/S0010-9452(13)80047-0; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hubert JP, 1998, DRUG DEVELOP RES, V45, P74, DOI 10.1002/(SICI)1098-2299(199810)45:2<74::AID-DDR4>3.0.CO;2-H; Jacobsen LK, 2007, BIOL PSYCHIAT, V61, P31, DOI 10.1016/j.biopsych.2006.02.014; Jager G, 2006, PSYCHOPHARMACOLOGY, V185, P358, DOI 10.1007/s00213-005-0298-7; Jager G, 2007, EUR NEUROPSYCHOPHARM, V17, P289, DOI 10.1016/j.euroneuro.2006.10.003; Jones GV, 2003, APPL COGNITIVE PSYCH, V17, P861, DOI 10.1002/acp.935; Kliegel M, 2005, J NEUROL NEUROSUR PS, V76, P1501, DOI 10.1136/jnnp.2004.051268; Knight RG, 2004, NEW ZEAL J PSYCHOL, V33, P163; KOLTAI DC, 1996, ASSESSMENT, V3, P443, DOI DOI 10.1177/107319119600300410; Lawston J, 2000, BRAIN RES, V877, P407, DOI 10.1016/S0006-8993(00)02739-6; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P336, DOI 10.1037/0278-7393.24.2.336; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; Messinis L, 2006, NEUROLOGY, V66, P737, DOI 10.1212/01.wnl.0000201279.83203.c6; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Montgomery C, 2005, PSYCHOPHARMACOLOGY, V182, P262, DOI 10.1007/s00213-005-0065-9; Montgomery C, 2005, PSYCHOPHARMACOLOGY, V180, P141, DOI 10.1007/s00213-004-2131-0; Morgan MJ, 1998, NEUROPSYCHOPHARMACOL, V19, P252, DOI 10.1016/S0893-133X(98)00012-8; Morgan MJ, 1999, PSYCHOPHARMACOLOGY, V141, P30, DOI 10.1007/s002130050803; Nelson H.E., 1982, NATL ADULT READING T; Olsson E, 2006, NEUROPSYCHOL REHABIL, V16, P257, DOI 10.1080/09602010500176328; Pope HG, 1997, PSYCHOTHER PSYCHOSOM, V66, P179; Raven J, 1998, MANUAL RAVENS PROGR; Rodgers J, 2000, PSYCHOPHARMACOLOGY, V151, P19, DOI 10.1007/s002130000467; Rodgers J, 2001, HUM PSYCHOPHARM CLIN, V16, P619, DOI 10.1002/hup.345; Sarne Y, 2004, MED HYPOTHESES, V63, P187, DOI 10.1016/j.mehy.2004.02.043; SARNE Y, 2005, INT ASS CANN MED IAC; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; SCHWARTZ RH, 1991, PSYCHIAT ANN, V21, P80, DOI 10.3928/0048-5713-19910201-07; Smith-Spark JH, 2004, MEMORY, V12, P174, DOI 10.1080/09658210244000450; Solowij N, 2002, JAMA-J AM MED ASSOC, V287, P1123, DOI 10.1001/jama.287.9.1123; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; VARMA VK, 1988, DRUG ALCOHOL DEPEN, V21, P147, DOI 10.1016/0376-8716(88)90061-0; Verdejo-Garcia A, 2006, ADDICT BEHAV, V31, P1373, DOI 10.1016/j.addbeh.2005.11.003; Verheul R, 2001, EUR PSYCHIAT, V16, P274, DOI 10.1016/S0924-9338(01)00578-8; Wallace JC, 2004, PERS INDIV DIFFER, V37, P307, DOI 10.1016/j.paid.2003.09.005; Wallace JC, 2002, J GEN PSYCHOL, V129, P238, DOI 10.1080/00221300209602098; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012	51	26	26	2	21	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-8811			J PSYCHOPHARMACOL	J. Psychopharmacol.	SEP	2008	22	7					727	736		10.1177/0269881107084000			10	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	341KK	WOS:000258713200004	18208908	Green Submitted			2022-02-06	
J	Oehmichen, M; Schleiss, D; Pedal, I; Saternus, KS; Gerling, I; Meissner, C				Oehmichen, Manfred; Schleiss, Daniela; Pedal, Ingo; Saternus, Klaus-Steffen; Gerling, Ivana; Meissner, Christoph			Shaken baby syndrome: re-examination of diffuse axonal injury as cause of death	ACTA NEUROPATHOLOGICA			English	Article						shaken baby syndrome; subdural hemorrhage; encephalopathy; retinal bleeding; diffuse axonal injury; cervical cord; global brain hypoxia/ischemia	TRAUMATIC BRAIN-INJURY; INFLICTED HEAD-INJURY; RETINAL HEMORRHAGE; INFANT DEATHS; NEUROPATHOLOGY; CHILDREN; BIOMECHANICS; MECHANISMS; DIAGNOSIS; FALLS	The discussion surrounding shaken baby syndrome (SBS) arose from the lack of evidence implicating diffuse axonal injury (DAI) as a cause of death. It was assumed instead that injury to the cervical cord, medulla, and nerve roots played a causal role. The present pathomorphological study examines 18 selected infants (< 1-year-old) whose deaths were highly suspicious for SBS, exhibiting the classical SBS triad of acute subdural hemorrhage (SDH), retinal bleeding, and encephalopathy. Gross autopsy and microscopic findings of these infants were compared with those of 19 victims of sudden infant death syndrome (SIDS; control group 1) and of 14 infants who died of disease or injuries/violence not involving the head, neck or eyes (control group 2). Symptoms of mechanical impact to the head were evident in seven of the SBS infants, but in none of the control infants. DAI was not detected in either the SBS or control cases. Localized axonal injury (AI) was regularly present in the brains of the SBS infants surviving longer than 1.5-3.0 h, but only occasionally in the craniocervical junction and within the nerve roots of the upper cervical cord; it was never present in the medulla. Epidural hemorrhage of the cervical cord was seen in four of the ten examined SBS cases, but in none of the control cases. Based on the absence of DAI in the brain and of signs of generalized cervical cord or nerve root injuries, we conclude that the cause of death in the SBS victims was a global cerebral ischemia secondary to SDH, focal vasospasm, trauma-induced transitory respiratory and/or circulatory failure.	[Oehmichen, Manfred; Schleiss, Daniela; Gerling, Ivana; Meissner, Christoph] Univ Hosp Schleswig Holstein, Inst Legal Med, Lubeck, Germany; [Pedal, Ingo] Heidelberg Univ, Inst Legal Med, Heidelberg, Germany; [Saternus, Klaus-Steffen] Univ Gottingen, Inst Legal Med, Gottingen, Germany		Oehmichen, M (corresponding author), Im Brandenbaumer Feld 39, D-23564 Lubeck, Germany.						ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; Alva NS, 2000, PEDIATR NEUROL, V23, P88, DOI 10.1016/S0887-8994(00)00151-X; Bell JE, 2005, CLIN DEV MED, P345; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Donohoe M, 2003, AM J FOREN MED PATH, V24, P239, DOI 10.1097/01.paf.0000083635.85457.97; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Durham SR, 2007, J NEUROTRAUM, V24, P5, DOI 10.1089/neu.2006.0054; Dyer C, 2005, BRIT MED J, V331, P253, DOI 10.1136/bmj.331.7511.253-a; ELDER JE, 1991, J PAEDIATR CHILD H, V27, P286, DOI 10.1111/j.1440-1754.1991.tb02539.x; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Forbes BJ, 2004, J PEDIAT OPHTH STRAB, V41, P80, DOI 10.3928/0191-3913-20040301-07; Geddes JF, 2004, BMJ-BRIT MED J, V328, P719, DOI 10.1136/bmj.328.7442.719; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Gleckman AM, 2000, J FORENSIC SCI, V45, P1151; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Koch LE, 1998, FORENSIC SCI INT, V97, P1, DOI 10.1016/S0379-0738(98)00124-8; Krous HF, 2004, PEDIATRICS, V114, P234, DOI 10.1542/peds.114.1.234; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; Kuhn J, 2005, ACTA NEUROPATHOL, V110, P579, DOI 10.1007/s00401-005-1090-9; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEDER LD, 1964, KLIN WOCHENSCHR, V42, P553, DOI 10.1007/BF01486688; May K, 2005, CLIN DEV MED, P185; Minns RA, 2005, CLIN DEV MED, P1; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; Oehmichen M, 2005, NEUROPEDIATRICS, V36, P240, DOI 10.1055/s-2005-872812; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; PIATT JH, 1995, PEDIATRICS, V96, P780; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Reece RM, 2004, BMJ-BRIT MED J, V328, P1316, DOI 10.1136/bmj.328.7451.1316; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Saternus KS, 2000, FORENSIC SCI INT, V109, P203, DOI 10.1016/S0379-0738(00)00144-4; Shannon P, 2001, LANCET, V358, P686, DOI 10.1016/S0140-6736(01)05849-4; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; [No title captured]; [No title captured]; [No title captured]; [No title captured]	49	26	26	0	7	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	SEP	2008	116	3					317	329		10.1007/s00401-008-0356-4			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	334QB	WOS:000258235200009	18365221				2022-02-06	
J	Jennische, E; Bergstrom, T; Johanssona, M; Nystrom, K; Tarkowski, A; Hansson, HA; Lange, S				Jennische, Eva; Bergstrom, Tomas; Johanssona, Maria; Nystrom, Kristina; Tarkowski, Andrej; Hansson, Hans-Arne; Lange, Stefan			The peptide AF-16 abolishes sickness and death at experimental encephalitis by reducing increase of intracranial pressure	BRAIN RESEARCH			English	Article						antisecretory factor; herpes simplex virus type 1; brain inflammation; neuroprotection	HERPES-SIMPLEX ENCEPHALITIS; TRAUMATIC BRAIN-INJURY; ANTISECRETORY FACTOR; PATTERNS; DISEASE	Elevated intracranial pressure (ICP) is strongly aggravating the injury at brain inflammation, resulting in persistent neurological and psychiatric malfunctions. There is no efficient pharmacological treatment to achieve beneficial ICP reduction. Here, the peptide AF-16, comprising the amino terminal part of the endogenous protein Antisecretory Factor (AF), was used to suppress the raised ICP in experimental herpes simplex encephalitis (HSE) in rats. Intranasal instillation of the peptide AF-16 counteracted the ICP elevation and the prevalence of ICP spikes, abrogated the neurological morbidity, and abolished the mortality in a dose-dependent manner. AF-16, 2S mu g twice daily intranasally, rescued all animals with HSE and abrogated neurological malfunction. In contrast, only 10% of the rats survived if treated with the vehicle. A single intranasal dose of 25 mu g AF-16 to a rat displaying overt HSE symptoms reduced the ICP to normal levels within an hour. No effects on viral replication or antigen distribution were demonstrable. Thus, AF-16 abolished the prevalence of sickness signs, ICP elevation, neurological malfunctions and completely prevented deaths. We advocate use of AF-16 for suppression of elevated ICP. (C) 2008 Elsevier B.V. All rights reserved.	[Lange, Stefan] Gothenburg Univ, Dept Clin Bacteriol, Inst Biomed, SE-41346 Gothenburg, Sweden; [Tarkowski, Andrej] Univ Gothenburg, Dept Rheumatol & Inflammat Res, SE-41346 Gothenburg, Sweden		Lange, S (corresponding author), Gothenburg Univ, Dept Clin Bacteriol, Inst Biomed, Guldhedsgatan 10, SE-41346 Gothenburg, Sweden.	stefan.lange@microbio.gu.se	Nystrom, Kristina/N-3125-2014	Bergstrom, Tomas/0000-0002-9257-6757	Goteborg Medical Society [7157]; Sahlgrenska University Hospital [8303]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [11255]	Financial support was provided by the Goteborg Medical Society, Lantmannen AS-Faktor AB, Nectin AB, W and M Lundgren's Stiftelse, the Swedish State under the LUA agreement (grant # 7157), the Sahlgrenska University Hospital (grant # 8303), and the Swedish Research Council (grant # 11255). We thank E. Lycke for the critical comments to the manuscript, I. Bosaeus for the helpful statistical analyses and S. Hojer, Samba Sensors AB, V. Frolunda, Sweden, for the technical support.	BARNETT GH, 1988, J NEUROSURG, V68, P585, DOI 10.3171/jns.1988.68.4.0585; Bjorck S, 2000, GUT, V46, P824, DOI 10.1136/gut.46.6.824; Brodbelt A, 2007, BRIT J NEUROSURG, V21, P510, DOI 10.1080/02688690701447420; Davidson TS, 2004, J LEUKOCYTE BIOL, V76, P835, DOI 10.1189/jlb.0204085; Davson H., 1996, PHYSL CSF BLOOD BRAI; Ebel H, 1999, CHILD NERV SYST, V15, P84, DOI 10.1007/s003810050337; ESIRI MM, 1982, J NEUROL SCI, V54, P209, DOI 10.1016/0022-510X(82)90183-6; Hanner P, 2004, HEARING RES, V190, P31, DOI 10.1016/S0378-5955(03)00368-X; Jennische E, 2006, APMIS, V114, P529, DOI 10.1111/j.1600-0463.2006.apm_464.x; JOHANSSON E, 1995, J BIOL CHEM, V270, P20615, DOI 10.1074/jbc.270.35.20615; Johansson E, 1997, BBA-MOL BASIS DIS, V1362, P177, DOI 10.1016/S0925-4439(97)00066-5; JOHNSON RT, 1998, VIRAL INFECTIONS NER; Kennedy, 2000, INFECT DIS NERVOUS S, P139; Krave U, 2005, EUR J NEUROSCI, V21, P2876, DOI 10.1111/j.1460-9568.2005.04115.x; Lange S, 2001, INT REV CYTOL, V210, P39; Lundberg N, 1960, ACTA PSYCHIAT NEUR S, V36, P149; Namvar L, 2005, J CLIN MICROBIOL, V43, P2058, DOI 10.1128/JCM.43.5.2058-2064.2005; Rangel-Castillo L, 2006, CRIT CARE CLIN, V22, P713, DOI 10.1016/j.ccc.2006.06.003; Raschilas F, 2002, CLIN INFECT DIS, V35, P254, DOI 10.1086/341405; Sorani MD, 2008, J NEUROTRAUM, V25, P291, DOI 10.1089/neu.2007.0411; Steiner I, 2005, EUR J NEUROL, V12, P331, DOI 10.1111/j.1468-1331.2005.01126.x; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Tyler Kenneth L, 2004, Herpes, V11 Suppl 2, p57A; Whitley RJ, 2006, ANTIVIR RES, V71, P141, DOI 10.1016/j.antiviral.2006.04.002; Yan HJ, 2002, SURG NEUROL, V57, P20, DOI 10.1016/S0090-3019(01)00688-7; [No title captured]	27	26	26	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 28	2008	1227						189	197		10.1016/j.brainres.2008.05.083			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	352PY	WOS:000259510700019	18586012				2022-02-06	
J	Principi, T; Morrison, GC; Matsui, DM; Speechley, KN; Seabrook, JA; Singh, RN; Kornecki, A				Principi, Tania; Morrison, Gavin C.; Matsui, Doreen M.; Speechley, Kathy N.; Seabrook, Jamie A.; Singh, Ram N.; Kornecki, Alik			Elective tracheostomy in mechanically ventilated children in Canada	INTENSIVE CARE MEDICINE			English	Article						tracheostomy; survey; practice; mechanical ventilation; acute respiratory distress syndrome; Acute lung injury	INTENSIVE-CARE-UNIT; CRITICALLY-ILL; SURGICAL TRACHEOSTOMY	Objective: To determine the current practice and opinions of paediatric intensivists in Canada regarding tracheostomy in children with potentially reversible conditions which are anticipated to require prolonged mechanical ventilation. Design and setting: Self-administered survey among paediatric intensivists within paediatrics critical care units (PCCU) across Canada. Measurements and results: All 16 PCCUs participated in the survey with a response rate of 81% (63 physicians). In 14 of 16 centres one to five tracheostomies were performed during 2006. Two centres did not perform any tracheostomies. The overall rate of tracheostomy is less than 1.5%. Percutaneous technique is used in 3/16 (19%) of centres. Readiness to undertake tracheostomy during the first 21 days of illness is influenced by patient diagnosis; severe traumatic brain injury 66% vs. 42% in a 2-year-old with Guillain-Barre syndrome, 48% in a 9- year-old with Guillain-Barre syndrome, and 12% in a child with isolated ARDS. In a child with ARDS 25% of respondents would never consider tracheostomy. Age does not affect timing nor keenness for tracheostomy. The majority, 81%, believe that the risks associated with the procedure do not outweigh the potential benefits. Finally, 51% believe that tracheostomy is underutilized in children. Conclusions: Elective tracheostomy is rarely performed among ventilated children in Canada. However, 51% of physicians believe it is underutilized. The role of elective tracheostomy and the percutaneous technique in children requires further investigation.	[Principi, Tania; Morrison, Gavin C.; Singh, Ram N.; Kornecki, Alik] Childrens Hosp, London Hlth Sci Ctr, Crit Care Unit, London, ON N6A 5W9, Canada; [Principi, Tania; Morrison, Gavin C.; Matsui, Doreen M.; Speechley, Kathy N.; Seabrook, Jamie A.; Singh, Ram N.; Kornecki, Alik] Childrens Hosp, London Hlth Sci Ctr, Dept Paediat, London, ON N6A 5W9, Canada; [Speechley, Kathy N.] Childrens Hosp, London Hlth Sci Ctr, Dept Epidemiol & Biostat, London, ON N6A 5W9, Canada; [Matsui, Doreen M.; Speechley, Kathy N.; Seabrook, Jamie A.; Kornecki, Alik] Univ Western Ontario, London Hlth Sci Ctr, Childrens Hlth Res Inst, London, ON, Canada		Kornecki, A (corresponding author), Childrens Hosp, London Hlth Sci Ctr, Crit Care Unit, 800 Commissioners Rd E, London, ON N6A 5W9, Canada.	Alik.kornecki@lhsc.on.ca	Principi, Tania/AAI-3644-2021	Principi, Tania/0000-0001-8684-2759			*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Albuali WH, 2007, PEDIATR CRIT CARE ME, V8, P324, DOI 10.1097/01.PCC.0000269390.48450.AF; Chastre J, 1998, REAN URG, V7, P435; CIAGLIA P, 1985, CHEST, V87, P715, DOI 10.1378/chest.87.6.715; Combes A, 2007, CRIT CARE MED, V35, P802, DOI 10.1097/01.CCM.0000256721.60517.B1; Corbett HJ, 2007, J PEDIATR SURG, V42, P1251, DOI 10.1016/j.jpedsurg.2007.02.017; Dillman DA, 1978, MAIL TELEPHONE SURVE, V19; Dulguerov P, 1999, CRIT CARE MED, V27, P1617, DOI 10.1097/00003246-199908000-00041; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Fantoni A, 2002, Minerva Anestesiol, V68, P433; Freeman BD, 2005, CRIT CARE MED, V33, P2513, DOI 10.1097/01.CCM.0000186369.91799.44; Freeman BD, 2000, CHEST, V118, P1412, DOI 10.1378/chest.118.5.1412; Frutos-Vivar F, 2005, CRIT CARE MED, V33, P290, DOI 10.1097/01.CCM.0000150026.85210.13; Groves DS, 2007, CURR OPIN CRIT CARE, V13, P90, DOI 10.1097/MCC.0b013e328011721e; Lawn ND, 1999, MUSCLE NERVE, V22, P1058; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Palmieri TL, 2002, CRIT CARE MED, V30, P922, DOI 10.1097/00003246-200204000-00036; Pierson David J, 2005, Respir Care, V50, P526; PUHAKKA HJ, 1992, ACTA PAEDIATR, V81, P231, DOI 10.1111/j.1651-2227.1992.tb12210.x; Simpson TP, 1999, ANAESTHESIA, V54, P186, DOI 10.1046/j.1365-2044.1999.00667.x; TOURSARKISSIAN B, 1994, J PEDIATR SURG, V29, P1421, DOI 10.1016/0022-3468(94)90135-X	21	26	26	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	AUG	2008	34	8					1498	1502		10.1007/s00134-008-1104-x			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330IH	WOS:000257933700021	18418569				2022-02-06	
J	Yang, J; Phillips, G; Xiang, H; Allareddy, V; Heiden, E; Peek-Asa, C				Yang, J.; Phillips, G.; Xiang, H.; Allareddy, V.; Heiden, E.; Peek-Asa, C.			Hospitalisations for sport-related concussions in US children aged 5 to 18 years during 2000-2004	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; CURRENT ISSUES; HEAD-INJURY; MANAGEMENT; RECOVERY; IMPACTS	Objectives: To describe patient and hospital characteristics associated with hospitalisation for a diagnosis of non-fatal sport-related concussion, and to determine factors associated with these hospitalisations. Methods: Children aged 5-18 years with a primary diagnosis of a sport-related concussion in the Nationwide Inpatient Sample (2000-2004) were identified. Length of stay and hospital charges for sport-related concussions were documented. Logistic regression was used to assess the association of patient or hospital characteristics with hospitalisations for sport-related concussion. Results: Between 2000 and 2004, a total of 755 non-fatal paediatric sport-related hospitalisations for concussion were identified. Nationwide, this represents 3712 hospitalisations and over US$29 million total hospital charges, with nearly US$6 million in total hospital charges per year. Over half (52.3%) of patients with concussion experienced loss of consciousness. Over 80% of the patients hospitalised for concussion received no procedures during their average 1.1 day (median 0.8 day) of hospital stay. Older age, but not gender, was associated with increased odds of sport-related hospitalisations for concussion. Non-teaching hospitals or hospitals in rural areas had significantly greater odds of admitting sport-related concussions versus other sport-related traumatic brain injuries compared with teaching or urban hospitals. Conclusions: Management of paediatric sport-related concussions varied, depending on the patient and the hospital. Better guidelines are needed for the identification and management of sport-related concussions. Standardised procedures for hospitals treating concussive injuries may also be warranted.	[Yang, J.; Heiden, E.] Univ Iowa, Dept Community & Behav Hlth, Coll Publ Hlth, Iowa City, IA 52242 USA; [Yang, J.; Allareddy, V.; Heiden, E.; Peek-Asa, C.] Univ Iowa, Injury Prevent Res Ctr, Iowa City, IA 52242 USA; [Phillips, G.] Univ Iowa, Dept Pediat, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Xiang, H.] Ohio State Univ, Ctr Injury Res & Policy, Columbus Childrens Res Inst, Dept Pediat, Columbus, OH 43210 USA; [Phillips, G.; Peek-Asa, C.] Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA		Yang, J (corresponding author), Univ Iowa, Dept Community & Behav Hlth, Coll Publ Hlth, 200 Hawkins Dr,E236 GH, Iowa City, IA 52242 USA.	jingzhen-yang@uiowa.edu	Yang, Jingzhen/N-4786-2014; Xiang, Huiyun/E-4335-2011				Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; *BUR LAB STAT, 2005, INFL RAT INP SERV; *CDCP, 2007, MORTALITY MORBIDITY, V0056; *CDCP NAT CTR INJ, HEADS CONC YOUTH SPO; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P785; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Colorado Medical Society School and Sports Medicine Committee, 1990, COLO MED, V87, P4; Dempsey RL, 2005, INJURY PREV, V11, P91, DOI 10.1136/ip.2004.006205; DICK RW, 1999, NCAA INJURY SURVEILL; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Greenspan AI, 2006, J TRAUMA, V61, P1234, DOI 10.1097/01.ta.0000231558.71696.1a; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; *HCUP DAT, 2006, HEALTHC COST UT PROJ; Kamerling SN, 2003, PEDIATR EMERG CARE, V19, P431, DOI 10.1097/01.pec.0000092590.40174.1f; Kelly JP, 1997, NEUROLOGY, V48, P581; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Maxwell RA, 2006, J TRAUMA, V60, P699; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mullins RJ, 2006, J TRAUMA, V60, P691, DOI 10.1097/01.ta.0000210454.92078.89; *NAT CTR INJ PREV, 1997, NEUROLOGY, V48, P581; *NAT FED STAT HIGH, 2004, NFHS 2003 04 HIGH SC; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Yang JZ, 2007, PEDIATRICS, V119, pE813, DOI 10.1542/peds.2006-2140; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	45	26	26	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2008	42	8					664	669		10.1136/bjsm.2007.040923			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	338UY	WOS:000258536100007	18216159				2022-02-06	
J	Jetter, GM; Cavazos, JE				Jetter, Gina Mapes; Cavazos, Jose E.			Epilepsy in the elderly	SEMINARS IN NEUROLOGY			English	Article						epilepsy; geriatrics; antiepileptic drugs	NONCONVULSIVE STATUS EPILEPTICUS; NURSING-HOME RESIDENTS; ANTIEPILEPTIC DRUG-USE; TONIC CLONIC SEIZURES; VITAMIN-D LEVELS; SERUM CONCENTRATIONS; BONE TURNOVER; CARBAMAZEPINE; PHENYTOIN; AGE	There are many unique characteristics in elderly patients with epilepsy. The incidence of seizures in this age group is the highest of any age group and continues to increase as people live longer. Etiology of seizures is different than for adults and includes cerebrovascular disease, dementia, closed head injury, and metabolic encephalopathies. The elderly patient with epilepsy most often presents with complex partial seizures that have a higher recurrence rate than the younger population. The seizures are often difficult to diagnose since they present with atypical symptoms, particularly prolonged postictal symptoms, including memory lapses, confusion, altered mental status, and inattention. There are also therapeutic challenges due to age-related changes in pharmacokinetics, including variations in absorption, distribution, metabolism, and excretion. These must be considered when selecting antiepileptic drug (AED) therapy to avoid harmful side effects. In addition, several of the AEDs have drug-drug interactions, a problem potentially exacerbated in this population of patients due to the use of medications for comorbid conditions.	[Jetter, Gina Mapes; Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA; [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA; [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA; [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Comprehens Epilepsy Ctr, San Antonio, TX 78229 USA; [Cavazos, Jose E.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA		Cavazos, JE (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, 7703 Floyd Curl Dr,MC7883, San Antonio, TX 78229 USA.	cavazosj@uthscsa.edu	Cavazos, Jose/J-4122-2016	Cavazos, Jose/0000-0001-5777-2608			BAUER LA, 1982, CLIN PHARMACOL THER, V31, P301, DOI 10.1038/clpt.1982.37; Bergey GK, 2004, NEUROLOGY, V63, pS40, DOI 10.1212/WNL.63.10_suppl_4.S40; Birnbaum A, 2003, NEUROLOGY, V60, P555, DOI 10.1212/01.WNL.0000052997.43492.E0; Brodie MJ, 1999, EPILEPSY RES, V37, P81, DOI 10.1016/S0920-1211(99)00039-X; Brodie MJ, 2005, BMJ-BRIT MED J, V331, P1317, DOI 10.1136/bmj.331.7528.1317; Cloyd J, 2006, EPILEPSY RES, V68, pS39, DOI 10.1016/j.eplepsyres.2005.07.016; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DeLorenzo RJ, 1996, NEUROLOGY, V46, P1029, DOI 10.1212/WNL.46.4.1029; Farhat G, 2002, NEUROLOGY, V58, P1348, DOI 10.1212/WNL.58.9.1348; Firth M, 2002, GASTROENTEROLOGY, V122, P1688, DOI 10.1053/gast.2002.33566; Garnett Linda K., 2002, Epilepsia, V43, P282; Garrard J, 2000, J GERONTOL A-BIOL, V55, pM384, DOI 10.1093/gerona/55.7.M384; Gidal BE, 2006, EPILEPSY RES, V68, pS65, DOI 10.1016/j.eplepsyres.2005.07.018; Gurwitz JH, 2000, AM J MED, V109, P87, DOI 10.1016/S0002-9343(00)00451-4; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HOIKKA V, 1984, ACTA NEUROL SCAND, V70, P77; HUDSON SA, 1990, J CLIN PHARM THER, V15, P25, DOI 10.1111/j.1365-2710.1990.tb00352.x; Jetter GM, 2006, EPILEPSIA, V47, P8; Le Couteur DG, 1998, CLIN PHARMACOKINET, V34, P359, DOI 10.2165/00003088-199834050-00003; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; Mintzer S, 2006, EPILEPSIA, V47, P510, DOI 10.1111/j.1528-1167.2006.00460.x; Muhlberg W, 1999, GERONTOLOGY, V45, P243, DOI 10.1159/000022097; Pack AM, 2005, ANN NEUROL, V57, P252, DOI 10.1002/ana.20378; Perucca E, 2006, EPILEPSY RES, V68, pS49, DOI 10.1016/j.eplepsyres.2005.07.017; Ramsay RE, 2004, NEUROLOGY, V62, pS24, DOI 10.1212/WNL.62.5_suppl_2.S24; RAMSAY RE, 2001, CLIN GERIATR MED, V9, P47; Rowan AJ, 2005, NEUROLOGY, V64, P1868, DOI 10.1212/01.WNL.0000167384.68207.3E; Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445; Shneker BF, 2003, NEUROLOGY, V61, P1066, DOI 10.1212/01.WNL.0000082653.40257.0B; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; Treiman DM, 2006, EPILEPSY RES, V68, pS77, DOI 10.1016/j.eplepsyres.2005.07.020; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Ucar M, 2004, EUR J CLIN PHARMACOL, V59, P879, DOI 10.1007/s00228-003-0700-5; Walker MC, 2001, CNS DRUGS, V15, P931, DOI 10.2165/00023210-200115120-00003; Wallace H, 1998, LANCET, V352, P1970, DOI 10.1016/S0140-6736(98)04512-7; WalterSack I, 1996, CLIN PHARMACOKINET, V31, P47, DOI 10.2165/00003088-199631010-00004; WILLMORE LJ, 1995, EPILEPSIA, V36, pS14, DOI 10.1111/j.1528-1157.1995.tb06005.x	41	26	27	0	1	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235			SEMIN NEUROL	Semin. Neurol.	JUL	2008	28	3					336	341		10.1055/s-2008-1079338			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	336OL	WOS:000258374400008	18777480				2022-02-06	
J	von Elm, E; Osterwalder, JJ; Graber, C; Schoettker, P; Stocker, R; Zangger, P; Vuadens, P; Egger, M; Walder, B				von Elm, Erik; Osterwalder, Joseph J.; Graber, Claire; Schoettker, Patrick; Stocker, Reto; Zangger, Peter; Vuadens, Phillipe; Egger, Matthias; Walder, Bernhard			Severe traumatic brain injury in Switzerland - feasibility and first results of a cohort study	SWISS MEDICAL WEEKLY			English	Article						cohort study; traumatic brain injury; case fatalit; morbidity; functional outcome; healthrelated quality-of-life	ACUTE SUBDURAL-HEMATOMA; GLASGOW COMA SCALE; HEAD-INJURY; HEALTH SURVEY; CARE; MORTALITY; SCORE; EPIDEMIOLOGY; MULTICENTER; VALIDATION	Background: We aimed to study the incidence and outcome of severe traumatic brain injury (TBI) in Switzerland and to test the feasibility of a large cohort study with case identification in the first 24 hours and 6-month follow-up. Methods: From January to June 2005, we consecutively enrolled and followed up all persons with severe TBI (Abbreviated Injury Score of the head region > 3 and Glasgow Coma Scale < 9) in the catchment areas of 3 Swiss medical centres with neurosurgical facilities. The primary outcome was the Extended Glasgow Outcome Scale (GOSE) after 6 months. Secondary outcomes included survival, Functional Independence Measure (FIM), and health-related quality of life (SF-12) at defined time-points up to 6 months after injury. Results: We recruited 101 participants from a source population of about 2.47 million (ie, about 3 3 % of Swiss population). The incidence of severe TBI was 8.2 per 100,000 person-years. The overall case fatality was 70%: 41 of 101 persons (41%) died at the scene of the accident. 23 of 60 hospitalised participants (38%) died within 48 hours, and 31 (53%) within 6 months. In all hospitalised patients, the median GOSE was I (range 1-8) after 6 months, and was 6 (2-8) in 6-month survivors. The median total FIM score was 125 (range 18-126); median-SF-12 component measures were 44 (25-55) for the physical scale and 52 (32-65) for the mental scale. Conclusions: Severe TBI was associated with high case fatality and considerable morbidity in survivors. We demonstrated the feasibility of a multicentre cohort study in Switzerland with the aim of identifying modifiable determinants of outcome and improving current trauma care.	[Osterwalder, Joseph J.] Univ Geneva, Kantonsspital, Privatdozent Med Sch, Emergency Dept,Zentrale Notfallaufnahme, CH-9007 St Gallen, Switzerland; [von Elm, Erik; Graber, Claire] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Stocker, Reto] Univ Zurich Hosp, Div Surg Intens Care, Zurich, Switzerland; [von Elm, Erik] Univ Med Ctr, Dept Med Biometry & Stat, Freiburg, Germany; [Walder, Bernhard] Univ Hosp Geneva, Div Anaesthesiol, Geneva, Switzerland		Osterwalder, JJ (corresponding author), Univ Geneva, Kantonsspital, Privatdozent Med Sch, Emergency Dept,Zentrale Notfallaufnahme, CH-9007 St Gallen, Switzerland.	joseph.osterwalder@kssg.ch	Schoettker, Patrick/AAE-4462-2020	Schoettker, Patrick/0000-0001-5370-048X; von Elm, Erik/0000-0002-7412-0406; Egger, Matthias/0000-0001-7462-5132			*AM ASS ADV AUT ME, 1990, ABBR INJ SCAL; Baethmann A, 2002, EUR SURG RES, V34, P42, DOI 10.1159/000048886; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Black KL, 2002, J HEAD TRAUMA REHAB, V17, P489, DOI 10.1097/00001199-200212000-00001; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; *BUND STAT, 2 1 6 VERL POT LEB J; *BUND STAT, STAND WOHNB STAATS G; Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; Clusmann H, 2001, J NEUROL NEUROSUR PS, V71, P175, DOI 10.1136/jnnp.71.2.175; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Dent DL, 1995, J TRAUMA, V39, P42; Dick WF, 1999, RESUSCITATION, V42, P81, DOI 10.1016/S0300-9572(99)00102-1; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Heim C, 2004, ANAESTHESIST, V53, P1245, DOI 10.1007/s00101-004-0777-y; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KOZLOWSKI P, 2002, ANN READAPT MED PHYS, V45, P466; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mazaux JM, 2002, ACT NEUR S, V79, P49; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Niemcryk SJ, 1998, AM J PREV MED, V14, P43, DOI 10.1016/S0749-3797(97)00013-5; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perneger TV, 2005, J CLIN EPIDEMIOL, V58, P142, DOI 10.1016/j.jclinepi.2004.06.005; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Sergides IG, 2006, BRIT J NEUROSURG, V20, P301, DOI 10.1080/02688690600999976; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	45	26	26	0	1	E M H SWISS MEDICAL PUBLISHERS LTD	MUTTENZ	FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND	1424-7860			SWISS MED WKLY	Swiss Med. Wkly.	JUN 14	2008	138	23-24					327	334					8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316FC	WOS:000256933500001	18561037				2022-02-06	
J	Reshef, A; Shirvan, A; Shohami, E; Grimberg, H; Levin, G; Cohen, A; Trembovler, V; Ziv, I				Reshef, Ayelet; Shirvan, Anat; Shohami, Esther; Grimberg, Hagit; Levin, Galit; Cohen, Avi; Trembovler, Victoria; Ziv, Ilan			Targeting cell death in vivo in experimental traumatic brain injury by a novel molecular probe	JOURNAL OF NEUROTRAUMA			English	Article						animal studies; apoptosis; molecular imaging; neuronal cell death; traumatic brain injury	CLOSED-HEAD INJURY; COGNITIVE DEFICITS; NEURONAL INJURY; MICE; MODEL; LIGAND	Traumatic brain injury (TBI) remains a frequent and major challenge in neurological and neurosurgical practice. Apoptosis may play a role in cerebral tissue damage induced by the traumatic insult, and thus its detection and inhibition may advance patient care. DDC (N, N'-didansyl-L-cystine) is a novel fluorescent probe for detection of apoptotic cells. We now report on the performance of DDC in experimental TBI. Closed head injury was induced in mice by weight-drop. DDC was administered intravenously in vivo. Two hours later, animals were sacrificed, and brain tissue was subjected to fluorescent microcopy, for assessment of DDC uptake, in correlation with histopathological assessment of apoptosis by TUNEL and caspase substrates, and also in correlation with the neurological deficits, as assessed by Neurological Severity Score (NSS). Selective uptake of DDC was observed at the primary site of injury, and also at remote sites. Uptake was at the cellular level, with accumulation of DDC in the cytoplasm. Cells manifesting DDC uptake were confirmed as apoptotic cells by detection of the characteristic apoptotic DNA fragmentation (positive TUNEL staining) and detection of activated caspases. The damaged region stained by DDC fluorescence correlated with the severity of neuronal deficits. Our study confirms the role of apoptosis in TBI, and proposes DDC as a useful tool for its selective targeting and detection in vivo. Such imaging of apoptosis, following future radiolabeling of DDC, may advance care for patients with head injury, by allowing real-time evaluation of the extent of tissue damage, assessment of novel therapeutic strategies, and optimization of treatment for the individual patient.	[Reshef, Ayelet; Shirvan, Anat; Grimberg, Hagit; Levin, Galit; Cohen, Avi; Ziv, Ilan] NST NeuroSurvival Technol Ltd, Petah Tiqwa, Israel; [Shohami, Esther; Trembovler, Victoria] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, Jerusalem, Israel; [Ziv, Ilan] Rabin Med Ctr, Dept Neurol, Petah Tiqwa, Israel		Reshef, A (corresponding author), NST, 5 Odem St,POB 7119, IL-49170 Petah Tiqwa, Israel.	ayelet@nst.co.il					Aloya R, 2006, APOPTOSIS, V11, P2089, DOI 10.1007/s10495-006-0282-7; Bacskai BJ, 2003, P NATL ACAD SCI USA, V100, P12462, DOI 10.1073/pnas.2034101100; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Boersma HH, 2005, J NUCL MED, V46, P2035; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cohen A, 2007, TECHNOL CANCER RES T, V6, P221, DOI 10.1177/153303460700600310; Damianovich M, 2006, EUR J NUCL MED MOL I, V33, P281, DOI 10.1007/s00259-005-1905-x; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Reshef A, 2007, BRAIN RES, V1144, P156, DOI 10.1016/j.brainres.2007.01.095; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Xu LJ, 2001, EXP NEUROL, V169, P416, DOI 10.1006/exnr.2001.7678; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	21	26	26	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					569	580		10.1089/neu.2007.0341			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900001	18447626				2022-02-06	
J	Tasky, KK; Rudrud, EH; Schulze, KA; Rapp, JT				Tasky, Kim K.; Rudrud, Epic H.; Schulze, Kimberly A.; Rapp, John T.			Using choice to increase on task behavior in individuals with trauaiatic brain injury	JOURNAL OF APPLIED BEHAVIOR ANALYSIS			English	Article						antecedent intervention; choice; motivating operations; traumatic brain injury	WORK PERFORMANCE; OPERATIONS	An ABA'B design was used to evaluate the effects of choice on task engagement for 3 adults who had been diagnosed with traumatic brain injury. A yoked-control condition, in which tasks that were selected by each participant were assigned subsequently to that participant by a trainer, was implemented to help distinguish between the effects of task preference and choice. The results for all 3 participants indicated that permitting individuals to choose from a list of tasks increased on-task behavior.	[Rapp, John T.] St Cloud State Univ, Educ Leadership & Community Psychol, St Cloud, MN 56301 USA		Rapp, JT (corresponding author), St Cloud State Univ, Educ Leadership & Community Psychol, 720 4th Ave S, St Cloud, MN 56301 USA.	j.trapp@stcloudstate.edu					BAMBARA LM, 1994, J APPL BEHAV ANAL, V27, P555, DOI 10.1901/jaba.1994.27-555; CHILDS KE, 1994, J APPL BEHAV ANAL, V27, P7, DOI 10.1901/jaba.1994.27-7; Heward J, 2007, APPL BEHAV ANAL; Kern L., 2001, J POSIT BEHAV INTERV, V3, P3, DOI DOI 10.1177/109830070100300102; Laraway S, 2003, J APPL BEHAV ANAL, V36, P407, DOI 10.1901/jaba.2003.36-407; McComas J, 2000, J APPL BEHAV ANAL, V33, P479, DOI 10.1901/jaba.2000.33-479; PARSONS MB, 1990, J APPL BEHAV ANAL, V23, P253, DOI 10.1901/jaba.1990.23-253; Vaughn BJ, 1997, J APPL BEHAV ANAL, V30, P299, DOI 10.1901/jaba.1997.30-299	8	26	26	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8855	1938-3703		J APPL BEHAV ANAL	J. Appl. Behav. Anal.	SUM	2008	41	2					261	265		10.1901/jaba.2008.41-261			5	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	309LL	WOS:000256461800012	18595291	Green Published, Bronze			2022-02-06	
J	Kramer, ME; Chiu, CYP; Walz, NC; Holland, SK; Yuan, WH; Karunanayaka, P; Wade, SL				Kramer, Megan E.; Chiu, C. -Y. Peter; Walz, Nicolay Chertkoff; Holland, Scott K.; Yuan, Weihong; Karunanayaka, Prasanna; Wade, Shari L.			Long-term neural processing of attention following early childhood traumatic brain injury: fMRI and neurobehavioral outcomes	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						childhood brain disorder; continuous performance test; brain imaging; children; head injury; neuropsychology	CONTINUOUS PERFORMANCE-TEST; WORKING-MEMORY LOAD; SUSTAINED ATTENTION; DEFICIT/HYPERACTIVITY DISORDER; RETROSPECTIVE ESTIMATION; SELF-REGULATION; HEAD-INJURY; CHILDREN; ADOLESCENTS; ACTIVATION	Attentional deficits are common and significant sequelae of pediatric traumatic brain injury (TBI). However. little is known about how file underlying neural processes that Support different components of attention are affected. The present Study examined brain activation patterns using fMRI ill a group Of young children who sustained a TBI ill early childhood (n = 5: mean age = 9.4) and a group of age-matched control children with orthopedic injuries (OI) (n=8) during a continuous performance task (CPT). Four children ill the TBI group had moderate injuries. and one had a severe injury. Performance oil the CPT task did not differ between groups. Both TBI and 01 children activated similar networks of brain regions relevant to sustained attention processing, but the TBI group demonstrated several areas of significantly greater activation relative to controls. including frontal and parietal regions. These findings of over-activation of the relevant attention network in the TBI group contrast with those obtained in imaging studies of Attention-Deficit/Hyperactivity Disorder where under-activation of the attention network has been documented. This Study provides evidence that young children's brains function differently following it traumatic brain injury, and that these differences persist for years after the injury.	[Kramer, Megan E.; Chiu, C. -Y. Peter] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA; [Chiu, C. -Y. Peter] Univ Cincinnati, Dept Commun Sci & Disorders, Cincinnati, OH 45221 USA; [Walz, Nicolay Chertkoff; Holland, Scott K.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA; [Walz, Nicolay Chertkoff; Holland, Scott K.; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Holland, Scott K.; Yuan, Weihong; Karunanayaka, Prasanna] Cincinnati Childrens Hosp Med Ctr, Childrens Hosp Res Fdn, Cincinnati, OH USA		Kramer, ME (corresponding author), Univ Cincinnati, Dept Psychol, 101A Dyer Hall,ML 0376, Cincinnati, OH 45221 USA.	kramerm2@email.uc.edu		Holland, Scott/0000-0003-3719-0875; Kramer, Megan/0000-0002-8813-7217	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1-HD044279]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Center for Research Resources, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 08084]; U.S. National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [RO1HD044279]; US National Institute of Child Health and Human Development.United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [RO1-HD38578]; Association of Volunteers of the Convalescent Hospital for Children; Cincinnati Children's Hospital Medical Center; University of Cincinnati; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD038578, R43HD044279] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER	The authors thank Vincent Schmithorst. Ph.D. for programming consultation, and Caleb Adler, M.D. for use of the CPT-IP paradigm. This work was Supported in part by (1) NIH grant RO1-HD044279 from the National Council on Medical Rehabilitation Research in the National Institute of Child Health and Human Development; (2) UPHS GCRC Grant #M01 RR 08084 from the National Center for Research Resources, NIH (3) NIH grant RO1HD044279 from the U.S. National Institute of Child Health and Human Development; and (4) NIH grant RO1-HD38578 from the US National Institute of Child Health and Human Development. Funding for the fMRI scans was provided by the Association of Volunteers of the Convalescent Hospital for Children, Cincinnati Children's Hospital Medical Center. The first author was supported by a University Dean's Distinguished Dissertation Award sponsored by the University of Cincinnati.	Achenbach TM, 1991, MANUAL CHILD BEHAV C; Adler CM, 2005, BIPOLAR DISORD, V7, P577, DOI 10.1111/j.1399-5618.2005.00257.x; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Borgaro S, 2003, J CLIN EXP NEUROPSYC, V25, P283, DOI 10.1076/jcen.25.2.283.13646; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CORNBLATT BA, 1989, PSYCHIAT RES, V29, P65, DOI 10.1016/0165-1781(89)90188-1; Elliott C. D., 1990, DIFFERENTIAL ABILITY; EPSTEIN JN, NEUROIMAGIN IN PRESS; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; HU XP, 1995, MAGNET RESON MED, V34, P201, DOI 10.1002/mrm.1910340211; Karunanayaka PR, 2007, NEUROREHABILITATION, V22, P355; Le TH, 1996, MAGNET RESON MED, V35, P290, DOI 10.1002/mrm.1910350305; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T., 1999, TEACH TEST EVERYDAY; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2005, J AM ACAD CHILD PSY, V44, P443, DOI 10.1097/01.chi.0000156661.38576.0f; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Muzik O, 2000, NEUROIMAGE, V12, P538, DOI 10.1006/nimg.2000.0651; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; POLVISHOCK JT, 2005, J HEAD TRAUMA REHAB, V20, P76; Robin DA, 1999, APHASIOLOGY, V13, P701, DOI 10.1080/026870399401812; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Rothbart MK, 2001, CHILD DEV, V72, P1394, DOI 10.1111/1467-8624.00355; Rothbart MK, 2001, DEV COGN NEUROSCI, P353; Rubia K, 2005, AM J PSYCHIAT, V162, P1067, DOI 10.1176/appi.ajp.162.6.1067; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Schmithorst VJ, 2001, IEEE T MED IMAGING, V20, P535, DOI 10.1109/42.929619; Smith AB, 2006, AM J PSYCHIAT, V163, P1044, DOI 10.1176/appi.ajp.163.6.1044; Strakowski SM, 2004, NEUROPSYCHOPHARMACOL, V29, P1734, DOI 10.1038/sj.npp.1300492; Talairach J., 1988, COPLANAR STEREOTACTI; Tamm L, 2006, AM J PSYCHIAT, V163, P1033, DOI 10.1176/appi.ajp.163.6.1033; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wilke M, 2002, HUM BRAIN MAPP, V17, P48, DOI 10.1002/hbm.10053; WORSLEY KJ, 1995, NEUROIMAGE, V2, P173, DOI 10.1006/nimg.1995.1023; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404; Yeates K., 2000, PEDIAT NEUROPSYCHOLO; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; [No title captured]	56	26	26	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2008	14	3					424	435		10.1017/S1355617708080545			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	338VK	WOS:000258537300008	18419841	Green Accepted, Bronze			2022-02-06	
J	Li, YF; Bai, Y				Li, Yingfeng; Bai, Yong			Comparison of characteristics between fatal and injury accidents in the highway construction zones	SAFETY SCIENCE			English	Article						accident; construction zone; highway; characteristics; safety		Highway construction zone safety has been a research focus in many countries for many decades. In the United States, regardless of the research efforts devoted, highway construction zones remain a serious safety concerti for government agencies, legislatures, the highway industry, and the traveling pub lic. In this study, the fatal and injury accidents between 1992 and 2004 in Kansas highway construction zones were examined systematically and their major characteristics were compared. The results showed significant differences between fatal and injury accidents in the construction zones. The researchers found that: (1) head-on was the dominant type for fatal accidents while rear-end was the dominant injury accident type; (2) a large percent of fatal accidents involved trucks while a majority of injury accidents involved light-duty vehicles only; (3) disregarded traffic control, alcohol impairment, and speeding caused a much larger proportion of fatal accidents while followed too close caused a much higher percentage of injury accidents; and (4) unfavorable light conditions and complicated road geometries contributed to causing a larger percentage of fatal accidents than to causing injury accidents. Based on the study results, practical safety countermeasures targeted at different severity of accidents are recommended in terms of construction zone traffic control and public education. (c) 2007 Elsevier Ltd. All rights reserved.	[Li, Yingfeng; Bai, Yong] Univ Kansas, Dept Civil Environm & Architectural Engn, Lawrence, KS 66045 USA		Li, YF (corresponding author), Univ Kansas, Dept Civil Environm & Architectural Engn, 1530 W l5th St,2160 Learned Hall, Lawrence, KS 66045 USA.	Lyf537@ku.edu; ybai@ku.edu	Bai, Yong/AAN-8674-2020	Bai, Yong/0000-0002-2814-0422			*AASHTO, 1987, SUMM REP WORK ZON CR; BAI Y, 2003, P 33 ANN M SE DEC SC, P367; Bai Y., 2006, KU0501 KTRAN U KANS; BAI Y, 2002, P FALL M AM SOC CIV; BENEKOHAL RF, 1995, 1509 TRANSP RES BOAR, P55; CHAMBLESS J, 2002, ITE J I TRANSPORTATI, P46; Daniel J, 2000, TRANSPORT RES REC, P18, DOI 10.3141/1715-03; *FHWA, 2006, HIGHW STAT 2004 3; *FHWA, 2004, WORK ZON SAF FACTS S; Garber N.J., 1990, 90R12 VTRC; Garber NJ, 2002, 02R12 VTRC; GRAHAM J, 1977, FHWARD7780 FHWA; Ha T.J., 1995, TRANSPORT RES REC, V1509, P38; HARGROVES BT, 1981, TRANSPORT ENG-J ASCE, V107, P525; HILL RW, 2003, THESIS TEXAS TU; LI Y, 2006, P CIW W99 INT C GLOB; Mohan S.B., 2002, PRACT PERIOD STRUCT, V7, DOI [10.1061/(ASCE)1084-0680(2002)7:2(68), DOI 10.1061/(ASCE)1084-0680(2002)7:2(68)]; Nemeth Z. A., 1978, TRANSPORT RES REC, V672, P19; PAL R, 1919, 1529 TRANSP RES BOAR, P43; Pigman J.G., 1990, TRANSPORT RES REC, V1270, P12; ROUPHAIL NM, 1988, 1163 TRANSP RES BOAR, P4; SCHROCK DS, 2004, FHWATX05040281 US DE; Sorock GS, 1996, ACCIDENT ANAL PREV, V28, P131, DOI 10.1016/0001-4575(95)00055-0; THOMPSON SK, 2002, SAMPLING, P11; ULLMAN GL, 1990, FHWATX9011082 FHWA; *UT, 2005, TESTS IND US 2 WAY C; Wang J., 1996, TRANSPORT RES REC, V1529, P54, DOI DOI 10.3141/1529-07	27	26	26	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0925-7535	1879-1042		SAFETY SCI	Saf. Sci.	APR	2008	46	4					646	660		10.1016/j.ssci.2007.06.019			15	Engineering, Industrial; Operations Research & Management Science	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Operations Research & Management Science	313NV	WOS:000256748200007		Green Published			2022-02-06	
J	Saganova, K; Orendacova, J; Cizkova, D; Vanicky, I				Saganova, Kamila; Orendacova, Judita; Cizkova, Dasa; Vanicky, Ivo			Limited minocycline neuroprotection after balloon-compression spinal cord injury in the rat	NEUROSCIENCE LETTERS			English	Article						secondary injury; neurological outcome; spinal cord white/gray matter	TRAUMATIC BRAIN-INJURY; MOUSE MODEL; ACTIVATION; MICROGLIA; RECOVERY; DEATH; PROLIFERATION; NEUROTOXICITY; REGENERATION; EXPRESSION	Minocycline (MC), a second-generation tetracycline and anti- inflammatory agent reportedly provides neuroprotection following CNS injury. The objective of this study was to examine the neuroprotective effects of short and long-term MC treatment using balloon -compres si on spinal cord injury (SCI) in the rat. Rats subjected to SCI were treated with MC for 1 day (IDMC group; total dose 180 mg/kg) or 5 days (5DMC group; total dose 450 mg/kg) or placebo. The effects of MC treatment on locomotor recovery (BBB scale) and spinal cord white and gray matter sparing were evaluated for up to 28 days. Morphometric analysis showed that while MC treatment spared spinal cord white and gray matter rostral to the lesion epicenter in both, 1DMC and 5DMC groups, sparing of white and gray matter areas was not observed caudal to the traumatic lesion. In addition, MC treatment had no effect on final locomotor recovery. Limited improvement of spinal cord post-compression consequences raises questions about the neuroprotection efficiency of MC treatment following compression SO in the rat. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Saganova, Kamila; Orendacova, Judita; Cizkova, Dasa; Vanicky, Ivo] Slovak Acad Sci, Inst Neurobiol, Ctr Excellence, Kosice 04001, Slovakia		Saganova, K (corresponding author), Slovak Acad Sci, Inst Neurobiol, Ctr Excellence, Soltesovej 6, Kosice 04001, Slovakia.	sagan@saske.sk	Vanicky, Ivo/ABB-2298-2021; Cizkova, Dasa/AAF-8976-2019	cizkova, dasa/0000-0002-2504-3993			Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cho KO, 2007, LIFE SCI, V80, P2030, DOI 10.1016/j.lfs.2007.03.005; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Fendrick SE, 2005, NEUROSCI LETT, V385, P220, DOI 10.1016/j.neulet.2005.05.047; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hains BC, 2006, J NEUROSCI, V26, P4308, DOI 10.1523/JNEUROSCI.0003-06.2006; Jendelova P, 2004, J NEUROSCI RES, V76, P232, DOI 10.1002/jnr.20041; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Lin SZ, 2003, LIFE SCI, V72, P1635, DOI 10.1016/S0024-3205(02)02442-6; Lin SZ, 2001, NEUROSCI LETT, V315, P61, DOI 10.1016/S0304-3940(01)02324-2; Liu XZ, 1997, J NEUROSCI, V17, P5395; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Schwab JM, 2006, PROG NEUROBIOL, V78, P91, DOI 10.1016/j.pneurobio.2005.12.004; Sedy J, 2007, NEUROSCI LETT, V423, P167, DOI 10.1016/j.neulet.2007.06.053; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Szymanska A, 2006, EXP NEUROL, V197, P189, DOI 10.1016/j.expneurol.2005.09.011; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Urdzikova L, 2006, J NEUROTRAUM, V23, P1379, DOI 10.1089/neu.2006.23.1379; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; Wasserman JK, 2007, BRAIN RES, V1136, P208, DOI 10.1016/j.brainres.2006.12.035; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Weng YC, 2007, EXP NEUROL, V204, P433, DOI 10.1016/j.expneurol.2006.12.003; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007	31	26	26	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 15	2008	433	3					246	249		10.1016/j.neulet.2008.01.041			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	284DR	WOS:000254686500017	18280653				2022-02-06	
J	Geeraerts, T; Friggeri, A; Mazoit, JX; Benhamou, D; Duranteau, J; Vigue, B				Geeraerts, Thomas; Friggeri, Arnaud; Mazoit, Jean-Xavier; Benhamou, Dan; Duranteau, Jacques; Vigue, Bernard			Posttraumatic brain vulnerability to hypoxia-hypotension: the importance of the delay between brain trauma and secondary insult	INTENSIVE CARE MEDICINE			English	Article						brain metabolism; hypoxia-hypotension; microdialysis; rat; secondary insult; traumatic brain injury	FREELY MOVING RATS; HEAD-INJURY; MICRODIALYSIS; EDEMA; MODEL; PERTURBATION; DYSFUNCTION; METABOLISM; HYPOXEMIA; ACID	Objective: To examine whether the effect of hypoxia-hypotension (HH) after traumatic brain injury (TBI) is affected by the delay between insults. Design: Thirty Sprague-Dawley rats were randomized into five groups: sham, TBI alone (trauma alone, impact-acceleration, 450 g weight drop from 1.8 m), HH alone (blood depletion, mean arterial pressure 40 mmHg, FIO2 = 10%, 15 min), TBI + early HH (TBI followed by HH, 45-min delay), and TBI + late HH (225-min delay). Cerebral perfusion pressure was continuously recorded. Brain microdialysis and PtiO(2) probes were inserted stereotaxically into the right thalamus. Measurements and results: After the HH period and for 60 min a significant increase in cerebral lactate-pyruvate ratio was observed in groups subjected to HH vs. TBI alone and sham groups (33.0 +/- 5.1 for HH alone and 51.9 +/- 6.7 for TBI + early HH vs. 16.7 +/- 2.4 for TBI alone at the same time, 27.6 +/- 4.4 for TBI + late HH vs. 13.1 v 1 for TBI alone at the same time). There was no significant difference in lactate-pyruvate ratio peaks between HH alone and TBI + late HH while it was higher in TBI + early HH. Similar results were obtained for cerebral glycerol. PtiO(2) during HH phase did not differ between HH alone, TBI + early HH and TBI + late HH (respectively, 4.2 +/- 3.1, 4.9 +/- 5.7, and 2.9 +/- 1.8 mmHg). Conclusions: A 45-min delay between HH and TBI has important metabolic consequences while a 225-min delay has a similar effect as HH in a noninjured brain. The posttraumatic brain vulnerability to HH depends on the delay between cerebral aggressions.	[Geeraerts, Thomas; Friggeri, Arnaud; Mazoit, Jean-Xavier; Benhamou, Dan; Duranteau, Jacques; Vigue, Bernard] Hop Bicetre, Dept Anethesie Reanimat, AP HP, F-94276 Le Kremlin Bicetre, France; [Geeraerts, Thomas; Friggeri, Arnaud; Mazoit, Jean-Xavier; Benhamou, Dan; Duranteau, Jacques; Vigue, Bernard] Univ Paris Sud, Lab Anesthesie, UPRES 3540, F-94276 Le Kremlin Bicetre, France		Geeraerts, T (corresponding author), Hop Bicetre, Dept Anethesie Reanimat, AP HP, F-94276 Le Kremlin Bicetre, France.	thgeeraerts@hotmail.com	Friggeri, Arnaud/AAE-7644-2020; Benhamou, Dan/ABG-7935-2021	Friggeri, Arnaud/0000-0003-4687-2173; 			Beaumont A, 2002, ACT NEUR S, V81, P217; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Carre E, 2004, J NEUROSCI METH, V140, P23, DOI 10.1016/j.jneumeth.2004.04.037; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; FELLOWS LK, 1992, J NEUROCHEM, V59, P2141; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Geeraerts T, 2006, J NEUROTRAUM, V23, P1059, DOI 10.1089/neu.2006.23.1059; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Holtzer S, 2001, CRIT CARE MED, V29, P1609, DOI 10.1097/00003246-200108000-00018; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KUHR WG, 1988, J CEREBR BLOOD F MET, V8, P130, DOI 10.1038/jcbfm.1988.17; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; MAGISTRETTI PJ, 2003, FUNDAMENTAL NEUROSCI, P339; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; PAXINOS J, 1982, RAT BRAIN STEREOTAXI; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Valtysson J, 1998, ACTA NEUROCHIR, V140, P387, DOI 10.1007/s007010050113; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487	31	26	28	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2008	34	3					551	560		10.1007/s00134-007-0863-0			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263EQ	WOS:000253200800025	17938889				2022-02-06	
J	Votruba, KL; Rapport, LJ; Vangel, SJ; Hanks, RA; Lequerica, A; Whitman, RD; Langenecker, S				Votruba, Kristen Loeher; Rapport, Lisa J.; Vangel, Stephen J., Jr.; Hanks, Robin A.; Lequerica, Anthony; Whitman, R. Douglas; Langenecker, Scott			Impulsivity and traumatic brain injury: the relations among Behavioral observation, performance measures, and rating scales	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	35th Annual Meeting of the International-Neuropsychological-Society	FEB 07-10, 2007	Portland, OR	Int Neuropsychol Soc		behavioral observation; impulsivity; inhibition; neuropsycbological assessment; traumatic brain injury rehabilitation	CLOSED-HEAD-INJURY; INHIBITORY CONTROL; REACTION-TIME; PERSONALITY DESCRIPTION; DIMENSIONAL SYSTEM; AWARENESS; DEFICITS; REHABILITATION; PREDICTORS; RESPONSES	Objective: To assess the interrelations of neuropsychological tests and rating scales with in vivo behavioral observation of impulsive behavior, accounting for the mode of expression (verbal or motor). Design: Cross-sectional, correlational. Setting: An urban, inpatient rehabilitation facility in the Midwestern United States. Participants: Forty patients who were hospitalized in the traumatic brain injury unit. Main outcome measures: Impulsivity Rating Scale and Agitated Behavior Scale (completed by rehabilitation therapists), Barratt Impulsivity Scale (patient self-report), neuropsychological tests, and in vivo behavioral observation of impulsivity using a structured checklist during rehabilitation therapy. Results: Relations of impulsivity rating scales and performance tests to in vivo behavior dissociated. Verbal impulsivity was best assessed by rating scales and was largely unrelated to performance measures of impulsivity, whereas motor impulsivity was best assessed by performance tests and was unrelated to rating scales. Performance tests also had poor specificity, showing equally strong associations with tests of other neuropsychological domains. Conclusions: Impulsivity is a multidimensional construct that should be assessed in a variety of ways. Using either rating scales or neuropsychological tests alone will not likely yield a comprehensive representation of TBI patients' impulsive behaviors. In vivo observation in the clinical setting showed strong ability to identify impulsivity in the presence of global deficits.	[Votruba, Kristen Loeher; Rapport, Lisa J.; Lequerica, Anthony; Whitman, R. Douglas] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Vangel, Stephen J., Jr.; Hanks, Robin A.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48202 USA; [Langenecker, Scott] Univ Michigan, Med Ctr, Dept Psychiat, Neuropsychol Sect, Ann Arbor, MI 48109 USA		Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	rapport@wayne.edu	Langenecker, Scott/F-3548-2012	Langenecker, Scott/0000-0002-7932-5494; Rapport, Lisa/0000-0001-8014-9523			BARRATT ES, 1965, PSYCHOL REP, V16, P547, DOI 10.2466/pr0.1965.16.2.547; BARTKO JJ, 1976, PSYCHOL BULL, V83, P762, DOI 10.1037/0033-2909.83.5.762; Benton A., 1978, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; CARRILLODELAPENA MT, 1993, PERCEPT MOTOR SKILL, V77, P567, DOI 10.2466/pms.1993.77.2.567; Cohen J., 2013, STAT POWER ANAL BEHA; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; DELIS DC, 2000, CALIFORNIA VERBAL LE; Eastwood EA, 1999, NURS ECON, V17, P96; Evenden J, 1999, J PSYCHOPHARMACOL, V13, P180, DOI 10.1177/026988119901300211; EYSENCK SBG, 1977, BRIT J SOC CLIN PSYC, V16, P57, DOI 10.1111/j.2044-8260.1977.tb01003.x; EYSENCK SBG, 1978, PSYCHOL REP, V43, P1247, DOI 10.2466/pr0.1978.43.3f.1247; Flory JD, 2006, J PSYCHIATR RES, V40, P438, DOI 10.1016/j.jpsychires.2006.01.008; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; GERBING DW, 1987, MULTIVAR BEHAV RES, V22, P357, DOI 10.1207/s15327906mbr2203_6; Golden CJ, 1978, STROOP COLOR WORD TE; Greve KW, 2001, BRAIN INJURY, V15, P255; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; KAMINER Y, 1995, ADOLESCENCE, V30, P483; Konrad KN, 2000, BRAIN INJURY, V14, P859; Langenecker SA, 2005, J CLIN EXP NEUROPSYC, V27, P320, DOI 10.1080/13803390490490515720; Lecrubier Y, 1995, EUR PSYCHIAT, V10, P331, DOI 10.1016/0924-9338(96)80333-6; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; LUENGO MA, 1994, J PERS SOC PSYCHOL, V66, P542, DOI 10.1037/0022-3514.66.3.542; OLSON SL, 1989, J CLIN CHILD PSYCHOL, V18, P176, DOI 10.1207/s15374424jccp1802_9; PAULSEN K, 1980, J ABNORM CHILD PSYCH, V8, P269, DOI 10.1007/BF00919070; Peterson BS, 1999, BIOL PSYCHIAT, V45, P1237, DOI 10.1016/S0006-3223(99)00056-6; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; Reitan RM, 1985, HALSTEADREITAN NEURO; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; SAUNDERS JT, 1973, AM J ORTHOPSYCHIAT, V43, P789, DOI 10.1111/j.1939-0025.1973.tb00851.x; SCHLEENBAKER RE, 1994, ARCH PHYS MED REHAB, V75, P427, DOI 10.1016/0003-9993(94)90166-X; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; Tabachnick BG, 2007, USING MULTIVARIATE S; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; Wingrove J, 1997, PERS INDIV DIFFER, V22, P333, DOI 10.1016/S0191-8869(96)00222-X; [No title captured]	47	26	26	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2008	23	2					65	73		10.1097/01.HTR.0000314525.93381.69			9	Clinical Neurology; Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	280KW	WOS:000254426700001	18362760				2022-02-06	
J	Nakase-Richardson, R; Yablon, SA; Sherer, M; Evans, CC; Nick, TG				Nakase-Richardson, R.; Yablon, S. A.; Sherer, M.; Evans, C. C.; Nick, T. G.			Serial yes/no reliability after traumatic brain injury: implications regarding the operational criteria for emergence from the minimally conscious state	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							DIAGNOSTIC-CRITERIA; COGNITIVE TEST; DEFINITION; DELIRIUM	Background: Published guidelines for defining the "minimally conscious state'' (MCS) included behaviours that characterise emergence, specifically "reliable and consistent'' functional interactive communication (accurate yes/no responding) and functional use of objects. Guidelines were developed by consensus because of the lack of empirical data to guide definitions. Criticism emerged that individuals with severely impaired cognition would have difficulty achieving the requisite threshold of accuracy and consistency proposed to demonstrate emergence from MCS. Objective: To determine the utility of the operational threshold for emergence from post-traumatic MCS, by evaluating a measure of yes/no accuracy (Cognitive Test for Delirium, auditory processing subtest (CTD-AP).) Methods: Prospective, consecutive cohort of responsive patients recovering from traumatic brain injury (TBI), including a subset meeting criteria for MCS at neurorehabilitation admission who improved and were able to undergo the study protocol. Participants were evaluated at least weekly, and given the CTD-AP to assess yes/no responding. Results: Of the 1434 observations from 336 participants, 767 observations yielded inaccurate yes/no responses. 75 participants (22%) never attained consistently accurate yes/no responses at any time during their hospitalisation. Generalised estimating equations analysis revealed that confused participants were more likely to respond inaccurately to yes/no questions. Further, the subset of individuals who were in MCS on rehabilitation admission and improved, were also more likely to respond inaccurately to yes/no questions. Conclusions: Consistent yes/no accuracy is uncommon among responsive patients in early recovery from TBI. These results suggest that the operational threshold for yes/no response accuracy as a diagnostic criterion for emergence from MCS should be revisited.	[Nakase-Richardson, R.; Yablon, S. A.; Evans, C. C.] Methodist Rehabil Ctr, Dept Neurophysiol, Jackson, MS 39216 USA; [Nakase-Richardson, R.; Yablon, S. A.; Evans, C. C.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Sherer, M.] Baylor Coll Med, Houston, TX 77030 USA; [Sherer, M.] Mem Hermann TIRR, Houston, TX 77030 USA; [Nick, T. G.] Univ Cincinnati, Cincinnati, OH USA; [Nick, T. G.] Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA		Nakase-Richardson, R (corresponding author), Methodist Rehabil Ctr, Dept Neurophysiol, 1350 E Woodrow Wilson Dr, Jackson, MS 39216 USA.	Nakase@aol.com					American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Bernat JL, 2002, NEUROLOGY, V58, P337, DOI 10.1212/WNL.58.3.337; Coleman D, 2002, NEUROLOGY, V58, P506, DOI 10.1212/WNL.58.3.506; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; Kennedy RE, 2003, PSYCHOSOMATICS, V44, P283, DOI 10.1176/appi.psy.44.4.283; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542	11	26	26	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2008	79	2							216	10.1136/jnnp.2007.127795			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	261PG	WOS:000253091900030	18202213				2022-02-06	
J	Williams, BL; Hornig, M; Yaddanapudi, K; Lipkin, WI				Williams, Bredt L.; Hornig, Mady; Yaddanapudi, Kavitha; Lipkin, W. Ian			Hippocampal poly(ADP-ribose) polymerase 1 and caspase 3 activation in neonatal Bornavirus infection	JOURNAL OF VIROLOGY			English	Article							APOPTOSIS-INDUCING FACTOR; TRAUMATIC BRAIN-INJURY; CELL-DEATH; DISEASE VIRUS; CEREBRAL-ISCHEMIA; NEURONAL DEATH; MICROGLIAL ACTIVATION; DNA FRAGMENTATION; CORTICAL CULTURE; GLUTAMATE UPTAKE	Infection of neonatal rats with Borna disease virus results in a characteristic behavioral syndrome and apoptosis of subsets of neurons in the hippocampus, cerebellum, and cortex (neonatal Borna disease [NBD]). In the NBD rat hippocampus, dentate gyrus granule cells progressively degenerate. Apoptotic loss of granule cells in NBD is associated with accumulation of zinc in degenerating neurons and reduced zinc in granule cell mossy fibers. Excess zinc can trigger poly (ADP-ribose) polymerase 1 (PARP-1) activation, and PARP-1 activation can mediate neuronal death. Here, we evaluate hippocampal PARP-1 mRNA and protein expression levels, activation, and cleavage, as well as apoptosis-inducing factor (AIF) nuclear translocation and executioner caspase 3 activation, in NBD rats. PARP-1 mRNA and protein levels were increased in NBD hippocampi. PARP-1 expression and activity were increased in granule cell neurons and glia with enhanced ribosylation of proteins, including PAR-P-1 itself. In contrast, levels of poly (ADP-ribose) glycohydrolase mRNA were decreased in NBD hippocampi. PARP-1 cleavage and AIF expression were also increased in astrocytes in NBD hippocampi. Levels of activated caspase 3 protein were increased in NBD hippocampi and localized to nuclei, mossy fibers, and dendrites of granule cell neurons. These results implicate aberrant zinc homeostasis, PARP-1, and caspase 3 activation as contributing factors in hippocampal neurodegeneration in NBD.	[Williams, Bredt L.; Hornig, Mady; Yaddanapudi, Kavitha; Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA		Lipkin, WI (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, 722 W 168th St,Romm 1801, New York, NY 10032 USA.	wil2001@columbia.edu	Lipkin, W. Ian/ABE-6216-2020; Hornig, Mady/AAE-8431-2020	Lipkin, W. Ian/0000-0002-8768-9386; Hornig, Mady/0000-0001-7572-3092	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD37546, R01 HD037546] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29425] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD037546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029425] Funding Source: NIH RePORTER		Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Armstrong RC, 1997, J NEUROSCI, V17, P553; BAKSI K, 1987, EXP CELL RES, V172, P110, DOI 10.1016/0014-4827(87)90098-X; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Billaud JN, 2000, J VIROL, V74, P10438, DOI 10.1128/JVI.74.22.10438-10446.2000; Bonicalzi ME, 2005, CELL MOL LIFE SCI, V62, P739, DOI 10.1007/s00018-004-4505-1; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; CARBONE KM, 1991, J NEUROPATH EXP NEUR, V50, P205, DOI 10.1097/00005072-199105000-00003; Carbone KM, 2001, CURR OPIN MICROBIOL, V4, P467, DOI 10.1016/S1369-5274(00)00237-X; Carbone M, 2006, J MOL BIOL, V363, P773, DOI 10.1016/j.jmb.2006.05.077; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Chu CT, 2005, J NEUROCHEM, V94, P1685, DOI 10.1111/j.1471-4159.2005.03329.x; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dawson VL, 1998, PROG BRAIN RES, V118, P215; DELATORRE JC, 1994, J VIROL, V68, P7669, DOI 10.1128/JVI.68.12.7669-7675.1994; DERY CV, 1986, VIRUS RES, V4, P313, DOI 10.1016/0168-1702(86)90078-X; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; Gaken JA, 1996, J VIROL, V70, P3992; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gordon-Shaag A, 2003, J VIROL, V77, P4273, DOI 10.1128/JVI.77.7.4273-4282.2003; GOSZTONYI G, 1995, CURR TOP MICROBIOL, V190, P39; Griffin DE, 2005, CURR TOP MICROBIOL, V289, P57; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Ha HC, 2001, P NATL ACAD SCI USA, V98, P3364, DOI 10.1073/pnas.051633498; Hatalski CG, 1998, J NEUROIMMUNOL, V90, P137, DOI 10.1016/S0165-5728(98)00076-9; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Hornig M, 1999, P NATL ACAD SCI USA, V96, P12102, DOI 10.1073/pnas.96.21.12102; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; NARAYAN O, 1983, SCIENCE, V220, P1401, DOI 10.1126/science.6602380; Nargi-Aizenman JL, 2002, VIROLOGY, V293, P164, DOI 10.1006/viro.2001.1253; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oh YK, 2006, NEUROSCI LETT, V406, P205, DOI 10.1016/j.neulet.2006.07.044; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Park JA, 2000, J NEUROSCI, V20, P9096; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Pletnikov MV, 2000, DEV BRAIN RES, V119, P179, DOI 10.1016/S0165-3806(99)00168-6; Rami A, 2003, NEUROCHEM INT, V43, P211, DOI 10.1016/S0197-0186(03)00002-0; Samuel MA, 2007, J VIROL, V81, P2614, DOI 10.1128/JVI.02311-06; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sheline CT, 2003, EUR J NEUROSCI, V18, P1402, DOI 10.1046/j.1460-9568.2003.02865.x; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Solbrig MV, 1996, VIROLOGY, V222, P332, DOI 10.1006/viro.1996.0430; Suh SW, 2007, MOL MED, V13, P344, DOI 10.2119/2007-00043.Suh; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2001, NEUROREPORT, V12, P1523, DOI 10.1097/00001756-200105250-00044; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Truong-Tran AQ, 2001, BIOMETALS, V14, P315, DOI 10.1023/A:1012993017026; Virag L, 1999, BRIT J PHARMACOL, V126, P769, DOI 10.1038/sj.bjp.0702332; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Weissenbock H, 2000, BRAIN PATHOL, V10, P260, DOI 10.1111/j.1750-3639.2000.tb00259.x; Willcocks L, 2001, J INFORM TECHNOL, V16, P1, DOI 10.1080/026839601750173660; Williams BL, 2007, J VIROL, V81, P2675, DOI 10.1128/JVI.02245-06; Williams DF, 2001, QUATERN INT, V80-1, P3, DOI 10.1016/S1040-6182(01)00015-5; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zocher M, 2000, J NEUROVIROL, V6, P462, DOI 10.3109/13550280009091947	67	26	29	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0022-538X	1098-5514		J VIROL	J. Virol.	FEB	2008	82	4					1748	1758		10.1128/JVI.02014-07			11	Virology	Science Citation Index Expanded (SCI-EXPANDED)	Virology	258ZQ	WOS:000252909300012	18057239	Bronze, Green Published			2022-02-06	
J	Gutierrez, PM; Brenner, LA; Huggins, JA				Gutierrez, Peter M.; Brenner, Lisa A.; Huggins, Joseph A.			A Preliminary Investigation of Suicidality in Psychiatrically Hospitalized Veterans with Traumatic Brain Injury	ARCHIVES OF SUICIDE RESEARCH			English	Article						suicide; traumatic brain injury; veterans		The objective of this study was to explore suicidal behaviors documented at time of discharge from acute psychiatric hospitalization. Data from 114 acute psychiatric admissions were reviewed for 22 veterans with a history of traumatic brain injury (TBI). Information extracted included presence of suicidal ideation, nature of suicide attempts, and TBI characteristics. The Lethality of Suicide Attempt Rating Scale was used to classify veterans' non-lethal self-harm behavior. Post-TBI, 6 patients (27.3%) made a total of 14 suicide attempts. Half of those attempts required wounds being sutured, stomach lavage, or other medical attention. Clinicians and researchers are strongly encouraged to focus increased attention on suicide prevention in those with a history of TBI.	[Gutierrez, Peter M.; Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Psychiat,Dept Phys Med & Rehabil,Dept Neurol, Denver VA Med Ctr,MIRECC,VA VISN 19, Denver, CO 80220 USA; [Huggins, Joseph A.] Univ Colorado Denver, Sch Med, Dept Family Med, MIRECC,MSW,MSCIS VA VISN 19, Denver, CO 80220 USA		Gutierrez, PM (corresponding author), Univ Colorado Denver, Sch Med, Dept Psychiat,Dept Phys Med & Rehabil,Dept Neurol, Denver VA Med Ctr,MIRECC,VA VISN 19, 1055 Clermont St, Denver, CO 80220 USA.	peter.gutierrez@va.gov	Brenner, Lisa A./AAG-2442-2019; Gutierrez, Peter/K-8905-2019	Gutierrez, Peter/0000-0001-8981-8404; Huggins, Joe/0000-0001-8151-5062			American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Berman AL, 2003, SUICIDE LIFE-THREAT, V33, P261, DOI 10.1521/suli.33.3.261.23211; Brenner L. A., J HEAD TRAU IN PRESS; *DEP VET AFF, 2004, VETEESA138 SP DEP VE; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jennett B, 1981, MANAGEMENT HEAD INJU; Jollant F, 2005, AM J PSYCHIAT, V162, P304, DOI 10.1176/appi.ajp.162.2.304; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Powell KB, 2004, J CHILD NEUROL, V19, P785, DOI 10.1177/08830738040190100801; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; SMITH K, 1984, SUICIDE LIFE-THREAT, V14, P215; STUSS DT, 2007, HUMAN FRONTAL LOBES, P293; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436	23	26	26	0	1	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1381-1118			ARCH SUICIDE RES	Arch. Suicide Res.		2008	12	4					336	343		10.1080/13811110802324961			8	Psychiatry; Psychology; Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychiatry; Psychology	V11CR	WOS:000207510200005	18828036				2022-02-06	
J	Slewa-Younan, S; Baguley, IJ; Heriseanu, R; Cameron, ID; Pitsiavas, V; Mudaliar, Y; Nayyar, V				Slewa-Younan, Shameran; Baguley, Ian J.; Heriseanu, Roxana; Cameron, Ian D.; Pitsiavas, Vicki; Mudaliar, Yugan; Nayyar, Vineet			Do men and women differ in their course following traumatic brain injury? A preliminary prospective investigation of early outcome	BRAIN INJURY			English	Article						traumatic brain injury; sex differences; injury severity; outcome	GENDER-DIFFERENCES; SEX-DIFFERENCES; HEAD-INJURY; MORTALITY; PROGESTERONE; HORMONES; DAMAGE; WORSE	Primary objective: To examine the effect of a patient's sex on measures of outcome in a matched sample of patients admitted for acute traumatic brain injury (TBI). Research design: A prospective multi-centred group comparison study based in metropolitan Sydney, Australia. Methods and procedures: Data was collected on 25 women admitted for treatment following non-penetrating TBI. Forty-five men were then matched with regards to age and injury severity. All subjects met the study criteria of having a moderate-to-severe TBI and aged 50 years old or younger. Exclusion criteria included history of previous head injury, psychiatric disturbance and significant alcohol and/or substance abuse. Data included injury details and physiological and psychometric measures of outcome. Main outcomes and results: Women demonstrated better outcomes as indicated by their Glasgow Outcome Scale scores (adjusted for initial injury severity and age at injury odds ratio [OR] 4.2, 95% CI 1.4-12.7) and having shorter Length of Stay (adjusted OR 9.03, 95% CI 3.13-26.08). Conclusions: Understanding the presence of sex differences in outcome following TBI is an emerging area of research. This study indicated that, after matching for initial injury severity and age at injury, women with severe TBI demonstrate a better early outcome than men.	[Slewa-Younan, Shameran; Baguley, Ian J.; Heriseanu, Roxana] Westmead Hosp, Brain Injury Rehabil Serv, Wentworthville, NSW 2145, Australia; [Slewa-Younan, Shameran; Baguley, Ian J.; Cameron, Ian D.] Univ Sydney, Fac Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Pitsiavas, Vicki] Westmead Hosp, Inst Clin Pathol & Med Res, Wentworthville, NSW 2145, Australia; [Mudaliar, Yugan; Nayyar, Vineet] Westmead Hosp, Dept Intens Care Med, Wentworthville, NSW 2145, Australia		Slewa-Younan, S (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	shameran@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705; Micallef, Sharon/0000-0002-8496-2324			Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Baguley I, 2000, BRAIN INJURY, V14, P505; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; GROSSMAN WF, 1994, J REPROD MED, V39, P738; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gujral IB, 2006, BRAIN INJURY, V20, P283, DOI 10.1080/02699050500488058; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; Johannes CB, 1999, SEMIN REPROD ENDOCR, V17, P299; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KLINGBEIL GEG, 1985, ARCH PHYS MED REHAB, V66, P44; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Maas D, 1997, DRUG AGING, V11, P45, DOI 10.2165/00002512-199711010-00005; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; O'Connor KA, 2001, AM J HUM BIOL, V13, P465, DOI 10.1002/ajhb.1078; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; WRIGHT DW, ANN EMERGENCY MED, V49, P391	33	26	26	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					183	191		10.1080/02699050801888808			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600009	18240047				2022-02-06	
J	Viano, DC				Viano, David C.			Seat Design Principles to Reduce Neck Injuries in Rear Impacts	TRAFFIC INJURY PREVENTION			English	Article; Proceedings Paper	World Congress on Neck Pain	JAN 20-22, 2008	Los Angeles, CA			Whiplash; Seats; Head restraints; Spinal cord injury; Rear crashes; Injury biomechanics		Objectives: In the 1990s, research was conducted at General Motors R&D Center on seat safety in rear impacts. It led to the development of high retention seats and an active head restraint to improve occupant safety. This article provides an overview of the design principles found from that research and focuses on seat characteristics that lower whiplash risks. Methods: Sled and quasistatic seat testing showed how occupants interact with the seat in rear impacts and what seat characteristics improve occupant retention, energy management, and support of the head-neck, lowering injury risks. Neck displacements, moments, and forces were used to assess whiplash and more severe injury risks. A QST test was developed to quasi-statically push a dummy rearward into the seat to determine seat stiffness (k), frame strength (j), and peak bending moment (M(Hpt)). These parameters were related to neck displacements associated with whiplash. Sled tests were run with in-position and out-of-position male and female Hybrid III dummies to assess performance. A high retention seat and active head restraint were developed and put into production in 1997. Results: High retention seats have 2.3 times greater moment, develop 2.2 times greater load, but have the same stiffness as earlier yielding seats. Seat stiffness was found to be a principle characteristic related to neck displacements associated with whiplash. The combination of a stronger frame, yielding seatback, and high-forward head restraint in the high retention seat provides early head support and low neck displacements in rear impacts. Larger reductions in neck displacement were obtained by adding an active head restraint that moves the head restraint forward and upward by occupant penetration into the seatback. This substantially reduces head contact time, neck displacements, and loads. Conclusions: Whiplash risks are related to seat stiffness, the position of the head restraint, and frame strength. Low seat stiffness allows the occupant to move into the seatback without high loads on the torso until the head-neck is supported by the head restraint. A strong seat frame reduces early seatback rotation that increases the gap to the head restraint and drops it in relation to the occupant's head. A high and forward head restraint provides support of the head and neck. Large forces can be applied to the occupant once the head, neck, and torso are supported by the seat and head restraint without adverse loading of the spine. The addition of an active head restraint closes the gap behind the head before significant load develops on the neck. The movement provides a more upward trajectory of the head restraint. Low- speed rear crashes are not just a matter of whiplash; older occupants, some with cervical stenosis, are at risk for paralyzing spinal cord injury.	ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA		Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					Anderson JO, 1961, R341295 RES LAB GEN; Blaisdell DM, 1993, 930340 SAE; Burnett R., 2008, 2008010188 SAE; Farmer Charles M, 2003, Traffic Inj Prev, V4, P83, DOI 10.1080/15389580309867; ONEILL B, 1972, AM J PUBLIC HEALTH N, V62, P399, DOI 10.2105/AJPH.62.3.399; Parenteau, 2008, 2008011485 SAE, DOI 10.4271/2008-01-1485; Partyka S, 1992, SUMMARY SAFETY ISSUE; Prasad P, 1997, 973343 SAE; *RCAR IIWPG, 2007, SEAT HEAD RESTR EV P; SCHWIMMER S, 1962, LEADING CAUSES INJUR; Severy DM, 1976, 760810 SAE; SEVERY DM, 1968, 680079 SAE; Viano, 2002, R3171491 SAE; Viano, 2003, 2003010173 SAE; Viano D.C., 2002, 2002010030 SAE; Viano D. C., 2003, 2003010180 SAE; Viano David C, 2003, Traffic Inj Prev, V4, P214, DOI 10.1080/15389580309877; Viano David C, 2003, Traffic Inj Prev, V4, P228, DOI 10.1080/15389580309880; Viano David C, 2003, Traffic Inj Prev, V4, P324, DOI 10.1080/714040490; Viano DC, 2001, J TRAUMA, V51, P959, DOI 10.1097/00005373-200111000-00022; Viano DC, 1996, ACCIDENT ANAL PREV, V28, P665, DOI 10.1016/S0001-4575(96)00011-5; Viano DC, 2008, 2008011851 SAE; VIANO DC, 2007, 2007010708 SAE; Viano DC, 2003, 2003011351 SAE; Viano DC, 2003, DEBATE STIFF YIELDIN; VIANO DC, 2003, COMMUNICATION; WARNER C, 1991, OCCUPANT PROTECTION, V2	27	26	26	1	8	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1538-9588			TRAFFIC INJ PREV	Traffic Inj. Prev.		2008	9	6					552	560		10.1080/15389580802381939			9	Public, Environmental & Occupational Health; Transportation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Public, Environmental & Occupational Health; Transportation	387DN	WOS:000261932000008	19058102				2022-02-06	
J	Chan, L				Chan, Leighton			The state-of-the-science: Challenges in designing postacute care payment policy	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						health policy; outcome and process assessment (health care); outcomes research; rehabilitation	TRAUMATIC BRAIN-INJURY; INPATIENT REHABILITATION; CASE-MIX; SYSTEM; IMPACT; OUTCOMES; FACILITIES; HOSPITALS; PROVIDERS	Chan L. The state-of-the-science: challenges in designing postacute care payment policy, Arch Phys Med Rehabil 2007;88:1522-5. This report describes Medicare's postacute care (PAC) payment systems and their incentives, as well as global changes in capacity, quality, and utilization over time. It assesses the payment systems' impact on PAC services, referencing relevant works in progress. Suggestions are made for future research.	NIH, Dept Rehabil Med, Bethesda, MD 20892 USA		Chan, L (corresponding author), Bldg 10,CRC,Room 1-1469,10 Ctr Dr,MSC 1604, Bethesda, MD 20892 USA.	chanle@cc.nih.gov					BROWN D, 2000, FIM STUDY STANDARDIZ; Chan L, 2000, ARCH PHYS MED REHAB, V81, P715, DOI 10.1016/S0003-9993(00)90098-4; Chan L, 1997, NEW ENGL J MED, V337, P978, DOI 10.1056/NEJM199710023371406; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS93, DOI 10.1016/j.apmr.2005.07.313; Dobrez DG, 2004, ARCH PHYS MED REHAB, V85, P1909, DOI 10.1016/j.apmr.2004.06.064; Frymark TB, 2005, AM J PHYS MED REHAB, V84, P12, DOI 10.1097/01.PHM.0000146501.71140.67; Gage B, 1999, HEALTH CARE FINANC R, V20, P103; HOENIG H, 2007, STAT SCI S POSTAC RE; HOFFMAN J, 2007, STAT SCI S POSTAC RE; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; JOHNSTON MV, 1986, ARCH PHYS MED REHAB, V67, P581; Kaplan SJ, 2007, ARCH PHYS MED REHAB, V88, P1494, DOI 10.1016/j.apmr.2007.08.112; Liu K, 2003, HEALTH CARE FINANC R, V25, P81; McCue MJ, 2006, ARCH PHYS MED REHAB, V87, P198, DOI 10.1016/j.apmr.2005.10.029; McNaughton H, 2005, ARCH PHYS MED REHAB, V86, pS115, DOI 10.1016/j.apmr.2005.08.115; *MED PAYM ADV COMM, 2006, DAT BOOK HEALTHC SPE; Newhouse JP, 2005, HEALTH CARE FINANC R, V27, P35; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; Saitto C, 2005, MED CARE, V43, P844, DOI 10.1097/01.mlr.0000173567.80190.32; Saitto C, 2005, MED CARE, V43, P856, DOI 10.1097/01.mlr.0000173568.67805.70; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SANDEL ME, 2007, STAT SCI S POSTAC RE; Schlenker RE, 2005, HEALTH SERV RES, V40, P177, DOI 10.1111/j.1475-6773.2005.00348.x; Schoenman JA, 2005, J RURAL HEALTH, V21, P122, DOI 10.1111/j.1748-0361.2005.tb00072.x; SIDNEY S, 2000, COST STROKE CARE PRE; Thompson J M, 2004, Health Serv Manage Res, V17, P13, DOI 10.1258/095148404322772697; Weinrich M, 2005, NEUROREHAB NEURAL RE, V19, P72, DOI 10.1177/1545968305275718; Yip JY, 2002, GERONTOLOGIST, V42, P653, DOI 10.1093/geront/42.5.653	28	26	26	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2007	88	11					1522	1525		10.1016/j.apmr.2007.05.032			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	229AT	WOS:000250774400025	17964899				2022-02-06	
J	Haider, AH; Efron, DT; Haut, ER; Chang, DC; Paidas, CN; Cornwell, EE				Haider, Adil H.; Efron, David T.; Haut, Elliott R.; Chang, David C.; Paidas, Charles N.; Cornwell, Edward E., III			Mortality in adolescent girls vs boys - Following traumatic shock an analysis of the national pediatric trauma registry	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	78th Annual Meeting of the Pacific-Coast-Surgical-Association	FEB   18, 2007	Kohala Coast, HI	Pacific Coast Surg Assoc			INJURY SEVERITY SCORE; GENDER DIFFERENCES; IMMUNE-RESPONSES; FUNCTIONAL OUTCOMES; HEMORRHAGIC-SHOCK; BRAIN-INJURY; AGE; TESTOSTERONE; SURVIVAL; MALES	Hypothesis: Female sex imparts a survival benefit after traumatic injury in children. Design, Setting, and Patients: Review of patients (aged 0-17 years) included in the National Pediatric Trauma Registry between April 1994 and September 2001. Multiple logistic regression was used to analyze the effect of sex on mortality, adjusting for age, severity of injury (New Injury Severity Score and Pediatric Trauma Score), severity of head or extremity injury, injury mechanism, intent, and comorbidities. Subset analysis focused on severely injured children (New Injury Severity Score >= 16) with shock (systolic blood pressure <= 90 mm Hg, adjusted for age). Main Outcome Measure: Adjusted odds of mortality between sexes. Results: Of 46 859 children, 67% were boys. Girls had a higher crude mortality rate than boys (3.1% vs 2.7%, respectively; p<.05), but after adjustment, no significant difference was found in the odds of mortality between sexes (odds ratio, 1.16; 95% confidence interval, 0.89-1.37). Among children meeting the definition. of severe injury with shock (n = 697), mortality was 39%. On regression analysis, sex did not predict outcomes in prepubescent children (aged: <= 11 years; n=532; 95% confidence interval, 0.56-1.22). However, among adolescents (aged 12-17 years), girls demonstrated significantly decreased odds of death when compared with equivalently injured boys (odds ratio, 0.38; 95% confidence interval, 0. 14-0.90; n = 165). Conclusions: Adolescent girls exhibit lower mortality than boys following traumatic shock. This effect is not seen in prepubescent children. These findings suggest that hormonal differences may play a role in the sex-based outcome disparities following traumatic shock in children.	Johns Hopkins Sch Med, Dept Surg, Div Trauma & Crit Care, Baltimore, MD 21287 USA; Univ S Florida, Dept Surg, Tampa, FL 33620 USA		Haider, AH (corresponding author), Johns Hopkins Sch Med, Dept Surg, Div Trauma & Crit Care, 600 N Wolfe St,Blalock 688, Baltimore, MD 21287 USA.	ahaider1@jhmi.edu	Haut, Elliott R./J-3948-2019	Haut, Elliott/0000-0001-7075-771X			Angele Martin K., 2006, Clinics, V61, P479, DOI 10.1590/S1807-59322006000500017; Angele MK, 2005, LANGENBECK ARCH SURG, V390, P333, DOI 10.1007/s00423-005-0557-4; Angele MK, 1998, AM J PHYSIOL-CELL PH, V274, pC1530, DOI 10.1152/ajpcell.1998.274.6.C1530; Angele MK, 1998, J TRAUMA, V44, P78, DOI 10.1097/00005373-199801000-00007; Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Chumlea WC, 2003, PEDIATRICS, V111, P110, DOI 10.1542/peds.111.1.110; Cornwell EE, 2003, ARCH SURG-CHICAGO, V138, P838, DOI 10.1001/archsurg.138.8.838; Cornwell EE, 1999, J GASTROINTEST SURG, V3, P648, DOI 10.1016/S1091-255X(99)80088-2; Diodato MD, 2001, CYTOKINE, V14, P162, DOI 10.1006/cyto.2001.0861; Gannon CJ, 2002, J AM COLL SURGEONS, V195, P11, DOI 10.1016/S1072-7515(02)01187-0; George RL, 2003, J TRAUMA, V54, P464, DOI 10.1097/01.TA.0000051939.95039.E6; George RL, 2003, SHOCK, V19, P28, DOI 10.1097/00024382-200301000-00006; Haider A, 2003, J AM COLL SURGEONS, V197, pS67; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Haider AH, 2004, J PEDIATR SURG, V39, P976, DOI 10.1016/j.jpedsurg.2004.02.028; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; Napolitano LM, 2001, J TRAUMA, V50, P274, DOI 10.1097/00005373-200102000-00013; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Samy TSA, 2001, ENDOCRINOLOGY, V142, P3519, DOI 10.1210/en.142.8.3519; Sullivan T, 2003, J TRAUMA, V55, P1083, DOI 10.1097/01.TA.0000102175.58306.2A; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Wichmann MW, 1997, SHOCK, V8, P242, DOI 10.1097/00024382-199710000-00002; Wichmann MW, 1996, CYTOKINE, V8, P853, DOI 10.1006/cyto.1996.0114; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7	28	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	SEP	2007	142	9					875	879		10.1001/archsurg.142.9.875			5	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	210KB	WOS:000249454000017	17875843	Bronze			2022-02-06	
J	Strobel, K; Skalsky, J; Kalff, V; Baumann, K; Seifert, B; Joller-Jemelka, H; Dummer, R; Steinert, HC				Strobel, Klaus; Skalsky, Jeannine; Kalff, Victor; Baumann, Katrin; Seifert, Burkhardt; Joller-Jemelka, Helen; Dummer, Reinhard; Steinert, Hans C.			Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING			English	Article						melanoma; PET; CT; S-100B; metastases	POSITRON-EMISSION-TOMOGRAPHY; SENTINEL NODE BIOPSY; CUTANEOUS MALIGNANT-MELANOMA; TRAUMATIC BRAIN-INJURY; CONSECUTIVE PATIENTS; S-100-BETA PROTEIN; PROGNOSTIC MARKER; PROSTATE-CANCER; F-18-FDG PET; FOLLOW-UP	Purpose To evaluate the usefulness of PET/CT in melanoma patients with an elevated serum S-100B tumour marker level. Methods Out of 165 consecutive high-risk melanoma patients referred for PET/CT imaging, 47 had elevated (> 0.2 mu g/l) S-100B serum levels and a contemporaneous F-18-FDG PET/CT scan. PET/CT scans were evaluated for the presence of metastases. To produce a composite reference standard, we used cytological, histological, MRI and PET/CT follow-up findings as well as clinical and S-100B follow-up. Results Among the 47 patients with increased S-100B levels, PET/CT correctly identified metastases in 38 (30 distant metastases and eight lymph node metastases). In one patient with cervical lymph node metastases, PET/CT was negative. Eight patients had no metastases and PET/CT correctly excluded metastases in all of them. Overall sensitivity for metastases was 97% (38/39), specificity 100% (8/8) and accuracy 98% (46/47). S-100B was significantly higher in patients with distant metastases (mean 1.93 mu g/l, range 0.3-14.3 mu g/l) than in patients with lymph node metastases (mean 0.49 mu g/l, range 0.3-1.6 mu g/l, p = 0.003) or patients without metastases (mean 0.625 mu g/l, range 0.3-2.6 mu g/l, p = 0.007). However, 6 of 14 patients with a tumour marker level of 0.3 mu g/l had no metastases. Conclusion In melanoma patients with elevated S-100B tumour marker levels, FDG-PET/CT accurately identifies lymph node or distant metastases and reliably excludes metastases. Because of the significant number of false positive S-100B tumour marker determinations (17%), we recommend repetition of tumour marker measurements if elevated S-100B levels occur before extensive imaging is used.	Univ Zurich Hosp, Dept Med Radiol, Div Nucl Med, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Alfred Hosp, Dept Nucl Med, Melbourne, Vic, Australia; Univ Zurich, Inst Biostat, Zurich, Switzerland		Strobel, K (corresponding author), Univ Zurich Hosp, Dept Med Radiol, Div Nucl Med, Raemistr 100, CH-8091 Zurich, Switzerland.	klaus.strobel@usz.ch		Seifert, Burkhardt/0000-0002-5829-2478			Abraha HD, 1997, BRIT J DERMATOL, V137, P381, DOI 10.1046/j.1365-2133.1997.18531946.x; Acland KM, 2001, J CLIN ONCOL, V19, P2674, DOI 10.1200/JCO.2001.19.10.2674; Andres R, 2004, TUMORI J, V90, P607, DOI 10.1177/030089160409000613; Banfalvi Teodora, 2004, Magy Onkol, V48, P71; Buer J, 1997, BRIT J CANCER, V75, P1373, DOI 10.1038/bjc.1997.232; Cimitan M, 2006, EUR J NUCL MED MOL I, V33, P1387, DOI 10.1007/s00259-006-0150-2; de Jong IJ, 2003, EUR UROL, V44, P32, DOI 10.1016/S0302-2838(03)00207-0; Delbeke D, 2006, J NUCL MED, V47, P885; Domingo-Domenech J, 2005, ONCOLOGY-BASEL, V68, P341, DOI 10.1159/000086973; Dummer R, 1997, DERMATOLOGY, V194, P208, DOI 10.1159/000246103; Dummer R, 2005, DERMATOLOGY, V210, P39, DOI 10.1159/000081482; Eigentler TK, 2003, LANCET ONCOL, V4, P748, DOI 10.1016/S1470-2045(03)01280-4; Fuster D, 2004, J NUCL MED, V45, P1323; Hansson LO, 1997, ANTICANCER RES, V17, P3071; Hauschild A, 1999, BRIT J DERMATOL, V140, P1065; Jury CS, 2000, BRIT J DERMATOL, V143, P269, DOI 10.1046/j.1365-2133.2000.03650.x; Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x; Libutti SK, 2001, ANN SURG ONCOL, V8, P779, DOI 10.1007/s10434-001-0779-9; Martenson ED, 2001, J CLIN ONCOL, V19, P824, DOI 10.1200/JCO.2001.19.3.824; Molina R, 2002, TUMOR BIOL, V23, P39, DOI 10.1159/000048687; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Morton DL, 2005, ANN SURG, V242, P302, DOI 10.1097/01.sla.0000181092.50141.fa; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Reinhardt MJ, 2006, J CLIN ONCOL, V24, P1178, DOI 10.1200/JCO.2005.03.5634; Reinhardt MJ, 2002, NUKLEARMED-NUCL MED, V41, P143; Rinne D, 1998, CANCER, V82, P1664, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2; Rohren EM, 2003, RADIOLOGY, V226, P181, DOI 10.1148/radiol.2261010920; Schultz ES, 1998, BRIT J DERMATOL, V138, P426; Schwimmer J, 2000, Q J NUCL MED, V44, P153; Smit LHM, 2005, INT J BIOL MARKER, V20, P34, DOI 10.1177/172460080502000106; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; SZE G, 1988, RADIOLOGY, V168, P187, DOI 10.1148/radiology.168.1.3380956; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Wagner JD, 2001, J SURG ONCOL, V77, P237, DOI 10.1002/jso.1102; Wagner JD, 1999, J CLIN ONCOL, V17, P1508, DOI 10.1200/JCO.1999.17.5.1508	36	26	28	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1619-7070	1619-7089		EUR J NUCL MED MOL I	Eur. J. Nucl. Med. Mol. Imaging	SEP	2007	34	9					1366	1375		10.1007/s00259-007-0403-8			10	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	203LG	WOS:000248975500007	17390135	Green Submitted, Green Accepted			2022-02-06	
J	Drobin, D; Gryth, D; Persson, JKE; Rocksen, D; Arborelius, UP; Olsson, LG; Bursell, J; Kjellstrom, BT				Drobin, Dan; Gryth, Dan; Persson, Jonas K. E.; Rocksen, David; Arborelius, Ulf P.; Olsson, Lars-Gunnar; Bursell, Jenny; Kjellstroem, B. Thomas			Electroencephalogram, circulation, and lung function after high-velocily behind armor blunt trauma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						behind armor blunt trauma; BABT; EEG; blunt trauma; pulmonary contusion	NERVOUS-SYSTEM; CONCUSSION; INJURY; IMPACT; DAMAGE	Background: Behind armor blunt trauma (BABT) is defined as the nonpenetrating injury resulting from a ballistic impact on personal body armor. The protective vest may impede the projectile, but some of the kinetic energy is transferred to the body, causing internal injuries and occasionally death. The aim in this study was to investigate changes in electroencephalogram (EEG) and physiologic parameters after high-velocity BABT. Methods: Eight anesthetized pigs, wearing body armor (including a ceramic plate) on the right side of their thorax, were shot with a 7.62-mm assault rifle (velocity approximately 800 m/s). The shots did not penetrate the armor and these animals were compared with control animals (n = 4), shot with blank ammunition. EEG and several physiologic parameters were thereafter monitored during a 2-hour period after the shot. Results: All animals survived during the experimental period. Five of the exposed animals showed a temporary effect on EEG. Furthermore, exposed animals displayed decreased cardiac capacity and an impaired oxygenation of the blood. Postmortem examination revealed subcutaneous hematomas and crush injuries to the right lung. Conclusions: The results in our animal model indicate that high-velocity BABT induce circulatory and respiratory dysfunction, and in some cases even transient cerebral functional disturbances.	Swedish Def Res Agcy FOI, Dept Def Med, Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Clin Neurophysiol, Stockholm, Sweden; Soder Hosp, Karolinska Inst, Dept Anaesthesiol & Intens Care, Stockholm, Sweden; Swedish Def Res Agcy FOI, Dept Armor & Survivabil, Tumba, Sweden; Stockholm Soder Hosp, Karolinska Inst, Stockholm, Sweden; FOI, Karolinska Inst, Dept Def Med, SE-17177 Stockholm, Sweden		Gryth, D (corresponding author), FOI, Karolinska Inst, Dept Def Med, Retzius Vag 8,B 1 5, SE-17177 Stockholm, Sweden.	dangryth@hotmail.com					AKESON J, 1993, ACTA ANAESTH SCAND, V37, P211, DOI 10.1111/j.1399-6576.1993.tb03703.x; BASS CR, 2004, PASS SY, P115; BLACK S, 1990, NEUROLOGIC MONITORIN, P1188; BROWN H, 1996, APPL MIXED MODEL MED; Butler F, 2003, J TRAUMA, V54, pS2; Cannon L, 2001, J R Army Med Corps, V147, P87; CARROLL AW, 1978, ANN SURG, V188, P753, DOI 10.1097/00000658-197812000-00007; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; Cooper G J, 1989, J R Army Med Corps, V135, P58; COOPER GJ, 1982, J TRAUMA, V22, P994, DOI 10.1097/00005373-198212000-00004; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; GOLDFARB MA, 1975, EBTR74073; GORANSSON AM, 1988, J TRAUMA, V28, pS204; HINSLEY DE, 2002, PASS S, P103; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; KNUDSEN PT, 1996, PASS S, P213; KNUDSEN PT, 2000, PASS S, P417; LIDEN E, 1988, J TRAUMA, V28, pS145, DOI 10.1097/00005373-198801001-00029; Mabry RL, 2000, J TRAUMA, V49, P515, DOI 10.1097/00005373-200009000-00021; MARINO PL, 1998, ICU BOOK, P339; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MAUNDER RJ, 1991, ADULT RESPIRATORY DI, P1; Melton SM, 1999, SHOCK, V11, P396; MISSLIWETZ J, 1995, J FORENSIC SCI, V40, P582; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; Risling M, 2004, PROCEEDINGS OF THE 7TH INTERNATIONAL NEUROTRAUMA SYMPOSIUM, P119; SARRON JC, 2000, PASS S, P381; SARRON JC, 2003, RTO SPEC M; SODERSTROM CA, 1978, ARCSLTR77057; STUHMILLER JH, 2003, MODELING MILITARY OP; SUNESON A, 1987, J TRAUMA, V27, P782, DOI 10.1097/00005373-198707000-00016; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; van Belzen J A, 1998, Passau Schr Psychologiegesch, P433; vanBree J, 2000, PASS S, P371; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; 1996, NIH PUBLICATION, V8623	38	26	29	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2007	63	2					405	413		10.1097/01.ta.0000236015.68105.48			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	200AC	WOS:000248735300029	17693844				2022-02-06	
J	Shi, J; Miles, DK; Orr, BA; Massa, SM; Kernie, SG				Shi, Jian; Miles, Darryl K.; Orr, Benjamin A.; Massa, Stephen M.; Kernie, Steven G.			Injury-induced neurogenesis in Bax-deficient mice: evidence for regulation by voltage-gated potassium channels	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; calcium; caspase; dentate gyrus; neural stem cell	TRAUMATIC BRAIN-INJURY; ACTIVATED PROTEIN-KINASE; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; APOPTOTIC CELL-DEATH; BCL-2 FAMILY-MEMBERS; NEURAL STEM-CELLS; SPREADING DEPRESSION; K+ CHANNELS; EXTRACELLULAR POTASSIUM	Adult neural stem and progenitor cells may help remodel the brain in response to injury. The pro-apoptotic molecule Bax has recently been identified as a key player in adult neural stem cell survival. In Bax-deficient mice that have undergone traumatic brain injury, we find increased numbers of neural progenitor cells in the dentate gyrus and improved remodeling of the hippocampus. Exogenous potassium chloride mimics spreading depression (SD)-like events in vitro, and Bax-deficient neural stem cells proliferate in response to these events more robustly than wild-type neural stem cells. Selective potassium channel blockers interrupt SD-mediated stimulation of stem cells. In addition, the potassium channel Kv4.1 is expressed within neural stem and progenitor cells in the dentate gyrus and is increased in Bax-deficiency. These data suggest that the neuroprotection observed after injury in Bax-deficiency may be due to increased neurogenesis via activation of the Kv4 family of potassium channels.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Dev Biol, Dallas, TX 75390 USA; VA Med Ctr, Dept Neurol, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94121 USA		Kernie, SG (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Steven.Kernie@utsouthwestern.edu	Kernie, Steven/AAT-9912-2020	Kernie, Steven/0000-0003-1371-0549	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048192] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS048192] Funding Source: Medline		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Arkhammar P, 2004, J BIOMOL SCREEN, V9, P382, DOI 10.1177/1087057104263911; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Conti AC, 1998, J NEUROSCI, V18, P5663; Dansen TB, 2006, J BIOL CHEM, V281, P10890, DOI 10.1074/jbc.M513655200; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Ekhterae D, 2001, AM J PHYSIOL-CELL PH, V281, pC157, DOI 10.1152/ajpcell.2001.281.1.C157; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hansen DV, 2006, P NATL ACAD SCI USA, V103, P608, DOI 10.1073/pnas.0509549102; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hebert SC, 2005, PHYSIOL REV, V85, P319, DOI 10.1152/physrev.00051.2003; Illario M, 2005, J CLIN ENDOCR METAB, V90, P2865, DOI 10.1210/jc.2004-1520; Illario M, 2003, J BIOL CHEM, V278, P45101, DOI 10.1074/jbc.M305355200; Jiao JW, 2005, EMBO J, V24, P1068, DOI 10.1038/sj.emboj.7600589; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kolch Walter, 2002, Expert Opin Pharmacother, V3, P709, DOI 10.1517/14656566.3.6.709; Lang F, 2005, J MEMBRANE BIOL, V205, P147, DOI 10.1007/s00232-005-0780-5; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Lee YJ, 2006, AM J PHYSIOL-RENAL, V291, pF98, DOI 10.1152/ajprenal.00486.2005; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Li Z, 2004, BRAIN RES, V1021, P8, DOI 10.1016/j.brainres.2004.05.115; Lindsten T, 2003, J NEUROSCI, V23, P11112; Liu JJ, 2005, CURR BIOL, V15, P1458, DOI 10.1016/j.cub.2005.07.030; Liu P, 1998, BEHAV NEUROSCI, V112, P512, DOI 10.1037/0735-7044.112.3.512; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Nilius B, 1998, J PHYSIOL-LONDON, V506, P353, DOI 10.1111/j.1469-7793.1998.353bw.x; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OBRENOVITCH TP, 1995, J NEUROPHYSIOL, V73, P2107, DOI 10.1152/jn.1995.73.5.2107; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Pardo LA, 2005, J MEMBRANE BIOL, V205, P115, DOI 10.1007/s00232-005-0776-1; Parent JM, 1997, J NEUROSCI, V17, P3727; Petzold GC, 2005, STROKE, V36, P1270, DOI 10.1161/01.STR.0000166023.51307.e0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sanguinetti MC, 1997, MOL PHARMACOL, V51, P491; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shamloo M, 1999, NEUROSCIENCE, V93, P81, DOI 10.1016/S0306-4522(99)00137-2; Shi J, 2005, CELL DEATH DIFFER, V12, P1601, DOI 10.1038/sj.cdd.4401676; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; SOMJEN GG, 1979, ANNU REV PHYSIOL, V41, P159, DOI 10.1146/annurev.ph.41.030179.001111; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Sun W, 2004, J NEUROSCI, V24, P11205, DOI 10.1523/JNEUROSCI.1436-04.2004; Sun W, 2003, MOL CELL NEUROSCI, V24, P875, DOI 10.1016/S1044-7431(03)00219-7; Tamura Y, 2004, NEUROSCI RES, V50, P129, DOI 10.1016/j.neures.2004.06.011; Thomas W, 2006, STEROIDS, V71, P256, DOI 10.1016/j.steroids.2005.10.010; Valjent E, 2001, MOL NEUROBIOL, V23, P83; Wang YG, 2006, J CARDIOVASC ELECTR, V17, P298, DOI 10.1111/j.1540-8167.2006.00362.x; Wang ZG, 2004, PFLUG ARCH EUR J PHY, V448, P274, DOI 10.1007/s00424-004-1258-5; Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x; Yanamoto H, 2005, STROKE, V36, P1544, DOI 10.1161/01.STR.0000169903.09253.c7; Yao XQ, 1999, LIFE SCI, V65, P55, DOI 10.1016/S0024-3205(99)00218-0; Yu TS, 2005, GENESIS, V41, P147, DOI 10.1002/gene.20110; Yuan LL, 2002, J NEUROSCI, V22, P4860, DOI 10.1523/JNEUROSCI.22-12-04860.2002; Zarayskiy VV, 2005, TOXICON, V45, P431, DOI 10.1016/j.toxicon.2004.11.015; Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675	75	26	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUN	2007	25	12					3499	3512		10.1111/j.1460-9568.2007.05624.x			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	184SK	WOS:000247662100002	17610570				2022-02-06	
J	Cheng, HY; Murdoch, BE; Goozee, JV; Scott, D				Cheng, Hei Yan; Murdoch, Bruce E.; Goozee, Justine V.; Scott, Dion			Physiologic development of tongue-jaw coordination from childhood to adulthood	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						speech development; motor control; articulation; EMA; tongue; jaw	TRAUMATIC BRAIN-INJURY; SPEECH MOTOR CONTROL; MOVEMENTS; DYSARTHRIA; LIP; STABILITY; PATTERNS; CHILDREN	Purpose: This investigation aimed to examine the development of tongue-jaw coordination during speech from childhood to adolescence. Method: Electromagnetic articulography was used to track tongue and jaw motion in 48 children and adults (aged 6-38 years) during productions of /t/ and /k/ embedded in sentences. Results: The coordinative organization of the tongue and jaw exhibited changes until the age of 8-11 years and continued to undergo refinement into late adolescence. The tongue-tip and tongue-body were observed to develop unique kinematic relations with the jaw. While tongue-tip movement became increasingly synchronized with jaw movement, tongue-body and jaw retained movement independence but developed a more consistent kinematic relation. Conclusion: The present results support the notion that speech motor development is nonuniform, with a refinement period from mid-childhood to late adolescence.	Univ Queensland, Brisbane, Qld 4072, Australia		Cheng, HY (corresponding author), Univ Queensland, Brisbane, Qld 4072, Australia.	y.cheng@shrs.uq.edu.au	Murdoch, Bruce E/C-1397-2012				Bartle CJ, 2006, BRAIN INJURY, V20, P529, DOI 10.1080/02699050500487613; EDWARDS J, 1990, SR103104 HASK LAB, P51; FABER A, 1991, J ACOUST SOC AM, V8, P1872; FARNETANI E, 1992, SPEECH COMMUN, V11, P401, DOI 10.1016/0167-6393(92)90045-9; FLETCHER SG, 1989, J SPEECH HEAR RES, V39, P732; GIBSON AR, 1985, J PHYSIOL-LONDON, V358, P551, DOI 10.1113/jphysiol.1985.sp015566; Goffman L, 1999, J EXP PSYCHOL HUMAN, V25, P649, DOI 10.1037/0096-1523.25.3.649; Goozee JV, 2000, BRAIN INJURY, V14, P153, DOI 10.1080/026990500120817; GRACCO VL, 1988, J NEUROSCI, V8, P4628; Green JR, 2002, J SPEECH LANG HEAR R, V45, P66, DOI 10.1044/1092-4388(2002/005); Green JR, 2000, J SPEECH LANG HEAR R, V43, P239, DOI 10.1044/jslhr.4301.239; HIXON TJ, 1976, J SPEECH HEAR RES, V19, P297, DOI 10.1044/jshr.1902.297; KENT JF, 1992, PHONOLOGICAL DEV MOD, P65; KENT RD, 1989, J SPEECH HEAR DISORD, V54, P482, DOI 10.1044/jshd.5404.482; KENT RD, 1972, J SPEECH HEAR RES, V15, P453, DOI 10.1044/jshr.1503.453; Lindblom Bjorn, 1967, SPEECH TRANSMISSION, V4, P1; MACNEILAGE PF, 1990, ATTENTION PERFORM, V13, P453; MACNEILAGE PF, 1990, SPEECH PRODUCTION MO, P56; McClean MD, 2000, J SPEECH LANG HEAR R, V43, P1524, DOI 10.1044/jslhr.4306.1524; NELSON WL, 1983, BIOL CYBERN, V46, P135, DOI 10.1007/BF00339982; NITTROUER S, 1993, J SPEECH HEAR RES, V36, P959, DOI 10.1044/jshr.3605.959; OJAKANGAS CL, 1994, J NEUROPHYSIOL, V72, P2617, DOI 10.1152/jn.1994.72.6.2617; Smith A, 2004, DEV PSYCHOBIOL, V45, P22, DOI 10.1002/dev.20009; Smith A, 1998, J SPEECH LANG HEAR R, V41, P18, DOI 10.1044/jslhr.4101.18; Smith A, 2000, J SPEECH LANG HEAR R, V43, P277, DOI 10.1044/jslhr.4301.277; STONE M, 1995, J PHONETICS, V23, P81, DOI 10.1016/S0095-4470(95)80034-4; Thelen E., 1991, BIOL BEHAV DETERMINA, P339; Thelen E., 1994, DYNAMIC SYSTEMS APPR; Tjaden K, 2000, J SPEECH LANG HEAR R, V43, P1466, DOI 10.1044/jslhr.4306.1466; VATIKIOTISBATES.E, 1999, IEEE SYST MAN CYB C; Walsh B, 2002, J SPEECH LANG HEAR R, V45, P1119, DOI 10.1044/1092-4388(2002/090); WATKIN KL, 1984, J ACOUST SOC AM, V75, P629, DOI 10.1121/1.390494; WEISS CE, 1980, WEISS COMPREHENSIVE; Wohlert AB, 2002, J SPEECH LANG HEAR R, V45, P1077, DOI 10.1044/1092-4388(2002/086); Yorkston K.M., 1981, ASSESSMENT INTELLIGI	35	26	29	0	3	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA	1092-4388			J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	APR	2007	50	2					352	360		10.1044/1092-4388(2007/025)			9	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	168XR	WOS:000246557800007	17463234				2022-02-06	
J	Greve, KW; Springer, S; Bianchini, KJ; Black, FW; Heinly, MT; Love, JM; Swift, DA; Ciota, MA				Greve, Kevin W.; Springer, Steven; Bianchini, Kevin J.; Black, F. William; Heinly, Matthew T.; Love, Jeffrey M.; Swift, Douglas A.; Ciota, Megan A.			Malingering in toxic exposure - Classification accuracy of reliable digit span and WAIS-III Digit Span scaled scores	ASSESSMENT			English	Article						digit span; reliable digit span; malingering; response bias; toxic exposure; neuropsychological assessment; traumatic brain injury; chronic pain	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; NEUROCOGNITIVE DYSFUNCTION; HEAD-INJURY; NEUROPSYCHOLOGICAL TESTS; PERFORMANCE PATTERNS; RESPONSE BIAS; MONEY MATTERS; INDICATORS; PAIN	This study examined the sensitivity and false-positive error rate of reliable digit Span (RDS) and the WAIS-III Digit Span (DS) scaled score in persons alleging toxic exposure and determined whether error rates differed from published rates in traumatic brain injury (TBI) and chronic pain (CP). Data were obtained from the files of 123 persons referred for neuropsychological evaluation related to alleged exposure to environmental and industrial substances. Malingering status was determined using the criteria of Slick, Sherman, and Iverson (1999). The sensitivity and specificity of RDS and DS in toxic exposure are consistent with those observed in TBI and CP These findings support the use of these malingering indicators in cases of alleged toxic exposure and suggest that the classification accuracy data of indicators derived from studies of TBI patients may also be validly applied to cases of alleged toxic exposure.	Univ New Orleans, Dept Psychol, Jefferson Neurobehav Grp, New Orleans, LA 70148 USA; Tulane Univ, Sch Med, Hlth Sci Ctr, New Orleans, LA 70118 USA; Tulane Univ, Neuropsychol Lab, New Orleans, LA 70118 USA		Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, Jefferson Neurobehav Grp, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Berger M.A, 2000, REFERENCE MANUAL SCI, V2nd, P9; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2003, J OCCUP ENVIRON MED, V45, P1087, DOI 10.1097/01.jom.0000085886.18136.7d; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, PORTLAND DIGIT RECOG; BOLLA KI, 2005, FORENSIC NEUROPSYCHO, P271; Butters N., 1980, ALCOHOLIC KORSAKOFFS; CONDER R, 1992, MANUAL COMPUTERIZED; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Duncan SA, 2002, ASSESSMENT, V9, P56, DOI 10.1177/1073191102009001007; Etherton J, 2005, ASSESSMENT, V12, P130, DOI 10.1177/1073191105274859; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GREEN P, 1996, WORLD MEMORY TEST US; Greiffenstein MF, 2006, LEGAL CRIMINOL PSYCH, V11, P131, DOI 10.1348/135532505X49828; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; GREVE KW, IN PRESS CLIN NEUROP; Harris I, 2005, JAMA-J AM MED ASSOC, V293, P1644, DOI 10.1001/jama.293.13.1644; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; HILSABECK RC, 2001, ARCH CLIN NEUROPSYCH, V18, P71; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; MAPOU RL, 1995, CLIN NEUROPSYCHOL, P295; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Tombaugh T.N., 1996, TEST MEMORY MALINGER; van Hout MSE, 2006, J NEUROL NEUROSUR PS, V77, P296, DOI 10.1136/jnnp.2004.047167; van Hout MSE, 2003, NEUROTOXICOLOGY, V24, P547, DOI 10.1016/S0161-813X(03)00054-8; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; [No title captured]	53	26	26	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	MAR	2007	14	1					12	21		10.1177/1073191106295095			10	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	139EO	WOS:000244415300002	17314176				2022-02-06	
J	Dunn, IF; Woodworth, GF; Siddiqui, AH; Smith, ER; Vates, GE; Day, AL; Goumnerova, LC				Dunn, Ian F.; Woodworth, Graeme F.; Siddiqui, Adnan H.; Smith, Edivvard R.; Vates, G. Edward; Day, Arthur L.; Goumnerova, Liliana C.			Traumatic pericallosal artery aneurysm: a rare complication of transcallosal surgery - Case report	JOURNAL OF NEUROSURGERY			English	Article						pericallosal artery aneurysm; traumatic aneurysm; anterior cerebral artery aneurysm; transcallosal approach; pediatric neurosurgery	ANTERIOR CEREBRAL-ARTERY; INTRACRANIAL ANEURYSMS; SUBARACHNOID HEMORRHAGE; NATURAL-HISTORY; CHILDHOOD; PSEUDOANEURYSM; ADOLESCENCE; CHILDREN	Traumatic intracranial aneurysms are rare in adults but account for up to 33% of all aneurysms encountered in a pediatric population. The most common location of such lesions in children is the pericallosal or adjacent branch of the anterior cerebral artery, where a head impact exerts sudden decelerating shearing forces on the arteries tethered on the brain surface against an immobile falx cerebri, weakening the arterial wall. This action can lead to dissection of the damaged vascular layers, with resultant expansion of the affected site into a fusiform aneurysm. Pericallosal aneurysms following a penetrating intracranial injury have also been described, and the resultant lesion in some cases can be a pseudoaneurysm. The incidence of iatrogenic pericallosal artery aneurysms, however, is extremely rare. The authors describe the first reported case of a traumatic pericallosal artery aneurysm following transcallosal surgery. This 6-year-old boy underwent resection of a hypothalamic pilocytic astrocytoma, which was approached via the transcallosal corridor. A follow-up magnetic resonance image obtained within 1 year of surgery disclosed a small flow void off the fight pericallosal artery, which was initially interpreted as residual tumor. Serial investigations showed the lesion enlarging over time, and subsequent angiography revealed a round 7-mm pericallosal artery aneurysm with an irregularly shaped 2- to 3-mm lumen. The aneurysm was difficult to treat with clip reconstruction or suturing of the affected segment, and an excellent outcome was ultimately achieved with resection of the lesion and autogenous arterial graft interposition. The authors also discuss the likely pathophysiology of the aneurysm and the surgical procedures undertaken to treat it.	Harvard Univ, Childrens Hosp Boston, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA		Goumnerova, LC (corresponding author), Harvard Univ, Childrens Hosp Boston, Sch Med, Dept Neurosurg, Bader 3,300 Longwood Ave, Boston, MA 02115 USA.	liliana.goumnerova@childrens.harvard.edu	Siddiqui, Adnan H./AAG-9781-2019				Alvarez J A, 1999, J Craniomaxillofac Trauma, V5, P39; APUZZO MLJ, 1982, NEUROSURGERY, V10, P547, DOI 10.1227/00006123-198205000-00001; Becker D H, 1978, Neurosurgery, V2, P1; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; de Sousa AA, 1999, SURG NEUROL, V52, P128, DOI 10.1016/S0090-3019(99)00066-X; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FRANK E, 1991, PEDIATR NEUROSURG, V16, P179, DOI 10.1159/000120521; HAYASHI A, 1986, Neurological Surgery, V14, P881; HOURIHAN MD, 1984, J NEUROSURG, V60, P1163, DOI 10.3171/jns.1984.60.6.1163; Inci S, 1998, SURG NEUROL, V50, P130, DOI 10.1016/S0090-3019(97)00344-3; LAKHANPAL SK, 1995, PEDIATR RADIOL, V25, P249, DOI 10.1007/BF02011088; LOCKSLEY HB, 1966, J NEUROSURG, V25, P219, DOI 10.3171/jns.1966.25.2.0219; McLaughlin MR, 1997, NEUROSURGERY, V41, P1400, DOI 10.1097/00006123-199712000-00034; NAKSTAD P, 1986, NEURORADIOLOGY, V28, P335, DOI 10.1007/BF00333440; OPESKIN K, 1995, AM J FOREN MED PATH, V16, P11, DOI 10.1097/00000433-199503000-00002; PATEL AN, 1971, J NEUROSURG, V35, P571, DOI 10.3171/jns.1971.35.5.0571; Raju BSV, 2001, NEUROL INDIA, V49, P295; SENEGOR M, 1991, J NEUROSURG, V75, P475, DOI 10.3171/jns.1991.75.3.0475; Shih TY, 2002, PEDIATR NEUROSURG, V37, P35, DOI 10.1159/000065100; Shirane R, 1999, J NEUROSURG, V91, P1031, DOI 10.3171/jns.1999.91.6.1031; SORIA ED, 1988, ANGIOLOGY, V39, P609, DOI 10.1177/000331978803900708; SUTTON LN, 1991, J NEUROSURG, V74, P695, DOI 10.3171/jns.1991.74.5.0695; VENTUREYRA ECG, 1994, CHILD NERV SYST, V10, P361, DOI 10.1007/BF00335125; Weir B, 2002, J NEUROSURG, V96, P64, DOI 10.3171/jns.2002.96.1.0064	25	26	27	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2007	106	2		S			153	157		10.3171/ped.2007.106.2.153			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	140QH	WOS:000244520100018	17330545				2022-02-06	
J	Leitgeb, J; Erb, K; Mauritz, W; Janciak, I; Wilbacher, I; Rusnak, M				Leitgeb, Johannes; Erb, Katharina; Mauritz, Walter; Janciak, Ivan; Wilbacher, Ingrid; Rusnak, Martin		Austrian Severe TBI Study Investig	Severe traumatic brain injury in Austria V: CT findings and surgical management	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						brain injury; traumatic; hematoma; epidural; subdural; intracerebral; hemorrhage; subarachnoid; surgery; osteoplastic; osteclastic; decompressive; outcome	ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; PROGNOSTIC-FACTORS; ADULT PATIENTS; LESION	OBJECTIVES: The aim of this paper is to describe CT findings and surgical management of patients with severe traumatic brain injury (TBI) in Austria. PATIENTS AND METHODS: Data sets from 415 patients treated by 5 Austrian hospitals were available. The analysis focused on incidence, surgical management, and outcome of different types of intracranial lesions, and outcome of surgical interventions with and without monitoring of intracranial pressure (ICP). For the first analysis we assigned the patients to 16 groups based on the type of lesion as evaluated by CT scan. For the second analysis we created 4 groups based on surgical treatment (yes/no) and ICP monitoring (yes/no). RESULTS: The mean age was 48.9 years with a male to female ratio of 299:116. The most frequent single lesions were contusions (CONT) and diffuse brain edema. Combined lesions were far more common than single lesions; the most frequently observed combinations included CONT and subarachnoid hemorrhage (SAH) with or without subdural hematoma (SDH). Surgery was done in 276 (66.5%) patients. Osteoplastic surgery (OPS; n = 221) was the most common method followed by osteoclastic surgery (OCS; n = 91) and decompressive craniectomy (DEC; n = 15). ICU mortality was 29.7% for all patients who had any kind of surgery, which was lower than that of patients who were treated non-operatively (33.1%). The ICU mortality of patients with SDH was lower with OCS (18.8%) than with OPS (36.0%). Patients who received ICP monitoring but did not require surgery had the lowest 90 day mortality (17.5%). CONCLUSIONS: ICP monitoring seems to be beneficial in both operatively and non-operatively treated patients with severe TBI. Patients with SDH who were operated on had significantly better outcomes. In patients with SDH, their outcome after osteoclastic surgery was significantly better than after osteoplastic procedures.	INRO Advisory Board, A-1080 Vienna, Austria; Univ Vienna, Gen Hosp, Dept Trauma Surg, Vienna, Austria; Trauma Hosp Lorenz Boehler, Dept Anaesthesia & Crit Care Med, Vienna, Austria		Mauritz, W (corresponding author), INRO Advisory Board, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Rusnak, Martin/K-9349-2016	Rusnak, Martin/0000-0003-3321-1042; Mauritz, Walter/0000-0001-9043-3712			*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P457; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Koumtchev Y, 1993, Folia Med (Plovdiv), V35, P55; Koumtchev Y, 1994, Folia Med (Plovdiv), V36, P49; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauritz W, 2003, CLIN RES REGUL AFF, V20, P81, DOI 10.1081/CRP-120018744; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; PARZHUBER A, 1994, UNFALLCHIRURG, V97, P615; Procaccio F, 2000, J Neurosurg Sci, V44, P1; Regel JP, 2005, UNFALLCHIRURG, V108, P246, DOI 10.1007/s00113-004-0865-0; Ruchholtz S, 2003, UNFALLCHIRURG, V106, P839; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; Servadei F, 1997, ACTA NEUROCHIR, V139, P273, DOI 10.1007/BF01808821; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944	23	26	26	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB	2007	119	1-2					56	63		10.1007/s00508-006-0764-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142GQ	WOS:000244637800011	17318751				2022-02-06	
J	Teasell, R; Bayona, N; Lippert, C; Villamere, J; Hellings, C				Teasell, Robert; Bayona, Nestor; Lippert, Corbin; Villamere, James; Hellings, Chelsea			Post-traumatic seizure disorder following acquired brain injury	BRAIN INJURY			English	Article						anticonvulsants; brain; brain injuries; craniocerebral trauma; epilepsy; epilepsy post-traumatic; post-traumatic seizure disorder; prophylaxis; seizure	POST-TRAUMATIC EPILEPSY; PROPHYLACTICALLY ADMINISTERED PHENYTOIN; HEAD-INJURY; CRANIOCEREBRAL TRAUMA; PRACTICE PARAMETER; RANDOMIZED-TRIAL; PROPHYLAXIS; PREVENTION; CHILDREN; REHABILITATION	Objective: The present study aimed to evaluate the effectiveness of prophylactic anticonvulsant pharmacological strategies for the prevention of seizure disorders following acquired brain injury (ABI) to provide guidance for clinical practice based on the best available evidence. Methods and main outcomes: A systematic review of the literature from 1980-2005 was conducted focusing on treatment interventions available for post-traumatic seizures following ABI. The evidence for the efficacy of a given intervention was ranked as strong (supported by at least two randomized controlled trials (RCTs), moderate (supported by a single RCT), or limited (supported by other types of studies in the absence of RCTs). Results: Based on a previous meta-analysis and the findings of this review, there is strong evidence that prophylactic anticonvulsant therapy decreases the occurrence of early seizures but only within the first week post-injury. Moreover, the evidence indicates that prophylactic anticonvulsant therapy does not decrease the incidence of seizure onset more than one week post-injury. In children, there is moderate evidence that prophylactic phenytoin does not reduce the incidence of early or late seizures. The efficacy of anticonvulsants after the development of seizures has not been specifically studied in ABI. Conclusions: Prophylactic anti-convulsants are effective in reducing seizures in the first week post-injury in adults. However, they do not reduce the occurrence of seizures after the first week.	St Josephs Hlth Care London, Dept Phys Med & Rehabil, London, ON, Canada; Lawson Hlth Resort Inst, London, ON, Canada; Univ Western Ontario, Schulich Sch Med & Dent, London, ON, Canada		Teasell, R (corresponding author), St Josephs Hlth Care London, Dept Phys Med & Rehabil, London, ON, Canada.	robert.teasell@sjhc.london.on.ca					ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Annegers JF., 1996, TREATMENT EPILEPSY P, P165; ARMSTRONG KK, 1990, ARCH PHYS MED REHAB, V71, P156; Ascroft PB, 1941, BMJ-BRIT MED J, V1941, P739, DOI 10.1136/bmj.1.4193.739; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; CAVENESS WF, 1961, EPILEPSIA, V2, P123; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CAVENESS WF, 1963, J NEUROSURG, V20, P570, DOI 10.3171/jns.1963.20.7.0570; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Cohen M, 1991, EPILEPSIA S1, V32, pS55; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HEIKKINEN ER, 1990, STEREOT FUNCT NEUROS, V54-5, P25, DOI 10.1159/000100186; JENNETT B, 1975, EPILEPSY NONMISSILE; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; Kollevold T, 1979, J Oslo City Hosp, V29, P35; Kollevold T, 1978, J OSLO CITY HOSP, V28, P78; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Moseley AM, 2002, AUST J PHYSIOTHER, V48, P43, DOI 10.1016/S0004-9514(14)60281-6; MURRI L, 1992, ITAL J NEUROL SCI, V13, P755, DOI 10.1007/BF02229161; MURRI L, 1980, ITAL J NEUROL SCI, V1, P225; Ng WK, 2000, ARCH PHYS MED REHAB, V81, P1266; PECHADRE JC, 1991, PRESSE MED, V20, P841; PRICE DJ, 1980, PLACE SODIUM VALPROA, P23; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Schierhout G, 2001, COCHRANE DB SYST REV, V4; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; SMITH KR, 1994, ARCH NEUROL-CHICAGO, V51, P653, DOI 10.1001/archneur.1994.00540190029012; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Watson NF, 2004, EPILEPSIA, V45, P690, DOI 10.1111/j.0013-9580.2004.59403.x; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; Wroblewski B A, 1989, Brain Inj, V3, P149, DOI 10.3109/02699058909004546; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86; WROBLEWSKI BA, 1992, CLIN NEUROPHARMACOL, V15, P44, DOI 10.1097/00002826-199202000-00006; Yablon S. A., 2001, PHYS MED REHABIL STA, V15, P301; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1983, CHILD BRAIN, V10, P185; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016	59	26	26	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2007	21	2					201	214		10.1080/02699050701201854			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	162SQ	WOS:000246110200006	17364531				2022-02-06	
J	Al-Adawi, S; Dorvlo, ASS; Al-Naamani, A; Glenn, MB; Karamouz, N; Chae, HC; Zaidan, ZAJ; Burke, DT				Al-Adawi, Samir; Dorvlo, Atsu S. S.; Al-Naamani, Aziz; Glenn, Mel B.; Karamouz, Nasser; Chae, Heechin; Zaidan, Ziad A. J.; Burke, David T.			The ineffectiveness of the Hospital Anxiety and Depression Scale for diagnosis in an Omani traumatic brain injured population	BRAIN INJURY			English	Article						anxiety; depression; traumatic brain injury; Arabic; Oman	INTERNAL CONSISTENCY; SELF-AWARENESS; OLDER-ADULTS; HAD SCALE; VALIDITY; REHABILITATION; VALIDATION; DISEASE; VERSION; SAMPLE	Background: The rehabilitation of the traumatic brain injury ( TBI) patient is especially challenging in non-western populations as the phenotypic indicators as well as the neurobehavioral assessments for the survivors of brain injury are limited. Objective: The study screened for the prevalence of anxiety and depressive states among patients with TBI and examined the validity of the Hospital Anxiety and Depression Scale ( HADS) to identify TBI patients with comorbid affective dysfunctions, specifically anxiety and depressive disorders, in an Omani population. Methods: Sixty-eight survivors of TBI were screened with the semi-structured, Composite International Diagnostic Interview ( CIDI) and the HADS. A receiver operating characteristics ( ROC) curve was calculated to discriminate the power of the HADS for every possible threshold score. Results: The semi-structured interview revealed the prevalence rate of 57.4% for depressive disorder and 50% for anxiety disorder. The sensitivity ( 53.8%) and specificity 75.9%, gave the best compromise using the cut- off score of 4, suggesting HADS is not a useful screening tool for this particular population. Conclusions: Phenotypic indicators as detected by CIDI revealed that prevalence of affective dysfunctionality is common among this TBI population. Although the HADS is the most widely used screening instrument in other clinical populations, it does not appear to be a reliable resource in identifying depression and anxiety in people with traumatic brain injury in Oman.	Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Behav Sci, Muscat, Oman; Sultan Qaboos Univ, Dept Math & Stat, Muscat, Oman; Harvard Univ, Spaulding Rehabil Hosp, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02115 USA		Al-Adawi, S (corresponding author), Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Behav Sci, POB 35,Al Khoudh 123, Muscat, Oman.	adawi@squ.edu.om	Al-Adawi, Samir/A-9663-2016	Al-Adawi, Samir/0000-0002-9858-5582			ABIODUN OA, 1994, BRIT J PSYCHIAT, V165, P669, DOI 10.1192/bjp.165.5.669; Al-Adawi S, 2001, J Sci Res Med Sci, V3, P61; Al-Adawi S, 2004, J NEUROPSYCH CLIN N, V16, P435, DOI 10.1176/appi.neuropsych.16.4.435; Al-Adawi S, 2001, EPILEPSIA, V42, P1476, DOI 10.1046/j.1528-1157.2001.05599.x; Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Al-Adawi S., 2005, JAPANESE J PSYCHOSOM, V45, P933; Al-Lawati J., 2000, SULTAN QABOOS UNI ME, V2, P105; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Bolton P, 2001, J NERV MENT DIS, V189, P238, DOI 10.1097/00005053-200104000-00005; Costantini M, 1999, SUPPORT CARE CANCER, V7, P121, DOI 10.1007/s005200050241; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P429, DOI 10.1348/014466501163904; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; ELRUFAIE OEF, 1995, SOC PSYCH PSYCH EPID, V30, P26, DOI 10.1007/BF00784431; ELRUFAIE OEFA, 1987, BRIT J PSYCHIAT, V151, P687, DOI 10.1192/bjp.151.5.687; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Harter M, 2001, DISABIL REHABIL, V23, P737; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Isella V, 2002, MOVEMENT DISORD, V17, P366, DOI 10.1002/mds.10041; JOHNSON G, 1995, ACTA PSYCHIAT SCAND, V91, P252, DOI 10.1111/j.1600-0447.1995.tb09778.x; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Kirmayer LJ, 2001, PSYCHIAT CLIN N AM, V24, P465, DOI 10.1016/S0193-953X(05)70241-0; Koss JD, 1990, TRANSCULT PSYCHIATRY, V27, P5, DOI DOI 10.1177/136346159002700101; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lawrence V, 2006, GERONTOLOGIST, V46, P23, DOI 10.1093/geront/46.1.23; LEFF J, 1977, Culture Medicine and Psychiatry, V1, P317; Leung CM, 1999, ACTA PSYCHIAT SCAND, V100, P456, DOI 10.1111/j.1600-0447.1999.tb10897.x; Lisspers J, 1997, ACTA PSYCHIAT SCAND, V96, P281, DOI 10.1111/j.1600-0447.1997.tb10164.x; Lloyd-Williams M, 2001, J PAIN SYMPTOM MANAG, V22, P990, DOI 10.1016/S0885-3924(01)00358-X; MALASI TH, 1991, ACTA PSYCHIAT SCAND, V84, P323, DOI 10.1111/j.1600-0447.1991.tb03153.x; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Mykletun A, 2001, BRIT J PSYCHIAT, V179, P540, DOI 10.1192/bjp.179.6.540; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; Roberts SB, 2001, BRIT J HEALTH PSYCH, V6, P373, DOI 10.1348/135910701169278; Sakamoto N, 2005, INT J PSYCHIAT MED, V35, P191, DOI 10.2190/7WEQ-216D-TVNH-PQJ1; Schnyder U, 2001, AM J RESP CRIT CARE, V164, P653, DOI 10.1164/ajrccm.164.4.2008087; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Simon GE, 1999, NEW ENGL J MED, V341, P1329, DOI 10.1056/NEJM199910283411801; *SPSS CORP, 1999, STAT PACK SOC SCI VE; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; Sutcliffe LM, 1998, CLIN REHABIL, V12, P506, DOI 10.1191/026921598672167702; Tang WK, 2004, AGING MENT HEALTH, V8, P397, DOI 10.1080/13607860410001725027; TEASDALE G, 1974, LANCET, V2, P81; Thompson JC, 2002, J NEUROPSYCH CLIN N, V14, P37, DOI 10.1176/appi.neuropsych.14.1.37; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Upadhyaya AK, 1997, INT J GERIATR PSYCH, V12, P35, DOI 10.1002/(SICI)1099-1166(199701)12:1<35::AID-GPS447>3.3.CO;2-8; Viguier D, 2001, BRAIN INJURY, V15, P263; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; World Health Organization, 1993, COMP INT DIAGN INT; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	58	26	26	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	4					385	393		10.1080/02699050701311059			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	168IY	WOS:000246518600004	17487636				2022-02-06	
J	Donders, J; Boonstra, T				Donders, Jacobus; Boonstra, Tyler			Correlates of invalid neuropsychological test performance after traumatic brain injury	BRAIN INJURY			English	Article							WORD MEMORY TEST; LEARNING TEST-II; HEAD-INJURY; RANDOMIZED-TRIAL; DIAGNOSIS; EXAGGERATION; CLAIMANTS; UTILITY; RATES	Primary objective: To investigate external correlates of invalid test performance after traumatic brain injury, as assessed by the California Verbal Learning Test - Second Edition ( CVLT - II) and Word Memory Test ( WMT). Research design: Consecutive 2- year series of rehabilitation referrals with a diagnosis of traumatic brain injury ( n 87). Methods and procedures: Logistic regression analysis was used to determine which demographic and neurological variables best differentiated those with vs. without actuarial CVLT - II or WMT evidence for invalid responding. Main outcomes and results: Twenty- one participants ( about 24%) performed in the invalid range. The combination of a premorbid psychiatric history with minimal or no coma was associated with an approximately four- fold increase in the likelihood of invalid performance. Conclusions: Premorbid psychosocial complicating factors constitute a significant threat to validity of neuropsychological test results after ( especially mild) traumatic brain injury. At the same time, care should be taken to not routinely assume that all persons with mild traumatic brain injury and premorbid psychiatric histories are simply malingering. The WMT appears to be a promising instrument for the purpose of identifying those cases where neuropsychological test results are confounded by factors not directly related to acquired cerebral impairment.	Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49603 USA; Hope Coll, Dept Psychol, Holland, MI USA		Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 234 Wealthy SE, Grand Rapids, MI 49603 USA.	jacobus.donders@maryfreebed.com					Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; *CTR DIS CONTR PRE, 2006, MORBIDITY MORTALITY, V55, P201; Delis DC, 2005, J INT NEUROPSYCH SOC, V11, P708, DOI 10.1017/S1355617705050812; DELIS DC, 2000, CALIFORNIA VERBAL LE; Dunn TM, 2003, ARCH CLIN NEUROPSYCH, V18, P121, DOI 10.1016/S0887-6177(01)00188-3; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; GERVAIS RO, 2001, J FORENSIC NEUROPSYC, V2, DOI DOI 10.1300/J151V02N02_01; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2003, GREENS WORD MEMORY T; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Hanks RA, 2004, DIFFERENTIAL DIAGNOSIS IN ADULT NEUROPSYCHOLOGICAL ASSESSMENT, P218; Heaton R. K., 2004, REVISED COMPREHENSIV; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; IVERSON GL, 2005, CURRENT OPINIONS PSY, V18, P310; Larrabee, 2005, FORENSIC NEUROPSYCHO, P209; Larrabee GJ, 2000, CLIN GUIDE NEUROPSYC, P301; LEESHALEY PR, 1991, PSYCHOL REP, V68, P208; Martin TA, 2003, APPL NEUROPSYCHOL, V10, P163, DOI 10.1207/S15324826AN1003_05; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Putnam S. H., 1994, ADV MED PSYCHOTHERAP, V7, P1; REITAN RM, 1993, HALSTEAD REITAN NEUR, P423; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherman EMS, 2000, BRAIN INJURY, V14, P621; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	44	26	26	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	3					319	326		10.1080/02699050701253129			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	168IW	WOS:000246518400007	17453760				2022-02-06	
J	Noe, E; Ferri, J; Trenor, C; Chirivella, J				Noe, Enrique; Ferri, Joan; Trenor, Carlos; Chirivella, Javier			Efficacy of ziprasidone in controlling agitation during post-traumatic amnesia	BEHAVIOURAL NEUROLOGY			English	Article						posttraumatic amnesia; traumatic brain injury; ziprasidone; neuroleptics; agitation	TRAUMATIC BRAIN-INJURY; CLOSED HEAD-INJURY; RESTLESSNESS; RISPERIDONE; OLANZAPINE; CLOZAPINE	Objectives: to provide our initial experience with ziprasidone in the management of behaviour problems of patients with traumatic brain injury (TBI) during the period of post-traumatic amnesia (PTA). Patients: Five patients with a mean age of 26.8 +/- 9.8 years who had suffered a severe TBI (Glasgow Coma Scale score < 8; length of coma: 16 +/- 7.1 days; and length of PTA: 62.4 +/- 14.8 days) were included in the study. Agitation was assessed by the Agitated Behaviour Scale (ABS) prior to the administration of ziprasidone, after two weeks of initiating treatment and at the moment of discontinuing ziprasidone. Results: ABS Total score decreased from 27.2 +/- 3 to 18 +/- 1.2 after two weeks of treatment. The same decrease was also noticed in each one of the subscales (dishinhibition, aggressiveness and lability). Mean dose of the drug was 52.8 +/- 27.11 mg/day (range: 20-80 mg), with the highest dose ranging between 40 and 80 mg (64 +/- 21.9 mg). Maximum period of administration of ziprasidone was 48.2 +/- 14.8 days (range: 35-68 days). No clinical or electrocardiographic side effects were reported. Conclusion: This study shows the efficacy of ziprasidone in controlling agitation during the PTA period. Despite the small size of our sample, ziprasidone reduced symptoms of agitation quickly and with good tolerability, safety and no side effects.	Inst Valenciano Neurorehabil IVAN, Serv Dano Cerebral Hosp NISA, Valencia, Spain		Noe, E (corresponding author), Hosp Valencia Mar, Inst Valenciano Neurorehabil IVAN, C Rio Tajo 1, Valencia 46011, Spain.	enoe@comv.es		Noe Sebastian, Enrique/0000-0002-2547-8727			BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P917; Butler PV, 2000, AUST NZ J PSYCHIAT, V34, P684, DOI 10.1080/j.1440-1614.2000.00758.x; GOLDBERG TE, 1994, J CLIN PSYCHIAT, V55, P88; Heinrich TW, 2004, GEN HOSP PSYCHIAT, V26, P490, DOI 10.1016/j.genhosppsych.2004.08.001; Keck P E Jr, 2001, Expert Opin Pharmacother, V2, P1033; Krieger D, 2003, NEUROREHABILITATION, V18, P205; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LLINAS RJ, 1995, NEUROLOGIA, V10, P14; Matza LS, 2005, CNS DRUGS, V19, P499, DOI 10.2165/00023210-200519060-00003; MICHALS ML, 1993, J CLIN PSYCHOPHARM, V13, P198; Mizoguchi Y, 2002, J NEUROPSYCH CLIN N, V14, P87, DOI 10.1176/appi.neuropsych.14.1.87-a; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Richard I., 2003, Annales de Readaptation et de Medecine Physique, V46, P49, DOI 10.1016/S0168-6054(02)00353-7; Sallee FR, 2000, J AM ACAD CHILD PSY, V39, P292, DOI 10.1097/00004583-200003000-00010; Schreiber S, 1998, INT CLIN PSYCHOPHARM, V13, P273, DOI 10.1097/00004850-199811000-00006; Silver BV, 2003, BRAIN INJURY, V17, P237, DOI 10.1080/0269905021000013192; Stahl SM, 2003, J CLIN PSYCHIAT, V64, P6	19	26	26	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0953-4180			BEHAV NEUROL	Behav. Neurol.		2007	18	1					7	11		10.1155/2007/529076			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	151OL	WOS:000245299900002	17297214	gold, Green Published, Green Submitted			2022-02-06	
J	Sabsovich, I; Rehman, Z; Yunen, J; Coritsidis, G				Sabsovich, Ilya; Rehman, Zia; Yunen, Jose; Coritsidis, George			Propofol infusion syndrome: A case of increasing morbidity with traumatic brain injury	AMERICAN JOURNAL OF CRITICAL CARE			English	Article							ACIDOSIS; SEDATION; RHABDOMYOLYSIS; FAILURE	A previously healthy 16-year-old boy with a closed, severe traumatic brain injury was admitted to a surgical and trauma intensive care unit. He was given a continuous infusion of propofol for sedation and to control intracranial pressure. About 3 days after the propofol infusion was started, metabolic acidosis and rhabdomyolysis developed Acute renal failure ensued as a result of the rhabdomyolysis. Tachycardia with wide QRS complexes developed without hyperkalemia. The patient died of refractory cardiac dysrhythmia and circulatory collapse approximately 36 hours after the first signs of propofol infusion syndrome appeared. Propofol infusion syndrome is a rare but frequently fatal complication in critically ill children who are given prolonged high-dose infusions of the drug. The syndrome is characterized by severe metabolic acidosis, rhabdomyolysis, acute renal failure, refractory myocardial failure, and hyperlipidemia. Despite several publications on the subject in the past decade, most cases still seem to remain undetectable.	[Sabsovich, Ilya; Rehman, Zia; Yunen, Jose; Coritsidis, George] Elmhurst Hosp Ctr, Surg & Trauma Intens Care Unit, New York, NY USA; [Sabsovich, Ilya; Rehman, Zia; Yunen, Jose; Coritsidis, George] Mt Sinai Sch Med, Dept Surg, New York, NY USA		Yunen, J (corresponding author), Montefiore Med Ctr, Albert Einstein Sch Med, 111 E 210th St, Bronx, NY 10467 USA.	jyunen@montefiore.org					AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BENNETT SN, 1995, NEW ENGL J MED, V333, P147, DOI 10.1056/NEJM199507203330303; BRANCA D, 1991, ARCH BIOCHEM BIOPHYS, V290, P517, DOI 10.1016/0003-9861(91)90575-4; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Eriksen J, 2006, ACTA ANAESTH SCAND, V50, P117, DOI 10.1111/j.1399-6576.2006.00904.x; Friedman JA, 2002, J NEUROSURG, V96, P1161; GROUNDS RM, 1987, BRIT MED J, V294, P397, DOI 10.1136/bmj.294.6569.397; Haase R, 2005, J NEUROSURG ANESTH, V17, P122, DOI 10.1097/01.ana.0000161267.63160.13; Hanna JP, 1998, NEUROLOGY, V50, P301, DOI 10.1212/WNL.50.1.301; Leisure GS, 1996, ANESTHESIOLOGY, V84, P224, DOI 10.1097/00000542-199601000-00027; Marinella MA, 1996, CHEST, V109, P292, DOI 10.1378/chest.109.1.292; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; McKeage K, 2003, CNS DRUGS, V17, P235, DOI 10.2165/00023210-200317040-00003; Myburgh JA, 2001, INTENS CARE MED, V27, P276, DOI 10.1007/s001340000793; Nathwani RA, 2005, HEPATOLOGY, V41, P380, DOI 10.1002/hep.20548; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Perrier ND, 2000, CRIT CARE MED, V28, P3071, DOI 10.1097/00003246-200008000-00066; Schenkman KA, 2000, CRIT CARE MED, V28, P172, DOI 10.1097/00003246-200001000-00028; Stelow EB, 2000, CLIN CHEM, V46, P577; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; *ZEN PHARM INC, DIPR PROP PROD MON; Zhou WG, 1999, ANESTH ANALG, V89, P604, DOI 10.1097/00000539-199909000-00011	25	26	26	0	0	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1062-3264	1937-710X		AM J CRIT CARE	Am. J. Crit. Care	JAN	2007	16	1					82	85		10.4037/ajcc2007.16.1.82			4	Critical Care Medicine; Nursing	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Nursing	271SQ	WOS:000253809400015	17192529				2022-02-06	
J	Vavilala, MS; Muangman, S; Waitayawinyu, P; Roscigno, C; Jaffe, K; Mitchell, P; Kirkness, C; Zimmerman, JJ; Ellenbogen, R; Lam, AM				Vavilala, Monica S.; Muangman, Saipin; Waitayawinyu, Pichaya; Roscigno, Cecelia; Jaffe, Kenneth; Mitchell, Pamela; Kirkness, Catherine; Zimmerman, Jerry J.; Ellenbogen, Richard; Lam, Arthur M.			Impaired cerebral autoregulation in infants and young children early after inflicted traumatic brain injury: A preliminary report	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; children; head injury	BLOOD-FLOW; INTRACRANIAL-PRESSURE; SUFENTANIL; SEVOFLURANE; METABOLISM; HYPERCAPNIA; DESFLURANE; FENTANYL	The objective of this report is to describe cerebral autoregulation after severe inflicted pediatric traumatic brain injury (iTBI). We examined cerebral autoregulation of both cerebral hemispheres (mean autoregulatory index; ARI) in children < 5 years with Glasgow Coma Scale (GCS) score of < 9 and no evidence of brain death within the first 48 h of pediatric intensive care unit (PICU) admission. Discharge and 6-month Glasgow Outcome Scale (GOS) scores were collected. GOS of < 4 reflected poor outcome. All three iTBI and all seven noninflicted TBI (nTBI) patients had admission GCS score of < 9. Eight of 10 patients had Autoregulatory Index (ARI) of < 0.4 (impaired cerebral autoregulation) of at least one hemisphere. All children with iTBI had poor outcome, and none had intact cerebral autoregulation in both hemispheres. Children with nTBI had better overall outcome than those with iTBL Two of the children with nTBI had intact autoregulation in both hemispheres and good outcome. Two of the three children with iTBI had differential effects on autoregulation between hemispheres despite bilateral injury. These are, to our knowledge, the first data on cerebral blood flow autoregulation in the unique setting of iTBI and provide a rationale for further study of their relationship to outcome and effects of therapy.	Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Behav Nursing, Seattle, WA 98195 USA		Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9Th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004501] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K23 HD 0044632-03] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [2R01 NR 004501-04] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALBANESE J, 1993, ANESTHESIOLOGY, V79, P493, DOI 10.1097/00000542-199309000-00012; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bedforth NM, 2001, BRIT J ANAESTH, V87, P193, DOI 10.1093/bja/87.2.193; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; BODE H, 1988, APPL PEDIAT TRANSCRA; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bourgoin A, 2005, CRIT CARE MED, V33, P1109, DOI 10.1097/01.CCM.0000162491.26292.98; COTEV S, 1975, ANESTHESIOLOGY, V43, P117, DOI 10.1097/00000542-197507000-00029; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Hanel F, 1997, J NEUROSURG ANESTH, V9, P223; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Kaiser JR, 2005, PEDIATR RES, V58, P931, DOI 10.1203/01.pdr.0000182180.80645.0c; Karabinis A, 2004, CRIT CARE, V8, pR268, DOI 10.1186/cc2896; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; LAM AM, 1995, ANESTHESIOLOGY, V82, P1536, DOI 10.1097/00000542-199506000-00035; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; McCulloch TJ, 2000, ANESTHESIOLOGY, V93, P1205, DOI 10.1097/00000542-200011000-00012; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; ODDEN JP, 1994, BIOL NEONATE, V65, P367; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Shah M, 2005, CHILD ABUSE NEGLECT, V29, P953, DOI 10.1016/j.chiabu.2004.08.011; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2003, J NEUROSURG ANESTH, V15, P307, DOI 10.1097/00008506-200310000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	38	26	26	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					87	96		10.1089/neu.2006.0058			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100008	17263672				2022-02-06	
J	Yeates, G; Henwood, K; Gracey, F; Evans, J				Yeates, Giles; Henwood, Karen; Gracey, Fergus; Evans, Jonathan			Awareness of disability after acquired brain injury and the family context	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							STAGE ALZHEIMERS-DISEASE; CLOSED HEAD-INJURY; SIGNIFICANT OTHERS; FOLLOW-UP; SELF; REHABILITATION; DEFICITS; INDIVIDUALS; ANOSOGNOSIA; UNAWARENESS	The dimension of family context for awareness of disability following acquired brain injury (ABI) is examined through a qualitative discourse analysis. Three participants with ABI, who were identified by clinicians and relatives as demonstrating difficulties with awareness of disability, and three relatives were interviewed. The findings highlight important contextual parameters influencing the emergence of families' accounts for disability after ABI: (1) availability of sense-making resources and use of pre-injury meanings, and (2) incongruity within family sense-making and resultant orientating, disputing and contesting of accounts within families. These findings are discussed in relation to pre-existing literature, and applications are suggested for family intervention following ABI.	Prince Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Ely CB6 1DN, Cambs, England; Cardiff Univ, Sch Social Sci, Cardiff, S Glam, Wales; Gartnavel Royal Hosp, Dept Psychol Med, Glasgow G12 0YN, Lanark, Scotland		Gracey, F (corresponding author), Prince Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Lynn Rd, Ely CB6 1DN, Cambs, England.	Fergus.Gracey@ozc.nhs.uk	Yeates, Giles/AAB-2875-2020	Gracey, Fergus/0000-0002-1416-7894; Yeates, Giles/0000-0002-0912-6027			BERGEN KJ, 1985, SOCIAL CONSTRUCTION; Bond J., 2002, DEMENTIA, V1, P313, DOI DOI 10.1177/147130120200100304; Bond M R, 1979, Acta Neurochir Suppl (Wien), V28, P124; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; BRODAL A, 1973, BRAIN, V96, P675, DOI 10.1093/brain/96.4.675; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burke W J, 1988, Alzheimer Dis Assoc Disord, V2, P356, DOI 10.1097/00002093-198802040-00004; CHARMAZ K, 1990, SOC SCI MED, V30, P1161, DOI 10.1016/0277-9536(90)90256-R; Clare L, 2004, BRIT J CLIN PSYCHOL, V43, P155, DOI 10.1348/014466504323088033; Clare L, 2003, SOC SCI MED, V57, P1017, DOI 10.1016/S0277-9536(02)00476-8; Clare L., 2002, DEMENTIA, V1, P295, DOI DOI 10.1177/147130120200100303; Cock J, 2003, BRAIN INJURY, V17, P561, DOI 10.1080/0269905031000088306; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; DAVIES B, 1990, J THEOR SOC BEHAV, V20, P43, DOI 10.1111/j.1468-5914.1990.tb00174.x; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; ELLIOTT J, 1982, AUSTR REHABILITATION, V6, P50; Elliott R, 1999, BRIT J CLIN PSYCHOL, V38, P215, DOI 10.1348/014466599162782; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Epston, 1990, NARRATIVE MEANS THER; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GAINOTTI G, 1975, PSYCHIAT CLIN, V8, P99, DOI 10.1159/000283622; GASQUOINE PG, 1992, NEUROPSYCHOLOGY, V3, P187; GASQUOINE PG, 1994, J HEAD TRAUMA REHAB, V9, P7; German W J, 1964, Clin Neurosurg, V12, P344; Gregory R J, 1998, J Psychosoc Nurs Ment Health Serv, V36, P28; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harr?, 1992, AGEING SOC, V12, P443, DOI DOI 10.1017/S0144686X00005262; HAYES N, 2003, CLIN PSYCHOL, V21, P36; Holstein J.A., 1995, ACTIVE INTERVIEW; Hutchinson SA, 1997, SOC SCI MED, V45, P1399, DOI 10.1016/S0277-9536(97)00064-6; JAFFE J, 1958, ARCH NEURO PSYCHIATR, V80, P653, DOI 10.1001/archneurpsyc.1958.02340110123019; JOHNSON J, 1997, FAMILY THERAPY NEURO; Jones E., 1993, FAMILY SYSTEMS THERA; Kinsella G, 1989, Int Disabil Stud, V11, P9; KREFTING L, 1990, SOC SCI MED, V30, P859, DOI 10.1016/0277-9536(90)90213-C; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LaBaw W L, 1968, Med Times, V96, P821; LaBaw W L, 1966, Med Times, V94, P407; LABAW WL, 1969, PSYCHIATR, V32, P174, DOI 10.1080/00332747.1969.11023582; LABAW WL, 1968, INJURED BRAINS MED M, P298; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; LEVINE J, 1975, J CONSULT CLIN PSYCH, V43, P751; Madill A, 2000, BRIT J PSYCHOL, V91, P1, DOI 10.1348/000712600161646; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MALIA K, 1997, J COGNITIVE REHABILI, V10, P10; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Marcel AJ, 2004, CORTEX, V40, P19, DOI 10.1016/S0010-9452(08)70919-5; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCGLYNN SM, 1990, PSYCHOL BULL, V108, P420, DOI 10.1037/0033-2909.108.3.420; McGlynn SM, 1991, AWARENESS DEFICIT BR, P84; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; ODDY M, 1995, TRAUMATIC BRAIN INJU, P167; Ownsworth T, 2006, NEUROPSYCHOL REHABIL, V16, P415, DOI 10.1080/09602010500505641; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Penn P., 1987, MILAN SYSTEMIC FAMIL; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Reisberg B., 1985, ALZHEIMERS DEMENT, P295; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Solms M., 2000, CLIN STUDIES NEUROPS, V2nd; STEEL RT, 1997, ARCH PHYS MED REHAB, V78, P1254; Stuss D., 1991, AWARENESS DEFICIT BR, P63; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Taylor S., 2001, DISCOURSE DATA GUIDE, P311; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1987, BRAIN INJURY, V47, P260; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Turnbull O. H., 2002, NEUROPSYCHANALYSIS, V4, P69, DOI 10.1080/15294145.2002.10773381; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; Wetherell, 1987, DISCOURSE SOCIAL PSY; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Yardley L, 2000, PSYCHOL HEALTH, V15, P215, DOI 10.1080/08870440008400302; YEATES GN, 2006, NEUROPSYCHOANALYSIS, V8, P175; YEATES GN, 2003, THESIS; ZIMOSTRAD SW, 1989, COGNITIVE REHABILITA, V7, P26; [No title captured], DOI DOI 10.1097/00001199-198812000-00004; [No title captured]	91	26	26	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2007	17	2					151	173		10.1080/09602010600696423			23	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	165IP	WOS:000246298400002	17454691				2022-02-06	
J	Zhou, ML; Zhu, L; Wang, J; Hang, CH; Shi, JX				Zhou, Meng-liang; Zhu, Lin; Wang, Jian; Hang, Chun-hua; Shi, Ji-xin			The inflammation in the gut after experimental subarachnoid hemorrhage	JOURNAL OF SURGICAL RESEARCH			English	Article						subarachnoid hemorrhage; intestine; inflammation; nuclear factor-kappa B	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; CARDIAC-ARRHYTHMIAS; COMPLICATIONS; LEUKOCYTOSIS; ANEURYSM; STROKE; FAMILY; IMMUNE; HEART	Background. Gastrointestinal dysfunction could be frequently observed in the patients suffering from SAH. This study test the hypothesis that experimental SAH could induce histopathological changes an inflammatory response associating with NF-kappa B activation pathway in the gut. Materials and methods. A total of 17 rabbits were randomly divided into two groups: control group (n = 8) and SAH group (n = 9). In the SAH group, the animals were subjected to experimental SAH according to the "two-hemorrhage" method. The histopathological study was performed to detect the intestinal mucosal morphological changes and immunohistochemical study was used to detect the TNF-alpha and ICAM-1 expressions. NF-kappa B binding activity was measured using the electrophoretic mobility shift assay. Results. It was demonstrated that some damage changes and leukocytes infiltration occurred in the intestinal mucosa after SAH. More positive cells for TNF-a and ICAM-1 were observed in the SAH group. The NF-kappa B binding activity in the intestines was significantly increased in the SAH group (P < 0.01). Conclusions. The results of the present study suggest that SAH in the rabbits could induce NF-kappa B and proinflammatory cytokines activation in the intestine, which is associated with morphological changes. (c) 2007 Elsevier Inc. All rights reserved.	Nanjing Univ, Dept Neurosurg, Sch Med, Jinling Hosp, Nanjing 210002, Peoples R China; Nanjing Univ, Dept Gen Surg, Sch Med, Jinling Hosp, Nanjing 210002, Peoples R China		Shi, JX (corresponding author), Nanjing Univ, Dept Neurosurg, Sch Med, Jinling Hosp, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	shijx52@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489			ASPLIN BR, 1994, AM J EMERG MED, V12, P370, DOI 10.1016/0735-6757(94)90163-5; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; D'Ancona G, 2003, TEX HEART I J, V30, P280; Davenport RJ, 1996, STROKE, V27, P421, DOI 10.1161/01.STR.27.3.421; DIPASQUALE G, 1987, AM J CARDIOL, V59, P596, DOI 10.1016/0002-9149(87)91176-3; Dooling Ellen, 2004, J Neurosci Nurs, V36, P130; ESTANOLVIDAL B, 1979, NEUROSURGERY, V5, P675; FRICK TW, 1992, J TRAUMA, V33, P870, DOI 10.1097/00005373-199212000-00013; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; KIRBY DF, 1991, JPEN-PARENTER ENTER, V15, P298, DOI 10.1177/0148607191015003298; Liang Y, 2004, CELL MOL IMMUNOL, V1, P343; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; MARION DW, 1986, NEUROSURGERY, V18, P101, DOI 10.1227/00006123-198601000-00019; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; PARKINSON D, 1984, SURG NEUROL, V21, P132, DOI 10.1016/0090-3019(84)90330-6; PHILLIPS LH, 1980, NEUROLOGY, V30, P1034, DOI 10.1212/WNL.30.10.1034; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHELL AR, 1987, ARCH INTERN MED, V147, P591, DOI 10.1001/archinte.147.3.591; Schottelius AJG, 1999, INT J COLORECTAL DIS, V14, P18, DOI 10.1007/s003840050178; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Souza DG, 2005, BRIT J PHARMACOL, V145, P246, DOI 10.1038/sj.bjp.0706190; SPALLONE A, 1987, SURG NEUROL, V27, P253, DOI 10.1016/0090-3019(87)90038-3; Svigelj V, 1996, ACTA NEUROL SCAND, V94, P120, DOI 10.1111/j.1600-0404.1996.tb07041.x; TANAKA S, 1979, ACTA NEUROCHIR, V48, P223, DOI 10.1007/BF02056970; Tegos TJ, 2000, ANGIOLOGY, V51, P793, DOI 10.1177/000331970005101001; WEIR BK, 1978, J NEUROSURG, V49, P502, DOI 10.3171/jns.1978.49.4.0502; Zingarelli B, 2005, CRIT CARE MED, V33, pS414, DOI 10.1097/01.CCM.0000186079.88909.94	32	26	28	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	JAN	2007	137	1					103	108		10.1016/j.jss.2006.06.023			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	125NS	WOS:000243449400015	17069855				2022-02-06	
J	Li, SH; Kuroiwa, T; Ishibashi, S; Sun, LY; Endo, S; Ohno, K				Li, Shihong; Kuroiwa, Toshihiko; Ishibashi, Satoru; Sun, Liyuan; Endo, Shu; Ohno, Kikuo			Transient cognitive deficits are associated with the reversible accumulation of amyloid precursor protein after mild traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						axonal injury; microtubule-associated protein2; Mongolian gerbil; neuronal cytoskeleton	MICROTUBULE-ASSOCIATED PROTEIN-2; AXONAL DAMAGE; WHITE-MATTER; HEAD-INJURY; ISCHEMIA; RECOVERY; RAT	Mild traumatic brain injury (MTBI) may frequently cause transient behavioral abnormalities without observable morphological findings. In this study, we investigated neuropathological mechanisms underlying transient cognitive deficits after MTBI. Mongolian gerbils were subjected to experimental MTBI. At various time points after injury, behavioral changes were evaluated by the open-field test and T-maze test, and immunohistochemistry of microtubule-associated protein (MAP2) and amyloid precursor protein (APP) was performed to examine disruptions of the neuronal cytoskeleton and axonal transport, respectively. Transient cognitive deficits were observed after MTBI. Sustained MAP2 loss was found within the cortical impact site, but not the hippocampus. Transient APP accumulation at the same time as transient cognitive deficits occurred in the ipsilateral hemisphere, particularly in the subcortical white matter. These results suggest that the axonal dysfunction indicated by the reversible APP accumulation in the white matter, but not the sustained neuronal cytoskeletal damage reflected by the cortical MAP2 loss confined to the impact site, is responsible for the transient functional deficits after MTBI. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Tokyo Med & Dent Univ, Dept Neurosurg, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Anim Res Ctr, Bunkyo Ku, Tokyo 1138510, Japan		Li, SH (corresponding author), Tokyo Med & Dent Univ, Dept Neurosurg, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138510, Japan.	lishihong.nsrg@tmd.ac.jp					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Briones TL, 2006, BEHAV BRAIN RES, V168, P261, DOI 10.1016/j.bbr.2005.11.015; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Flanagan S, 1999, MT SINAI J MED, V66, P152; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gerlai R, 1998, BEHAV BRAIN RES, V95, P91, DOI 10.1016/S0166-4328(97)00214-3; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GRONWALL D, 1974, LANCET, V2, P605; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Imai H, 2002, J CEREBR BLOOD F MET, V22, P1080, DOI 10.1097/00004647-200209000-00005; Ishibashi S, 2003, STROKE, V34, P1501, DOI 10.1161/01.STR.0000074034.32371.13; JOHNSON GVW, 1992, J NEUROSCI RES, V33, P505, DOI 10.1002/jnr.490330402; KUROIWA T, 1991, NEUROSCI LETT, V122, P141, DOI 10.1016/0304-3940(91)90842-H; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Qian L, 1996, ACTA NEUROCHIR, V138, P90, DOI 10.1007/BF01411731; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	28	26	26	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	DEC 6	2006	409	3					182	186		10.1016/j.neulet.2006.09.054			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	111JW	WOS:000242448500005	17029784				2022-02-06	
J	Ariza, M; del Matarin, M; Junque, C; Mataro, M; Clemente, I; Moral, P; Poca, MA; Garnacho, A; Sahuquillo, J				Ariza, M; del Matarin, M; Junque, C; Mataro, M; Clemente, I; Moral, P; Poca, MA; Garnacho, A; Sahuquillo, J			Influence of angiotensin-converting enzyme polymorphism on neuropsychological subacute performance in moderate and severe traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; COGNITIVE DECLINE; IMPAIRMENT; GENE; VASOSPASM; PRESSURE; ISCHEMIA; RATS	Traumatic brain injury (TBI) frequently results in cerebrovascular lesions that may increase secondary damage and cause neuropsychological impairment. Previous studies suggest an association among the insertion/deletion. (I/D) polymorphism of the angiotensin-converting enzyme (ACE), cardiovascular disease, and cognitive performance. Clinical and experimental studies have demonstrated the beneficial effects of ACE inhibitor treatment on vascular injury, hypertension, brain ischemia, and cognitive functioning. In a sample of 73 moderate and severe TBI patients, the authors assessed whether cognitive sequelae differed in relation to the ACE I/D polymorphism. D allele carrier patients performed worse than those with I/I polymorphism on tests involving attention and processing speed. Findings suggest that the physiopathological changes associated with TBI may have greater consequences in ACE D allele carriers.	Univ Barcelona, Dept Psychiat & Clin Psychobiol, IDIBAPS, Barcelona 08036, Spain; Univ Barcelona, Dept Anim Biol, Barcelona, Spain; Univ Barcelona, Vall Hebron Hosp, Dept Neurosurg & Neurotraumatol Intens Care Unit, Barcelona, Spain		Ariza, M (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, IDIBAPS, C Casanova 143, Barcelona 08036, Spain.	marizago7@docd4.ub.edu	Moral, Pedro/K-9587-2014; Junque, Carme/B-4400-2011; Sahuquillo, Juan/B-3577-2008; Garnacho, Angel/A-9309-2013; Mataro, Maria/B-4524-2011; Matarin, Mar/F-1771-2016; Clemente, I Concepcion/H-5399-2013; Poca, Maria A./B-8475-2008	Moral, Pedro/0000-0001-5072-5892; Junque, Carme/0000-0002-6381-3063; Sahuquillo, Juan/0000-0003-0713-5875; Mataro, Maria/0000-0002-9946-2656; Matarin, Mar/0000-0002-4717-5735; Clemente, I Concepcion/0000-0003-0728-0925; Poca, Maria A./0000-0002-3831-0536; Ariza, Mar/0000-0003-1020-6945			Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Amenta F, 2002, J NEUROL SCI, V203, P147, DOI 10.1016/S0022-510X(02)00281-2; Amouyel P, 1996, NEUROSCI LETT, V217, P203, DOI 10.1016/S0304-3940(96)13092-5; ANDREWS P, 1982, STROKE, V13, P480, DOI 10.1161/01.STR.13.4.480; Baranov D, 2003, ANESTHESIOLOGY, V99, P1118, DOI 10.1097/00000542-200311000-00018; Bartres-Faz D, 2000, NEUROSCI LETT, V290, P177, DOI 10.1016/S0304-3940(00)01349-5; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; FOGARTY DG, 1994, LANCET, V343, P851, DOI 10.1016/S0140-6736(94)92050-8; Gard PR, 2002, EUR J PHARMACOL, V438, P1, DOI 10.1016/S0014-2999(02)01283-9; Gerstein HC, 2000, LANCET, V355, P253; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; Mayer NJ, 2002, J CLIN PATHOL-MOL PA, V55, P29, DOI 10.1136/mp.55.1.29; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; PAULSON OB, 1985, J HYPERTENS, V3, pS487; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; POSTIGLIONE A, 1991, STROKE, V22, P1362, DOI 10.1161/01.STR.22.11.1363; Richard F, 2000, NEUROBIOL AGING, V21, P75, DOI 10.1016/S0197-4580(99)00102-5; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; Stenman E, 2004, STROKE, V35, P970, DOI 10.1161/01.STR.0000121642.53822.58; TIRET L, 1992, AM J HUM GENET, V51, P197; Tzourio C, 2003, ARCH INTERN MED, V163, P1069; UNGER T, 1988, CIRCULATION, V77, P40; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WERNER C, 1991, STROKE, V22, P910, DOI 10.1161/01.STR.22.7.910; Zubkov AY, 1999, J NEUROTRAUM, V16, P763, DOI 10.1089/neu.1999.16.763	28	26	29	0	4	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2006	18	1					39	44		10.1176/appi.neuropsych.18.1.39			6	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	014YU	WOS:000235519900006	16525069				2022-02-06	
J	Coulthard, E; Singh-Curry, V; Husain, M				Coulthard, Elizabeth; Singh-Curry, Victoria; Husain, Masud			Treatment of attention deficits in neurological disorders	CURRENT OPINION IN NEUROLOGY			English	Article						cholinesterase inhibitor; guanfacine; inattention; methylphenidate; prism	TRAUMATIC BRAIN-INJURY; GABA(B) RECEPTOR ANTAGONIST; PRISM ADAPTATION; DOUBLE-BLIND; COGNITIVE PERFORMANCE; IMPROVES COGNITION; ALZHEIMERS-DISEASE; SPATIAL NEGLECT; RIVASTIGMINE; PLACEBO	Purpose of review Recent work has revealed the impact of deficits of attention on patients with neurological disorders. Here we discuss therapeutic interventions that have been used across a range of conditions, highlighting common themes both in the nature of the attention deficits and the strategies employed to treat them. Recent findings Cholinesterase inhibitors improve attention, as well as memory, in several conditions including cortical Lewy body disease, Parkinson's disease dementia, traumatic brain injury and Alzheimer's disease. Recent studies suggest that cholinergic stimulation may boost attention further if more specific nicotinic cholinergic agonists are used, or if cholinesterase inhibitors are combined with other agents. Monoaminergic drugs have been shown to improve attention in traumatic brain injury, attention-deficit hyperactivity disorder and hemispatial neglect following right-hemisphere stroke. New compounds targeting other neurotransmitter systems are currently being tested, while several types of behavioural intervention have shown promise, particularly in stroke patients. Summary Pharmacological and behavioural interventions can improve attention in neurological patients. In the future, optimum therapy may depend on careful delineation of the components of attention that are impaired as well as assessment of the potential for surviving brain regions to compensate for attention deficits.	UCL, Inst Cognit Neurosci, London, England		Coulthard, E (corresponding author), Inst Cognit Neurosci, 17 Queen Square,Alexandra House, London WC1N 3AR, England.	l.coulthard@ion.ucl.ac.uk	Husain, Masud/C-2074-2008	Husain, Masud/0000-0002-6850-9255; coulthard, elizabeth/0000-0002-0017-9595	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Almkvist O, 2004, EUR J NEUROL, V11, P253, DOI 10.1046/j.1468-1331.2003.00757.x; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Coull JT, 1998, PROG NEUROBIOL, V55, P343, DOI 10.1016/S0301-0082(98)00011-2; Czeisler CA, 2005, NEW ENGL J MED, V353, P476, DOI 10.1056/NEJMoa041292; de Tommaso M, 2004, MOVEMENT DISORD, V19, P1516, DOI 10.1002/mds.20235; Dijkerman HC, 2004, NEUROPSYCHOLOGIA, V42, P1697, DOI 10.1016/j.neuropsychologia.2004.04.004; Emre M, 2004, NEW ENGL J MED, V351, P2509, DOI 10.1056/NEJMoa041470; Farne A, 2002, NEUROPSYCHOLOGIA, V40, P718, DOI 10.1016/S0028-3932(01)00186-5; Foldi NS, 2005, INT J GERIATR PSYCH, V20, P485, DOI 10.1002/gps.1319; Franowicz JS, 1998, PSYCHOPHARMACOLOGY, V136, P8, DOI 10.1007/s002130050533; Froestl W, 2004, BIOCHEM PHARMACOL, V68, P1479, DOI 10.1016/j.bcp.2004.07.030; Gill M, 2006, ACAD EMERG MED, V13, P158, DOI 10.1197/j.aem.2005.08.013; Husain M, 2003, NAT REV NEUROSCI, V4, P26, DOI 10.1038/nrn1005; Jakala P, 1999, NEUROPSYCHOPHARMACOL, V20, P460, DOI 10.1016/S0893-133X(98)00127-4; Khateb A, 2005, EUR NEUROL, V54, P39, DOI 10.1159/000087718; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; KLEIN C, 2006, BIOL PSYCHIAT; Lawrence AD, 1998, BRAIN, V121, P1329, DOI 10.1093/brain/121.7.1329; Leclercq M, 2002, APPL NEUROPSYCHOLOGY; Leroi I, 2004, INT J GERIATR PSYCH, V19, P1, DOI 10.1002/gps.993; Malhotra PA, 2006, ANN NEUROL, V59, P186, DOI 10.1002/ana.20701; Maravita A, 2003, NEUROLOGY, V60, P1829, DOI 10.1212/WNL.60.11.1829; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; McKeith IG, 2004, DEMENT GERIATR COGN, V18, P94, DOI 10.1159/000077816; Michelson D, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.5.e83; Molloy S, 2005, J NEUROL NEUROSUR PS, V76, P1313; Morton AJ, 2005, EUR J NEUROSCI, V21, P855, DOI 10.1111/j.1460-9568.2005.03895.x; Perry RJ, 1999, BRAIN, V122, P383, DOI 10.1093/brain/122.3.383; Porrino LJ, 2005, PLOS BIOL, V3, P1639, DOI 10.1371/journal.pbio.0030299; Rossetti Y, 1998, NATURE, V395, P166, DOI 10.1038/25988; Rousseaux M, 2006, STROKE, V37, P542, DOI 10.1161/01.STR.0000198877.09270.e8; SAHAKIAN BJ, 1994, DRUG DEVELOP RES, V31, P80, DOI 10.1002/ddr.430310112; Saletu M, 2004, J NEUROL, V251, P1354, DOI 10.1007/s00415-004-0543-8; Scahill L, 2001, AM J PSYCHIAT, V158, P1067, DOI 10.1176/appi.ajp.158.7.1067; Schneider JS, 2003, J PHARMACOL EXP THER, V306, P401, DOI 10.1124/jpet.103.051912; Serino A, 2006, NEUROPSYCHOLOGIA, V44, P1068, DOI 10.1016/j.neuropsychologia.2005.10.024; Shindo K, 2006, J REHABIL MED, V38, P65, DOI 10.1080/16501970500441807; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Thimm M, 2006, NEUROPSYCHOLOGIA, V44, P1230, DOI 10.1016/j.neuropsychologia.2005.09.008; Tilikete C, 2001, CURR BIOL, V11, P524, DOI 10.1016/S0960-9822(01)00151-8; Tomlinson J, 2004, NEUROLOGY, V62, pA128; Tucha O, 2006, PSYCHOPHARMACOLOGY, V185, P315, DOI 10.1007/s00213-006-0318-2; Tzavara ET, 2006, MOL PSYCHIATR, V11, P187, DOI 10.1038/sj.mp.4001763; Vellas B, 2005, CURR MED RES OPIN, V21, P1423, DOI 10.1185/030079905X61884; Wesnes KA, 2005, NEUROLOGY, V65, P1654, DOI 10.1212/01.wnl.0000184517.69816.e9; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	48	26	26	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2006	19	6					613	618		10.1097/01.wco.0000247605.57567.9a			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	115XJ	WOS:000242766800017	17102702				2022-02-06	
J	Taoufiq, Z; Pino, P; Dugas, N; Conti, M; Tefit, M; Mazier, D; Vouldoukis, I				Taoufiq, Zacharie; Pino, Paco; Dugas, Nathalie; Conti, Marc; Tefit, Maurel; Mazier, Dominique; Vouldoukis, Ioannis			Transient supplementation of superoxide dismutase protects endothelial cells against Plasmodium falciparum-induced oxidative stress	MOLECULAR AND BIOCHEMICAL PARASITOLOGY			English	Article						malaria; endothelium; superoxide dismutase; oxidative stress	HUMAN CEREBRAL MALARIA; BLOOD-BRAIN-BARRIER; NITRIC-OXIDE; INFECTED ERYTHROCYTES; IN-VITRO; DEPENDENT MECHANISM; ANTIOXIDANT ENZYMES; INDUCED APOPTOSIS; ADHESION; CYTOADHERENCE	The pathogenesis of cerebral malaria, a major complication of Plasinodium falciparum infection, relies on mechanisms such as cytokine production and cytoadherence of parasitized red blood cells (PRBCs) on microvascular endothelial cells. In this way parasites avoid spleen clearance by sequestration in post-capillary venules of various organs including the brain. Infected erythrocytes adhesion has also been shown to have molecular signaling consequences providing insight on how tissue homeostasis could be comprised by endothelium perturbation. Our previous work demonstrated that PRBCs adhesion to human lung endothelial cells (HLEC) induces caspases activation, oxidative stress and apoptosis. Cytoplasmic Cu/Zn superoxide dismutase (SOD1), which provides the first line of defense against oxidative stress within a cell, is now used as a treatment of numerous diseases including traumatic brain injury and ischemic stroke. In this report, we demonstrated that transient supplementation of SOD1 protects endothelial cells against P falciparun? induced oxidative stress and apoptosis. We also showed a significant decrease in PRBCs cytoadherence through a downregulation of ICAM-1 and an induction of iNOS. Protection of endothelium via antioxidant delivery may constitute a relevant strategy in cerebral malaria treatment. (c) 2006 Elsevier B.V. All rights reserved.	Univ Paris 06, INSERM, UMR511, CHU Pitie Salpetriere, F-75013 Paris, France; VigiCell sarl, F-94240 Le Kremlin Bicetre, France		Taoufiq, Z (corresponding author), Univ Paris 06, INSERM, UMR511, CHU Pitie Salpetriere, 91 Bd Hop, F-75013 Paris, France.	zacharie.taoufiq@etu.upmc.fr; vouldouk@ext.jussieu.fr		Taoufiq, Zacharie/0000-0003-4893-0322			BARET A, 1984, BIOCHEM PHARMACOL, V33, P2755, DOI 10.1016/0006-2952(84)90692-0; Brown H, 1999, NEUROPATH APPL NEURO, V25, P331; Chillemi R, 2004, CLIN CHIM ACTA, V348, P113, DOI 10.1016/j.cccn.2004.05.007; CLARK IA, 1983, INFECT IMMUN, V39, P1; Craig A, 2001, MOL BIOCHEM PARASIT, V115, P129, DOI 10.1016/S0166-6851(01)00275-4; DELAHARPE J, 1985, J IMMUNOL METHODS, V78, P323, DOI 10.1016/0022-1759(85)90089-4; Dugas B, 2003, CYTOKINE, V21, P270, DOI 10.1016/S1043-4666(03)00100-5; Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189; GOODYER ID, 1994, ANN TROP MED PARASIT, V88, P209, DOI 10.1080/00034983.1994.11812859; Hebert MJ, 1998, AM J PATHOL, V152, P523; Hemmer CJ, 2005, INFECT IMMUN, V73, P1764, DOI 10.1128/IAI.73.3.1764-1770.2005; Hollestelle MJ, 2006, BRIT J HAEMATOL, V133, P562, DOI 10.1111/j.1365-2141.2006.06067.x; JADOT G, 1995, CLIN PHARMACOKINET, V28, P17, DOI 10.2165/00003088-199528010-00003; Jin LH, 2001, FREE RADICAL BIO MED, V31, P1509, DOI 10.1016/S0891-5849(01)00734-1; KELNER MJ, 1995, FREE RADICAL BIO MED, V18, P497, DOI 10.1016/0891-5849(94)00167-I; Mazier D, 2000, PARASITE IMMUNOL, V22, P613, DOI 10.1046/j.1365-3024.2000.00342.x; Medana IM, 2006, INT J PARASITOL, V36, P555, DOI 10.1016/j.ijpara.2006.02.004; Muanza K, 1996, RES IMMUNOL, V147, P149, DOI 10.1016/0923-2494(96)83167-1; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; Pino P, 2003, ANN NY ACAD SCI, V1010, P582, DOI 10.1196/annals.1299.109; Pino P, 2004, CELL MICROBIOL, V6, P839, DOI 10.1111/j.1462-5822.2004.00406.x; Pino P, 2003, J INFECT DIS, V187, P1283, DOI 10.1086/373992; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; Schirmer R H, 1987, Free Radic Res Commun, V3, P3, DOI 10.3109/10715768709069763; Schwartz E, 1999, INFLAMMATION, V23, P361; Serirom S, 2003, AM J PATHOL, V162, P1651, DOI 10.1016/S0002-9440(10)64299-X; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Takahashi H, 2000, J DERMATOL SCI, V23, P12, DOI 10.1016/S0923-1811(99)00060-2; Takahashi M, 1996, CYTOKINE, V8, P817, DOI 10.1006/cyto.1996.0109; Taylor AM, 1998, T ROY SOC TROP MED H, V92, P170, DOI 10.1016/S0035-9203(98)90733-7; Vouldoukis I, 2004, J ETHNOPHARMACOL, V94, P67, DOI 10.1016/j.jep.2004.04.023; Vouldoukis I, 2000, MOL MED, V6, P1042, DOI 10.1007/BF03402055; Vouldoukis L, 2004, PHYTOTHER RES, V18, P957, DOI 10.1002/ptr.1542; Wang PH, 1998, P NATL ACAD SCI USA, V95, P4556, DOI 10.1073/pnas.95.8.4556; *WHO, 1997, 94 WHO, V72, P269; Yang YH, 2002, FEBS LETT, V532, P36, DOI 10.1016/S0014-5793(02)03624-4; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739	37	26	26	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-6851			MOL BIOCHEM PARASIT	Mol. Biochem. Parasitol.	DEC	2006	150	2					166	173		10.1016/j.molbiopara.2006.07.008			8	Biochemistry & Molecular Biology; Parasitology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Parasitology	111TF	WOS:000242476900005	16930739				2022-02-06	
J	Tenovuo, O				Tenovuo, Olli			Pharmacological enhancement of cognitive and behavioral deficits after traumatic brain injury	CURRENT OPINION IN NEUROLOGY			English	Article						cholinergic agents; cognition; dopaminergic agents; psychostimulants; traumatic brain injury	DOUBLE-BLIND; MODAFINIL; ATOMOXETINE; AMANTADINE; PLACEBO; METHYLPHENIDATE; REHABILITATION; FATIGUE; PERFORMANCE; MECHANISMS	Purpose of review To provide the clinician with a reasonable overview of the modern pharmacological alternatives to treat the cognitive and behavioral sequels of traumatic brain injury. Recent findings Original research in this area is sparse and more than half of the articles published on the subject recently have been reviews. Of the three randomized controlled trials, one studied methylphendate (n = 18), one methylphenidate and sertraline (n = 30) and one amantadine (n = 27). All these studies reported beneficial effects on various cognitive measures, but because of the study protocols, the evidence provided may be questioned. The various reviews, uncontrolled studies and case reports suggest that at least psychostimulants, cholinergic agents, dopaminergic agents and antidepressants may be beneficial in treating the cognitive and behavioral symptoms of traumatic brain injury. Summary The clinician trying to ameliorate the cognitive and behavioral symptoms of traumatic brain injury has to make decisions about pharmacotherapy that are still based mainly on clinical experience. Large randomized controlled trials giving high-quality evidence are so far missing. This review discusses the problems facing both the clinician and the scientist treating the cognitive and behavioral sequels of traumatic brain injury. A symptom-based approach is suggested for current practice.	Turku Univ, Dept Neurol, Turku 20521, Finland		Tenovuo, O (corresponding author), Turku Univ, Dept Neurol, POB 52, Turku 20521, Finland.	olli.tenovuo@tyks.fi					Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Apud Jose A, 2006, NeuroRx, V3, P106, DOI 10.1016/j.nurx.2005.12.004; Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554, DOI 10.4088/JCP.v67n0406; Beers SR, 2005, J HEAD TRAUMA REHAB, V20, P450, DOI 10.1097/00001199-200509000-00006; Bennouna M, 2005, J CLIN PSYCHOPHARM, V25, P505, DOI 10.1097/01.jcp.0000177851.31157.66; Beresford TP, 2005, BRAIN INJURY, V19, P309, DOI 10.1080/02699050410001720121; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; DeMarchi R, 2005, CAN J NEUROL SCI, V32, P4, DOI 10.1017/S0317167100016826; Faraone SV, 2005, J CHILD ADOL PSYCHOP, V15, P664, DOI 10.1089/cap.2005.15.664; Foster DJ, 2006, ARCH PHYS MED REHAB, V87, P216, DOI 10.1016/j.apmr.2005.08.131; Glenn MB, 2002, J HEAD TRAUMA REHAB, V17, P273, DOI 10.1097/00001199-200208000-00002; Glenn MB, 2005, J HEAD TRAUMA REHAB, V20, P51, DOI 10.1097/00001199-200501000-00006; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; Hernandez AV, 2005, NEUROSURGERY, V57, P1244, DOI 10.1227/01.NEU.0000186039.57548.96; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Khateb A, 2005, EUR NEUROL, V54, P39, DOI 10.1159/000087718; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Leone H, 2005, J CLIN PHARM THER, V30, P101, DOI 10.1111/j.1365-2710.2005.00628.x; Lipton Stuart A, 2004, NeuroRx, V1, P101, DOI 10.1602/neurorx.1.1.101; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Matsuda W, 2005, NEUROPSYCHOL REHABIL, V15, P414, DOI 10.1080/09602010443000588; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; Newburn G, 2005, BRAIN INJURY, V19, P149, DOI 10.1080/02699050410001719989; Ondo WG, 2005, J NEUROL NEUROSUR PS, V76, P1636, DOI 10.1136/jnnp.2005.065870; Papakostas GI, 2006, J PSYCHIAT RES, V40, P370, DOI 10.1016/j.jpsychires.2005.04.013; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; Randall DC, 2005, PHARMACOL BIOCHEM BE, V82, P133, DOI 10.1016/j.pbb.2005.07.019; Randall DC, 2005, J PSYCHOPHARMACOL, V19, P647, DOI 10.1177/0269881105056531; Ripley DL, 2006, J HEAD TRAUMA REHAB, V21, P85, DOI 10.1097/00001199-200601000-00010; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Stankoff B, 2005, NEUROLOGY, V64, P1139, DOI 10.1212/01.WNL.0000158272.27070.6A; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Sugden SG, 2006, NEUROREHABILITATION, V21, P3; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Tenovuo OS, 2006, CURR DRUG THER, V1, P187, DOI 10.2174/157488506776930932; Turner-Stokes L, 2005, CLIN MED, V5, P268, DOI 10.7861/clinmedicine.5-3-268; Tzavara ET, 2006, MOL PSYCHIATR, V11, P187, DOI 10.1038/sj.mp.4001763; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Wu TS, 2005, J EMERG MED, V28, P289, DOI 10.1016/j.jemermed.2004.11.016; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	51	26	26	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2006	19	6					528	533		10.1097/WCO.0b013e328010944f			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	115XJ	WOS:000242766800004	17102689				2022-02-06	
J	Bochicchio, GV; Bochicchio, K; Nehman, S; Casey, C; Andrews, P; Scalea, TM				Bochicchio, Grant V.; Bochicchio, Kelly; Nehman, Shelley; Casey, Colleen; Andrews, Penny; Scalea, Thomas M.			Tolerance and efficacy of enteral nutrition in traumatic brain-injured patients induced into barbiturate coma	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article							INTRACRANIAL-PRESSURE	Background: There is a paucity of data evaluating the efficacy of nutrition support in traumatic brain-injured patients induced into barbiturate coma for refractory intracranial hypertension. Our objective was to evaluate the efficacy of enteral nutrition in a select group of trauma patients. Methods: Prospective data were collected on severe traumatic brain-injured patients over a 4-year period. Patients were stratified by whether or not they were induced into a barbiturate coma. Barbiturate coma was defined as per American Association of Neurological Surgeons (AANS) guidelines. All patients were initially fed via the enteral route via a nasogastric feeding tube. Patients who did not tolerate feedings within 48 hours started receiving prokinetic,agents. Feeding tolerance was defined as ability to tolerate enteral feedings with < 150 mL of gastric residuals every 6 hours for > 72 hours. Results: Fifty-seven patients were induced into a barbiturate coma. All were victims of blunt-force trauma. Forty-two of 57 (74%) patients were men, with a mean age of 37 +/- 12 years and a mean injury severity score of 24 +/- 10. Thirty-eight of the 57 (67%) patients had an isolated traumatic brain injury. All 57 patients failed enteral nutrition via the nasogastric route after the first 48 hours of nutrition initiation after barbiturate coma was fully achieved by protocol criteria. Prokinetic agents demonstrated no improvement in feeding tolerance after the subsequent 48-72 hours. Of the 12 patients who had a postpyloric feeding tube placed, only 25% tolerated enteral nutrition for > 48 hours. Conclusions: Patients with traumatic brain injury induced into barbiturate coma develop a significant ileus that is refractory to prokinetic agents. Only a marginal improvement is seen when the postpyloric route is obtained. Early parenteral nutrition should be considered in this patient population.	Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Clin & Outcomes Res, Baltimore, MD 21201 USA		Bochicchio, GV (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Clin & Outcomes Res, Room TIR59,22 S Greene St, Baltimore, MD 21201 USA.	gbochicchio@umm.edu					Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; JOSEPHS LG, 1994, J TRAUMA, V36, P815, DOI 10.1097/00005373-199406000-00011; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kerwin AJ, 2000, J TRAUMA, V48, P878, DOI 10.1097/00005373-200005000-00011; MAGNUSON B, 1999, NUTR CLIN PRACT, V14, P131; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MILLER C H, 1991, Neurological Research, V13, P117; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Rosenthal RJ, 1997, SURG ENDOSC, V11, P376, DOI 10.1007/s004649900367; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; Wilson RF, 2001, NEUROL RES, V23, P121, DOI 10.1179/016164101101198451	13	26	33	0	6	AMER SOC PARENTERAL & ENTERAL NUTRITION	SILVER SPRING	8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910 USA	0148-6071			JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	NOV-DEC	2006	30	6					503	506		10.1177/0148607106030006503			4	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	195XC	WOS:000248444700007	17047175				2022-02-06	
J	Levasseur, JE; Alessandri, B; Reinert, M; Clausen, T; Zhou, ZW; Altemeni, N; Bullock, MR				Levasseur, Joseph E.; Alessandri, Beat; Reinert, Michael; Clausen, Tobias; Zhou, Zhengwen; Altemeni, Nabil; Bullock, M. Ross			Lactate not glucose, up-regulates mitochondrial oxygen consumption both in sham and lateral fluid percussed rat brains	NEUROSURGERY			English	Article						brain injury; glucose; lactate; oxygen; oxygen consumption	SEVERE HEAD-INJURY; ACUTE SUBDURAL-HEMATOMA; CEREBRAL-BLOOD-FLOW; CYCLOSPORINE-A; EXTRACELLULAR POTASSIUM; INTRACRANIAL-PRESSURE; COGNITIVE DEFICITS; N-ACETYLASPARTATE; ENERGY-METABOLISM; NEURONAL-ACTIVITY	OBJECTIVE: Failure of energy metabolism after traumatic brain injury may be a major factor limiting outcome. Although glucose is the primary metabolic substrate in the healthy brain, the well documented surge in tissue lactate after traumatic brain injury suggests that lactate may provide an energy need that cannot be met by glucose. We hypothesized, therefore, that administration of lactate or the combination of lactate and supraphysiological oxygen may improve mitochondrial oxidative respiration in the brain after rat fluid percussion injury. We measured oxygen consumption (VO2) to determine what effects glucose, lactate, oxygen, and the combination of lactate and oxygen have on mitochondrial respiration in both injured and uninjured rat brain tissue. METHODS: Anesthetized Sprague-Dawley rats were intubated and ventilated with either 0.21 or 1.0 fraction of inspired oxygen (FIO2). Brain tissue from acute sham animals was subjected in vitro to 1.1 mM, 12 mM and 100 mM concentrations of glucose and L-lactate. In another group, injury (fluid percussion injury of 2.5 +/- 0.02 atmospheres) was induced over the left hemisphere. The VO2 of mu g amounts of brain tissues were measured in a microrespirometry system (Cartesian diver). RESULTS: The VO2 was found to be independent of glucose concentrations, but dose-dependent for lactate. Moreover, the lactate dependent VO(2)s were all significantly higher than those generated by glucose. Injured rats on FIO2 0.21 had brain tissueVO(2) rates that were significantly lower than those of shams or preinjury levels. In injured rats treated with FIO2 1.0, the reduction in VO2 levels was prevented. Injured rats that received an intravenous infusion of.100 mM lactate had VO2 rates that were significantly higher than those obtained with FIO2 1.0. Combined treatment further boosted the lactate generated VO2 rates by approximately 15%. CONCLUSION: Glucose sustains mitochondrial respiration at a low level "fixed" rate because, despite increasing its concentration nearly 100-fold, it cannot up-regulate VO2 after fluid percussion injury. Lactate produces a dose-dependent VO2 response, possibly enabling mitochondria to meet the increased energy needs of the injured brain.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Med Ctr, Richmond, VA 23298 USA; Univ Halle Wittenberg, Dept Anesthesiol, Halle, Saale, Germany; Univ Halle Wittenberg, Dept Intens Care Med, Halle, Saale, Germany; Univ Bern, Inselspital, Dept Neurosurg, CH-3010 Bern, Switzerland; Univ Mainz, Inst Neurosurg Pathophysiol, D-6500 Mainz, Germany		Bullock, MR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Med Ctr, POB 980631,1200 E Broad St, Richmond, VA 23298 USA.	robulloc@mail2.vcu.edu	Reinert, Michael/AAA-3929-2019; Reinert, Michael/E-4964-2011	Reinert, Michael/0000-0002-0971-9543; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, R01NS019316, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 19316-16] Funding Source: Medline		Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Alessandri B, 1999, ACT NEUR S, V75, P21; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Aubert A, 2005, P NATL ACAD SCI USA, V102, P16448, DOI 10.1073/pnas.0505427102; Aubert A, 2005, J CEREBR BLOOD F MET, V25, P1476, DOI 10.1038/sj.jcbfm.9600144; Aubert A, 2002, NEUROIMAGE, V17, P1162, DOI 10.1006/nimg.2002.1224; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, ACT NEUR S, V76, P359; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; DAUGHERTY WP, 2003, J NEUROTRAUM, V20, P1162; Doppenberg EMR, 1999, J NEUROTRAUM, V16, P123, DOI 10.1089/neu.1999.16.123; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; FELLOWS LK, 1993, J NEUROCHEM, V60, P1258, DOI 10.1111/j.1471-4159.1993.tb03285.x; Friedemann TE, 1941, J BIOL CHEM, V141, P993; FUJISAWA H, 1994, ACT NEUR S, V60, P193; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Haljamae H, 1987, INTENSIVE CARE WORLD, V4, P118; HARPER HA, 1959, REV PHYSL CHEM, P179; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HAWK PB, 1954, PRACTICAL PHYSIOLOGI, P622; Holloway R, 2003, J NEUROTRAUM, V20, P1127; Holter H., 1943, COMPT REND TRAV LAB CARLSBERG [COPENHAGEN] SER CHIM, V24, P399; Hu YB, 1997, J NEUROCHEM, V69, P1484; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KORF J, 1990, INT J BIOCHEM, V22, P1371, DOI 10.1016/0020-711X(90)90225-R; KUHR WG, 1988, J CEREBR BLOOD F MET, V8, P848, DOI 10.1038/jcbfm.1988.142; LARABEE MG, 1996, J NEUROCHEM, V67, P1726; LARABEE MJ, 1995, J NEUROCHEM, V64, P1734; Leegsma-Vogt G, 2004, J CEREBR BLOOD F MET, V24, P1071, DOI 10.1097/01.WCB.0000129417.80261.A6; LEVASSEUR J, 1999, J NEUROTRAUM, V16, P991; LEVASSEUR JE, 1985, AM J PHYSIOL, V248, pH534, DOI 10.1152/ajpheart.1985.248.4.H534; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Linderstrom-Lang K., 1943, COMPT REND TRAV LAB CARLSBERG [COPENHAGEN] SER CHIM, V24, P333; MAGISTRETTI PJ, 1993, DEV NEUROSCI-BASEL, V15, P306, DOI 10.1159/000111349; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MCILWAIN H, 1953, BIOCHEM J, V55, P618, DOI 10.1042/bj0550618; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Reinert M, 2002, NEUROL RES, V24, P601, DOI 10.1179/016164102101200438; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; Schurr A, 2001, BRAIN RES, V895, P268, DOI 10.1016/S0006-8993(01)02082-0; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Schwandt ES, 2003, J NEUROTRAUM, V20, P1096; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; TSCAOPOULOS M, 1996, J NEUROSCI, V16, P877; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	70	26	27	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2006	59	5					1122	1130		10.1227/01.NEU.0000245581.00908.AF			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	128GI	WOS:000243645800035	17143246				2022-02-06	
J	Bangirana, P; Idro, R; John, CC; Boivin, MJ				Bangirana, Paul; Idro, Richard; John, Chandy C.; Boivin, Michael J.			Rehabilitation for cognitive impairments after cerebral malaria in African children: strategies and limitations	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						cerebral malaria; cognitive impairment; Africa; children; rehabilitation	PLASMODIUM-FALCIPARUM MALARIA; TRAUMATIC BRAIN-INJURY; ENVIRONMENTAL ENRICHMENT; ATTENTION; SEQUELAE; PERFORMANCE; THERAPY; SCHOOLCHILDREN; INTERVENTION; DISORDERS	Cerebral malaria results in short- to long-term cognitive impairments in many of its child survivors. Although some of the risk factors for impairments have been identified, no attempts have been made to address the plight of those who develop cognitive impairments. This paper discusses the burden of cognitive impairment caused by cerebral malaria and suggests some rehabilitation strategies based on brain injury and cognitive rehabilitation studies. Potential cognitive rehabilitation solutions such as cognitive exercises, environmental enrichment, nutritional supplementation, physical therapy and speech therapy are highlighted. The limitations of implementing these interventions and solutions are discussed in light of the limited human resources and infrastructure of the developing countries that are malaria endemic.	Makerere Univ, Inst Psychol, Dept Mental Hlth & Community Psychol, Kampala, Uganda; Makerere Univ, Mulago Hosp, Med Sch, Dept Paediat & Child Hlth, Kampala, Uganda; Univ Minnesota, Global Pediat Program, Minneapolis, MN USA; Univ Minnesota, Div Pediat Infect Dis, Minneapolis, MN USA; Michigan State Univ, INPEP, E Lansing, MI USA; Univ Michigan, Dept Psychiat, Neuropsychol Program, Ann Arbor, MI USA		Bangirana, P (corresponding author), Makerere Univ, Inst Psychol, Dept Mental Hlth & Community Psychol, POB 7062, Kampala, Uganda.	pbangirana@yahoo.com	, Ridro/ABD-3556-2020; John, Chandy C/B-4164-2008	Bangirana, Paul/0000-0002-7136-0594; Idro, Richard/0000-0003-4728-4605			Anderson V A, 1999, Pediatr Rehabil, V3, P159; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Blundell SW, 2003, CLIN REHABIL, V17, P48, DOI 10.1191/0269215503cr584oa; BOIVIN MJ, 1993, J PEDIATR PSYCHOL, V18, P249, DOI 10.1093/jpepsy/18.2.249; Boivin MJ, 2002, J DEV BEHAV PEDIATR, V23, P353, DOI 10.1097/00004703-200210000-00010; Boivin MJ, 1996, J PSYCHOL, V130, P95, DOI 10.1080/00223980.1996.9914992; BOIVIN MJ, 1993, HEALTH PSYCHOL, V12, P220, DOI 10.1037/0278-6133.12.3.220; Carter JA, 2005, J NEUROL NEUROSUR PS, V76, P476, DOI 10.1136/jnnp.2004.043893; Carter JA, 2005, TROP MED INT HEALTH, V10, P3, DOI 10.1111/j.1365-3156.2004.01345.x; Carter JA, 2003, BRAIN INJURY, V17, P217, DOI 10.1080/0269905021000038447; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Dickson R, 2000, BMJ-BRIT MED J, V320, P1697, DOI 10.1136/bmj.320.7251.1697; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; Dugbartey AT, 1998, AM J TROP MED HYG, V59, P393, DOI 10.4269/ajtmh.1998.59.393; DUGBARTEY AT, 1995, THESIS U VICTORIA CA; Fernandez-Teruel A, 2002, PHARMACOL BIOCHEM BE, V73, P233, DOI 10.1016/S0091-3057(02)00787-6; Genton B, 1997, INT J EPIDEMIOL, V26, P670, DOI 10.1093/ije/26.3.670; Gontkovsky ST, 2002, NEUROREHABILITATION, V17, P195; Goorhuis-Brouwer SM, 2002, INT J PEDIATR OTORHI, V63, P129, DOI 10.1016/S0165-5876(02)00004-6; Grantham-McGregor S, 2001, J NUTR, V131, p649S, DOI 10.1093/jn/131.2.649S; GREALY MA, 2001, PEDIAT REHABILITATIO, V4, P41; Holding PA, 1999, T ROY SOC TROP MED H, V93, P529, DOI 10.1016/S0035-9203(99)90368-1; Holding PA, 2004, J INT NEUROPSYCH SOC, V10, P246, DOI 10.1017/S1355617704102166; Holding PA, 2001, AM J TROP MED HYG, V64, P68, DOI 10.4269/ajtmh.2001.64.68; Klein PS, 2004, INFANT YOUNG CHILD, V17, P340, DOI 10.1097/00001163-200410000-00007; KLEIN PS, 1991, INF MENTAL HLTH J, V12, P321, DOI 10.1002/1097-0355(199124)12:4<321::AID-IMHJ2280120406>3.0.CO;2-Z; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; Laatsch L, 1997, BRAIN INJURY, V11, P851; Laatsch L, 2000, NEUROREHABILITATION, V15, P189; Lozoff, 2004, PEDIATRICS, V113, P1853; LOZOFF B, 1995, INT J BEHAV DEV, V18, P277, DOI 10.1177/016502549501800206; Lozoff B, 2003, PEDIATRICS, V112, P846; Marlowe WB, 2000, DEV NEUROPSYCHOL, V18, P445, DOI 10.1207/S1532694209Marlowe; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; Mohammed AH, 2002, PROG BRAIN RES, V138, P109, DOI 10.1016/S0079-6123(02)38074-9; Mung'Ala-Odera V, 2004, AM J TROP MED HYG, V71, P64, DOI 10.4269/ajtmh.2004.71.64; Muntendam AH, 1996, T ROY SOC TROP MED H, V90, P391, DOI 10.1016/S0035-9203(96)90518-0; Murphy SC, 2001, AM J TROP MED HYG, V64, P57, DOI 10.4269/ajtmh.2001.64.57; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Newton CRJC, 2000, J NEUROL NEUROSUR PS, V69, P433, DOI 10.1136/jnnp.69.4.433; Nordholm LA, 1999, DISABIL REHABIL, V21, P515; Olness K, 2003, J DEV BEHAV PEDIATR, V24, P120, DOI 10.1097/00004703-200304000-00009; Olumese PE, 1997, J TROP PEDIATRICS, V43, P217, DOI 10.1093/tropej/43.4.217; Palmese CA, 2000, BRAIN INJURY, V14, P535; Raine A, 2001, PSYCHOPHYSIOLOGY, V38, P254, DOI 10.1111/1469-8986.3820254; RICHTER LM, 1991, INF MENTAL HLTH J, V12, P88, DOI 10.1002/1097-0355(199122)12:2<88::AID-IMHJ2280120202>3.0.CO;2-Q; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Spiers MV., 2001, PRINCIPLES NEUROPSYC; Stoltzfus RJ, 2001, BRIT MED J, V323, P1389, DOI 10.1136/bmj.323.7326.1389; van't Hooft I, 2003, ACTA PAEDIATR, V92, P935, DOI 10.1080/08035250310004586	53	26	26	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2006	11	9					1341	1349		10.1111/j.1365-3156.2006.01685.x			9	Public, Environmental & Occupational Health; Tropical Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Tropical Medicine	077DF	WOS:000240007200003	16930255	Green Submitted			2022-02-06	
J	Grinsell, MM; Showalter, S; Gordon, KA; Norwood, VF				Grinsell, Matthew M.; Showalter, Sharon; Gordon, Katherine A.; Norwood, Victoria F.			Single kidney and sports participation: Perception versus reality	PEDIATRICS			English	Article						kidney; sports; wounds and injuries	BLUNT RENAL TRAUMA; AMERICAN FOOTBALL; ABDOMINAL-TRAUMA; INJURIES; CHILDREN; SECONDARY; GENITOURINARY; FATALITIES; LACERATION; RUPTURE	OBJECTIVES. Physician opinions and practice patterns regarding the participation of children and adolescents with single, normal kidneys in contact/collision sports are widely varied. We hypothesize that limitation of participation from play based only on the presence of a single kidney is not supported by available data. We sought to determine recommendations of pediatric nephrologists regarding the participation of patients with single, normal kidneys in contact/collision sports and review the literature to determine the rate of sports-related kidney injury compared with other organs. METHODS. Members of the American Society of Pediatric Nephrology were surveyed regarding their recommendations for participation of patients with single, normal kidneys in contact/collision sports. Medical and sports literature databases were searched to determine sports-related kidney, brain, spinal cord, and cardiac injury rates and the sports associated with kidney injury. RESULTS. Sixty-two percent of respondents would not allow contact/collision sports participation. Eighty-six percent of respondents barred participation in American football, whereas only 5% barred cycling. Most cited traumatic loss of function as the reason for discouraging participation. The literature search found an incidence of catastrophic sports-related kidney injury of 0.4 per 1 million children per year from all sports. Cycling was the most common cause of sports- related kidney injury causing > 3 times the kidney injuries as football. American football alone accounted for 0.9 to 5.3 fatal brain injuries and 4.9 to 7.3 irreversible spinal cord injuries per 1 million players per year. Commotio cordis causes 2.1 to 9.2 deaths per year. CONCLUSIONS. Most pediatric nephrologists prohibit contact/collision sports participation by athletes with a single kidney, particularly football. The available evidence suggests that cycling is far more likely to cause kidney injury. In addition, kidney injury from sports is much less common than catastrophic brain, spinal cord, or cardiac injury. Restricting participation of patients with a single, normal kidney from contact/collision sports is unwarranted.	Univ Virginia, Dept Pediat, Div Nephrol, Charlottesville, VA 22903 USA; Univ Virginia, Curry Sch Educ, Charlottesville, VA 22903 USA		Grinsell, MM (corresponding author), Univ Virginia, Dept Pediat, Div Nephrol, 1224 Jefferson Pk Ave,Suite 701, Charlottesville, VA 22903 USA.	mmg4x@virginia.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5T32HL07956-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007956] Funding Source: NIH RePORTER		ACTON CHC, 1994, MED J AUSTRALIA, V160, P344, DOI 10.5694/j.1326-5377.1994.tb138235.x; AHMED S, 1982, BRIT J UROL, V54, P470, DOI 10.1111/j.1464-410X.1982.tb13567.x; Anderson C R, 1995, Arch Fam Med, V4, P885, DOI 10.1001/archfami.4.10.885; BASS DH, 1991, J PEDIATR SURG, V26, P196, DOI 10.1016/0022-3468(91)90909-D; Bergqvist D, 1982, Br J Sports Med, V16, P76; Boggi U, 1998, SCAND J UROL NEPHROL, V32, P64; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Carmody DJ, 2005, MED J AUSTRALIA, V182, P561, DOI 10.5694/j.1326-5377.2005.tb06814.x; CASS AS, 1983, J TRAUMA, V23, P123, DOI 10.1097/00005373-198302000-00009; *COMM MED ASP SPOR, 1976, MED EV ATH GUID; DORSEN PJ, 1986, PHYSICIAN SPORTSMED, V14, P130, DOI 10.1080/00913847.1986.11709129; EMANUEL B, 1977, J TRAUMA, V17, P275, DOI 10.1097/00005373-197704000-00003; Geoghegan T, 2003, AM J ROENTGENOL, V181, P886, DOI 10.2214/ajr.181.3.1810886a; Ghosh A, 2000, J PEDIATR SURG, V35, P1766, DOI 10.1053/jpsu.2000.19247; HILDRETH TA, 1979, MINN MED, V62, P155; Itagaki MW, 2004, AM J SPORT MED, V32, P522, DOI 10.1177/0363546503258879; Johnson B, 2005, J UROLOGY, V174, P686, DOI 10.1097/01.ju.0000164719.91332.42; KRASNOW S, 1990, SPORTS ILLUSTRATED, V72, P14; KUZMAROV IW, 1981, J UROLOGY, V126, P648, DOI 10.1016/S0022-5347(17)54673-X; Lavard P., 1993, Scandinavian Journal of Medicine and Science in Sports, V3, P292; Lee S, 2004, ANZ J SURG, V74, P766, DOI 10.1111/j.1445-1433.2004.03137.x; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; LINKE CA, 1972, NEW YORK STATE J MED, V72, P2414; Machida T, 1999, INJURY, V30, P47, DOI 10.1016/S0020-1383(98)00210-1; Mador J A, 1996, J Emerg Nurs, V22, P358, DOI 10.1016/S0099-1767(96)80042-0; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1142, DOI 10.1001/jama.287.9.1142; Matlaga BR, 2002, J UROLOGY, V168, P672, DOI 10.1016/S0022-5347(05)64719-2; MCALEER IM, 1993, UROLOGY, V42, P563, DOI 10.1016/0090-4295(93)90274-E; McAleer IM, 2002, J UROLOGY, V168, P1805, DOI 10.1016/S0022-5347(05)64418-7; *NAT KIDN FDN, Q A LIV DON; Oliveria GHM, 2003, NEW ENGL J MED, V348, P129, DOI 10.1056/NEJMicm020037; PLISKIN M, 1988, J TRAUMA, V28, P520, DOI 10.1097/00005373-198804000-00018; Radmayr C, 2002, EUR UROL, V42, P297, DOI 10.1016/S0302-2838(02)00317-2; Richter E R, 2001, Urology, V58, P607, DOI 10.1016/S0090-4295(01)01314-0; RISSER WL, 1994, PEDIATRICS, V94, P757; SERUCA H, 1979, CAN J SURG, V22, P24; Sharp DS, 2002, J UROLOGY, V168, P1811, DOI 10.1016/S0022-5347(05)64420-5; Smith M, 2003, AM J ROENTGENOL, V180, P504, DOI 10.2214/ajr.180.2.1800504; SPARNON AL, 1986, J PEDIATR SURG, V21, P118, DOI 10.1016/S0022-3468(86)80061-6; Tator CH, 2004, CAN J NEUROL SCI, V31, P460, DOI 10.1017/S0317167100003632; Terrell T, 1997, PHYSICIAN SPORTSMED, V25, P75, DOI 10.3810/psm.1997.11.1442; Vincent GM, 2000, PHYSICIAN SPORTSMED, V28, P31, DOI 10.3810/psm.2000.11.1285; Waicus KM, 1999, CLIN J SPORT MED, V9, P236, DOI 10.1097/00042752-199910000-00011; Wan J, 2003, J UROLOGY, V170, P1525, DOI 10.1097/01.ju.0000084430.96658.05; Wan J, 2003, J UROLOGY, V170, P1528, DOI 10.1097/01.ju.0000083999.16060.ff; Wexler RK, 2003, PHYSICIAN SPORTSMED, V31, P43, DOI 10.3810/psm.2003.02.198; WICHMANN S, 1992, PHYSICIAN SPORTSMED, V20, P176, DOI 10.1080/00913847.1992.11947420; WOODWARD A, 1982, AUST NZ J SURG, V52, P66, DOI 10.1111/j.1445-2197.1982.tb05290.x; Xiang H, 2004, INJURY PREV, V10, P99, DOI 10.1136/ip.2003.004655	50	26	26	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2006	118	3					1019	1027		10.1542/peds.2006-0663			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	090NX	WOS:000240959100020	16950993				2022-02-06	
J	Pitel, AL; Beaunieux, H; Lebaron, N; Joyeux, F; Desgranges, B; Eustache, F				Pitel, Anne Lise; Beaunieux, Helene; Lebaron, Nathalie; Joyeux, Francoise; Desgranges, Beatrice; Eustache, Francis			Two case studies in the application of errorless learning techniques in memory impaired patients with additional executive deficits	BRAIN INJURY			English	Article						errorless learning; semantic learning; cognitive procedural learning; executive functions; episodic memory	HERPES-SIMPLEX ENCEPHALITIS; VANISHING CUES; AMNESIC PATIENT; IMPLICIT MEMORY; BRAIN INJURY; REHABILITATION; ACQUISITION; PEOPLE; ASSOCIATIONS; INDIVIDUALS	Primary objective: The purpose of the present study was to examine in what extent errorless learning can be applied to amnesic patients with additional executive dysfunction. Research design: Two case studies were used in which two patients with severe closed head-injury were compared according to their different neuropsychological profiles. Methods and procedures: Patients were taught complex semantic information about their therapists and cognitive procedures needed to programme an electronic organizer. Main outcomes and results: Both semantic and procedural results suggest that the errorless method can be very helpful for teaching complex new knowledge to amnesic patients with mild executive impairment, whereas the presence of a dysexecutive syndrome may hamper the success of this form of memory rehabilitation. Conclusions: The present study puts forward that executive deficits should be taken into account when neuropsychologists are planning to use errorless techniques.	Univ Caen, Unite EO219, INSERM, EPHE, F-14033 Caen, France; Ctr Hosp, Serv Reeducat & Readaptat Neurol, Aunay Sur Odon, France		Eustache, F (corresponding author), Univ Caen, E0218, INSERM, EPHE,Lab Neuropsychol,CHU Cote Nacre, F-14033 Caen, France.	neuropsycho@chu-caen.fr	Desgranges, Beatrice/L-7739-2015; Pitel, Anne Lise/L-9693-2015; DESGRANGES, BEATRICE/AAK-4756-2021; Eustache, Francis/J-9465-2015; Helene, Beaunieux/G-3751-2010	DESGRANGES, BEATRICE/0000-0002-3657-9996; Eustache, Francis/0000-0003-4460-8686; PITEL, Anne Lise/0000-0001-8573-9506; BEAUNIEUX, HELENE/0000-0003-1354-6558			Andrewes D, 1999, NEUROPSYCHOL REHABIL, V9, P77, DOI 10.1080/713755591; BACKMAN L, 1992, PSYCHOL BULL, V112, P259, DOI 10.1037/0033-2909.112.2.259; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; BUTTERS N, 1985, NEUROPSYCHOLOGIA, V23, P729, DOI 10.1016/0028-3932(85)90080-6; CARDEBAT D, 1990, ACTA NEUROL BELG, V90, P207; DAMASIO AR, 1995, ANN NY ACAD SCI, V15, P251; Deltour J.J., 1998, ECHELLE VOCABULAIRE; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; GLISKY EL, 1992, NEUROPSYCHOLOGIA, V30, P899, DOI 10.1016/0028-3932(92)90034-J; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; Guillery-Girard B, 2004, NEUROREPORT, V15, P377, DOI 10.1097/00001756-200402090-00033; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hunkin NM, 1998, NEUROPSYCHOLOGIA, V36, P25, DOI 10.1016/S0028-3932(97)00106-1; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P1255, DOI 10.1016/0028-3932(95)00061-7; Intons-Peterson M.J., 1992, MEMORY IMPROVEMENT I, P101; Kallosh R, 2000, J HIGH ENERGY PHYS; Kapur N, 2004, NEUROPSYCHOL REHABIL, V14, P41, DOI 10.1080/09602010343000138; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Komatsu S, 2000, NEUROPSYCHOL REHABIL, V10, P113, DOI 10.1080/096020100389200; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; McKenna P, 2002, CORTEX, V38, P37, DOI 10.1016/S0010-9452(08)70637-3; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Parkin AJ, 1998, COGNITIVE NEUROPSYCH, V15, P361, DOI 10.1080/026432998381131; Riley GA, 2004, NEUROPSYCHOL REHABIL, V14, P257, DOI 10.1080/09602010343000057; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; THOENE AIT, 1995, J INT NEUROPSYCH SOC, V1, P20; TULVING E, 1991, J EXP PSYCHOL LEARN, V17, P595, DOI 10.1037/0278-7393.17.4.595; VANDERLINDEN M, 1994, CORTEX, V30, P305, DOI 10.1016/S0010-9452(13)80201-8; VANDERLINDEN M, 1995, BROKEN MEMORIES NEUR, P54; Verfaellie M, 1995, NEUROCASE, V1, P291; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; WILSON BA, 1989, CORTEX, V25, P115, DOI 10.1016/S0010-9452(89)80011-5; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Winter WE, 2001, BRAIN COGNITION, V45, P79, DOI 10.1006/brcg.2000.1257; YEUDALL LT, 1987, J CLIN PSYCHOL, V43, P346, DOI 10.1002/1097-4679(198705)43:3<346::AID-JCLP2270430308>3.0.CO;2-Q	41	26	26	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2006	20	10					1099	1110		10.1080/02699050600909961			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	093FA	WOS:000241152100013	17060144				2022-02-06	
J	Bayly, PV; Dikranian, KT; Black, EE; Young, C; Qin, YQ; Labruyere, J; Olney, JW				Bayly, Philip V.; Dikranian, Krikor T.; Black, Erin E.; Young, Chainllie; Qin, Yue- Qin; Labruyere, Joann; Olney, John W.			Spatiotemporal evolution of apoptotic neurodegeneration following traumatic injury to the developing rat brain	BRAIN RESEARCH			English	Article						brain development; apoptosis; axonal injury; biomechanic; caspase-3	ANTERIOR THALAMIC NUCLEI; INFLICTED HEAD-INJURY; FUNCTIONAL RECOVERY; SPATIAL MEMORY; AXONAL INJURY; CELL-DEATH; LESIONS; MODEL; NEUROPATHOLOGY; DEGENERATION	Closed head injury to the developing rat brain causes an acute excitotoxic lesion and axonal disruption at the impact site followed by a delayed pattern of apoptotic damage at various distant sites. Using an electromagnetic impact device to deliver a precisely controlled degree of mechanical deformation to the P7 infant rat skull, we studied the distribution of distant apoptotic lesions and the sequence and time course with which these lesions evolve following relatively mild closed head injury. The first major wave of apoptotic neurodegeneration occurred at 8 h postimpact in the retrosplenial cortex and pre- and parasubiculum. The next major wave occurred in the 16- to 24-h interval and was localized to the anterior thalamic nuclei. A third wave was detected at 36 to 48 h in the mammillary nuclei. We propose that the first and second waves were triggered by injury to a specific fiber tract, the corpus callosum/cingulum bundle that conveys reciprocal connections between the anterior thalamic nuclei and retrosplenial/pre- and parasubicular neurons. This fiber tract passes through a zone of maximum mechanical strain, as measured by tagged MRI. The third wave affecting mammillary neurons occurred because the principal synaptic targets of these neurons are the anterior thalamic neurons that were destroyed in the second wave of degeneration. Prevention of these apoptotic waves of brain damage is a realistic goal in view of the long delay between the impact event and onset of apoptotic degeneration. (c) 2006 Elsevier B.V. All rights reserved.	Washington Univ, St Louis, MO 63130 USA; Washington Univ, St Louis, MO 63130 USA		Bayly, PV (corresponding author), Washington Univ, St Louis, MO 63130 USA.	pvb@me.wustl.edu		Bayly, Philip/0000-0003-4303-0704	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD037100, R37HD037100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS045237] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 37100, R37 HD037100, R01 HD037100] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS045237, R21 NS045237-01A1, R21 NS045237-02, NS 045237] Funding Source: Medline		Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; AGGLETON JP, 1995, BEHAV BRAIN RES, V68, P91, DOI 10.1016/0166-4328(94)00163-A; Aggleton JP, 1996, BEHAV BRAIN RES, V81, P189, DOI 10.1016/S0166-4328(96)89080-2; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; Dikranian K, 2001, NEUROBIOL DIS, V8, P359, DOI 10.1006/nbdi.2001.0411; Fox S, 1998, INFECT MED, V15, P8; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAZEM A, 1995, BEHAV BRAIN RES, V67, P51, DOI 10.1016/0166-4328(94)00103-M; Mitchell AS, 2002, J NEUROSCI, V22, P1922, DOI 10.1523/JNEUROSCI.22-05-01922.2002; Olney JW, 2002, BRAIN PATHOL, V12, P488, DOI 10.1111/j.1750-3639.2002.tb00467.x; Olney JW, 2002, NEUROBIOL DIS, V9, P205, DOI 10.1006/nbdi.2001.0475; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; PRICE JL, 1995, RAT NERVOUS SYSTEM; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; RINK A, 1995, AM J PATHOL, V147, P1575; SHIBATA H, 1993, J COMP NEUROL, V330, P533, DOI 10.1002/cne.903300409; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; SZIKLAS V, 1993, EUR J NEUROSCI, V5, P525, DOI 10.1111/j.1460-9568.1993.tb00518.x; van Groen T, 2002, BEHAV BRAIN RES, V132, P19, DOI 10.1016/S0166-4328(01)00390-4; Wozniak DF, 2004, NEUROBIOL DIS, V17, P403, DOI 10.1016/j.nbd.2004.08.006; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Young CL, 2004, CURR MOL MED, V4, P77, DOI 10.2174/1566524043479158	34	26	27	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 30	2006	1107						70	81		10.1016/j.brainres.2006.05.102			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	083TN	WOS:000240481200007	16822489	Green Accepted			2022-02-06	
J	Ito, Y; Oh-Hashi, K; Kiuchi, K; Hirata, Y				Ito, Yoshimasa; Oh-hashi, Kentaro; Kiuchi, Kazutoshi; Hirata, Yoko			p44/42 MAP kinase and c-Jun N-terminal kinase contribute to the up-regulation of caspase-3 in manganese-induced apoptosis in PC12 cells	BRAIN RESEARCH			English	Article						caspase-3; JNK; MAPK; manganese; rotenone	PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; JNK PATHWAY; HL-60 CELLS; INDUCTION; ACTIVATION; DEATH; INHIBITION; METABOLISM; PROTEASES	Caspase-3 (32 kDa) is one of the primary protease executioners of apoptosis and is activated by intra-chain proteolytic cleavage, which generates a large subunit (17 kDa) and a small subunit (12 kDa). Typically, after apoptotic stimuli, the level of cleaved caspase-3 increases while that of caspase-3 decreases. It has been shown that caspase-3 mRNA levels increase in cortex following traumatic brain injury or focal ischemia. In the present study, we demonstrate that both caspase-3 mRNA and protein increase in apoptotic PC12 cells following exposure to manganese which strongly induces caspase-3 cleavage. Up-regulation of caspase-3 protein was evident in manganese-treated PC12 cells and was moderate in cisplatin-, rotenone- and A23187-treated cells but was not observed in serum deprivation-, anisomycin-, camptothecin-, cycloheximide- or staurosporine-treated cells in which all treatments induced extensive DNA fragmentation. Manganese-induced up-regulation of caspase-3 mRNA was partially attenuated by the pretreatment with the MEK inhibitor U0126, but not with the c-Jun N-terminal kinase (INK) inhibitor SP600125. In contrast, the increase in caspase-3 protein was suppressed by both U0126 and SP600125. These results suggest that p44/42 MAPK contributes to the up-regulation of caspase-3 mRNA and the JNK pathway regulates caspase-3 protein levels posttranslationally in manganese-induced apoptosis in PC12 cells. (c) 2006 Elsevier B.V. All rights reserved.	Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan		Hirata, Y (corresponding author), Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan.	yoko@biomol.gifu-u.ac.jp	Hirata, Yoko/L-3142-2019; Hirata, Yoko/AAG-6798-2020	Hirata, Yoko/0000-0002-7081-4937; 			BARBEAU A, 1984, NEUROTOXICOLOGY, V5, P13; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BROUILLET EP, 1993, EXP NEUROL, V120, P89, DOI 10.1006/exnr.1993.1042; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Chen J, 1998, J NEUROSCI, V18, P4914; COOK DG, 1974, ARCH NEUROL-CHICAGO, V30, P59, DOI 10.1001/archneur.1974.00490310061010; Cotter T G, 1992, Semin Immunol, V4, P399; COTZIAS GC, 1971, ANNU REV MED, V22, P305, DOI 10.1146/annurev.me.22.020171.001513; Desole MS, 1996, NEUROSCI LETT, V209, P193, DOI 10.1016/0304-3940(96)12645-8; Dodel RC, 1998, NEUROSCIENCE, V86, P701, DOI 10.1016/S0306-4522(98)00154-7; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; HART J, 1994, MICROCONTAMINATION, V12, P63; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hirata Y, 2004, BRAIN RES, V1021, P241, DOI 10.1016/j.brainres.2004.06.064; Hirata Y, 2002, NEUROTOXICOL TERATOL, V24, P639, DOI 10.1016/S0892-0362(02)00215-5; Hirata Y, 1998, J NEUROCHEM, V71, P1607; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; NEFF NH, 1969, EXPERIENTIA, V25, P1140, DOI 10.1007/BF01900234; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; PROHASKA JR, 1987, PHYSIOL REV, V67, P858, DOI 10.1152/physrev.1987.67.3.858; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Scheid MP, 1999, BLOOD, V93, P217, DOI 10.1182/blood.V93.1.217.401k16_217_225; Spooren WPJM, 1998, NEUROSCIENCE, V85, P649; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tatton NA, 1997, NEUROSCIENCE, V77, P1037, DOI 10.1016/S0306-4522(96)00545-3; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	31	26	27	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 12	2006	1099						1	7		10.1016/j.brainres.2006.03.126			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	073HI	WOS:000239733200001	16787641				2022-02-06	
J	Gilworth, G; Carey, A; Eyres, S; Sloan, J; Rainford, B; Bodenham, D; Neumann, V; Tennant, A				Gilworth, Gill; Carey, Amy; Eyres, Sophie; Sloan, John; Rainford, Bruce; Bodenham, Debra; Neumann, Vera; Tennant, Alan			Screening for job loss: Development of a work instability scale for traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; work instability	MODERATE HEAD-INJURY; RETURN; EMPLOYMENT; MILD; STABILITY	Objective: The objective of this study was to explore the concept of work instability (a mis-match between an individual's functional and cognitive abilities and the demands of their job) following traumatic brain injury (TBI) and develop a work instability scale specific to this population. Method: Work instability (WI) following TBI was explored through qualitative interviews which were then used to generate items for a work instability scale (WIS). Rasch analysis was used to examine the scaling properties of the TBI-WIS which was then validated against a gold standard of expert vocational assessment by occupational psychologists. Results and conclusion: The resulting measure is a 36 item, self-administered scale which can be scored in three bands indicating low, medium and high risk of job retention problems. The scale meets modern psychometric requirements for measurement and presents an opportunity in routine clinical practice to take positive action to prevent job loss.	Univ Leeds, Acad Unit Musculoskeletal Med & Rehabil Med, Leeds LS2 9LN, W Yorkshire, England; Countess Chester NHS Fdn Trust, Chester, Cheshire, England; Job Ctr Plus Disabil Serv, Dept Work Psychol, Leeds, W Yorkshire, England		Gilworth, G (corresponding author), Univ Leeds, Acad Unit Musculoskeletal Med & Rehabil Med, 36 Clarendon Rd, Leeds LS2 9LN, W Yorkshire, England.	gilworths@aol.com					ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814; ANDRICH D, 2003, RUMM 2020; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; *BRIT SOC REH MED, 2003, REH FOLL ACQ BRAN IN; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; CHAMBERLAIN MA, 1995, TRAUMATIC BRAIN INJU; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; ELASHOFF JD, 2000, USER NQUERY ADVISOR; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Gilworth G, 2003, ARTHRIT RHEUM-ARTHR, V49, P349, DOI 10.1002/art.11114; Gilworth G, 2001, RHEUMATOLOGY, V40, P1206, DOI 10.1093/rheumatology/40.11.1206; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; GUTTMAN L, 1950, MEASUREMENT PREDICTI, V0004; Hobart J, 2003, J NEUROL NEUROSUR PS, V74, P22; Holland PW, 1993, DIFFERENTIAL ITEM FU; *HOUS COMM, 2001, HEAD INJ REH; JONG AD, 1987, J PSYCHIAT RES, V21, P137; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Linacre J M, 1999, J Outcome Meas, V3, P103; Linacre JM, 1994, RASCH MEASURE T, V7, P28; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Possl O, 2001, BRAIN INJURY, V15, P15; Rasch G., 1960, PROBABILISTIC MODELS; Richards L., 1999, USING NVIVO QUALITAT; Smith Everett V Jr, 2002, J Appl Meas, V3, P205; Smith R M, 2000, J Appl Meas, V1, P199; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Tennant A, 2004, VALUE HEALTH, V7, pS22, DOI 10.1111/j.1524-4733.2004.7s106.x; TENNANT A, 1991, J EPIDEMIOL COMMUN H, V45, P312, DOI 10.1136/jech.45.4.312; Tennant A, 2004, MED CARE, V42, P37, DOI 10.1097/01.mlr.0000103529.63132.77; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154	35	26	26	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					835	843		10.1080/02699050600832221			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300006	17060150				2022-02-06	
J	Yard, EE; Comstock, RD				Yard, Ellen Elizabeth; Comstock, R. Dawn			Injuries sustained by rugby players presenting to United States emergency departments, 1978 through 2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; epidemiology	UNION FOOTBALL; PROTECTIVE EQUIPMENT; PERFORMANCE PROJECT; EPIDEMIOLOGY; COHORT; PREVENTION; HEADGEAR; LESSONS	Context: Although the United States has nearly 60 000 rugby players, to date no nationally representative rugby injury studies have been conducted. Objective: To describe rugby players with injuries presenting to a representative sample of US emergency departments from 1978 through 2004. Design: Retrospective study. Setting: US Consumer Products Safety Commission's National Electronic Injury Surveillance System. Patients or Other Participants: Rugby players presenting to emergency departments in participating hospitals from October 1, 1978, through December 31, 2004. Main Outcome Measure(s): We reviewed all rugby players with injuries captured by the National Electronic Injury Surveillance System and categorized them by sex, age, injury site, and injury diagnosis. Results: An estimated 236539 rugby players presented to US emergency departments from 1978 through 2004. Injured athletes tended to be male (87.2%) and older than 18 years of age (86.0%). The face (20.5%), shoulder (14.1%), head (11.5%), and ankle (9.1%) were the most frequently injured sites. Strain/sprain (24.3%), laceration (22.1%), fracture (18.7%), and contusion/abrasion (16.6%) were the most common diagnoses. Males presented with more face injuries (injury proportion ratio [IPR] = 2.05, 95% confidence interval [CI] = 1.54-2.72, P < .001) and more lacerations (IPR = 4.23, 95% Cl = 2.87-6.22, P < .001) and dislocations (IPR = 2.17, 95% Cl 1.51-3.13, P < .001). Females presented with more knee injuries (IPR = 1.67, 95% CI = 1.36-2.06, P < .001) and more contusions/abrasions (IPR = 1.48, 95% CI = 1.14-1.92, P < .001) and strains/sprains (IPR = 1.39, 95% = CI 1.16-1.67, P < .001). Those 18 years of age or younger presented with more concussions (IPR = 1.62, 95% CI = 1.06-2.50, P < .001), while those over 18 presented with more lacerations (IPR = 1.83, 95% CI = 1.30-2.57, P < .001). In males, fractures were more common among those. 18 years of age or younger (IPR 1.47, 95% CI = 1.24-1.75 P < .001). Conclusions: Rugby injury patterns in the United States differed by, age and sex. Understanding such patterns should assist certified athletic trainers in developing targeted preventive interventions.	Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA		Yard, EE (corresponding author), Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	YardE@ccri.net					Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; Carson JD, 1999, CLIN J SPORT MED, V9, P75, DOI 10.1097/00042752-199904000-00006; Chalmers DJ, 2004, J SCI MED SPORT, V7, P74, DOI 10.1016/S1440-2440(04)80046-X; CHAPMAN PJ, 1989, AM J SPORT MED, V17, P690, DOI 10.1177/036354658901700518; Comstock RD, 2005, CLIN J SPORT MED, V15, P239, DOI 10.1097/01.jsm.0000171288.37293.54; Comstock RD, 2005, J SCI MED SPORT, V8, P101, DOI 10.1016/S1440-2440(05)80030-1; DAVIES JE, 1978, BRIT MED J, V2, P1759, DOI 10.1136/bmj.2.6154.1759; Dietzen C J, 1999, Phys Med Rehabil Clin N Am, V10, P159; Finch C, 1998, BRIT J SPORT MED, V32, P220, DOI 10.1136/bjsm.32.3.220; Gabbett TJ, 2005, J SCI MED SPORT, V8, P111, DOI 10.1016/S1440-2440(05)80031-3; Haylen PT, 2004, MED J AUSTRALIA, V181, P48, DOI 10.5694/j.1326-5377.2004.tb06161.x; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; INGLIS GS, 1981, NEW ZEAL MED J, V94, P349; *INT RUGB BOARD, 2005, MEMB UN US RUGB; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; Levy AS, 1997, AM J SPORT MED, V25, P360, DOI 10.1177/036354659702500315; LEWIS E, 1994, SPORTCARE J, V1, P8; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; Marshall SW, 2001, MED SCI SPORT EXER, V33, P2131, DOI 10.1097/00005768-200112000-00024; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; Quarrie KL, 2005, BRIT J SPORT MED, V39, P650, DOI 10.1136/bjsm.2004.016022; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; ROUX CE, 1987, S AFR MED J, V71, P307; RYAN JM, 1992, IRISH MED J, V85, P72; *US CONS PROD SAF, 2005, NEISS SAMPL DES IMPL; *US CONS PROD SAF, 2006, NEISS COD MAN; *US RUGB, 2005, US RUGB GAINS MULT D; Wetzler MJ, 1998, AM J SPORT MED, V26, P177, DOI 10.1177/03635465980260020501	30	26	27	0	6	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2006	41	3					325	331					7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	082ON	WOS:000240396300017	17043702				2022-02-06	
J	Dandona, R; Kumar, GA; Raj, TS; Dandona, L				Dandona, R.; Kumar, G. A.; Raj, T. S.; Dandona, L.			Patterns of road traffic injuries in a vulnerable population in Hyderabad, India	INJURY PREVENTION			English	Article							TRAUMATIC BRAIN-INJURIES; DEVELOPING-COUNTRIES; RECALL; RATES	Objective: To describe patterns of road traffic injuries (RTI) in a vulnerable population-pedestrians and users of motorized two-wheeled vehicles (MTVs)-in Hyderabad, India. Methods: 4019 pedestrians and 4183 MTV drivers provided information on the most recent road traffic crash (RTC) irrespective of the level of injury in the last one year for 17 454 and 17 242 household members, respectively. Crashes in which any household member was involved as a pedestrian or MTV user were analysed. Results: Involvement in an RTC as a pedestrian or MTV user was reported for 1513 (4.4%, 95% CI 4.2 to 4.6%) people in the last one year. In these crashes, the person involved was an MTV user in 1264 (83.5%), aged 21-40 years in 973 (64.3%), and male in 1202 (79.4%). Six (0.4%) people died in RTCs and the cause was collision with a vehicle/person in 1133 (75%) crashes. Among the 1306 people who were injured and survived, 174 (13.3%) were treated as inpatients, 38 (2.9%) could not return fully to routine daily activities, 630 (48.2%) took leave from their regular occupation, and 13 (1%) lost their jobs following injury. Using a three month recall period, the annual incidence per 100 000 population of RTC as a pedestrian or MTV user was 2288 and of non-fatal RTI was 1931, and that of fatal RTI using one year recall period was 17.3 in this population. Conclusions: These findings on how RTI are caused, their type, and outcomes in pedestrians and MTV users can assist in identifying interventions to improve road safety for this vulnerable population in India, and can also be useful for monitoring the effectiveness of such interventions.	Adm Staff Coll India, Hlth Studies Area, Ctr Human Dev, Hyderabad 500082, Andhra Pradesh, India		Dandona, R (corresponding author), Adm Staff Coll India, Hlth Studies Area, Ctr Human Dev, Raj Bhavan Rd, Hyderabad 500082, Andhra Pradesh, India.	rakhi@asci.org.in		Dandona, Rakhi/0000-0003-0926-788X; Thout, Sudhir raj/0000-0003-0383-4206			Aare Magnus, 2003, Inj Control Saf Promot, V10, P131, DOI 10.1076/icsp.10.3.131.14556; Dandona L, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-55; Dandona R, 2004, NATL MED J INDIA, V17, P74; DANDONA R, IN PRESS J SAFETY RE; Dandona Rakhi, 2005, Int J Inj Contr Saf Promot, V12, P167, DOI 10.1080/17457300500088840; Evans Tim, 2003, Inj Control Saf Promot, V10, P11, DOI 10.1076/icsp.10.1.11.14117; Garg N, 2006, SCAND J PUBLIC HEALT, V34, P100, DOI 10.1080/14034940510032149; Ghaffar A, 2004, PUBLIC HEALTH, V118, P211, DOI 10.1016/j.puhe.2003.05.003; GHAFFAR A, 2004, J COLL PHYS SURG PAK, V14, P742; *GOV ANDHR PRAD, CAT WIS VEH STRENGTH; *GOV IND, 2001, POP TOT IND CENS IND; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Hyder AA, 2003, LANCET, V362, P2034, DOI 10.1016/S0140-6736(03)15145-8; Mayou R, 2003, INJURY, V34, P197, DOI 10.1016/S0020-1383(02)00285-1; *MIN ROAD TRANSP H, ROAD ACC IND 1970 20; Mock C, 1999, INT J EPIDEMIOL, V28, P750, DOI 10.1093/ije/28.4.750; Mohan D, 2000, IMECHE CONF TRANS, V2000, P155; Mohan Dinesh, 2004, J Coll Physicians Surg Pak, V14, P746; MOHAN Dinesh, 2002, J TRANSPORT INFRASTR, V9, P79; Moshiro C, 2005, INJURY PREV, V11, P48, DOI 10.1136/ip.2004.005645; Nantulya Vinand M, 2003, Inj Control Saf Promot, V10, P3, DOI 10.1076/icsp.10.1.3.14109; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; Odero W, 1997, TROP MED INT HEALTH, V2, P445, DOI 10.1046/j.1365-3156.1997.d01-296.x; Odero Wilson, 2003, Inj Control Saf Promot, V10, P53, DOI 10.1076/icsp.10.1.53.14103; OJHA AK, 2002, ROAD ACCIDENTS DELHI; Peden M., 2004, WORLD REPORT ROAD TR; Peden M., 2002, INJURY CHART BOOK GR; Radin U, 2002, P 2 WORLD ENG C SAR, P93; Servadei F, 2003, INJURY PREV, V9, P257, DOI 10.1136/ip.9.3.257; Suriyawongpaisal Paibul, 2003, Inj Control Saf Promot, V10, P95, DOI 10.1076/icsp.10.1.95.14110; Wang Sheng-Yong, 2003, Inj Control Saf Promot, V10, P83, DOI 10.1076/icsp.10.1.83.14105; *WHO, 2002, GLOB BURD DIS PROJ V; Yang LF, 2003, LETT PEPT SCI, V10, P89, DOI 10.1007/BF02443647	33	26	27	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	JUN	2006	12	3					183	188		10.1136/ip.2005.010728			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	049PX	WOS:000238029700012	16751450	Green Published			2022-02-06	
J	Barbre, AB; Hoane, MR				Barbre, Adrianne B.; Hoane, Michael R.			Magnesium and riboflavin combination therapy following cortical contusion injury in the rat	BRAIN RESEARCH BULLETIN			English	Article						behavior; B-2; MgCl2; treatment; neuroprotection; sensorimotor; TBI	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; MILD HYPOTHERMIA; DRUG THERAPY; FACILITATE RECOVERY; SENSORIMOTOR CORTEX; OXIDATIVE INJURY; NMDA ANTAGONISTS; PROTECT TISSUES; REDUCES EDEMA	Previous research has shown that magnesium chloride (MgCl2) and riboflavin (B-2) both significantly improve functional recovery when administered shortly after frontal cortical contusion injury (M). The purpose of the present study was to examine the ability of combination treatments of MgCl2 and B-2 to improve functional outcome following unilateral CCI. One hour post-injury, rats were administered MgCl2 (1.0 mmol/kg), B-2 (7.5 mg/kg), MgCl2 + B-2 (1 mmol/kg + 7.5 mg/kg), 1/2 MgCl2 + 1/2 B-2 (0.5 mmol/kg and 3.75 mg/kg), or saline. Two days following CCI rats were tested on a battery of sensorimotor (vibrissae -> forelimb placing and tactile removal test) and motor (staircase test). A regimen of MgCl2 + B-2 significantly reduced the initial impairment and facilitated the rate of recovery on the tactile removal test and facilitated the rate of recovery on the forelimb placing test. The half-dose combination did not significantly improve functional recovery on the tactile removal test compared to the individual treatments: however, it did improve performance on the forelimb placing test compared to saline treatment. Administration of MgCl2 improved performance on the placing and tactile removal tests on 2 post-operative days, as did treatment with B-2 on the tactile removal test. The results indicate that the full combination of MgCl2 + B-2 significantly improved functional recovery to a greater extent than the individual treatments or the low dose combination group on forelimb placing but not on tactile removal. These findings suggest that administration of M-Cl-2 + B-2 may provide better therapeutic action than individual treatments. (c) 2006 Elsevier Inc. All rights reserved.	So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA		Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Life Sci 2 MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 045647] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER		Aikawa J.K., 1981, MAGNESIUM ITS BIOL S, V1st ed.; Atlante A, 2001, FEBS LETT, V497, P1, DOI 10.1016/S0014-5793(01)02437-1; Bara M., 1984, MAGNESIUM, V3, P212; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; BARTH TM, 1990, STROKE, V21, P153; BETZ AL, 1994, ACTA NEUROCHIR, P314; CHRISTENSEN HN, 1993, NUTR REV, V51, P149; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; CROMBLEHOLME W, 1998, CURRENT MED TREATMEN, P731; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; GARFINKEL L, 1985, Magnesium, V4, P60; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; HALL ED, 1993, MOL CELLULAR APPROAC; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; HOANE MR, 2005, RESTOR NEUROL NEUROS, P1; HULTQUIST DE, 1993, AM J HEMATOL, V42, P13, DOI 10.1002/ajh.2830420105; Koroshetz WJ, 1996, TRENDS PHARMACOL SCI, V17, P227, DOI 10.1016/0165-6147(96)10020-1; Ksendzova GA, 2004, FREE RADICAL RES, V38, P1183, DOI 10.1080/10715760400016162; Lin YP, 2004, NEUROREPORT, V15, P2241, DOI 10.1097/00001756-200410050-00020; Lindner MD, 1999, BEHAV BRAIN RES, V102, P1, DOI 10.1016/S0166-4328(98)00160-0; MCDONALD JW, 1990, NEUROSCIENCE, V36, P589, DOI 10.1016/0306-4522(90)90002-L; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Napolitano A, 2000, NEUROL SCI, V21, pS981, DOI 10.1007/s100720070015; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; Schmid-Elsaesser R, 1999, NEUROSURGERY, V44, P163, DOI 10.1097/00006123-199901000-00100; Schmid-Elsaesser R, 1999, STROKE, V30, P1891, DOI 10.1161/01.STR.30.9.1891; Schmid-Elsaesser R, 1998, EXP BRAIN RES, V122, P121, DOI 10.1007/s002210050498; Schoenen J, 1998, NEUROLOGY, V50, P466, DOI 10.1212/WNL.50.2.466; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van den Heuvel Corinna, 2004, Clin Calcium, V14, P9; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; Zausinger S, 2003, STROKE, V34, P1526, DOI 10.1161/01.STR.0000070841.31224.29; [No title captured]	54	26	26	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	MAY 31	2006	69	6					639	646		10.1016/j.brainresbull.2006.03.009			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	051SF	WOS:000238180400007	16716831				2022-02-06	
J	Salehi-Had, H; Brandt, JD; Rosas, AJ; Rogers, KK				Salehi-Had, H; Brandt, JD; Rosas, AJ; Rogers, KK			Findings in older children with abusive head injury: Does shaken-child syndrome exist?	PEDIATRICS			English	Article						shaken-baby syndrome; child abuse; retinal hemorrhages	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; RETINAL HEMORRHAGE; OPHTHALMOLOGIC FINDINGS; SUBDURAL HEMATOMAS; ADULT SYNDROME; BABY SYNDROME; INFANTS	Shaken-baby syndrome (SBS) has been hypothesized to occur after shaking by an adult during the first 2 years of life. We wondered whether it is possible to achieve rotational forces sufficient to cause SBS-like injuries in children > 2 years of age. The present study describes cases of child abuse in older children who presented with the classic ophthalmologic and intracranial findings of SBS. In this case series, 4 cases of older children (2.5-7 years old; 11.8-22 kg) who died from abusive head injuries and who had diffuse retinal hemorrhages identified antemortem were selected for review. The cases were abstracted from hospital charts, records from autopsies, coroners' and district attorneys' offices, and court transcripts. In all 4 cases the history provided by the primary caregiver did not match the severity of the injuries. Three case subjects presented with patterned bruises. Multilayered retinal hemorrhages and acute subdural hematoma were observed in all 4 cases. At autopsy, diffuse axonal injury was evident in 3 of the 4 cases; all 4 cases had optic nerve sheath hemorrhages. None of the victims had skeletal fractures on radiologic examination or at autopsy. This case series demonstrates that it is possible to observe SBS-like retinal and central nervous system findings in the older and heavier child. Our findings underscore the need for providers to consider intentional shaking as a mechanism of injury in the evaluation of abusive head injury in older children.	Univ Calif Davis, Med Ctr, Dept Ophthalmol, Sacramento, CA 95817 USA; Univ Calif Davis, Childrens Hosp, Dept Pediat, Child & Adolescent Resource & Evaluat Diagnost &, Sacramento, CA 95817 USA		Rogers, KK (corresponding author), Univ Calif Davis, Dept Pediat, CAARE Diagnost & Treatment Ctr, 3300 Stockton Blvd, Sacramento, CA 95820 USA.	kristen.rogers@ucdmc.ucdavis.edu	Brandt, James D/H-8249-2016	Brandt, James D/0000-0003-4509-615X			Alexander R. C, 2001, CHILD ABUSE MED DIAG, P47; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; CAFFEY J, 1974, PEDIATRICS, V54, P396; Carrigan TD, 2000, J ACCID EMERG MED, V17, P138; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; *CDCP, 2005, WISQARS; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; CONRADI S, 1986, FORENSIC SCI INT, V30, P195, DOI 10.1016/0379-0738(86)90014-9; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; DIMAUIO V, 2001, FORENSIC PATHOLOGY, V27, P592; DUHAIME AC, 1992, PEDIATRICS, V90, P179; ELDER JE, 1991, J PAEDIATR CHILD H, V27, P286, DOI 10.1111/j.1440-1754.1991.tb02539.x; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; HOSOKAWA T, 1986, OPHTHALMOLOGICA, V192, P17, DOI 10.1159/000309606; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kivlin J D, 1999, Trans Am Ophthalmol Soc, V97, P545; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; LEVIN, 1998, AM ACAD OPHTHALMOL, V16, P1; Levin AV, 2002, NEUROSURG CLIN N AM, V13, P201, DOI 10.1016/S1042-3680(02)00004-9; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; MCCLAIN PW, 1993, PEDIATRICS, V91, P338; Mierisch RF, 2004, PEDIATR EMERG CARE, V20, P118, DOI 10.1097/01.pec.0000113883.10140.c2; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Pounder DJ, 1997, AM J FOREN MED PATH, V18, P321, DOI 10.1097/00000433-199712000-00001; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; *US DEP HHS, 2004, CHILD MALTR 2002	28	26	26	0	1	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAY	2006	117	5					E1039	E1044		10.1542/peds.2005-0811			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	038GO	WOS:000237207300025	16651283				2022-02-06	
J	Geddes-Klein, DM; Serbest, G; Mesfin, MN; Cohen, AS; Meaney, DF				Geddes-Klein, DM; Serbest, G; Mesfin, MN; Cohen, AS; Meaney, DF			Pharmacologically induced calcium oscillations protect neurons from increases in cytosolic calcium after trauma	JOURNAL OF NEUROCHEMISTRY			English	Article						calcium oscillations; NMDA; spectrin; traumatic brain injury	NMDA RECEPTOR SUBUNITS; D-ASPARTATE RECEPTORS; VIVO AXONAL INJURY; IN-VITRO MODEL; CORTICAL-NEURONS; MECHANICAL STRETCH; CA2+ OSCILLATIONS; GABA(A) RECEPTOR; ALPHA-ACTININ; BRAIN-INJURY	Increases in cytosolic calcium ([Ca2+](i)) following mechanical injury are often considered a major contributing factor to the cellular sequelae in traumatic brain injury (TBI). However, very little is known on how developmental changes may affect the calcium signaling in mechanically injured neurons. One key feature in the developing brain that may directly impact its sensitivity to stretch is the reduced inhibition which results in spontaneous [Ca2+](i) oscillations. In this study, we examined the mechanism of stretch-induced [Ca2+](i) transients in 18-days in vitro (DIV) neurons exhibiting bicuculline-induced [Ca2+](i) oscillations. We used an in vitro model of mechanical trauma to apply a defined uniaxial strain to cultured cortical neurons and used increases in [Ca2+](i) as a measure of the neuronal response to the stretch insult. We found that stretch-induced increases in [Ca2+](i) in 18-DIV neurons were inhibited by pretreatment with either the NMDA receptor antagonist, APV [D(-)-2-Amino-5-phosphonopentanoic acid], or by depolymerizing the actin cytoskeleton prior to stretch. Blocking synaptic NMDA receptors prior to stretch significantly attenuated most of the [Ca2+](i) transient. In comparison, cultures with pharmacologically induced [Ca2+](i) oscillations showed a substantially reduced [Ca2+](i) peak after stretch. We provide evidence showing that a contributing factor to this mechanical desensitization from induced [Ca2+](i) oscillations is the PKC-mediated uncoupling of NMDA receptors (NMDARs) from spectrin, an actin-associated protein, thereby rendering neurons insensitive to stretch. These results provide novel insights into how the [Ca2+](i) response to stretch is initiated, and how reduced inhibition - a feature of the developing brain - may affect the sensitivity of the immature brain to trauma.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Penn, Abramson Res Ctr, Div Neurol, Philadelphia, PA USA; Childrens Hosp Penn, Sch Med, Dept Pediat, Philadelphia, PA USA		Geddes-Klein, DM (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk, Philadelphia, PA 19104 USA.	dmgeddes@seas.upenn.edu		Meaney, David/0000-0002-0954-4122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045975-05, R01 NS045975, R01 NS 35712] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01 41699] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712, R01NS045975] Funding Source: NIH RePORTER		Bacci A, 1999, EUR J NEUROSCI, V11, P389, DOI 10.1046/j.1460-9568.1999.00440.x; Badea T, 2001, J NEUROBIOL, V48, P215, DOI 10.1002/neu.1052; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; *CDC, 1998, TRAUM BRAIN INJ UN S; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Furukawa Y, 2000, NEUROSCIENCE, V96, P385, DOI 10.1016/S0306-4522(99)00553-9; Garaschuk O, 2000, NAT NEUROSCI, V3, P452, DOI 10.1038/74823; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Khazipov R, 2004, EUR J NEUROSCI, V19, P590, DOI 10.1111/j.0953-816X.2003.03152.x; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krupp JJ, 1999, J NEUROSCI, V19, P1165; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Li H, 2002, EUR J NEUROSCI, V16, P2358, DOI 10.1046/j.1460-9568.2002.02419.x; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; Liljelund P, 2000, J NEUROSCI, V20, P7394; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Numakawa T, 2002, J BIOL CHEM, V277, P6520, DOI 10.1074/jbc.M109139200; Nunez L, 1996, EUR J NEUROSCI, V8, P192, DOI 10.1111/j.1460-9568.1996.tb01180.x; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; Opitz T, 2002, J NEUROPHYSIOL, V88, P2196, DOI 10.1152/jn.00316.2002; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; Passafaro M, 1999, NAT NEUROSCI, V2, P1063, DOI 10.1038/15990; Rao VLR, 2001, BRAIN RES, V911, P96; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; ROBINSON HPC, 1993, J NEUROPHYSIOL, V70, P1606, DOI 10.1152/jn.1993.70.4.1606; Samii A, 1999, J NEUROTRAUM, V16, P879, DOI 10.1089/neu.1999.16.879; Schulz TW, 2004, J NEUROSCI, V24, P8584, DOI 10.1523/JNEUROSCI.2100-04.2004; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Siniscalchi A, 2005, NEUROCHEM INT, V46, P117, DOI 10.1016/j.neuint.2004.08.001; Smith DH, 1999, J NEUROSCI, V19, P4263; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Tovar KR, 1999, J NEUROSCI, V19, P4180; Toyoda H, 2003, J NEUROPHYSIOL, V89, P1353, DOI 10.1152/jn.00721.2002; Tymianski M, 1996, NEUROSURGERY, V38, P1176; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Wang XS, 1997, BRAIN RES, V767, P239, DOI 10.1016/S0006-8993(97)00585-4; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Wenzel A, 1997, J NEUROCHEM, V68, P469; Williams ST, 2003, APOPTOSIS, V8, P353, DOI 10.1023/A:1024168901003; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	56	26	31	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2006	97	2					462	474		10.1111/j.1471-4159.2006.03761.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	026GU	WOS:000236328200015	16539664	Bronze			2022-02-06	
J	Ng, I; Lee, KK; Lim, JHG; Wong, HB; Yan, XY				Ng, I.; Lee, K-K.; Lim, J. H. G.; Wong, H-B.; Yan, X-Y.			Investigating gender differences in outcome following severe traumatic brain injury in a predominantly Asian population	BRITISH JOURNAL OF NEUROSURGERY			English	Article						epidemiology; gender difference; outcome; risk factor; TBI	MINOR HEAD-INJURY; SEX-RELATED DIFFERENCES; BLOOD-FLOW; LIPID-PEROXIDATION; MALE-RATS; PROGESTERONE; ESTROGEN; WOMEN; EPIDEMIOLOGY; PREDICTORS	The objective of this study was to investigate if there are possible gender differences in relation to outcome following closed severe traumatic brain injury (TBI) in a predominantly Asian population. A study was conducted using our prospectively maintained TBI database of 672 patients with severe TBI admitted into our neurosurgical intensive care unit. All patients were managed on a standardized protocol in accordance with the Guidelines to the management of severe traumatic brain injury. Glasgow Outcome Score was used to measure the outcome of patients 6 months postinjury. There were 525 males and 147 females, with the latter significantly older than their counterpart. Females had a significantly higher mortality and poorer outcome compared with males. However, this difference was no longer significant when variables ( presence of multiple injuries, postresuscitation pupil abnormalities and Glasgow Coma Score) are controlled for. However, both crude and adjusted odd ratios revealed that females aged 60 and below were significantly more likely to have a poorer outcome.	Natl Inst Neurosci, Dept Neurosurg, Acute Brain Injury Res Lab, Singapore 308433, Singapore; Natl Inst Neurosci, Dept Nursing Adm, Acute Brain Injury Res Lab, Singapore 308433, Singapore; Clin Trials & Epidemiol Res Unit, Singapore, Singapore		Ng, I (corresponding author), Natl Inst Neurosci, Dept Neurosurg, Acute Brain Injury Res Lab, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	ivan_ng@nni.com.sg					Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; APFEL RJ, 1982, PSYCHOTHER PSYCHOSOM, V37, P106, DOI 10.1159/000287560; Asthana S, 2001, NEUROLOGY, V57, P605, DOI 10.1212/WNL.57.4.605; Balestreri M, 2003, J NEUROSURG, V99, P616; Bayir H, 2001, CRIT CARE MED, V29, pA5; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Czlonkowska A, 2005, CURR PHARM DESIGN, V11, P1017, DOI 10.2174/1381612053381693; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EDNA TH, 1987, ACTA NEUROCHIR, V85, P40, DOI 10.1007/BF01402368; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Farlow MR, 1998, NEUROLOGY, V50, P669, DOI 10.1212/WNL.50.3.669; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gur RC, 1999, J NEUROSCI, V19, P4065; Gur RC, 2002, CEREB CORTEX, V12, P998, DOI 10.1093/cercor/12.9.998; GUR RE, 1990, SCHIZOPHRENIA BULL, V16, P247, DOI 10.1093/schbul/16.2.247; Holroyd-Leduc JM, 2000, STROKE, V31, P1833, DOI 10.1161/01.STR.31.8.1833; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JENNETT B, 1975, LANCET, V1, P480; Jensen O K, 2001, Ugeskr Laeger, V163, P5029; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KLAUBER MR, 1981, NEUROSURGERY, V9, P236, DOI 10.1227/00006123-198109000-00003; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 2000, NEUROSURG FOCUS, V8; Krause JS, 2004, ARCH PHYS MED REHAB, V85, P355, DOI 10.1016/S0003-9993(03)00615-4; Lanza GA, 2004, HEART, V90, P595, DOI 10.1136/hrt.2003.026476; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Morrell MJ, 1999, NEUROLOGY, V53, pS42; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; Payami H, 1996, AM J HUM GENET, V58, P803; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; SHIBASAKI H, 1976, NEUROLOGY, V26, P821, DOI 10.1212/WNL.26.9.821; Silberstein SD, 2000, CEPHALALGIA, V20, P148, DOI 10.1046/j.1468-2982.2000.00034.x; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Stachenfeld NS, 1999, J APPL PHYSIOL, V86, P1092, DOI 10.1152/jappl.1999.86.3.1092; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Ward E, 2004, CA-CANCER J CLIN, V54, P78, DOI 10.3322/canjclin.54.2.78; Warkentin S, 1992, Clin Auton Res, V2, P119, DOI 10.1007/BF01819667	51	26	27	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	APR	2006	20	2					73	78		10.1080/02688690600682259			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	050NF	WOS:000238094300001	16753620				2022-02-06	
J	Zohar, O; Getslev, V; Miller, AL; Schreiber, S; Pick, CG				Zohar, O; Getslev, V; Miller, AL; Schreiber, S; Pick, CG			Morphine protects for head trauma induced cognitive deficits in mice	NEUROSCIENCE LETTERS			English	Article						minimal traumatic brain injury; morphine; Morris water maze; mice	EXPERIMENTAL BRAIN INJURY; RAT; SCOPOLAMINE; IMPAIRMENT; U-50488H; UPDATE	Victims of minor traumatic brain injury (mTBI) can show long lasting cognitive, emotional and concentration difficulties, amnesia, depression, apathy and anxiety. The symptoms are generally known as a post-concussive syndrome without clear morphological brain defects. Endogenous opiates are released after impact to the brain, suggesting they may play a role in TBI pathophysiology. Furthermore, the administration of opiates to the brain of injured animals has been shown to affect the injury, induce cellular changes and also have protective qualities for neurological impairments. Here, we examined the protective properties of the opiate morphine on cognitive performances following minimal brain injury in mice. For this purpose, we have used our non-invasive closed-head weight drop model in mice, which closely mimics real life mTBI and examined mice performance in the Morris water maze. Our procedure did not cause visible structural or neurological damage to the mice. A single morphine injection administrated immediately after the induction of minimal TBI protected the injured mice from cognitive impairment, checked 30, 60 and 90 days post injury. However, mice injected with morphine that were examined 7 days after the injury did not show better performance than the saline injected mice. Our results indicate that morphine has long but not short-term effects on the cognitive ability of brain-injured mice. Although the exact nature of opioid neuroprotection is still unknown, its elucidation may lead to the much-needed treatment for traumatic brain injury. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; Johns Hopkins Univ, Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA; Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel		Pick, CG (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il	Schreiber, Shaul/E-5821-2010; Pick, Chaim/D-4789-2009	Schreiber, Shaul/0000-0002-2189-0693; 			FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAYES RL, 1990, J NEUROSURG, V72, P251; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HUDSON CJ, 1991, BRAIN RES, V564, P261, DOI 10.1016/0006-8993(91)91462-A; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MORRIS RGM, 1988, J NEUROSCI METH, V11, P47; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; PERRY DC, 1992, MOL CHEM NEUROPATHOL, V16, P95, DOI 10.1007/BF03159963; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	20	26	26	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 20	2006	394	3					239	242		10.1016/j.neulet.2005.10.099			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	013FT	WOS:000235395900015	16356639				2022-02-06	
J	Juhasz-Vedres, G; Rozsa, E; Rakos, G; Dobszay, MB; Kis, Z; Wolfling, J; Toldi, J; Parducz, A; Farkas, T				Juhasz-Vedres, G; Rozsa, E; Rakos, G; Dobszay, MB; Kis, Z; Wolfling, J; Toldi, J; Parducz, A; Farkas, T			Dehydroepiandrosterone sulfate is neuroprotective when administered either before or after injury in a focal cortical cold lesion model	ENDOCRINOLOGY			English	Article							SPINE SYNAPSE DENSITY; HIPPOCAMPAL-NEURONS; BRAIN-DEVELOPMENT; BCL-2 EXPRESSION; IN-VIVO; KAPPA-B; ESTRADIOL; ESTROGEN; MEMORY; NEUROSTEROIDS	Dehydroepiandrosterone and its sulfate (DHEAS) are sex hormone precursors that exert marked neurotrophic and/or neuroprotective activity in the central nervous system. The present study evaluated the effects of DHEAS and 17 beta-estradiol (E2) in a focal cortical cold lesion model, in which DHEAS (50 mg/kg, sc) and E2 (35 mg/kg, sc) were administered either as pretreatment (two subsequent injections 1 d and 1 h before lesion induction) or posttreatment (immediately after lesion induction). The focal cortical cold lesion was induced in the primary motor cortex by means of a cooled copper cylinder placed directly onto the cortical surface. One hour later, the animals were killed, the brains cut into 0.4-mm-thick slices, and the sections stained with 1% triphenyltetrazolium chloride. The volume of the hemispheric lesion was calculated for each animal. The results demonstrated that the lesion area was significantly attenuated in both the DHEAS- and E2-pre- and posttreated groups and that in the presence of letrozole, a nonsteroidal aromatase inhibitor, no neuroprotection was observed, suggesting that the beneficial effect of DHEAS on the cold injury might depend on the conversion of DHEAS to E2 within the brain. It is concluded that even a single post-traumatic administration of DHEAS may be of substantial therapeutic benefit in the treatment of focal brain injury with vasogenic edema.	Univ Szeged, Dept Comparat Physiol, H-6726 Szeged, Hungary; Univ Szeged, Dept Organ Chem, H-6726 Szeged, Hungary; Biol Res Ctr, Inst Biophys, H-6701 Szeged, Hungary		Farkas, T (corresponding author), Univ Szeged, Dept Comparat Physiol, Kozep Fasor 52, H-6726 Szeged, Hungary.	tfarkas@bio.u-szeged.hu	Toldi, Jozsef/M-4858-2018; Wolfling, Janos/A-3922-2008; Farkas, Tamas/B-7193-2008; Kis, Zsolt/A-4583-2009	Toldi, Jozsef/0000-0001-7355-0503; Wolfling, Janos/0000-0002-3037-309X; Kis, Zsolt/0000-0002-6896-5883			Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; Cordey M, 2005, BRAIN RES, V1045, P217, DOI 10.1016/j.brainres.2005.03.032; Debonnel G, 1996, J ENDOCRINOL, V150, pS33; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Hajszan T, 2004, ENDOCRINOLOGY, V145, P1042, DOI 10.1210/en.2003-1252; HARRISON NL, 1984, BRAIN RES, V323, P287, DOI 10.1016/0006-8993(84)90299-3; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; Kurata K, 2001, EUR J PHARMACOL, V416, P203, DOI 10.1016/S0014-2999(01)00880-9; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Lapchak PA, 2000, STROKE, V31, P1953, DOI 10.1161/01.STR.31.8.1953; Lapchak PA, 2001, INT REV NEUROBIOL, V46, P379; Losem-Heinrichs E, 2004, J STEROID BIOCHEM, V89-90, P371, DOI 10.1016/j.jsbmb.2004.03.001; MacLusky NJ, 2004, ENDOCRINOLOGY, V145, P4154, DOI 10.1210/en.2004-0477; Majewska MD, 1995, ANN NY ACAD SCI, V774, P111, DOI 10.1111/j.1749-6632.1995.tb17375.x; Mao XR, 1998, NEUROREPORT, V9, P759, DOI 10.1097/00001756-199803090-00036; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Racchi M, 2001, BRAIN RES REV, V37, P287, DOI 10.1016/S0165-0173(01)00132-1; Rao ML, 2003, PSYCHONEUROENDOCRINO, V28, P83, DOI 10.1016/S0306-4530(02)00126-9; ROBERTS E, 1987, BRAIN RES, V406, P357, DOI 10.1016/0006-8993(87)90807-9; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Stutzmann GE, 2005, NEUROSCIENTIST, V11, P110, DOI 10.1177/1073858404270899; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yen SSC, 1995, ANN NY ACAD SCI, V774, P128, DOI 10.1111/j.1749-6632.1995.tb17377.x	35	26	29	0	1	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	FEB	2006	147	2					683	686		10.1210/en.2005-0693			4	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	005NN	WOS:000234831200007	16293666	Bronze			2022-02-06	
J	Waschbisch, A; Fiebich, BL; Akundi, RS; Schmitz, ML; Hoozemans, JJM; Candelario-Jalil, E; Virtainen, N; Veerhuis, R; Slawik, H; Yrjanheikki, J; Hull, M				Waschbisch, A; Fiebich, BL; Akundi, RS; Schmitz, ML; Hoozemans, JJM; Candelario-Jalil, E; Virtainen, N; Veerhuis, R; Slawik, H; Yrjanheikki, J; Hull, M			Interleukin-1 beta-induced expression of the prostaglandin E-2-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's desease; cyclooxygenase; cytokines; gene expression; neuroimmunology; signal transduction	RECEPTOR SUBTYPE; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; RAT-BRAIN; ACTIVATION; LIPOPOLYSACCHARIDE; CYCLOOXYGENASE-2; LOCALIZATION; INHIBITION; CULTURES	Both interleukin-1 beta (IL-1 beta) and prostaglandins (PGs) are important mediators of physiological and pathophysiological processes in the brain. PGE(2) exerts its effects by binding to four different types of PGE(2) receptors named EP1-EP4. EP3 has found to be expressed in neurons, whereas expression of EP3 in glial cells has not been reported in the brain yet. Here we describe IL-1 beta-induced EP3 receptor expression in human astrocytoma cells, primary astrocytes of rat and human origin and in rat brain. Using western blot, we found a marked up-regulation of EP3 receptor synthesis in human and rat primary glial cells. Intracerebroventricular administration of IL-1 beta stimulated EP3 receptor synthesis in rat hippocampus. The analysis of involved signal transduction pathways by pathway-specific inhibitors revealed an essential role of protein kinase C and nuclear factor-kappa B in astrocytic IL-1 beta-induced EP3 synthesis. Our data suggest that PGE(2) signaling in the brain may be altered after IL-1 beta release due to up-regulation of EP3 receptors. This might play an important role in acute and chronic conditions such as cerebral ischemia, traumatic brain injury, HIV-encephalitis, Alzheimer's disease and prion diseases in which a marked up-regulation of IL-1 beta is followed by a prolonged increase of PGE(2) levels in the brain.	Univ Freiburg, Sch Med, Dept Psychiat, Freiburg, Germany; Univ Bern, Dept Biochem, Bern, Switzerland; Vrije Univ Amsterdam, Inst Neurosci, Dept Psychiat, VU Univ Med Ctr, Amsterdam, Netherlands; Cerebricon Ltd, Kuopio, Finland		Fiebich, BL (corresponding author), Univ Freiburg, Sch Med, Dept Psychiat, Hugstetter Str 55, Freiburg, Germany.	bernd.fiebich@klinikum.uni-freiburg.de	Candelario-Jalil, Eduardo/A-3528-2008; Hull, Michael/F-2618-2012; Akundi, Ravi Shankar/J-2673-2019; Candelario-Jalil, Eduardo/I-1139-2019; Schmitz, M. Lienhard/D-9328-2017	Akundi, Ravi Shankar/0000-0003-3782-5965; Candelario-Jalil, Eduardo/0000-0003-3631-1989; Schmitz, M. Lienhard/0000-0002-6984-7192; Hoozemans, Jeroen/0000-0002-2888-8967			AKAIKE A, 1994, BRAIN RES, V663, P237, DOI 10.1016/0006-8993(94)91268-8; AN SZ, 1994, BIOCHEMISTRY-US, V33, P14496, DOI 10.1021/bi00252a016; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Blatteis CM, 2000, CLIN INFECT DIS, V31, pS168, DOI 10.1086/317522; Caggiano AO, 1999, J NEUROCHEM, V72, P565, DOI 10.1046/j.1471-4159.1999.0720565.x; Candelario-Jalil E, 2004, BRAIN RES, V1007, P98, DOI 10.1016/j.brainres.2004.01.078; CANDELARIOJALIL E, 2005, IN PRESS J MOL NEURO; CAZEVIEILLE C, 1994, NEUROCHEM INT, V24, P395, DOI 10.1016/0197-0186(94)90118-X; Chen C, 2002, J NEUROPHYSIOL, V87, P2851, DOI 10.1152/jn.2002.87.6.2851; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DeGroot CJA, 1997, J NEUROSCI RES, V49, P342, DOI 10.1002/(SICI)1097-4547(19970801)49:3<342::AID-JNR9>3.0.CO;2-C; Ek M, 2000, J COMP NEUROL, V428, P5, DOI 10.1002/1096-9861(20001204)428:1<5::AID-CNE2>3.0.CO;2-M; Fiebich BL, 1999, NEUROPHARMACOLOGY, V38, P1325, DOI 10.1016/S0028-3908(99)00055-6; Fiebich BL, 1997, J NEUROCHEM, V68, P704; Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hoozemans JJM, 2001, ACTA NEUROPATHOL, V101, P2, DOI 10.1007/s004010000251; HORIGUCHI S, 1986, EUR J PHARMACOL, V122, P173, DOI 10.1016/0014-2999(86)90100-7; Hull M, 2002, CURR MED CHEM, V9, P83, DOI 10.2174/0929867023371292; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Iwasaki K, 2003, ORAL MICROBIOL IMMUN, V18, P150, DOI 10.1034/j.1399-302X.2003.00046.x; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V237, P336, DOI 10.1006/bbrc.1997.7061; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kitanaka J, 1996, BRAIN RES, V707, P282, DOI 10.1016/0006-8993(95)01256-7; Kotani M, 1997, GENOMICS, V40, P425, DOI 10.1006/geno.1996.4585; KOTANI M, 2000, J CLIN ENDOCR METAB, V5, P4315; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE AS, 1981, PHARMACOL BIOCHEM BE, V15, P735, DOI 10.1016/0091-3057(81)90014-9; Lieb K, 2005, J NEUROCHEM, V93, P549, DOI 10.1111/j.1471-4159.2005.03079.x; Lieb K, 2003, J NEUROCHEM, V86, P69, DOI 10.1046/j.1471-4159.2003.01802.x; Lieb K, 1996, J NEUROCHEM, V67, P2039; Lieb K, 1996, J NEUROCHEM, V66, P1496; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Lynch AM, 2002, EUR J NEUROSCI, V15, P1779, DOI 10.1046/j.1460-9568.2002.02012.x; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matsuoka Y, 2003, P NATL ACAD SCI USA, V100, P4132, DOI 10.1073/pnas.0633341100; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; Minghetti L, 2000, J NEUROPATH EXP NEUR, V59, P866, DOI 10.1093/jnen/59.10.866; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; Nakamura K, 2000, J COMP NEUROL, V421, P543, DOI 10.1002/(SICI)1096-9861(20000612)421:4<543::AID-CNE6>3.0.CO;2-3; Nakamura K, 2001, NEUROSCIENCE, V103, P763, DOI 10.1016/S0306-4522(01)00027-6; Nakamura K, 1999, NEUROSCI LETT, V260, P117, DOI 10.1016/S0304-3940(98)00962-8; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Othman T, 2003, GLIA, V44, P166, DOI 10.1002/glia.10281; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Parker LC, 2002, BRIT J PHARMACOL, V136, P312, DOI 10.1038/sj.bjp.0704715; Pinteaux E, 2002, J NEUROCHEM, V83, P754, DOI 10.1046/j.1471-4159.2002.01184.x; Prasad KN, 1998, IN VITRO CELL DEV-AN, V34, P265, DOI 10.1007/s11626-998-0133-7; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Schlotzer-Schrehardt U, 2002, INVEST OPHTH VIS SCI, V43, P1475; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Slawik H, 2004, NEUROCHEM INT, V45, P653, DOI 10.1016/j.neuint.2004.04.007; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Vela JM, 2002, MOL CELL NEUROSCI, V20, P489, DOI 10.1006/mcne.2002.1127; Wang KQ, 2003, J IMMUNOL, V171, P1035, DOI 10.4049/jimmunol.171.2.1035; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wing DA, 2003, J SOC GYNECOL INVEST, V10, P124, DOI 10.1016/S1071-5576(03)00007-8; Zhang J, 1999, EUR J NEUROSCI, V11, P2651, DOI 10.1046/j.1460-9568.1999.00682.x; Zhang PS, 1996, J NEUROSCI RES, V46, P114, DOI 10.1002/(SICI)1097-4547(19961001)46:1<114::AID-JNR14>3.0.CO;2-5	71	26	27	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2006	96	3					680	693		10.1111/j.1471-4159.2005.03599.x			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	003GV	WOS:000234670700007	16405508	Bronze			2022-02-06	
J	Hashimoto, K; Okamoto, T; Watanabe, S; Ohashi, M				Hashimoto, K; Okamoto, T; Watanabe, S; Ohashi, M			Effectiveness of a comprehensive day treatment program for rehabilitation of patients with acquired brain injury in Japan	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; day treatment program; rehabilitation; Japan	HEAD-INJURY	Objective: To assess the effectiveness of a day treatment program with a comprehensive team approach for treating outpatients with acquired brain injury, which is offered by the Kanagawa Rehabilitation Hospital. Design: Non-randomized controlled study. Subjects: Twenty-five program graduates and 12 control patients with acquired brain injury. Methods: A prospective study using 25 brain-injured patients with cognitive dysfunction who were provided with a comprehensive day treatment program at Kanagawa Rehabilitation Hospital. The 25 enrolled patients had treatment sessions lasting 2-4 hours for 2 days a week over a 3-6-month period. Functional Independence Measure/Functional Assessment Measure (FIM/FAM) and the Community Integration Questionnaire (CIQ) were administered before and after the program to compare outcomes between the 25 program participants and the 12 control patients who did not receive the day treatment program. Results: Significant improvements in speech intelligibility, problem solving, memory, attention and social integration scores in the FIM/FAM and scores in social integration and productive activity in the CIQ were evident in the enrolled subjects. In addition, 9 of the 25 patients returned to work or school. Conclusion: These results demonstrate the effectiveness of this program in helping to rehabilitate patients with acquired brain injury.	Jikei Univ, Sch Med, Dept Rehabil Med, Minato Ku, Tokyo 1058461, Japan; Kanagawa Rehabil Hosp, Dept Rehabil Med, Atsugi, Kanagawa, Japan; Tokyo Metropolitan Univ Hlth Sci, Tokyo, Japan		Hashimoto, K (corresponding author), Jikei Univ, Sch Med, Dept Rehabil Med, Minato Ku, 3-25-8 Nishi Shimbashi, Tokyo 1058461, Japan.	keiman@theia.ocn.ne.jp		Hashimoto, Keiji/0000-0003-2412-860X			Armengol CG, 1999, J HEAD TRAUMA REHAB, V14, P233, DOI 10.1097/00001199-199906000-00004; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; *BUFF GEN HOSP STA, 1992, DAT MAN SERV GUID US; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; Christensen A., 2000, INT HDB NEUROPSYCHOL, P183; COCKBURN JM, 1988, CLIN REHABIL, V2, P315; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HASHIMOTO K, 2003, JPN J REHABIL MED, V40, P699; KATZ RT, 2000, SOGO REHABIL, V28, P115; KIMURA A, 2003, KEIO J MED, V5, P100; King J, 1998, REHABILITATION MED P, P269; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Ohashi M., 1990, JPN J REHABIL MED, V27, P399; Ohashi M, 2000, JPN J REHABIL MED, V37, P121; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; WATANABE S, 2003, SOGO RIHABIRITESHON, V31, P669; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wiseman-Hakes C, 1998, J HEAD TRAUMA REHAB, V13, P23, DOI 10.1097/00001199-199812000-00005	21	26	28	0	2	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JAN	2006	38	1					20	25		10.1080/16501970510038473			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	005SV	WOS:000234845000004	16548082	gold			2022-02-06	
J	Lai, YC; Stange, C; Wisniewski, SR; Adelson, PD; Janesko-Feldman, KL; Brown, DS; Kochanek, PM; Clark, RSB				Lai, Yichen; Stange, Christopher; Wisniewski, Stephen R.; Adelson, P. David; Janesko-Feldman, Keri L.; Brown, Danielle S.; Kochanek, Patrick M.; Clark, Robert S. B.			Mitochondrial heat shock protein 60 is increased in cerebrospinal fluid following pediatric traumatic brain injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						head injury; mitochondria; heat shock protein 60; stress response	FOCAL CEREBRAL-ISCHEMIA; CYTOCHROME-C; MESSENGER-RNAS; PROTEIN HSP60; CELL-DEATH; DYSFUNCTION; INFANTS; STRESS; INDUCTION; TRANSIENT	Mitochondrial dysfunction occurs after traumatic brain injury (TBI) and contributes significantly to subsequent cell death. Heat shock protein 60 (hsp60) is a predominantly mitochondrial protein with important homeostatic functions. Induction of hsp60 has been demonstrated in cerebral ischemia models, possibly reflecting mitochondrial stress. We measured hsp60 concentration in the cerebrospinal fluid (CSF) of 34 infants and children after severe TBI and of 7 control patients by ELISA. Peak CSF hsp60 concentration was increased in TBI patients versus controls (0.84 ng/ml, range 0-44.59, vs. 0.0 ng/ml, range 0-0.48; p < 0.05). Induction of hsp60 occurred early after the injury. Peak hsp60 concentration was independently associated with the severity of injury, defined as the admission Glasgow Coma Scale score. These data suggest that increased hsp60 in CSF might reflect the severity of early mitochondrial stress or damage after TBI. Copyright (c) 2006 S. Karger AG, Basel.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Epidemiol, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Neurol Surg, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pediat, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA		Clark, RSB (corresponding author), Pediat Crit Care Med, 3705 5th Ave, Pittsburgh, PA 15213 USA.	clarkrs@ccm.upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Lai, Yi-Chen/0000-0002-9450-5506; Wisniewski, Stephen/0000-0002-3877-9860	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD045968, T32 HD40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, P50 NS30318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, P50NS030318] Funding Source: NIH RePORTER		Abe K, 1998, CELL MOL NEUROBIOL, V18, P709, DOI 10.1023/A:1020230220971; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Cousar JL, 2006, DEV NEUROSCI-BASEL, V28, P342, DOI 10.1159/000094160; Gupta S, 2005, J CELL MOL MED, V9, P51, DOI 10.1111/j.1582-4934.2005.tb00336.x; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; HALLBERG EM, 1993, MOL CELL BIOL, V13, P3050, DOI 10.1128/MCB.13.5.3050; HAN YY, 2001, MO CL BI CC, V2, P145; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Izaki K, 2001, MOL BRAIN RES, V88, P14, DOI 10.1016/S0169-328X(01)00012-2; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Okubo A, 2000, MOL BRAIN RES, V84, P127, DOI 10.1016/S0169-328X(00)00200-X; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; Soltys BJ, 1996, EXP CELL RES, V222, P16, DOI 10.1006/excr.1996.0003; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Wagstaff MJD, 1996, MOL BRAIN RES, V42, P236, DOI 10.1016/S0169-328X(96)00127-1; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; ZHANG XP, 2001, MO CL BI CC, V2, P199	35	26	27	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					336	341		10.1159/000094159			6	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600010	16943656				2022-02-06	
J	Natale, JE				Natale, JoAnne E.			Clinical trials in pediatric traumatic brain injury: Unique challenges and potential responses	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric traumatic brain injury; translational research; patient recruitment	SEVERE HEAD-INJURY; RESEARCH INVOLVING CHILDREN; LACTATED RINGERS SOLUTION; PLACEBO-CONTROLLED TRIAL; HOSPITAL CARDIAC-ARREST; CONFLICTS-OF-INTEREST; INFORMED-CONSENT; THERAPEUTIC MISCONCEPTION; HYPERTONIC SALINE; INTRACRANIAL-PRESSURE	In order to optimize pediatric traumatic brain injury translational and clinical research, scientific and ethical challenges need to be recognized and addressed. Having recently conducted a multisite phase II safety/feasibility trial of magnesium sulfate as a neuroprotective agent, we supplement our own experience by a mini review of similar studies, identifying challenges and possible responses from the perspective of families, investigators, funding agencies and society. Copyright (c) 2006 S. Karger AG, Basel.	Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Off Dean, Sacramento, CA 95817 USA; Childrens Natl Med Ctr, Gen Clin Res Ctr, Washington, DC 20010 USA; Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada		Natale, JE (corresponding author), Univ Calif Davis, Med Ctr, Dept Pediat, Crit Care Sect, 2516 Stockton Blvd, Sacramento, CA 95817 USA.	joanne.natale@ucdmc.ucdavis.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS043146] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [5-M01-RR-020359-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS43146] Funding Source: Medline		Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; Anderson BD, 2004, J CLIN ONCOL, V22, P4846, DOI 10.1200/JCO.2004.02.138; [Anonymous], 2000, J Neurotrauma, V17, P537; APPELBAUM PS, 1982, INT J LAW PSYCHIAT, V5, P319, DOI 10.1016/0160-2527(82)90026-7; ARTRU F, 1976, EUR NEUROL, V14, P310, DOI 10.1159/000114753; Bartel DA, 2000, ARCH PEDIAT ADOL MED, V154, P1127, DOI 10.1001/archpedi.154.11.1127; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Boholm, 1996, ETHNOS, V61, P64, DOI [DOI 10.1080/00141844.1996.9981528, 10.1080/00141844.1996.9981528]; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Burns JP, 2003, CRIT CARE MED, V31, pS131, DOI 10.1097/01.CCM.0000054905.39382.58; Cabana MD, 2000, ARCH PEDIAT ADOL MED, V154, P685, DOI 10.1001/archpedi.154.7.685; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Conwit RA, 2005, ANN EMERG MED, V45, P388, DOI 10.1016/j.annemergmed.2004.08.006; Davis DP, 2005, J EMERG MED, V28, P89, DOI 10.1016/j.jemermed.2004.07.012; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; Dresser R, 2002, SOC PHILOS POLICY, V19, P271, DOI 10.1017/S0265052502192119; Eagle KA, 2005, J AM COLL CARDIOL, V46, P1242, DOI 10.1016/j.jacc.2004.12.083; Edwards P, 2005, LANCET, V365, P1957; Ette EI, 2004, ANN PHARMACOTHER, V38, P1907, DOI 10.1345/aph.1E259; Ette EI, 2004, ANN PHARMACOTHER, V38, P1702, DOI 10.1345/aph.1D374; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Field M.J., 2004, ETHICAL CONDUCT CLIN; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Fisher CB, 2004, J CLIN CHILD ADOLESC, V33, P832, DOI 10.1207/s15374424jccp3304_18; Flores G, 2000, PEDIATRICS, V105, P496, DOI 10.1542/peds.105.3.496; Fogas BS, 2001, J DEV BEHAV PEDIATR, V22, P211, DOI 10.1097/00004703-200108000-00001; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gill D, 2003, EUR J PEDIATR, V162, P455, DOI 10.1007/s00431-003-1192-0; Groeger JS, 2003, CRIT CARE MED, V31, pS137, DOI 10.1097/01.CCM.0000054904.87847.08; Guerguerian AM, 2005, J NEUROTRAUM, V22, P1247; HEINEN M, 2005, NATL TRENDS INJURY H, P12; Holland NT, 2005, TOXICOL APPL PHARM, V206, P261, DOI 10.1016/j.taap.2004.10.024; Isa Ruwaida, 2003, Neurosurg Focus, V15, pE1; Katz Russell, 2004, NeuroRx, V1, P307, DOI 10.1602/neurorx.1.3.307; KAUFFMAN RE, 1995, PEDIATRICS, V95, P286; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kipnis K, 2003, THEOR MED BIOETH, V24, P107, DOI 10.1023/A:1024646912928; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; KOHRMAN A, 1995, PEDIATRICS, V95, P314; LANGLOIS JA, 2000, TRAUMATIC BRAIN INJU, P7; Lidz CW, 2004, SOC SCI MED, V58, P1689, DOI 10.1016/S0277-9536(03)00338-1; Lidz CW, 2002, MED CARE, V40, P55, DOI 10.1097/01.MLR.0000023956.25813.18; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; McIntosh N, 2000, Arch Dis Child, V82, P177; Micieli G, 2002, STROKE, V33, P1341, DOI 10.1161/01.STR.0000013663.27776.DB; Miller FG, 2003, NEW ENGL J MED, V348, P1383, DOI 10.1056/NEJMsb030228; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Morin K, 2002, JAMA-J AM MED ASSOC, V287, P78, DOI 10.1001/jama.287.1.78; Morris MC, 2004, PEDIATRICS, V114, P776, DOI 10.1542/peds.2004-0482; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Muszynski CA, 2005, J NEUROSURG, V102, P374, DOI 10.3171/ped.2005.102.4.0374; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Connor AM, 2003, BMJ-BRIT MED J, V327, P736, DOI 10.1136/bmj.327.7417.736; O'Lonergan Theresa, 2003, Prot Hum Subj, P10; Paling J, 2003, BRIT MED J, V327, P745, DOI 10.1136/bmj.327.7417.745; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Parks Malcolm R, 2004, J Transl Med, V2, P28, DOI 10.1186/1479-5876-2-28; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Piantadosi S, 2005, WILEY SER PROBAB ST, P1, DOI 10.1002/0471740136; Pound P, 2004, BMJ-BRIT MED J, V328, P514, DOI 10.1136/bmj.328.7438.514; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Pretzlaff RK, 2005, HEALTH CARE ANAL, V13, P119, DOI 10.1007/s10728-005-4475-y; Puttagunta P Saradhi, 2002, Health Law Rev, V10, P30; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Schaeffer MH, 1996, AM J MED, V100, P261, DOI 10.1016/S0002-9343(97)89483-1; Schmidt TA, 2005, ACAD EMERG MED, V12, P1022, DOI 10.1197/j.aem.2005.06.012; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Simma B, 2001, ANESTH ANALG, V92, P641; Singhal Nalini, 2002, J Perinatol, V22, P57, DOI 10.1038/sj.jp.7210608; SLOVIC P, 1999, RISK DECIS POLICY, V3, P165; Sollitto S, 2003, KENNEDY INST ETHIC J, V13, P83, DOI 10.1353/ken.2003.0015; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; STOLBERG SG, 1999, NY TIMES        1128, P137; Stroup TS, 2006, SCHIZOPHRENIA BULL, V32, P147, DOI 10.1093/schbul/sbj026; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Wendler D, 2006, PLOS MED, V3, P201, DOI 10.1371/journal.pmed.0030019; Wendler D, 2005, JAMA-J AM MED ASSOC, V294, P826, DOI 10.1001/jama.294.7.826; Wilhelmsen L, 2002, STAT MED, V21, P2823, DOI 10.1002/sim.1286; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016; Youngblut JoAnne M, 2005, Pediatr Crit Care Med, V6, P550, DOI 10.1097/01.PCC.0000163283.27419.E9; Zerhouni EA, 2005, NEW ENGL J MED, V353, P1621, DOI 10.1056/NEJMsb053723; Zerhouni EA, 2005, JAMA-J AM MED ASSOC, V294, P1352, DOI 10.1001/jama.294.11.1352	92	26	26	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					276	290		10.1159/000094154			15	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600005	16943651				2022-02-06	
J	Nishio, M; Niimi, S				Nishio, M; Niimi, S			Comparison of speaking rate, articulation rate and alternating motion rate in dysarthric speakers	FOLIA PHONIATRICA ET LOGOPAEDICA			English	Article						dysarthria; speaking rate; articulation rate; alternating motion rates; motor speech	AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; SPEECH CHARACTERISTICS; PARKINSONS-DISEASE; ELECTROMAGNETIC ARTICULOGRAPHY; KINEMATIC ANALYSIS; ATAXIC DYSARTHRIA; INTELLIGIBILITY; DIADOCHOKINESIS; DISORDERS	Despite recent indications that speaking rate, articulation rate and alternating motion rate (AMR) are sensitive to the influence of neurological disease on speech production in dysarthric speakers, the relationship among these parameters remains largely questionable. In the current study, speech samples were collected from 62 dysarthric speakers and 34 controls while reading a passage. Acoustic analysis investigated speaking rate, articulation rate and AMR and compared these parameters between the dysarthric and control groups and within the control and dysarthric group. The major findings were: (1) Speaking rate, articulation rate and AMR were all markedly lower in dysarthric speakers than in controls. (2) Marked correlations were recognized between speaking rate, articulation rate and AMR in the dysarthric group. (3) Compared with the speaking rate and articulation rate, AMR is characterized as follows: (i) variation was more limited in controls, and (ii) the control group was clearly distinguishable from the dysarthric group. (4) Unlike in controls, AMR in the dysarthric speakers was notably lower than their articulation rate. We therefore conclude that AMR is a more easily detected sign of abnormal articulation than speaking rate and articulation rate. Copyright (c) 2006 S. Karger AG, Basel.	Niigata Univ Hlth & Welf, Dept Speech Therapy, Niigata 9503198, Japan; Int Univ Hlth & Welf, Dept Speech & Hearing Sci, Ohtawara, Tochigi, Japan		Nishio, M (corresponding author), Niigata Univ Hlth & Welf, Dept Speech Therapy, Shimami Cho 1398, Niigata 9503198, Japan.	nishio@nuhw.ac.jp					ACKERMANN H, 1995, FOLIA PHONIATR LOGO, V47, P15, DOI 10.1159/000266338; Brown J.R., 1975, MOTOR SPEECH DISORDE; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; CANTER GJ, 1965, J SPEECH HEAR DISORD, V30, P217, DOI 10.1044/jshd.3003.217; CANTER GJ, 1963, J SPEECH HEAR DISORD, V28, P221, DOI 10.1044/jshd.2803.221; CARROW E, 1974, ARCH OTOLARYNGOL, V100, P212; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; Dembowski J., 1993, ANN B RES I LOGOPEDI, V27, P13; Duffy JR., 2020, MOTOR SPEECH DISORDE; DWORKIN JP, 1980, J SPEECH HEAR RES, V23, P828, DOI 10.1044/jshr.2304.828; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fukusako Y., 1983, JPN J LOGOP PHONIATR, V24, P149; Goldman-Eisler F., 1968, PSYCHOLINGUISTICS EX; Goozee JV, 1999, J MED SPEECH-LANG PA, V7, P209; Goozee JV, 2000, BRAIN INJURY, V14, P153, DOI 10.1080/026990500120817; GROSJEAN F, 1979, PHONETICA, V36, P98, DOI 10.1159/000259950; HIROSE H, 1982, FOLIA PHONIATR, V34, P106, DOI 10.1159/000265636; HIROSE H, 1986, FOLIA PHONIATR, V38, P61, DOI 10.1159/000265824; HIROSE H, 1978, J SPEECH HEAR DISORD, V43, P96, DOI 10.1044/jshd.4301.96; Itoh M., 1992, JPN J LOGOP PHONIATR, V33, P227; Jaeger M, 2000, FOLIA PHONIATR LOGO, V52, P187, DOI 10.1159/000021533; Kent RD, 2000, J SPEECH LANG HEAR R, V43, P1275, DOI 10.1044/jslhr.4305.1275; KENT RD, 1991, J SPEECH HEAR RES, V34, P1269, DOI 10.1044/jshr.3406.1269; KENT RD, 1975, J SPEECH HEAR DISORD, V40, P459; KREUL EJ, 1972, J SPEECH HEAR RES, V15, P72, DOI 10.1044/jshr.1501.72; LANGMORE SE, 1994, J SPEECH HEAR RES, V37, P28, DOI 10.1044/jshr.3701.28; Linebaugh C. E., 1984, DYSARTHRIAS PHYSL AC, P197; Ludlow C., 1984, DYSARTHRIAS PHYSL AC, P163; MULLIGAN M, 1994, J SPEECH HEAR RES, V37, P496, DOI 10.1044/jshr.3703.496; Nishio M, 2000, CLIN LINGUIST PHONET, V14, P485; Nishio M, 2001, CLIN LINGUIST PHONET, V15, P309; Nishio M., 2001, JPN J LOGOP PHONIATR, V42, P9; Ozawa Y, 2001, FOLIA PHONIATR LOGO, V53, P67, DOI 10.1159/000052656; PETERSON GE, 1960, J ACOUST SOC AM, V32, P693, DOI 10.1121/1.1908183; PLATT LJ, 1980, J SPEECH HEAR RES, V23, P28, DOI 10.1044/jshr.2301.28; PORTNOY RA, 1982, J SPEECH HEAR DISORD, V47, P324, DOI 10.1044/jshd.4703.324; TAGUCHI T, 1966, INTRO LOGOPEDICS; TATSUMI IF, 1979, ANN B RILP, V13, P99; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; Tjaden K, 2003, FOLIA PHONIATR LOGO, V55, P241, DOI 10.1159/000072155; TRUBETZKOY NS, 1968, INTRO PRINCIPLES PHO; Tsao YC, 1997, J SPEECH LANG HEAR R, V40, P858, DOI 10.1044/jslhr.4004.858; TURNER GS, 1993, J SPEECH HEAR RES, V36, P1134, DOI 10.1044/jshr.3606.1134; Wang YT, 2004, CLIN LINGUIST PHONET, V18, P57, DOI 10.1080/02699200310001596160; Yorkson K., 1993, J MED SPEECH LANGUAG, V1, P35; YORKSTON KM, 1978, J COMMUN DISORD, V11, P499, DOI 10.1016/0021-9924(78)90024-2; YORKSTON KM, 1981, J SPEECH HEAR DISORD, V46, P296, DOI 10.1044/jshd.4603.296; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; Ziegler W, 1996, NEUROLOGY, V47, P208, DOI 10.1212/WNL.47.1.208; ZIEGLER W, 1988, BRIT J DISORD COMMUN, V23, P215	50	26	26	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7762			FOLIA PHONIATR LOGO	Folia Phoniatr. Logop.		2006	58	2					114	131		10.1159/000089612			18	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	013AU	WOS:000235382800004	16479133				2022-02-06	
J	Johnson, EA; Svetlov, SI; Wang, KKW; Hayes, RL; Pineda, JA				Johnson, EA; Svetlov, SI; Wang, KKW; Hayes, RL; Pineda, JA			Cell-specific DNA fragmentation may be attenuated by a survivin-dependent mechanism after traumatic brain injury in rats	EXPERIMENTAL BRAIN RESEARCH			English	Article						astrocyte; neuron; caspase-3; survivin; traumatic brain injury; inhibitor of apoptosis protein	APOPTOSIS INHIBITORY PROTEIN; CASPASE-ACTIVATED DNASE; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; TEMPORAL PROFILE; EXPRESSION; DEATH; PROLIFERATION; ASTROCYTES; IDENTIFICATION	Survivin attenuates apoptosis by inhibiting cleavage of some cell proteins by activated caspase-3. We recently discovered strong up-regulation of survivin, primarily in astrocytes and a sub-set of neurons, after traumatic brain injury (TBI) in rats. In this study we characterized co-expression of survivin with activated caspase-3 and downstream DNA fragmentation (TUNEL) in astrocytes and neurons after TBI. Western blot analysis revealed significant time-dependent increases in active caspase-3 between 5 and 14 days post-injury. No difference was observed between the proportion of survivin-positive and survivin-negative cells labeled with active caspase-3 at 5 or 7 days post-injury, as indicated by dual fluorescent immunostaining. Labeling of survivin-negative cells with TUNEL was, however, significantly greater than for survivin-positive cells, suggesting that expression of survivin may attenuate DNA cleavage and progression of apoptosis. A higher proportion of astrocytes than neurons accumulated active caspase-3. In contrast, co-localization with TUNEL was significantly higher for neurons than for astrocytes. These data suggest that survivin expression may attenuate DNA cleavage and cell death, and that this mechanism operates in a cell type-specific manner after TBI.	Univ Florida, Dept Pediat, EF & WL McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, CTBIS, EF & WL McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, EF & WL McKnight Brain Inst, Gainesville, FL 32610 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Univ Florida, Dept Anat & Cell Biol, EF & WL McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, EF & WL McKnight Brain Inst, Gainesville, FL 32610 USA		Pineda, JA (corresponding author), Univ Florida, Dept Pediat, EF & WL McKnight Brain Inst, 100 S Newell Dr Bldg 59,L1-118, Gainesville, FL 32610 USA.	svetlov@mbi.ufl.edu; kwang@psychiatry.ufl.edu; hayes@ufbi.ufl.edu; pineda_J@kids.wustl.edu	Pineda, Jose/W-2806-2019	Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS039091] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39091, R01 NS40182] Funding Source: Medline		Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Belluardo N, 2002, EUR J NEUROSCI, V15, P87, DOI 10.1046/j.0953-816x.2001.01847.x; Buki A, 2000, J NEUROSCI, V20, P2825; Chiou Shiun-Kwei, 2003, Med Sci Monit, V9, pPI25; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ebel RL., 1951, PSYCHOMETRIKA, V16, P407, DOI [10.1007/BF02288803, DOI 10.1007/BF02288803]; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Jiang XY, 2001, J CELL BIOCHEM, V83, P342, DOI 10.1002/jcb.1228; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Juan TSC, 1997, GENOMICS, V40, P86, DOI 10.1006/geno.1996.4548; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kim S, 2004, J PEDIATR SURG, V39, P516, DOI 10.1016/j.jpedsurg.2003.12.008; Kitagawa H, 1999, NEUROSCI LETT, V274, P45, DOI 10.1016/S0304-3940(99)00676-X; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Lei B, 2004, NEUROSCIENCE, V125, P691, DOI 10.1016/j.neuroscience.2004.02.034; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; Lu CD, 1998, CANCER RES, V58, P1808; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; Nakase T, 2004, AM J PATHOL, V164, P2067, DOI 10.1016/S0002-9440(10)63765-0; Namura S, 1998, J NEUROSCI, V18, P3659; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Noyan-Ashraf MH, 2005, GLIA, V49, P588, DOI 10.1002/glia.20140; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sasaki T, 2002, ACTA NEUROPATHOL, V104, P105, DOI 10.1007/s00401-002-0532-x; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; Van Haren K, 2004, J NEUROPATH EXP NEUR, V63, P618, DOI 10.1093/jnen/63.6.618; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Xia XG, 2002, MOL CELL NEUROSCI, V21, P379, DOI 10.1006/mcne.2002.1180; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997	54	26	30	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	NOV	2005	167	1					17	26		10.1007/s00221-005-2362-2			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	980NA	WOS:000233024000002	16193270				2022-02-06	
J	Seignourel, PJ; Robins, DL; Larson, MJ; Demery, JA; Cole, M; Perlstein, WM				Seignourel, PJ; Robins, DL; Larson, MJ; Demery, JA; Cole, M; Perlstein, WM			Cognitive control in closed head injury: Context maintenance dysfunction or prepotent response inhibition deficit?	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	31st Annual Meeting of the International-Neuropsychological-Society	FEB 05-08, 2003	HONOLULU, HI	Int Neuropsychol Soc		traumatic brain injury/TBI; cognitive control; Stroop; context maintenance	TRAUMATIC BRAIN-INJURY; COLOR-WORD TEST; WORKING-MEMORY LOAD; PREFRONTAL CORTEX; POSTTRAUMATIC AMNESIA; ATTENTION DEFICITS; TASK-PERFORMANCE; STROOP TASK; SCHIZOPHRENIA; INTERFERENCE	The authors contrasted 2 potential explanations for the cognitive control deficits observed in closed head injury (CHI): a prepotent response inhibition deficit or a deficit in context maintenance, defined as the guidance of appropriate responding by task-relevant information. Healthy and CHI participants performed the traditional card Stroop task and a single-trial Stroop task sensitive to context maintenance deficits. As predicted by a context maintenance deficit, moderate to severe CHI participants showed higher error rates in the single-trial Stroop task only, and only when task instructions had to be maintained over a long delay. Moreover, context maintenance impairment and generalized slowing were both related to reports of daily functioning in CHI participants. Thus, context maintenance could be a useful framework for characterizing cognitive control deficits in CHI.	Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA		Perlstein, WM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HSC Box 100165, Gainesville, FL 32610 USA.	wmp@grove.ufl.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065			ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson V, 2002, PRINCIPLES FRONTAL L, P504; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; Burgess P., 1997, METHODOLOGY FRONTAL, P81; Burgess P. W., 2002, PRINCIPLES FRONTAL L, P557, DOI 10.1093/acprof:oso/9780195134971.003.0033; Chapman LJ, 2001, J ABNORM PSYCHOL, V110, P31, DOI 10.1037/0021-843X.110.1.31; CHAPMAN LJ, 1994, DEV REV, V14, P159, DOI 10.1006/drev.1994.1007; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Cohen J., 2013, STAT POWER ANAL BEHA; Cohen JD, 1996, PHILOS T R SOC B, V351, P1515, DOI 10.1098/rstb.1996.0138; COHEN JD, 1993, SCHIZOPHRENIA BULL, V19, P85, DOI 10.1093/schbul/19.1.85; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Cohen JD, 1999, J ABNORM PSYCHOL, V108, P120, DOI 10.1037/0021-843X.108.1.120; Gerstenbrand F, 2001, BRAIN INJURY, V15, P95; GOLDEN CJ, 1978, UNPUB STROOP COLOR W; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; HOLZMAN PS, 1994, ARCH GEN PSYCHIAT, V51, P952; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LARSON MJ, 2004, 32 ANN M INT NEUR SO; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; LEVINE B, 2002, PRINCIPLES FRONTAL L, P504; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Logan GD, 2003, CURR DIR PSYCHOL SCI, V12, P45, DOI 10.1111/1467-8721.01223; MacDonald AW, 2003, J ABNORM PSYCHOL, V112, P689, DOI 10.1037/0021-843X.112.4.689; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MacDonald AW, 2002, J CLIN EXP NEUROPSYC, V24, P873, DOI 10.1076/jcen.24.7.873.8386; MacLeod CM, 2000, TRENDS COGN SCI, V4, P383, DOI 10.1016/S1364-6613(00)01530-8; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; Neter J., 1985, APPL LINEAR STAT MOD; *NIH, 1998, NIH CONS STAT REH PE; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perlstein WM, 1998, NEUROPSYCHOLOGY, V12, P414, DOI 10.1037/0894-4105.12.3.414; Perlstein WM, 2003, NEUROSCI LETT, V342, P191, DOI 10.1016/S0304-3940(03)00226-X; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PERLSTEIN WM, IN PRESS NEUROSPCYHO; PHILLIPS LJ, 1997, METHODOLOGY FRONTAL, P81; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; RABBITT PM, 1997, METHODOLOGY FRONTAL, P81; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; ROJAS DC, 1995, ARCH CLIN NEUROPSYCH, V10, P101, DOI 10.1016/0887-6177(94)E0038-Q; Rosnow RL, 1996, PSYCHOL METHODS, V1, P331, DOI 10.1037/1082-989X.1.4.331; Salo R, 2001, NEUROPSYCHOLOGY, V15, P462, DOI 10.1037/0894-4105.15.4.462; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Spielberger CD., 1970, STATE TRAIT ANXIETY; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; Strauss ME, 2001, J ABNORM PSYCHOL, V110, P6, DOI 10.1037//0021-843X.110.1.6; Strauss ME, 2001, J ABNORM PSYCHOL, V110, P4, DOI 10.1037//0021-843X.110.1.4; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TRENNERY MR, 1989, STROOP NEURUPSYCHOLO; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; Wechsler D, 1985, WECHSLER ADULT INTEL; Weiskrantz L., 1992, NEUROPSYCHOLOGY CONS, P1; West R, 2003, NEUROPSYCHOLOGIA, V41, P1122, DOI 10.1016/S0028-3932(02)00297-X	96	26	26	0	8	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	SEP	2005	19	5					578	590		10.1037/0894-4105.19.5.578			13	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology; Neurosciences & Neurology	970HU	WOS:000232296700003	16187876				2022-02-06	
J	Kwak, EK; Kim, JW; Kang, KS; Lee, YH; Hua, QH; Park, TI; Park, JY; Sohn, YK				Kwak, EK; Kim, JW; Kang, KS; Lee, YH; Hua, QH; Park, TI; Park, JY; Sohn, YK			The role of inducible nitric oxide synthase following spinal cord injury in rat	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						inducible nitric oxide synthase; spinal cord injuries; apoptosis; rats	TRAUMATIC BRAIN-INJURY; APOPTOSIS; PATHOPHYSIOLOGY; EXPRESSION	Acute spinal cord injury (SCl) is two-step process that first involves the primary mechanical injury and then the secondary injury is induced by various biochemical reactions. Apoptosis is one of secondary SCl mechanisms and it is thought to play an important role for the delayed neuronal injury. The enhanced formation of nitric oxide (NO) via inducible nitric oxide synthase (iNOS) has been implicated in the pathogenesis of apoptosis in SCl. The level of iNOS mRNA peaked at 6 hr after SCI and it declined until 72 hr after SCl in a rat model. Double-immunofluorescence staining revealed that iNOS positive cells were stained for ED-1, synaptophysin, GFAP, and oligodendrocyte marker. The terminal deoxynucleotidyl-transferase-mediated dUDP-biotin nick end-labeling (TUNEL) positive cell count was higher for the 72 hr post-SCl group than for the 24 hr post-SCl group. This cell count was also higher going in the caudal direction than in the rostral direction from the epicenter, and especially for the 72 hr group. Treatment with a selective iNOS inhibitor resulted in the reduction of TUNEL-positive cells at the lesion site. These findings suggest that nitric oxide generated by the iNOS of macrophages, neurons, oligodentrocytes, and astrocytes plays an important role for the acute secondary SCI that results from apoptotic cell death.	Kyungpook Natl Univ, Dept Pathol, Sch Med, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Dent, Dept Oral Pathol, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Dent, Dept Oral Microbiol, Taegu 700422, South Korea; Sungkyunkwan Univ, Dept Pathol, Sch Med, Samsung Cheil Hosp, Seoul, South Korea		Sohn, YK (corresponding author), Kyungpook Natl Univ, Dept Pathol, Sch Med, 101 2 Ga, Taegu 700422, South Korea.	yksohn@knu.ac.kr					Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dawson VL, 1996, J NEUROSCI, V16, P2479; DEMOPOULOS HB, 1979, MEMBRANE PERTURBATIO, P63; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; ROTELLO RJ, 1994, DEVELOPMENT, V120, P1421; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WOLMAN L, 1965, PARAPLEGIA, V59, P213	20	26	30	0	6	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	AUG	2005	20	4					663	669		10.3346/jkms.2005.20.4.663			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	961AE	WOS:000231633500024	16100462	Green Published			2022-02-06	
J	Arnbrosini, A; Louin, G; Croci, N; Plotkine, M; Jafarian-Tehrani, M				Arnbrosini, A; Louin, G; Croci, N; Plotkine, M; Jafarian-Tehrani, M			Characterization of a rat model to study acute neuroinflammation on histopathological, biochemical and functional outcomes	JOURNAL OF NEUROSCIENCE METHODS			English	Article						brain injury; lipopolysaccharides; nitric oxide; nitric oxide synthases; myeloperoxidase activity; NeuN; GFAP; neurological score	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; INTRACEREBRAL INJECTION; MICE LACKING; IN-VITRO; LIPOPOLYSACCHARIDE; MICROGLIA; INFLAMMATION; EXPRESSION	Neuroinflammation is one of the events occurring after acute brain injuries. The aim of the present report was to characterize a rat model to study acute neuroinflammation on the histopathological, biochemical and functional outcomes. Lipopolysaccharide (LPS), known as a strong immunostimulant, was directly injected into the hippocampus. The spatiotemporal evolution of inducible NOS (iNOS) and cell death was studied from 6h to 7 days. A perfect time course correlation was observed between iNOS inmunoreactivity and iNOS activity showing an acute, expansive and transient iNOS induction in the hippocampus With a peak at 24 h. It was associated with a marked increase in NO metabolite (NOx) levels, and a high level of myeloperoxidase (MPO) activity. This inflammation precedes a massive cellular loss including at least neurons and astrocytes, and a drop of constitutive NOS activity, restrictive to the ipsilateral hippocampus from 48 h after LPS injection. Moreover, sensorimotor function impairment occurred from 24h to 7 days with a maximum at 24h post-LPS injection. Therefore, we characterized an in vivo model of acute neuroinflammation and neurodegeneration, in relation with a neurological deficit, which may be a powerful tool for mechanistic studies and for further evaluation of the potential neuroprotective, agents. (c) 2004 Elsevier B.V. All rights reserved.	Univ Paris 05, Pharmacokinet Lab, UPRES, EA 2510, F-75270 Paris, France		Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Pharmacokinet Lab, UPRES, EA 2510, 4,Abe Observat, F-75270 Paris, France.	mehrnaz.jafarian@univ-paris5.fr		Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856			Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Batteur-Parmentier S, 2000, J CEREBR BLOOD F MET, V20, P812, DOI 10.1097/00004647-200005000-00007; Beray-Berthat V, 2003, BRAIN RES, V987, P32, DOI 10.1016/S0006-8993(03)03224-4; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Blond D, 2002, BRAIN RES, V958, P89, DOI 10.1016/S0006-8993(02)03473-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Dalmau I, 1998, HIPPOCAMPUS, V8, P458, DOI 10.1002/(SICI)1098-1063(1998)8:5<458::AID-HIPO6>3.0.CO;2-N; Garcion E, 1998, GLIA, V22, P282, DOI 10.1002/(SICI)1098-1136(199803)22:3<282::AID-GLIA7>3.0.CO;2-7; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Grandati M, 1997, BRIT J PHARMACOL, V122, P625, DOI 10.1038/sj.bjp.0701427; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; Jeohn GH, 2000, MOL BRAIN RES, V79, P32, DOI 10.1016/S0169-328X(00)00082-6; Jeohn GH, 2002, NEUROSCIENCE, V114, P689, DOI 10.1016/S0306-4522(02)00356-1; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Konsman JP, 1999, NEUROSCIENCE, V89, P535, DOI 10.1016/S0306-4522(98)00368-6; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; Matsuoka Y, 1999, NEUROCHEM INT, V34, P91, DOI 10.1016/S0197-0186(98)00053-9; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mirzoeva S, 2002, J MED CHEM, V45, P563, DOI 10.1021/jm015573g; MonteroMenei CN, 1996, BRAIN RES, V724, P55, DOI 10.1016/0006-8993(96)00268-5; Parmentier-Batteur S, 2001, J CEREBR BLOOD F MET, V21, P15, DOI 10.1097/00004647-200101000-00003; Possel H, 2000, GLIA, V32, P51, DOI 10.1002/1098-1136(200010)32:1<51::AID-GLIA50>3.0.CO;2-4; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stern EL, 2000, J NEUROIMMUNOL, V109, P244, DOI 10.1016/S0165-5728(00)00318-0; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581; Yamada K, 1999, NEUROSCIENCE, V88, P281, DOI 10.1016/S0306-4522(98)00237-1; Zamora R, 2000, MOL MED, V6, P347, DOI 10.1007/BF03401781; Zhao XR, 2000, BRAIN RES, V872, P215, DOI 10.1016/S0006-8993(00)02459-8	41	26	30	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUN 15	2005	144	2					183	191		10.1016/j.jbeumeth.2004.11.002			9	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	934JB	WOS:000229704000005	15910976				2022-02-06	
J	Baker, F; Kennelly, J; Tamplin, J				Baker, F; Kennelly, J; Tamplin, J			Themes within songs written by people with traumatic brain injury: Gender differences	JOURNAL OF MUSIC THERAPY			English	Article							IDENTITY	The study aimed to identify gender differences in the themes of songs written by patients with traumatic brain injury. Lyrics (1, 834) from 82 songs written by 11 female and 21 male patients were categorized into 8 main themes and 24 subcategories. Incidence of subcategories and themes were calculated and compared across gender Results showed that songs written by patients from both genders were predominantly focused on sending messages to significant others and on self-reflection. Males however tended to focus more on the concern for the future and expressing adversity in their lyrics when compared with females, and the lyrics of females more often reflected upon their relationships with others when compared with males.	Univ Queensland, Brisbane, Qld 4067, Australia; Royal Childrens Hosp, Queensland Pediat Rehabil Serv, Brisbane, Qld, Australia; Royal Talbot Rehabil Ctr, Melbourne, Vic, Australia		Baker, F (corresponding author), Univ Queensland, Brisbane, Qld 4067, Australia.		Tamplin, Jeanette/AAR-2855-2021	Tamplin, Jeanette/0000-0002-3623-033X			BAKER F, UNPUB AUSTR J MUSIC; BARNETT RC, 1987, GENDER STRESS; Charmaz K, 1995, SOCIOL QUART, V36, P657, DOI 10.1111/j.1533-8525.1995.tb00459.x; deRidder D., 2000, WOMEN HLTH MIND, P115; Edgerton C. D., 1990, MUSIC THERAPY PERSPE, V8, P15; ENDLER NS, 1990, J PERS SOC PSYCHOL, V58, P844, DOI 10.1037/0022-3514.58.5.844; FICKEN T, 1976, J MUSIC THER, V13, P163, DOI 10.1093/jmt/13.4.163; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Folkman S., 1992, PERSONAL COPING THEO, P31, DOI DOI 10.1037/0022-3514.50.5.992; FORTUNE N, 1999, DEFINITION INCIDENCE; Freed B. S., 1987, MUSIC THERAPY PERSPE, V4, P13, DOI [10.1093/mtp/4.1.13, DOI 10.1093/MTP/4.1.13]; GLASSMAN LR, 1991, ART PSYCHOTHER, V18, P149, DOI 10.1016/0197-4556(91)90022-3; GRAY J, 1993, MEN ARE MARS WOMEN A; HOVANITZ CA, 1990, J CLIN PSYCHOL, V45, P766; Kennelly J, 2001, MUSIC THERAPY PERSPE, V19, P104; Lindberg K. A., 1995, MUSIC THERAPY, V13, P93; NAUGLE RI, 1991, PSYCHOL SOCIAL IMPAC; O'Callaghan C, 1999, MUSIC THERAPY PALLIA, P43; OCallaghan CC, 1996, J MUSIC THER, V33, P74, DOI 10.1093/jmt/33.2.74; Olney MF, 2001, DISABIL SOC, V16, P563, DOI 10.1080/09687590120059540; PTACEK JT, 1992, J PERS, V60, P747, DOI 10.1111/j.1467-6494.1992.tb00272.x; Robb Sheri L, 2003, J Pediatr Oncol Nurs, V20, P16, DOI 10.1053/jpon.2003.4; Shontz F. C., 1991, PSYCHOL SOCIAL IMPAC; Silber F., 1995, MUSIC THERAPY PERSPE, V13, P31, DOI DOI 10.1093/MTP/13.1.31; Simpson G., 2002, AUST SOC WORK, V55, P24, DOI [10.1080/03124070208411669, DOI 10.1080/03124070208411669]; TAMPLIN J, 2001, 27 NAT C AUSTR MUS T; TURRY A, 1999, CLIN APPL MUSIC THER, P13; VINGERHOETS AJJM, 1990, PSYCHOL MED, V20, P125, DOI 10.1017/S0033291700013301; WALKER M, 1985, SURVIVING SECRETS; Weidner G, 1993, ATTENTION AVOIDANCE, P241	30	26	27	0	3	NATL ASSOC MUSIC THERAPY INC	SILVER SPRING	8455 COLESVILLE RD, STE 1000, SILVER SPRING, MD 20910 USA	0022-2917			J MUSIC THER	J. Music Ther.	SUM	2005	42	2					111	122		10.1093/jmt/42.2.111			12	Music; Rehabilitation	Social Science Citation Index (SSCI)	Music; Rehabilitation	929GY	WOS:000229331300002	15913389				2022-02-06	
J	Spitznagel, MB; Tremont, G				Spitznagel, MB; Tremont, G			Cognitive reserve and anosognosia in questionable and mild dementia	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						cognitive reserve; anosognosia; dementia	MINI-MENTAL-STATE; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; MEMORY DECLINE; EDUCATION; AWARENESS; DEFICIT; PERFORMANCE; OCCUPATION	Cognitive reserve (CR) theory posits that the clinical presentation of individuals with the same brain disease varies based upon premorbid variables (e.g., education, occupation, reading ability). Anosognosia (decreased insight regarding one's deficits) is common in dementia and has implications for safety, treatment, and caregiver burden. The current study examined the role of CR in anosognosia in individuals with mild dementia. Participants were individuals diagnosed with questionable or mild dementia (Clinical Dementia Rating 0.5 or 1) after neuropsychological evaluation. Anosognosia was measured by informant-patient discrepancy on the Cognitive Difficulties Scale. High and Low CR groups were created based upon reading performance. Low CR showed greater anosognosia than High CR. Anosognosia was associated with reduced reading performance, even after controlling for global cognitive decline. These findings suggest CR is related to anosognosia in questionable and mild dementia, and have clinical implications for the assessment of awareness in dementia. (c) 2004 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Brown Med Sch, Providence, RI USA; Rhode Isl Hosp, Neuropsychol Program, Providence, RI 02903 USA		Tremont, G (corresponding author), Brown Med Sch, Providence, RI USA.	gtremont@lifespan.org					Alexander GE, 1997, AM J PSYCHIAT, V154, P165; Arkin S, 2001, Am J Alzheimers Dis Other Demen, V16, P211, DOI 10.1177/153331750101600401; Backman L, 1998, SCAND J PSYCHOL, V39, P131, DOI 10.1111/1467-9450.393067; Bartus R., 1984, ASSESSMENT GERIATRIC, P119; Bland RC, 2001, CAN J PSYCHIAT, V46, P506, DOI 10.1177/070674370104600604; Bowler JV, 1998, J NEUROL NEUROSUR PS, V65, P184, DOI 10.1136/jnnp.65.2.184; COBB JL, 1995, NEUROLOGY, V45, P1707, DOI 10.1212/WNL.45.9.1707; Cotrell V, 1999, ALZ DIS ASSOC DIS, V13, P151, DOI 10.1097/00002093-199907000-00007; Derouesne C, 1999, INT J GERIATR PSYCH, V14, P1019, DOI 10.1002/(SICI)1099-1166(199912)14:12<1019::AID-GPS61>3.0.CO;2-F; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Fioravanti M, 2001, ARCH GERONTOL GERIAT, P127; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Glatt SL, 1996, NEUROEPIDEMIOLOGY, V15, P20, DOI 10.1159/000109885; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; Lamar M, 2002, J NEUROPSYCH CLIN N, V14, P430, DOI 10.1176/appi.neuropsych.14.4.430; Legendre SA, 2003, J NEUROPSYCH CLIN N, V15, P333, DOI 10.1176/jnp.15.3.333; Manly JJ, 2003, J CLIN EXP NEUROPSYC, V25, P680, DOI 10.1076/jcen.25.5.680.14579; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Qiu CX, 2001, ARCH NEUROL-CHICAGO, V58, P2034, DOI 10.1001/archneur.58.12.2034; Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; ROCCA WA, 1990, NEUROLOGY, V40, P626, DOI 10.1212/WNL.40.4.626; Ropacki MT, 2003, ARCH CLIN NEUROPSYCH, V18, P643, DOI 10.1016/S0887-6177(02)00153-1; Sanchez JL, 2002, NEUROPSY NEUROPSY BE, V15, P113, DOI 10.1097/01.WNN.0000016331.45409.7A; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Sawrie SM, 2000, EPILEPSY BEHAV, V1, P106, DOI 10.1006/ebeh.2000.0042; Seltzer B, 1997, GERONTOLOGIST, V37, P20, DOI 10.1093/geront/37.1.20; Seltzer B, 2001, NEUROPSY NEUROPSY BE, V14, P122; Seltzer B, 1995, J CLIN GEROPSYCHOL, V1, P79; Stern RA, 1996, ARCH NEUROL-CHICAGO, V53, P148, DOI 10.1001/archneur.1996.00550020052015; STERN Y, 1995, NEUROLOGY, V45, P55, DOI 10.1212/WNL.45.1.55; STERN Y, 1992, ANN NEUROL, V32, P371, DOI 10.1002/ana.410320311; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 1999, NEUROLOGY, V53, P1942, DOI 10.1212/WNL.53.9.1942; TENG EL, 1987, J CONSULT CLIN PSYCH, V55, P96, DOI 10.1037/0022-006X.55.1.96; van Exel E, 2001, J NEUROL NEUROSUR PS, V71, P29, DOI 10.1136/jnnp.71.1.29; Veenman M. V. J., 1993, INTELLECTUAL ABILITY; Veenman MVJ, 1997, LEARN INSTR, V7, P187, DOI 10.1016/S0959-4752(96)00025-4; Wilkinson, 1984, WIDE RANGE ACHIEVEME; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Wilson RS, 2000, ARCH NEUROL-CHICAGO, V57, P1718, DOI 10.1001/archneur.57.12.1718; Zanetti O, 1999, J GERONTOL B-PSYCHOL, V54, pP100, DOI 10.1093/geronb/54B.2.P100	42	26	27	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2005	20	4					505	515		10.1016/j.acn.2004.11.003			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	934DK	WOS:000229686900008	15896563	Bronze			2022-02-06	
J	Slemmer, JE; Weber, JT				Slemmer, JE; Weber, JT			The extent of damage following repeated injury to cultured hippocampal cells is dependent on the severity of insult and inter-injury interval	NEUROBIOLOGY OF DISEASE			English	Article						glia; in vitro injury; NSE; repetitive injury; S-100 beta; traumatic brain injury	TRAUMATIC BRAIN-INJURY; STRETCH-INDUCED INJURY; COGNITIVE IMPAIRMENT; PROTEIN; MODEL; S100B; VULNERABILITY; DEATH; S100-BETA; RELEASE	Recent evidence suggests repeated mild brain trauma may result in cumulative damage. We investigated cell damage and death in hippocampal cultures following repeated mechanical trauma in vitro by measuring propidium iodide (PrI) uptake, release of neuron-specific enolase (NSE) and glial S-100 beta protein, and performing neuronal counts. Cultures receiving two mild injuries (31% stretch) 1 or 24 h apart displayed different profiles of PrI uptake and S-100 beta release, although neuronal loss and NSE release was similar in both paradigms. Cells receiving a subthreshold, low-level stretch (10%) repeated several times eventually stained with PrI. Cultures administered 10% stretch before mild injury released less S-100 beta than mild injury alone, suggesting a preconditioning effect. Lastly, exogenous S-100 beta applied to injured cultures decreased PrI uptake, implying a protective role. These results suggest cumulative damage is dependent on injury severity and inter-injury interval, and that neurons and glia react differently to various injury paradigms. (c) 2004 Elsevier Inc. All rights reserved.	Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands		Weber, JT (corresponding author), Erasmus MC, Dept Neurosci, POB 1738, NL-3000 DR Rotterdam, Netherlands.	j.weber@erasmusmc.nl					Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; BARGER SW, 1992, J BIOL CHEM, V267, P9689; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; GERLAI R, 1995, LEARN MEMORY, V2, P26, DOI 10.1101/lm.2.1.26; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; OLSSON Y, 1971, ACTA NEUROPATHOL, V19, P225, DOI 10.1007/BF00684599; Pike BR, 2001, HEAD TRAUMA, P37; Pinto SS, 2000, FEBS LETT, V486, P203, DOI 10.1016/S0014-5793(00)02301-2; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Schaller B, 2002, J NEUROL, V249, P1503, DOI 10.1007/s00415-002-0933-8; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Slemmer JE, 2005, PROG BRAIN RES, V148, P367, DOI 10.1016/S0079-6123(04)48029-7; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	42	26	26	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	APR	2005	18	3					421	431		10.1016/j.nbd.2004.09.022			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	908WI	WOS:000227820500001	15755668				2022-02-06	
J	Newburn, G; Newburn, D				Newburn, G; Newburn, D			Selegiline in the management of apathy following traumatic brain injury	BRAIN INJURY			English	Article							METHYLPHENIDATE TREATMENT; HEAD-INJURY; AMANTADINE; DEPRESSION; REHABILITATION; DYSFUNCTION; PREVALENCE; PATIENT	Primary objective: To provide a brief review of apathy following traumatic brain injury (TBI) and describe the use of selegiline in a group of patients with this symptom. Main outcome: Four patients are described who showed improvement in Apathy Evaluation Scale scores and functional improvement, following the use of selegiline. In each case, selegiline was well tolerated whereas methylphenidate was not. Conclusions: Selegiline shows potential for the management of apathy following TBI. This provides further evidence that impaired dopaminergic processes are prominent in the genesis of these symptoms. However, these findings require confirmation in controlled studies.	Rotorua Rehabil Clin, Rotorua, New Zealand		Newburn, G (corresponding author), Rotorua Rehabil Clin, POB 920, Rotorua, New Zealand.	dengil@xtra.co.nz					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Galynker I, 1997, J NEUROPSYCH CLIN N, V9, P231; Glenn MB, 1998, J HEAD TRAUMA REHAB, V13, P87, DOI 10.1097/00001199-199810000-00010; GUALTIERI CT, 2002, BRAIN INJURY MENTAL, P301; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; KRAUS MF, 1995, INT J PSYCHIAT MED, V25, P39, DOI 10.2190/BXRM-3M58-WBC5-A7EL; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; MARIN RS, 1993, J AFFECT DISORDERS, V28, P117, DOI 10.1016/0165-0327(93)90040-Q; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MARIN RS, 1994, J NERV MENT DIS, V182, P235, DOI 10.1097/00005053-199404000-00008; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Murphy KJ., 2000, NEUROPSYCHOLOGY EMOT, P340; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Plutchik L, 1998, PSYCHOSOMATICS, V39, P118, DOI 10.1016/S0033-3182(98)71358-1; Schaller JL, 1997, J NEUROPSYCH CLIN N, V9, P301; Shiller AD, 1999, BRAIN INJURY, V13, P715; TEASDALE G, 1984, CLOSED HEAD INJURY P, P5; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WATANABE MD, 1995, J NEUROPSYCH CLIN N, V7, P502; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	32	26	27	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2005	19	2					149	154		10.1080/02699050410001719989			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	990JR	WOS:000233739600008	15841758				2022-02-06	
J	Gramsbergen, JB; Skjoth-Rasmussen, J; Rasmussen, C; Lambertsen, KL				Gramsbergen, JB; Skjoth-Rasmussen, J; Rasmussen, C; Lambertsen, KL			On-line monitoring of striatum glucose and lactate in the endothelin-1 rat model of transient focal cerebral ischemia using microdialysis and flow-injection analysis with biosensors	JOURNAL OF NEUROSCIENCE METHODS			English	Article; Proceedings Paper	10th International Conference on In Vivo Methods	JUN 24-27, 2003	Karolinska Inst, Stockholm, SWEDEN		Karolinska Inst	biosensor; cerebral ischemia; endothelin-1; glucose; lactate; microdialysis	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; SUBARACHNOID HEMORRHAGE; ARTERY OCCLUSION; CONSCIOUS RATS; ENERGY; METABOLISM; GLUTAMATE; NEURONS; OXYGEN	In vivo studies on cerebral glucose and lactate metabolism following a brain insult require fast and sensitive monitoring techniques. Here we report on-line monitoring of ischemic events and metabolic changes following reperfusion in striatum of freely moving rats subjected to endothelin-1 (60-240 pmol) induced. transient focal cerebral ischemia using slow microdialysis (0.5 mul/min). fast sampling (every minute) and flow-injection analysis with biosensors for glucose and lactate. The high-time resolution provides detailed information on lactate rise times and duration of low glucose. In rats, developing large striatal lesions, lactate increased from 1.0 +/- 0.1 to 4.2 +/- 0.7 mM within 37 +/- 1 min, whereas glucose dropped from 0.3 +/- 0.1 mM to below detection levels (<0.05 mM) for a period of 80 +/- 18 min. The lactate increase measured over a 2-h period after endothelin-1 infusion was highly correlated with striatal infarct size. In some rats oscillatory, changes are observed which cannot be detected in traditional assays. The here-described monitoring technique applied in a clinically relevant rat model is a sensitive tool to study post-ischemic energy metabolism, effects of therapeutic interventions and its relationship with histological outcome. (C) 2004 Elsevier B.V. All rights reserved.	Univ So Denmark, Med Biol Inst, Odense, Denmark; Univ So Denmark, Dept Neurosurg, Inst Clin, Odense, Denmark; Univ So Denmark, Biomed Lab, Odense, Denmark		Gramsbergen, JB (corresponding author), Univ So Denmark, Med Biol Inst, Odense, Denmark.	jbgramsbergcn@health.sdu.dk	Lambertsen, Kate L./I-8676-2014	Lambertsen, Kate L./0000-0001-9276-4902			Biernaskie J, 2001, MAGNET RESON MED, V46, P827, DOI 10.1002/mrm.1263; Bogaert L, 2000, BRAIN RES, V887, P266, DOI 10.1016/S0006-8993(00)02959-0; Callaway JK, 1999, STROKE, V30, P2704, DOI 10.1161/01.STR.30.12.2704; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chih CP, 2003, J CEREBR BLOOD F MET, V23, P1263, DOI 10.1097/01.WCB.0000081369.51727.6F; Chih CP, 2001, TRENDS NEUROSCI, V24, P573, DOI 10.1016/S0166-2236(00)01920-2; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Gartshore G, 1997, EXP NEUROL, V147, P353, DOI 10.1006/exnr.1997.6635; Gjedde A, 2002, J CEREBR BLOOD F MET, V22, P1, DOI 10.1097/00004647-200201000-00001; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gramsbergen JB, 2003, J NEUROCHEM, V85, P399, DOI 10.1046/j.1471-4159.2003.01673.x; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Jones DA, 2002, J ELECTROANAL CHEM, V538, P243, DOI 10.1016/S0022-0728(02)00839-2; Jones DA, 2000, J NEUROCHEM, V75, P1703, DOI 10.1046/j.1471-4159.2000.0751703.x; Kaptein WA, 1998, ANAL CHEM, V70, P4696, DOI 10.1021/ac980137w; Lambertsen KL, 2002, J CEREBR BLOOD F MET, V22, P785, DOI 10.1097/00004647-200207000-00004; Leegsma-Vogt G, 2003, J CEREBR BLOOD F MET, V23, P933, DOI 10.1097/01.WCB.0000080650.64357.8F; Leegsma-Vogt G, 2001, J NEUROSCI RES, V66, P795, DOI 10.1002/jnr.10046; LEEGSMAVOGT G, 2004, IN PRESS ANAL CHEM; Leth H, 1996, ACTA PAEDIATR, V85, P859, DOI 10.1111/j.1651-2227.1996.tb14168.x; Madsen PL, 1998, J CEREBR BLOOD F MET, V18, P742, DOI 10.1097/00004647-199807000-00005; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MARAN A, 1994, LANCET, V343, P16, DOI 10.1016/S0140-6736(94)90876-1; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; MOLLER A, 1995, NEUROL RES, V17, P353; Moyanova S, 2003, J NEUROL SCI, V212, P59, DOI 10.1016/S0022-510X(03)00102-3; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Petzold GC, 2003, ANN NEUROL, V54, P591, DOI 10.1002/ana.10723; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Ros J, 2002, J NEUROSCI METH, V119, P129, DOI 10.1016/S0165-0270(02)00174-7; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Schurr A, 1997, J NEUROCHEM, V69, P423; SHARKEY J, 1995, J NEUROSCI METH, V60, P125, DOI 10.1016/0165-0270(95)00003-D; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Van Hemelrijck A, 2003, J NEUROCHEM, V87, P66, DOI 10.1046/j.1471-4159.2003.01977.x; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Voutsinos-Porche B, 2003, NEURON, V37, P275, DOI 10.1016/S0896-6273(02)01170-4; Zimmermann M, 1998, NEUROSURGERY, V43, P863, DOI 10.1097/00006123-199810000-00083	42	26	27	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	DEC 30	2004	140	1-2					93	101		10.1016/j.jneumeth.2004.03.027			9	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Neurosciences & Neurology	885TO	WOS:000226180100014	15589339				2022-02-06	
J	Fuchtmeier, B; Maghsudi, M; Neumann, C; Hente, R; Roll, C; Nerlich, M				Fuchtmeier, B; Maghsudi, M; Neumann, C; Hente, R; Roll, C; Nerlich, M			The minimally invasive stabilization of the dorsal pelvic ring with the transiliacal internal fixator (TIFI) - Surgical technique and first clinical findings	UNFALLCHIRURG			German	Article							ILIOSACRAL SCREW PLACEMENT; SACRAL FRACTURES; SACROILIAC JOINT; OPEN REDUCTION; INJURIES; DISRUPTIONS; OSTEOSYNTHESIS; EXPERIENCES; MANAGEMENT; THERAPY	The Trans Iliacal Internal Fixator (TIFI) is a minimally invasive technique for the stabilization of sacro-iliac joint ruptures and fractures lateral to the sacral ala or through the sacral foramen. In this study, 7.0 mm pedicle screws of the Universal-Spine-System (USS, Synthes) were inserted 1-2 cm on the cranial side of the posterior superior iliac spine and parallel to the superior gluteal line. The connecting bar was inserted subfascially and fixed with the locking head pedicle screws to form an fixed-angle construction. In a prospective study 31 patients with vertical shear injuries of the pelvis were treated with the TIFI. There were two wound infections and one loosening of a pedicle screw. None of the screws were incorrectly positioned and no neuro-vascular lesions were caused by the implant. 2 years postoperatively we found 50% good and excellent results for type C pelvic ring injuries. Early findings show that the TIFI is well suited to stabilization of sacro-iliac joint ruptures and fractures of the lateral sacrum. Closed reduction and minimally invasive insertion technique are possible. The implant leads to sufficient biomechanical stability but there is a very low intraoperative risk of neuro-vascular lesion.	Klinikum Univ Regensburg, Abt Unfallchirurg, D-93042 Regensburg, Germany		Fuchtmeier, B (corresponding author), Klinikum Univ Regensburg, Abt Unfallchirurg, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.	bernd.fuechtmeier@klinik.uni-regensburg.de					Altman DT, 1999, J ORTHOP TRAUMA, V13, P220, DOI 10.1097/00005131-199903000-00011; Barei DP, 2001, INJURY, V32, P33, DOI 10.1016/S0020-1383(01)00059-6; DENIS F, 1988, CLIN ORTHOP RELAT R, P67; Fuchtmeier B., 2002, HEFTE UNFALLCHIRURG, V284, P393; Gansslen A, 2003, ZBL CHIR, V128, P40, DOI 10.1055/s-2003-37318; GANZ R, 1991, CLIN ORTHOP RELAT R, P71; GOLDSTEIN A, 1986, J TRAUMA, V26, P325; Grutzner PA, 2002, UNFALLCHIRURG, V105, P254, DOI 10.1007/s001130100339; Heini PF, 1996, INJURY, V27, P38, DOI 10.1016/S0020-1383(96)90110-2; Hufner T, 2002, CLIN ORTHOP RELAT R, P231; JOSTEN C, 1994, CHIRURG, V65, P970; KACH K, 1994, UNFALLCHIRURG, V97, P28; KELLAM JF, 1987, ORTHOP CLIN N AM, V18, P25; Lehmann J., 1934, ZENTRALBL CHIR, V37, P2149; Matta JM, 1996, CLIN ORTHOP RELAT R, P129; MATTA JM, 1989, CLIN ORTHOP RELAT R, P83; NELSON DW, 1991, RADIOLOGY, V180, P527, DOI 10.1148/radiology.180.2.2068323; Nepola JV, 1999, J TRAUMA, V46, P1024, DOI 10.1097/00005373-199906000-00007; Nerlich M, 1996, INJURY, V27, P29, DOI 10.1016/S0020-1383(96)90109-6; Pohlemann T, 1996, INJURY, V27, P31, DOI 10.1016/S0002-9378(15)33150-1; Pohlemann T, 1996, UNFALLCHIRURG, V99, P160; RAGNARSSON B, 1993, ACTA ORTHOP SCAND, V64, P138, DOI 10.3109/17453679308994554; Rommens PM, 2002, J ORTHOP TRAUMA, V16, P92, DOI 10.1097/00005131-200202000-00004; Routt MLC, 2000, CLIN ORTHOP RELAT R, P15; SIMPSON LA, 1987, J TRAUMA, V27, P1332, DOI 10.1097/00005373-198712000-00003; Stockle U, 2002, UNFALLCHIRURG, V105, P886, DOI 10.1007/s00113-002-0438-z; Templeman D, 1996, CLIN ORTHOP RELAT R, P194; TILE M, 1988, J BONE JOINT SURG BR, V70, P1; Tonetti J, 1998, CLIN ORTHOP RELAT R, P103; Tscherne H, 2000, ZBL CHIR, V125, P717, DOI 10.1055/s-2000-10662	30	26	31	3	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0177-5537	1433-044X		UNFALLCHIRURG	Unfallchirurg	DEC	2004	107	12					1142	1151		10.1007/s00113-004-0824-9			10	Emergency Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Surgery	884HZ	WOS:000226076800004	15338033				2022-02-06	
J	Hanten, G; Chapman, SB; Gamino, JF; Zhang, LF; Benton, SB; Stallings-Roberson, G; Hunter, JV; Levin, HS				Hanten, G; Chapman, SB; Gamino, JF; Zhang, LF; Benton, SB; Stallings-Roberson, G; Hunter, JV; Levin, HS			Verbal selective learning after traumatic brain injury in children	ANNALS OF NEUROLOGY			English	Article							ORBITOFRONTAL CORTEX; MEMORY	Selective learning (SL), the ability to select items to learn from among other items, engages cognitive control, which is purportedly mediated by the frontal cortex and its circuitry. Using incentive-based auditory word recall and expository discourse tasks, we studied the efficiency of SL in children ages, 6 to 16 years who had sustained severe traumatic brain injury (TBI) at least 1 year earlier. We hypothesized that SL would be compromised by severe TBI. Results indicated that children with severe TBI performed significantly worse than age-matched typically developing children on word- and discourse-level measures of SL efficiency with no significant group differences in number of items recalled from auditory word lists or declarative facts. We conclude that severe TBI disrupts incentive-based cognitive control processes, possibly due to involvement of frontal neural networks.	Baylor Coll Med, Dept Phys Med & Rehabil, Cognit Neurosci Lab, Houston, TX 77030 USA; Univ Texas, Ctr Brain Hlth, Dallas, TX 75230 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA		Hanten, G (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Cognit Neurosci Lab, 6560 Fannin St,Suite 1144, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		Adams JH, 1975, HDB CLIN NEUROLOGY, V23, P35; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson VA, 2000, BRAIN INJURY, V14, P679; BAUER RH, 1990, J GEN PSYCHOL, V117, P447, DOI 10.1080/00221309.1990.9921150; BAYLIS LL, 1991, EXP BRAIN RES, V86, P617; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; CHAPMAN SB, 1999, BRAIN DAM B, P235; Cohen J., 2013, STAT POWER ANAL BEHA; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; Drummey AB, 2002, DEVELOPMENTAL SCI, V5, P502, DOI 10.1111/1467-7687.00243; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; Francis S, 1999, NEUROREPORT, V10, P453, DOI 10.1097/00001756-199902250-00003; HAMM VP, 1992, PSYCHOL AGING, V7, P56, DOI 10.1037/0882-7974.7.1.56; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; HANTEN G, 2000, 3 INT C MEM VAL SPAI; Kufera J. A., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI 10.1044/1058-0360.0602.66; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; OSULLIVAN JT, 1993, J EXP CHILD PSYCHOL, V55, P396, DOI 10.1006/jecp.1993.1022; Pennington B. F., 1997, DEV PREFRONTAL CORTE, P265; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; WardLonergan JM, 1998, J COMMUN DISORD, V31, P1, DOI 10.1016/S0021-9924(97)00048-8; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; [No title captured]	35	26	26	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	DEC	2004	56	6					847	853		10.1002/ana.20298			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	876NV	WOS:000225504700012	15562406				2022-02-06	
J	Mattiasson, G				Mattiasson, G			Analysis of mitochondrial generation and release of reactive oxygen species	CYTOMETRY PART A			English	Article						mitochondria; reactive oxygen species; cell death; second-messenger systems; flow cytometry; oxidation reduction; neurodegenerative diseases; oxidative stress	FLOW-CYTOMETRIC ANALYSIS; TRAUMATIC BRAIN-INJURY; HYDROGEN-PEROXIDE; PERMEABILITY TRANSITION; OXIDATIVE STRESS; UNCOUPLING PROTEIN-2; SUPEROXIDE ANION; HEART-MITOCHONDRIA; REDOX REGULATION; NEURONAL DEATH	Background: Reactive oxygen species (ROS) are mainly produced in mitochondria and are important contributors to many forms of cell death. ROS also function as second messengers within the cell and may constitute a signaling pathway from mitochondria to the cytoplasm and nucleus. The aim of the present study was to develop a protocol to detect changes in intra- and extramitochondrial releases of ROS, which could be used to analyze the role of mitochondria in cell signaling and cell death. Methods: Fluorescence-based assays were used to measure (a) total production of ROS, (b) intramitochondrial ROS, (c) extramitochondrial hydrogen peroxide, and (d) superoxide outside inverted (inside-out) submitochondrial particles. ROS generation in the samples was increased or decreased by the addition of different substrates, enzymes, and inhibitors of the electron transport chain. Results: The individual assays used were sensitive to increased (e.g., after addition of antimycin A; increased signal) and decreased (ROS scavenging; decreased signal) levels of ROS. In combination, the assays provided information about mitochondrial ROS generation and release dynamics from small samples of isolated mitochondria. Conclusions: The combination of fluorescent techniques described is a useful tool to study the role of ROS in cell death and in cellular redox signaling. (C) 2004 Wiley-Liss, Inc.	Lund Univ, Expt Brain Res Lab, Wallenberg Neurosci Ctr, SE-22184 Lund, Sweden		Mattiasson, G (corresponding author), Lund Univ, Expt Brain Res Lab, Wallenberg Neurosci Ctr, BMC A13, SE-22184 Lund, Sweden.						Anderson MF, 2004, NEUROSCI LETT, V354, P163, DOI 10.1016/j.neulet.2003.09.067; Anderson MF, 2000, BRAIN RES PROTOC, V5, P95, DOI 10.1016/S1385-299X(99)00060-4; Arnaiz SL, 1999, NITRIC OXIDE-BIOL CH, V3, P235, DOI 10.1006/niox.1999.0229; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Bergamini CM, 2004, CURR PHARM DESIGN, V10, P1611, DOI 10.2174/1381612043384664; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Friberg H, 2002, NEUROSCI LETT, V334, P111, DOI 10.1016/S0304-3940(02)01116-3; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Gunter TE, 2004, J NEUROCHEM, V88, P266, DOI 10.1046/j.1471-4159.2003.02122.x; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Han MJ, 2003, MOL CELLS, V15, P94; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; Kowaltowski AJ, 1998, ARCH BIOCHEM BIOPHYS, V359, P77, DOI 10.1006/abbi.1998.0870; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kroemer G, 2003, BIOCHEM BIOPH RES CO, V304, P433, DOI 10.1016/S0006-291X(03)00614-4; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lenaz G, 2001, IUBMB LIFE, V52, P159, DOI 10.1080/15216540152845957; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lifshitz J, 2003, J NEUROTRAUM, V20, P139, DOI 10.1089/08977150360547062; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Mattiasson G, 2004, CYTOM PART A, V60A, P145, DOI 10.1002/cyto.a.20024; Mattiasson G, 2003, J NEUROCHEM, V87, P532, DOI 10.1046/j.1471-4159.2003.02026.x; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263	49	26	30	0	4	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0196-4763			CYTOM PART A	Cytom. Part A	DEC	2004	62A	2					89	96		10.1002/cyto.a.20089			8	Biochemical Research Methods; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	878HB	WOS:000225636300003	15517564				2022-02-06	
J	Sheibani, N; Grabowski, EF; Schoenfeld, DA; Whalen, MJ				Sheibani, N; Grabowski, EF; Schoenfeld, DA; Whalen, MJ			Effect of granulocyte colony-stimulating factor on functional and histoplathologic outcome after traumatic brain injury in mice	CRITICAL CARE MEDICINE			English	Article						brain injury; mice; granulocyte colony-stimulating factor; inflammation; Morris water maze; growth factors	INTERLEUKIN-1 RECEPTOR ANTAGONIST; ACUTE INFLAMMATORY RESPONSE; SEVERE HEAD-INJURIES; CEREBRAL BLOOD-FLOW; BARRIER PERMEABILITY; MILD HYPOTHERMIA; ERYTHROPOIETIN; RATS; ISCHEMIA; INFECTIONS	Objective: Granulocyte colony-stimulating factor has been used to reduce the risk of sepsis in patients with traumatic brain injury. However, granulocyte colony-stimulating factor exerts potent pro- and anti-inflammatory effects that could influence secondary injury, and outcome, after traumatic brain injury. Our objective was to determine the effect of granulocyte colony-stimulating factor on histopathologic, motor, and cognitive Design: Experimental study. Setting: Research laboratory at the Massachusetts General Hospital, Boston, MA. Subjects: Forty-eight adult male C57BI/6 mice. Interventions: Mice (8 wks of age, n = 16/group) were administered granulocyte colony-stimulating factor or saline subcutaneously twice per day for 7 days after controlled cortical impact or sham injury (n = 16). Absolute neutrophil counts, motor function, Morris water maze performance, and lesion volume were determined after controlled cortical impact or sham injury. Measurements and Main Results: At the time of controlled cortical impact, body weight, brain and body temperature, and systemic absolute neutrophil counts did not differ between groups. Compared with control, systemic absolute neutrophil count was increased more than ten-fold in granulocyte colony-stimulating factor-treated mice on posttrauma days 2 and 7 (p < .05, repeated-measures analysis of variance) but did not differ between groups by day 14. There. were no differences between groups in tests of motor function or histopathologic outcome. However, compared with control, mice given granulocyte colony-stimulating factor had improved Morris water maze performance after controlled cortical impact (p < .05, repeated-measures analysis of variance) but not sham injury. Conclusions: The data suggest a small beneficial effect of granulocyte colony-stimulating factor on functional outcome after traumatic brain injury in adult mice but do not show differences in histopathology or motor outcome between treated and control groups.	Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Epidemiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA		Sheibani, N (corresponding author), Massachusetts Gen Hosp, 149 13th St Room 6403, Charlestown, MA 02129 USA.		Sheibani, Nader/AAG-2379-2020	Sheibani, Nader/0000-0003-2723-9217	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS041969] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5K08NS41969] Funding Source: Medline		Aloe L, 1999, BRAIN RES, V840, P125, DOI 10.1016/S0006-8993(99)01748-5; AUBERT A, 1995, BRAIN BEHAV IMMUN, V9, P129, DOI 10.1006/brbi.1995.1013; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; GIBERTINI M, 1995, BRAIN BEHAV IMMUN, V9, P113, DOI 10.1006/brbi.1995.1012; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Hartung T, 1999, CLIN PHARMACOL THER, V66, P415, DOI 10.1053/cp.1999.v66.a101210; HARTUNG T, 1995, BLOOD, V85, P2482, DOI 10.1182/blood.V85.9.2482.bloodjournal8592482; Hartung T, 1998, Curr Opin Hematol, V5, P221, DOI 10.1097/00062752-199805000-00013; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Heard SO, 1999, CRIT CARE MED, V27, P1019, DOI 10.1097/00003246-199905000-00051; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; Iida R, 2000, FASEB J, V14, P1023, DOI 10.1096/fasebj.14.7.1023; Ishikawa K, 1999, J TRAUMA, V46, P999, DOI 10.1097/00005373-199906000-00004; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; Pugh CR, 2001, NEUROSCI BIOBEHAV R, V25, P29, DOI 10.1016/S0149-7634(00)00048-8; Qiu JH, 2002, J NEUROSCI, V22, P3504; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Six I, 2003, EUR J PHARMACOL, V458, P327, DOI 10.1016/S0014-2999(02)02785-1; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Squadrito F, 1997, BRIT J PHARMACOL, V120, P333, DOI 10.1038/sj.bjp.0700904; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1999, CRIT CARE MED, V27, P1014, DOI 10.1097/00003246-199905000-00049; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029	37	26	27	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	NOV	2004	32	11					2274	2278		10.1097/01.CCM.0000145998.11686.ED			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872MN	WOS:000225211400014	15640641				2022-02-06	
J	Whishaw, IQ; Piecharka, DM; Zeeb, F; Stein, DG				Whishaw, IQ; Piecharka, DM; Zeeb, F; Stein, DG			Unilateral frontal lobe contusion and forelimb function: Chronic quantitative and qualitative impairments in reflexive and skilled forelimb movements in rats	JOURNAL OF NEUROTRAUMA			English	Article						bilateral skilled limb use impairments; concussion; concussion and skilled movement impairment; contusion; skilled forelimb use; skilled forelimb use and recovery; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MOTOR CORTEX; PYRAMIDAL TRACT; RECOVERY; DOPAMINE; DEFICITS; LESIONS; LOCOMOTION; GENDER; IMPACT	Traumatic brain injury induced by mechanical impacts of the head can be modeled in rats in order to investigate acute and chronic therapy. Because frontal lobe contusion affects the neural representation of the forelimb in both the neocortex and basal ganglia, the purpose of the present experiments was to examine the chronic changes in reflexive and skilled forelimb induced by the injury. Contusions produced a cavity in the sensorimotor cortex, accompanied by shrinkage of the pyramidal tract, loss of cells in the dorsolateral striatum, and enlargement of the lateral ventricle. There were substantial individual differences in lesion size despite use of two different contusion forces, but all rats receiving contusions displayed chronic forelimb deficits. Reflexive tests of forelimb use (limb posture, placing, and support) indicated that impairments were most pronounced in the forelimb contralateral to the lesion. Tests of limb preference indicated that the contusion rats displayed a forelimb asymmetry: they were more likely to lean on their ipsilateral-to-lesion forelimb for support when rearing in a test cylinder, and this impairment was amplified in a home cage test. They also displayed a preference for the forelimb ipsilateral to the lesion when reaching for food, although both forelimbs were equally impaired on measures of success when reaching for food from a tray and reaching for a single food pellet on a shelf. A qualitative analysis from frame-by-frame video records indicated that when reaching for single pellets, impairments in forelimb use primarily affected the contralateral-to-lesion limb, especially limb aiming, supination, and food pellet release. Impairments in the ipsilateral-to-lesion forelimb were generally, but not exclusively, secondary to postural abnormalities. The wide range of chronic impairments in forelimb use following contusion injuries are discussed in relation to the anatomical and behavioral origins of the impairments and the potential use of forelimb tests in the assessment of therapy for traumatic brain injury to the frontal cortex.	Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA		Whishaw, IQ (corresponding author), Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada.	whishaw@uleth.ca	Stein, Donald/AAJ-5139-2020		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [5R01 38664-3] Funding Source: Medline		Al Moutaery K, 2003, NEUROSURGERY, V53, P704, DOI 10.1227/01.NEU.0000079487.66013.6F; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BORLONGAN CV, 1995, BRAIN RES, V676, P231, DOI 10.1016/0006-8993(95)00150-O; Buczek M, 2002, METAB BRAIN DIS, V17, P153, DOI 10.1023/A:1019973921217; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; De Mulder G, 2000, ACT NEUR S, V76, P409; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Feeney DM, 1997, ADV NEUROL, V73, P383; Gharbawie OA, 2004, BEHAV BRAIN RES, V151, P125, DOI 10.1016/j.bbr.2003.08.009; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Halliday A, 1999, TRAUMATIC BRAIN INJU, P29; HICKS SP, 1975, AM J ANAT, V143, P1, DOI 10.1002/aja.1001430102; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; ISACSON O, 1986, P NATL ACAD SCI USA, V83, P2728, DOI 10.1073/pnas.83.8.2728; Johnston RE, 1999, BEHAV BRAIN RES, V104, P189, DOI 10.1016/S0166-4328(99)00068-6; Ke C, 2000, ACT NEUR S, V76, P405; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321, DOI 10.1152/jn.1998.80.6.3321; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; LEVERE TE, 1998, BRAIN INJURY RECOVER, P15; MCINTOSH T, 1999, TRAUMATIC BRAIN INJU; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Metz GAS, 1998, BEHAV BRAIN RES, V96, P37, DOI 10.1016/S0166-4328(97)00195-2; MIKLYAEVA EI, 1994, J NEUROSCI, V14, P7148; MIKLYAEVA EI, 1995, BRAIN RES, V681, P23, DOI 10.1016/0006-8993(95)00277-W; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; NUDO RJ, 1990, J COMP NEUROL, V296, P584, DOI 10.1002/cne.902960406; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLIS SM, 1987, PHYSIOL BEHAV, V39, P127, DOI 10.1016/0031-9384(87)90409-4; PISA M, 1990, BEHAV BRAIN RES, V37, P281, DOI 10.1016/0166-4328(90)90140-A; ROBINSON TE, 1974, J COMP PHYSIOL PSYCH, V86, P768, DOI 10.1037/h0036397; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; SCHALLERT T, 1979, EXP NEUROL, V64, P33, DOI 10.1016/0014-4886(79)90003-7; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Vergara-Aragon P, 2003, J NEUROSCI, V23, P579, DOI 10.1523/JNEUROSCI.23-02-00579.2003; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; WHISHAW IQ, 1992, BEHAV BRAIN RES, V48, P113, DOI 10.1016/S0166-4328(05)80147-0; WHISHAW IQ, 1990, BEHAV BRAIN RES, V41, P49, DOI 10.1016/0166-4328(90)90053-H; WHISHAW IQ, 1992, BEHAV BRAIN RES, V47, P59, DOI 10.1016/S0166-4328(05)80252-9; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805; WHISHAW IQ, 1993, BEHAV BRAIN RES, V56, P59, DOI 10.1016/0166-4328(93)90022-I; Whishaw IQ, 2002, BEHAV BRAIN RES, V134, P323, DOI 10.1016/S0166-4328(02)00051-7; WHISHAW IQ, 1981, J COMP PHYSIOL PSYCH, V95, P85, DOI 10.1037/h0077760; WHISHAW IQ, 1996, INVERTEBRATES HUMANS, P130; Winer BJ, 1962, STAT PRINCIPLES EXPT; WINSLADE WJ, 1998, CONFRONTING BRAIN TR	56	26	26	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2004	21	11					1584	1600		10.1089/neu.2004.21.1584			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	872IL	WOS:000225200800006	15684651				2022-02-06	
J	Browne, KD; Leoni, MJ; Iwata, A; Chen, XH; Smith, DH				Browne, KD; Leoni, MJ; Iwata, A; Chen, XH; Smith, DH			Acute treatment with MgSO4 attenuates long-term hippocampal tissue loss after brain trauma in the rat	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article							D-ASPARTATE RECEPTORS; CONTROLLED CORTICAL IMPACT; HEAD-INJURY; POSTTRAUMATIC HYPOTHERMIA; COGNITIVE DYSFUNCTION; MAGNESIUM TREATMENT; UNITED-STATES; NEURON DEATH; ATROPHY; MEMORY	Previous studies have shown that magnesium salts and the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, NPS 1506, attenuated short-term cognitive deficits and histopathological changes associated with traumatic brain injury (TBI). We evaluated the longterm effects of both therapies after brain trauma. Young adult rats were subjected to parasagittal fluid-percussion brain injury and received either MgSO4 (125 mumol/400 g rat; n = 12) 15 min post-injury, NPS 1506 (1.15 mg/kg; n = 12) 15 min and 4 hr post-injury, or vehicle (n = 9) 15 min post-injury. Uninjured animals (sham) received vehicle (n = 10). Learning function in these animals was evaluated using a water maze paradigm 8 months after injury or sham treatment, and the brains were examined for cortical and hippocampal tissue loss. Compared to sham animals, injured vehicle-treated animals displayed a substantial learning dysfunction, indicated by an increased latency to find a hidden platform in the water maze (P < 0.001). No improvements in learning, however, were found for injured animals treated with NPS 1506 or MgSO4. Injury induced >30% loss of tissue in the ipsilateral cortex in vehicle-treated animals that was not reduced in animals treated with either NPS 1506 or MgSO4. Treatment with MgSO4 significantly reduced progressive tissue loss in the hippocampus (P < 0.001). These findings are the first to demonstrate long-term neuroprotection of hippocampal tissue by an acute treatment in a TBI model. These data also show that the previously reported broad efficacy of MgSO4 or NPS 1506 observed shortly after brain trauma could not be detected 8 months post-injury. (C) 2004 Wiley-Liss, Inc.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS38104] Funding Source: Medline		Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Kang TC, 2001, J NEUROCYTOL, V30, P945, DOI 10.1023/A:1021832004954; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mueller AL, 2000, AMINO ACIDS, V19, P177, DOI 10.1007/s007260070047; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; OLNEY J, 1987, EUR J PHARMACOL, V141, P357, DOI 10.1016/0014-2999(87)90552-8; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Smith D H, 1995, New Horiz, V3, P562; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VALTYSSON J, 1994, ACTA NEUROCHIR, V129, P58, DOI 10.1007/BF01400874; VINK R, 1988, J BIOL CHEM, V263, P757; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	43	26	28	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	SEP 15	2004	77	6					878	883		10.1002/jnr.20215			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	852DN	WOS:000223735500010	15334605				2022-02-06	
J	Zausinger, S; Thal, SC; Kreimeier, U; Messmer, K; Schmid-Elsaesser, R				Zausinger, S; Thal, SC; Kreimeier, U; Messmer, K; Schmid-Elsaesser, R			Hypertonic fluid resuscitation from subarachnoid hemorrhage in rats	NEUROSURGERY			English	Article						cerebral blood flow; global cerebral ischemia; hypertonic solutions; small-volume resuscitation; subarachnoid hemorrhage	CEREBRAL-BLOOD-FLOW; SMALL-VOLUME RESUSCITATION; BRAIN-BARRIER DAMAGE; SALINE DEXTRAN; INTRACRANIAL-PRESSURE; HYDROXYETHYL STARCH; PERFUSION-PRESSURE; ISCHEMIA; MODEL; DEATH	OBJECTIVE: Increased intracranial pressure (ICP) and decreased cerebral blood flow leading to global cerebral ischemia are the primary causes of death after severe subarachnoid hemorrhage (SAH). Hypertonic saline has been demonstrated to exert neuroprotective properties after traumatic brain injury by osmotic mobilization of parenchymal water and improvement of microcirculation. We used a rat model to investigate the effects of hypertonic fluid resuscitation after SAH on ICP, cerebral blood flow, body weight, neurological recovery, and morphological damage. METHODS: Sixty rats were subjected to SAH induced by an endovascular filament. ICP and local cerebral blood flow were recorded continuously. Animals were assigned to three groups: 1) NaCl 0.9%; 2) NaCl 7.5% (4 ml/kg); and 3) NaCl 7.5% plus 6% dextran 70 (4 ml/kg) given 30 minutes after SAH. Body weight and neurological deficits were assessed daily. Morphological damage was evaluated on Day 7. RESULTS: SAH resulted in an immediate increase of ICP to approximately 60 mm Hg initially, and then to approximately 30 mm Hg for the next 90 minutes. Although NaCl 7.5% alone and in combination with dextran led to an immediate, significant, and lasting decrease of ICP to 15 to 20 mm Hg, only the combined therapy significantly increased body weight and improved neurological recovery. Furthermore, the group that received combined therapy exhibited significantly more surviving neurons in hippocampus, cortex, caudoputamen, and cerebellum. Mortality was reduced nonsignificantly, from approximately 65% in groups I and II to 35% in Group III. CONCLUSION: Treatment with NaCl 7.5% plus 6% dextran 70 is significantly effective for reducing the initial harmful sequelae of SAH. The regimen resulted in lowered ICP, improved neurological recovery, and less morphological damage after SAH in the rat.	Univ Munich, Klinikum Grosshadern, Dept Neurosurg, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Dept Anesthesiol, D-81377 Munich, Germany		Zausinger, S (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurosurg, Marchioninistr 15, D-81377 Munich, Germany.	Stefan.Zausinger@med.uni-muenchen.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729			Akopov S, 1996, CEREBROVAS BRAIN MET, V8, P11; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; CROMPTON MR, 1964, BRAIN, V87, P263, DOI 10.1093/brain/87.2.263; DAVIS SM, 1992, STROKE, V23, P492, DOI 10.1161/01.STR.23.4.492; de Jonge E, 2001, CRIT CARE MED, V29, P1261, DOI 10.1097/00003246-200106000-00038; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; DOCZI T, 1986, NEUROSURGERY, V18, P733, DOI 10.1227/00006123-198606000-00010; GROTE E, 1988, NEUROSURGERY, V22, P654, DOI 10.1227/00006123-198804000-00006; HESS JR, 1992, J TRAUMA, V32, P40, DOI 10.1097/00005373-199201000-00009; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JAKUBOWSKI J, 1982, STROKE, V13, P601, DOI 10.1161/01.STR.13.5.601; JOHSHITA H, 1990, J NEUROSURG, V73, P410, DOI 10.3171/jns.1990.73.3.0410; Jones SB, 2003, ANESTH ANALG, V96, P363, DOI 10.1097/00000539-200302000-00012; JUVELA S, 1991, J NEUROSURG, V74, P386, DOI 10.3171/jns.1991.74.3.0386; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KATZ L, 1995, J CEREBR BLOOD F MET, V15, P1032, DOI 10.1038/jcbfm.1995.129; Kempski O, 1996, ACT NEUR S, V66, P114; Kramer GC, 1998, ACTA ANAESTH SCAND, V42, P141, DOI 10.1111/j.1399-6576.1998.tb05099.x; KRAUS GE, 1991, SURG NEUROL, V35, P20, DOI 10.1016/0090-3019(91)90197-H; Kreimeier U, 2002, ACTA ANAESTH SCAND, V46, P625, DOI 10.1034/j.1399-6576.2002.460601.x; Laubenthal H, 1998, ANASTH INTENSIV NOTF, V33, P251, DOI 10.1055/s-2007-994241; LAUBENTHAL H, 1986, ANASTH INTENSIVMED, V169, P1; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; MATSUDA M, 1990, ACTA NEUROCHIR, V105, P98, DOI 10.1007/BF01669990; MEYER CHA, 1983, NEUROSURGERY, V12, P58, DOI 10.1227/00006123-198301000-00010; MICKEY B, 1984, J NEUROSURG, V60, P916, DOI 10.3171/jns.1984.60.5.0916; NEILDWYER G, 1994, ACTA NEUROCHIR, V131, P137, DOI 10.1007/BF01401464; NOLTE D, 1992, AM J PHYSIOL, V263, pH1411, DOI 10.1152/ajpheart.1992.263.5.H1411; NORNES H, 1973, J NEUROSURG, V39, P226, DOI 10.3171/jns.1973.39.2.0226; Pellegrino L.J., 1979, STEREOTAXIC ATLAS RA; Petroianu GA, 2000, ANESTH ANALG, V90, P795; Prunell GF, 2003, NEUROSURGERY, V52, P165, DOI 10.1097/00006123-200301000-00022; Schwartz AY, 2000, J NEUROSCI METH, V96, P161, DOI 10.1016/S0165-0270(00)00156-4; Sehba FA, 2000, J CEREBR BLOOD F MET, V20, P604, DOI 10.1097/00004647-200003000-00018; Smith SL, 1996, J NEUROSURG, V84, P229, DOI 10.3171/jns.1996.84.2.0229; Steinbauer M, 1996, PROG APPL MICROCIR, V22, P114; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; WEST GB, 1985, INT ARCH ALLER A IMM, V78, P221, DOI 10.1159/000233888; Widenka DC, 1999, J NEUROSURG, V90, P1098, DOI 10.3171/jns.1999.90.6.1098; WILLIAMS RW, 1998, J COMP NEUROL, V15, P344; Zausinger S, 2002, BRAIN RES PROTOC, V9, P112, DOI 10.1016/S1385-299X(02)00138-1	49	26	27	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2004	55	3					679	686		10.1227/01.NEU.0000134558.28977.EE			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	860AH	WOS:000224309000047	15335436				2022-02-06	
J	McPherson, KM; Brander, P; Taylor, WJ; McNaughton, HK				McPherson, KM; Brander, P; Taylor, WJ; McNaughton, HK			Consequences of stroke, arthritis and chronic pain - are there important similarities?	DISABILITY AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; RHEUMATOID-ARTHRITIS; HEALTH-CARE; REHABILITATION; DISABLEMENT; OUTCOMES; MODELS; CLASSIFICATION; EXPERIENCE; MEDICINE	Purpose: This study aimed to explore the applicability of a previously derived model of what mattered most to people with arthritis across a number of different disabling conditions. Method: A qualitative study using interviews with 30 participants from three out-patient groups (rheumatoid arthritis, stroke and chronic pain) was conducted. Participants were asked to identify and discuss the most important consequences of living with their condition. Narratives were explored for similarities and differences within and across conditions. Results: While diagnostically related differences were clearly evident, particularly in categories within the Intrinsic, Extrinsic and Future Issues themes, a marked level of similarity in view was apparent in two themes, Taking Charge and Perceptions of Normality. Conclusions: The study identified a shared perspective about a number of issues, but also detailed where there were differences. We suggest explicit consideration of the themes highlighted in this research, and a deeper understanding of the inter-relatedness of seemingly separate issues will help health professionals and researchers re-think ways of working with people who have disabling conditions, and identify different factors to address in measuring the success of rehabilitation.	Univ Southampton, Sch Hlth Profess, Southampton SO17 1BJ, Hants, England; Univ Otago, Wellington Sch Med & Hlth Sci, Dunedin, New Zealand; Med Res Inst New Zealand, Wellington, New Zealand		McPherson, KM (corresponding author), Univ Southampton, Sch Hlth Profess, Bldg 45,Highfield Campus, Southampton SO17 1BJ, Hants, England.	K.McPherson@soton.ac.uk	McNaughton, Harry/AAC-6556-2020	McPherson, Kathryn/0000-0003-1240-8882; McPherson, Kath/0000-0003-0487-8497			ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; BECKER G, 1995, MED ANTHROPOL Q, V9, P165, DOI 10.1525/maq.1995.9.2.02a00040; Bickenbach JE, 1999, SOC SCI MED, V48, P1173, DOI 10.1016/S0277-9536(98)00441-9; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; CHARMAZ K, 1990, SOC SCI MED, V30, P1161, DOI 10.1016/0277-9536(90)90256-R; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Coughlin AM, 2000, ARCH PHYS MED REHAB, V81, P739, DOI 10.1053/apmr.2000.5586; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; Gustafsson M, 1996, PATIENT EDUC COUNS, V29, P179, DOI 10.1016/0738-3991(96)00864-6; HAAS J, 1993, AM J PHYS MED REHAB, V72, P228, DOI 10.1097/00002060-199308000-00011; Haigh R, 2001, J REHABIL MED, V33, P273; HALL RW, 1995, TRANSPORT PLAN TECHN, V19, P1, DOI 10.1080/03081069508717554; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9; Maclean N, 2000, SOC SCI MED, V50, P495; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; McPherson KM, 2001, DISABIL REHABIL, V23, P706; MCPHERSON KM, 2000, NZ J PHYSIOTHERAPY, V28, P1; Oliver M, 1998, BRIT MED J, V317, P1446, DOI 10.1136/bmj.317.7170.1446; Patton MQ, 1999, HEALTH SERV RES, V34, P1189; Persson LO, 1999, SCAND J RHEUMATOL, V28, P137; PETERS DJ, 1995, DISABIL REHABIL, V17, P135, DOI 10.3109/09638289509166708; Peters DJ, 1996, DISABIL REHABIL, V18, P593, DOI 10.3109/09638289609166320; Pound P, 1998, CLIN REHABIL, V12, P338, DOI 10.1191/026921598677661555; *QSR, 1997, NUDIST 4 0; Ray L, 1999, J ADV NURS, V30, P1017, DOI 10.1046/j.1365-2648.1999.01207.x; Strauss A., 1998, BASICS QUALITATIVE R, V2nd Edition; Wade DT, 2000, BMJ-BRIT MED J, V320, P1385, DOI 10.1136/bmj.320.7246.1385; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 1993, INT CLASS IMP DIS HA; World Health Organization, 2007, INT CLASS FUNCT DIS; World Health Organization, 1999, INT CLASS IMP DIS HA	34	26	26	0	0	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1464-5165			DISABIL REHABIL	Disabil. Rehabil.	AUG 19	2004	26	16					988	999		10.1080/09638280410001702414			12	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	846OJ	WOS:000223324800005	15371047				2022-02-06	
J	Deniselle, MCG; Garay, L; Lopez-Costa, JJ; Gonzalez, S; Mougel, A; Guennoun, R; Schumacher, M; De Nicola, AF				Deniselle, MCG; Garay, L; Lopez-Costa, JJ; Gonzalez, S; Mougel, A; Guennoun, R; Schumacher, M; De Nicola, AF			Progesterone treatment reduces NADPH-diaphorase/nitric oxide synthase in Wobbler mouse motoneuron disease	BRAIN RESEARCH			English	Article						progesterone; neuroprotection; Wobbler mouse; nitric oxide synthase; motoneuron disease	TRAUMATIC BRAIN-INJURY; SPINAL-CORD; LIPID-PEROXIDATION; TRANSGENIC MICE; CELLULAR BASIS; MOTOR-NEURONS; GENETIC MODEL; PROTEIN; NEUROPROTECTION; EXPRESSION	Previous work demonstrated that progesterone (PROG) treatment attenuates morphological, molecular and functional abnormalities in the spinal cord of the Wobbler (Wr) mouse, a genetic model of motoneuron degeneration. Wr mice show a marked up-regulation of the nitric oxide synthesizing enzyme (NOS). Since nitric oxide is a highly reactive species, it may play a role in neuropathology of Wr mice. We now studied if PROG neuroprotection involved changes of NOS activity in motoneurons and astrocytes, determined by the nicotinamide adenine dinucleotide phosphate-diaphorase (NADPHD) histochemical reaction. Two and four-month-old Wr mice at the progressive and stabilization stages of the disease, respectively, and their age-matched controls were left untreated or received a single 20-mg PROG pellet for 18 days. PROG reduced the high number of NADPHD-active motoneurons and white matter astrocytes in 2-month-old Wr mice but was unable to change the low number of NADPHD-active motoneurons in 4-month-old Wr mice or astrocytes in this age group. A large number of motoneurons in 2-month-old Wr mice showed a vacuolated phenotype.. which was significantly reverted by PROG treatment. In summary, PROG treatment during the early symptomatic stage of the disease caused a significant reduction of NADPHD-active motoneurons and astrocytes and also reduced vacuolated degenerating cells, suggesting that blockade of NO synthesis and oxidative damage may contribute to steroid neuroprotection. (C) 2004 Elsevier B.V. All rights reserved.	Univ Buenos Aires, Lab Neuroendocrine Biochem, Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Dept Human Biochem, Fac Med, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Inst Biol Celular & Neurociencias Prof Eduardo De, RA-1053 Buenos Aires, DF, Argentina; Fdn Barcelo, Inst Univ Ciencias Salud, Buenos Aires, DF, Argentina; Hop Bicetre, INSERM, U488, Paris, France		De Nicola, AF (corresponding author), Univ Buenos Aires, Lab Neuroendocrine Biochem, Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar	Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300			Abe K, 1997, J NEUROSCI RES, V48, P63; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; BEAL MF, 1998, BIOCHIM BIOPHYS ACTA, V1366, P217; Boillee S, 2003, MOL NEUROBIOL, V28, P65, DOI 10.1385/MN:28:1:65; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Clowry GJ, 1996, NEUROSCI LETT, V215, P177, DOI 10.1016/S0304-3940(96)12971-2; Corvino V, 2003, NEUROCHEM RES, V28, P341, DOI 10.1023/A:1022345720852; Dave KR, 2003, EXP NEUROL, V182, P412, DOI 10.1016/S0014-4886(03)00091-8; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Deniselle MCG, 1999, BRAIN RES, V841, P78, DOI 10.1016/S0006-8993(99)01783-7; Deniselle MCG, 2001, CELL MOL NEUROBIOL, V21, P237, DOI 10.1023/A:1010943104315; Deniselle MCG, 1999, NEUROCHEM RES, V24, P1, DOI 10.1023/A:1020918310281; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; GUANGPING X, 2001, NEUROSCI LETT, V300, P141; Gurney ME, 2000, BIOESSAYS, V22, P297, DOI 10.1002/(SICI)1521-1878(200003)22:3<297::AID-BIES12>3.0.CO;2-I; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1982, J NEUROSURG, V49, P563; Henderson JT, 1996, J NEUROSCI, V16, P7574; Ikeda K, 1998, J NEUROL SCI, V160, P9, DOI 10.1016/S0022-510X(98)00224-X; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kong JM, 1998, J NEUROSCI, V18, P3241; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LEHMANN A, 1974, ATLAS STEREOTAXIQUE; Melcangi RC, 2000, PROG NEUROBIOL, V60, P291, DOI 10.1016/S0301-0082(99)00028-3; MITSUMOTO H, 1982, BRAIN, V105, P811, DOI 10.1093/brain/105.4.811; PHUL RK, 2000, LATERAL SCLER OTHER, V4, P259; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Saravia FE, 2001, CELL MOL NEUROBIOL, V21, P15, DOI 10.1023/A:1007165127420; Sasaki S, 2002, ACTA NEUROPATHOL, V103, P421, DOI 10.1007/s00401-001-0484-6; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; Stewart VC, 2002, EUR J NEUROSCI, V15, P458, DOI 10.1046/j.0953-816x.2001.01878.x; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tsuzaka K, 2001, MUSCLE NERVE, V24, P474, DOI 10.1002/mus.1029; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; YUNG KKL, 1992, NEUROSCIENCE, V50, P209, DOI 10.1016/0306-4522(92)90393-G	43	26	26	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 16	2004	1014	1-2					71	79		10.1016/j.braines.2004.04.004			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	838PZ	WOS:000222726700008	15212993				2022-02-06	
J	Meixensberger, J; Renner, C; Simanowski, R; Schmidtke, A; Dings, J; Roosen, K				Meixensberger, J; Renner, C; Simanowski, R; Schmidtke, A; Dings, J; Roosen, K			Influence of cerebral oxygenation following severe head injury on neuropsychological testing	NEUROLOGICAL RESEARCH			English	Article						head injury; brain oxygenation; outcome; neuropsychological deficits	TRAUMATIC BRAIN-INJURY; TISSUE OXYGENATION; BLOOD-FLOW; CBF	Despite recent advances in the management of severe head injury the mortality and morbidity remains high. Intracranial pressure (ICP) and cerebral perfusion pressure (CPP) are crucial parameters for the correct management at the intensive care unit, due to their therapeutic and prognostic importance. In addition, regional brain tissue oxygenation (p(ti)O(2)) seems to be of importance. While different studies demonstrated the impact of cerebral hypoxia on outcome (mortality), no data are available focusing on morbidity (neuropsychological deficits). Therefore, our study is carried out to demonstrate a possible relationship between amount of cerebral oxygenation during acute stage after severe head injury and neuropsychological outcome. Besides ICP and CPP, p(ti)O(2) was monitored in 40 severely head injured patients during the ICU stay from the day of admission until day 10. Monitoring data were stored and amount of hypoxic episodes were calculated. Besides outcome using the Glasgow Outcome Scale neuropsychological testing was performed 2-3 years after injury. Analysing the quality of brain tissue oxygenation, a relationship to the performance in neuropsychological tests could be found. Patients with low brain tissue oxygenation had a worse outcome in neuropsychological testing, especially concerning intelligence and memory. Associated with these deficits patients showed a reduced performance in their profession. Our data suggest a possible predictive value of brain tissue oxygen on morbidity analysing neurocognitive function after head injury. This may implicate monitoring and treatment of cerebral hypoxia.	Univ Leipzig, Dept Neurosurg, Leipzig, Germany; Univ Wurzburg, Dept Neurosurg, Wurzburg, Germany; Univ Wurzburg, Dept Psychiat, Wurzburg, Germany		Meixensberger, J (corresponding author), Univ Klinikum Leipzig, Neurochirurg Klin & Poliklin, Dept Neurosurg, Liebigstr 20, D-04103 Leipzig, Germany.	meix@medizin.uni-leipzig.de		Schmidtke, Armin/0000-0001-5719-9856			Bardt TF, 1998, ACT NEUR S, V71, P153; BECKER DP, 1982, NEUROLOGICAL SURG, P2137; CHOI SC, 1995, NEUROTRAUMA, P779; Cruz J, 2000, J NEUROSURG, V92, P736; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HASS WK, 1976, HEAD INJURIES, P35; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Meixensberger J., 1998, Intensivmedizin und Notfallmedizin, V35, P72; MEIXENSBERGER J, 1999, ANASTH INTENSIVMED, V34, P548; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; UZZELL BP, 1986, INTRACRANIAL PRESSUR, V6, P687; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Vath A, 2001, NEUROL RES, V23, P315, DOI 10.1179/016164101101198677; [No title captured]	16	26	26	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2004	26	4					414	417		10.1179/016164104225014094			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	829CP	WOS:000222021400010	15198869				2022-02-06	
J	Atchison, TB; Sander, AM; Struchen, MA; High, WM; Roebuck, TM; Contant, CF; Wefel, JS; Novack, TA; Sherer, M				Atchison, TB; Sander, AM; Struchen, MA; High, WM; Roebuck, TM; Contant, CF; Wefel, JS; Novack, TA; Sherer, M			Relationship between neuropsychological test performance and productivity at 1-year following traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							COMMUNITY INTEGRATION QUESTIONNAIRE; CLOSED-HEAD-INJURY; COMA-DATA-BANK; SUPPORTED EMPLOYMENT; WORK; RETURN; REHABILITATION; PREDICTORS; ABILITY; EMPLOYABILITY	While there has been strong evidence for the ability of neuropsychological performance at resolution of posttraumatic amnesia to predict later productivity, there has been less conclusive evidence for the relationship of neuropsychological test scores to concurrent productivity status. The purpose of the current study was to evaluate the relationship of neuropsychological test performance at 1 year post-injury to productivity assessed at the same time point. Participants were 518 persons with medically documented TBI who were enrolled in the TBI Model Systems Research and Demonstration Project. Stepwise logistic regression was utilized to determine the contributions of neuropsychological test scores to productivity after accounting for demographic characteristics, injury severity, and pre-injury productivity. Missing neuropsychological test scores were accounted for in the model. Variables that remained in the model and accounted for a significant proportion of the variance included age, duration of impaired consciousness, pre-injury productivity, and scores on measures of GOAT, Logical Memory II, and Trail Making Test, part B. The results indicate that neuropsychological test performance provides important information regarding the ability of persons with injury to return to productive activities. The results also indicate that inability to complete neuropsychological tests at 1 year post-injury is associated with non-productive activity.	W Texas A&M Univ, Dept Behav Sci, Canyon, TX 79016 USA; Univ Houston, Dept Psychol, Houston, TX USA; Inst Rehabil & Res, Brain Injury Res Ctr, Houston, TX USA; Baylor Coll Med, Houston, TX 77030 USA; Natl Rehabil Hosp, Dept Neurosurg, Washington, DC USA; Natl Rehabil Hosp, Dept Phys Med & Rehabil, Washington, DC USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Alabama Birmingham, Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL USA; Methodist Rehabil Ctr, Dept Neuropsychol, Jackson, MS USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA		Atchison, TB (corresponding author), W Texas A&M Univ, Dept Behav Sci, Box 60296, Canyon, TX 79016 USA.	tatchison@mail.wtamu.edu					BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, BRAIN INJURY, V13, P417; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Goran DA, 1997, ARCH CLIN NEUROPSYCH, V12, P691, DOI 10.1016/S0887-6177(97)00004-8; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hamsher K., 1989, MULTILINGUAL APHASIA; Hanlon RE, 1999, BRAIN INJURY, V13, P873; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; Isaki E, 2000, BRAIN INJURY, V14, P441; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KlOve H, 1963, MED CLIN N AM; Kraus J. F., 1999, REHABILITATION ADULT, P3; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; KREUTZER JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Matthews CG., 1964, INSTRUCTION MANUAL A; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; MELAMED S, 1985, SCAND J REHABIL MED, P21; Najenson T, 1980, Int Rehabil Med, V2, P17; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Putnam S, 1999, REHABILITATION ADULT, P147; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sbordone R. J., 1998, ECOLOGICAL VALIDITY; Schneider JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P658; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith A., 1982, SYMBOL DIGIT MODALIT; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TAYLOR JM, 1959, PSYCHOL APPRAISAL CH; WEBER NC, 1984, STAT PROBABIL LETT, V2, P275, DOI 10.1016/0167-7152(84)90064-6; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	60	26	26	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	2004	18	2					249	265		10.1080/13854040490501475			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	850HU	WOS:000223602600005	15587672				2022-02-06	
J	Formisano, R; Carlesimo, GA; Sabbadini, M; Loasses, A; Penta, F; Vinicola, V; Caltagirone, C				Formisano, R; Carlesimo, GA; Sabbadini, M; Loasses, A; Penta, F; Vinicola, V; Caltagirone, C			Clinical predictors and neuropsychological outcome in severe traumatic brain injury patients	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; prolonged coma; neuropsychological outcome; predictive factors	CLOSED-HEAD-INJURY; POSTTRAUMATIC AMNESIA; PRACTICAL SCALE; NEUROGENIC DYSPHAGIA; COMA; MEMORY; REHABILITATION; DAMAGE	Background. The aim of the study was to evaluate the possible significant role of some clinical factors in predicting cognitive outcome in a group of severe traumatic brain injury (TBI) patients, with Glasgow Coma Scale (GCS) lower than 8 and duration of unconsciousness for at least 15 days (prolonged coma). Method. A consecutive sample of 25 survivors of severe TBI attending the Physical and Cognitive Rehabilitation program participated in this study. The neuropsychological test battery included: Word-list Learning, Prose recall, Rey Figure Delayed recall, Word fluency, Raven's Progressive Matrices' 47. The clinical variables evaluated in correlation with the neuropsychological outcome were the following: age, duration of unconsciousness, duration of post-traumatic amnesia, interval from head trauma to neuropsychological evaluation, interval from head trauma to recovery of oral feeding, and finally interval from head trauma to first verbal communication. Findings. The clinical variable with a significant predictive value on most neuropsychological scores was the interval from head trauma to the recovery of oral feeding. Conclusions. If this result is confirmed in larger samples, time interval of oral feeding recovery from head trauma should be considered as a possible predictor of neuropsychological outcome in TBI patients with prolonged coma.	Santa Lucia Fdn, IRCCS, Rehabil Hosp, I-00179 Rome, Italy; Pediat Hosp Bambino Gesu, Rome, Italy		Formisano, R (corresponding author), Santa Lucia Fdn, IRCCS, Rehabil Hosp, Via Ardeatina 306, I-00179 Rome, Italy.	r.formisano@hsantalucia.it	Caltagirone, Carlo/B-4930-2013				ALBERICO A, 1987, J NEUROSURG, V67, P649; ARNOLD K, 1969, CHIRURG, V40, P263; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; BROOKS D N, 1975, Cortex, V11, P329; Brooks D N, 1979, Int Rehabil Med, V1, P160; Carlesimo GA, 1997, CORTEX, V33, P131, DOI 10.1016/S0010-9452(97)80009-3; Carlesimo GA, 1998, CORTEX, V34, P1, DOI 10.1016/S0010-9452(08)70734-2; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CARLSSON GS, 1986, THESIS GOTEMBURG U; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; FORMISANO R, 1996, EUR J NEUROL S2, V3, P58; FORMISANO R, 1996, 5 C INT ASS STUD TTR; FROWEIN RA, 1989, ADV NEUROSURG, V17, P36; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauri M., 1997, ARCH PSICOL NEUROL P, V58, P621; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MILLER JD, 1986, ADV NEUROTRAUMATOLOG, V1; NEUMANN S, 1995, DYSPHAGIA, V10, P7; OVERGAARD J, 1973, LANCET, V2, P631; PHILIPPON M, 1973, NEUROCHIRURG PARIS, V19, P581; Prosiegel M, 2000, DYSPHAGIA, V15, P173, DOI 10.1007/s004550000024; RAVEN JC, 1947, PROGR MATRICS SET A, P1949; REID DB, 1993, J CLIN PSYCHOL, V49, P245, DOI 10.1002/1097-4679(199303)49:2<245::AID-JCLP2270490219>3.0.CO;2-1; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tognoni G., 1987, ITALIAN J NEUROLOG S, V8, P44; VAKIL E, 1992, J CONSULTANT CLIN PS, V5, P802; Vikki Juhani, 1994, Journal of Clinical and Experimental Neuropsychology, V16, P325; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; WILSON BA, 1999, BRAIN INJ       0713, P502; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992	41	26	29	0	7	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	MAY	2004	146	5					457	462		10.1007/s00701-004-0225-4			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	816MU	WOS:000221114800008	15118882				2022-02-06	
J	Ward, H; Shum, D; Dick, B; McKinlay, L; Baker-Tweney, S				Ward, H; Shum, D; Dick, B; McKinlay, L; Baker-Tweney, S			Interview study of the effects of paediatric traumatic brain injury on memory	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; EXPLICIT MEMORY; POSTTRAUMATIC AMNESIA; CHILDREN; IMPLICIT; DISSOCIATION; ADOLESCENTS; PERFORMANCE	Primary objective : To investigate the effects of traumatic brain injury (TBI) on children's day-to-day memory functioning. Research design : A qualitative, interview-based procedure. Methods and procedures : Thirteen parents of children and adolescents with TBI were interviewed for 2 hours. Data from 12 of the interviews were analysed using content analysis, which involved transcribing notes, sorting information into categories, identifying similarities or differences among the categories and isolating meaningful trends. Main outcomes and results : Over half of the children experienced explicit (past recall) and prospective memory (future intentions) loss, but few experienced implicit memory (e.g. procedural) loss. Further, parents utilized their own interventions in minimizing their children's memory disabilities. Conclusion : Memory loss is common and can impact on everyday living, but is selective in the types of memory affected. Follow-ups are recommended to assess quantitatively, the so-far, little-known effects of paediatric TBI on prospective memory and to examine more closely parent interventions to assess their wider applicability in TBI rehabilitation.	Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia; Griffith Univ, Neuropsychol Clin, Brisbane, Qld 4111, Australia; So Cross Univ, Lismore, Australia; Royal Childrens Hosp, Queensland Paediat Reahbil Serv, Brisbane, Qld 4029, Australia		Ward, H (corresponding author), Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia.	h.ward@griffith.edu.au	Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262; McKinlay, Lynne/0000-0002-6677-0628			Baddeley A.D., 1995, HDB MEMORY DISORDERS, P3; BAKERWARD L, 1993, MEMORY EVERYDAY LIFE, P13; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; Berg BL., 2001, QUALITATIVE RES METH; BLACKMAN P, 1990, BEHAV ANAL THEORY PR; BRANDIMONTE MA, 1996, PROSPECTIVE MEMORY T; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Cockburn J., 1996, PROSPECTIVE MEMORY T, P327; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GABRIELI JDE, 1995, PSYCHOL SCI, V6, P76, DOI 10.1111/j.1467-9280.1995.tb00310.x; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; Graf P, 2001, CONSCIOUS COGN, V10, P437, DOI 10.1006/ccog.2001.0504; HANNAY HJ, 1998, J CLIN EXPT NEUROPSY, V11, P444; JACOBS MP, 1993, NEUROPSYCHOL REHABIL, V3, P341, DOI 10.1080/09602019308401446; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JENNETT WB, 1981, MANAGEMENT HEAD INJU; JENNETT WB, 1969, BRIT J PSYCHIAT, V4, P40; Johnson SC, 2001, J INT NEUROPSYCH SOC, V7, P55, DOI 10.1017/S135561770171106X; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; LAZAR JJ, 1997, DISS ABSTR INT B, V57, P5969; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; Locke K., 2001, GROUNDED THEORY MANA; Marlowe WB, 2000, DEV NEUROPSYCHOL, V18, P445, DOI 10.1207/S1532694209Marlowe; Martin G, 1996, BEHAV MODIFICATION W; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; McDaniel M.A., 1996, PROSPECT MEM THEORY, P115; Meier B, 2000, APPL COGNITIVE PSYCH, V14, pS11, DOI 10.1002/acp.768; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MICHAUD LJ, 1999, REHABILITATION ADULT, P345; MILNER B, 1985, HUM NEUROBIOL, V4, P137; MOSCOVITCH M, 1992, NEUROPSYCHOLOGY MEMO, P5; NISSEN MJ, 1992, NEUROPSYCHOLOGY MEMO, P203; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Passolunghi MC, 1995, INT J BEHAV DEV, V18, P631, DOI 10.1177/016502549501800404; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Pushkar D, 1997, PSYCHOL AGING, V12, P600, DOI 10.1037/0882-7974.12.4.600; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; SAINTCYR JA, 1992, NEUROPSYCHOLOGY MEMO, P188; Schacter D. L., 2000, OXFORD HDB MEMORY, P627; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P149, DOI 10.1076/jcen.21.2.149.929; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; SHUM D, 2002, J INT NEUROPSYCH SOC, V8, P160; SILVER BV, 1994, ARCH PHYS MED REHAB, V75, P742; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slifer KJ, 1996, J HEAD TRAUMA REHAB, V11, P39, DOI 10.1097/00001199-199602000-00006; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; SUNDERLAND A, 1996, J GERONTOL, V41, P376; Vakil E, 1996, BRAIN COGNITION, V31, P75, DOI 10.1006/brcg.1996.0026; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348; Yakovlev PI, 1967, REGIONAL DEV BRAIN E, P3; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, Vxiv; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P181	74	26	26	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2004	18	5					471	495		10.1080/02699050310001646107			25	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	800SS	WOS:000220048600006	15195795				2022-02-06	
J	Cantor, JB; Gordon, WA; Schwartz, ME; Charatz, HJ; Ashman, TA; Abramowitz, S				Cantor, JB; Gordon, WA; Schwartz, ME; Charatz, HJ; Ashman, TA; Abramowitz, S			Child and parent responses to a brain injury screening questionnaire	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	brain injuries; disabled children; questionnaires; rehabilitation; signs and symptoms; schools	LEARNING-DISABILITIES; HEAD-INJURY; SELF-REPORT; INTERVENTION; SENSITIVITY; STUDENTS	Objectives: To determine, by using a Brain Injury Screening Questionnaire (BISQ), in a sample of urban public school students, what proportion of children are at risk for having sustained a brain injury, to measure the incidence of blows to the head and alterations in mental status, and to determine whether children and parents report differently on the BISQ. Design: Survey. Setting: Research facility and community. Participants: A total of 137 urban students (age range, 12-19y) of varied ethnicity, who were recruited in 2 public schools, and their parents. Interventions: Not applicable. Main Outcome Measure: The BISQ as completed by children and parents. Results: Fourteen children (10%) were at risk for having sustained a brain injury because they or their parents reported an alteration in mental status and 5 or more symptoms sensitive and specific to traumatic brain injury. Most children were reported to have experienced blows to the head, and 50% were reported to have experienced an alteration in mental status. In all areas, no significant differences were found between parent and child reports. Conclusions: There may be significant numbers of children with undetected brain injury in schools. The BISQ is a useful tool to identify children at risk for having sustained a brain injury. Histories should be obtained from parents and children who are older than 11 years when screening children for brain injury.	Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA		Cantor, JB (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240, New York, NY 10029 USA.	joshua.cantor@mssm.edu	Ashman, Teresa/B-1621-2013	Ashman, Teresa/0000-0003-2401-7192			ADELMAN HS, 1989, J LEARN DISABIL, V22, P608, DOI 10.1177/002221948902201004; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; BLASKEY J, 1999, DECISION MAKING PEDI, P84; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; Brooks BM, 2003, DISABIL REHABIL, V25, P51, DOI 10.1080/09638280210151987; Cronin AF, 2001, AM J OCCUP THER, V55, P377, DOI 10.5014/ajot.55.4.377; DAmato RC, 1996, J LEARN DISABIL, V29, P670, DOI 10.1177/002221949602900611; *DEP PHYS MED REH, REH NEUR SERV; DePompei R, 1997, J HEAD TRAUMA REHAB, V12, pR6, DOI 10.1097/00001199-199704000-00001; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1990, TRAUMATIC BRAIN INJU, P107; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gowers S, 2002, BRIT J PSYCHIAT, V180, P266, DOI 10.1192/bjp.180.3.266; Grimmer K, 2000, J ADOLESCENT HEALTH, V27, P273, DOI 10.1016/S1054-139X(00)00119-1; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keogh E, 2001, EUR J PAIN, V5, P11, DOI 10.1053/eujp.2000.0210; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LAZAR MF, 1995, J HEAD TRAUMA REHAB, V10, P55, DOI 10.1097/00001199-199510000-00007; le Coq EM, 2000, QUAL LIFE RES, V9, P625, DOI 10.1023/A:1008977200176; LEHMKUHL D, 1988, TIRR SYMPTOM CHECKL; MASTROPIERI MA, 1988, LEARNING DISABILITIE, P161; *NY CIT DEP ED, LEARN DIS FACTS; Picard M, 1991, HELPS BRIEF SCREENIN; *RES TRAIN CTR COM, 1997, BRAIN INJ SCREEN QUE; ROSENBAUM P, 1990, QUALITY LIFE ASSESSM, P205; RUTTER M, 1977, J CHILD PSYCHOL PSYC, V18, P1, DOI 10.1111/j.1469-7610.1977.tb00413.x; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; Scruggs TE, 2002, LEARN DISABILITY Q, V25, P155, DOI 10.2307/1511299; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; *US DEP ED, 2001, 33 US DEP ED	38	26	26	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S54	S60		10.1016/j.apmr.2003.08.113			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	812FL	WOS:000220825300007	15083422				2022-02-06	
J	Shi, RY				Shi, RY			The dynamics of axolemmal disruption in guinea pig spinal cord following compression	JOURNAL OF NEUROCYTOLOGY			English	Article							POLYETHYLENE-GLYCOL; ULTRASTRUCTURAL-CHANGES; CYTOCHEMICAL EVIDENCE; NERVE MEMBRANES; STRETCH INJURY; AXONAL INJURY; WHITE-MATTER; OPTIC-NERVE; CALCIUM; PERMEABILITY	Membrane damage has been postulated as a critical factor in mediating axonal degeneration in brain and spinal cord trauma. Despite compelling evidence of membrane disruption as a result of physical insults in both in vivo and in vitro studies, the dynamics of such damage over the time post injury in in vivo studies has not been well documented. Using a well-characterized in vivo guinea pig spinal cord compression model and horseradish peroxidase exclusion assay, we have documented significant membrane disruption at 1 hr, 3 days, and 7 days following injury. Furthermore, the membrane damage was found to spread laterally 10 mm beyond the center of original compression site in both rostral and caudal directions. A second-degree polynomial fit of the measured data predicts a bilateral spread of approximately 20-21 mm of membrane disruption from the epicenter of injury over a period of about 20 days. Thus, this study shows that membrane damage exists days, and possibly weeks, after spinal cord trauma in live guinea pigs. This provides the evidence necessary to investigate the role of membrane damage in triggering axonal deterioration in the future. Furthermore, this study has also revealed a long therapeutical window for membrane repair and functional enhancement following traumatic injury in the central nervous system.	Purdue Univ, Sch Vet Med, Inst Appl Neurol, Dept Basic Med Sci, W Lafayette, IN 47907 USA		Shi, RY (corresponding author), Purdue Univ, Sch Vet Med, Inst Appl Neurol, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	riyi@purdue.edu	duan, hf/F-9166-2011				ASANO T, 1995, J NEUROTRAUM, V12, P993; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 2002, J EXP BIOL, V205, P1; Duerstock BS, 2002, J EXP BIOL, V205, P13; EMERY DG, 1987, EXP BRAIN RES, V67, P41, DOI 10.1007/BF00269451; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; HUANG PP, 1994, J NEUROTRAUM, V11, P547, DOI 10.1089/neu.1994.11.547; Kim H, 1996, STROKE, V27, P114, DOI 10.1161/01.STR.27.1.114; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; Lucas JH, 1997, NEUROSCIENTIST, V3, P89; LUO J, 2003, NEUROBIOLOGY LIPIDS, V2, P3; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MEIRI H, 1981, SCIENCE, V211, P709, DOI 10.1126/science.7455707; Peasley MA, 2002, AM J PHYSIOL-CELL PH, V283, pC980, DOI 10.1152/ajpcell.00591.2001; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1996, ACT NEUR S, V66, P81; RANSOM BR, 1990, STROKE, V21, P52; ROEDERER E, 1983, J NEUROSCI, V3, P153; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 2001, J NEUROCYTOL, V30, P829, DOI 10.1023/A:1019645505848; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572, DOI 10.1152/jn.1996.76.3.1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; SHI R, 2002, J NEUROTRAUM, V19, P1394; Shi RY, 1989, J NEUROTRAUM, V6, P261, DOI 10.1089/neu.1989.6.261; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763, DOI 10.1152/jn.2000.84.4.1763; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; STRAUTMAN AF, 1990, J NEUROSCI, V10, P3564; XIE XY, 1991, J NEUROSCI, V11, P3257; YAWO H, 1985, J NEUROSCI, V5, P1626; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1	40	26	27	0	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-4864			J NEUROCYTOL	J. Neurocytol.	MAR	2004	33	2					203	211		10.1023/B:NEUR.0000030695.76840.19			9	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	827DO	WOS:000221879200003	15322378				2022-02-06	
J	Tunblad, K; Ederoth, P; Gardenfors, A; Hammarlund-Udenaes, M; Nordstrom, CH				Tunblad, K; Ederoth, P; Gardenfors, A; Hammarlund-Udenaes, M; Nordstrom, CH			Altered brain exposure of morphine in experimental meningitis studied with microdialysis	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						blood-brain barrier; disease states; drug transport; meningitis; microdialysis; morphine; pharmacokinetics and pig	CEREBRAL PERFUSION-PRESSURE; P-GLYCOPROTEIN; ENERGY-METABOLISM; BARRIER TRANSPORT; IN-VIVO; PERMEABILITY; PERSPECTIVES; EXPRESSION; LIVER; RATS	Background: During pathologic conditions such as meningitis and traumatic brain injury the function of the blood-brain barrier (BBB) is disturbed. In the present study we examined the cerebral pharmacokinetic pattern of morphine in the intact brain and during experimentally induced meningitis using a pig model. Secondly, the use of intracerebral microdialysis as a potential tool for monitoring damage in the BBB by studying the pharmacokinetics of morphine is addressed. Methods: Six pigs were studied under general anaesthesia. One occipital and two frontal microdialysis probes and one pressure transducer were inserted into the brain tissue. Another probe was placed into the jugularis interna. Morphine 1 mg kg(-1) was administered as a 10-min infusion, and morphine concentrations were then measured for 3 h. Meningitis was subsequently induced by injecting lipopolysaccharide into the cisterna magna. When meningitis was established, the morphine experiment was repeated. Results: The unbound area under the concentration-time curve (AUC(u)) ratio of morphine in brain to blood was 0.47 (0.19) during the control period, and 0.95 (0.20) (P<0.001) during meningitis. The increase in the brain/blood AUC(u) ratio during meningitis implies decreased active efflux and increased passive diffusion of morphine over the BBB. The half-life of morphine in brain was longer than in blood during both periods, and was unaffected by meningitis. Conclusion: This study demonstrates that the morphine exposure to the brain is significantly increased during meningitis as compared with the control situation.	Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, SE-75124 Uppsala, Sweden; Univ Lund Hosp, Dept Anaesthesiol & Intens Care, S-22185 Lund, Sweden; Malmo Univ Hosp, Dept Anaesthesiol & Intens Care, Malmo, Sweden; Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden		Tunblad, K (corresponding author), Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, POB 591, SE-75124 Uppsala, Sweden.	Karin.Tunblad@farmbio.uu.se					BOJE KMK, 1995, J PHARMACOL EXP THER, V274, P1199; Bouw MR, 1998, PHARMACEUT RES, V15, P1673, DOI 10.1023/A:1011992125204; Bouw MR, 2000, PHARMACEUT RES, V17, P1220, DOI 10.1023/A:1026414713509; Bouw R, 2001, ACTA ANAESTH SCAND, V45, P390, DOI 10.1034/j.1399-6576.2001.045003390.x; BUNGAY PM, 1990, LIFE SCI, V46, P105, DOI 10.1016/0024-3205(90)90043-Q; Childs S, 1996, BBA-GENE STRUCT EXPR, V1307, P205, DOI 10.1016/0167-4781(96)00048-6; DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122; FENSTERMACHER JD, 1984, EDEMA, P383; Gardenfors A, 2002, ACTA NEUROCHIR, V144, P601, DOI 10.1007/s00701-002-0954-1; Gutmann H, 1999, DRUG METAB DISPOS, V27, P937; Hammarlund-Udenaes M, 2000, ADV DRUG DELIVER REV, V45, P283, DOI 10.1016/S0169-409X(00)00109-5; JOEL SP, 1988, J CHROMATOGR-BIOMED, V430, P394, DOI 10.1016/S0378-4347(00)83176-X; King M, 2001, NAT NEUROSCI, V4, P268, DOI 10.1038/85115; Letrent SP, 1999, DRUG METAB DISPOS, V27, P827; MATOS FF, 1992, J NEUROCHEM, V58, P1773, DOI 10.1111/j.1471-4159.1992.tb10053.x; Park WS, 2000, J KOREAN MED SCI, V15, P203, DOI 10.3346/jkms.2000.15.2.203; Piquette-Miller M, 1998, PHARMACEUT RES, V15, P706, DOI 10.1023/A:1011962818051; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; QUAGLIARELLO VJ, 1993, CLIN INFECT DIS, V17, P603, DOI 10.1093/clinids/17.4.603; Sawchuk RJ, 2000, ADV DRUG DELIVER REV, V45, P295, DOI 10.1016/S0169-409X(00)00104-6; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Stain-Texier F, 1999, BRIT J PHARMACOL, V128, P917, DOI 10.1038/sj.bjp.0702873; Tunblad K, 2003, PHARMACEUT RES, V20, P618, DOI 10.1023/A:1023250900462; VANBELLE K, 1995, J PHARMACOL EXP THER, V272, P1217; Xie RJ, 1999, BRIT J PHARMACOL, V128, P563, DOI 10.1038/sj.bjp.0702804	26	26	26	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2004	48	3					294	301		10.1111/j.0001-5172.2003.0311.x			8	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	803SS	WOS:000220251400005	14982561				2022-02-06	
J	Hellal, F; Bonnefont-Rousselot, D; Croci, N; Palmier, B; Plotkine, M; Marchand-Verrecchia, C				Hellal, F; Bonnefont-Rousselot, D; Croci, N; Palmier, B; Plotkine, M; Marchand-Verrecchia, C			Pattern of cerebral edema and hemorrhage in a mice model of diffuse brain injury	NEUROSCIENCE LETTERS			English	Article						diffuse brain injury; cerebral edema; electrolytes; blood-brain barrier; cerebral hemorrhage; hemoglobin; iron	CLOSED-HEAD INJURY; ATPASE ACTIVITY; BARRIER; HEMOGLOBIN; RATS; CONTUSION; IRON	This study aims to examine the time course of the brain edema formation in relation with blood-brain barrier (BBB) disruption and cerebral hemorrhage in a murine model of diffuse brain injury. Brain water content increased at 1 h post-injury and persisted up to 7 days. This event was associated with electrolyte imbalance such as Na+ increase within 24 h. Prominent Evans blue extravasation was also observed from 1 to 6 h post-injury. Concurrently, hemoglobin increased markedly by 1 h, reached a peak at 4 h and declined progressively within a week in association with a rise of parenchyma iron content between 24 h and 7 days. These results suggest that brain edema is vasogenic and that the hemorrhage process is involved in the BBB disruption and edema, both leading to post-traumatic secondary events. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	Univ Paris 05, Pharmacol Lab, UPRES EA2510, F-75006 Paris, France; Univ Paris 05, Lab Biochim Metab & Clin, UPRES EA 3617, F-75006 Paris, France		Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Pharmacol Lab, UPRES EA2510, 4 Ave Observ, F-75006 Paris, France.	catherine.verrecehia@univ-paris5.fr	Hellal, Farida/D-1834-2015; MARCHAND-LEROUX, Catherine/L-7453-2017; Rousselot, Bonnefont/U-7434-2019; Hellal, Farida/E-8533-2013	Hellal, Farida/0000-0002-9344-1846; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Bonnefont-Rousselot, Dominique/0000-0003-4689-9202			Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CLENDENON NR, 1978, J NEUROSURG, V49, P563, DOI 10.3171/jns.1978.49.4.0563; Ding-Zhou L, 2002, EUR J PHARMACOL, V457, P137, DOI 10.1016/S0014-2999(02)02686-9; Go K G, 1997, Adv Tech Stand Neurosurg, V23, P47; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Ildan F, 1995, SURG NEUROL, V44, P573; Kawai N, 2001, BRAIN RES, V895, P50, DOI 10.1016/S0006-8993(01)02026-1; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Lee KR, 1996, ACTA NEUROCHIR, V138, P396, DOI 10.1007/BF01420301; Lomnitski L, 2000, EXP TOXICOL PATHOL, V52, P177; MISRA HP, 1972, J BIOL CHEM, V247, P6960; PANTER SS, 1994, METHOD ENZYMOL, V231, P502; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Xue MZ, 2000, STROKE, V31, P1721, DOI 10.1161/01.STR.31.7.1721	21	26	30	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 26	2004	357	1					21	24		10.1016/j.neulet.2003.12.036			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	777HE	WOS:000189169800006	15036604				2022-02-06	
J	Ashman, TA; Schwartz, ME; Cantor, JB; Hibbard, MR; Gordon, WA				Ashman, TA; Schwartz, ME; Cantor, JB; Hibbard, MR; Gordon, WA			Screening for substance abuse in individuals with traumatic brain injury	BRAIN INJURY			English	Article							ALCOHOL-USE; PSYCHIATRIC-DISORDERS; AXIS-I; CAGE; INVENTORY-3; CONCORDANCE; PREVALENCE; DEPENDENCE; VALIDITY; RATINGS	Primary objective: To determine the utility of the CAGE, the Brief Michigan Alcohol Screening Test (BMAST) and the Substance Abuse Subtle Screening Inventory (SASSI-3) with individuals with traumatic brain injury (TBI), two studies were conducted examining the accuracy, sensitivity and specificity of these instruments. Research design: Data from self-report instruments were compared to a clinical interview, Structured Clinical Interview for DSM-IV ( SCID), to determine the accuracy, sensitivity and specificity. Methods and procedures: Two studies were conducted. In study I, 100 individuals with TBI were screened for alcohol abuse using the CAGE and the resulting classifications were compared with those derived from the SCID. In study II, 223 individuals were screened for alcohol abuse and drug abuse using the BMAST and SASSI-3 and the results of these screenings were compared with diagnoses obtained by the SCID. Main outcomes and results: The specificity of the self-report instruments was moderately high, ranging between 81 - 83%. The specificity of the CAGE for alcohol abuse both pre- and post-TBI was high, 96% and 86%, respectively. The sensitivity of the self-report instruments was most variable, ranging from 32 - 95%, with the SASSI face valid drug scale and the CAGE alcohol post-TBI indicating the most sensitivity, 95 and 91%, respectively. Conclusions: The findings suggest that the CAGE may be useful in screening for alcohol abuse and the face valid drug sub-scale of the SASSI-3 may be useful in screening for drug abuse in individuals with TBI.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10021 USA		Ashman, TA (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10021 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013	Ashman, Teresa/0000-0003-2401-7192			ALLEN JP, 1995, ARCH INTERN MED, V155, P1726, DOI 10.1001/archinte.155.16.1726; Arenth PM, 2001, BRAIN INJURY, V15, P499, DOI 10.1080/02699050010006002; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Cherner M, 2001, ARCH PHYS MED REHAB, V82, P780, DOI 10.1053/apmr.2001.23263; Conigliaro J, 2000, J GERIATR PSYCH NEUR, V13, P106, DOI 10.1177/089198870001300303; Cooney N, 1995, HDB ALCOHOLISM TREAT, P45; CORNEL M, 1994, J STUD ALCOHOL, V55, P466, DOI 10.15288/jsa.1994.55.466; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DAVIS C, 2001, ANN M AM PSYCH ASS S; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FULLER MG, 1994, J NEUROPSYCH CLIN N, V6, P143; Gibbon M., 1997, USERS GUIDE STRUCTUR; Hearne R, 2002, J ROY SOC MED, V95, P84, DOI 10.1258/jrsm.95.2.84; Hibbert L, 1998, PROF ENG, V11, P24; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kranzler HR, 1996, ADDICTION, V91, P859, DOI 10.1111/j.1360-0443.1996.tb03580.x; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Lazowski LE, 1998, J PERS ASSESS, V71, P114, DOI 10.1207/s15327752jpa7101_8; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LISKOW B, 1995, J STUD ALCOHOL, V56, P277, DOI 10.15288/jsa.1995.56.277; Maisto SA, 1995, ALCOHOL CLIN EXP RES, V19, P1510, DOI 10.1111/j.1530-0277.1995.tb01015.x; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MILLER F, 1997, USERS GUIDE SASSI 3; MILLER FG, 1908, USERS GUIDE SASSI QU; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; Reid MC, 1999, ARCH INTERN MED, V159, P1681, DOI 10.1001/archinte.159.15.1681; RYDON P, 1992, J STUD ALCOHOL, V53, P197, DOI 10.15288/jsa.1992.53.197; Samet JH, 1996, ARCH INTERN MED, V156, P2287, DOI 10.1001/archinte.156.20.2287; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Zanarini MC, 2000, J PERS DISORD, V14, P291, DOI 10.1521/pedi.2000.14.4.291	37	26	26	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2004	18	2					191	202		10.1080/0269905031000149506			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000007	14660230				2022-02-06	
J	Crutcher, KA				Crutcher, KA			Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						ApoE; degeneration; toxicity; amyloid; hypothesis; pathology; Alzheimer's disease	AMYLOID-BETA-PEPTIDE; TRAUMATIC BRAIN-INJURY; RECEPTOR-RELATED PROTEIN; LONG-TERM PROGRESSION; TRANSGENIC MICE; APOE GENOTYPE; E GENE; NERVE REGENERATION; MOUSE MODEL; TRANSCRIPTIONAL ACTIVITY	There is now a large body of evidence suggesting that apolipoprotein E (apoE) genotype is the single most important genetic risk factor for the most common (sporadic) form of Alzheimer's disease. Yet in proportion to the total number of investigations in this field, relatively few groups are studying the contribution of this cholesterol-binding protein to disease risk and severity. Of those that are, a major focus is on the impact of apoE on amyloid-related mechanisms of disease. I argue here that apoE should be considered a major culprit in its own right, not simply in a supporting role. The argument is based on several lines of evidence, including the fact that apoE is associated with both plaques and tangles, the overwhelming evidence for genetic risk of the disease attributed to apoE, increasing evidence that apoE might also modify risk of other nonamyloidogenic neurological diseases, neurotoxicity attributed to apoE and/or proteolytic fragments of apoE, negative consequences of transgenic expression of apoE4 in mice, and genetic evidence for polymorphisms that increase both apoE expression and disease risk, regardless of isoform.	Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; ApoLog Inc, Cincinnati, OH 45219 USA		Crutcher, KA (corresponding author), Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA.	crutchka@email.uc.edu	Crutcher, Keith/B-5435-2019	Crutcher, Keith/0000-0002-9176-5759	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG20249] Funding Source: Medline		Aizawa Y, 1997, BRAIN RES, V768, P208, DOI 10.1016/S0006-8993(97)00640-9; Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Ashford JW, 2002, J ALZHEIMERS DIS, V4, P169, DOI 10.3233/JAD-2002-4307; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Becker KG, 2001, NEUROLOGY, V57, P2148, DOI 10.1212/WNL.57.11.2148; Bedlack RS, 2003, NEUROLOGY, V60, P1022, DOI 10.1212/01.WNL.0000056689.50682.94; Bedlack RS, 2000, ARCH NEUROL-CHICAGO, V57, P1561, DOI 10.1001/archneur.57.11.1561; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; Bullido MJ, 2000, MICROSC RES TECHNIQ, V50, P261, DOI 10.1002/1097-0029(20000815)50:4<261::AID-JEMT2>3.0.CO;2-B; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Cambon K, 2000, NEUROSCIENCE, V97, P685, DOI 10.1016/S0306-4522(00)00065-8; Cedazo-Minguez A, 2001, NEUROREPORT, V12, P201, DOI 10.1097/00001756-200102120-00006; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Cho HS, 2001, J NEUROPATH EXP NEUR, V60, P342, DOI 10.1093/jnen/60.4.342; Citron M, 2000, MOL MED TODAY, V6, P392, DOI 10.1016/S1357-4310(00)01759-7; Corder EH, 1998, NAT MED, V4, P1182, DOI 10.1038/2677; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; CRUTCHER KA, 1994, EXP NEUROL, V130, P120, DOI 10.1006/exnr.1994.1191; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; DeMattos RB, 1999, J NEUROSCI, V19, P2464; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Genden EM, 2002, J RECONSTR MICROSURG, V18, P495, DOI 10.1055/s-2002-33321; GOODRUM JF, 1995, J NEUROCHEM, V64, P408; HAN SH, 1994, EXP NEUROL, V128, P13, DOI 10.1006/exnr.1994.1108; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; Hogh P, 2000, MULT SCLER J, V6, P226, DOI 10.1191/135245800678827851; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.3.CO;2-#; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Irizarry MC, 2000, ACTA NEUROPATHOL, V100, P451, DOI 10.1007/s004010000263; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan J, 1998, J NEUROSCI, V18, P195; Kokubo Y, 2000, STROKE, V31, P1299, DOI 10.1161/01.STR.31.6.1299; Lacomblez L, 2002, NEUROLOGY, V58, P1112, DOI 10.1212/WNL.58.7.1112; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Laffont I, 2002, BIOCHEM BIOPH RES CO, V292, P83, DOI 10.1006/bbrc.2002.6586; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Liu YW, 2002, J CEREBR BLOOD F MET, V22, P1336, DOI 10.1097/01.WCB.0000033200.58646.B3; Luthra K, 2002, CLIN GENET, V62, P39, DOI 10.1034/j.1399-0004.2002.620105.x; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; Marques M, 1997, ALZHEIMER RES, V3, P1; Marques MA, 1996, NEUROREPORT, V7, P2529, DOI 10.1097/00001756-199611040-00025; Michikawa M, 1998, J NEUROSCI RES, V54, P58, DOI 10.1002/(SICI)1097-4547(19981001)54:1<58::AID-JNR7>3.0.CO;2-G; Nadig Prathibha, 1996, Society for Neuroscience Abstracts, V22, P1696; Naidu A, 2001, NEUROREPORT, V12, P1265, DOI 10.1097/00001756-200105080-00042; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; Nathan BP, 2002, BRAIN RES, V928, P96, DOI 10.1016/S0006-8993(01)03367-4; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nixon RA, 2000, ANN NY ACAD SCI, V924, P117; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; POPKO B, 1993, J NEUROCHEM, V60, P1155, DOI 10.1111/j.1471-4159.1993.tb03268.x; Roks G, 1998, NEUROSCI LETT, V258, P65, DOI 10.1016/S0304-3940(98)00857-X; Roks G, 2002, AM J MED GENET, V114, P570, DOI 10.1002/ajmg.10407; Schmidt S, 2002, AM J HUM GENET, V70, P708, DOI 10.1086/339269; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Smith G, 2002, DRUG DEV IND PHARM, V28, P151, DOI 10.1081/DDC-120002448; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Szolnoki Z, 2002, J NEUROL, V249, P1391, DOI 10.1007/s00415-002-0848-4; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Tesseur I, 2000, AM J PATHOL, V157, P1495, DOI 10.1016/S0002-9440(10)64788-8; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Tsuzuki S, 1998, Rinsho Byori, V46, P829; UCHIHARA T, 1995, NEUROSCI LETT, V195, P5, DOI 10.1016/0304-3940(95)11763-M; Veinbergs I, 2002, J NEUROSCI RES, V67, P379, DOI 10.1002/jnr.10138; Weir CJ, 2001, NEUROLOGY, V57, P1097, DOI 10.1212/WNL.57.6.1097; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WISNIEWSKI T, 1995, LANCET, V345, P956, DOI 10.1016/S0140-6736(95)90701-7; Woo D, 2002, STROKE, V33, P1190, DOI 10.1161/01.STR.0000014774.88027.22; Zhang D., 2001, ALZHEIMERS REP, V4, P67	85	26	26	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.		2004	23	3					181	188		10.1385/JMN:23:3:181			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	829ZS	WOS:000222092000005	15181246				2022-02-06	
J	Schmidt, OI; Morganti-Kossmann, MC; Heyde, CE; Perez, D; Yatsiv, I; Shohami, E; Ertel, W; Stahel, PF				Schmidt, Oliver I.; Morganti-Kossmann, Maria Cristina; Heyde, Christoph E.; Perez, Daniel; Yatsiv, Ido; Shohami, Esther; Ertel, Wolfgang; Stahel, Philip F.			Tumor necrosis factor-mediated inhibition of interleukin-18 in the brain: a clinical and experimental study in head-injured patients and in a murine model of closed head injury	JOURNAL OF NEUROINFLAMMATION			English	Article								Tumor necrosis factor (TNF) and interleukin-(IL)-18 are important mediators of neuroinflammation after closed head injury (CHI). Both mediators have been previously found to be significantly elevated in the intracranial compartment after brain injury, both in patients as well as in experimental model systems. However, the interrelation and regulation of these crucial cytokines within the injured brain has not yet been investigated. The present study was designed to assess a potential regulation of intracranial IL-18 levels by TNF based on a clinical study in head-injured patients and an experimental model in mice. In the first part, we investigated the interrelationship between the daily TNF and IL-18 cerebrospinal fluid levels in 10 patients with severe CHI for up to 14 days after trauma. In the second part of the study, the potential TNF-dependent regulation of intracerebral IL-18 levels was further characterized in an experimental set-up in mice: (1) in a standardized model of CHI in TNF/lymphotoxin-alpha gene-deficient mice and wild-type (WT) littermates, and (2) by intracerebro-ventricular injection of mouse recombinant TNF in WT C57BL/6 mice. The results demonstrate an inverse correlation of intrathecal TNF and IL-18 levels in head-injured patients and a TNF-dependent inhibition of IL-18 after intracerebral injection in mice. These findings imply a potential new anti-inflammatory mechanism of TNF by attenuation of IL-18, thus confirming the proposed "dual" function of this cytokine in the pathophysiology of traumatic brain injury.	[Schmidt, Oliver I.; Heyde, Christoph E.; Ertel, Wolfgang; Stahel, Philip F.] Charite, Sch Med, Dept Trauma & Reconstruct Surg, D-13353 Berlin, Germany; [Morganti-Kossmann, Maria Cristina] Monash Univ, Alfred Hosp, Dept Trauma Surg, Melbourne, Vic 3181, Australia; [Perez, Daniel] Univ Zurich Hosp, Dept Surg, CH-8091 Zurich, Switzerland; [Yatsiv, Ido; Shohami, Esther] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel		Stahel, PF (corresponding author), Charite, Sch Med, Dept Trauma & Reconstruct Surg, Campus Benjamin Franklin, D-13353 Berlin, Germany.	olischmidt@web.de; cristina.morganti-kossmann@med.monash.edu.au; ceheyde@aol.com; danielperezch@yahoo.com; idoyat@yahoo.com; esty@huji.ac.il; wolfgang.ertel@charite.de; pfstahel@aol.com	Heyde, Christoph - E./AAV-9440-2021	Perez, Daniel/0000-0002-3154-7311			Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Barnum SR, 2002, IMMUNOL RES, V26, P7, DOI 10.1385/IR:26:1-3:007; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Culhane AC, 1998, MOL PSYCHIATR, V3, P362, DOI 10.1038/sj.mp.4000389; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; Jander S, 2002, J CEREBR BLOOD F MET, V22, P62, DOI 10.1097/00004647-200201000-00008; JENNETT B, 1975, LANCET, V1, P480; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Menge T, 2001, J NEUROSCI RES, V65, P332, DOI 10.1002/jnr.1158; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Prinz M, 1999, J NEUROCHEM, V72, P2215, DOI 10.1046/j.1471-4159.1999.0722215.x; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Ransohoff RM, 2002, J INFECT DIS, V186, pS152, DOI 10.1086/344266; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Seabrook TJ, 2001, J NEUROIMMUNOL, V113, P81, DOI 10.1016/S0165-5728(00)00429-X; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	33	26	28	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.		2004	1								13	10.1186/1742-2094-1-13			6	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	V29PB	WOS:000208759200013	15285802	Green Accepted, Green Published, gold			2022-02-06	
J	Kalsotra, A; Turman, CM; Dash, PK; Strobel, HW				Kalsotra, A; Turman, CM; Dash, PK; Strobel, HW			Differential effects of traumatic brain injury on the cytochrome P450 system: A perspective into hepatic and renal drug metabolism	JOURNAL OF NEUROTRAUMA			English	Article						CYP450 drug substrates; inflammation and injury; leukotriene B-4; tissue-specific response	GENE-EXPRESSION; PROTEIN EXPRESSION; MESSENGER-RNA; P450; INFLAMMATION; INDUCTION; LIVER; LIPOPOLYSACCHARIDE; BIOTRANSFORMATION; INTERLEUKIN-6	Traumatic brain injury is known to cause several secondary effects, one of which is altered drug clearance. Given the fact that patients who sustain TBI are subsequently treated with a variety of pharmacological agents for the purpose of either neuroprotection or physiological support, it is imperative to clarify changes in expression and/or activities of enzymes involved in clearing drugs. The mixed function oxidase system, which consists of cytochrome P450 and cytochrome P450 reductase, plays a vital role in phase I drug metabolism. This paper addresses the issue as to what extent TBI affects the levels and activity of various rat CYP450 subfamilies. Our results show that TBI induces tissue-specific and time-dependent alterations. Total hepatic CYP450 content showed a biphasic response with a decrease seen at 24 h followed by an increase at 2 weeks. CYP450 reductase, in contrast, showed an opposite temporal profile. Immunoblot analyses and marker substrate metabolism demonstrated a clear decrease in hepatic CYP1A levels while a significant increase in kidney was seen at both 24 h and 2 weeks. A dramatic induction of CYP3A was evident at 2 weeks in liver, while no changes were noticed in CYP2B or CYP2D subfamilies. CYP4F subfamily showed induction in kidney only. Collectively, the data reveal the differential effects of TBI on hepatic and renal drug metabolism.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA		Strobel, HW (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA.	henry.w.strobel@uth.tmc.edu		Kalsotra, Auinash/0000-0002-1011-0006	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH58927] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS23327, NS35457] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R03MH058927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS023327, R01NS035457] Funding Source: NIH RePORTER		ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; ABDELRAZZAK Z, 1995, FEBS LETT, V366, P159, DOI 10.1016/0014-5793(95)00513-9; Anzenbacher P, 2001, CELL MOL LIFE SCI, V58, P737, DOI 10.1007/PL00000897; BARKER CW, 1992, J BIOL CHEM, V267, P8050; BOUCHER BA, 1991, CLIN PHARMACOL THER, V50, P487, DOI 10.1038/clpt.1991.173; Chen YZ, 2002, POSITIVITY, V6, P47, DOI 10.1023/A:1012079817987; Chen ZL, 1999, J NEUROSCI, V19, P9813; Clark MA, 1996, BIOCHEM PHARMACOL, V51, P701, DOI 10.1016/S0006-2952(95)02391-7; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Crespi CL, 1997, ANAL BIOCHEM, V248, P188, DOI 10.1006/abio.1997.2145; Cui X, 2003, BBA-GEN SUBJECTS, V1619, P325, DOI 10.1016/S0304-4165(02)00491-9; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DIGNAM JD, 1977, BIOCHEMISTRY-US, V16, P1116, DOI 10.1021/bi00625a014; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Geng J, 1998, BRAIN RES, V784, P276, DOI 10.1016/S0006-8993(97)01346-2; GUENGERICH FP, 1979, MOL PHARMACOL, V15, P154; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HEINEMEYER G, 1986, THER DRUG MONIT, V8, P145, DOI 10.1097/00007691-198606000-00003; Hiroi T, 1998, BBA-GEN SUBJECTS, V1380, P305, DOI 10.1016/S0304-4165(97)00157-8; Kalsotra A, 2002, DRUG METAB DISPOS, V30, P1022, DOI 10.1124/dmd.30.9.1022; Kawashima H, 1997, ARCH BIOCHEM BIOPHYS, V347, P148, DOI 10.1006/abbi.1997.0342; Kikuta Y, 2002, PROSTAG OTH LIPID M, V68-9, P345, DOI 10.1016/S0090-6980(02)00039-4; Kraus MF, 1999, TRAUMATIC BRAIN INJU, P173; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasker JM, 2000, J BIOL CHEM, V275, P4118, DOI 10.1074/jbc.275.6.4118; LU AYH, 1970, MOL PHARMACOL, V6, P213; Marion D W, 1999, Clin Neurosurg, V45, P184; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; McKindley DS, 1997, J CLIN PHARMACOL, V37, P129, DOI 10.1002/j.1552-4604.1997.tb04771.x; McKindley DS, 1998, PHARMACOTHERAPY, V18, P759; Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246; MORGAN ET, 1994, BBA-GENE STRUCT EXPR, V1219, P475, DOI 10.1016/0167-4781(94)90074-4; MORGAN ET, 1991, BIOCHEM PHARMACOL, V42, P51, DOI 10.1016/0006-2952(91)90680-4; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.bi.56.070187.004501; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; OMARA NB, 1995, CRIT CARE MED, V23, P1418, DOI 10.1097/00003246-199508000-00017; OMURA T, 1964, J BIOL CHEM, V239, P2370; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Poloyac SM, 2001, DRUG METAB DISPOS, V29, P296; Renton KW, 2001, PHARMACOL THERAPEUT, V92, P147, DOI 10.1016/S0163-7258(01)00165-6; Renton KW, 2000, J PHARMACOL EXP THER, V294, P524; SABEL BA, 1986, NATURE, V323, P493, DOI 10.1038/323493a0; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Shimamoto Y, 1998, ARCH TOXICOL, V72, P492, DOI 10.1007/s002040050533; Stresser DM, 2002, DRUG METAB DISPOS, V30, P845, DOI 10.1124/dmd.30.7.845; Strobel Henry W., 1995, P225; Strobel HW, 1997, DRUG METAB REV, V29, P1079, DOI 10.3109/03602539709002244; TOLER SM, 1993, DRUG METAB DISPOS, V21, P1064; Wang HM, 1997, ARCH BIOCHEM BIOPHYS, V344, P365, DOI 10.1006/abbi.1997.0230; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x	55	26	26	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2003	20	12					1339	1350		10.1089/089771503322686139			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	756XH	WOS:000187510700006	14748982				2022-02-06	
J	Ueda, Y; Wei, EP; Kontos, HA; Suehiro, E; Povlishock, JT				Ueda, Y; Wei, EP; Kontos, HA; Suehiro, E; Povlishock, JT			Effects of delayed, prolonged hypothermia on the pial vascular response after traumatic brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hypothermia; cerebrovascular reactivity; cranial window; rat	CEREBRAL BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; SEVERE HEAD-INJURY; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; CO2 REACTIVITY; RELAXING FACTOR; CARDIAC-ARREST; ENDOTHELIUM	Object. In the experimental setting, hypothermia has been demonstrated to attenuate the damaging consequences of stroke and traumatic brain injury (TBI). Laboratory studies of TBI have focused primarily on the use of early hypothermic intervention, with little consideration of the potential efficacy of more delayed but prolonged hypothermia, which would constitute a more clinically relevant approach. In this investigation, the authors evaluated whether delayed, prolonged hypothermia after TBI protected the cerebral microcirculation. Methods. Male Sprague-Dawley rats were equipped with cranial windows for direct visualization of the pial arterial circulation and then subjected to impact-acceleration brain injury. The rats were randomly divided into four experimental groups: Group I consisted of normothermic animals; in Group 2 the rats received a I-hour period of hypothermia (32degreesC) 30 minutes posttrauma, followed by slow rewarming (32-37degreesC/90 minutes); and in Groups 3 and 4 the rats received a more delayed induction (at I hour postinjury) of either I hour (Group 3) or 2 hours (Group 4) of hypothermia, followed by the slow rewarming. The pial arteriolar responses to acetylcholine (ACh) or hypercapnia were measured until up to 6 hours postinjury. With this approach the authors found that the normothermic group demonstrated severely impaired vasoreactivity in terms of ACh-dependent dilation and CO2 reactivity in comparison to baseline values (p < 0.001). In contrast, hypothermia of short duration that was initiated early (30 minutes postinjury) conferred significant cerebrovascular protection (p < 0.001), yet this protection was reduced when the onset of this I-hour hypothermic period was postponed to I hour postinjury. Nevertheless, reduced protection could be significantly improved (p < 0.001) with prolongation of the hypothermic period to 2 hours. Conclusions. The results of this study show that early as well as delayed but prolonged hypothermia attenuate the impaired vascular responsiveness seen after TBI, indicating the potential clinical usefulness of this treatment.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Yamaguchi Univ, Sch Med, Dept Neurosurg, Ube, Yamaguchi 755, Japan		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.		Suehiro, Eiichi/I-5852-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193, T32 NS7288] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS020193] Funding Source: NIH RePORTER		Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; ELLIS EF, 1983, PROSTAGLANDINS, V26, P917, DOI 10.1016/0090-6980(83)90154-5; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; Golding EM, 2000, J CEREBR BLOOD F MET, V20, P820, DOI 10.1097/00004647-200005000-00008; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1988, AM J PHYSIOL, V255, pH1259, DOI 10.1152/ajpheart.1988.255.5.H1259; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Nakamura Michio, 1995, Brain and Nerve (Tokyo), V47, P484; RERING EA, 1961, AM J PHYSIOL, V200, P417; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; WEI EP, 1992, STROKE, V23, P1623, DOI 10.1161/01.STR.23.11.1623; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	40	26	26	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	2003	99	5					899	906		10.3171/jns.2003.99.5.0899			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	737MY	WOS:000186237400018	14609171				2022-02-06	
J	Aquilani, R; Iadarola, P; Boschi, F; Pistarini, C; Arcidiaco, P; Contardi, A				Aquilani, R; Iadarola, P; Boschi, F; Pistarini, C; Arcidiaco, P; Contardi, A			Reduced plasma levels of tyrosine, precursor of brain catecholamines, and of essential amino acids in patients with severe traumatic brain injury after rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amino acids; head injuries; neurotransmitters; plasmas; rehabilitation	ENERGY-METABOLISM; FATTY-ACIDS; MEMORY; TRYPTOPHAN; PROTEIN; OXIDATION; STRESS; AVAILABILITY; STIMULATION; DEPRESSION	Objective: To investigate whether levels of plasma tyrosine and tryptophan, precursors of brain catecholamine and serotonin neurotransmitters, respectively, and other essential amino acids (EAA) may return to normal in patients with severe traumatic brain injury (TBI) after 2 months in a hospital rehabilitation center. Design: Peripheral plasma concentrations of tyrosine, tryptophan, and other EAAs in subjects with severe TBI, both at admission (44+/-11d postinjury) and at discharge from the center (110+/-15d after acute event) were compared with concentrations in control subjects. Setting: Tertiary care rehabilitation setting in Italy. Participants: Ten men (26.6+/-12.6y) with TBI and 6 healthy subjects (controls) matched for age, sex, voluntary loss of body weight, and sedentary lifestyle. Interventions: Not applicable. Main Outcome Measures: Concentrations of brain neurotransmitter precursor amino acids and of EAA. Results: On admission, patients had lower plasma tyrosine, leucine, valine, methionine, and phenylalanine concentrations than did control subjects. The plasma concentrations of tryptophan were similar in the 2 groups. These amino acid abnormalities were still present at discharge. Conclusion: The levels of plasma tyrosine and many EAA in patients with TBI did not recover by discharge (110+/-15d) from rehabilitation. Plasma tryptophan concentrations were similar in patients and controls.	Fdn S Maugeri, Ist Sci Montescano, Serv Fisiopatol Metab Nutriz & Nutriz Clin, Pavia, Italy; Univ Pavia, Dipartimento Biochim A Castellani, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Sci Fisiofarmacol, Sez Farmacol, I-27100 Pavia, Italy; Univ Pavia, Ctr Grandi Strumenti, I-27100 Pavia, Italy		Boschi, F (corresponding author), Univ Pavia, Fac Sci MM FF NN, Sez Farmacol & Biotecnol Farmacol, Dipartimento Sci Fisiol Farmacol Cellulari Mol, Piazza Botta 11, I-27100 Pavia, Italy.	labmio@unipv.it	Pistarini, CATERINA/K-5234-2018	Pistarini, CATERINA/0000-0001-8925-0484			ALBERS RW, 1998, BASIC NEUROCHEMISTRY, P96; ALLAIN H, 1995, BIOMED PHARMACOTHER, V49, P179, DOI 10.1016/0753-3322(96)82618-7; Aquilani R, 2000, ARCH PHYS MED REHAB, V81, P176, DOI 10.1053/apmr.2000.0810176; ARMSTRONG MD, 1973, METABOLISM, V22, P561, DOI 10.1016/0026-0495(73)90069-3; ASHLEY DVM, 1985, J NEURAL TRANSM, V63, P271, DOI 10.1007/BF01252031; Avraham Y, 1996, BRAIN RES, V732, P133, DOI 10.1016/0006-8993(96)00514-8; BANDERET LE, 1989, BRAIN RES BULL, V22, P759, DOI 10.1016/0361-9230(89)90096-8; BISTRIAN BR, 1975, SURG GYNECOL OBSTET, V141, P512; BOADLEBIBER MC, 1993, PROG BIOPHYS MOL BIO, V60, P1, DOI 10.1016/0079-6107(93)90009-9; CHAPLIN ER, 1976, J NEUROCHEM, V26, P701, DOI 10.1111/j.1471-4159.1976.tb04440.x; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; COPPEN A, 1967, LANCET, V2, P1178; CURCIO CA, 1984, J NEUROPATH EXP NEUR, V43, P359, DOI 10.1097/00005072-198407000-00001; CURZON G, 1973, NATURE, V242, P198, DOI 10.1038/242198a0; CURZON G, 1984, PROGR TRYPTOPHAN SER, P145; DEIJEN JB, 1994, BRAIN RES BULL, V33, P319, DOI 10.1016/0361-9230(94)90200-3; DOLLINS AB, 1995, PHYSIOL BEHAV, V57, P223, DOI 10.1016/0031-9384(94)00278-D; Dolp R, 1975, Infusionsther Klin Ernahr, V2, P321; Fernstrom J. D., 1994, FOOD COMPONENTS ENHA, P161; FERNSTROM JD, 1983, PHYSIOL REV, V63, P484, DOI 10.1152/physrev.1983.63.2.484; FERNSTROM JD, 1978, J NEUROCHEM, V30, P1531, DOI 10.1111/j.1471-4159.1978.tb10489.x; FERNSTROM JD, 1971, SCIENCE, V174, P1023, DOI 10.1126/science.174.4013.1023; FERNSTROM JD, 1972, SCIENCE, V178, P414, DOI 10.1126/science.178.4059.414; FERNSTROM MH, 1995, LIFE SCI, V57, pPL97, DOI 10.1016/0024-3205(95)02026-F; Ferry B, 1999, BIOL PSYCHIAT, V46, P1140, DOI 10.1016/S0006-3223(99)00157-2; FRAZER A, 1988, BASIC NEUROCHEMISTRY, P264; GERMAN DC, 1987, NEUROSCIENCE, V21, P305, DOI 10.1016/0306-4522(87)90123-0; GERNER RH, 1984, AM J PSYCHIAT, V141, P1441; GLAESER BS, 1983, J NEUROCHEM, V41, P1016, DOI 10.1111/j.1471-4159.1983.tb09045.x; GOLDBERG AL, 1978, FED PROC, V37, P2301; GOLDBERG AL, 1983, AMINO ACIDS METABOLI, P201; Grace A A, 1998, Adv Pharmacol, V42, P655; GROWDON JH, 1982, LIFE SCI, V30, P827, DOI 10.1016/0024-3205(82)90596-3; HARTMANN E, 1977, WAKING SLEEPING, V1, P155; HASSMEN P, 1994, NUTRITION, V10, P405; Heninger GR, 1996, PHARMACOPSYCHIATRY, V29, P2, DOI 10.1055/s-2007-979535; HORST D, 1984, HEPATOLOGY, V4, P279, DOI 10.1002/hep.1840040218; IKEDA M, 1965, BIOCHEM BIOPH RES CO, V18, P482, DOI 10.1016/0006-291X(65)90778-3; KIRKPATRICK LL, 1998, BASIC NEUROCHEMISTRY, P156; KOLPEK JH, 1989, JPEN-PARENTER ENTER, V13, P277, DOI 10.1177/0148607189013003277; LALONDE R, 1985, PHARMACOL BIOCHEM BE, V22, P377, DOI 10.1016/0091-3057(85)90035-8; LANCE JW, 1963, BRAIN, V86, P111, DOI 10.1093/brain/86.1.111; LONG CL, 1981, METABOLISM, V30, P765, DOI 10.1016/0026-0495(81)90022-6; Mann JJ, 1996, NEUROPSYCHOPHARMACOL, V15, P576, DOI 10.1016/S0893-133X(96)00102-9; Matsumoto N, 1999, J NEUROPHYSIOL, V82, P978, DOI 10.1152/jn.1999.82.2.978; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; NESTLER EJ, 1998, BASIC NEUROCHEMISTRY, P405; Nielsen DH, 1981, CARDIAC REHABILITATI, P11; O'Carroll RE, 1999, PSYCHOL MED, V29, P1083, DOI 10.1017/S0033291799008703; ODESSEY R, 1972, AM J PHYSIOL, V223, P1376, DOI 10.1152/ajplegacy.1972.223.6.1376; OGREN SO, 1986, BRAIN RES BULL, V16, P645; OWASOYO JO, 1992, AVIAT SPACE ENVIR MD, V63, P364; Pastoris O, 1997, SCAND J UROL NEPHROL, V31, P281, DOI 10.3109/00365599709070349; PIEK J, 1985, INTENS CARE MED, V11, P192, DOI 10.1007/BF00272402; PRANGE AJ, 1974, ARCH GEN PSYCHIAT, V30, P56; REINSTEIN DK, 1984, LIFE SCI, V34, P2225, DOI 10.1016/0024-3205(84)90209-1; ROSENTHAL RE, 1992, STROKE, V23, P1312, DOI 10.1161/01.STR.23.9.1312; Roth J. R, 1986, BIOCH BASIS NEUROPHA; SCHONHEYDER F, 1954, SCAND J CLIN LAB INV, V6, P178, DOI 10.3109/00365515409136355; SCHROT J, 1996, 9611 NMRI US DEP NAV; SHAW DM, 1967, BRIT J PSYCHIAT, V113, P1407, DOI 10.1192/bjp.113.505.1407; Shimizu I, 1999, BRAIN RES, V830, P94, DOI 10.1016/S0006-8993(99)01396-7; ShukittHale B, 1996, PHYSIOL BEHAV, V59, P867, DOI 10.1016/0031-9384(95)02107-8; SILIPRAN.N, 1965, BIOCHEM J, V96, P777, DOI 10.1042/bj0960777; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; Sokoloff L, 1969, PSYCHOCHEMICAL RES M, P237; SOLIVERI P, 1992, EUR J COGN PSYCHOL, V4, P161, DOI 10.1080/09541449208406181; Stone EA, 1975, CATECHOLAMINES BEHAV, P31; SUDHOF TC, 1998, BASIC NEUROCHEMISTRY, P176; Tam SY, 1997, BIOCHEM PHARMACOL, V53, P441; Thomas JR, 1999, PHARMACOL BIOCHEM BE, V64, P495, DOI 10.1016/S0091-3057(99)00094-5; THOMAS JR, 1989, AVIAT SPACE ENVIR MD, V60, P1063; THOMAS JR, 1990, J APPL PHYSIOL, V68, P962, DOI 10.1152/jappl.1990.68.3.962; TUCKER KR, 1981, J APPL PHYSIOL, V51, P73, DOI 10.1152/jappl.1981.51.1.73; VANPRAAG HM, 1974, INT PHARMACOPSYCHIAT, V9, P35, DOI 10.1159/000468114; WURTMAN RJ, 1974, SCIENCE, V185, P183, DOI 10.1126/science.185.4146.183; WURTMAN RJ, 1980, PHARMACOL REV, V32, P315; WURTMAN RJ, 1975, AM J CLIN NUTR, V28, P638, DOI 10.1093/ajcn/28.6.638	79	26	26	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2003	84	9					1258	1265		10.1016/S0003-9993(03)00148-5			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	718WT	WOS:000185170000001	13680559				2022-02-06	
J	Malhotra, AK; Schweitzer, JB; Fox, JL; Fabian, TC; Proctor, KG				Malhotra, AK; Schweitzer, JB; Fox, JL; Fabian, TC; Proctor, KG			Cerebral perfusion pressure directed therapy following traumatic brain injury and hypotension in swine	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid precursor protein; brain edema; brain injury; cerebral oxygenation; cerebral perfusion pressure; cerebro-vascular CO2 reactivity; pressor	VENOUS OXYGEN-SATURATION; BLOOD-FLOW; INTRACRANIAL-PRESSURE; HEAD-INJURY; COMATOSE PATIENTS; MANAGEMENT; IMPACT; FLUCTUATIONS; METABOLISM; EVOLUTION	There is a paucity of studies, clinical and experimental, attesting to the benefit of cerebral perfusion pressure (CPP) directed pressor therapy following traumatic brain injury (TBI). The current study evaluates this therapy in a swine model of TBI and hypotension. Forty-five anesthetized and ventilated swine received TBI followed by a 45% blood volume bleed. After 1 h, all animals were resuscitated with 0.9% sodium chloride equal to three times the shed blood volume. The experimental group (PHE) received phenylephrine to maintain CPP > 80 mm Hg; the control group (SAL) did not. Outcomes in the first phase (n = 33) of the study were as follows: cerebro-venous oxygen saturation (ScvO2), cerebro-vascular carbon dioxide reactivity (DeltaS(cv)O(2)), and brain structural damage (beta-amyloid precursor protein [betaAPP] immunoreactivity). In the second phase (n = 12) of the study, extravascular blood free water (EVBFW) was measured in the brain and lung. After resuscitation, intracranial and mean arterial pressures were >15 and >80 mm Hg, respectively, in both groups. CPP declined to 64 +/- 5 mm Hg in the SAL group, despite fluid supplements. CPP was maintained at >80 mm Hg with pressors in the PHE group. PHE animals maintained better ScvO2 (P < 0.05 at 180, 210, 240, 270, and 300 min post-TBI). At baseline, 5% CO2 evoked a 16 +/- 4% increase in ScvO2, indicating cerebral vasodilatation and luxury perfusion. By 240 min, this response was absent in SAL animals and preserved in PHE animals (p < 0.05). Brain EVBFW was higher in SAL animals; however, lung EVBFW was higher in PHE animals. There was no difference in betaAPP immunoreactivity between the SAL and PHE groups (p > 0.05). In this swine model of TBI and hypotension, CPP directed pressor therapy improved brain oxygenation and maintained cerebro-vascular CO2 reactivity. Brain edema was lower, but lung edema was greater, suggesting a higher propensity for pulmonary complications.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Surg, Richmond, VA 23298 USA; E Tennessee State Univ, Quillen Dishner Coll Med, Dept Pathol, Johnson City, TN 37614 USA; Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; Univ Miami, Sch Med, Dept Surg, Miami, FL 33152 USA		Malhotra, AK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Surg, Richmond, VA 23298 USA.	akmalhot@hsc.vcu.edu	Proctor, Kenneth/AAA-2199-2022	Proctor, Kenneth/0000-0003-1326-6628			Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; COOKE RS, 1995, INJURY, V26, P395, DOI 10.1016/0020-1383(95)00003-R; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Glass TF, 2001, J NEUROTRAUM, V18, P57, DOI 10.1089/089771501750055776; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MURR R, 1995, NEUROL RES, V17, P329, DOI 10.1080/01616412.1995.11740338; NEWELL DW, 1992, J NEUROSURG, V76, P415, DOI 10.3171/jns.1992.76.3.0415; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PEARCE ML, 1965, CIRC RES, V16, P482, DOI 10.1161/01.RES.16.5.482; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SHALMON E, 1994, INTRACRANIAL PRESSUR, V9, P357; SHALMON E, 1994, INTRACRANIAL PRESSUR, V9, P348; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; WEIDNER WJ, 1978, PHYSIOL ZOOL, V51, P267, DOI 10.1086/physzool.51.3.30155743; YOSHIDA A, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P309	43	26	26	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2003	20	9					827	839		10.1089/089771503322385764			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	725BB	WOS:000185521800002	14577861				2022-02-06	
J	Hoffman, JM; Doctor, JN; Chan, L; Whyte, J; Jha, A; Dikmen, S				Hoffman, JM; Doctor, JN; Chan, L; Whyte, J; Jha, A; Dikmen, S			Potential impact of the new Medicare prospective payment system on reimbursement for traumatic brain injury inpatient rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; health care economics and organizations; Medicare; prospective payment system; rehabilitation		Objective: To evaluate the potential impact of the new Medicare prospective payment system (PPS) on traumatic brain injury (TBI) rehabilitation. Design: Retrospective cohort study of patients with TBI. Patients were assigned to their appropriate case-mix group (CMG) based on Medicare criteria. Setting: Fourteen urban rehabilitation facilities throughout the United States. Participants: Patients with TBI admitted to inpatient rehabilitation and enrolled in the Traumatic Brain Injury Model Systems from 1998 to 2001 (N=1807). Interventions: Not applicable. Main Outcome Measures: Cost of inpatient rehabilitation admission, length of stay (LOS), and functional outcomes. Results: The median cost of inpatient rehabilitation or patients with TBI exceeded median PPS payments for all TBI CMGs by 16%. Only 3 of the 14 hospitals received reimbursement under PPS that exceeded costs for their TBI patients. Conclusions: Compared with current costs, the new Medicare payment system may reimburse facilities significantly less than their costs for the treatment of TBI. To maintain their current financial status, facilities may have to reduce LOS and/or reduce resource use. With a decreased LOS, inpatient rehabilitation services will have to improve FIM efficiency or discharge patients with lower discharge FIM scores. (C) 2003 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA; Univ Washington, Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Neurosurg, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Thomas Jefferson Univ, Moss Rehabil Res Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA; Craig Hosp, Englewood, CO USA; Univ Colorado, Denver, CO 80202 USA		Hoffman, JM (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.			Whyte, John/0000-0002-4381-1474	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD07424] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007424] Funding Source: NIH RePORTER		CARTER GM, 2001, ANAL INITIAL IMPLEME; Chan L, 1997, NEW ENGL J MED, V337, P978, DOI 10.1056/NEJM199710023371406; CMS, 2001, FED REGISTER, V66, P41316; Dada M, 1999, MANAGE SCI, V45, P316, DOI 10.1287/mnsc.45.3.316; FRUMMOND M, 1997, METHOD EC EVALUATION; Grimaldi Paul L, 2002, J Health Care Finance, V28, P32; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Reynolds M, 2001, Healthc Financ Manage, V55, P68; Rosenberg MA, 2001, N AM ACTUARIAL J, V5, P84; SCHEFFLER RM, 1994, MED CARE, V32, P471, DOI 10.1097/00005650-199405000-00006; Taheri PA, 2001, J AM COLL SURGEONS, V193, P1, DOI 10.1016/S1072-7515(01)00870-5; 1999, J HEAD TRAUMA REHABI, V14, P189	12	26	27	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2003	84	8					1165	1172		10.1016/S0003-9993(03)00232-6			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	709LQ	WOS:000184627000012	12917856				2022-02-06	
J	Rath, JF; Hennessy, JJ; Diller, L				Rath, JF; Hennessy, JJ; Diller, L			Social problem solving and community integration in postacute rehabilitation outpatients with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article; Proceedings Paper	108th Annual Convention of the American-Psychological-Association	AUG 04-08, 2000	WASHINGTON, DC	Amer Psychol Assoc			SELF-AWARENESS; TAT RESPONSES; ABILITIES; ADJUSTMENT; QUESTIONNAIRE; APPRAISAL; VALIDITY; SCORES; ADULTS; POWER	To enhance understanding of the role that social problem solving (SPS) plays in community integration following traumatic brain injury (TBI). Study Design: Regression analysis. Participants: Forty-five adults with TBI participating in higher level outpatient cognitive rehabilitation and 15 uninjured adults. Main Outcome Measures: Measures of community integration, problem-solving ability, and SPS self-appraisal and performance. Results: Individuals with TBI demonstrated poorer problem-solving as measured by both neuropsychological and SPS methods; however, the largest effect size was observed for SPS self-appraisal. Only SPS self-appraisal predicted a significant proportion of the variance in community integration. Conclusions: It is important to assess brain-injured persons' confidence in their ability to cope with problems. A focus on objective test scores alone may lead to underdetection of disabling problem-solving deficits.	NYU, Med Ctr, Rusk Inst Rehabil Med, Dept Rehabil Med, New York, NY 10016 USA; Fordham Univ, Div Psychol & Educ Serv, Grad Sch Educ, Bronx, NY 10458 USA		Rath, JF (corresponding author), NYU, Med Ctr, Rusk Inst Rehabil Med, Dept Rehabil Med, RR 515,400 E 34th St, New York, NY 10016 USA.	joseph.rath@med.nyu.edu	Rath, Joseph F./C-4823-2008	Rath, Joseph F./0000-0003-2933-6299; Diller, Leonard/0000-0001-7295-7846			Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; Adamovich BL, 1991, COGNITIVE REHABILITA, P75; Beck AT, 1987, BECK DEPRESSION INVE; BENTON AL, 1994, ANNU REV PSYCHOL, V45, P1, DOI 10.1146/annurev.ps.45.020194.000245; BENYISHAY Y, 1990, REHABILITATION ADULT, P393; BUTLER M, 1991, PROF PSYCHOL-RES PR, V22, P510, DOI 10.1037/0735-7028.22.6.510; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; D'Zurilla TJ, 2001, HANDBOOK OF COGNITIVE-BEHAVIORAL THERAPIES, SECOND EDITION, P211; D'Zurilla TJ., 1982, ADV COGNITIVE BEHAV, P201, DOI [10.1016/B978-0-12-010601-1.50010-3, DOI 10.1016/B978-0-12-010601-1.50010-3]; DANIEL M, 1986, BEHAV THERAPIST, V4, P71; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; DZURILLA TJ, 1995, BEHAV THER, V26, P409, DOI 10.1016/S0005-7894(05)80091-7; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; ELLIOTT TR, 1991, COGNITIVE THER RES, V15, P387, DOI 10.1007/BF01173033; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Elliott TR, 1999, REHABIL PSYCHOL, V44, P315, DOI 10.1037/0090-5550.44.4.315; ELLIOTT TR, 1994, J COUNS DEV, V72, P531, DOI 10.1002/j.1556-6676.1994.tb00987.x; Foxx R.M., 2000, BEHAV SOC ISSUES, V10, P71, DOI [DOI 10.5210/BSI.V10I0.129, 10.5210/bsi.v10i0.129]; GOLDSTEIN FC, 1987, NEUROPSYCHOL REHABIL, P327; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; HART T, 1986, CLIN NUEROPSYCHOLOGY; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1981, WISCONSIN CARD SORTI; HEPPNER PP, 1982, J COUNS PSYCHOL, V29, P66, DOI 10.1037/0022-0167.29.1.66; Heppner PP, 1997, MEAS EVAL COUNS DEV, V29, P229, DOI 10.1080/07481756.1997.12068907; HEPPNER PP, 1988, PROBLEM SOLVING INVE; Herrick SM, 2001, J CLIN PSYCHOL, V57, P75, DOI 10.1002/1097-4679(200101)57:1<75::AID-JCLP9>3.0.CO;2-6; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kendall E, 1997, J HEAD TRAUMA REHAB, V12, P68, DOI 10.1097/00001199-199706000-00007; KING MC, 1981, J CLIN PSYCHOL, V37, P400, DOI 10.1002/1097-4679(198104)37:2<400::AID-JCLP2270370233>3.0.CO;2-B; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Langenbahn DM, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P167; Luria A.R., 1966, HIGHER CORTICAL FUNC; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; MEYER GJ, 1998, BENEFITS COSTS PSYCH; Millis S R, 1994, Int J Neurosci, V79, P165; Montgomery GK, 1999, ARCH CLIN NEUROPSYCH, V14, P794, DOI 10.1016/S0887-6177(99)80337-0; Murray H. A, 1943, THEMATIC APPERCEPTIO; OVERALL JE, 1995, PSYCHOL REP, V77, P155, DOI 10.2466/pr0.1995.77.1.155; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Paniak C, 2000, BRAIN INJURY, V14, P219; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RABIN LA, 2001, THESIS FORDHAM U; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; RATH JF, 2003, UNPUB CONSTRUCT PROB; RATH JF, IN PRESS NEUROPSYCHO; ROMAN GF, 1990, UNPUB PERSONAL PROBL; RONAN GF, 1995, J PERS ASSESS, V64, P119, DOI 10.1207/s15327752jpa6401_8; Ronan GF, 1996, J PERS ASSESS, V67, P641, DOI 10.1207/s15327752jpa6703_16; RONAN GF, 1993, J PERS ASSESS, V61, P28, DOI 10.1207/s15327752jpa6101_3; RONAN GF, 1997, UNPUB PERSONAL PROBL; ROSENTHAL M, 1992, NEUROREHABILITATION, V2, P1; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; SHERR RL, 1992, NEUROPSYCHOLOGY, V6, P417, DOI DOI 10.1037/0894-4105.6.4.417; Sohlberg M., 2001, COGNITIVE REHABILITA; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; TOOBERT DJ, 1991, J BEHAV MED, V14, P71, DOI 10.1007/BF00844769; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; VONCRAMON DY, 1992, NEUROPSYCHOL REHABIL, V2, P207; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; [No title captured]	77	26	27	0	20	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2003	48	3					137	144		10.1037/0090-5550.48.3.137			8	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology; Rehabilitation	717FY	WOS:000185077900002					2022-02-06	
J	Emery, E				Emery, E			Intrathecal baclofen. Literature review of the results and complications	NEUROCHIRURGIE			French	Article; Proceedings Paper	53rd Annual Congress of the Societe-De-Neurochirurgie-De-Langue-Francaise	MAY 09-12, 2003	TOZEUR, TUNISIA	Soc Neurochirurgie Langue Francaise		spasticity; baclofen; intrathecal; results; functional gain; complication; quality of life	SEVERE SPINAL SPASTICITY; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN INJURY; TERM FOLLOW-UP; CEREBRAL-PALSY; INTRACTABLE SPASTICITY; FUNCTIONAL IMPROVEMENT; SUPRASPINAL SPASTICITY; ADMINISTERED BACLOFEN; CORD SPASTICITY	Intrathecally delivered baclofen has been used as a treatment for severe spasticity since 1984. A systematic literature review was conducted from 1984 to December 2002 to analyze the results of this treatment and to collect data on complications. Studies were included if the following criteria were met clear selection of patients suffering from spasticity of spinal or cerebral origin, clear measurements of outcome (Ashworth score, Spasm score and/or reflex score and/or functional scales), average follow-up of at least 6 months. Almost all the studies had open follow-up with no control groups (controls were used to examine the effect of test doses of baclofen rather than to assess long-term results). Studies often included heterogeneous patients groups with different causes of spasticity (spinal and/or cerebral etiology) and functional outcome was measured using different scales from one study to another. This literature review shows evidence that intrathecally administered baclofen is effective in reducing the positive signs of spasticity (tone, spasms, reflex activity). Significant reductions in spasm-related pain were noted. The reduction in spasticity led to improvement in ability to transfer and ease of nursing care in the majority of patients. Significant improvements were noted in terms of mobility. Benefits were most notable in bedridden patients who became able to sit in a wheelchair. Many benefited from improved wheelchair mobility, ability to sit down comfortably, and improvement in their ability to transfer. Such benefits were approved by all the patients as an improvement of their quality of life. Ambulatory patients could also benefit from an improved gait but were less often treated because they usually relied upon their spasticity for support during ambulation. Complications were rather rare and mainly were not life-threatening, although there was a high rate of catheter dysfunction (10 to 45 %) leading to reoperation. Wound complications were the leading cause of explantation in children with cerebral palsy. Despite the risks, patient satisfaction was high and was related to the improvement of the quality of life.	CHU Caen, Serv Neurochirurg, F-14033 Caen, France		Emery, E (corresponding author), CHU Caen, Serv Neurochirurg, Ave Cote Nacre, F-14033 Caen, France.						ABEL NA, 1994, ARCH PHYS MED REHAB, V75, P54; AKMAN MN, 1993, PARAPLEGIA, V31, P516, DOI 10.1038/sc.1993.84; ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; Albright AL, 1996, J CHILD NEUROL, V11, pS29, DOI 10.1177/0883073896011001S05; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; Armstrong RW, 1997, J NEUROSURG, V87, P409, DOI 10.3171/jns.1997.87.3.0409; Azouvi P, 1996, ARCH PHYS MED REHAB, V77, P35, DOI 10.1016/S0003-9993(96)90217-8; Barnes MP, 2001, GERONTOLOGY, V47, P295, DOI 10.1159/000052817; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; BENNETT MI, 1994, PAIN, V56, P243, DOI 10.1016/0304-3959(94)90100-7; BROSETA J, 1990, STEREOT FUNCT NEUROS, V54-5, P147, DOI 10.1159/000100205; Burns AS, 2001, SPINAL CORD, V39, P413, DOI 10.1038/sj.sc.3101178; Butler C, 2000, DEV MED CHILD NEUROL, V42, P634, DOI 10.1017/S0012162200001183; CAMPBELL SK, 1995, PHYS THER, V75, P352, DOI 10.1093/ptj/75.5.352; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; CONCALVES J, 1994, STEREOT FUNCT NEUROS, V62, P108, DOI 10.1159/000098605; Dario A, 2001, FUNCT NEUROL, V16, P311; Dario A, 2002, ACTA NEUROL SCAND, V105, P83, DOI 10.1034/j.1600-0404.2002.1o042.x; DELHAAS EM, 1991, INT J CLIN PHARM TH, V29, P274; Denys P, 1998, ARCH PHYS MED REHAB, V79, P494, DOI 10.1016/S0003-9993(98)90061-2; Fakhoury T, 1998, ELECTROEN CLIN NEURO, V107, P339, DOI 10.1016/S0013-4694(98)00085-6; Galloway A, 2000, SPINAL CORD, V38, P126, DOI 10.1038/sj.sc.3100954; Gerszten PC, 1998, J NEUROSURG, V88, P1009, DOI 10.3171/jns.1998.88.6.1009; Gerszten PC, 1997, PEDIATR NEUROSURG, V27, P40, DOI 10.1159/000121223; Gilmartin R, 2000, J CHILD NEUROL, V15, P71, DOI 10.1177/088307380001500201; Gormley ME, 2001, EUR J NEUROL, V8, P127, DOI 10.1046/j.1468-1331.2001.00045.x; Green LB, 1999, ARCH PHYS MED REHAB, V80, P1600, DOI 10.1016/S0003-9993(99)90337-4; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Huch K, 1999, SPINAL CORD, V37, P648, DOI 10.1038/sj.sc.3100880; Huraibi HA, 2000, ANESTH ANALG, V91, P429, DOI 10.1097/00000539-200008000-00037; Ivanhoe C B, 2001, Phys Med Rehabil Clin N Am, V12, P923; KOFLER M, 1992, ELECTROEN CLIN NEURO, V83, P83, DOI 10.1016/0013-4694(92)90136-6; KOFLER M, 1994, NEUROLOGY, V44, P25, DOI 10.1212/WNL.44.1.25; Lazorthes Y, 1998, NEUROCHIRURGIE, V44, P201; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; Levin AB, 1995, STEREOT FUNCT NEUROS, V65, P147, DOI 10.1159/000098887; LOUBSER PG, 1991, PARAPLEGIA, V29, P48, DOI 10.1038/sc.1991.7; Marquardt G, 2002, J NEUROL NEUROSUR PS, V72, P275, DOI 10.1136/jnnp.72.2.275; Marquardt G, 1999, J NEUROL, V246, P619, DOI 10.1007/s004150050417; MCLEAN BN, 1993, BRIT J HOSP MED, V49, P262; Mertens P, 1995, ADV STER F, V11, P17; MEVTHALER JM, 2001, STROKE, V32, P2099; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; MEYTHALER JM, 1992, AM J PHYS MED REHAB, V71, P321, DOI 10.1097/00002060-199212000-00003; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; Middel B, 1997, J NEUROL NEUROSUR PS, V63, P204, DOI 10.1136/jnnp.63.2.204; MULLERSCHWEFE G, 1989, J NEUROSURG, V71, P273, DOI 10.3171/jns.1989.71.2.0273; Murphy NA, 2002, ARCH PHYS MED REHAB, V83, P1721, DOI 10.1053/apmr.2002.36068; NANCE P, 1995, CAN J NEUROL SCI, V22, P22, DOI 10.1017/S0317167100040452; Nielsen JF, 2002, CLIN NEUROL NEUROSUR, V104, P142, DOI 10.1016/S0303-8467(02)00009-4; Ochs GA, 1996, J NEUROL REHABIL, V10, P159; Ordia JI, 1996, J NEUROSURG, V85, P452, DOI 10.3171/jns.1996.85.3.0452; PARKE B, 1989, ARCH PHYS MED REHAB, V70, P30; PENN RD, 1985, LANCET, V2, P125; PENN RD, 1987, J NEUROSURG, V66, P181, DOI 10.3171/jns.1987.66.2.0181; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1984, LANCET, V1, P1078; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Pirotte B, 1995, ACTA NEUROL BELG, V95, P216; Rawicki B, 1999, J NEUROSURG, V91, P733, DOI 10.3171/jns.1999.91.5.0733; Reeves RK, 1998, ARCH PHYS MED REHAB, V79, P353, DOI 10.1016/S0003-9993(98)90021-1; Rifici C, 1994, Funct Neurol, V9, P29; SAHUQUILLO J, 1991, ACTA NEUROCHIR, V110, P166, DOI 10.1007/BF01400686; Saltuari L, 1992, Acta Neurol (Napoli), V14, P187; Sampson FC, 2002, J NEUROSURG, V96, P1052, DOI 10.3171/jns.2002.96.6.1052; Scheinberg AM, 2001, J PAEDIATR CHILD H, V37, P283, DOI 10.1046/j.1440-1754.2001.00676.x; Stempien L, 2000, AM J PHYS MED REHAB, V79, P536, DOI 10.1097/00002060-200011000-00010; Stewart-Wynne E G, 1991, Clin Exp Neurol, V28, P244; TEDDY P, 1992, BRIT J NEUROSURG, V6, P115, DOI 10.3109/02688699209002912; Van Schaeybroeck P, 2000, NEUROSURGERY, V46, P603, DOI 10.1097/00006123-200003000-00017; Zed PJ, 2000, J NEUROSURG, V92, P347, DOI 10.3171/jns.2000.92.2.0347; Zierski J, 1988, Acta Neurochir Suppl (Wien), V43, P94	75	26	30	0	1	MASSON EDITEUR	PARIS 06	120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE	0028-3770			NEUROCHIRURGIE	Neurochirurgie	MAY	2003	49	2-3	2				276	288					13	Clinical Neurology; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	679JM	WOS:000182917100017	12746703				2022-02-06	
J	Kay, AD; Petzold, A; Kerr, M; Keir, G; Thompson, EJ; Nicoll, JAR				Kay, AD; Petzold, A; Kerr, M; Keir, G; Thompson, EJ; Nicoll, JAR			Cerebrospinal fluid apolipoprotein E concentration decreases after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						Alzheimer's disease; apolipoprotein E; cerebrospinal fluid; S100B; traumatic brain injury	INCREASED NEURONAL DAMAGE; ENTORHINAL CORTEX LESION; CENTRAL NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; E POLYMORPHISM; MOUSE MODEL; HEAD-INJURY; NEUROBIOCHEMICAL MARKERS; APOE IMMUNOREACTIVITY; AMYLOID DEPOSITION	The APOE epsilon4 allele has been associated with unfavorable outcome after several types of acute brain injury, yet the biological mechanisms underlying this observation are poorly understood. Postmortem and experimental brain injury studies suggest the presence of increased amounts of apolipoprotein E (apoE) within the neuropil after acute brain injury. We assayed the concentration of apolipoprotein E in the cerebrospinal fluid (CSF) of non-injured controls and patients with traumatic brain injury (TBI) to determine whether differences exist, and if these differences correlate with injury severity and clinical outcome. CSF apoE and S100B, a marker of injury severity, were measured by enzyme linked immunosorbant assay. CSF was sampled from 27 traumatic brain injury patients (mean age 32, median 25, range 16-65 years) within 3 days of injury, and 28 controls (mean age 40, median 37, range 19-73 years). The TBI patients all had a Glasgow Coma Score (GCS) of less than eight (i.e., severe head injury). Clinical outcome was determined using the Glasgow Outcome Score (GOS). The average concentration of apoE in the CSF of controls was 12.4 mg/L (95% CI: 10.5-14.3 mg/L) and in TBI patients was 3.7 mg/L (95% CI: 2.1-4.1 mg/L; Mann-Whitney: p < 0.0001). In contrast, the concentration of S100B in the CSF of TBI patients was significantly higher than that of controls (Mann-Whitney: p < 0.0001). We speculate that apoE is retained within the parenchyma of the central nervous system in response to injury where in view of previous data, it may have a protective role.	Univ Glasgow, Inst Neurol Sci, So Gen Hosp, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland; Univ London, Inst Neurol & Neurosurg, Dept Neuroimmunol, London, England; Univ Pittsburgh, Ctr Nursing Res, Pittsburgh, PA USA; Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton SO9 5NH, Hants, England		Kay, AD (corresponding author), Univ Glasgow, Inst Neurol Sci, So Gen Hosp, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland.		Petzold, Axel/C-1090-2009; Nicoll, James/I-9253-2017	Petzold, Axel/0000-0002-0344-9749; Nicoll, James/0000-0002-9444-7246			Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Baskin F, 1997, J NEUROL SCI, V148, P15, DOI 10.1016/S0022-510X(96)05335-X; Carlin C, 2000, J NEUROPATH EXP NEUR, V59, P361, DOI 10.1093/jnen/59.5.361; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Kargman DE, 1998, ATHEROSCLEROSIS, V139, P391, DOI 10.1016/S0021-9150(98)00085-9; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LUXTON RW, 1989, CLIN CHEM, V35, P1731; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; Nicoll JAR, 2001, NEUROREPORT, V12, P695, DOI 10.1097/00001756-200103260-00016; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Starck M, 2000, CELL BIOCHEM FUNCT, V18, P9, DOI 10.1002/(SICI)1099-0844(200001/03)18:1<9::AID-CBF841>3.0.CO;2-X; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THOMPSON EJ, 1990, ANN CLIN BIOCHEM, V27, P425, DOI 10.1177/000456329002700503; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	42	26	27	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2003	20	3					243	250		10.1089/089771503321532824			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	661GU	WOS:000181883500002	12820678				2022-02-06	
J	Gottfried, JA; Sancar, F; Chatterjee, A				Gottfried, JA; Sancar, F; Chatterjee, A			Acquired mirror writing and reading: evidence for reflected graphemic representations	NEUROPSYCHOLOGIA			English	Article						reading; dysgraphia; dyslexia; traumatic brain injury	LEFT-HANDERS; DYSLEXIA; STIMULI; INFARCTION; ACTIVATION; REVERSALS; BEHAVIOR; CORTEX; FMRI	Mirror writing occurs when individual letters and whole word strings are produced in reverse direction. By analogy, mirror reading refers to the preference to read mirror reversed over normally written words. These phenomena appear rarely after brain damage and offer insight into the nervous system's organization of visual-spatial and visual-motor representations. We present the case of a 51-year-old patient with persistent mirror writing and reading following traumatic brain injury. She preferred to write in the mirror direction with either hand. She drew asymmetric pictures with the same directional bias as normal right-handed subjects, and she did not exhibit left-right confusion regarding other pictures. By contrast, on picture-word matching and lexical decision tasks, she was faster and more accurate with mirrored than normally written words. This pattern of performance suggests that her behavior was not accounted for by reflected motor programs, or by the mirroring of visual-spatial representations in general. Rather, we suggest that her behavior was produced by privileged access to mirrored graphemes. Furthermore, because she seemed better able to read irregular words in mirrored than in normal formats, we suggest that mirrored representations may exist at the whole word level and not simply at the letter level. (C) 2003 Elsevier Science Ltd. All rights reserved.	Hosp Univ Penn, Ctr Cognit Neurosci, Dept Neurol, Philadelphia, PA 19104 USA		Chatterjee, A (corresponding author), Hosp Univ Penn, Ctr Cognit Neurosci, Dept Neurol, 3 W Gates,3400 Spruce St, Philadelphia, PA 19104 USA.				NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC 04817] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 37539] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC004817] Funding Source: NIH RePORTER		ACHIM A, 1977, NEUROPSYCHOLOGIA, V15, P475, DOI 10.1016/0028-3932(77)90102-6; BERLUCCHI G, 1972, BRAIN RES, V37, P371, DOI 10.1016/0006-8993(72)90708-1; BRIGGS G G, 1975, Cortex, V11, P230; Bruning JL, 1977, COMPUTATIONAL HDB ST, V2nd; BUXBAUM LJ, 1993, NEUROPSYCHOLOGIA, V31, P1417, DOI 10.1016/0028-3932(93)90108-C; CHAN JL, 1988, NEUROLOGY, V38, P59, DOI 10.1212/WNL.38.1.59; CHIA LG, 1987, NEUROSURGERY PSYCHIA, P50; Corballis M.C., 1976, PSYCHOL LEFT RIGHT; CORBALLIS MC, 1970, PSYCHOL REV, V77, P451, DOI 10.1037/h0029805; Critchley M., 1928, MIRROR WRITING; DELIS DC, 1986, NEUROPSYCHOLOGIA, V24, P205, DOI 10.1016/0028-3932(86)90053-9; Dong Y, 2000, BRAIN, V123, P790, DOI 10.1093/brain/123.4.790; Ellis A., 1988, HUMAN COGNITIVE NEUR; FEINBERG T, 1985, CORTEX, V21, P261, DOI 10.1016/S0010-9452(85)80031-9; FISCHER FW, 1978, CORTEX, V14, P496, DOI 10.1016/S0010-9452(78)80025-2; Goebel R, 1998, NEUROREPORT, V9, P713, DOI 10.1097/00001756-199803090-00028; Gonzalez-Rothi L. J., 1984, BATTERY ADULT READIN; HEILMAN KM, 1980, J NEUROL NEUROSUR PS, V43, P774, DOI 10.1136/jnnp.43.9.774; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; Karev GB, 1999, CORTEX, V35, P423, DOI 10.1016/S0010-9452(08)70810-4; Kay J., 1992, PSYCHOLINGUISTIC ASS; LambonRalph MA, 1997, NEUROCASE, V3, P249; Mello N K, 1965, Science, V149, P1519; MELLO NK, 1966, PHYSIOL BEHAV, V1, P293, DOI 10.1016/0031-9384(66)90020-5; NOBLE J, 1966, NATURE, V211, P1263, DOI 10.1038/2111263a0; NOBLE J, 1968, BRAIN RES, V10, P120; ORAM MW, 1994, J COGNITIVE NEUROSCI, V6, P99, DOI 10.1162/jocn.1994.6.2.99; Orton ST, 1928, J AMER MED ASSOC, V90, P1095, DOI 10.1001/jama.1928.02690410007003; PARADOWSKI W, 1971, PERCEPT MOTOR SKILL, V32, P617, DOI 10.2466/pms.1971.32.2.617; PERRETT DI, 1985, PROC R SOC SER B-BIO, V223, P293, DOI 10.1098/rspb.1985.0003; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; Poldrack RA, 1998, CEREB CORTEX, V8, P1, DOI 10.1093/cercor/8.1.1; PRICE C, 1996, CEREBRAL CORTEX, V6; RODRIGUEZ R, 1989, BRAIN LANG, V37, P122, DOI 10.1016/0093-934X(89)90104-1; Schott GD, 1999, LANCET, V354, P2158, DOI 10.1016/S0140-6736(99)07016-6; SCHOTT GD, 1980, J NEUROL NEUROSUR PS, V43, P768, DOI 10.1136/jnnp.43.9.768; Southwood MH, 1999, BRAIN LANG, V67, P1, DOI 10.1006/brln.1998.2046; STREIFLER M, 1976, CORTEX, V12, P356, DOI 10.1016/S0010-9452(76)80039-1; TANKLE RS, 1983, BRAIN LANG, V19, P115, DOI 10.1016/0093-934X(83)90058-5; TRUEMAN RH, 1965, POSTGRAD MED, V38, P469, DOI 10.1080/00325481.1965.11695681; Turnbull OH, 1996, NEUROCASE, V2, P63, DOI 10.1080/13554799608402390; WADE JB, 1991, J CLIN EXP NEUROPSYC, V13, P299, DOI 10.1080/01688639108401045; ZANGWILL OL, 1972, NEUROPSYCHOLOGIA, V10, P371, DOI 10.1016/0028-3932(72)90029-2	43	26	28	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2003	41	1					96	107	PII S0028-3932(02)00130-6	10.1016/S0028-3932(02)00130-6			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	622WD	WOS:000179669500008	12427568				2022-02-06	
J	Cannizzaro, MS; Coelho, CA				Cannizzaro, MS; Coelho, CA			Treatment of story grammar following traumatic brain injury: a pilot study	BRAIN INJURY			English	Article							NARRATIVE DISCOURSE; HEAD; CHILDREN	Recent investigations have documented a variety of discourse deficits following traumatic brain injuries (TBI). However, there is a paucity of information relating to the treatment of such deficits. The present study investigated the treatment of discourse production deficits, specifically story grammar ability, in an individual with TBI. Treatment emphasized meta-linguistic comprehension of story grammar structure and the identification and generation of episode components within stories. Over the course of treatment, a marked increase in the number of complete episodes generated by the individual with TBI was noted in story grammar probes. Follow-up probes at 1 and 3 months post-treatment, however, indicated limited carryover and poor generalization of the treatment effects. Findings are interpreted in terms of the individual's chronic cognitive deficits, disruptions in managerial knowledge, and the limitations of treating discourse acontextually.	Univ Connecticut, Dept Commun Sci, Storrs, CT 06269 USA		Cannizzaro, MS (corresponding author), Univ Connecticut, Dept Commun Sci, U10-85,850 Bolton Rd, Storrs, CT 06269 USA.	michael.cannizzaro@uconn.edu					Applebee A., 1978, CHILDS CONCEPT STORY; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; GLALSKI T, 1998, BRAIN INJURY, V12, P769; GLOSSER G, 1992, J GERONTOL, V47, pP266, DOI 10.1093/geronj/47.4.P266; Grafman J, 1995, ANN NY ACAD SCI, V769, P337, DOI 10.1111/j.1749-6632.1995.tb38149.x; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; GRAFMAN J, 1999, SCI PRACT NEUROPSYCH, P321; Grafman J., 1989, INTEGRATING THEORY P, P93; HAGAN C, 1980, REHABILITATION HEAD; Kertesz A., 1982, W APHASIA BATTERY; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1993, J SPEECH HEAR RES, V36, P868, DOI 10.1044/jshr.3605.868; MATTIS S, 1976, GERIATRIC PSYCHIATRY; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; Stein N. L., 1979, NEW DIRECTIONS DISCO, P53; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745	20	26	27	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2002	16	12					1065	1073		10.1080/02699050210155230			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	617KK	WOS:000179360700005	12487721				2022-02-06	
J	Reiche, W; Komenda, Y; Schick, B; Grunwald, I; Steudel, WI; Reith, W				Reiche, W; Komenda, Y; Schick, B; Grunwald, I; Steudel, WI; Reith, W			MR cisternography after intrathecal Gd-DTPA application	EUROPEAN RADIOLOGY			English	Article						cerebrospinal fluid fistula; intrathecal contrast media administration cisternography; gadolinium DTPA; magnetic resonance imaging	CEREBROSPINAL-FLUID RHINORRHEA; HIGH-RESOLUTION CT; GADOPENTETATE DIMEGLUMINE; GADOLINIUM-DTPA; SUBARACHNOID SPACE; CSF RHINORRHEA; CONTRAST-MEDIA; FISTULA; LOCALIZATION; DIAGNOSIS	The purpose of this study was to establish and to evaluate MR cisternography after intrathecal GdDTPA administration to detect rhinobasal cerebrospinal fluid (CSF) fistulae in patients with suspected CSF rhinorrhoea. Ten patients with suspected CSF rhinorrhoea were examined. The MR cisternography included the following investigation steps: acquisition of nonenhanced fat-suppressed T1-weighted spin-echo (SE) scans of the skull base and the para-nasal sinuses, lumbar puncture with administration of 1 ml Gd-DTPA solute with 4 ml NaCl and performance of MR cisternography with the same fat-suppressed T1-weighted sequences as used initially. In 10 patients with suspected CSF rhinorrhoea Gd-DTPA enhanced MR cisternography detected 5 CSF fistulae. In 3 of 5 CSF leaks were located in the cribriform plate and in 2 of 5 sphenoidal. Whereas 4 of these depicted leaks were confirmed surgically, in 1 case the CSF fistula closed spontaneously. In another case, CSF leakage after severe head injury was clinically highly suspected but ceased prior to MR cisternography with inability to detect the temporary fistula. In the remaining 4 patients with serous rhinorrhoea MR cisternography did not provide any evidences for CSF fistulae. Intrathecal Gd-DTPA injection was tolerated excellently. Clinical and EEG examinations showed no gross behavioural or neurological disturbances and no seizure activity, respectively. The MR cisternography after intrathecal administration of Gd-DTPA represents a safe, promising and minimally invasive method for detection of CSF fistulae. This MR investigation provides excellent depiction of CSF spaces and pinpoints CSF fistulae.	Saarland Univ Clin, Dept Neuroradiol, Radiol Clin, Ctr Skull Base Surg, Homburg, Germany; Saarland Univ Clin, Clin Ear Nose & Throat, Ctr Skull Base Surg, Homburg, Germany; Klinikum Lahr, Inst Radiol, D-77931 Lahr, Germany		Reiche, W (corresponding author), Saarland Univ Clin, Dept Neuroradiol, Radiol Clin, Ctr Skull Base Surg, Homburg, Germany.		Grunwald, Iris/AAY-2521-2021				ALLARD M, 1987, J NEURORADIOLOGY, V14, P383; CHOW JM, 1989, OTOLARYNG HEAD NECK, V100, P99, DOI 10.1177/019459988910000204; COLQUHOUN IR, 1993, CLIN RADIOL, V47, P403, DOI 10.1016/S0009-9260(05)81061-X; CURNES JT, 1985, RADIOLOGY, V154, P795, DOI 10.1148/radiology.154.3.3881800; DICHIRO G, 1986, RADIOLOGY, V160, P221, DOI 10.1148/radiology.160.1.3715036; DICHIRO G, 1985, RADIOLOGY, V157, P373, DOI 10.1148/radiology.157.2.4048444; Dietrich U, 1993, Zentralbl Neurochir, V54, P24; Eberhardt KEW, 1997, EUR RADIOL, V7, P1485, DOI 10.1007/s003300050321; El Gammal T, 1998, AM J NEURORADIOL, V19, P627; FARRELL VJ, 1993, SURG NEUROL, V40, P378, DOI 10.1016/0090-3019(93)90216-N; Gjuric M, 1998, HNO, V46, P205, DOI 10.1007/s001060050228; Grainger AJ, 2000, CLIN RADIOL, V55, P163, DOI 10.1053/crad.1999.0374; Gupta V, 1997, ACTA RADIOL, V38, P603; Har-El G, 1999, ANN OTO RHINOL LARYN, V108, P323, DOI 10.1177/000348949910800401; HARBURY OL, 1991, AM J NEURORADIOL, V12, P666; Ibarra R, 2000, J MAGN RESON IMAGING, V11, P20, DOI 10.1002/(SICI)1522-2586(200001)11:1<20::AID-JMRI3>3.0.CO;2-6; Jinkins JR, 2002, RADIOLOGY, V222, P555, DOI 10.1148/radiol.2222010249; Jinkins JR, 1999, INVEST RADIOL, V34, P156, DOI 10.1097/00004424-199902000-00009; NIENDORF HP, 1991, MAGNET RESON MED, V22, P222, DOI 10.1002/mrm.1910220212; NIENDORF HP, 1991, INVEST RADIOL, V26, pS221, DOI 10.1097/00004424-199111001-00075; PARIS S, 1999, NEURORADIOLOGY S1, V41, pS46; PIEPGRAS U, 1987, ACTA RADIOL S, V369, P290; Ray DE, 1996, AM J NEURORADIOL, V17, P365; Schick B, 1997, ARCH OTOLARYNGOL, V123, P77; Shetty PG, 1998, AM J NEURORADIOL, V19, P633; Siebner HR, 1997, NEURORADIOLOGY, V39, P418, DOI 10.1007/s002340050436; Simmen D, 1997, LARYNGO RHINO OTOL, V76, P583, DOI 10.1055/s-2007-997485; Skalpe IO, 1998, ACTA RADIOL, V39, P100; Skalpe IO, 1997, INVEST RADIOL, V32, P140, DOI 10.1097/00004424-199703000-00002; Speck U, 1997, NEURORADIOLOGY, V39, P422; Stone JA, 1999, AM J NEURORADIOL, V20, P706; TISHLER S, 1990, AM J NEURORADIOL, V11, P1167; Toney GM, 2001, INVEST RADIOL, V36, P33, DOI 10.1097/00004424-200101000-00005; VERBRUGGEN AM, 1994, EUR J NUCL MED, V21, P261, DOI 10.1007/BF00188676; WEINMANN HJ, 1984, AM J ROENTGENOL, V142, P619, DOI 10.2214/ajr.142.3.619; WEINMANN HJ, 1990, INVEST RADIOL S1, V25, P49; Wenzel R, 2000, NEURORADIOLOGY, V42, P874, DOI 10.1007/s002340000485; Zeng QY, 1999, AM J ROENTGENOL, V173, P1109, DOI 10.2214/ajr.173.4.10511188	38	26	26	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0938-7994			EUR RADIOL	Eur. Radiol.	DEC	2002	12	12					2943	2949		10.1007/s00330-002-1606-9			7	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	627GL	WOS:000179925300014	12439574				2022-02-06	
J	Herrmann, B				Herrmann, B			Child physical abuse. Physical findings and medical diagnosis	MONATSSCHRIFT KINDERHEILKUNDE			German	Article						child physical abuse; non accidental injury; medical diagnosis; physical findings; shaken baby syndrome	SHAKEN-INFANT SYNDROME; HEMORRHAGES	Child physical abuse may result in dramatic short and longtime damage of children's physical and emotional well being. Even after excluding abusive head injury, neurobiological research has demonstrated structural changes of the brain resulting from chronic child abuse. This underscores the clinician's special responsibility to contribute a sound professional and scientific approach to the multi professional diagnosis and intervention in suspected child abuse cases. Various traumatic changes of the skin,the skeletal system, the brain and other parts of the body may be caused by inflicted injuries. The essential approach is to correlate the probability of a given finding with the history and comparing it to physical and physiological principles of pediatric traumatology. Suspicious findings require a rational diagnostic strategy and consideration of numerous differential diagnoses. The skeletal survey and ophthalmologic retinal exam are of utmost importance. Of concern are especially all serious injuries with an alleged trivial mechanism, missing, vague or changing patterns of explanation, injury patterns inadequate for age, delay of medical care and allegations by independent observers or even the child. Without an adequate accidental explanation the strongest indicators of physical abuse are shaken baby syndrome, retinal hemorrhages, complex skull fractures, epi- and metaphyseal fractures, multiple fractures in different stages of healing, multiple bruising in an uncommon distribution, patterned bruises or burns, immersion burns and intramural duodenal hematoma. Several controversies and new developments in abuse research have derived and need to be considered.	Arztl Kinderschutzambulanz, Kinderklin Klinikums, D-34125 Kassel, Germany		Herrmann, B (corresponding author), Arztl Kinderschutzambulanz, Kinderklin Klinikums, Monchebergstr 43, D-34125 Kassel, Germany.	b.herrmann@t-online.de					*AAP, 2001, PEDIATRICS, V107, P437; Alexander R. C, 2001, CHILD ABUSE MED DIAG, P47; ARMBRUSTER S, 2002, THESIS U KLIN MAINZ; Ayoub C. C., 2002, CHILD MALTREATMENT, V7, P103, DOI 10.1177/1077559502007002001; Bays J., 2001, CHILD ABUSE MED DIAG, P177; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Glaser D, 2000, J CHILD PSYCHOL PSYC, V41, P97, DOI 10.1111/1469-7610.00551; HERMANN B, 2000, KINDESMISSHAND VERNA, V4, P123; HUYER D, 1994, APSAC ADVISOR, V7, P5; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jenny C., 2001, CHILD ABUSE MED DIAG, P23; Kairys SW, 2001, PEDIATRICS, V108, P206; *KIND ZENTR BERL, 2000, KIND HANDL; Kleinman PK, 1998, DIAGNOSTIC IMAGING C; Krous HF, 1999, PEDIATR DEVEL PATHOL, V2, P497, DOI 10.1007/s100249900156; LEVIN AV, 2000, RECENT ADV PAEDIAT, V18, P151; Lloyd B, 1998, BRIT MED J, V317, P1538, DOI 10.1136/bmj.317.7172.1538; NASHELSKY MB, 1995, AM J FOREN MED PATH, V16, P154, DOI 10.1097/00000433-199506000-00016; Sane SM, 2000, PEDIATRICS, V105, P1345; Schwartz AJ, 1996, PEDIATRICS, V97, P254; Sorantin E, 2002, MONATSSCHR KINDERH, V150, P1068, DOI 10.1007/s00112-002-0565-1; Southall DP, 1997, PEDIATRICS, V100, P735, DOI 10.1542/peds.100.5.735; Stephenson T, 1996, ARCH DIS CHILD, V74, P53, DOI 10.1136/adc.74.1.53; Taylor D, 1999, EYE, V13, P3; THYEN U, 1991, MONATSSCHR KINDERH, V139, P292	27	26	27	1	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0026-9298	1433-0474		MONATSSCHR KINDERH	Mon.schr. Kinderheilkd.	NOV	2002	150	11					1324	+		10.1007/s00112-002-0610-0			14	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	623ED	WOS:000179689600002					2022-02-06	
J	Marklund, N; Sihver, S; Langstrom, B; Bergstrom, M; Hillered, L				Marklund, N; Sihver, S; Langstrom, B; Bergstrom, M; Hillered, L			Effect of traumatic brain injury and nitrone radical scavengers on relative changes in regional cerebral blood flow and glucose uptake in rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow (CBF); FDG; fluid percussion; glucose uptake; HMPAO; nitrone; rat; reactive oxygen species; traumatic brain injury (TBI)	COMPRESSION CONTUSION TRAUMA; EXPERIMENTAL HEAD-INJURY; BUTYL-NITRONE; LUMPED CONSTANT; TRAPPING AGENT; NITRIC-OXIDE; AMINO-ACIDS; S-PBN; MITOCHONDRIAL DYSFUNCTION; DELAYED TREATMENT	Changes in regional cerebral blood flow (rCBF) and glucose metabolism are commonly associated with traumatic brain injury (TBI). Reactive oxygen species (ROS) have been implicated as key contributors to the secondary injury process after TBI. Here, pretreatment with the nitrone radical scavengers (alpha-phenyl-N-tert-butyl nitrone (PBN) or its sulfonated analogue sodium 2-sulfophenyl-N-tert-butyl nitrone (S-PBN) were used as tools to study the. effects of ROS on rCBF and glucose metabolism after moderate (2.4-2.6 atm) lateral fluid percussion injury (FPI) in rats. S-PBN has a half-life in plasma of 9 min and does not penetrate the blood-brain barrier (BBB). In contrast, PBN has a half-life of 3 h and readily penetrates the BBB. Regional cerebral blood flow (rCBF) and glucose metabolism was estimated by using Tc-99m-HMPAO and [F-18]Fluoro-2-deoxyglucose (FDG) antoradiography, respectively, at 42 min (n = 37) and 12 h (n = 34) after the injury. Regions of interest were the parietal. cortex and hippocampus bilaterally. As expected, FPI produced an early (42-min) hypoperfusion in ipsilateral cortex and an increase in glucose metabolism in both cortex and hippocampus, giving way to a state of hypoperfusion and decreased glucose metabolism at 12 h postinjury. On the contralateral side, a hypoperfusion in the cortex and hippocampus was seen at 12 h only, but no significant changes in glucose metabolism. Both S-PBN and PBN attenuated the trauma-induced changes in rCBF and glucose metabolism. Thus, the early improvement in rCBF and glucose metabolism correlates with and may partly mediate the improved functional and morphological outcome after TBI in nitrone-treated rats.	Uppsala Univ, Dept Neurosci, Uppsala, Sweden; Uppsala Univ, Dept Neurosurg, Uppsala, Sweden; Uppsala Univ, Dept Med Pharmacol, Uppsala, Sweden; Uppsala Univ, Dept Med Sci, Uppsala, Sweden; Uppsala Univ, Dept Clin Chem, Uppsala, Sweden; Uppsala Univ, PET Ctr, Uppsala, Sweden		Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Div Neurosurg, SE-75185 Uppsala, Sweden.			Marklund, Niklas/0000-0002-9797-5626			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Beckman JS, 1996, ADV NEUROL, V71, P339; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; Carlsson C, 1975, Acta Anaesthesiol Scand Suppl, V57, P1; CHEN GM, 1990, FREE RADICAL RES COM, V9, P317, DOI 10.3109/10715769009145690; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; Choi DW, 1997, NAT MED, V3, P1073, DOI 10.1038/nm1097-1073; CLARKE DD, 1999, NEUROCHEMISTRY MOL C, P637; CLOUGHHELFMAN C, 1991, FREE RADICAL RES COM, V15, P177, DOI 10.3109/10715769109049138; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; CSIBA L, 1985, BRAIN RES, V336, P167, DOI 10.1016/0006-8993(85)90430-5; DEVASKAR SU, 1991, ADV EXP MED BIOL, V293, P405; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Duncan R, 1996, J NUCL MED, V37, P661; Estevez AG, 1998, PROG BRAIN RES, V118, P269; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GREENBERG JH, 1992, J CEREBR BLOOD F MET, V12, P70, DOI 10.1038/jcbfm.1992.9; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hall ED, 1997, NEUROSURG CLIN N AM, V8, P195; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; Hovda D.A., 1996, NEUROTRAUMA, P1459; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INANAMI O, 1995, FREE RADICAL RES, V23, P33, DOI 10.3109/10715769509064017; KAPOOR R, 1989, J NEUROCHEM, V53, P37, DOI 10.1111/j.1471-4159.1989.tb07292.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; LUCIGNANI G, 1990, EUR J NUCL MED, V16, P249, DOI 10.1007/BF00842776; Maples KR, 2001, FREE RADICAL RES, V34, P417, DOI 10.1080/10715760100300351; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Marshall JWB, 2001, STROKE, V32, P190, DOI 10.1161/01.STR.32.1.190; MATSUDA H, 1988, BRAIN DEV-JPN, V10, P13, DOI 10.1016/S0387-7604(88)80039-1; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629, DOI 10.1152/ajplegacy.1971.221.6.1629; Pazos AJ, 1999, BRAIN RES, V846, P186, DOI 10.1016/S0006-8993(99)02010-7; RACKER E, 1983, J BIOL CHEM, V258, P3702; ROSE IA, 1964, BIOCHEM BIOPH RES CO, V15, P33, DOI 10.1016/0006-291X(64)90098-1; SAHA GB, 1994, SEMIN NUCL MED, V24, P324, DOI 10.1016/S0001-2998(05)80022-4; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; SCHULZ JB, 1995, J CEREBR BLOOD F MET, V15, P948, DOI 10.1038/jcbfm.1995.120; Schulz JB, 1997, AM J PHYSIOL-HEART C, V272, pH1986, DOI 10.1152/ajpheart.1997.272.4.H1986; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SPENCE AM, 1990, J CEREBR BLOOD F MET, V10, P190, DOI 10.1038/jcbfm.1990.34; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Tabatabaie T, 1996, ARCH BIOCHEM BIOPHYS, V336, P290, DOI 10.1006/abbi.1996.0560; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Yang Y, 2000, EXP NEUROL, V163, P39, DOI 10.1006/exnr.2000.7364; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU NC, 1995, MOL PHARMACOL, V48, P550; Zeller K, 1997, J CEREBR BLOOD F MET, V17, P204, DOI 10.1097/00004647-199702000-00010; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510	94	26	26	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2002	19	10					1139	1153		10.1089/08977150260337958			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	605MJ	WOS:000178681400004	12427324				2022-02-06	
J	Naunheim, R; McGurren, M; Standeven, J; Fucetola, R; Lauryssen, C; Deibert, E				Naunheim, R; McGurren, M; Standeven, J; Fucetola, R; Lauryssen, C; Deibert, E			Does the use of artificial turf contribute to head injuries?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; concussion; artificial turf		Background. A number of high-profile professional football players have suffered career-ending conclusions. The purpose of this article is to test the surfaces used by a professional team to determine their impact-attenuating properties. Methods: An accelerometer was dropped from a height of 48 inches onto three different playing fields in the St. Louis area: an indoor artificial turf practice field, a grass outdoor practice field, and the artificial turf field at a domed stadium. The accelerometer was dropped 20 times from a height of 48 inches onto each surface. Results: Statistical analysis of the peak Gs for impacts onto each surface indicate all three are statistically different. The artificial surface of the domed stadium was the hardest surface, with an average peak acceleration of 261 Gs compared with 183 Gs for the indoor artificial turf practice field and 246 Gs for the outdoor grass field. Conclusion. The surface used to play league games has the least impact attenuation of any field tested and may contribute to the high incidence of concussion in football players.	Washington Univ, Sch Med, Dept Emergency Med, St Louis, MO 63110 USA		Naunheim, R (corresponding author), Washington Univ, Sch Med, Dept Emergency Med, St Louis, MO 63110 USA.	naunheir@msnotes.wustl.edu					*ASTM, 1994, ANN BOOK ASTM STAND, V15, P7; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barth JT, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P81; EIBAND A, 1959, HUMAN TOLERANCE RA E, V69, P5; Gadd C. W., 1966, P 10 STAPP CAR CRASH; GOLDSMITH W, 1970, BIOMECHANICS ITS FDN, P585; GURDJIAN ES, 1961, SURG GYNECOL OBSTET, V113, P185; GURDJIAN ES, 1962, JAMA-J AM MED ASSOC, V182, P509, DOI 10.1001/jama.1962.03050440001001; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HADDAD B. F., 1955, NEUROLOGY, V5, P798; KIKUCHI A, 1993, BIOMECHANICS IMPACT, P361; LEWIS LM, 1993, J TRAUMA, V35, P932, DOI 10.1097/00005373-199312000-00020; *NFL PLAYERS ASS, 2000, 2000 NFL PLAYERS HLT; *SAE, 1966, SAE HDB; Thibault L.E.O.A., 1993, BIOMECHANICS IMPACT, P411; UNTERHARNSCHEID.F, 1993, BIOMECHANICS IMPACT, P407; Versace, 1971, P 15 STAPP CAR CRASH, DOI DOI 10.4271/710881; ZEMPER ED, 1989, PHYSICIAN SPORTSMED, V17, P100, DOI 10.1080/00913847.1989.11709915	18	26	26	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2002	53	4					691	694		10.1097/00005373-200210000-00012			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	604JZ	WOS:000178618400016	12394868				2022-02-06	
J	Imai, H; McCulloch, J; Graham, DI; Masayasu, H; Macrae, IM				Imai, H; McCulloch, J; Graham, DI; Masayasu, H; Macrae, IM			New method for the quantitative assessment of axonal damage in focal cerebral ischemia	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						white matter; focal ischemia; method; antioxidant; ebselen; amyloid precursor protein	AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; WHITE-MATTER; BRAIN INJURY; RAT-BRAIN; SELENOORGANIC COMPOUND; LIPID-PEROXIDATION; ARTERY OCCLUSION; EBSELEN; MODEL	Quantification of damage in both grey and white matter is required for comprehensive assessment of neuroprotective drug efficacy. Although methods for quantification of neuronal perikaryal damage after ischemia are Well established, assessment of axonal damage has been limited. This article describes a new method for quantitation of axonal injury after middle cerebral artery (MCA) occlusion in rats and its application to the study of the antioxidant ebselen. The methodology is based on immunohistochemical detection of amyloid precursor protein (APP) accumulation in deformed, swollen axons in zones of ischemia. Sixty-five axon-rich sites throughout the MCA territory are assessed for the presence (scored 1) or absence (scored 0) of accumulated APP in axonal swellings. Scores for individual sites are summated in predefined neuro-anatomic regions (e.g. corpus callosum), stereotaxic levels, or for a total hemisphere APP score. Both intra-rater and inter-rater reproducibility were high (r = 0.87 and 0.80, respectively). Ebselen (1 mg kg(-1) hr(-1), intravenously) significantly reduced the volume of neuronal perikaryal damage (24%, P < 0.01) and axonal damage (total APP score reduced from 27 [23.9 to 35.1, 95% CI] to 21.5 [18.2 to 23.3], P = 0.002 With ebselen treatment). In conclusion, a robust and generally applicable method is described for assessing pathologic features in myelinated fiber tracts that is sensitive for detection of drug effects on axonal damage.	Univ Glasgow, Wellcome Surg Inst, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Neuropathol, Glasgow G61 1QH, Lanark, Scotland; Daiichi Pharmaceut Co Ltd, Tokyo, Japan		Macrae, IM (corresponding author), Univ Glasgow, Wellcome Surg Inst, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.						BINDOLI A, 1988, FREE RADICAL BIO MED, V5, P247, DOI 10.1016/0891-5849(88)90018-4; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Boireau A, 1999, ANN NY ACAD SCI, V893, P254, DOI 10.1111/j.1749-6632.1999.tb07830.x; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRIERLEY JB, 1987, GREENFIELDS NEUROPAT, P125; COTGREAVE IA, 1989, BIOCHEM PHARMACOL, V38, P649, DOI 10.1016/0006-2952(89)90211-6; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; DEWAR D, 1995, BRAIN RES, V684, P70, DOI 10.1016/0006-8993(95)00417-O; Dewar D, 1999, EUR J PHARMACOL, V375, P41, DOI 10.1016/S0014-2999(99)00280-0; Dietrich WD, 1998, ACTA NEUROPATHOL, V95, P524, DOI 10.1007/s004010050833; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Gentleman SM, 1999, NEUROPATH APPL NEURO, V25, P41; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; HATTORI R, 1994, EUR J PHARM-MOLEC PH, V267, pR1, DOI 10.1016/0922-4106(94)90179-1; He Z, 1999, STROKE, V30, P2743, DOI 10.1161/01.STR.30.12.2743; Heiss WD, 2000, J CEREBR BLOOD F MET, V20, P1276, DOI 10.1097/00004647-200009000-00002; Herin GA, 2001, J NEUROCHEM, V78, P1307, DOI 10.1046/j.1471-4159.2001.00517.x; Imai H, 2001, STROKE, V32, P2149, DOI 10.1161/hs0901.095725; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOMJATI K, 2001, J CEREB BLOOD FLO S1, V21, pS14; Konig J. F. R., 1963, RAT BRAIN STEREOTAXI; Malecki A, 2000, J NEUROCHEM, V74, P2278, DOI 10.1046/j.1471-4159.2000.0742278.x; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; McCracken E, 2000, J CEREBR BLOOD F MET, V20, P1529, DOI 10.1097/00004647-200011000-00002; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; Parnham M, 2000, EXPERT OPIN INV DRUG, V9, P607, DOI 10.1517/13543784.9.3.607; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Petty MA, 1999, BRAIN RES REV, V31, P58, DOI 10.1016/S0165-0173(99)00025-9; Pierce JES, 1996, J NEUROSCI, V16, P1083; Schabitz WR, 2000, STROKE, V31, P1709, DOI 10.1161/01.STR.31.7.1709; SCHEWE C, 1994, BIOCHEM PHARMACOL, V48, P65, DOI 10.1016/0006-2952(94)90224-0; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Takasago T, 1997, BRIT J PHARMACOL, V122, P1251, DOI 10.1038/sj.bjp.0701426; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; Valeriani V, 2000, J CEREBR BLOOD F MET, V20, P765, DOI 10.1097/00004647-200005000-00002; WAKITA H, 1995, STROKE, V26, P1415, DOI 10.1161/01.STR.26.8.1415; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Yam PS, 1998, BRAIN RES PROTOC, V2, P315, DOI 10.1016/S1385-299X(98)00005-1; Yam PS, 2000, J CEREBR BLOOD F MET, V20, P772, DOI 10.1097/00004647-200005000-00003; Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399	46	26	26	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2002	22	9					1080	1089		10.1097/00004647-200209000-00005			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	592CP	WOS:000177919400005	12218413	Bronze			2022-02-06	
J	Lippert-Gruner, M; Wedekind, C; Klug, N				Lippert-Gruner, M; Wedekind, C; Klug, N			Functional and psychosocial outcome one year after severe traumatic brain injury and early-onset rehabilitation therapy	JOURNAL OF REHABILITATION MEDICINE			English	Article						outcome; rehabilitation; traumatic brain injury; occupational reintegration; behavioural deficits	HEAD-INJURY	This study evaluates the impact of early-onset continuous rehabilitation treatment on the 1-year outcome of patients after severe traumatic brain injury. Immediately after recovery from mechanical ventilation, a total of 48 patients underwent a complex early rehabilitation treatment until they were discharged from hospital and local ambulant care was deemed sufficient. The follow-up examination took place 12 months after trauma. Data reveal that at 1 year 91.6% of the patients were completely or restrictedly independent of care and capable of carrying out activities of daily living, although they frequently were still suffering from marked behavioural and also from certain sensorimotor deficits. Only 45.8% of the patients were obviously able to work without restrictions or had returned to work. In those subjects who were not or only very restrictedly able to work, behavioural and speech deficits were significantly more frequent. Behavioural and speech deficits seem to represent the major cause that hinders professional reintegration. Rehabilitation therapy therefore should be specifically directed to improve these deficits.	Univ Cologne, Dept Neurosurg, DE-50924 Cologne, Germany		Lippert-Gruner, M (corresponding author), Univ Cologne, Dept Neurosurg, DE-50924 Cologne, Germany.						Anderson SI, 1996, BRAIN INJURY, V10, P115, DOI 10.1080/026990596124601; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; CRAMON Y, 1988, NEUROPSYCHOLOGISCH R; CRAMON Y, 1993, NEUROPSYCHOLOGISCHE; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Frowein R A, 1992, Acta Neurochir Suppl (Wien), V55, P72; FROWEIN R A, 1975, Aktuelle Traumatologie, V5, P203; FROWEIN RA, 1978, ADV NEUROSURG, V5, P16; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; JENNETT B, 1976, LANCET, V1, P1031; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LIPPERTGRUNER M, 1999, BRAIN INJURY, V14, P585; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958	25	26	27	0	6	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	1650-1977			J REHABIL MED	J. Rehabil. Med.	SEP 1	2002	34	5					211	214		10.1080/165019702760279198			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	595HT	WOS:000178103600003	12392235	gold			2022-02-06	
J	Thanos, S; Indorf, L; Naskar, R				Thanos, S; Indorf, L; Naskar, R			In vivo FM: using conventional fluorescence microscopy to monitor retinal neuronal death in vivo	TRENDS IN NEUROSCIENCES			English	Article							CONFOCAL NEUROIMAGING ICON; IMAGED IN-VIVO; NERVE-CELLS; DYNAMICS; LINEAGE; PROBES; GROWTH; BRAIN; MICE	Post-traumatic death of mature retinal neurons occurs in glaucoma and after optic nerve injury. The death is a dynamic process that can be fully analyzed with methods that monitor changes over time. We have coupled the development of retrogradely transportable fluorescent dyes with modification of conventional epifluorescence microscopy to manipulate and visualize rat retinal neurons in vivo. The method is a relatively new concept and has potential for the monitoring of retinal conditions, such as glaucoma or optic nerve transection, and for evaluation of neuroprotective strategies in the near future.	Univ Munster, Hosp Eye, Dept Expt Ophthalmol, D-48149 Munster, Germany		Thanos, S (corresponding author), Univ Munster, Hosp Eye, Dept Expt Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.						BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Cullander C, 1999, METH MOL B, V122, P59; Dawson AJ, 2001, J COMP NEUROL, V434, P40, DOI 10.1002/cne.1163; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Engelmann R, 1999, METHOD ENZYMOL, V307, P563; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; FISHELL G, 1995, FASEB J, V9, P324, DOI 10.1096/fasebj.9.5.7896001; FRANK E, 1991, DEVELOPMENT, V111, P895; GARCIAVALENZUEL.E, 1993, J NEUROBIOL, V24, P431; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; Hollander H, 1966, Z Wiss Mikrosk, V67, P156; Jontes JD, 2000, NAT NEUROSCI, V3, P231, DOI 10.1038/72936; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; LICHTMAN JW, 1985, NATURE, V314, P357, DOI 10.1038/314357a0; Lichtman JW, 2001, NAT NEUROSCI, V4, P1215, DOI 10.1038/nn754; Meister M, 2001, J NEUROSCI, V21, P1351; Moritz OL, 1999, INVEST OPHTH VIS SCI, V40, P3276; NASKAR R, IN PRESS INVEST OPHT; PURVES D, 1987, TRENDS NEUROSCI, V10, P398, DOI 10.1016/0166-2236(87)90005-1; PURVES D, 1987, J NEUROSCI, V7, P1492; PURVES D, 1985, NATURE, V315, P404, DOI 10.1038/315404a0; Rousseau V, 1999, NEUROREPORT, V10, P3387, DOI 10.1097/00001756-199911080-00024; Sabel BA, 1997, NAT MED, V3, P244, DOI 10.1038/nm0297-244; THANOS S, 1994, TRENDS NEUROSCI, V17, P177, DOI 10.1016/0166-2236(94)90098-1	26	26	28	0	3	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0166-2236			TRENDS NEUROSCI	Trends Neurosci.	SEP	2002	25	9					441	444		10.1016/S0166-2236(02)02246-4			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	587AM	WOS:000177618400006	12183199				2022-02-06	
J	Franz, G; Beer, R; Intemann, D; Krajewski, T; Reed, JC; Engelhardt, K; Pike, BR; Hayes, RL; Wang, KK; Schmutzhard, E; Kampfl, A				Franz, G; Beer, R; Intemann, D; Krajewski, T; Reed, JC; Engelhardt, K; Pike, BR; Hayes, RL; Wang, KK; Schmutzhard, E; Kampfl, A			Temporal and spatial profile of bid cleavage after experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; bid; caspases; neurons; glia; traumatic brain injury	APOPTOTIC CELL-DEATH; CASPASE ACTIVATION; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; IN-VITRO; EXPRESSION; CALPAIN; RAT; MITOCHONDRIA; PROTEOLYSIS	Apoptosis plays an essential role in the cascade of CNS cell degeneration after traumatic brain injury. However., the underlying mechanisms are poorly understood, The authors examined the temporal profile and cell subtype distribution of the proapoptotic protein Bid from 6 hours to 7 days after cortical impact injury in the rat. Increased protein levels of tBid were seen in the cortex ipsilateral to the injury site from 6 hours to 3 days after trauma. Immunohistologic examinations revealed expression of tBid in neurons, astrocytes, and oligodendrocytes from 6 hours to 3 days after impact injury, and concurrent assessment of DNA damage using TUNEL identified tBid-immunopositive cells with apoptoticlike morphology in the traumatized cortex. Moreover, Bid cleavage and activation of caspase-8 and caspase-9 occurred at similar time points, and in similar brain regions (i.e., cortical layers 2 to 5) after impact injury. In contrast, there was no evidence of caspase-8 or caspase-9 processing or Bid cleavage in the ipsilateral hippocampus, contralateral cortex, and hippocampus up to 7 days after the injury. The results provide the first evidence of Bid cleavage in the traumatized cortex after experimental traumatic brain injury in vivo, and demonstrate that tBid is expressed in neurons and glial cells. Further, findings indicate that cleavage of Bid may be associated with the activation of the initiator caspase-8 and caspase-9. Finally, these data support the hypothesis that cleavage of Bid contributes to the apoptotic degeneration of different CNS cells in the injured cortex.	Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; Pfizer Inc, Dept Neurosci Therapeut, Ann Arbor, MI USA; Univ Florida, Everlyn F & William L McKnight Brain Inst, Dept Neurosci, Gainesville, FL USA; Burnham Inst, La Jolla, CA 92037 USA		Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.		Pike, Bruce/K-5562-2014	Pike, Bruce/0000-0001-8924-683X; Schmutzhard, Erich/0000-0003-3295-7491; Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036821] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36821] Funding Source: Medline		Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Buki A, 2000, J NEUROSCI, V20, P2825; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Franz G, 1999, J NEUROCHEM, V73, P1615, DOI 10.1046/j.1471-4159.1999.0731615.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Krajewska M, 2002, CELL DEATH DIFFER, V9, P145, DOI 10.1038/sj/cdd/4400934; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Neumar RW, 1996, J NEUROCHEM, V66, P421; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SPRINKLE TJ, 1989, CRIT REV NEUROBIOL, V4, P235; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; 1989, FEDERAL LAW GAZETTE, P501	39	26	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2002	22	8					951	958		10.1097/00004647-200208000-00006			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	579PL	WOS:000177187000006	12172380	hybrid			2022-02-06	
J	Giese, A; Koops, E; Lohmann, F; Westphal, M				Giese, A; Koops, E; Lohmann, F; Westphal, M			Head injury by gunshots from blank cartridges	SURGICAL NEUROLOGY			English	Article						trauma; head injury; gun shot; blank cartridge; gas pistol	WOUNDS; GAS	BACKGROUND Blank cartridge handguns are generally underestimated in their capacity to inflict serious and potentially life threatening injuries. The predominant reasons for these injuries are suicide or suicide attempts, followed by accidental injuries. METHODS A series of 26 gas gunshots to the neurocranium is presented. The injury pattern relevant to neurosurgical practice is illustrated in a case summary of 7 selected cases and the clinical courses as well as outcomes are presented. RESULTS he injury pattern demonstrates that the energy density of the gas jet and the high temperatures of the exploding gas volume cause extensive soft tissue injuries, In close-range shots the gas jet takes on physical properties of a projectile. In these injuries impression fractures and dislocation of bone fragments are common. CONCLUSIONS Gas handguns, contrary to public opinion, are dangerous weapons and may inflict potentially fatal injuries to the neurocranium when fired at close range. These weapons are frequently used in criminal or careless activities predominantly by young males. Extensive CNS injuries including hematomas, subarachnoid hemorrhage, foreign body contamination, and increased intracranial pressure are frequently observed. (C) 2002 by Elsevier Science Inc.	Univ Hamburg, Hosp Eppendorf, Dept Neurosurg, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Forens Med, D-20246 Hamburg, Germany		Giese, A (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany.						AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; BOCK G, 1980, HDB FAUSTIEUERWAFFEN, V13, P114; BRUNNER RG, 1990, AM SURGEON, V56, P104; CLARK MA, 1984, AM J FOREN MED PATH, V5, P75, DOI 10.1097/00000433-198403000-00014; COONEY WP, 1982, J TRAUMA, V22, P112, DOI 10.1097/00005373-198202000-00006; EISELE JW, 1981, J FORENSIC SCI, V26, P480, DOI 10.1520/JFS11388J; ERTL M, 1993, IWM, V11, P312; JACOB B, 1990, AM J FOREN MED PATH, V11, P285, DOI 10.1097/00000433-199012000-00003; LANGNER M, 1995, WAFFEN VERSAMMLUNGEN, P261; MARJEWSKI, 1907, UEBER BEHANDLUNGE EX; MAXEINER H, 1989, Archiv fuer Kriminologie, V184, P84; OKSALA A, 1975, ACTA OPHTHALMOL, V53, P908; ORDOG GJ, 1993, J TRAUMA, V34, P358, DOI 10.1097/00005373-199303000-00009; Pollak S, 1988, Beitr Gerichtl Med, V46, P401; Pollak S, 1982, Beitr Gerichtl Med, V40, P493; PUSCHEL K, 2001, IN PRESS ARCH KRIMIN; ROHLFING H, 1916, THESIS BERLIN; ROTHSCHILD M, 1999, FREIVERKAUFLICHE SCH; Rothschild MA, 1998, INT J LEGAL MED, V111, P78, DOI 10.1007/s004140050118; Rothschild MA, 1999, FORENSIC SCI INT, V101, P151, DOI 10.1016/S0379-0738(99)00020-1; Rothschild MA, 1996, FORENSIC SCI INT, V83, P1, DOI 10.1016/0379-0738(96)02019-1; ROTHSCHILD MA, 1994, INT J LEGAL MED, V106, P274, DOI 10.1007/BF01225420; ROTHSCHILD MA, 1998, RECHTSMEDIZIN, V8, P77; ROUGE D, 1994, J FORENSIC SCI, V39, P650; SALZMANN, 1881, DTSCH MILITARARZTL Z, V10, P183; SCHRODER H, 1971, JR, V71, P205; Schyma, 1999, RECHTSMEDIZIN, V9, P210, DOI 10.1007/s001940050112; SCHYMA C, 2000, VERSICHERUNGSMEDIZIN, V52, P141; Sellier KG, 1994, WOUND BALLISTICS SCI, p[17, 74, 103, 268]; Stahl C J, 1968, J Forensic Sci, V13, P442; SUWANJUTHA T, 1988, FORENSIC SCI INT, V37, P223, DOI 10.1016/0379-0738(88)90188-0; TAUSCH D, 1978, KRIMINALISTIK, V32, P451; TAUSCH D, 1974, Z RECHTSMED, V75, P71, DOI 10.1007/BF02114965; THORESEN S, 1984, Z RECHTSMED, V93, P65; Weimann W, 1927, ARCH KRIMINOL, V80, P40	35	26	28	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	APR	2002	57	4					268	277	PII S0090-3019(02)00643-2	10.1016/S0090-3019(02)00643-2			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	562XH	WOS:000176223900008	12173394				2022-02-06	
J	Sahuquillo, J; Biestro, A; Mena, MP; Amoros, S; Lung, M; Poca, MA; De Nadal, M; Baguena, M; Panzardo, H; Mira, JM; Garnacho, A; Lobato, RD				Sahuquillo, J; Biestro, A; Mena, MP; Amoros, S; Lung, M; Poca, MA; De Nadal, M; Baguena, M; Panzardo, H; Mira, JM; Garnacho, A; Lobato, RD			First tier therapeutic measures in the management of high intracranial pressure after severe head injury. Rationale and proposal for a protocol	NEUROCIRUGIA			Spanish	Article						clinical practice guidelines; evidence based medicine; severe head injuries; brain trauma; high intracranial pressure; management protocol	CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL HEMORRHAGE; CARE MANAGEMENT; BODY POSITION; CORTICOSTEROIDS; HYPOTHERMIA; GUIDELINES; VOLUME; MEDICINE	The management of severe head injuries in general and that of high intracranial pressure (ICP) in particular are among the most challenging tasks in neurocritical care. One of the difficulties still faced by clinicians is that of reducing variability among centers when implementing management protocols. The purpose of this paper is to propose a standardized protocol for the management of high ICP after severe head injury, consistent with recently published clinical practice guidelines and other clinical evidence such as that provided by the systematic reviews of the Cochrane Collaboration. Despite significant advances in neuromonitoring, deeper insight into the physiopathology of severe brain trauma and the many therapeutic options available, standardized protocols are still lacking. Recently published guidelines provide sketchy recommendations without details on how and when to apply different therapies. Consequently, great variability exists in daily clinical practice even though different centers apply the same evidence-based recommendations. In this paper we suggest a structured protocol in which each step is justified and integrated into an overall strategy for the management of severe head injuries. The most recent data from both the preliminary and definitive results of randomized clinical trials as well as from other sources are discussed. The main goal of this article is to provide neurotraumatology intensive care units with a unified protocol that can be easily modified as new evidence becomes available. This will reduce variation among centers when applying the same therapeutic measures. This goal will facilitate comparisons in outcomes among different centers and will also enable the implementation of more consistent clinical practice in centers involved in multicenter clinical trials.	Univ Barcelona, Hosp Gen Valle Hebron, Serv Neurocirugia, E-08036 Barcelona, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Unidad Invest Neurotraumatol, E-08036 Barcelona, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Unidad Ciudados Intens Neurotraumatol, E-08036 Barcelona, Spain; Hosp Clin Montevideo, Unidad Cuidados Intens, Montevideo, Uruguay; Hosp Santa Casa Misericordia, Serv Neurocirugia, Rio Grande Do Sul, Brazil; Hosp 12 Octubre, Serv Neurocirugia, E-28041 Madrid, Spain			sahuquillo@homemail.com	Sahuquillo, Juan/B-3577-2008; Poca, Maria A./B-8475-2008; Mena, Mari-Pau/AAC-7966-2020; de Nadal, Miriam/J-8127-2017; Garnacho, Angel/A-9309-2013	Sahuquillo, Juan/0000-0003-0713-5875; Poca, Maria A./0000-0002-3831-0536; de Nadal, Miriam/0000-0002-4559-2463; Lung, Mayli/0000-0002-2692-4370; Baguena, Marcelino/0000-0001-9598-4791; Mena Jaramillo, Maria de la Paz/0000-0001-9248-5997			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; ALI HH, 1971, BRIT J ANAESTH, V43, P478, DOI 10.1093/bja/43.5.478; ALI HH, 1971, BRIT J ANAESTH, V43, P473, DOI 10.1093/bja/43.5.473; *AM COLL EM PHYS, 1993, ANN EMERG MED, V22, P1101; Andrews Brian T., 1993, P227; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P103, DOI 10.1111/j.1399-6576.1995.tb04285.x; Bernard SA, 1999, CRIT CARE, V3, P167, DOI 10.1186/cc371; Biestro A, 1998, ACT NEUR S, V71, P5; BIESTRO AA, 1995, J NEUROSURG, V83, P627, DOI 10.3171/jns.1995.83.4.0627; BLOOM H, 2000, HOW TO READ AND WHY; BRODERICK JP, 1994, STROKE, V25, P1081, DOI 10.1161/str.25.5.1081b; BRODERICK JP, 1990, J NEUROSURG, V72, P195, DOI 10.3171/jns.1990.72.2.0195; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock MR, 1996, J NEUROTRAUM, V13, P719; Bullock R, 1995, GUIDELINES MANAGEMEN; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut R M, 1995, New Horiz, V3, P581; CHESTNUT RM, 2000, HEAD INJURY, P229; Cold GE, 1996, ANESTHESIOLOGY, V85, P1499; Cook DJ, 1996, CRIT CARE MED, V24, P334, DOI 10.1097/00003246-199602000-00025; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; CROWLEY MP, 1995, MONITORING ANESTHESI, P605; CRUZ J, 1986, NEUROTRAUMA, V1, P55; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; DEARDEN NM, 1996, BLOOD PRESSURE MANIP; deBoisblanc BP, 1999, CRIT CARE MED, V27, P678, DOI 10.1097/00003246-199904000-00006; Dishart MK, 2000, DRUGS, V59, P79, DOI 10.2165/00003495-200059010-00005; DONNELLY A, 1999, ANESTHESIOLOGY CRITI; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JB, 1996, NEUROTRAUMA, P1007; GRANDE PO, 1998, PATHOPHYSIOLOGICAL P, P123; GREENFIELD JC, 1968, J CLIN INVEST, V47, P1672, DOI 10.1172/JCI105858; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT G, 1993, MED TEACH, V15, P147, DOI 10.3109/01421599309006708; HARIRI RJ, 1992, J NEUROSURG, V76, pA397; HARTL R, 1998, ACTA NEUROCHIR SUPP, V71, P420; HENNEMAN EA, 1995, CRIT CARE NURSE, P82; Jackson R, 1998, BRIT MED J, V317, P427; Jensen K, 1992, Acta Neurochir Suppl (Wien), V55, P47; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JOVELL AJ, 1995, FORMACION MED CONTIN, V2, P152; KOPMAN AF, 1984, ANESTHESIOLOGY, V61, P83, DOI 10.1097/00000542-198461010-00015; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McKinely BA, 1999, J TRAUMA, V46, P271, DOI 10.1097/00005373-199902000-00013; MCKINLEY BA, 2000, COMMUNICATION; MORGAN GE, 1996, CLIN ANAESTHESIOL, P102; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; NORDSTROM CH, 1998, PATHOPHYSIOLOGICAL P, P67; Ohlinger MJ, 1998, SURG NEUROL, V49, P217, DOI 10.1016/S0090-3019(97)00279-6; POCA MA, 1996, TRAUMATISMO CRANEOEN, P96; RAVUSSIN PA, 1994, ANN FR ANESTH, V13, P88, DOI 10.1016/S0750-7658(94)80191-6; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roberts I, 1999, BRIT MED J, V319, P1069; ROBERTS I, 2001, BARBITURATES ACUTE T; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Sahuquillo J, 1999, NEUROCIRUGIA, V10, P185; Sahuquillo J, 1997, NEUROCIRUGIA, V8, P260; Sahuquillo J, 2000, ACTA NEUROCHIR SUPPL, V76, P485; Sahuquillo J, 2001, NEUROCIRUGIA, V12, P23; SAHUQUILLO J, 2000, MANAGEMENT HEAD INJU, P109; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Schierhout G, 1997, J NEUROL NEUROSUR PS, V63, P1, DOI 10.1136/jnnp.63.1.1; Schierhout G, 2001, ANTIEPILEPTIC DRUGS; SCHIERHOUT G, 2000, MANNITOL ACUTE TRAUN; SERVADEI F, 1996, COMMUNICATION; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SIGNORINI DF, 2001, THERAPEUTIC HYPOTHER; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; TOLEDO RB, 1997, JANO, V53, P279; TUHRIM S, 1995, CRIT CARE MED, V23, P950, DOI 10.1097/00003246-199505000-00026; VIBYMOGENSEN J, 1993, INTENS CARE MED, V19, pS74, DOI 10.1007/BF01708805; Vincent JL, 1995, INTEGRATED APPROACH, P98; Yates D, 1999, J ACCID EMERG MED, V16, P83	80	26	27	0	2	ELSEVIER ESPANA SLU	BARCELONA	AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN	1130-1473	2340-6305		NEUROCIRUGIA	Neurocirugia	APR	2002	13	2					78	100					23	Neurosciences; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	555CB	WOS:000175774600002	12058608				2022-02-06	
J	Matsuura, S; Ikegaya, Y; Yamada, MK; Nishiyama, N; Matsuki, N				Matsuura, S; Ikegaya, Y; Yamada, MK; Nishiyama, N; Matsuki, N			Endothelin downregulates the glutamate transporter GLAST in cAMP-differentiated astrocytes in vitro	GLIA			English	Article						endothelin receptor; Na+ -dependent glutamate transporter; astrocyte; glial cell; GLT-1	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN INJURY; PROTEIN-KINASE; GROWTH-FACTOR; RAT-BRAIN; MAP KINASE; ISCHEMIA; EXPRESSION; RECEPTOR; PATHWAY	Endothelin (ET) is a putative pathogenetic mediator associated with brain trauma and ischemia. Because a link between neuronal damage after these injuries and glial Na+-dependent L-glutamate transporter activity has been suggested, we investigated the effect of ET on the glutamate clearance ability of astrocytes. Dibutyryl cyclic adenosine monophosphate (dBcAMP), which is widely used to induce differentiation of cultured astrocytes, markedly increased [H-3]glutamate transport activity in a concentration- and time-dependent manner. In the presence of ET, however, dBcAMP decreased the glutamate uptake. This effect was efficiently prevented by an antagonist of ETB receptor, but not of ETA receptor. ET per se was virtually ineffective. Eadie-Hofstee analysis demonstrated that dBcAMP increased the V-max value of glutamate uptake activity by 43.4% in the absence of ET, but decreased it by 41.41%, in the presence of ET, without apparent changes in the K, value. Accordingly, Western blot analysis indicated that the change in transport activity correlated closely with that in expression level of the glial glutamate transporter GLAST. These results may represent the mechanisms by which ET aggravates trauma- and ischemia-elicited neuronal damage. (C) 2002 Wiley-Liss, Inc.	Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, Tokyo 1130033, Japan		Ikegaya, Y (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Yamada, Maki/U-5251-2019; Yamada, Maki K./A-1573-2015	Yamada, Maki K./0000-0002-1956-6069; Ikegaya, Yuji/0000-0003-2260-8191			AGNATI LF, 1991, ITAL J NEUROL SCI, V12, P49; BARONE FC, 1994, J CEREBR BLOOD F MET, V14, P337, DOI 10.1038/jcbfm.1994.41; BARONE FC, 1995, J CARDIOVASC PHAR S3, V26, P404; BIAN LG, 1994, NEUROSCI LETT, V174, P47, DOI 10.1016/0304-3940(94)90115-5; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Gartshore G, 1997, EXP NEUROL, V147, P353, DOI 10.1006/exnr.1997.6635; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; KASUYA Y, 1994, BIOCHEM BIOPH RES CO, V204, P1325, DOI 10.1006/bbrc.1994.2608; Koyama Y, 1999, GLIA, V26, P268, DOI 10.1002/(SICI)1098-1136(199905)26:3<268::AID-GLIA8>3.0.CO;2-G; Kurino M, 1996, J NEUROCHEM, V67, P2246; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIA BL, 1989, J NEURO-ONCOL, V7, P329, DOI 10.1007/BF02147090; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.3.CO;2-5; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; Pfister LA, 2000, ANN NEUROL, V47, P329, DOI 10.1002/1531-8249(200003)47:3<329::AID-ANA8>3.0.CO;2-R; Pluta RM, 1997, J NEUROSURG, V87, P287, DOI 10.3171/jns.1997.87.2.0287; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; RUBANYI GM, 1994, PHARMACOL REV, V46, P328; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Schubert P, 1997, ANN NY ACAD SCI, V825, P1, DOI 10.1111/j.1749-6632.1997.tb48409.x; Suzuki K, 2001, J CELL SCI, V114, P3717; Swanson RA, 1997, J NEUROSCI, V17, P932; TAKIGAWA M, 1995, EUR J BIOCHEM, V228, P102, DOI 10.1111/j.1432-1033.1995.0102o.x; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tatlisumak T, 1998, STROKE, V29, P850, DOI 10.1161/01.STR.29.4.850; Toulmond S, 1996, TRENDS NEUROSCI, V19, P409; Uesugi M, 1996, BRAIN RES, V728, P255, DOI 10.1016/0006-8993(96)00524-0; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; WILLETTE RN, 1993, LIFE SCI, V52, P35, DOI 10.1016/0024-3205(93)90286-C; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; Yin KJ, 1998, ANAT RECORD, V251, P9, DOI 10.1002/(SICI)1097-0185(199805)251:1<9::AID-AR3>3.0.CO;2-X	40	26	26	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	FEB	2002	37	2					178	182		10.1002/glia.10020			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	517DZ	WOS:000173597000008	11754215				2022-02-06	
J	Gontkovsky, ST; McDonald, NB; Clark, PG; Ruwe, WD				Gontkovsky, ST; McDonald, NB; Clark, PG; Ruwe, WD			Current directions in computer-assisted cognitive rehabilitation	NEUROREHABILITATION			English	Article						brain injury; cognitive rehabilitation; computers; neuropsychology; neurorehabilitation	TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL REHABILITATION	Technological advances over the past decade have given rise to the development of multiple computer-assisted cognitive rehabilitation programs. While results of investigations examining the efficacy of such techniques have been mixed, a positive trend for utilization of these procedures has been demonstrated. This review provides a discussion of the progression of research in this area, from anecdotal studies to controlled empirical investigations. Methodological shortcomings are examined and directions for future research in computer-assisted cognitive rehabilitation suggested.	INTEGRIS Jim Thorpe Rehabil Ctr, Oklahoma City, OK USA		Gontkovsky, ST (corresponding author), Methodist Rehabil Ctr, Neuropsychol Dept, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.						Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; BERROL S, 1990, ARCH NEUROL-CHICAGO, V47, P219, DOI 10.1001/archneur.1990.00530020127025; Bracy O.D., 1999, COGN TECHNOL, V4, P19; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; Brett A W, 1998, Pediatr Rehabil, V2, P27; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Ethier M, 1989, CANADIAN J REHABILIT, V2, P223; ETHIER M, 1989, CANADIAN J REHABILIT, V3, P7; FINLEY G, 1987, P AM ASSOC CANC RES, V28, P180; GOLDEN CJ, 1992, NEUROPSYCHOLOGICAL A; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Mazmanian Paul E., 1993, Brain Injury, V7, P319, DOI 10.3109/02699059309034958; MCGUIRE BE, 1990, IRISH J PSYCHOL, V11, P299, DOI 10.1080/03033910.1990.10557810; MCLELLAN DL, 1991, CLIN NEUROLOGY, P768; MESSERLY C, 1986, VOLTA REV, V88, P66; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; Pierce SM, 2001, J HEAD TRAUMA REHAB, V16, P406, DOI 10.1097/00001199-200108000-00009; Reitan R. M., 1996, NEUROPSYCHOLOGICAL A, P3; REITAN RM, 1983, ANN M AM PSYCH ASS A; Robertson I, 1988, Brain Inj, V2, P151, DOI 10.3109/02699058809150939; ROBERTSON IH, 1990, ARCH PHYS MED REHAB, V71, P663; ROSS FL, 1991, AM J OCCUPATIONAL TH, V46, P314; SBORDONE RJ, 1986, PSYCHOTHERAPY PRIVAT, V4, P51; Sena D. A., 1986, ARCH CLIN NEUROPSYCH, V1, P74; Skilbeck C., 1991, MICROCOMPUTERS CLIN, P95; STORY TB, 1988, J HEAD TRAUMA REHAB, V3, P45; THOMASS BA, 1994, EUR J COMMUN, V9, P25, DOI 10.1177/0267323194009001002; Wilson B, 1988, BEHAV INATTENTION TE; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Wood R L, 1987, Int Disabil Stud, V9, P149	35	26	26	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2002	17	3					195	199					5	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	611AJ	WOS:000178994000003	12237499				2022-02-06	
J	Natale, JE; Cheng, Y; Martin, LJ				Natale, JE; Cheng, Y; Martin, LJ			Thalamic neuron apoptosis emerges rapidly after cortical damage in immature mice	NEUROSCIENCE			English	Article						axotomy; brain injury; caspase-3; DNA damage; neuronal cell death; retrograde neurodegeneration	TRAUMATIC BRAIN INJURY; LATERAL GENICULATE-NUCLEUS; CELL-DEATH; RETROGRADE DEGENERATION; NERVOUS-SYSTEM; RAT; NEURODEGENERATION; CORTEX; TRANSPORT; ISCHEMIA	In adults and children, head trauma can have long-term neuropathological and functional consequences. The thalamus is a major site of remote neurodegeneration after cortical damage in adult humans and experimental animals, but less is known about thalamic responses to cortical injury in the immature brain. This study introduces an in vivo model of axotomy/target deprivation-induced neuronal apoptosis in the dorsal lateral geniculate nucleus of the thalamus produced by unilateral ablation of the occipital cortex in the immature mouse. We specifically examined whether occipital cortex ablation in the immature brain causes apoptotic death of projection neurons in the dorsal lateral geniculate nucleus. After unilateral occipital cortex aspiration, 10-day-old C57BL/6 mice were recovered for up to 28 days. Fluorogold-prelabeled thalamocortical projection neurons were apoptotic at 36-48 It after ablation. The structural progression of apoptosis in the immature lateral geniculate nucleus reveals typical chromatolytic morphology by 18-24 It, followed by cytoplasmic shrinkage and chromatin condensation characteristic of end-stage apoptosis after 36-48 It. Electron microscopy confirmed the presence of apoptosis. This study shows internucleosomal DNA fragmentation and expression of cleaved caspase-3 occurs rapidly, being noted first at 18 h, well before the peak of apoptotic cell death occurring at 36 h after cortical damage in the immature brain. From these data we suggest that axotomy/target deprivation-induced cell death in the immature brain may: (1) differ from that previously reported in adult mice with respect to the time required for progression to cell death; (2) be mediated by caspase-3 activation. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; George Washington Univ, Sch Med, Childresn Res Inst, Ctr Res Neurosci, Washington, DC USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA		Natale, JE (corresponding author), Childrens Natl Med Ctr, Med Genet Res Ctr, 111 Michigan Ave,NW, Washington, DC 20010 USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG16282] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG016282] Funding Source: NIH RePORTER		Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; Al-Abdulla NA, 1998, AM J PATHOL, V153, P447, DOI 10.1016/S0002-9440(10)65588-5; BARRON KD, 1973, J NEUROPATH EXP NEUR, V32, P218, DOI 10.1097/00005072-197304000-00004; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; Easton RM, 1997, J NEUROSCI, V17, P9656; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRICKE R, 1977, J COMP NEUROL, V173, P231, DOI 10.1002/cne.901730203; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; IIZAKA H, 1990, STROKE, V21, P790; LAVALLLE A, 1958, J EXPT ZOOLOGY, V137, P285; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mufson EJ, 1999, PROG NEUROBIOL, V57, P451, DOI 10.1016/S0301-0082(98)00059-8; Nakajima W, 2000, J NEUROSCI, V20, P7994; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PARNAVELAS JG, 1977, J COMP NEUROL, V171, P481, DOI 10.1002/cne.901710405; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; RINK A, 1995, AM J PATHOL, V147, P1575; Rosen GD, 2000, INT MOUSE GENOME C, V14, P166; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; SCHMUED LC, 1986, BRAIN RES, V377, P147, DOI 10.1016/0006-8993(86)91199-6; Sobreviela T, 1996, J COMP NEUROL, V375, P417; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; 1998, NIH CONSENSUS STATEM, V16, P1	32	26	28	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2002	112	3					665	676	PII S0306-4522(02)00098-2	10.1016/S0306-4522(02)00098-2			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	572JF	WOS:000176770200017	12074908				2022-02-06	
J	Petridou, E; Sibert, J; Dedoukou, X; Skalkidis, I; Trichopoulos, D				Petridou, E; Sibert, J; Dedoukou, X; Skalkidis, I; Trichopoulos, D			Injuries in public and private playgrounds: the relative contribution of structural, equipment and human factors	ACTA PAEDIATRICA			English	Article						case control; childhood injury; playground equipment; public versus private playground	CHILD-CARE-CENTERS; RISK; EPIDEMIOLOGY; SURFACES; FALLS	The aim of this case-control Study was to identify and quantify risk factors of injuries in playgrounds, where children spend an increasing amount of time in developed Countries. The study took place in Greater Athens during 1999. A continuous Emergency Departments Injury Surveillance System (EDISS) of hospitals that cover about 30% of the children's time at risk in Greater Athens identified 777 injuries in public and private playgrounds out of a total of 17 497 injuries. Public playgrounds differ from private ones, because the former generally have more equipment. usually of greater height, with less resilient surfaces. and supervision relies mainly on parents or guardians. Patterns of type of playground use were assessed in a sample of 294 children from the same study base who served as a control group in a hierarchical case-control design. The annual incidence of playground injuries in Greater Athens vas about 7 in 1000 among boys and 4 in 1000 among girls, with a 2.2 times higher risk for an injury in public than in private playgrounds (95% confidence interval 1.61-3.07). Children in public vs private playgrounds had a statistically significant eight times higher odds for concussion and six times higher for open wounds, whereas the odds for long bone fractures were four and for other fractures two; swings, slides and seesaws were the types of equipment most frequently associated with injuries. It was further shown that supervision of children was suboptimal (<60%) in both public and private playgrounds. and children in private playgrounds sustained an unduly high frequency of sprain/ dislocation injuries (odds ratio 1.75) because they were encouraged to play bare-footed. Conclusion: Close to 50%, of playground injuries could be prevented by structural and equipment changes. while further reduction could be accomplished through simple measures including closer supervision and encouraging children to wear proper shoes and use, whenever necessary.	Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-11527 Athens, Greece; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Wales, Coll Med, Dept Child Hlth, Penarth, S Glam, Wales		Petridou, E (corresponding author), Univ Athens, Sch Med, Dept Hyg & Epidemiol, 75 M Asias Str, GR-11527 Athens, Greece.			PETRIDOU, ELENI/0000-0003-3695-3439			Alkon A, 1999, ARCH PEDIAT ADOL MED, V153, P1248, DOI 10.1001/archpedi.153.12.1248; BOND MT, 1993, AM J PUBLIC HEALTH, V83, P731, DOI 10.2105/AJPH.83.5.731; BOYCE WT, 1984, AM J PUBLIC HEALTH, V74, P984, DOI 10.2105/AJPH.74.9.984; BRISS PA, 1995, ARCH PEDIAT ADOL MED, V149, P906, DOI 10.1001/archpedi.1995.02170210080014; BRISS PA, 1994, PEDIATRICS, V93, P364; Chalmers D J, 1996, Inj Prev, V2, P98, DOI 10.1136/ip.2.2.98; CHALMERS DJ, 1990, J PAEDIATR CHILD H, V26, P329, DOI 10.1111/j.1440-1754.1990.tb02446.x; DESSYPRIS N, UNPUB COUNTRYWIDE ES; *EHLASS, 1997, EUR HOM LEIS SURV SY, P1; Hudson S, 1999, J Sch Nurs, V15, P30; ILLINGWORTH C, 1975, BRIT MED J, V4, P332, DOI 10.1136/bmj.4.5992.332; *LAB CTR DIS CONTR, 1990, 1 CHIRPP LAB CTR DIS; Lillis KA, 1997, PEDIATR EMERG CARE, V13, P149, DOI 10.1097/00006565-199704000-00016; Macarthur C, 2000, ACCIDENT ANAL PREV, V32, P377, DOI 10.1016/S0001-4575(99)00079-2; MacMahon B, 1996, EPIDEMIOLOGY PRINCIP, V2nd; MAEK MG, 1997, INJURY PREV, V3, P100; Mardia K., 1979, MULTIVARIATE ANAL; MAYR J, 1995, ACTA PAEDIATR, V84, P573, DOI 10.1111/j.1651-2227.1995.tb13698.x; MOTT A, 1994, ARCH DIS CHILD, V71, P328, DOI 10.1136/adc.71.4.328; Mott A, 1997, LANCET, V349, P1874, DOI 10.1016/S0140-6736(96)10343-3; SACKS JJ, 1990, AM J PUBLIC HEALTH, V80, P986, DOI 10.2105/AJPH.80.8.986; Waltzman ML, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.5.e58; Warwick, 1984, MULTIVARIATE DESCRIP; World Health Organization, 1977, INT CLASS DIS; World Health Organization, 2004, ICD 10 INT STAT CLAS; 1999, MMWR MORB MORTAL WKL, V48, P329	26	26	26	1	5	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0803-5253			ACTA PAEDIATR	Acta Paediatr.		2002	91	6					691	697		10.1080/080352502760069133			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	570TQ	WOS:000176674400016	12162604				2022-02-06	
J	Shiozaki, T; Akai, H; Taneda, M; Hayakata, T; Aoki, M; Oda, J; Tanaka, H; Hiraide, A; Shimazu, T; Sugimoto, H				Shiozaki, T; Akai, H; Taneda, M; Hayakata, T; Aoki, M; Oda, J; Tanaka, H; Hiraide, A; Shimazu, T; Sugimoto, H			Delayed hemispheric neuronal loss in severely head-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						cerebral atrophy; delayed neuronal loss; head injury	TRAUMATIC BRAIN INJURY; AMYLOID PROTEIN; ISCHEMIA; DEATH; RAT; HYPOTHERMIA; DAMAGE	Recent experimental studies have revealed that traumatic brain injury as well as ischemic brain injury can cause chronic progressive neuronal damage. In the present study, we demonstrate previously unreported delayed cerebral atrophy on computerized tomography (CT) scans in severely head-injured patients. Seventeen severely head-injured patients who required mild hypothermia to control intracranial hypertension after the failure of conventional therapies were retrospectively analyzed. All 17 patients survived more than 1 year. Delayed neuronal loss (DNL) was observed in only eight of the 17 patients. Eight patients with DNL required longer durations of mild hypothermia to control intracranial hypertension than nine patients without DNL. Six of these eight patients with DNL achieved functional recovery despite progressive atrophic changes demonstrated on CT scans. On CT scans, DNL was characterized by (1) the sudden appearance at several months postinjury of a low-density area in the hemisphere ipsilateral to the injury; (2) the preservation of essential cortical structure although related white matter structures showed severe atrophic changes; and (3) no spread of the low-density area to the contiguous territory of the other main cerebral artery. It is concluded that focal primary injury to underlying brain, if severe enough, can result in delayed hemispheric atrophy.	Osaka Univ, Sch Med, Dept Traumatol, Suita, Osaka 565, Japan; Kinki Univ, Sch Med, Dept Neurosurg, Osaka 589, Japan		Shiozaki, T (corresponding author), Osaka Univ, Sch Med, Dept Traumatol, 2-2 Yamadaoka, Suita, Osaka 565, Japan.		Oda, Jun/D-8353-2012	Oda, Jun/0000-0002-8254-3716			Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Evans WA, 1942, ARCH NEURO PSYCHIATR, V47, P931, DOI 10.1001/archneurpsyc.1942.02290060069004; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; JENNETT B, 1975, LANCET, V1, P480; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; NAKANO S, 1990, NEUROSCIENCE, V38, P115, DOI 10.1016/0306-4522(90)90378-H; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; SYNEK V, 1976, NEUROLOGY, V26, P231, DOI 10.1212/WNL.26.3.231; Tomita Hiroki, 1997, Neurologia Medico-Chirurgica, V37, P819, DOI 10.2176/nmc.37.819; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	16	26	26	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2001	18	7					665	674		10.1089/089771501750357618			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	457CK	WOS:000170119400003	11497093				2022-02-06	
J	Bate, AJ; Mathias, JL; Crawford, JR				Bate, AJ; Mathias, JL; Crawford, JR			The covert orienting of visual attention following severe traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; PARKINSONS-DISEASE; ORIENTATION; SYSTEMS	Attentional problems have frequently been identified following traumatic brain injuries (TBIs) using both clinical assessments and self-report measures. Unfortunately, most measures of attention do not enable us to determine the underlying basis of these attentional deficits. One exception is Posner's Covert Orienting of Attention Task (COAT), which is designed to identify some of the fundamental mental operations underlying attention. This study sought to determine whether the COAT task could identify discrete attentional deficits following TBI beyond those caused by reduced speed of information processing. Thirty five patients who had sustained a severe TBI were compared to 35 age-matched controls. Results revealed that, although the reaction times of the patients with TBI were significantly slower than the controls, there were no differences between the two groups in terms of their ability to disengage, move, and engage their attention. The introduction of a secondary (language) task produced no significant difference between the two groups on the COAT task. However, there was a significant difference between the two groups on the language-based task, suggesting a deficit in auditory-verbal attention under dual task conditions.	Julia Farr Serv, Community Rehabil Program, Adelaide, SA, Australia; Univ Adelaide, Dept Psychol, Adelaide, SA 5001, Australia; Univ Aberdeen, Kings Coll, Dept Psychol, Aberdeen, Scotland		Bate, AJ (corresponding author), Julia Farr Serv, Community Rehabil Program, 8 Briar Rd, Felixstow, SA 5070, Australia.	abate@vtown.com.au	Crawford, John R/A-4165-2008; Mathias, J L/L-6295-2013	Crawford, John R/0000-0003-3403-3428; Mathias, Jane/0000-0001-8957-8594			BLUMBERGS PC, 1997, HEAD INJURY; CLARK CR, 1989, NEUROPSYCHOLOGIA, V27, P131, DOI 10.1016/0028-3932(89)90166-8; Crawford J. R., 1992, HDB NEUROPSYCHOLOGIC; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; FORRESTER G, 1995, J FARR SERVICES POST; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; GRONWALL D, 1987, NEUROBEHAVIOURAL REC, P354; JONIDES J, 1984, PSYCHOL BULL, V96, P29, DOI 10.1037/0033-2909.96.1.29; Kuera H., 1967, COMPUTATIONAL ANAL P; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; PAVESE A, 2000, UNPUB PATHOLOGIES AT; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Posner M I, 1989, J Cogn Neurosci, V1, P50, DOI 10.1162/jocn.1989.1.1.50; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1982, PHILOS T ROY SOC B, V298, P187, DOI 10.1098/rstb.1982.0081; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; Posner MI., 1994, IMAGES MIND; ROBERTSON IH, 1995, INT NEUR SOC AUSTR S; ROLAND PE, 1985, HUM NEUROBIOL, V4, P155; Sandson J, 1988, COGNITIVE APPROACHES; Schmitter-Edgecombe M, 1998, J INT NEUROPSYCH SOC, V4, P144, DOI 10.1017/S1355617798001441; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; Spreen O, 1991, COMPENDIUM NEUROPSYC; *SPSS INC, 1998, SPSS WIND; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; SWANSON JM, 1991, J CHILD NEUROL, V6, pS119, DOI 10.1177/0883073891006001S12; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; WRIGHT MJ, 1994, AUST J PSYCHOL, V46, P63, DOI 10.1080/00049539408259475; WRIGHT MJ, 1990, NEUROPSYCHOLOGIA, V28, P151, DOI 10.1016/0028-3932(90)90097-8; [No title captured]	42	26	26	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	2001	23	3					386	398		10.1076/jcen.23.3.386.1190			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	439JG	WOS:000169112900012	11404815	Green Submitted			2022-02-06	
J	Hellawell, DJ; Pentland, B				Hellawell, DJ; Pentland, B			Relatives' reports of long term problems following traumatic brain injury or subarachnoid haemorrhage	DISABILITY AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; EARLY OPERATION; HEMORRHAGE; RECOVERY; RELIABILITY; IMPAIRMENT; ADJUSTMENT; COGNITION; OUTCOMES; MODERATE	Purpose: To describe and compare the late outcome of traumatic brain injury (TBI) and subarachnoid haemorrhage (SAH) in terms of the carers' perspectives, and their symptoms profiles. Method: Postal survey to surviving patients who had been discharged from a Regional Neurosurgical Unit five to seven years previously. There were 288 patients identified retrospectively from hospital records, of whom 209 (126 TBI and 83 SAH) were alive and traced at follow-up. The Glasgow Outcome Scale (GOS) and the Relatives Questionnaire (RQ) were used. Results: Relative's questionnaires were returned by 128 patients; 70 TBI and 58 SAH, giving response rates of 56 % and 70% respectively. In terms of outcome, there was a high degree of similarity between groups. On the GOS, approximately half of each group were classified as moderately disabled (49 % and 48 % of the TBI and SAH groups respectively); a quarter remained severely disabled (27 % and 22%); and the remaining quarter were adjudged to have made a good recovery (24 % and 29 %). There was a considerable overlap in terms of the most commonly reported symptoms. Cognitive and physical problems tended to be more commonly reported by relatives of the TBI patients, whilst emotional and subjective symptoms were reported equally in both patient groups. Conclusions: The effects of TBI and SAH persist for many years post-injury, leading to considerable disability and increased dependency. Although the demographic details and mechanisms of injury in these two patient groups differ, there is a high degree of similarity in the pattern of sequelae reported by carers.	Univ Edinburgh, Rehabil Studies Unit, Edinburgh EH8 9YL, Midlothian, Scotland		Pentland, B (corresponding author), Astley Ainslie Hosp, Scottish Injury Rehabil Serv, Grange Loan, Edinburgh EH9 2HL, Midlothian, Scotland.						Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; ANDERSON SI, 1994, CLIN REHABIL, V8, P301; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1984, CLOSED HEAD INJURY P; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dombovy ML, 1998, BRAIN INJURY, V12, P887; Gray J.M, 1994, CLIN REHABIL, V8, P188, DOI [10.1177/026921559400800302, DOI 10.1177/026921559400800302, DOI 10.1080/09602010902949207]; Hellawell DJ, 2000, DISABIL REHABIL, V22, P446, DOI 10.1080/09638280050045910; Hellawell DJ, 1999, CLIN REHABIL, V13, P333, DOI 10.1191/026921599669500092; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; HUTTER BO, 1995, BRIT J NEUROSURG, V9, P465, DOI 10.1080/02688699550041106; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1975, LANCET, V1, P480; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LINDBERG M, 1996, CLIN REHABIL, V10, P69; LINDSAY K, 1991, NEUROLOGY NEUROSURGE; LJUNGGREN B, 1985, J NEUROSURG, V62, P673, DOI 10.3171/jns.1985.62.5.0673; MCKENNA P, 1989, BRIT MED J, V299, P485, DOI 10.1136/bmj.299.6697.485; MCKENNA P, 1989, NEUROSURGERY, V24, P361, DOI 10.1227/00006123-198903000-00009; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PONSFORD JL, 1996, RECOVERY TRAUMATIC B, V15, P219; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SIBBALD B, 1994, BRIT J GEN PRACT, V44, P297; SONESSON B, 1987, NEUROSURGERY, V21, P279, DOI 10.1227/00006123-198709000-00001; SORYAL I, 1992, CLIN REHABIL, V6, P103; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437	40	26	26	0	3	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.	MAY 10	2001	23	7					300	305		10.1080/769979114			6	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	428RC	WOS:000168473800005	11354583				2022-02-06	
J	Claassen, J; Hansen, HC				Claassen, J; Hansen, HC			Early recovery after closed traumatic head injury: Somatosensory evoked potentials and clinical findings	CRITICAL CARE MEDICINE			English	Article						somatosensory evoked potentials; traumatic diffuse axonal; closed head injury; recovery; diffuse axonal head injury; outcome prediction	DIFFUSE AXONAL INJURY; BRAIN-FUNCTION; PROGNOSTIC IMPLICATIONS; INTRACRANIAL-PRESSURE; COMA; CT; DYSFUNCTION; CONDUCTION; RESPONSES; SEPS	Objective: To determine the ability of somatosensory evoked potentials (SEP) compared with clinical findings to monitor and predict recovery in patients suffering from closed head injury with predominantly diffuse axonal injury (DAI). Design: Prospective cohort study. Setting: Neurologic intensive care unit (ICU) of a university hospital. Patients: Serial SEP recordings were obtained from 31 consecutive patients with closed head injury. The first SEP was recorded within 48 hrs after trauma, followed by recordings after another 2 days, after which the time interval for each consecutive recording was doubled. Clinical examinations were performed every 6 hrs during the ICU stay and daily after transfer to a general neurologic ward. Interventions: None. Measurements and Main Results: Twenty-three of 31 patients demonstrated pathologic SEP findings at initial examination. Of these patients, 11 recovered clinically, two remained vegetative, and ten died. In all 11 patients with clinical recovery, SEP also recovered. In 8 of 31 patients, initial SEPs were normal and remained normal until discharge, all eight had a good outcome. Initial SEP findings were related with outcome at 6 months (p = .02), and follow-up studies increased the predictive value of SEP studies (p = .009). Other factors related to outcome included age, severity of DAI, and length of ICU/hospital stay. In the 11 patients with SEP and clinical recovery, early (day 2) and late (greater than or equal to2 months) recovery was documented. Early and reliable SEP indicators of improvement included N20-P25-Amplitudes (mean recovery, 8.5 days) and central conduction time (9.6 days). Pupillary light reaction (6.4 days), Babinski reflex (12.4 days), and Glasgow Coma Score (9.6 days) were the most valuable clinical findings. Recovery of the Glasgow Coma Score frequently coincided with reduction of sedatives. In most patients, recovery was detected with SEP before clinical recovery (7/11 patients, time difference 1 wk). Conclusions: Initial SEP findings correlate with long-term outcome in patients with closed head injury with DAl. Initial bilaterally absent cortical responses in the SEP reliably predicted death, whereas completely normal SEP findings predicted good longterm outcome. Early recovery after DAl can be detected with serial SEP recordings despite sedative medications. Electrophysiologic recovery frequently precedes clinical recovery.	Univ Hamburg Hosp, Neurol Intens Care Unit, Dept Neurol, D-2000 Hamburg, Germany		Claassen, J (corresponding author), Univ Hamburg Hosp, Neurol Intens Care Unit, Dept Neurol, D-2000 Hamburg, Germany.		Claassen, Jan/AAA-5451-2020				ABBRUZZESE G, 1981, J NEUROL NEUROSUR PS, V44, P942, DOI 10.1136/jnnp.44.10.942; ALLISON T, 1983, ELECTROEN CLIN NEURO, V55, P619, DOI 10.1016/0013-4694(83)90272-9; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Cheung DS, 1999, EMERG MED CLIN N AM, V17, P9, DOI 10.1016/S0733-8627(05)70044-4; CUSUMANO S, 1992, ELECTROEN CLIN NEURO, V84, P499, DOI 10.1016/0168-5597(92)90039-E; DAWSON GD, 1947, J NEUROL NEUROSUR PS, V10, P141, DOI 10.1136/jnnp.10.4.141; DELATORRE JC, 1977, EXP NEUROL, V60, P304; DUBOIS M, 1981, ELECTROEN CLIN NEURO, V52, P157, DOI 10.1016/0013-4694(81)90163-2; GANES T, 1988, ELECTROEN CLIN NEURO, V69, P6, DOI 10.1016/0013-4694(88)90030-2; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gennarelli TA, 1993, HEAD INJURY, P137; GOLDIE WD, 1981, NEUROLOGY, V31, P248, DOI 10.1212/WNL.31.3.248; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; Ito H, 1997, Ann Nucl Med, V11, P167; JONES SJ, 1993, EVOKED POTENTIALS CL, P421; Kane NM, 1998, ELECTROEN CLIN NEURO, V106, P244, DOI 10.1016/S0013-4694(97)00141-7; KEREN O, 1991, Brain Injury, V5, P233, DOI 10.3109/02699059109008094; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KOCHS E, 1991, EUR J ANAESTH, V8, P257; KONASIEWICZ SJ, 1994, J TRAUMA, V37, P370, DOI 10.1097/00005373-199409000-00006; KONASIEWICZ SJ, 1994, CAN J NEUROL SCI, V21, P219, DOI 10.1017/S0317167100041196; LEANDRI M, 1981, J NEUROL NEUROSUR PS, V44, P718, DOI 10.1136/jnnp.44.8.718; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; MANZANO GM, 1995, EVOKED POTENTIAL, V96, P229, DOI 10.1016/0168-5597(94)00271-F; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mayer S, 2000, MERRITTS NEUROLOGY, P401; Mayer S A, 1999, J Stroke Cerebrovasc Dis, V8, P183, DOI 10.1016/S1052-3057(99)80025-1; MICHELOYANNIS J, 1989, ACTA NEUROL SCAND, V79, P146, DOI 10.1111/j.1600-0404.1989.tb03727.x; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NARAYAN RK, 1995, PRINCIPLES NEUROSURG; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; PINTO F, 1990, ACTA ANAESTH SCAND, V34, P389, DOI 10.1111/j.1399-6576.1990.tb03108.x; RIFFEL B, 1994, DIAGNOSTIK PROGNOSTI, P22; RUMPL E, 1988, J CLIN NEUROPHYSIOL, V5, P237, DOI 10.1097/00004691-198807000-00002; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SHAW NA, 1986, J NEUROL SCI, V73, P145, DOI 10.1016/0022-510X(86)90126-7; TEASDALE G, 1974, LANCET, V2, P81; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x	47	26	29	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	2001	29	3					494	502		10.1097/00003246-200103000-00005			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	411WM	WOS:000167522400004	11373410				2022-02-06	
J	Ducrocq, F; Vaiva, G; Cottencin, O; Molenda, S; Bailly, D				Ducrocq, F; Vaiva, G; Cottencin, O; Molenda, S; Bailly, D			Post-traumatic stress disorder, post-traumatic depression and major depressive disorder : about literature	ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE			French	Article						comorbidity; epidemiology; major depressive disorder; post-traumatic depression; post-traumatic stress disorder	PSYCHIATRIC-DISORDERS; HOLOCAUST SURVIVORS; VIETNAM VETERANS; COMBAT VETERANS; BRAIN INJURY; CORTISOL; TRAUMA; MOOD; COMORBIDITY; SEVERITY	Although they are likely to add their effects, physical and psychic traumata (or traumas) can provoke in different ways the appearence of depressive symptoms sometimes common. Post-traumatic depression, reactional depression, major depressive disorder and post-traumatic stress disorder represent different clinical and nosographic disorders in despite of their occasionally common symptomatic core. Historically, it is interesting to note during the XXth century the true semantic change of the terms of trauma from the somatic field to the psychic sphere. Physical traumatism is often represented by a material shock for the subject and by its organic consequences. It is defined as an event that leaves its mark which itself inflects and handicaps the vital trajectory of the subject. It primarily comprises brain and rachis injuries, whose evolution is frequently characterized by the occurrence/appearance of a depressive disorder, whose genesis rests on psychological but also neurobiologic and physical arguments. Thus major depressive disorders are often present in the course of various physical traumatisms mainly related to nervous system. In accordance with several studies, the prevalence of major depressive disorders ranges from 25% to 50%. These mood disorders occur in the year which follows the accidental event. Their average time of revelation is estimated at four months and their average duration lies between three and six months. Lastly, although these depressive illnesses present clinical symptoms comparable with those observed in other contexts, some nuances can be raised. Nonetheless, they confine sometimes with true clinical forms depending on the intensity the form, the circumstances or the consequences of the trauma. Psychic traumatism doesn't have the same profile and rests for much dedicated with the reexperiencing. Thus for some authors, depression illness represents a disorder that occurs after a traumatic event whereas others see a differential diagnosis which exludes or which represents a comorbidity with post-traumatic stress disorder. The review of the literature allows us to emphasize the complexity of the links as well as the clinical and epidemiologic differences between stress disorder and major depressive disorder. From the clinical point of view, the major features of PTSD are articulated around a triad of symptoms. They include the reexperiencing symptoms of the traumatic event such as intrusive memories and recurrent nightmares the protective reactions such as avoidance of the stimuli associated with the trauma and emotional numbing and the arousal symptoms such as the startled response and hypervigilance. The complexity of this syndrom is due to the frequent combination of these symptoms with other nonspecific ones. As far as the mood is concerned (the mood symptoms are concerned), the regrouping of some of these symptoms allows the clinician to sometimes releave a depressive symptomatology without being able to assess the DSM diagnosis of major depressive disorder. Epidemiologic studies dealing with the risk of installation of a PTSD after a traumatic event reveal differences in the prevalence depending on the nature of the traumatic events: ranging from 1% in general population to 80% following some situations of extreme and durable psychic suffering. Between both poles, one finds a prevalence ranging between 20 and 50% following other events such as serious accidents, natural disasters or criminal assaults. The clinical features of depressive episodes comorbid or associated with PTSD have some characteristics making it possible to individualize various clinical farms as a function of traumatic event type :asthenic, characterial or with somatic symptoms. According to the majority of authors, the co-occurrence of post-traumatic stress disorder and major depressive disorder is high although differential diagnosis is sometimes difficult However, conceptual differences remain and two conceptions are distinguished. For some authors, like Bleich and Shalev, there would not be true chronological evolution from PTSD to MDD. Moreover the presence of symptoms considered as pertaining to the mood register within the criteria of PTSD would be clearly predictive of the occurrence and the severity of the diagnosis but not of the chronicity. For others, there would be a continuity between post-traumatic stress disorder and major depressive disorder. It is the case in many studies of veterans but also for civilian traumatic events. It is also the case for the American national study of comorbidity in which Kessler concludes that for 78% of the subjects who present a comorbidity PTSD/MDD (comorbidity raised for 48% of the 5 877 subjects included), the mood disorder is secondary to PTSD. In spite of these conceptual differences on the etiology and on the chronology of installation of both disorders, authors agree to affirm and to show a very high level of instantaneous or lifetime comorbidity between them, going until more than 60% in some studies. In conclusion, we have firstly proved that if is possible to individualize a high proportion of depressive syndroms secondary to physical traumatisms. Next we have insisted on the significant frequency of the diagnosis of PTSD in the subjects exposed to a traumatic event in which they experienced or were confronted with actual or threatened death or severe injury. We have then raised the differences of prevalence as a function of the event type. Finally, we have approached the complexity of the links between PTSD and MDD from a psychopathological point of view as well as from an epidemiologic one. A rigorous evaluation of those links remains difficult because of the disparities of clinical forms, of symptomatic combinations and of orders of appearance.	CHRU Lille, Clin Fontan, Ctr Accueil & Crise, F-59037 Lille, France; CHRU Lille, SAMU Reg Lille, F-59037 Lille, France; CHRU Lille, Ctr Informat & Traitement Dependances, F-59037 Lille, France				DUCROCQ, Francois/O-7342-2014; VAIVA, Guillaume/J-8983-2015; /I-4024-2015	DUCROCQ, Francois/0000-0002-0664-761X; VAIVA, Guillaume/0000-0003-2462-008X; BAILLY, Daniel/0000-0002-2809-0525; /0000-0003-3663-1405			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baker DG, 1999, AM J PSYCHIAT, V156, P585; Barrois C., 1998, NEVROSES TRAUMATIQUE; BASOGLU M, 1994, AM J PSYCHIAT, V151, P76; Beckham JC, 1998, AM J PSYCHIAT, V155, P1565, DOI 10.1176/ajp.155.11.1565; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; Bleich A, 1997, BRIT J PSYCHIAT, V170, P479, DOI 10.1192/bjp.170.5.479; Bremner JD, 1997, AM J PSYCHIAT, V154, P624; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; BRIOLE G, 1987, OMICAR, V43, P38; Briole G., 1994, TRAUMATISME PSYCHIQU; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; CROCQ L, 1987, MED CATASTROPHE, P520; Crocq L, 1994, VICTIMOLOGIE, V1, P25; CROCQ L, 1998, PSYCHIATRIE; CROCQ L, 1995, THERAPEUTIQUE PSYCHI, P989; Crocq L., 1992, PSYCHOL MED, V24, P395; DAVIDSON J, 1985, AM J PSYCHIAT, V142, P90; Deb S, 1999, AM J PSYCHIAT, V156, P374; DUCROCQ F, 1999, REV FR PSYCHIAT PSYC, V24, P150; Engdahl B, 1998, AM J PSYCHIAT, V155, P1740, DOI 10.1176/ajp.155.12.1740; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Favaro A, 1999, PSYCHOL MED, V29, P87, DOI 10.1017/S0033291798007855; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FERREY G, 1996, DEPRESSION SYNDROMES; FREUD S, 1920, ESSAIS PSYCHANALYSE, P43; FRIEDMAN MJ, 1988, AM J PSYCHIAT, V145, P281; Fukunishi I, 1999, PSYCHOTHER PSYCHOSOM, V68, P82, DOI 10.1159/000012317; Goenjian AK, 1996, AM J PSYCHIAT, V153, P929; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; GREEN BL, 1992, J NERV MENT DIS, V180, P760, DOI 10.1097/00005053-199212000-00004; GUALTIERI CT, 1998, BR J INJURY, V2, P101, DOI DOI 10.3109/02699058809150936; HOUGEN HP, 1988, FORENSIC SCI INT, V39, P5, DOI 10.1016/0379-0738(88)90113-2; Jenkins MA, 1998, AM J PSYCHIAT, V155, P278; Jensen CF, 1997, AM J PSYCHIAT, V154, P266; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; JOSEPHSON PR, 1994, MINERVA, V32, P1, DOI 10.1007/BF01096654; Keane TM, 1997, J ANXIETY DISORD, V11, P317, DOI 10.1016/S0887-6185(97)00013-3; Kellner M, 1998, AM J PSYCHIAT, V155, P1299, DOI 10.1176/ajp.155.9.1299; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; LAUFER RS, 1985, AM J PSYCHIAT, V142, P1304; Lebigot F, 1997, ANN MED-PSYCHOL, V155, P522; LEBIGOT F, 1991, ANN MED-PSYCHOL, V149, P131; LEBIGOT F, 1995, MALADIES DEPRESSIVES, P234; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MADAKASIRA S, 1987, J NERV MENT DIS, V175, P286, DOI 10.1097/00005053-198705000-00008; MARION EW, 1990, POST TRAUMATIC STRES; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCFARLANE AC, 1992, J NERV MENT DIS, V180, P498, DOI 10.1097/00005053-199208000-00004; MELLMAN TA, 1992, AM J PSYCHIAT, V149, P1568; North CS, 1997, AM J PSYCHIAT, V154, P1696, DOI 10.1176/ajp.154.12.1696; NORTH CS, 1994, AM J PSYCHIAT, V151, P82; NORTH CS, 1989, HOSP COMMUNITY PSYCH, V40, P1293; RESNICK HS, 1995, AM J PSYCHIAT, V152, P1675; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; ROBINSON RG, 1985, AM J PSYCHIAT, V142, P1424; ROBINSON RG, 1994, NEUROPSYCHIATRY TRAU; ROCA RP, 1992, AM J PSYCHIAT, V149, P1234; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; SIERLES FS, 1983, AM J PSYCHIAT, V140, P1177; SMITH EM, 1990, AM J PSYCHIAT, V147, P202; SOUTHWICK SM, 1991, AM J PSYCHIAT, V148, P179; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; Stolp-Smith KA, 1999, ARCH PHYS MED REHAB, V80, P339, DOI 10.1016/S0003-9993(99)90148-X; SUTKER PB, 1993, AM J PSYCHIAT, V150, P240; THOMAS AP, 1995, CIBA F SYMP, V188, P18; Trappler B, 1996, AM J PSYCHIAT, V153, P705; TYRODE Y, 1996, J EUROP URG, V9, P143; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Vila G, 1999, ENFANT VICTIME AGRES; Wagner D, 1998, AM J PSYCHIAT, V155, P1727, DOI 10.1176/ajp.155.12.1727; WEINE SM, 1995, AM J PSYCHIAT, V152, P536; World Health Organization, 1993, ICD 10 CLASS MENT BE; Yehuda R, 1999, CAN J PSYCHIAT, V44, P34, DOI 10.1177/070674379904400104; YEHUDA R, 1991, AM J PSYCHIAT, V148, P499; YEHUDA R, 1995, AM J PSYCHIAT, V152, P1705; YEHUDA R, 1995, AM J PSYCHIAT, V152, P982; YEHUDA R, 1993, AM J PSYCHIAT, V150, P83; Yehuda R, 1998, BIOL PSYCHIAT, V44, P56, DOI 10.1016/S0006-3223(98)80007-3; YEHUDA R, 1994, J TRAUMA STRESS, V7, P699, DOI 10.1002/jts.2490070414	89	26	32	1	25	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0013-7006			ENCEPHALE	Enceph.-Rev. Psychiatr. Clin. Biol. Ther.	MAR-APR	2001	27	2					159	168					10	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	439DE	WOS:000169094900007	11407268				2022-02-06	
J	Movsesyan, VA; Yakovlev, AG; Fan, L; Faden, AI				Movsesyan, VA; Yakovlev, AG; Fan, L; Faden, AI			Effect of serine protease inhibitors on posttraumatic brain injury and neuronal apoptosis	EXPERIMENTAL NEUROLOGY			English	Article						brain trauma; serine protease; TPCK; neuronal death; apoptosis	CELL-DEATH; NEUROBLASTOMA-CELLS; OXIDATIVE STRESS; NMDA RECEPTORS; NERVOUS-SYSTEM; IN-VITRO; RAT; CULTURES; INVOLVEMENT; CONTRIBUTES	N-Tosyl-L-phenylalanyl chloromethyl ketone (TPCK), an inhibitor of chymotrypsin-like serine protease (CSP), prevents DNA fragmentation and apoptotic cell death in certain blood cell lines and was reported to reduce hippocampal neuronal damage caused by cerebral ischemia, We examined the role of CSP on recovery after lateral fluid percussion-induced traumatic brain injury (TBI) in rats, as well as on cell survival in various in vitro models of neuronal cell death. TBI caused significant time-dependent upregulation of CSP activity, but not trypsin-like serine protease activity in injured cortex, Intracerebroventricular administration of TPCK to rats after TBI did not significantly affect deficits of spatial learning but exacerbated motor dysfunction after injury, Moreover, TPCK did not prevent apoptotic neuronal cell death caused by serum/K+ deprivation or by application of staurosporine or etoposide in cultured rat cerebellar granule cells, rat cortical neurons, or in the human neuroblastoma SH-SY5Y cell line. Instead, at doses from 10 to 100 muM, TPCK was cytotoxic in all cultures tested. Similar results were obtained in cultures treated with another CSP inhibitor, 3,4-dichloroisocoumarin. Cell death caused by CSP inhibitors was neither caspase-dependent nor associated with oligonucleosomal DNA fragmentation. Taken together, these data do not support a neuroprotective role for CSP inhibitors. Rather, they suggest that CSPs may serve an endogenous neuroprotective role, possibly by modulating necrotic cell death, (C) 2001 Academic Press.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurosci, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurosci, 3900 Reservoir Rd NW,Res Bldg,Room EP12, Washington, DC 20007 USA.						Atabay C, 1996, J NEUROSCI RES, V43, P465; Back SA, 1999, J NEUROSCI METH, V91, P47, DOI 10.1016/S0165-0270(99)00062-X; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Davies BJ, 1998, J BIOL CHEM, V273, P23004, DOI 10.1074/jbc.273.36.23004; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Faden AI, 1999, ANN NEUROL, V46, P496; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hara A, 1998, J CEREBR BLOOD F MET, V18, P819, DOI 10.1097/00004647-199808000-00001; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Komatsu N, 1998, J BIOCHEM-TOKYO, V124, P1038, DOI 10.1093/oxfordjournals.jbchem.a022197; Martins LM, 1998, BLOOD, V92, P3042, DOI 10.1182/blood.V92.9.3042.421k55_3042_3049; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; NAKAJIMA M, 1994, BRAIN RES, V641, P350, DOI 10.1016/0006-8993(94)90165-1; Nath R, 1997, BIOCHEM MOL BIOL INT, V43, P197; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RINK A, 1995, AM J PATHOL, V147, P1575; ROBICHON A, 1991, ENDOCRINOLOGY, V128, P1974, DOI 10.1210/endo-128-4-1974; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SINENSKY MC, 1995, TOXICOL LETT, V75, P101; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Turgeon VL, 1997, BRAIN RES REV, V25, P85, DOI 10.1016/S0165-0173(97)00015-5; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; Yakovlev AG, 1999, NUCLEIC ACIDS RES, V27, P1999, DOI 10.1093/nar/27.9.1999; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	31	26	26	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	FEB	2001	167	2					366	375		10.1006/exnr.2000.7567			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	400BG	WOS:000166848300017	11161625				2022-02-06	
J	Bianchini, KJ; Mathias, CW; Greve, KW; Houston, RJ; Crouch, JA				Bianchini, KJ; Mathias, CW; Greve, KW; Houston, RJ; Crouch, JA			Classification accuracy of the Portland digit recognition test in traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							MEMORY; DEFICITS	This study examined the classification accuracy of the Portland Digit Recognition Test (PDRT) in traumatic brain injury (TBI). It differs from past studies in assigning patients to malingering and control groups on the basis of compensation-seeking status and the presence of external markers for malingering. Sensitivity and Specificity were .77 and 1.00, respectively. Past research comparing compensation-seekers to noncompensation-seekers reported Sensitivities of .33 or lower (Specificity is always high). This study demonstrates that past research has seriously underestimated the Sensitivity of the PDRT and raises questions about the true Sensitivity of other malingering techniques as well.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA; Inst Living, Hartford, CT USA		Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.			Mathias, Charles/0000-0003-1902-673X			BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Denney RL, 1996, ARCH CLIN NEUROPSYCH, V11, P589, DOI 10.1016/0887-6177(95)00042-9; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; FELDBAUM C, 1998, GUIDE REHABILITATION, P1; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Haines ME, 1995, NEUROPSYCHOL REV, V5, P125, DOI 10.1007/BF02208438; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; Heubrock D, 1998, EUR J PSYCHOL ASSESS, V14, P211, DOI 10.1027/1015-5759.14.3.211; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Pankratz L., 1988, CLIN ASSESSMENT MALI, P169; Rey A., 1964, EXAMEN CLIN PSYCHOL; REYNOLDS C, 1998, DETECTION MALINGERIN; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Wasyliw O. E., 1985, BEHAV SCI LAW, V3, P149, DOI [10.1002/bsl.2370030204, DOI 10.1002/BSL.2370030204]; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1997, WECHSLER ADULT INTEL, VIII; Wechsler D., 1997, WECHSLER MEMORY SCAL, VIII	29	26	26	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2001	15	4					461	470		10.1076/clin.15.4.461.1890			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535QR	WOS:000174656100004	11935447				2022-02-06	
J	Grossman, KJ; Stein, DG				Grossman, KJ; Stein, DG			Does endogenous progesterone promote recovery of chronic sensorimotor deficits following contusion to the forelimb representation of the sensorimotor cortex?	BEHAVIOURAL BRAIN RESEARCH			English	Article						traumatic brain injury; progesterone; pseudopregnant; sex differences; sensorimotor; forelimb use; foot fault; recovery	TRAUMATIC BRAIN INJURY; CORTICAL CONTUSION; NEOCORTICAL DAMAGE; MALE-RATS; PROTECTS; ABLATION; LESIONS; STROKE; AREAS	We studied sensorimotor recovery in male, normal-cycling and pseudopregnant female rats following unilateral FL-SMC contusions. Forelimb use (push off before a rear, support against the walls, and landing after a rear) and the foot fault test (foot misplacements during locomotion on an elevated grid) were analyzed from videotapes taken before surgery, and then again on post-surgical days 2 and 36. High endogenous progesterone levels in females at the time of injury did not affect recovery as there were no differences between males, pseudopregnant females and normal-cycling female rats on these behaviors. None of the brain-injured rats recovered symmetrical forelimb use between 2 and 36 days after injury (P > 0.05) and they also showed foot misplacements (P > 0.05) in the foot fault test. Male and female rats with contusions had fewer mean foot misplacements on day 36 than 2 days after injury (P < 0.001), indicating that there was partial recovery on this task. These results were taken to show that there were no sex differences in motor deficits caused by unilateral FL-SMC injury. In addition, higher endogenous progesterone levels in females did not protect them from the chronic sensorimotor deficits caused by unilateral FL-SMC contusions. (C) 2000 Elsevier Science B.V. All rights reserved.	Emory Univ, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Brain Res Lab, Dept Neurol, Atlanta, GA 30322 USA		Grossman, KJ (corresponding author), Emory Univ, Dept Psychol, 532 N Kilgo Circle, Atlanta, GA 30322 USA.		Stein, Donald/AAJ-5139-2020				Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P353; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Goldstein LB, 1999, RESTOR NEUROL NEUROS, V15, P39; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; KOZLOWSKI DA, 1996, J NEUROTRAUM, V13, P620; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Stibick D. L., 1996, Society for Neuroscience Abstracts, V22, P1186; Stibick D. L., 1997, Society for Neuroscience Abstracts, V23, P2193; Swanson LW, 1992, BRAIN MAPS STRUCTURE, P240; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6	25	26	26	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	DEC 5	2000	116	2					141	148		10.1016/S0166-4328(00)00275-8			8	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	377YA	WOS:000165552800004	11080545				2022-02-06	
J	Coolidge, FL; Segal, DL; Stewart, SE; Ellett, JAC				Coolidge, FL; Segal, DL; Stewart, SE; Ellett, JAC			Neuropsychological dysfunction in children with borderline personality disorder features: A preliminary investigation	JOURNAL OF RESEARCH IN PERSONALITY			English	Article							DIMENSIONS; TWIN	Borderline personality disorder (BPD) is often linked to neuropsychological deficits, yet few studies have examined BPD or its features and concomitant neuropsychological dysfunction in childhood. This study examined children with borderline features (n = 21) using the Coolidge Personality and Neuropsychological Inventory for Children and compared them to controls (n = 21) with features of at least one personality disorder, but not BPD. As hypothesized, the BPD group scored significantly higher than the control group on the Attention Deficit/Hyperactivity Disorder, Executive Functions Deficits, Mild Neurocognitive Disorder, Conduct Disorder. and Oppositional Defiant Disorder scales. It appears that behavioral disturbances associated with BPD are linked strongly with neuropsychological dysfunction. Because none of the children with BPD features in the present sample had a history of traumatic brain injury (TBI), it appears likely that TBI in the histories of adult BPD patients may not be the cause of BPD, but traits such as anger and impulsivity in BPD may cause TBI. Clinical implications and future research directions are discussed. (C) 2000 Academic Press.	Univ Colorado, Dept Psychol, Colorado Springs, CO 80933 USA		Coolidge, FL (corresponding author), Univ Colorado, Dept Psychol, POB 7150, Colorado Springs, CO 80933 USA.			Segal, Daniel L/0000-0001-6518-2966; Ellett, Julie/0000-0002-7034-5691			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDRULONIS PA, 1981, PSYCHIAT CLIN N AM, V4, P47; ANDRULONIS PA, 1982, J NERV MENT DIS, V170, P670, DOI 10.1097/00005053-198211000-00006; BEMPORAD JR, 1982, AM J PSYCHIAT, V139, P596; COOLIDGE FL, 1990, J PERSONALITY CLIN S, V6, P225; COOLIDGE FL, 1999, M SOC PERS ASS NEW O; COOLIDGE FL, 1998, COOLIDGE PERSONALITY; COOLIDGE FL, 2000, COOLIDGE PERSONALITY; FRIEDMAN MC, 1998, THESIS U COLOARDO CO; GARDNER D, 1987, J NERV MENT DIS, V175, P177, DOI 10.1097/00005053-198703000-00009; GIOIA GA, 1999, M AM PSYCH ASS BOST; HECHTMAN L, 1994, J PSYCHIATR NEUROSCI, V19, P193; HOLM S, 1979, SCAND J STAT, V6, P65; Jang KL, 1996, ACTA PSYCHIAT SCAND, V94, P438, DOI 10.1111/j.1600-0447.1996.tb09887.x; KERNBERG PF, 1983, PSYCHIAT HOSP, V13, P137; KIMBLE CR, 1997, ROLE SEXUAL ABUSE ET, P165; KREUTZER JS, 1999, M AM PSYCH ASS BOST; LEWIS M, 1976, J AM ACAD CHILD PSY, V15, P131, DOI 10.1016/S0002-7138(09)62265-2; LIVESLEY WJ, 1993, AM J PSYCHIAT, V150, P1826; MURRAY ME, 1979, AM J PSYCHOTHER, V33, P391, DOI 10.1176/appi.psychotherapy.1979.33.3.391; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; PHILBRICK PB, 1990, THESIS U COLARDO COL; QUITKIN F, 1976, ARCH GEN PSYCHIAT, V33, P845; REILMAN BJ, 1993, THESIS U COLARDO COL; Rosnow R. L., 1996, BEGINNING BEHAV RES; Sherman DK, 1997, J AM ACAD CHILD PSY, V36, P745, DOI 10.1097/00004583-199706000-00010; SILVER CH, 1999, M AM PSYCH ASS BOST; SOLOFF PH, 1983, COMPR PSYCHIAT, V24, P574, DOI 10.1016/0010-440X(83)90026-3; SPREEN O, 1989, J CLIN EXP NEUROPSYC, V11, P117, DOI 10.1080/01688638908400880; VANREEKUM R, 1993, CAN J PSYCHIAT S1, V38, P4; VERHULST FC, 1984, ACTA PAEDOPSYCHIATR, V50, P161; [No title captured]; [No title captured]	33	26	27	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0092-6566			J RES PERS	J. Res. Pers.	DEC	2000	34	4					554	561		10.1006/jrpe.2000.2298			8	Psychology, Social	Social Science Citation Index (SSCI)	Psychology	376ME	WOS:000165460700010					2022-02-06	
J	Shimizu, T; Hino, T; Komori, T; Hirai, S				Shimizu, T; Hino, T; Komori, T; Hirai, S			Loss of the muscle silent period evoked by transcranial magnetic stimulation of the motor cortex in patients with cervical cord lesions	NEUROSCIENCE LETTERS			English	Article						transcranial magnetic stimulation; cortical silent period; cervical cord lesion; cortical excitability; cortical reorganization; paired cortical stimulation	BRAIN-STIMULATION; INHIBITION; INJURY; HUMANS; ORIGIN	The silent period following motor evoked potentials in small hand muscles after transcranial magnetic stimulation (TMS) of the human motor cortex is considered to be cortical origin. The authors report three patients with cervical spinal cord lesions who showed loss of the cortical silent period (CSP) after TMS. One patient had traumatic cervical cord injury, and the other two patients had cervical spondylosis. All the patients had cervical cord compression on magnetic resonance imaging. TMS study showed loss of the CSP in both the hand and foot muscles in two patients and only in the foot muscle in one patient. Paired TMS study in one patient with pseudoathetotic hands showed reduced inhibition within the motor cortex. The hand weakness or interrupted sensory afferents might have caused motor cortical reorganization or hyperexcitability, leading to the loss of the CSP. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Tokyo Metropolitan Neurol Hosp, Dept Neurol, Tokyo 1830042, Japan		Shimizu, T (corresponding author), Tokyo Metropolitan Neurol Hosp, Dept Neurol, 2-6-1 Musashidai, Tokyo 1830042, Japan.						CANTELLO R, 1992, NEUROLOGY, V42, P1951; Davey NJ, 1998, J NEUROL NEUROSUR PS, V65, P80, DOI 10.1136/jnnp.65.1.80; Hess A, 1999, EXP BRAIN RES, V124, P321, DOI 10.1007/s002210050629; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; LEVY WJ, 1990, BRAIN RES, V510, P130, DOI 10.1016/0006-8993(90)90738-W; ROICK H, 1993, EXP BRAIN RES, V94, P489, DOI 10.1007/BF00230207; Rossini PM, 1996, MUSCLE NERVE, V19, P1302; Schnitzler A, 1996, EXP BRAIN RES, V112, P381; SCHNITZLER A, 1994, NEUROSCI LETT, V180, P41, DOI 10.1016/0304-3940(94)90909-1; Shimizu T, 1999, BRAIN RES, V834, P74, DOI 10.1016/S0006-8993(99)01553-X; TOPKA H, 1991, NEUROLOGY, V41, P1276, DOI 10.1212/WNL.41.8.1276; TRIGGS WJ, 1992, ANN NEUROL, V32, P345, DOI 10.1002/ana.410320307; TRIGGS WJ, 1993, BRAIN RES, V628, P39, DOI 10.1016/0006-8993(93)90935-G; UGAWA Y, 1994, ELECTROEN CLIN NEURO, V93, P225, DOI 10.1016/0168-5597(94)90044-2	15	26	26	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUN 9	2000	286	3					199	202		10.1016/S0304-3940(00)01125-3			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	321RX	WOS:000087469400012	10832019				2022-02-06	
J	Bentzer, P; Davidsson, H; Grande, PO				Bentzer, P; Davidsson, H; Grande, PO			Microdialysis-based long-term measurements of energy-related metabolites in the rat brain following a fluid percussion trauma	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion injury; glucose; lactate; lactate/pyruvate ratio; microdialysis	CEREBRAL EXTRACELLULAR GLUCOSE; EXPERIMENTAL HEAD-INJURY; LACTATE CONCENTRATIONS; SKELETAL-MUSCLE; AMINO-ACIDS; DAMAGE; HYPERLACTATEMIA; HYPOXIA; SEPSIS	The aim of the study was to evaluate an experimental approach based on a fluid percussion rat trauma model in combination with the microdialysis technique for the analysis of cerebral interstitial biochemical alterations following head trauma, and to test the hypothesis that the previously observed acute accumulation of lactate and increase in the lactate pyruvate ratio may persist for several days following trauma. We analyzed how lactate, pyruvate, and glucose were altered in the cortex adjacent to the contusion and in the contralateral side of the brain following a traumatic brain injury. The results were compared with those from sham-operated animals. The lactate concentration in the cortex adjacent to the contusion was 0.73 +/- 0.13 mmol/L and 0.71 +/- 0.08 mmol/L 24 and 48 h posttrauma, respectively, and 0.42 +/- 0.07 mmol/L in the sham group (p < 0.05). The lactate/pyruvate ratio of 18.3 +/- 2.3 in the cortex adjacent to the contusion 24 h posttrauma was higher than corresponding value of 10.3 +/- 1.5 in the sham group (p < 0.05). The lactate/pyruvate ratio 48 h posttrauma did not differ from that in the sham group. Interstitial glucose in the cortex adjacent to the contusion and the sham group were similar. Microdialysis measurements from the contralateral side did not differ from those in the sham group. We conclude that the previously oh. served acute alterations in brain metabolism persist for at least 48 h posttrauma. Further, the measured parameters from the contralateral side can be used as controls since they did not differ from the sham group. Combining microdialysis with a fluid percussion trauma model may be a tool to explore secondary brain injury mechanisms and evaluate new therapies for the treatment of traumatic brain injury.	Lund Univ, Dept Physiol Sci, SE-22362 Lund, Sweden		Bentzer, P (corresponding author), Lund Univ, Dept Physiol Sci, Solvegatan 19, SE-22362 Lund, Sweden.	peter.bentzer@mphy.lu.se					Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; HARADA M, 1992, ANESTHESIOLOGY, V77, P728, DOI 10.1097/00000542-199210000-00017; HOTCHKISS RS, 1992, JAMA-J AM MED ASSOC, V267, P1503, DOI 10.1001/jama.267.11.1503; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SIESJO BK, 1978, BRAIN ENERGY METABOL, P192; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; Vary TC, 1999, JPEN-PARENTER ENTER, V23, P213, DOI 10.1177/0148607199023004213; Vary TC, 1998, J SURG RES, V80, P44, DOI 10.1006/jsre.1998.5324; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	27	26	28	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2000	17	5					441	447		10.1089/neu.2000.17.441			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	316BB	WOS:000087146500007	10833063				2022-02-06	
J	Adkins, SB; Figler, RA				Adkins, SB; Figler, RA			Hip pain in athletes	AMERICAN FAMILY PHYSICIAN			English	Article							STRESS-FRACTURES; INJURIES; OSTEOARTHRITIS; KNEE; PELVIS; SPORTS	Hip pain in athletes involves a wide differential diagnosis. Adolescents and young adults are at particular risk for various apophyseal and epiphyseal injuries due to lack of ossification of these cartilaginous growth plates. Older athletes are more likely to present with tendinitis in these areas because their growth plates have closed. Several bursae in the hip area are prone to inflammation. The trochanteric bursa is the most commonly injured, and the lesion is easily identified by palpation of the area. Iliotibial band syndrome presents with similar lateral hip pain and may be identified by provocative testing (Ober's test). A methodical physical examination that specifically tests the various muscle groups that move the hip joint can help determine a more specific diagnosis for the often vague complaint of hip pain. A number of hip conditions are more prevalent in athletes of certain ages. Transient synovitis is a common diagnosis in the very young, Legg-Calve-Perthes disease causes bony disruption of the femoral head in prepubescents, and slipped capital femoral epiphysis is seen most commonly in obese adolescent males. Femoral neck stress fractures are seen in adult athletes, especially those involved in endurance sports, and can progress to necrosis of the femoral head if not found early. Older athletes may be limited by degenerative joint disease but nonetheless should be encouraged to stay active.	E Carolina Univ, Sch Med, Dept Family Med, Family Med Residency Program, Greenville, NC 27858 USA		Adkins, SB (corresponding author), E Carolina Univ, Sch Med, Dept Family Med, Family Med Residency Program, Greenville, NC 27858 USA.						Boyd KT, 1997, SPORTS MED, V24, P273, DOI 10.2165/00007256-199724040-00005; COFFEY J, 1978, PEDIAT XRAY DIAGNOSI; EDEESON J, 1994, J BONE JOINT SURG, V76, P993; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1343, DOI 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9; FULLERTON LR, 1990, SPORTS MED, V9, P192, DOI 10.2165/00007256-199009030-00006; Guidera K J, 1995, Adv Pediatr, V42, P501; HOLLINGWORTH P, 1995, BRIT J RHEUMATOL, V34, P78; Lane NE, 1998, J RHEUMATOL, V25, P334; METZMAKER JN, 1985, AM J SPORT MED, V13, P349, DOI 10.1177/036354658501300510; NATTIV A, 1994, CLIN SPORT MED, V13, P405; PALETTA GA, 1995, CLIN SPORT MED, V14, P591; PRATHER JL, 1977, J BONE JOINT SURG AM, V59, P869, DOI 10.2106/00004623-197759070-00006; Rich Brent S E, 1992, Phys Sportsmed, V20, P104, DOI 10.1080/00913847.1992.11947506; Spector TD, 1996, ARTHRITIS RHEUM, V39, P988, DOI 10.1002/art.1780390616; Stanitski, 1994, J Am Acad Orthop Surg, V2, P96; Stiell IG, 1997, JAMA-J AM MED ASSOC, V278, P2075, DOI 10.1001/jama.1997.03550230051036; Tandeter HB, 1997, AM FAM PHYSICIAN, V55, P2721; Vingard E, 1998, AM J SPORT MED, V26, P78, DOI 10.1177/03635465980260013101	18	26	29	1	5	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X			AM FAM PHYSICIAN	Am. Fam. Physician	APR 1	2000	61	7					2109	2118					10	Primary Health Care; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304FZ	WOS:000086474100014	10779252				2022-02-06	
J	Cullinane, DC; Jenkins, JM; Reddy, S; VanNatta, T; Eddy, VA; Bass, JG; Chen, A; Schwartz, M; Lavin, P; Morris, JA				Cullinane, DC; Jenkins, JM; Reddy, S; VanNatta, T; Eddy, VA; Bass, JG; Chen, A; Schwartz, M; Lavin, P; Morris, JA			Anterior ischemic optic neuropathy: A complication after systemic inflammatory response syndrome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	59th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 16-18, 1999	BOSTON, MASSACHUSETTS	Amer Assoc Surgery Trauma			CARDIOPULMONARY BYPASS; SURGERY; HYPOTENSION; PATHOGENESIS; VISION	Background: Patients are surviving previously fatal injuries, Unique morbidities are occurring in these survivors. Anterior ischemic optic neuropathy represents a previously unrecognized cause of blindness in the trauma victim. We hypothesize that this phenomenon is caused by unique characteristics of optic edema/ pressure or decreased blood flow associated with massive resuscitation. Methods: Between November of 1991 and August of 1998, there were 18,199 admissions to our trauma center. Of this group, 350 patients required massive volume resuscitation (> 20 liters infused over first 24 hours). Patients having closed head injuries, facial fractures or direct orbital trauma were excluded from study. The following variables were studied: demographics, injury severity (Injury Severity; Score, highest lactate, worst base deficit, and lowest pH) crystalloid and transfusion requirements, ventilator requirements (PEEP) Results: Of the 350 patients with massive resuscitation, 9 patients were diagnosed with anterior ischemic optic neuropathy (2.6%). Of these, seven patients required celiotomy (78%). Six of the seven celiotomy patients had damage control celiotomies and abdominal compartment syndrome (86%). One patient had a repair of a subclavian artery; one had a complex acetabular repair. Blindness was unilateral in five patients and bilateral in four. All nine patients had evidence of global hypoperfusion, systemic inflammatory response, massive resuscitation, and high ventilatory support; one patient required cardiopulmonary resuscitation. Conclusion: Prone positioning is known to be associated with an increased intraocular pressure. We postulate that the combination of massive resuscitation and prone positioning will increase the incidence of anterior ischemic optic neuropathy. As such,,ve recommend that prone positioning for adult respiratory, distress syndrome be reserved for only those patients at risk of death.	Vanderbilt Univ, Med Ctr, Nashville, TN USA		Cullinane, DC (corresponding author), Mayo Clin, Dept Surg, 200 1st St SW, Rochester, MN 55907 USA.			Cullinane, Daniel/0000-0002-0414-1949			Bloomfield GL, 1996, J TRAUMA, V40, P936, DOI 10.1097/00005373-199606000-00012; BOGHEN DR, 1975, BRAIN, V98, P689, DOI 10.1093/brain/98.4.689; BROWN RH, 1994, ANESTHESIOLOGY, V80, P222, DOI 10.1097/00000542-199401000-00033; CHISHOLM IA, 1969, BRIT J OPHTHALMOL, V53, P289, DOI 10.1136/bjo.53.5.289; CONNOLLY SE, 1994, AM J OPHTHALMOL, V117, P235, DOI 10.1016/S0002-9394(14)73082-X; CULLEN JF, 1967, BRIT J OPHTHALMOL, V51, P513, DOI 10.1136/bjo.51.8.513; DORO S, 1985, ARCH OPHTHALMOL-CHIC, V103, P1143; Eddy V, 1997, SURG CLIN N AM, V77, P801, DOI 10.1016/S0039-6109(05)70585-5; FEIT RH, 1984, AM J OPHTHALMOL, V98, P105, DOI 10.1016/0002-9394(84)90196-X; HAYREH SS, 1987, OPHTHALMOLOGY, V94, P1488; JOHNSON MW, 1987, OPHTHALMOLOGY, V94, P1577; JOHNSON MW, 1994, OPHTHALMOLOGY, V94, P1557; Jolliet P, 1998, CRIT CARE MED, V26, P1977, DOI 10.1097/00003246-199812000-00023; KATZ DM, 1994, ARCH OPHTHALMOL-CHIC, V112, P925, DOI 10.1001/archopht.1994.01090190073024; LARKIN DFP, 1987, BRIT J OPHTHALMOL, V71, P344, DOI 10.1136/bjo.71.5.344; LOCKET S, 1949, BRIT J OPHTHALMOL, V33, P543, DOI 10.1136/bjo.33.9.543; MORRIS JA, 1996, CURR PROB SURG, V33, P609; PINCUS F, 1919, ARCH CLIN EXP OPHTHA, V98, P152; RIZZO JF, 1987, AM J OPHTHALMOL, V103, P808; SERVILLA KS, 1986, AM J KIDNEY DIS, V8, P61, DOI 10.1016/S0272-6386(86)80156-1; Shaked G, 1998, J TRAUMA, V44, P923, DOI 10.1097/00005373-199805000-00032; SWEENEY PJ, 1982, NEUROLOGY, V32, P560, DOI 10.1212/WNL.32.5.560; WEINSTEIN JM, 1983, INVEST OPHTH VIS SCI, V24, P1559; WILSON JF, 1991, ARCH OTOLARYNGOL, V117, P1304	24	26	28	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2000	48	3					381	386		10.1097/00005373-200003000-00003			6	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	295QT	WOS:000085979900005	10744273				2022-02-06	
J	Connolly, B; Turner, C; DeVine, J; Gerlinger, T				Connolly, B; Turner, C; DeVine, J; Gerlinger, T			Jefferson fracture resulting in Collet-Sicard syndrome	SPINE			English	Article						cranial nerve palsy; Collet-Sicard syndrome; Jefferson fracture	CLOSED-HEAD-INJURY; ATLAS	Study Design. A case report and review of the literature. Objective. To increase awareness of and add to the spectrum of injury that can result from Jefferson fractures, to suggest a possible mechanism of injury, and to give a brief review of pertinent facts regarding C1 burst fractures and the Collet-Sicard Syndrome. Summary of Background Data. To the author's knowledge, this is the first reported case of a Jefferson fracture resulting in Collet-Sicard Syndrome. It represents only the second reported case of cranial nerve palsy caused by Jefferson fracture. Methods. A 56-year-old man sustained a C1 burst fracture in a rollover motor vehicle accident. Repeated neurologic examinations over the ensuing days revealed lesions of cranial nerves IX, X, XI, and XII on the left side. Results. Two weeks of traction, 10 weeks in a halo vest, and 2 weeks in a cervical collar resulted in adequate fracture healing and almost complete resolution of the patient's neurologic symptoms; Conclusion. Although this is the first reported case of Collet-Sicard Syndrome caused by Jefferson fracture, the authors' review of the literature suggests that cranial nerve injuries may go unrecognized in some patients with C1 burst fractures. The importance of a thorough neurologic examination, including examination of the cranial nerves, in all cases of cervical spine injury cannot be overemphasized.	Madigan Army Med Ctr, Dept Orthoped Surg, Tacoma, WA 98431 USA; Madigan Army Med Ctr, Dept Gen Surg, Tacoma, WA 98431 USA		Connolly, B (corresponding author), Madigan Army Med Ctr, Dept Orthoped Surg, Tacoma, WA 98431 USA.						Collet F., 1915, LYON MED, V124, P121; FERNER H, 1980, PERSKPOF ATLAS TOPOG, P126; FIELDING JW, 1974, J BONE JOINT SURG AM, VA 56, P1683, DOI 10.2106/00004623-197456080-00019; FOWLER JL, 1990, J SPINAL DISORD, V3, P19; FRYMOYER JW, 1997, ADULT SPINE, P1090; HADLEY MN, 1988, NEUROSURGERY, V23, P31, DOI 10.1227/00006123-198807000-00007; HAN SY, 1976, J NEUROSURG, V44, P368, DOI 10.3171/jns.1976.44.3.0368; HASHIMOTO T, 1988, NEUROSURGERY, V23, P367, DOI 10.1227/00006123-198809000-00015; HAVELIUS U, 1982, J NEUROSURG, V56, P850, DOI 10.3171/jns.1982.56.6.0850; Jefferson G, 1920, BRIT J SURG, V7, P407; JUNIOS JL, 1987, BRAIN, V110, P197; Larson WL, 1997, MUSCLE NERVE, V20, P1173, DOI 10.1002/(SICI)1097-4598(199709)20:9<1173::AID-MUS13>3.0.CO;2-U; LEVINE AM, 1986, ORTHOP CLIN N AM, V17, P31; LIPSON SJ, 1977, J BONE JOINT SURG AM, V59, P940, DOI 10.2106/00004623-197759070-00018; MOHANTY SK, 1973, J NEUROSURG, V38, P86, DOI 10.3171/jns.1973.38.1.0086; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; ROTHMAN RH, 1982, SPINE, P613; Ruiz J, 1995, Neurologia, V10, P391; SCHLICKE LH, 1981, CLIN ORTHOP RELAT R, P18; SHARMA BS, 1994, CLIN NEUROL NEUROSUR, V96, P197, DOI 10.1016/0303-8467(94)90063-9; SHERK HH, 1970, J BONE JOINT SURG AM, VA 52, P1017, DOI 10.2106/00004623-197052050-00016; Sicard J, 1917, MARSEILLE MED, V53, P383; Silvestrini M, 1991, Riv Neurol, V61, P135; SPENCE KF, 1970, J BONE JOINT SURG AM, VA 52, P543, DOI 10.2106/00004623-197052030-00013; Tappin JA, 1996, J NEUROL NEUROSUR PS, V60, P14, DOI 10.1136/jnnp.60.1.14; VERNET M, 1918, J LARYNGOL OTOL, V33, P354; WANI MA, 1991, J TRAUMA, V31, P1437, DOI 10.1097/00005373-199110000-00025; ZIELINSKI CJ, 1982, J BONE JOINT SURG AM, V63, P1382	28	26	30	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	FEB 1	2000	25	3					395	398		10.1097/00007632-200002010-00023			4	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	283KQ	WOS:000085275100026	10703116				2022-02-06	
J	Smith, JS; Fulop, ZL; Levinsohn, SA; Darrell, RS; Stein, DG				Smith, JS; Fulop, ZL; Levinsohn, SA; Darrell, RS; Stein, DG			Effects of the novel NMDA receptor antagonist gacyclidine on recovery from medial frontal cortex contusion injury in rats	NEURAL PLASTICITY			English	Article						gacyclidine; contusion; medial frontal cortex; trauma; Morris water maze; recovery of function; inflammation; NMDA-receptor antagonist	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; GROWTH-HORMONE SECRETION; D-ASPARTATE RECEPTORS; BLOOD-FLOW; NONCOMPETITIVE BLOCKADE; NEUROCHEMICAL SEQUELAE; GLUTAMATE ANTAGONISTS; FUNCTIONAL RECOVERY; CORTICAL CONTUSION	Gacyclidine, a novel, noncompetitive NMDA receptor,antagonist, was injected (i.v.) into rats at three different doses to determine if the drug could promote behavioral recovery and reduce the behavioral and anatomical impairments that occur after bilateral contusions of the medial frontal cortex (MFC), In the Morris water maze, contused rats treated with gacyclidine at a dosage of 0.1 mg/kg performed better than their vehicle-treated conspecifics. Rats given gacyclidine at either 0.3 or 0.03 mg/kg performed better than brain-injured controls, but not as well as those treated:with 0.1 mg/kg, Counts of surviving neurons in the nucleus basalis magnocellularis (NBM) and the medial dorsal nucleus (MDN) of the thalamus were used to determine whether gacyclidine treatment attenuated secondary cell death. In both the NBM and the MDN, the counts revealed fewer surviving neurons in untreated contused rats than in gacyclidine-treated rats. Increases in the size and number of microglia and astrocytes were observed in the striatum of gacyclidine-treated contused brains. Although most consequences of MFC contusions were attenuated, we still observed increases in ventricle dilation and thinning of the cortex. In fact, the ventricles of rats treated with 0.1 mg/kg of gacyclidine were larger than those of their vehicle treated counterparts, although we observed no behavioral impairment.	Emory Univ, Brain Res Lab, Dept Neurol, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Brain Res Lab, Dept Neurol, 575 Rollins Way, Atlanta, GA 30322 USA.	dgstein@gsas.emory.edu	Stein, Donald/AAJ-5139-2020	Smith, Jeffrey/0000-0001-5499-4475			ARSLAN M, 1992, LIFE SCI, V50, P295, DOI 10.1016/0024-3205(92)90337-O; ASSOULINE JG, 1987, DEV BRAIN RES, V31, P103, DOI 10.1016/0165-3806(87)90087-3; ATTELLA MJ, 1992, BEHAV NEURAL BIOL, V57, P157, DOI 10.1016/0163-1047(92)90665-Q; BALASINGAM V, 1994, J NEUROSCI, V14, P846; Bissonnette JM, 1997, J PHYSIOL-LONDON, V501, P415, DOI 10.1111/j.1469-7793.1997.415bn.x; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Bullock R, 1995, ANN NY ACAD SCI, V765, P272, DOI 10.1111/j.1749-6632.1995.tb16584.x; Conti F, 1996, GLIA, V17, P254, DOI 10.1002/(SICI)1098-1136(199607)17:3<254::AID-GLIA7>3.0.CO;2-0; Conti F, 1997, MOL NEUROBIOL, V14, P1, DOI 10.1007/BF02740618; CULLCANDY S, 1995, CURR BIOL, V5, P841, DOI 10.1016/S0960-9822(95)00168-0; DEKKER AJAM, 1991, NEUROSCI BIOBEHAV R, V15, P299, DOI 10.1016/S0149-7634(05)80008-9; DRIAN MJ, 1991, J NEUROSCI RES, V29, P133, DOI 10.1002/jnr.490290116; ESPANOL MT, 1994, ACTA NEUROCHIR, P58; Estienne MJ, 1996, J ANIM SCI, V74, P597; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fox RM, 1996, NEUROTOXICOLOGY, V17, P705; Fulop ZL, 1997, INT J NEUROSCI, V90, P203, DOI 10.3109/00207459709000639; GALLYAS F, 1970, ACTA NEUROPATHOL, V16, P35, DOI 10.1007/BF00686961; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GOLDING EM, 1995, MOL CHEM NEUROPATHOL, V24, P137, DOI 10.1007/BF02962139; GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3; HAGLID KG, 1991, J NEUROCHEM, V56, P1957, DOI 10.1111/j.1471-4159.1991.tb03453.x; HANKER G, 1980, SCIENCE, V209, P809; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; IRLE E, 1990, BRAIN RES REV, V15, P181, DOI 10.1016/0165-0173(90)90001-5; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KOLB B, 1982, BEHAV BRAIN RES, V6, P365, DOI 10.1016/0166-4328(82)90018-3; KURODA Y, 1994, NEUROSURGERY, V35, P106, DOI 10.1227/00006123-199407000-00016; Leggate J R, 1988, Br J Neurosurg, V2, P327, DOI 10.3109/02688698809001003; LEONARD CM, 1969, BRAIN RES, V12, P321, DOI 10.1016/0006-8993(69)90003-1; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lu XW, 1997, NEUROCHEM RES, V22, P705, DOI 10.1023/A:1027354110563; Maione S, 1998, PHARMACOL BIOCHEM BE, V59, P233, DOI 10.1016/S0091-3057(97)00337-7; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MEYER FB, 1990, J CEREBR BLOOD F MET, V10, P895, DOI 10.1038/jcbfm.1990.146; Miller RD, 1996, J NEUROL SCI, V136, P37, DOI 10.1016/0022-510X(95)00309-P; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; MURPHY S, 1987, NEUROSCIENCE, V22, P381, DOI 10.1016/0306-4522(87)90342-3; Myseros JS, 1995, ANN NY ACAD SCI, V765, P262, DOI 10.1111/j.1749-6632.1995.tb16583.x; Nordqvist ACS, 1997, NEUROREPORT, V8, P455, DOI 10.1097/00001756-199701200-00016; O'Brien M D, 1982, Exp Brain Res, VSuppl 5, P196; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PAXINOS G, 1986, RAT BRAIN; PEARCE B, 1991, ANN NY ACAD SCI, V633, P432; Pinilla L, 1996, J ENDOCRINOL INVEST, V19, P353, DOI 10.1007/BF03344969; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUDGE JS, 1985, BRAIN RES, V31, P161; SAUER D, 1988, NEUROSCI LETT, V91, P327, DOI 10.1016/0304-3940(88)90701-X; SLUKA KA, 1994, PAIN, V59, P95, DOI 10.1016/0304-3959(94)90052-3; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Stein DG, 1991, J NEUROTRAUM, V8, P281, DOI 10.1089/neu.1991.8.281; STEVENS MK, 1990, J CEREBR BLOOD F MET, V10, P77, DOI 10.1038/jcbfm.1990.10; VACA K, 1992, EXP NEUROL, V118, P62, DOI 10.1016/0014-4886(92)90023-J; WALTZ W, 1989, PROG NEUROBIOL, V33, P309; WATSON RE, 1986, PEPTIDES, V7, P155, DOI 10.1016/0196-9781(86)90076-8; WILKIN GP, 1991, ANN NY ACAD SCI, V633, P475	66	26	26	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-5904	1687-5443		NEURAL PLAST	Neural. Plast.		2000	7	1-2					73	91		10.1155/NP.2000.73			19	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	260BP	WOS:000083928700009	10709216	Green Published, gold, Green Submitted			2022-02-06	
J	Rousseau, V; Engelmann, R; Sabel, BA				Rousseau, V; Engelmann, R; Sabel, BA			Restoration of vision III: soma swelling dynamics predicts neuronal death or survival after optic nerve crush in vivo	NEUROREPORT			English	Article						axonal injury; cell death; ICON microscopy; neuron survival; plasticity; recovery; retinal ganglion cells; vision	ADULT-RATS; INJURY; MICROSCOPY; RECOVERY; MODEL; CAT	PREDICTING neuron death or survival after axonal injury is important in neurotrauma research. We now used in vivo confocal neuroimaging microscopy to repeatedly visualize retinal ganglion cells after optic nerve crush and studied their morphological alterations and ultimate fate. An intracollicular injection of a retrograde fluorescent tracer was made before or after optic nerve crush. Retinal ganglion cell sizes were then determined at different time points up to post-surgery day 75. Cell death was inevitable when soma swelling was fast and massive (86% above baseline or higher), but when it was slower and moderate (32% above baseline) long-term neuron survival could be predicted with high accuracy as early as post-operative day 5. Moderate swelling continued until day 15 (64%) and after about 3 weeks these cells started shrinking again, as a sign of recovery. We propose that moderate soma swelling is an adaptive rather than pathogenic posttraumatic reaction to axonal injury. NeuroReport 10:3387-3391 (C) 1999 Lippincott Williams & Wilkins.	Univ Magdeburg, Inst Med Psychol, D-39120 Magdeburg, Germany; Leibniz Inst Neurobiol, D-39118 Magdeburg, Germany		Sabel, BA (corresponding author), Univ Magdeburg, Inst Med Psychol, Leipzigerstr 44, D-39120 Magdeburg, Germany.		Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543			BERARDI N, 1999, IN PRESS RESTOR NEUR, V15; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; CHINO MY, 1999, IN PRESS RESTOR NEUR, V15; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; EYSEL UT, 1985, EXP NEUROL, V88, P757, DOI 10.1016/0014-4886(85)90086-X; EYSEL UT, 1999, IN PRESS RESTOR NEUR, V15; FINE A, 1988, TRENDS NEUROSCI, V11, P346, DOI 10.1016/0166-2236(88)90056-2; FROST D, 1999, IN PRESS RESTOR NEUR, V15; Gennarelli T.A., 1986, MECHANISMS SECONDARY, P15; Kasten E, 1998, NAT MED, V4, P1083, DOI 10.1038/2079; KASTEN E, 1999, IN PRESS RESTOR NEUR, V15; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; PAYNE B, 1999, IN PRESS RESTOR NEUR, V15; Sabel BA, 1997, NAT MED, V3, P244, DOI 10.1038/nm0297-244; Sabel BA, 1997, ADV NEUROL, V73, P251; SABEL BA, 1999, IN PRESS RESTOR NEUR, V15; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SHOTTON DM, 1989, J CELL SCI, V94, P175; SILVEIRA LCL, 1994, J NEUROCYTOL, V23, P75, DOI 10.1007/BF01183863; STEWARD O, 1982, INT REV NEUROBIOL, V23, P197, DOI 10.1016/S0074-7742(08)60626-1; Tetzlaff W, 1990, Restor Neurol Neurosci, V1, P189, DOI 10.3233/RNN-1990-13403; ULFHAKE B, 1991, J NEUROSCI METH, V40, P39, DOI 10.1016/0165-0270(91)90115-G; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; WHITNALL MH, 1983, BRAIN RES, V272, P49, DOI 10.1016/0006-8993(83)90363-3	24	26	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	NOV 8	1999	10	16					3387	3391		10.1097/00001756-199911080-00024			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	257QH	WOS:000083792700025	10599850				2022-02-06	
J	Zwienenberg, M; Gong, QZ; Lee, LL; Berman, RF; Lyeth, BG				Zwienenberg, M; Gong, QZ; Lee, LL; Berman, RF; Lyeth, BG			ICP monitoring in the rat: Comparison of monitoring in the ventricle, brain parenchyma, and cisterna magna	JOURNAL OF NEUROTRAUMA			English	Article						intracranial pressure monitoring; rat; subdural hematoma	INTRACRANIAL-PRESSURE; LESIONS	Various methods of continuous intracranial pressure (ICP) monitoring during experimental procedures in the rat have been described. However, no systematic comparison of ICP monitoring in the ventricle, brain parenchyma, and cisterna magna has been reported. Since accurate and reliable ICP measurements are important in experimental models of traumatic brain injury, the present study was conducted to compare simultaneous ICP measurements from ventricular, cisterna magna, and intraparenchymal monitors during ICP changes, Subdural hematoma was produced by infusion of 0.3 ml of autologous blood into the subdural space over 6 min, The ventricular and the intraparenchymal fiberoptic catheter produced reliable and comparable pressure recordings, that did not statistically differ (p = 0.4), throughout the one hour monitoring time, In contrast, the cisterna magna catheter was less reliable and produced significantly lower readings throughout the monitoring time (p < 0.001). The intraparenchymal device produced greater cortical damage than the ventricular catheter, In conclusion, ventricular LCP monitoring is the preferred method under these circumstances, since it is accurate and induces least brain damage.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-29995] Funding Source: Medline		ANDREWS B T, 1988, Neurological Research, V10, P123; BARTH KNM, 1992, NEUROSURGERY, V30, P138, DOI 10.1227/00006123-199201000-00028; BRAKKEE JH, 1979, LAB ANIM SCI, V29, P78; BULLOCK R, 1990, ACT NEUR S, V51, P274; CRUTCHFIELD JS, 1990, J NEUROSURG, V72, P482, DOI 10.3171/jns.1990.72.3.0482; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; Giulioni M, 1986, J Neurosurg Sci, V30, P177; Kanter M J, 1991, Neurosurg Clin N Am, V2, P257; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MANDELL EC, 1980, PHYSIOL BEHAV, V24, P399, DOI 10.1016/0031-9384(80)90105-5; MILLER JD, 1987, ACTA NEUROCHIR, V85, P80, DOI 10.1007/BF01456102; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; NAKAMURA K, 1987, HYPERTENSION, V10, P635, DOI 10.1161/01.HYP.10.6.635; NATH FP, 1986, J NEUROSURG, V65, P697, DOI 10.3171/jns.1986.65.5.0697; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; Smyth GE, 1938, J NEUROL PSYCHIATRY, V1, P226, DOI 10.1136/jnnp.1.3.226; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; YANO M, 1987, NEUROSURGERY, V21, P688, DOI 10.1227/00006123-198711000-00015	18	26	27	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1999	16	11					1095	1102		10.1089/neu.1999.16.1095			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	260MM	WOS:000083954500007	10595825				2022-02-06	
J	Glass, TF; Fabian, MJ; Schweitzer, JB; Weinberg, JA; Proctor, KG				Glass, TF; Fabian, MJ; Schweitzer, JB; Weinberg, JA; Proctor, KG			Secondary neurologic injury resulting from nonhypotensive hemorrhage combined with mild traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral contusion; hemorrhage; secondary brain injury; swine; traumatic brain injury	CEREBRAL BLOOD-FLOW; ISCHEMIA; METABOLISM; RATS; PROPOFOL; OXYGEN; SHOCK; MODEL; RESUSCITATION; HYPOTENSION	Although the emergency physician often treats patients with multiple injuries, there are relatively few clinically relevant models that mimic these situations. To describe the changes after a hemorrhagic insult superimposed on traumatic brain injury (TBI), anesthetized and ventilated juvenile pigs were assigned to 35% hemorrhage (35H), TBI (via fluid percussion); TBI + 35H, and TBI + 40H (40% hemorrhage). Animals were resuscitated with shed blood and crystalloid. Hemodynamic, metabolic, behavioral, and histologic parameters were assessed for 48 h. In TBI, mean arterial pressure (MAP) was not significantly different from baseline. For TBI + 40H, MAP fell by 60% (p < 0.05). This was corrected with resuscitation. Interestingly, TBI + 35H did not show a fall in MAP, while in 35H, MAP was reduced similarly to the TBI + 40H group. ICP was elevated only initially in the TBI group. In TBI + 40H and TBI + 35H, ICP increased markedly with resuscitation, remaining elevated for 60 min. ICP remained at baseline with 35 H. Hemorrhagic focal cerebal contusions at the gray-white interface we:re observed in 3/5 of TBI + 40H and 5/7 of TBI + 35H. Despite the presence of subarachnoid hemorrhage (SAH) in all the animals in the TBI alone group, none of these animals demonstrated grossly discernible intraparenchymal injury. There was no evidence of intracranial injury in the 35H group. Only in animals receiving a secondary insult of hemorrhage following the primary TBI were cerebral contusions found. These experiments demonstrate the evolution of cerebral contusions as a form of secondary neurologic injury following resuscitation from traumatic brain injury and hemorrhage, even in the absence of significant blood pressure changes.	Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; Lebonheur Childrens Hosp & Med Ctr, Memphis, TN USA; Childrens Hosp, Med Ctr, Div Pediat Emergency Med, Cincinnati, OH 45229 USA		Glass, TF (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA.	glast0@chmcc.org	Proctor, Kenneth/AAA-2199-2022	Proctor, Kenneth/0000-0003-1326-6628			ABRAHAM E, 1995, CRIT CARE MED, V23, P1319, DOI 10.1097/00003246-199508000-00004; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Boswell WC, 1996, SOUTHERN MED J, V89, P218, DOI 10.1097/00007611-199602000-00012; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CIPOLLE MD, 1993, CRIT CARE CLIN, V9, P261, DOI 10.1016/S0749-0704(18)30196-9; COLLINS T, 1995, SCI AM SCI MED   NOV, P28; Conti AC, 1998, J NEUROSCI, V18, P5663; DELMAESTRO RF, 1979, ACTA U UPSAL, V304, pV1; DeWitt D S, 1995, New Horiz, V3, P376; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; FABIAN TC, 1994, ANN SURG, V220, P552, DOI 10.1097/00000658-199410000-00013; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; HANNON JP, 1990, LAB ANIM SCI, V40, P293; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Lang E W, 1995, New Horiz, V3, P400; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; MILLEN JE, 1980, J APPL PHYSIOL, V49, P856, DOI 10.1152/jappl.1980.49.5.856; MILLEN JE, 1983, J APPL PHYSIOL, V54, P666, DOI 10.1152/jappl.1983.54.3.666; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; *NAT I DIS REH RES, 1995, NAT PED TRAUM REG BI; Pepperman ML, 1997, PAEDIATR ANAESTH, V7, P143, DOI 10.1046/j.1460-9592.1997.d01-56.x; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; ROBERTSON CS, 1995, NEW HORIZONS, V3, P210; ROUMEN RMH, 1995, CRIT CARE MED, V23, P474, DOI 10.1097/00003246-199503000-00010; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; SCHWEITZER JB, 1993, ACTA NEUROPATHOL, V85, P503; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; Smith D H, 1995, New Horiz, V3, P562; Stoffel M, 1997, ACT NEUR S, V70, P91; TREVISANI GT, 1994, J TRAUMA, V37, P452, DOI 10.1097/00005373-199409000-00021; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Wei JN, 1998, BRAIN RES, V791, P146, DOI 10.1016/S0006-8993(98)00089-4; Weinbroum AA, 1997, INTENS CARE MED, V23, P1258, DOI 10.1007/s001340050495; WEISS SJ, 1986, ACTA PHYSIOL SCAND, V126, P9; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	50	26	26	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	1999	16	9					771	782		10.1089/neu.1999.16.771			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	241EL	WOS:000082869700003	10521137				2022-02-06	
J	Conners, GP; Sacks, WK; Leahey, NF				Conners, GP; Sacks, WK; Leahey, NF			Variations in sedating uncooperative, stable children for post-traumatic head CT	PEDIATRIC EMERGENCY CARE			English	Article						sedation; head injury; CT scan; survey	COMPUTED-TOMOGRAPHY; PEDIATRIC-PATIENTS; HELICAL CT; CRITERIA	Objective: To characterize variations among pediatric emergency physicians and their hospital facilities regarding sedation of the uncooperative, stable child for head CT following closed head injury. Design: Mail survey with two follow-up mailings. Participants: Surveys were sent to all members of the Emergency Medicine Section of the American Academy of Pediatrics (AAP), Results: Of 596 surveys sent, 431 (72%) were returned, with 304 (51%) usable responses. Respondents annually sedate over 17,500 children for post-traumatic head CT. Formal training to sedate children for head CT was noted by 73%, Published guidelines for sedation are followed by 74%; 10% were unaware of the existence of published guidelines for sedation, Twenty-six percent of the respondents were very or somewhat dissatisfied with their sedation-related practices. In response to three clinical scenarios involving sedation of 8-month-old, 3-year-old, and 6-year-old children for head CT, midazolam was the most commonly chosen drug. Over 20 different sedation strategies were selected for each scenario. Conclusions: Sedation practices for post-traumatic pediatric head CT vary widely, among both physicians and individual practitioners. Institutional and individual sedation-relation policies vary widely as well, Variation and dissatisfaction with sedation practices may reflect uncertainty regarding optimal sedation strategies. Further cost-effectiveness research is necessary.	Univ Rochester, Dept Emergency Med, Ctr Med, Rochester, NY 14642 USA		Conners, GP (corresponding author), Univ Rochester, Dept Emergency Med, Ctr Med, 601 Elmwood Ave,Box 4-9200, Rochester, NY 14642 USA.						[Anonymous], 1997, ANN EMERG MED, V29, P834; BLUMENTHAL D, 1994, NEW ENGL J MED, V331, P1017, DOI 10.1056/NEJM199410133311511; COOK BA, 1992, CLIN PEDIATR, V31, P137, DOI 10.1177/000992289203100302; COTE CJ, 1994, PEDIATRICS, V94, P281; COTE CJ, 1994, PEDIATR CLIN N AM, V41, P31; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Eddy D M, 1984, Health Aff (Millwood), V3, P74, DOI 10.1377/hlthaff.3.2.74; Frush DP, 1996, AM J ROENTGENOL, V167, P1381, DOI 10.2214/ajr.167.6.8956563; Frush DP, 1997, RADIOL CLIN N AM, V35, P789; HAWK W, 1990, Pediatric Emergency Care, V6, P84, DOI 10.1097/00006565-199006000-00003; HUBBARD AM, 1992, J COMPUT ASSIST TOMO, V16, P3, DOI 10.1097/00004728-199201000-00002; Kaste SC, 1997, AM J ROENTGENOL, V168, P1001, DOI 10.2214/ajr.168.4.9124104; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; KEETER S, 1990, RADIOLOGY, V175, P745, DOI 10.1148/radiology.175.3.2343126; Parker RI, 1997, PEDIATRICS, V99, P427, DOI 10.1542/peds.99.3.427; PEREIRA JK, 1993, PEDIATR RADIOL, V23, P341, DOI 10.1007/BF02011952; RIVARA F, 1987, PEDIATRICS, V80, P579; ROARK R, 1995, ARCH PEDIAT ADOL MED, V149, P839, DOI 10.1001/archpedi.1995.02170210013002; SACCHETTI A, 1994, ANN EMERG MED, V23, P237, DOI 10.1016/S0196-0644(94)70037-0; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; SCHYNOLL W, 1993, AM J EMERG MED, V11, P321, DOI 10.1016/0735-6757(93)90160-D; STEINBERG EP, 1993, MED CARE, V31, pYS86, DOI 10.1097/00005650-199305001-00014; VARNER PD, 1985, ANESTH ANALG, V64, P643; WHITE KS, 1995, PEDIATR RADIOL, V25, P344, DOI 10.1007/BF02021698	24	26	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	AUG	1999	15	4					241	244					4	Emergency Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	225HN	WOS:000081952500001	10460075				2022-02-06	
J	Elmaraghy, AW; Aksenov, S; Byrick, RJ; Richards, RR; Schemitsch, EH				Elmaraghy, AW; Aksenov, S; Byrick, RJ; Richards, RR; Schemitsch, EH			Pathophysiological effect of fat embolism in a canine model of pulmonary contusion	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							RESPIRATORY-DISTRESS SYNDROME; MULTIPLE TRAUMA; FEMORAL-SHAFT; FRACTURES; FIXATION; DOGS	Background The objective of this study was to determine the individual and combined effects of pulmonary contusion and fat embolism on the hemodynamics and pulmonary pathophysiology in a canine model of acute traumatic pulmonary injury, Methods: After a thoracotomy, twenty-one skeletally mature dogs were randomly assigned to one of three groups, Unilateral, pulmonary contusion alone was produced in Group 1 (seven dogs); pulmonary contusion and fat embolism, in Group 2 (seven dogs); and fat embolism alone, in Group 3 (seven dogs). Pulmonary contusion was produced by standardized compression of the left lung with a piezoelectric force transducer, Fat embolism was produced by femoral and tibial reaming followed by pressurization of the intramedullary canals. Cardiac output, systolic blood pressure, peak airway pressure, pulmonary arterial pressure, pulmonary capillary wedge pressure, partial pressure of arterial oxygen, and partial pressure of carbon dioxide were monitored for all groups. From these data, several outcome parameters were calculated: total thoracic compliance, alveolar-arterial oxygen gradient, and ratio of partial pressure of arterial oxygen to fractional inspired oxygen concentration. All of the dogs were killed after eight hours, and tissue samples were obtained from the brain, kidneys, and lungs for histological analysis, Lung samples were assigned scores for pulmonary edema (the presence of fluid in the: alveoli) and inflammation (the presence of neutrophils or hyaline membranes, or both). The percentage of the total area occupied by fat was determined. Results: Pulmonary contusion alone caused a significant increase in the alveolar-arterial oxygen gradient but only after seven hours (p = 0.034), Fat embolism alone caused a significant transient decrease in systolic blood pressure (p = 0.001) and a significant transient increase in pulmonary arterial pressure (p = 0.01) and pulmonary capillary wedge pressure (p = 0.015), Fat embolism alone also caused a significant sustained decrease in the ratio of partial pressure of arterial oxygen to fractional inspired oxygen concentration (p = 0.0001) and a significant increase in the alveolar-arterial oxygen gradient (p = 0.0001). The combination of pulmonary contusion and fat embolism caused a significant transient increase in pulmonary capillary wedge pressure (p = 0.0013) as well as a significant sustained decrease in partial pressure of arterial oxygen (p = 0.0001) and a significant decrease in systolic blood pressure (p = 0.001) that lasted for an hour. Pulmonary contusion followed by fat embolism caused a significant increase in peak airway pressure (p = 0.015), alveolar-arterial oxygen gradient (p = 0.0001), and pulmonary arterial pressure (p = 0.01), and these effects persisted for five hours. Total thoracic compliance was decreased 6.4 percent by pulmonary contusion alone, 4.6 percent by fat embolism alone, and 23.5 percent by pulmonary contusion followed by fat embolism. The ratio of partial pressure of arterial oxygen to fractional inspired oxygen concentration was decreased 23.7 percent by pulmonary contusion alone, 52.3 percent by fat embolism alone, and 65.8 percent by pulmonary contusion followed by fat embolism. The mean pulmonary edema score was significantly higher with the combined injury than with either injury alone (p = 0.0001), None of the samples from the lungs demonstrated inflammation. Fat embolism combined with pulmonary contusion resulted in a significantly greater mean percentage of the area occupied by fat in the noncontused right lung than in the contused left lung (p = 0.001); however, no significant difference between the right and left lungs could be detected with fat embolism alone, The mean percentage of the glomerular and cerebral areas occupied by fat was greater with fat embolism combined with pulmonary contusion than with fat embolism alone (p = 0.0001 and p = 0.01, respectively). Conclusions: The combination of pulmonary contusion and fat embolism leads to more substantial pulmonary dysfunction than does either form of injury alone. The histological results suggest that the early effects seen following the combination of pulmonary contusion and fat embolism are mediated not by inflammatory changes but by redistribution of pulmonary perfusion by mechanical mechanisms, Clinical Relevance: The redistribution of pulmonary perfusion that occurs as a result of pulmonary contusion may potentiate both the pulmonary and the systemic complications associated with fat emboli if intramedullary nailing adds an embolic load to the venous circulation. The optimum timing and method of fracture fixation may depend not only on the time elapsed since the injury but also on the severity and stage of the associated pulmonary contusion.	Univ Toronto, St Michaels Hosp, Dept Surg, Div Orthopaed Surg,Musculoskeletal Res Lab, Toronto, ON M5C 1R6, Canada; Univ Toronto, St Michaels Hosp, Dept Anaesthesia, Toronto, ON M5C 1R6, Canada		Elmaraghy, AW (corresponding author), Univ Toronto, St Michaels Hosp, Dept Surg, Div Orthopaed Surg,Musculoskeletal Res Lab, 55 Queen St E,Suite 800, Toronto, ON M5C 1R6, Canada.		Schemitsch, Emil/G-5706-2017	Schemitsch, Emil/0000-0002-6435-9069			Alexander RH, 1993, ADV TRAUMA LIFE SUPP, P11; BENUMOF JL, 1975, J APPL PHYSIOL, V38, P846, DOI 10.1152/jappl.1975.38.5.846; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BONE LB, 1992, SKELETAL TRAUMA, P127; BYRICK RJ, 1994, AM J RESP CRIT CARE, V150, P1416, DOI 10.1164/ajrccm.150.5.7952570; CLARK GC, 1988, J TRAUMA, V28, P298, DOI 10.1097/00005373-198803000-00004; Cohn SM, 1996, J TRAUMA, V41, P565, DOI 10.1097/00005373-199609000-00036; CRAVEN KD, 1979, J APPL PHYSIOL, V47, P729, DOI 10.1152/jappl.1979.47.4.729; Duwelius PJ, 1997, J BONE JOINT SURG AM, V79A, P194, DOI 10.2106/00004623-199702000-00005; FABIAN TC, 1993, NEW ENGL J MED, V329, P961, DOI 10.1056/NEJM199309233291313; GORIS RJA, 1982, J TRAUMA, V22, P895, DOI 10.1097/00005373-198211000-00002; HULMAN G, 1995, J PATHOL, V176, P3, DOI 10.1002/path.1711760103; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; KADIRI YZ, 1980, CAN ANAESTH SOC J, V27, P216, DOI 10.1007/BF03007431; KERSTELL J, 1971, AM J SURG, V121, P712, DOI 10.1016/0002-9610(71)90053-5; KISHIKAWA M, 1991, J TRAUMA, V31, P1203, DOI 10.1097/00005373-199109000-00002; LEWIS FR, 1982, SURG CLIN N AM, V62, P97; LHOWE DW, 1994, ORTHOP CLIN N AM, V25, P573; LINDEQUE BGP, 1987, J BONE JOINT SURG BR, V69, P128, DOI 10.1302/0301-620X.69B1.3818718; MALIK AB, 1983, PHYSIOL REV, V63, P1114, DOI 10.1152/physrev.1983.63.3.1114; OPPENHEIMER L, 1979, J APPL PHYSIOL, V47, P718, DOI 10.1152/jappl.1979.47.4.718; PAHUD B, 1987, J BONE JOINT SURG BR, V69, P391, DOI 10.1302/0301-620X.69B3.3584191; PAPE HC, 1993, J TRAUMA, V34, P540, DOI 10.1097/00005373-199304000-00010; PAPE HC, 1993, J TRAUMA, V35, P709, DOI 10.1097/00005373-199311000-00010; PELL ACH, 1993, NEW ENGL J MED, V329, P926, DOI 10.1056/NEJM199309233291305; PELTIER LF, 1988, CLIN ORTHOP RELAT R, P263; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PETTY TL, 1978, WESTERN J MED, V128, P399; Schemitsch EH, 1997, J BONE JOINT SURG AM, V79A, P984, DOI 10.2106/00004623-199707000-00004; SCOPA M, 1994, J TRAUMA, V36, P906, DOI 10.1097/00005373-199406000-00030; Shepard G H, 1969, Ann Thorac Surg, V7, P110; Trinkle J K, 1973, Ann Thorac Surg, V16, P568; WEIGELT JA, 1984, MULTIPLY INJURED PAT, P42; WOZASEK GE, 1994, J TRAUMA, V37, P249, DOI 10.1097/00005373-199408000-00017; WOZASEK GE, 1994, J TRAUMA, V36, P202, DOI 10.1097/00005373-199402000-00010	35	26	27	0	1	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	AUG	1999	81A	8					1155	1164		10.2106/00004623-199908000-00011			10	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	228ER	WOS:000082124600011	10466648				2022-02-06	
J	Ippolito, E; Formisano, R; Farsetti, P; Caterini, R; Penta, F				Ippolito, E; Formisano, R; Farsetti, P; Caterini, R; Penta, F			Excision for the treatment of periarticular ossification of the knee in patients who have a traumatic brain injury	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							HETEROTOPIC OSSIFICATION	Background: Patients who are comatose after a traumatic brain injury often have heterotopic periarticular ossification that can be treated with excision to improve the range of motion of the joint; Methods: Areas of periarticular ossification were resected at an average of twenty-three months after recovery from a coma in seven knees of five patients who had a traumatic brain injury. Before the procedure, all of the knees were fixed in a flexed position that ranged from 10 to 40 degrees and they had a painful are of motion that ranged from 20 to 70 degrees of flexion, None of the patients could walk, and some of them could barely sit in a wheelchair. At the end of the operation, the are of motion was markedly improved in all of the knees (0 to 130 degrees in three knees, 0 to 120 degrees in three, and 10 to 120 degrees in one). In an attempt to prevent postoperative loss of motion and recurrence of the ossification, continuous passive motion was applied to the involved knee: for six weeks before a full rehabilitation program was started. The latest follow-up evaluation was at an average of thirty-four months (range, twenty-five to sixty months). Results: At the time of follow-up, all of the patients could walk and all of the knees were pain-free. One knee had an are of flexion of 0 to 90 degrees; two, an arc of 10 to 100 degrees; one, an are of 5 to 110 degrees; two, an are of 0 to 120 degrees; and one, an are of 0 to 130 degrees. Ossification did not recur in any of the knees. Conclusions: Patients,vith good neuromuscular control had the best general functional result, The routine use of a continuous-passive-motion machine was associated with no recurrence of ossification, and there was some late loss of motion after its use was discontinued.	Univ Roma Tor Vergata, Dept Orthopaed Surg, I-00173 Rome, Italy; Ist Ric & Cura Carattere Sci Santa Lucia, Postcoma Neurorehabil Unit, I-00179 Rome, Italy		Ippolito, E (corresponding author), Univ Roma Tor Vergata, Dept Orthopaed Surg, Via Ric Sci 135, I-00173 Rome, Italy.						Charnley G, 1996, INJURY, V27, P125, DOI 10.1016/0020-1383(95)00180-8; GACON G, 1978, REV CHIR ORTHOP, V64, P375; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; McAuliffe JA, 1997, J BONE JOINT SURG AM, V79A, P749, DOI 10.2106/00004623-199705000-00015; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623-197961050-00018; ROSEN MA, 1992, AM J SPORT MED, V20, P122, DOI 10.1177/036354659202000205; VEVERELI PA, 1995, CLIN ORTHOPAEDICS, V321, P208	10	26	28	0	1	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	JUN	1999	81A	6					783	789		10.2106/00004623-199906000-00005			7	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	207JE	WOS:000080933100005	10391543				2022-02-06	
J	Johnstone, B; Schopp, LH; Harper, J; Koscuilek, J				Johnstone, B; Schopp, LH; Harper, J; Koscuilek, J			Neuropsychological impairments, vocational outcomes, and financial costs for individuals with traumatic brain injury receiving state vocational rehabilitation services	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							PREMORBID INTELLIGENCE; EMPLOYMENT; WORK; RETURN; PROGRAM; SCHOOL; ISSUES; TESTS; LIFE	Objective: To determine the relationship among neuropsychological variables, vocational outcomes, and vocational costs for Missouri Division of Vocational Rehabilitation (MO-DVR) clients with traumatic brain injury (TBI). Design: Clients referred for neuropsychological evaluations were followed until DVR case closure. Subjects were grouped according to the following DVR status at case closure: Successfully Employed, Services Interrupted, and No Services Provided. Spearman correlations with Bonferroni corrections were calculated to determine relationships among variables, and Kruskal-Wallis nonparametric one-way analyses of variance (ANOVAs) were conducted to evaluate differences in DVR group status in terms of neuropsychological variables and DVR costs. Setting: All evaluations were completed through a Midwestern university neuropsychology laboratory. Patients: 110 consecutively referred DVR clients with nonacute TBI referred for neuropsychological evaluation. Main outcome measures: Absolute level (ie, raw/standard scores) of neuropsychological functioning and relative degree of decline in: intelligence (WAIS-R), memory (WMS-R General and Delayed Memory Indices), attention (WMS-R Attention Index), speed of processing (Trails A), and cognitive flexibility (Trails B); DVR costs at closure. Results: 1) Surprisingly, the Successfully Employed group had significantly greater neuropsychological impairments; 2) Greater decline in delayed memory was associated with higher DVR costs (r = -0.30, P < .05); and 3) More indices of relative decline were significantly correlated with vocational outcomes (5/6) than were indices of absolute functioning (3/6). Conclusions: DVR is effective in providing services to individuals with the most significant neuropsychological deficits; it is important to consider both absolute level of functioning and relative decline in functioning when evaluating TBI.	Univ Missouri, Sch Med, Dept Phys Med & Rehabil, Columbia, MO 65212 USA; Univ Missouri, Dept Educ & Counseling Psychol, Columbia, MO 65212 USA		Johnstone, B (corresponding author), Univ Missouri, Sch Med, Dept Phys Med & Rehabil, DC046-00,1 Hosp Dr, Columbia, MO 65212 USA.			Johnstone, Brick/0000-0001-8845-9649			Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Bistany D. V., 1994, BRAIN INJURY NEUROPS, P245; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; CHEREK L, 1995, NEUROREHABILITATION, V5, P87, DOI 10.3233/NRE-1995-5108; COOK J, 1990, REHABILITATION ADULT, P493; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Crawford J.R., 1992, HDB NEUROPSYCHOLOGIC, P21; DODRILL CB, 1984, J CONSULT CLIN PSYCH, V52, P520, DOI 10.1037/0022-006X.52.4.520; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GOODALL P, 1994, J HEAD TRAUMA REHAB, V9, P61; GOUVIER D, 1986, NEUROPSYCHOLOGY HDB, P278; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hannay HJ, 1998, ARCH CLIN NEUROPSYCH, V13, P157, DOI 10.1016/S0887-6177(98)00003-1; Hartman D E, 1991, Arch Clin Neuropsychol, V6, P147, DOI 10.1016/0887-6177(91)90030-D; HARTMAN DE, 1989, ARCH CLIN NEUROPSYCH, V4, P285; Heaton RK, 1991, COMPREHENSIVE NORMS; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Jastak S., 1984, WRAT R WIDE RANGE AC; Johnstone B, 1996, J Int Neuropsychol Soc, V2, P282; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Johnstone B, 1997, ARCH CLIN NEUROPSYCH, V12, P523, DOI 10.1016/S0887-6177(97)00034-6; Johnstone B, 1997, NEUROREHABILITATION, V8, P57, DOI 10.3233/NRE-1997-8108; JOHNSTONE B, 1995, NEUROREHABILITATION, V5, P75, DOI 10.3233/NRE-1995-5107; Johnstone B, 1997, ARCH CLIN NEUROPSYCH, V12, P591, DOI 10.1016/S0887-6177(97)00002-4; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; LANDRUM PK, 1998, OUTCOME ORIENTED REH; MALEC J, 1991, NEUROPSYCHOLOGY, V5, P29; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; Reitan R, 1986, TRAIL MAKING TEST MA; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Wechsler D, 1987, MANUAL WECHSLER MEMO; WECHSTER D, 1981, WECHSLER ADULT INTEL; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEST M, 1991, ARCH PHYS MED REHAB, V72, P127; Wilkinson G. S, 1993, WRAT 3 WIDE RANGE AC	45	26	26	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1999	14	3					220	232		10.1097/00001199-199906000-00003			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	203XY	WOS:000080734500003	10381975				2022-02-06	
J	Franzen, R; Martin, D; Daloze, A; Moonen, G; Schoenen, J				Franzen, R; Martin, D; Daloze, A; Moonen, G; Schoenen, J			Grafts of meningeal fibroblasts in adult rat spinal cord lesion promote axonal regrowth	NEUROREPORT			English	Article						fibroblasts; neurotrophins; regeneration; spinal cord injury; transplantation	SCHWANN-CELLS; INJURY; RECOVERY; GROWTH; TRANSPLANTATION; DELIVERY; BRAIN; BDNF; SCAR; NGF	WE have studied the morphological consequences of implantation into the injured adult rat spinal cord of fibroblasts derived from the meninges overlying the cerebral cortex. Our initial objective was to reproduce the well known post-traumatic fibroadhesive scar observed in the clinical situation. One month after implantation, instead of having formed a fibroadhesive scar, fibroblasts had promoted the regeneration of peptidergic axons originating from dorsal root afferents and, to a lesser extent, of supraspinal serotonergic fibers at the periphery of the grafts. Using RT-PCR Ne were able to identify in cultures of meningeal-derived fibroblasts mRNAs for beta-NGF, NT3, aFGF and bFGF, which suggests that the promoting effect on axonal regeneration of these cells is at least in part due to their capacity to synthesize neurotrophic factors. NeuroReport 10:1551-1556 (C) 1999 Lippincott Williams & Wilkins.	Univ Liege, Dept Neuroanat, B-4020 Liege, Belgium; Univ Liege, Dept Human Physiol & Pathophysiol, B-4020 Liege, Belgium; Univ Liege, Dept Neurol, B-4020 Liege, Belgium; Univ Liege, Dept Neurosurg, B-4020 Liege, Belgium		Schoenen, J (corresponding author), Univ Liege, Dept Neuroanat, Rue Pitteurs 20, B-4020 Liege, Belgium.						CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.3.CO;2-6; Grill R, 1997, J NEUROSCI, V17, P5560; Kim DH, 1996, NEUROREPORT, V7, P2221, DOI 10.1097/00001756-199609020-00033; KOBAYASHI S, 1995, NEUROSCI LETT, V188, P191, DOI 10.1016/0304-3940(95)11429-Z; KRIKORIAN JG, 1981, EXP NEUROL, V72, P698, DOI 10.1016/0014-4886(81)90018-2; KROMER LF, 1985, P NATL ACAD SCI USA, V82, P6330, DOI 10.1073/pnas.82.18.6330; KRUGER S, 1986, J COMP NEUROL, V249, P103, DOI 10.1002/cne.902490108; MARTIN D, 1991, NEUROSCI LETT, V124, P44, DOI 10.1016/0304-3940(91)90818-E; Martin D, 1996, J NEUROSCI RES, V45, P588; MARTIN D, 1992, J NEUROSCI RES, V32, P539, DOI 10.1002/jnr.490320409; MARTIN D, 1993, BRAIN RES BULL, V30, P507, DOI 10.1016/0361-9230(93)90285-J; MATTHIESSEN HP, 1991, J NEUROCHEM, V56, P759, DOI 10.1111/j.1471-4159.1991.tb01989.x; Menei P, 1998, EUR J NEUROSCI, V10, P607, DOI 10.1046/j.1460-9568.1998.00071.x; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; SENUT MC, 1995, EXP NEUROL, V135, P36, DOI 10.1006/exnr.1995.1064; SIEVERS J, 1994, J NEUROCYTOL, V23, P97, DOI 10.1007/BF01183865; Tuszynski MH, 1996, EXP NEUROL, V137, P157, DOI 10.1006/exnr.1996.0016; Tuszynski MH, 1997, CELL TRANSPLANT, V6, P361, DOI 10.1016/S0963-6897(97)00021-3; TUSZYNSKI MH, 1994, EXP NEUROL, V126, P1, DOI 10.1006/exnr.1994.1037	20	26	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	MAY 14	1999	10	7					1551	1556		10.1097/00001756-199905140-00029			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	202LG	WOS:000080653300030	10380979				2022-02-06	
J	Prigatano, GP				Prigatano, GP			Impaired awareness, finger tapping, and rehabilitation outcome after brain injury	REHABILITATION PSYCHOLOGY			English	Article; Proceedings Paper	106th Annual Convention of the American-Psychological-Association	AUG, 1998	SAN FRANCISCO, CALIFORNIA	Amer Psychol Assoc			CLOSED HEAD-INJURY; BEHAVIORAL LIMITATIONS; NEUROPSYCHOLOGICAL REHABILITATION; FUNCTIONAL REORGANIZATION; RECOVERY; DYSFUNCTION; INFARCTION	Speed of finger tapping after traumatic brain injury has been related to the problem of impaired self-awareness as well as to rehabilitation outcome. This article summarizes selected literature that documents the potentially rich information this "simple" task can provide. It supports Leonard Diller's emphasis on using developmentally sensitive tasks that allow for simple inferences to be applied to issues of diagnosis and rehabilitation after brain injury.	Barrow Neurol Inst, Dept Clin Neuropsychol, St Josephs Hosp & Med Ctr, Phoenix, AZ 85013 USA		Prigatano, GP (corresponding author), Barrow Neurol Inst, Dept Clin Neuropsychol, St Josephs Hosp & Med Ctr, Phoenix, AZ 85013 USA.						Anton G., 1896, MITTEILUNGEN VEREINS, V33, P41; Anton G., 1898, WIEN KLIN WOCHENSCHR, V11, P227; Bisiach E., 1991, AWARENESS DEFICIT BR, P17; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; DIKMEN S, 1980, J NERV MENT DIS, V168, P236, DOI 10.1097/00005053-198004000-00008; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DILLER L, 1964, BRAIN DAMAGE CHILDRE, P27; DOYLE AC, 1986, S HOLMES COMPLETE NO, V2; FINLAYSON MAJ, 1976, PERCEPT MOTOR SKILL, V43, P475, DOI 10.2466/pms.1976.43.2.475; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Halstead W.C., 1947, BRAIN INTELLIGENCE; HEATON RK, 1978, J NERV MENT DIS, V166, P408, DOI 10.1097/00005053-197806000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Muller G., 1991, DEMENTIA, V2, P169; OBOYLE MW, 1994, CORTEX, V30, P519, DOI 10.1016/S0010-9452(13)80347-4; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Prigatano G. P., 1997, CLIN NEUROPSYCHOL, V11, P1; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1999, ARCH PHYS MED REHAB, V80, P77, DOI 10.1016/S0003-9993(99)90311-8; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1997, ARCH PHYS MED REHAB, V78, P847, DOI 10.1016/S0003-9993(97)90198-2; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; PRIGATANO GP, 1991, AWARENESS DEFICITY B; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; PRIGATANO GP, IN PRESS PRINCIPLES; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Spreen O, 1991, COMPENDIUM NEUROPSYC; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WEILLER C, 1993, ANN NEUROL, V33, P181; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; WESSEL K, 1995, BRAIN, V118, P379, DOI 10.1093/brain/118.2.379	39	26	26	0	4	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	1999	44	2					145	159		10.1037/0090-5550.44.2.145			15	Psychology, Clinical; Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Psychology; Rehabilitation	198ED	WOS:000080409000002					2022-02-06	
J	Aloni, A; Keren, O; Cohen, M; Rosentul, N; Romm, M; Groswasser, Z				Aloni, A; Keren, O; Cohen, M; Rosentul, N; Romm, M; Groswasser, Z			Incidence of sexual dysfunction in TBI patients during the early post-traumatic in-patient rehabilitation phase	BRAIN INJURY			English	Article							HEAD-INJURY	Objective: The aim of the study is to find whether sexuality acid intimacy dysfunction are already present at the early rehabilitation phase of TBI patients. Methods: Forty-four consequent severe TBI patients. were studied. The GCS and the duration of unconsciousness determined the initial severity of the injury. Patients' function regarding motor, language, cognition and behaviour were assessed by an interdisciplinary team. Sexuality and intimacy were evaluated by using a special closed questionnaire. Results: Regarding self confidence 81% of patients described themselves as having high or average self confidences; 78% described themselves as having high or average feeling of being sexually appealing; mood level was average or high in 80% of patients. Only 7.7% of patients reported having sexual dysfunction at that phase of rehabilitation. Conclusions: Sexual dysfunction in Severe TBI patients is uncommon at the early post-traumatic phase. It is suggested that sexual dysfunction appearing during later stages of recovery is most probably related to reactive behavioural changes.	Loewenstein Rehabil Hosp, IL-43100 Raanana, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel		Groswasser, Z (corresponding author), Loewenstein Rehabil Hosp, 278 Achuza St,POB 3, IL-43100 Raanana, Israel.						Benyakar M, 1988, Brain Inj, V2, P351, DOI 10.3109/02699058809150907; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Groswasser Z, 1998, J HEAD TRAUMA REHAB, V13, P69, DOI 10.1097/00001199-199802000-00009; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; KATZ N, 1989, AM J OCCUP THER, V43, P184, DOI 10.5014/ajot.43.3.184; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; KREUTZER SJ, 1989, BRAIN INJURY, V3, P177; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; ZASLER ND, 1995, PHYS MED REHABIL STA, V9, P361	12	26	26	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1999	13	2					89	97		10.1080/026990599121755			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	167HQ	WOS:000078626800002	10079954				2022-02-06	
J	Hermann, DM; Mies, G; Hossmann, KA				Hermann, DM; Mies, G; Hossmann, KA			Expression of c-fos, junB, c-jun, MKP-1 and hsp72 following traumatic neocortical lesions in rats - Relation to spreading depression	NEUROSCIENCE			English	Article						cortical injury; cortical spreading depression; activator protein-1 (AP-1); mitogen-activated protein (MAP) kinase phosphatase; heat shock protein	ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; HEAT-SHOCK PROTEIN; MESSENGER-RNA EXPRESSION; CORTICAL IMPACT INJURY; BRAIN INJURY; TRANSCRIPTION FACTORS; SYNTHESIS INHIBITORS; 3T3 CELLS; INDUCTION	The effects of a traumatic neocortical lesion on c-fos, junB, c-jun, MKP-1 and hsp72 expression were examined by in situ hybridization and immunocytochemistry 1-6 h following transcranial cold injury. The direct current potential was recorded in the injury-remote cortex to evaluate the role of transient direct current shifts, i.e. spreading depressions, in gene expression. In 14 out of 21 injured rats, spreading depression-like depolarizations of the direct current potential were noticed, which were accompanied by a transient decrease in electroencephalographic activity and increase in laser Doppler flow. In seven injured animals, no spontaneous spreading depressions were seen. In animals without spreading depressions, only a short-lasting response of c-fos, junB, c-jun and MKP-1 messenger RNAs as well as c-Fos protein was bilaterally found in the piriform cortex, and-with ipsilateral dominance-the dentate gyrus and hippocampal CA3/4 fields at Ih after lesioning. In injured animals with spreading depressions however, a strong elevation was seen in layers II-TV and VI of the injury-remote ipsilateral cerebral cortex, which persisted over as long as 6 h. Messenger RNA levels for c-Sos, junB and MKP-1 were closely related to the time interval between the last depolarization and the end of experiment. Levels were highest shortly after transient direct current shifts, and decreased thereafter mono-exponentially with half-lives of 48, 75 and 58 min for c-Sos, junB and MKP-1 messenger RNAs, respectively. In 6 h animals with spreading depressions, hsp72 messenger RNA was slightly elevated in layer II of the injury-remote cortex, but heat shock protein 72 was not increased. The present results demonstrate that spreading depression is the most prominent factor influencing the trauma-related gene response in the lesion-remote cortical tissue. (C) 1998 IBRO. Published by Elsevier Science Ltd.	Max Planck Inst Neurol Res, Dept Expt Neurol, D-50931 Cologne, Germany		Hermann, DM (corresponding author), Max Planck Inst Neurol Res, Dept Expt Neurol, Gleueler Str 50, D-50931 Cologne, Germany.		Hermann, Dirk M./AAT-3652-2021; Hermann, Dirk M/AAP-5538-2020	Hermann, Dirk M./0000-0003-0198-3152; 			ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHARLES CH, 1992, ONCOGENE, V7, P187; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CURRAN T, 1987, ONCOGENE, V2, P79; DIETRICH WD, 1994, J CEREBR BLOOD F MET, V14, P20, DOI 10.1038/jcbfm.1994.4; DRAGUNOW M, 1995, BRAIN RES REV, V21, P1, DOI 10.1016/0165-0173(95)00003-L; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FIFKOVA E, 1964, PHYSIOL BOHEMOSLOV, V13, P1; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; Gass P, 1996, MOL BRAIN RES, V41, P74, DOI 10.1016/0169-328X(96)00068-X; GASS P, 1993, NEUROSCI LETT, V162, P39, DOI 10.1016/0304-3940(93)90554-X; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HERMANN DM, 1998, IN PRESS NEUROREPORT, V9; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; HUSZ T, 1992, NEUROREPORT, V3, P51, DOI 10.1097/00001756-199201000-00013; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; KOCHER M, 1990, J CEREBR BLOOD F MET, V10, P564, DOI 10.1038/jcbfm.1990.99; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Lindsberg PJ, 1996, J CEREBR BLOOD F MET, V16, P82, DOI 10.1097/00004647-199601000-00010; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MCLACHLAN RS, 1994, BRAIN RES, V666, P133, DOI 10.1016/0006-8993(94)90295-X; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; NEUMANNHAEFELIN T, 1994, J CEREBR BLOOD F MET, V14, P206, DOI 10.1038/jcbfm.1994.27; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Piper RD, 1996, CEPHALALGIA, V16, P87, DOI 10.1046/j.1468-2982.1996.1602087.x; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sall J. M., 1997, Society for Neuroscience Abstracts, V23, P1122; SHARP JW, 1990, EXP NEUROL, V109, P323, DOI 10.1016/S0014-4886(05)80023-8; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; WIESSNER C, 1995, NEUROSCIENCE, V64, P959, DOI 10.1016/0306-4522(94)00418-5; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Yamashita K, 1996, BRAIN RES, V735, P285, DOI 10.1016/0006-8993(96)00578-1; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	47	26	27	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	JAN	1999	88	2					599	608		10.1016/S0306-4522(98)00249-8			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	130EJ	WOS:000076506700023	10197778				2022-02-06	
J	Horowitz, MB; Kopitnik, TA; Landreneau, F; Ramnani, DM; Rushing, EJ; George, E; Purdy, PP; Samson, DS				Horowitz, MB; Kopitnik, TA; Landreneau, F; Ramnani, DM; Rushing, EJ; George, E; Purdy, PP; Samson, DS			Multidisciplinary approach to traumatic intracranial aneurysms secondary to shotgun and handgun wounds	SURGICAL NEUROLOGY			English	Article						aneurysm; traumatic; shotgun; coils; bypass	ARTERY; BRAIN	BACKGROUND Traumatic intracranial aneurysms (TICAs) may develop following gunshot injuries to the head. Management of these lesions often combines various aspects of micro-neurosurgical and endovascular techniques to safely repair or obliterate vessel defects. METHODS We reviewed our experience over the last 18 years and identified five cases of intracranial aneurysms following gunshot and handgun wounds that were treated surgically and/or endovascularly. RESULTS All patients had successful obliteration of their lesions using a variety of therapeutic modalities aimed at preserving neurologic function while at the same time eliminating the aneurysm from the circulation. CONCLUSION Both micro-neurosurgery and endovascular surgery have important roles to play in the management of TICAs. In some cases, both methods can be combined to eliminate lesions and maximize patient recovery in a safe, efficient, and effective fashion. (C) 1999 by Elsevier Science Inc.	Univ Texas, SW Med Ctr, Dept Neurosurg, Dallas, TX 75235 USA		Horowitz, MB (corresponding author), Univ Texas, SW Med Ctr, Dept Neurosurg, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.						AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; BANK WO, 1978, AM J ROENTGENOL, V130, P975, DOI 10.2214/ajr.130.5.975; COURVILLE C B, 1960, Bull Los Angel Neuro Soc, V25, P48; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HIRSCH JF, 1962, NEURO-CHIR, V8, P189; Jackson F E, 1970, J Trauma, V10, P1158, DOI 10.1097/00005373-197012000-00008; KAUFMAN HH, 1980, NEUROSURGERY, V6, P181, DOI 10.1227/00006123-198002000-00011; Martin E M, 1986, J Neurosci Nurs, V18, P89; MOORE D, 1979, SURG NEUROL, V11, P115; PEERLESS S, 1988, OPERATIVE NEUROSURGI, P973; PETTY J M, 1969, Journal of Neurosurgery, V30, P741, DOI 10.3171/jns.1969.30.6.0741; RAIMONDI AJ, 1960, NEUROCHIRURGIA STUTT, V11, P219; ROBBINS JB, 1976, LARYNGOSCOPE, V86, P893, DOI 10.1288/00005537-197607000-00001; SADAR ES, 1973, SURG GYNECOL OBSTET, V137, P59; SALAR G, 1978, J NEUROSURG, V49, P100, DOI 10.3171/jns.1978.49.1.0100; SARWAR M, 1976, RADIOLOGY, V120, P603, DOI 10.1148/120.3.603; SCHMIDT-VANDERHEYDEN W, 1971, Archiv fuer Psychiatrie und Nervenkrankheiten, V214, P10, DOI 10.1007/BF00344623; SPETZLER RF, 1979, NEUROSURGERY, V4, P334, DOI 10.1227/00006123-197904000-00011	20	26	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JAN	1999	51	1					31	41		10.1016/S0090-3019(98)00029-9			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	160PW	WOS:000078241000014	9952121				2022-02-06	
S	Kelley, KM; Tkachenko, TA; Pliskin, NH; Fink, JW; Lee, RC		Chen, CT; Lee, RC; Shih, JX; Zhong, MH		Kelley, KM; Tkachenko, TA; Pliskin, NH; Fink, JW; Lee, RC			Life after electrical injury - Risk factors for psychiatric sequelae	OCCUPATIONAL ELECTRICAL INJURY: AN INTERNATIONAL SYMPOSIUM	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	3rd International Conference on Electrical Injury and Safety	OCT 26-28, 1998	SHANGHAI, PEOPLES R CHINA	Univ Chicago, Elect Trauma Res Program, Shanghai Elect Power Hosp, China Burn Assoc, China Hydro Elect Power Med Sci Assoc, Cooper Bussmann, Dupont Co, US Electr Power Res Inst, Integra Lifesci, China Med Assoc, Shanghai Branch, Soc Phys Regulat Biol & Med, US Natl Sci Fdn, Univ Chicago, Off Continuing Med Educ, Westaim Biomed Corp			POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN INJURY; AMNESIA; MEMORY; EVENT	Long-term cognitive and emotional deficits have been commonly reported in electrical injury (EI) survivors. However, it remains undetermined what factors may lead to the development of such effects in some patients and not in others. In this study, we hypothesized that certain elements of subjective EI experience may predict specific psychiatric sequelae. A group of 73 postacute EI patients were included in this retrospective study. Statistical associations were examined between major psychiatric diagnoses (posttraumatic stress disorder and major depression) and such EI descriptors as having experienced "no-let-go" or having been knocked away on contact, as well as loss of consciousness or altered states of consciousness at the scene of the accident (including amnesia for the event). The study results will help physicians determine which patients may be at increased risk of developing psychiatric symptoms and address these issues as part of their total rehabilitation plan.	Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Chicago, IL 60637 USA		Kelley, KM (corresponding author), Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA.			Lee, Raphael C./0000-0002-6628-1867			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; KELLEY KM, 1994, ANN NY ACAD SCI, V720, P213, DOI 10.1111/j.1749-6632.1994.tb30449.x; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LEDOUX J, 1992, NEUROPSYCHOLOGY MEMO, P463; Lee RC, 1997, CURR PROB SURG, V34, P682, DOI 10.1016/S0011-3840(97)80007-X; Mancusi-Ungaro H R Jr, 1986, J Burn Care Rehabil, V7, P521, DOI 10.1097/00004630-198611000-00015; MELLEN PF, 1992, J FORENSIC SCI, V37, P1016; Pliskin NH, 1998, J TRAUMA, V44, P709, DOI 10.1097/00005373-199804000-00027; Premalatha G D, 1994, Med J Malaysia, V49, P292; PRIMEAU M, 1995, SEMIN NEUROL, V15, P279, DOI 10.1055/s-2008-1041033; Saffle Jeffrey R., 1995, Journal of Burn Care and Rehabilitation, V16, P219, DOI 10.1097/00004630-199505000-00002; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; ZAHARINI MC, 1991, STRUCTURED CLIN INTE	16	26	26	0	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-233-9; 1-57331-232-0	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	888						356	363		10.1111/j.1749-6632.1999.tb07970.x			8	Emergency Medicine; Public, Environmental & Occupational Health; Multidisciplinary Sciences; Rehabilitation	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Public, Environmental & Occupational Health; Science & Technology - Other Topics; Rehabilitation	BP20J	WOS:000084392200036	10842647				2022-02-06	
J	Britton, KR				Britton, KR			Medroxyprogesterone in the treatment of aggressive hypersexual behaviour in traumatic brain injury	BRAIN INJURY			English	Article								Sexual function is among the many areas affected by traumatic brain injury. The most common change is decreased sexual performance and satisfaction, for the brain injured person and the sexual partner. Hypersexuality, especially inappropriate sexual, comments and gestures, is also a common result of traumatic brain injury. A. case of hypersexuality in a severely disabled brain injured man is presented. He was successfully treated with medroxyprogesterone acetate after failure of multiple other treatment strategies. The literature is reviewed. An evaluation and treatment strategy for sexual dysfunction post traumatic brain injury is presented.	Univ Minnesota, Vet Adm Med Ctr, Minneapolis, MN 55415 USA		Britton, KR (corresponding author), Univ Minnesota, Vet Adm Med Ctr, 701 Pk Ave, Minneapolis, MN 55415 USA.						BERLIN F, 1987, CURRENTS AFFECTIVE I, V6, P5015; BLACKENBY W, 1989, PHYSICAL MED REHABIL, V3; Buxton J, 1991, COMMUNITY LIVING SKI; COLE T, 1990, KRUSENS HDB PHYSICAL, P1000; COOPER AJ, 1987, J CLIN PSYCHIAT, V48, P368; DEBOSKY D, 1991, ED FAMILIES HEAD INJ; GRABER B, 1982, J FORENSIC SCI, V27, P125; JENIKE MA, 1989, GERIATRIC PSYCHIAT P; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; MILLER BL, 1986, J NEUROL NEUROSUR PS, V49, P867, DOI 10.1136/jnnp.49.8.867; O'Hara CC, 1991, REHABILITATION BRAIN; ROSENTHAL M, 1983, REHABILITATION ADULT; SACHS P, 1988, TREATING FAMILIES BR; VALENTICH M, 1986, SEX DISABIL, V7, P28; WEHMAN P, 1990, VOCATIONAL REHABILIT; WHYTE J, 1993, REHABILITATION MED P, P849; WOOD R, 1988, J HEAD TRAUMA REHAB, V3, P53; Wood RLL, 1990, NEUROBEHAVIORAL SEQU; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163	19	26	27	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1998	12	8					703	707		10.1080/026990598122269			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	108AN	WOS:000075243800007	9724841				2022-02-06	
J	Nelson, LD; Drebing, C; Satz, P; Uchiyama, C				Nelson, LD; Drebing, C; Satz, P; Uchiyama, C			Personality change in head trauma: A validity study of the Neuropsychology Behavior and Affect Profile	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							RELATIVES VIEW; INJURY; INDIVIDUALS; SEQUELAE	This study represets the first attempt to cross validate and report on the Neuropsychology Behavior and Affect Profile (NBAP) using closed head injury (CHI) participants. The NBAP is designed to measure emotional functioning before and following a brain event. Two CHI samples, differing primarily by method of ascertainment, were compared to a group of normal controls. Results provided support for concurrent and predictive validity the NBAP across both CHI samples. Significantly higher levels postinjury emotional functioning in clinic-referred CHI patients compared to CHI individuals not seeking treatment (strictly research participants) was demonstrated. A surprising finding was that pre-injury emotional levels of clinic-referred subjects were rated as less severe than that of controls. Based on this finding, the possibility of a gradient effect was discussed in which raters appeared to place selectively greater weight on current condition, while simultaneously making premorbid levels less severe than they really were. Results were discussed in the context of study limitations and directions further research. (C) 1998 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Univ Calif Irvine, Med Ctr, Dept Neurol, Orange, CA 92868 USA; Edith Nourse Rogers Mem VA Med Ctr, Bedford, MA USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA		Nelson, LD (corresponding author), Univ Calif Irvine, Med Ctr, Dept Neurol, 101 City Dr,Route 81,Bldg 53,Room 225, Orange, CA 92868 USA.						Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Bond M R, 1975, Ciba Found Symp, P141; Borod J. C., 1993, NEUROPSYCHOLOGY, V7, P427; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FINSET A, 1988, CEREBRAL HEMISPHERE, P51; Gass CS, 1997, ARCH CLIN NEUROPSYCH, V12, P199, DOI 10.1016/S0887-6177(96)00032-7; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; Lees-Haley P. R., 1992, FORENSIC REPORTS, V5, P385; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; NELSON L, 1995, AM J MENT RETARD, V99, P616; Nelson L., 1994, MANUAL NEUROPSYCHOLO; Nelson LD, 1995, PSYCHOL ASSESSMENT, V7, P404, DOI 10.1037/1040-3590.7.3.404; NELSON LD, 1994, J CLIN EXP NEUROPSYC, V16, P796, DOI 10.1080/01688639408402693; Nelson LD, 1991, PSYCHOL ASSESSMENT, V3, P55; NELSON LD, 1993, PSYCHOL ASSESSMENT, V5, P374; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Ramachandran VS, 1996, NATURE, V382, P501, DOI 10.1038/382501a0; Satz P, 1993, NEUROPSYCHOLOGY, V7, P553, DOI DOI 10.1037/0894-4105.7.4.553; [No title captured]	25	26	27	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	1998	13	6					549	560		10.1016/S0887-6177(97)00052-8			12	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	100JH	WOS:000074812700007	14590639	Bronze			2022-02-06	
J	Zou, LL; Burmeister, LA; Styren, SD; Kochanek, PM; DeKosky, ST				Zou, LL; Burmeister, LA; Styren, SD; Kochanek, PM; DeKosky, ST			Up-regulation of type 2 iodothyronine deiodinase mRNA in reactive astrocytes following traumatic brain injury in the rat	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; in situ hybridization; mRNA; thyroid hormone; 3,5,3 '-triiodothyronine; type 2 5 '-deiodinase; traumatic brain injury	CEREBRAL-CORTEX; AXONAL REGENERATION; INTRACELLULAR 3,5,3'-TRIIODOTHYRONINE; ONSET HYPOTHYROIDISM; THYROXINE TREATMENT; THYROID-HORMONES; PYRAMIDAL CELLS; NERVOUS-SYSTEM; RECOVERY; TISSUES	Type 2 5'-deiodinase (5'-D2), which converts thyroxine to the more active thyroid hormone 3,5,3'-triiodothyronine (T3), is believed to be an important source of intracellular T3 in the brain. The activity of this enzyme is increased in hypothyroidism and decreased in hyperthyroidism, and as such, it serves an important role to protect the brain from wide fluctuations in T3 during changes in thyroidal state. Although it has been hypothesized that T3 may facilitate neuronal regeneration after CNS injury, the 5'-D2 response to brain injury is unknown. To assess the 5'-D2 mRNA response to injury, we performed in situ hybridization following traumatic brain injury. In unlesioned animals, 5'-D2 mRNA was undetectable. At 3 days posttrauma, 5'-D2 mRNA was detected in ipsilateral cortex near the contusion. A significant further increase of 5'-D2 mRNA was noted 7 days posttrauma in both hippocampus and cortex. Similar response was also observed on the contralateral side. Colocalization of 5'-D2 mRNA with glial fibrillary acidic protein indicates that reactive astrocytes were the major cellular source for the trauma-induced 5'-D2 expression. These data demonstrate, for the first time, a trauma-induced, astrocytic up-regulation of 5'-D2 mRNA, suggesting a potential role for T3 action in adult brain's response to injury and recovery.	Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Neurobiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15213 USA		DeKosky, ST (corresponding author), Univ Pittsburgh, Med Ctr, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.		Kochanek, Patrick M/D-2371-2015; Burmeister, Lynn/AAA-5434-2020	Kochanek, Patrick M/0000-0002-2627-913X; Burmeister, Lynn/0000-0003-4795-2546; DeKosky, Steven/0000-0003-3743-2758	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK02147-03] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K11DK002147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P01NS030318, P20NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER		BERNAL J, 1995, EUR J ENDOCRINOL, V133, P390, DOI 10.1530/eje.0.1330390; Burmeister LA, 1997, ENDOCRINOLOGY, V138, P5231, DOI 10.1210/en.138.12.5231; Clark RSB, 1997, J NEUROSCI, V17, P9172; CRANTZ FR, 1980, J CLIN INVEST, V65, P935, DOI 10.1172/JCI109749; CRANTZ FR, 1982, ENDOCRINOLOGY, V110, P367, DOI 10.1210/endo-110-2-367; Croteau W, 1996, J CLIN INVEST, V98, P405, DOI 10.1172/JCI118806; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEONA CR, 1988, PEDIATR RES, V24, P588, DOI 10.1203/00006450-198811000-00010; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; FERTIG A, 1971, EXP NEUROL, V33, P372, DOI 10.1016/0014-4886(71)90029-X; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GuadanoFerraz A, 1997, P NATL ACAD SCI USA, V94, P10391, DOI 10.1073/pnas.94.19.10391; GUTH L, 1974, EXP NEUROL, V45, P606, DOI 10.1016/0014-4886(74)90165-4; HARVEY JE, 1967, J NEUROPATH EXP NEUR, V26, P661, DOI 10.1097/00005072-196710000-00011; HEINICKE E, 1977, J NEUROL SCI, V31, P293, DOI 10.1016/0022-510X(77)90114-9; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LEONARD JL, 1981, SCIENCE, V214, P571, DOI 10.1126/science.7291997; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Oppenheimer Jack H., 1995, P249; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; POLITIS MJ, 1985, BRAIN RES, V346, P186, DOI 10.1016/0006-8993(85)91114-X; RUDGE JS, 1989, EXP NEUROL, V103, P1, DOI 10.1016/0014-4886(89)90180-5; RUIZDEONA C, 1980, BRAIN RES, V85, P91; RUIZMARCOS A, 1994, J NEUROBIOL, V25, P808, DOI 10.1002/neu.480250706; RUIZMARCOS A, 1988, EXP BRAIN RES, V73, P583, DOI 10.1007/BF00406617; RUIZMARCOS A, 1982, BRAIN RES, V239, P559, DOI 10.1016/0006-8993(82)90530-3; Tu HM, 1997, ENDOCRINOLOGY, V138, P3359, DOI 10.1210/en.138.8.3359; VANDOORN J, 1982, ACTA ENDOCRINOL-COP, V101, P386, DOI 10.1530/acta.0.1010386; VANDOORN J, 1983, J CLIN INVEST, V72, P1778, DOI 10.1172/JCI111138; VANDOORN J, 1984, ENDOCRINOLOGY, V115, P174, DOI 10.1210/endo-115-1-174; ZOU L, 1997, J NEUROTRAUM, V14, P769	33	26	27	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	1998	71	2					887	890					4	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	102FB	WOS:000074912800050	9681483				2022-02-06	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Blood-free magnesium concentration declines following graded experimental traumatic brain injury	SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION			English	Article						head injury; ion-selective electrodes; ionised magnesium; trauma	IONIZED MAGNESIUM; AXONAL INJURY; RATS; CATECHOLAMINES; CALCIUM	Traumatic brain injury has been shown to result in a decrease in brain-free magnesium concentration that is associated with the development of neurologic motor deficits. Although these changes have been well characterized in the brain, changes in free magnesium homeostasis have not been characterized in other fluid compartments. The current experiments use ion selective electrodes to measure alterations in blood-free magnesium concentration following graded experimental brain injury in rats and to compare these changes with subsequent neurologic outcome. After severe impact-acceleration-induced injury, blood-free magnesium levels significantly declined (p<0.05) by 25% and remained depressed for at least 4 days after injury. After moderate injury, the decline in blood-free magnesium was less than that observed in the severe injury group, with respect to both degree of decline and duration of decline. The post-traumatic blood-free magnesium concentration correlated to observed motor deficits as assessed by rotarod evaluation (p<0.001). We conclude that blood-free magnesium levels may be a prognostic indicator of outcome following severe traumatic brain injury.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia		Heath, DL (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			Altura Bella T., 1994, Scandinavian Journal of Clinical and Laboratory Investigation, V54, P53, DOI 10.3109/00365519409095211; CAVALIERE F, 1985, RECENT PROGR MED, V76, P561; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; Elin RJ, 1996, SCAND J CLIN LAB INV, V56, P203, DOI 10.3109/00365519609088641; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1996, NEUROSCI RES COMMUN, V18, P163; HENROTTE JG, 1995, ANN NUTR METAB, V39, P285, DOI 10.1159/000177874; HENROTTE JG, 1985, J AM COLL NUTR, V4, P165, DOI 10.1080/07315724.1985.10720073; Howarth Frank C., 1994, Magnesium Research, V7, P187; JOBORN H, 1985, CLIN ENDOCRINOL, V23, P219, DOI 10.1111/j.1365-2265.1985.tb00217.x; KING LR, 1973, ANN SURG, V177, P126, DOI 10.1097/00000658-197301000-00022; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; Ritter C, 1996, SCAND J CLIN LAB INV, V56, P275, DOI 10.3109/00365519609088647; SEELIG MS, 1994, J AM COLL NUTR, V13, P429; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; Zoppi F, 1996, SCAND J CLIN LAB INV, V56, P259, DOI 10.3109/00365519609088646	23	26	26	0	0	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0036-5513			SCAND J CLIN LAB INV	Scand. J. Clin. Lab. Invest.	APR	1998	58	2					161	166		10.1080/00365519850186751			6	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	ZH381	WOS:000073102800010	9587169				2022-02-06	
J	Anderson, RM; Opeskin, K				Anderson, RM; Opeskin, K			Timing of early changes in brain trauma	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						brain; physical injury; timing of changes	DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD-INJURY; DAMAGE	One hundred and fourteen fatal cases of brain trauma were examined prospectively; in 100 of these cases, death occurred within 48 hours of injury. The methods of injury included motor vehicle accidents (MVA), gunshot wounds, blunt instrument injuries, and falls. All cases showed subarachnoid and parenchymal hemorrhages. Paraffin sections were studied with hematoxylin and eosin (H&E) stain and also with special stains in selected slides. The cases were examined histologically before having exact clinical knowledge of the time of death. Eosinophilic neurons were noted in many cases surviving <1 hour after injury and increased in frequency and severity with time. These were most commonly seen in areas of contusion, the hippocampus, and the arterial boundary zones of the cerebral cortex. Neuronal incrustation was seen from 3 to 48 hours postinjury in areas of contusion. Axonal swelling and spheroids were seen in the white matter in areas of laceration and hemorrhage at 1 hour postinjury in many cases and continuing through all time periods. Glial swelling was seen in the subpial and subependymal regions and around hemorrhages from very early to 48 hours postinjury. Polymorphonuclear leukocytes (granulocytes) were present in the tissues at all time periods with increasing frequency over time. They were also found surrounding corpora amylacea in cases with <1 hour survival. Axonal swelling, eosinophilia of neurons, and incrustation of neurons were noted at earlier time periods than previously reported in the literature. Determining the time of injury based on histologic evidence is difficult. We believe that the data reported here will allow more accurate appreciation of timing of the early interval between brain trauma and death.	Victorian Inst Forens Med, Melbourne, Vic 3006, Australia		Anderson, RM (corresponding author), Victorian Inst Forens Med, 57-83 Kavanagh St, Melbourne, Vic 3006, Australia.						Adams J H, 1988, Curr Top Pathol, V76, P1; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, RECENT ADV NEUROPATH, P165; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brown A W, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P155; Cammermeyer J, 1972, STRUCTURE FUNCTION N, V6, P131; Clark ER, 1936, AM J ANAT, V59, P123, DOI 10.1002/aja.1000590106; COURVILLE CB, 1945, PATHOLOGY CENTRAL NE, P28; CROOKS DA, 1992, MED SCI LAW, V32, P109, DOI 10.1177/106002809203200204; Gallyas Ferenc, 1994, Neurobiology (Budapest), V2, P245; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; KITAMURA O, 1994, INT J LEGAL MED, V107, P69, DOI 10.1007/BF01225492; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LOBERG EM, 1989, MED SCI LAW, V29, P109, DOI 10.1177/002580248902900205; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Nishino Hitoo, 1994, Neurobiology (Budapest), V2, P223; OEHMICHEN M, 1980, Z RECHTSMED, V84, P79, DOI 10.1007/BF02114577; OPESKIN K, 1994, BIOTECH HISTOCHEM, V69, P253, DOI 10.3109/10520299409106297; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1	24	26	27	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0195-7910			AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	MAR	1998	19	1					1	9		10.1097/00000433-199803000-00001			9	Medicine, Legal; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine; Pathology	ZB026	WOS:000072427400001	9539384				2022-02-06	
J	Wenden, FJ; Crawford, S; Wade, DT; King, NS; Moss, NEG				Wenden, FJ; Crawford, S; Wade, DT; King, NS; Moss, NEG			Assault, post-traumatic amnesia and other variables related to outcome following head injury	CLINICAL REHABILITATION			English	Article							EPIDEMIOLOGY; DISABILITY; ADMISSION; MILD	Objective: To estimate how many patients who sustain a head injury might benefit from intervention and support each year and to consider whether relationships can be found between demographic data relating to patients' circumstances at the time of head injury, and their outcomes six months later. Design: Data collected on 625 patients through follow-up interviews and assessments by the Oxford Head Injury Service for a randomized controlled trial of intervention conducted in 1993-94. Setting: A mixed rural and urban Health District with a population of approximately 560 000. Patients: Patients were aged between 16 and 65 years and resident in Oxfordshire. They presented over 13 months to accident and emergency departments, or were admitted to hospital. All were diagnosed as having suffered a head injury. Outcome measures: The Rivermead Head Injury Follow Up Questionnaire and the Rivermead Post Concussion Symptoms Questionnaire. Results: Data are given on age, sex, social circumstances, employment, cause of injury, severity of associated injuries, post-traumatic amnesia (PTA), anticonvulsants, postconcussion symptoms and activities of everyday life. Outcome at six months was significantly worse for those who had been assaulted as against all other causes of injury combined (p = 0.0001); and/or had been admitted to hospital (p = 0.0001); and/or had sustained more severe additional injuries (p = 0.04); and/or had experienced any PTA (p = 0.00001). The minimum incidence of such injuries in those aged 16-65, calculated for Oxfordshire, is 292 per annum (74/100 000 aged 16-65 per year). Conclusions: In the general population 52/100 000 patients per annum will experience more serious head injuries as indicated by hospital admission and/or one or more fractures and/or any length of PTA and/or having been assaulted. This group may benefit from monitoring and support and their needs should be considered when planning services.	Rivermead Rehabil Ctr, Oxford Head Injury Serv, Oxford OX1 4XD, England		Wenden, FJ (corresponding author), Rivermead Rehabil Ctr, Oxford Head Injury Serv, Abingdon Rd, Oxford OX1 4XD, England.			Wade, Derick/0000-0002-1188-8442			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BRIGGS M, 1984, BRIT MED J, V288, P983; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1976, LANCET, V1, P1031; Jennett B, 1990, HDB CLIN NEUROLOGY, V13; JOHNSON R, 1987, INJURY, V18, P7, DOI 10.1016/0020-1383(87)90374-3; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1990, HDB CLIN NEUROLOGY, V13; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Moss NE, 1996, DISABIL REHABIL, V18, P169, DOI 10.3109/09638289609166296; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 1994, OFFICE POP CENS SURV	27	26	26	0	1	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON, ENGLAND NW1 3BH	0269-2155			CLIN REHABIL	Clin. Rehabil.	FEB	1998	12	1					53	63		10.1191/026921598675567949			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	ZC019	WOS:000072531400008	9549026				2022-02-06	
J	Alon, G; Dar, A; Katz-Behiri, D; Weingarden, H; Nathan, S				Alon, G; Dar, A; Katz-Behiri, D; Weingarden, H; Nathan, S			Efficacy of a hybrid upper limb neuromuscular electrical stimulation system in lessening selected impairments and dysfunctions consequent to cerebral damage	JOURNAL OF NEUROLOGIC REHABILITATION			English	Article						chronic; stroke; brain injury; electrical stimulation; motor recovery	STROKE PATIENTS; HEMIPLEGIC PATIENTS; FUNCTIONAL STATUS; CONTROLLED TRIAL; LEARNED NONUSE; REHABILITATION; RECOVERY; UNIT; SPASTICITY; DISABILITY	Objective: The purpose of this study was to test the efficacy of a new computerized neuromuscular electric stimulation system (Handmaster(TM)) in improving selected impairments and functional measures of patients who survived stroke and traumatic brain injury (TBI). Methods: Survivors of stroke (n = 13) and TBI (n = 7) with chronic paralysis lasting 6.8 +/- 7.8 years (range 1 to 29 years) participated in a home program of electrical stimulation. The device is a hybrid of a hand-forearm splint that incorporates five surface electrodes and a computerized electrical stimulator. The patterned stimulation elicits finger flexion and extension, lateral pinch, and grasp of the paralyzed hand. Patients practiced daily for 3.4 +/- 0.5 hours over a mean duration of 13.1 +/- 6.6 weeks. Assessment included goniometric measurements of wrist and elbow resting posture, passive and active joints motion, linear distance of fingers to palm, Ashworth scale, and the ability to hold a 1 kg load in the affected hand. The Frenchay arm test represented hand function. Results: ANOVA tests and Wilcoxon signed rank test were employed. There were significant improvements (p = 0.01) in elbow, wrist, and fingers posture; Ashworth scale; volitional active elbow flexion (32.5 +/- 12.7 degrees); wrist extension (12.7 +/- 11.1 degrees) and flexion (9.03 +/- 4.5 degrees). Passive wrist extension improved 13.1 +/- 3.6 degrees. Thirteen patients (65 percent) had active wrist extension post stimulation compared with only three (15 percent) before study commencement. Partial completion of the Frenchay tasks were observed before stimulation in only three patients compared with partial completion of tasks by nine patients at study conclusion. Post stimulation, 16 of 20 patients were able to hold a I kg weight with the NESS system active, compared with only three patients without it. Conclusions: Application of the NESS system for three to four hours daily improves selected impairments and may help to restore partial hand functions of patients with chronic stroke or head injury.	Univ Maryland, Sch Med, Baltimore, MD 21201 USA; NESS Ltd, IL-43654 Raanana, Israel; Chaim Sheba Med Ctr, Dept Neurol Rehabil, IL-52621 Tel Hashomer, Israel; Ben Gurion Univ Negev, Dept Mech Engn, Beer Sheva, Israel			galon@physio.ab.umd.edu					ALFIERI V, 1982, SCAND J REHABIL MED, V14, P177; BACHYRITA P, 1987, J NEURO REHAB, V1, P67; BAKER LL, 1986, PHYS THER, V66, P1930, DOI 10.1093/ptj/66.12.1930; BAKER LL, 1983, PHYS THER, V63, P1967, DOI 10.1093/ptj/63.12.1967; BAKER LL, 1979, PHYS THER, V59, P1495, DOI 10.1093/ptj/59.12.1495; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BOWMAN BR, 1979, ARCH PHYS MED REHAB, V60, P497; COZAN CD, 1988, ARCH PHYS MED REHAB, V69, P401; DAM M, 1993, STROKE, V24, P1186, DOI 10.1161/01.STR.24.8.1186; DOBKIN B, 1995, NEUROLOGY, V45, pS6; FAGHRI PD, 1994, ARCH PHYS MED REHAB, V75, P73; FIELDS RW, 1987, ARCH PHYS MED REHAB, V68, P407; GOWLAND C, 1992, PHYS THER, V72, P624, DOI 10.1093/ptj/72.9.624; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; Indredavik B, 1997, STROKE, V28, P1861, DOI 10.1161/01.STR.28.10.1861; KALRA L, 1995, STROKE, V26, P990, DOI 10.1161/01.STR.26.6.990; KRAFT GH, 1992, ARCH PHYS MED REHAB, V73, P220; Lincoln NB, 1996, STROKE, V27, P18, DOI 10.1161/01.STR.27.1.18; MCCANN BC, 1976, J AM GERIATR SOC, V24, P211, DOI 10.1111/j.1532-5415.1976.tb06781.x; MERLETTI R, 1978, SCAND J REHABIL MED, V10, P147; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Parker V M, 1986, Int Rehabil Med, V8, P69; REDING MJ, 1988, ARCH NEUROL-CHICAGO, V45, P700; RUSIN MJ, 1990, ARCH PHYS MED REHAB, V71, P914; SCHARFENBERGER JA, 1989, PHYS MED REHABIL STA, V3, P653; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; SMITH ME, 1982, ARCH PHYS MED REHAB, V63, P21; STRAND T, 1985, STROKE, V16, P29, DOI 10.1161/01.STR.16.1.29; SUNDERLAND A, 1992, J NEUROL NEUROSUR PS, V55, P532; TANGEMAN PT, 1990, ARCH PHYS MED REHAB, V71, P876; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; TAUB NA, 1994, STROKE, V25, P352, DOI 10.1161/01.STR.25.2.352; Triolo R, 1996, J REHABIL RES DEV, V33, P111; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6; WOLF SL, 1983, PHYS THER, V63, P1393, DOI 10.1093/ptj/63.9.1393; WOODDAUPHINEE SL, 1990, STROKE, V21, P731, DOI 10.1161/01.STR.21.5.731	38	26	26	0	8	DEMOS MEDICAL PUBLISHING	NEW YORK	386 PARK AVE SOUTH, STE 201, NEW YORK, NY 10016 USA	0888-4390			J NEUROL REHABIL	J. Neurol. Rehabil.		1998	12	2					73	79					7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	123RB	WOS:000076137200005					2022-02-06	
J	Warren, WL; Bailes, JE				Warren, WL; Bailes, JE			On the field evaluation of athletic head injuries	CLINICS IN SPORTS MEDICINE			English	Article								This article reviews the diagnosis and management of athletic-related head injury. Cerebral concussion, diffuse; axonal injury, brain contusion, and the spectrum of intracranial hematoma is discussed. Emphasis is placed on the need to evaluate when it is prevented from further participation.	Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA; Orlando Reg Healthcare Syst, Orlando, FL USA		Warren, WL (corresponding author), Allegheny Gen Hosp, Dept Neurosurg, 320 East North Ave, Pittsburgh, PA 15212 USA.						ALVES WM, 1996, NEUROTRAUMA, P913; *AM COLL SURG, 1993, ADV TRAUM LIF SUPP M; *BRAIN TRAUM FDN, 1995, GUID MAN SEV HEAD IN; BRUNO LA, 1987, CLIN SPORTS MED, V6, P1; BUCKLEY WE, 1988, AM J SPORTS MED, V16, P1; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CLEMETT RS, 1980, NZ MED J, V92, P663; FICK DS, 1995, POSTGRAD MED, V97, P2; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P12; GRAHAM DI, NEUROTRAUMA, P46; JAFFE R, 1986, PRIMARY CARE, V13, P1; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P20; LEHMAN LB, 1988, AFP, V38, P4; LEHMAN LB, 1990, CLIN SPORTS MED, V9, P2; LINDSAY KW, 1980, BRIT MED J, V281, P20; MCLATCHIE G, 1994, BRIT MED J, V308, P1624; MUELLER FO, 1987, CLIN SPORTS MED, V6, P1; PATTERSON D, 1987, CLIN SPORTS MED, V6, P1; PLUM F, 1982, DIAGNOSIS STUPOR COM, P119; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P4; SONZOGNI JJ, 1993, CLIN SPORTS MED, V12, P2; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P24; TYSVAER A, 1989, AM J SPORTS MED, V17, P4; VEGSO JJ, 1987, CLIN SPORT MED, V6, P1; Wekesa M, 1996, BRIT J SPORT MED, V30, P61, DOI 10.1136/bjsm.30.1.61; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; WILBERGER JE, 1993, SPORTS MED, V15, P5	29	26	26	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0278-5919			CLIN SPORT MED	Clin. Sports Med.	JAN	1998	17	1					13	+		10.1016/S0278-5919(05)70057-0			15	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	YU153	WOS:000071687600003	9475967				2022-02-06	
J	Obrenovitch, TP; Urenjak, J; Zilkha, E				Obrenovitch, TP; Urenjak, J; Zilkha, E			Effects of increased extracellular glutamate levels on the local field potential in the brain of anaesthetized rats	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						glutamate; excitotoxicity; glutamate-uptake; microdialysis; L-trans-pyrrolidine-2,4-dicarboxylate; glutamate receptors	D-ASPARTATE RECEPTORS; INTRACEREBRAL MICRODIALYSIS; ANOXIC DEPOLARIZATION; MOUSE CORTEX; IN-VIVO; SODIUM; INHIBITION; ISCHEMIA; RELEASE; ACTIVATION	1 It is generally considered that glutamate-mediated transmission can be altered from a physiological to neurotoxic action when extracellular glutamate levels become excessive subsequent to impaired uptake and/or excessive release. However, high extracellular glutamate does not consistently correlate with neuronal dysfunction and death in vivo. The purpose of this study was to examine in situ the local depolarizations, as indicated by negative shifts of the extracellular field (d.c.) potential, produced by local inhibition of high-affinity glutamate uptake, with or without co-application of exogenous glutamate, in three brain regions of anaesthetized rats. 2 Microdialysis probes incorporating an electrode were used to apply exogenous glutamate and/or its uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylate (L-trans-PDC), and to monitor the resulting changes in extracellular glutamate and d.c. potential at the sites of application within the cortex, striatum and hippocampus. 3 Perfusion of 1 to 10 mM L-trans-PDC markedly and concentration-dependently increased extracellular glutamate levels (by up to 1700% of basal level in the parietal cortex). Despite their large magnitude, glutamate changes were associated with minor negative shifts of the d.c. potential (<2 mV), which were not suppressed by the N-methyl-D-aspartate (NMDA)-channel blocker, dizocilpine (MK-801, 2 mg kg(-1), i.v.), or the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate-receptor antagonist, 6-nitro-7-sulphamoylbenzo(f)quinoxaline-2,3-dione (NBQX, 30 mg kg(-1), i.p.). L-trans-PDC had virtually identical concentration-dependent effects on dialysate glutamate in the hippocampus and striatum, but those induced in the cortex were around 40% larger (P<0.002). In contrast, the associated depolarizations were around twice as large in the striatum and cortex as in the hippocampus (P<0.002). Finally, co-application of L-trans-PDC did not enhance the d.c. potential changes evoked by perfusion of 5 or 20 mM glutamate. 4 As the neurotoxic potency of glutamate agonists is considered to be linked to excessive opening of glutamate-operated ion channels, these results challenge the notion that high extracellular glutamate levels may be the key to excitotoxicity in neurological disorders. In particular, they do not support the hypothesis that high extracellular glutamate causes the sudden negative shifts of the d.c. potential associated with ischaemia (i.e. anoxic depolarization), traumatic brain injury and spreading depression. Impaired uptake and excessive release of glutamate may well lead to excitotoxicity, but only at the synaptic level, not by spreading through the interstitial fluid.	INST NEUROL, GOUGH COOPER DEPT NEUROL SURG, LONDON WC1N 3BG, ENGLAND; PFIZER LTD, CENT RES, DISCOVERY BIOL, SANDWICH CT13 9NJ, KENT, ENGLAND								BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; CARLA V, 1992, NEUROSCI LETT, V146, P21, DOI 10.1016/0304-3940(92)90162-Z; CHIZH BA, 1994, BRIT J PHARMACOL, V112, P843, DOI 10.1111/j.1476-5381.1994.tb13156.x; CHOI DW, 1987, J NEUROSCI, V7, P369; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; Desai M. A., 1995, Society for Neuroscience Abstracts, V21, P1112; ERIKSSON G, 1995, GLIA, V15, P152, DOI 10.1002/glia.440150207; GARTHWAITE G, 1992, EUR J NEUROSCI, V4, P353, DOI 10.1111/j.1460-9568.1992.tb00882.x; GRIFFITHS R, 1994, BIOCHEM PHARMACOL, V47, P267, DOI 10.1016/0006-2952(94)90016-7; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; MARRANNES R, 1989, ACTA PHYSL SCAN S582, V136, P75; MARTIN DC, 1995, BIOCHEM PHARMACOL, V49, P809, DOI 10.1016/0006-2952(94)00519-R; MASSIEU L, 1995, J NEUROCHEM, V64, P2262; McCulloch J, 1993, Acta Neurochir Suppl (Wien), V57, P73; MELDRUM BS, 1994, NEUROLOGY, V44, P14; MILLER S, 1994, EUR J PHARM-MOLEC PH, V269, P235, DOI 10.1016/0922-4106(94)90091-4; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OBRENOVITCH TP, 1994, BRIT J PHARMACOL, V113, P1295, DOI 10.1111/j.1476-5381.1994.tb17139.x; OBRENOVITCH TP, 1995, J NEUROPHYSIOL, V73, P2107, DOI 10.1152/jn.1995.73.5.2107; OBRENOVITCH TP, 1993, J NEUROSCI METH, V47, P139, DOI 10.1016/0165-0270(93)90030-U; Obrenovitch TP, 1996, ACT NEUR S, V66, P50; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; OBRENOVITCH TP, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P23; OBRENOVITCH TP, 1993, J NEUROCHEM, V61, P178, DOI 10.1111/j.1471-4159.1993.tb03553.x; Obrenovitch TP, 1996, J NEUROCHEM, V66, P2446; RAUEN T, 1992, FEBS LETT, V312, P15, DOI 10.1016/0014-5793(92)81401-7; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SARANTIS M, 1993, J PHYSIOL-LONDON, V459, pP246; SMITH AD, 1994, J NEUROSCI METH, V54, P75, DOI 10.1016/0165-0270(94)90161-9; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; THOMPSON SM, 1986, J NEUROPHYSIOL, V56, P507, DOI 10.1152/jn.1986.56.2.507; THOMSEN C, 1994, J NEUROCHEM, V63, P2038; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; Urenjak J, 1997, N-S ARCH PHARMACOL, V355, P36; Urenjak J, 1997, LIFE SCI, V61, P523, DOI 10.1016/S0024-3205(97)00412-8; Urenjak J, 1996, PHARMACOL REV, V48, P21; Urenjak J, 1996, BRIT J PHARMACOL, V117, pP67; URENJAK J, 1995, BRIT J PHARMACOL, V116, pP339; WALDMEIER PC, 1993, N-S ARCH PHARMACOL, V348, P478; XIE YX, 1994, BRAIN RES, V652, P216, DOI 10.1016/0006-8993(94)90230-5; XIE YX, 1995, J CEREBR BLOOD F MET, V15, P587, DOI 10.1038/jcbfm.1995.72; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	48	26	27	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	SEP	1997	122	2					372	378		10.1038/sj.bjp.0701372			7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	XW039	WOS:A1997XW03900026	9313949	Green Published, Bronze			2022-02-06	
J	Brooks, CA; Gabella, B; Hoffman, R; Sosin, D; Whiteneck, G				Brooks, CA; Gabella, B; Hoffman, R; Sosin, D; Whiteneck, G			Traumatic brain injury: Designing and implementing a population-based follow-up system	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEALTH; SCALE	Craig Hospital and the Colorado Department of Public Health and Environment began designing a population-based followup system for persons with traumatic brain injury (TBI) in 1994. With funding from the Centers for Disease Control and Prevention, the Colorado TBI Follow-up System addresses the issue, ''What happens to persons with TBI after they are dis charged from the hospital?'' Two methods of data collection are used, medical record review and annual telephone surveys to gather long-term outcomes. The design calls for following all persons hospitalized with severe TBI (defined as any person with inpatient rehabilitation and/or with an Abbreviated Injury Scale [AIS] score for the head of 3 or greater) and a 20% random sample of persons hospitalized with less severe TBI. An expert panel was used to select variables for retrospective abstracting and prospective interviewing. Information obtained from medical records includes data verifying eligibility, diagnoses, radiological results, circumstances of injury, and severity of injury, as well as demographic data. The interview instrument includes questions and scales related to health status, disability, handicap, quality of life, and service utilization. Both methods of data collection have been pilot-tested and are now used routinely in the Colorado TBI Follow-up System. (C) 1997 by the American Congress of Rehabilitation Medicine.	COLORADO DEPT PUBL HLTH & ENVIRONM,DENVER,CO; CTR DIS CONTROL & PREVENT,ATLANTA,GA		Brooks, CA (corresponding author), CRAIG HOSP RES,3425 S CLARKSON ST,ENGLEWOOD,CO 80110, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU812447] Funding Source: Medline		BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BENYISHAY Y, 1987, J HEAD TRAUMA REHABI, V2, P224; BERKMAN PL, 1971, AM J EPIDEMIOL, V94, P105, DOI 10.1093/oxfordjournals.aje.a121301; BRESLAU N, 1985, PSYCHIAT RES, V15, P219, DOI 10.1016/0165-1781(85)90079-4; *CDC, 1997, MMWR MORB MORTAL WLD, V6, P8; Derogatis L.R., 1975, BRIEF SYMPTOM INVENT; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; GRANGER CV, 1994, AM J PHYS MED REHAB, V73, P51, DOI 10.1097/00002060-199473010-00012; GREENSPAN A, 1996, FIREARM INJURY OUTCO; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; *J HOPK U, 1993, INJ SEV SCOR ICDMAP; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; MCDOWELL I, 1987, MEASURING HLTH GUIDE; *NAT CTR HLTH STAT, 1995, VIT HLTH STAT, V10; *NAT MULT SCLER SO, 1987, MIN REC DIS MULT SCL; POLLARD WE, 1976, MED CARE, V14, P146, DOI 10.1097/00005650-197602000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RADOSEVICH DM, 1995, UPDATE NEWSLETTER HL, V2, P2; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; *SOC TEACH FAM MED, 240890038 HRSA DHHS, P18; Truelle J L, 1990, Brain Inj, V4, P305, DOI 10.3109/02699059009026181; WARE JG, 1992, MED CARE, V30, P470; *WAYN STAT U, 1996, TRAUM BRAIN INJ MOD; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WOOD V, 1969, J GERONTOL, V24, P465, DOI 10.1093/geronj/24.4.465	28	26	27	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1997	78	8		4			S26	S30		10.1016/S0003-9993(97)90152-0			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	XR538	WOS:A1997XR53800005	9270485				2022-02-06	
J	Korda, RJ; Douglas, JM				Korda, RJ; Douglas, JM			Attention deficits in stroke patients with aphasia	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SIMPLE REACTION-TIME; UNILATERAL BRAIN-DAMAGE; CLOSED-HEAD-INJURY; SUSTAINED ATTENTION; RIGHT-HEMISPHERE; MULTIPLE RESOURCES; DIVIDED ATTENTION; PERFORMANCE; VIGILANCE; DISEASE	Attentional capacity and sustained attention were investigated in 21 aphasic stroke patients and 21 non-brain-damaged patients. Attentional capacity was assessed using a series of reaction time (RT) tasks. The aphasic patients demonstrated impaired attentional capacity as shown by slower processing speed than the non-brain-damaged group (p <.01) and greater increases in RT with increased processing load (p <.05). Similar patterns were found for both verbal and spatial material. There was no significant relationship between severity of auditory comprehension deficits and attentional capacity. Sustained attention was assessed using a cognitive vigilance task requiring identification of a target letter presented infrequently over 32 minutes. Both the aphasic and the non-brain-damaged group demonstrated a decline in performance with time on task as shown by a steady increase in RTs (p <.0001), but the decline was equivalent across the groups. Thus, the aphasic group did not show a specific deficit in the ability to sustain attention.	LA TROBE UNIV,FAC HLTH SCI,SCH HUMAN COMMUN SCI,BUNDOORA,VIC 3083,AUSTRALIA; AUSTIN & REPATRIAT MED CTR,DEPT SPEECH PATHOL,HEIDELBERG,VIC,AUSTRALIA				Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624; Korda, Rosemary/0000-0002-9390-2171			BLACKBURN H L, 1955, Confin Neurol, V15, P327; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Bryden M, 1982, LATERALITY FUNCTIONA, P157; BUB D, 1990, CORTEX, V26, P227, DOI 10.1016/S0010-9452(13)80352-8; CAMPBELL TF, 1985, J SPEECH HEAR RES, V28, P513, DOI 10.1044/jshr.2804.513; CAPLAN LR, 1993, STROKE CLIN APPROACH; Carson DH, 1968, CORTEX, V4, P92; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; COSLETT HB, 1987, NEUROLOGY, V37, P957, DOI 10.1212/WNL.37.6.957; DEE HL, 1973, ARCH NEUROL-CHICAGO, V28, P163, DOI 10.1001/archneur.1973.00490210043004; DEE HL, 1971, ACTA PSYCHIAT SCAND, V47, P315, DOI 10.1111/j.1600-0447.1971.tb02217.x; DEE HL, 1972, NEUROLOGY, V22, P845, DOI 10.1212/WNL.22.8.845; DIMOND SJ, 1979, CORTEX, V15, P43, DOI 10.1016/S0010-9452(79)80005-2; DONNAN GA, 1993, CEREBROVASC DIS, V3, P248, DOI 10.1159/000108710; ELSASS P, 1985, ACTA NEUROL SCAND, V71, P11; FRIEDMAN A, 1981, J EXP PSYCHOL HUMAN, V7, P1031, DOI 10.1037/0096-1523.7.5.1031; FRIEDMAN A, 1982, J EXP PSYCHOL HUMAN, V8, P625, DOI 10.1037/0096-1523.8.5.625; GLOSSER G, 1990, J CLIN EXP NEUROPSYC, V12, P485, DOI 10.1080/01688639008400995; Goodglass H, 1983, ASSESSMENT APHASIA R; GOPHER D, 1984, COGNITION MOTOR PROC, P231; GRADY CL, 1989, ARCH NEUROL-CHICAGO, V46, P317, DOI 10.1001/archneur.1989.00520390083021; HAGEMAN CF, 1980, DISS ABSTR INT, V42, P157; HOM J, 1990, J CLIN EXP NEUROPSYC, V12, P644, DOI 10.1080/01688639008401008; HOWES D, 1975, BRAIN, V98, P317, DOI 10.1093/brain/98.2.317; KAIZER F, 1988, STROKE, V19, P335, DOI 10.1161/01.STR.19.3.335; Keppel G., 1991, DESIGN ANAL RES HDB; LAPOINTE LL, 1991, APHASIOLOGY, V5, P511, DOI 10.1080/02687039108248556; LILES BZ, 1975, J COMMUN DISORD, V8, P221, DOI 10.1016/0021-9924(75)90015-5; MCDONALD RD, 1964, J NEUROL NEUROSUR PS, V27, P206, DOI 10.1136/jnnp.27.3.206; NEBES RD, 1993, CORTEX, V29, P77, DOI 10.1016/S0010-9452(13)80213-4; NORMAN DA, 1975, COGNITIVE PSYCHOL, V7, P44, DOI 10.1016/0010-0285(75)90004-3; ODONNELL BF, 1993, NEUROPSYCHOLOGY ATTE, P375; Pachella R., 1974, HUMAN INFORMATION PR, P41; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PEACH RK, 1992, J SPEECH HEAR RES, V35, P810, DOI 10.1044/jshr.3504.810; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RAMSING S, 1991, APHASIOLOGY, V5, P583, DOI 10.1080/02687039108248567; Salthouse TA, 1985, THEORY COGNITIVE AGI, V28th; Spreen O., 1977, NEUROSENSORY CTR COM, VRev; Spreen O, 1991, COMPENDIUM NEUROPSYC; SUNDERLAND A, 1992, NEUROPSYCHOL REHABIL, V2, P137; TARTAGLIONE A, 1991, BRAIN, V114, P1441, DOI 10.1093/brain/114.3.1441; TARTAGLIONE A, 1987, CORTEX, V23, P285, DOI 10.1016/S0010-9452(87)80038-2; TARTAGLIONE A, 1986, NEUROPSYCHOLOGIA, V24, P649, DOI 10.1016/0028-3932(86)90004-7; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; ULRICH R, 1989, BRIT J MATH STAT PSY, V42, P1, DOI 10.1111/j.2044-8317.1989.tb01111.x; VANMOURIK M, 1992, APHASIOLOGY, V6, P491, DOI 10.1080/02687039208249486; WICKENS C. D., 1984, VARIETIES ATTENTION, P63; WICKENS CD, 1981, HUM FACTORS, V23, P211, DOI 10.1177/001872088102300209; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; [No title captured]	51	26	29	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1997	19	4					525	542		10.1080/01688639708403742			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	YA413	WOS:A1997YA41300006	9342688				2022-02-06	
J	Smith, GA; Bowman, MJ; Luria, JW; Shields, BJ				Smith, GA; Bowman, MJ; Luria, JW; Shields, BJ			Babywalker-related injuries continue despite warning labels and public education	PEDIATRICS			English	Article						babywalker; pediatric trauma; falls; injury prevention	WALKER-RELATED INJURIES; INFANT WALKER; BABY WALKERS; CHILDREN; HAZARD	Objective. To describe the epidemiology of babywalker-related injuries to children treated in a pediatric emergency department despite current prevention efforts, and to investigate the beliefs of parents regarding babywalker use. Design. A descriptive study of a consecutive series of patients. Setting. The emergency department of a large, academic children's hospital. Participants. Children treated for babywalker-related injuries during the 3-year period of March 1993 through February 1996. Results. There were 271 children treated for babywalker-related injuries. The mean age was 9.2 months, and 62% of patients were boys. Ninety-six percent of children were injured when they fell down stairs in their babywalker. The number of stairs that a child fell down was significantly associated with skull fracture and admission to the hospital, and a fall down more than 10 stairs had a relative risk (RR) of skull fracture = 3.28 (95% confidence interval, 1.35 < RR < 7.98). There were 159 children with conlusions/abrasions (58.6%), 35 concussions/head injuries (12.9%), 33 lacerations (12.2%), 26 skull fractures (9.6%), 9 epistaxis (3.3%), 4 nonskull fractures (1.5%), 4 avulsed teeth (1.5%), and 1 burn (0.4%). Three of the skull fractures were depressed, and three also had accompanying intracranial hemorrhage. Ten patients (3.7%) were admitted to the hospital, and all had skull fractures resulting from falls down stairs. Supervision was present in 78% of cases, including supervision by an adult in 69% of cases. Forty-five percent of families kept the walker, and 32% used the walker again for the study patient or another child after the injury episode. Fifty-nine percent of parents acknowledged that they were aware of the potential dangers of babywalkers before the injury event. Fifty-six percent of parents favored a national ban on the sale of walkers, and 20% were opposed. Conclusion. Despite the currently used prevention strategies, including adult supervision, warning labels, care giver education programs, and stairway gates, serious injuries associated with babywalkers continue to occur to young children. The US Consumer Product Safety Commission should promulgate a rule, similar to the voluntary standard adopted in Canada, regarding design requirements for babywalkers that will prevent their passage through household doorways at the head of stairs. The manufacture and sale of mobile babywalkers that do not meet this new standard should be banned in the US. A recall or trade-in campaign should be conducted nationally to decrease the number of existing babywalkers.			Smith, GA (corresponding author), OHIO STATE UNIV, CHILDRENS HOSP,COLL MED,DEPT PEDIAT, DIV EMERGENCY MED, 700 CHILDRENS DR, COLUMBUS, OH 43205 USA.						*AM MED ASS BOARD, 1991, AM J DIS CHILD, V145, P933; Baker S P, 1981, J Public Health Policy, V2, P235, DOI 10.2307/3342369; BIRCHALL MA, 1988, BRIT MED J, V296, P1641, DOI 10.1136/bmj.296.6637.1641; BIRCHALL MA, 1988, BURNS, V14, P244, DOI 10.1016/0305-4179(88)90049-6; BOYLE WE, 1995, PEDIATRICS, V95, P778; CHIAVIELLO CT, 1994, PEDIATRICS, V93, P974; COATS TJ, 1991, ARCH EMERG MED, V8, P52; COURY DL, 1992, AM J DIS CHILD, V146, P507; CROUCHMAN M, 1986, DEV MED CHILD NEUROL, V28, P757; DEAN AG, 1990, EPILNFO; DIMARIO FJ, 1990, CLIN PEDIATR, V29, P405, DOI 10.1177/000992289002900709; FAZEN LE, 1982, PEDIATRICS, V70, P106; GLEADHILL DNS, 1987, ARCH DIS CHILD, V62, P491, DOI 10.1136/adc.62.5.491; HOLM VA, 1983, AM J DIS CHILD, V137, P1189, DOI 10.1001/archpedi.1983.02140380049016; INWOOD S, 1989, CAN NURSE, V4, P14; JAMES W, 1988, CAN MED ASSOC J, V139, P73; JOFFE M, 1988, PEDIATRICS, V82, P457; JOHNSON C F, 1990, Pediatric Emergency Care, V6, P58, DOI 10.1097/00006565-199003000-00017; KAUFFMAN IB, 1977, PERCEPT MOTOR SKILL, V45, P1323, DOI 10.2466/pms.1977.45.3f.1323; KAVANAGH CA, 1982, AM J DIS CHILD, V136, P205, DOI 10.1001/archpedi.1982.03970390019005; KOSER M, 1995, ARCH PEDIAT ADOL MED, V149, P1275, DOI 10.1001/archpedi.1995.02170240093016; LANGRUNTZ H, 1983, CAN MED ASSOC J, V129, P482; Marcella S, 1990, Conn Med, V54, P127; MAYR J, 1994, EUR J PEDIATR, V153, P531, DOI 10.1007/s004310050186; MEYER M, 1988, BURNS, V14, P145, DOI 10.1016/0305-4179(88)90222-7; MILLAR R, 1975, INJURY, V7, P8, DOI 10.1016/0020-1383(75)90051-0; Morrison CD, 1996, PEDIATR EMERG CARE, V12, P180, DOI 10.1097/00006565-199606000-00008; PARTINGTON MD, 1991, ANN EMERG MED, V20, P652, DOI 10.1016/S0196-0644(05)82386-8; RIEDER MJ, 1986, PEDIATRICS, V78, P488; Sendut I H, 1995, Med J Malaysia, V50, P192; SHEEHAN KM, 1995, PEDIATR EMERG CARE, V11, P27, DOI 10.1097/00006565-199502000-00008; STOFFMAN JM, 1984, CAN MED ASSOC J, V131, P573; TRINKOFF A, 1993, PUBLIC HEALTH REP, V108, P784; WELLMAN S, 1984, CLIN PEDIATR, V23, P98, DOI 10.1177/000992288402300206; 1994, FED REGISTER, V59, P39306	35	26	28	0	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	1997	100	2							e1	10.1542/peds.100.2.e1			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	XP050	WOS:A1997XP05000016	9233972				2022-02-06	
J	Evers, P; Johnston, GR; Wallace, LJ; Lipowitz, AJ; King, VL				Evers, P; Johnston, GR; Wallace, LJ; Lipowitz, AJ; King, VL			Long-term results of treatment of traumatic coxofemoral joint dislocation in dogs: 64 cases (1973-1992)	JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article							PELVIC OSTEOTOMY; HIP DISLOCATION; FEMORAL-HEAD; LUXATION; REPAIR; EXCISION; NECK; CAT	Objective-To determine long-term results of various treatments for traumatic coxofemoral joint dislocation in dogs. Design-Retrospective case series. Animals-64 dogs that underwent closed reduction and bandage stabilization, extracapsular suture stabilization, transacetabular pinning, toggle pinning, DeVita pinning, or femoral head and neck excision. Procedure-Follow-up evaluations included owner evaluation (64 dogs), physical evaluation (23), and radiography (19). Follow-up time ranged from 8 to 156 months. Results-Owner evaluation scores after closed reduction were significantly better than scores after DeVita pinning, extracapsular suture stabilization, and femoral head and neck excision. On physical examination, 6 of 23 dogs were lame on the side of the previous dislocation. Signs of pain and crepitation were evident during palpation of 12 and 8 of 25 joints, respectively. Thirteen of 21 joints had radiographic evidence of degenerative joint disease. There was a greater progression of degenerative joint disease in previously dislocated joints than in unaffected joints. There were not any significant differences between treatments in regard to results of physical and radiographic evaluation. Time between trauma and treatment and existence of concomitant injuries did not influence follow-up results, but there was a significant association between body weight and radiographic evaluation score. Clinical Implications-Concomitant injuries do not appear to justify a worse prognosis in dogs with traumatic coxofemoral joint dislocation, nor does a delay in treatment of > 3 days. Gait abnormalities and degenerative joint disease might develop in the long term. Proper body weight should be maintained regardless of treatment.	UNIV MINNESOTA,VET TEACHING HOSP,DEPT SMALL ANIM CLIN SCI,ST PAUL,MN 55108; UNIV MINNESOTA,VET TEACHING HOSP,DEPT CLIN & POPULAT SCI,ST PAUL,MN 55108								ALLEN SW, 1986, COMP CONT EDUC PRACT, V8, P457; BASHER AWP, 1986, VET SURG, V15, P356, DOI 10.1111/j.1532-950X.1986.tb00243.x; BEALE BS, 1991, VET COMP ORTHOPAED T, V38, P28; BENNETT D, 1980, J SMALL ANIM PRACT, V21, P373, DOI 10.1111/j.1748-5827.1980.tb01264.x; BONE DL, 1984, VET SURG, V13, P263, DOI 10.1111/j.1532-950X.1984.tb00807.x; Braden T. D., 1988, Veterinary and Comparative Orthopaedics and Traumatology, V1, P26; BRINKER WO, 1990, HDB SMALL ANIMAL ORT, P285; BRINKER WO, 1990, HDB SMALL ANIMAL ORT, P345; BRINKER WO, 1990, HDB SMALL ANIMAL ORT, P76; BURNS J, 1987, VET MED-US, V82, P694; CORLEY EA, 1985, J AM VET MED ASSOC, V187, P805; Dallman M. J., 1984, Journal of Veterinary Orthopedics, V3, P7; DAVIS MA, 1989, AM J EPIDEMIOL, V130, P278, DOI 10.1093/oxfordjournals.aje.a115334; De Vita J, 1952, P AM VET MED ASS 89, P191; DeAngelis M., 1973, Journal of the American Animal Hospital Association, V9, P175; DUFF SRI, 1982, VET REC, V111, P140, DOI 10.1136/vr.111.7.140; EHMER EE, 1934, N AM VET         DEC, P31; ELKINS AD, 1991, J AM ANIM HOSP ASSOC, V27, P53; ELKINS AD, 1981, CALIF VET, V10, P19; FLYNN MF, 1994, VET SURG, V23, P311, DOI 10.1111/j.1532-950X.1994.tb00490.x; FRY PD, 1974, J SMALL ANIM PRACT, V15, P661, DOI 10.1111/j.1748-5827.1974.tb05648.x; GARRETT JC, 1979, J BONE JOINT SURG AM, V61, P2, DOI 10.2106/00004623-197961010-00002; GUTHRIE S, 1989, J SMALL ANIM PRACT, V30, P639, DOI 10.1111/j.1748-5827.1989.tb01497.x; HAMMER DL, 1980, J AM VET MED ASSOC, V177, P1018; HEFFRON LE, 1979, J SMALL ANIM PRACT, V20, P603, DOI 10.1111/j.1748-5827.1979.tb06669.x; Herron M. R., 1979, Journal of Veterinary Orthopedics, V1, P30; HUNT CA, 1985, J AM VET MED ASSOC, V187, P828; JOHNSON JA, 1994, VET COMP ORTHOPAED, V7, P56; JOHNSON ME, 1987, VET SURG, V16, P346, DOI 10.1111/j.1532-950X.1987.tb00965.x; KATCHERIAN G, 1990, CANINE PRACT, V15, P7; KNOWLES AT, 1953, J AM VET MED ASSOC, V123, P508; Lawson DD, 1964, J SMALL ANIM PRACT, V6, P57; LEEDS EB, 1979, J VET ORTHOP, V1, P37; LEIGHTON RL, 1985, VET MED-US, V80, P53; LIPOWITZ AJ, 1993, SMALL ANIMAL ORTHOPE, P198; LIPPINCOTT CL, 1987, VET CLIN N AM-SMALL, V17, P857, DOI 10.1016/S0195-5616(87)50081-X; Manley PA, 1993, TXB SMALL ANIMAL SUR, P1786; MANN FA, 1987, VET SURG, V16, P223, DOI 10.1111/j.1532-950X.1987.tb00943.x; MCLAUGHLIN RM, 1991, VET SURG, V20, P291, DOI 10.1111/j.1532-950X.1991.tb01270.x; OTTENSCHOT TRF, 1986, TIJDSCHR DIERGENEESK, V111, P1229; PETTIT GD, 1956, CALIF VET        MAR, P14; ROY RG, 1992, VET SURG, V21, P475, DOI 10.1111/j.1532-950X.1992.tb00084.x; Schwarz E J, 1972, Mod Vet Pract, V53, P52; SHUTTLEWORTH A C, 1950, Vet Rec, V62, P365; STADER O, 1955, N AM VET         DEC, P1026; STEAD AC, 1970, J SMALL ANIM PRACT, V11, P591, DOI 10.1111/j.1748-5827.1970.tb05620.x; TIRGARI M, 1978, J AM ANIM HOSP ASSOC, V14, P757	47	26	26	0	9	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360	0003-1488			J AM VET MED ASSOC	J. Am. Vet. Med. Assoc.	JAN 1	1997	210	1					59	&					7	Veterinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Veterinary Sciences	VZ462	WOS:A1997VZ46200021	8977650				2022-02-06	
J	ChathamShowalter, PE				ChathamShowalter, PE			Carbamazepine for combativeness in acute traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							BEHAVIOR	Psychiatrists increasingly consult on the treatment of acute traumatic brain injury (TBI) when combativeness compromises safe critical care. The author discusses use of carbamazepine for 7 combative patients with multiple trauma including TBI. This cohort had a clinical decrease in combativeness within 4 days after carbamazepine, compared with this Level I trauma center's experience of prolonged combative periods without its use.			ChathamShowalter, PE (corresponding author), LEHIGH VALLEY HOSP CTR,DEPT PSYCHIAT,CONSULTAT LIAISON DIV,ALLENTOWN,PA 18103, USA.						GUALTIERI CT, 1991, J CLIN PSYCHOPHARM, V11, P280, DOI 10.1097/00004714-199108000-00027; MATLES JA, 1990, J NEUROPSYCHIATRY CL, V2, P159; Mellow A M, 1993, J Geriatr Psychiatry Neurol, V6, P205; SCHIFF HB, 1982, AM J PSYCHIAT, V139, P1346; SMALL JG, 1991, ARCH GEN PSYCHIAT, V48, P915; STUPPAECK CH, 1992, ALCOHOL ALCOHOLISM, V27, P153; YUDOFSKY S, 1981, AM J PSYCHIAT, V138, P218; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Yudofsky SC, 1987, TXB NEUROPSYCHIATRY, P179; 1981, RANCHO LOS AMIGOS CO	10	26	26	0	0	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1996	8	1					96	99					4	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	TR911	WOS:A1996TR91100016	8845710				2022-02-06	
J	Englander, JS; Cifu, DX; Wright, J; Zafonte, R; Mann, N; Yablon, S; Ivanhoe, C				Englander, JS; Cifu, DX; Wright, J; Zafonte, R; Mann, N; Yablon, S; Ivanhoe, C			The impact of acute complications, fractures, and motor deficits on functional outcome and length of stay after traumatic brain injury: A multicenter analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						fractures; functional outcomes; length of stay; medical complications; motor weakness	HEAD-INJURY; REHABILITATION; SEVERITY	Objective: To determine the influence of acute respiratory complications, gastrointestinal procedures, fractures, and motor deficits on length of stay (LOS) and functional outcome following traumatic brain injury (TBI). Design: Prospective multicenter analysis of consecutive admissions to designated TBI Model Systems of Care. Setting: Four National institute for Disability and Rehabilitation Research (NIDRR) TBI Model Systems centers for coordinated acute and rehabilitation care. Participants: 637 adults with TBI were enrolled in the study from February 1989 through June 1995. One-year follow cv-up data were available on 270 subjects. Main Outcome Measures: Acute and rehabilitation LOS, Disability Rating Scale (DRS) score, and Functional Independence Measure (FIM)) score. Results: Gastrostomies or jejunostomies were placed in 44% of individuals and were associated with swallowing and feeding problems at rehabilitation admission and discharge. Respiratory complications occurred in 39% of individuals and were associated with increased acute and rehabilitation LOS (P <.0005). Pelvic and lower extremity fractures occurred in 21% of individuals, and upper extremity fractures occurred in 11%; both were associated with increased acute and rehabilitation LOS. Only lower extremity fractures were associated with the need for physical assistance with functional activities at rehabilitation admission and discharge. Less-than-antigravity strength and moderate to severe incoordination were associated with the need for physical assistance with mobility and self-care at admission, at discharge, and at 1-year follow-up. AU of these associations diminished over time. Conclusions: Medical complications associated with TBI and resultant motor impairment negatively affect functioning at time of rehabilitation admission and discharge. These effects diminish by 1 year post injury.	STANFORD UNIV,SCH MED,STANFORD,CA; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,RICHMOND,VA; WAYNE STATE UNIV,DETROIT,MI; BAYLOR COLL MED,HOUSTON,TX 77030		Englander, JS (corresponding author), SANTA CLARA VALLEY MED CTR,DEPT PHYS MED & REHABIL,751 S BASCOM AVE,SAN JOSE,CA 95128, USA.			Cifu, David/0000-0003-1600-9387			BENNETT BR, 1989, J TRAUMA, V29, P556, DOI 10.1097/00005373-198905000-00003; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; EIDE PK, 1992, ACTA NEUROL SCAND, V86, P194, DOI 10.1111/j.1600-0404.1992.tb05065.x; GOBIET W, 1995, ZBL CHIR, V120, P544; GROSSWASSER Z, 1990, BRAIN INJURY, V4, P247; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; Hamilton BB, 1987, REHABILITATION OUTCO; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; MYSIW W J, 1990, Brain Injury, V4, P247, DOI 10.3109/02699059009026174; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; SPLAINGARD ML, 1989, ARCH PHYS MED REHAB, V70, P318; *TRAUM BRAIN INJ M, 1994, TRAUM BRAIN INJ MOD; WONG PP, 1994, BRAIN INJURY, V8, P509, DOI 10.3109/02699059409151003	16	26	26	0	2	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1996	11	5					15	26		10.1097/00001199-199610000-00003			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	VP053	WOS:A1996VP05300003					2022-02-06	
J	Moonis, M; Swearer, JM; Blumstein, SE; Kurowski, K; Licho, R; Kramer, P; Mitchell, A; Osgood, DL; Drachman, DA				Moonis, M; Swearer, JM; Blumstein, SE; Kurowski, K; Licho, R; Kramer, P; Mitchell, A; Osgood, DL; Drachman, DA			Foreign accent syndrome following a closed head injury: Perfusion deficit on single photon emission tomography with normal magnetic resonance imaging	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						foreign accent syndrome; caudate nucleus; frontal gyrus	APHASIA	Foreign accent syndrome is a rare speech disorder characterized by the emergence of an apparent foreign accent after an anterior left-hemispheric lesion. We report a case where the patient experienced foreign accent syndrome without other significant neurological deficits, consequent to a minor head injury. Results of single photon emission tomography (SPECT) studies suggest abnormal function of the left dorsolateral inferior frontal gyrus (sparing Broca's area) and the caudate nucleus as the underlying functional/anatomic basis of the syndrome, and acoustic analysis showed prosodic and vowel anomalies that contributed to the listener's perception of a ''foreign accent.''	UNIV MASSACHUSETTS,SCH MED,DEPT NUCL MED,WORCESTER,MA 01655; BROWN UNIV,DEPT COGNIT & LINGUIST SCI,PROVIDENCE,RI 02912		Moonis, M (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT NEUROL,SCH MED,55 LAKE AVE N,WORCESTER,MA 01655, USA.						ARDILA A, 1988, APHASIOLOGY, V2, P493, DOI 10.1080/02687038808248955; Aronson A. E, 1990, CLIN VOICE DISORDERS; BEHRENS SJ, 1987, PHOENTIC APPROACHES, P81; BLUMSTEIN SE, 1987, BRAIN LANG, V31, P215, DOI 10.1016/0093-934X(87)90071-X; COMALLI PE, 1962, J GENET PSYCHOL, V100, P47, DOI 10.1080/00221325.1962.10533572; Damasio A., 1979, CLIN NEUROPSYCHOLOGY, P360; DELIS D, 1987, CALIFORNIA VERBAL LE; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; GRAFFRADFORD NR, 1986, BRAIN LANG, V28, P86, DOI 10.1016/0093-934X(86)90093-3; GURD JM, 1988, NEUROPSYCHOLOGIA, V26, P237, DOI 10.1016/0028-3932(88)90077-2; INGRAM JCL, 1992, J PHONETICS, V20, P457, DOI 10.1016/S0095-4470(19)30650-3; LIEBERMAN P, 1967, INTONATION PERCEPTIO; MONRADKROHN GH, 1947, BRAIN, V70, P405, DOI 10.1093/brain/70.4.405; Osterrieth P., 1944, ARCH PSYCHOLOGIE, V30, P206; PETERSON GE, 1952, J ACOUST SOC AM, V24, P175, DOI 10.1121/1.1906875; Ross E, 1985, PRINCIPLES BEHAV NEU, P239; SCHIFF HB, 1983, ARCH NEUROL-CHICAGO, V40, P720, DOI 10.1001/archneur.1983.04050110038005; SWEETING PM, 1982, J SPEECH HEAR RES, V25, P129, DOI 10.1044/jshr.2501.129; TAKAYAMA Y, 1993, NEUROLOGY, V43, P1361, DOI 10.1212/WNL.43.7.1361; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1974, WECHSLER MEMORY SCAL; WHITTY CWM, 1964, J NEUROL NEUROSUR PS, V27, P507, DOI 10.1136/jnnp.27.6.507	22	26	26	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	OCT	1996	9	4					272	279					8	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	VG776	WOS:A1996VG77600009					2022-02-06	
J	Gurney, JG; PrestonMartin, S; McDaniel, AM; Mueller, BA; Holly, EA				Gurney, JG; PrestonMartin, S; McDaniel, AM; Mueller, BA; Holly, EA			Head injury as a risk factor for brain tumors in children: Results from a multicenter case-control study	EPIDEMIOLOGY			English	Article						brain neoplasms; cancer; children; etiology; head injury; neurology; traumatic brain injury	EXPLORATORY CASE-CONTROL; MALIGNANT GLIOMA; TRAUMA; CANCER; GLIOBLASTOMA	We evaluated the risk of brain tumor occurrence in relation to previous head injury in a population-based case control study of 540 children with a primary brain tumor and 801 control children. The risk of a brain tumor among children with a previous head injury that resulted in medical attention was slightly elevated when compared with children with no re ported head injury [odds ratio (OR)=1.4; 95% confidence limits (CL)=1.0, 1.9]. This effect was stronger when;we restricted the head-injured group to the few children with loss of consciousness (OR=1.6; 95% CL=0.6, 3.9) or an overnight admission to a hospital (OR=1.7; 95% CL 0.7, 4.6), relative to those with no head injury. We observed no appreciable association between brain tumor occurrence and birth injury involving the head or a forceps delivery. Among the few children with either a birth injury or forceps delivery and a subsequent head injury, we observed approximately twofold elevations in risk. The OR was 2.6 (95% CL=1.1, 6.9) for those with a birth injury and subsequent head injury, relative to those with neither a birth injury nor head injury. Our results provide only weak evidence in support of head injury as an etiologic agent for brain tumor occurrence in children, although most of our exposed group had only mild head injury.	WAYNE STATE UNIV,SCH MED,KARMANOS CANC INST,DETROIT,MI						DIVISION OF CANCER PREVENTION AND CONTROLUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA017054, R01CA047082] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [N01-CN-05230, CA17054, CA47082] Funding Source: Medline		ANNEGERS JF, 1979, NEUROSURGERY, V4, P203, DOI 10.1227/00006123-197903000-00001; Breslow N.E., 1980, IARC SCI PUB, V1; BUNIN GR, 1994, CANCER EPIDEM BIOMAR, V3, P197; BURCH JD, 1987, J NATL CANCER I, V78, P601; CARPENTER AV, 1987, AM J PUBLIC HEALTH, V77, P1180, DOI 10.2105/AJPH.77.9.1180; CUSHING H, 1938, MENINGIOMAS THEIR CL; Gruss P, 1993, Zentralbl Neurochir, V54, P186; HARTGE P, 1984, AM J EPIDEMIOL, V120, P825, DOI 10.1093/oxfordjournals.aje.a113955; HOCHBERG F, 1984, NEUROLOGY, V34, P1511, DOI 10.1212/WNL.34.11.1511; HOWE GR, 1989, CANCER RES, V49, P4349; KUIJTEN RR, 1989, CANCER RES, V49, P4349; Linn Shai, 1995, Annals of Epidemiology, V5, P440, DOI 10.1016/1047-2797(95)00059-3; MCCREDIE M, 1994, INT J CANCER, V56, P11; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PEREZDIAZ C, 1985, SURG NEUROL, V24, P581, DOI 10.1016/0090-3019(85)90278-2; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; PRESTONMARTIN S, 1982, CANCER RES, V42, P5240; PRESTONMARTIN S, 1983, J NATL CANCER I, V70, P863; RYAN P, 1992, INT J CANCER, V51, P20, DOI 10.1002/ijc.2910510105; SCHIFFER J, 1985, NEUROSURGERY, V14, P84; SCHLEHOFER B, 1992, CANCER, V69, P2541, DOI 10.1002/1097-0142(19920515)69:10<2541::AID-CNCR2820691025>3.0.CO;2-H; SCHMITT HP, 1983, FORTSCHR NEUROL PSYC, V51, P227, DOI 10.1055/s-2007-1002228; SMITH CML, 1984, NEUROPATH APPL NEURO, V10, P235, DOI 10.1111/j.1365-2990.1984.tb00354.x; TROOST D, 1984, CLIN NEUROPATHOL, V3, P139; WITZMANN A, 1981, NEUROCHIRURGIA, V24, P202	25	26	27	1	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1044-3983			EPIDEMIOLOGY	Epidemiology	SEP	1996	7	5					485	489		10.1097/00001648-199609000-00006			5	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	VC739	WOS:A1996VC73900006	8862978				2022-02-06	
J	Britt, LD; Zolfaghari, D; Kennedy, E; Pagel, KJ; Minghini, A				Britt, LD; Zolfaghari, D; Kennedy, E; Pagel, KJ; Minghini, A			Incidence and prophylaxis of deep vein thrombosis in a high risk trauma population	AMERICAN JOURNAL OF SURGERY			English	Article								BACKGROUND: Pelvic fractures, lower extremity injuries, acute head or spinal injury, and extended bedrest place trauma patients at an increased risk for deep vein thrombosis (DVT) and pulmonary embolism (PE). We reviewed patients with traumatic brain injuries (TBI), spinal cord injuries (SCI), and lower extremity fractures (LEF) to examine our DVT and PE incidence and evaluate the success of our DVT and PE prophylaxis. METHODS: From January 1, 1994 to March 1, 1995, the records of trauma patients with TBI, SCI, and LEF who were admitted to the trauma service and transferred to an inpatient rehabilitation facility were reviewed. RESULTS: Twenty-two patients had a TBI, 16 patients with SCI, and 12 patients with LEF. Forty-nine of the 50 patients received DVT prophylaxis, with 7 inferior vena cava (IVC) filters placed. The DVT incidence was 6% and the PE incidence was 2%. CONCLUSION: The 6% incidence of DVT was lower than expected due to diligent DVT prophylaxis and appropriate screening of symptomatic patients for clinically significant DVT. The 2% incidence of PE was also lower than expected, most likely due to our lower DVT incidence and the use of IVC filters. The lower DVT and PE incidence verifies our success at DVT and PE prophylaxis.	EASTERN VIRGINIA MED SCH,DEPT PHYS MED & REHABIL,NORFOLK,VA 23507		Britt, LD (corresponding author), EASTERN VIRGINIA MED SCH,DEPT SURG,825 FAIRFAX AVE,SUITE 610,NORFOLK,VA 23507, USA.						COON WW, 1977, ANN SURG, V186, P149, DOI 10.1097/00000658-197708000-00006; KUDSK KA, 1989, AM J SURG, V158, P515, DOI 10.1016/0002-9610(89)90182-7; Moser, 1988, J INTENSIVE CARE MED, V3, P87, DOI DOI 10.1177/088506668800300205; OMALLEY KF, 1990, J TRAUMA, V30, P6; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; 1986, JAMA-J AM MED ASSOC, P256	7	26	28	0	0	CAHNERS PUBL CO	NEW YORK	249 WEST 17 STREET, NEW YORK, NY 10011	0002-9610			AM J SURG	Am. J. Surg.	JUL	1996	172	1					13	14		10.1016/S0002-9610(96)00079-7			2	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	UY817	WOS:A1996UY81700004	8686794				2022-02-06	
J	Ford, MR; Khalil, M				Ford, MR; Khalil, M			Evoked potential findings in mild traumatic brain injury .1. Middle latency component augmentation and cognitive component attenuation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED HEAD-INJURY; P300; DYSFUNCTION; CONCUSSION; RESPONSES; SYMPTOMS; RECOVERY; SEQUELAE	Objective: To compare evoked potential (EP) and electroencephalogram (EEG) recordings from patients with suspected mild traumatic brain injury (TBI) versus normal controls using computerized EP and EEG analysis procedures. Design: Matched two-group comparison design, with a second matched replication group, and a second group of normals. Setting: Private, ambulatory, non-emergency facility specializing in assessment, pain management, and rehabilitation of spine and related injuries. Patients and Other Participants: Patients were 54 consecutive referrals for computerized EP/EEG evaluation with histories of primarily motor vehicle accidents and symptoms consistent with mild TBI. Normal controls were 27 screened volunteers. Patients were arbitrarily divided into two groups and matched to the controls on the basis of age and gender. Main Outcome Measures: Outcome measures not included in this phase of investigation. Auditory and visual EPs were obtained in resting and P300 task sessions (in which subjects counted the number of randomly occurring target stimuli). The paucity of existing Literature did not permit prediction of all critical EP or EEG variables. Results: Middle latency EP components tie, after brain stem responses yet before long latency, cognitive components) showed amplitude increases (auditory P1, P2, and N2, and visual P2, 50-220 milliseconds poststimulus). Long latency cognitive components (auditory and visual P300 and N3, 290-700 milliseconds) showed amplitude decreases. Similar findings were present in the replication group of patients and in comparison to a second group of normal controls. Conclusions: Significant and reliable EP differences were present in patients whose histories and symptoms were consistent with mild TBI.	AUSTIN NEUROL INST PA,FUNCT NEUROIMAGING LAB,AUSTIN,TX								Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1; EVANS RW, 1992, PHYSICAL MED REHABIL; EVANS RW, 1992, NEUROLOGIC CLIN NEUR; Ford Martin R., 1993, Brain Topography, V6, P43, DOI 10.1007/BF01234126; FORD MR, 1990, J CLIN EXP NEUROPSYC, V12, P52; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GREENBERG RP, 1982, J NEUROSURG, V56, P1, DOI 10.3171/jns.1982.56.1.0001; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P154, DOI 10.1177/155005948101200402; RAPPAPORT M, 1991, CLIN ELECTROENCEPHAL, V22, P199, DOI 10.1177/155005949102200407; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P167, DOI 10.1177/155005948101200403; RAPPAPORT M, 1994, J HEAD TRAUMA REHAB, V9, P94; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; WARD AA, 1966, HEAD INJURY C U CHIC; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; YOUNG WB, 1994, SEMIN NEUROL, V14, P46, DOI 10.1055/s-2008-1041058; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13, DOI 10.1097/00001199-199309000-00004	35	26	26	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1996	11	3					1	15		10.1097/00001199-199606000-00004			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UP774	WOS:A1996UP77400004					2022-02-06	
J	vanBalen, HGG; Mulder, T; Keyser, A				vanBalen, HGG; Mulder, T; Keyser, A			Towards a disability-oriented epidemiology of traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						epidemiology; functional recovery; traumatic brain injury	SICKNESS IMPACT PROFILE; HEALTH-STATUS MEASURE; HEAD-INJURY; FAMILY	The aim of this study was to investigate the value of using a disability-oriented approach to the epidemiology of traumatic brain injury (TBI) in order to improve health administration by preventing long-term sequelae. The epidemiology of disease was established by a registration system of inpatients which covers more than 99% of all hospital admissions in The Netherlands. Some international differences and national trends are discussed. The disability-related epidemiology was investigated by means of structured interviews, 3-7 years after the injury, in a clustered sample of 51 patients with major TBI according to the ICD-9-CM. The survey included evaluation scales such as the Sickness Impact Profile, the Barthel Index, and a Disability Rating Questionnaire. Concerning the disease-related epidemiological data, the overwhelming majority of all TBI patients went home, which suggests good recovery. Nevertheless, the disability-oriented research revealed long-term situational, cognitive and behavioural disabilities in at least 67% of the major-TBI population, whereas only 10% received any rehabilitation services at all after the acute-care period. It is concluded that preventive measures and a comprehensive service for brain injury survivors should be based both on disease and disability-oriented data.			vanBalen, HGG (corresponding author), ST MAARTENS CLIN,DEPT RES & DEV,POB 9011,6500 GM NIJMEGEN,NETHERLANDS.						Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1976, INT J HEALTH SERV, V6, P393, DOI 10.2190/RHE0-GGH4-410W-LA17; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; CAVENESS WF, 1979, ADV NEUROL, V20, P1; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; *CTR BUR STAT, 1994, STAT JB 1994 GRAV; FIELD JH, 1975, EPIDEMIOLOGY HEAD IN; HORTON AM, 1984, CURRENT TOPICS REHAB, P77; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1989, HEAD INJURY, P1; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MAHONEY F I, 1965, Md State Med J, V14, P61; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCLELLAND RJ, 1988, BRIT J PSYCHIAT, V153, P141; MINDERHOUD JM, 1984, TRAUMATISCH HERSENLE; Morris JN, 1964, USES OF EPIDEMIOLOGY; ODDY M, 1989, CLIN REHABIL, V3, P253; Pentland B, 1990, Int Disabil Stud, V12, P86; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; RELLER J, 1984, PICKING PIECES; *SIG ZORG, 1993, TOEL KLIN; SNIVELY SA, 1991, J HEAD TRAUMA REHAB, V6, P11; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; STURMANS F, 1975, EPIDEMIOLOGIE MED ST; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; van Balen HG, 1992, MENSEN TRAUMATISCH H; VANBALEN HGG, 1990, P 5 EUR REG C REH IN, P82; VANBALEN HGG, 1993, S NEUROREHABILITATIO, P90; VANZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397; Wade D T, 1988, Int Disabil Stud, V10, P64; WADE DT, 1991, CLIN REHABIL, V5, P141; WEHMAN P, 1990, VOCATIONAL REHABILIT, P1; WEHMAN P, 1990, VOCATIONAL REHABILIT; WILLER B, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P18; WINTEMUTE GJ, 1991, J HEAD TRAUMA REHAB, V6, P38; World Health Organization, 1980, INT CLASS IMP DIS HA; [No title captured]	45	26	26	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0963-8288			DISABIL REHABIL	Disabil. Rehabil.	APR	1996	18	4					181	190		10.3109/09638289609166298			10	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	UG134	WOS:A1996UG13400004	8744906	Green Published			2022-02-06	
J	Gansler, DA; Covall, S; McGrath, N; OscarBerman, M				Gansler, DA; Covall, S; McGrath, N; OscarBerman, M			Measures of prefrontal dysfunction after closed head injury	BRAIN AND COGNITION			English	Article							DIFFUSE AXONAL INJURY; COMPARATIVE NEUROPSYCHOLOGY; KORSAKOFFS SYNDROME; DELAYED ALTERNATION; PERFORMANCE; ATROPHY	Tasks sensitive to frontal lobe dysfunction (delayed response, delayed alternation, object alternation, and Wisconsin Card Sort) were administered to 20 patients with post-acute closed-head injury (CHI). Time since injury varied (6 to 280 months; mean, 48 months), as did length of coma (2 hr to 120 days; mean, 38 days). Compared to normal controls, CHI patients showed no deficits on delayed response tasks, but were impaired on delayed alternation, object alternation, and the Wisconsin Card Sort Test. Analyses of the performance profiles of the CHI patients suggested that they may have difficulty in establishing set (a consequence of damage to the orbitofrontal system). (C) 1996 Academic Press, Inc.	TUFTS UNIV,SCH MED,DEPT PSYCHIAT,MEDFORD,MA 02155; BOSTON UNIV,SCH MED,DEPT REHABIL MED,BOSTON,MA 02215; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02215; BOSTON UNIV,SCH MED,DIV PSYCHIAT,BOSTON,MA 02215		Gansler, DA (corresponding author), VET AFFAIRS MED CTR,PSYCHOL SERV 116B,150 S HUNTINGTON AVE,BOSTON,MA 02130, USA.			Berman, Marlene Oscar/0000-0003-0100-8883	NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA07112] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA007112, R37AA007112] Funding Source: NIH RePORTER		ADAMS JA, 1984, GREENFIELDS NEUROPAT; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1984, RECENT ADV HISTOPATH, V12; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Cohen J., 2013, STAT POWER ANAL BEHA; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DENCKER SJ, 1960, ARCH GEN PSYCHIAT, V2, P569; ELAWAR M, 1991, BRAIN COGNITION, V16, P121, DOI 10.1016/0278-2626(91)90001-O; FREEDMAN M, 1986, CAN J NEUROL SCI, V13, P410; FREEDMAN M, 1990, BRAIN COGNITION, V14, P134, DOI 10.1016/0278-2626(90)90025-J; FREEDMAN M, 1994, UNPUB FRONTAL LOBE F; GELLERMANN LW, 1933, J GENET PSYCHOL, V42, P207; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRANT DA, 1948, J EXP PSYCHOL, V38, P2404; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Klove H, 1972, Scand J Rehabil Med, V4, P55; Levin HS., 1982, NEUROBEHAVIORAL CONS; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; OSCARBERMAN M, 1982, NEUROPSYCHOLOGIA, V20, P187, DOI 10.1016/0028-3932(82)90009-4; OSCARBERMAN M, 1980, NEUROPSYCHOLOGIA, V18, P513, DOI 10.1016/0028-3932(80)90153-0; OSCARBERMAN M, 1980, NEUROPSYCHOLOGIA, V18, P499, DOI 10.1016/0028-3932(80)90152-9; OSCARBERMAN M, 1984, NEUROPSYCHOLOGY MEMO; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Reynolds C. R., 1983, CLIN NEUROPSYCHOLOGY, V5, P111; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Warren J.M., 1964, FRONTAL GRANULAR COR; Wechsler, 1997, WECHSLER ADULT INTEL; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	36	26	26	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0278-2626			BRAIN COGNITION	Brain Cogn.	MAR	1996	30	2					194	204		10.1006/brcg.1996.0012			11	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	UA078	WOS:A1996UA07800003	8811997				2022-02-06	
J	Curl, RM; Fraser, RT; Cook, RG; Clemmons, D				Curl, RM; Fraser, RT; Cook, RG; Clemmons, D			Traumatic brain injury vocational rehabilitation: Preliminary findings for the coworker as trainer project	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						functional skills training; traumatic brain injury; vocational rehabilitation intervention	EMPLOYMENT	Persons with severe traumatic brain injury (TBI) who return to work represent a group of consumers who may require high levels of interdisciplinary support and long-term maintenance. The coworker model, previously demonstrated to be effective for youths with cognitive and behavioral deficits, was modified for use with new and returning workers with a severe TBI, even at professional levels of employment. Preliminary results show that coworker trainers learned to apply the basic teaching sequence and basic organizational tools. Individual coworker salary subsidies to date have been under $400. Although natural supports of this type may not be required for a majority of individuals experiencing TBI, they appear to be extremely assistive for approximately one third of all project participants.	UNIV WASHINGTON,VACAT SERV EPILEPSY CTR,SEATTLE,WA 98195; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT REHABIL MED,SEATTLE,WA 98104		Curl, RM (corresponding author), MINOT STATE UNIV,N DAKOTA CTR DISABIL,DEPT PSYCHOL,500 UNIV AVE W,MINOT,ND 58707, USA.						CALLAHAN M, 1992, NATURAL SUPPORTS SCH; CURL R, 1990, PUT PERSON WORK MANU; CURL RM, 1991, ID G008400604 UT STA; CURL RM, 1987, PUT PERSON WORK COWO; CURL RM, 1990, 87 TECHN REP; CURL RM, 1987, TRAINER WORKER IMPLE; CURL RM, 1993, J VOCATIONAL REHABIL, V3, P72; CURL RM, 1991, ID H078C80034 US OFF; DEMCHAK MA, 1987, EDUC TRAIN MENT RET, V22, P205; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; FRASER R, 1990, SUMMARY NIDRR STUDIE; FRASER RT, IN PRESS NEURO REHAB; HAGNER D, 1992, NATURAL SUPPORTS SCH; LIKINS M, 1989, J APPL BEHAV ANAL, V22, P381, DOI 10.1901/jaba.1989.22-381; MCCONAUGHY EK, 1989, REHABIL PSYCHOL, V34, P3, DOI 10.1037//0090-5550.34.1.3; MCCONAUGHY EK, 1987, 13TH ANN CONV ASS BE; NISBET J, 1988, J ASSOC PERS SEVERE, V13, P260; REPP AC, 1987, RES DEV DISABIL, V8, P331, DOI 10.1016/0891-4222(87)90011-4; ROGAN P, 1993, J ASSOC PERS SEVERE, V18, P275, DOI 10.1177/154079699301800410; WALLS RT, 1980, AM J MENT DEF, V84, P495; WALLS RT, 1979, EDUC TRAIN MENT RET, V14, P120; WALLS RT, 1982, AM J MENT DEF, V87, P309; WALLS RT, 1981, AM J MENT DEF, V85, P357; Wehman P., 1990, COMMUNITY INTEGRATIO; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27	26	26	26	0	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1996	11	1					75	85		10.1097/00001199-199602000-00009			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	TU021	WOS:A1996TU02100009					2022-02-06	
J	MIKAWA, S; SHARP, FR; KAMII, H; KINOUCHI, H; EPSTEIN, CJ; CHAN, PH				MIKAWA, S; SHARP, FR; KAMII, H; KINOUCHI, H; EPSTEIN, CJ; CHAN, PH			EXPRESSION OF C-FOS AND HSP70 MESSENGER-RNA AFTER TRAUMATIC BRAIN INJURY IN TRANSGENIC MICE OVEREXPRESSING CUZN-SUPEROXIDE DISMUTASE	MOLECULAR BRAIN RESEARCH			English	Article						C-FOS MESSENGER-RNA; HSP70 MESSENGER-RNA; TRAUMATIC BRAIN INJURY; FREE RADICAL; SUPEROXIDE DISMUTASE; TRANSGENIC MOUSE; SPREADING DEPRESSION	HEAT-SHOCK PROTEIN; FOCAL CEREBRAL-ISCHEMIA; MESSENGER-RNA; CORTICAL INJURY; FREE-RADICALS; NITRIC-OXIDE; RAT-BRAIN; INDUCTION; NEUROTOXICITY; NEURONS	The aim of this study was to determine the role of oxidative stress on c-fos and hsp70 gene expression in transgenic (Tg) mice overexpressing CuZn-superoxide dismutase (SOD-l) following traumatic brain injury (TBI). hsp70 mRNA, as investigated using in situ hybridization, was induced around the lesion at 4 and 24 h, but not at 1 and 48 h, in both Tg and non-transgenic (nTg) mice littermates. The degree of hsp70 induction was somewhat greater in nTg than Tg mice at 4 and 24 h after TBI. c-fos mRNA was induced throughout cortex, hippocampus, caudate putamen and the ventricular wall in Tg and nTg mice. TBI induced c-fos bilaterally in the cortex in both animals. There was a time-dependent difference in cortical c-fos expression between nTg and Tg mice. The induction of c-fos mRNA in the striatum was greater in nTg at 24 h and decreased in both animals by 48 h. Edema of the injured cortex was significantly attenuated in Tg mice at all time points (1-48 h). These data show that the degree of hsp70 induction and the degree, extent, and duration of c-fos induction produced by TBI are affected by levels of superoxide dismutase activity. It is proposed that superoxide radicals affect spreading depression and brain edema produced by TBI and that this effect may either directly or indirectly modulate the expression of the c-fos and hsp70 genes after TBI.	UNIV CALIF SAN FRANCISCO, DEPT NEUROSURG, CNS INJURY & EDEMA RES CTR, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA; VET ADM MED CTR, DEPT NEUROL, SAN FRANCISCO, CA 94121 USA; TOHOKU UNIV, SCH MED, DEPT NEUROSURG, SENDAI, MIYAGI 980, JAPAN								AMSTAD PA, 1992, CANCER RES, V52, P3952; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHAN PH, 1990, STROKE, V21, P80; CHAN PH, 1989, ANN NY ACAD SCI, V559, P237; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; CHOPP M, 1991, ACTA NEUROPATHOL, V83, P66, DOI 10.1007/BF00294432; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FU L, 1992, NEUROSCIENCE, V46, P329, DOI 10.1016/0306-4522(92)90055-7; GONZALEZ MF, 1991, BRAIN RES BULL, V26, P241, DOI 10.1016/0361-9230(91)90234-B; HABY C, 1994, J NEUROCHEM, V62, P496; KAMII H, 1994, BRAIN RES, V662, P240, DOI 10.1016/0006-8993(94)90818-4; KAMII H, 1994, J CEREBR BLOOD F MET, V14, P478, DOI 10.1038/jcbfm.1994.59; KINOUCHI H, 1993, J CEREBR BLOOD F MET, V13, P105, DOI 10.1038/jcbfm.1993.13; KINOUCHI H, 1993, BRAIN RES, V619, P334, DOI 10.1016/0006-8993(93)91630-B; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUBOTA M, 1989, BRAIN NERVE, V41, P99; LABANDEIRA-GARCIA JL, 1994, BRAIN RES, V652, P87, DOI 10.1016/0006-8993(94)90321-2; LAURITZEN M, 1982, ANN NEUROL, V12, P469, DOI 10.1002/ana.410120510; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; MIKAWA S, 1995, IN PRESS 17 INT S CE; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; NOWAK TS, 1991, J CEREBR BLOOD F MET, V11, P432, DOI 10.1038/jcbfm.1991.84; PECHAN PA, 1992, NEUROREPORT, V3, P469, DOI 10.1097/00001756-199206000-00003; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SHARP JW, 1990, EXP NEUROL, V109, P323, DOI 10.1016/S0014-4886(05)80023-8; SHI YP, 1994, MAMM GENOME, V5, P337, DOI 10.1007/BF00356551; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	40	26	27	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	NOV	1995	33	2					288	294		10.1016/0169-328X(95)00146-J			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TA393	WOS:A1995TA39300013					2022-02-06	
J	ASGEIRSSON, B; GRANDE, PO; NORDSTROM, CH; MESSETER, K; SJOHOLM, H				ASGEIRSSON, B; GRANDE, PO; NORDSTROM, CH; MESSETER, K; SJOHOLM, H			CEREBRAL HEMODYNAMIC-EFFECTS OF DIHYDROERGOTAMINE IN PATIENTS WITH SEVERE TRAUMATIC BRAIN-LESIONS	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						DIHYDROERGOTAMINE; HYPERVENTILATION; INTRACRANIAL PRESSURE; TRAUMATIC BRAIN INJURY; CEREBRAL HEMODYNAMICS	SEVERE HEAD-INJURY; RAISED INTRACRANIAL-PRESSURE; BLOOD-FLOW; PERFUSION-PRESSURE; HYPERTENSION; MANAGEMENT; THERAPY; VASOREACTIVITY; AUTOREGULATION; CIRCULATION	Dihydroergotamine (DHE) is used in our recently introduced therapy of post-traumatic brain oedema and is suggested to reduce ICP through reduction in both cerebral blood volume and brain water content. This study aims at increasing our knowledge of the mechanisms behind the ICP reducing effect of DHE by analysing cerebrovascular effects of a bolus dose of DHE in severely head injured patients (GCS<8). Mean hemispheric cerebral blood flow (CBF) calculated from the clearance of i.v. (133)Xenon, ICP, and cerebral arterio-venous difference in oxygen content (AVDO(2)); were measured before and after hyperventilation and after a bolus dose of DHE (4 mu g/kg). The patients were divided into two groups, one with preserved and one with impaired cerebrovascular CO2-reactivity to hyperventilation, the latter being predictive of poor outcome. The haemodynamic effects of DHE were compared to those of hyperventilation. Regional CBF and brain volume SPECT measurements were performed in two patients. DHE increased cerebrovascular resistance (CVR) by about 20% and significantly reduced ICP in both groups of patients, resulting in unchanged AVDO(2). Hyperventilation with preserved CO2-reactivity caused a similar decrease in ICP as by DHE but with a much larger increase in CVR (by 70%) and a substantial increase in AVDO(2). Hyperventilation with impaired CO2-reactivity reduced ICP but otherwise had no significant cerebrovascular effects. The study supports the concept that the ICP reducing effect of DHE results more from constriction of the large veins than from arterial vasoconstriction, also implying a relatively smaller risk of ischaemia with DHE than with hyperventilation.	UNIV LUND HOSP,DEPT PHYSIOL & BIOPHYS,S-22185 LUND,SWEDEN; UNIV LUND HOSP,DEPT NEUROSURG,S-22185 LUND,SWEDEN; UNIV LUND HOSP,DEPT CLIN NEUROPHYSIOL,S-22185 LUND,SWEDEN; LUND UNIV,LUND,SWEDEN		ASGEIRSSON, B (corresponding author), UNIV LUND HOSP,DEPT ANAESTHESIA & INTENS CARE,S-22185 LUND,SWEDEN.						ALBRECHT RF, 1987, STROKE, V18, P649, DOI 10.1161/01.STR.18.3.649; ANDERSEN AR, 1987, STROKE, V18, P120, DOI 10.1161/01.STR.18.1.120; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P567, DOI 10.1007/BF01705723; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; ASGEIRSSON B, 1991, 8TH INT S INTR PRESS; ASTRUP J, 1991, CURR OPIN ANAESTH, V4, P653; BOREL C, 1990, CHEST, V198, P180; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GOSSELIN RE, 1991, J THEOR BIOL, V149, P265, DOI 10.1016/S0022-5193(05)80281-4; GRANDE PO, 1989, INTENS CARE MED, V15, P523, DOI 10.1007/BF00273564; GRANDE PO, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P319; GUTYON A, 1991, TXB MED PHYSL, P150; HACHINSKI V, 1978, STROKE, V9, P594, DOI 10.1161/01.STR.9.6.594; Jennett B, 1991, J NEUROTRAUMA S1, V8, P15; JENSEN K, 1991, ACTA NEUROCHIR, V108, P116, DOI 10.1007/BF01418518; KAUFMAN AM, 1992, J NEUROSURG, V77, P854; MCCARTHY BG, 1989, HEADACHE, V29, P420, DOI 10.1111/j.1526-4610.1989.hed2907420.x; MELLANDER S, 1970, CLIN SCI, V39, P183, DOI 10.1042/cs0390183; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MILLER JD, 1992, J NEUROTRAUMA S1, V9, P317; Muizelaar JP, 1991, J NEUROSURG, V64, P81; MULLER H, 1988, PHARMACOLOGY, V37, P248, DOI 10.1159/000138473; MULLERSCHWEINIT.E, 1987, J CARDIOVASC PHARM, V9, P686; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1985, CEREBRAL BLOOD FLOW, P30; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; RISBERG J, 1975, STROKE, V6, P142, DOI 10.1161/01.STR.6.2.142; Rosner M., 1987, CEREBRAL BLOOD FLOW, P425; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TEASDALE G, 1974, LANCET, V2, P81; TODD NV, 1990, ACT NEUR S, V51, P296; YADA K, 1973, J NEUROSURG, V39, P723, DOI 10.3171/jns.1973.39.6.0723; [No title captured]	46	26	29	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	1995	39	7					922	930		10.1111/j.1399-6576.1995.tb04199.x			9	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	RX864	WOS:A1995RX86400012	8848893				2022-02-06	
J	HAYES, RL; YANG, K; WHITSON, JS; POSMANTUR, R				HAYES, RL; YANG, K; WHITSON, JS; POSMANTUR, R			CYTOSKELETAL DERANGEMENTS FOLLOWING CENTRAL-NERVOUS-SYSTEM INJURY - MODULATION BY NEUROTROPHIC GENE TRANSFECTION	JOURNAL OF NEUROTRAUMA			English	Article						CYTOSKELETON; TRAUMATIC BRAIN INJURY; NEUROFILAMENTS; MAP2; CALPAIN; NEUROTROPHINS	TRAUMATIC BRAIN INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; CALCIUM-ACTIVATED PROTEOLYSIS; CONTROLLED CORTICAL IMPACT; MIDDLE CEREBRAL-ARTERY; NEUROFILAMENT PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; FOREBRAIN ISCHEMIA; GROWTH-FACTOR; RAT	This paper reviews important new evidence indicating that traumatic brain injury can produce more widespread derangements to the neuronal cytoskeleton than previously recognized. Although cytoskeletal derangements in axons have long been documented, recent data suggest that traumatic brain injury can produce structural derangements to dendrites and cell bodies as well. Many of these investigations have employed in vivo models to provide important insights into mechanisms possibly mediating the acute loss of cytoskeletal proteins, including disturbances in calcium homeostasis and activation of calcium-dependent proteolytic enzymes. However, we have little understanding of processes mediating the recovery of cytoskeletal proteins following injury. This paper provides recent evidence from in vitro models of central nervous system injury that neurotrophic proteins can enhance the recovery of the neuronal cytoskeleton. Neurotrophin-based therapy could employ either administration of exogenous neurotrophic proteins and/or transfection of cDNA for appropriate neurotrophins.			HAYES, RL (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT NEUROSURG, 6431 FANNIN ST, SUITE 7148, HOUSTON, TX 77030 USA.						Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; ARAI A, 1991, BRAIN RES, V555, P276, DOI 10.1016/0006-8993(91)90352-V; BARINAGA M, 1994, SCIENCE, V264, P772, DOI 10.1126/science.8171331; BEATTIE MS, 1988, PHARM APPROACHES TRE, P43; CLARK EA, 1991, J NEUROCHEM, V57, P802, DOI 10.1111/j.1471-4159.1991.tb08222.x; CORK LC, 1986, J NEUROPATH EXP NEUR, V45, P56, DOI 10.1097/00005072-198601000-00005; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DAUTIGNY A, 1988, BIOCHEM BIOPH RES CO, V154, P1099, DOI 10.1016/0006-291X(88)90254-9; DIETZEL I, 1986, ADV NEUROL, V44, P619; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FANG XJ, 1989, HEPATOLOGY, V10, P781; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FORNO LS, 1986, NEUROSCI LETT, V64, P253, DOI 10.1016/0304-3940(86)90337-X; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GIORDANO T, 1991, EXP CELL RES, V992, P993; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1995, NEUROSCI LETT, V191, P121, DOI 10.1016/0304-3940(95)11561-X; HEFTI F, 1986, J NEUROSCI, V6, P2155; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HORWITZ M S, 1990, P1679; HUG P, 1991, BIOCHIM BIOPHYS ACTA, V1097, P1, DOI 10.1016/0925-4439(91)90016-3; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; IP NY, 1993, J NEUROSCI, V13, P3394; JENSEN AM, 1990, J NEUROSCI, V10, P1165; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON PA, 1992, MOL BRAIN RES, V12, P95, DOI 10.1016/0169-328X(92)90072-J; JULIEN JP, 1982, J BIOL CHEM, V257, P467; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KUDO T, 1993, STROKE, V24, P259, DOI 10.1161/01.STR.24.2.259; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LI AP, 1992, IN VITRO CELL DEV-AN, V28A, P373; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MATTSON MP, 1989, BRAIN RES, V478, P337, DOI 10.1016/0006-8993(89)91514-X; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; NAKAMURA M, 1992, EXP BRAIN RES, V89, P31; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NIXON RA, 1984, J NEUROCHEM, V43, P507, DOI 10.1111/j.1471-4159.1984.tb00928.x; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OGATA N, 1989, J NEUROSURG, V70, P103, DOI 10.3171/jns.1989.70.1.0103; PERLMUTTER LS, 1988, SYNAPSE, V2, P79, DOI 10.1002/syn.890020111; PIETRINI V, 1993, CLIN NEUROPATHOL, V12, P1; POLTORAK M, 1988, BRAIN RES, V475, P328, DOI 10.1016/0006-8993(88)90621-X; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POSMANTUR R, 1995, IN PRESS J NEUROPATH; POSMANTUR R, 1994, NEUROTRAUMA SOC ABST; ROESSLER BJ, 1994, NEUROSCI LETT, V167, P5, DOI 10.1016/0304-3940(94)91015-4; SAMBROOK J, 1989, MOL CLONING, V18, P32; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; SCHLAEPFER WW, 1985, PROG BRAIN RES, V63, P185; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; SHAW G, 1986, BIOESSAYS, V4, P161, DOI 10.1002/bies.950040406; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; THOMPSON TA, 1993, IN VITRO CELL DEV-AN, V29, P165, DOI 10.1007/BF02630949; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROOST D, 1992, ACTA NEUROPATHOL, V84, P664, DOI 10.1007/BF00227744; ULRICH J, 1987, PATHOL IMMUNOPATH R, V6, P273, DOI 10.1159/000157058; WANG S, 1994, J NEUROCHEM, V62, P739; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WHITSON JS, 1995, IN PRESS BRAIN RES; WOLF D, 1988, MOL BIOL MED, V5, P43; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YANG K, 1994, NEUROSCI LETT, V182, P287, DOI 10.1016/0304-3940(94)90818-4; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG K, 1994, NEUROSCI LETT, V182, P291, DOI 10.1016/0304-3940(94)90819-2	83	26	27	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					933	941		10.1089/neu.1995.12.933			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600020	8594223				2022-02-06	
J	SCHMIDT, SH; OORTMARBURGER, D; MEIJMAN, TF				SCHMIDT, SH; OORTMARBURGER, D; MEIJMAN, TF			EMPLOYMENT AFTER REHABILITATION FOR MUSCULOSKELETAL IMPAIRMENTS - THE IMPACT OF VOCATIONAL-REHABILITATION AND WORKING ON A TRIAL BASIS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; DISABILITY; RETURN; CONTEXT; POLICY	Objective: To investigate to what extent vocational rehabilitation and working on a trial basis have an impact on employment after rehabilitation. Design: Follow-up survey, conducted in 1991, among all patients, aged 14 to 64, who were treated between 1984 and 1987. Setting: An out-clinic department of a rehabilitation center in the west of The Netherlands. Subjects: 395 patients (59% of the original sample) participated in the study. They suffer from musculoskeletal impairments due to back pain (41%), brain injury (20%), neurological disorder (12%), trauma to the upper and/or lower extremities (8%), rheumatoid arthritis (7%), or other disorders (12%). No differences were found between those who did and those who did not respond with regard to age, gender, marital status, disorder, work experience, and participation in vocational rehabilitation. Main Outcome Measure: Odds ratio of having a paid job after rehabilitation. Results: Participation in vocational rehabilitation and working on a trial basis depends on age, gender, work experience, and disorder. When statistically controlled for these variables vocational rehabilitation (odds ratio 1.96; 95% confidence interval 1.12 to 3.42) and working on a trial basis (odds ratio 3.26; 95% confidence interval 1.74 to 6.11) proved to have a significant impact on employment after rehabilitation. Conclusions: The findings suggest that rehabilitation programs that aim specifically at promoting employment for people with disabilities are effective, in particular when they take place in both a laboratory and a natural setting. The validity of this suggestion must be further tested by means of an experimental design. (C) 1995 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV GRONINGEN,DEPT EXPTL & OCCUPAT PSYCHOL,9700 AB GRONINGEN,NETHERLANDS		SCHMIDT, SH (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,INST SOCIAL MED,INST WORK & HLTH,MEIBERGDREEF 15,1105 AZ AMSTERDAM,NETHERLANDS.						BEEK KWH, 1992, ESB, V77, P560; Cornes P, 1987, Int Rehabil Med, V8, P138; CREWE N, 1987, INDEPENDENT LIVING P; DEVIVO MJ, 1987, ARCH PHYS MED REHAB, V68, P494; DOMARACKI JW, 1992, RES DEV DISABIL, V13, P363, DOI 10.1016/0891-4222(92)90011-T; EKLUND M, 1991, SCAND J REHABIL MED, V23, P73; Fawber HL, 1987, J HEAD TRAUMA REHAB, V2, P27; FOX DM, 1989, MILBANK Q, V67, P1; FRASER RT, 1983, EPILEPSIA, V24, P734, DOI 10.1111/j.1528-1157.1983.tb04636.x; GALVIN DE, 1986, REHABIL LIT, V47, P218; GEURTS D, 1992, LAAT MIJ MAAR WERKEN; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HARDERING J, 1990, REHABILITATION STUTT, V31, P40; HEARNE PG, 1991, MILBANK Q, V69, P121; HOSMER DW, 1989, APPLIED LOGISTIC REG, V87, P109; LONSDALE S, 1992, SOCIAL SECURITY 50 Y, V3, P73; MCLOUGHLIN CS, 1987, GETTING EMPLOYED STA; Oliver M, 1993, DISABLING BARRIERS E, P267; POPE AM, 1991, DISABILITY AM NATION; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAVAUD JF, 1992, SOC SCI MED, V35, P951, DOI 10.1016/0277-9536(92)90234-H; REVELL WG, 1978, REHABIL LIT, V39, P226; SANDSTROM J, 1986, SCAND J REHABIL MED, V18, P29; SAXON JP, 1983, J REHABIL, V49, P69; Schmidt S H, 1986, Tijdschr Gerontol Geriatr, V17, P183; SCHMIDT SH, 1988, REVALIDATIE ARBEID; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STRAATON KV, 1992, ARTHRITIS RHEUM, V35, P503, DOI 10.1002/art.1780350503; TATE DG, 1992, AM J PHYS MED REHAB, V71, P92, DOI 10.1097/00002060-199204000-00006; Townsend P., 1981, DISABILITY BRITAIN M; VANDENELSHOUT S, 1993, SOC EC MNDSTAT S1, V10, P4; VANDERGOOT D, 1987, REHABIL COUNS BULL, V30, P243; VANSONSBEEK JLA, 1991, STAT MAG, V11, P47; VEERMAN TJ, 1994, SMA, V49, P79; VROOMAN JC, 1990, EC STAT BERICHTEN, V75, P942; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEST J, 1991, MILBANK Q, V69, P3, DOI 10.2307/3350156; WEST J, 1991, MILBANK Q, V69, pR11; YELIN E, 1986, MILBANK Q, V64, P622, DOI 10.2307/3349928; YELIN E, 1989, MILBANK Q, V67, P114, DOI 10.2307/3350238; YELIN EH, 1991, MILBANK Q, V69, P129, DOI 10.2307/3350161; 1989, 23 INT SOC SEC ASS R; 1992, HANDELINGEN TWEEDE K, P13; 1989, 22 INT SOC SEC ASS R; 1985, TARGETS HLTH ALL TAR	45	26	27	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1995	76	10					950	954		10.1016/S0003-9993(95)80073-5			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	RY975	WOS:A1995RY97500012	7487437				2022-02-06	
J	MCLEAN, AJ				MCLEAN, AJ			BRAIN INJURY WITHOUT HEAD IMPACT	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		TRAUMATIC BRAIN INJURY; NONIMPACT INJURY; POSTMORTEM ANALYSIS	CEREBRAL CONCUSSION	The proposition that acceleration of the brain without direct impact to the head can result in brain injury is examined by reviewing a series of 414 road users who were fatally injured in the vicinity of Adelaide, South Australia. The series comprises 170 pedestrians, 10 pedal cyclists, 143 motorcyclists, and 91 vehicle occupants, In each case a member of the research team attended the autopsy to look for evidence of impact on the body, particularly to the head or face, The brain was examined by a neuropathologist and the type and pattern of injury was recorded, The circumstances of the crash were investigated, including an examination of the crash site and the vehicles involved and, where relevant, interviews with witnesses, In cases involving a motorcyclist the helmet worn was retrieved by the police and assigned to the research unit for examination, Particular attention was paid to the identification of objects causing injury to the head or face and also to objects impacted by a helmet, Brain injury was recorded as a cause of death in 55% of the 403 cases for which there was a dear classification of cause of death, Brain injury, at any level of severity, was identified by a neuropathologist in 86 percent of the 414 fatally injured road users in the sample, including 24 cases that were examined microscopically, There were no cases in which there was an injury to the brain in the absence of evidence of an impact to the head.			MCLEAN, AJ (corresponding author), UNIV ADELAIDE,NHMRC,RD ACCIDENT RES UNIT,ADELAIDE,SA 5005,AUSTRALIA.						BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDSMITH W, 1966, HEAD INJURY C P, P350; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Thiabault LE, 1990, 34 ANN P ASS ADV AUT, V34, P337	8	26	27	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					621	625		10.1089/neu.1995.12.621			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000013	8683613				2022-02-06	
J	NEWTON, RA				NEWTON, RA			BALANCE ABILITIES IN INDIVIDUALS WITH MODERATE AND SEVERE TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article								Balance characteristics, latency, amplitude, and symmetry were measured in 23 moderate and 23 severe traumatic brain-injured (TBI) patients. Patients received two graded forward and two graded backward linear perturbations. Although within normal limits, latency was high. Patients were able to appropriately grade force in relation to the size of the perturbation. Standing posture prior to and during perturbation was recorded by the amount of force generation through each lower extremity. Some individuals used an asymmetrical balance response following perturbations, whereas others shifted to a more symmetrical weight-bearing balance response. TBI patients may be prone to instability due to a combination of long latency of onset of the balance response coupled with asymmetrical stance patterns during recovery from an unexpected linear perturbation.			NEWTON, RA (corresponding author), TEMPLE UNIV,COLL ALLIED HLTH PROFESS,DEPT PHYS THERAPY,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.						DIENER HC, 1988, J NEUROPHYSIOL, V59, P1888, DOI 10.1152/jn.1988.59.6.1888; FREGLY AR, 1968, AEROSPACE MED, V39, P277; HORAK FB, 1986, J NEUROPHYSIOL, V55, P1369, DOI 10.1152/jn.1986.55.6.1369; JENNETT B, 1975, LANCET, V1, P480; NASHNER LM, 1990, 1989 P BAL S APTA NA, P5; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROMBERG MH, 1853, MANUAL NERVOUS DIS M, P395; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; VORHEES RL, 1989, LARYNGOSCOPE, V99, P995; WINTER DA, 1990, MED PROG TECHNOL, V16, P31	10	26	26	0	3	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1995	9	5					445	451		10.3109/02699059509008204			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	RJ331	WOS:A1995RJ33100003	7550216				2022-02-06	
J	HUNT, J; HILL, D; BESSER, M; WEST, R; RONCAL, S				HUNT, J; HILL, D; BESSER, M; WEST, R; RONCAL, S			OUTCOME OF PATIENTS WITH NEUROTRAUMA - THE EFFECT OF A REGIONALIZED TRAUMA SYSTEM	AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY			English	Article						NEUROTRAUMA; OUTCOMES; REGIONALIZATION; TRAUMA CENTER	SEVERE HEAD-INJURY; IMPACT; MANAGEMENT; EXPERIENCE; MODEL; TEAM; CARE	A system of regionalized trauma care was introduced to Sydney in early 1992. This study was carried out to assess the effect of regionalization on the outcome of patients suffering major head injury within the central Sydney area. A prospective before and after study extending over 3 years and centred on the time of designation of Royal Prince Alfred Hospital (RPAH) as a trauma centre, was the methodology used. The study group consisted of all patients admitted with head injury (Glasgow Coma Score < 9; admission systolic brood pressure > 90 mmHg; Injury Severity Score > 15) to RPAH from the central Sydney area. Outcome criteria include survival rates, transfer numbers, and time to definitive neurosurgical care. Fifty patients were entered during the first 18 months of the study, and 38 during the second 18 months. Fifteen in the first group required evacuation of intracranial mass lesions, as did nine in the second group. The overall mortality fell from 42 to 26% (P=0.13). During the study period there were 77 primary retrievals and 20 required evacuation of mass lesions. The median time from injury to commencement of operation in these patients was 2 h 13 min (range 1 h 3 min-5 h 35 min). There were 11 transfers, four requiring craniotomy. The median time from injury to surgery was 7 h 24 min (range 3 h 2 min-10 h 25 min; P < 0.01). A trend towards a decreased mortality following regionalization, as well as a statistical difference (P < 0.01) in the time taken for primary retrieval patients to undergo craniotomy when compared to transferred patients has been shown. This evidence, in conjunction with the decrease in transferred patients post-regionalization, helps validate regionalization in the setting of major neurotrauma.	UNIV SYDNEY,SYDNEY,NSW,AUSTRALIA		HUNT, J (corresponding author), ROYAL PRINCE ALFRED HOSP,DIV SURG,MISSENDEN RD,CAMPERDOWN,NSW 2050,AUSTRALIA.						BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; CALES RH, 1983, ANN EMERG MED, V13, P1; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DEANE SA, 1989, AUST NZ J SURG, V59, P373; DEANE SA, 1990, J TRAUMA, V30, P806, DOI 10.1097/00005373-199007000-00007; FRIEDMAN AH, 1991, TXB SURGERY BIOL BAS, P1252; HILL DA, 1993, AUST NZ J SURG, V63, P940, DOI 10.1111/j.1445-2197.1993.tb01723.x; HILL DA, 1992, AUST NZ J SURG, V62, P204, DOI 10.1111/j.1445-2197.1992.tb05464.x; HILL DA, 1993, MED TEACH, V15, P179, DOI 10.3109/01421599309006712; KANE G, 1992, J TRAUMA, V32, P576, DOI 10.1097/00005373-199205000-00007; KLAUBER MR, 1985, J NEUROSURG, V57, P528; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; MARCH H, 1989, BRIT J NEUROSURG, V3, P13; MCDERMOTT FT, 1994, AUST NZ J SURG, V64, P147, DOI 10.1111/j.1445-2197.1994.tb02168.x; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; ROY PD, 1987, CAN J SURG, V30, P17; SELECKI BR, 1986, AUST NZ J SURG, V56, P529, DOI 10.1111/j.1445-2197.1986.tb07095.x; SIMPSON D, 1986, AUST NZ J SURG, V56, P527, DOI 10.1111/j.1445-2197.1986.tb07094.x; TEASDALE G, 1976, LANCET, V1, P1031; WEST JG, 1983, ARCH SURG-CHICAGO, V118, P740	21	26	26	0	0	BLACKWELL SCIENCE PUBL AUSTR	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON 3053, AUSTRALIA	0004-8682			AUST NZ J SURG	Aust. N. Z. J. Surg.	FEB	1995	65	2					83	86		10.1111/j.1445-2197.1995.tb07266.x			4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	QF429	WOS:A1995QF42900004	7857235				2022-02-06	
J	SCOTT, DE; WU, WT; SLUSSER, J; DEPTO, A; HANSEN, S				SCOTT, DE; WU, WT; SLUSSER, J; DEPTO, A; HANSEN, S			NEURAL REGENERATION AND NEURONAL MIGRATION FOLLOWING INJURY .1. THE ENDOCRINE HYPOTHALAMUS AND NEUROHYPOPHYSEAL SYSTEM	EXPERIMENTAL NEUROLOGY			English	Article							NITRIC-OXIDE SYNTHASE; 3RD CEREBRAL VENTRICLE; RAT-BRAIN; NADPH DIAPHORASE; MEDIAN-EMINENCE; MAGNOCELLULAR NEURONS; INCREASED EXPRESSION; POSTERIOR PITUITARY; ELECTRON-MICROSCOPY; SUPRAOPTIC NUCLEUS	Central to this investigation are several basic hypotheses that are designed to test the role of nitric oxide (NO) in the complex process of central regeneration and plasticity in a well established model system of the mammalian brain. We have employed histochemical techniques at the light and ultrastructural level coupled with correlative scanning electron microscopy, immunoelectron microscopy, and in situ hybridization in order to determine the functional significance of the increased expression of nitric oxide synthase (NOS) in neurons of the supraoptic (SON) and paraventricular (PVN) nuclei which accompanies regeneration of their axotomized neurites following hypophysectomy. The aim of this investigation was to determine the potential role and temporal up-regulation of NOS in this basic regenerative process and to establish the ultrastructural and neuroanatomical correlates during critical periods of regeneration and regrowth of SON and PVN axons following hypophysectomy in the endocrine hypothalamus of the rat. Our data support the hypothesis that NO may serve as a second messenger molecule that may act in some fashion to govern not only the process of central regeneration and regrowth of magnocellular (SON/PVN) axons into the median eminence, neural stem, and neural lobe (the neurohypophyseal system) but may also influence the regeneration of neurites into new neuroanatomical domains such as the adjacent lumen of the third cerebral ventricle. We have demonstrated a distinct temporal relationship between injury (axotomy) of SON/PVN axons and the establishment of new neurovascular zones following hypophysectomy with the up-regulation of NOS, This up-regulation appears to correlate well with successful regeneration in the mammalian neurohypophyseal system. We have also successfully inhibited axonal regeneration with the use of nitroarginine, a competitive antagonist of NO. NOS up-regulation attendant to regeneration of SON and PVN axons may have inestimable clinical implications, particularly with respect to closed head injury and cerebral contusion that involves the mechanical shearing of the infundibular stalk. In addition, this investigation has reaffirmed that large numbers of bona fide neurons migrate and emerge upon the floor of the adjacent third cerebral ventricle shortly following hypophysectomy (within 2 weeks). The origin and mechanisms of neuronal migration and plasticity following hypophysectomy are the subject of interpretation and discussion in this investigation. (C) 1995 Academic Press, Inc.	EASTERN VIRGINIA MED SCH,DEPT SURG,INST DIABET,NORFOLK,VA 23501; EASTERN VIRGINIA MED SCH,DEPT INTERNAL MED,NORFOLK,VA 23501		SCOTT, DE (corresponding author), EASTERN VIRGINIA MED SCH,DEPT ANAT & NEUROBIOL,DIV NEUROSURG,NORFOLK,VA 23501, USA.						ADAMS JH, 1968, J COMP NEUROL, V135, P121; BARNES PRJ, 1990, CELL TISSUE RES, V260, P211, DOI 10.1007/BF00297508; BEAGLEY GH, 1992, BRAIN RES BULL, V28, P613, DOI 10.1016/0361-9230(92)90111-A; BECK E, 1969, NEUROENDOCRINOLOGY, V5, P161, DOI 10.1159/000121858; BILLENSTIEN DC, 1955, ENDOCRINOLOGY, V56, P704, DOI 10.1210/endo-56-6-704; BLOTTNER D, 1992, J COMP NEUROL, V316, P45, DOI 10.1002/cne.903160105; BRIGHTMAN MW, 1955, ANAT REC, V121, P268; BURD GD, 1985, J COMP NEUROL, V240, P143, DOI 10.1002/cne.902400204; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DELLMANN HD, 1993, J NEURAL TRANSP PLAS, V4, P127, DOI 10.1155/NP.1993.127; GAINER H, 1977, J CELL BIOL, V73, P366, DOI 10.1083/jcb.73.2.366; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GASH D, 1980, CELL TISSUE RES, V211, P191; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; HOFER H, 1955, VORH DTSCH ZOOL GES, V8, P202; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; LAYCHOCK SG, 1991, ENDOCRINOLOGY, V129, P3043, DOI 10.1210/endo-129-6-3043; LEBEAU JM, 1991, J NEUROSCI RES, V28, P299, DOI 10.1002/jnr.490280217; LEVEQUE TF, 1959, ENDOCRINOLOGY, V6, P909; LIUZZI F, 1991, SURGICAL MANAGEMENT, V1042, P331; LIUZZI FJ, 1993, EXP NEUROL, V12, P275; MARCIANO FF, 1989, BRAIN RES, V483, P135, DOI 10.1016/0006-8993(89)90044-9; MARZBAN F, 1992, BRAIN RES BULL, V28, P757, DOI 10.1016/0361-9230(92)90256-W; MCKENNA OC, 1979, J COMP NEUROL, V184, P127, DOI 10.1002/cne.901840108; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONROE BG, 1966, J ULTRASTRUCT RES, V14, P405; NOTTEBOHM F, 1985, ANN NY ACAD SCI, V457, P143, DOI 10.1111/j.1749-6632.1985.tb20803.x; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; POULAIN DA, 1982, NEUROSCIENCE, V7, P773, DOI 10.1016/0306-4522(82)90044-6; RAISMAN G, 1973, BRAIN RES, V55, P245, DOI 10.1016/0006-8993(73)90294-1; RIOCH D, 1940, RES NERV MENT DIS PR, P3; ROBINSON AG, 1983, NEUROENDOCRINOLOGY, V36, P347, DOI 10.1159/000123479; SAGAR SM, 1987, BRAIN RES, V400, P348, DOI 10.1016/0006-8993(87)90633-0; SANDMAN CA, 1984, SCIENCE, V224, P1355, DOI 10.1126/science.6729458; SCHARRER EA, 1929, Z VERGL PHYSIOL, V7, P1; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCOTT DE, 1984, BRAIN RES BULL, V12, P453, DOI 10.1016/0361-9230(84)90161-8; SCOTT DE, 1972, Z ZELLFORSCH MIK ANA, V132, P203, DOI 10.1007/BF00307011; SCOTT DE, 1978, CELL TISSUE RES, V190, P317; SCOTT DE, 1986, BRAIN RES BULL, V17, P367, DOI 10.1016/0361-9230(86)90240-6; SCOTT DE, 1982, FRONT HORM RES, V9, P15; SHEPARD GM, 1988, DEV NEUROBIOL, V2, P197; SILVERMAN AJ, 1983, ANNU REV NEUROSCI, V6, P357, DOI 10.1146/annurev.ne.06.030183.002041; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SNYDER SH, 1992, SCI AM, V226, P68; STILLMAN MA, 1977, ENDOCRINOLOGY, V101, P42, DOI 10.1210/endo-101-1-42; THORNGRE.KG, 1973, CALC TISS RES, V11, P281, DOI 10.1007/BF02547228; TODA N, 1990, BIOCHEM BIOPH RES CO, V170, P308, DOI 10.1016/0006-291X(90)91275-W; TWEEDLE CD, 1987, NEUROSCIENCE, V20, P241, DOI 10.1016/0306-4522(87)90016-9; VALSTCHANOFF JG, 1993, J COMP NEUROL, V331, P111; VIGHTEICHMANN I, 1974, ADV ANATOMY EMBRYOLO, P1; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WHITNALL MH, 1988, J COMP NEUROL, V275, P13, DOI 10.1002/cne.902750103; WICKHAM MG, 1973, STAIN TECHNOL, V48, P63, DOI 10.3109/10520297309116583; WU W, 1989, BRAIN RES BULL, V22, P399, DOI 10.1016/0361-9230(89)90067-1; WU WT, 1993, EXP NEUROL, V121, P279, DOI 10.1006/exnr.1993.1097; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; [No title captured]	62	26	28	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	1995	131	1					23	38		10.1016/0014-4886(95)90004-7			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QN056	WOS:A1995QN05600003	7534719				2022-02-06	
J	MCHENRY, MA; MINTON, JT; WILSON, RL; POST, YV				MCHENRY, MA; MINTON, JT; WILSON, RL; POST, YV			INTELLIGIBILITY AND NONSPEECH OROFACIAL STRENGTH AND FORCE CONTROL FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF SPEECH AND HEARING RESEARCH			English	Article; Proceedings Paper	1992 American-Speech-Language-Hearing-Association Annual Convention	NOV, 1992	SAN ANTONIO, TX	Amer Speech Language Hearing Assoc		OROFACIAL STRENGTH; FORCE CONTROL; INTELLIGIBILITY; TRAUMATIC BRAIN INJURY	AMYOTROPHIC-LATERAL-SCLEROSIS; LOWER LIPS; POSITION CONTROL; FINE FORCE; MAXIMUM	Objective measures of nonspeech orofacial strength and force control were obtained for 20 individuals with traumatic brain injury. The dynamic and static force generating abilities of the upper lip, lower lip, tongue, and jaw were assessed. Based on sentence intelligibility scores, the subjects were divided into two groups, more and less intelligible. Force measures included reaction time, slope, derivative, peak overshoot, and first- and second-half mean hold and standard deviation. Groups differed only in the ability to sustain the 2 N force level with the tongue. Other potential contributors to the differences in intelligibility are discussed.			MCHENRY, MA (corresponding author), GALVESTON INST HUMAN COMMUN,TRANSIT LEARNING COMMUNITY,1528 POSTOFFICE ST,GALVESTON,TX 77553, USA.						ABBS JH, 1985, SPEECH SCI RECENT AD, P155; AMERMAN JD, 1993, J SPEECH HEAR RES, V36, P460, DOI 10.1044/jshr.3603.460; BARLOW S M, 1989, Journal of Voice, V3, P283, DOI 10.1016/S0892-1997(89)80050-5; BARLOW SM, 1985, J SPEECH HEAR RES, V28, P373, DOI 10.1044/jshr.2803.373; BARLOW SM, 1983, J SPEECH HEAR RES, V26, P616, DOI 10.1044/jshr.2604.616; BARLOW SM, 1986, EXP NEUROL, V94, P699, DOI 10.1016/0014-4886(86)90248-7; BARLOW SM, 1986, J SPEECH HEAR RES, V29, P163, DOI 10.1044/jshr.2902.163; BARLOW SM, 1990, J SPEECH HEAR RES, V33, P660, DOI 10.1044/jshr.3304.660; BARLOW SM, 1991, J COMPUTER USERS SPE, V7, P211; DWORKIN JP, 1986, J COMMUN DISORD, V19, P115, DOI 10.1016/0021-9924(86)90015-8; DWORKIN JP, 1980, J SPEECH HEAR RES, V23, P828, DOI 10.1044/jshr.2304.828; FRICK T, 1978, REV EDUC RES, V48, P157, DOI 10.2307/1169913; GENTIL M, 1990, SPEECH PRODUCTION SP, P1; KEARNS KP, 1988, J SPEECH HEAR RES, V31, P131, DOI 10.1044/jshr.3101.131; KENT JF, 1992, J SPEECH HEAR RES, V35, P723, DOI 10.1044/jshr.3504.723; KENT RD, 1987, J SPEECH HEAR DISORD, V52, P367, DOI 10.1044/jshd.5204.367; LUSCHEI ES, 1991, DYSARTHRIA AND APRAXIA OF SPEECH, P3; MCHENRY M, 1994, MOTOR SPEECH DISORDE, P135; MCNEIL MR, 1990, J SPEECH HEAR RES, V33, P255, DOI 10.1044/jshr.3302.255; Muller E. M., 1985, Mathematics and computers in biomedical applications, P363; MULLER EM, 1977, AM SPEECH HEARING AS; ROBIN DA, 1992, J SPEECH HEAR RES, V35, P1239, DOI 10.1044/jshr.3506.1239; ROBIN DA, 1991, DYSARTHRIA APRAXIA S, P3; SMITHERAN JR, 1981, J SPEECH HEAR DISORD, V46, P138, DOI 10.1044/jshd.4602.138; STIERWALT JG, 1994, C MOTOR SPEECH SEDON; Wechsler, 1997, WECHSLER ADULT INTEL; Yorkston K., 1984, COMPUTERIZED ASSESSM; 1989, MINITAB VERSION 7 2	28	26	28	0	1	AMER SPEECH-LANG-HEARING ASSN	ROCKVILLE	10801 ROCKVILLE PIKE RD, ROCKVILLE, MD 20852-3279	0022-4685			J SPEECH HEAR RES	J. Speech Hear. Res.	DEC	1994	37	6					1271	1283		10.1044/jshr.3706.1271			13	Language & Linguistics; Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Linguistics; Rehabilitation	PX191	WOS:A1994PX19100005	7877286				2022-02-06	
J	CREMONAMETEYARD, SL; GEFFEN, GM				CREMONAMETEYARD, SL; GEFFEN, GM			EVENT-RELATED POTENTIAL INDEXES OF VISUAL-ATTENTION FOLLOWING MODERATE TO SEVERE CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							TASK; P300; TIME	Covert orientation of visual attention was studied in eight closed head injury (CHI) subjects who fixated warning cues and pressed a button at peripheral target onset. Directional cues (arrows) indicated the most probable (p=0.8) side of target occurrence while neutral cues (crosses) gave no directional information. A NoGo cue (vertical bar) indicated no response was required. Compared to eight matched controls the CHI subjects displayed slowed processing of all cues (increased P2, N2 and P3 latencies). Also, evidence was found for very early impairment (increased P2 amplitude) in directing attention. Further, the CHI group did not show the normal attenuated CNV after NoGo signals, suggesting perseverative behaviour. Finally, the amplitude and latency of the P3 component (post-cue and post-target) approached normal as time since injury increased.	UNIV QUEENSLAND, DEPT PSYCHOL, COGNIT PYSCHOPHYSIOL LAB, BRISBANE, QLD 4000, AUSTRALIA; UNIV QUEENSLAND, CLIN STUDIES UNIT, BRISBANE, QLD 4000, AUSTRALIA								BROOKS N, 1984, CLOSED HEAD INJURY P; CAMPBELL K, 1986, CEREBRAL PSYCHOPHYSI, V38, P486; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; CURRY SH, 1986, CEREBRAL PSYCH EEG S, V38, P169; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DONCHIN E, 1984, COGNITIVE PSYCHOPHYS, V1, P107; GEVINS AS, 1987, HDB ELECTROENCEPHALO, V2, P335; Harter M R, 1989, J Cogn Neurosci, V1, P223, DOI 10.1162/jocn.1989.1.3.223; HARTER MR, 1991, ELECTROEN CLIN NEURO, P183; KEPPEL S, 1982, DESIGN ANAL RES HDB; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Levin HS., 1982, NEUROBEHAVIORAL CONS; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; LINDHOLM E, 1985, INT J PSYCHOPHYSIOL, V3, P121, DOI 10.1016/0167-8760(85)90032-7; LOVELESS NE, 1975, BIOL PSYCHOL, V2, P217, DOI 10.1016/0301-0511(75)90021-6; MACAR F, 1985, BIOL PSYCHOL, V21, P293, DOI 10.1016/0301-0511(85)90184-X; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1982, PHILOS T ROY SOC B, V298, P187, DOI 10.1098/rstb.1982.0081; Posner MI, 1975, INFORM PROCESSING CO, P55; Posner MI., 1978, MODES PERCEIVING PRO, P137; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; Rohrbaugh J W, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P189; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; SANDMAN CA, 1987, INT J PSYCHOPHYSIOL, V5, P215, DOI 10.1016/0167-8760(87)90008-0; SHUM DHK, 1988, J CLIN EXPT NEUROPSY, V12, P125; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANVOORHIS S, 1977, PERCEPT PSYCHOPHYS, V22, P54, DOI 10.3758/BF03206080; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Vogenthaler D R, 1987, Brain Inj, V1, P113; WALTER WG, 1964, NATURE, V203, P380, DOI 10.1038/203380a0; 1983, APSS STATISTICAL PAC	36	26	26	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					541	558		10.3109/02699059409151006			18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200006	7987290				2022-02-06	
J	JORDAN, FM; MURDOCH, BE				JORDAN, FM; MURDOCH, BE			SEVERE CLOSED-HEAD INJURY IN CHILDHOOD - LINGUISTIC OUTCOMES INTO ADULTHOOD	BRAIN INJURY			English	Article							CHILDREN; SEQUELAE	The language functioning of a group of adults who had sustained a severe closed-head injury in childhood was evaluated. The subjects were administered a battery of language assessments including measures of syntax, semantics and pragmatics, as well as a measure of metalinguistic ability. Performance of the experimental group was compared with that of a control group matched for age, sex and educational level. Results indicated that all areas of language competence assessed (syntax, semantics, pragmatics) appeared to be compromised by the childhood closed-head injury.					Murdoch, Bruce E/C-1397-2012				CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CROKER A, 1991, ED IMPLICATIONS CHIL; Dunn LM., 1981, PEABODY PICTURE VOCA; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Ewing-Cobbs L., 1985, SPEECH LANGUAGE EVAL, P97; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; GAIDOLFI E, 1980, ITALIAN J NEUROLOGIC, V39, P213; JORDAN F M, 1990, Brain Injury, V4, P27; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; Kaplan E, 1983, BOSTON NAMING TEST; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Spreen O., 1969, NEUROSENSORY CTR COM; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; WILG EH, 1989, TEST LANGUAGE COMPET; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; [No title captured]	22	26	26	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					501	508		10.3109/02699059409151002			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200002	7527267				2022-02-06	
J	JONES, R; HUX, K; MORTONANDERSON, KA; KNEPPER, L				JONES, R; HUX, K; MORTONANDERSON, KA; KNEPPER, L			AUDITORY-STIMULATION EFFECT ON A COMATOSE SURVIVOR OF TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SCALE		UNIV NEBRASKA,DEPT SPECIAL EDUC & COMMUN DISORDERS,318E BARKLEY MEM CTR,LINCOLN,NE 68583; MADONNA REHABIL CTR,LINCOLN,NE								ANSELL BJ, 1991, J SPEECH HEAR RES, V24, P1017; BERGIN AE, 1970, J ABNORM PSYCHOL, V76, P13, DOI 10.1037/h0029634; HAGEN C, 1981, TOP LANG DISORD, V14, P73; Johnson D, 1989, Nurs Times, V85, P25; KATER KM, 1989, W J NURS RES, V1, P20; LUCAS B, 1992, HEADLINES        JUL, P16; McCain LJ, 1979, QUASIEXPERIMENTATION, P233; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; MOORE J, 1980, RECOVERY FUNCTION TH, P1; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenzwelg M., 1980, RECOVERY FUNCTION TH, P127; SISSON R, 1990, HEART LUNG, V19, P373; SMITH GJ, 1985, HEAD INJURY REHABILI, P275; TEASDALE G, 1974, LANCET, V2, P81; TICE R, 1991, DIGIT O SCOPE COMPUT; WHYTE J, 1989, TRAUMATIC BRAIN INJU, P13; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112; WOOD R L, 1991, Brain Injury, V5, P401, DOI 10.3109/02699059109008113; Yorkston K. M., 1988, CLIN MANAGEMENT DYSA; [No title captured]	20	26	28	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1994	75	2					164	171					8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	MW994	WOS:A1994MW99400007	8311672				2022-02-06	
J	MUIZELAAR, JP				MUIZELAAR, JP			CEREBRAL ISCHEMIA-REPERFUSION INJURY AFTER SEVERE HEAD-INJURY AND ITS POSSIBLE TREATMENT WITH POLYETHYLENEGLYCOL-SUPEROXIDE DISMUTASE	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	SYMP ON NEUROTRAUMA : CONCEPTS, CURRENT PRACTICE AND EMERGING THERAPIES	JUN 11-12, 1992	DEARBORN, MI	WAYNE STATE UNIV SCH MED, DEPT EMERGENCY MED		BRAIN INJURY; ISCHEMIA-REPERFUSION		Oxygen radical-mediated mechanisms play a role both in cerebral ischemia-reperfusion injury and in traumatic brain injury. Moreover, my work with measurements of cerebral blood flow with the Xe-133 method and the stable xenon-computed tomography method and through measurements of arteriovenous difference of oxygen indicates that ischemia and ischemia-reperfusion are also part of traumatic brain injury but only in the first few hours after injury. The contributions of the research laboratories at the Medical College of Virginia, Richmond, to the understanding of the role of oxygen free radicals in traumatic brain injury are discussed. Finally, a trial of the oxygen radical scavenger polyethyleneglycol-superoxide dismutase in human beings with severe head injuries shows that death and vegetative state occurred twice as often in the 26 patients receiving placebo compared with the group of 26 patients receiving a 10,000 U/kg bolus of polyethyleneglycol-superoxide dismutase (43%, respectively; 20% at three months; P < .03).			MUIZELAAR, JP (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,BOX 631,MCV STN,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587, NS-29412-01A1, NS-1-54600-1768] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, R01NS029412, P01NS012587] Funding Source: NIH RePORTER			0	26	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUN	1993	22	6					1014	1021		10.1016/S0196-0644(05)82744-1			8	Emergency Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	LE338	WOS:A1993LE33800010	8503521				2022-02-06	
J	MCINTOSH, TK				MCINTOSH, TK			PHARMACOLOGICAL STRATEGIES IN THE TREATMENT OF EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL BLOOD-FLOW; SPINAL-CORD INJURY; INTRACELLULAR FREE MG-2+; OPIOID RECEPTOR AGONIST; EXCITATORY AMINO-ACIDS; CENTRAL NERVOUS-SYSTEM; MOTOR CORTEX INJURY; DYNORPHIN-A 1-13; TRAUMATIC BRAIN; ENDOGENOUS OPIOIDS	Although the mechanisms underlying secondary or delayed damage after traumatic injury to the central nervous system (CNS) are poorly understood, delayed neuronal injury may result from pathologic changes in the brain's endogenous neurochemistry. These neurochemical changes may include the overactivation of neurotransmitter release systems, changes in presynaptic or postsynaptic receptor binding, or the pathologic release or synthesis of autodestructive injury factors. Identification of such factors and the timing of the neurochemical cascade after CNS injury provides a window of opportunity for treatment with pharmacologic agents that modify synthesis, release, receptor binding, or physiologic activity with subsequent limitation of damage and disability. Over the past decade, a number of experimental studies have reported that modification of postinjury events by pharmacologic manipulation can promote functional recovery in a variety of animal models of CNS injury. This article summarizes the recent work suggesting that endogenous opioid peptides, catecholamines, and magnesium all play a role in the pathophysiologic cascade after brain injury and that pharmacologic manipulation of these endogenous systems may improve functional outcome after brain injury.			MCINTOSH, TK (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT SURG L1096,SURG RES CTR,FARMINGTON,CT 06030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818] Funding Source: NIH RePORTER		Aikawa J.K., 1981, MAGNESIUM ITS BIOL S, V1st ed.; ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524; ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; BASKIN DS, 1985, NEUROPEPTIDES, V5, P307, DOI 10.1016/0143-4179(85)90014-9; BECKER DP, 1985, CENTRAL NERVOUS SYST, P229; BOYESON M G, 1984, Society for Neuroscience Abstracts, V10, P68; Cavaliere F, 1985, Recenti Prog Med, V76, P563; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CLARK AF, 1980, J BIOL CHEM, V255, P6556; CLIFTON GL, 1985, CENTRAL NERVOUS SYST, P139; COHN M, 1962, J BIOL CHEM, V237, P176; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; COX B, 1982, LIFE SCI, V31, P1655; CROCKARD HA, 1977, J NEUROSURG, V46, P784, DOI 10.3171/jns.1977.46.6.0784; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DELGADO TJ, 1986, J CEREBR BLOOD F MET, V6, P600, DOI 10.1038/jcbfm.1986.107; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DEVLIN T, 1990, J PHARMACOL EXP THER, V253, P749; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FAGG G, 1985, TRENDS NEUROSCI, V2, P207; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; GARFINKEL L, 1985, Magnesium, V4, P60; Gennarelli T, 1982, HEAD INJURY BASIC CL, V1982, P129; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; GLOBUS MYT, 1989, J CEREBR BLOOD F MET, V9, P892, DOI 10.1038/jcbfm.1989.123; GORDON K, 1990, J NEUROCHEM, V54, P605, DOI 10.1111/j.1471-4159.1990.tb01914.x; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HALLE D, 1990, IN PRESS STROKE; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; HOLADAY JW, 1980, BRAIN RES, V189, P295, DOI 10.1016/0006-8993(80)90032-3; Hossman K, 1976, DYNAMICS BRAIN EDEMA, P219; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; JENNETT B, 1981, CONT NEUROLOGY SERIE, V20; KHACHATURIAN H, 1985, TRENDS NEUROSCI, V8, P111, DOI 10.1016/0166-2236(85)90048-7; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LONG JB, 1987, BRAIN RES, V436, P374, DOI 10.1016/0006-8993(87)91683-0; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1167; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1158; LONG JB, 1989, BRAIN RES, V10, P1; LYETH BG, 1990, J NEUROTRAUM, V9, P143; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH T, 1988, NEUROL NEUR, V46, P653; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, J CEREB BLOOD FLOW S, V11, pS734; MCINTOSH TK, 1987, J CEREB BLOOD FLOW M, V7, pS620; MCINTOSH TK, 1988, PHARM APPROACH TREAT, P89; MCINTOSH TK, 1988, AM J PHYSIOL, V257, pR785; MCINTOSH TK, 1988, PERSPECTIVES SHOCK R, P415; MCINTOSH TK, 1989, J CEREB BLOOD FLO S1, V9, pS78; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; NIGAM R, 1986, ESSENTIAL FATTY ACID, V233, P1; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PAPPIUS HM, 1987, J NEUROCHEM, V49, P321, DOI 10.1111/j.1471-4159.1987.tb03433.x; PAPPIUS HM, 1988, J CEREBR BLOOD F MET, V8, P324, DOI 10.1038/jcbfm.1988.67; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PERRY DC, 1990, NEUR ABSTR, V16, P242; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROBINSON SE, 1988, NEUR ABSTR, V2, P1254; Romhanyi R, 1990, J NEUROTRAUM, V9, P164; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSNER MJ, 1985, CENTRAL NERVOUS SYST, P405; ROSNER MJ, 1982, HEAD INJURY BASIC CL, P103; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SADEE W, 1982, J NEUROCHEM, V39, P659, DOI 10.1111/j.1471-4159.1982.tb07943.x; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SCHOENFELD TA, 1977, PHYSIOL BEHAV, V18, P951, DOI 10.1016/0031-9384(77)90206-2; Siesj? BK., 1978, BRAIN ENERGY METABOL; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SILVIA RC, 1987, BRAIN RES, V403, P52, DOI 10.1016/0006-8993(87)90121-1; SVENDGAARD NA, 1987, J CEREBR BLOOD F MET, V7, P21, DOI 10.1038/jcbfm.1987.4; SVENDGAARD NA, 1986, J CEREBR BLOOD F MET, V6, P650, DOI 10.1038/jcbfm.1986.120; Tandian D, 1990, J NEUROTRAUM, V9, P174; TANG AH, 1985, LIFE SCI, V37, P1475, DOI 10.1016/0024-3205(85)90178-X; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; VINK R, 1988, J NEUROTRAUM, V5, P105; WEAVER MS, 1988, NEUR ABSTR, V14, P1451; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEST M, 1981, BRAIN RES, V225, P271, DOI 10.1016/0006-8993(81)90835-0; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061; ZUKIN RS, 1961, LIFE SCI, V29, P2681; [No title captured]; [No title captured]	131	26	26	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S201	S209					9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600019	1588609				2022-02-06	
J	WIRSEN, A; STENBERG, G; ROSEN, I; INGVAR, DH				WIRSEN, A; STENBERG, G; ROSEN, I; INGVAR, DH			QUANTIFIED EEG AND CORTICAL EVOKED-RESPONSES IN PATIENTS WITH CHRONIC TRAUMATIC FRONTAL LESIONS	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						FRONTAL TRAUMA; QUANTIFIED EEG; SEP; P300; LESION VOLUME; OUTCOME	EVENT-RELATED POTENTIALS; CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; ENDOGENOUS POTENTIALS; HIPPOCAMPAL-FORMATION; CLINICAL-APPLICATION; SCHIZOPHRENIA; METABOLISM; STIMULI; MEMORY	Eighteen frontal trauma patients and 17 age-matched control subjects had quantified EEGs and measurements of sensory (SEP) and auditory evoked potentials (P300) using a Biologic Brain Atlas Ill system. The findings were compared to the conventional paper EEG, and to the frontal lesion volumes, severity of head injury, and outcome variables. The quantified EEG confirmed the pathological findings detected by visual inspection, but some regional abnormalities were more easily detected by topographic mapping. The regional distribution of pathological slowing corresponded well with the morphological lesions in most patients. The modal frequency of EEG correlated both with lesion volume and injury severity and with the outcome variables. There were no pathological findings in the SEPs, and all but one patient had clearly distinguishable P300 responses. There was a significant reduction in P300 amplitude in the frontal patients at the anterior, but not at the posterior electrodes. The topographical distribution of the P300 changes corresponded well with the morphological lesions. Our findings indicate that the P300 potential is, in part, dependent upon the prefrontal cortical areas. The present study thus supports P300 investigations which have shown amplitude reduction in other disorders (e.g., schizophrenia) with a presumed prefrontal dysfunction.			WIRSEN, A (corresponding author), UNIV LUND HOSP,DEPT CLIN NEUROPHYSIOL,S-22185 LUND,SWEDEN.		Stenberg, Georg/B-9375-2009	Stenberg, Georg/0000-0002-3246-2790			ALTER I, 1990, Brain Injury, V4, P19, DOI 10.3109/02699059009026144; Aminoff M.J., 1986, ELECTRODIAGNOSIS CLI, P21; BARTFAI A, 1986, PRELIMINARY SWEDISH; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DUFFY FH, 1981, ELECTROEN CLIN NEURO, V51, P455, DOI 10.1016/0013-4694(81)90221-2; Duffy FH, 1986, TOPOGRAPHIC MAPPING; FAUX SF, 1988, BIOL PSYCHIAT, V23, P776, DOI 10.1016/0006-3223(88)90066-2; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; HILLYARD SA, 1983, ANNU REV PSYCHOL, V34, P33, DOI 10.1146/annurev.ps.34.020183.000341; HILLYARD SA, 1973, SCIENCE, V182, P177, DOI 10.1126/science.182.4108.177; INGVAR DH, 1976, ELECTROEN CLIN NEURO, V41, P268, DOI 10.1016/0013-4694(76)90119-X; INGVAR DH, 1979, PHARMAKOPSYCH NEURO, V12, P200, DOI 10.1055/s-0028-1094611; ISRAEL J. B., 1980, PSYCHOPHYSIOLOGY, V17, P259; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KILOH LG, 1981, CLIN ELECTROENCEPHAL; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Levander S., 1987, AUTOMATED PSYCHOL TE; Levin HS., 1982, NEUROBEHAVIORAL CONS; MAEDER P, 1991, ACTA RADIOL, V32, P271; MAURER K, 1988, Z EEG EMG, V19, P21; MAURER K, 1988, Z EEG EMG, V19, P26; NAGATA K, 1986, TOPOGRAPHIC MAPPING, P357; Niedermeyer E, 1982, ELECTROENCEPHALOGRAP, P71; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OKADA YC, 1983, ELECTROEN CLIN NEURO, V55, P417, DOI 10.1016/0013-4694(83)90130-X; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; Picton TW, 1988, HDB ELECTROENCEPHALO, V3, P361; RUMPL E, 1982, ELECTROENCEPHALOGRAP, P291; SHIRAHATA N, 1985, J COMPUT ASSIST TOMO, V9, P861, DOI 10.1097/00004728-198509000-00004; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; Wechsler, 1997, WECHSLER ADULT INTEL; WIRSEN A, 1991, NEUROPSYCHOLOGY, V5, P151; WIRSEN A, 1991, UNPUB DIFFUSE NEUROP; WIRSEN A, 1991, UNPUB PROBLEM RECRUI; WIRSEN A, 1991, UNPUB NORMAL RCBF AC; [No title captured]; [No title captured]	50	26	26	0	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	MAR-APR	1992	84	2					127	138		10.1016/0168-5597(92)90017-6			12	Engineering, Biomedical; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology	HL143	WOS:A1992HL14300004	1372227				2022-02-06	
J	SCHER, AT				SCHER, AT			SPINAL-CORD CONCUSSION IN RUGBY PLAYERS	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article								During an analysis of a group of 40 rugby players who had sustained cervical spinal cord injury, 9 players were identified who had sustained only transient paralysis. These players showed no radiologic evidence of any injury to the cervical spine. We did a retrospective analysis of the clinical and radiological findings in this group of rugby players. The cervical spine radiographs were analyzed for evidence of spinal stenosis, congenital anomalies, and degenerative disk disease. Using the ratio method of assessment for spinal stenosis, we found spinal canal narrowing maximally at C-3 and C-4 in five of the nine players. In the remaining four players, one showed evidence of osteoarthritic change at two levels while another had congenital fusion of two vertebral bodies. In two players, no radiologic evidence of any abnormality was detected. The mechanism of transient disturbance of the spinal cord function after trauma is discussed here.			SCHER, AT (corresponding author), UNIV STELLENBOSCH,DEPT RADIOL,TYGERBERG 7505,SOUTH AFRICA.							0	26	26	0	1	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154	0363-5465			AM J SPORT MED	Am. J. Sports Med.	SEP-OCT	1991	19	5					485	488		10.1177/036354659101900511			4	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	GG868	WOS:A1991GG86800011	1962714				2022-02-06	
J	NOUCHI, I; ITO, O; HARAZONO, Y; KOBAYASHI, K				NOUCHI, I; ITO, O; HARAZONO, Y; KOBAYASHI, K			EFFECTS OF CHRONIC OZONE EXPOSURE ON GROWTH, ROOT RESPIRATION AND NUTRIENT-UPTAKE OF RICE PLANTS	ENVIRONMENTAL POLLUTION			English	Article							PHASEOLUS-VULGARIS L; SULFUR-DIOXIDE; NET PHOTOSYNTHESIS; NITROGEN-DIOXIDE; YIELD; RADISH; REDUCTIONS; INJURY; IMPACT; LEAF	To clarify the response of growth and root functions to low concentrations of ozone (O3), rice plants (Oryza sativa L.) were exposed to O3 at 0.0 (control), 0.05 and 0.10 ppm for 8 weeks from vegetative to early heading stages. Exposure to 0.05 ppm O3 tended to slightly stimulate the dry weight of whole plants up to 5 weeks and then slightly decrease the dry weight of whole plants. However, these effects were statistically significant only at 6 weeks. Exposure to 0.10 ppm O3 reduced the dry weight of whole plants by 50% at 5 and 6 weeks, and thereafter the reduction of the dry weight of whole plants was gradually alleviated. Those changes in dry weight can be accounted for by a decrease or increase in the relative growth rate (RGR). The changes in the RGR caused by 0.05 and 0.10 ppm O3 could be mainly attributed to the effect of O3 on the net assimilation rate. Root/shoot ratio was lowered by both 0.05 and 0.10 ppm O3 throughout the exposure period. The root/shoot ratio which had severely decreased at 0.10 ppm O3 in the first half period of exposure (1-4 weeks) became close to the control in the latter part of exposure (5-8 weeks). Time-course changes in NH4-N root uptake rate were similar to those in the root/shoot ratio especially for 0.10 ppm O3. On the other hand, root respiration increased from the middle to later periods. Since it is to be supposed that plants grown under stressed conditions change the ratio of plant organ weight to achieve balance between the proportion of shoots to roots in the plant and their activity for maintaining plant growth, these changes in root/shoot ratio and nitrogen uptake rate under long-term exposure can be considered to be an adaptive response to maintain rice growth under O3 stress.			NOUCHI, I (corresponding author), NATL INST AGROENVIRONM SCI,TSUKUBA,IBARAKI 305,JAPAN.						AMUNDSON RG, 1987, PHYTOPATHOLOGY, V77, P75, DOI 10.1094/Phyto-77-75; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ASAKAWA F, 1981, JPN J SOIL SCI PLANT, V51, P201; ATKINSON CJ, 1988, NEW PHYTOL, V10, P173; Baba I, 1956, EXPT METHODS CROP SC, P157; BENNETT JP, 1976, J AM SOC HORTIC SCI, V101, P638; BROWN KA, 1988, ENVIRON POLLUT, V55, P55, DOI 10.1016/0269-7491(88)90159-5; CHAYKIN S, 1969, ANAL BIOCHEM, V31, P375, DOI 10.1016/0003-2697(69)90278-4; COOLEY DR, 1987, ENVIRON POLLUT, V47, P95, DOI 10.1016/0269-7491(87)90040-6; DAVIDSON RL, 1969, ANN BOT-LONDON, V33, P561, DOI 10.1093/oxfordjournals.aob.a084308; ENDRESS AG, 1985, AGR ECOSYST ENVIRON, V13, P9, DOI 10.1016/0167-8809(85)90097-0; FUHRER J, 1989, ENVIRON POLLUT, V60, P273, DOI 10.1016/0269-7491(89)90109-7; HEAGLE AS, 1979, PHYTOPATHOLOGY, V69, P21, DOI 10.1094/Phyto-69-21; Heck W.W., 1988, ASSESSMENT CROP LOSS; HECK WW, 1983, ENVIRON SCI TECHNOL, V17, pA572, DOI 10.1021/es00118a716; HECK WW, 1984, JAPCA J AIR WASTE MA, V34, P810, DOI 10.1080/00022470.1984.10465815; HOFSTRA G, 1981, ATMOS ENVIRON, V15, P483, DOI 10.1016/0004-6981(81)90178-5; HORSMAN DC, 1980, AUST J PLANT PHYSIOL, V7, P511, DOI 10.1071/PP9800511; ITO O, 1985, J EXP BOT, V36, P652, DOI 10.1093/jxb/36.4.652; KATS G, 1985, AGR ECOSYST ENVIRON, V14, P103, DOI 10.1016/0167-8809(85)90088-X; KOBAYASHI K, 1988, ENVIRON POLLUT, V53, P437, DOI 10.1016/0269-7491(88)90066-8; Koziol M. J., 1984, GASEOUS AIR POLLUTAN; Murphy J., 1962, ANAL CHIM ACTA, V27, P31, DOI [10.1016/S0003-2670(00)88444-5, DOI 10.1016/S0003-2670(00)88444-5]; OKANO K, 1985, ENVIRON POLLUT A, V38, P361, DOI 10.1016/0143-1471(85)90107-2; OSHIMA RJ, 1978, J AM SOC HORTIC SCI, V103, P348; OSHIMA RJ, 1979, J ENVIRON QUAL, V8, P575; RADFORD PJ, 1967, CROP SCI, V7, P171, DOI 10.2135/cropsci1967.0011183X000700030001x; REICH PB, 1985, SCIENCE, V230, P566, DOI 10.1126/science.230.4725.566; REICH PB, 1985, ENVIRON POLLUT A, V39, P39, DOI 10.1016/0143-1471(85)90061-3; REICH PB, 1986, J ENVIRON QUAL, V15, P31, DOI 10.2134/jeq1986.00472425001500010008x; Reich PB, 1987, TREE PHYSIOL, V3, P63, DOI 10.1093/treephys/3.1.63; REINERT RA, 1982, PLANT DIS, V66, P122, DOI 10.1094/PD-66-122; REINERT RA, 1980, J ENVIRON QUAL, V10, P240; SATOH S, 1983, STUDIES COMBINED EFF, V2; SHIMIZU H, 1981, Environment Control in Biology, V19, P137; TINGEY DT, 1973, CAN J PLANT SCI, V53, P875, DOI 10.4141/cjps73-169; TINGEY DT, 1971, J AM SOC HORTIC SCI, V96, P369; WALMSLEY L, 1980, ENVIRON POLLUT A, V23, P165, DOI 10.1016/0143-1471(80)90044-6	38	26	45	4	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0269-7491			ENVIRON POLLUT	Environ. Pollut.		1991	74	2					149	164		10.1016/0269-7491(91)90111-9			16	Environmental Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology	GH011	WOS:A1991GH01100006	15092071				2022-02-06	
J	NOWAK, P; COHN, AM; GUIDICE, MA				NOWAK, P; COHN, AM; GUIDICE, MA			AIRWAY COMPLICATIONS IN PATIENTS WITH CLOSED-HEAD INJURIES	AMERICAN JOURNAL OF OTOLARYNGOLOGY			English	Article									WAYNE STATE UNIV,SCH MED,DEPT OTOLARYNGOL,DETROIT,MI 48201									0	26	26	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0196-0709			AM J OTOLARYNG	Am. J. Otolaryngol.	MAR-APR	1987	8	2					91	96		10.1016/S0196-0709(87)80030-3			6	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	G9294	WOS:A1987G929400004	3592081				2022-02-06	
J	RICHARDSON, JTE; BARRY, C				RICHARDSON, JTE; BARRY, C			THE EFFECTS OF MINOR CLOSED HEAD-INJURY UPON HUMAN-MEMORY - FURTHER EVIDENCE ON THE ROLE OF MENTAL-IMAGERY	COGNITIVE NEUROPSYCHOLOGY			English	Article											RICHARDSON, JTE (corresponding author), BRUNEL UNIV,DEPT PSYCHOL,UXBRIDGE UB8 3PH,MIDDX,ENGLAND.			Richardson, John/0000-0002-6267-0603			Baddeley A. D., 1976, PSYCHOL MEMORY; BAHRICK HP, 1968, J EXP PSYCHOL, V78, P417, DOI 10.1037/h0026458; BEGG I, 1973, CAN J PSYCHOL, V27, P159, DOI 10.1037/h0082465; Bower G.H., 1972, COGNITION LEARNING M; BOWER GH, 1970, J VERB LEARN VERB BE, V9, P529, DOI 10.1016/S0022-5371(70)80096-2; BOWER GH, 1970, AM SCI, V58, P496; BROOKS D N, 1974, Cortex, V10, P224; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; COHEN ME, 1978, B PSYCHONOMIC SOC, V12, P317; COHEN RL, 1968, J VERB LEARN VERB BE, V7, P653, DOI 10.1016/S0022-5371(68)80121-5; COHEN RL, 1970, Q J EXP PSYCHOL, V22, P450, DOI 10.1080/14640747008401918; CONKEY RC, 1938, ARCH PSYCHOL, V33; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; CROVITZ HF, 1979, CORTEX, V15, P225, DOI 10.1016/S0010-9452(79)80027-1; CROVITZ HF, 1979, CORTEX, V15, P131, DOI 10.1016/S0010-9452(79)80013-1; DEFFENBACHER KA, 1981, PERCEIVING REMEMBERI; DEMPSTER FN, 1974, J EXP PSYCHOL, V103, P400, DOI 10.1037/h0037162; ELLIS HD, 1975, BRIT J PSYCHOL, V66, P409, DOI 10.1111/j.2044-8295.1975.tb01477.x; ELLIS HD, 1981, PERCEIVING REMEMBERI; FODOR IE, 1972, J NEUROL NEUROSUR PS, V35, P818, DOI 10.1136/jnnp.35.6.818; GASPARRINI B, 1979, Journal of Clinical Neuropsychology, V1, P137, DOI 10.1080/01688637908414447; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; GOLDSTEIN AG, 1979, B PSYCHONOMIC SOC, V13, P15, DOI 10.3758/BF03334999; GOLDSTEIN AG, 1976, B PSYCHONOMIC SOC, V7, P407, DOI 10.3758/BF03337231; GOLDSTEIN AG, 1971, PERCEPT PSYCHOPHYS, V9, P237, DOI 10.3758/BF03212641; GOLDSTEIN AG, 1981, PERCEIVING REMEMBERI; GRIFFITH D, 1978, B PSYCHONOMIC SOC, V12, P347; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; GRONWALL D, 1974, LANCET, V2, P605; GUPTON T, 1970, J EXP PSYCHOL, V86, P461, DOI 10.1037/h0030178; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HUNTER IML, 1977, J MENTAL IMAGERY, V1, P65; JANSSEN W, 1976, NATURE MENTAL IMAGE; JONES MK, 1974, NEUROPSYCHOLOGIA, V12, P21, DOI 10.1016/0028-3932(74)90023-2; Kuera H., 1967, COMPUTATIONAL ANAL P; KURTZ KH, 1953, J EXP PSYCHOL, V45, P157, DOI 10.1037/h0061022; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; LEVIN HS, 1977, CORTEX, V13, P119, DOI 10.1016/S0010-9452(77)80003-8; LEVIN HS, 1976, DIS NERV SYST, V37, P68; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEWINSOHN PM, 1977, J CONSULT CLIN PSYCH, V45, P717, DOI 10.1037/0022-006X.45.5.717; LIDVALL HF, 1974, ACTA NEUROLOGICA S56, V50; MALPASS RS, 1973, PERCEPT PSYCHOPHYS, V14, P285, DOI 10.3758/BF03212392; MORRIS P, 1977, ADULT LEARNING PSYCH; MORRIS PE, 1974, J VERB LEARN VERB BE, V13, P310, DOI 10.1016/S0022-5371(74)80067-8; MORRIS PE, 1974, BRIT J PSYCHOL, V65, P7, DOI 10.1111/j.2044-8295.1974.tb02765.x; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAIVIO A, 1973, COGNITIVE PSYCHOL, V5, P176, DOI 10.1016/0010-0285(73)90032-7; PAIVIO A, 1972, FUNCTION NATURE IMAG; Paivio A., 1978, HDB PERCEPTION, V8; PAIVIO A, 1968, J EXPT PSYCHOL MON 2, V76; Paivio A., 1971, IMAGERY VERBAL PROCE; Paivio A., 1967, PSYCHON SCI, V8, P65; PARKER SA, 1976, ACTA NEUROCHIR, V34, P71, DOI 10.1007/BF01405864; PATTEN BM, 1972, ARCH NEUROL-CHICAGO, V26, P25, DOI 10.1001/archneur.1972.00490070043006; PELLEGRINO JW, 1975, J EXPT PSYCHOL HUMAN, V1, P95, DOI DOI 10.1037/0278-7393.1.2.95; Poon L. W., 1980, NEW DIRECTIONS MEMOR; Richardson J. T. E., 1980, MENTAL IMAGERY HUMAN; RICHARDSON JT, 1974, J VERB LEARN VERB BE, V13, P709, DOI 10.1016/S0022-5371(74)80057-5; RICHARDSON JTE, 1984, COGN NEUROPSYCHOL, V1, P217, DOI 10.1080/02643298408252023; RICHARDSON JTE, 1979, BRIT J SOC CLIN PSYC, V18, P319, DOI 10.1111/j.2044-8260.1979.tb00342.x; RICHARDSON JTE, 1984, CORTEX, V20, P413, DOI 10.1016/S0010-9452(84)80009-X; RICHARDSON JTE, 1978, PERCEPT MOTOR SKILL, V47, P967, DOI 10.2466/pms.1978.47.3.967; RICHARDSON JTE, 1978, Q J EXP PSYCHOL, V30, P471, DOI 10.1080/00335557843000061; RICHARDSON JTE, 1976, BRIT J PSYCHOL, V67, P487, DOI 10.1111/j.2044-8295.1976.tb01537.x; RICHARDSON JTE, 1979, CORTEX, V15, P145, DOI 10.1016/S0010-9452(79)80016-7; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SAVINO PJ, 1980, NEUROLOGY, V30, P963, DOI 10.1212/WNL.30.9.963; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Shepherd J., 1981, PERCEIVING REMEMBERI; THOMSEN IV, 1977, SCAND J REHABIL MED, V9, P73; Thorndike E. L., 1944, TEACHERS WORD BOOK 3; TULVING E, 1973, PSYCHOL REV, V80, P352, DOI 10.1037/h0020071; *UK OFF POP CENS S, 1970, 1970 CLASS OCC; WARREN MW, 1977, MEM COGNITION, V5, P362, DOI 10.3758/BF03197584; WINER BJ, 1962, STATISTICAL PRINCIPL; YIN RK, 1970, NEUROPSYCHOLOGIA, V8, P395, DOI 10.1016/0028-3932(70)90036-9; YIN RK, 1969, J EXP PSYCHOL, V81, P141, DOI 10.1037/h0027474; YUILLE JC, 1968, J EXP PSYCHOL, V78, P436, DOI 10.1037/h0026457; [No title captured]	84	26	26	0	0	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.		1985	2	2					149	168		10.1080/02643298508252864			20	Psychology; Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	AKH49	WOS:A1985AKH4900002					2022-02-06	
J	PARSONS, LC; SHOGAN, JSO				PARSONS, LC; SHOGAN, JSO			THE EFFECTS OF THE ENDOTRACHEAL-TUBE SUCTIONING MANUAL HYPERVENTILATION PROCEDURE ON PATIENTS WITH SEVERE CLOSED HEAD-INJURIES	HEART & LUNG			English	Article											PARSONS, LC (corresponding author), UNIV VIRGINIA,SCH NURSING,CHARLOTTESVILLE,VA 22903, USA.						BEDFORD RF, 1980, ANESTH ANALG, V59, P435; CAVENESS WF, 1979, ADV NEUROLOGY, V22; Cushing H, 1903, AM J MED SCI, V125, P1017, DOI 10.1097/00000441-190306000-00006; DONEGAN MF, 1980, ANESTHESIOLOGY, V52, P516, DOI 10.1097/00000542-198006000-00014; DOWNES JJ, 1961, ANESTHESIOLOGY, V22, P29, DOI 10.1097/00000542-196101000-00007; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; LUNDBERG N, 1960, ACTA PSYCHIAT S S149, V35, P1; MARSHALL LF, 1977, ACTA NEUROL SCAND, V56, P156; MITCHELL PH, 1978, NURSING RES, V21, P4; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; RODBARD S, 1955, CIRCULATION, V12, P883, DOI 10.1161/01.CIR.12.5.883; SHALIT MN, 1977, ISRAEL J MED SCI, V13, P881; SKELLY BFH, 1981, HEART LUNG, V9, P316; TEASDALE G, 1974, LANCET, V2, P81; URBAN BJ, 1969, ANESTHESIOLOGY, V31, P473, DOI 10.1097/00000542-196911000-00024	15	26	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0147-9563			HEART LUNG	Heart Lung		1984	13	4					372	380					9	Cardiac & Cardiovascular Systems; Nursing; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Nursing; Respiratory System	TB345	WOS:A1984TB34500010	6564106				2022-02-06	
J	NEWCOMBE, F				NEWCOMBE, F			THE PSYCHOLOGICAL CONSEQUENCES OF CLOSED HEAD-INJURY - ASSESSMENT AND REHABILITATION	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article											NEWCOMBE, F (corresponding author), RADCLIFFE INFIRM,NEUROPSYCHOL UNIT,NEUROSCI GRP,OXFORD OX2 6HE,ENGLAND.							0	26	26	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0020-1383			INJURY	Injury-Int. J. Care Inj.		1982	14	2					111	136		10.1016/0020-1383(82)90046-8			26	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	PJ320	WOS:A1982PJ32000001	6754607				2022-02-06	
J	PARSONS, LC; BEEK, DV				PARSONS, LC; BEEK, DV			SLEEP-AWAKE PATTERNS FOLLOWING CEREBRAL CONCUSSION	NURSING RESEARCH			English	Article									UNIV VIRGINIA,SCH MED,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22903; GREENVILLE GEN HOSP,GREENVILLE,SC		PARSONS, LC (corresponding author), UNIV VIRGINIA,SCH NURSING,CHARLOTTESVILLE,VA 22903, USA.						ADEY WR, 1968, ARCH NEUROL-CHICAGO, V19, P377, DOI 10.1001/archneur.1968.00480040043003; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; BERGAMASCO B, 1968, ACTA NEUROL SCAND, V44, P495, DOI 10.1111/j.1600-0404.1968.tb05588.x; COURJON J, 1972, CLIN EEG 4, V14, P47; COURJON J, 1962, CAH MED LYON, V38, P315; Duensing F, 1948, NERVENARZT, V19, P544; FINK ROBERT P., 1967, BRAIN RES, V4, P369, DOI 10.1016/0006-8993(67)90166-7; Foulkes D, 1970, Int Psychiatry Clin, V7, P147; GRONWALL, 1974, LANCET, V2, P605; HARTMANN E, 1970, INT PSYCHIATRY CLIN, V7, P64; LADURNER G, 1970, ELECTROENCEPHALOGER, V28, pP326; LENARD HG, 1970, ACTA PAEDIATR SCAND, V59, P565, DOI 10.1111/j.1651-2227.1970.tb16809.x; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; LORENZONI E, 1963, WIEN MED WSCHR, V42, P787; MONROE LJ, 1967, J ABNORM PSYCHOL, V72, P255, DOI 10.1037/h0024563; MONROE LJ, 1965, J PERS SOC PSYCHOL, V2, P456, DOI 10.1037/h0022218; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARSONS LC, 1981, NEUROSCI LETT, V24, P199, DOI 10.1016/0304-3940(81)90248-2; PARSONS LC, 1967, PHYSIOLOGIST, V10, P273; PARSONS LC, 1980, NEUR ABST, V8, P12; PARSONS LC, 1968, THESIS U TEXAS MED B; PETERSON PJ, 1981, THESIS U VIRGINIA SC; RICHARDSON JC, 1951, CAN MED ASSOC J, V64, P414; STRICH SJ, 1961, LANCET, V2, P443; TAUB JM, 1973, PSYCHOPHYSIOLOGY, V10, P559, DOI 10.1111/j.1469-8986.1973.tb00805.x; TEASDALE G, 1974, LANCET, V2, P81	27	26	26	0	2	AMER J NURSING CO	NEW YORK	555 W 57TH ST, NEW YORK, NY 10019-2961	0029-6562			NURS RES	Nurs. Res.		1982	31	5					260	264					5	Nursing	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Nursing	PG320	WOS:A1982PG32000002	6922465				2022-02-06	
J	Mantovani, E; Zucchella, C; Bottiroli, S; Federico, A; Giugno, R; Sandrini, G; Chiamulera, C; Tamburin, S				Mantovani, Elisa; Zucchella, Chiara; Bottiroli, Sara; Federico, Angela; Giugno, Rosalba; Sandrini, Giorgio; Chiamulera, Cristiano; Tamburin, Stefano			Telemedicine and Virtual Reality for Cognitive Rehabilitation: A Roadmap for the COVID-19 Pandemic	FRONTIERS IN NEUROLOGY			English	Article						augmented reality; cognitive; COVID-19; rehabilitation; telemedicine; virtual reality	THERAPY; TELEREHABILITATION; NEUROREHABILITATION; NEUROLOGY; DISEASE	The current COVID-19 pandemic presents unprecedented new challenges to public health and medical care delivery. To control viral transmission, social distancing measures have been implemented all over the world, interrupting the access to routine medical care for many individuals with neurological diseases. Cognitive disorders are common in many neurological conditions, e.g., stroke, traumatic brain injury, Alzheimer's disease, and other types of dementia, Parkinson's disease and parkinsonian syndromes, and multiple sclerosis, and should be addressed by cognitive rehabilitation interventions. To be effective, cognitive rehabilitation programs must be intensive and prolonged over time; however, the current virus containment measures are hampering their implementation. Moreover, the reduced access to cognitive rehabilitation might worsen the relationship between the patient and the healthcare professional. Urgent measures to address issues connected to COVID-19 pandemic are, therefore, needed. Remote communication technologies are increasingly regarded as potential effective options to support health care interventions, including neurorehabilitation and cognitive rehabilitation. Among them, telemedicine, virtual reality, augmented reality, and serious games could be in the forefront of these efforts. We will briefly review current evidence-based recommendations on the efficacy of cognitive rehabilitation and offer a perspective on the role of tele- and virtual rehabilitation to achieve adequate cognitive stimulation in the era of social distancing related to COVID-19 pandemic. In particular, we will discuss issues related to their diffusion and propose a roadmap to address them. Methodological and technological improvements might lead to a paradigm shift to promote the delivery of cognitive rehabilitation to people with reduced mobility and in remote regions.	[Mantovani, Elisa; Federico, Angela; Tamburin, Stefano] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy; [Zucchella, Chiara] Verona Univ Hosp, Neurol Sect, Dept Neurosci, Verona, Italy; [Bottiroli, Sara] Giustino Fortunato Univ, Benevento, Italy; [Bottiroli, Sara; Sandrini, Giorgio] IRCCS Mondino Fdn, Pavia, Italy; [Giugno, Rosalba] Univ Verona, Dept Comp Sci, Verona, Italy; [Sandrini, Giorgio] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy; [Chiamulera, Cristiano] Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy		Tamburin, S (corresponding author), Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy.	stefano.tamburin@univr.it	Tamburin, Stefano/AAB-9500-2019; Mantovani, Elisa/AAO-8695-2021; Bottiroli, Sara/K-7548-2016; Chiamulera, Cristiano/C-4917-2015	Mantovani, Elisa/0000-0003-3717-7697; Bottiroli, Sara/0000-0002-0151-3962; Chiamulera, Cristiano/0000-0001-5076-8518			Alzahrani H, 2018, J PARKINSON DIS, V8, P233, DOI 10.3233/JPD-171250; [Anonymous], **NON-TRADITIONAL**; [Anonymous], **NON-TRADITIONAL**; Bahar-Fuchs A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003260.pub2; Bartolo Michelangelo, 2020, FRONT NEUROL, V11; Bergquist TF, 1997, NEUROREHABILITATION, V8, P49, DOI 10.3233/NRE-1997-8107; Bird K., 1975, TELEMEDICINE EXPLORA, P89; Bloem BR, 2020, JAMA NEUROL, V77, P927, DOI 10.1001/jamaneurol.2020.1452; Bowen A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003586.pub3; Brennan D, 2010, INT J TELEREHABILITA, V2, P31, DOI [10.5195/IJT.2010.6063, 10.5195/ijt.2010.6063]; Burdea Grigore C, 2003, VIRTUAL REALITY TECH, DOI DOI 10.1162/105474603322955950; Cappa SF, 2005, EUR J NEUROL, V12, P665; Centers for Disease Control and Prevention, 2020, PUBL HLTH REC COMM R; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2019, ARCH PHYS MED REHAB, V100, P1515, DOI 10.1016/j.apmr.2019.02.011; Cotelli M, 2019, J TELEMED TELECARE, V25, P67, DOI 10.1177/1357633X17740390; Danzl Megan M, 2012, J Allied Health, V41, P35; Dial HR, 2019, CLIN INTERV AGING, V14, P453, DOI 10.2147/CIA.S178878; Duncan C, 2010, SCOT MED J, V55, P3, DOI 10.1258/rsmsmj.55.1.3; Ferguson C, 2020, AM J HOSP PALLIAT ME, V37, P809, DOI 10.1177/1049909120901525; Ferrer-Garcia M, 2013, J CONTEMP PSYCHOTHER, V43, P207, DOI 10.1007/s10879-013-9240-1; Gamito P., 2014, INT J DISABIL HUMAN, V13, DOI [10.1515/ijdhd-2014-0325, DOI 10.1515/IJDHD-2014-0325]; Gamito P, 2017, DISABIL REHABIL, V39, P385, DOI 10.3109/09638288.2014.934925; Gamito P, 2011, VIRTUAL REALITY, P515; Giglioli IAC, 2015, COMPUT MATH METHOD M, V2015, DOI 10.1155/2015/862942; Griffiths PC, 2018, AM J ALZHEIMERS DIS, V33, P269, DOI 10.1177/1533317518755331; Grossman SN, 2020, NEUROLOGY, V94, P1077, DOI 10.1212/WNL.0000000000009677; Hopwood J, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9548; Isernia S, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01206; Khademi M, 2013, IEEE ENG MED BIO, P4613, DOI 10.1109/EMBC.2013.6610575; Khattab S, 2021, DISABIL REHABIL, V43, P3574, DOI 10.1080/09638288.2020.1744199; Kovaleva M, 2019, J APPL GERONTOL, V38, P159, DOI 10.1177/0733464817705958; Kumar KS, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007935.pub2; Lange B, 2012, DISABIL REHABIL, V34, P1863, DOI 10.3109/09638288.2012.670029; Laver KE, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010255.pub3; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4, 10.1002/14651858.CD008349.pub2]; Li JH, 2014, CYBERPSYCH BEH SOC N, V17, P519, DOI 10.1089/cyber.2013.0481; Lohse KR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093318; LOPES S, 2018, FRONT PSYCHOL, V0009; Lupinacci G, 2018, DISABIL REHABIL-ASSI, V13, P234, DOI 10.1080/17483107.2017.1306592; Maggio MG, 2020, EXPERT REV MED DEVIC, V17, P473, DOI 10.1080/17434440.2020.1776607; Maggio MG, 2019, J NATL MED ASSOC, V111, P457, DOI 10.1016/j.jnma.2019.01.003; Manera V, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01243; Manera V, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00024; MATAMALAGOMEZ M, 2020, FRONT NEUROL, V0011; McCallum Simon, 2013, Serious Games Development and Applications. 4th International Conference, SGDA 2013. Proceedings: LNCS 8101, P15, DOI 10.1007/978-3-642-40790-1_2; McCann RA, 2014, J ANXIETY DISORD, V28, P625, DOI 10.1016/j.janxdis.2014.05.010; Mishkind MC, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0836-0; Montaner J, 2020, STROKE, V51, P2307, DOI 10.1161/STROKEAHA.120.030106; Moreno A, 2019, ALZH DEMENT-TRCI, V5, P834, DOI 10.1016/j.trci.2019.09.016; Moyle W, 2018, GERONTOLOGIST, V58, P478, DOI 10.1093/geront/gnw270; Nesbitt TS, 2000, WESTERN J MED, V173, P169, DOI 10.1136/ewjm.173.3.169-a; PLATZ T, 2020, FRONT NEUROL, V0011; Riva G, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00164; Robert PH, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00054; Rogers JM, 2018, NEUROPSYCHOL REV, V28, P285, DOI 10.1007/s11065-018-9378-4; Rosti-Otajarvi EM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009131.pub3; Rouse R, 2015, DIGIT CREAT, V26, P175, DOI 10.1080/14626268.2015.1100123; Sokolov AA, 2020, CURR OPIN NEUROL, V33, P239, DOI 10.1097/WCO.0000000000000791; Solomon MD, 2020, NEW ENGL J MED, V383, P691, DOI 10.1056/NEJMc2015630; Tarr MJ, 2002, NAT NEUROSCI, V5, P1089, DOI 10.1038/nn948; Tchero H, 2018, J MED INTERNET RES, V20, DOI 10.2196/10867; Teo WP, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00284; Tieri G, 2018, EXPERT REV MED DEVIC, V15, P107, DOI 10.1080/17434440.2018.1425613; Triberti S, 2014, CYBERPSYCH BEH SOC N, V17, P335, DOI 10.1089/cyber.2014.0054; Turner-Stokes L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub3; Valimaki M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009928.pub2; van der Kuil MNA, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00846; van der Linden SD, 2018, J NEURO-ONCOL, V137, P523, DOI 10.1007/s11060-017-2738-8; Weiss P, 2006, TXB NEURAL REPAIR RE, P182; Weiss PLT., 2009, ADV TECHNOLOGIES REH; Wiederhold BK, 2019, CYBERPSYCH BEH SOC N, V22, P3, DOI 10.1089/cyber.2018.29136.bkw; Wiederhold BK, 2018, CYBERPSYCH BEH SOC N, V21, P341, DOI 10.1089/cyber.2018.29114.bkw; Winters JM, 2002, ANNU REV BIOMED ENG, V4, P287, DOI 10.1146/annurev.bioeng.4.112801.121923; Wolf SL, 2002, NEUROLOGIST, V8, P325, DOI 10.1097/00127893-200211000-00001; Wollersheim D, 2010, INT J EMERGING TECHN, V8, P15; World Health Organization, 2010, TEL OPP DEV MEMB STA; Yeroushalmi S, 2020, J TELEMED TELECARE, V26, P400, DOI 10.1177/1357633X19840097; Zhou RJ, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00597; Zucchella C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01058; Zyda M, 2005, COMPUTER, V38, P25, DOI 10.1109/MC.2005.297	81	25	25	7	23	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	SEP 15	2020	11								926	10.3389/fneur.2020.00926			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	NY2AD	WOS:000576198100001	33041963	Green Published, gold			2022-02-06	
J	Shahim, P; Politis, A; van der Merwe, A; Moore, B; Chou, YY; Pham, DL; Butman, JA; Diaz-Arrastia, R; Gill, JM; Brody, DL; Zetterberg, H; Blennow, K; Chan, L				Shahim, Pashtun; Politis, Adam; van der Merwe, Andre; Moore, Brian; Chou, Yi-Yu; Pham, Dzung L.; Butman, John A.; Diaz-Arrastia, Ramon; Gill, Jessica M.; Brody, David L.; Zetterberg, Henrik; Blennow, Kaj; Chan, Leighton			Neurofilament light as a biomarker in traumatic brain injury	NEUROLOGY			English	Article							AFTERMATH; PROTEIN; MARKER	Objective To determine whether serum neurofilament light (NfL) correlates with CSF NfL, traumatic brain injury (TBI) diagnosis, injury severity, brain volume, and diffusion tensor imaging (DTI) estimates of traumatic axonal injury (TAI). Methods Participants were prospectively enrolled in Sweden and the United States between 2011 and 2019. The Swedish cohort included 45 hockey players with acute concussion sampled at 6 days, 31 with repetitive concussion with persistent postconcussive symptoms (PCS) assessed with paired CSF and serum (median 1.3 years after concussion), 28 preseason controls, and 14 nonathletic controls. Our second cohort included 230 clinic-based participants (162 with TBI and 68 controls). Patients with TBI also underwent serum, functional outcome, and imaging assessments at 30 (n = 30), 90 (n = 48), and 180 (n = 59) days and 1 (n = 84), 2 (n = 57), 3 (n = 46), 4 (n = 38), and 5 (n = 29) years after injury. Results In athletes with paired specimens, CSF NfL and serum NfL were correlated (r = 0.71, p < 0.0001). CSF and serum NfL distinguished players with PCS >1 year from PCS <= 1 year (area under the receiver operating characteristic curve [AUROC] 0.81 and 0.80). The AUROC for PCS >1 year vs preseason controls was 0.97. In the clinic-based cohort, NfL at enrollment distinguished patients with mild from those with moderate and severe TBI (p < 0.001 and p = 0.048). Serum NfL decreased over the course of 5 years (beta = -0.09 log pg/mL, p < 0.0001) but remained significantly elevated compared to controls. Serum NfL correlated with measures of functional outcome, MRI brain atrophy, and DTI estimates of TAI. Conclusions Serum NfL shows promise as a biomarker for acute and repetitive sports-related concussion and patients with subacute and chronic TBI. Classification of evidence This study provides Class III evidence that increased concentrations of NfL distinguish patients with TBI from controls.	[Shahim, Pashtun; Politis, Adam; Chou, Yi-Yu; Pham, Dzung L.; Butman, John A.; Gill, Jessica M.; Brody, David L.; Chan, Leighton] NIH, Bldg 10, Bethesda, MD 20892 USA; [Shahim, Pashtun; van der Merwe, Andre; Moore, Brian; Chou, Yi-Yu; Pham, Dzung L.; Butman, John A.; Gill, Jessica M.; Brody, David L.; Chan, Leighton] Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Shahim, Pashtun; van der Merwe, Andre; Moore, Brian; Gill, Jessica M.; Brody, David L.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA; [Shahim, Pashtun; Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Molndal, Sweden; [Shahim, Pashtun; Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Brody, David L.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Zetterberg, Henrik] UK Dementia Res Inst UCL, London, England; [Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England		Shahim, P (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.; Shahim, P (corresponding author), Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA.; Shahim, P (corresponding author), Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA.; Shahim, P (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Molndal, Sweden.; Shahim, P (corresponding author), Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden.	pashtun-poh.shahim@nih.gov			Intramural Research Program at the NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Department of Defense (Center for Neuroscience and Regenerative Medicine)United States Department of Defense	Funding provided by the Intramural Research Program at the NIH and the Department of Defense (Center for Neuroscience and Regenerative Medicine). The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.	[Anonymous], 2009, VA DOD CLIN PRACTICE; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Bazin PL, 2011, NEUROIMAGE, V58, P458, DOI 10.1016/j.neuroimage.2011.06.020; Burman E, 2016, BMJ OPEN SPORT EXERC, V2, pe000092, DOI DOI 10.1136/BMJSEM-2015-000092; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Gill J, 2018, NEUROLOGY, V91, pE1385, DOI 10.1212/WNL.0000000000006321; Gisslen M, 2016, EBIOMEDICINE, V7, P287, DOI 10.1016/j.ebiom.2016.04.021; Hossain I, 2019, J NEUROTRAUM, V36, P1551, DOI 10.1089/neu.2018.5952; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hunter LE, 2019, J NEUROTRAUM, V36, P1222, DOI 10.1089/neu.2018.5838; Iverson GL, 2019, J NEUROTRAUM, V36, P2400, DOI 10.1089/neu.2018.6341; Kalm M, 2017, BRAIN RES, V1668, P12, DOI 10.1016/j.brainres.2017.05.011; Khalil M, 2018, NAT REV NEUROL, V14, P577, DOI 10.1038/s41582-018-0058-z; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Marion CM, 2018, J NEUROSCI, V38, P8723, DOI 10.1523/JNEUROSCI.0819-18.2018; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Novakova L, 2017, NEUROLOGY, V89, P2230, DOI 10.1212/WNL.0000000000004683; Pierpaoli C, 2010, ISMRM 18 ANN M MAY 1; Posti JP, 2019, J NEUROTRAUM, V36, P2178, DOI 10.1089/neu.2018.6254; Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3; Roy S, 2017, NEUROIMAGE, V146, P132, DOI 10.1016/j.neuroimage.2016.11.017; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Skillback T, 2017, NEUROBIOL AGING, V59, P1, DOI 10.1016/j.neurobiolaging.2017.06.028; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Werner JK, 2020, NEUROLOGY, V94; Wilke C, 2016, J NEUROL NEUROSUR PS, V87, P1270, DOI 10.1136/jnnp-2015-312972; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yuan AD, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a018309	39	25	25	3	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG 11	2020	95	6					E610	E622		10.1212/WNL.0000000000009983			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OH2AX	WOS:000582373300016	32641538	Green Submitted, Green Published			2022-02-06	
J	Sharma, R; Kambhampati, SP; Zhang, Z; Sharma, A; Chen, S; Duh, EI; Kannan, S; Tso, MOM; Kannan, RM				Sharma, Rishi; Kambhampati, Siva P.; Zhang, Zhi; Sharma, Anjali; Chen, Samuel; Duh, Erica I.; Kannan, Sujatha; Tso, Mark O. M.; Kannan, Rangaramanujam M.			Dendrimer mediated targeted delivery of sinomenine for the treatment of acute neuroinflammation in traumatic brain injury	JOURNAL OF CONTROLLED RELEASE			English	Article							ACUTE LUNG INJURY; MICROGLIAL ACTIVATION; INFLAMMATION; INVOLVEMENT; DRUG; CONJUGATE; APOPTOSIS; CYTOKINES; PROTECTS; MICE		[Sharma, Rishi; Kambhampati, Siva P.; Sharma, Anjali; Chen, Samuel; Duh, Erica I.; Kannan, Sujatha; Tso, Mark O. M.; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Sch Med, Ctr Nanomed, Dept Ophthalmol,Wilmer Eye Inst, Baltimore, MD 21231 USA; [Zhang, Zhi; Kannan, Sujatha; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Chen, Samuel] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; [Duh, Erica I.] Bryn Mawr Sch, Baltimore, MD 21210 USA; [Kannan, Sujatha; Kannan, Rangaramanujam M.] Kennedy Krieger Inc, Hugo W Moser Res Inst, Baltimore, MD 21205 USA; [Zhang, Zhi] Univ Michigan, Dept Nat Sci, Dearborn, MI 48128 USA		Kannan, RM (corresponding author), Johns Hopkins Sch Med, Ophthalmol, Ctr Nanomed, Wilmer Eye Inst, 400 North Broadway, Baltimore, MD 21231 USA.	krangar1@jhmi.edu	Kambhampati, Siva Pramodh/AAK-6269-2020	Zhang, Zhi/0000-0001-6256-9516	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD076901]; NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [RO1 EY025304]; Wilmer core facility and imaging center [P30EY001765]	This study was partly funded by the NICHD grant number R01HD076901 (R.M.K.) and NEI grant number RO1 EY025304 (R.M.K). We also thank the Wilmer core facility and imaging center (core grant: P30EY001765) for confocal microscopy facilities.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Agoston DV, 2012, FRONT NEUROL, V3; Alnasser Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23051025; Bagaev AV, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36052-5; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Bharadwaj VN, 2016, SCI REP-UK, V6, DOI 10.1038/srep29988; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chai XY, 2012, BIOORG MED CHEM LETT, V22, P5849, DOI 10.1016/j.bmcl.2012.07.087; Chandra S, 2011, J MATER CHEM, V21, P5729, DOI 10.1039/c0jm04198j; de Araujo RV, 2018, MOLECULES, V23, DOI 10.3390/molecules23112849; Devoto C, 2017, CELL TRANSPLANT, V26, P1169, DOI 10.1177/0963689717714098; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Gallentine WB, 2017, EPILEPSIA, V58, P1102, DOI 10.1111/epi.13750; Gao TL, 2019, DATA BRIEF, V27, DOI 10.1016/j.dib.2019.104633; Guo Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154437; Hanlon LA, 2016, J NEUROPATH EXP NEUR, V75, P214, DOI 10.1093/jnen/nlv021; He XB, 2005, IMMUNOL LETT, V98, P91, DOI 10.1016/j.imlet.2004.10.027; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Hernadez-Ontiveros D., 2013, FRONT NEUROL, V4; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Jain K., 2019, HDB NEUROPROTECTION, P281, DOI DOI 10.1007/978-1-4939-9465-6_4; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kambhampati SP, 2015, EUR J PHARM BIOPHARM, V95, P239, DOI 10.1016/j.ejpb.2015.02.013; Kannan G, 2017, J CONTROL RELEASE, V263, P192, DOI 10.1016/j.jconrel.2017.03.032; Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162; Kolhatkar RB, 2007, BIOCONJUGATE CHEM, V18, P2054, DOI 10.1021/bc0603889; Liu SZ, 2018, BIOMED PHARMACOTHER, V107, P696, DOI 10.1016/j.biopha.2018.08.048; Llorian-Salvador M, 2016, BASIC CLIN PHARMACOL, V119, P32, DOI 10.1111/bcpt.12543; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lucas K, 2013, MOL NEUROBIOL, V48, P190, DOI 10.1007/s12035-013-8425-7; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Miller HA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52622-7; Nance E, 2016, BIOMATERIALS, V101, P96, DOI 10.1016/j.biomaterials.2016.05.044; Nance E, 2015, J CONTROL RELEASE, V214, P112, DOI 10.1016/j.jconrel.2015.07.009; Nemeth CL, 2017, NANOMED-NANOTECHNOL, V13, P2359, DOI 10.1016/j.nano.2017.06.014; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Paulo CSO, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/49/494002; Perumal OP, 2008, BIOMATERIALS, V29, P3469, DOI 10.1016/j.biomaterials.2008.04.038; Price L., 2016, TRANSLATIONAL RES TR; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Schimmel Samantha J, 2017, Brain Circ, V3, P135, DOI 10.4103/bc.bc_18_17; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sevenson S, 2012, ADV DRUG DELIVER REV, V64, P102, DOI 10.1016/j.addr.2012.09.030; Sharma A, 2018, THERANOSTICS, V8, P5529, DOI 10.7150/thno.29039; Sharma R, 2018, BIOENG TRANSL MED, V3, P87, DOI 10.1002/btm2.10094; Sharma R, 2017, BIOCONJUGATE CHEM, V28, P2874, DOI 10.1021/acs.bioconjchem.7b00569; Shi H, 2016, J NEUROIMMUNOL, V299, P28, DOI 10.1016/j.jneuroim.2016.08.010; Shukla SM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-117; Soiberman U, 2017, BIOMATERIALS, V125, P38, DOI 10.1016/j.biomaterials.2017.02.016; Tang J, 2018, MINI-REV MED CHEM, V18, P906, DOI 10.2174/1389557517666171123212557; Tao WW, 2015, INT IMMUNOPHARMACOL, V27, P138, DOI 10.1016/j.intimp.2015.05.005; Varin A, 2009, IMMUNOBIOLOGY, V214, P630, DOI 10.1016/j.imbio.2008.11.009; Wang AL, 2007, INT IMMUNOPHARMACOL, V7, P1552, DOI 10.1016/j.intimp.2007.07.030; Wang QX, 2011, INT IMMUNOPHARMACOL, V11, P373, DOI 10.1016/j.intimp.2010.11.018; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wu WN, 2011, BRIT J PHARMACOL, V164, P1445, DOI 10.1111/j.1476-5381.2011.01487.x; Xiong Y, 2018, CHIN J TRAUMATOL, V21, P137, DOI 10.1016/j.cjtee.2018.02.003; Xu M, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00220; YAMASAKI H, 1976, ACTA MED OKAYAMA, V30, P1; Yang YQ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00580; Yang Z, 2014, MOL IMMUNOL, V60, P109, DOI 10.1016/j.molimm.2014.03.005; Zhang LL, 2019, NEUROCHEM RES, V44, P763, DOI 10.1007/s11064-018-02706-z; Zhang Z, 2019, J NEUROTRAUM, V36, P74, DOI 10.1089/neu.2017.5450; Zhang Z, 2015, J NEUROTRAUM, V32, P1369, DOI 10.1089/neu.2014.3701; Zhao ZJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21111520; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Zhu Q, 2014, SCI REP-UK, V4, DOI 10.1038/srep07270; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	72	25	27	4	30	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0168-3659	1873-4995		J CONTROL RELEASE	J. Control. Release	JUL 10	2020	323						361	375		10.1016/j.jconrel.2020.04.036			15	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Pharmacology & Pharmacy	LY7FW	WOS:000540694200004	32339548				2022-02-06	
J	Dickstein, DL; De Gasperi, R; Sosa, MGA; Perez-Garcia, G; Short, JA; Sosa, H; Perez, GM; Tschiffely, AE; Dams-O'Connor, K; Pullman, MY; Knesaurek, K; Knutsen, A; Pham, DL; Soleimani, L; Jordan, BD; Gordon, WA; Delman, BN; Shumyatsky, G; Shahim, PP; DeKosky, ST; Stone, JR; Peskind, E; Blennow, K; Zetterberg, H; Chance, SA; Torso, M; Kostakoglu, L; Sano, M; Hof, PR; Ahlers, ST; Gandy, S; Elder, GA				Dickstein, Dara L.; De Gasperi, Rita; Gama Sosa, Miguel A.; Perez-Garcia, Georgina; Short, Jennifer A.; Sosa, Heidi; Perez, Gissel M.; Tschiffely, Anna E.; Dams-O'Connor, Kristen; Pullman, Mariel Y.; Knesaurek, Karin; Knutsen, Andrew; Pham, Dzung L.; Soleimani, Lale; Jordan, Barry D.; Gordon, Wayne A.; Delman, Bradley N.; Shumyatsky, Gleb; Shahim, Pashtun-Poh; DeKosky, Steven T.; Stone, James R.; Peskind, Elaine; Blennow, Kaj; Zetterberg, Henrik; Chance, Steven A.; Torso, Mario; Kostakoglu, Lale; Sano, Mary; Hof, Patrick R.; Ahlers, Stephen T.; Gandy, Sam; Elder, Gregory A.			Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure	MOLECULAR PSYCHIATRY			English	Article							PERSISTENT POSTCONCUSSIVE SYMPTOMS; MILITARY SERVICE MEMBERS; PET TRACER F-18-AV-1451; DISORDER-RELATED TRAITS; COGNITIVE IMPAIRMENT; TAU; MODEL; EXPRESSION; DEMENTIA; DISEASE	Traumatic brain injury (TBI) is a risk factor for the later development of neurodegenerative diseases that may have various underlying pathologies. Chronic traumatic encephalopathy (CTE) in particular is associated with repetitive mild TBI (mTBI) and is characterized pathologically by aggregation of hyperphosphorylated tau into neurofibrillary tangles (NFTs). CTE may be suspected when behavior, cognition, and/or memory deteriorate following repetitive mTBI. Exposure to blast overpressure from improvised explosive devices (IEDs) has been implicated as a potential antecedent for CTE amongst Iraq and Afghanistan Warfighters. In this study, we identified biomarker signatures in rats exposed to repetitive low-level blast that develop chronic anxiety-related traits and in human veterans exposed to IED blasts in theater with behavioral, cognitive, and/or memory complaints. Rats exposed to repetitive low-level blasts accumulated abnormal hyperphosphorylated tau in neuronal perikarya and perivascular astroglial processes. Using positron emission tomography (PET) and the [F-18]AV1451 (flortaucipir) tau ligand, we found that five of 10 veterans exhibited excessive retention of [F-18]AV1451 at the white/gray matter junction in frontal, parietal, and temporal brain regions, a typical localization of CTE tauopathy. We also observed elevated levels of neurofilament light (NfL) chain protein in the plasma of veterans displaying excess [F-18]AV1451 retention. These findings suggest an association linking blast injury, tauopathy, and neuronal injury. Further study is required to determine whether clinical, neuroimaging, and/or fluid biomarker signatures can improve the diagnosis of long-term neuropsychiatric sequelae of mTBI.	[Dickstein, Dara L.] Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Dickstein, Dara L.; Knutsen, Andrew; Pham, Dzung L.; Shahim, Pashtun-Poh] Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [De Gasperi, Rita; Gama Sosa, Miguel A.; Perez-Garcia, Georgina; Sosa, Heidi; Perez, Gissel M.; Sano, Mary; Gandy, Sam] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [De Gasperi, Rita; Gama Sosa, Miguel A.; Short, Jennifer A.; Sosa, Heidi; Pullman, Mariel Y.; Sano, Mary; Gandy, Sam; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave Levy Pl, New York, NY 10029 USA; [Perez-Garcia, Georgina; Dams-O'Connor, Kristen; Gandy, Sam; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave Levy Pl, New York, NY 10029 USA; [Tschiffely, Anna E.; Ahlers, Stephen T.] Naval Med Res Ctr, Dept Neurotrauma, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil & Phys Med, One Gustave Levy Pl, New York, NY 10029 USA; [Knesaurek, Karin; Soleimani, Lale; Delman, Bradley N.; Kostakoglu, Lale] Icahn Sch Med Mt Sinai, Dept Mol & Intervent Radiol, One Gustave L Levy Pl, New York, NY 10029 USA; [Jordan, Barry D.] Burke Rehabil & Res, 785 Mamaroneck Ave, White Plains, NY 10605 USA; [Shumyatsky, Gleb] Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; [Shahim, Pashtun-Poh] NINDS, NIH, Neurol Inst, POB 5081, Bethesda, MD 20824 USA; [DeKosky, Steven T.] Univ Florida, Dept Neurol, Gainesville, FL 32611 USA; [Stone, James R.] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA; [Peskind, Elaine] VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA 98195 USA; [Peskind, Elaine] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Sahlgrenska Acad, S-43180 Molndal, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, S-43180 Molndal, Sweden; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London WC1E 6BT, England; [Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, Queen Sq, London WC1N 3BG, England; [Chance, Steven A.; Torso, Mario] Univ Oxford, Nuffield Dept Clin Neurosci, Neuropathol, West Wing,Level 1, Oxford OX3 9DU, England; [Sano, Mary; Hof, Patrick R.; Gandy, Sam; Elder, Gregory A.] Mt Sinai Alzheimers Dis Res Ctr, New York, NY 10029 USA; [Sano, Mary; Hof, Patrick R.; Gandy, Sam; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA; [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Nash Family Dept Neurosci, One Gustave Levy, New York, NY 10029 USA; [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, One Gustave Levy, New York, NY 10029 USA; [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA; [Gandy, Sam] Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA; [Gandy, Sam; Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Gandy, Sam] South Australian Hlth & Res Med Inst, Adelaide, SA 5000, Australia		Gandy, S (corresponding author), James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Gandy, S; Elder, GA (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave Levy Pl, New York, NY 10029 USA.; Gandy, S; Elder, GA (corresponding author), Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave Levy Pl, New York, NY 10029 USA.; Gandy, S; Elder, GA (corresponding author), Mt Sinai Alzheimers Dis Res Ctr, New York, NY 10029 USA.; Gandy, S; Elder, GA (corresponding author), Icahn Sch Med Mt Sinai, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA.; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA.; Gandy, S; Elder, GA (corresponding author), James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Gandy, S (corresponding author), South Australian Hlth & Res Med Inst, Adelaide, SA 5000, Australia.	samuel.gandy@mssm.edu; gregory.elder@va.gov	Pham, Dzung/AAR-8263-2020	Torso, Mario/0000-0002-5284-9167; Delman, Bradley/0000-0002-9792-8942	Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service AwardsUS Department of Veterans Affairs [1I01RX000996, I01RX002660, 1I01BX004067, 1I01RX000684, 1I01RX002333, I21RX002069, I21RX002876]; Alzheimer's Disease Drug Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS 5U01NS086625, NICHD K01HD074651-01A]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG11508]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [2018-02532]; European Research CouncilEuropean Research Council (ERC)European Commission [681712]; Swedish State Support for Clinical Research [ALFGBG-720931]; Werber Family Foundation; Sara and Gideon Gartner Foundation; Louis B. Mayer Foundation; Jennifer and Scott Moskowitz Foundation; Jane Martin and Stuart Katz Foundation; Lady Va and Sir Deryck Maughan Foundation; Georgianne and Dr. Reza Khatib Foundation; George B. Link Foundation; Department of DefenseUnited States Department of Defense [0000B999.0000.000. A1503]	This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000996 (GAE), I01RX002660 (GAE), 1I01BX004067 (GAE), 1I01RX000684 (SG), 1I01RX002333 (SG), I21RX002069 (MAGS) and I21RX002876 (MAGS), by Department of Defense work unit number 0000B999.0000.000. A1503, by the Alzheimer's Disease Drug Foundation (SG and DLD) and by NIH grants NINDS 5U01NS086625 (WAG and KD-O) and NICHD K01HD074651-01A (KD-O), NIA P50AG11508 (MS, SG, PRH). KB holds the Torsten Soderberg Professorship of Medicine. HZ is a Wallenberg Academy Fellow supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712) and Swedish State Support for Clinical Research (#ALFGBG-720931). The Werber Family Foundation, the Sara and Gideon Gartner Foundation, the Louis B. Mayer Foundation, the Jennifer and Scott Moskowitz Foundation, the Jane Martin and Stuart Katz Foundation, the Lady Va and Sir Deryck Maughan Foundation, the Georgianne and Dr. Reza Khatib Foundation, and the George B. Link Foundation provided additional support.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; Arun P, 2015, NEUROSCI LETT, V609, P152, DOI 10.1016/j.neulet.2015.10.036; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Baker SL, 2017, DATA BRIEF, V15, P648, DOI 10.1016/j.dib.2017.10.024; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Barret O, 2017, J NUCL MED, V58, P1124, DOI 10.2967/jnumed.116.182881; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Cao JM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09047-x; Chance SA, 2011, CEREB CORTEX, V21, P1870, DOI 10.1093/cercor/bhq264; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; Chen ST, 2018, J ALZHEIMERS DIS, V65, P79, DOI 10.3233/JAD-171152; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; DENENBERG VH, 1981, BEHAV BRAIN SCI, V4, P1, DOI 10.1017/S0140525X00007330; Dickstein DL, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.175; Diedrichsen J, 2011, NEUROIMAGE, V54, P1786, DOI 10.1016/j.neuroimage.2010.10.035; Du XP, 2017, FREE RADICAL BIO MED, V108, P627, DOI 10.1016/j.freeradbiomed.2017.04.343; Du XP, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4159357; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Farhang S, 2014, SYNAPSE, V68, P387, DOI 10.1002/syn.21746; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gerson J, 2016, J NEUROTRAUM, V33, P2034, DOI 10.1089/neu.2015.4262; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hanes J, 2009, J NEUROCHEM, V108, P1167, DOI 10.1111/j.1471-4159.2009.05869.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huber BR, 2016, PHYS MED REH CLIN N, V27, P503, DOI 10.1016/j.pmr.2015.12.007; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Ivanov I, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00127; Klur S, 2009, HIPPOCAMPUS, V19, P800, DOI 10.1002/hipo.20562; Kovacs GG, 2017, BRAIN PATHOL, V27, P675, DOI 10.1111/bpa.12536; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Liu MD, 2014, CHIN J TRAUMATOL, V17, P317, DOI 10.3760/cma.j.issn.1008-1275.2014.06.003; Logsdon AF, 2017, ARCH NEUROSCI, V4, DOI 10.5812/archneurosci.44254; Lopes S, 2016, P NATL ACAD SCI USA, V113, pE3755, DOI 10.1073/pnas.1600953113; Lowe VJ, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0315-6; Lucke-Wold BP, 2015, TRANSL RES, V166, P509, DOI 10.1016/j.trsl.2015.08.005; Lucke-Wold BP, 2016, J NEUROSURG, V124, P687, DOI 10.3171/2015.3.JNS141802; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Mammadova N, 2017, AM J PATHOL, V187, P1459, DOI 10.1016/j.ajpath.2017.03.005; Marquie M, 2017, ANN NEUROL, V81, P117, DOI 10.1002/ana.24844; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; MESSING RB, 1980, LIFE SCI, V26, P921, DOI 10.1016/0024-3205(80)90112-5; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Mohamed AZ, 2019, EUR J NUCL MED MOL I, V46, P1139, DOI 10.1007/s00259-018-4241-7; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; National Research Council, 2008, GULF WAR HLTH, V7; Nolan, 2017, J NEUROL NEUROSUR PS, V4; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu B, 2018, NEUROSURGERY, V82, P237, DOI 10.1093/neuros/nyx536; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Perez-Garcia G, 2018, ENEURO, V5, DOI 10.1523/ENEURO.0357-17.2018; Perez-Garcia G, 2018, BEHAV BRAIN RES, V340, P117, DOI 10.1016/j.bbr.2016.09.061; Perez-Garcia G, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00176; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Robinson ME, 2019, NEUROIMAGE-CLIN, V21, DOI 10.1016/j.nicl.2019.101651; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Sajja VSSS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15075; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shcherbinin S, 2016, J NUCL MED, V57, P1535, DOI 10.2967/jnumed.115.170027; Shinohara Y, 2012, HIPPOCAMPUS, V22, P117, DOI 10.1002/hipo.20886; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Sosa MAG, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-018-0647-5; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Sullivan RM, 2014, PROG NEURO-PSYCHOPH, V54, P59, DOI 10.1016/j.pnpbp.2014.05.002; Tanielian T, 2016, PSYCHIAT SERV, V67, P718, DOI 10.1176/appi.ps.201500237; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tsai RM, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0470-7; Vincent AS, 2014, ALZHEIMERS DEMENT, V10, pS174, DOI 10.1016/j.jalz.2014.04.006; Wooten DW, 2019, J NEUROTRAUM, V36, P3233, DOI 10.1089/neu.2018.6178; Zetterberg H, 2018, J ALZHEIMERS DIS, V64, pS271, DOI 10.3233/JAD-179926	84	25	25	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	OCT	2021	26	10					5940	5954		10.1038/s41380-020-0674-z		FEB 2020	15	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	YG3SX	WOS:000515474300001	32094584	Green Published, hybrid			2022-02-06	
J	Williams, AM; Bhatti, UF; Brown, JF; Biesterveld, BE; Kathawate, RG; Graham, NJ; Chtraklin, K; Siddiqui, AZ; Dekker, SE; Andjelkovic, A; Higgins, GA; Buller, B; Alam, HB				Williams, Aaron M.; Bhatti, Umar F.; Brown, Jordana F.; Biesterveld, Ben E.; Kathawate, Ranganath G.; Graham, Nathan J.; Chtraklin, Kiril; Siddiqui, Ali Z.; Dekker, Simone E.; Andjelkovic, Anuska; Higgins, Gerald A.; Buller, Benjamin; Alam, Hasan B.			Early single-dose treatment with exosomes provides neuroprotection and improves blood-brain barrier integrity in swine model of traumatic brain injury and hemorrhagic shock	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	78th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 18-21, 2019	Dallas, TX	Amer Assoc Surg Trauma		Exosomes; mesenchymal stem cells; neuroprotection; traumatic brain injury; swine	VALPROIC ACID; EXTRACELLULAR VESICLES; STROMAL CELLS; RECOVERY; LIGHT	BACKGROUND Administration of human mesenchymal stem cell (MSC)-derived exosomes can enhance neurorestoration in models of traumatic brain injury (TBI) and hemorrhagic shock (HS). The impact of early treatment with MSC-derived exosomes on brain injury in a large animal model remains unknown. We sought to evaluate the impact of early single-dose exosome treatment on brain swelling and lesion size, blood-based cerebral biomarkers, and blood-brain barrier (BBB) integrity. METHODS Female Yorkshire swine were subjected to a severe TBI (12-mm cortical impact) and HS (40% estimated total blood volume). One hour into shock, animals were randomized (n = 5/cohort) to receive either lactated Ringer's (LR; 5 mL) or LR + exosomes (1 x 10(12) exosome particles in 5 mL LR). Animals then underwent additional shock (1 hour) followed by normal saline resuscitation. After 6 hours of observation, brain swelling (% increase compared with the uninjured side) and lesion size (mm(3)) were assessed. Cerebral hemodynamics and blood-based biomarkers of brain injury were compared. Immunofluorescence and RNA sequencing with differential gene expression and pathway analysis were used to assess the integrity of the perilesion BBB. RESULTS Exosome-treated animals had significantly less (p < 0.05) brain swelling and smaller lesion size. They also had significantly decreased (p < 0.05) intracranial pressures and increased cerebral perfusion pressures. Exosome-treated animals had significantly decreased (p < 0.05) albumin extravasation and significantly higher (p < 0.05) laminin, claudin-5, and zonula occludens 1 levels. Differential gene expression and pathway analysis confirmed these findings. Serum glial fibrillary acidic protein levels were also significantly lower (p < 0.05) in the exosome-treated cohort at the end of the experiment. CONCLUSION In a large animal model of TBI and HS, early treatment with a single dose of MSC-derived exosomes significantly attenuates brain swelling and lesion size, decreases levels of blood-based cerebral biomarkers, and improves BBB integrity.	[Williams, Aaron M.; Bhatti, Umar F.; Brown, Jordana F.; Biesterveld, Ben E.; Kathawate, Ranganath G.; Graham, Nathan J.; Chtraklin, Kiril; Siddiqui, Ali Z.; Dekker, Simone E.; Alam, Hasan B.] Univ Michigan, Dept Surg, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA; [Andjelkovic, Anuska] Univ Michigan, Dept Neuropathol, Ann Arbor, MI 48109 USA; [Higgins, Gerald A.] Univ Michigan, Dept Bioinformat & Computat Med, Ann Arbor, MI 48109 USA; [Buller, Benjamin] Henry Ford Hlth Syst, Dept Neurol, Neurol Res Educ & Res Bldg,Room 3013, Detroit, MI USA		Alam, HB (corresponding author), Univ Michigan, Dept Surg, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.; Buller, B (corresponding author), Henry Ford Hlth Syst, Dept Neurol, Neurol Res Educ & Res Bldg,Room 3013, Detroit, MI USA.	bbuller1@hfhs.org; alamh@med.umich.edu	Biesterveld, Ben/AAM-1087-2021	Kathawate, Ranganath/0000-0002-5090-5188; Higgins, Gerry/0000-0002-0434-1465	Massey TBI Research Grant; U.S. Army Medical Research Materiel Command grant [W81XWH-09-1-0520]	For all authors, no conflicts are declared. This study was supported by the Massey TBI Research Grant (to A.M.W. and H.B.A.) and the U.S. Army Medical Research Materiel Command grant W81XWH-09-1-0520 (to H.B.A.). The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy, or decision unless so designated by other documentation.	Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chopp M, 2015, EXPERT OPIN EMERG DR, V20, P523, DOI 10.1517/14728214.2015.1061993; Frazee AC, 2015, NAT BIOTECHNOL, V33, P243, DOI 10.1038/nbt.3172; Gao WW, 2018, EXP NEUROL, V307, P99, DOI 10.1016/j.expneurol.2018.06.001; Georgoff PE, 2017, J NEUROTRAUM, V34, P2167, DOI 10.1089/neu.2016.4859; Gunzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012; Halaweish I, 2016, J TRAUMA ACUTE CARE, V81, P1080, DOI 10.1097/TA.0000000000001204; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]; Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Korley FK, 2018, J NEUROTRAUM, V35, P1185, DOI 10.1089/neu.2017.5581; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lin T, 2006, SURGERY, V139, P365, DOI 10.1016/j.surg.2005.08.022; Lu YH, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00209; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Moore TL, 2019, RESTOR NEUROL NEUROS, V37, P347, DOI 10.3233/RNN-190910; Ni HQ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00014; Nikolian VC, 2019, J TRAUMA ACUTE CARE, V86, P232, DOI 10.1097/TA.0000000000002119; Nikolian VC, 2018, J TRAUMA ACUTE CARE, V84, P459, DOI 10.1097/TA.0000000000001765; Nikolian VC, 2018, CRIT CARE MED, V46, pE59, DOI 10.1097/CCM.0000000000002800; Nikolian VC, 2017, J TRAUMA ACUTE CARE, V83, P1066, DOI 10.1097/TA.0000000000001612; Otero-Ortega L, 2018, J CEREBR BLOOD F MET, V38, P767, DOI 10.1177/0271678X17708917; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Reinhold AK, 2017, PFLUG ARCH EUR J PHY, V469, P123, DOI 10.1007/s00424-016-1920-8; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Varet H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157022; Webb RL, 2018, STROKE, V49, P1248, DOI 10.1161/STROKEAHA.117.020353; Williams AM, 2019, J NEUROTRAUM, V36, P54, DOI 10.1089/neu.2018.5711; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yuan XC, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00319; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang ZG, 2019, NAT REV NEUROL, V15, P193, DOI 10.1038/s41582-018-0126-4	41	25	25	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2020	88	2					207	217		10.109711-A.0000000000002563			11	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	KJ3LI	WOS:000511958800026	31804413				2022-02-06	
J	Langer, L; Levy, C; Bayley, M				Langer, Laura; Levy, Charissa; Bayley, Mark			Increasing Incidence of Concussion: True Epidemic or Better Recognition?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						administrative health databases; concussion; epidemiology; incidence; sex differences; urban rural differences	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; EXTERNAL CAUSES; UNITED-STATES; PREVALENCE; DIAGNOSIS; OUTCOMES; TRENDS; AREA	Objectives: To provide updated estimates of the incidence of concussion from all causes diagnosed by all physicians in a large jurisdiction, as previous studies have examined only single causes of injury or from smaller specific populations. Design: Physician Billing and National Ambulatory Care Reporting System (NACRS) databases were used to identify all Ontario residents with a diagnosis of concussion (ICD-9 850.0 and ICD-10 S06.0) made by physicians between 2008 and 2016, excluding those with moderate to severe traumatic brain injury. Results: In total, 1 330 336 people were diagnosed with a concussion between 2008 and 2016. The annual average was 147 815, and 79% were diagnosed in the emergency department. The average annual incidence was 1153 per 100 000 residents. Incidence varied by age, sex, and geography; children younger than 5 years had the highest incidence of concussion, more than 3600 per 100 000 individuals of that age group. Males had higher incidence than females except in older than 65 years age groups. There was a Pearson correlation (+0.669) between sustaining a concussion and living in rural locations. Conclusion: The annual incidence of approximately 1.2% of the population is the highest rate of concussion ever reported thorough sampling methods and may represent a closer estimate of the true picture of concussion. Findings may inform future concussion treatment and healthcare planning.	[Langer, Laura; Bayley, Mark] Univ Hlth Network, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada; [Levy, Charissa] GTA Rehab Network, Toronto ABI Network, Toronto, ON, Canada; [Levy, Charissa] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Bayley, Mark] Univ Toronto, Div Physiatry, Toronto, ON, Canada		Langer, L (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	laura.langer@uhn.ca		Langer, Laura/0000-0003-4408-355X	Institute for Clinical and Evaluative Sciences (ICES); Ontario Neurotrauma Foundation (ONF)	This study was supported through the provision of data from the Institute for Clinical and Evaluative Sciences (ICES) and through the funding support to ICES from an Ontario Neurotrauma Foundation (ONF) research grant. The authors acknowledge Dr Susan Jaglal, Jennifer Voth, Symron Bansal, and Refik Saskin, for their assistance and expertise with the ICES databases, and Sarah Cote and Andrew Ho, for manuscript editing assistance. The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES or ONF is intended or should be inferred.	Amaranath JE, 2014, ANZ J SURG, V84, P424, DOI 10.1111/ans.12445; Amoo-Achampong K, 2017, PHYSICIAN SPORTSMED, V45, P239, DOI 10.1080/00913847.2017.1327304; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Berrigan L, 2011, BRAIN INJURY, V25, P742, DOI 10.3109/02699052.2011.580317; Boutis K, 2018, J EMERG MED, V54, P757, DOI 10.1016/j.jemermed.2018.02.041; Burke MJ, 2012, CAN J NEUROL SCI, V39, P763, DOI 10.1017/S0317167100015584; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Centers for Disease Control and Prevention National Center for Health Statistics, 2010, NAT HOSP AMB MED CAR; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gordon KE, 2018, BRAIN INJURY, V32, P41, DOI 10.1080/02699052.2017.1403046; Kerr ZY, 2017, NEUROL CLIN, V35, P409, DOI 10.1016/j.ncl.2017.03.001; Kim H, 2006, NEUROREHABILITATION, V21, P269; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Laflamme Lucie., 2009, SOCIOECONOMIC DIFFER; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Liu M, 2011, WORK, V39, P283, DOI 10.3233/WOR-2011-1176; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Oddy M, 2012, BRAIN INJURY, V26, P1058, DOI 10.3109/02699052.2012.667595; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P75, DOI 10.1097/HTR.0b013e31823029f6; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Statistics Canada, 2018, CENS CAN 2006 2011 2; Topolovec-Vranic Jane, 2014, CMAJ Open, V2, pE69, DOI 10.9778/cmajo.20130046; van Pelt ED, 2011, EUR J PAEDIATR NEURO, V15, P519, DOI 10.1016/j.ejpn.2011.05.005; Veliz P, 2017, JAMA-J AM MED ASSOC, V318, P1180, DOI 10.1001/jama.2017.9087; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Zemek R, 2015, CAN J EMERG MED, V17, P115, DOI 10.1017/cem.2014.38; Zemek RL, 2017, J PEDIATR-US, V181, P222, DOI 10.1016/j.jpeds.2016.10.067	35	25	26	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2020	35	1			SI		E60	E66		10.1097/HTR.0000000000000503			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	KL0UE	WOS:000513147300013	31246881				2022-02-06	
J	Zeiler, FA; Ercole, A; Beqiri, E; Cabeleira, M; Thelin, EP; Stocchetti, N; Steyerberg, EW; Maas, AIR; Menon, DK; Czosnyka, M; Smielewski, P; Anke, A; Beer, R; Helbok, R; Bellander, BM; Nelson, D; Buki, A; Chevallard, G; Chieregato, A; Citerio, G; Czeiter, E; Depreitere, B; Eapen, G; Frisvold, S; Jankowski, S; Kondziella, D; Koskinen, LO; Meyfroidt, G; Moeller, K; Piippo-Karjalainen, A; Raj, R; Radoi, A; Sahuquillo, J; Ragauskas, A; Rocka, S; Rhodes, J; Rossaint, R; Stevanovic, A; Sakowitz, O; Sundstrom, N; Takala, R; Tamosuitis, T; Tenovuo, O; Vajkoczy, P; Vargiolu, A; Vilcinis, R; Wolf, S; Younsi, A				Zeiler, Frederick A.; Ercole, Ari; Beqiri, Erta; Cabeleira, Manuel; Thelin, Eric P.; Stocchetti, Nino; Steyerberg, Ewout W.; Maas, Andrew I. R.; Menon, David K.; Czosnyka, Marek; Smielewski, Peter; Anke, Audny; Beer, Ronny; Helbok, Raimund; Bellander, Bo-Michael; Nelson, David; Buki, Andras; Chevallard, Giorgio; Chieregato, Arturo; Citerio, Giuseppe; Czeiter, Endre; Depreitere, Bart; Eapen, George; Frisvold, Shirin; Jankowski, Stefan; Kondziella, Daniel; Koskinen, Lars-Owe; Meyfroidt, Geert; Moeller, Kirsten; Piippo-Karjalainen, Anna; Raj, Rahul; Radoi, Andreea; Sahuquillo, Juan; Ragauskas, Arminas; Rocka, Saulius; Rhodes, Jonathan; Rossaint, Rolf; Stevanovic, Ana; Sakowitz, Oliver; Sundstrom, Nina; Takala, Riikka; Tamosuitis, Tomas; Tenovuo, Olli; Vajkoczy, Peter; Vargiolu, Alessia; Vilcinis, Rimantas; Wolf, Stefan; Younsi, Alexander		CTR-TBI High Resolution ICU HR ICU	Association between Cerebrovascular Reactivity Monitoring and Mortality Is Preserved When Adjusting for Baseline Admission Characteristics in Adult Traumatic Brain Injury: A CENTER-TBI Study	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; cerebrovascular reactivity; IMPACT; outcome analysis	AUTOREGULATION MEASUREMENT TECHNIQUES; PRESSURE; MANAGEMENT; MODERATE	Cerebral autoregulation, as measured using the pressure reactivity index (PRx), has been related to global patient outcome in adult patients with traumatic brain injury (TBI). To date, this has been documented without accounting for standard baseline admission characteristics and intracranial pressure (ICP). We evaluated this association, adjusting for baseline admission characteristics and ICP, in a multi-center, prospective cohort. We derived PRx as the correlation between ICP and mean arterial pressure in prospectively collected multi-center data from the High-Resolution Intensive Care Unit (ICU) cohort of the Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) study. Multi-variable logistic regression models were analyzed to assess the association between global outcome (measured as either mortality or dichotomized Glasgow Outcome Score-Extended [GOSE]) and a range of covariates (IMPACT [International Mission for Prognosis and Analysis of Clinical Trials] Core and computed tomography [CT] variables, ICP, and PRx). Performance of these models in outcome association was compared using area under the receiver operating curve (AUC) and Nagelkerke's pseudo-R-2. One hundred ninety-three patients had a complete data set for analysis. The addition of percent time above threshold for PRx improved AUC and displayed statistically significant increases in Nagelkerke's pseudo-R-2 over the IMPACT Core and IMPACT Core + CT models for mortality. The addition of PRx monitoring to IMPACT Core +/- CT + ICP models accounted for additional variance in mortality, when compared to models with IMPACT Core +/- CT + ICP alone. The addition of cerebrovascular reactivity monitoring, through PRx, provides a statistically significant increase in association with mortality at 6 months. Our data suggest that cerebrovascular reactivity monitoring may provide complementary information regarding outcomes in TBI.	[Zeiler, Frederick A.; Ercole, Ari; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Beqiri, Erta; Cabeleira, Manuel; Czosnyka, Marek; Smielewski, Peter] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Brain Phys Lab, Cambridge, England; Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Winnipeg, MB, Canada; Univ Manitoba, Rady Fac Hlth Sci, Human Anat & Cell Sci, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Manitoba, Dept Biomed Engn, Fac Engn, Winnipeg, MB, Canada; [Thelin, Eric P.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Stocchetti, Nino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neuro ICU, Milan, Italy; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Steyerberg, Ewout W.] Erasmus MC, Univ Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands; [Maas, Andrew I. R.] Univ Hosp Antwerp, Dept Neurosurg, Edegem, Belgium; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Anke, Audny] Univ Hosp Northern Norway, Dept Phys Med & Rehabil, Tromso, Norway; [Beer, Ronny; Helbok, Raimund] Med Univ Innsbruck, Dept Neurol, Neurol Intens Care Unit, Innsbruck, Austria; [Bellander, Bo-Michael; Nelson, David] Karolinska Univ Hosp, Dept Neurosurg & Anesthesia & Intens Care Med, Stockholm, Sweden; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Buki, Andras; Czeiter, Endre] Univ Pecs, Hungarian Brain Res Program, MTA PTE Clin Neurosci MR Res Grp, Pecs, Hungary; [Buki, Andras; Czeiter, Endre] Univ Pecs, Hungarian Brain Res Program, Janos Szentagothai Res Ctr, Pecs, Hungary; [Chevallard, Giorgio; Chieregato, Arturo] Osped Niguarda Ca Granda, NeuroIntens Care, Milan, Italy; [Citerio, Giuseppe] ASST Monza, NeuroIntens Care Unit, Dept Anesthesia & Intens Care, Monza, Italy; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Depreitere, Bart] Univ Hosp Leuven, Dept Neurosurg, Leuven, Belgium; [Frisvold, Shirin] Univ Hosp Northern Norway, Dept Anesthesiol & Intens care, Tromso, Norway; [Jankowski, Stefan] Sheffield Teaching Hosp NHS Fdn Trust, Neurointens Care, Sheffield, S Yorkshire, England; [Kondziella, Daniel] Rigshosp, Dept Neurol, Reg Hovedstaden, Copenhagen, Denmark; [Kondziella, Daniel] Rigshosp, Dept Clin Neurophysiol, Reg Hovedstaden, Copenhagen, Denmark; [Kondziella, Daniel; Moeller, Kirsten] Rigshosp, Dept Neuroanesthesiol, Reg Hovedstaden, Copenhagen, Denmark; [Koskinen, Lars-Owe] Umea Univ, Dept Clin Neurosci, Neurosurg, Umea, Sweden; [Meyfroidt, Geert] Univ Hosp Leuven, Intens Care Med, Leuven, Belgium; [Piippo-Karjalainen, Anna; Raj, Rahul] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Radoi, Andreea; Sahuquillo, Juan] Vall dHebron Univ Hosp, Dept Neurosurg, Barcelona, Spain; [Ragauskas, Arminas; Rocka, Saulius] Kaunas Univ Technol, Dept Neurosurg, Vilnius, Lithuania; [Ragauskas, Arminas; Rocka, Saulius] Vilnius Univ, Vilnius, Lithuania; [Rhodes, Jonathan] NHS Lothian, Dept Anaesthesia Crit Care & Pain Med, Edinburgh, Midlothian, Scotland; [Rhodes, Jonathan] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Rossaint, Rolf; Stevanovic, Ana] Univ Hosp Aachen, Dept Anaesthesiol, Aachen, Germany; [Sakowitz, Oliver] Klinikum Ludwigsburg, Klin Neurochirurg, Ludwigsburg, Germany; [Sakowitz, Oliver; Younsi, Alexander] Univ Hosp Heidelberg, Dept Neurosurg, Heidelberg, Germany; [Sundstrom, Nina] Umea Univ, Biomed Engn, Dept Radiat Sci, Umea, Sweden; [Takala, Riikka] Turku Univ, Cent Hosp, Perioperat Serv, Intens Care Med & Pain Management, Turku, Finland; [Takala, Riikka; Tenovuo, Olli] Univ Turku, Turku, Finland; [Tamosuitis, Tomas] Kaunas Univ Hlth Sci, Neurointens Care Unit, Kaunas, Lithuania; [Tenovuo, Olli] Turku Univ, Cent Hosp, Rehabil & Brain Trauma, Turku, Finland; [Vajkoczy, Peter] Charite Univ Med Berlin, Neurol Neurochirurg & Psychiat, Berlin, Germany; [Vargiolu, Alessia] ASST Monza, Dept Anesthesia & Intens Care, NeuroIntens Care Unit, Monza, Italy; [Vilcinis, Rimantas] Kaunas Univ Hlth Sci, Dept Neurosurg, Kaunas, Lithuania; [Wolf, Stefan] Charite Univ Med Berlin, Interdisciplinary Neuro Intens Care Unit, Berlin, Germany		Zeiler, FA (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Neurosurg, 750 Bannatyne Ave, Winnipeg, MB R3A 1R9, Canada.	umzeiler@myumanitoba.ca	Raj, Rahul/K-7693-2012; Helbok, Raimund/AAA-8361-2021; Sahuquillo, Juan/B-3577-2008; Ercole, Ari/B-6288-2009; Thelin, Eric Peter/K-2144-2012; Younsi, Alexander/AAW-7869-2020; Koskinen, Lars-Owe/AAQ-8957-2020; Moller, Kirsten/A-4751-2009	Raj, Rahul/0000-0003-4243-9591; Sahuquillo, Juan/0000-0003-0713-5875; Ercole, Ari/0000-0001-8350-8093; Thelin, Eric Peter/0000-0002-2338-4364; Younsi, Alexander/0000-0002-8218-9243; Zeiler, Frederick/0000-0003-1737-0510; Moller, Kirsten/0000-0003-3058-1072; Nelson, David/0000-0003-2530-8207; Radoi, Andreea/0000-0002-0677-3544; Sakowitz, Oliver/0000-0003-3248-6335	European UnionEuropean Commission [602150]; Hannelore Kohl Stiftung (Germany); OneMind (USA); Integra LifeSciences Corporation (USA)	Data used in preparation of this article were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Union 7th Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA), and from Integra LifeSciences Corporation (USA).	Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Beqiri E, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030727; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2014, NEUROCRIT CARE, V21, P95, DOI 10.1007/s12028-014-0046-0; Doiron D, 2017, INT J EPIDEMIOL, V46, P1372, DOI 10.1093/ije/dyx180; Donnelly J, 2019, NEUROSURGERY, V85, pE75, DOI 10.1093/neuros/nyy468; Helbok R, 2014, NEUROCRIT CARE, V21, P85, DOI 10.1007/s12028-014-0040-6; Le Roux P, 2014, NEUROCRIT CARE, V21, P282, DOI 10.1007/s12028-014-0077-6; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; Nourallah B, 2018, ACTA NEUROCHIR, V160, P1315, DOI 10.1007/s00701-018-3555-3; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Zeiler FA, 2018, J NEUROTRAUM, V35, P963, DOI 10.1089/neu.2017.5241; Zeiler FA, 2019, ACTA NEUROCHIR, V161, P1955, DOI 10.1007/s00701-019-03980-8; Zeiler FA, 2018, J NEUROTRAUM, V35, P1107, DOI 10.1089/neu.2017.5472; Zeiler FA, 2017, J NEUROTRAUM, V34, P3224, DOI 10.1089/neu.2017.5086; Zeiler FA, 2017, J NEUROTRAUM, V34, P3207, DOI 10.1089/neu.2017.5085	22	25	25	4	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2020	37	10					1233	1241		10.1089/neu.2019.6808		DEC 2019	9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	LL3VP	WOS:000504889700001	31760893	Green Published, Green Submitted			2022-02-06	
J	Thibaut, A; Bodien, YG; Laureys, S; Giacino, JT				Thibaut, Aurore; Bodien, Yelena G.; Laureys, Steven; Giacino, Joseph T.			Minimally conscious state "plus": diagnostic criteria and relation to functional recovery	JOURNAL OF NEUROLOGY			English	Article						Minimally conscious state; Disorders of consciousness; Brain-injuries; Coma recovery scale-revised; Disability rating scale; Command-following; Intentional communication; Intelligible verbalization	DISORDERS; LANGUAGE; SCALE; COMA	Background We investigated the relationship between three language-dependent behaviors (i.e., command-following, intelligible verbalization, and intentional communication) and the functional status of patients with disorders of consciousness (DoC). We hypothesized that patients in minimally conscious state (MCS) who retain behavioral evidence of preserved language function would have similar levels of functional disability, while patients who lack these behaviors would demonstrate significantly greater disability. We reasoned that these results could then be used to establish empirically-based diagnostic criteria for MCS+. Methods In this retrospective cohort study we included rehabilitation inpatients diagnosed with DoC following severe-acquired brain injury (MCS = 57; vegetative state/unresponsive wakefulness syndrome [VS/UWS] = 63); women: 46; mean age: 47 +/- 19 years; traumatic etiology: 68; time post-injury: 40 +/- 23 days). We compared the scores of the Disability Rating Scale score (DRS) at time of transition from VS/UWS to MCS or from MCS- to MCS+, and at discharge between groups. Results Level of disability on the DRS was similar in patients with any combination of the three language-related behaviors. MCS patients with no behavioral evidence of language function (i.e., MCS-) were more functionally impaired than patients with MCS+ at time of transition and at discharge. Conclusions Command-following, intelligible verbalization, and intentional communication are not associated with different levels of functional disability. Thus, the MCS+ syndrome can be diagnosed based on the presence of any one of these language-related behaviors. Patients in MCS+ may evidence less functional disability compared to those in MCS who fail to demonstrate language function (i.e., MCS-).	[Thibaut, Aurore; Laureys, Steven] Univ Liege, Coma Sci Grp, GIGA Consciousness, Allee Hop 11-B34, B-4000 Liege, Belgium; [Thibaut, Aurore; Laureys, Steven] Univ Hosp Liege, Allee Hop 11-B34, B-4000 Liege, Belgium; [Bodien, Yelena G.] Harvard Med Sch, Ctr Neurotechnol & Neurorecovery, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA; [Bodien, Yelena G.; Giacino, Joseph T.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Giacino, Joseph T.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Thibaut, Aurore; Laureys, Steven] Univ Hosp Liege, Ctr Cerveau2, Liege, Belgium		Thibaut, A (corresponding author), Univ Liege, Coma Sci Grp, GIGA Consciousness, Allee Hop 11-B34, B-4000 Liege, Belgium.; Thibaut, A (corresponding author), Univ Hosp Liege, Allee Hop 11-B34, B-4000 Liege, Belgium.; Thibaut, A (corresponding author), Univ Hosp Liege, Ctr Cerveau2, Liege, Belgium.	athibaut@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Giacino, Joseph/AAF-1952-2021	Laureys, Steven/0000-0002-3096-3807; Giacino, Joseph/0000-0002-7916-9698; Bodien, Yelena/0000-0003-4858-2903	Wallonie Brussel International (WBI) scholarship; Belgian American Educational Foundation (BAEF); Leon Fredericq Foundation; National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR), Administration for Community Living (Spaulding-Harvard TBI Model System) [90DP0039]; NIDILRR (SpauldingHarvard TBI Model System) [90DP0039]; James S. McDonnell Foundation	Dr. Aurore Thibaut is a FNRS is a post-doctoral research fellow and has been supported by the Wallonie Brussel International (WBI) scholarship, the Belgian American Educational Foundation (BAEF), and the Leon Fredericq Foundation. Dr. Bodien is supported by the National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR), Administration for Community Living (90DP0039, Spaulding-Harvard TBI Model System). Dr. Giacino received support from NIDILRR (90DP0039, SpauldingHarvard TBI Model System) and the James S. McDonnell Foundation (Understanding Human Cognition-Collaborative). The authors thank the clinical staff at Spaulding Hospital Cambridge and Spaulding Rehabilitation Hospital for acquiring the clinical metrics used in this study.	Airenti G, 2010, COGN SYST RES, V11, P165, DOI 10.1016/j.cogsys.2009.03.002; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Aubinet C, 2018, HUM BRAIN MAPP, V39, P4519, DOI 10.1002/hbm.24303; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Bara BG, 2011, INTERCULT PRAGMAT, V8, P443, DOI 10.1515/IPRG.2011.020; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Davis MH, 2003, J NEUROSCI, V23, P3423; Demertzi A, 2011, J NEUROL, V258, P1058, DOI 10.1007/s00415-010-5882-z; Di Perri C, 2016, LANCET NEUROL, V15, P1115, DOI 10.1016/S1474-4422(16)30205-8; Estraneo A, 2016, CLIN NEUROPHYSIOL, V127, P2379, DOI 10.1016/j.clinph.2016.03.021; Gabrieli JDE, 1998, P NATL ACAD SCI USA, V95, P906, DOI 10.1073/pnas.95.3.906; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GOODWIN C, 1995, RES LANG SOC INTERAC, V28, P233, DOI 10.1207/s15327973rlsi2803_4; Gosseries O, 2014, BRAIN INJURY, V28, P1141, DOI 10.3109/02699052.2014.920522; Guldenmund P, 2016, BRAIN INJURY, V30, P343, DOI 10.3109/02699052.2015.1118765; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hickok G, 2007, NAT REV NEUROSCI, V8, P393, DOI 10.1038/nrn2113; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Longoni Francesca, 2005, Brain Cogn, V57, P131, DOI 10.1016/j.bandc.2004.08.032; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Riecker A, 2005, NEUROLOGY, V64, P700, DOI 10.1212/01.WNL.0000152156.90779.89; Schnakers C, 2015, NEUROLOGY CONSCIOUSN; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Tomasello M, 2005, BEHAV BRAIN SCI, V28, P675, DOI 10.1017/S0140525X05000129; Tomasello M, 2008, JEAN NICOD LECT, P1; Vigneau M, 2006, NEUROIMAGE, V30, P1414, DOI 10.1016/j.neuroimage.2005.11.002; Willems RM, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00203; Zheng ZS, 2017, HUM BRAIN MAPP, V38, P431, DOI 10.1002/hbm.23370	31	25	26	2	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	MAY	2020	267	5					1245	1254		10.1007/s00415-019-09628-y		NOV 2019	10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LH5IB	WOS:000520990100001	31773246	Green Submitted			2022-02-06	
J	Sims, CA; Holena, D; Kim, P; Pascual, J; Smith, B; Martin, N; Seamon, M; Shiroff, A; Raza, S; Kaplan, L; Grill, E; Zimmerman, N; Mason, C; Abella, B; Reilly, P				Sims, Carrie A.; Holena, Daniel; Kim, Patrick; Pascual, Jose; Smith, Brian; Martin, Neils; Seamon, Mark; Shiroff, Adam; Raza, Shariq; Kaplan, Lewis; Grill, Elena; Zimmerman, Nicole; Mason, Christopher; Abella, Benjamin; Reilly, Patrick			Effect of Low-Dose Supplementation of Arginine Vasopressin on Need for Blood Product Transfusions in Patients With Trauma and Hemorrhagic Shock: A Randomized Clinical Trial	JAMA SURGERY			English	Article							VENOUS THROMBOEMBOLISM; LIVER TRAUMA; RISK; RESUSCITATION; SURVIVAL; DESMOPRESSIN; ASSOCIATION; MECHANISMS; INJURY; VASODILATION	Key PointsQuestionDoes low-dose arginine vasopressin supplementation decrease the need for blood product transfusions in patients with trauma and hemorrhagic shock? FindingsIn this randomized clinical trial of 100 adult trauma patients in hemorrhagic shock, arginine vasopressin supplementation significantly decreased the volume of blood products given in the first 48 hours by a median of 1.4 L without increasing complications. MeaningIncluding low-dose arginine vasopressin supplementation when resuscitating trauma patients in hemorrhagic shock may safely decrease the need for blood products. This randomized clinical trial assesses whether low-dose supplementation of arginine vasopressin during the resuscitation of hemorrhagic shock decreases the need for transfusions in patients with trauma. ImportanceCurrent therapies for traumatic blood loss focus on hemorrhage control and blood volume replacement. Severe hemorrhagic shock, however, is associated with a state of arginine vasopressin (AVP) deficiency, and supplementation of this hormone may decrease the need for blood products in resuscitation. ObjectiveTo determine whether low-dose supplementation of AVP in patients with trauma (hereinafter referred to as trauma patients) and with hemorrhagic shock decreases their need for transfused blood products during resuscitation. Design, Setting, and ParticipantsThis randomized, double-blind placebo-controlled clinical trial included adult trauma patients (aged 18-65 years) who received at least 6 U of any blood product within 12 hours of injury at a single urban level 1 trauma center from May 1, 2013, through May 31, 2017. Exclusion criteria consisted of prehospital cardiopulmonary resuscitation, emergency department thoracotomy, corticosteroid use, chronic renal insufficiency, coronary artery disease, traumatic brain injury requiring any neurosurgical intervention, pregnancy, prisoner status, or AVP administration before enrollment. Data were analyzed from May 1, 2013, through May 31, 2017, using intention to treat and per protocol. InterventionsAfter administration of an AVP bolus (4 U) or placebo, participants received AVP (<= 0.04 U/min) or placebo for 48 hours to maintain a mean arterial blood pressure of at least 65 mm Hg. Main OutcomesThe primary outcome was total volume of blood product transfused. Secondary end points included total volume of crystalloid transfused, vasopressor requirements, secondary complications, and 30-day mortality. ResultsOne hundred patients underwent randomization (49 to the AVP group and 51 to the placebo group). Patients were primarily young (median age, 27 years [interquartile range {IQR}, 22-25 years]) and male (n=93) with penetrating trauma (n=79). Cohort characteristics before randomization were well balanced. At 48 hours, patients who received AVP required significantly less blood products (median, 1.4 [IQR, 0.5-2.6] vs 2.9 [IQR, 1.1-4.8] L; P=.01) but did not differ in requirements for crystalloids (median, 9.9 [IQR, 7.9-13.0] vs 11.0 [8.9-15.0] L; P=.22) or vasopressors (median, 400 [IQR, 0-5900] vs 1400 [IQR, 200-7600] equivalent units; P=.22). Although the groups had similar rates of mortality (6 of 49 [12%] vs 6 of 51 [12%]; P=.94) and total complications (24 of 44 [55%] vs 30 of 47 [64%]; P=.37), the AVP group had less deep venous thrombosis (5 of 44 [11%] vs 16 of 47 [34%]; P=.02). Conclusions and RelevanceLow-dose AVP during the resuscitation of trauma patients in hemorrhagic shock decreases blood product requirements. Additional research is necessary to determine whether including AVP improves morbidity or mortality. Trial RegistrationClinicalTrials.gov identifier: NCT01611935	[Sims, Carrie A.; Holena, Daniel; Kim, Patrick; Pascual, Jose; Smith, Brian; Martin, Neils; Seamon, Mark; Shiroff, Adam; Raza, Shariq; Kaplan, Lewis; Grill, Elena; Reilly, Patrick] Univ Penn, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, 51N 39th St Med Off Bldg Ste120, Philadelphia, PA 19104 USA; [Sims, Carrie A.] Univ Penn, Perelman Sch Med, PARC, Philadelphia, PA 19104 USA; [Holena, Daniel] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Zimmerman, Nicole] Cleveland Clin Fdn, Dept Quantitat Hlth Sci & Outcomes Res, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Mason, Christopher] Univ Penn, Perelman Sch Med, Dept Anesthesia, Philadelphia, PA 19104 USA; [Abella, Benjamin] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA		Sims, CA (corresponding author), Univ Penn, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, 51N 39th St Med Off Bldg Ste120, Philadelphia, PA 19104 USA.	carrie.sims@uphs.upenn.edu	Martin, Niels/AAQ-8152-2021; Seamon, Mark/AAM-4713-2021	Martin, Niels/0000-0002-2157-0825; Holena, Daniel/0000-0003-3424-5754	National Trauma Institute [NTI-TRA-09-062]; Department of the Army [W81XWH-10-0924]	This study was supported by award NTI-TRA-09-062 from the National Trauma Institute and prime award W81XWH-10-0924 from the Department of the Army (Dr Sims).	Al-Refaie WB, 2012, SURGERY, V152, P344, DOI 10.1016/j.surg.2012.06.008; ALTURA BM, 1980, EXPERIENTIA, V36, P1080, DOI 10.1007/BF01965981; American College of Surgeons, 2018, ADV TRAUM LIF SUPP 1; [Anonymous], 2015, PENNS OUTC PERF IMPR; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Barrett LK, 2007, CRIT CARE MED, V35, P33, DOI 10.1097/01.CCM.0000251127.45385.CD; Bolland K, 2000, STAT MED, V19, P2899, DOI 10.1002/1097-0258(20001115)19:21<2899::AID-SIM597>3.0.CO;2-O; Boutin A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014472; Brown SM, 2013, CHEST, V143, P664, DOI 10.1378/chest.12-1106; Cohn SM, 2013, J TRAUMA ACUTE CARE, V75, P620, DOI 10.1097/TA.0b013e31829eff31; Cohn SM, 2011, WORLD J SURG, V35, P430, DOI 10.1007/s00268-010-0875-8; Collier B, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2009.05.003; Colucci G, 2014, BLOOD, V123, P1905, DOI 10.1182/blood-2013-04-497123; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Dhillon NK, 2018, J SURG RES, V222, P115, DOI 10.1016/j.jss.2017.09.038; Douros A, 2016, BRIT J CLIN PHARMACO, V82, P839, DOI 10.1111/bcp.13019; EDWARDS RM, 1989, AM J PHYSIOL, V256, pF274, DOI 10.1152/ajprenal.1989.256.2.F274; ERRINGTON ML, 1972, J PHYSIOL-LONDON, V227, P395, DOI 10.1113/jphysiol.1972.sp010039; Gearhart MM, 2000, SURGERY, V128, P631, DOI 10.1067/msy.2000.108224; Glance LG, 2011, ANESTHESIOLOGY, V114, P283, DOI 10.1097/ALN.0b013e3182054d06; Goel R, 2018, JAMA SURG, V153, P826, DOI 10.1001/jamasurg.2018.1565; Haas T, 2004, J TRAUMA, V57, P177, DOI 10.1097/01.TA.0000044357.25191.1B; Heron Melonie, 2018, Natl Vital Stat Rep, V67, P1; Holmes CL, 2004, CRIT CARE, V8, P15, DOI 10.1186/cc2338; Karcutskie CA, 2017, JAMA SURG, V152, P35, DOI 10.1001/jamasurg.2016.3116; Kaufmann JE, 2003, J THROMB HAEMOST, V1, P682, DOI 10.1046/j.1538-7836.2003.00190.x; Landry DW, 1997, CIRCULATION, V95, P1122; Landry DW, 2001, NEW ENGL J MED, V345, P588, DOI 10.1056/NEJMra002709; Landy DW, 1997, CRIT CARE MED, V25, P1279, DOI 10.1097/00003246-199708000-00012; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; MOHRING J, 1980, J CARDIOVASC PHARM, V2, P367; Morales D, 1999, CIRCULATION, V100, P226, DOI 10.1161/01.CIR.100.3.226; Oliver JA, 2007, CURR OPIN CRIT CARE, V13, P376, DOI 10.1097/MCC.0b013e3282435e16; Pecci A, 2014, BLOOD, V123, P1779, DOI 10.1182/blood-2014-01-551242; RUDICHENKO VM, 1995, J VASC RES, V32, P100, DOI 10.1159/000159082; Russell JA, 2010, J INNATE IMMUN, V2, P446, DOI 10.1159/000318531; Sihler KC, 2010, CHEST, V137, P209, DOI 10.1378/chest.09-0252; Sims CA, 2017, AM J SURG, V214, P589, DOI 10.1016/j.amjsurg.2017.06.015; Sims CA, 2013, J TRAUMA ACUTE CARE, V74, P157, DOI 10.1097/TA.0b013e318278908a; Sperry JL, 2008, J TRAUMA, V64, P9, DOI 10.1097/TA.0b013e31815dd029; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; Tisherman SA, 2015, ANN SURG, V261, P586, DOI 10.1097/SLA.0000000000000837; Turan A, 2013, CAN J ANESTH, V60, P761, DOI 10.1007/s12630-013-9937-3; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; WILLIAMS TDM, 1986, CLIN SCI, V71, P173, DOI 10.1042/cs0710173; Xenos ES, 2012, THROMB RES, V129, P568, DOI 10.1016/j.thromres.2011.07.047	49	25	26	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	NOV	2019	154	11					994	1003		10.1001/jamasurg.2019.2884			10	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	JT9LP	WOS:000501303100004	31461138	Green Published, Bronze			2022-02-06	
J	Daglas, M; Draxler, DF; Ho, H; McCutcheon, F; Galle, A; Au, AE; Larsson, P; Gregory, J; Alderuccio, F; Sashindranath, M; Medcalf, RL				Daglas, Maria; Draxler, Dominik F.; Ho, Heidi; McCutcheon, Fiona; Galle, Adam; Au, Amanda E.; Larsson, Pia; Gregory, Julia; Alderuccio, Frank; Sashindranath, Maithili; Medcalf, Robert L.			Activated CD8(+) T Cells Cause Long-Term Neurological Impairment after Traumatic Brain Injury in Mice	CELL REPORTS			English	Article							SPINAL-CORD-INJURY; LIMIT CNS INFLAMMATION; EXPERIMENTAL STROKE; MULTIPLE-SCLEROSIS; MYELIN CLEARANCE; GAIT IMPAIRMENT; DEFICIENT MICE; LYMPHOCYTES; SYSTEM; MOTOR	Traumatic brain injury (TBI) leaves many survivors with long-term disabilities. A prolonged immune response in the brain may cause neurodegeneration, resulting in chronic neurological disturbances. In this study, using a TBI mouse model, we correlate changes in the local immune response with neurodegeneration/neurological dysfunction over an 8-month period. Flow cytometric analysis reveals a protracted increase in effector/memory CD8(+) T cells (expressing granzyme B) in the injured brain. This precedes interleukin-17(+)CD4(+) T cell infiltration and is associated with progressive neurological/motor impairment, increased circulating brain-specific autoantibodies, and myelin-related pathology. Genetic deficiency or pharmacological depletion of CD8(+) T cells, but not depletion of CD4(+) T cells, improves neurological outcomes and produces a neuroprotective Th2/Th17 immunological shift, indicating a persistent detrimental role for cytotoxic T cells post-TBI. B cell deficiency results in severe neurological dysfunction and a heightened immune reaction. Targeting these adaptive immune cells offers a promising approach to improve recovery following TBI.	[Daglas, Maria; Draxler, Dominik F.; Ho, Heidi; McCutcheon, Fiona; Galle, Adam; Au, Amanda E.; Larsson, Pia; Gregory, Julia; Sashindranath, Maithili; Medcalf, Robert L.] Monash Univ, Mol Neurotrauma & Haemostasis, Australian Ctr Blood Dis, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Alderuccio, Frank] Monash Univ, Dept Immunol & Pathol, Cent Clin Sch, Melbourne, Vic 3004, Australia		Sashindranath, M; Medcalf, RL (corresponding author), Monash Univ, Mol Neurotrauma & Haemostasis, Australian Ctr Blood Dis, Cent Clin Sch, Melbourne, Vic 3004, Australia.	maithili.sashindranath@monash.edu; robert.medcalf@monash.edu	Gregory, Julia/AAW-6017-2020; Gregory, Julia L/K-8726-2012; Sashindranath, Maithili/AAI-7408-2021	Gregory, Julia/0000-0003-2408-677X; Sashindranath, Maithili/0000-0002-9712-4784; Daglas, Maria/0000-0002-9356-4061; Au, Amanda/0000-0003-3656-2673	NHMRC of AustraliaNational Health and Medical Research Council of Australia [APP1045755, APP1126636, APP1044152]; Monash University, Faculty of Medicine, Nursing, and Health SciencesMonash University	The authors acknowledge the facilities, and scientific and technical assistance of Mr. Steve Cody at Monash Micro Imaging and members of the AMREP Flow Cytometry Core Facility at Monash University. We also acknowledge Dr. Rachael Borg, Dr. Evelyn Tsantikos, Dr. Jie-Yu Chung, Dr. Zeyad Nasa, Professor Magdalena Plebanski, Dr. Jennifer Boer, and Volga Tarlac for their assistance with experiments and for technical assistance. We acknowledge Professor Fabienne Mackay for supplying the mu-MT mice, Dr. Linda Wakim for the design of the antibody depletion experiment, Professor Joseph Trapani and Dr. Vivien Sutton (Peter MacCallum Cancer Centre) for help with the GrB and FasL analyses, and Dr. Nigel Jones and Dr. Bridgette Semple for assistance with the Morris water maze procedure. This study was supported by grants (APP1045755 and APP1126636) and a Fellowship (APP1044152) awarded to R.L.M. by the NHMRC of Australia, and by a Monash University, Faculty of Medicine, Nursing, and Health Sciences, Early Career Strategic Grant awarded to M.S.	Abromson-Leeman S, 2004, AM J PATHOL, V165, P1519, DOI 10.1016/S0002-9440(10)63410-4; Acharya D, 2017, J VIROL, V91, DOI [10.1128/JVI.01529-16, 10.1128/jvi.01529-16]; Adelson JD, 2012, NEURON, V73, P1100, DOI 10.1016/j.neuron.2012.01.020; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Ankeny DP, 2006, J NEUROCHEM, V99, P1073, DOI 10.1111/j.1471-4159.2006.04147.x; Ankeny DP, 2009, J CLIN INVEST, V119, P2990, DOI 10.1172/JCI39780; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Bodhankar S, 2015, METAB BRAIN DIS, V30, P911, DOI 10.1007/s11011-014-9639-8; Bodhankar S, 2013, METAB BRAIN DIS, V28, P375, DOI 10.1007/s11011-013-9413-3; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Braun M, 2017, J IMMUNOL, V198, P3615, DOI 10.4049/jimmunol.1601948; Bromley-Brits Kelley, 2011, J Vis Exp, DOI 10.3791/2920; Callaway JK, 2012, EUR J ANAESTH, V29, P239, DOI 10.1097/EJA.0b013e32835103c1; Chaitanya GV, 2010, NEUROSCIENCE, V165, P1203, DOI 10.1016/j.neuroscience.2009.10.067; Chaitanya GV, 2009, NEUROPATHOLOGY, V29, P270, DOI 10.1111/j.1440-1789.2008.00980.x; Christianson GJ, 1997, J IMMUNOL, V159, P4781; Dardiotis E., 2012, TRAUMATIC BRAIN INJU; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Doyle KP, 2015, J NEUROSCI, V35, P2133, DOI 10.1523/JNEUROSCI.4098-14.2015; Duan MC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/898053; Elkins J, 2017, LANCET NEUROL, V16, P217, DOI 10.1016/S1474-4422(16)30357-X; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Gonzalez-Quintela A, 2008, CLIN EXP IMMUNOL, V151, P42, DOI 10.1111/j.1365-2249.2007.03545.x; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Hillhouse EE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00006; Hurn PD, 2007, J CEREBR BLOOD F MET, V27, P1798, DOI 10.1038/sj.jcbfm.9600482; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Jazayeri MH., 2013, BIOMEDICINE AGING PA, V3, P241, DOI [DOI 10.1016/J.BIOMAG.2013.09.002, 10.1016/j.biomag.2013.09.002]; Kapitza S, 2012, EXP NEUROL, V236, P179, DOI 10.1016/j.expneurol.2012.04.023; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Kruisbeek AM, 2001, CURR PROTOC IMMUNOL, DOI DOI 10.1002/; Kumar V, 2014, IMMUNOLOGY, V142, P321, DOI 10.1111/imm.12247; Kuric E, 2014, EUR J NEUROSCI, V40, P2463, DOI 10.1111/ejn.12598; Liu ZX, 2019, BIOCHEM BIOPH RES CO, V512, P367, DOI 10.1016/j.bbrc.2019.03.002; Lunny CA, 2014, J NEUROL SCI, V336, P13, DOI 10.1016/j.jns.2013.08.011; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mars LT, 2011, BBA-MOL BASIS DIS, V1812, P151, DOI 10.1016/j.bbadis.2010.07.006; Mracsko E, 2014, J NEUROSCI, V34, P16784, DOI 10.1523/JNEUROSCI.1867-14.2014; Nasa Z, 2012, AM J TRANSPLANT, V12, P2062, DOI 10.1111/j.1600-6143.2012.04068.x; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Ngankam L, 2011, ZH NEVROL PSIKHIATR, V111, P61; Ortega SB, 2015, DISCOV MED, V19, P381; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Pohl HBF, 2011, J NEUROSCI, V31, P1069, DOI 10.1523/JNEUROSCI.5035-10.2011; Porter JR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138220; Raad M, 2014, NEUROSCIENCE, V281, P16, DOI 10.1016/j.neuroscience.2014.08.045; Ren XF, 2011, J NEUROSCI, V31, P8556, DOI 10.1523/JNEUROSCI.1623-11.2011; Rothhammer V, 2011, J EXP MED, V208, P2465, DOI 10.1084/jem.20110434; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Sashindranath M, 2015, BEHAV BRAIN RES, V286, P33, DOI 10.1016/j.bbr.2015.02.038; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; Semple BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143386; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Shibata D, 2012, J NEUROIMMUNOL, V252, P106, DOI 10.1016/j.jneuroim.2012.08.006; Shichita T, 2009, NAT MED, V15, P946, DOI 10.1038/nm.1999; Siebold L, 2018, EXP NEUROL, V310, P48, DOI 10.1016/j.expneurol.2018.07.004; Sundman MH, 2014, J ALZHEIMERS PARKINS, V4, P137; Takeuchi A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00194; Tripathi RB, 2010, J NEUROSCI, V30, P16383, DOI 10.1523/JNEUROSCI.3411-10.2010; Vargas ME, 2010, P NATL ACAD SCI USA, V107, P11993, DOI 10.1073/pnas.1001948107; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Walsh JT, 2015, J CLIN INVEST, V125, P699, DOI [10.1172/JCI176210, 10.1172/JCI76210]; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Wu B, 2012, EXP NEUROL, V237, P274, DOI 10.1016/j.expneurol.2012.07.016; Wu L, 2021, J NEUROTRAUM, V38, P1450, DOI 10.1089/neu.2017.5607; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	75	25	25	2	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	OCT 29	2019	29	5					1178	+		10.1016/j.celrep.2019.09.046			20	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	JJ1GB	WOS:000493907800010	31665632	gold			2022-02-06	
J	Webster, KM; Shultz, SR; Ozturk, E; Dill, LK; Sun, M; Casillas-Espinosa, P; Jones, NC; Crack, PJ; O'Brien, TJ; Semple, BD				Webster, Kyria M.; Shultz, Sandy R.; Ozturk, Ezgi; Dill, Larissa K.; Sun, Mujun; Casillas-Espinosa, Pablo; Jones, Nigel C.; Crack, Peter J.; O'Brien, Terence J.; Semple, Bridgette D.			Targeting high-mobility group box protein 1 (HMGB1) in pediatric traumatic brain injury: Chronic neuroinflammatory, behavioral, and epileptogenic consequences	EXPERIMENTAL NEUROLOGY			English	Article						High-mobility group box protein-1 (HMGB1); Glycyrrhizin; Inflammation; Post-traumatic epilepsy; Seizures; Pediatric; Neurotrauma; Traumatic brain injury; Behavior	EARLY POSTTRAUMATIC SEIZURES; CONTROLLED CORTICAL IMPACT; TEMPORAL-LOBE EPILEPSY; QUALITY-OF-LIFE; TERM-FOLLOW-UP; GLYCYRRHIZIC ACID; INTERLEUKIN-1 RECEPTOR; BARRIER PERMEABILITY; SOCIAL-RECOGNITION; HEAD TRAUMA	High mobility group box protein-1 (HMGB1) has been implicated as a key mediator of neuroinflammation and neurodegeneration in a range of neurological conditions including traumatic brain injury (TBI) and epilepsy. To date, however, most studies have examined only acute outcomes, and the adult brain. We have recently demonstrated HMGB1 release after experimental TBI in the pediatric mouse. This study therefore examined the chronic consequences of acute HMGB1 inhibition in the same model, to test the hypothesis that HMGB1 is a pivotal mediator of neuropathological, neurobehavioral, and epilepsy outcomes in pediatric TBI. HMGB1 was inhibited by treatment with 50 mg/kg i.p. Glycyrrhizin (Gly), compared to vehicle controls, commencing 1 h prior to moderate TBI or sham surgery in post-natal day 21 mice. We first demonstrated that Gly reduced brain HMGB1 levels and brain edema at an acute time point of 3 days post-injury. Subsequent analysis over a chronic time course found that pediatric TBI resulted in short-term spatial memory and motor learning deficits alongside an apparent increase in hippocampal microglial reactivity, which was prevented in Gly-treated TBI mice. In contrast, Gly treatment did not reduce the severity of evoked seizures, the proportion of animals exhibiting chronic spontaneous seizure activity, or cortical tissue loss. Together, our findings contribute to a growing appreciation for HMGB1's role in neuropathology and associated behavioral outcomes after TBI. However, further work is needed to fully elucidate the contribution of HMGB1 to epileptogenesis in this context.	[Webster, Kyria M.; Shultz, Sandy R.; Jones, Nigel C.; O'Brien, Terence J.; Semple, Bridgette D.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Parkville, Vic, Australia; [Shultz, Sandy R.; Ozturk, Ezgi; Dill, Larissa K.; Sun, Mujun; Casillas-Espinosa, Pablo; Jones, Nigel C.; O'Brien, Terence J.; Semple, Bridgette D.] Monash Univ, Dept Neurosci, Melbourne, Vic, Australia; [Shultz, Sandy R.; Ozturk, Ezgi; Dill, Larissa K.; Jones, Nigel C.; O'Brien, Terence J.] Alfred Hlth, Dept Neurol, Prahran, Vic, Australia; [Crack, Peter J.] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic, Australia		Semple, BD (corresponding author), Monash Univ, Dept Neurosci, Alfred Ctr, Level 6,99 Commercial Rd, Prahran, Vic 3004, Australia.	kyria.webster@genesearch.com.au; sandy.shultz@monash.edu; ezgi.ozturk@monash.edu; larissa.dill@monash.edu; mujun.sun@monash.edu; Pablo.casillas-espinosa@monash.edu; nigel.jones@monash.edu; pcrack@unimelb.edu.au; Terence.obrien@monash.edu; Bridgette.Semple@monash.edu	O'Brien, Terence/AAU-5525-2021; Crack, Peter/ABE-2065-2020; O'Brien, Terence/L-8102-2013	Crack, Peter/0000-0002-5030-0330; O'Brien, Terence/0000-0002-7198-8621; Sun, Mujun/0000-0002-9923-9913	National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia	The authors acknowledge funding support from the National Health and Medical Research Council of Australia (NHMRC) in the form of Project Grants and Career Development Fellowships to BDS and SRS. The authors also thank the Biomedical Histology Facility at the University of Melbourne, and Monash Histology Platform, Monash University at the Alfred Hospital.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Akao T, 2000, BIOL PHARM BULL, V23, P1418, DOI 10.1248/bpb.23.1418; Akman T, 2015, INFLAMMATION, V38, P1581, DOI 10.1007/s10753-015-0133-1; Alcaraz C, 1990, J Vet Diagn Invest, V2, P191; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Arase Y, 1997, CANCER, V79, P1494, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Balosso S, 2014, ANTIOXID REDOX SIGN, V21, P1726, DOI 10.1089/ars.2013.5349; Bannerman DM, 2001, EXP BRAIN RES, V138, P100, DOI 10.1007/s002210100687; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Chen XD, 2019, EXP NEUROL, V311, P1, DOI 10.1016/j.expneurol.2018.09.007; Chhor V, 2017, BRAIN BEHAV IMMUN, V63, P197, DOI 10.1016/j.bbi.2016.11.001; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Claus CP, 2010, DEV NEUROSCI-BASEL, V32, P454, DOI 10.1159/000316805; Costello DA, 2011, J NEUROSCI, V31, P3871, DOI 10.1523/JNEUROSCI.6676-10.2011; Crespel A, 2002, BRAIN RES, V952, P159, DOI 10.1016/S0006-8993(02)03050-0; David Y, 2009, J NEUROSCI, V29, P10588, DOI 10.1523/JNEUROSCI.2323-09.2009; Dent KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121541; Descotes J, 2009, MABS, V1, P104, DOI 10.4161/mabs.1.2.7909; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Gao TL, 2018, BIOCHEM BIOPH RES CO, V497, P430, DOI 10.1016/j.bbrc.2018.02.102; Gong G, 2012, ACTA PHARMACOL SIN, V33, P11, DOI 10.1038/aps.2011.151; Gu XJ, 2014, CHIN J TRAUMATOL, V17, P1, DOI 10.3760/cma.j.issn.1008-1275.2014.01.001; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222; Hayakawa K, 2012, P NATL ACAD SCI USA, V109, P7505, DOI 10.1073/pnas.1121146109; Heinemann U, 2012, GLIA, V60, P1251, DOI 10.1002/glia.22311; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Iori V, 2013, NEUROBIOL DIS, V58, P102, DOI 10.1016/j.nbd.2013.03.006; Jacewicz M, 2009, FOLIA NEUROPATHOL, V47, P321; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Karve IP, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0128-15.2016; Keret A, 2017, J NEUROSURG-PEDIATR, V20, P64, DOI 10.3171/2017.2.PEDS16585; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kieslich M, 2001, DISABIL REHABIL, V23, P665; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Langlois J. A., 2000, DIVISION ACUTE CARE; Larkin M, 2016, CUREUS, V8, DOI 10.7759/cureus.744; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Li D, 2015, NEUROSCI LETT, V609, P109, DOI 10.1016/j.neulet.2015.10.035; Li YJ, 2019, J PHARM PHARMACOL, V71, P390, DOI 10.1111/jphp.13040; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Liu SJ, 2016, BRAIN, V139, P1919, DOI 10.1093/brain/aww116; Luo L, 2014, CELL MOL NEUROBIOL, V34, P987, DOI 10.1007/s10571-014-0075-4; Luo Lidan, 2013, Exp Neurobiol, V22, P107, DOI 10.5607/en.2013.22.2.107; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maaswinkel H, 1996, PHYSIOL BEHAV, V60, P55, DOI 10.1016/0031-9384(95)02233-3; Maroso M, 2011, J INTERN MED, V270, P319, DOI 10.1111/j.1365-2796.2011.02431.x; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Mazarati A, 2011, EXP NEUROL, V232, P143, DOI 10.1016/j.expneurol.2011.08.012; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Morganti-Kossmann MC, 2019, ACTA NEUROPATHOL, V137, P731, DOI 10.1007/s00401-018-1944-6; Musumeci D, 2014, PHARMACOL THERAPEUT, V141, P347, DOI 10.1016/j.pharmthera.2013.11.001; Nehlig A, 1996, EPILEPSY RES, V26, P93, DOI 10.1016/S0920-1211(96)00045-9; Ohnishi M, 2014, NEUROCHEM INT, V75, P32, DOI 10.1016/j.neuint.2014.05.007; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Okuma Y, 2019, WORLD NEUROSURG, V122, pE864, DOI 10.1016/j.wneu.2018.10.164; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; Pang HG, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4569521; Passalacqua M, 1998, NEUROSCIENCE, V82, P1021; Paudel YN, 2019, J NEUROCHEM, V151, P542, DOI 10.1111/jnc.14663; Ploeger B, 2001, DRUG METAB REV, V33, P125, DOI 10.1081/DMR-100104400; Potts Mathew B, 2006, NeuroRx, V3, P143; Raible DJ, 2015, EXP NEUROL, V271, P445, DOI 10.1016/j.expneurol.2015.07.001; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Riazi K, 2010, EPILEPSY RES, V89, P34, DOI 10.1016/j.eplepsyres.2009.09.004; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schoderboeck L, 2009, NEUROBIOL DIS, V35, P368, DOI 10.1016/j.nbd.2009.05.026; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Semple BD, 2017, J NEUROSCI, V37, P7864, DOI 10.1523/JNEUROSCI.0982-17.2017; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Semple BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143386; Semple BD, 2015, NEUROBIOL DIS, V74, P263, DOI 10.1016/j.nbd.2014.12.003; Semple BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103386; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Sha YG, 2008, J IMMUNOL, V180, P2531, DOI 10.4049/jimmunol.180.4.2531; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Sun MJ, 2017, BRAIN BEHAV IMMUN, V66, P359, DOI 10.1016/j.bbi.2017.08.005; Sun Q, 2013, MED HYPOTHESES, V81, P681, DOI 10.1016/j.mehy.2013.07.026; Tabuchi M, 2012, CELL MOL NEUROBIOL, V32, P1139, DOI 10.1007/s10571-012-9839-x; Tarr AJ, 2011, BEHAV BRAIN RES, V217, P481, DOI 10.1016/j.bbr.2010.10.036; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Webster KM, 2019, J COMP NEUROL, V527, P1102, DOI 10.1002/cne.24589; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; YAMAMURA Y, 1995, BIOL PHARM BULL, V18, P337, DOI 10.1248/bpb.18.337; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Yang LJ, 2018, CELL PHYSIOL BIOCHEM, V46, P2532, DOI 10.1159/000489659; Zhang J, 2016, J NEUROPATH EXP NEUR, V75, P527, DOI 10.1093/jnen/nlw030; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334	117	25	25	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2019	320								112979	10.1016/j.expneurol.2019.112979			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IU2OR	WOS:000483420200016	31229637				2022-02-06	
J	Shekh-Ahmad, T; Lieb, A; Kovac, S; Gola, L; Wigley, WC; Abramov, AY; Walker, MC				Shekh-Ahmad, Tawfeeq; Lieb, Andreas; Kovac, Stjepana; Gola, Lukas; Wigley, W. Christian; Abramov, Andrey Y.; Walker, Matthew C.			Combination antioxidant therapy prevents epileptogenesis and modifies chronic epilepsy	REDOX BIOLOGY			English	Article						Epileptogenesis; Spontaneous seizures; Oxidative stress; Keap1-Nrf2 pathway; NADPH oxidase	OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION; NADPH OXIDASE; STATUS EPILEPTICUS; RAT MODEL; SEIZURE; SUPEROXIDE; INHIBITION; ACTIVATION; MECHANISMS	Many epilepsies are acquired conditions following an insult to the brain such as a prolonged seizure, traumatic brain injury or stroke. The generation of reactive oxygen species (ROS) and induction of oxidative stress are common sequelae of such brain insults and have been shown to contribute to neuronal death and the development of epilepsy. Here, we show that combination therapy targeting the generation of ROS through NADPH oxidase inhibition and the endogenous antioxidant system through nuclear factor erythroid 2-related factor 2 (Nrf2) activation prevents excessive ROS accumulation, mitochondrial depolarisation and neuronal death during in vitro seizure-like activity. Moreover, this combination therapy prevented the development of spontaneous seizures in 40% of animals following status epilepticus (70% of animals were seizure free after 8 weeks) and modified the severity of epilepsy when given to chronic epileptic animals.	[Shekh-Ahmad, Tawfeeq; Lieb, Andreas; Abramov, Andrey Y.; Walker, Matthew C.] UCL, UCL Queen Sq Inst Neurol, Queen Sq, London WC1N, England; [Kovac, Stjepana; Gola, Lukas] Univ Munster, Dept Neurol, D-48149 Munster, Germany; [Wigley, W. Christian] Reata Pharmaceut, 2801 Gateway Dr,Suite 150, Irving, TX 75063 USA; [Shekh-Ahmad, Tawfeeq] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, Jerusalem, Israel; [Lieb, Andreas] Med Univ Innsbruck, Dept Pharmacol, Peter Mayr Str 1A, A-6020 Innsbruck, Austria		Walker, MC (corresponding author), UCL, UCL Queen Sq Inst Neurol, Queen Sq, London WC1N, England.	m.walker@ucl.ac.uk	Abramov, Andrey Y/H-9053-2012; Walker, Matthew C/C-1577-2008	Abramov, Andrey Y/0000-0002-7646-7235; Walker, Matthew C/0000-0002-0812-0352; Shekh-Ahmad, Tawfeeq/0000-0002-6165-2219; Lieb, Andreas/0000-0001-9567-649X	European UnionEuropean Commission [602102]; Epilepsy Research UK [P1301]; Ursula von Euch Stiftung; Innovative Medizinische Forschung (IMF) [KO111715]	European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no602102 (EPITARGET) Matthew C Walker; Epilepsy Research UK (Project Grant P1301) Matthew C Walker; Innovative Medizinische Forschung (IMF grant KO111715 grant to Stjepana Kovac) and Ursula von Euch Stiftung (fellowship to Stjepana Kovac).	Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007; Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Betteridge DJ, 2000, METABOLISM, V49, P3, DOI 10.1016/S0026-0495(00)80077-3; Bhatti J, 2018, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00744; Buico A, 2009, REDOX REP, V14, P125, DOI 10.1179/135100009X392557; Chang PS, 2011, J NEUROSCI METH, V201, P106, DOI 10.1016/j.jneumeth.2011.07.018; Cheignon C, 2018, REDOX BIOL, V14, P450, DOI 10.1016/j.redox.2017.10.014; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Haynes L.W., 1999, IBRO HDB SERIES; Hellier JL, 1998, EPILEPSY RES, V31, P73, DOI 10.1016/S0920-1211(98)00017-5; Kim JH, 2013, BRAIN RES, V1499, P163, DOI 10.1016/j.brainres.2013.01.007; Kovac S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.390; Kovacs R, 2002, J NEUROPHYSIOL, V88, P2909, DOI 10.1152/jn.00149.2002; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Mazzuferi M, 2013, ANN NEUROL, V74, P560, DOI 10.1002/ana.23940; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Pauletti A, 2017, BRAIN, V140, P1885, DOI 10.1093/brain/awx117; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Pearson-Smith JN, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112365; Pestana RRF, 2010, NEUROSCI LETT, V484, P187, DOI 10.1016/j.neulet.2010.08.049; Puspita L, 2017, MOL BRAIN, V10, DOI 10.1186/s13041-017-0340-9; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Shekh-Ahmad T, 2018, BRAIN, V141, P1390, DOI 10.1093/brain/awy071; Waldbaum S, 2010, J BIOENERG BIOMEMBR, V42, P449, DOI 10.1007/s10863-010-9320-9; Wang XL, 2014, BBA-MOL BASIS DIS, V1842, P1240, DOI 10.1016/j.bbadis.2013.10.015; Williams S, 2015, NEUROSCIENCE, V303, P160, DOI 10.1016/j.neuroscience.2015.07.005; Zhang RR, 2017, MOL NEUROBIOL, V54, P6006, DOI 10.1007/s12035-016-0111-0	30	25	27	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	2213-2317			REDOX BIOL	Redox Biol.	SEP	2019	26								101278	10.1016/j.redox.2019.101278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JI9ZE	WOS:000493821500011	31382215	gold, Green Published			2022-02-06	
J	Wu, TT; Alshareef, A; Giudice, JS; Panzer, MB				Wu, Taotao; Alshareef, Ahmed; Giudice, J. Sebastian; Panzer, Matthew B.			Explicit Modeling of White Matter Axonal Fiber Tracts in a Finite Element Brain Model	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Axonal fibers; Brain model; Finite element model validation	MECHANICAL-PROPERTIES; STRAIN RESPONSES; HEAD; TISSUE; BEHAVIOR; VALIDATION; ATLAS	Many human brain finite element (FE) models lack mesoscopic (similar to 1 mm) white matter structures, which may limit their capability in predicting TBI and assessing tissue-based injury metrics such as axonal strain. This study investigated an embedded method to explicitly incorporate white matter axonal fibers into an existing 50th percentile male brain model. The white matter was decomposed into myelinated axon tracts and an isotropic ground substance that had similar material properties to gray matter. The axon tract bundles were derived from a population-based tractography template explicitly modeled using 1-D cable elements. The axonal fibers and ground substance material were implemented using hyper-viscoelastic constitutive models, which were calibrated using white and gray matter brain tissue material testing data available in the literature. Finally, the new axon-based model was extensively validated for brain-skull relative deformation under various loading conditions (n = 17) and showed good biofidelity compared to other brain models. Through these analyses, we demonstrated the applicability of this method for incorporating axonal fiber tracts into an existing FE brain model. The axon-based model will be a useful tool for understanding the mechanisms of TBI, evaluating tissue-based injury metrics, and developing injury mitigation systems.	[Wu, Taotao; Alshareef, Ahmed; Giudice, J. Sebastian; Panzer, Matthew B.] Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA		Panzer, MB (corresponding author), Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA.	tw2dx@virginia.edu; aa4kw@virginia.edu; jsg4fd@virginia.edu; mpb2q@virginia.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Alshareef, Ahmed/0000-0003-4512-1618; Giudice, Sebastian/0000-0003-1074-4890	16 NIH Institutes and CentersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Clinical Center (CC) [1U54MH091657]; McDonnell Center for Systems Neuroscience at Washington University; Football Research, Inc. (FRI)	Diffusion MRI data were provided in part by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. The research presented in this paper was made possible in part by a grant from Football Research, Inc. (FRI). The views expressed are solely those of the authors and do not represent those of FRI or any of its affiliates or funding sources.	Alshareef A, 2018, J NEUROTRAUM, V35, P780, DOI 10.1089/neu.2017.5362; [Anonymous], 2015, C TRAUM BRAIN INJ US; Arbogast KB, 1997, SAE TECHNICAL PAPER; Bermejo M, 2017, SHOCK VIB, V2017, DOI 10.1155/2017/4636381; BESL PJ, 1992, IEEE T PATTERN ANAL, V14, P239, DOI 10.1109/34.121791; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Brands D. W., 1999, SAE TECHNICAL PAPER; Bryan R, 2010, MED ENG PHYS, V32, P57, DOI 10.1016/j.medengphy.2009.10.008; Budday S, 2017, ACTA BIOMATER, V48, P319, DOI 10.1016/j.actbio.2016.10.036; Budday S, 2015, J MECH BEHAV BIOMED, V46, P318, DOI 10.1016/j.jmbbm.2015.02.024; Chatelin Simon, 2013, Journal of Biorheology, V27, P26, DOI 10.1007/s12573-012-0055-6; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Davis ML, 2016, SAE TECHNICAL PAPER; Feng Y, 2013, J MECH BEHAV BIOMED, V23, P117, DOI 10.1016/j.jmbbm.2013.04.007; FISH J, 1992, COMPUT STRUCT, V43, P539, DOI 10.1016/0045-7949(92)90287-A; Fung Y.C., 2013, BIOMECHANICS MECH PR; Gabler LF, 2018, ANN BIOMED ENG, V46, P972, DOI 10.1007/s10439-018-2015-9; Gabler LF, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4038357; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; Ganpule S, 2017, J NEUROTRAUM, V34, P2154, DOI 10.1089/neu.2016.4744; Garimella HT, 2017, INT J NUMER METH BIO, V33, DOI 10.1002/cnm.2823; Garo A, 2007, BIORHEOLOGY, V44, P51; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Gehre C., 2009, OBJECTIVE RATING SIG; Gennarelli T.A., 1972, SAE TECHNICAL PAPER; Giordano C, 2014, SAE TECHNICAL PAPER; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Giudice JS, 2019, ANN BIOMED ENG, V47, P1855, DOI 10.1007/s10439-018-02161-5; Golman A., 2013, P 41 INT WORKSH; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hardy WN., 2001, SAE TECHNICAL PAPER; Holzapfel GA, 2017, J ELASTICITY, V129, P49, DOI 10.1007/s10659-016-9605-2; Holzapfel GA, 2015, EUR J MECH A-SOLID, V49, P561, DOI 10.1016/j.euromechsol.2014.09.005; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Jin X., 2006, SAE TECHNICAL PAPER; Jin X, 2013, J BIOMECH, V46, P2795, DOI 10.1016/j.jbiomech.2013.09.001; Johnson CL, 2013, NEUROIMAGE, V79, P145, DOI 10.1016/j.neuroimage.2013.04.089; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Latorre M, 2016, APPL MATH MODEL, V40, P3938, DOI 10.1016/j.apm.2015.10.045; Lippert SA, 2004, BIORHEOLOGY, V41, P681; Maier-Hein KH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01285-x; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Miller LE, 2016, BIOMECH MODEL MECHAN, V15, P1201, DOI 10.1007/s10237-015-0754-1; Nicolle S., 2004, SAE TECHNICAL PAPER; Nilsson M, 2012, NMR BIOMED, V25, P795, DOI 10.1002/nbm.1795; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Park G, 2017, COMPUT METHOD BIOMEC, V20, P1151, DOI 10.1080/10255842.2017.1340459; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Peters GWM, 1997, BIORHEOLOGY, V34, P127, DOI 10.1016/S0006-355X(97)00009-7; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Sahoo D, 2016, ACCIDENT ANAL PREV, V92, P53, DOI 10.1016/j.aap.2016.03.013; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; Sanchez EJ, 2019, CLIN BIOMECH, V64, P82, DOI 10.1016/j.clinbiomech.2018.02.019; Sanchez EJ, 2017, J NEUROTRAUM, V34, P2410, DOI 10.1089/neu.2016.4681; Shen F, 2006, J BIOMECH ENG-T ASME, V128, P797, DOI 10.1115/1.2264393; Tabatabaei SA, 2015, COMPUT STRUCT, V152, P142, DOI 10.1016/j.compstruc.2015.02.014; Takhounts EG, 2008, SAE TECHNICAL PAPER; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Yeh FC, 2018, NEUROIMAGE, V178, P57, DOI 10.1016/j.neuroimage.2018.05.027; Zhao W, 2019, J NEUROTRAUM, V36, P250, DOI 10.1089/neu.2018.5634; Zhao W, 2018, J MECH BEHAV BIOMED, V80, P222, DOI 10.1016/j.jmbbm.2018.02.005	66	25	25	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	SEP	2019	47	9			SI		1908	1922		10.1007/s10439-019-02239-8			15	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	JD1MH	WOS:000489738300006	30877404				2022-02-06	
J	Che, LB; Lei, ZY; Wu, PY; Song, DW				Che, Lingbin; Lei, Zhouyue; Wu, Peiyi; Song, Dianwen			A 3D Printable and Bioactive Hydrogel Scaffold to Treat Traumatic Brain Injury	ADVANCED FUNCTIONAL MATERIALS			English	Article						3D printing; bioactive; double-networks; hydrogels; traumatic brain injury	DOUBLE-NETWORK HYDROGELS; TOUGH HYDROGELS; DELIVERY; CALCIUM	Traumatic brain injury accompanied by intracranial hypertension remains one of the most fatal injuries worldwide. Usually, patients must undergo two surgeries, craniectomy and cranioplasty, to reduce the intracranial pressure and then repair the skull. Traditional biomaterials, such as autologous bones and titanium meshes, which have poor stretchability and very high Young's modulus values up to hundreds of GPa, tend to constrain intracranial tissue and cannot be implanted directly after craniectomy. Thus far, finding elastic and degradable biomaterials to be immediately implanted after a craniectomy has remained a great challenge, which should not only repair cranial defects but also avoid secondary surgery and reduce the risk of complications, has remained a great challenge. Herein, a 3D printable bioactive hydrogel scaffold with high elasticity that can protect brain tissue, adapt to intracranial pressure changes, allow for the transport of nutrients and the proliferation and osteogenic differentiation of bone mesenchymal stem cells is presented. As indicated by in vivo experiments, the hydrogel scaffold helps to treat traumatic brain injury within 8 weeks and degrades safely. With these advantages, this material shows the potential to open up new horizons for cranioplasty and to help patients survive traumatic brain injury.	[Che, Lingbin; Song, Dianwen] Shanghai Paotong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai 200080, Peoples R China; [Lei, Zhouyue; Wu, Peiyi] Donghua Univ, State Key Lab Modificat Chem Fibers & Polymer Mat, Coll Chem Chem Engn & Biotechnol, Ctr Adv Low Dimens Mat, Shanghai 201620, Peoples R China; [Lei, Zhouyue; Wu, Peiyi] Fudan Univ, State Key Lab Mol Engn Polymers, Dept Macromol Sci, Shanghai 200433, Peoples R China; [Lei, Zhouyue; Wu, Peiyi] Fudan Univ, Lab Adv Mat, Shanghai 200433, Peoples R China		Song, DW (corresponding author), Shanghai Paotong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai 200080, Peoples R China.; Wu, PY (corresponding author), Donghua Univ, State Key Lab Modificat Chem Fibers & Polymer Mat, Coll Chem Chem Engn & Biotechnol, Ctr Adv Low Dimens Mat, Shanghai 201620, Peoples R China.; Wu, PY (corresponding author), Fudan Univ, State Key Lab Mol Engn Polymers, Dept Macromol Sci, Shanghai 200433, Peoples R China.; Wu, PY (corresponding author), Fudan Univ, Lab Adv Mat, Shanghai 200433, Peoples R China.	wupeiyi@dhu.edu.cn; dianwen.song@shgh.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571828, 51733003, 21674025]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [14411963700]	L.C. and Z.L. contributed equally to this work. This work was supported from the National Natural Science Foundation of China (Nos. 81571828, 51733003, and 21674025) and Science and Technology Commission of Shanghai Municipality (No. 14411963700).	Addison WN, 2010, J BONE MINER RES, V25, P1191, DOI 10.1002/jbmr.110; Cordonnier C, 2018, LANCET, V392, P1257, DOI 10.1016/S0140-6736(18)31878-6; Dan Y, 2016, NANOSCALE RES LETT, V11, DOI 10.1186/s11671-016-1669-1; Geckil H, 2010, NANOMEDICINE-UK, V5, P469, DOI 10.2217/NNM.10.12; Gong JP, 2003, ADV MATER, V15, P1155, DOI 10.1002/adma.200304907; Gonzalez-Vazquez A, 2014, ACTA BIOMATER, V10, P2824, DOI 10.1016/j.actbio.2014.02.004; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Holloway JL, 2014, J CONTROL RELEASE, V191, P63, DOI 10.1016/j.jconrel.2014.05.053; Hong SM, 2015, ADV MATER, V27, P4035, DOI [10.1002/adma.201501099, 10.1002/adma.201570182]; Lee MN, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0170-6; Lei ZY, 2018, ACS NANO, V12, P12860, DOI 10.1021/acsnano.8b08062; Lei ZY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03456-w; Lu BY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09003-5; Maeno S, 2005, BIOMATERIALS, V26, P4847, DOI 10.1016/j.biomaterials.2005.01.006; Marcellini S, 2012, BIOESSAYS, V34, P953, DOI 10.1002/bies.201200061; Pati F, 2015, BIOMATERIALS, V62, P164, DOI 10.1016/j.biomaterials.2015.05.043; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409; Sun TL, 2017, MACROMOLECULES, V50, P2923, DOI 10.1021/acs.macromol.7b00162; Tian K, 2017, ADV MATER, V29, DOI 10.1002/adma.201604827; Wang WH, 2014, J NEUROTRAUM, V31, P1444, DOI 10.1089/neu.2013.3142; Yan YF, 2019, BIOMATERIALS, V190, P97, DOI 10.1016/j.biomaterials.2018.10.033; Yu HC, 2019, MACROMOLECULES, V52, P629, DOI 10.1021/acs.macromol.8b02269; Zhang D, 2013, BIOMATERIALS, V34, P10258, DOI 10.1016/j.biomaterials.2013.09.027; Zhang YS, 2017, SCIENCE, V356, DOI 10.1126/science.aaf3627; Zhao XH, 2014, SOFT MATTER, V10, P672, DOI 10.1039/c3sm52272e; Zheng SY, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201803366	27	25	25	27	286	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1616-301X	1616-3028		ADV FUNCT MATER	Adv. Funct. Mater.	SEP	2019	29	39							1904450	10.1002/adfm.201904450		AUG 2019	10	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	IZ8TR	WOS:000478852600001					2022-02-06	
J	Brett, BL; Huber, DL; Wild, A; Nelson, LD; McCrea, MA				Brett, Benjamin L.; Huber, Daniel L.; Wild, Alexa; Nelson, Lindsay D.; McCrea, Michael A.			Age of First Exposure to American Football and Behavioral, Cognitive, Psychological, and Physical Outcomes in High School and Collegiate Football Players	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						adolescence; sports; football; concussion; traumatic brain injury; age of first exposure	CHRONIC TRAUMATIC ENCEPHALOPATHY; HEAD IMPACT EXPOSURE; BASE-LINE; NEUROCOGNITIVE PERFORMANCE; SPORTS PARTICIPATION; CONCUSSION SYMPTOMS; POSTURAL STABILITY; SINGLE SEASON; RELIABILITY; SPECTRUM	Background: Although some studies have observed a relationship between age of first exposure (AFE) to American football and long-term outcomes, recent findings in collegiate athletes did not observe a relationship between AFE and more intermediate outcomes at early adulthood. This, however, requires independent replication. Hypothesis: There will be no association between AFE to football and behavioral, cognitive, emotional/psychological, and physical functioning in high school and collegiate athletes. Study Design: Cross-sectional study. Methods: Active high school and collegiate football players (N = 1802) underwent a comprehensive preseason evaluation on several clinical outcome measures. Demographic and health variables that significantly differed across AFE groups were identified as potential covariates. General linear models (GLMs) with AFE as the independent variable were performed for each clinical outcome variable. Similar GLMs that included identified covariates, with AFE as the predictor, were subsequently performed for each clinical outcome variable. Results: After controlling for covariates of age, concussion history, race, and a diagnosis of ADHD, earlier AFE (<12 vs >= 12 years) did not significantly predict poorer performance on any clinical outcome measures (all P > 0.05). A single statistically significant association between AFE group and somatization score was recorded, with AFE Conclusion: In a large cohort of active high school and collegiate football student-athletes, AFE before the age of 12 years was not associated with worse behavioral, cognitive, psychological, and physical (oculomotor functioning and postural stability) outcomes.	[Brett, Benjamin L.; Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Brett, Benjamin L.; Huber, Daniel L.; Wild, Alexa; Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA		Brett, BL (corresponding author), Med Coll Wisconsin, Dept Neurol, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.; Brett, BL (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.	bbrett@mcw.edu		Huber, Daniel/0000-0003-2079-0647	Defense Health Program under the Department of Defense Broad Agency Announcement for Extramural Medical Research [W81XWH-14-1-0561]; National Center for Advancing Translational Sciences, National Institutes of Health (NIH) [UL1TR001436]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001436] Funding Source: NIH RePORTER	This work was supported by the Defense Health Program under the Department of Defense Broad Agency Announcement for Extramural Medical Research through Award No. W81XWH-14-1-0561. The REDCap electronic database used for this project was supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), Award Number UL1TR001436. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense or the NIH.	Alosco ML, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.197; Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; [Anonymous], 2009, DISCOVERING STAT USI; Asken BM, 2017, ARCH CLIN NEUROPSYCH, V32, P963, DOI 10.1093/arclin/acx018; Babiss LA, 2009, J DEV BEHAV PEDIATR, V30, P376, DOI 10.1097/DBP.0b013e3181b33659; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Barr WB, 2013, NEUROPSYCHOL REV, V23, P271, DOI 10.1007/s11065-013-9244-3; Brett BL, 2017, DEV NEUROPSYCHOL, V42, P70, DOI 10.1080/87565641.2016.1243114; Cook NE, 2017, CLIN NEUROPSYCHOL, V31, P1341, DOI 10.1080/13854046.2017.1317031; Cottle JE, 2017, J ATHL TRAINING, V52, P77, DOI 10.4085/1062-6050-51.12.21; Covassin T, 2010, OPEN ACCESS J SPORTS, V1, P55; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Davenport EM, 2016, J NEUROTRAUM, V33, P2133, DOI 10.1089/neu.2015.4267; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Derogatis LR, 2001, BRIEF SYMPT INV 18 B; Fishman M, 2017, J PEDIATR-US, V184, P19, DOI 10.1016/j.jpeds.2017.01.048; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gardner RM, 2017, PHYSICIAN SPORTSMED, V45, P1, DOI 10.1080/00913847.2017.1248221; Gong NJ, 2018, NEUROBIOL DIS, V119, P79, DOI 10.1016/j.nbd.2018.07.020; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Houck Z, 2018, J INT NEUROPSYCH SOC, V24, P1, DOI 10.1017/S1355617717000716; Hoyle RH, 2002, PERS INDIV DIFFER, V32, P401, DOI 10.1016/S0191-8869(01)00032-0; ImPACT Applications, IMM POSTC ASS TEST I; Janigro D, 2018, JAMA NEUROL, V75, P381, DOI 10.1001/jamaneurol.2017.4890; Katz BP, 2018, SPORTS MED, V48, P1971, DOI 10.1007/s40279-018-0875-7; Kuhn AW, 2017, BRIT J SPORT MED, V51, P1732, DOI 10.1136/bjsports-2016-096508; Kuzminski SJ, 2018, AM J NEURORADIOL, V39, P245, DOI 10.3174/ajnr.A5489; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130507; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Paniccia M, 2018, SPORTS HEALTH, V10, P175, DOI 10.1177/1941738117741651; Patrick CJ, 2013, PSYCHOL ASSESSMENT, V25, P1332, DOI 10.1037/a0034864; Reitan R, 1985, HALSTEAD REITAN NEUR; Russo Ralph D., US TODAY; Schultz V, 2018, J NEUROTRAUM, V35, P278, DOI 10.1089/neu.2017.5145; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shao J., 2003, MATH STAT; Solomon GS, 2014, PHYSICIAN SPORTSMED, V42, P26, DOI 10.3810/psm.2014.09.2072; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Turner RW, 2014, J ADOLESCENT HEALTH, V54, pS79, DOI 10.1016/j.jadohealth.2013.10.172; Wallace J, 2017, J ATHL TRAINING, V52, P682, DOI 10.4085/1062-6050-52.3.06; Wechsler D., 2008, WECHSLER ADULT INTEL; Wojtowicz M, 2017, J NEUROTRAUM, V34, P322, DOI 10.1089/neu.2016.4412; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	58	25	25	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	JUL	2019	11	4					332	342		10.1177/1941738119849076			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	IF7FT	WOS:000473247600006	31173699	Green Published			2022-02-06	
J	Kim, T; Chelluboina, B; Chokkalla, AK; Vemuganti, R				Kim, TaeHee; Chelluboina, Bharath; Chokkalla, Anil K.; Vemuganti, Raghu			Age and sex differences in the pathophysiology of acute CNS injury	NEUROCHEMISTRY INTERNATIONAL			English	Article							SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; ESTROGEN REPLACEMENT THERAPY; FOCAL CEREBRAL-ISCHEMIA; KAPPA-B ACTIVATION; EXPERIMENTAL STROKE; INFLAMMATORY CYTOKINES; UNITED-STATES; FEMALE RATS; GENDER	Despite the immeasurable burden on patients and families, no effective therapies to protect the CNS after an acute injury are available yet. Furthermore, the underlying mechanisms that promote neuronal death and functional deficits after injury remain to be poorly understood. The prevalence, age of onset, pathophysiology, and symptomatology of many CNS insults differ significantly between males and females. In the case of stroke, younger males tend to show a higher risk than younger females, while this trend reverses with age. Accumulating evidence from preclinical studies have shown that sex hormones play a crucial role in providing neuroprotection following ischemic stroke and other acute CNS injuries. Estrogen, in particular, exerts a neuroprotective effect by modulating the immune responses after injury. In addition, there exists a sexual dimorphism in cell death pathways between males and females that are independent of hormones. Meanwhile, recent studies suggest that microRNAs are critically involved in the sex-specific mechanisms of cell death. This review discusses the current knowledge on the contribution of sex and age to outcome after stroke. Implication of the interplay between these two factors on other CNS injuries (spinal cord injury and traumatic brain injury) from the experimental evidence were also discussed.	[Kim, TaeHee; Chelluboina, Bharath; Chokkalla, Anil K.; Vemuganti, Raghu] Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA; [Chokkalla, Anil K.; Vemuganti, Raghu] Univ Wisconsin, Cellular & Mol Pathol Program, Madison, WI 53792 USA; [Vemuganti, Raghu] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA		Vemuganti, R (corresponding author), Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA.	vemuganti@neurosurgery.wisc.edu	Kim, TaeHee/AAS-5541-2020; Chokkalla, Anil Kiran/AAD-6977-2022	Kim, TaeHee/0000-0002-1980-7774; Chokkalla, Anil Kiran/0000-0002-0101-0417; Chelluboina, Bharath/0000-0001-8834-6484	U.S. Department of Veterans Affairs Merit Review GrantUS Department of Veterans Affairs [I01 BX002985]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS101960, RO1 N5099531, RO1 NS109459]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS101960, R01NS109459, R01NS099531] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002985] Funding Source: NIH RePORTER	This work was supported, in part, by the U.S. Department of Veterans Affairs Merit Review Grant (I01 BX002985) and NIH grants RO1 NS101960, RO1 N5099531, RO1 NS109459. Figures were created using the Servier Medical Art image bank with appropriate modifications.	Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Arias E., 1840, NCHS DATA BRIEF, V22, P46, DOI DOI 10.1056/NEJM184002260220306; Barber PA, 2001, NEUROLOGY, V56, P1015, DOI 10.1212/WNL.56.8.1015; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Biswas RK, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0211-y; Boehme AK, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00500; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; Broughton BRS, 2014, STROKE, V45, P835, DOI 10.1161/STROKEAHA.113.001499; Broughton BRS, 2013, NEUROSIGNALS, V21, P229, DOI 10.1159/000338019; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; Cai M, 2014, NEUROSCI LETT, V558, P115, DOI 10.1016/j.neulet.2013.11.007; Carrasquilla GD, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002445; Carswell HV, 2004, J CEREBR BLOOD F MET, V24, P298, DOI 10.1097/01.WCB.0000112322.75217.FD; Chan WM, 2013, TRANSL STROKE RES, V4, P447, DOI 10.1007/s12975-012-0249-7; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Chen YY, 2016, ARCH PHYS MED REHAB, V97, P1610, DOI 10.1016/j.apmr.2016.03.017; Chiappetta O, 2007, INT REV NEUROBIOL, V82, P357, DOI 10.1016/S0074-7742(07)82019-8; Chu MC, 2003, HUM REPROD, V18, P1570, DOI 10.1093/humrep/deg330; Cole JA, 2007, OBSTET GYNECOL, V109, P339, DOI 10.1097/01.AOG.0000250968.82370.04; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178; Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500; Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157; DiNapoli VA, 2008, NEUROBIOL AGING, V29, P753, DOI 10.1016/j.neurobiolaging.2006.12.007; DiNapoli VA, 2006, J NEUROSCI METH, V154, P233, DOI 10.1016/j.jneumeth.2005.12.026; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Edwards P, 2005, LANCET, V365, P1957; Fang Jing, 2012, Morbidity and Mortality Weekly Report, V61, P379; Farooque M, 2006, SPINAL CORD, V44, P182, DOI 10.1038/sj.sc.3101816; Fee DB, 2007, BRAIN RES, V1137, P146, DOI 10.1016/j.brainres.2006.12.024; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Galea J, 2013, J INFLAMM RES, V6, P121, DOI 10.2147/JIR.S35629; Gordon KB, 2005, BRAIN RES, V1036, P155, DOI 10.1016/j.brainres.2004.12.052; Hagberg H, 2004, J NEUROCHEM, V90, P1068, DOI 10.1111/j.1471-4159.2004.02547.x; Hauben E, 2002, EUR J NEUROSCI, V16, P1731, DOI 10.1046/j.1460-9568.2002.02241.x; Herman P, 2018, J NEUROTRAUM, V35, P1819, DOI 10.1089/neu.2017.5519; Hollander M, 2003, J NEUROL NEUROSUR PS, V74, P317, DOI 10.1136/jnnp.74.3.317; Jin R, 2013, J CARDIOVASC TRANSL, V6, P834, DOI 10.1007/s12265-013-9508-6; Kim TH, 2015, CNS NEUROSCI THER, V21, P327, DOI 10.1111/cns.12346; Kleindorfer DO, 2010, STROKE, V41, P1326, DOI 10.1161/STROKEAHA.109.575043; Koellhoffer EC, 2013, TRANSL STROKE RES, V4, P390, DOI 10.1007/s12975-012-0230-5; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Laliberte F, 2011, MENOPAUSE, V18, P1052, DOI 10.1097/gme.0b013e3182175e5c; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Lang JT, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-33; Ley EJ, 2013, J TRAUMA ACUTE CARE, V75, P682, DOI 10.1097/TA.0b013e31829d024f; Li H, 2005, ANN NEUROL, V58, P317, DOI 10.1002/ana.20538; Lin CW, 2016, NEUROSCI BULL, V32, P137, DOI 10.1007/s12264-016-0017-x; Liu FD, 2011, STROKE, V42, P1090, DOI 10.1161/STROKEAHA.110.594861; Liu FD, 2009, STROKE, V40, P1842, DOI 10.1161/STROKEAHA.108.538686; Lokkegaard E, 2017, STROKE, V48, P2266, DOI 10.1161/STROKEAHA.117.017132; Low PC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4450; Lu D, 2016, BIOCHEM BIOPH RES CO, V477, P209, DOI 10.1016/j.bbrc.2016.06.044; Lusardi TA, 2014, FRONT MOL NEUROSCI, V7, DOI [10.3389/fnmo1.2014.00011, 10.3389/fnmol.2014.00011]; Madsen TE, 2015, STROKE, V46, P717, DOI 10.1161/STROKEAHA.114.006737; Manwani B, 2015, J CEREBR BLOOD F MET, V35, P221, DOI 10.1038/jcbfm.2014.186; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; McCullough LD, 2016, AGING-US, V8, P1432, DOI 10.18632/aging.100997; Murphy AJ, 2010, J IMMUNOL, V184, P5029, DOI 10.4049/jimmunol.0903463; Mychasiuk R, 2016, J NEUROSCI METH, V257, P168, DOI 10.1016/j.jneumeth.2015.10.002; Nadkarni S, 2013, CURR OPIN PHARMACOL, V13, P576, DOI 10.1016/j.coph.2013.05.007; Niemeier JP, 2013, NEUROPSYCHOL REHABIL, V23, P363, DOI 10.1080/09602011.2012.761944; Nys GMS, 2006, J NEUROL SCI, V247, P149, DOI 10.1016/j.jns.2006.04.005; Ouyang YB, 2012, NEUROBIOL DIS, V45, P555, DOI 10.1016/j.nbd.2011.09.012; Petrone AB, 2014, AGING DIS, V5, P340, DOI 10.14336/AD.2014.0500340; Poynter B, 2009, PSYCHOSOMATICS, V50, P563, DOI 10.1176/appi.psy.50.6.563; Rahnama M, 2002, B VET I PULAWY, V46, P273; Reeves MJ, 2008, LANCET NEUROL, V7, P915, DOI 10.1016/S1474-4422(08)70193-5; Renolleau S, 2007, J NEUROCHEM, V100, P1062, DOI 10.1111/j.1471-4159.2006.04269.x; Ridder DA, 2009, NEUROSCIENCE, V158, P995, DOI 10.1016/j.neuroscience.2008.07.007; Ritz MF, 2008, BRAIN RES, V1203, P177, DOI 10.1016/j.brainres.2008.01.091; Rosen CL, 2005, J NEUROSURG, V103, P687, DOI 10.3171/jns.2005.103.4.0687; Santizo RA, 2002, BRAIN RES, V956, P86, DOI 10.1016/S0006-8993(02)03484-4; Sealy-Jefferson S, 2012, GENDER MED, V9, P121, DOI 10.1016/j.genm.2012.02.002; Selvamani A, 2017, NEUROCHEM INT, V107, P168, DOI 10.1016/j.neuint.2016.10.008; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Selvamani A, 2010, J NEUROSCI, V30, P6852, DOI 10.1523/JNEUROSCI.0761-10.2010; Seshadri S, 2006, STROKE, V37, P345, DOI 10.1161/01.STR.0000199613.38911.b2; Sharma S, 2014, BIOL SEX DIFFER, V5, DOI 10.1186/2042-6410-5-3; Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Spani CB, 2018, FRONT NEUROENDOCRIN, V50, P52, DOI 10.1016/j.yfrne.2018.03.006; Spinal Cord Injury (SCI), 2016, J SPINAL CORD MED, V39, P493, DOI [10.1080/10790268.2016.1210925, DOI 10.1080/10790268.2016.1210925]; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; Stary CM, 2017, MOL CELL NEUROSCI, V82, P118, DOI 10.1016/j.mcn.2017.05.004; Strom JO, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-22; Strom JO, 2011, INT J MOL SCI, V12, P1533, DOI 10.3390/ijms12031533; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Swartz KR, 2007, J NEUROTRAUM, V24, P473, DOI 10.1089/neu.2006.0167; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Toung TK, 2000, STROKE, V31, P2701, DOI 10.1161/01.STR.31.11.2701; Turtzo LC, 2011, J NEUROSCI, V31, P13255, DOI 10.1523/JNEUROSCI.0621-11.2011; Vagnerova K, 2010, NEUROSCIENCE, V166, P476, DOI 10.1016/j.neuroscience.2009.12.041; Vannucci SJ, 2001, J CEREBR BLOOD F MET, V21, P52, DOI 10.1097/00004647-200101000-00007; Vega T, 2009, J STROKE CEREBROVASC, V18, P11, DOI 10.1016/j.jstrokecerebrovasdis.2008.06.010; von Leden RE, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0933-3; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xing DQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036890; Yanhong Li, 2007, Neural Regeneration Research, V2, P471; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Zahuranec DB, 2014, NEUROLOGY, V82, P2180, DOI 10.1212/WNL.0000000000000519; Zhao TZ, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.449; Zhu CL, 2006, J NEUROCHEM, V96, P1016, DOI 10.1111/j.1471-4159.2005.03639.x	112	25	25	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JUL	2019	127						22	28		10.1016/j.neuint.2019.01.012			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	IH2LY	WOS:000474327500004	30654116	Green Accepted			2022-02-06	
J	Kirschen, MP; Francoeur, C; Murphy, M; Traynor, D; Zhang, BQ; Mensinger, JL; Ichord, R; Topjian, A; Berg, RA; Nishisaki, A; Morrison, W				Kirschen, Matthew P.; Francoeur, Conall; Murphy, Marie; Traynor, Danielle; Zhang, Bingqing; Mensinger, Janell L.; Ichord, Rebecca; Topjian, Alexis; Berg, Robert A.; Nishisaki, Akira; Morrison, Wynne			Epidemiology of Brain Death in Pediatric Intensive Care Units in the United States	JAMA PEDIATRICS			English	Article							CONTROVERSIES; WITHDRAWAL; DIAGNOSIS; CHILDREN; SUPPORT; VOLUME; PICU	IMPORTANCE Guidelines for declaration of brain death in children were revised in 2011 by the Society of Critical Care Medicine, American Academy of Pediatrics, and Child Neurology Society. Despite widespread medical, legal, and ethical acceptance, ongoing controversies exist with regard to the concept of brain death and the procedures for its determination. OBJECTIVES To determine the epidemiology and clinical characteristics of pediatric patients declared brain dead in the United States. DESIGN, SETTING. AND PARTICIPANTS This study involved the abstraction of all patient deaths from the Virtual Pediatric Systems national multicenter database between January 1, 2012, and June 30, 2017. All patients who died in pediatric intensive care units (PICUs) were included. MAIN OUTCOMES AND MEASURES Patient demographics, preillness developmental status, severity of illness, cause of death, PICU medical and physical length of stay, and organ donation status, as well as comparison between patients who were declared brain dead vs those who sustained cardiovascular or cardiopulmonary death. RESULTS Of the 15 344 patients who died, 3170 (20.7%) were declared brain dead; 1861 of these patients (58.7%) were male, and 1401(44.2%) were between 2 and 12 years of age. There was a linear association between PICU size and number of patients declared brain dead per year, with an increase of 4.27 patients (95% CI, 3.46-5.08) per 1000-patient increase in discharges (P <.001). The median (interquartile range) of patients declared brain dead per year ranged from 1(0-3) in smaller PICUs (defined as those with <500 discharges per year) to 10 (7-15) for larger PICUs (those with 2000-4000 discharges per year). The most common causative mechanisms of brain death were hypoxic-ischemic injury owing to cardiac arrest (1672 of 3170 [52.7%]), shock and/or respiratory arrest without cardiac arrest (399 of 3170 [12.6%]), and traumatic brain injury (634 of 3170 [20.0%]). Most patients declared brain dead (681of 807 [84.4%]) did not have preexisting neurological dysfunction. Patients who were organ donors (1568 of 3144 [49.9%]) remained in the PICU longer after declaration of brain death compared with those who were not donors (median [interquartile range], 29 [6-41] hours vs 4 [1-8] hours; P <.001). CONCLUSIONS AND RELEVANCE Brain death occurred in one-fifth of PICU deaths. Most children declared brain dead had no preexisting neurological dysfunction and had an acute hypoxic-ischemic or traumatic brain injury. Brain death determinations are infrequent, even in large PICUs, emphasizing the importance of ongoing education for medical professionals and standardization of protocols to ensure diagnostic accuracy and consistency.	[Kirschen, Matthew P.; Zhang, Bingqing; Topjian, Alexis; Berg, Robert A.; Nishisaki, Akira; Morrison, Wynne] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Kirschen, Matthew P.; Ichord, Rebecca] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Kirschen, Matthew P.; Ichord, Rebecca; Topjian, Alexis; Berg, Robert A.; Nishisaki, Akira; Morrison, Wynne] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Francoeur, Conall] Univ Laval, Ctr Hosp Univ Quebec, Ctr Mere Enfant Soleil, Quebec City, PQ, Canada; [Murphy, Marie; Traynor, Danielle] Childrens Hosp Philadelphia, Dept Nursing, Philadelphia, PA 19104 USA; [Mensinger, Janell L.] Drexel Univ, Dornsife Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA		Kirschen, MP (corresponding author), Childrens Hosp Philadelphia, Dept Crit Care Med, 3401 Civ Ctr Blvd,Wood Ctr,Ste 6108, Philadelphia, PA 19104 USA.	kirschenm@chop.edu	Mensinger, Janell/AAR-3375-2021		Department of Anesthesiology and Critical Care Medicine at Children's Hospital of Philadelphia	Financial support for this study was from the Department of Anesthesiology and Critical Care Medicine at Children's Hospital of Philadelphia.	[Anonymous], 1987, PEDIATRICS, V80, P298; Au AK, 2011, PEDIATR CRIT CARE ME, V12, P566, DOI 10.1097/PCC.0b013e3181fe3420; Ausmus AM, 2018, PEDIATR CRIT CARE ME, V19, P643, DOI 10.1097/PCC.0000000000001548; Burkle CM, 2015, SEMIN NEUROL, V35, P174, DOI 10.1055/s-0035-1547537; Burkle CM, 2011, NEUROLOGY, V76, P837, DOI 10.1212/WNL.0b013e31820e7bbe; Burns JP, 2014, CRIT CARE MED, V42, P2101, DOI 10.1097/CCM.0000000000000498; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Gupta P, 2014, RESUSCITATION, V85, P1473, DOI 10.1016/j.resuscitation.2014.07.016; Lewis A, 2018, NEUROLOGY, V90, P423, DOI 10.1212/WNL.0000000000005033; Lewis A, 2017, J CHILD NEUROL, V32, P975, DOI 10.1177/0883073817724697; Lewis A, 2017, CRIT CARE MED, V45, pE916, DOI 10.1097/CCM.0000000000002452; Lewis A, 2017, NAT REV NEUROL, V13, P505, DOI 10.1038/nrneurol.2017.72; Lewis A, 2016, NEUROLOGY, V87, P827, DOI 10.1212/WNL.0000000000003008; Lewis A, 2016, NEUROCRIT CARE, V24, P481, DOI 10.1007/s12028-015-0209-7; Lewis A, 2016, CHEST, V149, P607, DOI 10.1016/j.chest.2015.09.040; LoPresti MA, 2016, AM J HOSP PALLIAT ME, V33, P291, DOI 10.1177/1049909114565658; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Markovitz BP, 2016, PEDIATR CRIT CARE ME, V17, P483, DOI 10.1097/PCC.0000000000000697; Mathur M, 2015, SEMIN NEUROL, V35, P116, DOI 10.1055/s-0035-1547540; Meert KL, 2015, PEDIATR CRIT CARE ME, V16, pE231, DOI 10.1097/PCC.0000000000000520; MINK RB, 1992, PEDIATRICS, V89, P961; Nakagawa TA, 2011, PEDIATRICS, V128, pE720, DOI 10.1542/peds.2011-1511; Sands R, 2009, NURS CRIT CARE, V14, P235, DOI 10.1111/j.1478-5153.2009.00348.x; Sharpe D., 2015, 2015 ANN IEEE IND C, V20, P1; Shewmon DA, 2017, J CHILD NEUROL, V32, P1104, DOI 10.1177/0883073817736961; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; STAWORN D, 1994, CRIT CARE MED, V22, P1301, DOI 10.1097/00003246-199408000-00014; Stockwell JA, 2011, PEDIATR CRIT CARE ME, V12, P271, DOI 10.1097/PCC.0b013e3181fe27da; Trowbridge A, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2017-4182; Truog RD, 2018, JAMA-J AM MED ASSOC, V320, P335, DOI 10.1001/jama.2018.6990; Truog RD, 2018, JAMA-J AM MED ASSOC, V319, P1859, DOI 10.1001/jama.2018.3441; VERNON DD, 1993, CRIT CARE MED, V21, P1798, DOI 10.1097/00003246-199311000-00035; Virtual Pediatric Systems LLC, 2018, WHO WE AR	33	25	26	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	MAY	2019	173	5					469	476		10.1001/jamapediatrics.2019.0249			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	HX6HR	WOS:000467505200015	30882855	Green Published, Bronze			2022-02-06	
J	Wang, ZF; Gao, C; Chen, W; Gao, Y; Wang, HC; Meng, Y; Luo, CL; Zhang, MY; Chen, G; Chen, XP; Wang, T; Tao, LY				Wang, Zu-feng; Gao, Cheng; Chen, Wei; Gao, Yuan; Wang, Hao-chen; Meng, Ying; Luo, Cheng-liang; Zhang, Ming-yang; Chen, Guang; Chen, Xi-ping; Wang, Tao; Tao, Lu-yang			Salubrinal offers neuroprotection through suppressing endoplasmic reticulum stress, autophagy and apoptosis in a mouse traumatic brain injury model	NEUROBIOLOGY OF LEARNING AND MEMORY			English	Article						Traumatic brain injury; Salubrinal; Endoplasmic reticulum stress; Apoptosis; Autophagy	CONTROLLED CORTICAL IMPACT; INDUCED CELL-DEATH; ER-STRESS; REDUCES HISTOPATHOLOGY; ANIMAL-MODELS; PATHOPHYSIOLOGY; ACTIVATION; MECHANISMS; CASPASE-12; MANAGEMENT	Traumatic brain injury (TBI) is a complex injury that can cause severe disabilities and even death. TBI can induce secondary injury cascades, including but not limited to endoplasmic reticulum (ER) stress, apoptosis and autophagy. Although the investigators has previously shown that salubrinal, the selective phosphatase inhibitor of p-eIF2 alpha, ameliorated neurologic deficits in murine TBI model, the neuroprotective mechanisms of salubrinal need further research to warrant the preclinical value. This study was undertaken to characterize the effects of salubrinal on cell death and neurological outcomes following TBI in mice and the potential mechanisms. In the current study, ER stress-related proteins including p-eIF2 alpha, GRP78 and CHOP showed peak expressions both in the cortex and hippocampus from day 2 to day 3 after TBI, indicating ER stress was activated in our TBI model. Immunofluorescence staining showed that CHOP co-located NeuN-positive neuron, GFAP-positive astrocyte, Iba-1-positive microglia, CD31-positive vascular endothelial cell and PDGFR-beta-positive pericyte in the cortex on day 2 after TBI, and these cells mentioned above constitute the neurovascular unit (NVU). We also found TBI-induced plasmalemma permeability, motor dysfunction, spatial learning and memory deficits and brain lesion volume were alleviated by continuous intraperitoneal administration of salubrinal post TBI. To investigate the underlying mechanisms further, we determined that salubrinal suppressed the expression of ER stress, autophagy and apoptosis related proteins on day 2 after TBI. In addition, salubrinal administration decreased the number of CHOP + /TUNEL + and CHOP + /LC3 + cells on day 2 after TBI, detected by immunofluorescence. In conclusion, these data imply that salubrinal treatment improves morphological and functional outcomes caused by TBI in mice and these neuroprotective effects may be associated with inhibiting apoptosis, at least in part by suppressing ER stress-autophagy pathway.	[Wang, Zu-feng; Gao, Cheng; Chen, Wei; Wang, Hao-chen; Luo, Cheng-liang; Zhang, Ming-yang; Chen, Guang; Chen, Xi-ping; Wang, Tao; Tao, Lu-yang] Soochow Univ, Med Sch, Dept Forens Med, 178 Ganjiang East Rd, Suzhou 215123, Peoples R China; [Gao, Yuan] Wenzhou Med Univ, Dept Forens Med, Wenzhou 325035, Peoples R China; [Meng, Ying] Suzhou Western Ecocity, Community Hlth Ctr, Suzhou 215161, Peoples R China; [Wang, Tao] Acad Forens Sci, Shanghai Forens Serv Platform, Shanghai Key Lab Forens Med, Shanghai 200063, Peoples R China		Wang, T; Tao, LY (corresponding author), Soochow Univ, Med Sch, Dept Forens Med, 178 Ganjiang East Rd, Suzhou 215123, Peoples R China.	taowang@suda.edu.cn; taoluyang@suda.edu.cn	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81601643, 81530062, 81871536]; National High Technology Research and Development Program of China (863 Program)National High Technology Research and Development Program of China [2015AA020503]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2017M620226]; Shanghai Key Lab of Forensic Medicine [KF1701]; Jiangsu Planned Projects for Postdoctoral Research Funds [1701124C]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This study was supported by grants 81601643, 81530062 and 81871536 from the National Natural Science Foundation of China, National High Technology Research and Development Program of China (863 Program, No. 2015AA020503), China Postdoctoral Science Foundation Funded Project (No. 2017M620226), Shanghai Key Lab of Forensic Medicine (No. KF1701), Jiangsu Planned Projects for Postdoctoral Research Funds (No. 1701124C), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Balduini W, 2009, AUTOPHAGY, V5, P221, DOI 10.4161/auto.5.2.7363; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2012, J NEUROCHEM, V120, P622, DOI 10.1111/j.1471-4159.2011.07606.x; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Deegan S, 2013, CELL MOL LIFE SCI, V70, P2425, DOI 10.1007/s00018-012-1173-4; Gao B, 2013, ACTA PHARMACOL SIN, V34, P657, DOI 10.1038/aps.2013.34; Gao Y, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00095; Gao Y, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00423; Gorman AM, 2012, PHARMACOL THERAPEUT, V134, P306, DOI 10.1016/j.pharmthera.2012.02.003; Grandhi R, 2014, J NEUROSURG SCI, V58, P249; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Lee WS, 2015, CURR MOL MED, V15, P735, DOI 10.2174/1566524015666150921105453; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Logsdon AE, 2016, BRAIN RES, V1643, P140, DOI 10.1016/j.brainres.2016.04.063; Logsdon AF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00421; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Morris RGM, 2001, PHILOS T R SOC B, V356, P1453, DOI 10.1098/rstb.2001.0945; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakka VP, 2016, MOL NEUROBIOL, V53, P532, DOI 10.1007/s12035-014-9029-6; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Rubiolo JA, 2014, CELL SIGNAL, V26, P419, DOI 10.1016/j.cellsig.2013.10.004; Rubovitch V, 2015, NEUROMOL MED, V17, P58, DOI 10.1007/s12017-015-8340-3; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Su YC, 2016, INT J NEUROSCI, V126, P681, DOI 10.3109/00207454.2015.1059836; Torres M, 2015, VIRUS RES, V207, P69, DOI 10.1016/j.virusres.2014.12.018; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Wang T, 2013, NEUROSCIENCE, V231, P70, DOI 10.1016/j.neuroscience.2012.11.019; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Wu Q, 2018, INT J BIOCHEM CELL B, V94, P44, DOI 10.1016/j.biocel.2017.11.007; Xiang CC, 2017, APOPTOSIS, V22, P1, DOI 10.1007/s10495-016-1296-4; Xilouri M, 2010, CNS NEUROL DISORD-DR, V9, P701, DOI 10.2174/187152710793237421; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44	45	25	26	1	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1074-7427	1095-9564		NEUROBIOL LEARN MEM	Neurobiol. Learn. Mem.	MAY	2019	161						12	25		10.1016/j.nlm.2019.03.002			14	Behavioral Sciences; Neurosciences; Psychology; Psychology, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	IA9QU	WOS:000469892700002	30851432				2022-02-06	
J	Voormolen, DC; Cnossen, MC; Polinder, S; Gravesteijn, BY; Von Steinbuechel, N; Real, RGL; Haagsma, JA				Voormolen, Daphne C.; Cnossen, Maryse C.; Polinder, Suzanne; Gravesteijn, Benjamin Y.; Von Steinbuechel, Nicole; Real, Ruben G. L.; Haagsma, Juanita A.			Prevalence of post-concussion-like symptoms in the general population in Italy, The Netherlands and the United Kingdom	BRAIN INJURY			English	Article						Post-concussion symptoms; traumatic brain injury; post-concussion syndrome; quality of life; rivermead post-concussion symptoms questionnaire	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION-LIKE SYMPTOMS; MILD HEAD-INJURY; BASE RATES; STRESS; LIFE	Objectives: To evaluate the frequency of post-concussion symptoms and prevalence and risk factors of post-concussion syndrome (PCS) in the general population, investigate the association between the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) and self-perceived health, and evaluate differences between three European countries. Methods: A web-based survey including the RPQ and EQ-5D was conducted among representative samples in three European countries. Results: A total of 11,759 respondents completed the questionnaire. The most frequently reported symptom was fatigue (49.9%). Almost half (45.1%) of the respondents were classified as having PCS considering rating score 2 (three RPQ items with score >= 2) as a cut-off. Chronic health complaints were found as a significant risk factor for PCS. All items of the RPQ were positively correlated with the EQ-5D and the strongest positive correlation (0.633, p<0.001) was between RPQ item 'feeling depressed or tearful' and EQ-5D domain 'anxiety/depression'. Conclusions: We found a high frequency of post-concussion-like symptoms and PCS in the general population, indicating that these symptoms are not specific for patients with traumatic brain injury (TBI), and PCS is not a unique syndrome after TBI. Therefore, the use of post-concussion symptoms and PCS as outcome following mild TBI should be interpreted with caution.	[Voormolen, Daphne C.; Cnossen, Maryse C.; Polinder, Suzanne; Gravesteijn, Benjamin Y.; Haagsma, Juanita A.] Erasmus Univ, Dept Publ Hlth, Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Von Steinbuechel, Nicole; Real, Ruben G. L.] Georg August Univ, Inst Med Psychol & Med Sociol, Gottingen, Germany; [Haagsma, Juanita A.] Erasmus Univ, Dept Emergency Med, Med Ctr, Rotterdam, Netherlands		Voormolen, DC (corresponding author), Erasmus Univ, Dept Publ Hlth, Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.voormolen@erasmusmc.nl	Gravesteijn, Benjamin/AAN-9524-2020	Gravesteijn, Benjamin/0000-0001-8096-5803	European UnionEuropean Commission [602150]; National Institutes of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS086090]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER	The paper has been written in the context of the CENTER-TBI project. CENTER-TBI has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no 602150. TRACK-TBI has received funding from the National Institutes of Neurologic Disorders and Stroke, grant no U01 NS086090. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; FP7 Health [no 602150];	[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Cabases J, 2014, SELF REPORTED POPULA, P19, DOI DOI 10.1007/978-94-007-7596-1_3; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Clough M, 2018, J NEUROTRAUM, V35, P730, DOI 10.1089/neu.2017.5204; Cnossen MC, 2017, J NEUROTRAUM, V34, P2396, DOI 10.1089/neu.2016.4819; COHEN J, 1988, APPL PSYCH MEAS, V12, P425, DOI 10.1177/014662168801200410; Edmed SL, 2014, BRAIN INJURY, V28, P1277, DOI 10.3109/02699052.2014.915988; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Subbian V, 2014, IEEE ENG MED BIO, P5353, DOI 10.1109/EMBC.2014.6944835; Versteegh MM, 2016, VALUE HEALTH, V19, P343, DOI 10.1016/j.jval.2016.01.003; Voormolen DC, 2018, J NEUROTRAUM, V35, P1233, DOI 10.1089/neu.2017.5257; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1993, ICD 10 CLASS MENT BE; Zakzanis KK, 2011, ARCH CLIN NEUROPSYCH, V26, P461, DOI 10.1093/arclin/acr021	33	25	25	1	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL 3	2019	33	8					1078	1086		10.1080/02699052.2019.1607557		APR 2019	9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	IM6FW	WOS:000469575400001	31032649	hybrid, Green Published			2022-02-06	
J	Fernandes, FAO; de Sousa, RJA; Ptak, M; Migueis, G				Fernandes, Fabio A. O.; Alves de Sousa, Ricardo J.; Ptak, Mariusz; Migueis, Goncalo			Helmet Design Based on the Optimization of Biocomposite Energy-Absorbing Liners under Multi-Impact Loading	APPLIED SCIENCES-BASEL			English	Article						agglomerated cork; helmets; finite element head model; brain injuries; head trauma; cellular materials; protective devices; passive safety; traumatic brain injury; sustainable solutions	MOTORCYCLE HELMETS; AGGLOMERATED CORK; BICYCLE HELMETS; HEAD; PERFORMANCE; SIMULATION; RISK	Cellular materials have been used in many applications such as insulation, packaging, and protective gear. Expanded polystyrene has been widely used as energy-absorbing liner in helmets due to its excellent cost-benefit relation. This synthetic material can absorb reasonable amounts of energy via permanent deformation. However, in real-world accidents, helmets may be subjected to multi-impact scenarios. Additionally, oil-derived plastic is presently a major source of societal concern regarding pollution and waste. As a sustainable alternative, cork is a natural cellular material with great crashworthiness properties and it has the remarkable capacity to recover after compression, due to its viscoelastic behavior, which is a desired characteristic in multi-impact applications. Therefore, the main goal is to analyze the applicability of agglomerated cork as padding material in safety helmets. First, a finite element model of a motorcycle helmet available on the market was developed to assess its safety performance and to establish a direct comparison between expanded polystyrene and cork agglomerates as liners. Secondly, a new helmet model with a generic geometry was developed to assess the applicability of agglomerated cork as liner for different types of helmets, based on the head injury risk predictions by the finite element head model, YEt Another Head Model (YEAHM), developed by the authors. Several versions of helmet liners were created by varying its thickness and removing sections of material. In other words, this generic helmet was optimized by carrying out a parametric study, and by comparing its performance under double impacts. The results from these tests indicate that agglomerated cork liners are an excellent alternative to the synthetic ones. Thus, agglomerated cork can be employed in protective gear, improving its overall performance and capacity to withstand multi-impacts.	[Fernandes, Fabio A. O.; Alves de Sousa, Ricardo J.; Migueis, Goncalo] Univ Aveiro, TEMA Ctr Mech Technol & Automat, Dept Mech Engn, Campus Santiago, P-3810193 Aveiro, Portugal; [Ptak, Mariusz] Wroclaw Univ Sci & Technol, Fac Mech Engn, Dept Machine Design & Res, Lukasiewicza 7-9, PL-50371 Wroclaw, Poland		Fernandes, FAO (corresponding author), Univ Aveiro, TEMA Ctr Mech Technol & Automat, Dept Mech Engn, Campus Santiago, P-3810193 Aveiro, Portugal.	fabiofernandes@ua.pt; rsousa@ua.pt; mariusz.ptak@pwr.edu.pl; migueisgoncalo@ua.pt	de Sousa, Ricardo Alves/E-4405-2010; Fernandes, Fabio A.O./H-2680-2012; Ptak, Mariusz/B-1493-2013	de Sousa, Ricardo Alves/0000-0002-5848-6424; Fernandes, Fabio A.O./0000-0001-9751-8807; Ptak, Mariusz/0000-0001-8081-8336	Fundacao para a Ciencia e a Tecnologia (FCT)Portuguese Foundation for Science and TechnologyEuropean Commission [UID/EMS/00481/2013-FCT, CENTRO-01-0145-FEDER-022083, CEECIND/01192/2017]	The authors greatly acknowledge the support given by Fundacao para a Ciencia e a Tecnologia (FCT): UID/EMS/00481/2013-FCT, CENTRO-01-0145-FEDER-022083 and CEECIND/01192/2017.	ABNT (AssociacAo Brasileira de Normas Tecnicas), 2001, 74712001 ABNT NBR; [Anonymous], 2010, ABAQUS 6 10 DOC; de Oliveira NLB, 2011, REV LAT-AM ENFERM, V19, P403, DOI 10.1590/S0104-11692011000200024; Becker E.B., 2015, P IRCOBI C LYON FRAN; Bil M, 2018, SAFETY SCI, V105, P71, DOI 10.1016/j.ssci.2018.02.005; Bilston LE, 2011, BIOL MED PHYS BIOMED, P69, DOI 10.1007/978-1-4419-9997-9_4; Blanco DH, 2014, P I MECH ENG P-J SPO, V228, P95, DOI 10.1177/1754337113518748; Brugger O., 2010, SNOW SPORT HELMETS I; Caserta GD, 2011, COMPOS STRUCT, V93, P2748, DOI 10.1016/j.compstruct.2011.05.029; Coelho RM, 2013, MATER DESIGN, V43, P384, DOI 10.1016/j.matdes.2012.07.020; Cui L, 2009, MATER DESIGN, V30, P3414, DOI 10.1016/j.matdes.2009.03.044; Deck C, 2003, STRUCT MAT, V13, P319; DeMarco AL, 2016, ACCIDENT ANAL PREV, V92, P175, DOI 10.1016/j.aap.2016.03.027; Fay P.A., 2001, P IRCOBI C ISL MAN U, P1; Fernandes FAO, 2017, PROCEDIA MANUF, V13, P227, DOI 10.1016/j.promfg.2017.09.055; Fernandes FAO, 2015, MATER DESIGN, V82, P335, DOI 10.1016/j.matdes.2015.06.004; Fernandes FAO, 2014, MATER DESIGN, V58, P499, DOI 10.1016/j.matdes.2014.02.011; Fernandes FAO, 2013, ACCIDENT ANAL PREV, V56, P1, DOI 10.1016/j.aap.2013.03.011; Fernandes F. A. O., 2013, P IRCOBI C GOTH, P431; Fernandes FAO, 2018, SPRINGERBR APPL SCI, P1, DOI 10.1007/978-3-319-89926-8_1; Fernandes FAO, 2018, SPRINGERBR APPL SCI, P41, DOI 10.1007/978-3-319-89926-8_3; Fernandes FAO, 2018, SPRINGERBR APPL SCI, P59, DOI 10.1007/978-3-319-89926-8_4; Fernandes FAO, 2018, SPRINGERBR APPL SCI, P25, DOI 10.1007/978-3-319-89926-8_2; Fernandes FAO, 2018, ENG COMPUTATION, V35, P477, DOI 10.1108/EC-09-2016-0321; Fernandes FAO, 2015, P I MECH ENG H, V229, P592, DOI 10.1177/0954411915592906; Fernandes FAO, 2013, STRUCT ENG MECH, V48, P661, DOI 10.12989/sem.2013.48.5.661; Fernandes FAO, 2018, SPRINGERBR APPL SCI, P1, DOI 10.1007/978-3-319-89926-8; Gadd C. W, 1966, SAE TECHNICAL PAPER, DOI 10.4271/660793; Gibson LJ, 2005, J BIOMECH, V38, P377, DOI 10.1016/j.jbiomech.2004.09.027; Goel R, 2011, THESIS; Hansen K, 2013, ACCIDENT ANAL PREV, V59, P109, DOI 10.1016/j.aap.2013.05.019; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Jardin RT, 2015, MATER DESIGN, V68, P121, DOI 10.1016/j.matdes.2014.12.016; Kaczynski P, 2019, INT J IMPACT ENG, V126, P109, DOI 10.1016/j.ijimpeng.2018.12.001; Khosroshahi SF, 2018, MATER TODAY COMMUN, V14, P312, DOI 10.1016/j.mtcomm.2018.02.002; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Klug C., 2015, P IRCOBI C LYON FRAN; Lin MR, 2008, ACCIDENT ANAL PREV, V40, P1653, DOI 10.1016/j.aap.2008.05.005; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mills NJ, 2009, INT J IMPACT ENG, V36, P913, DOI 10.1016/j.ijimpeng.2008.12.011; MILLS NJ, 1992, P ANN C ASS, P149; Morgan D.E., 2007, CONE HEAD TECHNOLOGY; Nahum A., 1977, 21 STAPP CAR CRASH C, DOI DOI 10.4271/770922; Pinnoji P.K., 2006, P IRCOBI C MADR, P159; Pinnoji PK, 2008, INT J CRASHWORTHINES, V13, P265, DOI 10.1080/13588260801933626; Post A., 2014, P IRCOBI C BERL GERM, P72; Pratellesi A, 2011, INT J CRASHWORTHINES, V16, P523, DOI 10.1080/13588265.2011.611397; Ptak M, 2017, INT J IMPACT ENG, V106, P238, DOI 10.1016/j.ijimpeng.2017.04.014; Ptak M, 2019, MATERIALS, V12, DOI 10.3390/ma12010151; Ren LH, 2017, INT CONF MEAS, P279, DOI [10.1109/ICMTMA.2017.0074, 10.1109/ICMTMA.2017.73]; Rice TM, 2016, ACCIDENT ANAL PREV, V91, P200, DOI 10.1016/j.aap.2016.03.002; Richter M, 2001, J TRAUMA, V51, P949, DOI 10.1097/00005373-200111000-00021; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rueda MAF, 2009, MATER DESIGN, V30, P3405, DOI 10.1016/j.matdes.2009.03.037; Sahoo D, 2016, ACCIDENT ANAL PREV, V92, P53, DOI 10.1016/j.aap.2016.03.013; Santos PT, 2017, COMPOS STRUCT, V178, P277, DOI 10.1016/j.compstruct.2017.07.035; Shuaeib FM, 2007, MATER DESIGN, V28, P182, DOI 10.1016/j.matdes.2005.04.015; Smith T., 2014, THEORETICAL CALCULAT; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tinard V, 2012, MATER DESIGN, V37, P79, DOI 10.1016/j.matdes.2011.12.005; U. S. Department of Transportation Federal Motor Carrier Safety Administration, 218 US DEP TRANSP FE; Vallee H., 1984, IRCOBI C DELFT, P99; Vallee H., 1981, P IRCOBI C SALON DE, P176; World Health Organization, 2009, GLOB STAT REP ROAD S; Yang J, 2011, COMPUTATIONAL BIOMEC; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	68	25	25	5	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-3417		APPL SCI-BASEL	Appl. Sci.-Basel	FEB 2	2019	9	4							735	10.3390/app9040735			26	Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials Science, Multidisciplinary; Physics, Applied	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Chemistry; Engineering; Materials Science; Physics	HO1UL	WOS:000460696500121		Green Submitted, gold			2022-02-06	
J	Kilgannon, JH; Hunter, BR; Puskarich, MA; Shea, L; Fuller, BM; Jones, C; Donnino, M; Kline, JA; Jones, AE; Shapiro, NI; Abella, BS; Trzeciak, S; Roberts, BW				Kilgannon, J. Hope; Hunter, Benton R.; Puskarich, Michael A.; Shea, Lisa; Fuller, Brian M.; Jones, Christopher; Donnino, Michael; Kline, Jeffrey A.; Jones, Alan E.; Shapiro, Nathan I.; Abella, Benjamin S.; Trzeciak, Stephen; Roberts, Brian W.			Partial pressure of arterial carbon dioxide after resuscitation from cardiac arrest and neurological outcome: A prospective multi-center protocol-directed cohort study	RESUSCITATION			English	Article						Cardiac arrest; Heart arrest; Partial pressure of arterial carbon dioxide; PaCO2	POSTRESUSCITATION PARTIAL-PRESSURE; MODIFIED RANKIN SCALE; CARDIOPULMONARY-RESUSCITATION; HOSPITAL MORTALITY; ASSOCIATION; HYPERCAPNIA; CARE; GUIDELINES; INJURY; HYPERVENTILATION	Aims: Partial pressure of arterial carbon dioxide (PaCO2) is a regulator of cerebral blood flow after brain injury. We sought to test the association between PaCO2 after resuscitation from cardiac arrest and neurological outcome. Methods: A prospective protocol-directed cohort study across six hospitals. Inclusion criteria: age >= 18, non-traumatic cardiac arrest, mechanically ventilated after return of spontaneous circulation (ROSC), and receipt of targeted temperature management. Per protocol, PaCO2 was measured by arterial blood gas analyses at one and six hours after ROSC. We determined the mean PaCO2 over this initial six hours after ROSC. The primary outcome was good neurological function at hospital discharge, defined a priori as a modified Rankin Scale <= 3. Multivariable Poisson regression analysis was used to test the association between PaCO2 and neurological outcome. Results: Of the 280 patients included, the median (interquartile range) PaCO2 was 44 (37-52) mmHg and 30% had good neurological function. We found mean PaCO2 had a quadratic (inverted "U" shaped) association with good neurological outcome, with a mean PaCO2 of 68 mmHg having the highest predictive probability of good neurological outcome, and worse neurological outcome at higher and lower PaCO2. Presence of metabolic acidosis attenuated the association between PaCO2 and good neurological outcome, with a PaCO2 of 51 mmHg having the highest predictive probability of good neurological outcome among patients with metabolic acidosis. Conclusion: PaCO2 has a "U" shaped association with neurological outcome, with mild to moderate hypercapnia having the highest probability of good neurological outcome.	[Kilgannon, J. Hope; Jones, Christopher; Trzeciak, Stephen; Roberts, Brian W.] Rowan Univ, Cooper Univ Hosp, Cooper Med Sch, Dept Emergency Med, Camden, NJ USA; [Shea, Lisa; Trzeciak, Stephen] Rowan Univ, Cooper Univ Hosp, Cooper Med Sch, Dept Med,Div Crit Care Med, Camden, NJ USA; [Hunter, Benton R.; Kline, Jeffrey A.] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA; [Puskarich, Michael A.; Jones, Alan E.] Univ Mississippi, Med Ctr, Dept Emergency Med, Jackson, MS 39216 USA; [Fuller, Brian M.] Washington Univ, Sch Med, Dept Emergency Med, Div Crit Care Med, St Louis, MO USA; [Fuller, Brian M.] Washington Univ, Sch Med, Dept Anesthesiol, Div Crit Care Med, St Louis, MO 63110 USA; [Donnino, Michael; Shapiro, Nathan I.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Abella, Benjamin S.] Univ Penn, Ctr Resuscitat Sci, Philadelphia, PA 19104 USA; [Abella, Benjamin S.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA		Roberts, BW (corresponding author), Cooper Univ Hosp, One Cooper Plaza,K152, Camden, NJ 08103 USA.	roberts-brian-w@cooperhealth.edu	Puskarich, Michael/N-7849-2014	Puskarich, Michael/0000-0001-6358-4670	National Heart, Lung, and Blood Institute (U.S.)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL112815, K23HL126979]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL112815, K23HL126979] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (U.S.), R01HL112815 and K23HL126979.	Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Ausina A, 1998, ACT NEUR S, V71, P1; Beitler JR, 2017, AM J RESP CRIT CARE, V195, P1198, DOI 10.1164/rccm.201609-1771OC; Beylin ME, 2013, INTENS CARE MED, V39, P1981, DOI 10.1007/s00134-013-3075-9; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; Buunk G, 1997, STROKE, V28, P1569, DOI 10.1161/01.STR.28.8.1569; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; Eastwood GM, 2016, RESUSCITATION, V104, P83, DOI 10.1016/j.resuscitation.2016.03.023; Eastwood GM, 2016, RESUSCITATION, V102, P11, DOI 10.1016/j.resuscitation.2016.02.009; Falkenbach P, 2009, RESUSCITATION, V80, P990, DOI 10.1016/j.resuscitation.2009.04.044; Helmerhorst HJF, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1067-6; Laffey JG, 2000, AM J RESP CRIT CARE, V162, P2287, DOI 10.1164/ajrccm.162.6.2003066; Lee BK, 2014, AM J EMERG MED, V32, P55, DOI 10.1016/j.ajem.2013.09.044; NEGOVSKY VA, 1995, RESUSCITATION, V30, P23, DOI 10.1016/0300-9572(95)00861-M; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nin N, 2017, INTENS CARE MED, V43, P200, DOI 10.1007/s00134-016-4611-1; Nolan JP, 2015, RESUSCITATION, V95, pE1, DOI 10.1016/j.resuscitation.2015.07.039; Nolan JP, 2015, RESUSCITATION, V95, P202, DOI 10.1016/j.resuscitation.2015.07.018; Nolan Jerry P, 2010, Int Emerg Nurs, V18, P8, DOI 10.1016/j.ienj.2009.07.001; Quinn TJ, 2007, STROKE, V38, P2257, DOI 10.1161/STROKEAHA.106.480723; Roberts BW, 2018, CIRCULATION, V137, P2114, DOI 10.1161/CIRCULATIONAHA.117.032054; Roberts BW, 2018, CRIT CARE MED, V46, pe213, DOI 10.1097/CCM.0000000000002918; Roberts BW, 2015, RESUSCITATION, V91, P32, DOI 10.1016/j.resuscitation.2015.03.015; Roberts BW, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/2110-5820-4-9; Roberts BW, 2013, CIRCULATION, V127, P2107, DOI 10.1161/CIRCULATIONAHA.112.000168; Schneider AG, 2013, RESUSCITATION, V84, P927, DOI 10.1016/j.resuscitation.2013.02.014; Tiruvoipati R, 2017, CRIT CARE MED, V45, pE649, DOI 10.1097/CCM.0000000000002332; Trzeciak S, 2009, CRIT CARE MED, V37, P2895, DOI 10.1097/CCM.0b013e3181b01d8c; Vaahersalo J, 2014, CRIT CARE MED, V42, P1463, DOI 10.1097/CCM.0000000000000228; VANNUCCI RC, 1995, PEDIATRICS, V95, P868; von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010; West MA, 1996, J SURG RES, V63, P269, DOI 10.1006/jsre.1996.0259; Wilson JTL, 2005, STROKE, V36, P777, DOI 10.1161/01.STR.0000157596.13234.95; Wilson JTL, 2002, STROKE, V33, P2243, DOI 10.1161/01.STR.0000027437.22450.BD; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	37	25	25	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572	1873-1570		RESUSCITATION	Resuscitation	FEB	2019	135						212	220		10.1016/j.resuscitation.2018.11.015			9	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	HM9EO	WOS:000459785900030	30452939	Green Submitted, Green Accepted			2022-02-06	
J	Zhang, T; Ni, SF; Luo, ZX; Lang, Y; Hu, JZ; Lu, HB				Zhang, Tao; Ni, Shuangfei; Luo, Zixiang; Lang, Ye; Hu, Jianzhong; Lu, Hongbin			The protective effect of microRNA-21 in neurons after spinal cord injury	SPINAL CORD			English	Article							TRAUMATIC BRAIN-INJURY; RAT-HEART; APOPTOSIS; MIR-21; EXPRESSION; IDENTIFICATION; CELLS	Study design Experimental animal study. Objectives To validate the anti-apoptosis effect of microRNA-21 in neurons after spinal cord injury (SCI) and explore the mechanism. Setting Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Methods In situ hybridization was used to detect the expression of miR-21 in spinal cord neurons (n = 24). In a rat contusion SCI model (n = 48), we upregulated the miR-21 level around the injured area using miR-21 lentiviral vectors and evaluated the therapeutic effect with histology and behavioural scores. In neuronal cells, oxygen-glucose deprivation (OGD) was exerted to imitate SCI, and we explored the biomechanism using molecular biology and a dual-luciferase reporter assay. Results miR-21 was expressed in spinal cord neurons and was found to improve neuronal survival and promote functional recovery in rat SCI models. The in vitro results in PC-12 cells revealed that the augmentation of endogenous miR-21 was able to reduce neuronal cell death after OGD. In addition, overexpression of miR-21 was able to reduce cellular apoptosis via decreasing PDCD4 protein levels, and caspase-3 activity was also influenced. Transfection of miR-21 into 293T cells was able to decrease luciferase activity in a reporter assay system, including the 3' untranslated region of PDCD4. Conclusions miR-21 may have a protective role in neuronal apoptosis after SCI. PDCD4 may be a functional target gene involved in the miR-21-mediated anti-apoptotic effect through an miR-21/PDCD4/caspase-3 pathway.	[Zhang, Tao; Lu, Hongbin] Cent S Univ, Xiangya Hosp, Res Ctr Sports Med, Dept Sports Med, Changsha, Hunan, Peoples R China; [Zhang, Tao; Hu, Jianzhong; Lu, Hongbin] Key Lab Organ Injury Aging & Regenerat Med Hunan, Changsha, Hunan, Peoples R China; [Ni, Shuangfei; Luo, Zixiang; Lang, Ye; Hu, Jianzhong] Cent S Univ, Xiangya Hosp, Dept Spine Surg, Changsha, Hunan, Peoples R China		Lu, HB (corresponding author), Cent S Univ, Xiangya Hosp, Res Ctr Sports Med, Dept Sports Med, Changsha, Hunan, Peoples R China.; Lu, HB (corresponding author), Key Lab Organ Injury Aging & Regenerat Med Hunan, Changsha, Hunan, Peoples R China.	hongbinlu@hotmail.com		hongbin, lu/0000-0001-7749-3593	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371956, 81171698, 81672174]	This work was supported by the National Natural Science Foundation of China (No. 81371956, No. 81171698 and No. 81672174).	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Cheng YH, 2010, CARDIOVASC RES, V87, P431, DOI 10.1093/cvr/cvq082; Cheng YH, 2009, J MOL CELL CARDIOL, V47, P5, DOI 10.1016/j.yjmcc.2009.01.008; Dong J, 2014, NEUROL SCI, V35, P1663, DOI 10.1007/s10072-014-1940-0; Duan X, 2012, CARDIOLOGY, V122, P36, DOI 10.1159/000338149; Eto K, 2012, CELL DEATH DIFFER, V19, P573, DOI 10.1038/cdd.2011.126; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Godwin JG, 2010, P NATL ACAD SCI USA, V107, P14339, DOI 10.1073/pnas.0912701107; Hannan JL, 2016, SCI REP-UK, V6, DOI 10.1038/srep29416; Hao N, 2014, NEUROSCI LETT, V564, P37, DOI 10.1016/j.neulet.2013.12.050; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Hu JZ, 2013, J NEUROTRAUM, V30, P1349, DOI 10.1089/neu.2012.2748; Jiang LP, 2017, ONCOTARGET, V8, P23675, DOI 10.18632/oncotarget.15644; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Liu G, 2010, EXP NEUROL, V226, P200, DOI 10.1016/j.expneurol.2010.08.032; Liu XS, 2009, J BIOL CHEM, V284, P22680, DOI 10.1074/jbc.M109.006551; Nardone R, 2016, DRUG DISCOV TODAY, V21, P1632, DOI 10.1016/j.drudis.2016.06.015; Ruan QG, 2011, P NATL ACAD SCI USA, V108, P12030, DOI 10.1073/pnas.1101450108; Shen ZL, 2017, NEUROCHEM RES, V42, P2336, DOI 10.1007/s11064-017-2251-7; Tian R, 2017, J NEUROCHEM, V141, P708, DOI 10.1111/jnc.14025; van den Bogaart G, 2011, NATURE, V479, P552, DOI 10.1038/nature10545; Wang G, 2015, ARCH BIOCHEM BIOPHYS, V580, P64, DOI 10.1016/j.abb.2015.07.001; White K, 2014, HYPERTENSION, V64, P185, DOI 10.1161/HYPERTENSIONAHA.113.03037; Xiang MQ, 2014, BIOCHEM BIOPH RES CO, V454, P210, DOI 10.1016/j.bbrc.2014.10.064; Yip PK, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-6; Zhang L, 2012, GLIA, V60, P1888, DOI 10.1002/glia.22404; Zhu JB, 2016, CELL PHYSIOL BIOCHEM, V39, P2364, DOI 10.1159/000452506	33	25	26	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	FEB	2019	57	2					141	149		10.1038/s41393-018-0180-1			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	HJ8PV	WOS:000457462800009	30089893	Green Published, hybrid			2022-02-06	
J	Zhou, Z; Li, XG; Kleiven, S				Zhou, Zhou; Li, Xiaogai; Kleiven, Svein			Fluid-structure interaction simulation of the brain-skull interface for acute subdural haematoma prediction	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Traumatic brain injury; Brain-skull interface; Fluid-structure interaction; Arbitrary Lagrangian-Eulerian; Finite element analysis	FINITE-ELEMENT-ANALYSIS; PERIODIC MOTION; HEAD IMPACT; DURA-MATER; INJURY; MODEL; MECHANICS; TISSUE; VALIDATION; CAVITATION	Traumatic brain injury is a leading cause of disability and mortality. Finite element-based head models are promising tools for enhanced head injury prediction, mitigation and prevention. The reliability of such models depends heavily on adequate representation of the brain-skull interaction. Nevertheless, the brain-skull interface has been largely simplified in previous three-dimensional head models without accounting for the fluid behaviour of the cerebrospinal fluid (CSF) and its mechanical interaction with the brain and skull. In this study, the brain-skull interface in a previously developed head model is modified as a fluid-structure interaction (FSI) approach, in which the CSF is treated on a moving mesh using an arbitrary Lagrangian-Eulerian multi-material formulation and the brain on a deformable mesh using a Lagrangian formulation. The modified model is validated against brain-skull relative displacement and intracranial pressure responses and subsequently imposed to an experimentally determined loading known to cause acute subdural haematoma (ASDH). Compared to the original model, the modified model achieves an improved validation performance in terms of brain-skull relative motion and is able to predict the occurrence of ASDH more accurately, indicating the superiority of the FSI approach for brain-skull interface modelling. The introduction of the FSI approach to represent the fluid behaviour of the CSF and its interaction with the brain and skull is crucial for more accurate head injury predictions.	[Zhou, Zhou; Li, Xiaogai; Kleiven, Svein] Royal Inst Technol KTH, Neuron Engn, Stockholm, Sweden		Zhou, Z (corresponding author), Royal Inst Technol KTH, Neuron Engn, Stockholm, Sweden.	zhouz@kth.se		zhou, zhou/0000-0002-3910-0418; Li, Xiaogai/0000-0001-8522-4705	European Union's Horizon 2020 research and innovation programme under the Marie-Curie Grant [642662]	This research has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie-Curie Grant Agreement No. 642662. The help of Markos Kapeliotis from KU Leuven in providing the experimental data is gratefully acknowledged. The authors declare that they have no conflict of interest.	Aimedieu P, 2004, J NEUROSURG, V100, P111, DOI 10.3171/jns.2004.100.1.0111; Al-Bsharat A. S., 1999, STAPP CAR CRASH J, V43, P321; Aquelet N, 2006, COMPUT METHOD APPL M, V195, P110, DOI 10.1016/j.cma.2005.01.010; Batterbee DC, 2011, P I MECH ENG H, V225, P1036, DOI 10.1177/0954411911420002; BENSON DJ, 1989, COMPUT METHOD APPL M, V72, P305, DOI 10.1016/0045-7825(89)90003-0; Bloomfield IG, 1998, PEDIATR NEUROSURG, V28, P246, DOI 10.1159/000028659; Bradshaw DRS, 2001, P 17 INT TECHN C ENH; BYLSKI DI, 1986, J BIOMECH, V19, P19, DOI 10.1016/0021-9290(86)90105-3; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Cheng J, 2010, J BIOMECH, V43, P2887, DOI 10.1016/j.jbiomech.2010.07.023; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Crawford, 1981, LLNL EXPLOSIVES HDB; Cui ZY, 2017, COMPUT METHOD BIOMEC, V20, P530, DOI 10.1080/10255842.2016.1255942; Darvish K. K., 2002, P 2002 INT IRCOBI C, P339; Depreitere B, 2006, J NEUROSURG, V104, P950, DOI 10.3171/jns.2006.104.6.950; Fahlstedt M, 2015, THESIS; Faul M, 2010, TRAUMATIC BRAIN INJU; FELIPPA CA, 1984, COMPUT METHOD APPL M, V44, P297, DOI 10.1016/0045-7825(84)90134-8; Fontenier B, 2014, COMPUT METHOD BIOMEC, V17, P46, DOI 10.1080/10255842.2014.931104; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Gehre C., 2009, 21 INT TECHN C ENH S 21 INT TECHN C ENH S; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Giordano Chiara, 2016, Stapp Car Crash J, V60, P363; Goriely A, 2015, BIOMECH MODEL MECHAN, V14, P931, DOI 10.1007/s10237-015-0662-4; Gu LX, 2012, COMPOS PART B-ENG, V43, P3160, DOI 10.1016/j.compositesb.2012.04.014; Hallquist JO, 2007, LS DYNA KEYW US MAN; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Herbert E, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.041603; Ho J, 2017, J BIOMECH, V60, P243, DOI 10.1016/j.jbiomech.2017.06.023; Ho J, 2009, INT J CRASHWORTHINES, V14, P555, DOI 10.1080/13588260902895708; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Iwamoto Masami, 2015, Stapp Car Crash J, V59, P53; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Jin X, 2014, ANN BIOMED ENG, V42, P812, DOI 10.1007/s10439-013-0948-6; Jin X, 2011, J BIOMECH, V44, P467, DOI 10.1016/j.jbiomech.2010.09.035; Jin X, 2007, STAPP CAR CRASH JO, V51, P115; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Klug C, 2013, EXPT SPHERE IN SPHER, P483; Larson BC, 2002, NATURE, V415, P887, DOI 10.1038/415887a; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; Li XG, 2017, BIOMECH MODEL MECHAN, V16, P823, DOI 10.1007/s10237-016-0855-5; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Luraghi G, 2017, J BIOMECH, V58, P45, DOI 10.1016/j.jbiomech.2017.04.004; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mao HJ, 2011, INT J NUMER METH BIO, V27, P357, DOI 10.1002/cnm.1403; Miller LE, 2016, BIOMECH MODEL MECHAN, V15, P1201, DOI 10.1007/s10237-015-0754-1; Nahum AM, 1977, P 21 STAPP CAR CRASH, P337; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Salzar RS, 2017, J NEUROTRAUM, V34, P1589, DOI 10.1089/neu.2016.4600; Scott GG, 2016, BIOMECH MODEL MECHAN, V15, P1101, DOI 10.1007/s10237-015-0747-0; Scott GG, 2015, IEEE T MED IMAGING, V34, P1452, DOI 10.1109/TMI.2015.2396527; Souli M, 2000, COMPUT METHOD APPL M, V190, P659, DOI 10.1016/S0045-7825(99)00432-6; Stitzel Joel D, 2002, Stapp Car Crash J, V46, P81; Van Leer B, 1997, J COMPUT PHYS, V135, P229, DOI 10.1006/jcph.1997.5704; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/ijcr.2003.0264; Wismans, 1997, P 41 STAPP CAR CRASH, V41, P315, DOI DOI 10.4271/973338; Zhang A, 2006, INT J CRASHWORTHINES, V11, P291, DOI 10.1533/ijcr.2005.0105; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; Zhao W, 2015, BIOMECH MODEL MECHAN, V14, P753, DOI 10.1007/s10237-014-0634-0; Zhou C, 1995, P STAPP CAR CRASH J, V39, P121, DOI DOI 10.4271/952714; Zhou Z, 2016, COMPUT METH PROG BIO, V131, P13, DOI 10.1016/j.cmpb.2016.04.013	70	25	26	0	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	FEB	2019	18	1					155	173		10.1007/s10237-018-1074-z			19	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	HK4ZU	WOS:000457974500012	30151812	Green Published, hybrid			2022-02-06	
J	Vaca, SD; Kuo, BJ; Vissoci, JRN; Staton, CA; Xu, LW; Muhumuza, M; Ssenyonjo, H; Mukasa, J; Kiryabwire, J; Rice, HE; Grant, GA; Haglund, MM				Vaca, Silvia D.; Kuo, Benjamin J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.; Xu, Linda W.; Muhumuza, Michael; Ssenyonjo, Hussein; Mukasa, John; Kiryabwire, Joel; Rice, Henry E.; Grant, Gerald A.; Haglund, Michael M.			Temporal Delays Along the Neurosurgical Care Continuum for Traumatic Brain Injury Patients at a Tertiary Care Hospital in Kampala, Uganda	NEUROSURGERY			English	Article						Global neurosurgery; Traumatic brain injury; Care continuum; Prospective registry; Mulago	SUBDURAL-HEMATOMA; MORTALITY; PROGNOSIS; OUTCOMES; IMPACT	BACKGROUND: Significant care continuum delays between acute traumatic brain injury (TBI) and definitive surgery are associated with poor outcomes. Use of the "3 delays" model to evaluate TBI outcomes in low-and middle-income countries has not been performed. OBJECTIVE: To describe the care continuum, using the 3 delays framework, and its association with TBI patient outcomes in Kampala, Uganda. METHODS: Prospective data were collected for 563 TBI patients presenting to a tertiary hospital in Kampala from 1 June to 30 November 2016. Four time intervals were constructed along 5 time points: injury, hospital arrival, neurosurgical evaluation, computed tomography (CT) results, and definitive surgery. Time interval differences among mild, moderate, and severe TBI and their association with mortality were analyzed. RESULTS: Significant care continuum differences were observed for interval 3 (neurosurgical evaluation to CT result) and 4 (CT result to surgery) between severe TBI patients (7 h for interval 3 and 24 h for interval 4) and mild TBI patients (19 h for interval 3 and 96 h for interval 4). These postarrival delays were associated with mortality for mild (P =.05) and moderate TBI (P=. 03) patients. Significant hospital arrival delays for moderate TBI patients were associated with mortality (P=.04). CONCLUSION: Delays for mild and moderate TBI patients were associated with mortality, suggesting that quality improvement interventions could target current triage practices. Future research should aim to understand the contributors to delays along the care continuum, opportunities for more effective resource allocation, and the need to improve prehospital logistical referral systems.	[Vaca, Silvia D.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Vaca, Silvia D.; Grant, Gerald A.] Stanford Ctr Innovat Global Hlth, Palo Alto, CA USA; [Kuo, Benjamin J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.; Haglund, Michael M.] Duke Univ, Div Global Neurosurg & Neurol, Durham, NC USA; [Kuo, Benjamin J.; Haglund, Michael M.] Duke Univ, Global Hlth Inst, Durham, NC USA; [Kuo, Benjamin J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.] Duke NUS Med Sch, Singapore, Singapore; [Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.] Duke Univ, Med Ctr, Duke Emergency Med, Durham, NC USA; [Xu, Linda W.; Grant, Gerald A.] Stanford Univ, Med Ctr, Dept Neurosurg, Palo Alto, CA 94304 USA; [Muhumuza, Michael; Ssenyonjo, Hussein; Mukasa, John; Kiryabwire, Joel] Mulago Hosp, Dept Neurosurg, Kampala, Uganda; [Rice, Henry E.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Haglund, Michael M.] Duke Univ, Med Ctr, Div Neurosurg, Durham, NC 27710 USA		Haglund, MM (corresponding author), Duke Univ, Dept Neurol Surg, 4508 Hosp South, Durham, NC 27710 USA.	michael.haglund@dm.duke.edu		Staton, Catherine/0000-0002-6468-2894	FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [K01 TW010000] Funding Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [K01TW010000] Funding Source: NIH RePORTER		Abdelgadir J, 2017, WORLD NEUROSURG, V101, P651, DOI 10.1016/j.wneu.2017.02.048; Ament JD, 2014, J NEUROSURG-SPINE, V20, P436, DOI 10.3171/2014.1.SPINE1228; Bullock M Ross, 2006, Neurosurgery, V58, pS7; BULLOCK MR, 2006, NEUROSURGERY S, V58; Chandran A, 2010, EPIDEMIOL REV, V32, P110, DOI 10.1093/epirev/mxq009; Crandall M, 2013, AM J PUBLIC HEALTH, V103, P1103, DOI 10.2105/AJPH.2013.301223; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Di Saverio S, 2014, LANGENBECK ARCH SURG, V399, P109, DOI 10.1007/s00423-013-1143-9; Emejulu JKC, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.09.002; Gagne M, 2017, J TRAUMA ACUTE CARE, V82, P374, DOI 10.1097/TA.0000000000001319; Gupta D, 2016, WORLD NEUROSURG, V89, P169, DOI 10.1016/j.wneu.2015.12.097; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Rocha TAH, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0645-4; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JAMIESON KG, 1968, J NEUROSURG, V29, P13, DOI 10.3171/jns.1968.29.1.0013; Jayaraman Sudha, 2009, World J Surg, V33, P2512, DOI 10.1007/s00268-009-0180-6; Jayaraman S, 2011, WORLD J SURG, V35, P505, DOI 10.1007/s00268-010-0871-z; Long C, 2015, SURGERY, V158, P756, DOI 10.1016/j.surg.2015.04.016; Marcoux J, 2016, J NEUROSURG, V125, P642, DOI 10.3171/2015.6.JNS15175; Mowafi H, 2016, WORLD J SURG, V40, P2868, DOI 10.1007/s00268-016-3629-4; Raykar NP, 2015, LANCET, V385, P15, DOI 10.1016/S0140-6736(15)60810-8; Scotter J, 2015, EMERG MED J, V32, P654, DOI 10.1136/emermed-2014-204260; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Sorensen Bjarke Lund, 2011, Afr J Reprod Health, V15, P117; Staton CA, 2017, INT J INJ CONTROL SA, V24, P69, DOI 10.1080/17457300.2015.1061562; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Tran TM, 2015, WORLD NEUROSURG, V83, P269, DOI 10.1016/j.wneu.2014.12.028; Uganda Bureau of Statistics, UG NAT HOUS SURV 200; Urgessa F, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-358	30	25	25	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2019	84	1					95	102		10.1093/neuros/nyy004			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	HQ7GP	WOS:000462588300059	29490070	hybrid, Green Published			2022-02-06	
J	Corrigan, JD; Yang, JZ; Singichetti, B; Manchester, K; Bogner, J				Corrigan, John D.; Yang, Jingzhen; Singichetti, Bhavna; Manchester, Kara; Bogner, Jennifer			Lifetime prevalence of traumatic brain injury with loss of consciousness	INJURY PREVENTION			English	Article						Traumatic Brain Injury; Concussion; Descriptive Epidemiology	UNITED-STATES; SUBSTANCE USE; POPULATION; HEALTH; IDENTIFICATION; RELIABILITY; DISABILITY; VALIDITY; HISTORY; TBI	Objective To determine the prevalence of lifetime history of traumatic brain injury (TBI) with loss of consciousness (LOC) among adult, non-institutionalised residents of Ohio. Methods We analysed data from 2014 Ohio Behavioral Risk Factor Surveillance System, which included a state-specific module designed to elicit lifetime history of TBI. Results Of non-institutionalised adults 18 years and over living in Ohio, 21.7% reported at least one lifetime TBI with LOC, 2.6% experienced at least one moderate or severe such injury, 9.1% experienced a TBI with LOC before age 15 years and 10.8% experienced either TBI with LOC before age 15 years or a moderate or severe injury. Males, those with lower incomes and those unable to work were more likely to have incurred at least one TBI with LOC, multiple TBIs with LOC, a moderate or severe TBI and a TBI with LOC before age15. Conclusions One in five adults experienced TBIs of sufficient severity to cause LOC; 3% experienced at least one moderate or severe TBI and almost 10% experienced a first TBI with LOC before the age of 15 years. The prevalence of lifetime TBI in the present study suggests that there may be a substantially greater burden of injury than concluded from previous prevalence estimates.	[Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA; [Yang, Jingzhen; Singichetti, Bhavna] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Columbus, OH USA; [Manchester, Kara] Ohio Dept Hlth, Violence & Injury Prevent Program, Columbus, OH 43266 USA		Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Corrigan, John D./E-2921-2011	Singichetti, Bhavna/0000-0002-2188-3979			[Anonymous], 2015, C TRAUM BRAIN INJ US; [Anonymous], BEH RISK FACT SURV S; [Anonymous], 2015, OH 2013 BRFSS ANN RE; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bureau of Health Statistics and Data Management, 1998, NEW HAMPSH BEH RISK; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Coronado V.G., 2012, BRAIN INJURY MED PRI; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cuthbert JP, 2016, J HEAD TRAUMA REHAB, V31, pE36, DOI 10.1097/HTR.0000000000000075; Cuthbert JP, 2015, ARCH PHYS MED REHAB, V96, P2128, DOI 10.1016/j.apmr.2015.07.020; Dams-O'Connor K, 2014, J HEAD TRAUMA REHAB, V29, P479, DOI 10.1097/HTR.0000000000000099; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Frost RB, 2013, NEUROEPIDEMIOLOGY, V40, P154, DOI 10.1159/000343275; Han K, 2016, J INT NEUROPSYCH SOC, V22, P263, DOI 10.1017/S1355617715001393; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Ilie G, 2015, J NEUROTRAUM, V32, P1130, DOI 10.1089/neu.2014.3619; IOM NRC, 2014, SPORTS RELATED CONCU; Janak JC, 2015, TRAUMATIC BRAIN INJU; King JB, 2016, NEUROIMAGE-CLIN, V11, P81, DOI 10.1016/j.nicl.2016.01.003; Lee T. A., 2013, DEV PROTOCOL OBSERVA; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; McKinlay A, 2016, J INT NEUROPSYCH SOC, V22, P717, DOI 10.1017/S1355617716000497; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Section HS, 2001, COL BEH RISK FACT SU; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Warner M, 2005, INJURY PREV, V11, P282, DOI 10.1136/ip.2004.006965; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE55, DOI 10.1097/HTR.0000000000000140; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE43, DOI 10.1097/HTR.0000000000000141; Winqvist S, 2006, J ADOLESC HLTH, V39, p275e1, DOI DOI 10.1016/J.JADOHEALTH.2005.12.019; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	40	25	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	DEC	2018	24	6					396	404		10.1136/injuryprev-2017-042371			9	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	HD7XQ	WOS:000452767700002	28848057				2022-02-06	
J	Madathil, SK; Wilfred, BS; Urankar, SE; Yang, WH; Leung, LY; Gilsdorf, JS; Shear, DA				Madathil, Sindhu K.; Wilfred, Bernard S.; Urankar, Sarah E.; Yang, Weihong; Leung, Lai Yee; Gilsdorf, Janice S.; Shear, Deborah A.			Early Microglial Activation Following Closed-Head Concussive Injury Is Dominated by Pro-Inflammatory M-1 Type	FRONTIERS IN NEUROLOGY			English	Article						microglia; inflammation; polarization; concussion; traumatic brain injury	TRAUMATIC BRAIN-INJURY; WHITE-MATTER; NEURODEGENERATION; FOOTBALL; STATES; MODEL; MICE; NEUROINFLAMMATION; NEUROPROTECTION; ENCEPHALOPATHY	Microglial activation is a pathological hallmark of traumatic brain injury (TBI) Following brain injury, activated microglia/macrophages adopt different phenotypes, generally categorized as M-1, or classically activated, and M-2, or alternatively activated. While the M-1, or pro-inflammatory phenotype is detrimental to recovery, M-2, or the anti-inflammatory phenotype, aids in brain repair. Recent findings also suggest the existence of mixed phenotype following brain injury, where activated microglia simultaneously express both M-1 and M-2 markers. The present study sought to determine microglial activation states at early time points (6-72h) following single or repeated concussive injury in rats. Closed-head concussive injury was modeled in rats using projectile concussive impact injury, with either single or repeated impacts (4 impacts, 1 h apart). Brain samples were examined using immunohistochemical staining, inflammatory gene profiling and real-time polymerase chain reaction analyses to detect concussive injury induced changes in microglial activation and phenotype in cortex and hippocampal regions. Our findings demonstrate robust microglial activation following concussive brain injury. Moreover, we show that multiple concussions induced a unique rod-shaped microglial morphology that was also observed in other diffuse brain injury models. Histological studies revealed a predominance of MHC-Il positive M-1 phenotype in the post-concussive microglial milieu following multiple impacts. Although there was simultaneous expression of M-1 and M-2 markers, gene expression results indicate a clear dominance in M-1 pro-inflammatory markers following both single and repeated concussions. While the increase in M-1 markers quickly resolved after a single concussion, they persisted following repeated concussions, indicating a pro-inflammatory environment induced by multiple concussions that may delay recovery and contribute to long-lasting consequences of concussion.	[Madathil, Sindhu K.; Wilfred, Bernard S.; Urankar, Sarah E.; Yang, Weihong; Leung, Lai Yee; Gilsdorf, Janice S.; Shear, Deborah A.] Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Leung, Lai Yee] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA		Madathil, SK (corresponding author), Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA.	Sindhu.kizhakkemadathil.ctr@mail.mil	Wilfred, Bernard Srambical/AAC-8221-2020; Madathil, Sindhu K/E-9407-2012	Wilfred, Bernard Srambical/0000-0002-0674-0187; 	Combat Casualty Care Research ProgramUnited States Department of Defense [H_026_2014]; U.S. Army Medical Research and Materiel Command Congressionally Directed Medical Research Programs [W81XWH-12-2-0134]	This research is funded by Combat Casualty Care Research Program (H_026_2014,) and U.S. Army Medical Research and Materiel Command Congressionally Directed Medical Research Programs (W81XWH-12-2-0134). We thank Dr. Xi-Chun Lu and Ms. Savannah Barannikov for critical reading of the manuscript.	Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bell-Temin H, 2015, MOL CELL PROTEOMICS, V14, P3173, DOI 10.1074/mcp.M115.053926; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Bugno M, 1999, FEBS LETT, V448, P9, DOI 10.1016/S0014-5793(99)00323-3; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen ZY, 2012, J NEUROTRAUM, V29, P268, DOI 10.1089/neu.2011.2057; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Freilich RW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079416; Gao M, 2017, BRAIN BEHAV IMMUN, V59, P288, DOI 10.1016/j.bbi.2016.09.020; Gao TL, 2018, BIOCHEM BIOPH RES CO, V497, P430, DOI 10.1016/j.bbrc.2018.02.102; Goldstein L.E., 2012, SCI TRANSL MED, V4; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Heneka MT, 2001, J NEUROIMMUNOL, V114, P8, DOI 10.1016/S0165-5728(01)00246-6; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lange PS, 2004, J NUTR, V134, p2812S, DOI 10.1093/jn/134.10.2812S; Leung LY, 2014, ANN BIOMED ENG, V42, P1618, DOI 10.1007/s10439-014-1014-8; Li YN, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0657-4; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McAteer KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160220; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McPherson CA, 2014, NEUROTOX RES, V25, P45, DOI 10.1007/s12640-013-9422-3; Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Mountney A, 2017, J NEUROTRAUM, V34, P2768, DOI 10.1089/neu.2016.4679; Mouzon BC, 2018, ANN CLIN TRANSL NEUR, V5, P64, DOI 10.1002/acn3.510; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Ojo JO, 2015, J NEUROPATH EXP NEUR, V74, P1012, DOI 10.1097/NEN.0000000000000247; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Potts Mathew B, 2006, NeuroRx, V3, P143; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Suryadevara R, 2003, GLIA, V44, P47, DOI 10.1002/glia.10266; Thelin EP, 2018, J NEUROTRAUM, V35, P341, DOI 10.1089/neu.2017.5155; Truettner JS, 2017, J CEREBR BLOOD F MET, V37, P2952, DOI 10.1177/0271678X16680003; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Wang B, 2018, CEREBELLUM, V17, P477, DOI 10.1007/s12311-018-0934-5; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Weinstein E, 2013, J NEUROSURG-PEDIATR, V11, P331, DOI 10.3171/2012.11.PEDS12343; Xu HZ, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/5405104; XU X, 2017, J NEUROINFLAMM, V14; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Zheng KB, 2013, NEUROL INDIA, V61, P606, DOI 10.4103/0028-3886.125258; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	61	25	25	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	NOV 15	2018	9								964	10.3389/fneur.2018.00964			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HA4QJ	WOS:000450247500001	30498469	Green Published, gold			2022-02-06	
J	Zheng, B; Zhang, SC; Ying, YL; Guo, XY; Li, HC; Xu, LX; Ruan, XC				Zheng, Bin; Zhang, Shuncai; Ying, Yanlu; Guo, Xinying; Li, Hengchang; Xu, Lixin; Ruan, Xiangcai			Administration of Dexmedetomidine inhibited NLRP3 inflammasome and microglial cell activities in hippocampus of traumatic brain injury rats	BIOSCIENCE REPORTS			English	Article							INNATE IMMUNE-RESPONSE; ACTIVATION; EXPRESSION; ISCHEMIA; STRESS	The abnormally high nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activity is a typical characteristic of traumatic brain injury (TBI). Dexmedetomidine (Dex) is a highly selective alpha-2 adrenergic receptor agonist that inhibits the activation of NLRP3. Thus, it was hypothesized that Dex could attenuate TBI by inhibiting NLRP3 inflammasome activity in hippocampus. Rats were subjected to controlled cortical impact method to induce TBI, and treated with Dex. The effect of Dex treatment on the cognitive function, NLRP3 activity, and microglial activation in rat brain tissues was assessed. The administration of Dex improved performance of TBI rats in Morris water maze (MWM) test, which was associated with the increased neurone viability and suppressed microglia activity. Moreover, the administration of Dex inhibited the neuroinflammation in brain tissue as well as the expressions of NLRP3 and caspase-1. Additionally, Dex and NLRP3 inhibitor, BAY-11-7082 had a synergistic effect in inhibiting NLRP3/caspase-1 axis activity and improving TBI. The findings outlined in the current study indicated that the improvement effect of Dex on TBI was related to its effect on NLRP3 activity.	[Zheng, Bin] Jinan Univ, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China; [Zheng, Bin; Zhang, Shuncai; Ying, Yanlu; Guo, Xinying; Li, Hengchang; Xu, Lixin; Ruan, Xiangcai] South China Univ Technol, Guangzhou Peoples Hosp 1, Dept Anesthesiol, Sch Med, Guangzhou, Guangdong, Peoples R China; [Zhang, Shuncai] Jieyang Peoples Hosp, Dept Anesthesiol, Jieyang, Peoples R China		Ruan, XC (corresponding author), South China Univ Technol, Guangzhou Peoples Hosp 1, Dept Anesthesiol, Sch Med, Guangzhou, Guangdong, Peoples R China.	xc_ruan@hotmail.com	Ruan, Xiangcai/L-9904-2016	Ruan, Xiangcai/0000-0001-6112-7994; Zheng, Bin/0000-0002-6580-8233	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271196]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2016A030313440]; Guangzhou Planned Project of Scinece and Technology [201607010119, 201607010132]	This work was supported by the National Natural Science Foundation of China [grant number 81271196]; the Natural Science Foundation of Guangdong Province [grant number 2016A030313440]; and the Guangzhou Planned Project of Scinece and Technology [grant numbers 201607010119, 201607010132].	Chi XH, 2016, J CARDIOTHOR VASC AN, V30, P44, DOI 10.1053/j.jvca.2015.06.026; Cho JS, 2016, KIDNEY INT, V89, P693, DOI 10.1038/ki.2015.306; [褚芹 Chu Qin], 2005, [中国行为医学科学, Chinese Journal of Behavioral Medical Science], V14, P964; Dowling JK, 2012, CRIT REV BIOCHEM MOL, V47, P424, DOI 10.3109/10409238.2012.694844; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Faul M., 2004, EMERGENCY SERVICE HO, V16, pA268; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Franchi L, 2014, J IMMUNOL, V193, P4214, DOI 10.4049/jimmunol.1400582; Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231; Gao SQ, 2015, INT J CLIN EXP PATHO, V8, P3144; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Keating GM, 2015, DRUGS, V75, P1119, DOI 10.1007/s40265-015-0419-5; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu CZ, 2006, EXP NEUROL, V201, P452, DOI 10.1016/j.expneurol.2006.04.025; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu YJ, 2017, BMC ANESTHESIOL, V17, DOI 10.1186/s12871-017-0413-4; Lv MH, 2018, INT IMMUNOPHARMACOL, V54, P46, DOI 10.1016/j.intimp.2017.10.030; Man SM, 2015, IMMUNOL REV, V265, P6, DOI 10.1111/imr.12296; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Sahin T, 2013, J SURG RES, V183, P385, DOI 10.1016/j.jss.2012.11.034; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sato K, 2010, ACTA ANAESTH SCAND, V54, P377, DOI 10.1111/j.1399-6576.2009.02139.x; Schoeler M, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-20; Sha WW, 2014, P NATL ACAD SCI USA, V111, P16059, DOI 10.1073/pnas.1412487111; Shen M, 2017, BIOMED PHARMACOTHER, V95, P885, DOI 10.1016/j.biopha.2017.08.125; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wu J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23003-3; Zendedel A, 2018, MOL NEUROBIOL, V55, P1364, DOI 10.1007/s12035-017-0400-2; Zhang MH, 2018, MOL MED REP, V17, P8079, DOI 10.3892/mmr.2018.8898; Zhang QY, 2017, CELL PHYSIOL BIOCHEM, V42, P1907, DOI 10.1159/000479609; Zhou KR, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9238290	42	25	25	1	6	PORTLAND PRESS LTD	LONDON	5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND	0144-8463	1573-4935		BIOSCIENCE REP	Biosci. Rep.	OCT 31	2018	38		5						BSR20180892	10.1042/BSR20180892			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GY8QO	WOS:000448897800077	30232232	Green Published, Green Submitted, gold			2022-02-06	
J	Zhang, L; Wang, HD; Zhou, YL; Zhu, YH; Fei, MX				Zhang, Li; Wang, Handong; Zhou, Yali; Zhu, Yihao; Fei, Maoxin			Fisetin alleviates oxidative stress after traumatic brain injury via the Nrf2-ARE pathway	NEUROCHEMISTRY INTERNATIONAL			English	Article						Fisetin; Neuroprotection; Traumatic brain injury; Nrf2-ARE pathway	ANTIOXIDANT RESPONSE ELEMENT; ACID PHENETHYL ESTER; PROVIDES NEUROPROTECTION; ACTIVATION; PROTECTS; MODULATION; EXPRESSION; MODELS; DEGRADATION; HEMORRHAGE	Fisetin, a natural flavonoid, has neuroprotection properties in many brain injury models. However, its role in traumatic brain injury (TBI) has not been fully explained. In the present study, we aimed to explore the neuroprotective effects of fisetin in a mouse model of TBI. We found that fisetin improved neurological function, reduced cerebral edema, attenuated brain lesion and ameliorated blood-brain barrier (BBB) disruption after TBI. Moreover, the up-regulation of malondialdehyde (MDA) and the activity of glutathione peroxidase (GPx) were reversed by fisetin treatment. Furthermore, administration of fisetin suppressed neuron cell death and apoptosis, increased the expression of B-cell lymphoma 2 (Bcl-2), while decreased the expression of Bcl-2-associated X protein (Bax) and caspase-3 after TBI. In addition, fisetin activated the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway following TBI. However, fisetin only failed to suppress oxidative stress in Nrf2(-/-) mice. In conclusion, our data provided the first evidence that fisetin played a critical role in neuroprotection after TBI partly through the activation of the Nrf2-ARE pathway.	[Zhang, Li; Wang, Handong; Zhou, Yali; Zhu, Yihao; Fei, Maoxin] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China		Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81672503, 81702484]	This work was supported by Grants from the National Natural Science Foundation of China (No. 81672503 and 81702484).	Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Arai Y, 2000, J NUTR, V130, P2243; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Chandran R., 2017, J CEREB BLOOD FLOW M, DOI DOI 10.1177/0271678X1773870129083257; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Friedrich V, 2012, NEUROSCI LETT, V512, P6, DOI 10.1016/j.neulet.2012.01.036; Gelderblom M, 2012, J CEREBR BLOOD F MET, V32, P835, DOI 10.1038/jcbfm.2011.189; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Higa S, 2003, J ALLERGY CLIN IMMUN, V111, P1299, DOI 10.1067/mai.2003.1456; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Jin W, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/502564; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Kalayci M, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-75; Kerman M, 2012, J MOL HISTOL, V43, P49, DOI 10.1007/s10735-011-9376-9; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Liu-Smith F, 2016, MOL NUTR FOOD RES, V60, P1264, DOI 10.1002/mnfr.201500822; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Nabavi SF, 2016, CURR TOP MED CHEM, V16, P1910, DOI 10.2174/1568026616666160204121725; Nagai K, 2009, BRIT J PHARMACOL, V158, P907, DOI 10.1111/j.1476-5381.2009.00365.x; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Sandireddy R, 2016, CELL MOL NEUROBIOL, V36, P883, DOI 10.1007/s10571-015-0272-9; Sauzeau V, 2003, J BIOL CHEM, V278, P9472, DOI 10.1074/jbc.M212776200; Sun Q, 2016, ALCOHOL CLIN EXP RES, V40, P2076, DOI 10.1111/acer.13172; Tsai CY, 2013, INT J CARDIOL, V168, P1286, DOI 10.1016/j.ijcard.2012.12.004; Villeneuve NF, 2010, ANTIOXID REDOX SIGN, V13, P1699, DOI 10.1089/ars.2010.3211; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu PY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040782; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46763; Zhang Lijuan, 2016, Zhongguo Zhen Jiu, V36, P131; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858; Zhou CH, 2015, BRAIN RES, V1629, P250, DOI 10.1016/j.brainres.2015.10.016; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	44	25	26	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	SEP	2018	118						304	313		10.1016/j.neuint.2018.05.011			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	GO0ZC	WOS:000439674200033	29792955				2022-02-06	
J	Nasi, D; Dobran, M; Di Rienzo, A; di Somma, L; Gladi, M; Moriconi, E; Scerrati, M; Iacoangeli, M				Nasi, Davide; Dobran, Mauro; Di Rienzo, Alessandro; di Somma, Lucia; Gladi, Maurizio; Moriconi, Elisa; Scerrati, Massimo; Iacoangeli, Maurizio			Decompressive Craniectomy for Traumatic Brain Injury: The Role of Cranioplasty and Hydrocephalus on Outcome	WORLD NEUROSURGERY			English	Article						Cranioplasty; Decompressive craniectomy; Hydrocephalus; Traumatic brain injury	INTRACRANIAL HYPERTENSION; TRIAL	OBJECTIVE: After severe traumatic brain injury (sTBI) associated with uncontrollable high intracranial pressure (ICP), today the main challenge for neurosurgeons remains to identify who may obtain benefit from decompressive craniectomy (DC) and which factors after DC influence the prognosis of these patients. The aim of this paper was to identify the pre- and postoperative determinants of outcome after DC. METHODS: This retrospective study included all patients undergoing DC for sTBI from 2003 to 2011. The 6-month outcome, assessed using the Glasgow Outcome Scale (GOS), was dichotomized into favorable (GOS scores 4 and 5) and unfavorable (GOS scores 1-3) outcome. Predictors of outcome were identified by uni- and multivariate analysis. RESULTS: There were 190 patients who underwent DC for sTBI in this study. Sixty patients (31.6%) died within 30 days after DC. Independent prognostic factors for survival after 30 days were Glasgow Coma Scale score at admission greater than 5 (P = 0.002) and bilateral pupil reactivity (P < 0.0001). Thirty days after DC, 67 patients (51.5%) out of 130 had unfavorable outcome (GOS scores 1-3) and 63 patients (49.5%) presented favorable outcome (GOS scores 4 and 5). The independent preoperative prognostic factors for poor outcome were age over 65 years (P < 0.0001) and bilateral absence of pupil reactivity (P = 0.0165). After DC, onset of postoperative hydrocephalus and delayed cranioplasty (3 months after DC) was associated with unfavorable outcome at multivariate analysis (P = 0.002 and P < 0.0001, respectively). CONCLUSIONS: In our study, the development of hydrocephalus after DC for sTBI and delayed cranial reconstruction were associated with unfavorable outcome.	[Nasi, Davide; Dobran, Mauro; Di Rienzo, Alessandro; di Somma, Lucia; Gladi, Maurizio; Moriconi, Elisa; Scerrati, Massimo; Iacoangeli, Maurizio] Univ Politecn Marche, Umberto Gen Hosp 1, Dept Neurosurg, Ancona, Italy		Nasi, D (corresponding author), Univ Politecn Marche, Umberto Gen Hosp 1, Dept Neurosurg, Ancona, Italy.	davidenasi83@gmail.com		Nasi, Davide/0000-0002-7357-7455			Bender A, 2013, BRAIN INJURY, V27, P1073, DOI 10.3109/02699052.2013.794972; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cotte J, 2014, NEW ENGL J MED, V371, P971, DOI 10.1056/NEJMc1407775; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Di Rienzo A, 2013, NEUROL MED-CHIR, V53, P329, DOI 10.2176/nmc.53.329; di Somma Lucia, 2016, Surg Neurol Int, V7, pS12, DOI 10.4103/2152-7806.173561; Honeybul S, 2017, J CLIN NEUROSCI, V43, P11, DOI 10.1016/j.jocn.2017.04.032; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Iaccarino C, 2013, WORLD NEUROSURG, V79, P78, DOI 10.1016/j.wneu.2012.10.061; Khalili Hosseinali, 2017, Bull Emerg Trauma, V5, P190; Malcolm JG, 2018, NEUROSURGERY, V82, P278, DOI 10.1093/neuros/nyx182; Nasi D, 2016, WORLD NEUROSURG, V91, DOI 10.1016/j.wneu.2016.04.041; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Sharma R, 2017, NEUROSURGERY, V81, pE58, DOI 10.1093/neuros/nyx398; Tagliaferri F, 2012, ACTA NEUROCHIR, V154, P919, DOI 10.1007/s00701-012-1318-0	16	25	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	AUG	2018	116						E543	E549		10.1016/j.wneu.2018.05.028			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	GN9GM	WOS:000439498500070	29772371				2022-02-06	
J	Seal, KH; Bertenthal, D; Barnes, DE; Byers, AL; Gibson, CJ; Rife, TL; Yaffe, K				Seal, Karen H.; Bertenthal, Daniel; Barnes, Deborah E.; Byers, Amy L.; Gibson, Carolyn J.; Rife, Tessa L.; Yaffe, Kristine		Chronic Effects Neurotrauma Consor	Traumatic Brain Injury and Receipt of Prescription Opioid Therapy for Chronic Pain in Iraq and Afghanistan Veterans: Do Clinical Practice Guidelines Matter?	JOURNAL OF PAIN			English	Article						Traumatic brain injury; chronic pain; opioids; veterans; post-traumatic stress disorder	CHRONIC NONCANCER PAIN; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH DISORDERS; SUBSTANCE USE; PRIMARY-CARE; LONG-TERM; US VETERANS; ASSOCIATION; RISK; PREVALENCE	Clinical practice guidelines admonish against prescribing opioids for individuals with chronic pain and traumatic brain injury (TBI) because of increased risk for adverse outcomes, yet no studies have described opioid prescribing patterns in these higher-risk patients. Between October 2007 and March 2015, 53,124 Iraq and Afghanistan veterans with chronic pain not prescribed opioids in the previous year were followed for 1 year after completing a Comprehensive TBI Evaluation within the Department of Veterans Affairs health care facilities. Veterans reporting the most severe TBI sequelae (eg, loss of consciousness >30 minutes) were significantly more likely to receive short-term and long-term opioid therapy than those with less severe or no TBI sequelae (P values < .001). In analyses adjusted for sociodemographic characteristics, military service, pain disability, and previous nonopioid treatment modalities, veterans with moderate to severe TBI had a significantly increased risk of receiving opioid therapy. Veterans with moderate to severe TBI and comorbid post-traumatic stress disorder and depression had an even greater risk of initiating long-term opioid therapy in the year after the Comprehensive TBI Evaluation (adjusted relative risk = 3.57 [95% confidence interval = 2.85-4.47]). Higher risk patients with chronic pain and TBI with mental health comorbidities may benefit from improved access to behavioral health and nonpharmacological therapies for chronic pain. Perspective: Paradoxically, veterans with greater TBI severity and comorbid mental health burden are more likely to be prescribed opioids for chronic pain. More vulnerable veterans may benefit from improved access to behavioral health and nonpharmacological modalities for chronic pain, because of the health and safety risks of opioids. (C) Published by Elsevier Inc. on behalf of the American Pain Society	[Seal, Karen H.; Bertenthal, Daniel; Barnes, Deborah E.; Byers, Amy L.; Gibson, Carolyn J.; Rife, Tessa L.; Yaffe, Kristine] San Francisco Vet Affairs Hlth Care Syst, San Francisco, CA USA; [Seal, Karen H.; Barnes, Deborah E.; Byers, Amy L.; Gibson, Carolyn J.; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA		Seal, KH (corresponding author), Univ Calif San Francisco, San Francisco VA Hlth Care Syst, Dept Med, 4150 Clement St,Box 116-A, San Francisco, CA 94121 USA.; Seal, KH (corresponding author), Univ Calif San Francisco, San Francisco VA Hlth Care Syst, Dept Psychiat, 4150 Clement St,Box 116-A, San Francisco, CA 94121 USA.	Karen.Seal@va.gov		Rife, Tessa/0000-0002-5397-3012	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); U.S. Department of Veterans Affairs Chronic Effects of Neurotrauma Consortium [W81XWH-13-2-0095]	This work was supported by the U.S. Army Medical Research and Materiel Command and the U.S. Department of Veterans Affairs Chronic Effects of Neurotrauma Consortium under award number W81XWH-13-2-0095.	Anderson Daren, 2012, Qual Prim Care, V20, P421; Barry DT, 2015, PSYCHIAT RES, V227, P324, DOI 10.1016/j.psychres.2015.03.006; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Centers for Disease Control and Prevention, 2016, WID RANG ONL DAT EP; Chang JS, 2017, SUBST USE MISUSE, V52, P251, DOI 10.1080/10826084.2016.1223138; Chaparro LE, 2014, SPINE, V39, P556, DOI 10.1097/BRS.0000000000000249; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Department of Veterans Affairs and the Department of Defense, 2017, MAN OP THER OT CHRON; Dobscha SK, 2013, CLIN J PAIN, V29, P102, DOI 10.1097/AJP.0b013e3182490bdb; Edlund MJ, 2010, CLIN J PAIN, V26, P1, DOI 10.1097/AJP.0b013e3181b99f35; Frayne SM, 2005, ARCH INTERN MED, V165, P2631, DOI 10.1001/archinte.165.22.2631; Golub A, 2013, SUBST USE MISUSE, V48, P811, DOI 10.3109/10826084.2013.796988; Griffin ML, 2015, AM J ADDICTION, V24, P308, DOI 10.1111/ajad.12188; Gruber SA, 2007, NEUROPSYCHOL REV, V17, P299, DOI 10.1007/s11065-007-9041-y; Hawkins EJ, 2015, PAIN MED, V16, P1943, DOI 10.1111/pme.12787; Hendricks AM, 2013, BRAIN INJURY, V27, P125, DOI 10.3109/02699052.2012.729284; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hudson TJ, 2017, PAIN, V158, P1039, DOI 10.1097/j.pain.0000000000000874; Ilie G, 2015, J NEUROTRAUM, V32, P1130, DOI 10.1089/neu.2014.3619; Im JJ, 2015, J GEN INTERN MED, V30, P979, DOI 10.1007/s11606-015-3220-y; Jamison Robert N, 2014, J Opioid Manag, V10, P375, DOI 10.5055/jom.2014.0234; Kerns RD, 2003, J REHABIL RES DEV, V40, P371, DOI 10.1682/JRRD.2003.09.0371; Krebs EE, 2014, J PAIN, V15, P1148, DOI 10.1016/j.jpain.2014.08.006; LeResche L, 2015, J WOMENS HEALTH, V24, P629, DOI 10.1089/jwh.2015.5222; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lin LWA, 2017, PAIN, V158, P833, DOI 10.1097/j.pain.0000000000000837; Mathew N, 2016, COMMUNITY MENT HLT J, V52, P165, DOI 10.1007/s10597-015-9939-4; Matthias MS, 2010, PAIN MED, V11, P1688, DOI 10.1111/j.1526-4637.2010.00980.x; Morasco BJ, 2014, PAIN MED, V15, P1902, DOI 10.1111/pme.12472; Morasco BJ, 2013, DRUG ALCOHOL DEPEN, V127, P193, DOI 10.1016/j.drugalcdep.2012.06.032; Morasco BJ, 2010, PAIN, V151, P625, DOI 10.1016/j.pain.2010.08.002; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Outcalt SD, 2014, J REHABIL RES DEV, V51, P559, DOI 10.1682/JRRD.2013.06.0134; Ramirez S, 2017, AM J THER, V24, pE150, DOI 10.1097/MJT.0000000000000141; Reinecke H, 2015, BRIT J PHARMACOL, V172, P324, DOI 10.1111/bph.12634; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Salas J, 2017, PAIN, V158, P306, DOI 10.1097/j.pain.0000000000000763; Scherrer JF, 2016, J PAIN, V17, P473, DOI 10.1016/j.jpain.2015.12.012; Seal K, 2017, J GEN INTERN MED, V32, P931, DOI 10.1007/s11606-017-4047-5; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087; Sullivan MD, 2010, PAIN, V151, P567, DOI 10.1016/j.pain.2010.08.036; Sullivan MD, 2006, J GEN INTERN MED, V21, P360, DOI 10.1111/j.1525-1497.2006.00352.x; Trafton J, 2010, PAIN MED, V11, P575, DOI 10.1111/j.1526-4637.2010.00818.x	44	25	25	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	AUG	2018	19	8					931	941		10.1016/j.jpain.2018.03.005			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	GP9GZ	WOS:000441226800010	29597083				2022-02-06	
J	Yuan, J; Wang, DF; Liu, Y; Chen, XJ; Zhang, HL; Shen, F; Liu, X; Fu, JQ				Yuan, Jia; Wang, Difen; Liu, Ying; Chen, Xianjun; Zhang, Hailing; Shen, Feng; Liu, Xu; Fu, Jiangquan			Hydrogen-rich water attenuates oxidative stress in rats with traumatic brain injury via Nrf2 pathway	JOURNAL OF SURGICAL RESEARCH			English	Article						Hydrogen-rich water; Nrf2 pathway; Traumatic brain injury; Oxidative stress	ANTIOXIDANT ENZYMES; SALINE PROTECTS; SYSTEM; MODEL; HIPPOCAMPUS; MECHANISMS; APOPTOSIS; TARGETS; DAMAGE; ROLES	Background: Several studies have recently found that oxidative stress plays a pivotal role in the pathogenesis of traumatic brain injury (TBI) and may represent a target in TBI treatment. Hydrogen-rich water was recently shown to exert neuroprotective effects in various neurological diseases through its antioxidant properties. However, the mechanisms underlying its effects in TBI are not clearly understood. The purpose of our study was to evaluate the neuroprotective role of hydrogen-rich water in rats with TBI and to elucidate the possible mechanisms underlying its effects. Materials and methods: The TBI model was constructed according to the modified Feeney weight-drop method. In part 1 of the experiment, we measured oxidative stress levels by observing the changes in catalase (CAT), glutathione peroxidase (GPx), and malondialdehyde (MDA) expressions. We also evaluated nuclear factor erythroid 2-related factor 2 (Nrf2) levels to determine the role of the protein in the neuroprotective effects against TBI. In part 2, we verified the neuroprotective effects of hydrogen-rich water in TBI and observed its effects on Nrf2. All the experimental rats were divided into sham group, TBI group, and TBI + hydrogen-rich water-treated (TBI + HW) group. We randomly chose 20 rats from each group and recorded their 7-d survival rates. Modified neurological severity scores were recorded from an additional six rats per group, which were then sacrificed 24 h after testing. Spectrophotometry was used to measure GPx, CAT, and MDA levels, whereas western blotting, reverse transcription polymerase chain reaction, and immunohistochemistry were used to measure the expression of Nrf2 and downstream factors like heme oxygenase 1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1). Results: GPx and CAT activity was significantly decreased, and MDA content was increased in the TBI group compared with the sham group at 6 h after TBI. MDA content peaked at 24 h after TBI. Nrf2 nucleoprotein levels were upregulated in the TBI group compared with the sham group and peaked at 24 h after TBI; however, no significant changes in Nrf2 mRNA levels were noted after TBI. Hydrogen-rich water administration significantly increased 7-d survival rates, reduced neurologic deficits, and lowered intracellular oxidative stress levels. Moreover, hydrogen-rich water caused Nrf2 to enter the cell nucleus, which resulted in increases in the expression of downstream factors such as HO-1 and NQO1. Conclusions: Our results indicate that hydrogen-rich water has neuroprotective effects against TBI by reducing oxidative stress and activating the Nrf2 pathway. (C) 2018 Elsevier Inc. All rights reserved.	[Yuan, Jia; Wang, Difen; Liu, Ying; Chen, Xianjun; Zhang, Hailing; Shen, Feng; Liu, Xu; Fu, Jiangquan] Guizhou Med Univ, Dept Crit Care Med, Affiliated Hosp, Guiyi Rd 28, Guiyang 550004, Guizhou, Peoples R China		Wang, DF (corresponding author), Guizhou Med Univ, Dept Crit Care Med, Affiliated Hosp, Guiyi Rd 28, Guiyang 550004, Guizhou, Peoples R China.	DifenWang123@163.com	SHEN, Feng/AAQ-8531-2020		High-level Personnel of Special Support Program [TZJF-2011-25]; Science & Technology Department [SY [2010] 3079]; Key Specialty Construction of Clinical Projects in Guizhou Province [[2011] 52]; National Key Specialty Construction of Clinical Projects in China [[2011] 170]	This work was supported by grants from the High-level Personnel of Special Support Program (No. TZJF-2011-25), the Science & Technology Department (No. SY [2010] 3079), and the Key Specialty Construction of Clinical Projects (No. [2011] 52) in Guizhou Province, as well as the National Key Specialty Construction of Clinical Projects (No. [2011] 170) in China. The authors thank the Clinical Research Center of the Affiliated Hospital of Guizhou Medical University for their support during the experiment.	Arent AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723060; Baird L, 2011, ARCH TOXICOL, V85, P241, DOI 10.1007/s00204-011-0674-5; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Cui T, 2015, CELL BIOCHEM BIOPHYS, V71, P595, DOI 10.1007/s12013-014-0239-3; Dash B, 2012, GENE, V501, P144, DOI 10.1016/j.gene.2012.04.015; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding H, 2017, NEUROCHEM RES, V42, P337, DOI 10.1007/s11064-016-2077-8; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dohi K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108034; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fujita K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007247; Gao YY, 2017, AM J TRANSL RES, V9, P887; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Iketani M, 2017, SHOCK, V48, P85, DOI 10.1097/SHK.0000000000000810; Ji XT, 2012, J SURG RES, V178, pE9, DOI 10.1016/j.jss.2011.12.038; Kawamura T, 2013, AM J PHYSIOL-LUNG C, V304, pL646, DOI 10.1152/ajplung.00164.2012; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Li J, 2010, BRAIN RES, V1328, P152, DOI 10.1016/j.brainres.2010.02.046; Liu Y, 2017, INT J CLIN EXP PATHO, V10, P3807; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; Manaenko A, 2013, CRIT CARE MED, V41, P1266, DOI 10.1097/CCM.0b013e31827711c9; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; Nagata K, 2009, NEUROPSYCHOPHARMACOL, V34, P501, DOI 10.1038/npp.2008.95; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Shen MH, 2014, MED GAS RES, V4, DOI 10.1186/2045-9912-4-17; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Sun Y, 2017, CNS NEUROL DISORD-DR, V16, P326, DOI 10.2174/1871527316666170102120211; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Tanaka N, 2011, BRAIN RES, V1370, P246, DOI 10.1016/j.brainres.2010.11.010; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wang C, 2011, NEUROSCI LETT, V491, P127, DOI 10.1016/j.neulet.2011.01.022; Wang F, 2011, J SURG RES, V167, pE339, DOI 10.1016/j.jss.2010.11.005; Wang L, 2017, BIOSCIENCE REP, V37, P1; Wang Z, 2014, CLIN INTERV AGING, V9, P1, DOI [10.2147/CIA.S41356, 10.1186/1556-276X-9-643]; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu G, 2016, MED SCI MONITOR, V22, P2161, DOI 10.12659/MSM.896568; Xie Q, 2014, MOL MED REP, V10, P1143, DOI 10.3892/mmr.2014.2283; Yang CH, 2009, BRAIN RES, V1282, P133, DOI 10.1016/j.brainres.2009.05.009; Yang YY, 2012, MED SCI MONITOR, V18, pBR144, DOI 10.12659/MSM.882616; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yilmaz N, 2007, BRAIN RES, V1164, P132, DOI 10.1016/j.brainres.2007.06.017; Zhang DQ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/731932; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003	44	25	27	3	24	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	AUG	2018	228						238	246		10.1016/j.jss.2018.03.024			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	GK8TB	WOS:000436499700033	29907217				2022-02-06	
J	Matei, N; Camara, J; McBride, D; Camara, R; Xu, NB; Tang, JP; Zhang, JH				Matei, Nathanael; Camara, Justin; McBride, Devin; Camara, Richard; Xu, Ningbo; Tang, Jiping; Zhang, John H.			Intranasal wnt3a Attenuates Neuronal Apoptosis through Frz1/PIWIL1a/FOXM1 Pathway in MCAO Rats	JOURNAL OF NEUROSCIENCE			English	Article						FOXM1; Frizzled-1; MCAO; PIWI1a; stroke; wnt3a	GLYCOGEN-SYNTHASE KINASE-3-BETA; CEREBRAL-ARTERY OCCLUSION; ISCHEMIC BRAIN-INJURY; SIGNALING PATHWAYS; NERVOUS-SYSTEM; STROKE; NEUROPROTECTION; RECEPTOR; CELLS; MODEL	After ischemic stroke, apoptosis of neurons is a primary factor in determining outcome. Wnt3a is a naturally occurring protein that has been shown to have protective effects in the brain for traumatic brain injury. Although wnt3a has been investigated in the phenomena of neurogenesis, anti-apoptosis, and anti-inflammation, it has never been investigated as a therapy for stroke. We hypothesized that the potential neuroprotective agent wnt3a would reduce infarction and improve behavior following ischemic stroke by attenuating neuronal apoptosis and promoting cell survival through the Frizzled-1/PIWI1a/FOXM1 pathway in middle cerebral artery occlusion (MCAO) rats. A total of 229 Sprague Dawley rats were assigned to male, female, and 9-month-old male MCAO or sham groups followed by reperfusion 2 h after MCAO. Animals assigned to MCAO were either given wnt3a or its control. To explore the downstream signaling of wnt3a, the following interventions were given: Frizzled-1 siRNA, PIWI1a siRNA, and PIWI1a-clustered regularly interspaced short palindromic repeats, along with the appropriate controls. Post-MCAO assessments included neurobehavioral tests, infarct volume, Western blot, and immunohistochemistry. Endogenous levels of wnt3a and Frizzled-1/PIWI1a/FOXM1 were lowered after MCAO. The administration of intranasal wnt3a, 1 h after MCAO, increased PIWIL1a and FOXM1 expression through Frizzled-1, reducing brain infarction and neurological deficits at 24 and 72 h. Frizzled-1 and PIWI1a siRNAs reversed the protective effects of wnt3a after MCAO. Restoration of PIWI1a after knockdown of Frizzled-1 increased FOXM1 survival protein and reduced cleaved caspase-3 levels. In summary, wnt3a decreases neuronal apoptosis and improves neurological deficits through Frizzled-1/PIWI1a/FOXM1 pathway after MCAO in rats. Therefore, wnt3a is a novel intranasal approach to decrease apoptosis after stroke.	[Matei, Nathanael; Camara, Justin; McBride, Devin; Camara, Richard; Xu, Ningbo; Tang, Jiping; Zhang, John H.] Loma Linda Univ, Dept Physiol & Pharmacol, Loma Linda, CA 92354 USA; [Zhang, John H.] Loma Linda Univ, Dept Anesthesiol, Loma Linda, CA 92354 USA; [Zhang, John H.] Loma Linda Univ, Dept Neurosurg, Loma Linda, CA 92354 USA; [McBride, Devin] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Vivian L Smith Dept Neurosurg, Houston, TX USA		Zhang, JH (corresponding author), Loma Linda Univ, Sch Med, Dept Anesthesiol, Risley Hall,Room 219,11041 Campus St, Loma Linda, CA 92354 USA.; Zhang, JH (corresponding author), Loma Linda Univ, Sch Med, Dept Physiol, Risley Hall,Room 219,11041 Campus St, Loma Linda, CA 92354 USA.	Johnzhang3910@yahoo.com	Xu, Ningbo/Q-3820-2017; McBride, Devin/I-4872-2018	Xu, Ningbo/0000-0001-9055-3597; McBride, Devin/0000-0001-8988-3353; Tang, Jiping/0000-0002-2392-9280; Zhang, John H./0000-0002-4319-4285	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS081740]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS081740] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant NS081740 to J.H.Z.	Abe T, 2013, STROKE, V44, P2284, DOI 10.1161/STROKEAHA.113.001320; Arrazola MS, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00166; Ayer RE, 2012, J NEUROSURG, V116, P246, DOI 10.3171/2011.8.JNS11883; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bortesi L, 2015, BIOTECHNOL ADV, V33, P41, DOI 10.1016/j.biotechadv.2014.12.006; Bourhis E, 2010, J BIOL CHEM, V285, P9172, DOI 10.1074/jbc.M109.092130; Candelario-Jalil E, 2009, CURR OPIN INVEST DR, V10, P644; Cerpa W, 2009, DRUG NEWS PERSPECT, V22, P579, DOI [10.1358/dnp.2009.22.10.1443391, 10.1358/dnp.2009.10.1436817]; Chacon MA, 2008, J CELL PHYSIOL, V217, P215, DOI 10.1002/jcp.21497; Chen CH, 2010, J NEUROSCI RES, V88, P2046, DOI 10.1002/jnr.22361; Chen S, 2013, NEUROBIOL DIS, V58, P296, DOI 10.1016/j.nbd.2013.06.011; Chen WQ, 2011, STROKE, V42, P764, DOI 10.1161/STROKEAHA.110.599118; Chen X, 2016, SCI REP-UK, V6, DOI 10.1038/srep20196; Chen YJ, 2015, STROKE, V46, P529, DOI 10.1161/STROKEAHA.114.007265; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Collino M, 2009, DIABETES, V58, P235, DOI 10.2337/db08-0691; Demagny H, 2014, CELL REP, V9, P688, DOI 10.1016/j.celrep.2014.09.020; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Fisher M, 2003, STROKE, V34, P359, DOI 10.1161/01.STR.0000054627.69159.C2; Gratz SJ, 2013, GENETICS, V194, P1029, DOI 10.1534/genetics.113.152710; Horvath P, 2010, SCIENCE, V327, P167, DOI 10.1126/science.1179555; Hu Q, 2009, EXP NEUROL, V216, P35, DOI 10.1016/j.expneurol.2008.11.007; Inestrosa NC, 2014, J MOL CELL BIOL, V6, P64, DOI 10.1093/jmcb/mjt051; Jiang LZ, 2014, INT J CLIN EXP PATHO, V7, P5450; Jiang WY, 2013, NAT BIOTECHNOL, V31, P233, DOI 10.1038/nbt.2508; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Kawabori M, 2015, J NEUROSCI, V35, P3384, DOI 10.1523/JNEUROSCI.2620-14.2015; Kelly S, 2004, EXP NEUROL, V188, P378, DOI 10.1016/j.expneurol.2004.04.004; Kusaka I, 2004, AM J PHYSIOL-HEART C, V286, pH2442, DOI 10.1152/ajpheart.01169.2003; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Li C, 2017, SCI REP, V7; Lin SY, 2009, EXP NEUROL, V217, P361, DOI 10.1016/j.expneurol.2009.03.021; Liu LX, 2007, BLOOD, V110, P1191, DOI 10.1182/blood-2006-11-060103; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mackay J., 2004, ATLAS HEART DIS STRO; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; McBride DW, 2016, ACTA NEUROCHIR SUPPL, V121, P103, DOI 10.1007/978-3-319-18497-5_18; Michalski D, 2012, EUR J HISTOCHEM, V56, P78, DOI [10.4081/ejh.2012.e14, 10.4081/ejh.2012.14]; Min JiangYong, 2013, Clinical Investigation, V3, P1167; Minde DP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-101; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Oderup C, 2013, J IMMUNOL, V190, P6126, DOI 10.4049/jimmunol.1203002; Pang LJ, 2011, EXP CELL RES, V317, P1608, DOI 10.1016/j.yexcr.2011.02.004; Perez-Pinera P, 2013, NAT METHODS, V10, P973, DOI [10.1038/NMETH.2600, 10.1038/nmeth.2600]; R& D Systems, 2018, WNT REC PATHW; Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840; Reeves Mark E, 2012, BMC Res Notes, V5, P239, DOI 10.1186/1756-0500-5-239; Rha JH, 2007, STROKE, V38, P967, DOI 10.1161/01.STR.0000258112.14918.24; Roth Jennifer M, 2011, Proc (Bayl Univ Med Cent), V24, P257; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Senda DM, 2011, BEHAV BRAIN RES, V216, P29, DOI 10.1016/j.bbr.2010.06.026; Shruster A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040843; Song JL, 2015, CELL SIGNAL, V27, P1380, DOI 10.1016/j.cellsig.2015.03.018; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; Ueno K, 2013, INT J CANCER, V132, P1731, DOI 10.1002/ijc.27746; Wang Y, 2017, J PLANT BIOCH PHYSL, V5, P2, DOI [10.4172/2329-9029.1000179, DOI 10.1080/16000889.2017.1299672]; Wu XL, 2014, INT J MOL SCI, V15, P5045, DOI 10.3390/ijms15035045; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhao YY, 2017, CELL TRANSPLANT, V26, P395, DOI 10.3727/096368916X694364	60	25	28	1	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 25	2018	38	30					6787	6801		10.1523/JNEUROSCI.2352-17.2018			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GP1CI	WOS:000440550000015	29954850	Bronze, Green Published			2022-02-06	
J	Michinaga, S; Kimura, A; Hatanaka, S; Minami, S; Asano, A; Ikushima, Y; Matsui, S; Toriyama, Y; Fujii, M; Koyama, Y				Michinaga, Shotaro; Kimura, Akimasa; Hatanaka, Shunichi; Minami, Shizuho; Asano, Arisa; Ikushima, Yuki; Matsui, Shingo; Toriyama, Yoshiya; Fujii, Manami; Koyama, Yutaka			Delayed Administration of BQ788, an ETB Antagonist, after Experimental Traumatic Brain Injury Promotes Recovery of Blood-Brain Barrier Function and a Reduction of Cerebral Edema in Mice	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; blood-brain barrier; brain edema; endothelin	ENDOTHELIAL GROWTH-FACTOR; CLOSED-HEAD INJURY; RECEPTOR ANTAGONISTS; SUBARACHNOID HEMORRHAGE; CEREBROSPINAL-FLUID; RAT-BRAIN; VEGF-A; ACTIVATION; DISRUPTION; ASTROCYTES	Traumatic brain injury (TBI) is induced by immediate physical disruption of brain tissue, and causes death and disability. Studies on experimental TBI animal models show that disruption of the blood-brain barrier (BBB) underlies brain edema and neuroinflammation during the delayed phase of TBI. In neurological disorders, endothelin-1 (ET-1) is involved in BBB dysfunction and brain edema. In this study, the effect of ET antagonists on BBB dysfunction and brain edema were examined in a mouse focal TBI model using lateral fluid percussion injury (FPI). ET-1 and ETB receptors were increased at 2-7 days after FPI, which was accompanied by extravasation of Evans blue (EB) and brain edema. Repeated intracerebroventricular administration of BQ788 (15nmol/day), an ETB antagonist, from 2 days after FPI promoted recovery of EB extravasation and brain edema, while FR 139317, an ETA antagonist, had no effect. Delayed intravenous administration of BQ788 also promoted recovery from FPI-induced EB extravasation and brain edema. While FPI caused decreases in claudin-5, occludin, and zonula occludens-1 proteins, BQ788 reversed FPI-induced reductions of them. Immunohistochemical observation of the cerebrum after FPI showed that ETB receptors are predominantly expressed in glial fibrillary acidic protein (GFAP)-positive astrocytes. BQ788 reduced FPI-induced increases in GFAP-positive astrocytes. GFAP-positive astrocytes produced vascular endothelial growth factor-A (VEGF-A) and matrix metalloproteinase-9 (MMP9). FPI-induced increases in VEGF-A and MMP-9 production were reversed by BQ788. These results suggest that ETB receptor antagonism during the delayed phase of focal TBI promotes recovery of BBB function and reduction of brain edema.	[Michinaga, Shotaro; Kimura, Akimasa; Hatanaka, Shunichi; Minami, Shizuho; Asano, Arisa; Ikushima, Yuki; Matsui, Shingo; Toriyama, Yoshiya; Fujii, Manami] Osaka Ohtani Univ, Lab Pharmacol, Osaka, Japan; [Koyama, Yutaka] Kobe Pharmaceut Univ, Dept Pharmacol, Kobe, Hyogo, Japan		Koyama, Y (corresponding author), 4-19-1 Motoyama Kita, Kobe, Hyogo 6688558, Japan.	koyama-y@kobepharma-u.ac.jp			Japan Society for the Promotion of Science (JSPS)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15K07981, 16K18890]	This work was supported by a Grant-in-Aid for Scientific Research (C; Grant Number: 15K07981) and Grant-in-Aid for Young Scientists (B; Grant Number: 16K18890) from the Japan Society for the Promotion of Science (JSPS). We also thank Rachel James, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.	Albert-Weissenberger C, 2012, J CEREBR BLOOD F MET, V32, P1747, DOI 10.1038/jcbfm.2012.62; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575; Argaw AT, 2012, J CLIN INVEST, V122, P2454, DOI 10.1172/JCI60842; Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106; Asl SZ, 2013, J NEUROSURG, V119, P353, DOI 10.3171/2013.4.JNS121636; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Blixt J, 2015, BRAIN RES, V1611, P18, DOI 10.1016/j.brainres.2015.03.004; Boroujerdi A, 2015, ANGIOGENESIS, V18, P255, DOI 10.1007/s10456-015-9464-7; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Chatfield DA, 2011, NEUROCRIT CARE, V14, P55, DOI 10.1007/s12028-010-9413-7; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Didier N, 2003, J NEUROCHEM, V86, P246, DOI 10.1046/j.1471-4159.2003.01829.x; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Gao WW, 2015, BRAIN RES, V1622, P230, DOI 10.1016/j.brainres.2015.04.035; Gong D, 2011, J TRAUMA, V70, P1480, DOI 10.1097/TA.0b013e31821ac9e1; Hostenbach S, 2016, PROG NEUROBIOL, V144, P88, DOI 10.1016/j.pneurobio.2016.04.009; Kim JY, 2015, NEUROSCIENCE, V304, P355, DOI 10.1016/j.neuroscience.2015.07.065; Kim JE, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0069961, 10.1371/journal.pone.0074458, 10.1371/journal.pone.0051986, 10.1371/journal.pone.0060505]; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Koyama Y, 2011, NEUROSCIENCE, V192, P689, DOI 10.1016/j.neuroscience.2011.05.058; Koyama Y, 1999, GLIA, V26, P268, DOI 10.1002/(SICI)1098-1136(199905)26:3<268::AID-GLIA8>3.0.CO;2-G; Koyama Yutaka, 2013, Biomol Concepts, V4, P335, DOI 10.1515/bmc-2013-0004; Koyama Y, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-51; Koyama Y, 2012, GLIA, V60, P1954, DOI 10.1002/glia.22411; Koyama Y, 2012, J PHARMACOL SCI, V118, P401, DOI 10.1254/jphs.11R13CP; Koyama Y, 2010, J PHARMACOL SCI, V114, P433, DOI 10.1254/jphs.10195FP; Laban KG, 2015, J CEREBR BLOOD F MET, V35, P1085, DOI 10.1038/jcbfm.2015.89; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maier B, 2007, SHOCK, V27, P610, DOI 10.1097/shk.0b013e31802f9eaf; Matsuo Y, 2001, STROKE, V32, P2143, DOI 10.1161/hs0901.94259; Michinaga S, 2015, EUR J NEUROSCI, V42, P2356, DOI 10.1111/ejn.13020; Michinaga S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102009; Min H, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0116-z; Moldes O, 2012, NEUROPHARMACOLOGY, V63, P1279, DOI 10.1016/j.neuropharm.2012.08.019; Morga E, 2000, J NEUROCHEM, V74, P603, DOI 10.1046/j.1471-4159.2000.740603.x; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Palmer J, 2011, PHARMACOL RES, V63, P525, DOI 10.1016/j.phrs.2010.12.008; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Petrov T, 2009, CAN J PHYSIOL PHARM, V87, P379, DOI [10.1139/Y09-022, 10.1139/y09-022]; Ranno E, 2014, NEUROBIOL DIS, V65, P160, DOI 10.1016/j.nbd.2014.01.002; Reinhold AK, 2017, PFLUG ARCH EUR J PHY, V469, P123, DOI 10.1007/s00424-016-1920-8; Reynolds CA, 2011, NEUROL RES, V33, P197, DOI 10.1179/016164111X12881719352499; Reynolds CA, 2011, NEUROL RES, V33, P192, DOI 10.1179/016164111X12881719352453; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Yang Y, 2013, J CEREBR BLOOD F MET, V33, P1104, DOI 10.1038/jcbfm.2013.56; Yang Y, 2011, METHODS MOL BIOL, V762, P333, DOI 10.1007/978-1-61779-185-7_24; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858; Zuccarello M, 1998, STROKE, V29, P1924, DOI 10.1161/01.STR.29.9.1924	64	25	26	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	13					1481	1494		10.1089/neu.2017.5421			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GJ4CQ	WOS:000435328000006	29316834				2022-02-06	
J	Ohri, SS; Bankston, AN; Mullins, SA; Liu, Y; Andres, KR; Beare, JE; Howard, RM; Burke, DA; Riegler, AS; Smith, AE; Hetman, M; Whittemore, SR				Ohri, Sujata Saraswat; Bankston, Andrew N.; Mullins, S. Ashley; Liu, Yu; Andres, Kariena R.; Beare, Jason E.; Howard, Russell M.; Burke, Darlene A.; Riegler, Amberly S.; Smith, Allison E.; Hetman, Michal; Whittemore, Scott R.			Blocking Autophagy in Oligodendrocytes Limits Functional Recovery after Spinal Cord Injury	JOURNAL OF NEUROSCIENCE			English	Article						autophagy; oligodendrocytes; spinal cord injury	ENDOPLASMIC-RETICULUM STRESS; CELL TRANSPLANTATION THERAPY; TRAUMATIC BRAIN-INJURY; CNS MYELINATION; MAMMALIAN TARGET; ER STRESS; TRANSGENIC MICE; STEM-CELLS; NEUROPROTECTION; RAPAMYCIN	Autophagy mechanisms are well documented in neurons after spinal cord injury (SCI), but the direct functional role of autophagy in oligodendrocyte (OL) survival in SCI pathogenesis remains unknown. Autophagy is an evolutionary conserved lysosomal-mediated catabolic pathway that ensures degradation of dysfunctional cellular components to maintain homeostasis in response to various forms of stress, including nutrient deprivation, hypoxia, reactive oxygen species, DNA damage, and endoplasmic reticulum (ER) stress. Using pharmacological gain and loss of function and genetic approaches, we investigated the contribution of autophagy in OL survival and its role in the pathogenesis of thoracic contusive SCI in female mice. Although upregulation of Atg5 (an essential autophagy gene) occurs after SCI, autophagy flux is impaired. Purified myelin fractions of contused 8 d post-SCI samples show enriched protein levels of LC3B, ATG5, and BECLIN 1. Data show that, while the nonspecific drugs rapamycin (activates autophagy) and spautin 1 (blocks autophagy) were pharmacologically active on autophagy in vivo, their administration did not alter locomotor recovery after SCI. To directly analyze the role of autophagy, transgenic mice with conditional deletion of Atg5 in OLs were generated. Analysis of hindlimb locomotion demonstrated a significant reduction in locomotor recovery after SCI that correlated with a greater loss in spared white matter. Immunohistochemical analysis demonstrated that deletion of Atg5 from OLs resulted in decreased autophagic flux and was detrimental to OL function after SCI. Thus, our study provides evidence that autophagy is an essential cytoprotective pathway operating in OLs and is required for hindlimb locomotor recovery after thoracic SCI.	[Ohri, Sujata Saraswat; Bankston, Andrew N.; Mullins, S. Ashley; Liu, Yu; Andres, Kariena R.; Beare, Jason E.; Howard, Russell M.; Burke, Darlene A.; Riegler, Amberly S.; Smith, Allison E.; Hetman, Michal; Whittemore, Scott R.] Univ Louisville, Sch Med, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; [Ohri, Sujata Saraswat; Bankston, Andrew N.; Mullins, S. Ashley; Liu, Yu; Andres, Kariena R.; Howard, Russell M.; Burke, Darlene A.; Riegler, Amberly S.; Smith, Allison E.; Hetman, Michal; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; [Hetman, Michal; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA; [Hetman, Michal; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; [Beare, Jason E.] Univ Louisville, Sch Med, Cardiovasc Innovat Inst, Louisville, KY 40292 USA		Ohri, SS (corresponding author), Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, MDR 616,511 South Floyd St, Louisville, KY 40202 USA.	sujata.saraswat@louisville.edu; swhittemore@louisville.edu	Beare, Jason E/D-2870-2016	Beare, Jason E/0000-0003-3988-1223; Smith, Allison/0000-0001-5659-8062; Andres, Kariena/0000-0002-1201-7657	NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045734]; NIH-NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM10350]; Norton Healthcare; Kentucky Spinal Cord and Head Injury Research Trust; Commonwealth of Kentucky Research Challenge for Excellence Trust Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045734] Funding Source: NIH RePORTER	This work was supported by NIH-NINDS NS045734, NIH-NIGMS GM10350, Norton Healthcare, the Kentucky Spinal Cord and Head Injury Research Trust, and Commonwealth of Kentucky Research Challenge for Excellence Trust Fund to S. R. W. We thank Christine Nunn for surgical assistance and animal care; and Johnny Morehouse for BMS analyses.	Alluin O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111072; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Bareyre FM, 2008, J NEUROL SCI, V265, P63, DOI 10.1016/j.jns.2007.05.004; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bercury KK, 2014, J NEUROSCI, V34, P4466, DOI 10.1523/JNEUROSCI.4314-13.2014; Cai ZB, 2015, NEUROSCI BULL, V31, P452, DOI 10.1007/s12264-015-1540-x; Cao L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.317; Chen HC, 2013, J SURG RES, V179, pE203, DOI 10.1016/j.jss.2012.02.023; Coutts M, 2008, EXP NEUROL, V209, P368, DOI 10.1016/j.expneurol.2007.09.002; D'Antonio M, 2009, J NEUROSCI RES, V87, P3241, DOI 10.1002/jnr.22066; Dietz V, 2014, BRAIN, V137, P654, DOI 10.1093/brain/awt262; Dincman TA, 2012, J NEUROSCI METH, V209, P219, DOI 10.1016/j.jneumeth.2012.06.017; Doerflinger NH, 2003, GENESIS, V35, P63, DOI 10.1002/gene.10154; Emery B, 2010, CURR OPIN NEUROBIOL, V20, P601, DOI 10.1016/j.conb.2010.05.005; Enzmann GU, 2006, J NEUROTRAUM, V23, P479, DOI 10.1089/neu.2006.23.479; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014; Fawcett JW, 2006, ADV EXP MED BIOL, V557, P11; Fuss B, 2001, MOL CELL NEUROSCI, V18, P221, DOI 10.1006/mcne.2001.1011; Gomez-Sanchez JA, 2015, J CELL BIOL, V210, P153, DOI 10.1083/jcb.201503019; Grummisch JA, 2016, MOL CELL NEUROSCI, V74, P25, DOI 10.1016/j.mcn.2016.03.005; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; He Z, 2008, CELL DEATH DIFFER, V20, P1415; Hesp ZC, 2015, J NEUROSCI, V35, P1274, DOI 10.1523/JNEUROSCI.2568-14.2015; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hu LY, 2010, NEUROSCIENCE, V169, P1046, DOI 10.1016/j.neuroscience.2010.05.046; Jang SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116624; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Kanno H, 2009, NEUROBIOL DIS, V33, P143, DOI 10.1016/j.nbd.2008.09.009; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kulbatski I, 2008, PROG HISTOCHEM CYTO, V43, P123, DOI 10.1016/j.proghi.2008.04.001; Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Larocca JN, 2006, CURR PROTOC CELL BIO, V33; Lebrun-Julien F, 2014, J NEUROSCI, V34, P8432, DOI 10.1523/JNEUROSCI.1105-14.2014; Lin WS, 2009, NAT NEUROSCI, V12, P379, DOI 10.1038/nn.2273; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Liu S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.527; Lv XH, 2014, SCI REP-UK, V4, DOI 10.1038/srep06010; Magnuson DSK, 2005, J NEUROTRAUM, V22, P529, DOI 10.1089/neu.2005.22.529; Mallon BS, 2002, J NEUROSCI, V22, P876, DOI 10.1523/JNEUROSCI.22-03-00876.2002; Marino G, 2011, CURR OPIN CELL BIOL, V23, P198, DOI 10.1016/j.ceb.2010.10.001; Messer JS, 2017, CELL MOL LIFE SCI, V74, P1281, DOI 10.1007/s00018-016-2403-y; Miller RH, 2002, PROG NEUROBIOL, V67, P451, DOI 10.1016/S0301-0082(02)00058-8; Narayanan SP, 2009, J NEUROSCI, V29, P6860, DOI 10.1523/JNEUROSCI.0232-09.2009; Ohri SS, 2013, NEUROBIOL DIS, V58, P29, DOI 10.1016/j.nbd.2013.04.021; Ohri SS, 2011, GLIA, V59, P1489, DOI 10.1002/glia.21191; Penas C, 2007, J NEUROCHEM, V102, P1242, DOI 10.1111/j.1471-4159.2007.04671.x; Pengo N, 2013, NAT IMMUNOL, V14, P298, DOI 10.1038/ni.2524; Pla A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153097; Radad K, 2015, EXPERT REV NEUROTHER, V15, P195, DOI 10.1586/14737175.2015.1002087; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Shen CZ, 2016, EXP THER MED, V12, P2803, DOI 10.3892/etm.2016.3736; Shi XD, 2017, J CEREBR BLOOD F MET, V37, P1447, DOI 10.1177/0271678X16656201; Simons M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a020479; Su P, 2016, NEUROSCIENCE, V319, P155, DOI 10.1016/j.neuroscience.2016.01.035; Tanabe F, 2011, AUTOPHAGY, V7, P1462, DOI 10.4161/auto.7.12.17892; Tang PF, 2014, MOL NEUROBIOL, V49, P276, DOI 10.1007/s12035-013-8518-3; Tyler WA, 2009, J NEUROSCI, V29, P6367, DOI 10.1523/JNEUROSCI.0234-09.2009; Valenzuela V, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.8; Vazquez P, 2012, AUTOPHAGY, V8, P187, DOI 10.4161/auto.8.2.18535; Wahl SE, 2014, J NEUROSCI, V34, P4453, DOI 10.1523/JNEUROSCI.4311-13.2014; Walker CL, 2012, PLOS ONE, V7, P315, DOI 10.1371/journal.pone.0030012; Wang SK, 2014, EMBO REP, V15, P1053, DOI 10.15252/embr.201338343; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; WIGHT PA, 1993, J CELL BIOL, V123, P443, DOI 10.1083/jcb.123.2.443; Williams A, 2006, CURR TOP DEV BIOL, V76, P89, DOI 10.1016/S0070-2153(06)76003-3; Yin Y, 2017, AGEING RES REV, V34, P3, DOI 10.1016/j.arr.2016.08.008; Yoon C, 2012, ADV EXP MED BIOL, V760, P1; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Zhang XJ, 2013, ACTA PHARMACOL SIN, V34, P595, DOI 10.1038/aps.2012.184; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051	79	25	25	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 27	2018	38	26					5900	5912		10.1523/JNEUROSCI.0679-17.2018			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GM7MO	WOS:000438372400008	29793971	Bronze, Green Published			2022-02-06	
J	Lepage, C; de Pierrefeu, A; Koerte, IK; Coleman, MJ; Pasternak, O; Grant, G; Marx, CE; Morey, RA; Flashman, LA; George, MS; McAllister, TW; Andaluz, N; Shutter, L; Coimbra, R; Zafonte, RD; Stein, MB; Shenton, ME; Bouix, S				Lepage, Christian; de Pierrefeu, Amicie; Koerte, Inga K.; Coleman, Michael J.; Pasternak, Ofer; Grant, Gerald; Marx, Christine E.; Morey, Rajendra A.; Flashman, Laura A.; George, Mark S.; McAllister, Thomas W.; Andaluz, Norberto; Shutter, Lori; Coimbra, Raul; Zafonte, Ross D.; Stein, Murray B.; Shenton, Martha E.; Bouix, Sylvain			White matter abnormalities in mild traumatic brain injury with and without post-traumatic stress disorder: a subject-specific diffusion tensor imaging study	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury; Post-traumatic stress disorder; Diffusion tensor imaging; Fractional anisotropy; Magnetic resonance imaging	CONCUSSION SYMPTOMS QUESTIONNAIRE; POSTCONCUSSION SYMPTOMS; AXONAL INJURY; HEAD-INJURY; VETERANS; VALIDITY; METAANALYSIS; DEPRESSION; ANISOTROPY; RELIABILITY	Mild traumatic brain injuries (mTBIs) are often associated with posttraumatic stress disorder (PTSD). In cases of chronic mTBI, accurate diagnosis can be challenging due to the overlapping symptoms this condition shares with PTSD. Furthermore, mTBIs are heterogeneous and not easily observed using conventional neuroimaging tools, despite the fact that diffuse axonal injuries are the most common injury. Diffusion tensor imaging (DTI) is sensitive to diffuse axonal injuries and is thus more likely to detect mTBIs, especially when analyses account for the inter-individual variability of these injuries. Using a subject-specific approach, we compared fractional anisotropy (FA) abnormalities between groups with a history of mTBI (n = 35), comorbid mTBI and PTSD (mTBI + PTSD; n = 22), and healthy controls (n = 37). We compared all three groups on the number of abnormal FA clusters derived from subject-specific injury profiles (i.e., individual z-score maps) along a common white matter skeleton. The mTBI + PTSD group evinced a greater number of abnormally low FA clusters relative to both the healthy controls and the mTBI group without PTSD (p < .05). Across the groups with a history of mTBI, increased numbers of abnormally low FA clusters were significantly associated with PTSD symptom severity, depression, post-concussion symptoms, and reduced information processing speed (p < .05). These findings highlight the utility of subject-specific microstructural analyses when searching for mTBI-related brain abnormalities, particularly in patients with PTSD. This study also suggests that patients with a history of mTBI and comorbid PTSD, relative to those without PTSD, are at increased risk of FA abnormalities.	[Lepage, Christian; de Pierrefeu, Amicie; Koerte, Inga K.; Coleman, Michael J.; Pasternak, Ofer; Shenton, Martha E.; Bouix, Sylvain] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA; [Lepage, Christian] Univ Ottawa, Dept Psychol, Ottawa, ON, Canada; [de Pierrefeu, Amicie] Ecole Polytech Fed Lausanne, Sch Life Sci, Lausanne, Switzerland; [Koerte, Inga K.] Ludwig Maximilians Univ Munchen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Grant, Gerald] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA; [Grant, Gerald] Duke Univ, Durham, NC USA; [Marx, Christine E.; Morey, Rajendra A.] Duke Univ, Med Ctr, Durham, NC USA; [Marx, Christine E.; Morey, Rajendra A.] VA Mid Atlantic MIRECC, Durham, NC USA; [Flashman, Laura A.; McAllister, Thomas W.] Geisel Sch Med Dartmouth, Hanover, NH USA; [George, Mark S.] Med Univ South Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Andaluz, Norberto] Univ Cincinnati, Coll Med, Dept Neurosurg, Mayfield Clin,Neurotrauma Ctr,UC Neurosci Inst, Cincinnati, OH 45267 USA; [Shutter, Lori] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Shutter, Lori] Univ Cincinnati, Pittsburgh, PA USA; [Coimbra, Raul] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Zafonte, Ross D.] Brigham & Womens Hosp, Massachusetts Gen Hosp, Spaulding Rehabil Hosp, 75 Francis St, Boston, MA 02115 USA; [Zafonte, Ross D.; Shenton, Martha E.] Harvard Med Sch, Boston, MA USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; [Shenton, Martha E.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA		Bouix, S (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	sylvain@bwh.harvard.edu	Coimbra, Raul/AAP-3019-2020; Koerte, Inga Katharina/AAW-3031-2021; Shenton, Martha/V-8780-2019; Morey, Rajendra A/P-3079-2018; Shutter, Lori A/G-2957-2013	Coimbra, Raul/0000-0002-3759-6851; Morey, Rajendra A/0000-0002-6517-6969; George, Mark/0000-0003-1767-1815; Lepage, Chris/0000-0001-5719-0982; Shutter, Lori/0000-0002-1390-0628	Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral Award;  [W81XWH-08-2-0159]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD090641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015902] Funding Source: NIH RePORTER	CL was supported by the Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral Award, which was awarded in support of his PhD in clinical psychology from the University of Ottawa. The authors would like to acknowledge the following grants that, in part, supported this work: W81XWH-08-2-0159 (Imaging core PI: Shenton, Consortium PI: Stein, Site PIs: George, Grant, Marx, McAllister, and Zafonte).	Aoki Y, 2016, NEUROSCI BIOBEHAV R, V66, P119, DOI 10.1016/j.neubiorev.2016.04.021; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Army U.S., 1944, ARMY INDIVIDUAL TEST; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Delic J, 2016, RADIOLOGY, V279, P859, DOI 10.1148/radiol.2015151388; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Faul M, 2010, TRAUMATIC BRAIN INJU; Ginzburg K, 2010, J AFFECT DISORDERS, V123, P249, DOI 10.1016/j.jad.2009.08.006; Helmer K. G., 2016, SPIE MED IMAGING; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOLM S, 1979, SCAND J STAT, V6, P65; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; Mirzaalian H, 2016, NEUROIMAGE, V135, P311, DOI 10.1016/j.neuroimage.2016.04.041; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mounce LTA, 2013, J HEAD TRAUMA REHAB, V28, P397, DOI 10.1097/HTR.0b013e318252dd75; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Rytwinski NK, 2013, J TRAUMA STRESS, V26, P299, DOI 10.1002/jts.21814; Sartory G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058150; SHEEHAN DV, 1998, J CLIN PSYCHIAT S20, V59, P1; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tsourtos G, 2002, PSYCHOL MED, V32, P259, DOI 10.1017/S0033291701005001; Watts R, 2014, RADIOLOGY, V272, P217, DOI 10.1148/radiol.14131856; Wechsler D., 1997, WECHSLER MEMORY SCAL; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Wrocklage KM, 2016, J INT NEUROPSYCH SOC, V22, P399, DOI 10.1017/S1355617716000059	55	25	26	1	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2018	12	3					870	881		10.1007/s11682-017-9744-5			12	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GI6PB	WOS:000434491400023	28676987	Green Accepted			2022-02-06	
J	Meconi, A; Wortman, RC; Wright, DK; Neale, KJ; Clarkson, M; Shultz, SR; Christie, BR				Meconi, Alicia; Wortman, Ryan C.; Wright, David K.; Neale, Katie J.; Clarkson, Melissa; Shultz, Sandy R.; Christie, Brian R.			Repeated mild traumatic brain injury can cause acute neurologic impairment without overt structural damage in juvenile rats	PLOS ONE			English	Article							SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; CLOSED-HEAD-INJURY; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; HYPERPHOSPHORYLATED TAU; POSTCONCUSSION SYNDROME; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; OXIDATIVE STRESS	Repeated concussion is becoming increasingly recognized as a serious public health concern around the world. Moreover, there is a greater awareness amongst health professionals of the potential for repeated pediatric concussions to detrimentally alter the structure and function of the developing brain. To better study this issue, we developed an awake closed head injury (ACHI) model that enabled repeated concussions to be performed reliably and reproducibly in juvenile rats. A neurological assessment protocol (NAP) score was generated immediately after each ACHI to help quantify the cumulative effects of repeated injury on level of consciousness, and basic motor and reflexive capacity. Here we show that we can produce a repeated ACHI (4 impacts in two days) in both male and female juvenile rats without significant mortality or pain. We show that both single and repeated injuries produce acute neurological deficits resembling clinical concussion symptoms that can be quantified using the NAP score. Behavioural analyses indicate repeated ACHI acutely impaired spatial memory in the Barnes maze, and an interesting sex effect was revealed as memory impairment correlated moderately with poorer NAP score performance in a subset of females. These cognitive impairments occurred in the absence of motor impairments on the Rotarod, or emotional changes in the open field and elevated plus mazes. Cresyl violet histology and structural magnetic resonance imaging (MRI) indicated that repeated ACHI did not produce significant structural damage. MRI also confirmed there was no volumetric loss in the cortex, hippocampus, or corpus callosum of animals at 1 or 7 days post-ACHI. Together these data indicate that the ACHI model can provide a reliable, high throughput means to study the effects of concussions in juvenile rats.	[Meconi, Alicia; Wortman, Ryan C.; Neale, Katie J.; Clarkson, Melissa; Shultz, Sandy R.; Christie, Brian R.] Univ Victoria, Div Med Sci, Victoria, BC, Canada; [Wright, David K.; Shultz, Sandy R.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Wright, David K.; Shultz, Sandy R.] Monash Univ, Dept Neurosci, Melbourne, Vic, Australia; [Shultz, Sandy R.] Univ Melbourne, Dept Med, Parkville, Vic, Australia; [Christie, Brian R.] Univ British Columbia, Ctr Brain Hlth, Vancouver, BC, Canada; [Christie, Brian R.] Univ British Columbia, Program Neurosci, Vancouver, BC, Canada; [Christie, Brian R.] Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC, Canada		Christie, BR (corresponding author), Univ Victoria, Div Med Sci, Victoria, BC, Canada.; Christie, BR (corresponding author), Univ British Columbia, Ctr Brain Hlth, Vancouver, BC, Canada.; Christie, BR (corresponding author), Univ British Columbia, Program Neurosci, Vancouver, BC, Canada.; Christie, BR (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC, Canada.	brain64@uvic.ca	Christie, Brian Ross/AAF-3766-2019	Christie, Brian Ross/0000-0002-6830-0160	NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); CFICanada Foundation for Innovation; Australian NHMRCNational Health and Medical Research Council of Australia; CIHR/NSERC graduate fellowships	This development of this model was supported by funding from NSERC and CFI to BRC. MRI investigations by SS were supported by the Australian NHMRC. AM, RCW, and MC were supported by CIHR/NSERC graduate fellowships.	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brocardo PS, 2012, NEUROPHARMACOLOGY, V62, P1607, DOI 10.1016/j.neuropharm.2011.10.006; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Clough M, 2018, J NEUROTRAUM, V35, P730, DOI 10.1089/neu.2017.5204; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Dimou S, 2014, J NEUROTRAUM, V31, P413, DOI 10.1089/neu.2013.3050; Ding JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063850; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Erlanger DM, 2015, BRAIN INJURY, V29, P171, DOI 10.3109/02699052.2014.965211; Faul M, 2010, TRAUMATIC BRAIN INJU; Flower O, 2012, EMERG MED INT, V2012, DOI 10.1155/2012/637171; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gibb R, 1998, J NEUROSCI METH, V79, P1, DOI 10.1016/S0165-0270(97)00163-5; Gilliland J, EPIDEMIOLOGIC PROFIL, DOI [10.1097/TA.0b013e3182aafdf5, DOI 10.1097/TA.0B013E3182AAFDF5]; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hawley DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030222; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; Hsieh TH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178186; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; List J, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00228; Luo YW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11458-9; Marshall Stephen W, 2015, Inj Epidemiol, V2, P13; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2017, BRIT J SPORT MED, V47; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Nelson LD, 2016, J ATHL TRAINING, V51, P142, DOI 10.4085/1062-6050-51.4.04; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Petraglia Anthony L, 2014, Neurosurgery, V75 Suppl 4, pS34, DOI 10.1227/NEU.0000000000000472; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Ricciardi MC, 2017, J NEUROTRAUM, V34, P23, DOI 10.1089/neu.2015.4338; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rosenfeld CS, 2014, JOVE-J VIS EXP, DOI 10.3791/51194; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; TEASDALE G, 1974, LANCET, V2, P81; Tkachenko N, 2016, PEDIATR NEUROL, V57, P46, DOI 10.1016/j.pediatrneurol.2015.12.019; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; White ER, 2017, J NEUROTRAUM, V34, P1111, DOI 10.1089/neu.2016.4638; Wilde EA, 2015, BRAIN IMAGING BEHAV, V9, P367, DOI 10.1007/s11682-015-9444-y; Wright AD, 2017, BRIT J SPORT MED, V51, DOI [10.1136/bjsports-2016-097270.96, DOI 10.1136/BJSPORTS-2016-097270.96]; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Xiong KL, 2014, BRAIN IMAGING BEHAV, V8, P487, DOI 10.1007/s11682-013-9288-2; Xiong Y, 2013, ANIMAL MODELS TRAUMA, V18, P1199; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	92	25	25	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2018	13	5							e0197187	10.1371/journal.pone.0197187			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF1VY	WOS:000431724900053	29738554	Green Published, gold			2022-02-06	
J	Reglodi, D; Tamas, A; Jungling, A; Vaczy, A; Rivnyak, A; Fulop, BD; Szabo, E; Lubics, A; Atlasz, T				Reglodi, D.; Tamas, A.; Jungling, A.; Vaczy, A.; Rivnyak, A.; Fulop, B. D.; Szabo, E.; Lubics, A.; Atlasz, T.			Protective effects of pituitary adenylate cyclase activating polypeptide against neurotoxic agents	NEUROTOXICOLOGY			English	Article							CEREBELLAR GRANULE NEURONS; RAT CORTICAL-NEURONS; MONOSODIUM GLUTAMATE TREATMENT; STRESS-INDUCED APOPTOSIS; INDUCED RETINAL DEGENERATION; NMDA-INDUCED EXCITOTOXICITY; SH-SY5Y CELLS IMPLICATION; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; PARKINSONS-DISEASE	Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide highly expressed in the central and peripheral nervous system, where it exerts several neuromodulatory functions and is an important trophic and protective factor. PACAP has been shown to activate several protective pathways, mainly through its specific PAC1 receptor and protein kinase A, C and MAP kinases downstream. It has been shown to have very potent neuroprotective actions against different neurotoxic agents both in vitro and in vivo. The aim of the present review is to provide an overview on the neurotoxic injuries against which PACAP exerts protection, and to give an insight into its protective mechanism. We give a summary of the neuroprotective effects against the most commonly used neurotoxic agents, such as 6-OHDA, MPTP, glutamate and some less well-known neurotoxic compounds. Also endogenous PACAP has neuroprotective effects, known from studies in PACAP knockout mice or from blocking endogenous effects by antagonists. Altogether, the vast amount of data for the neuroprotective effects of PACAP give a firm background for its endogenous role as part of the neuroprotective machinery and its possible future therapeutic use as a neuroprotective factor. (C) 2018 Elsevier B.V. All rights reserved.	[Reglodi, D.; Tamas, A.; Jungling, A.; Vaczy, A.; Rivnyak, A.; Fulop, B. D.; Szabo, E.; Lubics, A.; Atlasz, T.] Univ Pecs, Med Sch, MTA PTE PACAP Res Grp, Dept Anat, Pecs, Hungary; [Atlasz, T.] Univ Pecs, Szentagothai Res Ctr, Dept Sportbiol, Pecs, Hungary		Reglodi, D (corresponding author), Univ Pecs, Med Sch, Dept Anat, Szigeti U 12, H-7624 Pecs, Hungary.	dora.reglodi@aok.pte.hu			NAP [2017-1.2.1-NKP-2017-00002]; Bolyai ScholarshipHungarian Academy of Sciences; MTA-TKI [14016, EFOP-3.6.3-VEKOP-16-15 2017-00008, UNKP-16-4]; Centre for neuroscience, PTE AOK Research Grant [KA-2017-15, NKFIH119759]; PEPSYS [GINOP-2.3.2-15-2016-00050]	NAP 2017-1.2.1-NKP-2017-00002, Bolyai Scholarship, GINOP-2.3.2-15-2016-00050 "PEPSYS", MTA-TKI 14016, EFOP-3.6.3-VEKOP-16-15 2017-00008, UNKP-16-4. Centre for neuroscience, PTE AOK Research Grant KA-2017-15, NKFIH119759	Amato R, 2016, INVEST OPHTH VIS SCI, V57, P3066, DOI 10.1167/iovs.16-19285; ARIMURA A, 1994, ANN NY ACAD SCI, V739, P228, DOI 10.1111/j.1749-6632.1994.tb19825.x; Atlasz T., 2012, PITUITARY ADENYLATE; Atlasz T, 2016, PITUITARY ADENYLATE, V11, P501; Atlasz T, 2006, ANN NY ACAD SCI, V1070, P143, DOI 10.1196/annals.1317.002; Atlasz T, 2008, J MOL NEUROSCI, V36, P97, DOI 10.1007/s12031-008-9059-5; Atlasz T, 2009, ANN NY ACAD SCI, V1163, P348, DOI 10.1111/j.1749-6632.2008.03650.x; Aubert N, 2008, NEUROBIOL DIS, V32, P66, DOI 10.1016/j.nbd.2008.06.014; Babai N, 2005, NEUROTOX RES, V8, P227, DOI 10.1007/BF03033976; Babai N, 2006, ANN NY ACAD SCI, V1070, P149, DOI 10.1196/annals.1317.003; Botia B, 2007, PEPTIDES, V28, P1746, DOI 10.1016/j.peptides.2007.04.013; Botia B, 2011, NEUROTOX RES, V19, P423, DOI 10.1007/s12640-010-9186-y; Botia B, 2008, J MOL NEUROSCI, V36, P61, DOI 10.1007/s12031-008-9075-5; Brenneman DE, 2002, NEUROPEPTIDES, V36, P271, DOI 10.1016/S0143-4179(02)00045-8; Brifault C, 2016, PITUITARY ADENYLATE, V11, P583; Brown D, 2014, NEUROTOX RES, V26, P230, DOI 10.1007/s12640-014-9468-x; Brown D, 2013, J MOL NEUROSCI, V50, P600, DOI 10.1007/s12031-013-0015-7; Castel H, 2006, ANN NY ACAD SCI, V1070, P173, DOI 10.1196/annals.1317.008; Cheng HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108090; Chtourou Y, 2015, J MOL NEUROSCI, V56, P349, DOI 10.1007/s12031-015-0547-0; Chung CY, 2005, HUM MOL GENET, V14, P1709, DOI 10.1093/hmg/ddi178; COLLINS MA, 1975, LIFE SCI, V16, P585; D'Amico AG, 2017, PEPTIDES, V97, P64, DOI 10.1016/j.peptides.2017.09.014; D'Amico AG, 2015, J MOL NEUROSCI, V57, P501, DOI 10.1007/s12031-015-0621-7; Deguil J, 2007, J NEUROSCI RES, V85, P2017, DOI 10.1002/jnr.21318; Deguil J, 2010, NEUROTOX RES, V17, P142, DOI 10.1007/s12640-009-9091-4; Delgado M, 2003, ANN NY ACAD SCI, V992, P141, DOI 10.1111/j.1749-6632.2003.tb03145.x; Dickson L, 2009, PHARMACOL THERAPEUT, V121, P294, DOI 10.1016/j.pharmthera.2008.11.006; Douiri S, 2016, J NEUROCHEM, V137, P913, DOI 10.1111/jnc.13614; Elmann A, 2017, J MOL NEUROSCI, V62, P99, DOI 10.1007/s12031-017-0916-y; Fabian E, 2012, J MOL NEUROSCI, V48, P493, DOI 10.1007/s12031-012-9812-7; Feher M, 2018, NEUROTOX RES, V33, P702, DOI 10.1007/s12640-017-9841-7; Ferencz A, 2009, J MOL NEUROSCI, V37, P168, DOI 10.1007/s12031-008-9132-0; Frechilla D, 2001, NEUROREPORT, V12, P919, DOI 10.1097/00001756-200104170-00011; Fulop B. D., 2016, PITUITARY ADENYLATE, P529; Gasz B, 2006, ANN NY ACAD SCI, V1070, P293, DOI 10.1196/annals.1317.029; Grumolato L, 2003, ENDOCRINOLOGY, V144, P2368, DOI 10.1210/en.2002-0106; Gui Lan-Run, 2003, Shengli Xuebao, V55, P42; Guillot TS, 2008, NEUROPEPTIDES, V42, P423, DOI 10.1016/j.npep.2008.04.003; Han PC, 2014, NEUROBIOL AGING, V35, P2064, DOI 10.1016/j.neurobiolaging.2014.03.022; Hartfield PJ, 1998, J NEUROCHEM, V71, P161; Horvath G., 2017, INT J PEPT RES THER, V65, P106; Horvath G, 2010, NEUROSCI LETT, V484, P148, DOI 10.1016/j.neulet.2010.08.039; Huang H, 2016, NEUROTOX RES, V30, P185, DOI 10.1007/s12640-016-9615-7; Illes A, 2017, NEUROPEPTIDES, V65, P106, DOI 10.1016/j.npep.2017.07.002; Ito Y, 1999, NEUROSCI RES, V35, P321, DOI 10.1016/S0168-0102(99)00097-8; Kasica N, 2016, NEUROTOX RES, V30, P633, DOI 10.1007/s12640-016-9659-8; Kiss P, 2006, ANN NY ACAD SCI, V1070, P365, DOI 10.1196/annals.1317.046; Kiss P, 2005, NEUROTOX RES, V8, P235, DOI 10.1007/BF03033977; Kong LY, 1999, NEUROSCIENCE, V91, P493, DOI 10.1016/S0306-4522(98)00606-X; Kraft AD, 2016, NEUROTOX RES, V30, P53, DOI 10.1007/s12640-016-9606-8; Kurnik-Lucka M, 2018, NEUROTOX RES, V33, P485, DOI 10.1007/s12640-017-9818-6; Lacaille H, 2017, MOL NEUROBIOL, V54, P7534, DOI 10.1007/s12035-016-0204-9; Lakk M, 2015, NEUROCHEM RES, V40, P1402, DOI 10.1007/s11064-015-1607-0; Lambuk L, 2017, NEUROTOX RES, V31, P31, DOI 10.1007/s12640-016-9658-9; Lamine A, 2016, NEUROPHARMACOLOGY, V108, P440, DOI 10.1016/j.neuropharm.2015.05.014; Lamine-Ajili A, 2016, BBA-MOL BASIS DIS, V1862, P688, DOI 10.1016/j.bbadis.2016.01.005; Liu GJ, 1998, BRAIN RES, V791, P290, DOI 10.1016/S0006-8993(97)01567-9; Castaneda-Cabral JL, 2017, J MOL NEUROSCI, V63, P17, DOI 10.1007/s12031-017-0952-7; Maasz G, 2017, DIS MODEL MECH, V10, P127, DOI 10.1242/dmm.027185; Manavalan S, 2017, NEUROTOX RES, V32, P8, DOI 10.1007/s12640-017-9727-8; Manecka DL, 2016, PITUITARY ADENYLATE, P549; Mansouri S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170496; Mansouri S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156867; Mansouri S, 2012, J NEUROSCI RES, V90, P759, DOI 10.1002/jnr.22803; Masmoudi-Kouki O, 2011, J NEUROCHEM, V117, P403, DOI 10.1111/j.1471-4159.2011.07185.x; Maugeri G, 2017, J CELL PHYSIOL, V232, P1209, DOI 10.1002/jcp.25616; May V, 2010, J BIOL CHEM, V285, P9749, DOI 10.1074/jbc.M109.043117; Mei YA, 2004, EUR J NEUROSCI, V19, P1446, DOI 10.1111/j.1460-9568.2004.03227.x; Mester L, 2011, J MOL NEUROSCI, V43, P35, DOI 10.1007/s12031-010-9427-9; Miyamoto K, 2014, J MOL NEUROSCI, V54, P370, DOI 10.1007/s12031-014-0309-4; Moody TW, 2016, CURR OPIN ENDOCRINOL, V23, P38, DOI 10.1097/MED.0000000000000218; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Morio H, 1996, ANN NY ACAD SCI, V805, P476; Morita Y, 2006, ANN NY ACAD SCI, V1070, P450, DOI 10.1196/annals.1317.060; Nakamachi T, 2011, CURR PHARM DESIGN, V17, P973, DOI 10.2174/138161211795589346; Nemeth A, 2014, NEUROTOX RES, V25, P57, DOI 10.1007/s12640-013-9428-x; Ohtaki H, 2010, J MOL NEUROSCI, V42, P397, DOI 10.1007/s12031-010-9350-0; Onoue S, 2002, PEPTIDES, V23, P1471, DOI 10.1016/S0196-9781(02)00085-2; Onoue S, 2002, FEBS LETT, V522, P65, DOI 10.1016/S0014-5793(02)02886-7; Pathakoti K, 2017, NEUROTOX RES, V31, P521, DOI 10.1007/s12640-016-9697-2; Pecoraro V, 2017, NEUROSCIENCE, V340, P551, DOI 10.1016/j.neuroscience.2016.10.061; Racz B, 2007, GEN COMP ENDOCR, V153, P115, DOI 10.1016/j.ygcen.2006.12.006; Racz B., 2007, EFFECTS PITUITARY AD; Racz B, 2006, REGUL PEPTIDES, V137, P20, DOI 10.1016/j.regpep.2006.02.009; Racz B, 2006, ANN NY ACAD SCI, V1070, P507, DOI 10.1196/annals.1317.070; Racz B, 2010, REGUL PEPTIDES, V160, P91, DOI 10.1016/j.regpep.2009.12.003; Rat D, 2011, FASEB J, V25, P3208, DOI 10.1096/fj.10-180133; Reglodi D, 2006, ANN NY ACAD SCI, V1070, P518, DOI 10.1196/annals.1317.072; Reglodi D, 2006, NEUROPEPTIDES, V40, P265, DOI 10.1016/j.npep.2006.06.001; Reglodi D, 2004, REGUL PEPTIDES, V123, P85, DOI 10.1016/j.regpep.2004.05.016; Reglodi D, 2004, REGUL PEPTIDES, V123, P51, DOI 10.1016/j.regpep.2004.05.012; Reglodi D, 2004, BEHAV BRAIN RES, V151, P303, DOI 10.1016/j.bbr.2003.09.007; Reglodi D, 2011, CURR PHARM DESIGN, V17, P962, DOI 10.2174/138161211795589355; Reglodi D, 2003, BEHAV BRAIN RES, V140, P131, DOI 10.1016/S0166-4328(02)00289-9; Reglodi D., 2016, PITUITARY ADENYLATE, V1st; Reglodi D, 2017, PROG NEUROBIOL, V155, P120, DOI 10.1016/j.pneurobio.2015.10.004; Rozzi SJ, 2017, NEUROTOX RES, V32, P723, DOI 10.1007/s12640-017-9776-z; Rozzi SJ, 2014, J MOL NEUROSCI, V54, P485, DOI 10.1007/s12031-014-0273-z; Said SI, 1998, ANN NY ACAD SCI, V865, P226, DOI 10.1111/j.1749-6632.1998.tb11182.x; Sanchez A, 2009, REGUL PEPTIDES, V152, P33, DOI 10.1016/j.regpep.2008.07.004; Sanchez A, 2008, NEUROSCI LETT, V448, P52, DOI 10.1016/j.neulet.2008.10.021; Segura-Aguilar J, 2015, NEUROTOX RES, V27, P328, DOI 10.1007/s12640-015-9519-y; Seki T, 2006, ANN NY ACAD SCI, V1070, P531, DOI 10.1196/annals.1317.074; Shieh PC, 2008, NEUROSCI LETT, V434, P1, DOI 10.1016/j.neulet.2007.12.032; Shintani N, 2005, REGUL PEPTIDES, V126, P123, DOI 10.1016/j.regpep.2004.08.014; Shintani N, 2007, YAKUGAKU ZASSHI, V127, P451, DOI 10.1248/yakushi.127.451; Shioda S, 2006, ANN NY ACAD SCI, V1070, P550, DOI 10.1196/annals.1317.080; Silveira MS, 2002, J BIOL CHEM, V277, P16075, DOI 10.1074/jbc.M110106200; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Szabadfi K, 2016, NEUROTOX RES, V29, P432, DOI 10.1007/s12640-015-9593-1; Szabadfi K, 2014, NEUROCHEM INT, V64, P84, DOI 10.1016/j.neuint.2013.11.005; Szabadfi K, 2012, CELL TISSUE RES, V348, P37, DOI 10.1007/s00441-012-1349-0; Szabadfi K, 2009, BRAIN RES, V1259, P107, DOI 10.1016/j.brainres.2009.01.004; Tabuchi A, 2003, J NEUROSCI RES, V71, P504, DOI 10.1002/jnr.10505; Takei N, 1998, J NEUROSCI RES, V54, P698, DOI 10.1002/(SICI)1097-4547(19981201)54:5<698::AID-JNR15>3.0.CO;2-5; Tamas A, 2006, ANN NY ACAD SCI, V1070, P570, DOI 10.1196/annals.1317.083; Tamas A, 2004, NEUROSCI LETT, V372, P110, DOI 10.1016/j.neulet.2004.09.021; Tani K, 2016, NEUROTOX RES, V29, P35, DOI 10.1007/s12640-015-9563-7; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Teuchner B, 2011, ACTA OPHTHALMOL, V89, P670, DOI 10.1111/j.1755-3768.2009.01828.x; Tomimatsu N, 2008, J NEUROCHEM, V107, P628, DOI 10.1111/j.1471-4159.2008.05638.x; Varga B, 2011, J MOL NEUROSCI, V43, P44, DOI 10.1007/s12031-010-9406-1; Vaudry D, 2005, PEPTIDES, V26, P2518, DOI 10.1016/j.peptides.2005.05.015; Vaudry D, 2004, REGUL PEPTIDES, V123, P43, DOI 10.1016/j.regpep.2004.05.025; Vaudry D, 2003, J NEUROSCI RES, V72, P303, DOI 10.1002/jnr.10530; Vaudry D, 2002, EUR J NEUROSCI, V15, P1451, DOI 10.1046/j.1460-9568.2002.01981.x; Vaudry D, 2002, P NATL ACAD SCI USA, V99, P6398, DOI 10.1073/pnas.082112699; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Wada Y, 2013, J MOL NEUROSCI, V51, P493, DOI 10.1007/s12031-013-0017-5; Wang G, 2005, FEBS LETT, V579, P4005, DOI 10.1016/j.febslet.2005.06.013; Wang G, 2008, NEUROPEPTIDES, V42, P267, DOI 10.1016/j.npep.2008.03.002; Waschek JA, 2002, DEV NEUROSCI-BASEL, V24, P14, DOI 10.1159/000064942; Watanabe J, 2016, PITUITARY ADENYLATE, P65, DOI DOI 10.1007/978-3-319-35135-3_6; Watson MB, 2013, NEUROSCIENCE, V240, P277, DOI 10.1016/j.neuroscience.2013.03.002; Webb IC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076365; Wilhelm I, 2014, J MOL NEUROSCI, V54, P469, DOI 10.1007/s12031-014-0260-4; Yang SJ, 2017, NEUROTOX RES, V32, P107, DOI 10.1007/s12640-017-9717-x; Yang SF, 2006, J PHARMACOL EXP THER, V319, P595, DOI 10.1124/jpet.106.102236; Yu JT, 2015, NEUROTOX RES, V28, P43, DOI 10.1007/s12640-015-9531-2; ZHANG D, 1995, NEUROSCIENCE, V67, P177, DOI 10.1016/0306-4522(94)00627-H; Zuo DY, 2016, NEUROTOX RES, V30, P159, DOI 10.1007/s12640-016-9611-y	143	25	25	1	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	MAY	2018	66						185	194		10.1016/j.neuro.2018.03.010			10	Neurosciences; Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	GG2DK	WOS:000432499900021	29604313				2022-02-06	
J	Huijben, JA; Volovici, V; Cnossen, MC; Haitsma, IK; Stocchetti, N; Maas, AIR; Menon, DK; Ercole, A; Citerio, G; Nelson, D; Polinder, S; Steyerberg, EW; Lingsma, HF; van der Jagt, M				Huijben, Jilske A.; Volovici, Victor; Cnossen, Maryse C.; Haitsma, Iain K.; Stocchetti, Nino; Maas, Andrew I. R.; Menon, David K.; Ercole, Ari; Citerio, Giuseppe; Nelson, David; Polinder, Suzanne; Steyerberg, Ewout W.; Lingsma, Hester F.; van der Jagt, Mathieu		CTR-TBI Investigators Participants	Variation in general supportive and preventive intensive care management of traumatic brain injury: a survey in 66 neurotrauma centers participating in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study	CRITICAL CARE			English	Article						Intensive care unit; Traumatic brain injury; Glucose; Nutrition; Fever; Ventilation; Blood pressure; Seizure; Survey; Europe	CRITICALLY-ILL PATIENTS; HEAD-INJURY; INTRACRANIAL HYPERTENSION; MRC CRASH; GUIDELINES; MODERATE; OUTCOMES; RESUSCITATION; IMPROVEMENT; ALBUMIN	Background: General supportive and preventive measures in the intensive care management of traumatic brain injury (TBI) aim to prevent or limit secondary brain injury and optimize recovery. The aim of this survey was to assess and quantify variation in perceptions on intensive care unit (ICU) management of patients with TBI in European neurotrauma centers. Methods: We performed a survey as part of the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. We analyzed 23 questions focused on: 1) circulatory and respiratory management; 2) fever control; 3) use of corticosteroids; 4) nutrition and glucose management; and 5) seizure prophylaxis and treatment. Results: The survey was completed predominantly by intensivists (n = 33, 50%) and neurosurgeons (n = 23, 35%) from 66 centers (97% response rate). The most common cerebral perfusion pressure (CPP) target was > 60 mmHg (n = 39, 60%) and/or an individualized target (n = 25, 38%). To support CPP, crystalloid fluid loading (n = 60, 91%) was generally preferred over albumin (n = 15, 23%), and vasopressors (n = 63, 96%) over inotropes (n = 29, 44%). The most commonly reported target of partial pressure of carbon dioxide in arterial blood (PaCO2) was 36-40 mmHg (4.8-5.3 kPa) in case of controlled intracranial pressure (ICP) < 20 mmHg (n = 45, 69%) and PaCO2 target of 30-35 mmHg (4-4.7 kPa) in case of raised ICP (n = 40, 62%). Almost all respondents indicated to generally treat fever (n = 65, 98%) with paracetamol (n = 61, 92%) and/or external cooling (n = 49, 74%). Conventional glucose management (n = 43, 66%) was preferred over tight glycemic control (n = 18, 28%). More than half of the respondents indicated to aim for full caloric replacement within 7 days (n = 43, 66%) using enteral nutrition (n = 60, 92%). Indications for and duration of seizure prophylaxis varied, and levetiracetam was mostly reported as the agent of choice for both seizure prophylaxis (n = 32, 49%) and treatment (n = 40, 61%). Conclusions: Practice preferences vary substantially regarding general supportive and preventive measures in TBI patients at ICUs of European neurotrauma centers. These results provide an opportunity for future comparative effectiveness research, since a more evidence-based uniformity in good practices in general ICU management could have a major impact on TBI outcome.	[Huijben, Jilske A.; Volovici, Victor; Cnossen, Maryse C.; Polinder, Suzanne; Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Volovici, Victor; Haitsma, Iain K.] Erasmus MC, Erasmus MC Stroke Ctr, Dept Neurosurg, Off H 703, Rotterdam, Netherlands; [Volovici, Victor; Haitsma, Iain K.] Erasmus MC, Brain Tumor Ctr, Rotterdam, Netherlands; [Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplants, Milan, Italy; [Stocchetti, Nino] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Dept Anesthesia & Crit Care, Neurosci Intens Care Unit, Milan, Italy; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Menon, David K.; Ercole, Ari] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] San Gerardo Hosp, ASST Monza, Neurointens Care, Monza, Italy; [Nelson, David] Karolinska Inst, Dept Physiol & Pharmacol, Sect Perioperat Med & Intens Care, Stockholm, Sweden; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands; [van der Jagt, Mathieu] Erasmus MC, Dept Intens Care, Rotterdam, Netherlands; [van der Jagt, Mathieu] Erasmus MC, Erasmus MC Stroke Ctr, Rotterdam, Netherlands		Huijben, JA (corresponding author), Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands.	a.huijben@erasmusmc.nl	Lagares, Alfonso/B-2969-2011; Maas, Andrew IR/C-5584-2013; Castano-Leon, Ana M/ABF-6322-2020; Gomez, Pedro/N-5051-2019; Citerio, Giuseppe/B-1839-2015; Raj, Rahul/K-7693-2012; Vande Vyvere, Thijs/AAB-5180-2022; Volovici, Victor/AAZ-8901-2020; Boogert, Hugo F den/B-2782-2016; Laureys, Steven/AAN-2097-2021; Badenes, Rafael/K-6628-2019; Ercole, Ari/B-6288-2009; Sahuquillo, Juan/B-3577-2008; Sahakian, Barbara/AAW-1198-2020; Lanyon, Linda/L-9238-2019; Santos, Edgar/AAV-2506-2021; Cooper, D. James/G-7961-2013; Bartels, R.H.M.A./L-4184-2015	Lagares, Alfonso/0000-0003-3996-0554; Maas, Andrew IR/0000-0003-1612-1264; Castano-Leon, Ana M/0000-0002-7918-5049; Gomez, Pedro/0000-0002-4185-5238; Citerio, Giuseppe/0000-0002-5374-3161; Raj, Rahul/0000-0003-4243-9591; Vande Vyvere, Thijs/0000-0003-4032-5443; Volovici, Victor/0000-0002-5798-5360; Laureys, Steven/0000-0002-3096-3807; Badenes, Rafael/0000-0001-7017-0150; Ercole, Ari/0000-0001-8350-8093; Sahuquillo, Juan/0000-0003-0713-5875; Sahakian, Barbara/0000-0001-7352-1745; Lanyon, Linda/0000-0002-0885-1825; Santos, Edgar/0000-0002-8976-5549; Cooper, D. James/0000-0002-5872-9051; Parizel, Paul M./0000-0002-0221-2854; Rossi, Sandra/0000-0002-9963-8121; Coles, Jonathan/0000-0003-4013-679X; Bartels, R.H.M.A./0000-0002-8638-4660; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601; Newcombe, Virginia/0000-0001-6044-9035; Esser, Patrick/0000-0002-3227-0115; Pullens, Pim/0000-0003-2014-7248; czosnyka, marek/0000-0003-2446-8006; Kondziella, Daniel/0000-0001-5562-9808; Blaabjerg, Morten/0000-0001-6007-1861; Nelson, David/0000-0003-2530-8207; Huijben, Jilske (Antonia)/0000-0002-2892-5406; Kolias, Angelos/0000-0003-3992-0587; Dippel, Diederik/0000-0002-9234-3515; Bullinger, Monika/0000-0001-8876-0159; Sakowitz, Oliver/0000-0003-3248-6335; Sanchez-Porras, Renan/0000-0002-9084-8114; Stewart, William/0000-0003-2199-2582; Dawes, Helen/0000-0002-2933-5213; Van Essen, Thomas/0000-0003-4657-5283; Hutchinson, Peter/0000-0002-2796-1835	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [602150]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601025, G9439390, G0502030, G1002277, G0600986] Funding Source: UKRI	European Commission FP7 Framework Program 602150. Data used in the preparation of this manuscript were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Commission 7th Framework program (602150). The funder had no role in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.	Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; American College of Surgeons, TRAUM QUAL IMPR PROG; Bonds BW, 2015, BRAIN INJURY, V29, P1642, DOI 10.3109/02699052.2015.1075157; Bragge P, 2016, J NEUROTRAUM, V33, P1461, DOI 10.1089/neu.2015.4233; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chiumello D, 2017, J CRIT CARE, V38, P245, DOI 10.1016/j.jcrc.2016.10.021; Cinotti R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0498-9; Cnossen MC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1816-9; Cnossen MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161367; Cooper DJ, 2013, J NEUROTRAUM, V30, P512, DOI 10.1089/neu.2012.2573; Cormio M, 2007, NEUROCRIT CARE, V6, P82, DOI 10.1007/s12028-007-0002-3; Corp IBM, 2012, IBM SPSS STAT WIND M; Costello LAS, 2014, INJURY, V45, P1834, DOI 10.1016/j.injury.2014.06.004; Cnossen MC, 2017, CRIT CARE MED, V45, P660, DOI 10.1097/CCM.0000000000002263; Edwards P, 2005, LANCET, V365, P1957; European Commission, 2007, REM RES PUBL PRIV SE; Finfer S, 2015, INTENS CARE MED, V41, P1037, DOI 10.1007/s00134-015-3757-6; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Khan NR, 2016, NEUROSURGERY, V79, P775, DOI 10.1227/NEU.0000000000001445; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Majidi S, 2017, NEUROCRIT CARE, V27, P90, DOI 10.1007/s12028-016-0363-6; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Moore L, 2017, ANN SURG, V265, P212, DOI 10.1097/SLA.0000000000001614; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7; Stocchetti N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0887-8	37	25	25	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	APR 13	2018	22								90	10.1186/s13054-018-2000-6			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC7NJ	WOS:000429979700001	29650049	Green Published, Green Submitted, gold			2022-02-06	
J	Xie, BS; Wang, YQ; Lin, Y; Zhao, CC; Mao, Q; Feng, JF; Cao, JY; Gao, GY; Jiang, JY				Xie, Bao-shu; Wang, Yi-qin; Lin, Yong; Zhao, Cheng-cheng; Mao, Qing; Feng, Jun-feng; Cao, Jia-yu; Gao, Guo-yi; Jiang, Ji-yao			Circular RNA Expression Profiles Alter Significantly after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						circRNA; hippocampus; microarray; TBI	LONG NONCODING RNA; NEURONAL CELL-DEATH; MICRORNA EXPRESSION; MESSENGER-RNA; IN-VITRO; MIR-21; CORTEX; MILD; APOPTOSIS; IMPROVES	Circular RNAs (circRNAs) are involved in a variety of diseases. However, the roles of circRNAs in traumatic brain injury (TBI) remain unknown. In this study, circRNA microarray was used to profile the altered circRNAs in the rat hippocampus following TBI. A total of 192 circRNAs were observed to be differentially expressed (fold change [FC] >= 1.5 and p < 0.05) after TBI, including 98 upregulated and 94 downregulated. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis indicated that many messenger RNAs (mRNAs) transcribed from the host genes of altered circRNAs were implicated in brain damage and neural regeneration. CircRNA/microRNA (miRNA) interaction was predicted using Arraystar's homemade miRNA target prediction software based on TargetScan and miRanda. Thus, our studies have demonstrated altered circRNA expression pattern in the rat hippocampus after TBI, which may play important roles in post-TBI physiological and pathological processes. These findings may provide not only a new direction for studying the molecular mechanisms underlying TBI but also a new possibility for the treatment of TBI by modulating circRNAs.	[Xie, Bao-shu; Lin, Yong; Zhao, Cheng-cheng; Mao, Qing; Feng, Jun-feng; Cao, Jia-yu; Gao, Guo-yi; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China; [Xie, Bao-shu; Lin, Yong; Zhao, Cheng-cheng; Feng, Jun-feng; Gao, Guo-yi; Jiang, Ji-yao] Shanghai Inst Head Trauma, Shanghai, Peoples R China; [Wang, Yi-qin] Shanghai Jiao Tong Univ, Rui Jin Hosp, Sino French Res Ctr Life Sci & Gen, Sch Med,State Key Lab Med Gen, Shanghai, Peoples R China		Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China.; Jiang, JY (corresponding author), Shanghai Inst Head Trauma, Shanghai, Peoples R China.	jiyaojiang@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772058, 81471856]	This research was supported by the National Natural Science Foundation of China (No. 81772058 and 81471856).	Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Ban JJ, 2017, BIOCHEM BIOPH RES CO, V488, P316, DOI 10.1016/j.bbrc.2017.05.040; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Boone DK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06341-6; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Cai Q, 2016, NEURAL REGEN RES, V11, P1285, DOI 10.4103/1673-5374.189194; Cancelliere C, 2017, J HEAD TRAUMA REHAB, V32, pE37, DOI 10.1097/HTR.0000000000000260; Chandran R, 2017, NEUROCHEM INT, V111, P12, DOI 10.1016/j.neuint.2017.01.015; Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92; Chen Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120217; Di Pietro V, 2017, J NEUROTRAUM, V34, P1948, DOI 10.1089/neu.2016.4857; Ebbesen KK, 2016, BBA-GENE REGUL MECH, V1859, P163, DOI 10.1016/j.bbagrm.2015.07.007; El-Menyar A, 2017, WORLD NEUROSURG, V107, P6, DOI [10.1016/J.WNEU.2017.07.070, 10.1016/j.wneu.2017.07.070]; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Kumar L, 2017, MOL NEUROBIOL, V54, P7224, DOI 10.1007/s12035-016-0213-8; Lasda E, 2014, RNA, V20, P1829, DOI 10.1261/rna.047126.114; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liu NK, 2011, PHYSIOL GENOMICS, V43, P571, DOI 10.1152/physiolgenomics.00168.2010; Liu Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep22572; Liu T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24547; Ma J, 2016, AM J TRANSL RES, V8, P1895; Mehta SL, 2017, STROKE, V48, P2541, DOI 10.1161/STROKEAHA.117.017469; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Pan RY, 2017, ONCOTARGET, V8, P60280, DOI 10.18632/oncotarget.19941; Popovich P. G, 2017, NEUROSCIENTIST; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Rybak-Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Shin JH, 2014, BBA-GENE REGUL MECH, V1839, P826, DOI 10.1016/j.bbagrm.2014.06.019; Sun LQ, 2018, BEHAV BRAIN RES, V340, P126, DOI 10.1016/j.bbr.2016.09.020; Sun LQ, 2017, ONCOTARGET, V8, P59181, DOI 10.18632/oncotarget.19469; Sun LQ, 2017, BIOCHEM BIOPH RES CO, V482, P1141, DOI 10.1016/j.bbrc.2016.12.001; Wang CF, 2017, J NEUROTRAUM, V34, P2100, DOI 10.1089/neu.2016.4642; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zhao CC, 2017, J NEUROTRAUM, V34, P1636, DOI 10.1089/neu.2016.4759; Zhong JJ, 2017, BRAIN BEHAV IMMUN, V65, P183, DOI 10.1016/j.bbi.2017.05.001; Zhong JJ, 2016, BRAIN RES, V1646, P589, DOI 10.1016/j.brainres.2016.07.002	47	25	27	3	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1659	1666		10.1089/neu.2017.5468		APR 2018	8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000430056000001	29357736				2022-02-06	
J	Grauwmeijer, E; Heijenbrok-Kal, MH; Peppel, LD; Hartjes, CJ; Haitsma, IK; de Koning, I; Ribbers, GM				Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Peppel, Lianne D.; Hartjes, Chantalle J.; Haitsma, Iain K.; de Koning, Inge; Ribbers, Gerard M.			Cognition, Health-Related Quality of Life, and Depression Ten Years after Moderate to Severe Traumatic Brain Injury: A Prospective Cohort Study	JOURNAL OF NEUROTRAUMA			English	Article						outcome measures; prospective studies; rehabilitation; TBI	PREDICTORS; DISABILITY; SF-36; REHABILITATION; QUESTIONNAIRE; EPIDEMIOLOGY; COMMUNITY; OUTCOMES; DISEASE; IMPACT	The aim of this study was to evaluate cognitive function 10 years after moderate-severe traumatic brain injury (TBI) and to investigate the associations among cognitive function, depression, and health-related quality of life (HRQoL). In this prospective cohort study, with measurements at 3, 6, 12, 18, 24, 36, and 120 months post-TBI, patients 18-67 years of age (n=113) with moderate-severe TBI were recruited. Main outcome measures were depression (Center for Epidemiologic Studies-Depression Scale [CES-D]), subjective cognitive functioning (Cognitive Failure Questionnaire [CFQ]), objective cognitive functioning, and HRQoL (Medical Outcomes Study 36-Item Short Form Health Survey [SF-36]). Fifty of the initial 113 patients completed the 10 year follow-up. Twenty percent showed symptoms of depression (CES-D 16). These patients had more psychiatric symptoms at hospital discharge (p=0.048) and were more often referred to rehabilitation or nursing homes (p=0.015) than non-depressed patients. Further, they also had significantly lower scores in six of the eight subdomains of the SF-36. The non-depressed patients had equivalent scores to those of the Dutch norm-population on all subdomains of the SF-36. Cognitive problems at hospital discharge were related with worse cognitive outcome 10 years post-TBI, but not with depression or HRQoL. Ten years after moderate-severe TBI, only weak associations (p<0.05) between depression scores and two objective cognitive functioning scores were found. However, there were moderate associations (p<0.01) among depression scores, HRQoL, and subjective cognitive functioning. Therefore, signaling and treatment of depressive symptoms after moderate-severe TBI may be of major importance for optimizing HRQoL in the long term. We did not find strong evidence for associations between depression and objective cognitive functioning in the long term post-TBI. Disease awareness and selective dropping out may play a role in long-term follow-up studies in moderate-severe TBI. More long-term research is needed in this field.	[Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Peppel, Lianne D.; Hartjes, Chantalle J.; de Koning, Inge; Ribbers, Gerard M.] Rijndam Rehabil, Rotterdam, Netherlands; [Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Peppel, Lianne D.; Ribbers, Gerard M.] Erasmus Univ, Med Ctr, Dept Rehabil Med, Rotterdam, Netherlands; [Haitsma, Iain K.] Erasmus Univ, Med Ctr, Dept Neurosurg, Rotterdam, Netherlands		Grauwmeijer, E (corresponding author), Rotterdam Neurorehabil Res RoNeRes, Rijndam Rehabil Ctr, POB 23181, NL-3001 KD Rotterdam, Netherlands.	egrauwmeijer@rijndam.nl	Ribbers, Gerard/N-3623-2019; Ribbers, Gerard M/C-1454-2014	Ribbers, Gerard M/0000-0002-6114-349X; Heijenbrok-Kal, Majanka H./0000-0002-2982-4404	Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development [1435.0020]	This study was financially supported by the Netherlands Organisation for Health Research and Development (project no.: 1435.0020).	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Bogner JA, 2017, J HEAD TRAUMA REHAB, V32, pE1, DOI 10.1097/HTR.0000000000000291; Bouma A., 2012, NEUROPSYCHLOGICAL AS; Brickenkamp R., 1998, D2 TEST ATTENTION H; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Cieza A, 2005, QUAL LIFE RES, V14, P1225, DOI 10.1007/s11136-004-4773-0; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; Dahm J, 2015, J REHABIL MED, V47, P932, DOI 10.2340/16501977-2016; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Failla MD, 2016, J HEAD TRAUMA REHAB, V31, pE62, DOI 10.1097/HTR.0000000000000214; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Grauwmeijer E, 2017, J NEUROTRAUM, V34, P2575, DOI 10.1089/neu.2016.4846; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Harrison-Felix C, 2015, J NEUROTRAUM, V32, P1893, DOI 10.1089/neu.2014.3353; Hoofien D, 2001, BRAIN INJURY, V15, P189; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Marsh NV, 2016, NEUROREHABILITATION, V38, P71, DOI 10.3233/NRE-151297; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Peeters W, 2017, NEUROEPIDEMIOLOGY, V48, P63, DOI 10.1159/000471877; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Riihimaki K, 2016, EUR PSYCHIAT, V37, P28, DOI 10.1016/j.eurpsy.2016.04.008; Scholten AC, 2016, J NEUROTRAUM, V33, P1969, DOI 10.1089/neu.2015.4252; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sigurdardottir S, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000039; Skandsen T, 2008, CLIN REHABIL, V22, P653, DOI 10.1177/0269215508089067; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Stenberg M, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/680308; Valk-Kleibeuker L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087414; van Boxtel M., 2006, TIJDSCHRIFT NEUROPSY, V1, P37; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Ware J.E., 1994, SF 36 PHYS MENTAL SU; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377; Williamson MLC, 2013, BRAIN INJURY, V27, P992, DOI 10.3109/02699052.2013.801512; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Yue JK, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080093; Zgaljardic DJ, 2015, J NEUROTRAUM, V32, P1911, DOI 10.1089/neu.2014.3569	54	25	25	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	13					1543	1551		10.1089/neu.2017.5404		APR 2018	9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	GJ4CQ	WOS:000429541100001	29343203				2022-02-06	
J	Howell, DR; Stillman, A; Buckley, TA; Berkstresser, B; Wang, F; Meehan, WP				Howell, David R.; Stillman, Alexandra; Buckley, Thomas A.; Berkstresser, Brant; Wang, Francis; Meehan, William P., III			The utility of instrumented dual-task gait and tablet-based neurocognitive measurements after concussion	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Postural control; Locomotion; Neurocognitive test; Mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTION; SPORT CONCUSSION; SINGLE-TASK; HIGH-SCHOOL; MANAGEMENT; ATTENTION; RECOVERY; METAANALYSIS; ADOLESCENTS	Objectives: Quantitative and non-invasive measurements acquired by neurocognitive or gait evaluations are useful concussion management components. Emerging technology has allowed for the development of portable and objective tests which may be potentially useful across many settings where evaluations take place. Our aim was to examine the association between instrumented dual-task gait and tablet-based neurocognitive outcome variables with an acute concussion. Design: A total of 59 collegiate athletes were identified and tested within 5 days of concussion (n = 18, 50% female, 20 +/- 1 years of age) or as a part of a baseline examination (n = 41, 29% female, 19 +/- 1 years of age). Methods: Participants completed an instrumented dual-task gait evaluation and a tablet-based neurocognitive evaluation. Outcome variables were compared with t-tests, and a multivariable logistic regression model was constructed to identify the association between the presence of a concussion and test performance. Results: Compared with controls, participants with concussion reported significantly more severe symptoms (PCSS = 19.1 +/- 15.2 vs. 4.1 +/- 6.3; p < 0.001), walked significantly slower during dual-task conditions (87.7 +/- 10.4 cm/s vs. 98.1 +/- 15.4 cm/s; p = 0.01), and responded with significantly slower simple reaction times (305.2 +/- 32.4 ms vs. 275.4 +/- 22.1 ms; p < 0.001). After adjusting for the effect of potential confounding variables, these three variables (more severe symptoms, slower walking speed, and slower reaction time) remained independently associated with concussion (adjusted odds ratios = 1.181, 0.916, and 1.043, respectively). Conclusions: Relatively simple quantitative measurements of dual-task gait and reaction time may be useful and portable clinical tests in the multifaceted assessment of concussion. (C) 2017 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Howell, David R.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Howell, David R.; Meehan, William P., III] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA USA; [Howell, David R.; Meehan, William P., III] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Stillman, Alexandra] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Berkstresser, Brant; Wang, Francis] Harvard Univ, Hlth Serv, Cambridge, MA 02138 USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA; [Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat & Orthoped Surg, Boston, MA USA		Howell, DR (corresponding author), Univ Colorado, Sch Med, Childrens Hosp Colorado, Sports Med Ctr, 13123 E 16th Ave,8060, Aurora, CO 80045 USA.; Howell, DR (corresponding author), Univ Colorado, Sch Med, Dept Orthoped, 13123 E 16th Ave,8060, Aurora, CO 80045 USA.	David.Howell2@childrens.harvard.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; Howell, David/0000-0002-2955-0191			Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Borges A, 2017, INT J SPORTS PHYS TH, V12, P381; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.3.CO;2-M; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2011, PM&R, V3, pS445, DOI 10.1016/j.pmrj.2011.08.009; Hocking DR, 2014, RES DEV DISABIL, V35, P203, DOI 10.1016/j.ridd.2013.10.005; Howel DR, 2017, J APPL BIOMECH, V33, P24, DOI 10.1123/jab.2015-0323; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2017, J SCI MED SPORT, V20, P622, DOI 10.1016/j.jsams.2016.11.020; Howell DR, 2017, GAIT POSTURE, V54, P284, DOI 10.1016/j.gaitpost.2017.03.034; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Langner R, 2013, PSYCHOL BULL, V139, P870, DOI 10.1037/a0030694; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Sawyer Q, 2016, J ATHL TRAINING, V51, P739, DOI 10.4085/1062-6050-51.12.01; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Woods DL, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00595; Yasen AL, 2017, MED SCI SPORT EXER, V49, P1066, DOI 10.1249/MSS.0000000000001217; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zhou GW, 2015, OTOLARYNG HEAD NECK, V152, P1133, DOI 10.1177/0194599815576720	31	25	25	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	APR	2018	21	4					358	362		10.1016/j.jsams.2017.08.004			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	GB5DL	WOS:000429082500007	28919121				2022-02-06	
J	Khetani, S; Kollath, VO; Kundra, V; Nguyen, MD; Debert, C; Sen, A; Karan, K; Sanati-Nezhad, A				Khetani, Sultan; Kollath, Vinayaraj Ozhukil; Kundra, Varun; Minh Dang Nguyen; Debert, Chantel; Sen, Arindom; Karan, Kunal; Sanati-Nezhad, Amir			Polyethylenimine Modified Graphene-Oxide Electrochemical Immunosensor for the Detection of Glial Fibrillary Acidic Protein in Central Nervous System Injury	ACS SENSORS			English	Article						central nervous system injury; glial fibrillary acidic protein; biomarkers; graphene electrode; polyethylenimine; immunosensor; electrochemical impedance spectroscopy	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; CEREBROSPINAL-FLUID; SUSPENDED GRAPHENE; BLOOD BIOMARKERS; ANTICANCER DRUG; SPECTROSCOPY; DIAGNOSTICS; MICROCHIP; ELECTRODE	Glial fibrillary acidic protein (GFAP) is as an intermediate filament protein expressed by certain cells in the central nervous system (CNS). GFAP has been recognized as a reliable biomarker of CNS injury. However, due to the absence of rapid and easy-to-use assays for the detection of CNS injury biomarkers, measuring GFAP levels to identify CNS injury has not attained widespread clinical implementation. In the present work, we developed a polyethylenimine (PEI) coated graphene screen-printed electrode and used it for highly sensitive immunosensing of GFAP. Covalent binding of GFAP antibody to the PEI-modified electrode surface along with electrochemical impedance spectroscopy was used for detecting the change in the electrical conductivity of the electrodes. A highly linear response was recorded for various GFAP concentrations. Quantitative, selective, and label-free detection was achieved in the dynamic range of 1 pg mL(-1) to 100 ng mL(-1) for GFAP spiked in phosphate buffer saline, artificial cerebrospinal fluid, and human blood serum. The performance of the immunosensor was further validated and correlated by testing samples with the commercially available enzyme-linked immunosorbent assay method. This functionalized electrode could be used clinically for rapid detection and monitoring of CNS injury.	[Khetani, Sultan; Kundra, Varun; Sanati-Nezhad, Amir] Univ Calgary, Dept Mech & Mfg Engn, BioMEMS & Bioinspired Microfluid Lab, Calgary, AB T2N 1N4, Canada; [Sen, Arindom; Sanati-Nezhad, Amir] Univ Calgary, Schulich Sch Engn, Ctr Bioengn Res & Educ, Calgary, AB T2N 1N4, Canada; [Khetani, Sultan; Sen, Arindom; Sanati-Nezhad, Amir] Univ Calgary, Biomed Engn Grad Program, Calgary, AB T2N 1N4, Canada; [Sen, Arindom] Univ Calgary, Schulich Sch Engn, Pharmaceut Prod Res Facil, Calgary, AB T2N 1N4, Canada; [Kollath, Vinayaraj Ozhukil; Sen, Arindom; Karan, Kunal] Univ Calgary, Dept Chem & Petr Engn, Calgary, AB T2N 1N4, Canada; [Minh Dang Nguyen] Univ Calgary, Alberta Children Hosp, Res Inst Child & Maternal Hlth, Dept Clin Neurosci,Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada; [Debert, Chantel] Univ Calgary, Foothills Med Ctr, Div Phys Med & Rehabil, Dept Clin Neurosci, Calgary, AB T2H 2T9, Canada		Sanati-Nezhad, A (corresponding author), Univ Calgary, Dept Mech & Mfg Engn, BioMEMS & Bioinspired Microfluid Lab, Calgary, AB T2N 1N4, Canada.; Sanati-Nezhad, A (corresponding author), Univ Calgary, Schulich Sch Engn, Ctr Bioengn Res & Educ, Calgary, AB T2N 1N4, Canada.; Sanati-Nezhad, A (corresponding author), Univ Calgary, Biomed Engn Grad Program, Calgary, AB T2N 1N4, Canada.	amir.sanatinezhad@ucalgary.ca	Karan, Kunal/N-3983-2019; Ozhukil Kollath, Vinayaraj/D-7792-2015	Karan, Kunal/0000-0001-5432-8050; Ozhukil Kollath, Vinayaraj/0000-0001-9814-339X; Debert, Chantel/0000-0002-2704-0438; Sen, Arindom/0000-0002-8994-8601	Natural Sciences and Engineering Research of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); Alberta Prion Research Institute (APRI); CMC Microsystems, Canada; Alberta Innovates BioSolution (AIBS); University of Calgary	The authors acknowledge Natural Sciences and Engineering Research of Canada (NSERC); Alberta Prion Research Institute (APRI), CMC Microsystems, Canada; and Alberta Innovates BioSolution (AIBS) for supporting this research. V.O.K. acknowledges University of Calgary for Eyes High Postdoctoral Scholarship. We would also like to thank Farbod Ehsan Hosseini, and Udit Shrivastava for inputs and suggestions for this work.	Arya SK, 2013, LANGMUIR, V29, P6770, DOI 10.1021/la401109r; Bell J, 2004, NATURE, V429, P453, DOI 10.1038/nature02624; Bolotin KI, 2008, SOLID STATE COMMUN, V146, P351, DOI 10.1016/j.ssc.2008.02.024; Bunch JS, 2008, NANO LETT, V8, P2458, DOI 10.1021/nl801457b; Cummins BM, 2016, BIOTECHNOL ADV, V34, P161, DOI 10.1016/j.biotechadv.2016.01.005; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Du X, 2008, NAT NANOTECHNOL, V3, P491, DOI 10.1038/nnano.2008.199; Elias DC, 2009, SCIENCE, V323, P610, DOI 10.1126/science.1167130; Haselwood BA, 2015, BIOSENS BIOELECTRON, V67, P752, DOI 10.1016/j.bios.2014.09.032; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Horcas I, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2432410; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Ju L, 2011, NAT NANOTECHNOL, V6, P630, DOI [10.1038/nnano.2011.146, 10.1038/NNANO.2011.146]; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Khetani S., 2016, CMBES P, V39, P1; Khetani S, 2017, SENSOR ACTUAT B-CHEM, V247, P163, DOI 10.1016/j.snb.2017.02.169; Kollath VO, 2016, PHYS CHEM CHEM PHYS, V18, P26144, DOI 10.1039/c6cp04457c; Kollath VO, 2013, ADV ENG MATER, V15, P295, DOI 10.1002/adem.201200177; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee C, 2008, SCIENCE, V321, P385, DOI 10.1126/science.1157996; Lequin RM, 2005, CLIN CHEM, V51, P2415, DOI 10.1373/clinchem.2005.051532; Liu Y, 2013, ELECTROANAL, V25, P1050, DOI 10.1002/elan.201200525; Lu HL, 2015, RSC ADV, V5, P64925, DOI 10.1039/c5ra11528k; North SH, 2012, ANNU REV ANAL CHEM, V5, P35, DOI 10.1146/annurev-anchem-062011-143105; Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26; Pouw MH, 2009, SPINAL CORD, V47, P519, DOI 10.1038/sc.2008.176; Pradhan R, 2014, BIOSENS BIOELECTRON, V55, P44, DOI 10.1016/j.bios.2013.11.060; Pumera M, 2011, MATER TODAY, V14, P308, DOI 10.1016/S1369-7021(11)70160-2; Ricci F, 2012, ELECTROCHIM ACTA, V84, P74, DOI 10.1016/j.electacta.2012.06.033; Safavieh M, 2017, NANOSCALE, V9, P1852, DOI 10.1039/c6nr06417e; Safavieh M, 2016, BIOSENS BIOELECTRON, V80, P230, DOI 10.1016/j.bios.2016.01.060; Schedin F, 2007, NAT MATER, V6, P652, DOI 10.1038/nmat1967; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shao YY, 2010, ELECTROANAL, V22, P1027, DOI 10.1002/elan.200900571; Silva NA, 2014, PROG NEUROBIOL, V114, P25, DOI 10.1016/j.pneurobio.2013.11.002; Tang XW, 2006, NANO LETT, V6, P1632, DOI 10.1021/nl060613v; Tuteja SK, 2015, BIOSENS BIOELECTRON, V66, P129, DOI 10.1016/j.bios.2014.10.072; Valente KP, 2017, DRUG DISCOV TODAY, V22, P1654, DOI 10.1016/j.drudis.2017.06.010; Vashist SK, 2014, SCI REP-UK, V4, DOI 10.1038/srep04407; Walt DR, 2005, SCIENCE, V308, P217, DOI 10.1126/science.1108161; WANG Y, 1990, CHEM MATER, V2, P557, DOI 10.1021/cm00011a018; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; 2013, INT PERSP SPIN CORD, P1	46	25	25	3	42	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	2379-3694			ACS SENSORS	ACS Sens.	APR	2018	3	4					844	851		10.1021/acssensors.8b00076			15	Chemistry, Multidisciplinary; Chemistry, Analytical; Nanoscience & Nanotechnology	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics	GE4DT	WOS:000431165200015	29516727				2022-02-06	
J	Farhadi, HF; Kukreja, S; Minnema, A; Vatti, L; Gopinath, M; Prevedello, L; Chen, C; Xiang, HY; Schwab, JM				Farhadi, H. Francis; Kukreja, Sunil; Minnema, Amy; Vatti, Lohith; Gopinath, Meera; Prevedello, Luciano; Chen, Cheng; Xiang, Huiyun; Schwab, Jan M.			Impact of Admission Imaging Findings on Neurological Outcomes in Acute Cervical Traumatic Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						AIS conversion; cervical; intramedullary high-signal intensity; magnetic resonance imaging; spinal cord injury	INTRAMEDULLARY LESION EXPANSION; PREDICTION; BIOMARKERS; SEVERITY; IMPAIRMENT; RECOVERY; SURGERY; TRIALS; LENGTH; PHASE	Variable and unpredictable spontaneous recovery can occur after acute cervical traumatic spinal cord injury (tSCI). Despite the critical clinical and interventional trial planning implications of this tSCI feature, baseline measures to predict neurologic recovery accurately are not well defined. In this study, we used data derived from 99 consecutive patients (78 male, 21 female) with acute cervical tSCIs to assess the sensitivity and specificity of various clinical and radiological factors in predicting recovery at one year after injury. Categorical magnetic resonance imaging parameters included maximum canal compromise (MCC), maximum spinal cord compression (MSCC), longitudinal length of intramedullary lesion (IML), Brain and Spinal Injury Center (BASIC) score, and a novel derived Combined Axial and Sagittal Score (CASS). Logistic regression analysis of the area under the receiver operating characteristic curve (AUC) was applied to assess the differential predictive value of individual imaging markers. Admission American Spinal Injury Association Impairment Scale (AIS) grade, presence of a spinal fracture, and central cord syndrome were predictive of AIS conversion at one year. Both BASIC and IML were stronger predictors of AIS conversion compared with MCC and MSCC (p=0.0002 and p=0.04). The BASIC score demonstrated the highest overall predictive value for AIS conversion at one year (AUC 0.94). We conclude that admission intrinsic cord signal findings are robust predictive surrogate markers of neurologic recovery after cervical tSCI. Direct comparison of imaging parameters in this cohort of patients indicates that the BASIC score is the single best acute predictor of the likelihood of AIS conversion.	[Farhadi, H. Francis; Kukreja, Sunil; Minnema, Amy; Vatti, Lohith; Gopinath, Meera] Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, 410 W 10th Ave, Columbus, OH 43210 USA; [Prevedello, Luciano] Ohio State Univ, Wexner Med Ctr, Dept Radiol, Columbus, OH 43210 USA; [Xiang, Huiyun; Schwab, Jan M.] Ohio State Univ, Wexner Med Ctr, Dept Neurol, Columbus, OH 43210 USA; [Chen, Cheng] Nationwide Childrens Hosp, Ctr Pediat Trauma Res, Columbus, OH USA		Farhadi, HF (corresponding author), Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, 410 W 10th Ave, Columbus, OH 43210 USA.	Francis.Farhadi@osumc.edu		Prevedello, Luciano/0000-0002-6768-6452; Schwab, Jan/0000-0001-6784-4919; Farhadi, H Francis/0000-0002-4668-8512	OSU Neurosignature Program; Else-Kroehner-Fresenius Foundation [2012_A32]; Wings-for-Life Spinal Cord Research Foundation [DE-047/14, DE-16/16]; Era-Net-NEURON Program of the European Union (EU) (SILENCE) [01EW1701A]; National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services [90SI5020]; W.E. Hunt and C.M. Curtis Endowment; Era-Net-NEURON Program of the European Union (EU) (SCI-Net) [01EW1710]	We thank all colleagues who have added data to the COTS and OSU IW, which serve as the basis for these analyses. We thank Dr. David Evans and the Trauma Service faculty. Moreover, we thank Dr. Sam Colachis for his work assessing recovery of patients after traumatic spinal cord injury. HFF received start-up funding support from the OSU Neurosignature Program. JMS received funding support from the Else-Kroehner-Fresenius Foundation (#2012_A32), the Wings-for-Life Spinal Cord Research Foundation (#DE-047/14, DE-16/16), the Era-Net-NEURON Program of the European Union (EU) (SILENCE #01EW1701A and SCI-Net #01EW1710), the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR #90SI5020), and by the W.E. Hunt and C.M. Curtis Endowment. JMS is a Discovery Theme Initiative Scholar of the Ohio State University (Brain Injury).	Aarabi B, 2017, NEUROSURGERY, V80, P610, DOI 10.1093/neuros/nyw053; Aarabi B, 2012, J NEUROSURG-SPINE, V17, P243, DOI 10.3171/2012.6.SPINE12122; Ahmad FU, 2014, WORLD NEUROSURG, V82, P207, DOI 10.1016/j.wneu.2013.01.008; Ahuja CS, 2017, NEUROSURGERY, V80, pS9, DOI 10.1093/neuros/nyw080; Bechtel Nancie, 2004, J Trauma Nurs, V11, P79; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Curt A, 2012, SPINAL CORD, V50, P352, DOI 10.1038/sc.2011.113; Curt A, 2017, JAMA NEUROL, V74, P635, DOI 10.1001/jamaneurol.2017.0318; Dalkilic T, 2018, J NEUROTRAUM, V35, P435, DOI 10.1089/neu.2017.5357; Dhall S.S., 2017, NEUROSURGERY; Dvorak MF, 2015, J NEUROTRAUM, V32, P645, DOI 10.1089/neu.2014.3632; Dvorak MF, 2014, J NEUROTRAUM, V31, P1540, DOI 10.1089/neu.2013.3278; Elizei SS, 2017, NEURAL REGEN RES, V12, P385, DOI 10.4103/1673-5374.202933; Facchinello Y., 2017, J NEUROTRAUMA; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Fehlings M. G., 2016, NEUROSURGERY, V63, P196, DOI DOI 10.1227/01.NEU.0000489818.21218.72; Fehlings MG, 2006, SPINE, V31, P1719, DOI 10.1097/01.brs.0000224164.43912.e6; Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037; Fehlings MG, 2011, J NEUROTRAUM, V28, P787, DOI 10.1089/neu.2011.1765; Haefeli J, 2017, AM J NEURORADIOL, V38, P648, DOI 10.3174/ajnr.A5021; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HAYASHI K, 1995, PARAPLEGIA, V33, P212, DOI 10.1038/sc.1995.47; Hosier H, 2015, J NEUROTRAUM, V32, P1633, DOI 10.1089/neu.2015.3892; Kaminski L, 2017, J NEUROTRAUM, V34, P2027, DOI 10.1089/neu.2016.4955; Kunte H, 2015, LANCET NEUROL, V14, P352, DOI 10.1016/S1474-4422(15)70013-X; Kwon BK, 2017, J NEUROTRAUM, V34, P567, DOI 10.1089/neu.2016.4435; Le E, 2015, J NEUROSURG-SPINE, V22, P611, DOI 10.3171/2014.10.SPINE14576; Mahabaleshwarkar R, 2014, SPINAL CORD, V52, P139, DOI 10.1038/sc.2013.144; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Noonan VK, 2018, J NEUROTRAUM, V35, P478, DOI 10.1089/neu.2017.5036; SCHAEFER DM, 1992, J NEUROSURG, V76, P218, DOI 10.3171/jns.1992.76.2.0218; Schisterman EF, 2005, EPIDEMIOLOGY, V16, P73, DOI 10.1097/01.ede.0000147512.81966.ba; Shanmuganathan K, 2017, J NEUROTRAUM, V34, P2964, DOI 10.1089/neu.2016.4901; Simard JM, 2012, EXP NEUROL, V233, P829, DOI 10.1016/j.expneurol.2011.11.048; Talbott JF, 2015, J NEUROSURG-SPINE, V23, P495, DOI 10.3171/2015.1.SPINE141033; Tanadini LG, 2015, NEUROREHAB NEURAL RE, V29, P867, DOI 10.1177/1545968315570322; Wilson JR, 2012, J NEUROTRAUM, V29, P2263, DOI 10.1089/neu.2012.2417; Yamazaki T, 2005, SURG NEUROL, V63, P95, DOI 10.1016/j.surneu.2004.03.020; Ydens E, 2017, MOL NEUROBIOL, V54, P1482, DOI 10.1007/s12035-016-9757-x	39	25	25	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2018	35	12					1398	1406		10.1089/neu.2017.5510		MAR 2018	9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GJ4ID	WOS:000428449400001	29361876				2022-02-06	
J	Wu, J; Vogel, T; Gao, X; Lin, B; Kulwin, C; Chen, JH				Wu, Jin; Vogel, Todd; Gao, Xiang; Lin, Bin; Kulwin, Charles; Chen, Jinhui			Neuroprotective effect of dexmedetomidine in a murine model of traumatic brain injury	SCIENTIFIC REPORTS			English	Article							AGONIST; NEURONS; DEATH; ERYTHROPOIETIN; MECHANISMS; PROPOFOL; SEDATION; DAMAGE; MICE; UNIT	No FDA approved pharmacological therapy is available that would reduce cell death following traumatic brain injury (TBI). Dexmedetomidine (Dex) is a highly selective agonist of alpha-2 adrenergic receptors and has demonstrated neuroprotective effects in hippocampal slice cultures undergoing direct impact. However, no one has tested whether Dex, in addition to its sedative action, has neuroprotective effects in an animal model of TBI. Thus, in the present study, we investigated the effects of Dex on an animal model of TBI. Mice received different doses of Dex (1, 10, or 100 mu g/kg bodyweight, n = 10 each group) or saline as control at 1 hour and 12 hours following TBI. The mice treated with Dex lost less cortical tissue than the control mice. Further analysis found that Dex treatment reduced cell death in the cortex and the hippocampus measured by Fluoro-Jade B (FJB) staining, prevented axonal degeneration detected by immunostaining with antibody against beta-amyloid precursor protein (beta-APP), and protected synapses from elimination with synaptophysin staining. Taken together, in an in vivo murine model of TBI, Dex at the dose of 100 mu g/kg not only prevented tissue lesion and cell death, but also reduced axonal injury and synaptic degeneration caused by TBI.	[Wu, Jin; Lin, Bin] Xiamen Univ, Affiliated Southeast Hosp, Dept Orthopaed, Zhangzhou, Peoples R China; [Vogel, Todd; Kulwin, Charles; Chen, Jinhui] Indiana Univ, Dept Neurosurg, Indianapolis, IN 46204 USA; [Gao, Xiang; Chen, Jinhui] Stark Neurosci Res Inst, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA		Chen, JH (corresponding author), Indiana Univ, Dept Neurosurg, Indianapolis, IN 46204 USA.; Chen, JH (corresponding author), Stark Neurosci Res Inst, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA.	chen204@iupui.edu			Goodman Campbell Foundation; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81402217]	This study was supported by the Goodman Campbell Foundation and the Natural Science Foundation of China (No. 81402217).	Alzheimer C, 2002, ADV EXP MED BIOL, V513, P335; Aryan HE, 2006, BRAIN INJURY, V20, P791, DOI 10.1080/02699050600789447; Bansal V, 2012, INFLAMMATION, V35, P214, DOI 10.1007/s10753-011-9307-7; Bejian S, 2009, CARDIOL YOUNG, V19, P98, DOI 10.1017/S1047951109003515; Cai Y, 2014, MOL MED REP, V9, P1542, DOI 10.3892/mmr.2014.2034; Chen L, 2015, J NEUROPATH EXP NEUR, V74, P557, DOI 10.1097/NEN.0000000000000199; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Dahmani S, 2008, ANESTHESIOLOGY, V108, P457, DOI 10.1097/ALN.0b013e318164ca81; Faul M, 2010, TRAUMATIC BRAIN INJU; Flower O, 2012, EMERG MED INT, V2012, DOI 10.1155/2012/637171; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2016, SCI REP-UK, V6, DOI 10.1038/srep22490; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; GENTLEMAN D, 1992, INT SURG, V77, P297; Grof TM, 2010, NEUROCRIT CARE, V12, P356, DOI 10.1007/s12028-008-9156-x; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Ibrahim S, 2016, SCI REP-UK, V6, DOI 10.1038/srep21793; James ML, 2012, ANAESTH INTENS CARE, V40, P949, DOI 10.1177/0310057X1204000605; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Keating GM, 2015, DRUGS, V75, P1119, DOI 10.1007/s40265-015-0419-5; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laudenbach V, 2002, ANESTHESIOLOGY, V96, P134, DOI 10.1097/00000542-200201000-00026; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; Miao YF, 2010, BIOMED PHARMACOTHER, V64, P583, DOI 10.1016/j.biopha.2010.03.006; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Schoeler M, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-20; Schroeppel TJ, 2010, J TRAUMA, V69, P776, DOI 10.1097/TA.0b013e3181e981b8; Sigel Erwin, 2002, Current Topics in Medicinal Chemistry, V2, P833, DOI 10.2174/1568026023393444; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Wang XT, 2016, J NEUROTRAUM, V33, P721, DOI 10.1089/neu.2015.4097; Wang XM, 2013, BRAIN INJURY, V27, P1617, DOI 10.3109/02699052.2013.831130; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhao S, 2016, MOL NEUROBIOL, V53, P1884, DOI 10.1007/s12035-015-9128-z	43	25	27	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAR 21	2018	8								4935	10.1038/s41598-018-23003-3			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ9IV	WOS:000427925000015	29563509	gold, Green Published			2022-02-06	
J	Perez-Garcia, G; Sosa, MAG; De Gasperi, R; Lashof-Sullivan, M; Maudlin-Jeronimo, E; Stone, JR; Haghighi, F; Ahlers, ST; Elder, GA				Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Lashof-Sullivan, Margaret; Maudlin-Jeronimo, Eric; Stone, James R.; Haghighi, Fatemeh; Ahlers, Stephen T.; Elder, Gregory A.			Chronic post-traumatic stress disorder-related traits in a rat model of low-level blast exposure	BEHAVIOURAL BRAIN RESEARCH			English	Article						Animal models; Blast; Postconcussion syndrome; Post-traumatic stress disorder; Rat; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; PERSISTENT POSTCONCUSSIVE SYMPTOMS; MILITARY SERVICE MEMBERS; OXIDATIVE STRESS; STARTLE RESPONSE; RODENT MODEL; MOUSE MODEL; MILD TBI; OVERPRESSURE; VETERANS	The postconcussion syndrome following mild traumatic brain injuries (mTBI) has been regarded as a mostly benign syndrome that typically resolves in the immediate months following injury. However, in some individuals, symptoms become chronic and persistent. This has been a striking feature of the mostly blast-related mTBIs that have been seen in veterans returning from the recent conflicts in Iraq and Afghanistan. In these veterans a chronic syndrome with features of both the postconcussion syndrome and post-traumatic stress disorder has been prominent. Animal modeling of blast-related TBI has developed rapidly over the last decade leading to advances in the understanding of blast pathophysiology. However, most studies have focused on acute to subacute effects of blast on the nervous system and have typically studied higher intensity blast exposures with energies more comparable to that involved in human moderate to severe TBI. Fewer animal studies have addressed the chronic effects of lower level blast exposures that are more comparable to those involved in human mTBI or subclinical blast. Here we describe a rat model of repetitive low-level blast exposure that induces a variety of anxiety and PTSD-related behavioral traits including exaggerated fear responses that were present when animals were tested between 28 and 35 weeks after the last blast exposure. These animals provide a model to study the chronic and persistent behavioral effects of blast including the relationship of PTSD to mTBI in dual diagnosis veterans. Published by Elsevier B.V.	[Perez-Garcia, Georgina; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave Levy Pl, New York, NY 10029 USA; [Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh] James J Peters Dept Vet Affairs, Med Ctr, Res & Dev Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, 1 Gustave Levy Pl, New York, NY 10029 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, 1 Gustave Levy Pl, New York, NY 10029 USA; [Lashof-Sullivan, Margaret; Maudlin-Jeronimo, Eric; Ahlers, Stephen T.] US Naval Med Res Ctr, Dept Neurotrauma, Operat & Undersea Med Directorate, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Stone, James R.] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA 22908 USA; [Stone, James R.] Univ Virginia, Dept Neurosurg, Charlottesville, VA 22908 USA; [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, 1 Gustave Levy Pl, New York, NY 10029 USA; [Haghighi, Fatemeh] James J Peters Dept Vet Affairs, Med Ctr, Neurol Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA		Elder, GA (corresponding author), James J Peters VA Med Ctr, Neurol Serv 3E16, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.	gregory.elder@va.gov			NMRCNational Medical Research Council, Singapore [0000B999.0000.000.A1503]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service AwardUS Department of Veterans Affairs [1I01RX000996-01]; Veterans AffairsUS Department of Veterans Affairs [I01RX001705, I21RX002069, I01RX000996] Funding Source: NIH RePORTER	This work was supported by NMRC work unit number 0000B999.0000.000.A1503 and by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award 1I01RX000996-01. The funding source played no direct role in the study design, execution, the writing of the report or the decision to submit the article for publication.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ainge JA, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00008; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Awwad HO, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00132; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; BUTLER RW, 1990, AM J PSYCHIAT, V147, P1308; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; Dere E, 2007, NEUROSCI BIOBEHAV R, V31, P673, DOI 10.1016/j.neubiorev.2007.01.005; Divani AA, 2015, J NEUROTRAUM, V32, P1109, DOI 10.1089/neu.2014.3686; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Genovese RF, 2013, NEUROSCIENCE, V254, P120, DOI 10.1016/j.neuroscience.2013.09.021; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guley NH, 2016, J NEUROTRAUM, V33, P403, DOI 10.1089/neu.2015.3886; Haghighi F, 2015, J NEUROTRAUM, V32, P1200, DOI 10.1089/neu.2014.3640; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang E, 2013, BRAIN RES, V1529, P125, DOI 10.1016/j.brainres.2013.06.042; Jablonski SA, 2013, BEHAV BRAIN RES, V256, P140, DOI 10.1016/j.bbr.2013.07.055; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Miyazaki H, 2015, ACTA NEUROCHIR, V157, P2111, DOI 10.1007/s00701-015-2613-3; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Ning YL, 2015, CHIN J TRAUMATOL, V18, P204, DOI 10.1016/j.cjtee.2015.10.003; Paylor R, 1997, PSYCHOPHARMACOLOGY, V132, P169, DOI 10.1007/s002130050333; Perez-Garcia G, 2016, SCI REP-UK, V6, DOI 10.1038/srep21275; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sajja VSSS, 2015, SHOCK, V44, P71, DOI 10.1097/SHK.0000000000000311; Sajja VSSS, 2014, MOL CELL NEUROSCI, V59, P119, DOI 10.1016/j.mcn.2014.02.004; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Stemper BD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00031; Sweis BM, 2016, BEHAV BRAIN RES, V296, P149, DOI 10.1016/j.bbr.2015.09.015; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Tweedie D, 2016, ALZHEIMERS DEMENT, V12, P34, DOI 10.1016/j.jalz.2015.07.489; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Vieweg WVR, 2006, AM J MED, V119, P383, DOI 10.1016/j.amjmed.2005.09.027; Wang H., 2016, J NEUROPATHOL EXP NE; Xie K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064907; Yolken RH, 2014, P NATL ACAD SCI USA, V111, P16106, DOI 10.1073/pnas.1418895111; Zuckerman A., 2016, J NEUROTRAUMA	69	25	25	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 15	2018	340				SI		117	125		10.1016/j.bbr.2016.09.061			9	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology	FU9JY	WOS:000424173400014	27693852				2022-02-06	
J	Dang, S; Gomez-Orozco, CA; van Zuilen, MH; Levis, S				Dang, Stuti; Gomez-Orozco, Carlos A.; van Zuilen, Maria H.; Levis, Silvina			Providing Dementia Consultations to Veterans Using Clinical Video Telehealth: Results from a Clinical Demonstration Project	TELEMEDICINE AND E-HEALTH			English	Article						clinical video telehealth; dementia; technology; access to care	NURSING-HOME PLACEMENT; MINI-MENTAL-STATE; COGNITIVE IMPAIRMENT; PSYCHOSOCIAL INTERVENTIONS; CAREGIVER BURDEN; TELEMEDICINE; DEPRESSION; MANAGEMENT; PEOPLE; HEALTH	Purpose:Veterans with dementia and their caregivers in remote areas may not have access to specialists to provide diagnosis, treatment, and education. The purpose of this clinical demonstration project was to examine the feasibility, acceptability, and impact of a video consultations clinic for veterans with dementia or memory complaints and their caregivers.Methods:The dementia clinical video telehealth (CVT) consultation clinic was established to identify, diagnose, and treat dementia in veterans at sites distant from the main medical center. A geriatrician at the main facility provided video consultation to patients and caregivers at seven satellite facilities. Diagnoses made and services provided were recorded after the initial consultation. Patient and caregiver satisfaction with the CVT clinic were assessed.Findings:Ninety-four patients were evaluated in the CVT dementia clinic (average age=74.7; average Mini-Mental State Exam=24.4). Forty patients had a prior dementia diagnosis, 15 received a new dementia diagnosis, and 20 a new mild cognitive impairment diagnosis. Of the remaining patients evaluated for memory complaints, seven were found to have depression, three had hearing loss, and three had traumatic brain injury. After CVT consultation, common referrals included social work (n=43), neuropsychology (n=36), and brain imaging (n=26). Patients and caregivers expressed high satisfaction with the video consultation and 90% of caregivers indicated they would rather use CVT than travel to see the specialist in person.Conclusions:Video consultation was well accepted by both dementia patients and caregivers. CVT may facilitate timely diagnosis and management and provide support for rural dementia patients and caregivers.	[Dang, Stuti; van Zuilen, Maria H.; Levis, Silvina] Miami Vet Affairs Healthcare Syst, Geriatr Res Educ & Clin Ctr, Miami, FL USA; [Dang, Stuti; van Zuilen, Maria H.; Levis, Silvina] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Gomez-Orozco, Carlos A.] South Florida Vet Affairs Fdn Res & Educ Inc, Miami, FL USA		Dang, S (corresponding author), Miami VA Geriatr Res Educ & Clin Ctr, Bruce W Carter Vet Affairs Med Ctr, 1201 NW 16th St,11GRC, Miami, FL 33125 USA.	stuti.dang@va.gov			VHA Office of Rural Health; Miami VA Geriatric Research, Education, and Clinical Center	Funding for this project was provided by the VHA Office of Rural Health. The project was also supported by the Miami VA Geriatric Research, Education, and Clinical Center. Findings in this article were presented, in part, at the Gerontological Society of America's 68th Annual Scientific Meeting (November 18, 2015) and the Geriatrics & Extended Care Leads Virtual Conference (April 26, 2016).	Azad N, 2012, CAN GERIATR J, V15, P96, DOI 10.5770/cgj.15.28; Barton C, 2011, TELEMED E-HEALTH, V17, P789, DOI 10.1089/tmj.2011.0083; Bass DM, 2013, J AM GERIATR SOC, V61, P1377, DOI 10.1111/jgs.12362; Bedard M, 2001, GERONTOLOGIST, V41, P652, DOI 10.1093/geront/41.5.652; Brodaty H, 2003, J AM GERIATR SOC, V51, P657, DOI 10.1034/j.1600-0579.2003.00210.x; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; Chodosh J, 2004, J AM GERIATR SOC, V52, P1051, DOI 10.1111/j.1532-5415.2004.52301.x; Chua R, 2001, J NEUROL NEUROSUR PS, V71, P63, DOI 10.1136/jnnp.71.1.63; Ciemins EL, 2009, TELEMED J E-HEALTH, V15, P476, DOI 10.1089/tmj.2008.0144; COLERICK EJ, 1986, J AM GERIATR SOC, V34, P493, DOI 10.1111/j.1532-5415.1986.tb04239.x; Cooke DD, 2001, AGING MENT HEALTH, V5, P120; Craig JJ, 1999, J TELEMED TELECARE, V5, P177, DOI 10.1258/1357633991933594; Cullum CM, 2006, ASSESSMENT, V13, P385, DOI 10.1177/1073191106289065; Dang S, 2008, J TELEMED TELECARE, V14, P443, DOI 10.1258/jtt.2008.080608; Dang S, 2008, SOUTH MED J, V101, P1246, DOI 10.1097/SMJ.0b013e318187cccc; DeKosky S, 2003, ALZ DIS ASSOC DIS, V17, pS99, DOI 10.1097/00002093-200307004-00004; Dunkin JJ, 1998, NEUROLOGY, V51, pS53, DOI 10.1212/WNL.51.1_Suppl_1.S53; Dyer CB, 2000, J AM GERIATR SOC, V48, P205, DOI 10.1111/j.1532-5415.2000.tb03913.x; Easter Seals Disability Services, 2006, CAR RUR AM; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Harrell KM, 2014, J AM MED DIR ASSOC, V15, P600, DOI 10.1016/j.jamda.2014.04.015; Katz AE, 2006, INTERACTIVE DEMENTIA; KOENIG HG, 1988, INT J PSYCHIAT MED, V18, P17; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Loh PK, 2007, J TELEMED TELECARE, V13, P90, DOI 10.1258/135763307780096159; MAHONEY F I, 1965, Md State Med J, V14, P61; Martin-Khan M, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2012.03.004; Morgan DG, 2009, AGING MENT HEALTH, V13, P17, DOI 10.1080/13607860802154432; Morgan DG, 2002, SOC SCI MED, V55, P1129, DOI 10.1016/S0277-9536(01)00255-6; Sclan S G, 1992, Int Psychogeriatr, V4 Suppl 1, P55; Shores MM, 2004, INT J GERIATR PSYCH, V19, P101, DOI 10.1002/gps.1029; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Wackerbarth SB, 2002, PATIENT EDUC COUNS, V47, P95, DOI 10.1016/S0738-3991(01)00194-X; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090	37	25	25	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627	1556-3669		TELEMED E-HEALTH	Telemed. e-Health	MAR	2018	24	3					203	209		10.1089/tmj.2017.0089			7	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services	GA3IQ	WOS:000428222400005	28686082				2022-02-06	
J	Rabinowitz, AR; Hart, T; Whyte, J; Kim, J				Rabinowitz, Amanda R.; Hart, Tessa; Whyte, John; Kim, Junghoon			Neuropsychological Recovery Trajectories in Moderate to Severe Traumatic Brain Injury: Influence of Patient Characteristics and Diffuse Axonal Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain injury; Neuropsychological tests; Cognition; Executive function; Verbal learning; Diffusion tensor imaging	WHITE-MATTER INTEGRITY; FOLLOW-UP; COGNITIVE FUNCTION; OUTCOME MEASURES; MILD; PREDICTORS; VARIABLES; MEMORY; ABNORMALITIES; RESERVE	Objectives: The goal of the present study was to elucidate the influence of demographic and neuropathological moderators on the longitudinal trajectory neuropsychological functions during the first year after moderate to severe traumatic brain injury (TBI). In addition to examining demographic moderators such as age and education, we included a measure of whole-brain diffuse axonal injury (DAI), and examined measures of processing speed (PS), executive function (EF), and verbal learning (VL) separately. Methods: Forty-six adults with moderate to severe TBI were examined at 3, 6, and 12 months post-injury. Participants underwent neuropsychological evaluation and neuroimaging including diffusion tensor imaging. Using linear mixed effects modeling, we examined longitudinal trajectories and moderating factors of cognitive outcomes separately for three domains: PS, VL, and EF. Results: VL and EF showed linear improvements, whereas PS exhibited a curvilinear trend characterized by initial improvements that plateaued or declined, depending on age. Age moderated the recovery trajectories of EF and PS. Education and DAI did not influence trajectory but were related to initial level of functioning for PS and EF in the case of DAI, and all three cognitive domains in the case of education. Conclusions: We found disparate recovery trajectories across cognitive domains. Younger age was associated with more favorable recovery of EF and PS. These findings have both clinical and theoretical implications. Future research with a larger sample followed over a longer time period is needed to further elucidate the factors that may influence cognitive change over the acute to chronic period after TBI.	[Rabinowitz, Amanda R.; Hart, Tessa; Whyte, John; Kim, Junghoon] Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA; [Rabinowitz, Amanda R.] CUNY City Coll, Sch Med, New York, NY 10031 USA		Rabinowitz, AR (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	rabinowa@einstein.edu	Kim, Junghoon John/I-6702-2019	Kim, Junghoon John/0000-0001-5729-8993; Whyte, John/0000-0002-4381-1474	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS065980]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065980] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (R01NS065980; Principal Investigator, J.K.). The authors have no conflicts of interest to disclose. The authors thank JeffreyWare, M.D., for DTI image processing. We also thank Morgan Rohrbach, Sigrid Williamson, Grayce Selig, Riya Rajan, Tincy Philip, and Devon Kratchman for their contributions to participant recruitment and data collection.	Baayen RH, 2008, J MEM LANG, V59, P390, DOI 10.1016/j.jml.2007.12.005; Beglinger LJ, 2005, ARCH CLIN NEUROPSYCH, V20, P517, DOI 10.1016/j.acn.2004.12.003; Benton L. A., 1994, CONTROLLED ORAL WORD; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Fitzmaurice G.M., 2012, APPL LONGITUDINAL AN, V998; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Haberg AK, 2015, J NEUROSCI RES, V93, P1109, DOI 10.1002/jnr.23534; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; HURVICH CM, 1989, BIOMETRIKA, V76, P297, DOI 10.1093/biomet/76.2.297; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lannoo E, 2001, BRAIN INJURY, V15, P1, DOI 10.1080/02699050150209084; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Rabinowitz A.R., 2016, GENES ENV ALZHEIMERS, P267; Reitan R. M., 1985, HALSTEAD REITAN NEUR, V4; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Salthouse TA, 2010, J INT NEUROPSYCH SOC, V16, P754, DOI 10.1017/S1355617710000706; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schultz R., 2013, BRAIN IMPAIRMENT, V14; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Spitz G, 2013, BRAIN TOPOGR, V26, P648, DOI 10.1007/s10548-013-0283-0; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Ware JB, 2017, J NEUROTRAUM, V34, P2243, DOI 10.1089/neu.2016.4817; Watts R, 2014, RADIOLOGY, V272, P217, DOI 10.1148/radiol.14131856; Wechsler D., 2014, WECHSLER ADULT INTEL, Vfourth; White T, 2011, SCHIZOPHRENIA BULL, V37, P222, DOI 10.1093/schbul/sbp088; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171	50	25	25	0	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2018	24	3					237	246		10.1017/S1355617717000996			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	FW9IX	WOS:000425650000003	29032776	Green Accepted			2022-02-06	
J	Ryan, NP; Genc, S; Beauchamp, MH; Yeates, KO; Hearps, S; Catroppa, C; Anderson, VA; Silk, TJ				Ryan, N. P.; Genc, S.; Beauchamp, M. H.; Yeates, K. O.; Hearps, S.; Catroppa, C.; Anderson, V. A.; Silk, T. J.			White matter microstructure predicts longitudinal social cognitive outcomes after paediatric traumatic brain injury: a diffusion tensor imaging study	PSYCHOLOGICAL MEDICINE			English	Article						Brain injuries; childhood; diffusion tensor imaging; social cognition; theory of mind	DEFAULT MODE NETWORK; UNCINATE FASCICULUS; PRAGMATIC LANGUAGE; SPATIAL STATISTICS; CORPUS-CALLOSUM; EARLY-CHILDHOOD; DTI FINDINGS; CHILDREN; CONNECTIVITY; MIND	Background. Deficits in social cognition may be among the most profound and disabling sequelae of paediatric traumatic brain injury (TBI); however, the neuroanatomical correlates of longitudinal outcomes in this domain remain unexplored. This study aimed to characterize social cognitive outcomes longitudinally after paediatric TBI, and to evaluate the use of sub-acute diffusion tensor imaging (DTI) to predict these outcomes. Methods. The sample included 52 children with mild complex-severe TBI who were assessed on cognitive theory of mind (ToM), pragmatic language and affective ToM at 6-and 24-months post-injury. For comparison, 43 typically developing controls (TDCs) of similar age and sex were recruited. DTI data were acquired sub-acutely (mean = 5.5 weeks post-injury) in a subset of 65 children (TBI = 35; TDC = 30) to evaluate longitudinal prospective relationships between white matter microstructure assessed using Tract-Based Spatial Statistics and social cognitive outcomes. Results. Whole brain voxel-wise analysis revealed significantly higher mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD) in the sub-acute TBI group compared with TDC, with differences observed predominantly in the splenium of the corpus callosum (sCC), sagittal stratum (SS), dorsal cingulum (DC), uncinate fasciculus (UF) and middle and superior cerebellar peduncles (MCP & SCP, respectively). Relative to TDCs, children with TBI showed poorer cognitive ToM, affective ToM and pragmatic language at 6-months post-insult, and those deficits were related to abnormal diffusivity of the sCC, SS, DC, UF, MCP and SCP. Moreover, children with TBI showed poorer affective ToM and pragmatic language at 24-months post-injury, and those outcomes were predicted by sub-acute alterations in diffusivity of the DC and MCP. Conclusions. Abnormal microstructure within frontal-temporal, limbic and cerebro-cerebellar white matter may be a risk factor for long-term social difficulties observed in children with TBI. DTI may have potential to unlock early prognostic markers of long-term social outcomes.	[Ryan, N. P.; Hearps, S.; Catroppa, C.; Anderson, V. A.] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Ryan, N. P.; Catroppa, C.; Anderson, V. A.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Ryan, N. P.; Catroppa, C.; Anderson, V. A.] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Genc, S.; Silk, T. J.] Murdoch Childrens Res Inst, Dev Imaging, Melbourne, Vic, Australia; [Genc, S.; Anderson, V. A.; Silk, T. J.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Beauchamp, M. H.] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Beauchamp, M. H.] Ste Justine Res Ctr, Montreal, PQ, Canada; [Yeates, K. O.] Hotchkiss Brain Inst, Dept Psychol, Calgary, AB, Canada; [Yeates, K. O.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada		Ryan, NP (corresponding author), Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia.; Ryan, NP (corresponding author), Univ Melbourne, Melbourne Sch Psychol Sci, Parkville, Vic 3052, Australia.	nicholas.ryan@unimelb.edu.au	Hearps, Stephen/L-6853-2016; Ryan, Nicholas/K-5445-2019; Yeates, Keith/AAJ-4223-2020; Silk, Tim/K-4295-2019; Catroppa, Cathy/AAX-9458-2021	Ryan, Nicholas/0000-0002-0878-8889; Catroppa, Cathy/0000-0002-9750-0436; Hearps, Stephen/0000-0003-2984-1172; Silk, Tim/0000-0002-7290-512X; Genc, Sila/0000-0002-4624-7071; Yeates, Keith/0000-0001-7680-2892	Victoria Neurotrauma Initiative, Australia [CO6E1]; Victorian Government Operational Infrastructure Support Program; Australian Postgraduate AwardAustralian Government; MCRI Ph.D. scholarship; NHMRC Moving Ahead Centre for Research Excellence in Brain Injury Recovery Seed GrantNational Health and Medical Research Council of Australia; NHMRC Senior Practitioner FellowshipNational Health and Medical Research Council of Australia	This work was supported by a grant from the Victoria Neurotrauma Initiative (CO6E1), Australia; the Victorian Government Operational Infrastructure Support Program; an Australian Postgraduate Award, MCRI Ph.D. scholarship, and NHMRC Moving Ahead Centre for Research Excellence in Brain Injury Recovery Seed Grant to NR; and an NHMRC Senior Practitioner Fellowship to VA. The funding bodies did not play a role in the design of the study, collection, analysis and interpretation of the data, or writing of the manuscript.	Adamson C, 2013, BRAIN INJURY, V27, P454, DOI 10.3109/02699052.2012.750756; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Ameis SH, 2015, CORTEX, V62, P158, DOI 10.1016/j.cortex.2014.10.014; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Ashwal S, 2014, J CHILD NEUROL, V29, P1704, DOI 10.1177/0883073814538504; Aung Wint Yan, 2013, Imaging Med, V5, P427; Bach M, 2014, NEUROIMAGE, V100, P358, DOI 10.1016/j.neuroimage.2014.06.021; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Bellerose J, 2015, J INT NEUROPSYCH SOC, V21, P483, DOI 10.1017/S1355617715000569; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Burnett S, 2009, ANN NY ACAD SCI, V1167, P51, DOI 10.1111/j.1749-6632.2009.04509.x; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Carrington SJ, 2009, HUM BRAIN MAPP, V30, P2313, DOI 10.1002/hbm.20671; Catroppa C, 2015, J NEUROTRAUM, V32, P109, DOI 10.1089/neu.2013.3276; Chiong W, 2013, BRAIN, V136, P1929, DOI 10.1093/brain/awt066; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; D'Mello AM, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00408; Davis CL, 2016, NEUROCASE, V22, P22, DOI 10.1080/13554794.2015.1024137; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2012, INT J DEV NEUROSCI, V30, P247, DOI 10.1016/j.ijdevneu.2011.07.004; Genc S, 2017, J NEUROTRAUM, V34, P798, DOI 10.1089/neu.2016.4584; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gilliam M, 2011, BIOL PSYCHIAT, V69, P839, DOI 10.1016/j.biopsych.2010.11.024; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jalbrzikowski M, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00393; Kennedy DP, 2012, TRENDS COGN SCI, V16, P559, DOI 10.1016/j.tics.2012.09.006; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Liu PC, 2016, AIP ADV, V6, DOI 10.1063/1.4954997; Mahoney CJ, 2011, BRIT J PSYCHIAT, V198, P365, DOI 10.1192/bjp.bp.110.082677; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P528, DOI 10.1017/S1355617713000039; Miyata J, 2010, SCHIZOPHR RES, V119, P232, DOI 10.1016/j.schres.2009.12.038; Newcombe V, 2009, BRIT J NEUROSURGERY, V21, P340; Ochsner KN, 2004, J COGNITIVE NEUROSCI, V16, P1746, DOI 10.1162/0898929042947829; Oishi K, 2015, ANN NEUROL, V77, P68, DOI 10.1002/ana.24300; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Pandya D., 2009, FIBER PATHWAYS BRAIN; Phan KL, 2009, BIOL PSYCHIAT, V66, P691, DOI 10.1016/j.biopsych.2009.02.028; Philippi CL, 2009, J NEUROSCI, V29, P15089, DOI 10.1523/JNEUROSCI.0796-09.2009; Pugliese L, 2009, NEUROIMAGE, V47, P427, DOI 10.1016/j.neuroimage.2009.05.014; Roberts RM, 2014, DEV NEUROPSYCHOL, V39, P600, DOI 10.1080/87565641.2014.973958; Roberts RM, 2016, DEV NEUROPSYCHOL, V41, P176, DOI 10.1080/87565641.2016.1186167; Robinson KE, 2014, J NEUROTRAUM, V31, P1835, DOI 10.1089/neu.2014.3422; Ryan NP, 2015, HUM BRAIN MAPP, V36, P1677, DOI 10.1002/hbm.22729; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; Sethi A, 2015, CORTEX, V62, P11, DOI 10.1016/j.cortex.2014.07.018; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Supekar K, 2010, NEUROIMAGE, V52, P290, DOI 10.1016/j.neuroimage.2010.04.009; Tartaglia MC, 2012, J NEUROL, V259, P1071, DOI 10.1007/s00415-011-6300-x; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TEASDALE G, 1974, LANCET, V2, P81; Tesink CMJY, 2009, BRAIN, V132, P1941, DOI 10.1093/brain/awp103; Thompson PM, 2005, INT REV NEUROBIOL, V67, P285, DOI 10.1016/S0074-7742(05)67009-2; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tournier JD, 2008, NEUROIMAGE, V42, P617, DOI 10.1016/j.neuroimage.2008.05.002; Van Overwalle F, 2015, HUM BRAIN MAPP, V36, P5137, DOI 10.1002/hbm.23002; Van Overwalle F, 2016, NEUROIMAGE, V124, P248, DOI 10.1016/j.neuroimage.2015.09.001; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; VOGEL S, 1992, ED ALTERNATIVES STUD; Von Der Heide RJ, 2013, BRAIN, V136, P1692, DOI 10.1093/brain/awt094; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wiig E. H., 1989, TEST LANGUAGE COMPET; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2016, J NEUROTRAUM, V33, P2000, DOI 10.1089/neu.2015.4212; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wozniak JR, 2006, NEUROSCI BIOBEHAV R, V30, P762, DOI 10.1016/j.neubiorev.2006.06.003; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zupan B, 2017, BRAIN IMPAIR, V18, P36, DOI 10.1017/BrImp.2016.22	90	25	27	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	MAR	2018	48	4					679	691		10.1017/S0033291717002057			13	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	GB8OZ	WOS:000429336500013	28780927				2022-02-06	
J	Weaver, LK; Wilson, SH; Lindblad, AS; Churchill, S; Deru, K; Price, RC; Williams, CS; Orrison, WW; Walker, JM; Meehan, A; Mirow, S				Weaver, Lindell K.; Wilson, Steffanie H.; Lindblad, Anne S.; Churchill, Susan; Deru, Kayla; Price, Robert C.; Williams, Chris S.; Orrison, William W.; Walker, James M.; Meehan, Anna; Mirow, Susan		BIMA Study Team	Hyperbaric oxygen for post-concussive symptoms in United States military service members: a randomized clinical trial	UNDERSEA AND HYPERBARIC MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; PERSISTENT POSTCONCUSSION SYMPTOMS; OF-DEFENSE TRIALS; HEAD-INJURY; SLEEP-DISORDERS; TBI ISSUES; RELIABILITY; DESIGN; QUESTIONNAIRE; VALIDITY	Background: In prior military randomized trials, participants with persistent symptoms after mild traumatic brain injury (TBI) reported improvement regardless of receiving hyperbaric oxygen (HBO2) or sham intervention. This study's objectives were to identify outcomes for future efficacy trials and describe changes by intervention. Methods: This Phase II, randomized, double-blind, sham-controlled trial enrolled military personnel with mild TBI and persistent post-concussive symptoms. Participants were randomized to receive 40 HBO2 (1.5 atmospheres absolute (ATA), >99% oxygen, 60 minutes) or sham chamber sessions (1.2 ATA, room air, 60 minutes) over 12 weeks. Participants and evaluators were blinded to allocation. Outcomes assessed at baseline, 13 weeks and six months included symptoms, quality of life, neuropsychological, neurological, electroencephalography, sleep, auditory, vestibular, autonomic, visual, neuroimaging, and laboratory testing. Participants completed 12-month questionnaires. Intention-to-treat results are reported. Results: From 9/11/2012 to 5/19/2014, 71 randomized participants received HBO2 (n=36) or sham (n=35). At baseline, 35 participants (49%) met post-traumatic stress disorder (PTSD) criteria. By the Neurobehavioral Symptom Inventory, the HBO2 group had improved 13-week scores (mean change -3.6 points, P=0.03) compared to sham (+3.9 points). In participants with PTSD, change with HBO2 was more pronounced (-8.6 vs. +4.8 points with sham, P=0.02). PTSD symptoms also improved in the HBO2 group, and more so in the subgroup with PTSD. Improvements regressed at six and 12 months. Hyperbaric oxygen improved some cognitive processing speed and sleep measures. Participants with PTSD receiving HBO2 had improved functional balance and reduced vestibular complaints at 13 weeks. Conclusions: By 13 weeks, HBO2 improved post-concussive and PTSD symptoms, cognitive processing speed, sleep quality, and balance function, most dramatically in those with PTSD. Changes did not persist beyond six months. Several outcomes appeared sensitive to change; additional studies are warranted.	[Weaver, Lindell K.; Churchill, Susan; Deru, Kayla] Intermt Med Ctr, Div Hyperbar Med, Murray, UT 84107 USA; [Weaver, Lindell K.; Churchill, Susan; Deru, Kayla] Intermt LDS Hosp, Salt Lake City, UT 84143 USA; [Weaver, Lindell K.; Mirow, Susan] Univ Utah, Sch Med, Salt Lake City, UT 84112 USA; [Wilson, Steffanie H.; Lindblad, Anne S.] Emmes Corp, Rockville, MD USA; [Price, Robert C.] Evans Army Community Hosp, Ft Carson, CO USA; [Williams, Chris S.; Orrison, William W.; Walker, James M.; Meehan, Anna; Mirow, Susan] Lovelace Biomed Res, Albuquerque, NM USA		Weaver, LK (corresponding author), Intermt Med Ctr, Div Hyperbar Med, Murray, UT 84107 USA.; Weaver, LK (corresponding author), Intermt LDS Hosp, Salt Lake City, UT 84143 USA.; Weaver, LK (corresponding author), Univ Utah, Sch Med, Salt Lake City, UT 84112 USA.	lindell.weaver@imail.org			U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-15-D-0039-0003]	This work is supported by the U.S. Army Medical Research and Materiel Command under Contract No. W81XWH-15-D-0039-0003.	Allen RP, 2003, SLEEP MED, V4, P101, DOI 10.1016/S1389-9457(03)00010-8; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Anic-Labat S, 1999, SLEEP, V22, P77; [Anonymous], 2008, BALANCE FUNCTION ASS; Badke MB, 2004, ARCH PHYS MED REHAB, V85, P227, DOI 10.1016/j.apmr.2003.06.006; Basco MR, 2000, AM J PSYCHIAT, V157, P1599, DOI 10.1176/appi.ajp.157.10.1599; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Becker S, 2003, J COGNITIVE NEUROSCI, V15, P821, DOI 10.1162/089892903322370744; Benedict R, 1996, REVISION BRIEF VISUO; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; Bishop GD, 1998, PERS INDIV DIFFER, V24, P867, DOI 10.1016/S0191-8869(98)00024-5; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; >Centers for Disease Control and Prevention (CDC) the National Institutes of Health (NIH) the Department of Defense (DoD) & the Department of Veterans Affairs (VA) Leadership Panel, 2013, C TRAUM BRAIN INJ US; Chiu WT, 2006, J NEUROTRAUM, V23, P1609, DOI 10.1089/neu.2006.23.1609; Chung F, 2014, J CLIN SLEEP MED, V10, P951, DOI 10.5664/jcsm.4022; Cifu DX, 2015, J HEAD TRAUMA REHAB, V30, P21, DOI 10.1097/HTR.0000000000000036; Cifu DX, 2014, J REHABIL RES DEV, V51, P1047, DOI 10.1682/JRRD.2014.01.0013; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; Cifu DX, 2014, J HEAD TRAUMA REHAB, V29, P11, DOI 10.1097/HTR.0b013e3182a6aaf0; Clark JF, 2017, CLIN J SPORT MED, V27, P457, DOI 10.1097/JSM.0000000000000381; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Edwards R H, 1977, Physiotherapy, V63, P51; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Felipe L, 2014, INT ARCH OTORHINOLAR, V18, P77, DOI 10.1055/s-0033-1352503; Figueroa XA, 2016, NEUROLOGY, V87, P1400, DOI 10.1212/WNL.0000000000003146; Flaherty S A, 1996, AANA J, V64, P133; FURMAN JM, 1995, OTOLARYNG HEAD NECK, V112, P8, DOI 10.1016/S0194-5998(95)70300-4; Golden C.J., 1978, MANUAL STROOP COLOR; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Hanna-Pladdy B, 2002, J NEUROL NEUROSUR PS, V73, P574, DOI 10.1136/jnnp.73.5.574; Harch PG, 2013, UNDERSEA HYPERBAR M, V40, P469; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hirvonen TP, 1999, J VESTIBUL RES-EQUIL, V9, P119; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; Hoge C, 2015, JAMA INTERN MED, V175, P53, DOI 10.1001/jamainternmed.2014.3375; Hurst H, 2004, J MANIP PHYSIOL THER, V27, P26, DOI 10.1016/j.jmpt.2003.11.003; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; King N, 2014, NEUROREHABILITATION, V34, P741, DOI 10.3233/NRE-141072; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kothari Mihir T., 2005, Indian Journal of Ophthalmology, V53, P43; Lee C T, 1998, SPUMS J, V28, P125; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCrary BF, 2013, UNDERSEA HYPERBAR M, V40, P443; Meehan A, 2016, UNDERSEA HYPERBAR M, V43, P567; Miller RS, 2015, JAMA INTERN MED, V175, P43, DOI 10.1001/jamainternmed.2014.5479; Mirow S, 2016, UNDERSEA HYPERBAR M, V43, P531; Mitchell SJ, 2014, DIVING HYPERB MED, V44, P228; Moher D., 2010, BMJ, V340; Morgenthaler T, 2007, SLEEP, V30, P519, DOI 10.1093/sleep/30.4.519; OLEARY DP, 1990, NEUROL CLIN, V8, P297, DOI 10.1016/S0733-8619(18)30357-8; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scorza KA, 2013, UNDERSEA HYPERBAR M, V40, P548; Shandley S, 2017, UNDERSEA HYPERBAR M, V44, P257; Skipper LD, 2016, UNDERSEA HYPERBAR M, V43, P601; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; TANG DI, 1993, BIOMETRICS, V49, P23, DOI 10.2307/2532599; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Walker JM, 2016, UNDERSEA HYPERBAR M, V43, P549; Walker WC, 2014, NEUROREHAB NEURAL RE, V28, P420, DOI 10.1177/1545968313516869; Weaver LK, 2016, UNDERSEA HYPERBAR M, V43, P485; Weaver LK, 2013, UNDERSEA HYPERBAR M, V40, P471; Weaver LK, 2012, UNDERSEA HYPERBAR M, V39, P807; Wechsler D., 2008, WECHSLER ADULT INTEL; WechslerD, 2001, WECHSLER TEST ADULT; Williams CS, 2016, UNDERSEA HYPERBAR M, V43, P511; Williams CS, 2016, UNDERSEA HYPERBAR M, V43, P521; Wilson SH, 2016, UNDERSEA HYPERBAR M, V43, P615; Wilson SH, 2016, UNDERSEA HYPERBAR M, V43, P585; Wolf EG, 2015, UNDERSEA HYPERBAR M, V42, P313; Wolf EG, 2012, UNDERSEA HYPERBAR M, V39, P1075; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	85	25	27	2	11	UNDERSEA & HYPERBARIC MEDICAL SOC INC	DURHAM	21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA	1066-2936			UNDERSEA HYPERBAR M	Undersea Hyperb. Med.	MAR-APR	2018	45	2					129	156					28	Marine & Freshwater Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Marine & Freshwater Biology; Research & Experimental Medicine	GF0XQ	WOS:000431655500001	29734566				2022-02-06	
J	Lagerstedt, L; Egea-Guerrero, JJ; Rodriguez-Rodriguez, A; Bustamante, A; Montaner, J; El Rahal, A; Andereggen, E; Rinaldi, L; Sarrafzadeh, A; Schaller, K; Sanchez, JC				Lagerstedt, Linnea; Jose Egea-Guerrero, Juan; Rodriguez-Rodriguez, Ana; Bustamante, Alejandro; Montaner, Joan; El Rahal, Amir; Andereggen, Elisabeth; Rinaldi, Lara; Sarrafzadeh, Asita; Schaller, Karl; Sanchez, Jean-Charles			Early measurement of interleukin-10 predicts the absence of CT scan lesions in mild traumatic brain injury	PLOS ONE			English	Article							FIBRILLARY ACIDIC PROTEIN; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; SERUM; EXPRESSION; BIOMARKERS; S100-BETA; MARKER; S100B	Traumatic brain injury is a common event where 70%-90% will be classified as mild TBI (mTBI). Among these, only 10% will have a brain lesion visible via CT scan. A triage biomarker would help clinicians to identify patients with mTBI who are at risk of developing a brain lesion and require a CT scan. The brain cells damaged by the shearing, tearing and stretching of a TBI event set off inflammation cascades. These cause altered concentrations of a high number of both pro-inflammatory and anti-inflammatory proteins. This study aimed to discover a novel diagnostic biomarker of mTBI by investigating a broad panel of inflammation biomarkers and their capacity to correctly identify CT-positive and CT-negative patients. Patients enrolled in this study had been diagnosed with mTBI, had a GCS score of 15 and suffered from at least one clinical symptom. There were nine patients in the discovery group, 45 for verification, and 133 mTBI patients from two different European sites in the validation cohort. All patients gave blood samples, underwent a CT scan and were dichotomised into CT-positive and CT-negative groups for statistical analyses. The ability of each protein to classify patients was evaluated with sensitivity set at 100%. Three of the 92 inflammation proteins screened-MCP-1, MIP-1alpha and IL-10-were further investigated in the verification group, and at 100% sensitivity their specificities reached 7%, 0% and 31%, respectively. IL-10 was validated on a larger cohort in comparison to the most studied mTBI diagnostic triage protein to date, S100B. Levels of both proteins were significantly higher in CT-positive than in CT-negative patients (p < 0.001). S100B's specificity at 100% sensitivity was 18% (95% CI 10.8-25.2), whereas IL-10 reached a specificity of 27% (95% CI 18.9-35.1). These results showed that IL-10 might be an interesting and clinically useful diagnostic tool, capable of differentiating between CT-positive and CT-negative mTBI patients.	[Lagerstedt, Linnea; Sanchez, Jean-Charles] Univ Geneva, Fac Med, Dept Human Prot Sci, Geneva, Switzerland; [Jose Egea-Guerrero, Juan; Rodriguez-Rodriguez, Ana] Virgen del Rocio Univ Hosp, NeuroCrit Care Unit, Seville, Spain; [Bustamante, Alejandro; Montaner, Joan] Univ Autonoma Barcelona, VHIR, Neurovasc Res Lab, Barcelona, Spain; [Montaner, Joan] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Stroke Res Programme,IBiS, Seville, Spain; [Montaner, Joan] Hosp Univ Virgen Macarena, Dept Neurol, Seville, Spain; [El Rahal, Amir; Sarrafzadeh, Asita; Schaller, Karl] Geneva Univ Hosp, Dept Clin Neurosci, Geneva Neurosci Ctr, Div Neurosurg, Geneva, Switzerland; [Andereggen, Elisabeth; Rinaldi, Lara] Geneva Univ Hosp, Emergency Ctr, Geneva, Switzerland; [Andereggen, Elisabeth] Geneva Univ Hosp, Dept Surg, Geneva, Switzerland		Sanchez, JC (corresponding author), Univ Geneva, Fac Med, Dept Human Prot Sci, Geneva, Switzerland.	Jean-Charles.Sanchez@unige.ch	Montaner, Joan/D-3063-2015; IBiS, Neurovascular/P-5842-2016; Egea-Guerrero, Juan Jose JJ/P-5080-2014	Montaner, Joan/0000-0003-4845-2279; IBiS, Neurovascular/0000-0001-9511-0672; Egea-Guerrero, Juan Jose JJ/0000-0002-4166-313X; Lagerstedt, Linnea/0000-0002-3405-9938			Adrian H, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0294-16.2016; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bogoslovsky T, 2016, DIAGNOSTICS, P6; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Graber DJ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0298-4; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Heidari K, 2015, BRAIN INJURY, V29, P1146, DOI [10.3109/02699052.2014.948068, 10.3109/02699052.2015.1037349]; Ho L, 2012, J ALZHEIMERS DIS, V31, P301, DOI 10.3233/JAD-2012-120598; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Lagerstedt L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175572; Lescuyer Pierre, 2005, Mol Diagn, V9, P1, DOI 10.2165/00066982-200509010-00001; Liu S, 2013, J MOL NEUROSCI, V51, P1021, DOI 10.1007/s12031-013-0091-8; Mayer CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062101; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Neher MD, 2014, SOUTH MED J, V107, P248, DOI 10.1097/SMJ.0000000000000086; North SH, 2012, ANNU REV ANAL CHEM, V5, P35, DOI 10.1146/annurev-anchem-062011-143105; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L., 2015, BRAIN NEUROTRAUMA MO; Papa L, 2016, JAMA NEUROL; Papa L, 2017, J NEUROTRAUMA; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pelsers MMAL, 2005, CLIN CHEM LAB MED, V43, P802, DOI 10.1515/CCLM.2005.135; Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361; Posti J.P., 2017, J NEUROTRAUMA; Raj R, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-67; Trifunovic J, 2015, BIOCHEM MEDICA, V25, P36, DOI 10.11613/BM.2015.004; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Wang YP, 2016, COLD REG SCI TECHNOL, V126, P10, DOI 10.1016/j.coldregions.2016.02.013; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Werhane ML, 2017, CONCUSSION CNC30; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	44	25	27	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2018	13	2							e0193278	10.1371/journal.pone.0193278			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW8RO	WOS:000425604300107	29466474	Green Published, Green Submitted, gold			2022-02-06	
J	Georgoff, PE; Nikolian, VC; Bonham, T; Pai, MP; Tafatia, C; Halaweish, I; To, K; Watcharotone, K; Parameswaran, A; Luo, RJ; Sun, DX; Alam, HB				Georgoff, Patrick E.; Nikolian, Vahagn C.; Bonham, Tess; Pai, Manjunath P.; Tafatia, Celia; Halaweish, Ihab; To, Kathleen; Watcharotone, Kuanwong; Parameswaran, Aishwarya; Luo, Ruijuan; Sun, Duxin; Alam, Hasan B.			Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial	CLINICAL PHARMACOKINETICS			English	Article							TRAUMATIC BRAIN-INJURY; HISTONE DEACETYLASE INHIBITION; PHARMACOLOGICAL RESUSCITATION; HEMORRHAGIC-SHOCK; CLINICAL-TRIAL; MODEL; ACETYLATION; CANCER	Background Valproic acid, a histone deacetylase inhibitor, has beneficial effects in the setting of cancer, neurologic diseases, and traumatic injuries. In animal models of traumatic injury, a single dose of valproic acid has been shown to reduce mortality. The purpose of this trial was to determine the maximum tolerated single dose of intravenous valproic acid in healthy humans. Methods A double-blinded, placebo-controlled, dose-escalation trial design was used to identify dose-limiting toxicities in healthy subjects who received a single dose of intravenous valproic acid. Patients were monitored for adverse events and data were collected for pharmacokinetic, pharmacodynamic, and safety profiling of valproic acid. Results Fifty-nine healthy subjects (mean 30 +/- 12 years) were enrolled. Forty-four subjects received valproic acid in doses from 15 to 150 mg/kg. The most common adverse events were hypoacusis (n = 19), chills (n = 18), and headache (n = 16). The maximum tolerated dose was 140 mg/kg. Dose-limiting toxicities included headache and nausea lasting longer than 12 h. No drug-related abnormalities were seen in other safety measures including laboratory tests, hemodynamic parameters, cardiac rhythm monitoring, and cognitive testing. A two-compartment model was predictive of valproic acid concentration-time profiles, with a strong correlation (R-2 = 0.56) observed between the number of reported adverse events and the dose level. Conclusions The maximum tolerated dose of intravenous valproic acid in healthy subjects is 140 mg/kg. This is significantly higher than the previously established maximum tolerated dose of 60-75 mg/kg. Next, the safety and tolerability of high-dose valproic acid will be tested in trauma patients in hemorrhagic shock.	[Georgoff, Patrick E.; Nikolian, Vahagn C.; Bonham, Tess; Tafatia, Celia; Halaweish, Ihab; To, Kathleen; Alam, Hasan B.] Univ Michigan, Sch Med, Dept Gen Surg, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA; [Pai, Manjunath P.] Univ Michigan, Coll Pharm, Dept Clin Pharm, 428 Church St, Ann Arbor, MI 48109 USA; [Watcharotone, Kuanwong; Parameswaran, Aishwarya] Univ Michigan, Sch Med, Michigan Inst Clin & Hlth Res, Ann Arbor, MI USA; [Luo, Ruijuan; Sun, Duxin] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA		Alam, HB (corresponding author), Univ Michigan, Sch Med, Dept Gen Surg, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu	Sun, Duxin/AAA-1774-2022		Department of Defense Office of Naval ResearchOffice of Naval ResearchUnited States Department of Defense [N000141310071]; National Institutes of Health Center for Advancing Translational Sciences [UL1TR000433]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000433, UL1TR002240] Funding Source: NIH RePORTER	This work was funded by the Department of Defense Office of Naval Research (N000141310071) and the National Institutes of Health Center for Advancing Translational Sciences (UL1TR000433). The Michigan Institute for Clinical Health Research provided guidance, data design, and clinical research space. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, or the US Department of Defense.	Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851; BOYUM A, 1977, LYMPHOLOGY, V10, P71; Brown E., 2006, PHARMACOVIGILANCE; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Dekker SE, 2014, J TRAUMA ACUTE CARE, V77, P906, DOI 10.1097/TA.0000000000000345; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fukudome EY, 2010, J SURG RES, V163, P118, DOI 10.1016/j.jss.2010.04.013; Georgoff PE, 2016, J TRAUMA ACUTE CARE, V81, P1020, DOI 10.1097/TA.0000000000001249; Gottlicher M, 2004, Ann Hematol, V83 Suppl 1, pS91; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUGLER R, 1980, CLIN PHARMACOKINET, V5, P67, DOI 10.2165/00003088-198005010-00002; Halaweish I, 2015, J TRAUMA ACUTE CARE, V79, P911, DOI 10.1097/TA.0000000000000789; Halaweish I, 2015, SHOCK, V44, P6, DOI 10.1097/SHK.0000000000000319; Higgins GA, 2017, NETWORK RECONSTRUCTI, DOI [10.1007/s11095-017-2130-6, DOI 10.1007/S11095-017-2130-6]; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Jepsen CH, 2014, J TRAUMA ACUTE CARE, V77, P292, DOI 10.1097/TA.0000000000000333; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Li YQ, 2010, SURGERY, V148, P246, DOI 10.1016/j.surg.2010.05.003; Munster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165; Nikolian V, 2016, PHARM RESUSCITATION; Perucca E, 2002, CNS DRUGS, V16, P695, DOI 10.2165/00023210-200216100-00004; Pons PT, 2015, J EMERG MED, V49, P878, DOI 10.1016/j.jemermed.2015.09.013; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Spiller HA, 2000, J TOXICOL-CLIN TOXIC, V38, P755, DOI 10.1081/CLT-100102388; Toussirot E, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0002-6; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Zhao T, 2013, SURGERY, V154, P206, DOI 10.1016/j.surg.2013.04.003	30	25	25	0	4	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0312-5963	1179-1926		CLIN PHARMACOKINET	Clin. Pharmacokinet.	FEB	2018	57	2					209	219		10.1007/s40262-017-0553-1			11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	FT7QS	WOS:000423348300005	28497259	Green Accepted			2022-02-06	
J	Merritt, VC; Rabinowitz, AR; Arnett, PA				Merritt, Victoria C.; Rabinowitz, Amanda R.; Arnett, Peter A.			The Influence of the Apolipoprotein E (APOE) Gene on Subacute Post-Concussion Neurocognitive Performance in College Athletes	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						APOE gene; Genetics; Mild traumatic brain injury; Neuropsychological tests; Performance variability; Sports-related concussion	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; INTRAINDIVIDUAL VARIABILITY; ALZHEIMERS-DISEASE; HEAD-INJURY; RISK-FACTORS; E GENOTYPE; COGNITIVE PERFORMANCE; MILITARY POPULATION; PROSPECTIVE COHORT	Objective: The purpose of this study was to determine whether the epsilon 4 allele of the APOE gene influences neurocognitive outcome following sports-related concussion. It was hypothesized that participants with an epsilon 4 allele would show poorer neurocognitive performance and greater neurocognitive variability than those without an epsilon 4 allele. Method: Participants included 57 concussed collegiate athletes (77.2% male) who participated in a concussion management program at a large university. All athletes underwent a comprehensive neuropsychological assessment and provided a DNA sample for determination of their APOE genotype. The test battery included measures sensitive to concussion, covering the broad domains of learning and memory, attention, processing speed, and executive functions. Results: The sample was divided into epsilon 4 + (n = 20) and epsilon 4 -(n = 37) groups. No significant differences were found between athletes with and without an epsilon 4 allele when examining mean neurocognitive standardized scores (all p >.05; d = 0.16-0.18). However, athletes with an epsilon 4 allele were more likely to show a greater number of impaired neurocognitive scores post-injury compared to athletes without an epsilon 4 allele, chi(2)(1, N = 57) = 3.96, p = <.05, phi = 0.26. Additionally, athletes with an epsilon 4 allele demonstrated greater neurocognitive variability than athletes without an epsilon 4 allele, t(55) = -2.04, p <.05, d = 0.53. Conclusions: This research furthers our understanding of how genetic factors uniquely contribute to neurocognitive performance differences following concussion. Our findings suggest a possible relationship between the epsilon 4 allele and post-concussion impairment, as well as between the epsilon 4 allele and neurocognitive performance variability, suggesting that the epsilon 4 genotype may be a risk factor for less efficient cognitive processing in concussed athletes.	[Merritt, Victoria C.; Arnett, Peter A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Rabinowitz, Amanda R.] Moss Rehabil Res Inst, Elkins Pk, PA USA		Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, University Pk, PA 16802 USA.	vcabarnes@gmail.com		Merritt, Victoria/0000-0001-5683-4168	American Psychological Foundation	This work was supported by a grant from the American Psychological Foundation (no grant number exists).	Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Allen L. M., 1999, MANUAL COMPUTERIZED; Anstey KJ, 2007, NEUROPSYCHOLOGIA, V45, P1911, DOI 10.1016/j.neuropsychologia.2006.11.020; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Arnett P., 2014, CONCUSSION ATHLETICS, P35; Backman L, 2006, NEUROSCI BIOBEHAV R, V30, P791, DOI 10.1016/j.neubiorev.2006.06.005; Bartzokis G, 2006, ARCH GEN PSYCHIAT, V63, P63, DOI 10.1001/archpsyc.63.1.63; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benedict, 2001, HOPKINS VERBAL LEARN; Benedict R., 1997, BRIEF VISUOSPATIAL M; Burton CL, 2006, J CLIN EXP NEUROPSYC, V28, P67, DOI 10.1080/13803390490918318; Cegalis J.A., 1994, VIGIL W CONTINUOUS P; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Christensen Helen, 2008, BMC Geriatr, V8, P14, DOI 10.1186/1471-2318-8-14; Cole VT, 2011, SCHIZOPHR RES, V129, P91, DOI 10.1016/j.schres.2011.03.007; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Finnoff JT, 2011, PM&R, V3, pS452, DOI 10.1016/j.pmrj.2011.07.014; Fjell AM, 2011, J NEUROSCI, V31, P18060, DOI 10.1523/JNEUROSCI.4735-11.2011; Freeman B, 2003, BEHAV GENET, V33, P67, DOI 10.1023/A:1021055617738; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Han SD, 2009, J HEAD TRAUMA REHAB, V24, P57, DOI 10.1097/HTR.0b013e3181957055; Holtzer R, 2008, JAMA-J AM MED ASSOC, V300, P823, DOI 10.1001/jama.300.7.823; Hong Eun Pyo, 2012, Genomics & Informatics, V10, P117, DOI 10.5808/GI.2012.10.2.117; Hultsch DF, 2000, NEUROPSYCHOLOGY, V14, P588, DOI 10.1037/0894-4105.14.4.588; Ingelsson M, 2003, CURRENT PROTOCOLS HU, DOI DOI 10.1002/0471142905.HG0914S38.; Iverson G. L., 2011, HDB SPORT NEUROPSYCH, P131; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P923, DOI 10.1007/978-0-387-76978-3_32; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lovden M, 2007, NEUROPSYCHOLOGIA, V45, P2827, DOI 10.1016/j.neuropsychologia.2007.05.005; Lovell M, 2000, IMPACT IMMEDIATE POS; Lovell M. R., 2012, IMMEDIATE POSTCONCUS; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Merritt V. C., 2016, ARCH CLIN NEUROPSYCH, V31, P1; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; PETERSEN RC, 1995, JAMA-J AM MED ASSOC, V273, P1274, DOI 10.1001/jama.273.16.1274; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; *PSYCH CORP, 2001, WECHSL TEST AD READ; Rabinowitz AR, 2013, NEUROPSYCHOLOGY, V27, P481, DOI 10.1037/a0033023; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; Schretlen DJ, 2003, J INT NEUROPSYCH SOC, V9, P864, DOI 10.1017/S1355617703960061; Silver JM, 2011, TXB TRAUMATIC BRAIN, VSecond; Smith A., 1991, SYMBOL DIGIT MODALIT; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Tierney RT, 2010, CLIN J SPORT MED, V20, P464, DOI 10.1097/JSM.0b013e3181fc0a81; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Walhovd KB, 2007, NEUROPSYCHOLOGIA, V45, P2277, DOI 10.1016/j.neuropsychologia.2007.02.022; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Wilson M, 2007, BRIT J ANAESTH, V99, P43, DOI 10.1093/bja/aem142	72	25	25	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2018	33	1					36	46		10.1093/arclin/acx051			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	FU8XL	WOS:000424139500004	28541413	Bronze			2022-02-06	
J	Silverberg, ND; Panenka, WJ; Iverson, GL				Silverberg, Noah D.; Panenka, William J.; Iverson, Grant L.			Work Productivity Loss After Mild Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Craniocerebral trauma; Occupational health; Post-concussion syndrome; Presenteeism; Rehabilitation; Return to work	HEAD-INJURY; TO-WORK; DSM-IV; RETURN; SYMPTOMS; CONCUSSION; DISABILITY; EMPLOYMENT; PREDICTION; COMPLAINTS	Objectives: To examine the completeness of return to work (RTW) and the degree of productivity loss in individuals who do achieve a complete RTW after mild traumatic brain injury (MTBI). Design: Multisite prospective cohort. Setting: Outpatient concussion clinics. Participants: Patients (N=79; mean age, 41.5y; 55.7% women) who sustained an MTBI and were employed at the time of the injury. Participants were enrolled at their first clinic visit and assessed by telephone 6 to 8 months postinjury. Interventions: Not applicable. Main Outcome Measures: Structured interview of RTW status, British Columbia Postconcussion Symptom Inventory (BC-PSI), Lam Employment Absence and Productivity Scale (LEAPS), Mini International Neuropsychiatric Interview, and brief pain questionnaire. Participants who endorsed symptoms from >= 3 categories with at least moderate severity on the BC-PSI were considered to meet International Classification of Diseases, 10th Revision criteria for postconcussional syndrome. RTW status was classified as complete if participants returned to their preinjury job with the same hours and responsibilities or to a new job that was at least as demanding. Results: Of the 46 patients (58.2%) who achieved an RTW, 33 (71.7%) had a complete RTW. Participants with complete RTW had high rates of postconcussional syndrome (44.5%) and comorbid depression (18.2%), anxiety disorder (24.2%), and bodily pain (30.3%). They also reported productivity loss on the LEAPS, such as "getting less work done" (60.6%) and "making more mistakes" (42.4%). In a regression model, productivity loss was predicted by the presence of postconcussional syndrome and a comorbid psychiatric condition, but not bodily pain. Conclusions: Even in patients who RTW after MTBI, detailed assessment revealed underemployment and productivity loss associated with residual symptoms and psychiatric complications. (C) 2017 by the American Congress of Rehabilitation Medicine	[Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada; [Silverberg, Noah D.; Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Panenka, William J.] British Columbia Neuropsychiat Program, Vancouver, BC, Canada; [Panenka, William J.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] A Red Sox Fdn, Home Base, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA		Silverberg, ND (corresponding author), GF Strong Rehab Ctr, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Panenka, William/0000-0001-7143-6512; Iverson, Grant/0000-0001-7348-9570	WorkSafeBC [RS2014-SP03]; Vancouver Coastal Health Research Institute	Supported by a Specific Priorities Research Grant from WorkSafeBC (grant no. RS2014-SP03), and by a Clinician-Scientist Career Development Award from the Vancouver Coastal Health Research Institute.	Baldwin ML, 1996, AM J IND MED, V29, P632; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Burton A.K., 2006, IS WORK GOOD YOUR HL; BUTLER RJ, 1995, IND LABOR RELAT REV, V48, P452, DOI 10.2307/2524774; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Koning ME, 2017, J NEUROTRAUM, V34, P257, DOI 10.1089/neu.2015.4377; Franche RL, 2005, J OCCUP REHABIL, V15, P607, DOI 10.1007/s10926-005-8038-8; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Jackson CE, 2017, BRAIN INJURY, V31, P485, DOI 10.1080/02699052.2017.1280740; Kendrick D, 2012, BRAIN INJURY, V26, P1243, DOI 10.3109/02699052.2012.672787; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Krause N, 1998, J OCCUP REHABIL, V8, P113, DOI 10.1023/A:1023015622987; Kristman VL, 2010, OPEN OCCUP HLTH SAF, V2, P1, DOI [10.2174/1876216601002010001, DOI 10.2174/1876216601002010001]; Lam RW, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-78; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8; Lucas S, 2016, HEADACHE, V56, P323, DOI 10.1111/head.12762; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; Ospina MB, 2015, AM J MANAG CARE, V21, pE171; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Schultz AB, 2007, J OCCUP REHABIL, V17, P547, DOI 10.1007/s10926-007-9096-x; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vikane E, 2014, BRAIN INJURY, V9052, P1; Vikane E, 2016, BEHAV NEUROL, V2016, DOI 10.1155/2016/8026414; Waljas M, 2014, J HEAD TRAUMA REHAB, V29, P443, DOI 10.1097/HTR.0000000000000002	35	25	25	1	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2018	99	2					250	256		10.1016/j.apmr.2017.07.006			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	FU7YX	WOS:000424069800005	28760573				2022-02-06	
J	Moszczynski, AJ; Strong, W; Xu, K; McKee, A; Brown, A; Strong, MJ				Moszczynski, Alexander J.; Strong, Wendy; Xu, Kathy; McKee, Ann; Brown, Arthur; Strong, Michael J.			Pathologic Thr(175) tau phosphorylation in CTE and CTE with ALS	NEUROLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; ALZHEIMER-DISEASE; FIBRIL FORMATION; HYPERPHOSPHORYLATION; INJURY; AGGREGATION; OLIGOMERS; IMPACT	ObjectiveTo investigate whether chronic traumatic encephalopathy (CTE) and CTE with amyotrophic lateral sclerosis (CTE-ALS) exhibit features previously observed in other tauopathies of pathologic phosphorylation of microtubule-associated protein tau at Thr(175) (pThr(175) tau) and Thr(231) (pThr(231) tau), and glycogen synthase kinase-3 (GSK3) activation, and whether these pathologic features are a consequence of traumatic brain injury (TBI).MethodsTau isoform expression was assayed by western blot in 6 stage III CTE cases. We also used immunohistochemistry to analyze 5 cases each of CTE, CTE-ALS, and 5 controls for expression of activated GSK3, pThr(175) tau, pThr(231) tau, and oligomerized tau within spinal cord tissue and hippocampus. Using a rat model of moderate TBI, we assessed tau pathology and phospho-GSK3 expression at 3 months postinjury.ResultsCTE and CTE-ALS are characterized by the presence of all 6 tau isoforms in both soluble and insoluble tau isolates. Activated GSK3, pThr(175) tau, pThr(231) tau, and oligomerized tau protein expression was observed in hippocampal neurons and spinal motor neurons. We observed tau neuronal pathology (fibrillar inclusions and axonal damage) and increased levels of pThr(175) tau and activated GSK3 in moderate TBI rats.ConclusionsPathologic phosphorylation of tau at Thr(175) and Thr(231) and activation of GSK3 are features of the tauopathy of CTE and CTE-ALS. These features can be replicated in an animal model of moderate TBI.	[Moszczynski, Alexander J.; Strong, Wendy; Xu, Kathy; Brown, Arthur; Strong, Michael J.] Western Univ, Schulich Sch Med & Dent, Mol Med Res Grp, Robarts Res Inst, London, ON, Canada; [Strong, Michael J.] Western Univ, Schulich Sch Med & Dent, Dept Clin Neurol Sci, London, ON, Canada; [McKee, Ann] Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, VA Boston Healthcare Syst, Boston, MA 02215 USA		Strong, MJ (corresponding author), Western Univ, Schulich Sch Med & Dent, Mol Med Res Grp, Robarts Res Inst, London, ON, Canada.; Strong, MJ (corresponding author), Western Univ, Schulich Sch Med & Dent, Dept Clin Neurol Sci, London, ON, Canada.	mstrong@uwo.ca	Strong, Michael/AAU-5699-2020; Strong, Michael J/H-9689-2012; Lang, Steven/AAE-8102-2021; Brown, Arthur/K-8328-2013	Strong, Michael/0000-0003-1988-6262; Lang, Steven/0000-0003-1669-9146; Brown, Arthur/0000-0002-8725-3195	Ontario Neurodegenerative Disease Research Initiative; Windsor-Essex ALS Society; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	Research supported by an operating grant from the Ontario Neurodegenerative Disease Research Initiative and the Windsor-Essex ALS Society.	Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; BueeScherrer V, 1996, ACTA NEUROPATHOL, V91, P351, DOI 10.1007/s004010050436; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Delacourte A, 1996, J NEUROPATH EXP NEUR, V55, P159, DOI 10.1097/00005072-199602000-00004; Delacourte A, 1998, ANN NEUROL, V43, P193, DOI 10.1002/ana.410430209; Foote Molly, 2012, Int J Biochem Mol Biol, V3, P152; GARRUTO RM, 1991, NEUROTOXICOLOGY, V12, P347; Gohar M, 2009, J NEUROCHEM, V108, P634, DOI 10.1111/j.1471-4159.2008.05791.x; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HIRANO A, 1961, BRAIN, V84, P662, DOI 10.1093/brain/84.4.662; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Li DW, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00290; Lin YT, 2007, J NEUROCHEM, V103, P802, DOI 10.1111/j.1471-4159.2007.04792.x; Mattsson N, 2009, JAMA-J AM MED ASSOC, V302, P385, DOI 10.1001/jama.2009.1064; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Moszczynski AJ, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-016-0406-4; Moszczynski AJ, 2015, NEUROBIOL AGING, V36, P1590, DOI 10.1016/j.neurobiolaging.2014.12.001; Nakamura K, 2013, PRION, V7, P117, DOI 10.4161/pri.22849; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Schwalbe M, 2015, STRUCTURE, V23, P1448, DOI 10.1016/j.str.2015.06.002; Strong MJ, 2006, NEUROLOGY, V66, P1770, DOI 10.1212/01.wnl.0000218161.15834.db; Tartaglia MC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00030; Thomsen GM, 2016, J TRAUMA ACUTE CARE, V81, P1070, DOI 10.1097/TA.0000000000001248; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Ward SM, 2012, BIOCHEM SOC T, V40, P667, DOI 10.1042/BST20120134; Yang WC, 2005, DEV BRAIN RES, V156, P127, DOI 10.1016/j.devbrainres.2005.02.004; Yang WC, 2012, AMYOTROPH LATERAL SC, V13, P178, DOI 10.3109/17482968.2011.622405	34	25	25	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 30	2018	90	5					E380	+		10.1212/WNL.0000000000004899			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FZ7RQ	WOS:000427799000004	29298849	Green Published, hybrid			2022-02-06	
J	Armistead-Jehle, P; Cooper, DB; Grills, CE; Cole, WR; Lippa, SM; Stegman, RL; Lange, RT				Armistead-Jehle, Patrick; Cooper, Douglas B.; Grills, Chad E.; Cole, Wesley R.; Lippa, Sara M.; Stegman, Robert L.; Lange, Rael T.			Clinical utility of the mBIAS and NSI validity-10 to detect symptom over-reporting following mild TBI: A multicenter investigation with military service members	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						mBIAS; MMPI-2-RF; NSI Validity-10; symptom over-reporting; military	TRAUMATIC BRAIN-INJURY; DEFINED MALINGERING GROUPS; BIAS SCALE RBS; POSTCONCUSSIVE SYMPTOMS; PSYCHOMETRIC PROPERTIES; ANALOG SIMULATION; PTSD CHECKLIST; CUTOFF SCORES; SAMPLE; MMPI-2-RF	Self-report measures are commonly relied upon in military healthcare environments to assess service members following a mild traumatic brain injury (mTBI). However, such instruments are susceptible to over-reporting and rarely include validity scales. This study evaluated the utility of the mild Brain Injury Atypical Symptoms scale (mBIAS) and the Neurobehavioral Symptom Inventory Validity-10 scale to detect symptom over-reporting. A total of 359 service members with a reported history of mTBI were separated into two symptom reporting groups based on MMPI-2-RF validity scales (i.e., non-over-reporting versus symptom over-reporting). The clinical utility of the mBIAS and Validity-10 as diagnostic indicators and screens of symptom over-reporting were evaluated by calculating sensitivity, specificity, positive test rate, positive predictive power (PPP), and negative predictive power (NPP) values. An mBIAS cut score of 10 was optimal as a diagnostic indicator, which resulted in high specificity and PPP; however, sensitivity was low. The utility of the mBIAS as a screening instrument was limited. A Validity-10 cut score of 33 was optimal as a diagnostic indicator. This resulted in very high specificity and PPP, but low sensitivity. A Validity-10 cut score of 7 was considered optimal as a screener, which resulted in moderate sensitivity, specificity, NPP, but relatively low PPP. Owing to low sensitivity, the current data suggests that both the mBIAS and Validity-10 are insufficient as stand-alone measures of symptom over-reporting. However, Validity-10 scores above the identified cut-off of 7should be taken as an indication that further evaluation to rule out symptom over-reporting is necessary.	[Armistead-Jehle, Patrick] Munson Army Hlth Ctr, Concuss Clin, 550 Pope Ave, Ft Leavenworth, KS 66027 USA; [Cooper, Douglas B.] San Antonio Mil Med Ctr, Dept Neurol, San Antonio, TX USA; [Cooper, Douglas B.; Cole, Wesley R.; Lippa, Sara M.; Lange, Rael T.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Grills, Chad E.] US Army Hlth Clin, Brain Injury Clin, Schofield Barracks, HI USA; [Cole, Wesley R.; Stegman, Robert L.] Womack Army Med Ctr, Dept Brain Injury Med, Ft Bragg, NC USA; [Lippa, Sara M.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Dept Neurol, Bethesda, MD USA; [Lippa, Sara M.; Lange, Rael T.] Natl Intrepid Ctr Excellence, Bethesda, MD USA		Armistead-Jehle, P (corresponding author), Munson Army Hlth Ctr, Concuss Clin, 550 Pope Ave, Ft Leavenworth, KS 66027 USA.	patrick.j.armistead-jehle.civ@mail.mil	Armistead-Jehle, Patrick/AAU-5741-2020	Armistead-Jehle, Patrick/0000-0002-6784-1432			American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Ben-Porath Y. S., 2011, MANUAL ADM SCORING I; Ben-Porath YS, 2008, MANUAL ADM SCORING I; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Butcher J. N., 2001, MMPI 2 MINNESOTA MUL; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Defense and Veteran Brain Injury Center, DOD WORLDW NUMB TBI; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Grills CE, 2016, APPL NEUROPSYCH-ADUL, V23, P295, DOI 10.1080/23279095.2015.1079713; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ingram PB, 2016, CLIN NEUROPSYCHOL, V30, P473, DOI 10.1080/13854046.2016.1187769; Jones A, 2016, ARCH CLIN NEUROPSYCH, V31, P786, DOI 10.1093/arclin/acw035; Jones A, 2016, ARCH CLIN NEUROPSYCH, V31, P273, DOI 10.1093/arclin/acw006; Jones A, 2011, CLIN NEUROPSYCHOL, V25, P1207, DOI 10.1080/13854046.2011.600726; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P853, DOI 10.1080/13803395.2015.1064864; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P325, DOI 10.1080/13803395.2015.1013021; Lange RT, 2013, J CLIN EXP NEUROPSYC, V35, P192, DOI 10.1080/13803395.2012.761677; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lippa SM, 2016, J CLIN EXP NEUROPSYC, V38, P721, DOI 10.1080/13803395.2016.1161732; Lippa SM, 2016, J REHABIL RES DEV, V53, P379, DOI 10.1682/JRRD.2015.01.0009; Lippa SM, 2014, ARCH CLIN NEUROPSYCH, V29, P236, DOI 10.1093/arclin/acu002; McCrea M., 2008, MILD TRAUMATIC BRAIN; Morey, 1991, PERSONALITY ASSESSME; Sullivan KA, 2016, APPL NEUROPSYCH-ADUL, V23, P353, DOI 10.1080/23279095.2015.1079714; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tarescavage AM, 2013, CLIN NEUROPSYCHOL, V27, P313, DOI 10.1080/13854046.2012.744099; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001	39	25	25	1	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2018	40	3					213	223		10.1080/13803395.2017.1329406			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	FV7WV	WOS:000424797100001	28539077				2022-02-06	
J	Bailey, KC; Soble, JR; O'Rourke, JJF				Bailey, K. Chase; Soble, Jason R.; O'Rourke, Justin J. F.			Clinical utility of the Rey 15-Item Test, recognition trial, and error scores for detecting noncredible neuropsychological performance in a mixed clinical sample of veterans	CLINICAL NEUROPSYCHOLOGIST			English	Article						Performance Validity Assessment; Rey 15-Item Test; Test of Memory Malingering (TOMM); veterans; psychometrics	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; MEMORY MALINGERING TOMM; SCREENING MEASURE; SPECIFICITY; SEVERITY; NAN	Objective: This cross-sectional study examined the Rey 15-Item Test (RFIT), Recognition Trial, and Error Scores for identifying noncredible performance in a mixed clinical veteran sample compared to another widely used validity measure, the Test of Memory Malingering (TOMM). Method: Sixty-two veterans who completed the RFIT (Recall/Recognition Trials), TOMM, and Word Memory Test (WMT) during clinical evaluation were included. Using the WMT as the criterion, 71% (N = 44) were classified as valid and 29% (N = 18) as invalid. Results: Among valid participants, 25% failed the RFIT Recall, whereas 78% of invalid participants passed (sensitivity: 22%; specificity: 75%; diagnostic odds ratio [DOR]: .86). The Recognition Trial increased sensitivity to 39% for identifying invalid performance, but 25% of valid participants still scored below cut-off (specificity: 75%; DOR: 1.91). RFIT Recall and Recognition Trial logistic regression and receiver operating characteristic (ROC) analyses were nonsignificant, with respective classification accuracies of 71 and 72.6% and areas under the curve (AUCs) of .52 and .55. RFIT Error Scores also failed to differentiate validity groups. In contrast, TOMM had stronger psychometric properties (sensitivity: 50%; specificity: 97.7%; DOR: 43; classification accuracy: 82.3%; AUC: .91). Moreover, RFIT Recall and Recognition failure rates were 14 and 22% greater, respectively, among those with cognitive impairment, whereas 95% of those with impairment and 100% without passed the TOMM. Conclusion: Despite frequent use among VA neuropsychologists, the RFIT displayed limited ability to detect noncredible performance and misclassified a large percentage of valid participants in this mixed clinical veteran sample, suggesting limited utility with this population.	[Bailey, K. Chase; Soble, Jason R.; O'Rourke, Justin J. F.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA; [O'Rourke, Justin J. F.] South Texas Vet Hlth Care Syst, Polytrauma Rehabil Ctr, San Antonio, TX USA		Bailey, KC (corresponding author), South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA.	Kenneth.Bailey2@va.gov		Bailey, Kenneth/0000-0002-5389-5229			American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Benedict R., 1997, BRIEF VISUOSPATIAL M; Boone K. B., 2002, DOT COUNTING TEST MA; Boone K. B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Brewin B., 2012, NATL J; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Dandachi-FitzGerald B, 2016, PSYCHIAT RES, V239, P47, DOI 10.1016/j.psychres.2016.02.061; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Flaherty JM, 2015, BRAIN INJURY, V29, P1630, DOI 10.3109/02699052.2015.1075249; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P., 1996, WORD MEMORY TEST USE; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Griffin GAE, 1996, PSYCHOL ASSESSMENT, V8, P383; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hill BD, 2013, ARCH CLIN NEUROPSYCH, V28, P640, DOI 10.1093/arclin/act045; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Love CM, 2014, ASSESSMENT, V21, P618, DOI 10.1177/1073191114528028; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; National Center for Veterans Analysis and Statistics, 2015, US VET EL TRENDS STA; Nitch S. R., 2007, ASSESSMENT FEIGNED C, P29; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Pearson, 2009, ADV CLIN SOL WAIS 4; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rey A., 1964, EXAMEN CLIN PSYCHOL; Russo AC, 2012, ARCH CLIN NEUROPSYCH, V27, P840, DOI 10.1093/arclin/acs090; Sawyer RJ, 2017, CLIN NEUROPSYCHOL, V31, P207, DOI 10.1080/13854046.2016.1245787; Shamieh E., 1996, THESIS; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Soble JR, 2016, ARCH CLIN NEUROPSYCH, V31, P79, DOI 10.1093/arclin/acv084; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Spiegel E., 2007, THESIS; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wolfson, 1993, HALSTEAD REITAN NEUR; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730; [No title captured]	43	25	25	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2018	32	1					119	131		10.1080/13854046.2017.1333151			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	GD3XB	WOS:000430436000010	28555516				2022-02-06	
J	Chibbaro, S; Cebula, H; Todeschi, J; Fricia, M; Vigouroux, D; Abid, H; Kourbanhoussen, H; Pop, R; Nannavecchia, B; Gubian, A; Prisco, L; Ligarotti, GKI; Proust, F; Ganau, M				Chibbaro, Salvatore; Cebula, Helene; Todeschi, Julien; Fricia, Marco; Vigouroux, Doris; Abid, Houssem; Kourbanhoussen, Houssen; Pop, Raoul; Nannavecchia, Beniamino; Gubian, Arthur; Prisco, Lara; Ligarotti, Gianfranco K. I.; Proust, Francois; Ganau, Mario			Evolution of Prophylaxis Protocols for Venous Thromboembolism in Neurosurgery: Results from a Prospective Comparative Study on Low-Molecular-Weight Heparin, Elastic Stockings, and Intermittent Pneumatic Compression Devices	WORLD NEUROSURGERY			English	Article						Deep venous thrombosis (DVT); Intermittent pneumatic compression (IPC) devices; Low-molecular-weight heparin (LMWH); Neurosurgery; Pulmonary embolism (PE)	TRAUMATIC BRAIN-INJURY; THROMBOSIS; HEMORRHAGE; COHORT; RISK	BACKGROUND: The incidence of venous thromboembolism (VT) in neurosurgical practice is astonishingly high, representing a major cause of morbidity and mortality. Prophylaxis strategies include elastic stockings, low-molecular-weight heparin (LMWH), and intermittent pneumatic compression (IPC) devices. OBJECTIVE: To assess the safety and efficacy of 2 different VT prophylaxis protocols implemented in a European neurosurgical center. METHODS: All patients admitted for neurosurgical intervention between 2012 and 2016 were stratified as low, moderate, and high risk of VT and received a combination of elastic stockings and LMWH. The protocol was modified in 2014 with the inclusion of perioperative IPC devices for all patients and only in the high-risk group also postoperatively. RESULTS: At time of post-hoc analysis, data obtained from patients included in this study before 2014 (Protocol A, 3169 patients) were compared with those obtained after the introduction of IPC (Protocol B, 3818 patients). Among patients assigned to protocol A, 73 (2.3%) developed deep-vein thrombosis (DVT) and 28 (0.9%) developed pulmonary embolism (PE), 9 of which were fatal (0.3%). Among patients assigned to protocol B, 32 developed DVT (0.8%) and 7 (0.18%) developed PE, with 2 eventually resulting in the death of the patient. A post-hoc analysis confirmed that the use of preoperative LMWH was not associated with a statistically significant greater risk of postoperative bleeding. CONCLUSIONS: This study, despite its limitations of the nonrandomized design, seems to suggest that perioperative IPC devices are a non-negligible support in the prophylaxis of clinically symptomatic DVT and PE.	[Chibbaro, Salvatore; Cebula, Helene; Todeschi, Julien; Fricia, Marco; Vigouroux, Doris; Abid, Houssem; Kourbanhoussen, Houssen; Pop, Raoul; Nannavecchia, Beniamino; Gubian, Arthur; Prisco, Lara; Ligarotti, Gianfranco K. I.; Proust, Francois; Ganau, Mario] Hop Hautepierre, Dept Neurosurg, Strasbourg, France		Todeschi, J (corresponding author), Hop Hautepierre, Dept Neurosurg, Strasbourg, France.	julien.tod@gmail.com	Chibbaro, Salvatore/AAI-6368-2020; Prisco, Lara/X-9310-2018; Prisco, Lara/I-9267-2019; Pop, Raoul/S-9431-2019; Ganau, Mario/AAY-7233-2020	Prisco, Lara/0000-0001-6727-7870; Pop, Raoul/0000-0003-4417-1496; Ganau, Mario/0000-0002-8676-1147; Gubian, Arthur/0000-0002-3236-8163			Algattas H, 2017, NEUROSURGERY; Alshehri N, 2016, J NEURO-ONCOL, V130, P561, DOI 10.1007/s11060-016-2259-x; Borde TD, 2017, NEUROL INDIA, V65, P787, DOI 10.4103/neuroindia.NI_1237_15; Byrne JP, 2016, J AM COLL SURGEONS, V223, P621, DOI 10.1016/j.jamcollsurg.2016.06.382; Dengler BA, 2016, NEUROCRIT CARE, V25, P215, DOI 10.1007/s12028-016-0280-8; Dickinson LD, 1998, NEUROSURGERY, V43, P1074, DOI 10.1097/00006123-199811000-00039; Gallus AS, 1994, PREVENTION VENOUS TH; Ganau M, 2017, J CLIN NEUROSCI; Ganau M, 2012, CASE REP SURG, V2012, DOI 10.1155/2012/614321; Haines ST, 2003, AM J HEALTH-SYST PH, V60, pS3, DOI 10.1093/ajhp/60.suppl_7.S3; Iorio A, 2000, ARCH INTERN MED, V160, P2327, DOI 10.1001/archinte.160.15.2327; Maimone Giuseppe, 2013, Surg Neurol Int, V4, P67, DOI 10.4103/2152-7806.112605; Prisco L, 2012, J NEUROSURG SCI, V56, P131; Raabe A, 2001, ACTA NEUROCHIR, V143, P1, DOI 10.1007/s007010170131; Roderick P, 2005, HEALTH TECHNOL ASSES, V9, P1; RUFF RL, 1983, ANN NEUROL, V13, P334, DOI 10.1002/ana.410130320; Scherer AG, 2017, J NEUROSURG-PEDIATR, V20, P71, DOI 10.3171/2017.3.PEDS16588; Syrmos N, 2013, CASE REP SURG, V2013, DOI 10.1155/2013/209750; VALLADARES JB, 1980, NEUROSURGERY, V6, P138, DOI 10.1227/00006123-198002000-00004	19	25	28	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2018	109						E510	E516		10.1016/j.wneu.2017.10.012			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	FR4DD	WOS:000419015000063	29033376				2022-02-06	
J	Erdodi, LA; Tyson, BT; Abeare, CA; Zuccato, BG; Rai, JK; Seke, KR; Sagar, S; Roth, RM				Erdodi, Laszlo A.; Tyson, Bradley T.; Abeare, Christopher A.; Zuccato, Brandon G.; Rai, Jaspreet K.; Seke, Kristian R.; Sagar, Sanya; Roth, Robert M.			Utility of critical items within the Recognition Memory Test and Word Choice Test	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Critical item analysis; performance validity testing; Recognition Memory Test; Word Choice Test	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; COMPLEX FIGURE TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; ADVANCED CLINICAL SOLUTIONS; PERFORMANCE TEST-II; CARD SORTING TEST; RESPONSE BIAS; CLASSIFICATION ACCURACY; NEUROPSYCHOLOGICAL ASSESSMENT	This study was designed to examine the clinical utility of critical items within the Recognition Memory Test (RMT) and the Word Choice Test (WCT). Archival data were collected from a mixed clinical sample of 202 patients clinically referred for neuropsychological testing (54.5% male; mean age=45.3 years; mean level of education=13.9 years). The credibility of a given response set was psychometrically defined using three separate composite measures, each of which was based on multiple independent performance validity indicators. Critical items improved the classification accuracy of both tests. They increased sensitivity by correctly identifying an additional 2-17% of the invalid response sets that passed the traditional cutoffs based on total score. They also increased specificity by providing additional evidence of noncredible performance in response sets that failed the total score cutoff. The combination of failing the traditional cutoff, but passing critical items was associated with increased risk of misclassifying the response set as invalid. Critical item analysis enhances the diagnostic power of both the RMT and WCT. Given that critical items require no additional test material or administration time, but help reduce both false positive and false negative errors, they represent a versatile, valuable, and time- and cost-effective supplement to performance validity assessment.	[Erdodi, Laszlo A.; Abeare, Christopher A.; Zuccato, Brandon G.; Rai, Jaspreet K.; Seke, Kristian R.; Sagar, Sanya] Univ Windsor, Dept Psychol, Windsor, ON, Canada; [Erdodi, Laszlo A.; Tyson, Bradley T.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [Tyson, Bradley T.] Western Washington Med Grp, Everett, WA USA		Erdodi, LA (corresponding author), 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434; Sagar, Sanya/0000-0001-7381-0803			Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Barhon LI, 2015, APPL NEUROPSYCH-ADUL, V22, P114, DOI 10.1080/23279095.2013.863775; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; Berry DTR, 1996, J PERS ASSESS, V67, P26, DOI 10.1207/s15327752jpa6701_2; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Bilker WB, 2014, ASSESSMENT, V21, P669, DOI 10.1177/1073191114524270; Blaskewitz N, 2009, APPL NEUROPSYCHOL, V16, P54, DOI 10.1080/09084280802644227; Boone K.B., 2013, CLIN PRACTICE FORENS; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Delis D.C., 2000, CALIFORNIA VERBAL LE; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Embretson SE, 1996, PSYCHOL ASSESSMENT, V8, P341, DOI 10.1037/1040-3590.8.4.341; Erdodi LA, 2017, APPL NEUROPSYCH-CHIL, V6, P355, DOI 10.1080/21622965.2016.1198908; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fazio RL, 2017, CLIN NEUROPSYCHOL, V31, P251, DOI 10.1080/13854046.2016.1213316; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; Heaton R. K., 2004, REVISED COMPREHENSIV; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Horner MD, 2006, INT J NEUROSCI, V116, P1181, DOI 10.1080/00207450500514029; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee G. J., 2012, FORENSIC NEUROPSYCHO, P117; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lichtenstein JD, 2018, CHILD NEUROPSYCHOL, V24, P247, DOI 10.1080/09297049.2016.1259402; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOLUTIONS W; Randolph C., 1998, REPEATABLE BATTERY A; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Trueblood W., 1994, J CLIN EXPT NEUROPSY, V4, P697, DOI DOI 10.1080/01688639408402671; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wisdom NM, 2012, ARCH CLIN NEUROPSYCH, V27, P208, DOI 10.1093/arclin/acr107; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	74	25	25	0	0	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult		2018	25	4			SI		327	339		10.1080/23279095.2017.1298600			13	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	GG4SF	WOS:000432685800007	28306349				2022-02-06	
J	Fakharian, E; Abedzadeh-Kalahroudi, M; Atoof, F				Fakharian, Esmaeil; Abedzadeh-Kalahroudi, Masoumeh; Atoof, Fatemeh			Effect of Tranexamic Acid on Prevention of Hemorrhagic Mass Growth in Patients with Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Intracranial hemorrhage; Tranexamic acid; Traumatic brain injury	HEAD-INJURY	BACKGROUND: Intracranial hemorrhage is a common complication of traumatic brain injury (TBI). The purpose of this study is evaluation of the effect of tranexamic acid (TXA) on hemorrhagic mass growth in TBI patients. PATIENTS AND METHODS: In this randomized, doubleblind clinical trial, 149 patients with TBI and any kind of blood on their computed tomography scan enrolled in the study and were randomly allocated to receive TXA or placebo. After 24 hours, computed tomography scan was repeated for assessing the changes in hemorrhage, new bleeding, and mass effects of blood on brain tissue. The primary outcome was growth of the hemorrhagic lesion. Data were analyzed by SPSS software using Fisher exact, chi-square, and Mann-Whitney U tests, as well as linear and logistic regression models. FINDINGS: The incidence of hemorrhagic lesion growth was 20.5% in the TXA group and 22.7% in the placebo group. The difference was not significant (P = 0.87, RR = 0.89). The mean (standard deviation) of hemorrhagic lesion growth was 9.4 (15.3) in the TXA group and 10.2 (10.1) in the placebo group without significant difference (P =d 0.27). The frequency of deaths (2.7% vs. 4%), adverse outcome at discharge (10.8% vs. 17.3%), and 3 months later (6.8% vs. 14.7%) in the TXA group were lower than the placebo, but the difference was not statistically significant. No side effect was observed with the administration of TXA. CONCLUSION: Administration of a short dose of TXA does not lead to significant prevention of growth of posttraumatic hemorrhagic lesion or improvement of clinical outcomes.	[Fakharian, Esmaeil; Abedzadeh-Kalahroudi, Masoumeh; Atoof, Fatemeh] Kashan Univ Med Sci, Trauma Res Ctr, Kashan, Iran		Abedzadeh-Kalahroudi, M (corresponding author), Kashan Univ Med Sci, Trauma Res Ctr, Kashan, Iran.	Abedzadeh@kaums.ac.ir	Abedzadeh-Kalahroudi, Masoumeh/G-4114-2017	Abedzadeh-Kalahroudi, Masoumeh/0000-0002-7318-6294	Kashan University of Medical Sciences [91098]	We express our thanks to the staff of Trauma Research Center and Shahid Beheshti Hospital for their cooperation. This study was supported by the deputy of research, Kashan University of Medical Sciences (Grant No: 91098).	Arumugam A, 2015, MALAYS J MED SCI, V22, P62; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Edwards P, 2005, LANCET, V365, P1957; Jokar A, 2017, CHIN J TRAUMATOL, V20, P49, DOI 10.1016/j.cjtee.2016.02.005; Lobato RD, 2005, NEUROCIRUGIA, V16, P217; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Perel P, 2011, BMJ CLIN RES ED, V34, P1; Rahimi-Movaghar V, 2011, AM SURGEON, V77, pE112; Roberts I, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5839; Roos YB, 2003, COCHRANE DB SYST REV, V2, DOI [DOI 10.1002/14651858.CD001245, 10.1002/14651858.CD001245]; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; TEASDALE G, 1974, LANCET, V2, P81; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109; Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20; Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023; 2011, WHO TECHNICAL REPORT, P1	18	25	26	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2018	109						E748	E753		10.1016/j.wneu.2017.10.075			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	FR4DD	WOS:000419015000093	29074420				2022-02-06	
J	Kosari-Nasab, M; Shokouhi, G; Ghorbanihaghjo, A; Abbasi, MM; Salari, AA				Kosari-Nasab, Morteza; Shokouhi, Ghaffar; Ghorbanihaghjo, Amir; Abbasi, Mehran Mesgari; Salari, Ali-Akbar			Anxiolytic- and antidepressant-like effects of Silymarin compared to diazepam and fluoxetine in a mouse model of mild traumatic brain injury	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Depression; Anxiety; Traumatic brain injury; Inflammation; Silymarin	DEPRESSION-LIKE BEHAVIORS; NECROSIS-FACTOR-ALPHA; NEONATAL IMMUNE ACTIVATION; ANXIETY-LIKE BEHAVIORS; MAJOR DEPRESSION; TNF-ALPHA; OXIDATIVE STRESS; NEUROBEHAVIORAL ALTERATIONS; ANTIINFLAMMATORY CYTOKINES; INFLAMMATORY CYTOKINES	Clinical and experimental studies have shown that mild traumatic brain injury (mTBI) is associated with increased anxiety- and depression-related behaviors and inflammation in the brain. Unfortunately, there are no specific therapies for long-term behavioral consequences of mTBI. This study set out to determine whether silymarin treatment compared to diazepam (DZP) and fluoxetine (FLX) can reduce neuroinflammation, anxiety and depression-like behaviors after mTBI induction in mice. We used open field, elevated plus maze, light-dark box, zero maze, sucrose preference, forced swim, and tail suspension tests to assess anxiety and depression-like behaviors in mTBI-induced mice. The levels of tumor necrosis factor (TNF)-alpha protein, a marker of inflammation, in the prefrontal cortex and hippocampus was also measured. This study identified that the long-term treatment with DZP, FLX or SIL results in decreased anxiety and depression-like behaviors in mTBI-induced mice. The results also showed that these drugs reduced TNF-alpha levels in the prefrontal cortex and hippocampus. In addition, there were no significant differences between the effects of SIL and DZP or SIL and FLX on behavioral and cytokine levels in mTBI-induced mice. Our findings support the idea that mTBI could be a risk factor for anxiety and depression-related disorders and neuroinflammation in the brain. Taken together, this study demonstrates that DZP, FLX or SIL can significantly reduce anxiety- and depression-like symptoms, and neuroinflammation after mTBI induction in mice.	[Kosari-Nasab, Morteza; Shokouhi, Ghaffar; Ghorbanihaghjo, Amir; Abbasi, Mehran Mesgari; Salari, Ali-Akbar] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran; [Shokouhi, Ghaffar] Tabriz Univ Med Sci, Dept Neurosurg, Tabriz, Iran; [Shokouhi, Ghaffar] Tabriz Univ Med Sci, Neurosci Res Ctr, Tabriz, Iran; [Ghorbanihaghjo, Amir] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran; [Salari, Ali-Akbar] SICBD, Alborz, Iran		Shokouhi, G; Salari, AA (corresponding author), Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.	shokouhigh@yahoo.com; aa.salari@yahoo.com	Salari, Ali-Akbar/I-7843-2013; Tabrizi, Ghaffar Shokouhi/L-6326-2017	Salari, Ali-Akbar/0000-0002-4970-0337; Tabrizi, Ghaffar Shokouhi/0000-0001-5081-9928; ghorbanihaghjo, amir/0000-0001-6742-0526; Kosari-Nasab, Morteza/0000-0001-8454-5873	Drug Applied Research Center at Tabriz University of Medical Sciences [94/77]	This study was supported by a grant from the Drug Applied Research Center at Tabriz University of Medical Sciences (grant number 94/77).	Al-Drees AM, 2016, HISTOL HISTOPATHOL, V31, P1259, DOI 10.14670/HH-11-757; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Amani M, 2013, NEUROPHARMACOLOGY, V73, P87, DOI 10.1016/j.neuropharm.2013.04.056; Amitai M, 2016, J CHILD ADOL PSYCHOP, V26, P727, DOI 10.1089/cap.2015.0147; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Ayatollahi A. M., 2017, NEUROL RES, P1; Babri S, 2014, BRAIN BEHAV IMMUN, V37, P164, DOI 10.1016/j.bbi.2013.12.003; Babri S, 2014, BEHAV BRAIN RES, V261, P305, DOI 10.1016/j.bbr.2013.12.037; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Bansal N, 2013, J PHARM INNOV, V5, P93; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bercik P, 2010, GASTROENTEROLOGY, V139, P2102, DOI 10.1053/j.gastro.2010.06.063; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Busse CS, 2004, NEUROPSYCHOPHARMACOL, V29, P1971, DOI 10.1038/sj.npp.1300540; Campbell S, 2004, J PSYCHIATR NEUROSCI, V29, P417; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chtourou Y, 2010, BIOMETALS, V23, P985, DOI 10.1007/s10534-010-9345-x; da Silva GD, 2016, J PSYCHIATR RES, V75, P57, DOI 10.1016/j.jpsychires.2016.01.008; Davidson RJ, 2002, BIOL PSYCHIAT, V51, P68, DOI 10.1016/S0006-3223(01)01328-2; Davies DR, 2016, FRONT BEHAV NEUROSCI, V10, DOI [10.3389/fnbeh.2016.00071, 10.3339/fnbeh.2015.00071]; De Jongh B. S. K. G., 1999, NEUROPSYCHOPHARMACOL, V20, P370; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Doosti MH, 2013, PROG NEURO-PSYCHOPH, V43, P55, DOI 10.1016/j.pnpbp.2012.12.003; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Drevets WC, 2000, PROG BRAIN RES, V126, P413; Enayati M, 2012, BRAIN RES BULL, V87, P295, DOI 10.1016/j.brainresbull.2011.08.015; Engin E, 2007, BEHAV PHARMACOL, V18, P365, DOI 10.1097/FBP.0b013e3282de7929; Epstein R. S., 1994, ANXIETY DISORDERS; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Felger JC, 2013, NEUROSCIENCE, V246, P199, DOI 10.1016/j.neuroscience.2013.04.060; Fenn AM, 2015, J NEUROTRAUM, V32, P127, DOI 10.1089/neu.2014.3514; Fiore M, 1998, PHYSIOL BEHAV, V63, P571, DOI 10.1016/S0031-9384(97)00514-3; Fiore M, 1996, BRAIN BEHAV IMMUN, V10, P126, DOI 10.1006/brbi.1996.0013; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Gharagozloo M, 2013, INT IMMUNOPHARMACOL, V16, P243, DOI 10.1016/j.intimp.2013.04.016; Gomes EPP, 2013, J PERIODONTAL RES, V48, P151, DOI 10.1111/j.1600-0765.2012.01515.x; Gupta OP, 2000, PHYTOMEDICINE, V7, P21, DOI 10.1016/S0944-7113(00)80017-3; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Higashi Y, 2014, J NEUROTRAUM, V31, P1689, DOI 10.1089/neu.2014.3331; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Isaac L, 2015, BIOL PSYCHOL, V105, P20, DOI 10.1016/j.biopsycho.2014.12.011; Jain NK, 2001, METHOD FIND EXP CLIN, V23, P441, DOI 10.1358/mf.2001.23.8.662131; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Kaster MP, 2012, NEUROPHARMACOLOGY, V62, P419, DOI 10.1016/j.neuropharm.2011.08.018; Khoshnoodi M, 2015, PHARM BIOL, V53, P739, DOI 10.3109/13880209.2014.942787; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kraus J. F., 1999, REHABILITATION ADULT, P3; Krishnan R, 2007, BRIT J DERMATOL, V157, P1275, DOI 10.1111/j.1365-2133.2007.08205.x; Lavoie S, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00634; Lazzarini R, 2006, LIFE SCI, V78, P3027, DOI 10.1016/j.lfs.2005.11.032; Lesniak A, 2017, BEHAV BRAIN RES, V326, P209, DOI 10.1016/j.bbr.2017.03.015; Lim CM, 2009, J NEUROSCI RES, V87, P1037, DOI 10.1002/jnr.21899; Loftis JM, 2010, NEUROBIOL DIS, V37, P519, DOI 10.1016/j.nbd.2009.11.015; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Majidi J, 2016, BRAIN RES BULL, V120, P1, DOI 10.1016/j.brainresbull.2015.10.009; Majidi-Zolbanin J, 2015, NEUROSCIENCE, V294, P69, DOI 10.1016/j.neuroscience.2015.03.016; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Moreno-Lopez L, 2016, BRAIN INJURY, V30, P1319, DOI 10.1080/02699052.2016.1186839; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morishima C, 2010, GASTROENTEROLOGY, V138, P671, DOI 10.1053/j.gastro.2009.09.021; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nazemian F, 2010, PHYTOTHER RES, V24, P1654, DOI 10.1002/ptr.3175; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Ravindran LN, 2010, J CLIN PSYCHIAT, V71, P839, DOI 10.4088/JCP.10r06218blu; Roumestan C, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-35; Sacre S, 2010, ARTHRITIS RHEUM-US, V62, P683, DOI 10.1002/art.27304; Salari AA, 2016, BEHAV BRAIN RES, V311, P354, DOI 10.1016/j.bbr.2016.05.062; Salari AA, 2015, EUR NEUROPSYCHOPHARM, V25, P1260, DOI 10.1016/j.euroneuro.2015.04.022; Schiepers OJG, 2005, PROG NEURO-PSYCHOPH, V29, P201, DOI 10.1016/j.pnpbp.2004.11.003; Schlumpf M, 1995, Arch Toxicol Suppl, V17, P261; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shaker E, 2010, FOOD CHEM TOXICOL, V48, P803, DOI 10.1016/j.fct.2009.12.011; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Solati J, 2012, NEUROPHYSIOLOGY+, V44, P49, DOI 10.1007/s11062-012-9266-0; Solati J, 2011, NEUROCHEM J+, V5, P194, DOI 10.1134/S1819712411030081; Song C, 2009, PHARMACOPSYCHIATRY, V42, P182, DOI 10.1055/s-0029-1202263; Soo C, 2007, COCHRANE DB SYST REV, V18; Soon K. J., 2004, BIOCHEM PHARMACOL, V67, P175; Thakare VN, 2017, PHYSIOL BEHAV, V179, P401, DOI 10.1016/j.physbeh.2017.07.010; Thakare VN, 2016, PHARMACOL REP, V68, P1020, DOI 10.1016/j.pharep.2016.06.002; Toklu HZ, 2008, J SURG RES, V145, P214, DOI 10.1016/j.jss.2007.03.072; Torres SR, 2000, EUR J PHARMACOL, V408, P199, DOI 10.1016/S0014-2999(00)00760-3; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Tyring S, 2006, LANCET, V367, P29, DOI 10.1016/S0140-6736(05)67763-X; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Violle N, 2006, PHARMACOL BIOCHEM BE, V84, P517, DOI 10.1016/j.pbb.2006.06.017; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xia ZL, 1996, IMMUNOPHARMACOLOGY, V34, P27, DOI 10.1016/0162-3109(96)00111-7; Yamada K, 2000, J NEUROIMMUNOL, V111, P131, DOI 10.1016/S0165-5728(00)00375-1; Yirmiya R, 2001, NEUROPSYCHOPHARMACOL, V24, P531, DOI 10.1016/S0893-133X(00)00226-8; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang Feng, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS213, DOI 10.1016/S1353-8020(11)70066-9; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; Zorrilla EP, 2001, BRAIN BEHAV IMMUN, V15, P199, DOI 10.1006/brbi.2000.0597	115	25	26	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X	1096-0333		TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	JAN 1	2018	338						159	173		10.1016/j.taap.2017.11.012			15	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pharmacology & Pharmacy; Toxicology	FT1KI	WOS:000422894200016	29175455				2022-02-06	
J	McNutt, MK; Kale, AC; Kitagawa, RS; Turkmani, AH; Fields, DW; Baraniuk, S; Gill, BS; Cotton, BA; Moore, LJ; Wade, CE; Day, A; Holcomb, JB				McNutt, Michelle K.; Kale, A. Cozette; Kitagawa, Ryan S.; Turkmani, Ali H.; Fields, David W.; Baraniuk, Sarah; Gill, Brijesh S.; Cotton, Bryan A.; Moore, Laura J.; Wade, Charles E.; Day, Arthur; Holcomb, John B.			Management of blunt cerebrovascular injury (BCVI) in the multisystem injury patient with contraindications to immediate anti-thrombotic therapy	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						BCVI; Stroke; Traumatic brain injury (TBI); Solid organ injury; Antithrombotic therapy	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; HEMORRHAGIC NEUROLOGIC INJURY; SCREENING CRITERIA; APPROPRIATE ROLE; TRAUMA PATIENTS; STROKE RATE; DIAGNOSIS; ANTICOAGULATION; ASSOCIATION; GUIDELINES	Introduction: Practice management guidelines for screening and treatment of patients with blunt cerebrovascular injury (BCVI) have been associated with a decreased risk of ischemic stroke. Treatment: of patients with BCVI and multisystem injuries that delays immediate antithrombotic therapy remains controversial. The purpose of this study was to determine the timing of BCVI treatment initiation, the incidence of stroke, and bleeding complications as a result of antithrombotic therapy in patients with isolated BCVI in comparison to those with BCVI complicated by multisystem injuries. Materials and methods: This study was a retrospective review of all adult blunt trauma patients admitted to a level 1 trauma center from 2009 to 2014 with a diagnosis of BCVI. Results: A total of 28,305 blunt trauma patients were admitted during the study period. Of these, 323 (1.1%) had 481 BCEVIs and were separated into two groups. Isolated BCVI was reported in 111 (34.4%) patients and 212 (65.6%) patients had accompanying multisystem injuries (traumatic brain injury (TBI), solid organ injury, or spinal cord injury) that contraindicated immediate antithrombotic therapy. Treatment: started in patients with isolated BCVI at a median time of 30.3 (15, 52) hours after injury in contrast to 62.4 (38, 97) hours for those with multisystem injuries (p<0.001). The incidence of stroke was identical (9.9%) between groups and no bleeding complications related to antithrombotic therapy were identified. Conclusion: The lack of bleeding complications and equivalent stroke rates between groups suggests that the presence of TBI, solid organ injury, and spinal cord injury are not contraindications to anti-thrombotic therapy for stroke prevention in patients with BCVI. (c) 2017 Elsevier Ltd. All rights reserved.	[McNutt, Michelle K.; Cotton, Bryan A.; Moore, Laura J.; Holcomb, John B.] Univ Texas Hlth Sci Ctr Houston, Mem Hermann Hosp, Red Duke Trauma Inst, Dept Surg, Houston, TX 77030 USA; [Kale, A. Cozette; Fields, David W.] Univ Texas Houston, Sch Med, McGovern Med Sch, Houston, TX USA; [Kitagawa, Ryan S.; Day, Arthur] Univ Texas Hlth Sci Ctr Houston, Texas Med Ctr, Mischer Neurosci Inst, Dept Neurosurg, Houston, TX 77030 USA; [Turkmani, Ali H.] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA; [Baraniuk, Sarah] Ctr Translat Injury Res CeTIR, Houston, TX USA; [Gill, Brijesh S.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA; [Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res CeTIR, Dept Surg, Houston, TX 77030 USA		McNutt, MK (corresponding author), FACS, 6431 Fannin St,MSB 4-278, Houston, TX 77030 USA.	Michelle.K.McNutt@uth.tmc.edu; Alixandra.C.Kale@uth.tmc.edu; Ryan.S.Kitagawa@uth.tmc.edu; Ali.HassounTurkmani@uth.tmc.edu; David.W.Fields@uth.tmc.edu; Mary.Baraniuk@uth.tmc.edu; Brijesh.S.Gill@uth.tmc.edu; Bryan.A.Cotton@uth.tmc.edu; Laura.J.Moore@uth.tmc.edu; Charles.E.Wade@uth.tmc.edu; Arthur.L.Day@uth.tmc.edu; John.Holcomb@uth.tmc.edu		holcomb, john/0000-0001-8312-9157			[Anonymous], 2002, BLUNT VASCULAR NECK, P1, DOI [10.1097/01.TA.0000022083.35916.8A, DOI 10.1097/01.TA.0000022083.35916.8A]; Berne JD, 2004, J TRAUMA, V57, P11, DOI 10.1097/01.TA.0000135499.70048.C7; Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Biffl W, 2012, J TRAUMA ACUTE CARE, V72, P345; Biffl WL, 2009, J TRAUMA, V67, P1150, DOI 10.1097/TA.0b013e3181c1c1d6; Bromberg WJ, 2011, J TRAUMA, V70, P1063; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Brott TG, 2012, J AM COLL CARDIOL, V60, P566, DOI [10.1016/j.jacc.2010.11.006, 10.1016/j.jacc.2012.06.006]; Bruns BR, 2014, J TRAUMA ACUTE CARE, V76, P691, DOI 10.1097/TA.0b013e3182ab1b4d; Burlew CC, 2012, J TRAUMA ACUTE CARE, V72, P539; Burlew CC, 2012, J TRAUMA ACUTE CARE, V72, P330, DOI 10.1097/TA.0b013e31823de8a0; Callcut RA, 2012, J TRAUMA ACUTE CARE, V72, P338, DOI 10.1097/TA.0b013e318243d978; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2005, AM J SURG, V190, P845, DOI 10.1016/j.amsurg.2005.08.007; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; DiCocco JM, 2011, ANN SURG, V253, P444, DOI 10.1097/SLA.0b013e31820d946b; Eastman AL, 2009, J TRAUMA, V67, P551, DOI 10.1097/TA.0b013e3181b84408; Emmett KP, 2011, J TRAUMA, V70, P1058, DOI 10.1097/TA.0b013e318213f849; Goodwin RB, 2009, J TRAUMA, V67, P1046, DOI 10.1097/TA.0b013e3181b83b63; Malhotra AK, 2007, ANN SURG, V246, P632, DOI 10.1097/SLA.0b013e3181568cab; Miller PR, 2001, J TRAUMA, V51, P1; Miller PR, PROSPECTIVE SCREENIN; Paulus EM, 2014, J TRAUMA ACUTE CARE, V76, P279, DOI 10.1097/TA.0000000000000101; Roberts DJ, 2013, ANN SURG, V257, P621, DOI 10.1097/SLA.0b013e318288c514; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Wahl WL, 2002, J TRAUMA, V52, P896, DOI 10.1097/00005373-200205000-00012; Wang AC, 2012, J TRAUMA ACUTE CARE, V72, P1599, DOI 10.1097/TA.0b013e318246ead4; Wei CW, 2010, CAN J NEUROL SCI, V37, P574, DOI 10.1017/S0317167100010726	28	25	25	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2018	49	1					67	74		10.1016/j.injury.2017.07.036			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	FS9VT	WOS:000422767800011	28789779				2022-02-06	
J	Misquitta, K; Dadar, M; Tarazi, A; Hussain, MW; Alatwi, MK; Ebraheem, A; Multani, N; Khodadadi, M; Goswami, R; Wennberg, R; Tator, C; Green, R; Colella, B; Davis, KD; Mikulis, D; Grinberg, M; Sato, C; Rogaeva, E; Collins, DL; Tartaglia, MC				Misquitta, Karen; Dadar, Mahsa; Tarazi, Apameh; Hussain, Mohammed W.; Alatwi, Mohammed K.; Ebraheem, Ahmed; Multani, Namita; Khodadadi, Mozhgan; Goswami, Ruma; Wennberg, Richard; Tator, Charles; Green, Robin; Colella, Brenda; Davis, Karen Deborah; Mikulis, David; Grinberg, Mark; Sato, Christine; Rogaeva, Ekaterina; Collins, D. Louis; Tartaglia, Maria Carmela			The relationship between brain atrophy and cognitive-behavioural symptoms in retired Canadian football players with multiple concussions	NEUROIMAGE-CLINICAL			English	Article						Sport-related concussion; Mild traumatic brain injury; Deformation based morphometry; Aging	CHRONIC TRAUMATIC ENCEPHALOPATHY; DEFORMATION-BASED MORPHOMETRY; HEAD-INJURY; RECURRENT CONCUSSION; HIPPOCAMPAL VOLUME; LEAGUE PLAYER; MILD; MRI; SEGMENTATION; ASSOCIATION	Multiple concussions, particularly in contact sports, have been associated with cognitive deficits, psychiatric impairment and neurodegenerative diseases like chronic traumatic encephalopathy. We used volumetric and deformation-based morphometric analyses to test the hypothesis that repeated concussions may be associated with smaller regional brain volumes, poorer cognitive performance and behavioural symptoms among former professional football players compared to healthy controls. This study included fifty-three retired Canadian Football League players, 25 age-and education-matched healthy controls, and controls from the Cambridge Centre for Aging and Neuroscience database for validation. Volumetric analyses revealed greater hippocampal atrophy than expected for age in former athletes with multiple concussions than controls and smaller left hippocampal volume was associated with poorer verbal memory performance in the former athletes. Deformation-based morphometry confirmed smaller bilateral hippocampal volume that was associated with poorer verbal memory performance in athletes. Repeated concussions may lead to greater regional atrophy than expected for age.	[Misquitta, Karen; Multani, Namita; Grinberg, Mark; Sato, Christine; Rogaeva, Ekaterina; Tartaglia, Maria Carmela] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Krembil Discovery Tower,60 Leonard Ave, Toronto, ON M5T 0S8, Canada; [Dadar, Mahsa; Collins, D. Louis] McConnell Brain Imaging Ctr, Montreal Neurol Inst, 3801 Rue Univ, Montreal, PQ H3A 2B4, Canada; [Tarazi, Apameh; Hussain, Mohammed W.; Alatwi, Mohammed K.; Ebraheem, Ahmed; Multani, Namita; Khodadadi, Mozhgan; Goswami, Ruma; Wennberg, Richard; Tator, Charles; Green, Robin; Colella, Brenda; Davis, Karen Deborah; Mikulis, David; Tartaglia, Maria Carmela] Toronto Western Hosp, Canadian Concuss Ctr, 399 Bathurst St, Toronto, ON M5T 2S8, Canada; [Tarazi, Apameh; Hussain, Mohammed W.; Alatwi, Mohammed K.; Ebraheem, Ahmed; Khodadadi, Mozhgan; Wennberg, Richard; Tator, Charles; Tartaglia, Maria Carmela] Toronto Western Hosp, Krembil Neurosci Ctr, Div Neurol, 399 Bathurst St, Bathurst, ON M5T 2S8, Canada; [Goswami, Ruma; Davis, Karen Deborah] Toronto Western Hosp, Krembil Neurosci Ctr, Div Brain Imaging & Behav Syst Neurosci, 399 Bathurst St, Toronto, ON M5T 2S8, Canada; [Tator, Charles] Univ Toronto, Dept Surg, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada; [Tator, Charles] Toronto Western Hosp, Krembil Neurosci Ctr, Div Neurosurg, 399 Bathurst St, Bathurst, ON M5T 2S8, Canada; [Green, Robin; Colella, Brenda] Univ Hlth Network, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada; [Mikulis, David] Toronto Western Hosp, Dept Med Imaging, 399 Bathurst St, Toronto, ON M5T 2S8, Canada; [Misquitta, Karen; Tator, Charles; Green, Robin; Davis, Karen Deborah; Mikulis, David; Tartaglia, Maria Carmela] Univ Toronto, Inst Med Sci, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada		Tartaglia, MC (corresponding author), Tanz Ctr Res Neurodegenerat Dis, Krembil Discovery Tower,60 Leonard Ave, Toronto, ON M5T 0S8, Canada.	carmela.tartaglia@uhn.ca	Mikulis, David J/H-5167-2019; Collins, D. Louis/ABD-7708-2021	Collins, D. Louis/0000-0002-8432-7021; Green, Robin/0000-0001-9451-3963; Alatwi, Mohammed/0000-0002-0163-6698; Mikulis, David/0000-0003-3956-0892; Dadar, Mahsa/0000-0003-4008-2672	Physicians' Services Incorporated Foundation; Toronto General and Western Hospital Foundation; UK Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/H008217/1]; UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); University of Cambridge, UKUniversity of Cambridge; CIHRCanadian Institutes of Health Research (CIHR); Andre Carron Family	This study was funded by the Physicians' Services Incorporated Foundation and the Toronto General and Western Hospital Foundation through specific donations to the Canadian Concussion Centre. We thank Leo Ezerins of the CFLAA for his help in recruiting participants. Data collection and sharing for this project was provided by the Cambridge Centre for Aging and Neuroscience (CamCAN). CamCAN funding was provided by the UK Biotechnology and Biological Sciences Research Council (grant number BB/H008217/1), together with support from the UK Medical Research Council and University of Cambridge, UK. KM funded by CIHR. DLC received a grant from the Andre Carron Family. DLC and MCT contributed to study concept and design. KM, MD, AT, MWH, MKA, AE, NM, MK, R Goswami, RW, CT, R Green, BC, KD, MG, CS, ER, DM, and MCT contributed to data acquisition and analysis. KM, MD and MCT contributed to preparing the manuscript. We thank all the participants for the generous contribution of their time.	Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Ashburner J, 1998, HUM BRAIN MAPP, V6, P348, DOI 10.1002/(SICI)1097-0193(1998)6:5/6<348::AID-HBM4>3.0.CO;2-P; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Collins DL, 2010, NEUROIMAGE, V52, P1355, DOI 10.1016/j.neuroimage.2010.04.193; COLLINS DL, 1995, COMP IMAG VIS, V3, P139; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Collins DL, 1997, INT J PATTERN RECOGN, V11, P1271, DOI 10.1142/S0218001497000597; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Coupe P, 2008, IEEE T MED IMAGING, V27, P425, DOI 10.1109/TMI.2007.906087; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Debette S, 2011, NEUROLOGY, V77, P461, DOI 10.1212/WNL.0b013e318227b227; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Fjell AM, 2013, NEUROBIOL AGING, V34, P2239, DOI 10.1016/j.neurobiolaging.2013.04.006; FRISK V, 1990, NEUROPSYCHOLOGIA, V28, P349, DOI 10.1016/0028-3932(90)90061-R; Gaser C, 2001, NEUROIMAGE, V13, P1140, DOI 10.1006/nimg.2001.0771; Goswami R, 2016, BRAIN STRUCT FUNCT, V221, P1911, DOI 10.1007/s00429-015-1012-0; Green REA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00067; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; Matthies S, 2012, WORLD J BIOL PSYCHIA, V13, P75, DOI 10.3109/15622975.2010.541282; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meier TB, 2016, HUM BRAIN MAPP, V37, P833, DOI 10.1002/hbm.23072; Merritt VC, 2018, ARCH CLIN NEUROPSYCH, V33, P36, DOI 10.1093/arclin/acx051; Morey L.C., 1991, PSYCHOL ASSESSMENT R; Multani N, 2016, J NEUROL, V263, P1332, DOI 10.1007/s00415-016-8141-0; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Rey A., 1964, EXAMEN CLIN PSYCHOL; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shafto MA, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0204-1; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Spreen O, 1991, COMPENDIUM NEUROPSYC; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tajima-Pozo K, 2015, ACTA NEUROPSYCHIATR, V27, P362, DOI 10.1017/neu.2015.34; Taylor JR, 2017, NEUROIMAGE, V144, P262, DOI 10.1016/j.neuroimage.2015.09.018; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Zagorchev L, 2016, J NEUROTRAUM, V33, P29, DOI 10.1089/neu.2014.3831	55	25	25	2	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2018	19						551	558		10.1016/j.nicl.2018.05.014			8	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	GQ7PL	WOS:000441936300057	29984163	gold, Green Published			2022-02-06	
J	Pearce, AJ; Rist, B; Fraser, CL; Cohen, A; Maller, JJ				Pearce, Alan J.; Rist, Billymo; Fraser, Clare L.; Cohen, Adrian; Maller, Jerome J.			Neurophysiological and cognitive impairment following repeated sports concussion injuries in retired professional rugby league players	BRAIN INJURY			English	Article						Sport; concussion; mild traumatic brain injury; transcranial magnetic stimulation; motor cortex inhibition; motor execution slowness; rugby league	TRANSCRANIAL MAGNETIC STIMULATION; MOTOR EVOKED-POTENTIALS; INTERVAL INTRACORTICAL INHIBITION; SILENT PERIOD; FOOTBALL PLAYERS; LONG-TERM; ELECTROPHYSIOLOGICAL CHANGES; PSYCHIATRIC-DISORDERS; CORTEX EXCITABILITY; 1ST EXPOSURE	Background: Concussion is regarded as a common injury in rugby league, however no studies have explored the long-term neurophysiological and cognitive effects of repeated concussion injuries in this sport.Methods: Former professional rugby athletes (n=25) were compared to 25 age-matched participants with no history of a concussion. All participants completed standardised motor dexterity, reaction time, and cognitive tasks for working memory, associative learning and rule acquisition and reversal. Single-pulse transcranial magnetic stimulation (TMS) acquired motor evoked potentials and cortical silent period (cSP), as well as paired-pulse TMS for short latency intracortical inhibition and long intracortical inhibition (LICI).Results: Compared to controls, dexterity and visuomotor reaction time was slower in the rugby group compared to controls (p=0.02, p<0.01, respectively). The rugby group also demonstrated poorer cognitive performance than controls (p range 0.02 to < 0.01). TMS revealed significantly reduced cSP at suprathreshold stimulation intensities (p range 0.02 to <0.01), and increased LICI (p=0.03) in the rugby group.Discussion: These findings of motor and cognitive changes, along with neurophysiological alterations, particularly with intracortical inhibition, nearly two decades post-concussion provides evidence for long-term sequelae for athletes with a history of repeated head trauma in contact sports.	[Pearce, Alan J.; Rist, Billymo] La Trobe Univ, Dept Rehabil Nutr & Sport, Melbourne, Vic, Australia; [Rist, Billymo] Mental Edge Consulting, Melbourne, Vic, Australia; [Fraser, Clare L.] Univ Sydney, Save Sight Inst, Dept Ophthalmol, Sydney, NSW, Australia; [Cohen, Adrian] Univ Sydney, Cent Clin Sch, Discipline Clin Ophthalmol & Eye Hlth, Sydney, NSW, Australia; [Maller, Jerome J.] The Alfred, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia; [Maller, Jerome J.] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia; [Maller, Jerome J.] Gen Elect Healthcare, Melbourne, Vic, Australia		Pearce, AJ (corresponding author), La Trobe Univ, Dept Rehabil Exercise & Sport, Melbourne, Vic, Australia.	alan.pearce@latrobe.edu.au	Pearce, Alan J/W-1195-2018	Pearce, Alan J/0000-0002-9264-9880; Fraser, Clare/0000-0002-0379-7743	Smart Head Play Charity; Impact Technologies; Australian Football League and Samsung CorporationSamsung; NHMRCNational Health and Medical Research Council of Australia	This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. AJP is funded, in part, by a grant from Smart Head Play Charity, and Impact Technologies; and has been previously supported by funding from the Australian Football League and Samsung Corporation. AJP has also received equipment support for research from MagVenture and AD Instruments. AC is a director of Necksafe Ltd Charity. JJM has previously been funded by a NHMRC fellowship. Other authors declare no sources of research funding.	AFL Medical Officers Association, 2011, MAN CONC AUSTR FOOTB; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Benwell NM, 2007, EXP BRAIN RES, V179, P255, DOI 10.1007/s00221-006-0790-2; Berger MAM, 2009, APPL ERGON, V40, P145, DOI 10.1016/j.apergo.2008.01.014; BRYDEN MP, 1977, NEUROPSYCHOLOGIA, V15, P617, DOI 10.1016/0028-3932(77)90067-7; Bunse T, 2014, BRAIN STIMUL, V7, P158, DOI 10.1016/j.brs.2013.08.009; CANTELLO R, 1992, NEUROLOGY, V42, P1951; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; Cohen J., 2013, STAT POWER ANAL BEHA; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; CORLETT EN, 1971, OCCUP PSYCHOL, V45, P57; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Di Virgilio TG, 2016, EBIOMEDICINE, V13, P66, DOI 10.1016/j.ebiom.2016.10.029; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Gardner AJ, 2017, INT J SPORTS MED, V38, P241, DOI 10.1055/s-0042-120843; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; GHEZZI A, 1991, ACTA NEUROL SCAND, V84, P503, DOI 10.1111/j.1600-0404.1991.tb05003.x; GLOSS DS, 1981, PERCEPT MOTOR SKILL, V53, P659, DOI 10.2466/pms.1981.53.2.659; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Hammond G, 2007, BRAIN RES, V1158, P63, DOI 10.1016/j.brainres.2007.05.014; Haraldsson HM, 2004, SCHIZOPHR RES, V71, P1, DOI 10.1016/j.schres.2003.10.006; Hermens HJ., 1999, EUROPEAN RECOMMENDAT; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; Hoskins W, 2006, J SCI MED SPORT, V9, P46, DOI 10.1016/j.jsams.2006.03.013; Hume PA, 2017, SPORTS MED, V47, P1209, DOI 10.1007/s40279-016-0608-8; Jordan BD, 2000, NEUROLOGY, V54, pA410; Keller CJ, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0528; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kidgell DJ, 2010, HUM MOVEMENT SCI, V29, P631, DOI 10.1016/j.humov.2010.01.004; Kim DH, 2007, SPINE, V32, P3041, DOI 10.1097/BRS.0b013e31815d0072; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Koerte IK, 2016, BRAIN IMAGING BEHAV, V10, P792, DOI 10.1007/s11682-015-9442-0; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lieberman JA, 2006, ANESTH ANALG, V103, P316, DOI 10.1213/01.ane.0000226142.15746.b2; Livingston SC, 2010, J CLIN MONIT COMPUT, V24, P427, DOI 10.1007/s10877-010-9267-8; Major BP, 2015, CLIN EXP PHARMACOL P, V42, P394, DOI 10.1111/1440-1681.12363; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McGinley M, 2010, EXP GERONTOL, V45, P671, DOI 10.1016/j.exger.2010.04.005; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McMillan TM, 2017, J NEUROL NEUROSUR PS, V88, P505, DOI 10.1136/jnnp-2016-314279; Mills KR, 1999, MAGNETIC STIMULATION; Modugno N, 2001, CLIN NEUROPHYSIOL, V112, P1470, DOI 10.1016/S1388-2457(01)00599-5; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Nardone Raffaele, 2013, Handb Clin Neurol, V116, P599, DOI 10.1016/B978-0-444-53497-2.00048-6; Nollet H, 2004, EQUINE VET J, V36, P51, DOI 10.2746/0425164044864660; Oliviero A, 2006, NEUROSCI RES, V55, P74, DOI 10.1016/j.neures.2006.02.002; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Pearce AJ, 2000, EXP BRAIN RES, V130, P238, DOI 10.1007/s002219900236; Pearce AJ, 2016, EBIOMEDICINE, V13, P3, DOI 10.1016/j.ebiom.2016.10.043; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Pearce AJ, 2013, BRAIN STIMUL, V6, P306, DOI 10.1016/j.brs.2012.05.010; Pearce AJ, 2010, J SCI MED SPORT, V13, P167, DOI 10.1016/j.jsams.2008.12.632; Pearce AJ, 2009, J SCI MED SPORT, V12, P280, DOI 10.1016/j.jsams.2007.12.005; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Radhu N, 2013, CLIN NEUROPHYSIOL, V124, P1309, DOI 10.1016/j.clinph.2013.01.014; Rijckaert J, 2016, VET J, V216, P178, DOI 10.1016/j.tvjl.2016.08.006; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Roberts SP, 2017, AM J SPORT MED, V45, P480, DOI 10.1177/0363546516668296; Rossini P M, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P171; Sale MV, 2005, J APPL PHYSIOL, V99, P1483, DOI 10.1152/japplphysiol.00371.2005; Sandberg M.A., 2011, ENCY CLIN NEUROPSYCH, P480, DOI [10.1007/978-0-387-79948-3_169, DOI 10.1007/978-0-387-79948-3_169]; Sandbrink F., 2008, OXFORD HDB TRANSCRAN, P237, DOI DOI 10.1093/OXFORDHB/9780198568926.001.0001; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Ward A A Jr, 1964, Clin Neurosurg, V12, P95; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1; WILSON SA, 1993, NEUROSCI LETT, V154, P52, DOI 10.1016/0304-3940(93)90169-L; WILSON SA, 1993, J NEUROL SCI, V114, P216, DOI 10.1016/0022-510X(93)90301-E; Wolters A., 2008, OXFORD HDB TRANSCRAN, P91; Yancosek KE, 2009, J HAND THER, V22, P258, DOI 10.1016/j.jht.2008.11.004; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306; Ziemann Ulf, 2013, Handb Clin Neurol, V116, P387, DOI 10.1016/B978-0-444-53497-2.00032-2	81	25	25	1	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	4					498	505		10.1080/02699052.2018.1430376			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	FV9WZ	WOS:000424942400014	29388850				2022-02-06	
J	Habiyaremye, G; Morales, DM; Morgan, CD; McAllister, JP; CreveCoeur, TS; Han, RH; Gabir, M; Baksh, B; Mercer, D; Limbrick, DD				Habiyaremye, Gakwaya; Morales, Diego M.; Morgan, Clinton D.; McAllister, James P.; CreveCoeur, Travis S.; Han, Rowland H.; Gabir, Mohamed; Baksh, Brandon; Mercer, Deanna; Limbrick, David D., Jr.			Chemokine and cytokine levels in the lumbar cerebrospinal fluid of preterm infants with post-hemorrhagic hydrocephalus	FLUIDS AND BARRIERS OF THE CNS			English	Article						Cytokines; Chemokines; Post-hemorrhagic; Hydrocephalus; CSF; Cerebrospinal fluid; Preterm; Prematurity	NECROSIS-FACTOR-ALPHA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; PREMATURE-INFANTS; IN-VITRO; TRANSFORMING GROWTH-FACTOR-BETA-1; LYMPHOID CHEMOKINES; EXPRESSION; BLOOD	Background: Neuroinflammation has been implicated in the pathophysiology of post-hemorrhagic hydrocephalus (PHH) of prematurity, but no comprehensive analysis of signaling molecules has been performed using human cerebrospinal fluid (CSF). Methods: Lumbar CSF levels of key cytokines (IL-1 alpha, IL-1 beta, IL-4, IL-6, IL-8, IL-10, IL-12, TNF-alpha, TGF-beta 1, IFN-gamma) and chemokines (XCL-1, CCL-2, CCL-3, CCL-19, CXCL-10, CXCL-11, CXCL-12) were measured using conventional and multiplexed Enzyme-linked Immunosorbent Assays and compared between preterm infants with PHH and those with no known neurological injury. The relationships between individual biomarker levels and specific CSF cell counts were examined. Results: Total protein (TP) CSF levels were elevated in the PHH subjects compared to controls. CSF levels of IL-1 alpha, IL-4, IL-6, IL-12, TNF-alpha, CCL-3, CCL-19, and CXCL-10 were significantly increased in PHH whereas XCL-1 was significantly decreased in PHH. When normalizing by TP, IL-1 alpha, IL-1 beta, IL-10, IL-12, CCL-3, and CCL-19 levels were significantly elevated compared to controls, while XCL-1 levels remained significantly decreased. Among those with significantly different levels in both absolute and normalized levels, only absolute CCL-19 levels showed a significant correlation with CSF nucleated cells, neutrophils, and lymphocytes. IL-1 beta and CXCL-10 also were correlated with total cell count, nucleated cells, red blood cells, and neutrophils. Conclusions: Neuroinflammation is likely to be an important process in the pathophysiology of PHH. To our knowledge, this is the first study to investigate CSF levels of chemokines in PHH as well as the only one to show XCL-1 selectively decreased in a diseased state. Additionally, CCL-19 was the only analyte studied that showed significant differences between groups and had significant correlation with cell count analysis. The selectivity of CCL-19 and XCL-1 should be further investigated. Future studies will further delineate the role of these cytokines and chemokines in PHH.	[Habiyaremye, Gakwaya; Morales, Diego M.; McAllister, James P.; CreveCoeur, Travis S.; Han, Rowland H.; Gabir, Mohamed; Baksh, Brandon; Mercer, Deanna] Washington Univ St Louis, Sch Med, Dept Neurol Surg, 1 Childrens Way,4S20, St Louis, MO 63110 USA; [Morgan, Clinton D.] Barrow Neurol Inst, 350 West Thomas Rd, Phoenix, AZ 85013 USA; [Limbrick, David D., Jr.] Washington Univ St Louis, Sch Med, Dept Neurol Surg & Pediat, 1 Childrens Way,4S20, St Louis, MO 63110 USA		Morales, DM (corresponding author), Washington Univ St Louis, Sch Med, Dept Neurol Surg, 1 Childrens Way,4S20, St Louis, MO 63110 USA.	d.morales@wustl.edu	McAllister, James P./N-9657-2019; Han, Rowland/J-5210-2019	Han, Rowland/0000-0002-8615-8532; Morgan, Clinton/0000-0002-7511-0488; Morales, Diego/0000-0001-6672-9046	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS075151]; ICTS [UL1 TR000448]; CTSAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 RR024992, TL1 TR000449]; Children's Surgical Sciences Institute, St. Louis Children's Hospital; Hydrocephalus Association Innovator Award; Washington University Hope Center for Neurological Disorders; Rudi Schulte Research Institute; STARS-kids; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002345, TL1TR000449, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T34GM083914] Funding Source: NIH RePORTER	This project was supported by NIH/NINDS K23 NS075151, ICTS UL1 TR000448, CTSA UL1 RR024992, TL1 TR000449, and a grant from the Children's Surgical Sciences Institute, St. Louis Children's Hospital (D.L.). JPM received support from a Hydrocephalus Association Innovator Award, a Seed Grant from the Washington University Hope Center for Neurological Disorders, the Rudi Schulte Research Institute, and STARS-kids.	Alt C, 2002, EUR J IMMUNOL, V32, P2133, DOI 10.1002/1521-4141(200208)32:8<2133::AID-IMMU2133>3.0.CO;2-W; Ambrosini E, 2005, J NEUROPATH EXP NEUR, V64, P706, DOI 10.1097/01.jnen.0000173893.01929.fc; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Baumeister FAM, 2000, INFECTION, V28, P234, DOI 10.1007/s150100070043; Botfield H, 2013, BRAIN, V136, P2842, DOI 10.1093/brain/awt203; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; CHAZAL J, 1985, ANAT CLIN, V7, P61, DOI 10.1007/BF01654631; Cherian S, 2004, BRAIN PATHOL, V14, P305; Chow LC, 2005, BIOL NEONATE, V88, P1, DOI 10.1159/000083945; Chui R, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-1; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Di Paolo NC, 2016, NAT IMMUNOL, V17, P906, DOI 10.1038/ni.3503; Dorner BG, 2009, IMMUNITY, V31, P823, DOI 10.1016/j.immuni.2009.08.027; Eder C, 2009, IMMUNOBIOLOGY, V214, P543, DOI 10.1016/j.imbio.2008.11.007; Gahring LC, 1996, NEUROIMMUNOMODULAT, V3, P289, DOI 10.1159/000097283; GOMEZ DG, 1981, ACTA ANAT, V111, P247; HAYASHI M, 1995, J NEUROIMMUNOL, V60, P143, DOI 10.1016/0165-5728(95)00064-9; Heep A, 2004, PEDIATR RES, V56, P768, DOI 10.1203/01.PDR.0000141524.32142.53; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Karman J, 2006, J IMMUNOL, V177, P7750, DOI 10.4049/jimmunol.177.11.7750; Kivisakk P, 2004, ANN NEUROL, V55, P627, DOI 10.1002/ana.20049; Klein RS, 2004, J CELL BIOCHEM, V92, P213, DOI 10.1002/jcb.20052; Krumbholz M, 2007, J NEUROIMMUNOL, V190, P72, DOI 10.1016/j.jneuroim.2007.07.024; Lalor SJ, 2010, J NEUROIMMUNOL, V224, P56, DOI 10.1016/j.jneuroim.2010.05.017; Lei Y, 2012, MICROBES INFECT, V14, P262, DOI 10.1016/j.micinf.2011.10.003; Lekic T, 2012, EXP NEUROL, V236, P69, DOI 10.1016/j.expneurol.2012.04.003; Merhar S, 2012, NEONATOLOGY, V101, P1, DOI 10.1159/000323498; Montgomery SL, 2012, J NEUROIMMUNE PHARM, V7, P42, DOI 10.1007/s11481-011-9287-2; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morales DM, 2017, NEUROSURGERY, V80, P82, DOI 10.1227/NEU.0000000000001415; Morales DM, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.011973; Murphy BP, 2002, ARCH DIS CHILD-FETAL, V87, pF37, DOI 10.1136/fn.87.1.F37; O'Hayon BB, 1998, PEDIATR NEUROSURG, V29, P245, DOI 10.1159/000028730; Okamura T, 2012, J NEUROSCI RES, V90, P2127, DOI 10.1002/jnr.23105; Robinson S, 2012, J NEUROSURG-PEDIATR, V9, P242, DOI 10.3171/2011.12.PEDS11136; Rochfort KD, 2016, J NEUROCHEM, V136, P564, DOI 10.1111/jnc.13408; Rochfort KD, 2015, BIOCHEM SOC T, V43, P702, DOI 10.1042/BST20140319; Rothaug M, 2016, BBA-MOL CELL RES, V1863, P1218, DOI 10.1016/j.bbamcr.2016.03.018; Sakka L, 2011, EUR ANN OTORHINOLARY, V128, P309, DOI 10.1016/j.anorl.2011.03.002; Savman K, 2002, ACTA PAEDIATR, V91, P1357; Schmitz T, 2007, PEDIATR RES, V61, P722, DOI 10.1203/pdr.0b013e31805341f1; Schutt RC, 2012, STROKE, V43, P3382, DOI 10.1161/STROKEAHA.112.660878; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Strahle J, 2012, TRANSL STROKE RES, V3, pS25, DOI 10.1007/s12975-012-0182-9; Szpecht D, 2016, CHILD NERV SYST, V32, P2097, DOI 10.1007/s00381-016-3217-9; Takizawa T, 2001, NEUROL RES, V23, P724, DOI 10.1179/016164101101199243; Trifilo MJ, 2004, VIROLOGY, V327, P8, DOI 10.1016/j.virol.2004.06.027; Trifilo MJ, 2003, J NEUROVIROL, V9, P315, DOI 10.1080/13550280390201029; Tsitouras V, 2011, CHILD NERV SYST, V27, P1595, DOI 10.1007/s00381-011-1521-y; Turner MD, 2014, BBA-MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014; Viscardi RM, 2004, PEDIATR RES, V55, P1009, DOI 10.1203/01.pdr.0000127015.60185.8a; Wellons JC, 2013, J NEUROSURG-PEDIATR, V11, P12, DOI 10.3171/2012.10.PEDS12329; Welser-Alves JV, 2013, NEUROCHEM INT, V63, P47, DOI 10.1016/j.neuint.2013.04.007; Whitelaw A, 1999, PEDIATR RES, V46, P576, DOI 10.1203/00006450-199911000-00014; Williams JL, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00154; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Xia MQ, 1998, AM J PATHOL, V153, P31, DOI 10.1016/S0002-9440(10)65542-3; Yung YC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002095; Zundler S, 2015, CYTOKINE GROWTH F R, V26, P559, DOI 10.1016/j.cytogfr.2015.07.003	68	25	25	1	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-8118			FLUIDS BARRIERS CNS	Fluids Barriers CNS	DEC 12	2017	14								35	10.1186/s12987-017-0083-0			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FQ2IV	WOS:000418181000001	29228970	gold, Green Published			2022-02-06	
J	Salberg, S; Yamakawa, G; Christensen, J; Kolb, B; Mychasiuk, R				Salberg, Sabrina; Yamakawa, Glenn; Christensen, Jennaya; Kolb, Bryan; Mychasiuk, Richelle			ASSESSMENT OF A NUTRITIONAL SUPPLEMENT CONTAINING RESVERATROL, PREBIOTIC FIBER, AND OMEGA-3 FATTY ACIDS FOR THE PREVENTION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY IN RATS	NEUROSCIENCE			English	Article						adolescence; concussion; RT-qPCR; Golgi-Cox; prefrontal cortex; primary auditory cortex	POST-CONCUSSION SYMPTOMS; PREFRONTAL CORTEX; PROFESSIONAL FOOTBALL; SEX-DIFFERENCES; POSTCONCUSSION SYNDROME; SYNAPTIC CONNECTIVITY; DENDRITIC MORPHOLOGY; COGNITIVE RESERVE; DNA METHYLATION; GENE-EXPRESSION	Children and adolescents have the highest rates of traumatic brain Injury (TBI), with mild TBI (mTBI) accounting for most of these injuries. Adolescents are particularly vulnerable and often suffer from post-injury symptomologies that may persist for months. We hypothesized that the combination of resveratrol (RES), prebiotic fiber (PBF), and omega-3 fatty acids (docosahexaenoic acid (DHA)) would be an effective therapeutic supplement for the mitigation of mTBI outcomes In the developing brain. Adolescent male and female Sprague-Dawley rats were randomly assigned to the supplement (3S) or control condition, which was followed by a mTBI or sham insult. A behavioral test battery designed to examine symptomologies commonly associated with mTBI was administered. Following the test battery, tissue was collected from the prefrontal cortex (PFC) and primary auditory cortex for Golgi-Cox analysis of spine density, and for changes In expression of 6 genes (Aqp4, Gfap, Igf1, Nfl, Sirt1, and Tau). 3S treatment altered the behavioral performance of sham animals indicating that dietary manipulations modify premorbid characteristics. 3S treatment prevented Injury-related deficits In the longer-term behavior measures, medial prefrontal cortex (mPFC) spine density, and levels of Aqp4, Gfap, Igf1, Nfl, and Sirt1 expression in the PFC. Although not fully protective, treatment with the supplement significantly improved post-mTBI function and warrants further Investigation. (C) 2017 IBRO. Published by Elsevier Ltd. All rights reserved.	[Salberg, Sabrina; Yamakawa, Glenn; Christensen, Jennaya; Mychasiuk, Richelle] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Kolb, Bryan] Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB, Canada		Mychasiuk, R (corresponding author), Alberta Childrens Prov Gen Hosp, Res Inst, Hotchkiss Brain Inst, Heritage Med Res Bldg Room 274,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rmmychas@ucalgary.ca		Yamakawa, Glenn/0000-0003-3079-6532	Alberta Children's Hospital Foundation; Alberta Children's Hospital Research Institute; NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); O'Brien Centre Summer Studentships	The authors would like to acknowledge Yilin Li and Kehe Xe for their technical assistance with the Golgi-Cox analysis. They would also like to thank the Alberta Children's Hospital Research Institute, Alberta Children's Hospital Foundation, the O'Brien Centre Summer Studentships, and NSERC for their financial contribution.	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2015, PEDIATR NEUROL, V53, P491, DOI 10.1016/j.pediatrneurol.2015.04.011; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cole GM, 2009, PROSTAG LEUKOTR ESS, V81, P213, DOI 10.1016/j.plefa.2009.05.015; Collins MA, 2013, NEUROTOX RES, V23, P105, DOI 10.1007/s12640-012-9360-5; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crews F, 2007, PHARMACOL BIOCHEM BE, V86, P189, DOI 10.1016/j.pbb.2006.12.001; Crombag HS, 2005, CEREB CORTEX, V15, P341, DOI 10.1093/cercor/bhh136; Das Samarjit, 2007, Inflammation & Allergy Drug Targets, V6, P168, DOI 10.2174/187152807781696464; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Eckles-Smith K, 2000, MOL BRAIN RES, V78, P154, DOI 10.1016/S0169-328X(00)00088-7; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Fuentes A, 2010, BRAIN INJURY, V24, P995, DOI 10.3109/02699052.2010.489791; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Gibb R, 1998, J NEUROSCI METH, V79, P1, DOI 10.1016/S0165-0270(97)00163-5; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hehar H, 2016, NEUROBIOL DIS, V87, P11, DOI 10.1016/j.nbd.2015.12.007; Heijtza RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/pnas.1010529108; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Hudert CA, 2006, P NATL ACAD SCI USA, V103, P11276, DOI 10.1073/pnas.0601280103; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Kamphuis W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042823; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Ladd-Acosta C, 2007, AM J HUM GENET, V81, P1304, DOI 10.1086/524110; Langdon KD, 2011, NEUROSCIENCE, V182, P82, DOI 10.1016/j.neuroscience.2011.03.028; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Mangiola A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/736104; Martin Leslie R, 2005, Ther Clin Risk Manag, V1, P189; Mathias JL, 2015, NEUROSCI BIOBEHAV R, V55, P573, DOI 10.1016/j.neubiorev.2015.06.001; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Mychasiuk R, 2016, NEUROSCIENCE, V322, P489, DOI 10.1016/j.neuroscience.2016.02.053; Mychasiuk R, 2015, NEUROSCIENCE, V288, P145, DOI 10.1016/j.neuroscience.2014.12.034; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R, 2016, EUR J NEUROSCI, P1; Mychasiuk R, 2016, J NEUROSCI METH, V257, P168, DOI 10.1016/j.jneumeth.2015.10.002; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2015, NEUROBIOL DIS, V73, P1, DOI 10.1016/j.nbd.2014.09.003; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Mychasiuk R, 2012, SYNAPSE, V66, P308, DOI 10.1002/syn.21512; Mychasiuk R, 2011, BRAIN RES, V1412, P55, DOI 10.1016/j.brainres.2011.07.023; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Parnell J, 2012, GUT MICROBES, V3, P19246; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rassovsky Y, 2015, J CLIN EXP NEUROPSYC, V37, P354, DOI 10.1080/13803395.2015.1015498; Rich NJ, 2010, J NEUROSCI RES, V88, P2933, DOI 10.1002/jnr.22443; Schallert T., 2002, PHARM CEREB ISCHEMIA, V2002, P201; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Shukla Y, 2011, ANN NY ACAD SCI, V1215, P1, DOI 10.1111/j.1749-6632.2010.05870.x; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Suzuki T, 2012, EUR J NEUROSCI, V36, P3653, DOI 10.1111/j.1460-9568.2012.08280.x; Tees, 1990, CEREBRAL CORTEX RAT; Van Geel WJA, 2005, J IMMUNOL METHODS, V296, P179, DOI 10.1016/j.jim.2004.11.015; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Welch R, 2016, J NEUROTRAU; Whishaw IQ, 2005, BEHAV LAB RAT HDB TE; Wright D, 2017, ANN CLIN TRANSL NEUR; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Zhang Z., 2010, METHOD MOL BIOL, V662; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zilles K., 1985, CORTEX RAT STEREOTAX	82	25	26	1	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 4	2017	365						146	157		10.1016/j.neuroscience.2017.09.053			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FN4HP	WOS:000415966200013	28988852				2022-02-06	
J	Campolettano, ET; Gellner, RA; Rowson, S				Campolettano, Eamon T.; Gellner, Ryan A.; Rowson, Steven			High-magnitude head impact exposure in youth football	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; biomechanics; linear; rotational; acceleration; pediatric; trauma	TRAUMATIC BRAIN-INJURIES; HIGH-SCHOOL FOOTBALL; UNITED-STATES; PLAYERS; EPIDEMIOLOGY; SPORTS; ACCELERATION; CONCUSSIONS; KINEMATICS; LOCATION	OBJECTIVE Even in the absence of a clinically diagnosed concussion, research suggests that neurocognitive changes may develop in football players as a result of frequent head impacts that occur during football games and practices. The objectives of this study were to determine the specific situations in which high-magnitude impacts (accelerations exceeding 40g) occur in youth football games and practices and to assess how representative practice activities are of games with regard to high-magnitude head impact exposure. METHODS A total of 45 players (mean age 10.7 +/- 1.1 years) on 2 youth teams (Juniors [mean age 9.9 +/- 0.6 years; mean body mass 38.9 +/- 9.9 kg] and Seniors [mean age 11.9 +/- 0.6 years; mean body mass 51.4 +/- 11.8 kg]) wore helmets instrumented with accelerometer arrays to record head impact accelerations for all practices and games. Video recordings from practices and games were used to verify all high-magnitude head impacts, identify specific impact characteristics, and determine the amount of time spent in each activity. RESULTS A total of 7590 impacts were recorded, of which 571 resulted in high-magnitude head impact accelerations exceeding 40g (8%). Impacts were characterized based on the position played by the team member who received the impact, the part of the field where the impact occurred, whether the impact occurred during a game or practice play, and the cause of the impact. High-magnitude impacts occurred most frequently in the open field in both games (59.4%) and practices (67.5%). "Back" position players experienced a greater proportion of high-magnitude head impacts than players at other positions. The 2 teams in this study structured their practice sessions similarly with respect to time spent in each drill, but impact rates differed for each drill between the teams. CONCLUSIONS High-magnitude head impact exposure in games and practice drills was quantified and used as the basis for comparison of exposure in the 2 settings. In this cohort, game impact rates exceeded those for practice. Back players, who were often positioned in the open field, were shown to experience elevated levels of head impact exposure relative to players at other positions. The analysis also suggests that practice intensity, which may be influenced by coaching style, may also affect high-magnitude head impact exposure. Future studies should investigate this aspect as a factor affecting head impact exposure.	[Campolettano, Eamon T.; Gellner, Ryan A.; Rowson, Steven] Virginia Tech, Dept Biomed Engn & Mech, Blacksburg, VA 24061 USA		Rowson, S (corresponding author), Virginia Tech, Biomed Engn & Mech, 343 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	rowson@vt.edu	Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	National Institute of Neurological Disorders and Stroke of the NIH [R01NS094410]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094410] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the NIH under Award Number R01NS094410. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. We gratefully acknowledge the Blacksburg youth football teams for their participation in this study.	Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Breslow N. E., 1987, STAT METHODS CANC RE, VII; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Campolettano ET, 2016, J NEUROSURG-PEDIATR, V18, P536, DOI 10.3171/2016.5.PEDS1696; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027872; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dick R, 2007, J ATHL TRAINING, V42, P221; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Gottschalk AW, 2011, SPORTS MED ARTHROSC, V19, P2, DOI 10.1097/JSA.0b013e31820b95fc; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055	33	25	25	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2017	20	6					604	612		10.3171/2017.5.PEDS17185			9	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	FO5JU	WOS:000416892900015	29037104	Green Accepted, Bronze			2022-02-06	
J	Reneker, JC; Hassen, A; Phillips, RS; Moughiman, MC; Donaldson, M; Moughiman, J				Reneker, J. C.; Hassen, A.; Phillips, R. S.; Moughiman, M. C.; Donaldson, M.; Moughiman, J.			Feasibility of early physical therapy for dizziness after a sports-related concussion: A randomized clinical trial	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						cervical spine; dizziness; head injuries; concussion; physical therapy; rehabilitation	CERVICOGENIC DIZZINESS; MANUAL THERAPY; VESTIBULAR REHABILITATION; REST; DISORDERS; STATEMENT; SYMPTOMS; RECOVERY; INJURY	The purpose of this study was to (a) assess the feasibility of recruitment/retention of participants, protocol/resource management, and participant safety, and (b) estimate the size of the effect between the experimental and control groups. This was a feasibility study conducted as a prospective pilot double-blind randomized clinical trial. Subjects aged 10-23years old with acute concussion and dizziness were enrolled from sports medicine centers. Forty-one participants were randomized into treatment and were seen for physical therapy beginning at 10days post-concussion. Subjects in the experimental group received individually tailored, pragmatically delivered progressive interventions. Subjects in the control received prescriptive sham to minimally progressive interventions. The two primary outcomes were medical clearance for return-to-play and symptomatic recovery. The median number of days to medical clearance for the experimental group was 15.5 and for the control was 26. The median number of days to symptomatic recovery was 13.5 for the experimental group and was 17 for the control. According to Cox proportional hazards regression for time to medical release for return-to-play, the experimental group demonstrated a hazard ratio of 2.91 (95% CI: 1.01, 8.43) compared to the control. For time-to-symptomatic recovery, those in the experimental group demonstrated a hazard ratio of 1.99 (95% CI: 0.95, 4.15) compared to the control. The results indicate that it is feasible and safe to complete this type of intervention study. The results provide strong support for the allocation of resources to conduct well-powered randomized clinical trials of this intervention.	[Reneker, J. C.] Univ Mississippi, Med Ctr, Sch Hlth Related Profess, Dept Phys Therapy, Jackson, MS USA; [Hassen, A.; Phillips, R. S.; Donaldson, M.] Walsh Univ, North Canton, OH USA; [Moughiman, M. C.; Moughiman, J.] Louis Stokes Cleveland Vet Adm Med Ctr, Akron, OH USA		Reneker, JC (corresponding author), Univ Mississippi, Med Ctr, Sch Hlth Related Profess, Dept Phys Therapy, Jackson, MS USA.	JReneker@UMC.edu	Reneker, Jennifer/N-2038-2016	Reneker, Jennifer/0000-0003-3617-5681	American Academy of Orthopaedic Manual Physical Therapists, Cardon Grant; Ohio Physical Therapy Association	American Academy of Orthopaedic Manual Physical Therapists, Cardon Grant; Ohio Physical Therapy Association	Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Barozzi Stefania, 2006, Int Tinnitus J, V12, P45; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Carlesso LC, 2010, J ORTHOP SPORT PHYS, V40, P455, DOI 10.2519/jospt.2010.3229; Craton N, 2014, CURR SPORT MED REP, V13, P201, DOI 10.1249/JSR.0000000000000072; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Faul M, 2010, TRAUMATIC BRAIN INJU; Fife Terry D, 2012, Continuum (Minneap Minn), V18, P1060, DOI 10.1212/01.CON.0000418376.80099.24; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Herdman SJ, 2014, VESTIBULAR REHABILIT; Howell DR, 2016, AM J SPORT MED, V44, P1040, DOI 10.1177/0363546515625045; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Malmstrom EM, 2007, DISABIL REHABIL, V29, P1193, DOI 10.1080/09638280600948383; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Moor HM, 2015, INT J SPORTS PHYS TH, V10, P225; Reid SA, 2005, MANUAL THER, V10, P4, DOI 10.1016/j.math.2004.03.006; Reid SA, 2015, MANUAL THER, V20, P148, DOI 10.1016/j.math.2014.08.003; Reid SA, 2014, PHYS THER, V94, P466, DOI 10.2522/ptj.20120483; Reid SA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-201; Reneker JC, 2015, BRIT J SPORT MED, V49, P491, DOI 10.1136/bjsports-2014-093634; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Treleaven J, 2008, MANUAL THER, V13, P266, DOI 10.1016/j.math.2007.11.002; Wells EM, 2016, J CHILD NEUROL, V31, P86, DOI 10.1177/0883073815570152	32	25	26	1	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	DEC	2017	27	12					2009	2018		10.1111/sms.12827			10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	FO0DA	WOS:000416411800051	28211600				2022-02-06	
J	Zhang, J; Pu, HJ; Zhang, HY; Wei, ZS; Jiang, XY; Xu, MY; Zhang, LL; Zhang, WT; Liu, JL; Meng, HX; Stetler, RA; Sun, DD; Chen, J; Gao, YQ; Chen, L				Zhang, Jun; Pu, Hongjian; Zhang, Haiyue; Wei, Zhishuo; Jiang, Xiaoyan; Xu, Mingyue; Zhang, Lili; Zhang, Wenting; Liu, Jialin; Meng, Hengxing; Stetler, R. Anne; Sun, Dandan; Chen, Jun; Gao, Yanqin; Chen, Ling			Inhibition of Na+-K+-2Cl(-) cotransporter attenuates blood-brain-barrier disruption in a mouse model of traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Bumetanide; NKCC1; MMP9	FOCAL CEREBRAL-ISCHEMIA; WHITE-MATTER INJURY; CL-COTRANSPORTER; NEURONAL DAMAGE; EDEMA FORMATION; BREAKDOWN; RATS; MICE; OVEREXPRESSION; PERMEABILITY	Traumatic brain injury (TBI) can lead to long-term motor and cognitive dysfunction, which can be at least partly attributed to blood-brain barrier (BBB) disruption. The mechanisms underlying post-TBI BBB disruption, however, are poorly understood thus far. Na+-K+-2Cl(-) cotransporter isoform 1 (NKCC1) is a universally expressed ion transporter that maintains intracellular ion homeostasis by increasing intra-cellular K+ and Cl-. Having been characterized in stroke models, NKCC1 is activated in various cell types in the ischemic brain, and is thought to mediate BBB disruption, brain edema, and neuronal cell death. In this study, we tested the hypothesis that inhibition of NKCC1 may improve neurological outcomes via protecting against BBB disruption in a TBI mouse model. Adult male C57BL/6 j mice or NKCC1 deficient mice were subjected to controlled cortical impact (CCI). As an alternative to the genetic-based NKCC1 depletion, bumetanide, a selective NKCC1 inhibitor, was administrated (25 mg/kg, i.p.) 15 min after CCI and then every 6 h up to 48 h. Short-term sensorimotor function recovery was determined by rotarod, cylinder test, grid walking and foot fault test. BBB integrity was examined at 48 h post-CCI by measuring Evans blue extravasation, brain water content, and expression levels of tight junction proteins. Our results revealed that administration of bumetanide or genetic depletion of NKCC1 improved short-term neurological recovery against TBI. Bumetanide treatment markedly decreased brain water content and BBB leakage, correlated with reduction of MMP-9 expression and preventing the degradation of tight junction proteins. These findings suggest an important role of NKCC1 activation in mediating BBB disruption after TBI. Thus, NKCC1 inhibition may offer the potential for improving neurological outcomes in clinical TBI. (C) 2017 Published by Elsevier Ltd.	[Zhang, Jun; Liu, Jialin; Meng, Hengxing; Chen, Ling] Gen Hosp PLA, Dept Neurosurg, 28 Fuxing Rd, Beijing 100853, Peoples R China; [Pu, Hongjian; Jiang, Xiaoyan; Xu, Mingyue; Zhang, Wenting; Chen, Jun; Gao, Yanqin] Fudan Univ, State Key Lab Med Neurobiol, Shanghai, Peoples R China; [Pu, Hongjian; Jiang, Xiaoyan; Xu, Mingyue; Zhang, Wenting; Chen, Jun; Gao, Yanqin] Fudan Univ, Inst Brain Sci, Shanghai, Peoples R China; [Pu, Hongjian; Zhang, Haiyue; Wei, Zhishuo; Jiang, Xiaoyan; Xu, Mingyue; Zhang, Lili; Stetler, R. Anne; Sun, Dandan; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Sch Med, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA USA		Chen, L (corresponding author), Gen Hosp PLA, Dept Neurosurg, 28 Fuxing Rd, Beijing 100853, Peoples R China.; Gao, YQ (corresponding author), Fudan Univ, State Key Lab Med Neurobiol, 131 Dongan Rd, Shanghai 200032, Peoples R China.	yqgao@shmu.edu.cn; chen_ling301@163.com	Pu, Hongjian/AAW-3322-2020; Gao, Yanqin/I-6790-2016	Gao, Yanqin/0000-0002-4915-9819	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30970939, 81272804, 81571285, 81371306, 81271365]; Shanghai Committee of Science and Technology Support Program [14431907002]	*J.Z. and *H.P. contributed equally to this research. This project was supported by the National Natural Science Foundation of China grants (#30970939 and #81272804 to L.C., #81571285 and #81371306 to Y.G. and #81271365 to J.Z.) and the Shanghai Committee of Science and Technology Support Program (#14431907002 to Y.G.).	Alluri H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154427; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Cong DM, 2015, CURR MED CHEM, V22, P1171, DOI 10.2174/0929867322666150114151946; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Kahle KT, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/9/E22; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Krueger M, 2015, J CEREBR BLOOD F MET, V35, P292, DOI 10.1038/jcbfm.2014.199; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; Lykke K, 2015, BRIT J PHARMACOL, V172, P4469, DOI 10.1111/bph.13231; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; O'Donnell ME, 2004, J CEREBR BLOOD F MET, V24, P1046, DOI 10.1097/01.WCB.0000130867.32663.90; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shi H, 2015, CNS NEUROSCI THER, V21, P374, DOI 10.1111/cns.12366; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang LX, 2013, ANN NEUROL, V73, P189, DOI 10.1002/ana.23762; Yan YP, 2003, BRAIN RES, V961, P22, DOI 10.1016/S0006-8993(02)03832-5; Yu Qiong, 2011, Front Biosci (Elite Ed), V3, P978; Zhang F, 2006, J NEUROSCI RES, V83, P1241, DOI 10.1002/jnr.20816	31	25	27	2	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		23	31		10.1016/j.neuint.2017.05.020			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600004	28577991				2022-02-06	
J	Zhao, Y; Dong, QL; Chen, HB; Iraji, A; Li, YJ; Makkie, M; Kou, ZF; Liu, TM				Zhao, Yu; Dong, Qinglin; Chen, Hanbo; Iraji, Armin; Li, Yujie; Makkie, Milad; Kou, Zhifeng; Liu, Tianming			Constructing fine-granularity functional brain network atlases via deep convolutional autoencoder	MEDICAL IMAGE ANALYSIS			English	Article						fMRI; Functional brain networks; Deep learning	RESTING-STATE FMRI; SPARSE REPRESENTATION; INDEPENDENT COMPONENT; CONNECTIVITY; ARCHITECTURE; SIGNALS; REGIONS; INJURY	State-of-the-art functional brain network reconstruction methods such as independent component analysis (ICA) or sparse coding of whole-brain fMRI data can effectively infer many thousands of volumetric brain network maps from a large number of human brains. However, due to the variability of individual brain networks and the large scale of such networks needed for statistically meaningful group-level analysis, it is still a challenging and open problem to derive group-wise common networks as network atlases. Inspired by the superior spatial pattern description ability of the deep convolutional neural networks (CNNs), a novel deep 3D convolutional autoencoder (CAE) network is designed here to extract spatial brain network features effectively, based on which an Apache Spark enabled computational framework is developed for fast clustering of larger number of network maps into fine-granularity atlases. To evaluate this framework, 10 resting state networks (RSNs) were manually labeled from the sparsely decomposed networks of Human Connectome Project (HCP) fMRI data and 5275 network training samples were obtained, in total. Then the deep CAE models are trained by these functional networks' spatial maps, and the learned features are used to refine the original 10 RSNs into 17 network atlases that possess fine-granularity functional network patterns. Interestingly, it turned out that some manually mislabeled outliers in training networks can be corrected by the deep CAE derived features. More importantly, fine granularities of networks can be identified and they reveal unique network patterns specific to different brain task states. By further applying this method to a dataset of mild traumatic brain injury study, it shows that the technique can effectively identify abnormal small networks in brain injury patients in comparison with controls. In general, our work presents a promising deep learning and big data analysis solution for modeling functional connectomes, with fine granularities, based on fMRI data. (C) 2017 Elsevier B.V. All rights reserved.	[Zhao, Yu; Dong, Qinglin; Chen, Hanbo; Li, Yujie; Makkie, Milad; Liu, Tianming] Univ Georgia, Dept Comp Sci, Cort Architecture Imaging & Discovery Lab, Athens, GA 30602 USA; [Zhao, Yu; Dong, Qinglin; Chen, Hanbo; Li, Yujie; Makkie, Milad; Liu, Tianming] Univ Georgia, Bioimaging Res Ctr, Athens, GA 30602 USA; [Iraji, Armin; Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA		Liu, TM (corresponding author), Univ Georgia, Dept Comp Sci, Cort Architecture Imaging & Discovery Lab, Athens, GA 30602 USA.; Liu, TM (corresponding author), Univ Georgia, Bioimaging Res Ctr, Athens, GA 30602 USA.	tliu@uga.edu	Dong, Qinglin/V-9204-2019; Liu, Tianming/AAA-4602-2022	Iraji, Armin/0000-0002-0605-593X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA033393, AG042599, R21NS090153]; National Science FoundationNational Science Foundation (NSF) [IIS-1149260, CBET-1302089, BCS-1439051, DBI-1564736]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS090153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG042599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA033393] Funding Source: NIH RePORTER	T. Liu was partially supported by National Institutes of Health (DA033393, AG042599) and National Science Foundation (IIS-1149260, CBET-1302089, BCS-1439051 and DBI-1564736). Z. Kou was partially supported by National Institutes of Health (R21NS090153). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Barch DM, 2013, NEUROIMAGE, V80, P169, DOI 10.1016/j.neuroimage.2013.05.033; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bengio Y, 2007, GREEDY LAYER WISE TR; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Calhoun VD, 2004, NEUROPSYCHOPHARMACOL, V29, P2097, DOI 10.1038/sj.npp.1300543; Chen HB, 2013, IEEE T MED IMAGING, V32, P1576, DOI [10.1109/TMI.2013.2259248, 10.1007/978-3-642-33454-2_37]; DEVALOIS RL, 1982, VISION RES, V22, P531, DOI 10.1016/0042-6989(82)90112-2; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Duncan J, 2010, TRENDS COGN SCI, V14, P172, DOI 10.1016/j.tics.2010.01.004; Fedorenko E, 2013, P NATL ACAD SCI USA, V110, P16616, DOI 10.1073/pnas.1315235110; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Ge B, 2016, BRAIN IMAGING BEHAV, V10, P1206, DOI 10.1007/s11682-015-9487-0; Gilmore CS, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.454; He K., 2015, DELVING DEEP RECTIFI; Heeger DJ, 2002, NAT REV NEUROSCI, V3, P142, DOI 10.1038/nrn730; Hinton GE, 2006, NEURAL COMPUT, V18, P1527, DOI 10.1162/neco.2006.18.7.1527; Hu XT, 2015, IEEE T AUTON MENT DE, V7, P65, DOI 10.1109/TAMD.2015.2409835; Huettel S. A., 2004, FUNCTIONAL MAGNETIC; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Jiang X, 2015, HUM BRAIN MAPP, V36, P5301, DOI 10.1002/hbm.23013; Karpathy A, 2014, PROC CVPR IEEE, P1725, DOI 10.1109/CVPR.2014.223; Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lecun Y., 1998, P V SVM VIRT SUPP VE; Li X, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P511, DOI 10.1145/2939672.2939730; Liu N, 2015, PROC CVPR IEEE, P362, DOI 10.1109/CVPR.2015.7298633; Lowe D. G., 1999, Proceedings of the Seventh IEEE International Conference on Computer Vision, P1150, DOI 10.1109/ICCV.1999.790410; Lv JL, 2015, LECT NOTES COMPUT SC, V9349, P239, DOI 10.1007/978-3-319-24553-9_30; Lv JL, 2015, PSYCHIAT RES-NEUROIM, V233, P254, DOI 10.1016/j.pscychresns.2015.07.012; Lv JL, 2015, IEEE T BIO-MED ENG, V62, P1120, DOI 10.1109/TBME.2014.2369495; Lv JL, 2015, MED IMAGE ANAL, V20, P112, DOI 10.1016/j.media.2014.10.011; Mairal J, 2010, J MACH LEARN RES, V11, P19; Masci J, 2011, LECT NOTES COMPUT SC, V6791, P52, DOI 10.1007/978-3-642-21735-7_7; Pessoa L, 2012, BEHAV BRAIN SCI, V35, P158, DOI 10.1017/S0140525X11001567; Schairer K., 2012, AM SPEECH LANGUAGE H, V16, P18, DOI DOI 10.1044/HHD16.1.18; Serre T, 2005, PROC CVPR IEEE, P994; Simonyan K., 2014, VERY DEEP CONVOLUTIO; Smith SM, 2013, NEUROIMAGE, V80, P144, DOI 10.1016/j.neuroimage.2013.05.039; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sporns Olaf, 2013, Dialogues Clin Neurosci, V15, P247; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Vander Werff KR, 2012, PERSPECTIVES HEARING, V16, P3, DOI DOI 10.1044/HHD16.13; von Luxburg U, 2007, STAT COMPUT, V17, P395, DOI 10.1007/s11222-007-9033-z; Worsley KJ, 1997, HUM BRAIN MAPP, V5, P254, DOI 10.1002/(SICI)1097-0193(1997)5:4<254::AID-HBM9>3.0.CO;2-2; Xu JS, 2016, NEUROSCI BIOBEHAV R, V71, P83, DOI 10.1016/j.neubiorev.2016.08.035; Zeiler M.D., 2012, J ARXIV COMPUT SCI; Zhang S, 2016, BRAIN IMAGING BEHAV, V10, P21, DOI 10.1007/s11682-015-9359-7; Zhao S., 2017, BRAIN IMAGI IN PRESS; Zhao SJ, 2015, IEEE T MED IMAGING, V34, P2036, DOI 10.1109/TMI.2015.2418734; Zhao Y, 2016, NEUROIMAGE-CLIN, V12, P23, DOI 10.1016/j.nicl.2016.06.004	51	25	25	1	41	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1361-8415	1361-8423		MED IMAGE ANAL	Med. Image Anal.	DEC	2017	42						200	211		10.1016/j.media.2017.08.005			12	Computer Science, Artificial Intelligence; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging	FN1VA	WOS:000415778100014	28843214	Green Accepted			2022-02-06	
J	Camacho-Soto, A; Warden, MN; Searles Nielsen, S; Salter, A; Brody, DL; Prather, H; Racette, BA				Camacho-Soto, Alejandra; Warden, Mark N.; Searles Nielsen, Susan; Salter, Amber; Brody, David L.; Prather, Heidi; Racette, Brad A.			Traumatic brain injury in the prodromal period of Parkinson's disease: A large epidemiological study using medicare data	ANNALS OF NEUROLOGY			English	Article								ObjectiveStudies suggest a greater risk of Parkinson's disease (PD) after traumatic brain injury (TBI), but it is possible that the risk of TBI is greater in the prodromal period of PD. We aimed to examine the time-to-TBI in PD patients in their prodromal period compared to population-based controls. MethodsWe identified 89,790 incident PD cases and 118,095 comparable controls aged>65 years in 2009 using Medicare claims data. Using data from the preceding 5 years, we compared time-to-TBI in PD patients in their prodromal period to controls. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for TBI in a Cox regression, while adjusting for age, sex, race/ethnicity, modified Charlson comorbidity index, smoking, and alcohol use. ResultsRisk of TBI was greater in PD patients in their prodromal period across all age and sex groups, with HRs consistently increasing with proximity to PD diagnosis. HRs ranged from 1.64 (95% CI, 1.52, 1.77) 5 years preceding diagnosis to 3.93 (95% CI, 3.74, 4.13) in the year before. The interaction between PD, TBI, and time was primarily observed for TBI attributed to falls. Motor dysfunction and cognitive impairment, suggested by corresponding International Classification of Diseases, Ninth Revision codes, partially mediated the PD-TBI association. InterpretationThere is a strong association between PD and a recent TBI in the prodromal period of PD. This association strengthens as PD diagnosis approaches and may be a result of undetected nonmotor and motor symptoms, but confirmation will be required. Ann Neurol 2017;82:744-754	[Camacho-Soto, Alejandra; Warden, Mark N.; Searles Nielsen, Susan; Brody, David L.; Prather, Heidi; Racette, Brad A.] Washington Univ, Dept Neurol, Sch Med, Campus Box 8111,660 South Euclid Ave, St Louis, MO 63110 USA; [Salter, Amber] Washington Univ, Div Biostat, St Louis, MO USA; [Prather, Heidi] Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO USA; [Racette, Brad A.] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa		Racette, BA (corresponding author), Washington Univ, Dept Neurol, Sch Med, Campus Box 8111,660 South Euclid Ave, St Louis, MO 63110 USA.	racetteb@wustl.edu	Prather, Heidi/AAN-8851-2021	Searles Nielsen, Susan/0000-0001-7768-4736; Warden, Mark/0000-0002-1630-6018	Rehabilitation Medicine Scientist Training Program [5K12 HD001097-19]; NIEHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [K24ES017765-07]; Michael J. Fox Foundation; American Parkinson Disease Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [K24ES017765] Funding Source: NIH RePORTER	This study was supported by the Rehabilitation Medicine Scientist Training Program, 5K12 HD001097-19 (to A.C.S.) and NIEHS K24ES017765-07 (to B.A.R.), the Michael J. Fox Foundation (to B.A.R., S.S.N., and M.N.W.), and the American Parkinson Disease Association (to B.A.R., S.S.N., and M.N.W.).		0	25	25	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	NOV	2017	82	5					744	754		10.1002/ana.25074			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FN3UG	WOS:000415925900009	29024046	Green Accepted			2022-02-06	
J	Nissinen, J; Andrade, P; Natunen, T; Hiltunen, M; Malm, T; Kanninen, K; Soares, JI; Shatillo, O; Sallinen, J; Ndode-Ekane, XE; Pitkanen, A				Nissinen, Jari; Andrade, Pedro; Natunen, Teemu; Hiltunen, Mikko; Malm, Tarja; Kanninen, Katja; Soares, Joana I.; Shatillo, Olena; Sallinen, Jukka; Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla			Disease-modifying effect of atipamezole in a model of post-traumatic epilepsy	EPILEPSY RESEARCH			English	Article						alpha 2-Adrenoceptor; Beam walking; Cannabinoid 1 receptor antagonist; Composite neuroscore; Epileptogenesis; Lateral fluid-percussion; Memory; Seizure susceptibility; Somato-motor performance; SR141716A	TRAUMATIC BRAIN-INJURY; CB1 RECEPTOR ANTAGONIST; FREELY-MOVING RATS; SELECTIVE ALPHA(2)-ADRENOCEPTOR ANTAGONIST; LONG-TERM HYPEREXCITABILITY; FOCAL CEREBRAL-ISCHEMIA; ELECTRICAL-STIMULATION; STATUS EPILEPTICUS; NEURONAL DAMAGE; FRONTAL-CORTEX	Treatment of TBI remains a major unmet medical need, with 2.5 million new cases of traumatic brain injury (TBI) each year in Europe and 1.5 million in the USA. This single-center proof-of-concept preclinical study tested the hypothesis that pharmacologic neurostimulation with proconvulsants, either atipamezole, a selective alpha(2)-adrenoceptor antagonist, or the cannabinoid receptor 1 antagonist SR141716A, as monotherapy would improve functional recovery after TBI. A total of 404 adult Sprague-Dawley male rats were randomized into two groups: sham-injured or lateral fluid-percussion induced TBI. The rats were treated with atipamezole (started at 30 min or 7 d after TBI) or SR141716A (2 min or 30 min post-TBI) for up to 9 wk. Total follow-up time was 14 wk after treatment initiation. Outcome measures included motor (composite neuroscore, beam-walking) and cognitive performance (Morris water-maze), seizure susceptibility, spontaneous seizures, and cortical and hippocampal pathology. All injured rats exhibited similar impairment in the neuroscore and beam-walking tests at 2 d post-TBI. Atipamezole treatment initiated at either 30 min or 7 d post-TBI and continued for 9 wk via subcutaneous osmotic minipumps improved performance in both the neuroscore and beam-walking tests, but not in the Morris water-maze spatial learning and memory test. Atipamezole treatment initiated at 7 d post-TBI also reduced seizure susceptibility in the pentylenetetrazol test 14 wk after treatment initiation, although it did not prevent the development of epilepsy. SR141716A administered as a single dose at 2 min post-TBI or initiated at 30 min post-TBI and continued for 9 wk had no recovery-enhancing or antiepileptogenic effects. Mechanistic studies to assess the alpha(2)-adrenoceptor subtype specificity of the disease-modifying effects of atipametzole revealed that genetic ablation of alpha(2A)-noradrenergic receptor function in Adra2A mice carrying an N79P point mutation had antiepileptogenic effects after TBI. On the other hand, blockade of alpha(2C)-adrenoceptors using the receptor subtype specific antagonist ORM-12741 had no favorable effects on the post-TBI outcome. Finally, to assess whether regulation of the post-injury inflammatory response by atipametzole in glial cells contributed to a favorable outcome, we investigated the effect of atipamezole on spontaneous and/or lipopolysaccharide-stimulated astroglial or microglial cytokine release in vitro. We observed no effect. Our data demonstrate that a 9-wk administration of alpha 2A-noradrenergic antagonist, atipamezole, is recovery-enhancing after TBI.	[Nissinen, Jari; Andrade, Pedro; Malm, Tarja; Kanninen, Katja; Shatillo, Olena; Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FI-70211 Kuopio, Finland; [Natunen, Teemu; Hiltunen, Mikko] Univ Eastern Finland, Inst Biomed, POB 1627, FI-70211 Kuopio, Finland; [Natunen, Teemu; Hiltunen, Mikko] Kuopio Univ Hosp, Dept Neurol, POB 1627, FI-70211 Kuopio, Finland; [Soares, Joana I.] Univ Porto, Inst Invest & Inovacao Saude, Oporto, Portugal; [Soares, Joana I.] Univ Porto, Inst Biol Mol & Celular, Oporto, Portugal; [Soares, Joana I.] Univ Porto, Programa Doutoral Neurociencias, Oporto, Portugal; [Sallinen, Jukka] Orion Corp Orion Pharma, POB 425,Tengstrominkatu 8, Turku 20101, Finland		Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FI-70211 Kuopio, Finland.	asla.pitkanen@uef.fi	Andrade, Pedro/N-8410-2018; Soares, Joana Isabel/ABC-5544-2021	Andrade, Pedro/0000-0001-9118-8341; Malm, Tarja/0000-0002-9530-7472; Ndode-Ekane, Xavier Ekolle/0000-0001-5682-5632; Soares, Joana I./0000-0002-3549-6873	CURE (Citizens United for Research in Epilepsy); Academy of FinlandAcademy of FinlandEuropean Commission	We thank Mr. Jarmo Hartikainen and Mrs. Merja Lukkari for excellent technical assistance. This study was supported by CURE (Citizens United for Research in Epilepsy) (AP) and The Academy of Finland (AP). Atipamezole was a gift from Orion Pharma.	Aoki C, 1998, CEREB CORTEX, V8, P269, DOI 10.1093/cercor/8.3.269; Barbelivien A, 2002, NEUROPHARMACOLOGY, V42, P117, DOI 10.1016/S0028-3908(01)00150-2; BIEGON A, 1992, EUR J PHARMACOL, V224, P27, DOI 10.1016/0014-2999(92)94814-C; Birder LA, 1999, J PHYSIOL-LONDON, V515, P533, DOI 10.1111/j.1469-7793.1999.533ac.x; Biters L. V., 2002, J COMP NEUROL, V444, P63; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Chen K, 2007, J NEUROSCI, V27, P46, DOI 10.1523/JNEUROSCI.3966-06.2007; Chen YJ, 2014, P NATL ACAD SCI USA, V111, P17296, DOI 10.1073/pnas.1409513111; Chi XJ, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0554-5; Christopoulou FD, 2011, J CLIN PHARM THER, V36, P10, DOI 10.1111/j.1365-2710.2010.01164.x; Citraro R, 2013, EPILEPSY RES, V106, P74, DOI 10.1016/j.eplepsyres.2013.06.004; Comelli F, 2010, EUR J PHARMACOL, V637, P62, DOI 10.1016/j.ejphar.2010.03.061; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Costa B, 2005, PAIN, V116, P52, DOI 10.1016/j.pain.2005.03.043; Deshpande LS, 2007, NEUROSCI LETT, V411, P11, DOI 10.1016/j.neulet.2006.09.046; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Flugge G, 2003, EUR J NEUROSCI, V17, P917, DOI 10.1046/j.1460-9568.2003.02510.x; Gobert A, 1998, NEUROSCIENCE, V84, P413, DOI 10.1016/S0306-4522(97)00565-4; Gobert A, 1997, J NEUROCHEM, V69, P2616; Goldstein LB, 1999, REV NEUROL-FRANCE, V155, P731; Goldstein LB, 1997, PHARMACOL BIOCHEM BE, V58, P1151, DOI 10.1016/S0091-3057(97)00324-9; Gribble FM, 2010, NEW ENGL J MED, V362, P361, DOI 10.1056/NEJMcibr0911499; Haapalinna A, 1997, N-S ARCH PHARMACOL, V356, P570, DOI 10.1007/PL00005092; Halonen T, 1996, EUR J PHARMACOL, V299, P69, DOI 10.1016/0014-2999(95)00835-7; HALONEN T, 1995, BRAIN RES, V693, P217, DOI 10.1016/0006-8993(95)00744-B; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Herrick AL, 2014, RHEUMATOLOGY, V53, P948, DOI 10.1093/rheumatology/ket421; Hutchinson DS, 2011, J NEUROCHEM, V117, P915, DOI 10.1111/j.1471-4159.2011.07261.x; Jansson CC, 1998, MOL PHARMACOL, V53, P963; Janumpalli S, 1998, J NEUROSCI, V18, P2004; Jolkkonen J, 2000, EUR J PHARMACOL, V400, P211, DOI 10.1016/S0014-2999(00)00409-X; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; LAITINEN KSM, 1995, EUR J PHARMACOL, V285, P255, DOI 10.1016/0014-2999(95)00410-M; Lehto J, 2015, SYNAPSE, V69, P172, DOI 10.1002/syn.21798; LEVIN BE, 1994, RESTOR NEUROL NEUROS, V7, P5, DOI 10.3233/RNN-1994-7102; Herrera-Garcia AM, 2014, J IMMUNOL, V193, P3023, DOI 10.4049/jimmunol.1400255; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Ndode-Ekane XE, 2010, NEUROSCIENCE, V166, P312, DOI 10.1016/j.neuroscience.2009.12.002; Ndode-Ekane XE, 2017, J NEUROTRAUM, V34, P459, DOI 10.1089/neu.2016.4404; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Oliviero A, 2012, EUR NEUROPSYCHOPHARM, V22, P27, DOI 10.1016/j.euroneuro.2011.04.004; Olli-Lahdesmaki T, 1999, J NEUROSCI, V19, P9281; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pertovaara A, 2005, CNS DRUG REV, V11, P273; Pitkanen A, 2004, EPILEPSY RES, V61, P119, DOI 10.1016/j.eplepsyres.2004.07.005; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Piwnica D, 2014, J DERMATOL SCI, V75, P49, DOI 10.1016/j.jdermsci.2014.04.002; Puurunen K, 2001, NEUROPHARMACOLOGY, V40, P597, DOI 10.1016/S0028-3908(00)00182-9; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ren X., 2016, J NEUROIMMUNE PHARM, P1; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; SARA SJ, 1991, NEUROSCI LETT, V126, P1, DOI 10.1016/0304-3940(91)90356-X; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Sukegawa S, 2014, ANESTH ANALG, V118, P473, DOI 10.1213/ANE.0000000000000060; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; VIRTANEN R, 1989, ARCH INT PHARMACOD T, V297, P190; Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99; Wang XT, 2014, EUR J PHARMACOL, V724, P16, DOI 10.1016/j.ejphar.2013.12.026; Wang X, 2016, BRAIN RES, V1646, P174, DOI 10.1016/j.brainres.2016.05.055; Yao H, 2015, SCI REP-UK, V5, DOI 10.1038/srep16849	68	25	25	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	OCT	2017	136						18	34		10.1016/j.eplepsyres.2017.07.005			17	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FI8MD	WOS:000412255800004	28753497				2022-02-06	
J	Vergara, VM; Mayer, AR; Damaraju, E; Calhoun, VD				Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Calhoun, Vince D.			The effect of preprocessing in dynamic functional network connectivity used to classify mild traumatic brain injury	BRAIN AND BEHAVIOR			English	Article						dynamic functional network connectivity; functional MRI; independent component analysis; traumatic brain injury	STRUCTURAL CONNECTIVITY; CLASSIFICATION; CONSCIOUSNESS; DISRUPTION; DISORDER; STATES; RISK; FMRI	IntroductionDynamic functional network connectivity (dFNC), derived from magnetic resonance imaging (fMRI), is an important technique in the search for biomarkers of brain diseases such as mild traumatic brain injury (mTBI). At the individual level, mTBI can affect cognitive functions and change personality traits. Previous research aimed at detecting significant changes in the dFNC of mTBI subjects. However, one of the main concerns in dFNC analysis is the appropriateness of methods used to correct for subject movement. In this work, we focus on the effect that rearranging movement correction at different points of the processing pipeline has in dFNC analysis utilizing mTBI data. MethodsThe sample cohort consists of 50 mTBI patients and matched healthy controls. A 5-min resting-state run was completed by each participant. Data were preprocessed using different pipeline alternatives varying with the place where motion-related variance was removed. In all pipelines, group-independent component analysis (gICA) followed by dFNC analysis was performed. Additional tests were performed varying the detection of temporal spikes, the number of gICA components, and the sliding-window size. A linear support vector machine was used to test how each pipeline affects classification accuracy. ResultsResults suggest that correction for motion variance before spatial smoothing, but leaving correction for spiky time courses after gICA produced the best mean classification performance. The number of gICA components and the sliding-window size were also important in determining classification performance. Variance in spikes correction affected some pipelines more than others with fewer significant differences than the other parameters. ConclusionThe sequence of preprocessing steps motion regression, smoothing, gICA, and despiking produced data most suitable for differentiating mTBI from healthy subjects. However, the selection of optimal preprocessing parameters strongly affected the final results.	[Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM 87106 USA; [Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychiat, Albuquerque, NM USA		Vergara, VM (corresponding author), Mind Res Network, Albuquerque, NM 87106 USA.	vvergara@mrn.org		Vergara, Victor/0000-0001-9404-0924	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24HD050836, R21NS064464, 3R21NS064464, P20GM103472, 1R01EB006841, R01REB020407]; NSFNational Science Foundation (NSF) [1539067, 1631819]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER; Office Of The DirectorNational Science Foundation (NSF)NSF - Office of the Director (OD) [1539067] Funding Source: National Science Foundation	NIH, Grant/Award Number: R24HD050836/ R21NS064464/3R21NS064464 to A. R. Mayer, P20GM103472/1R01EB006841/ R01REB020407/P20GM103472 and NSF grants 1539067/1631819 to V. D. Calhoun	Allen EA, 2014, CEREB CORTEX, V24, P663, DOI 10.1093/cercor/bhs352; Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun Vince D, 1800, IEEE Rev Biomed Eng, V5, P60, DOI 10.1109/RBME.2012.2211076; Cawley GC, 2010, J MACH LEARN RES, V11, P2079; Damaraju E., 2014, BRAIN CONNECTIVITY, V4, pA1; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Friston K., 2003, STAT PARAMETRIC MAPP; Grouiller F, 2011, BRAIN, V134, P2867, DOI 10.1093/brain/awr156; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Hutchison RM, 2013, NEUROIMAGE, V80, P360, DOI 10.1016/j.neuroimage.2013.05.079; Lemieux L, 2007, MAGN RESON IMAGING, V25, P894, DOI 10.1016/j.mri.2007.03.009; Levine E, 2001, NEURAL COMPUT, V13, P2573, DOI 10.1162/089976601753196030; Ma S, 2011, IEEE T BIO-MED ENG, V58, P3406, DOI 10.1109/TBME.2011.2167149; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Redelmeier DA, 2003, LANCET, V361, P2177, DOI 10.1016/S0140-6736(03)13770-1; Sakoglu U, 2010, MAGN RESON MATER PHY, V23, P351, DOI 10.1007/s10334-010-0197-8; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shirer WR, 2012, CEREB CORTEX, V22, P158, DOI 10.1093/cercor/bhr099; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Sours C, 2015, BRAIN IMAGING BEHAV, V9, P550, DOI 10.1007/s11682-015-9424-2; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; TEASDALE G, 1974, LANCET, V2, P81; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vergara VM, 2017, J NEUROTRAUM, V34, P1045, DOI 10.1089/neu.2016.4526; Vergara VM, 2017, NEUROIMAGE, V145, P365, DOI 10.1016/j.neuroimage.2016.03.038; Vergara VM, 2015, IEEE ENG MED BIO, P5432, DOI 10.1109/EMBC.2015.7319620; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	41	25	25	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	OCT	2017	7	10							e00809	10.1002/brb3.809			11	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	FK5IX	WOS:000413532400016	29075569	Green Published, gold			2022-02-06	
J	Bosco, FM; Parola, A; Valentini, MC; Morese, R				Bosco, Francesca M.; Parola, Alberto; Valentini, Maria C.; Morese, Rosalba			Neural correlates underlying the comprehension of deceitful and ironic communicative intentions	CORTEX			English	Article						Communicative intention; Pragmatics; Deceit; Irony; fMRI; Speech act; Comprehension	TRAUMATIC BRAIN-INJURY; MIDDLE TEMPORAL GYRUS; EXECUTIVE FUNCTION; SOCIAL COGNITION; LANGUAGE NETWORK; FRONTAL-LOBE; SPEECH ACTS; MIND; METAANALYSIS; METAPHOR	Neuroimaging studies have shown that a left fronto-temporo-parietal cerebral network is recruited in the comprehension of both deceitful and ironic speech acts. However, no studies to date have directly compared neural activation during the comprehension of these pragmatic phenomena. We used fMRI to investigate the existence of common and specific neural circuits underlying the comprehension of the same speech act, uttered with different communicative intentions, i.e., of being sincere, deceitful or ironic. In particular, the novelty of the present study is that it explores the existence of a specific cerebral area involved in the recognition of irony versus deceit. We presented 23 healthy participants with 48 context stories each followed by a target sentence. For each story we designed different versions eliciting, respectively, different pragmatic interpretations of the same target sentence literal, deceitful or ironic. We kept the semantic and syntactic complexity of the target sentence constant across the conditions. Our results showed that the recognition of ironic communicative intention activated the left temporo-parietal junction (ITPJ), the left inferior frontal gyrus (IIFG), the left middle frontal gyms (IMFG), the left middle temporal gyms (IMTG), and the left dorsolateral prefrontal cortex (IDLPFC). Comprehension of deceitful communicative intention activated the IIFG, the IMFG, and the IDLPFC. fMRI analysis revealed that a left fronto-temporal network including the inferior frontal gyms (IFG), the dorsolateral prefrontal cortex (DLPFC) and the middle frontal gyms (MFG) is activated in both irony and deceit recognition. The original result of the present investigation is that the IMTG was found to be more active in the comprehension of ironic versus deceitful communicative intention, thus suggesting its specific role in irony recognition. To conclude, our results showed that common cerebral areas are recruited in the comprehension of both pragmatic phenomena, while the IMTG has a key role in the recognition of ironic versus deceitful communicative intention. (C) 2017 Elsevier Ltd. All rights reserved.	[Bosco, Francesca M.; Parola, Alberto; Morese, Rosalba] Univ Turin, Dept Psychol, Ctr Cognit Sci, Turin, Italy; [Bosco, Francesca M.; Valentini, Maria C.] Neurosci Inst Turin, Turin, Italy; [Valentini, Maria C.] Hosp Citta Salute & Sci, Dept Neuroradiol, Turin, Italy; [Morese, Rosalba] Univ Svizzera Italiana, Fac Commun Sci, Lugano, Switzerland		Parola, A (corresponding author), Univ Turin, Dept Psychol, Via Po 14, I-10123 Turin, Italy.	alparola@unito.it	Morese, Rosalba/AAI-1008-2019; bosco, francesca marina/B-6746-2013; Morese, Rosalba/B-5444-2014; Parola, alberto/AAK-3748-2020	Morese, Rosalba/0000-0003-4939-6539; bosco, francesca marina/0000-0001-6101-8587; PAROLA, ALBERTO/0000-0002-6039-0907	MIUR PRIN-Progetti di Ricerca di Rilevante Interesse NazionaleMinistry of Education, Universities and Research (MIUR);  [201577HA9M]	The research was funded by MIUR PRIN-Progetti di Ricerca di Rilevante Interesse Nazionale_2017. Project 'The interpretative brain: Understanding and promoting pragmatic abilities across lifespan and in mental illness' project code 201577HA9M. We wish to thank to Luana De Faveri and Giulia Iunco for their precious technical support during fMRI acquisition sessions.	Acheson DJ, 2013, J COGNITIVE NEUROSCI, V25, P1664, DOI 10.1162/jocn_a_00430; Akimoto Y, 2014, HUM BRAIN MAPP, V35, P1167, DOI 10.1002/hbm.22242; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; [Anonymous], 2014, MINERVA PSICHIATRICA; Azim E, 2005, P NATL ACAD SCI USA, V102, P16496, DOI 10.1073/pnas.0408456102; Badre D, 2007, NEUROPSYCHOLOGIA, V45, P2883, DOI 10.1016/j.neuropsychologia.2007.06.015; Bambini V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105634; Bambini V, 2011, BRAIN RES BULL, V86, P203, DOI 10.1016/j.brainresbull.2011.07.015; Bara BG, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00007; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Bohrn IC, 2012, NEUROPSYCHOLOGIA, V50, P2669, DOI 10.1016/j.neuropsychologia.2012.07.021; Bosco F. M., 2017, J COMMUN DISORD, V145, P181; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00021; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bosco FM, 2014, CONSCIOUS COGN, V24, P84, DOI 10.1016/j.concog.2014.01.003; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bucciarelli M, 2003, J PRAGMATICS, V35, P207, DOI 10.1016/S0378-2166(02)00099-1; Chan YC, 2015, FRONT PSYCHOL, V6, DOI [10.3389/fpgyg.2015.01235, 10.3389/fpsyg.2015.01285]; Ciaramidaro A, 2007, NEUROPSYCHOLOGIA, V45, P3105, DOI 10.1016/j.neuropsychologia.2007.05.011; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Dapretto M, 1999, NEURON, V24, P427, DOI 10.1016/S0896-6273(00)80855-7; Davey J, 2016, NEUROIMAGE, V137, P165, DOI 10.1016/j.neuroimage.2016.05.051; De Smet HJ, 2013, BRAIN LANG, V127, P334, DOI 10.1016/j.bandl.2012.11.001; De Smet HJ, 2011, BRAIN COGNITION, V76, P424, DOI 10.1016/j.bandc.2010.12.006; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Eviatar Z, 2006, NEUROPSYCHOLOGIA, V44, P2348, DOI 10.1016/j.neuropsychologia.2006.05.007; Ferstl EC, 2008, HUM BRAIN MAPP, V29, P581, DOI 10.1002/hbm.20422; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; Gobbini MI, 2007, J COGNITIVE NEUROSCI, V19, P1803, DOI 10.1162/jocn.2007.19.11.1803; Grice H. P, 1991, STUDIES WAY WORDS; Grice H. P., 1975, SYNTAX SEMANTICS; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; Harada T, 2009, NEUROSCI RES, V63, P24, DOI 10.1016/j.neures.2008.09.010; Hayashi A, 2014, BRAIN RES, V1556, P46, DOI 10.1016/j.brainres.2014.02.011; Honan CA, 2015, BRAIN LANG, V150, P69, DOI 10.1016/j.bandl.2015.08.007; Huber W, 1984, Adv Neurol, V42, P291; Jang G, 2013, NEUROIMAGE, V81, P61, DOI 10.1016/j.neuroimage.2013.05.027; Jung-Beeman M, 2005, TRENDS COGN SCI, V9, P512, DOI 10.1016/j.tics.2005.09.009; Leh SE, 2010, NEUROPSYCHOPHARMACOL, V35, P70, DOI 10.1038/npp.2009.88; Levinson Stephen., 1983, PRAGMATICS; Mar RA, 2011, ANNU REV PSYCHOL, V62, P103, DOI 10.1146/annurev-psych-120709-145406; Marien P, 2001, BRAIN LANG, V79, P580, DOI 10.1006/brln.2001.2569; Marien P, 2014, CEREBELLUM, V13, P386, DOI 10.1007/s12311-013-0540-5; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; Masia V, 2017, J NEUROLINGUIST, V42, P31, DOI 10.1016/j.jneuroling.2016.11.005; Mason R.A., 2006, HDB PSYCHOLINGUISTIC, P765, DOI DOI 10.1016/B978-012369374-7/50020-1; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; McDonald S, 2014, NEUROPSYCHOLOGY, V28, P801, DOI 10.1037/neu0000089; Menenti L, 2009, J COGNITIVE NEUROSCI, V21, P2358, DOI 10.1162/jocn.2008.21163; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Minzenberg MJ, 2009, ARCH GEN PSYCHIAT, V66, P811, DOI 10.1001/archgenpsychiatry.2009.91; Mo SL, 2008, PSYCHIAT RES, V157, P21, DOI 10.1016/j.psychres.2006.04.002; Murdoch BE, 2010, CORTEX, V46, P858, DOI 10.1016/j.cortex.2009.07.018; Noppeney U, 2004, J COGNITIVE NEUROSCI, V16, P702, DOI 10.1162/089892904323057399; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parola A, 2016, J NEUROLINGUIST, V39, P10, DOI 10.1016/j.jneuroling.2015.12.003; Perner Josef, 1991, UNDERSTANDING REPRES; Peskin J, 1996, CHILD DEV, V67, P1735, DOI 10.2307/1131728; Piemontese M. E., 1996, CAPIRE FARSI CAPIRE; Poldrack RA, 2008, NEUROIMAGE, V40, P409, DOI 10.1016/j.neuroimage.2007.11.048; Premack David, 1978, BEHAV BRAIN SCI, V34, P1401; Rapp AM, 2012, NEUROIMAGE, V63, P600, DOI 10.1016/j.neuroimage.2012.06.022; Rapp AM, 2004, COGNITIVE BRAIN RES, V20, P395, DOI 10.1016/j.cogbrainres.2004.03.017; RUSSELL J, 1994, BRIT J DEV PSYCHOL, V12, P301, DOI 10.1111/j.2044-835X.1994.tb00636.x; Saxe R, 2006, CURR OPIN NEUROBIOL, V16, P235, DOI 10.1016/j.conb.2006.03.001; Schnell Z, 2016, J PRAGMATICS, V92, P74, DOI 10.1016/j.pragma.2015.11.004; Schurz M, 2014, NEUROSCI BIOBEHAV R, V42, P9, DOI 10.1016/j.neubiorev.2014.01.009; Searle J.R., 1979, EXPRESSION MEANING; Shammi P, 1999, BRAIN, V122, P657, DOI 10.1093/brain/122.4.657; Shany-Ur T, 2012, CORTEX, V48, P1329, DOI 10.1016/j.cortex.2011.08.003; Shibata M, 2010, BRAIN RES, V1308, P114, DOI 10.1016/j.brainres.2009.10.030; Spence SA, 2004, PHILOS T R SOC B, V359, P1755, DOI 10.1098/rstb.2004.1555; Sperber D, 2002, MIND LANG, V17, P3, DOI 10.1111/1468-0017.00186; Spotorno N, 2012, NEUROIMAGE, V63, P25, DOI 10.1016/j.neuroimage.2012.06.046; Stoodley CJ, 2009, BRAIN LANG, V110, P149, DOI 10.1016/j.bandl.2009.07.006; Strick M, 2009, EMOTION, V9, P574, DOI 10.1037/a0015951; Strick PL, 2009, ANNU REV NEUROSCI, V32, P413, DOI 10.1146/annurev.neuro.31.060407.125606; SULLIVAN K, 1994, DEV PSYCHOL, V30, P395, DOI 10.1037/0012-1649.30.3.395; Turken AU, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00001; Uchiyama H, 2006, BRAIN RES, V1124, P100, DOI 10.1016/j.brainres.2006.09.088; Uchiyama HT, 2012, CORTEX, V48, P563, DOI 10.1016/j.cortex.2011.01.004; Van Overwalle F, 2009, NEUROIMAGE, V48, P564, DOI 10.1016/j.neuroimage.2009.06.009; Van Overwalle F, 2009, HUM BRAIN MAPP, V30, P829, DOI 10.1002/hbm.20547; Vandenberghe R, 2002, J COGNITIVE NEUROSCI, V14, P550, DOI 10.1162/08989290260045800; Wakusawa K, 2007, NEUROIMAGE, V37, P1417, DOI 10.1016/j.neuroimage.2007.06.013; Walter H, 2004, J COGNITIVE NEUROSCI, V16, P1854, DOI 10.1162/0898929042947838; Walter H, 2009, SOC COGN AFFECT NEUR, V4, P166, DOI 10.1093/scan/nsn047; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; Wu DC, 2011, BRAIN RES, V1389, P115, DOI 10.1016/j.brainres.2011.02.084	95	25	26	6	35	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452	1973-8102		CORTEX	Cortex	SEP	2017	94						73	86		10.1016/j.cortex.2017.06.010			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	FH9RB	WOS:000411548300007	28728080				2022-02-06	
J	Moritz, KE; McCormack, NM; Abera, MB; Viollet, C; Yauger, YJ; Sukumar, G; Dalgard, CL; Burnett, BG				Moritz, Kasey E.; McCormack, Nikki M.; Abera, Mahlet B.; Viollet, Coralie; Yauger, Young J.; Sukumar, Gauthaman; Dalgard, Clifton L.; Burnett, Barrington G.			The role of the immunoproteasome in interferon-gamma-mediated microglial activation	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; 26S PROTEASOME; IN-VIVO; CONSTITUTIVE PROTEASOMES; PARKINSONS-DISEASE; SUBUNIT EXPRESSION; 20S PROTEASOMES; IMMUNE-SYSTEM; NITRIC-OXIDE; CELLS	Microglia regulate the brain microenvironment by sensing damage and neutralizing potentially harmful insults. Disruption of central nervous system (CNS) homeostasis results in transition of microglia to a reactive state characterized by morphological changes and production of cytokines to prevent further damage to CNS tissue. Immunoproteasome levels are elevated in activated microglia in models of stroke, infection and traumatic brain injury, though the exact role of the immunoproteasome in neuropathology remains poorly defined. Using gene expression analysis and native gel electrophoresis we characterize the expression and assembly of the immunoproteasome in microglia following interferon-gamma exposure. Transcriptome analysis suggests that the immunoproteasome regulates multiple features of microglial activation including nitric oxide production and phagocytosis. We show that inhibiting the immunoproteasome attenuates expression of pro-inflammatory cytokines and suppresses interferon-gamma-dependent priming of microglia. These results imply that targeting immunoproteasome function following CNS injury may attenuate select microglial activity to improve the pathophysiology of neurodegenerative conditions or the progress of inflammation-mediated secondary injury following neurotrauma.	[Moritz, Kasey E.; McCormack, Nikki M.; Yauger, Young J.; Dalgard, Clifton L.; Burnett, Barrington G.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Neurosci Program, Bethesda, MD 20814 USA; [Abera, Mahlet B.; Dalgard, Clifton L.; Burnett, Barrington G.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Viollet, Coralie; Sukumar, Gauthaman; Dalgard, Clifton L.] Uniformed Serv Univ Hlth Sci, Collaborat Hlth Initiat Res Program, Bethesda, MD 20814 USA; [Dalgard, Clifton L.] Uniformed Serv Univ Hlth Sci, Amer Genome Ctr, Bethesda, MD 20814 USA		Burnett, BG (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Neurosci Program, Bethesda, MD 20814 USA.; Burnett, BG (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA.	barrington.burnett@usuhs.edu	Sukumar, Gauthaman/A-1697-2018	Sukumar, Gauthaman/0000-0003-3129-4171; Dalgard, Clifton/0000-0003-2025-8239; Burnett, Barrington/0000-0002-5001-3358	Department of DefenseUnited States Department of Defense	We thank Dr. Yumin Zhang for generous gift of the BV-2 cell lines, Dr. Joseph McCabe for fruitful discussions, Kelsey Voss and Michael Shaughness for technical assistance and Kimberly Byrnes for critical reading of the manuscript. These studies were supported from Intramural funds provided by new investigator startup funds from the Department of Defense.	AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bai M, 2014, BIOMOLECULES, V4, P662, DOI 10.3390/biom4030662; Barton LF, 2002, J IMMUNOL, V169, P3046, DOI 10.4049/jimmunol.169.6.3046; Basler M, 2014, EMBO MOL MED, V6, P226, DOI 10.1002/emmm.201303543; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Bose S, 2004, BIOCHEM J, V378, P177, DOI 10.1042/BJ20031122; Chen FT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064262; Chen X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.586; Colton CA, 2013, J NEUROIMMUNE PHARM, V8, P4, DOI 10.1007/s11481-013-9437-9; Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523/JNEUROSCI.2614-05.2005; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Deol P, 2007, J IMMUNOL, V178, P7557, DOI 10.4049/jimmunol.178.12.7557; Diaz-Hernandez M, 2003, J NEUROSCI, V23, P11653; Doty KR, 2015, BRAIN RES, V1617, P155, DOI 10.1016/j.brainres.2014.09.008; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Ebstein F, 2013, CELL, V152, P935, DOI 10.1016/j.cell.2013.02.018; Farini A, 2016, MOL THER, V24, P1898, DOI [10.1038/mt.2016.162, 10.1038/MT.2016.162]; Fine SM, 1999, J NEUROIMMUNOL, V95, P55, DOI 10.1016/S0165-5728(98)00267-7; Frakes AE, 2014, NEURON, V81, P1009, DOI 10.1016/j.neuron.2014.01.013; Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hawthorne AL, 2011, NEUROTHERAPEUTICS, V8, P252, DOI 10.1007/s13311-011-0032-6; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heink S, 2005, P NATL ACAD SCI USA, V102, P9241, DOI 10.1073/pnas.0501711102; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Henn A, 2009, ALTEX-ALTERN TIEREXP, V26, P83; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hirano Y, 2005, NATURE, V437, P1381, DOI 10.1038/nature04106; Huang Q, 2013, J BIOL CHEM, V288, P12161, DOI 10.1074/jbc.M113.464552; Huber EM, 2012, CELL, V148, P727, DOI 10.1016/j.cell.2011.12.030; Huh Y, 2003, NEUROSCI LETT, V349, P63, DOI 10.1016/S0304-3940(03)00743-2; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005; Kopec KK, 1998, J NEUROCHEM, V71, P2123; Liu B, 2006, AAPS J, V8, pE606, DOI 10.1208/aapsj080369; Livnat-Levanon N, 2014, CELL REP, V7, P1371, DOI 10.1016/j.celrep.2014.04.030; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; MA CP, 1992, J BIOL CHEM, V267, P10515; Marques AJ, 2009, CHEM REV, V109, P1509, DOI 10.1021/cr8004857; Marshall RS, 2015, MOL CELL, V58, P1053, DOI 10.1016/j.molcel.2015.04.023; McCarthy MK, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00021; McGeer PL, 2003, ANN NEUROL, V54, P599, DOI 10.1002/ana.10728; Mi HY, 2016, NUCLEIC ACIDS RES, V44, pD336, DOI 10.1093/nar/gkv1194; Moran LB, 2004, NEUROGENETICS, V5, P95, DOI 10.1007/s10048-004-0172-5; Moran LB, 2007, J NEUROIMMUNOL, V183, P1, DOI 10.1016/j.jneuroim.2006.10.023; Mount MP, 2007, J NEUROSCI, V27, P3328, DOI 10.1523/JNEUROSCI.5321-06.2007; Muchamuel T, 2009, NAT MED, V15, P781, DOI 10.1038/nm.1978; Nathan JA, 2013, CELL, V152, P1184, DOI 10.1016/j.cell.2013.01.037; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Noda C, 2000, BIOCHEM BIOPH RES CO, V277, P348, DOI 10.1006/bbrc.2000.3676; PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111; Qu CS, 2010, J NEUROTRAUM, V27, P1625, DOI 10.1089/neu.2010.1359; Qureshi N, 2005, IMMUNOL RES, V31, P243, DOI 10.1385/IR:31:3:243; Qureshi N, 2012, BBA-MOL CELL RES, V1823, P2087, DOI 10.1016/j.bbamcr.2012.06.016; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Ridnour LA, 2012, J NEUROCHEM, V123, P736, DOI 10.1111/jnc.12028; Sasaki K, 2010, MOL CELL BIOL, V30, P3864, DOI 10.1128/MCB.00216-10; Seifert U, 2010, CELL, V142, P613, DOI 10.1016/j.cell.2010.07.036; Shen J, 2006, SHOCK, V25, P472, DOI 10.1097/01.shk.0000209554.46704.64; Spencer NG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162497; Surendranathan A, 2015, PARKINSONISM RELAT D, V21, P1398, DOI 10.1016/j.parkreldis.2015.10.009; Tai H. C., 2010, FRONTIERS MOL NEUROS, V3; Tamashiro TT, 2012, JOVE-J VIS EXP, DOI 10.3791/3814; Vilchez D, 2012, NATURE, V489, P304, DOI 10.1038/nature11468; Wilcock DM, 2011, ASN NEURO, V3, DOI 10.1042/AN20110018; Wink DA, 2011, J LEUKOCYTE BIOL, V89, P873, DOI 10.1189/jlb.1010550; Witt E, 2000, J MOL BIOL, V301, P1, DOI 10.1006/jmbi.2000.3959; Xiang Z, 2006, DIS MARKERS, V22, P95, DOI 10.1155/2006/276239; Yao XL, 2008, J NEUROCHEM, V104, P353, DOI 10.1111/j.1471-4159.2007.04970.x; Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134	74	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 24	2017	7								9365	10.1038/s41598-017-09715-y			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE8FS	WOS:000408441600089	28839214	Green Published, gold			2022-02-06	
J	DuPrey, KM; Webner, DD; Lyons, A; Kucuk, CH; Ellis, JT; Cronholm, PF				DuPrey, Kevin M.; Webner, David; Lyons, Adam; Kucuk, Crystal H.; Ellis, Jeffrey T.; Cronholm, Peter F.			Convergence Insufficiency Identifies Athletes at Risk of Prolonged Recovery From Sport-Related Concussion	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries/concussion; eye injuries; clinical assessment/grading scales; pediatric sports medicine	TRAUMATIC BRAIN-INJURY; EMERGENCY-DEPARTMENT; HIGH-SCHOOL; PREDICTORS; NEARPOINT; ADOLESCENTS; RELIABILITY; POPULATION; STATEMENT; SYMPTOMS	Background: Sensitive and specific screening methods are needed to identify athletes at risk of prolonged recovery after sport-related concussion (SRC). Convergence insufficiency (CI) is a common finding in concussed athletes. Purpose: To assess the relationship between CI and recovery after SRC at the initial office visit. Study Design: Case-control study; Level of evidence, 3. Methods: In this retrospective cohort study, 270 athletes (147 male, 123 female), mean +/- SD age 14.7 +/- 2.0 years (range, 10-21 years), with the diagnosis of SRC who presented for initial office visit between January 2014 and January 2016 were evaluated for near point of convergence (NPC). The athletes were categorized into 2 groups: normal near point of convergence (NPC <= 6 cm), and convergence insufficiency (NPC > 6 cm). These athletes were then followed to determine recovery time. Results: Athletes presented for initial office visit at a mean of 5.2 +/- 4.2 days (range, 1-21 days) after SRC. Half of the athletes had CI after SRC (50.4%; n = 136). Athletes with CI (NPC 12.3 +/- 4.7 cm) took significantly longer to recover after SRC, requiring 51.6 +/- 53.9 days, compared with athletes with normal NPC (4.1 +/- 1.3 cm), who required 19.2 +/- 14.7 days (P < .001). After controlling for potential confounding variables, CI significantly increased the odds of prolonged recovery (>= 28 days from injury) by 12.3-fold (P < .001; 95% confidence interval, 6.6-23.0). CI screening correctly classified 75.2% of our sample with 84.2% sensitivity and 70.0% specificity. The positive predictive value for CI and prolonged recovery was 62.5%, and the negative predictive value was 88.1%. Conclusion: CI at the initial office visit identified athletes at increased risk of prolonged recovery after SCR. Clinicians should consider measuring NPC in concussed athletes as a quick and inexpensive prognostic screening method.	[DuPrey, Kevin M.; Webner, David; Lyons, Adam; Kucuk, Crystal H.; Ellis, Jeffrey T.; Cronholm, Peter F.] Crozer Keystone Hlth Syst, Healthplex Sports Med Inst, 196 West Sproul Rd,Suite 110, Springfield, PA 19064 USA; [DuPrey, Kevin M.; Webner, David; Ellis, Jeffrey T.] Crozer Keystone Hlth Syst, Dept Sports Med, Springfield, PA USA; [Lyons, Adam; Cronholm, Peter F.] Univ Penn, Dept Family & Community Hlth, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA; [Kucuk, Crystal H.] Philadelphia Coll Osteopath Med, Philadelphia, PA USA; [Cronholm, Peter F.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA		DuPrey, KM (corresponding author), Crozer Keystone Hlth Syst, Healthplex Sports Med Inst, 196 West Sproul Rd,Suite 110, Springfield, PA 19064 USA.	kevin.duprey@crozer.org					Abraham Neethu G, 2015, Oman J Ophthalmol, V8, P14, DOI 10.4103/0974-620X.149856; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Casson IR, 2015, NEUROLOGY, V85, P110, DOI 10.1212/WNL.0000000000001700; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; COOPER J, 1978, J AM OPTOM ASSOC, V49, P673; Cooper J, 2012, OPTOMETRY, V83, P20; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Duke-Elder S., 1973, SYSTEM OPHTHALMOLOGY; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Hamed MM, 2013, INDIAN J OPHTHALMOL, V61, P325, DOI 10.4103/0301-4738.97553; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Kontos AP, 2016, AM J SPORT MED, V44, P1400, DOI 10.1177/0363546516632754; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Root JM, 2016, J PEDIATR-US, V174, P39, DOI 10.1016/j.jpeds.2016.03.020; Rosner B, 2011, FUNDAMENTALS BIOSTAT; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Scheiman M, 2005, ARCH OPHTHALMOL-CHIC, V123, P14, DOI 10.1001/archopht.123.1.14; Siderov J, 2001, OPHTHAL PHYSL OPT, V21, P356, DOI 10.1046/j.1475-1313.2001.00609.x; Sussman ES, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15610; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Ventura RE, 2016, J NEUROL SCI, V361, P79, DOI 10.1016/j.jns.2015.12.010; Ventura RE, 2015, J NEURO-OPHTHALMOL, V35, P73, DOI 10.1097/WNO.0000000000000223; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Viera AJ, 2005, FAM MED, V37, P360	37	25	25	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2017	45	10					2388	2393		10.1177/0363546517705640			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	FC4VS	WOS:000406839600023	28511593				2022-02-06	
J	McDonald, BC; Flashman, LA; Arciniegas, DB; Ferguson, RJ; Xing, L; Harezlak, J; Sprehn, GC; Hammond, FM; Maerlender, AC; Kruck, CL; Gillock, KL; Frey, K; Wall, RN; Saykin, AJ; McAllister, TW				McDonald, Brenna C.; Flashman, Laura A.; Arciniegas, David B.; Ferguson, Robert J.; Xing, Li; Harezlak, Jaroslaw; Sprehn, Gwen C.; Hammond, Flora M.; Maerlender, Arthur C.; Kruck, Carrie L.; Gillock, Karen L.; Frey, Kim; Wall, Rachel N.; Saykin, Andrew J.; McAllister, Thomas W.			Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial	NEUROPSYCHOPHARMACOLOGY			English	Article							DOUBLE-BLIND; REHABILITATION; GUIDELINES; INDIVIDUALS; IMPROVEMENT; VALIDATION; DOPAMINE; THERAPY; APHASIA; ADULT	The purpose of this multicenter, prospective, randomized, placebo-controlled study was to evaluate and compare the efficacy of two cognitive rehabilitation interventions (Memory and Attention Adaptation Training (MAAT) and Attention Builders Training (ABT)), with and without pharmacological enhancement (ie, with methylphenidate (MPH) or placebo), for treating persistent cognitive problems after traumatic brain injury (TBI). Adults with a history of TBI at least 4 months before study enrollment with either objective cognitive deficits or subjective cognitive complaints were randomized to receive MPH or placebo and MAAT or ABT, yielding four treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT/placebo (N=18). Assessments were conducted pretreatment (baseline) and after 6 weeks of treatment (post treatment). Outcome measures included scores on neuropsychological measures and subjective rating scales. Statistical analyses used linear regression models to predict post-treatment scores for each outcome variable by treatment type, adjusting for relevant covariates. Statistically significant (P<0.05) treatment-related improvements in cognitive functioning were found for word-list learning (MAAT/placebo>ABT/placebo), nonverbal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH),andauditory working memory and divided attention (MAAT/MPH>ABT/MPH). These results suggest that combined treatment with metacognitive rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention, episodic and working memory, and executive functioning after TBI.	[McDonald, Brenna C.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indiana, PA USA; [McDonald, Brenna C.; Sprehn, Gwen C.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; [McDonald, Brenna C.; Wall, Rachel N.; Saykin, Andrew J.; McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Flashman, Laura A.; Kruck, Carrie L.; Gillock, Karen L.] Geisel Sch Med, Dept Psychiat, Hanover, NH USA; [Arciniegas, David B.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; [Arciniegas, David B.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Arciniegas, David B.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Arciniegas, David B.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA; [Ferguson, Robert J.] Univ Pittsburgh, Dept Med, Div Hematol Oncol, 930 Scaife Hall, Pittsburgh, PA USA; [Xing, Li; Harezlak, Jaroslaw] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA; [Xing, Li; Harezlak, Jaroslaw] Indiana Univ, Dept Biostat, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Maerlender, Arthur C.] Univ Nebraska, Ctr Brain Biol & Behav, Lincoln, NE USA; [Frey, Kim] Craig Hosp, Dept Speech Language Pathol, Englewood, CO USA; [Saykin, Andrew J.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA		McAllister, TW (corresponding author), Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA.; McAllister, TW (corresponding author), Indiana Univ Sch Med, IU Hlth Neurosci Ctr, Dept Psychiat, 355 W 16th St,GH Suite 4800, Indianapolis, IN 46202 USA.	twmcalli@iupui.edu	Saykin, Andrew/A-1318-2007; Harezlak, Jaroslaw/P-8557-2014	Saykin, Andrew/0000-0002-1376-8532; Harezlak, Jaroslaw/0000-0002-3070-7686	Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD047242]; National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133A120020, H133A130047]; Department of Veterans AffairsUS Department of Veterans Affairs [CX000239]	This study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (R01 HD047242). The authors declare no conflict of interest. DBA receives research support from the National Institute on Disability, Independent Living, and Rehabilitation Research (H133A120020, H133A130047) and Department of Veterans Affairs (CX000239) and receives compensation from American Psychiatric Association Publishing.	Ahles TA, 2008, BREAST CANCER RES TR, V110, P143, DOI 10.1007/s10549-007-9686-5; American Psychiatric Association (APA), 2000, DIAGN STAT MAN MENT, VIV; [Anonymous], 1999, WECHSLER ABBREVIATED; Arciniegas D B, 2013, BEHAV NEUROLOGY NEUR, P225; Arciniegas DB, 2013, BEHAV NEUROLOGY NEUR, P511; Aylward, 1996, GORDON DIAGNOSTIC SY; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Berg IJ, 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI DOI 10.1080/09602019108401384; Berthier ML, 2009, ANN NEUROL, V65, P577, DOI 10.1002/ana.21597; Bragoni M, 2000, NEUROL SCI, V21, P19, DOI 10.1007/s100720070114; Brown FC, 2007, CLIN NEUROPSYCHOL, V21, P811, DOI 10.1080/13854040600878777; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Craft S, 1996, NEUROBIOL AGING, V17, P123, DOI 10.1016/0197-4580(95)02002-0; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Ferguson R.J., 1996, SOURCEBOOK PSYCHOL T; Ferguson RJ, 2007, PSYCHO-ONCOL, V16, P772, DOI 10.1002/pon.1133; Ferguson RJ, 2012, PSYCHO-ONCOLOGY, V21, P176, DOI 10.1002/pon.1878; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Huang CH, 2016, CURR NEUROPHARMACOL, V14, P272, DOI 10.2174/1570159X13666150514233033; Joensson M, 2015, HUM BRAIN MAPP, V36, P1866, DOI 10.1002/hbm.22742; Johansson B, 2015, BRAIN INJURY, V29, P758, DOI 10.3109/02699052.2015.1004747; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lafayette Instrument, 1989, GROOV PEGB INSTR OWN; McAllister TW, 2016, NEUROPSYCHOPHARMACOL, V41, P1191, DOI 10.1038/npp.2015.282; Palmese CA, 2000, BRAIN INJURY, V14, P535; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Saykin A J, 1995, Appl Neuropsychol, V2, P79, DOI 10.1207/s15324826an0202_5; SEIDENBERG M, 1994, J CLIN EXP NEUROPSYC, V16, P93, DOI 10.1080/01688639408402620; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Spielberger CD., 1983, STATE TRAIT ANXIETY; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; The Psychological Corporation, 1997, WAIS 3 WECHSL AD INT; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Weathers F. W., 1993, 9 ANN CONV INT SOC T; Westbrook A, 2016, NEURON, V89, P695, DOI [10.1016/j.neuron.2015.12.029, 10.1016/j.neuron.2016.07.020]; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Wilkinson GaryS, 2006, WRAT4 WIDE RANGE ACH; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632; Wolfson, 1993, HALSTEAD REITAN NEUR	50	25	26	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	AUG	2017	42	9					1766	1775		10.1038/npp.2016.261			10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	FA3VJ	WOS:000405372200003	27874023	Green Published, Bronze			2022-02-06	
J	McNett, M; Moran, C; Janki, C; Gianakis, A				McNett, Molly; Moran, Cristina; Janki, Clare; Gianakis, Anastasia			Correlations Between Hourly Pupillometer Readings and Intracranial Pressure Values	JOURNAL OF NEUROSCIENCE NURSING			English	Article						neurologic injury; pupil assessment; pupillometer	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; SEVERE HEAD-INJURY; PREDICTION; IMPACT	Introduction: Automated pupillometry is emerging as a mainstay in neurocritical care primarily because it overcomes limitations of manual pupillary examinations. Although several recent studies show improved assessment accuracy with a pupillometer, few investigate clinical use, specifically how well parameters correlate with multimodality monitoring and outcomes. The primary aim of this study was to examine correlations between serial pupillometer readings and intracranial pressure (ICP) values among neurocritically ill patients. Design: Prospective cohort, repeated measures. Sample: The study sample was composed of adult patients with neurological injury who were admitted to intensive care unit, requiring hourly neurological assessment and pupillary checks within a level I trauma, urban, academic medical center. Procedures: Hourly pupillometer readings and corresponding ICP values were consecutively recorded for 72 hours after intensive care unit admission. Results: Serial assessments resulted in more than 2100 pupillometer readings from 76 subjects. Mean age of the study sample was 55.4 years, with a mean Glasgow Coma Scale score of 8.9. The mean pupillometer values for the enrolled subjects included left constriction velocity of 1.22, left neurological pupil index of 4.21, left pupil size of 2.69, right constriction velocity of 1.18, right neurological pupil index of 4.18, and right pupil size of 2.57. The mean ICP of the study sample was 12, with mean cerebral perfusion pressure of 77. Pupillometer values significantly correlated with ICP values in bivariate (P < .001, r = 0.13-0.23) and multivariate regression models (F(6) = 17.63, P < .001). Conclusions: Automated pupillometry in neurocritical care is a valuable adjunct to traditional invasive monitoring. Integration of routine pupillometer assessments not only improves accuracy of examinations but also correlates with ICP values.	[McNett, Molly] MetroHlth Syst, Nursing Res, Cleveland, OH 44109 USA; [McNett, Molly] MetroHlth Syst, Nursing Educ & Profess Practice, Cleveland, OH 44109 USA; [Moran, Cristina; Janki, Clare; Gianakis, Anastasia] MetroHlth Syst, Surg Intens Care Unit, Cleveland, OH USA		McNett, M (corresponding author), MetroHlth Syst, Nursing Res, Cleveland, OH 44109 USA.; McNett, M (corresponding author), MetroHlth Syst, Nursing Educ & Profess Practice, Cleveland, OH 44109 USA.	mmcnett@metrohealth.org					Adoni Andea, 2007, J Trauma Nurs, V14, P191; Brain Trauma Foundation American Association of Neuro-logical Surgeons, 2000, J NEUROTRAUM, V17, P583; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Clark A, 2006, EMERG MED J, V23, P440, DOI 10.1136/emj.2005.030247; FISHER CM, 1995, CAN J NEUROL SCI, V22, P83, DOI 10.1017/S0317167100040142; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hoffmann M, 2012, BRIT J SURG, V99, P122, DOI 10.1002/bjs.7707; Hou RHH, 2006, BRIT J CLIN PHARMACO, V61, P752, DOI 10.1111/j.1365-2125.2006.02632.x; Larson MD, 2015, ANESTH ANALG, V120, P1242, DOI 10.1213/ANE.0000000000000314; Litvan I, 2000, NEUROLOGY, V54, P530, DOI 10.1212/WNL.54.2.530; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Olson DM, 2016, NEUROCRIT CARE, V24, P251, DOI 10.1007/s12028-015-0182-1; Olson DM, 2016, CRIT CARE NURS CLIN, V28, P101, DOI 10.1016/j.cnc.2015.09.003; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Shamim MS, 2011, J NEUROSURG, V115, P1007, DOI 10.3171/2011.7.JNS101829; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205	21	25	25	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	AUG	2017	49	4					229	234		10.1097/JNN.0000000000000290			6	Clinical Neurology; Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Nursing	EZ4CM	WOS:000404658700006	28661946				2022-02-06	
J	Wang, WZ; Zhang, H; Lee, DH; Yu, JT; Cheng, T; Hong, M; Jiang, SS; Fan, H; Huang, X; Zhou, JY; Wang, J				Wang, Wenzhu; Zhang, Hong; Lee, Doon-Hoon; Yu, Jintao; Cheng, Tian; Hong, Michael; Jiang, Shanshan; Fan, Heng; Huang, Xi; Zhou, Jinyuan; Wang, Jian			Using functional and molecular MRI techniques to detect neuroinflammation and neuroprotection after traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						APT imaging; Flavonoid; Molecular imaging; MRI; Neuroinflammation; Neuroprotection; Traumatic brain injury	CEREBRAL-BLOOD-FLOW; INTRACEREBRAL HEMORRHAGE; ISCHEMIC PENUMBRA; WHITE-MATTER; RAT-BRAIN; PINOCEMBRIN; PROTECTS; STROKE; MODEL; DIFFERENTIATION	This study was designed to investigate whether functional and molecular MRI techniques are sensitive biomarkers for assessment of neuroinflammation and drug efficacy after traumatic brain injury (TBI) in rats. We subjected rats to a controlled cortical impact model and used behavioral tests, histology, and immunofluorescence to assess whether flavonoid pinocembrin provides cerebral protection and improves functional recovery. Most importantly, we used multiple noninvasive structural, functional, and molecular MRI techniques to examine whether the pinocembrin-related neuroprotection and attenuation of neuroinflammation can be detected in vivo. Significant increases in cerebral blood flow (CBF) and amide proton transfer-weighted (APTw) MRI signals were observed in the perilesional areas in untreated TBI rats at 3 days and could be attributed to increased glial response. In addition, increased apparent diffusion coefficient and decreased magnetization transfer ratio signals in untreated TBI rats over time were likely due to edema. Post-treatment with pinocembrin decreased microglial/macrophage activation at 3 days, consistent with the recovery of CBF and APTw MRI signals in regions of secondary injury. These findings suggest that pinocembrin provides cerebral protection for TBI and that multiple MRI signals, CBF and APTw in particular, are sensitive biomarkers for identification and assessment of neuroinflammation and drug efficacy in the TBI model. (C) 2017 Elsevier Inc. All rights reserved.	[Wang, Wenzhu; Wang, Jian] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Sch Med, Baltimore, MD 21205 USA; [Wang, Wenzhu] Huazhong Univ Sci & Technol, Union Hosp, Dept Integrated Chinese & Western Med, Tongji Med Coll, Wuhan 430022, Hunan, Peoples R China; [Jiang, Shanshan] Johns Hopkins Univ, Div MR Res, Dept Radiol, Sch Med, Baltimore, MD 21287 USA; [Zhang, Hong] Beijing Childrens Hosp, Capital Med Univ, Dept Radiol, Beijing 100045, Peoples R China; [Hong, Michael] Huazhong Univ Sci & Technol, Union Hosp, Dept Otorhinolaryngol, Tongji Med Coll, Wuhan 430022, Hunan, Peoples R China; [Huang, Xi] Affiliated Hosp Nanjing Univ Chinese Med, Gerontol Dept, Nanjing 210029, Jiangsu, Peoples R China; [Huang, Xi] Nanjing Univ Chinese Med, Inst TCM Related Comorbid Depress, 138 Xianling Rd, Nanjing 210046, Jiangsu, Peoples R China		Wang, J (corresponding author), Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Sch Med, Baltimore, MD 21205 USA.	huangx59@163.com; jzhou@mri.jhu.edu; jwang79@jhmi.edu	hong, zhang/AAM-3862-2020; Lee, Dong-Hoon/G-4959-2016; Wang, Jian/I-4874-2019; Jiang, Shanshan/O-8265-2019	Lee, Dong-Hoon/0000-0002-5013-4440; Wang, Jian/0000-0003-2291-640X; Jiang, Shanshan/0000-0003-2853-9991	American Heart AssociationAmerican Heart Association [13GRNT15730001]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317, R01NS078026, R01EB009731, R01CA166171, R01NS083435]; "Stimulating and Advancing ACCM Research (StAAR)" grant from the Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University; China Scholarship Council Joint PhD Training award (CSC) [201406370078]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS083435, R01NS078026] Funding Source: NIH RePORTER	We thank Claire Levine for assistance with this manuscript. This work was supported by grants from the American Heart Association (13GRNT15730001), the National Institutes of Health (R01AT007317, R01NS078026, R01EB009731, R01CA166171, R01NS083435), and a "Stimulating and Advancing ACCM Research (StAAR)" grant from the Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University. Wenzhu Wang is the recipient of the China Scholarship Council Joint PhD Training award (CSC NO. 201406370078).	Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Cao GY, 2015, J ETHNOPHARMACOL, V168, P31, DOI 10.1016/j.jep.2015.03.041; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; de Oliveira M. R., 2016, MOL NEUROBIOL; Frey L, 2014, NEUROL RES, V36, P26, DOI 10.1179/1743132813Y.0000000269; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; Guang HM, 2006, EUR J PHARMACOL, V542, P77, DOI 10.1016/j.ejphar.2006.04.054; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Han XN, 2016, J CEREBR BLOOD F MET, V36, P1059, DOI 10.1177/0271678X15606462; Jaiswal MK, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00148; Jiang SS, 2016, EUR RADIOL, V26, P64, DOI 10.1007/s00330-015-3805-1; Jin T, 2012, NEUROIMAGE, V59, P1218, DOI 10.1016/j.neuroimage.2011.08.014; Kapoor S, 2013, J AGR FOOD CHEM, V61, P1416, DOI 10.1021/jf304482d; Lan X, 2017, BRAIN BEHAV IMMUN, V61, P326, DOI 10.1016/j.bbi.2016.12.012; Lan X, 2016, MOL NEUROBIOL, V53, P1794, DOI 10.1007/s12035-015-9125-2; Li W, 2016, BRAIN RES, V1646, P53, DOI 10.1016/j.brainres.2016.05.036; Liu R, 2008, BRAIN RES, V1216, P104, DOI 10.1016/j.brainres.2008.03.049; Liu R, 2014, NEUROBIOL AGING, V35, P1275, DOI 10.1016/j.neurobiolaging.2013.12.031; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Long JA, 2015, J CEREBR BLOOD F MET, V35, P1852, DOI 10.1038/jcbfm.2015.143; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maegele M, 2015, ACTA RADIOL OPEN, V4, DOI 10.1177/2047981614555142; Mao W, 2013, P NATL ACAD SCI USA, V110, P8842, DOI 10.1073/pnas.1303884110; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Meng FR, 2014, EXP THER MED, V8, P1285, DOI 10.3892/etm.2014.1923; NAKASU Y, 1995, AM J NEURORADIOL, V16, P1185; Niv F, 2012, STROKE, V43, P2468, DOI 10.1161/STROKEAHA.112.660977; Rasul A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/379850; Saad MA, 2015, PHARMACOL REP, V67, P115, DOI 10.1016/j.pharep.2014.08.014; Sayre CL, 2015, J PHARM PHARM SCI, V18, P368, DOI 10.18433/J3BK5T; Shi LL, 2011, LIFE SCI, V88, P521, DOI 10.1016/j.lfs.2011.01.011; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Sun PZ, 2007, J CEREBR BLOOD F MET, V27, P1129, DOI 10.1038/sj.jcbfm.9600424; Tietze A, 2014, NMR BIOMED, V27, P163, DOI 10.1002/nbm.3048; Tu TW, 2016, ANN NEUROL, V79, P907, DOI 10.1002/ana.24641; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang JP, 2013, BRAIN BEHAV IMMUN, V34, P56, DOI 10.1016/j.bbi.2013.07.010; Wang MY, 2015, MAGN RESON MED, V74, P42, DOI 10.1002/mrm.25690; Wang WZ, 2016, MOL NEUROBIOL, V53, P4809, DOI 10.1007/s12035-015-9385-x; Wang YM, 2016, J NEUROL SCI, V368, P223, DOI 10.1016/j.jns.2016.07.010; Watts LT, 2015, J NEUROTRAUM, V32, P1001, DOI 10.1089/neu.2014.3737; Wei XE, 2012, J NEUROTRAUM, V29, P2413, DOI 10.1089/neu.2010.1510; Wu CX, 2013, NEUROSCI LETT, V546, P57, DOI 10.1016/j.neulet.2013.04.060; Yan B, 2014, BIOMED CHROMATOGR, V28, P1601, DOI 10.1002/bmc.3186; Yan K, 2015, MOL IMAGING BIOL, V17, P479, DOI 10.1007/s11307-015-0828-6; Yang J, 2017, SCI REP-UK, V7, DOI 10.1038/srep40358; Yang ZJ, 2013, J CEREBR BLOOD F MET, V33, P1612, DOI 10.1038/jcbfm.2013.117; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011; Zhou JY, 2013, J MAGN RESON IMAGING, V38, P1119, DOI 10.1002/jmri.24067; Zhou JY, 2012, TRANSL STROKE RES, V3, P76, DOI 10.1007/s12975-011-0110-4; Zhou JY, 2011, NAT MED, V17, P130, DOI 10.1038/nm.2268; Zhou JY, 2003, NAT MED, V9, P1085, DOI 10.1038/nm907	52	25	25	0	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	AUG	2017	64						344	353		10.1016/j.bbi.2017.04.019			10	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	EZ1XR	WOS:000404504600033	28455264	Green Accepted			2022-02-06	
J	Ho, J; Zhou, Z; Li, XG; Kleiven, S				Ho, Johnson; Zhou, Zhou; Li, Xiaogai; Kleiven, Svein			The peculiar properties of the faix and tentorium in brain injury biomechanics	JOURNAL OF BIOMECHANICS			English	Article						Biomechanics; Falx; Tentorium; Traumatic brain injuries; Diffuse axonal injuries	DIFFUSE AXONAL INJURY; MAXIMUM PRINCIPAL STRAIN; HEAD; IMPACT; CONCUSSION; MATER; DURA	The influence of the faix and tentorium on brain injury biomechanics during impact was studied with finite element (FE) analysis. Three detailed 3D FE head models were created based on the images of a healthy, normal size head. Two of the models contained the addition of falx and tentorium with material properties from previously published experiments. Impact loadings from a reconstructed concussive case in a sport accident were applied to the two players involved. The results suggested that the faix and tentorium could induce large strains to the surrounding brain tissues, especially to the corpus callosum and brainstem. The tentorium seemed to constrain the motion of the cerebellum while inducing large strain in the brainstem in both players involved in the accident (one player had mainly coronal head rotation and the other had both coronal and transversal rotations). Since changed strain levels were observed in the brainstem and corpus callosum, which are classical sites for diffuse axonal injuries (DAI), we confirmed the importance of using accurate material properties for falx and tentorium in a FE head model when studying traumatic brain injuries. (C) 2017 Published by Elsevier Ltd.	[Ho, Johnson; Zhou, Zhou; Li, Xiaogai; Kleiven, Svein] KTH Royal Inst Technol, Neuron Engn, Stockholm, Sweden		Kleiven, S (corresponding author), KTH Flemingsberg, Halsovagen 11C, SE-14157 Huddinge, Sweden.	sveink@kth.se		Li, Xiaogai/0000-0001-8522-4705; zhou, zhou/0000-0002-3910-0418			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Aimedieu P, 2004, J NEUROSURG, V100, P111, DOI 10.3171/jns.2004.100.1.0111; [Anonymous], 2007, LS DYNA KEYW US MAN; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Dick R, 2007, J ATHL TRAINING, V42, P221; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giordano Chiara, 2016, Stapp Car Crash J, V60, P363; Golman A., 2013, P 41 INT WORKSH; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Ho J, 2009, INT J CRASHWORTHINES, V14, P555, DOI 10.1080/13588260902895708; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Li XG, 2017, BIOMECH MODEL MECHAN, V16, P823, DOI 10.1007/s10237-016-0855-5; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Miller R., 1998, FINITE ELEMENT MODEL; Netter F. H., 1953, COMPILATION PAINTING; Newman J A, 2000, Stapp Car Crash J, V44, P215; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Pedersen K, 2015, NEUROEPIDEMIOLOGY, V45, P20, DOI 10.1159/000381780; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; VOIGT GE, 1977, ACTA NEUROPATHOL, V39, P201, DOI 10.1007/BF00691698; Wilcox Ruth K, 2003, J Orthop Sci, V8, P432, DOI 10.1007/s10776-003-0644-9	31	25	25	1	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUL 26	2017	60						243	247		10.1016/j.jbiomech.2017.06.023			5	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	FE5YN	WOS:000408287300033	28673666				2022-02-06	
J	Sun, DD; Gu, G; Wang, JH; Chai, Y; Fan, YS; Yang, MC; Xu, X; Gao, WW; Li, F; Yin, DP; Zhou, S; Chen, X; Zhang, JN				Sun, Dongdong; Gu, Gang; Wang, Jianhao; Chai, Yan; Fan, Yueshan; Yang, Mengchen; Xu, Xin; Gao, Weiwei; Li, Fei; Yin, Dongpei; Zhou, Shuai; Chen, Xin; Zhang, Jianning			Administration of Tauroursodeoxycholic Acid Attenuates Early Brain Injury via Akt Pathway Activation	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						traumatic brain injury (TBI); tauroursodeoxycholic acid (TUDCA); endoplasmic reticulum stress (ER stress); apoptosis; Akt signal pathway	UNFOLDED PROTEIN RESPONSE; URSODEOXYCHOLIC ACID; SIGNALING PATHWAY; OXIDATIVE STRESS; CELL-DEATH; ER STRESS; RATS; MODEL; INHIBITION; IMPROVES	Traumatic brain injury (TBI) is one of the leading causes of trauma-induced mortality and disability, and emerging studies have shown that endoplasmic reticulum (ER) stress plays an important role in the pathophysiology of TBI. Tauroursodeoxycholic acid (TUDCA), a hydrophilic bile acid, has been reported to act as an ER stress inhibitor and chemical chaperone and to have the potential to attenuate apoptosis and inflammation. To study the effects of TUDCA on brain injury, we subjected mice to TBI with a controlled cortical impact (CCI) device. Using western blotting, we first examined TBI-induced changes in the expression levels of GRP78, an ER stress marker, p-PERK, PERK, p-eIF2a, eIF2a, ATF4, p-Akt, Akt, Pten, Bax, Bcl-2, Caspase-12 and CHOP, as well as changes in the mRNA levels of Akt, GRP78, Caspase-12 and CHOP using RT-PCR. Neuronal cell death was assessed by a terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) assay, and CHOP expression in neuronal cells was detected by double-immunofluorescence staining. Neurological and motor deficits were assessed by modified neurological severity scores (mNSS) and beam balance and beam walking tests, and brain water content was also assessed. Our results indicated that ER stress peaked at 72 h after TBI and that TUDCA abolished ER stress and inhibited p-PERK, p-eIF2a, ATF4, Pten, Caspase-12 and CHOP expression levels. Moreover, our results show that TUDCA also improved neurological function and alleviated brain oedema. Additionally, TUDCA increased p-Akt expression and the Bcl-2/Bax ratio. However, the administration of the Akt inhibitor MK2206 or siRNA targeting of Akt abolished the beneficial effects of TUDCA. Taken together, our results indicate that TUDCA may attenuate early brain injury via Akt pathway activation.	[Sun, Dongdong; Gu, Gang; Wang, Jianhao; Chai, Yan; Fan, Yueshan; Yang, Mengchen; Xu, Xin; Gao, Weiwei; Li, Fei; Yin, Dongpei; Zhou, Shuai; Chen, Xin; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Sun, Dongdong; Gu, Gang; Wang, Jianhao; Chai, Yan; Fan, Yueshan; Yang, Mengchen; Xu, Xin; Gao, Weiwei; Li, Fei; Yin, Dongpei; Zhou, Shuai; Chen, Xin; Zhang, Jianning] Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin, Peoples R China		Chen, X; Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.; Chen, X; Zhang, JN (corresponding author), Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin, Peoples R China.	xinchentianjin@me.com; jianningzhang@hotmail.com		Xu, Xin/0000-0003-3395-9923; Dongpei, Yin/0000-0003-2572-3689	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [813300151, 81501704, 81671902, 81370029]; Tianjin Research Program of Application Foundation and Advanced Technology [13JCQNJC10500, 17JCYBJC25200]	This work was supported by grants from the National Natural Science Foundation of China (grant nos. 813300151, 81501704, 81671902 and 81370029) and the Tianjin Research Program of Application Foundation and Advanced Technology (grant no. 13JCQNJC10500 and 17JCYBJC25200). We are grateful to Guoqiang Chang, Guili Yang, Weiyun Cui, Lei Zhou and Li Liu from the Tianjin Neurological Institute for providing technical support.	Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Beuers U, 1996, GASTROENTEROLOGY, V110, P1553, DOI 10.1053/gast.1996.v110.pm8613063; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Castro-Caldas M, 2012, MOL NEUROBIOL, V46, P475, DOI 10.1007/s12035-012-8295-4; Chen CH, 2009, NEUROBIOL DIS, V33, P509, DOI 10.1016/j.nbd.2008.12.010; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen X, 2010, NEUROL RES, V32, P1097, DOI 10.1179/016164110X12681290831162; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Cuello-Carrion FD, 1999, J HISTOCHEM CYTOCHEM, V47, P837, DOI 10.1177/002215549904700614; Dash PK, 2015, J NEUROTRAUM, V32, P1608, DOI 10.1089/neu.2014.3772; Faridar Alireza, 2011, Front Neurol, V2, P80, DOI 10.3389/fneur.2011.00080; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fonseca I, 2017, MOL NEUROBIOL, V54, P6120, DOI 10.1007/s12035-016-0228-1; Gao C, 2017, MOL NEUROBIOL, V54, P8348, DOI 10.1007/s12035-016-0318-0; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Jindal A, 2017, NEUROCHEM INT, V111, P3, DOI 10.1016/j.neuint.2016.12.004; Keene CD, 2002, P NATL ACAD SCI USA, V99, P10671, DOI 10.1073/pnas.162362299; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lim SC, 2010, INT J CANCER, V126, P1582, DOI 10.1002/ijc.24853; Logsdon AE, 2016, BRAIN RES, V1643, P140, DOI 10.1016/j.brainres.2016.04.063; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Nakka VP, 2016, MOL NEUROBIOL, V53, P532, DOI 10.1007/s12035-014-9029-6; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Paumgartner G, 2002, HEPATOLOGY, V36, P525, DOI 10.1053/jhep.2002.36088; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; Rodrigues CMP, 2000, J NEUROCHEM, V75, P2368, DOI 10.1046/j.1471-4159.2000.0752368.x; Rodrigues TMP, 2002, J CEREBR BLOOD F MET, V22, P463, DOI 10.1097/00004647-200204000-00010; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Seyhun E, 2011, AM J PHYSIOL-GASTR L, V301, pG773, DOI 10.1152/ajpgi.00483.2010; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang HC, 2016, WORLD NEUROSURG, V87, P463, DOI 10.1016/j.wneu.2015.10.010; Wang ZF, 2017, BIOCHEM BIOPH RES CO, V482, P948, DOI 10.1016/j.bbrc.2016.11.138; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yan F, 2017, MOL NEUROBIOL, V54, P1808, DOI 10.1007/s12035-016-9790-9; Yang H, 2017, ACTA PHARMACOL SIN, V38, P168, DOI 10.1038/aps.2016.130; Yanguas-Casas N, 2017, MOL NEUROBIOL, V54, P6737, DOI 10.1007/s12035-016-0142-6; Yanguas-Casas N, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-50; Zhang C, 2014, BRAIN RES, V1555, P1, DOI 10.1016/j.brainres.2014.01.051; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; Zhao ZL, 2016, J NEUROL SCI, V364, P12, DOI 10.1016/j.jns.2016.03.007	45	25	27	3	10	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	JUL 6	2017	11								193	10.3389/fncel.2017.00193			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EZ9UG	WOS:000405074900001	28729823	gold, Green Published			2022-02-06	
J	Liu, YL; Bao, ZY; Xu, XP; Chao, HL; Lin, C; Li, Z; Liu, Y; Wang, XM; You, YP; Liu, N; Ji, J				Liu, Yinlong; Bao, Zhongyuan; Xu, Xiupeng; Chao, Honglu; Lin, Chao; Li, Zheng; Liu, Yan; Wang, Xiaoming; You, Yongping; Liu, Ning; Ji, Jing			Extracellular Signal-Regulated Kinase/Nuclear Factor-Erythroid2-like2/Heme Oxygenase-1 Pathway-Mediated Mitophagy Alleviates Traumatic Brain Injury-Induced Intestinal Mucosa Damage and Epithelial Barrier Dysfunction	JOURNAL OF NEUROTRAUMA			English	Article						intestinal dysfunction; intestinal mucosa damage; mitophagy; oxidative stress; TBI	OXIDATIVE STRESS; CELL-DEATH; MITOCHONDRIAL PRODUCTION; AUTOPHAGY PROTECTS; ORGAN DYSFUNCTION; NITRIC-OXIDE; KAPPA-B; PERMEABILITY; ACTIVATION; APOPTOSIS	Gastrointestinal dysfunction is one of several physiologic complications in patients with traumatic brain injury (TBI). TBI can result in increased intestinal permeability resulting from apoptosis of intestinal epithelial cells, which contain a large number of mitochondria for persisting barrier function. Autophagy of damaged mitochondria (mitophagy) controls the quality of the mitochondria and regulates cellular homeostasis. However, the exact mechanism of mitophagy that underlies the pathological changes induced by TBI is unknown. Here, we report that mitophagy decreases the intestinal epithelial cell damage and apoptosis that are activated in a rat model of controlled cortical impact (CCI). CCI-induced mitophagy is associated with an increase in 3-nitrotyrosine and 4-hydroxynonenal, indicating that oxidative stress may increase in response to mitochondrial disturbance. CCI also results in the expression of the tight junction proteins zonula occludens-1 (ZO-1) and occludin, which may regulate the in vivo intestinal hyperpermeability induced by CCI. Additionally, CCIinduced mitophagy was shown to be mediated by the oxidative stress-related extracellular signal-regulated kinase (ERK)/nuclear factor-erythroid2-like2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway, which may serve to reduce the apoptosis induced by oxidative stress. These results suggest that CCI-induced mitophagy serves to diminish apoptosis-mediated intestinal epithelial cell damage and to improve intestinal permeability, via ERK/Nrf2/HO-1 signaling. These findings may be useful in the design of rational approaches for the prevention and treatment of symptoms associated with TBI.	[Liu, Yinlong; Bao, Zhongyuan; Xu, Xiupeng; Chao, Honglu; Lin, Chao; Li, Zheng; You, Yongping; Liu, Ning; Ji, Jing] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Liu, Yan] Nanjing Med Univ, Sch Pharm, Inst Stem Cell & Neural Regenerat, Nanjing, Jiangsu, Peoples R China; [Wang, Xiaoming] Nanjing Med Univ, Dept Immunol, Nanjing, Jiangsu, Peoples R China		Ji, J (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	jijing@njmu.edu.cn			Jiangsu Province's Key Discipline of Medicine. Jiangsu Province [XK201117]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Outstanding Youth of Jiangsu Province [BK20160047, BK20160044]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471269, 81300998, 31570881]	This study was supported by grants from Jiangsu Province's Key Discipline of Medicine (XK201117). Jiangsu Province and the Priority Academic Program Development of Jiangsu Higher Education Institutions (2016, PAPD), Outstanding Youth of Jiangsu Province (BK20160047 and BK20160044), and National Natural Science Foundation of China (81471269, 81300998, and 31570881).	Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]; Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; Brown D, 1996, J EXP BIOL, V199, P2345; Carchman EH, 2011, HEPATOLOGY, V53, P2053, DOI 10.1002/hep.24324; Castillo L, 1999, REV MED CHILE, V127, P639; Choi HY, 2016, CHEM-BIOL INTERACT, V245, P110, DOI 10.1016/j.cbi.2015.06.024; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Cook AM, 2008, NUTR CLIN PRACT, V23, P608, DOI 10.1177/0884533608326060; Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014; Dias V, 2013, J PARKINSON DIS, V3, P461, DOI 10.3233/JPD-130230; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Elbrond VS, 2004, COMP BIOCHEM PHYS A, V137, P683, DOI 10.1016/j.cbpb.2004.02.006; Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1_7; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Fung TS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00296; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Grivennikova VG, 2013, BIOCHEMISTRY-MOSCOW+, V78, P1490, DOI 10.1134/S0006297913130087; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Hazeldine J, 2015, INJURY, V46, P975, DOI 10.1016/j.injury.2015.03.028; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jin W, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/502564; Jin W, 2009, J SURG RES, V157, P251, DOI 10.1016/j.jss.2008.08.003; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kemp CD, 2008, AM SURGEON, V74, P866; Kim I, 2011, AM J PHYSIOL-CELL PH, V300, pC308, DOI 10.1152/ajpcell.00056.2010; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156; LAWRENCE CB, 1986, BIOCHIM BIOPHYS ACTA, V848, P35, DOI 10.1016/0005-2728(86)90157-X; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Maynard AA, 2010, AM J PHYSIOL-GASTR L, V299, pG614, DOI 10.1152/ajpgi.00076.2010; Mei QA, 2011, ACTA PHARMACOL SIN, V32, P495, DOI 10.1038/aps.2010.225; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Moran M, 2012, FREE RADICAL BIO MED, V53, P595, DOI 10.1016/j.freeradbiomed.2012.05.009; Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Sasaki K, 2015, J BIOCHEM, V157, P185, DOI 10.1093/jb/mvv010; Serrano I, 2015, J EXP BOT, V66, P2869, DOI 10.1093/jxb/erv083; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979; Stone JR, 2015, TECH VASC INTERV RAD, V18, P24, DOI 10.1053/j.tvir.2014.12.004; Tan M, 2011, BRIT J NEUROSURG, V25, P2, DOI 10.3109/02688697.2010.522745; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Wang GZ, 2016, ANTIOXID REDOX SIGN, V24, P961, DOI 10.1089/ars.2015.6492; Wang N, 2016, DIGEST DIS SCI, V61, P2522, DOI 10.1007/s10620-016-4184-4; Wang YB, 2011, WORLD J GASTROENTERO, V17, P657, DOI 10.3748/wjg.v17.i5.657; Wang Yan-bin, 2010, Zhonghua Yi Xue Za Zhi, V90, P1716; Xu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072528; Yasuhara H, 2005, SURG TODAY, V35, P185, DOI 10.1007/s00595-004-2924-0; Yu YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069620; Zhang XN, 2014, AUTOPHAGY, V10, P1801, DOI 10.4161/auto.32136; Zhang XN, 2013, AUTOPHAGY, V9, P1321, DOI 10.4161/auto.25132; Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057; Zhu KJ, 2014, WORLD J GASTROENTERO, V20, P9585, DOI 10.3748/wjg.v20.i28.9585; Zhu LQ, 2016, ONCOTARGET, V7, P27122, DOI 10.18632/oncotarget.8345	62	25	31	3	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2119	2131		10.1089/neu.2016.4764			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400450	28093052				2022-02-06	
J	Ljungqvist, J; Candefjord, S; Persson, M; Jonsson, L; Skoglund, T; Elae, M				Ljungqvist, Johan; Candefjord, Stefan; Persson, Mikael; Jonsson, Lars; Skoglund, Thomas; Elae, Mikael			Clinical Evaluation of a Microwave-Based Device for Detection of Traumatic Intracranial Hemorrhage	JOURNAL OF NEUROTRAUMA			English	Article						chronic subdural hematoma; intracranial hemorrhage detection; microwave technology; traumatic brain injury; triage	SUBDURAL-HEMATOMA; MAJOR TRAUMA; BRAIN-INJURY; MORTALITY; DIAGNOSIS	Traumatic brain injury (TBI) is the leading cause of death and disability among young persons. A key to improve outcome for patients with TBI is to reduce the time from injury to definitive care by achieving high triage accuracy. Microwave technology (MWT) allows for a portable device to be used in the pre-hospital setting for detection of intracranial hematomas at the scene of injury, thereby enhancing early triage and allowing for more adequate early care. MWT has previously been evaluated for medical applications including the ability to differentiate between hemorrhagic and ischemic stroke. The purpose of this study was to test whether MWT in conjunction with a diagnostic mathematical algorithm could be used as a medical screening tool to differentiate patients with traumatic intracranial hematomas, chronic subdural hematomas (cSDH), from a healthy control (HC) group. Twenty patients with cSDH and 20 HC were measured with a MWT device. The accuracy of the diagnostic algorithm was assessed using a leave-one-out analysis. At 100% sensitivity, the specificity was 75%-i.e., all hematomas were detected at the cost of 25% false positives (patients who would be overtriaged). Considering the need for methods to identify patients with intracranial hematomas in the pre-hospital setting, MWT shows promise as a tool to improve triage accuracy. Further studies are under way to evaluate MWT in patients with other intracranial hemorrhages.	[Ljungqvist, Johan; Skoglund, Thomas] Sahlgrens Univ Hosp, Dept Neurosurg, SE-41345 Gothenburg, Sweden; [Ljungqvist, Johan; Skoglund, Thomas] Univ Gothenburg, Inst Neurosci & Physiol, Dept Clin Neurosci, Sahlgrenska Acad, Gothenburg, Sweden; [Candefjord, Stefan; Persson, Mikael] Chalmers, Dept Signals & Syst, Gothenburg, Sweden; [Candefjord, Stefan; Persson, Mikael; Elae, Mikael] Sahlgrens Univ Hosp, MedTech West, Gothenburg, Sweden; [Candefjord, Stefan] SAFER Vehicle & Traff Safety Ctr Chalmers, Gothenburg, Sweden; [Jonsson, Lars] Sahlgrens Univ Hosp, Dept Neuroradiol, Gothenburg, Sweden; [Elae, Mikael] Sahlgrens Univ Hosp, Dept Clin Neurophysiol, Gothenburg, Sweden		Ljungqvist, J (corresponding author), Sahlgrens Univ Hosp, Dept Neurosurg, SE-41345 Gothenburg, Sweden.	johan.ljungqvist@vgregion.se		/0000-0001-7942-2190	Swedish Research CouncilSwedish Research CouncilEuropean Commission [921-2014-7116]; Gothenburg medical faculty [ALFGBG 542231]; Chalmers Innovation Office [V126]	The authors would like to thank Dr. Andreas Bartley and Gudrun Barrows for assisting with clinical examination and data collection. The authors would like to thank David Andtbacka and Lukas Lonnroth for assisting with CT scan assessment. This study was supported by the Swedish Research Council (proj no. 921-2014-7116), the Gothenburg medical faculty (ALFGBG 542231) and the Chalmers Innovation Office (proj no. V126).	Ashkenazi I, 2016, JAMA SURG, V151, P954, DOI 10.1001/jamasurg.2016.1742; Bonaccorsi M, 2016, INT J SOC ROBOT, P1; Candefjord S, 2016, MED BIOL ENG COMPUT; Candefjord S, 2016, TRAFFIC INJ PREV, V17, P16, DOI 10.1080/15389588.2016.1198872; Candefjord S, 2013, IEEE ENG MED BIO, P1948, DOI 10.1109/EMBC.2013.6609909; Dehli T, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0295-3; Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y; Fhager A, 2009, IEEE ANTENN WIREL PR, V8, P1353, DOI 10.1109/LAWP.2009.2039032; Gabriel C, 1996, PHYS MED BIOL, V41, P2231, DOI 10.1088/0031-9155/41/11/001; Gabriel S, 1996, PHYS MED BIOL, V41, P2251, DOI 10.1088/0031-9155/41/11/002; Haas B, 2010, J AM COLL SURGEONS, V211, P804, DOI 10.1016/j.jamcollsurg.2010.08.014; Lecky F, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20010; Leon-Carrion J, 2010, BRAIN INJURY, V24, P1193, DOI 10.3109/02699052.2010.506636; LIN JC, 1982, P IEEE, V70, P523, DOI 10.1109/PROC.1982.12341; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mahmood Q, 2015, J ELECTROMAG ANAL AP, V7, P152, DOI [DOI 10.4236/JEMAA.2015.75017, DOI 10.4236/jemaa.2015.75017]; Meaney PM, 2013, MED PHYS, V40, DOI 10.1118/1.4820361; Mobashsher AT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152351; Mohammed BJ, 2014, IEEE T INSTRUM MEAS, V63, P117, DOI 10.1109/TIM.2013.2277562; Parker BJ, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-326; Persson M, 2014, IEEE T BIO-MED ENG, V61, P2806, DOI 10.1109/TBME.2014.2330554; Poplack SP, 2007, RADIOLOGY, V243, P350, DOI 10.1148/radiol.2432060286; Preece AW, 2016, J MED IMAGING, V3, DOI 10.1117/1.JMI.3.3.033502; Prichep LS, 2015, J NEUROTRAUM, V32, P17, DOI 10.1089/neu.2014.3365; Robertson CS, 2010, J NEUROTRAUM, V27, P1597, DOI 10.1089/neu.2010.1340; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Semenova ZB, 2016, BRAIN INJURY, V30, P18, DOI 10.3109/02699052.2014.989401; Xiang HY, 2014, AM J EMERG MED, V32, P997, DOI 10.1016/j.ajem.2014.05.038	28	25	25	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2176	2182		10.1089/neu.2016.4869			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400456	28287909	Green Published, Bronze			2022-02-06	
J	Patel, SP; Cox, DH; Gollihue, JL; Bailey, WM; Geldenhuys, WJ; Gensel, JC; Sullivan, PG; Rabchevsky, AG				Patel, Samir P.; Cox, David H.; Gollihue, Jenna L.; Bailey, William M.; Geldenhuys, Werner J.; Gensel, John C.; Sullivan, Patrick G.; Rabchevsky, Alexander G.			Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery	EXPERIMENTAL NEUROLOGY			English	Article						PPAR; mitoNEET; Neuroprotection; Bioenergetics; Locomotor recovery	TRAUMATIC BRAIN-INJURY; PROLIFERATOR-ACTIVATED RECEPTORS; MEMBRANE PROTEIN; LOCOMOTOR RECOVERY; CRYSTAL-STRUCTURE; CONTROLLED-TRIAL; GAMMA AGONISTS; HUMAN MITONEET; METHYLPREDNISOLONE; BIOENERGETICS	Pioglitazone is an FDA-approved PPAR-gamma agonist drug used to treat diabetes, and it has demonstrated neuroprotective effects in multiple models of central nervous system (CNS) injury. Acute treatment after spinal cord injury (SCI) in rats is reported to suppress neuroinflammation, rescue injured tissues, and improve locomotor recovery. In the current study, we additionally assessed the protective efficacy of pioglitazone treatment on acute mitochondrial respiration, as well as functional and anatomical recovery after contusion SCI in adult male C57BL/6 mice. Mice received either vehicle or pioglitazone (10 mg/kg) at either 15 min or 3 h after injury (75 kdyn at T9) followed by a booster at 24 h post-injury. At 25 h, mitochondria were isolated from spinal cord segments centered on the injury epicenters and assessed for their respiratory capacity. Results showed significantly compromised mitochondrial respiration 25 h following SCI, but pioglitazone treatment that was initiated either at 15 min or 3 h post-injury significantly maintained mitochondrial respiration rates near sham levels. A second cohort of injured mice received pioglitazone at 15 min post injury, then once a day for 5 days post-injury to assess locomotor recovery and tissue sparing over 4 weeks. Compared to vehicle, pioglitazone treatment resulted in significantly greater recovery of hind-limb function over time, as determined by serial locomotor BMS assessments and both terminal BMS subscores and gridwalk performance. Such improvements correlated with significantly increased grey and white matter tissue sparing, although pioglitazone treatment did not abrogate long-term injury-induced inflammatory microglia/macrophage responses. In sum, pioglitazone significantly increased functional neuroprotection that was associated with remarkable maintenance of acute mitochondria! bioenergetics after traumatic SCI. This sets the stage for dose-response and delayed administration studies to maximize pioglitazone's efficacy for SCI while elucidating the precise role that mitochondria play in governing its neuroprotection; the ultimate goal to develop novel therapeutics that specifically target mitochondrial dysfunction. (C) 2017 Elsevier Inc. All rights reserved.	[Patel, Samir P.; Cox, David H.; Gollihue, Jenna L.; Bailey, William M.; Gensel, John C.; Sullivan, Patrick G.; Rabchevsky, Alexander G.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Patel, Samir P.; Gollihue, Jenna L.; Gensel, John C.; Rabchevsky, Alexander G.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA; [Sullivan, Patrick G.] Univ Kentucky, Coll Med, Dept Neurosci, Lexington, KY 40536 USA; [Geldenhuys, Werner J.] West Virginia Univ, Dept Pharmaceut Sci, Sch Pharm, Morgantown, WV 26506 USA		Rabchevsky, AG (corresponding author), Spinal Cord & Brain Injury Res Ctr SCoBIRC, B471,Biomed & Biol Sci Res Bldg, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915; Cox, David/0000-0002-9483-5900	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS069633, 2P30NS051220]; KSCHIRT [15-14A]; SCoBIRC Chair Endowment; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS077889, P30NS051220, R01NS069633] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX003405] Funding Source: NIH RePORTER	The authors extend special thanks to Dr. Bei Zhang and Mr. Michael Orr for helping with gridwalk, and Mr. Taylor Smith for helping with BMS assessments. This study was supported by NIH/NINDS R01 NS069633 (AGR & PGS); KSCHIRT 15-14A (PGS); SCoBIRC Chair Endowment (AGR); NIH/NINDS 2P30NS051220.	ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.1984.03340250025015; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; Bracken MB, 2001, SPINE, V26, pS47, DOI 10.1097/00007632-200112151-00010; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Center N.S.C.I.S., 2016, SPINAL CORD INJURY S; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Christman JW, 2000, BRAIN PATHOL, V10, P153; Colca JR, 2004, AM J PHYSIOL-ENDOC M, V286, pE252, DOI 10.1152/ajpendo.00424.2003; Conlan AR, 2009, J MOL BIOL, V392, P143, DOI 10.1016/j.jmb.2009.06.079; Cummings BJ, 2007, BEHAV BRAIN RES, V177, P232, DOI 10.1016/j.bbr.2006.11.042; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Drew PD, 2006, NEUROCHEM INT, V49, P183, DOI 10.1016/j.neuint.2006.04.003; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Finkel E, 2001, SCIENCE, V292, P624, DOI 10.1126/science.292.5517.624; Frazier-Wood AC, 2013, PHARMACOGENOMICS J, V13, P312, DOI 10.1038/tpj.2012.9; Geldenhuys WJ, 2011, BIOORG MED CHEM LETT, V21, P5498, DOI 10.1016/j.bmcl.2011.06.111; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; HALL ED, 1993, RES P ARNMD, V71, P81; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hou XW, 2007, J BIOL CHEM, V282, P33242, DOI 10.1074/jbc.C700172200; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kusminski CM, 2012, NAT MED, V18, P1539, DOI 10.1038/nm.2899; Landry AP, 2014, J BIOL CHEM, V289, P4307, DOI 10.1074/jbc.M113.542050; Lin JZ, 2007, P NATL ACAD SCI USA, V104, P14640, DOI 10.1073/pnas.0702426104; Liu M, 2017, J NEUROTRAUM, V34, P414, DOI 10.1089/neu.2015.4361; Martin HL, 2012, EXP NEUROL, V235, P528, DOI 10.1016/j.expneurol.2012.02.017; McEwen ML, 2011, NEUROTHERAPEUTICS, V8, P168, DOI 10.1007/s13311-011-0031-7; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Paddock ML, 2007, P NATL ACAD SCI USA, V104, P14342, DOI 10.1073/pnas.0707189104; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Patel SP, 2012, NEUROSCIENCE, V210, P296, DOI 10.1016/j.neuroscience.2012.03.006; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Pedada KK, 2014, J CHROMATOGR B, V945, P141, DOI 10.1016/j.jchromb.2013.11.048; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rabchevsky AG, 2011, PHARMACOL THERAPEUT, V132, P15, DOI 10.1016/j.pharmthera.2011.05.001; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Sood HS, 2003, AM J PHYSIOL-LUNG C, V284, pL333, DOI 10.1152/ajplung.00183.2002; Sood V, 2000, Diabetes Technol Ther, V2, P429, DOI 10.1089/15209150050194297; Springer JE, 1997, J NEUROCHEM, V68, P2469; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Wiley SE, 2007, P NATL ACAD SCI USA, V104, P5318, DOI 10.1073/pnas.0701078104; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yonutas HM, 2015, J BIOENERG BIOMEMBR, V47, P149, DOI 10.1007/s10863-014-9593-5; Yonutas HM, 2013, CURR DRUG TARGETS, V14, P733, DOI 10.2174/1389450111314070003; Zhang B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0440-3; Zhang B, 2015, EXP NEUROL, V273, P83, DOI 10.1016/j.expneurol.2015.08.001	59	25	26	0	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2017	293						74	82		10.1016/j.expneurol.2017.03.021			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EV5EC	WOS:000401784300007	28365473	Green Accepted, Green Published			2022-02-06	
J	Russell, K; Selci, E; Chu, S; Fineblit, S; Ritchie, L; Ellis, MJ				Russell, Kelly; Selci, Erin; Chu, Stephanie; Fineblit, Samuel; Ritchie, Lesley; Ellis, Michael J.			Longitudinal Assessment of Health-Related Quality of Life following Adolescent Sports-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						concussion; health-related quality of life; patient-reported outcomes; pediatric; post-concussion syndrome	MILD TRAUMATIC BRAIN; GENERIC CORE SCALES; POSTCONCUSSIVE SYMPTOMS; HIGH-SCHOOL; 1ST YEAR; CHILDREN; RELIABILITY; INJURY; PEDSQL(TM)-4.0; PREDICTORS	To examine initial and longitudinal health-related quality of life (HRQOL) in adolescent sports-related concussion (SRC) patients, a prospective observational case-series study was conducted among adolescent SRC patients who were evaluated at a multi-disciplinary pediatric concussion program. Health-related quality of life was measured using the child selfreport Pediatric Quality of Life Inventory (PedsQL) generic score scale (age 13-18 version) and the PedsQL Cognitive Functioning scale. Initial and longitudinal HRQOL outcomes were compared between patients who did and did not develop post-concussion syndrome (PCS). A total of 63 patients met the inclusion criteria during the study period. The mean age of the cohort was 14.57 years (standard deviation, 1.17) and 61.9% were male. The median time from injury to initial consultation was 6.5 days (interquartile range, 5, 11). At initial consultation, impairments in physical and cognitive HRQOL but not social or emotional HRQOL were observed. Initial symptom burden and length of recovery were associated with greater impairment in physical and cognitive HRQOL. Patients who went on to develop PCS had significantly worse physical and cognitive HRQOL at initial consultation and demonstrated a slower rate of recovery in these domains, compared with those who recovered in less than 30 days. Adolescent SRC was associated with HRQOL impairments that correlated with clinical outcomes. No persistent impairments in HRQOL were detected among patients who achieved physician-documented clinical recovery. Future studies are needed to evaluate the clinical utility of HRQOL measurement in the longitudinal management of adolescent SRC and PCS patients.	[Ellis, Michael J.] Pan Am Concuss Program, Winnipeg, MB, Canada; [Russell, Kelly; Selci, Erin; Chu, Stephanie; Fineblit, Samuel; Ritchie, Lesley; Ellis, Michael J.] Canada North Concuss Network, Winnipeg, MB, Canada; [Ritchie, Lesley] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Dept Surg, Winnipeg, MB, Canada; [Russell, Kelly; Selci, Erin; Chu, Stephanie; Fineblit, Samuel] Univ Manitoba, Dept Pediat & Child Hlth, 656-715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada; [Ellis, Michael J.] Univ Manitoba, Sect Neurosurg, Winnipeg, MB, Canada; [Russell, Kelly; Selci, Erin; Chu, Stephanie; Fineblit, Samuel; Ellis, Michael J.] Childrens Hosp Res Inst Manitoba, Winnipeg, MB, Canada		Russell, K (corresponding author), Univ Manitoba, Dept Pediat & Child Hlth, 656-715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	krussell@chrim.ca		Russell, Kelly/0000-0002-9159-9201	University Research Grants Program from the University of Manitoba	All phases of this study were supported by a grant from University Research Grants Program from the University of Manitoba.	Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Cordingley D, 2016, J NEUROSURG-PEDIATR, V18, P693, DOI 10.3171/2016.5.PEDS16139; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Eiser C, 2001, QUAL LIFE RES, V10, P347, DOI 10.1023/A:1012253723272; Ellis MJ, 2017, CAN J NEUROL SCI, V44, P24, DOI 10.1017/cjn.2016.312; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ferracini GN, 2014, HEADACHE, V54, P325, DOI 10.1111/head.12251; Fineblit S, 2016, J NEUROTRAUM, V33, P1561, DOI 10.1089/neu.2015.4292; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Houston MN, 2016, BRAIN INJURY, V30, P891, DOI 10.3109/02699052.2016.1146960; Iadevaia C, 2015, J ATHL TRAINING, V50, P1182, DOI 10.4085/1062-6050-50.11.02; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Novak Z, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.2900; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Pieper P, 2015, J PEDIATR HEALTH CAR, V29, P343, DOI 10.1016/j.pedhc.2015.01.008; Pieper P, 2014, BRAIN INJURY, V28, P105, DOI 10.3109/02699052.2013.847208; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Uzark K, 2013, CONGENIT HEART DIS, V8, P211, DOI 10.1111/chd.12002; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-43; Varni JW, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-26; Varni JW, 2007, J PEDIATR PSYCHOL, V32, P1151, DOI 10.1093/jpepsy/jsm008; Varni JW, 2011, QUAL LIFE RES, V20, P913, DOI 10.1007/s11136-010-9823-1; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2002, J BEHAV MED, V25, P175, DOI 10.1023/A:1014836921812; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	40	25	25	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2147	2153		10.1089/neu.2016.4704			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400453	28077006				2022-02-06	
J	Tucker, B; Aston, J; Dines, M; Caraman, E; Yacyshyn, M; McCarthy, M; Olson, JE				Tucker, Brian; Aston, Jill; Dines, Megan; Caraman, Elena; Yacyshyn, Marianne; McCarthy, Mary; Olson, James E.			EARLY BRAIN EDEMA IS A PREDICTOR OF IN-HOSPITAL MORTALITY IN TRAUMATIC BRAIN INJURY	JOURNAL OF EMERGENCY MEDICINE			English	Article						logistic regression; mild traumatic brain injury; mortality; secondary insult	GLASGOW COMA SCALE; CRANIAL COMPUTED-TOMOGRAPHY; PROGNOSTIC VALUE; HEAD-INJURY; CELLULAR EDEMA; IMPACT; MILD; VOLUME; MODELS; SCORE	Background: Identifying patients who may progress to a poor clinical outcome will encourage earlier appropriate therapeutic interventions. Brain edema may contribute to secondary injury in traumatic brain injury (TBI) and thus, may be a useful prognostic indicator. Objective: We determined whether the presence of brain edema on the initial computed tomography (CT) scan of TBI patients would predict poor in-hospital outcome. Methods: We performed a retrospective review of all trauma patients with nonpenetrating head trauma at a Level I Trauma Center. International Classification of Diseases, Ninth Revision codes indicated the presence of brain edema and we evaluated the validity of this pragmatic assessment quantitatively in a random subset of patients. In-hospital mortality was the primary outcome variable. Univariate analysis and logistic regression identified predictors of mortality in all TBI patients and those with mild TBI. Results: Over 7200 patients were included in the study, including 6225 with mild TBI. Measurements of gray and white matter CT density verified radiological assessments of brain edema. Patients with documented brain edema had a mortality rate over 10 times that of the entire study population. With logistic regression accounting for Injury Severity Score, Glasgow Coma Scale score, other CT findings, and clinical variables, brain edema predicted an eightfold greater mortality rate in all patients (odds ratio 8.0, 95% confidence interval 4.6-14.0) and fivefold greater mortality rate for mild TBI patients (odds ratio 4.9, 95% confidence interval 2.0-11.7). Conclusions: Brain edema is an independent prognostic variable across all categories of TBI severity. By alerting emergency physicians to patients with poor predicted clinical outcomes, this finding will drive better resource allocation, earlier intervention, and reduced patient mortality. (C) 2017 Elsevier Inc. All rights reserved.	[Tucker, Brian; Aston, Jill; Dines, Megan; Caraman, Elena; Yacyshyn, Marianne; Olson, James E.] Wright State Univ, Boonshoft Sch Med, Dept Emergency Med, Dayton, OH 45435 USA; [McCarthy, Mary] Wright State Univ, Boonshoft Sch Med, Dept Surg, Dayton, OH 45435 USA; [Olson, James E.] Wright State Univ, Boonshoft Sch Med, Dept Neurosci Cell Biol & Physiol, Dayton, OH 45435 USA		Olson, JE (corresponding author), Cox Inst, Dept Emergency Med, 3525 Southern Blvd, Kettering, OH 45429 USA.				Research Fund of the Department of Emergency Medicine, Wright State University, Boonshoft School of Medicine, Dayton, Ohio, USA	This research was supported by the Research Fund of the Department of Emergency Medicine, Wright State University, Boonshoft School of Medicine, Dayton, Ohio, USA.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Battey TWK, 2014, STROKE, V45, P3643, DOI 10.1161/STROKEAHA.114.006884; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P453; BTF Guidelines, 2000, J NEUROTRAUM, V17, P591; BTF Guidelines The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P563; Bullock RM, 2000, J NEUROTRAUM, V17, P573; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Gatson JW, 2013, J NEUROSURG, V118, P1336, DOI 10.3171/2013.2.JNS121771; Gomez PA, 2014, J NEUROSURG, V121, P1314, DOI 10.3171/2014.7.JNS131874; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; HOSSMANN KA, 1980, STROKE, V11, P583, DOI 10.1161/01.STR.11.6.583; Huff JS, 2014, AM J EMERG MED, V32, P606, DOI 10.1016/j.ajem.2014.03.010; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Iaccarino C, 2014, J NEUROSURG, V120, P908, DOI 10.3171/2013.12.JNS131090; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kamal Hm, 2007, Libyan J Med, V2, P90, DOI 10.4176/070210; Laalo JP, 2009, J NEUROTRAUM, V26, P2169, DOI 10.1089/neu.2009.1011; Lambert IH, 2003, J MEMBRANE BIOL, V192, P19, DOI 10.1007/s00232-002-1061-1; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou A, 1996, ACT NEUR S, V66, P118; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Metter RB, 2011, RESUSCITATION, V82, P1180, DOI 10.1016/j.resuscitation.2011.04.001; Murray C. J., 1996, GLOBAL HLTH STAT COM; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nelson DW, 2012, J NEUROTRAUM, V29, P2613, DOI 10.1089/neu.2012.2468; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Schliess F, 2004, GLIA, V47, P21, DOI 10.1002/glia.20019; Shi HY, 2014, J NEUROSURG, V121, P1323, DOI 10.3171/2014.8.JNS131526; Shi HY, 2013, J NEUROSURG, V118, P732, DOI 10.3171/2012.12.JNS12693; Shi HY, 2013, J NEUROSURG, V118, P746, DOI 10.3171/2013.1.JNS121130; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Stroop R, 1998, ACT NEUR S, V71, P303; TEASDALE G, 1974, LANCET, V2, P81; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P597; Tierney KJ, 2016, J NEUROSURG, V124, P538, DOI 10.3171/2015.4.JNS142440; UNGER E, 1988, AM J NEURORADIOL, V9, P687; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Varela D, 2004, J BIOL CHEM, V279, P13301, DOI 10.1074/jbc.C400020200; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181	62	25	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	JUL	2017	53	1					18	29		10.1016/j.jemermed.2017.02.010			12	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	FE0VO	WOS:000407938000008	28343797				2022-02-06	
J	Wang, CF; Zhao, CC; Weng, WJ; Lei, J; Lin, Y; Mao, Q; Gao, GY; Feng, JF; Jiang, JY				Wang, Chuan-fang; Zhao, Cheng-cheng; Weng, Wei-ji; Lei, Jin; Lin, Yong; Mao, Qing; Gao, Guo-yi; Feng, Jun-feng; Jiang, Ji-yao			Alteration in Long Non-Coding RNA Expression after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						co-expression; hippocampus; long non-coding RNA (lncRNA); pathway; traumatic brain injury (TBI)	SPINAL-CORD-INJURY; NEURONAL APOPTOSIS; DEATH; HYPOTHERMIA; MECHANISMS; MODERATE; INFLAMMATION; ASTROCYTES; RESPONSES; TRIGGERS	Traumatic brain injury (TBI) causes a primary insult and initiates a secondary injury cascade. The mechanisms underlying the secondary injury are multifactorial and may include the aberrant expression of long non-coding RNA (lncRNA) post-TBI. Here, lncRNA microarray analysis was performed to profile the altered lncRNAs in the rat hippocampus after TBI. A total of 271 lncRNA probe sets and 1046 messenger RNA (mRNA) probe sets were differentially expressed after TBI. Gene ontology analysis showed that the main components of the most significantly changed categories were inflammation, DNA transcription, apoptosis, and necroptosis. Additionally, the pathway analysis and the pathway relation network revealed correlated pathways mainly involving inflammation, cell cycle, and apoptosis. A co-expression network of these aberrantly expressed lncRNAs and mRNAs was further constructed to predict the potential function of individual lncRNAs. Sub-co-expression networks were formed for the top three lncRNAs: NR_002704, ENSRNOT00000062543, and Zfas1. Thus, our study demonstrated differential expression of a series of lncRNAs in the rat hippocampus after TBI, which may be correlated with post-TBI physiological and pathological processes. The findings also may provide novel targets for further investigation of both the molecular mechanisms underlying TBI and potential therapeutic interventions.	[Wang, Chuan-fang; Zhao, Cheng-cheng; Weng, Wei-ji; Lei, Jin; Lin, Yong; Mao, Qing; Gao, Guo-yi; Feng, Jun-feng; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China; [Wang, Chuan-fang; Zhao, Cheng-cheng; Lin, Yong; Gao, Guo-yi; Feng, Jun-feng; Jiang, Ji-yao] Shanghai Inst Head Trauma, Shanghai, Peoples R China		Gao, GY; Feng, JF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China.	gao3@sina.com; fengjfmail@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30901543, 31371406, 81671198, 81571883]; National Key Basic Research ProgramNational Basic Research Program of China [2012CB518100]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [13ZR1424500]; Shanghai Municipal Health Bureau [XYQ2013094]; SMC-Star Award for Young Scholars	We would like to thank Genminix Informatics and Zhi-han Sun for their excellent technical assistance with the data analysis. We also thank Dr. Lei Wang and other members of the Shanghai Institute of Head Trauma for assistance. We thank Dr. Bruce G. Lyeth, Department of Neurological Surgery, University of California Davis, for his critical English language editing. We gratefully acknowledge the following funding sources: the National Natural Science Foundation of China (30901543, 31371406, 81671198, and 81571883) and the National Key Basic Research Program (2012CB518100). JFF also received funding from the Science and Technology Commission of Shanghai Municipality (13ZR1424500), Shanghai Municipal Health Bureau (XYQ2013094) and SMC-Star Award for Young Scholars (B).	Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Becker EBE, 2004, PROG NEUROBIOL, V72, P1, DOI 10.1016/j.pneurobio.2003.12.005; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bond AM, 2009, NAT NEUROSCI, V12, P1020, DOI 10.1038/nn.2371; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Briggs JA, 2015, NEURON, V88, P861, DOI 10.1016/j.neuron.2015.09.045; Chang L, 2016, MOL MED REP, V13, P1541, DOI 10.3892/mmr.2015.4716; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; Colak T, 2012, INJURY, V43, P1264, DOI 10.1016/j.injury.2012.01.021; Costa FF, 2010, BIOESSAYS, V32, P599, DOI 10.1002/bies.200900112; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; de Bruin A, 2016, NUCLEIC ACIDS RES, V44, P3549, DOI 10.1093/nar/gkv1471; Demircan K, 2013, NEUROSCI LETT, V544, P25, DOI 10.1016/j.neulet.2013.02.064; Dewan MC, 2016, WORLD NEUROSURG, V91, P497, DOI 10.1016/j.wneu.2016.03.045; Feng JF, 2010, NEUROSURGERY, V67, P730, DOI 10.1227/01.NEU.0000378023.81727.6E; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Huang XJ, 2013, J NEUROTRAUM, V30, P39, DOI 10.1089/neu.2012.2508; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Kita EM, 2013, DEVELOPMENT, V140, P2933, DOI 10.1242/dev.088286; Li T, 2015, CANCER RES, V75, P3181, DOI 10.1158/0008-5472.CAN-14-3721; Liao Q, 2011, NUCLEIC ACIDS RES, V39, P3864, DOI 10.1093/nar/gkq1348; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Liu R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/470393; Ma CH, 2016, TUMOR BIOL, V37, P1437, DOI 10.1007/s13277-015-4521-9; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mathur S, 2011, SHOCK, V36, P478, DOI 10.1097/SHK.0b013e31822d6442; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Perez-Polo JR, 2016, J NEUROSCI RES, V94, P27, DOI 10.1002/jnr.23617; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Popescu C, 2015, J Med Life, V8, P272; Quadrato G, 2012, INT REV NEUROBIOL, V105, P71, DOI 10.1016/B978-0-12-398309-1.00005-6; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Shih RH, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00077; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Thorenoor N, 2016, ONCOTARGET, V7, P622, DOI 10.18632/oncotarget.5807; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Tsuruma K, 2006, J BIOL CHEM, V281, P11397, DOI 10.1074/jbc.M510597200; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang HQ, 2014, NEUROPHARMACOLOGY, V86, P9, DOI 10.1016/j.neuropharm.2014.06.018; White TE, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2412-0; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Yu B, 2015, PROG NEUROBIOL, V134, P122, DOI 10.1016/j.pneurobio.2015.09.006; Yu X, 2015, ONCOL LETT, V10, P1953, DOI 10.3892/ol.2015.3553; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078	52	25	29	5	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2100	2108		10.1089/neu.2016.4642			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400448	28145813				2022-02-06	
J	Au, AK; Aneja, RK; Bayir, H; Bell, MJ; Janesko-Feldman, K; Kochanek, PM; Clark, RSB				Au, Alicia K.; Aneja, Rajesh K.; Bayir, Hulya; Bell, Michael J.; Janesko-Feldman, Keri; Kochanek, Patrick M.; Clark, Robert S. B.			Autophagy Biomarkers Beclin 1 and p62 are Increased in Cerebrospinal Fluid after Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Autophagy; Autophagic flux; Traumatic brain injury; Biomarkers; Pediatrics; Cerebrospinal fluid; Outcome	CELL-DEATH; NEURODEGENERATIVE DISEASE; APOPTOSIS; MICE; PROTEIN; SYSTEM; SECRETION; PATHOLOGY; RAPAMYCIN; PATHWAY	Background Autophagy is a process that recycles damaged proteins and organelles. Beclin 1 is involved in the nucleation phase, while p62 is consumed during the elongation phase. We hypothesized that these autophagy biomarkers are increased in cerebrospinal fluid (CSF) after traumatic brain injury (TBI) in children and associated with unfavorable outcome. Methods Thirty children with severe TBI had CSF collected on days 1, 3, and 7. Patients without TBI or meningoencephalitis served as controls. Beclin 1 and p62 were measured by ELISA. Outcome was assigned 6 months after injury (Glasgow Outcome Scale score; GOS). Results Mean and peak CSF beclin 1 and p62 levels were increased compared to controls (P < 0.05). Peak p62 levels were higher in patients with unfavorable versus favorable outcome (0.79 +/- 1.03 vs. 0.17 +/- 0.54 ng/ml, respectively; mean +/- SD, P = 0.002) and were independently associated with outcome when controlling for age and initial Glasgow Coma Scale score (P = 0.019; AUC 0.88, 95% CI 0.76, 1.00). Conclusion Beclin 1 and p62 are increased in CSF after TBI, suggesting increased autophagy with impairment of, and/or exceeding the capacity for, autophagic flux. The association of increased p62 with unfavorable outcome suggests that autophagy in excess of the capacity to clear degradation products may be deleterious after TBI.	[Au, Alicia K.; Aneja, Rajesh K.; Bayir, Hulya; Bell, Michael J.; Janesko-Feldman, Keri; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Dept Crit Care Med, 4401 Penn Ave,Fac Pavil,Suite 2000, Pittsburgh, PA 15224 USA; [Au, Alicia K.; Aneja, Rajesh K.; Bayir, Hulya; Bell, Michael J.; Janesko-Feldman, Keri; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, UPMC, 4401 Penn Ave,Fac Pavil,Suite 2000, Pittsburgh, PA 15224 USA; [Au, Alicia K.; Aneja, Rajesh K.; Bayir, Hulya; Bell, Michael J.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Med Ctr, Dept Pediat, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bell, Michael J.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Au, AK (corresponding author), Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Dept Crit Care Med, 4401 Penn Ave,Fac Pavil,Suite 2000, Pittsburgh, PA 15224 USA.; Au, AK (corresponding author), Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, UPMC, 4401 Penn Ave,Fac Pavil,Suite 2000, Pittsburgh, PA 15224 USA.	auak@upmc.edu			Children's Hospital of Pittsburgh Scientific Program;  [R01 NS38620]	Funding was provided by R01 NS38620 and the Children's Hospital of Pittsburgh Scientific Program.	Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Boland B, 2008, J NEUROSCI, V28, P6926, DOI 10.1523/JNEUROSCI.0800-08.2008; Bove J, 2011, NAT REV NEUROSCI, V12, P437, DOI 10.1038/nrn3068; Brandner S, 2013, EUR NEUROL, V70, P189, DOI 10.1159/000352032; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Deisenhammer F, 2006, EUR J NEUROL, V13, P913, DOI 10.1111/j.1468-1331.2006.01493.x; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001; Jiang S, 2013, J INNATE IMMUN, V5, P471, DOI 10.1159/000346707; Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004; Li HH, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0726-3; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; McKnight NC, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004626; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Nezis IP, 2012, ANTIOXID REDOX SIGN, V17, P786, DOI 10.1089/ars.2011.4394; Nickel W, 2009, NAT REV MOL CELL BIO, V10, P148, DOI 10.1038/nrm2617; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Ponpuak M, 2015, CURR OPIN CELL BIOL, V35, P106, DOI 10.1016/j.ceb.2015.04.016; Puy V, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00154; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sakai K, 2014, AM J FOREN MED PATH, V35, P38, DOI 10.1097/PAF.0000000000000067; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Seibenhener ML, 2013, BIOCHIM BIOPHYS ACTA, V3, P452; Sommer JB, 2002, EUR NEUROL, V47, P224, DOI 10.1159/000057904; Stepkowski TM, 2011, FREE RADICAL BIO MED, V50, P1186, DOI 10.1016/j.freeradbiomed.2011.01.033; Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143; Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x; Zhou YL, 2016, INT J BIOL SCI, V12, P87, DOI 10.7150/ijbs.13229	44	25	29	1	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2017	26	3					348	355		10.1007/s12028-016-0351-x			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EV9JA	WOS:000402101100005	28000126				2022-02-06	
J	Zhang, WT; Wang, YF				Zhang, Wei-Tao; Wang, Ya-Fei			Efficacy of methylphenidate for the treatment of mental sequelae after traumatic brain injury	MEDICINE			English	Article						mental sequelae; methylphenidate; randomized controlled trial; traumatic brain injury	REHABILITATION; DEPRESSION; FATIGUE; DISORDERS; SYMPTOMS	Background: This study aimed to evaluate the effect of methylphenidate for treating mental sequelae after traumatic brain injury (TBI). Methods: Thirty-six patients with TBI were randomly divided into the intervention group and placebo group. The participants in the intervention group received methylphenidate, while subjects in the placebo group were administered a placebo. This study was conducted from January 2014 to December 2016. The outcome measurements included Mental Fatigue Scale, Choice Reaction Time, Compensatory Tracking Task, Mental Arithmetic Test, Digit Symbol Substitution Test, Mini-Mental State Examination (MMSE), Beck Depression Inventory (BDI), and Hamilton Rating Scale for Depression. In addition, safety was also recorded and assessed. Results: A total of 33 subjects completed the study. Methylphenidate showed greater efficacy than placebo, with decreased scores on the Mental Fatigue Scale, Choice Reaction Time, and Compensatory Tracking Task in the intervention group compared to the placebo group (P < .01, respectively). Furthermore, increased scores on the Mental Arithmetic Test, Digit Symbol Substitution Test, and MMSE in the intervention group, compared to those in the placebo group (P < .01 respectively), were observed. In addition, a significant difference in the scores on the BDI (P = .04) and Hamilton Rating Scale for Depression (P = .005) was observed between the 2 groups. The safety at the end of the 30 week-treatment was similar between the 2 groups (P > .05). Conclusion: The results of this study demonstrated that methylphenidate could effectively improve mental fatigue and cognitive functions in patients with TBI.	[Zhang, Wei-Tao] Peoples Hosp Yanan, Dept Neurosurg, Yanan 716000, Peoples R China; [Wang, Ya-Fei] Peoples Hosp Ningxia, Dept Neurosurg, 301 Zhengyuan North St, Yinchuan 750001, Peoples R China		Zhang, WT (corresponding author), Peoples Hosp Yanan, Dept Neurosurg, Yanan 716000, Peoples R China.; Wang, YF (corresponding author), Peoples Hosp Ningxia, Dept Neurosurg, 301 Zhengyuan North St, Yinchuan 750001, Peoples R China.	weitao20000@outlook.com; wangds1958@163.com					American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Garcia-Baran D, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002886; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HINDMARCH I, 1980, BRIT J CLIN PHARMACO, V10, P189, DOI 10.1111/j.1365-2125.1980.tb01745.x; HINDMARCH I, 1977, BRIT J CLIN PHARMACO, V4, pS167, DOI 10.1111/j.1365-2125.1977.tb05747.x; HINDMARCH I, 1983, ACTA PSYCHIAT SCAND, V68, P141, DOI 10.1111/j.1600-0447.1983.tb11115.x; Huang CH, 2016, CURR NEUROPHARMACOL, V14, P272, DOI 10.2174/1570159X13666150514233033; Jang SH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005009; Jang SH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002628; Johansson B, 2017, ACTA NEUROL SCAND, V135, P100, DOI 10.1111/ane.12587; Johansson B., 2012, BRAIN INJURY FUNCTIO, V1, P3, DOI [10.5772/27042, DOI 10.5772/27042]; Johansson B., 2014, INT J PHYS MED REHAB, V2, P1, DOI [10.4172/2329-9096.1000182, DOI 10.4172/2329-9096.1000182]; Johansson B, 2010, BRAIN INJURY, V24, P2, DOI 10.3109/02699050903452961; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; McAllister Thomas W., 1994, P357; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Sashika H, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005968; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shire US Inc WPA, 2009, PROD INF DAYTR TM TR; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Sivan M, 2010, CLIN REHABIL, V24, P110, DOI 10.1177/0269215509343234; Wang Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006458; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Weber P, 2002, PEDIATR NEUROL, V26, P261, DOI 10.1016/S0887-8994(01)00408-8; Wechsler, 1997, WECHSLER ADULT INTEL; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003	33	25	26	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JUN	2017	96	25							e6960	10.1097/MD.0000000000006960			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY6TT	WOS:000404116900005	28640076	Green Published, gold			2022-02-06	
J	Weng, L; Xie, QY; Zhao, L; Zhang, RB; Ma, Q; Wang, JJ; Jiang, W; He, YB; Chen, Y; Li, CH; Ni, XX; Xu, Q; Yu, RH; Huang, RW				Weng, Ling; Xie, Qiuyou; Zhao, Ling; Zhang, Ruibin; Ma, Qing; Wang, Junjing; Jiang, Wenjie; He, Yanbin; Chen, Yan; Li, Changhong; Ni, Xiaoxiao; Xu, Qin; Yu, Ronghao; Huang, Ruiwang			Abnormal structural connectivity between the basal ganglia, thalamus, and frontal cortex in patients with disorders of consciousness	CORTEX			English	Article						Network-based statistic; Fractional anisotropy; Head motion; Fronto-parietal network; Basal ganglia-thalamo-cortical; network	TRAUMATIC BRAIN-INJURY; ANTERIOR FOREBRAIN MESOCIRCUIT; PROBABILISTIC DIFFUSION TRACTOGRAPHY; WHITE-MATTER INTEGRITY; DEFAULT MODE NETWORK; FUNCTIONAL CONNECTIVITY; FRONTOPARIETAL NETWORK; VEGETATIVE STATE; RESTING-STATE; MRI	Consciousness loss in patients with severe brain injuries is associated with reduced functional connectivity of the default mode network (DMN), fronto-parietal network, and thalamo-cortical network. However, it is still unclear if the brain white matter connectivity between the above mentioned networks is changed in patients with disorders of consciousness (DOC). In this study, we collected diffusion tensor imaging (DTI) data from 13 patients and 17 healthy controls, constructed whole-brain white matter (WM) structural networks with probabilistic tractography. Afterward, we estimated and compared topological properties, and revealed an altered structural organization in the patients. We found a disturbance in the normal balance between segregation and integration in brain structural networks and detected significantly decreased nodal centralities primarily in the basal ganglia and thalamus in the patients. A network-based statistical analysis detected a subnetwork with uniformly significantly decreased structural connections between the basal ganglia, thalamus, and frontal cortex in the patients. Further analysis indicated that along the WM fiber tracts linking the basal ganglia, thalamus, and frontal cortex, the fractional anisotropy was decreased and the radial diffusivity was increased in the patients compared to the controls. Finally, using the receiver operating characteristic method, we found that the structural connections within the NBS-derived component that showed differences between the groups demonstrated high sensitivity and specificity (>90%). Our results suggested that major consciousness deficits in DOC patients may be related to the altered WM connections between the basal ganglia, thalamus, and frontal cortex. (C) 2017 Elsevier Ltd. All rights reserved.	[Weng, Ling; Zhao, Ling; Wang, Junjing; Jiang, Wenjie; Li, Changhong; Xu, Qin; Huang, Ruiwang] South China Normal Univ, Ctr Study Appl Psychol, Guangdong Key Lab Mental Hlth & Cognit Sci, Sch Psychol,Inst Brain Sci & Rehabil, Guangzhou 510631, Guangdong, Peoples R China; [Xie, Qiuyou; Ma, Qing; He, Yanbin; Chen, Yan; Ni, Xiaoxiao; Yu, Ronghao] Guangzhou Gen Hosp Guangzhou Mil Command, Ctr Hyperbar Oxygen & Neurorehabil, Guangzhou 510010, Guangdong, Peoples R China; [Zhang, Ruibin] Univ Hong Kong, Dept Psychol, Hong Kong, Hong Kong, Peoples R China		Huang, RW (corresponding author), South China Normal Univ, Sch Psychol, Ctr Studies Psychol Applicat, Guangdong Key Lab Mental Hlth & Cognit Sci, Guangzhou 510631, Guangdong, Peoples R China.; Yu, RH (corresponding author), Guangzhou Gen Hosp Guangzhou Mil Command, Coma Res Grp, Ctr Hyperbar Oxygen & Neurorehabil, Guangzhou 510010, Guangdong, Peoples R China.	gesund@21cn.com; ruiwang.huang@gmail.com		Li, Changhong/0000-0001-9067-4110	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271548, 81371535, 81428013, 81471654]; Natural Science Foundation of Guangdong Province, ChinaNational Natural Science Foundation of Guangdong Province [2015A030313609]	This work was supported by funding from the National Natural Science Foundation of China (Grant numbers: 81271548, 81371535, 81428013, and 81471654), Natural Science Foundation of Guangdong Province, China (2015A030313609)). The authors express appreciation to Drs. Rhoda E. and Edmund F. Perozzi for editing assistance. The authors thank the two anonymous reviewers for their constructive comments and their suggestions.	Akeju O, 2014, ELIFE, V3, DOI 10.7554/eLife.04499; Andersen SM, 2010, NEUROIMAGE, V53, P78, DOI 10.1016/j.neuroimage.2010.06.003; Annen J, 2016, HUM BRAIN MAPP, V37, P3707, DOI 10.1002/hbm.23269; Bagnato S., 2016, J NEUROTRAUM; Barttfeld P, 2015, P NATL ACAD SCI USA, V112, P887, DOI 10.1073/pnas.1418031112; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Beaulieu C., 2013, DIFFUSION MRI QUANTI, P1; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Borst JP, 2013, P NATL ACAD SCI USA, V110, P1628, DOI 10.1073/pnas.1221572110; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2012, NEUROIMAGE-CLIN, V1, P106, DOI 10.1016/j.nicl.2012.09.011; Cao QJ, 2013, J NEUROSCI, V33, P10676, DOI 10.1523/JNEUROSCI.4793-12.2013; Casali AG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006294; Catani M, 2005, BRAIN, V128, P2224, DOI 10.1093/brain/awh622; Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349; Cavaliere C, 2015, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.01028; Cavinato M, 2015, BRAIN TOPOGR, V28, P570, DOI 10.1007/s10548-014-0383-5; Caviness VS, 1996, J COGNITIVE NEUROSCI, V8, P566, DOI 10.1162/jocn.1996.8.6.566; Chatelle C, 2016, ARCH PHYS MED REHAB, V97, P1295, DOI 10.1016/j.apmr.2016.02.009; Chatelle C, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00917; Chennu S, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003887; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cortese MD, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0455-5; Crone JS, 2015, NEUROIMAGE, V110, P101, DOI 10.1016/j.neuroimage.2015.01.037; Crone JS, 2014, NEUROIMAGE-CLIN, V4, P240, DOI 10.1016/j.nicl.2013.12.005; Crossley NA, 2014, BRAIN, V137, P2382, DOI 10.1093/brain/awu132; Cui ZX, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00042; de Reus MA, 2013, NEUROIMAGE, V80, P397, DOI 10.1016/j.neuroimage.2013.03.053; Demertzi A, 2015, BRAIN, V138, P2619, DOI 10.1093/brain/awv169; Demertzi A, 2013, CURR OPIN NEUROBIOL, V23, P239, DOI 10.1016/j.conb.2012.12.003; Desco M, 2001, HUM BRAIN MAPP, V14, P16, DOI 10.1002/hbm.1038; Di Perri C, 2013, NEUROLOGY, V81, P1417, DOI 10.1212/WNL.0b013e3182a43b78; Draganski B, 2008, J NEUROSCI, V28, P7143, DOI 10.1523/JNEUROSCI.1486-08.2008; Duff EP, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3008438; Edlow BL, 2013, J NEUROPATH EXP NEUR, V72, P505, DOI 10.1097/NEN.0b013e3182945bf6; Eickhoff SB, 2015, HUM BRAIN MAPP, V36, P4771, DOI 10.1002/hbm.22933; Estraneo A, 2015, CLIN REHABIL, V29, P803, DOI 10.1177/0269215514556002; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Farrer C, 2008, CEREB CORTEX, V18, P254, DOI 10.1093/cercor/bhm050; Fernandez-Espejo D, 2013, NAT REV NEUROSCI, V14, P801, DOI 10.1038/nrn3608; Fernandez-Espejo D, 2012, ANN NEUROL, V72, P335, DOI 10.1002/ana.23635; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Fernandez-Espejo D, 2010, J NEUROTRAUM, V27, P1187, DOI 10.1089/neu.2010.1297; Fridman EA, 2014, P NATL ACAD SCI USA, V111, P6473, DOI 10.1073/pnas.1320969111; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Gong GL, 2009, J NEUROSCI, V29, P15684, DOI 10.1523/JNEUROSCI.2308-09.2009; Gosseries O, 2014, ANNU REV NEUROSCI, V37, P457, DOI 10.1146/annurev-neuro-062012-170339; Haber SN, 2003, J CHEM NEUROANAT, V26, P317, DOI 10.1016/j.jchemneu.2003.10.003; Hagmann P., 2005, THESIS, DOI [10.5075/epfl-thesis-323, DOI 10.5075/EPFL-THESIS-323]; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Ishai A, 2000, J COGNITIVE NEUROSCI, V12, P35, DOI 10.1162/089892900564055; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Koch C, 2016, NAT REV NEUROSCI, V17, P307, DOI 10.1038/nrn.2016.22; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lant ND, 2016, NEUROIMAGE-CLIN, V10, P27, DOI 10.1016/j.nicl.2015.11.004; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2011, NEUROLOGY CONSCIOUSN; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Le Bihan D, 2012, NEUROIMAGE, V61, P324, DOI 10.1016/j.neuroimage.2011.11.006; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Long JY, 2016, SCI REP-UK, V6, DOI 10.1038/srep38866; Lutkenhoff ES, 2015, ANN NEUROL, V78, P68, DOI 10.1002/ana.24423; Lutkenhoff ES, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115551; Luyt CE, 2012, ANESTHESIOLOGY, V117, P1311, DOI 10.1097/ALN.0b013e318275148c; MacDonald AA, 2015, TRENDS COGN SCI, V19, P100, DOI 10.1016/j.tics.2014.12.005; Monti MM, 2015, NEUROLOGY, V84, P167, DOI 10.1212/WNL.0000000000001123; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Owen AM, 2013, ANNU REV PSYCHOL, V64, P109, DOI 10.1146/annurev-psych-113011-143729; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Posnansky O, 2011, INT J IMAG SYST TECH, V21, P271, DOI 10.1002/ima.20292; Proix T, 2016, NEUROIMAGE, V142, P135, DOI 10.1016/j.neuroimage.2016.06.016; Renier LA, 2010, NEURON, V68, P138, DOI 10.1016/j.neuron.2010.09.021; Ripolles P, 2012, NEUROIMAGE, V60, P1296, DOI 10.1016/j.neuroimage.2012.01.094; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Salazar RF, 2012, SCIENCE, V338, P1097, DOI 10.1126/science.1224000; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff ND, 2007, CURR OPIN NEUROL, V20, P638, DOI 10.1097/WCO.0b013e3282f1c6e4; Schiff ND, 2016, J NEURAL TRANSM, V123, P797, DOI 10.1007/s00702-016-1547-0; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schurger A, 2010, SCIENCE, V327, P97, DOI 10.1126/science.1180029; Shadlen M. N., 2011, CONSCIOUSNESS DECISI; Silva S, 2015, NEUROLOGY, V85, P2036, DOI 10.1212/WNL.0000000000002196; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Sporns O, 2000, NEURAL NETWORKS, V13, P909, DOI 10.1016/S0893-6080(00)00053-8; Sporns O, 2011, ANN NY ACAD SCI, V1224, P109, DOI 10.1111/j.1749-6632.2010.05888.x; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Telesford QK, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00067; van den Heuvel MP, 2013, TRENDS COGN SCI, V17, P683, DOI 10.1016/j.tics.2013.09.012; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; van der Eerden AW, 2014, RADIOLOGY, V270, P506, DOI 10.1148/radiol.13122720; Wang JH, 2015, FRONT HUM NEUROSCI, V9, DOI [10.3389/fnhum.2015.00386, 10.3389/fnhum.2015.00458]; Wendelken C., 2015, CEREB CORTEX; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wu XH, 2015, J NEUROSCI, V35, P12932, DOI 10.1523/JNEUROSCI.0415-15.2015; Yendiki A, 2014, NEUROIMAGE, V88, P79, DOI 10.1016/j.neuroimage.2013.11.027; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zalesky A, 2010, NEUROIMAGE, V50, P970, DOI 10.1016/j.neuroimage.2009.12.027; Zanto TP, 2013, TRENDS COGN SCI, V17, P602, DOI 10.1016/j.tics.2013.10.001; Zhang RB, 2015, BRAIN STRUCT FUNCT, V220, P1145, DOI 10.1007/s00429-014-0706-z; Zheng ZS, 2017, HUM BRAIN MAPP, V38, P431, DOI 10.1002/hbm.23370; Zhong SY, 2015, HUM BRAIN MAPP, V36, P1995, DOI 10.1002/hbm.22751	113	25	25	4	28	ELSEVIER MASSON, CORP OFF	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	MAY	2017	90						71	87		10.1016/j.cortex.2017.02.011			17	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	EX2BG	WOS:000403029900007	28365490				2022-02-06	
J	Milikovsky, DZ; Weissberg, I; Kamintsky, L; Lippmann, K; Schefenbauer, O; Frigerio, F; Rizzi, M; Sheintuch, L; Zelig, D; Ofer, J; Vezzani, A; Friedman, A				Milikovsky, Dan Z.; Weissberg, Itai; Kamintsky, Lyn; Lippmann, Kristina; Schefenbauer, Osnat; Frigerio, Federica; Rizzi, Massimo; Sheintuch, Liron; Zelig, Daniel; Ofer, Jonathan; Vezzani, Annamaria; Friedman, Alon			Electrocorticographic Dynamics as a Novel Biomarker in Five Models of Epileptogenesis	JOURNAL OF NEUROSCIENCE			English	Article						biomarker; EEG; epilepsy; epileptogenesis; stroke; traumatic brain injury	TEMPORAL-LOBE EPILEPSY; HIGH-FREQUENCY OSCILLATIONS; INDUCED STATUS EPILEPTICUS; BRAIN-BARRIER DYSFUNCTION; HIPPOCAMPAL THETA RHYTHM; GAMMA-OSCILLATIONS; KAINIC ACID; MEDIATES EPILEPTOGENESIS; PILOCARPINE MODEL; ACQUIRED EPILEPSY	Postinjury epilepsy (PIE) is a devastating sequela of various brain insults. While recent studies offer novel insights into the mechanisms underlying epileptogenesis and discover potential preventive treatments, the lack of PIE biomarkers hinders the clinical implementation of such treatments. Here we explored the biomarker potential of different electrographic features in five models of PIE. Electrocorticographic or intrahippocampal recordings of epileptogenesis (from the insult to the first spontaneous seizure) from two laboratories were analyzed in three mouse and two rat PIE models. Time, frequency, and fractal and nonlinear properties of the signals were examined, in addition to the daily rate of epileptiform spikes, the relative power of five frequency bands (theta, alpha, beta, low gamma, and high gamma) and the dynamics of these features over time. During the latent pre-seizure period, epileptiform spikes were more frequent in epileptic compared with nonepileptic rodents; however, this feature showed limited predictive power due to high inter-and intra-animal variability. While nondynamic rhythmic representation failed to predict epilepsy, the dynamics of the theta band were found to predict PIE with a sensitivity and specificity of > 90%. Moreover, theta dynamics were found to be inversely correlated with the latency period (and thus predict the onset of seizures) and with the power change of the high-gamma rhythm. In addition, changes in theta band power during epileptogenesis were associated with altered locomotor activity and distorted circadian rhythm. These results suggest that changes in theta band during the epileptogenic period may serve as a diagnostic biomarker for epileptogenesis, able to predict the future onset of spontaneous seizures.	[Milikovsky, Dan Z.; Weissberg, Itai; Kamintsky, Lyn; Schefenbauer, Osnat; Sheintuch, Liron; Zelig, Daniel; Ofer, Jonathan; Friedman, Alon] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Physiol & Cell Biol, IL-84105 Beer Sheva, Israel; [Milikovsky, Dan Z.; Weissberg, Itai; Kamintsky, Lyn; Schefenbauer, Osnat; Sheintuch, Liron; Zelig, Daniel; Ofer, Jonathan; Friedman, Alon] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Cognit & Brain Sci, IL-84105 Beer Sheva, Israel; [Kamintsky, Lyn; Friedman, Alon] Dalhousie Univ, Dept Med Neurosci, Halifax, NS B3H 4R2, Canada; [Lippmann, Kristina] Charite, Inst Neurophysiol, D-10117 Berlin, Germany; [Frigerio, Federica; Rizzi, Massimo; Vezzani, Annamaria] Ist Ric Farmacol Mario Negri, IRCCS, Dept Neurosci, Expt Neurol, I-20156 Milan, Italy; [Lippmann, Kristina] Univ Leipzig, Carl Ludwig Inst Physiol, D-04103 Leipzig, Germany; [Sheintuch, Liron] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel		Friedman, A (corresponding author), Dalhousie Univ, Dept Med Neurosci, Halifax, NS B3H 4R2, Canada.	alon.friedman@dal.ca	Lippmann, Kristina/AAA-6709-2019; Rizzi, Massimo/ABF-2116-2020; Vezzani, Annamaria/AAB-1882-2020; Sheintuch, Liron/AAY-6936-2021	Vezzani, Annamaria/0000-0003-0573-6175; Weissberg, Itai/0000-0002-5513-1599; , Alon/0000-0003-4780-8456; Kamintsky, Lyna/0000-0001-6776-0969; Rizzi, Massimo/0000-0002-5477-2263; Milikovsky, Dan Z/0000-0002-4826-5273; Sheintuch, Liron/0000-0003-4245-5786; Lippmann, Kristina/0000-0001-7719-0437			Adeli H, 2003, J NEUROSCI METH, V123, P69, DOI 10.1016/S0165-0270(02)00340-0; Aeschbach D, 1997, NEUROSCI LETT, V239, P121, DOI 10.1016/S0304-3940(97)00904-X; Arabadzisz D, 2005, EXP NEUROL, V194, P76, DOI 10.1016/j.expneurol.2005.01.029; Bankstahl M, 2012, BEHAV BRAIN RES, V230, P182, DOI 10.1016/j.bbr.2012.02.004; Bar-Klein G, 2014, ANN NEUROL, V75, P864, DOI 10.1002/ana.24147; Bastlund JF, 2005, EPILEPSIA, V46, P934, DOI 10.1111/j.1528-1167.2005.63204.x; Becker AJ, 2008, J NEUROSCI, V28, P13341, DOI 10.1523/JNEUROSCI.1421-08.2008; Borges K, 2003, EXP NEUROL, V182, P21, DOI 10.1016/S0014-4886(03)00086-4; BRAGIN A, 1995, J NEUROPHYSIOL, V73, P1691, DOI 10.1152/jn.1995.73.4.1691; Butler JL, 2016, J NEUROSCI, V36, P4155, DOI 10.1523/JNEUROSCI.3150-15.2016; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; CANT BR, 1976, NEW ZEAL MED J, V83, P416; Chauviere L, 2009, J NEUROSCI, V29, P5402, DOI 10.1523/JNEUROSCI.4699-08.2009; Choi SJ, 2016, EPILEPSY RES, V120, P19, DOI 10.1016/j.eplepsyres.2015.11.010; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; DEMENT W, 1957, ELECTROEN CLIN NEURO, V9, P673, DOI 10.1016/0013-4694(57)90088-3; El-Hassar L, 2007, J PHYSIOL-LONDON, V578, P193, DOI 10.1113/jphysiol.2006.119297; Engel J, 2012, PROG NEUROBIOL, V98, P316, DOI 10.1016/j.pneurobio.2012.02.001; Friedman A, 2014, EXPERT REV NEUROTHER, V14, P1365, DOI 10.1586/14737175.2014.972945; Goldenholz DM, 2012, NEUROLOGY, V78, P224, DOI 10.1212/01.wnl.0000410956.29629.4d; GOTMAN J, 1991, CAN J NEUROL SCI, V18, P573, DOI 10.1017/S031716710003273X; Helmstaedter C, 2003, ANN NEUROL, V54, P425, DOI 10.1002/ana.10692; Herrmann CS, 2005, CLIN NEUROPHYSIOL, V116, P2719, DOI 10.1016/j.clinph.2005.07.007; Inoue T, 2008, BRAIN DEV-JPN, V30, P321, DOI 10.1016/j.braindev.2007.10.003; Jukic MM, 2015, NEUROPSYCHOPHARMACOL, V40, P839, DOI 10.1038/npp.2014.244; Kahana MJ, 1999, NATURE, V399, P781, DOI 10.1038/21645; Kelly KM, 2001, EPILEPSY RES, V47, P189, DOI 10.1016/S0920-1211(01)00294-7; Ketzef M, 2011, NEUROSCIENCE, V189, P108, DOI 10.1016/j.neuroscience.2011.05.030; Kobayashi K, 2004, EPILEPSIA, V45, P488, DOI 10.1111/j.0013-9580.2004.45703.x; Kobayashi K, 2010, EPILEPSIA, V51, P2190, DOI 10.1111/j.1528-1167.2010.02565.x; Kohling R, 2000, J NEUROSCI, V20, P6820, DOI 10.1523/JNEUROSCI.20-18-06820.2000; Lapilover EG, 2012, NEUROBIOL DIS, V48, P495, DOI 10.1016/j.nbd.2012.06.024; Levy N, 2015, J IMMUNOL, V195, P1713, DOI 10.4049/jimmunol.1401446; Lippmann K, 2017, J CEREBR BLOOD F MET, V37, P1803, DOI 10.1177/0271678X16652631; Maheshwari A, 2016, EPILEPSIA, V57, P79, DOI 10.1111/epi.13265; Marcelin B, 2009, NEUROBIOL DIS, V33, P436, DOI 10.1016/j.nbd.2008.11.019; McLin JP, 2006, EUR J NEUROSCI, V24, P2191, DOI 10.1111/j.1460-9568.2006.05111.x; Medvedev A, 2000, BRAIN RES BULL, V52, P89, DOI 10.1016/S0361-9230(00)00239-2; Medvedev AV, 2002, BRAIN RES BULL, V58, P115, DOI 10.1016/S0361-9230(02)00768-2; Montagne A, 2015, NEURON, V85, P296, DOI 10.1016/j.neuron.2014.12.032; Noe FM, 2013, NEUROBIOL DIS, V59, P183, DOI 10.1016/j.nbd.2013.07.015; Noe F, 2008, BRAIN, V131, P1506, DOI 10.1093/brain/awn079; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; Pascente R, 2016, NEUROBIOL DIS, V93, P146, DOI 10.1016/j.nbd.2016.05.001; Pitkanen A, 2016, LANCET NEUROL, V15, P843, DOI 10.1016/S1474-4422(16)00112-5; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; Pung T, 2006, EPILEPSIA, V47, P111, DOI 10.1111/j.1528-1167.2006.00707.x; Quigg M, 2016, EPILEPSY RES, V122, P91, DOI 10.1016/j.eplepsyres.2016.02.014; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Rizzi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep31129; Roseman E, 1944, RES PUBL ASSOC RES N, V25, P200; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Schauwecker PE, 2012, NEUROBIOL DIS, V45, P297, DOI 10.1016/j.nbd.2011.08.013; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Strijkstra AM, 2003, NEUROSCI LETT, V340, P17, DOI 10.1016/S0304-3940(03)00033-8; Swanson LW, 2004, BRAIN MAPS 3 STRUCTU; Tarasiuk A, 2014, SLEEP, V37, P987, DOI 10.5665/sleep.3676; Traub RD, 2005, J NEUROPHYSIOL, V94, P1225, DOI 10.1152/jn.00069.2005; van Vliet EA, 2012, EPILEPSIA, V53, P1254, DOI 10.1111/j.1528-1167.2012.03513.x; Vyazovskiy VV, 2005, BRAIN RES, V1050, P64, DOI 10.1016/j.brainres.2005.05.022; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Weissberg I., 2011, EPILEPSY RES TREAT, V2011, DOI DOI 10.1155/2011/143908; Weissberg I, 2015, NEUROBIOL DIS, V78, P115, DOI 10.1016/j.nbd.2015.02.029; White A, 2010, EPILEPSIA, V51, P371, DOI 10.1111/j.1528-1167.2009.02339.x; WHITNEY AW, 1971, IEEE T COMPUT, VC 20, P1100, DOI 10.1109/T-C.1971.223410; Willoughby JO, 2003, J NEUROL NEUROSUR PS, V74, P51, DOI 10.1136/jnnp.74.1.51; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646; WINSON J, 1974, ELECTROEN CLIN NEURO, V36, P291, DOI 10.1016/0013-4694(74)90171-0; Wu JY, 2008, EPILEPSY RES, V82, P99, DOI 10.1016/j.eplepsyres.2008.07.010; Yaari Y, 2007, J PHYSIOL-LONDON, V580, P435, DOI 10.1113/jphysiol.2007.127670; Yamazaki M, 2009, EPILEPSY RES, V83, P198, DOI 10.1016/j.eplepsyres.2008.11.008; Yang J, 2005, NEUROSCIENCE, V131, P853, DOI 10.1016/j.neuroscience.2004.09.064; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009	75	25	25	2	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 26	2017	37	17					4450	4461		10.1523/JNEUROSCI.2446-16.2017			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EU4YQ	WOS:000401038400004	28330876	Green Published, Bronze			2022-02-06	
J	Scott, JC; Harb, G; Brownlow, JA; Greene, J; Gur, RC; Ross, RJ				Scott, J. Cobb; Harb, Gerlinde; Brownlow, Janeese A.; Greene, Jennifer; Gur, Ruben C.; Ross, Richard J.			Verbal memory functioning moderates psychotherapy treatment response for PTSD-Related nightmares	BEHAVIOUR RESEARCH AND THERAPY			English	Article						Posttraumatic stress disorder; Psychotherapy; Nightmares; Insomnia; Memory; Neuropsychology; Sleep; Imagery rehearsal therapy	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; SLEEP QUALITY INDEX; COMPUTERIZED NEUROCOGNITIVE BATTERY; COGNITIVE PROCESSING THERAPY; RANDOMIZED CONTROLLED-TRIAL; PROLONGED EXPOSURE THERAPY; SEXUAL ASSAULT SURVIVORS; NEUROPSYCHOLOGICAL PERFORMANCE; IMAGERY REHEARSAL	Posttraumatic stress disorder (PTSD) is associated with cognitive deficits in attention, executive control, and memory, although few studies have investigated the relevance of cognitive difficulties for treatment outcomes. We examined whether cognitive functioning and history of traumatic brain injury (TBI) were associated with response to cognitive-behavioral therapy (CBT) for PTSD-related sleep problems. In a randomized controlled trial of Imagery Rehearsal (IR) added to components of CBT for Insomnia (IR + cCBT-I) compared to cCBT-I alone for PTSD-related recurrent nightmares, 94 U.S. veterans completed a battery of cognitive tests. TBI was assessed via structured clinical interview. Mixed-effects models examined main effects of cognitive functioning and interactions with time on primary sleep and nightmare outcomes. Significant verbal immediate memory by time interactions were found for nightmare distress, nightmare frequency, and sleep quality, even after controlling for overall cognitive performance and depression. TBI exhibited main effects on outcomes but no interactions with time. Findings indicated that individuals with lower verbal memory performance were less likely to respond to treatment across two sleep interventions. Veterans with TBI displayed greater symptoms but no altered trajectories of treatment response. Together with prior literature, findings suggest that verbal memory functioning may be important to consider in PTSD treatment implementation. Published by Elsevier Ltd.	[Scott, J. Cobb; Harb, Gerlinde; Brownlow, Janeese A.; Greene, Jennifer; Gur, Ruben C.; Ross, Richard J.] Corporal Michael J Crescenz VA Med Ctr, VISN4 Mental Illness Res Educ & Clin Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA; [Scott, J. Cobb; Brownlow, Janeese A.; Greene, Jennifer; Gur, Ruben C.; Ross, Richard J.] Univ Penn, Perelman Sch Med, Dept Psychiat, 3400 Spruce St,10 Gates, Philadelphia, PA 19104 USA		Scott, JC (corresponding author), Corporal Michael J Crescenz VA Med Ctr, MIRECC 116, 3900 Woodland Ave, Philadelphia, PA 19104 USA.	scottl@upenn.edu	Gur, Ruben/K-1999-2019	Gur, Ruben/0000-0002-9657-1996; Scott, J. Cobb/0000-0001-6538-9043	Department of Defense (DOD) CDMRP Award [W81XWH-08-2-0104, NCT00691626]; Department of Veterans Affairs Career Development AwardUS Department of Veterans Affairs [IK2CX000772]	This work was supported by a Department of Defense (DOD) CDMRP Award (W81XWH-08-2-0104, Clinical trial #NCT00691626) to Dr. Ross, and a Department of Veterans Affairs Career Development Award (IK2CX000772) to Dr. Scott. The authors also wish to thank Dr. Warren Bilker for statistical consultation. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors declare no conflicts of interest.	Almasy L, 2008, AM J PSYCHIAT, V165, P1185, DOI 10.1176/appi.ajp.2008.07121869; American Psychiatric Association, 2000, DIAGN STAT MAN TEXT; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; BELICKI K, 1992, J ABNORM PSYCHOL, V101, P592, DOI 10.1037/0021-843X.101.3.592; Belicki K., 1992, DREAMING, V2, P143, DOI [DOI 10.1037/H0094355, 10.1037/h0094355]; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Breslau N, 2006, ARCH GEN PSYCHIAT, V63, P1238, DOI 10.1001/archpsyc.63.11.1238; Brewin CR, 2007, MEMORY, V15, P227, DOI 10.1080/09658210701256423; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Brewin CR, 2014, PSYCHOL BULL, V140, P69, DOI 10.1037/a0033722; Brewin CR, 2005, J BEHAV THER EXP PSY, V36, P61, DOI 10.1016/j.jbtep.2004.11.006; Brownlow JA, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0587-8; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; BUYSSE DJ, 1991, SLEEP, V14, P331; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Cohen JD, 1996, PHILOS T R SOC B, V351, P1515, DOI 10.1098/rstb.1996.0138; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; Davis JJ, 2013, REHABIL PSYCHOL, V58, P36, DOI 10.1037/a0031525; Delis D.C., 2000, CALIFORNIA VERBAL LE; DIKMEN S, 2009, NEUROPSYCHOLOGICAL A, P597; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Etkin A, 2015, J CLIN PSYCHIAT, V76, pE1035, DOI 10.4088/JCP.14com09752; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Forbes D, 2010, J TRAUMA STRESS, V23, P537, DOI 10.1002/jts.20565; Gehrman P, 2013, SLEEP, V36, P1009, DOI 10.5665/sleep.2798; Geuze E, 2009, DEPRESS ANXIETY, V26, P7, DOI 10.1002/da.20476; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Goldman-Mellor S, 2015, SLEEP, V38, P623, DOI 10.5665/sleep.4584; Gur RC, 2001, NEUROPSYCHOPHARMACOL, V25, P766, DOI 10.1016/S0893-133X(01)00278-0; Gur RC, 2010, J NEUROSCI METH, V187, P254, DOI 10.1016/j.jneumeth.2009.11.017; Gutner CA, 2013, BEHAV RES THER, V51, P817, DOI 10.1016/j.brat.2013.09.008; Haagen JFG, 2015, CLIN PSYCHOL REV, V40, P184, DOI 10.1016/j.cpr.2015.06.008; Harb GC, 2013, J TRAUMA STRESS, V26, P570, DOI 10.1002/jts.21854; Harvey AG, 2014, PERSPECT PSYCHOL SCI, V9, P161, DOI 10.1177/1745691614521781; Jak AJ, 2015, CONTEMP CLIN TRIALS, V45, P210, DOI 10.1016/j.cct.2015.10.009; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kiluk BD, 2011, DRUG ALCOHOL DEPEN, V114, P169, DOI 10.1016/j.drugalcdep.2010.09.019; Koenen KC, 2001, BRAIN COGNITION, V45, P64, DOI 10.1006/brcg.2000.1256; Krakow B, 2001, JAMA-J AM MED ASSOC, V286, P537, DOI 10.1001/jama.286.5.537; Krakow B, 2002, J ANXIETY DISORD, V16, P175, DOI 10.1016/S0887-6185(02)00093-2; Krakow Barry, 2006, Behav Sleep Med, V4, P45, DOI 10.1207/s15402010bsm0401_4; Lane RD, 2015, BEHAV BRAIN SCI, V38, DOI 10.1017/S0140525X14000041; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Manber R., 2014, COGNITIVE BEHAV THER; Martinez M.P., 2005, SLEEP HYPNOSIS, V7, P29, DOI DOI 10.1037/T02025-000; McNally RJ, 2006, TRENDS COGN SCI, V10, P271, DOI 10.1016/j.tics.2006.04.007; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Moore TM, 2015, NEUROPSYCHOLOGY, V29, P235, DOI 10.1037/neu0000093; National Collaborating Centre for Mental Health (UK), 2005, POSTTR STRESS DIS MA; National Institute on Alcohol Abuse and Alcoholism, 2010, RETH DRINK ALC YOUR; Nijdam MJ, 2015, J CLIN PSYCHIAT, V76, pE1023, DOI 10.4088/JCP.14m09438; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Pascual-Leone A, 2015, BEHAV BRAIN SCI, V38, DOI 10.1017/S0140525X14000387; Patkar AA, 2004, J ADDICT DIS, V23, P109, DOI 10.1300/J069v23n02_08; Roalf DR, 2014, NEUROPSYCHOLOGY, V28, P161, DOI 10.1037/neu0000011; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Satterthwaite TD, 2013, J NEUROSCI, V33, P16249, DOI 10.1523/JNEUROSCI.2345-13.2013; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; SMITH DE, 1991, ADDICT BEHAV, V16, P265, DOI 10.1016/0306-4603(91)90019-E; Swagerman SC, 2016, NEUROPSYCHOLOGY, V30, P53, DOI 10.1037/neu0000248; Teichner G, 2002, ADDICT BEHAV, V27, P751, DOI 10.1016/S0306-4603(01)00207-6; Teichner G, 2001, INT J NEUROSCI, V106, P253, DOI 10.3109/00207450109149753; Thomas ML, 2013, J CLIN EXP NEUROPSYC, V35, P225, DOI 10.1080/13803395.2012.762974; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Vermetten E, 2003, BIOL PSYCHIAT, V54, P693, DOI 10.1016/S0006-3223(03)00634-6; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wild J, 2008, BRIT J PSYCHIAT, V193, P254, DOI 10.1192/bjp.bp.107.045922; Wolf GK, 2015, J TRAUMA STRESS, V28, P339, DOI 10.1002/jts.22029; Wolf GK, 2012, J HEAD TRAUMA REHAB, V27, P26, DOI 10.1097/HTR.0b013e31823cd01f; Wrocklage K. M., 2016, J INT NEUROPSYCH SOC, V22, P1; Yehuda R, 2004, BIOL PSYCHIAT, V55, P291, DOI 10.1016/S0006-3223(03)00641-3	77	25	25	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0005-7967	1873-622X		BEHAV RES THER	Behav. Res. Ther.	APR	2017	91						24	32		10.1016/j.brat.2017.01.004			9	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	EP0JC	WOS:000397072600003	28110112	Bronze			2022-02-06	
J	Fountain, DM; Kolias, AG; Lecky, FE; Bouamra, O; Lawrence, T; Adams, H; Bond, SJ; Hutchinson, PJ				Fountain, Daniel M.; Kolias, Angelos G.; Lecky, Fiona E.; Bouamra, Omar; Lawrence, Thomas; Adams, Hadie; Bond, Simon J.; Hutchinson, Peter J.			Survival Trends After Surgery for Acute Subdural Hematoma in Adults Over a 20-year Period	ANNALS OF SURGERY			English	Article						craniotomy; neurosurgery; trauma; traumatic brain injury	MULTIPLE IMPUTATION; HEAD-INJURY; TRAUMA CARE; MORTALITY; ENGLAND; TIME; REDUCTION; OUTCOMES; WALES	Objective: We sought to determine 30-day survival trends and prognostic factors following surgery for acute subdural hematomas (ASDHs) in England and Wales over a 20-year period. Summary of Background Data: ASDHs are still considered the most lethal type of traumatic brain injury. It remains unclear whether the adjusted odds of survival have improved significantly over time. Methods: Using the Trauma Audit and Research Network (TARN) database, we analyzed ASDH cases in the adult population (> 16 yrs) treated surgically between 1994 and 2013. Two thousand four hundred ninety-eight eligible cases were identified. Univariable and multiple logistic regression analyses were performed, using multiple imputation for missing data. Results: The cohort was 74% male with a median age of 48.9 years. Over half of patients were comatose at presentation (53%). Mechanism of injury was due to a fall (<2 m 34%, > 2 m 24%), road traffic collision (25%), and other (17%). Thirty-six per cent of patients presented with polytrauma. Gross survival increased from 59% in 1994 to 1998 to 73% in 2009 to 2013. Under multivariable analysis, variables independently associated with survival were year of injury, Glasgow Coma Scale, Injury Severity Score, age, and pupil reactivity. The time interval from injury to craniotomy and direct admission to a neurosurgical unit were not found to be significant prognostic factors. Conclusions: A significant improvement in survival over the last 20 years was observed after controlling for multiple prognostic factors. Prospective trials and cohort studies are expected to elucidate the distribution of functional outcome in survivors.	[Fountain, Daniel M.; Kolias, Angelos G.; Adams, Hadie; Hutchinson, Peter J.] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Fountain, Daniel M.; Kolias, Angelos G.; Adams, Hadie; Hutchinson, Peter J.] Univ Cambridge, Cambridge, England; [Lecky, Fiona E.; Bouamra, Omar; Lawrence, Thomas] Univ Manchester, Trauma Audit & Res Network, Salford, Lancs, England; [Bond, Simon J.] Cambridge Univ Hosp NHS Fdn Trust, Cambridge Clin Trials Unit, Cambridge, England; [Bond, Simon J.] Univ Cambridge, Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England; [Lecky, Fiona E.] Univ Sheffield, Sch Hlth & Related Res, Hlth Serv Res, Emergency Med Res Sheffield EMRiS, Sheffield, S Yorkshire, England		Kolias, AG (corresponding author), Univ Cambridge, Div Neurosurg, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	angeloskolias@gmail.com	Bond, Simon/AAB-9077-2020	Bond, Simon/0000-0003-2528-1040; bouamra, omar/0000-0002-3155-4634; Lawrence, Thomas/0000-0003-3648-7634; Fountain, Daniel/0000-0001-6227-9930; Kolias, Angelos/0000-0003-3992-0587	Royal College of Surgeons of England Research Fellowship; National Institute for Health Research (NIHR) Academic Clinical FellowshipNational Institute for Health Research (NIHR); Raymond and Beverly Sackler Studentship; NIHR Research Professorship; NIHR Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); National Institute for Health ResearchNational Institute for Health Research (NIHR) [12/35/57, 13/15/02, NIHR-RP-R3-12-013] Funding Source: researchfish	AGK is supported by a Royal College of Surgeons of England Research Fellowship, a National Institute for Health Research (NIHR) Academic Clinical Fellowship, and a Raymond and Beverly Sackler Studentship. PJH is supported by a NIHR Research Professorship and the NIHR Cambridge Biomedical Research Centre.	Altman DG, 2014, BMJ-BRIT MED J, V332, P16; Arifin MZ, 2013, J NEUROSURG SCI, V57, P277; Bullock AR, 2006, NEUROSURGERY, V58, pVI; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Fuller G, 2011, BRIT J NEUROSURG, V25, P414, DOI 10.3109/02688697.2011.570882; Harrell FE Jr, 2017, REGRESSION MODELING; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Heraud-Bousquet V, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-73; Hutchinson PJ, 2014, BIOMED CENTRAL; Kalanithi P, 2011, J NEUROSURG, V115, P1013, DOI 10.3171/2011.6.JNS101989; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; Lecky FE, 2002, EMERG MED J, V19, P520, DOI 10.1136/emj.19.6.520; National Institute for Health and Care Excellence, 2014, HEAD INJ TRIAG ASS I; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; R Development Core Team, 2008, R LANG ENV STAT COMP; Raj R, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-67; *ROYAL COLL SURG E, 1999, REP WORK PART MAN PA; Rubin D.B., 1987, MULTIPLE IMPUTATION; Ruff LM, 2013, BRIT J NEUROSURG, V27, P19, DOI 10.3109/02688697.2012.709555; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Sergides IG, 2006, BRIT J NEUROSURG, V20, P301, DOI 10.1080/02688690600999976; TARN, 2006, TRAUM AUD RES NETW O; Tien HCN, 2011, ANN SURG, V253, P1178, DOI 10.1097/SLA.0b013e318217e339; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R; Walcott BP, 2014, J CLIN NEUROSCI, V21, P2107, DOI 10.1016/j.jocn.2014.05.016; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wilson MH, 2014, INT J CLIN PRACT, V68, P5, DOI 10.1111/ijcp.12246; YATES DW, 1990, BRIT MED J, V301, P1090, DOI 10.1136/bmj.301.6760.1090	34	25	25	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	MAR	2017	265	3					590	596		10.1097/SLA.0000000000001682			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	EL1ON	WOS:000394389800026	27172128	Green Accepted, Green Published			2022-02-06	
J	Fuller, GW; Kemp, SPT; Raftery, M				Fuller, G.; Kemp, S.; Raftery, M.			The accuracy and reproducibility of video assessment in the pitch-side management of concussion in elite rugby	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain concussion; Rugby; Video analysis; Reproducibility of results; Sensitivity and specificity	INTERRATER RELIABILITY; AGREEMENT; KAPPA	Objectives: To investigate the accuracy and reliability of side-line video review of head impact events to aid identification of concussion in elite sport. Design: Diagnostic accuracy and inter-rater agreement study. Methods: Immediate care, match day and team doctors involved in the 2015 Rugby Union World Cup viewed 20 video clips showing broadcaster's footage of head impact events occurring during elite Rugby matches. Subjects subsequently recorded whether any criteria warranting permanent removal from play or medical room head injury assessment were present. The accuracy of these ratings were compared to consensus expert opinion by calculating mean sensitivity and specificity across raters. The reproducibility of doctor's decisions was additionally assessed using raw agreement and Gwets AC1 chance corrected agreement coefficient. Results: Forty rugby medicine doctors were included in the study. Compared to the expert reference standard overall sensitivity and specificity of doctors decisions were 77.5% (95% Cl 73.1-81.5%) and 53.3% (95% CI 48.2-58.2%) respectively. Overall there was raw agreement of 67.8% (95% CI 57.9-77.7%) between doctors across all video clips. Chance corrected Gwets AC1 agreement coefficient was 0.39 (95% CI 0.17-0.62), indicating fair agreement. Conclusions: Rugby World Cup doctors' demonstrated moderate accuracy and fair reproducibility in head injury event decision making when assessing video clips of head impact events. The use of real-time video may improve the identification, decision making and management of concussion in elite sports. (C) 2016 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Fuller, G.] Univ Sheffield, Emergency Med Res Sheffield Grp, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England; [Kemp, S.] Rugby Football Union, Rugby House, Twickenham, England; [Raftery, M.] World Rugby, World Rugby House, Dublin, Ireland		Fuller, GW (corresponding author), Univ Sheffield, Emergency Med Res Sheffield Grp, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England.	g.fuller@sheffield.ac.uk		Kemp, Simon/0000-0002-3250-2713; Fuller, Gordon Ward/0000-0001-8532-3500	World Rugby; National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish	The authors would like to match day doctors, team doctors and intermediate care doctors participating in the 2015 Rugby World Cup for their assistance with the study. Funding was received by World Rugby.	Brolinson P Gunnar, 2014, Clin J Sport Med, V24, P89, DOI 10.1097/JSM.0000000000000062; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061865; Feiss JL, 2003, STAT METHODS RATES P; Fuller GW, 2015, BRIT J SPORT MED, V49, P529, DOI 10.1136/bjsports-2014-093498; Gardner AJ, 2016, INT J SPORTS MED, V37, P267, DOI 10.1055/s-0035-1565203; Gwet K, 2001, HDB INTERTATER RELIA; Gwet K., 2002, STAT METHODS INTERRA, V2, P9; Helmy A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5748; Kottner J, 2011, J CLIN EPIDEMIOL, V64, P96, DOI 10.1016/j.jclinepi.2010.03.002; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Makdissi M, 2016, J SCI MED SPORT; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Moore IS, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115596194; NFL Head NaSC, 2015, NFL HEAD NECK SPIN C; Rugby W, 2016, MED PROTOCOLS MATCH; Rugby W, 2016, CONCUSSION MANAGEMEN; Rutjes A W S, 2007, Health Technol Assess, V11, pix; Wongpakaran N, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-61	18	25	25	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAR	2017	20	3					246	249		10.1016/j.jsams.2016.07.008			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	EQ8IF	WOS:000398327400007	27544658	Green Accepted			2022-02-06	
J	Massenburg, BB; Veetil, DK; Raykar, NP; Agrawal, A; Roy, N; Gerdin, M				Massenburg, Benjamin B.; Veetil, Deepa K.; Raykar, Nakul P.; Agrawal, Amit; Roy, Nobhojit; Gerdin, Martin			A systematic review of quantitative research on traumatic brain injury in India	NEUROLOGY INDIA			English	Article						India; neurotrauma; TBI; traumatic Brain Injury	MODERATE HEAD-INJURY; GLASGOW COMA SCALE; OUTCOME PREDICTION MODEL; PLACEBO-CONTROLLED TRIAL; DECOMPRESSIVE CRANIECTOMY; INTENSIVE-CARE; INTRACEREBRAL HEMORRHAGE; OXIDATIVE CHANGES; CLINICAL ARTICLE; MILD	Introduction: Over a quarter of the world's trauma deaths occur in India, with traumatic brain injury (TBI) as the leading cause of death and disability within trauma. With little known about TBI in India, we set out to do a systematic review to characterize the quantitative literature on TBI in India. Materials and Methods: The following databases were searched from their inception to December 31, 2015: PubMed, Cochrane, Web of Science, and the World Health Organization's Global Health Library, using the keywords: neurotrauma, brain injury, traumatic brain injury, TBI, head injury, and India. Articles were screened by two independent reviewers, with disagreements arbitrated by discussion or a third reviewer. Results: A total of 72 manuscripts were included, encapsulating 19962 patients over 27 years in 14 states of India. The sample-size-weighted mean age was 31.3 years, male-to-female ratio was 3.8: 1, and sample-size-weighted mean in-hospital mortality was 24.6%. Age and mortality did not change significantly over time. Road traffic accidents (55.5%) and falls (29.2%) were the most commonly reported mechanisms of injury for TBI in India. The mean quality of reporting on TBI in India was 65.7%, according to the appropriate EQUATOR guideline score. Conclusion: The quality of reporting of quantitative studies published on TBI in India is low, and future methodological excellence should be ensured. The demographics and outcomes identified can be used as an epidemiological baseline for future research on TBI in India. Future research can build upon this platform to develop and refine context-appropriate policy recommendations and treatment protocols.	[Massenburg, Benjamin B.] Icahn Sch Med Mt Sinai, Dept Med Educ, New York, NY 10029 USA; [Massenburg, Benjamin B.; Raykar, Nakul P.] Harvard Med Sch, Program Global Surg & Social Change, Boston, MA USA; [Massenburg, Benjamin B.; Raykar, Nakul P.] Boston Childrens Hosp, Dept Plast & Oral Surg, Boston, MA USA; [Veetil, Deepa K.; Roy, Nobhojit] Bhabha Atom Res Ctr Hosp, Dept Surg, Mumbai, Maharashtra, India; [Raykar, Nakul P.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; [Agrawal, Amit] Narayana Med Coll Hosp, Dept Surg, Nellore, Andhra Pradesh, India; [Roy, Nobhojit] Tata Inst Social Sci, Sch Habitat, Mumbai, Maharashtra, India; [Roy, Nobhojit; Gerdin, Martin] Karolinska Inst, Dept Publ Hlth Sci, Hlth Syst & Policy, Stockholm, Sweden		Massenburg, BB (corresponding author), 50 E 98th St, New York, NY 10029 USA.	Ben.massenburg@mssm.edu	Agrawal, Amit/C-1511-2011; Warnberg, Martin Gerdin/D-7482-2019; Massenburg, Benjamin B./AAB-9349-2019	Agrawal, Amit/0000-0002-3287-5448; Warnberg, Martin Gerdin/0000-0001-6069-4794; Massenburg, Benjamin B./0000-0002-8570-5178; Roy, Nobhojit/0000-0003-2022-7416			Abraham AP, 2014, NEUROL INDIA, V62, P285, DOI 10.4103/0028-3886.136929; Agarwal Ajay, 1999, Indian Journal of Ophthalmology, V47, P233; Agrawal A, 2012, INDIAN J NEUROTRAUM, V9, P87, DOI 10.1016/j.ijnt.2012.11.001; Agrawal D, 2011, NEUROL INDIA, V59, P91, DOI 10.4103/0028-3886.86551; Agrawal M, 2014, BRAIN INJURY, V28, P292, DOI 10.3109/02699052.2013.865266; Ahmad FU, 2006, NEUROL INDIA, V54, P73; Ahmed M, 2015, BRIT J NEUROSURG, V29, P544, DOI 10.3109/02688697.2015.1016892; Amin AP, 2000, SURGERY, V127, P245, DOI 10.1067/msy.2000.104296; Bhattacharjee S, 2014, J NEUROSURG ANESTH, V26, P313, DOI 10.1097/ANA.0000000000000057; Bhole AM, 2007, PAK J MED SCI, V23, P724; Brooke BS, 2009, ANN SURG, V249, P162, DOI 10.1097/SLA.0b013e31819291f9; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Dalvie S S, 1993, J Postgrad Med, V39, P5; Deepika A, 2013, J HEAD TRAUMA REHAB, V28, P442, DOI 10.1097/HTR.0b013e31825e19e5; Dhandapani M, 2014, J CLIN NURS, V23, P1114, DOI 10.1111/jocn.12396; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Dhandapani S, 2015, WORLD NEUROSURG, V84, P1244, DOI 10.1016/j.wneu.2015.05.058; Dhandapani S, 2014, J CLIN NEUROSCI, V21, P745, DOI 10.1016/j.jocn.2013.07.038; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; Faul M, 2010, TRAUMATIC BRAIN INJU; Francis R, 2015, BRIT J NEUROSURG, V29, P655, DOI 10.3109/02688697.2015.1054349; GARDNER JW, 1960, SCIENCE, V131, P633, DOI 10.1126/science.131.3401.633; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Goel RS, 2008, INJURY, V39, P519, DOI 10.1016/j.injury.2007.09.029; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Harish G, 2015, J NEUROCHEM, V134, P156, DOI 10.1111/jnc.13082; Hopewell S, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4178; Horton R, 2012, LANCET, V380, P2053, DOI DOI 10.1016/S0140-6736(12)62133-3.PUBMED; Hunskaar S, 2009, BMC MED EDUC, V9, DOI 10.1186/1472-6920-9-43; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jain A, 2014, ASIAN J PSYCHIATR, V8, P99, DOI 10.1016/j.ajp.2013.12.017; Jain S, 2008, INJURY, V39, P598, DOI 10.1016/j.injury.2007.06.003; Kannan S, 1999, INTENS CARE MED, V25, P855, DOI 10.1007/s001340050965; Kaushal S., 2000, Indian Journal of Pharmacology, V32, P246; Khan A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132229; Kumar R, 2003, MAGN RESON IMAGING, V21, P893, DOI 10.1016/S0730-725X(03)00189-9; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Menon Anand, 2008, J Forensic Leg Med, V15, P75, DOI 10.1016/j.jflm.2007.06.001; Misra UK, 2003, J NEUROL SCI, V208, P25, DOI 10.1016/S0022-510X(02)00415-X; Mohanty S, 2005, MED SCI LAW, V45, P244, DOI 10.1258/rsmmsl.45.3.244; Mukherjee K, 2000, NEUROL INDIA, V48, P43; Munjal SK, 2010, J TRAUMA, V68, P13, DOI 10.1097/TA.0b013e3181c9f274; Mwita CC, 2016, J NEUROSCI RURAL PRA, V7, P97, DOI 10.4103/0976-3147.165390; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nayak C, 2008, NEUROL RES, V30, P461, DOI 10.1179/016164107X251790; Nayak C, 2007, CLIN CHEM LAB MED, V45, P629, DOI 10.1515/CCLM.2007.123; Nayak CD, 2008, NEUROL INDIA, V56, P31, DOI 10.4103/0028-3886.39309; Ng-Kamstra JS, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2015-000011; Norton R, 2013, NEW ENGL J MED, V368, P1723, DOI 10.1056/NEJMra1109343; Ozcakir A, 2004, TRAUMACARE, V14, P135; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perel P, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16130; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Pillai SV, 2003, NEUROL INDIA, V51, P361; Pillai SV, 2003, NEUROL INDIA, V51, P345; Prasad GL, 2015, BRAIN INJURY, V29, P1717, DOI 10.3109/02699052.2015.1075146; Prasanna KL, 2015, BRAIN INJURY, V29, P336, DOI 10.3109/02699052.2014.955882; Pruthi N, 2012, INDIAN J MED RES, V136, P1039; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Puvanachandra P, 2009, PAK J NEUROL SCI, V4, P27; Puvanachandra P, 2008, SALUD PUBLICA MEXICO, V50, pS3; Ramesh VG, 2008, J CLIN NEUROSCI, V15, P1110, DOI 10.1016/j.jocn.2007.08.033; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Ratan SK, 2001, CLIN PEDIATR, V40, P375, DOI 10.1177/000992280104000702; Ray S, 2016, CURRENT MED RES PRAC, V6, P49, DOI DOI 10.1016/J.CMRP.2016.04.002; Reddy RP, 2014, INDIAN J PSYCHOL MED, V36, P40, DOI 10.4103/0253-7176.127246; de Almeida CER, 2016, WORLD NEUROSURG, V87, P540, DOI 10.1016/j.wneu.2015.10.020; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Saika A, 2015, ACTA NEUROCHIR, V157, P1323, DOI 10.1007/s00701-015-2469-6; Salunke P, 2015, J NEUROSURG, V122, P602, DOI 10.3171/2014.10.JNS14780; Santhanam R, 2007, NEUROL INDIA, V55, P349; Shanmukhi S, 2003, NEUROL INDIA, V51, P518; Sharma B, 2014, INT OPHTHALMOL, V34, P893, DOI 10.1007/s10792-014-9898-8; Singh AK, 2014, NEUROL INDIA, V62, P169, DOI 10.4103/0028-3886.132364; Singh M, 2006, NEUROL INDIA, V54, P78; Singh P, 2003, NEUROL INDIA, V51, P215; Singh SB, 2013, RES J PHARM BIOL CHE, V4, P420; Sinha S, 2015, NEUROL INDIA, V63, P175, DOI 10.4103/0028-3886.156277; Sinha S, 2013, NEUROL INDIA, V61, P501, DOI 10.4103/0028-3886.121920; Sitsapesan HA, 2013, WORLD NEUROSURG, V79, P568, DOI 10.1016/j.wneu.2012.09.018; Srinivasan US, 2006, NEUROL INDIA, V54, P28, DOI 10.4103/0028-3886.24698; Suresh HS, 2003, NEUROL INDIA, V51, P16; Tabish A, 2006, INJURY, V37, P410, DOI 10.1016/j.injury.2006.01.039; Tandon A, 2009, ACTA NEUROCHIR, V151, P1411, DOI 10.1007/s00701-009-0444-9; TANDON DA, 1994, CLIN OTOLARYNGOL, V19, P98, DOI 10.1111/j.1365-2273.1994.tb01190.x; Thapa A, 2010, SEIZURE-EUR J EPILEP, V19, P211, DOI 10.1016/j.seizure.2010.02.004; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Tran TM, 2015, WORLD NEUROSURG, V83, P269, DOI 10.1016/j.wneu.2014.12.028; Tripathi M, 2014, NEUROL INDIA, V62, P610, DOI 10.4103/0028-3886.149382; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wani AA, 2011, J NEUROSURG-PEDIATR, V7, P276, DOI 10.3171/2010.12.PEDS10241; World Bank, RUR POP TOT POP; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109; Yousuf A, 2015, J MOL NEUROSCI, V56, P597, DOI 10.1007/s12031-015-0554-1; Yuan Q, 2012, INJURY, V43, P2094, DOI 10.1016/j.injury.2012.03.028	97	25	26	0	11	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	MAR-APR	2017	65	2					305	314		10.4103/neuroindia.NI_719_16			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	ER2BH	WOS:000398598400019	28290394				2022-02-06	
J	Speck, V; Schlereth, T; Birklein, F; Maihofner, C				Speck, V.; Schlereth, T.; Birklein, F.; Maihoefner, C.			Increased prevalence of posttraumatic stress disorder in CRPS	EUROPEAN JOURNAL OF PAIN			English	Article							REGIONAL PAIN SYNDROME; SYNDROME TYPE-I; REFLEX SYMPATHETIC DYSTROPHY; SYNDROME TYPE-1; PSYCHOLOGICAL DYSFUNCTION; SUBARACHNOID HEMORRHAGE; LONGITUDINAL COURSE; DIAGNOSTIC SCALE; BRAIN-INJURY; RISK-FACTORS	Background: Although specific psychological disorders in complex regional pain syndrome (CRPS) have not been identified, studies suggest that CRPS patients may have increased rates of traumatic life events. Because these events do not always lead to apparent psychological symptoms, we systematically screened CRPS patients for posttraumatic stress disorder (PTSD) to determine if PTSD could be a risk factor for CRPS. Methods: Consecutive CRPS patients referred to two university hospital centres (University of Erlangen, UMC Mainz) between December 2011 and April 2013 were prospectively examined using a diagnostic PTSD instrument (Post-traumatic Stress Diagnostic Scale (PDS). We also tested maladaptive coping strategies (brief-COPE inventory) and the PDS severity score as predictors for CRPS. Patients with non-CRPS extremity pain and healthy individuals were used as control groups. Results: We collected data from 152 patients with CRPS, 55 control patients and 55 age-and sex-matched healthy individuals. Fifty-eight CRPS patients (38%), six non-CRPS pain patients (10%) and two healthy individuals (4%) met diagnostic criteria for PTSD. Initial PTSD symptom onset was prior to CRPS in 50 CRPS patients (86%) and during the course of CRPS in eight patients. Results of a logistic regression revealed that the PTSD severity score was associated with CRPS (p < 0.0001). Maladaptive coping strategies (p < 0.0001) were related to PTSD. Conclusions: posttraumatic stress disorder (PTSD) is more frequent in patients with CRPS than it is in the general population. Significance: Research has not yet provided support for specific psychological predictors for CRPS.	[Speck, V.; Schlereth, T.; Birklein, F.] Univ Hosp Mainz, Dept Neurol, Mainz, Germany; [Maihoefner, C.] Univ Erlangen Nurnberg, Gen Hosp Furth, Dept Neurol, Erlangen, Germany		Speck, V (corresponding author), Univ Hosp Mainz, Dept Neurol, Mainz, Germany.	verena.speck@unimedizin-mainz.de			German Federal Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF)	Supported by BGW, Mainz and by German Federal Ministry of Education and Research (BMBF, NIVIL-Project/Maihofner).	Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Barkin R L, 1996, Dis Mon, V42, P457, DOI 10.1016/S0011-5029(96)90013-9; Beerthuizen A, 2011, EUR J PAIN, V15, P971, DOI 10.1016/j.ejpain.2011.02.008; Beerthuizen A, 2009, PAIN, V145, P52, DOI 10.1016/j.pain.2009.05.003; BENEDIKT RA, 1986, AM J PSYCHIAT, V143, P908; Bennett GJ, 2003, PAIN, V106, P209, DOI 10.1016/S0304-3959(03)00313-0; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bruehl S, 2006, CLIN J PAIN, V22, P430, DOI 10.1097/01.ajp.0000194282.82002.79; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; Bryant RA, 2007, J CONSULT CLIN PSYCH, V75, P812, DOI 10.1037/0022-006X.75.5.812; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; Ciccone DS, 1997, PAIN, V71, P323, DOI 10.1016/S0304-3959(97)00009-2; COOPER J, 1995, BRIT J PSYCHIAT, V166, P4, DOI 10.1192/bjp.166.1.4; de Jong JR, 2011, J PAIN, V12, P1209, DOI 10.1016/j.jpain.2011.06.010; de Mos M, 2009, PAIN PRACT, V9, P86, DOI 10.1111/j.1533-2500.2009.00262.x; DEGOOD DE, 1993, PAIN, V54, P317, DOI 10.1016/0304-3959(93)90031-J; Dijkstra PU, 2003, CLIN REHABIL, V17, P454, DOI 10.1191/0269215503cr631oa; Dilek B, 2012, RHEUMATOL INT, V32, P915, DOI 10.1007/s00296-010-1714-9; Feliu MH, 2010, CLIN J PAIN, V26, P258, DOI 10.1097/AJP.0b013e3181bff815; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Frettloh J., 2003, PSYCHOL SCHMERZTHERA, P467; Geertzen JHB, 1998, CLIN J PAIN, V14, P143, DOI 10.1097/00002508-199806000-00009; Gil S, 2006, CNS SPECTRUMS, V11, P603, DOI 10.1017/S1092852900013651; Griesel D, 2006, PSYCHOL ASSESSMENT, V18, P262, DOI 10.1037/1040-3590.18.3.262; Hauser W, 2013, PAIN, V154, P1216, DOI 10.1016/j.pain.2013.03.034; Harden RN, 2010, PAIN, V150, P268, DOI 10.1016/j.pain.2010.04.030; Hauffa R, 2011, J NERV MENT DIS, V199, P934, DOI 10.1097/NMD.0b013e3182392c0d; Hutter BO, 1999, ACT NEUR S, V72, P157; Lohnberg JA, 2013, J CLIN PSYCHOL MED S, V20, P247, DOI 10.1007/s10880-012-9322-3; Marinus J, 2013, CLIN J PAIN, V29, P563, DOI 10.1097/AJP.0b013e31826f9a8a; McFarlane AC, 2000, J CLIN PSYCHIAT, V61, P15; Moeller-Bertram T, 2012, NEUROPHARMACOLOGY, V62, P586, DOI 10.1016/j.neuropharm.2011.04.028; Monti DA, 1998, CLIN J PAIN, V14, P295, DOI 10.1097/00002508-199812000-00005; Morasco BJ, 2013, PAIN, V154, P609, DOI 10.1016/j.pain.2013.01.001; Moseley GL, 2014, J PAIN, V15, P16, DOI 10.1016/j.jpain.2013.08.009; Noble AJ, 2008, NEUROSURGERY, V63, P1095, DOI 10.1227/01.NEU.0000327580.91345.78; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Perkonigg A, 2000, ACTA PSYCHIAT SCAND, V101, P46, DOI 10.1034/j.1600-0447.2000.101001046.x; Perkonigg A, 2005, AM J PSYCHIAT, V162, P1320, DOI 10.1176/appi.ajp.162.7.1320; Petrovic P, 2005, NEURON, V46, P957, DOI 10.1016/j.neuron.2005.05.023; Ploghaus A, 2003, TRENDS COGN SCI, V7, P197, DOI 10.1016/S1364-6613(03)00061-5; Puchalski P, 2005, J HAND SURG-BRIT EUR, V30B, P574, DOI 10.1016/j.jhsb.2005.06.023; SCARINCI IC, 1994, AM J MED, V97, P108, DOI 10.1016/0002-9343(94)90020-5; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; van der Laan L, 1999, J PAIN SYMPTOM MANAG, V17, P357, DOI 10.1016/S0885-3924(99)00009-3	46	25	25	0	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	MAR	2017	21	3					466	473		10.1002/ejp.940			8	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Anesthesiology; Neurosciences & Neurology	EK4MS	WOS:000393901600007	27650922				2022-02-06	
J	Teel, EF; Marshall, SW; Shankar, V; McCrea, M; Guskiewicz, KM				Teel, Elizabeth F.; Marshall, Stephen W.; Shankar, Viswanathan; McCrea, Michael; Guskiewicz, Kevin M.			Predicting Recovery Patterns After Sport-Related Concussion	JOURNAL OF ATHLETIC TRAINING			English	Article						traumatic brain injuries; return to play; Standardized Assessment of Concussion; Balance Error Scoring System	PROFESSIONAL FOOTBALL PLAYERS; HIGH-SCHOOL; POSTURAL STABILITY; RECURRENT CONCUSSION; PROLONGED RECOVERY; NCAA CONCUSSION; COLLEGIATE; PERFORMANCE; SYMPTOMS; STATEMENT	Context: Clinicians sometimes treat concussed individuals who have amnesia, loss of consciousness (LOC), a concussion history, or certain symptom types more conservatively, but it is unclear whether recovery patterns differ in individuals with these characteristics. Objective: To determine whether (1) amnesia, LOC, and concussion history influence the acute recovery of symptoms, cognition, and balance; and (2) cognition and balance are influenced by acute symptom type. Design: Cohort study. Setting: Seven sports at 26 colleges and 210 high schools. Patients or Other Participants: A total of 8905 collegiate (n = 1392) and high school (n = 7513) athletes. Main Outcome Measure(s): The Graded Symptom Checklist, Standardized Assessment of Concussion, and Balance Error Scoring System were administered to all athletes during the preseason. To allow us to track recovery patterns, athletes diagnosed with a concussion (n = 375) repeated these assessments immediately after the injury, 3 hours postinjury, 1 day postinjury, and at 2, 3, 5, 7, and 90 days after injury. Results: Athletes who experienced amnesia had markedly greater deficits in and a slower recovery trajectory on measures of symptoms, cognition, and balance. Athletes with 2 or more prior concussions demonstrated poorer balance than those with no previous history. Otherwise, LOC and concussion history largely did not affect symptoms, cognition, or balance. Greater deficits in balance scores were observed in athletes with all symptom types. Regardless of these characteristics, most athletes recovered within 7 to 10 days. Conclusions: Athletes who experienced amnesia had more symptoms and greater deficits in cognition and balance. Symptoms and cognitive or balance deficits were not consistently associated with LOC or concussion history. Acute symptoms had a strong influence on balance scores and, to a lesser extent, on cognition. However, we found no evidence to support more cautious return-to-play decisions for athletes with these characteristics, as group recovery occurred within normal timelines. Our study supports current clinical practice: recommending that athletes be withheld from activity until they are asymptomatic, followed by a graduated return-to-play progression.	[Teel, Elizabeth F.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Sch Med,Dept Allied Hlth Sci, Dept Exercise & Sport Sci & Curriculum Human Move, Chapel Hill, NC USA; [Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Shankar, Viswanathan] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA		Guskiewicz, KM (corresponding author), Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Campus Box 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Viswanathan, Shankar/AAX-5281-2020	Teel, Elizabeth/0000-0002-2846-5884; Viswanathan, Shankar/0000-0003-3349-9090	Centers for Disease Control and Prevention (Atlanta, GA)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; National Operating Committee on Standards for Athletic Equipment (Overland Park, KS); National Collegiate Athletic Association (Indianapolis, IN)	This study was supported in part by grants from the Centers for Disease Control and Prevention (Atlanta, GA), the National Operating Committee on Standards for Athletic Equipment (Overland Park, KS), and the National Collegiate Athletic Association (Indianapolis, IN).	[Anonymous], CONC GUID; Bock S, 2015, CHILD NERV SYST, V31, P2111, DOI 10.1007/s00381-015-2846-8; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Dick RW, 2008, MED SCI SPORT EXER, V40, pS231, DOI 10.1249/01.mss.0000322493.95532.98; Diggle P., 2002, ANAL LONGITUDINAL DA; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kirschen MP, 2014, NEUROLOGY, V83, P352, DOI 10.1212/WNL.0000000000000613; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall Stephen W, 2015, Inj Epidemiol, V2, P13; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Nelson LD, 2016, J ATHL TRAINING, V51, P142, DOI 10.4085/1062-6050-51.4.04; Patel AV, 2007, J ATHL TRAINING, V42, P66; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Plummer P, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00225; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; Yardley L, 2001, J ANXIETY DISORD, V15, P107, DOI 10.1016/S0887-6185(00)00045-1	47	25	25	1	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAR	2017	52	3					288	298		10.4085/1062-6050-52.1.12			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	ES0NE	WOS:000399222500013	28387552	Green Published, Bronze			2022-02-06	
J	Zhang, L; Li, Z; Feng, DX; Shen, HT; Tian, XD; Li, HY; Wang, Z; Chen, G				Zhang, Li; Li, Zhen; Feng, Dongxia; Shen, Haitao; Tian, Xiaodi; Li, Haiying; Wang, Zhong; Chen, Gang			Involvement of Nox2 and Nox4 NADPH oxidases in early brain injury after subarachnoid hemorrhage	FREE RADICAL RESEARCH			English	Article						Subarachnoid hemorrhage; early brain injury; Nox2; Nox4; gp91ds-tat; GKT137831; apoptosis; rat	NAD(P)H OXIDASE; HYPERBARIC-OXYGEN; OXIDATIVE STRESS; ANGIOTENSIN-II; RAT MODEL; INHIBITION; EXPRESSION; BARRIER; STROKE	Oxidative stress is responsible for a poor prognosis of subarachnoid hemorrhage (SAH) patients. Nox2 has been shown to participate in SAH-induced early brain injury (EBI). Nox4 is another major subtype of Nox family widely expressed in central nervous system (CNS). Here, we investigated the role of Nox4 and whether there was a synergistic effect of Nox2 and Nox4 in SAH-induced EBI. Clinical brain biopsies of four patients with traumatic brain injury (TBI) and perihematomal brain tissue from six subjects with SAH were examined. Gp91ds-tat (a specific inhibitor of Nox2), GKT137831 (a specific inhibitor of Nox4), and apocynin (a non-specific Nox inhibitor) were used to test the role of Nox2 and Nox4. The protein levels of Nox2 and Nox4 were elevated in rat neurons and astrocytes at 12h after SAH, and in cultured brain microvascular endothelial cells at 24h after exposure to OxyHb. Similarly, there were higher Nox2 and Nox4 protein levels in perihematomal neurons and astrocytes in SAH patients than that in brain tissue from subjects with TBI. In SAH rat model, gp91ds-tat and GKT137831 could reduce SAH-induced neuronal death and degeneration, whereas apocynin did not induce a more intense neuroprotection. Consistently, in in vitro SAH model, siRNA-mediated silencing of Nox2 and Nox4 suppressed the OxyHb-induced neuronal apoptosis, whereas Nox2 and Nox4 co-knockdown also did not show a remarkable overlay effect. In conclusion, Nox4 should contribute to the pathological processes in SAH-induced EBI, and there was not an overlay effect of Nox2 inhibition and Nox4 inhibition on preventing SAH-induced EBI.	[Zhang, Li; Shen, Haitao; Tian, Xiaodi; Li, Haiying; Wang, Zhong; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China; [Zhang, Li; Shen, Haitao; Tian, Xiaodi; Li, Haiying; Wang, Zhong; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Brain & Nerve Res Lab, Suzhou, Jiangsu, Peoples R China; [Li, Zhen] Jingjiang Peoples Hosp, Dept Neurosurg, Jingjiang, Jiangsu, Peoples R China; [Feng, Dongxia] Scott & White Clin Temple, Temple, TX USA		Wang, Z; Chen, G (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China.	lhy1015@suda.edu.cn; nju_neurosurgery@163.com			Suzhou Key Medical Center [Szzx201501]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571115, 81422013, 81471196]; Scientific Department of Jiangsu Province [BL2014045]; Suzhou Government [SZS201413, KJXW2015041, LCZX201601, SYS201608]; Zhangjiagang Government [ZKS1511]; Jiangsu Province [16KJB320008]	This work was supported by Suzhou Key Medical Center [Szzx201501], grants from the National Natural Science Foundation of China [No. 81571115, 81422013, and 81471196], Scientific Department of Jiangsu Province [No. BL2014045], Suzhou Government [No. SZS201413, KJXW2015041, LCZX201601, and SYS201608], Zhangjiagang Government [No. ZKS1511] Jiangsu Province [No. 16KJB320008].	Brown DI, 2009, FREE RADICAL BIO MED, V47, P1239, DOI 10.1016/j.freeradbiomed.2009.07.023; Byrne JA, 2003, CIRC RES, V93, P802, DOI 10.1161/01.RES.0000099504.30207.F5; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Cairns B, 2012, CURR DRUG TARGETS, V13, P199, DOI 10.2174/138945012799201676; Cetas JS, 2015, TRANSL STROKE RES, V6, P140, DOI 10.1007/s12975-014-0378-2; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Chen Y, 2017, MOL NEUROBIOL, V54, P392, DOI 10.1007/s12035-015-9629-9; Cheng CJ, 2015, TRANSL STROKE RES, V6, P446, DOI 10.1007/s12975-015-0426-6; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cui YH, 2016, MOL NEUROBIOL, V53, P3646, DOI 10.1007/s12035-015-9304-1; Dang BQ, 2015, CRIT CARE MED, V43, pE369, DOI 10.1097/CCM.0000000000001146; Deliyanti D, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0363-z; DiNapoli VA, 2008, NEUROBIOL AGING, V29, P753, DOI 10.1016/j.neurobiolaging.2006.12.007; Ersahin M, 2011, ACTA NEUROCHIR, V153, P333, DOI 10.1007/s00701-010-0853-9; Etminan N, 2015, TRANSL STROKE RES, V6, P167, DOI 10.1007/s12975-015-0398-6; Guresir E, 2015, TRANSL STROKE RES, V6, P242, DOI 10.1007/s12975-015-0392-z; Hasegawa Y, 2015, TRANSL STROKE RES, V6, P458, DOI 10.1007/s12975-015-0423-9; Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28; Huang W, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8263926; Kusaka I, 2004, AM J PHYSIOL-HEART C, V286, pH2442, DOI 10.1152/ajpheart.01169.2003; Lapchak PA, 2017, TRANSL STROKE RES, V8, P307, DOI 10.1007/s12975-016-0518-y; Li HY, 2014, TRANSL STROKE RES, V5, P618, DOI 10.1007/s12975-014-0354-x; Liu SM, 2007, CAN J NEUROL SCI, V34, P356, DOI 10.1017/S031716710000682X; Lu XH, 2010, AM J PHYSIOL-LUNG C, V299, pL559, DOI 10.1152/ajplung.00090.2010; Ostrowski RP, 2006, ACTA NEUROCHIR SUPPL, V96, P188; Ostrowski RP, 2006, STROKE, V37, P1314, DOI 10.1161/01.STR.0000217310.88450.c3; Pang JW, 2017, TRANSL STROKE RES, V8, P257, DOI 10.1007/s12975-016-0507-1; Ray R, 2011, ARTERIOSCL THROM VAS, V31, P1368, DOI 10.1161/ATVBAHA.110.219238; Raz L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027039; Reinehr R, 2007, GLIA, V55, P758, DOI 10.1002/glia.20504; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Serrano F, 2003, BRAIN RES, V988, P193, DOI 10.1016/S0006-8993(03)03364-X; Shen HT, 2015, STROKE, V46, P2607, DOI 10.1161/STROKEAHA.115.009729; Shin HK, 2002, J CEREBR BLOOD F MET, V22, P869, DOI 10.1097/00004647-200207000-00012; Song JP, 2015, TRANSL STROKE RES, V6, P290, DOI 10.1007/s12975-015-0396-8; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Suzuki H, 2015, TRANSL STROKE RES, V6, P1, DOI 10.1007/s12975-014-0380-8; Tong X, 2009, FREE RADICAL BIO MED, V47, P1578, DOI 10.1016/j.freeradbiomed.2009.08.026; Vallet P, 2005, NEUROSCIENCE, V132, P233, DOI 10.1016/j.neuroscience.2004.12.038; Wang Y, 2015, MOL NEUROBIOL, V52, P64, DOI 10.1007/s12035-014-8846-y; Won SJ, 2011, ANN NEUROL, V70, P583, DOI 10.1002/ana.22538; Yang Y, 2017, CURR DRUG DELIV, V14, P832, DOI 10.2174/1567201813666161025115531; ZHANG L, 2016, OXID MED CELL LONGEV, V2016, P1, DOI [10.1155/2016/5026984, DOI 10.1155/2016/7954154]; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	44	25	26	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-5762	1029-2470		FREE RADICAL RES	Free Radic. Res.	MAR	2017	51	3					316	328		10.1080/10715762.2017.1311015			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ES7NM	WOS:000399736900007	28330417				2022-02-06	
J	Zhang, YL; Zhang, ZG; Chopp, M; Meng, YL; Zhang, L; Mahmood, A; Xiong, Y				Zhang, Yanlu; Zhang, Zheng Gang; Chopp, Michael; Meng, Yuling; Zhang, Li; Mahmood, Asim; Xiong, Ye			Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline	JOURNAL OF NEUROSURGERY			English	Article						angiogenesis; N-acetyl-seryl-aspartyl-lysyl-proline; functional outcome; controlled cortical impact; neurogenesis; traumatic brain injury	ANGIOTENSIN-CONVERTING ENZYME; FIBRINOGEN SIGNAL-TRANSDUCTION; CENTRAL-NERVOUS-SYSTEM; ANGIOGENESIS IN-VITRO; MARROW STROMAL CELLS; STEM-CELL; ALZHEIMERS-DISEASE; HYPERTENSIVE-RATS; SPATIAL MEMORY; ADULT BRAIN	OBJECTIVE The authors' previous studies have suggested that thymosin beta 4 (T beta 4), a major actin-sequestering protein, improves functional recovery after neural injury. N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an active peptide fragment of T beta 4. Its effect as a treatment of traumatic brain injury (TBI) has not been investigated. Thus, this study was designed to determine whether AcSDKP treatment improves functional recovery in rats after TBI. METHODS Young adult male Wistar rats were randomly divided into the following groups: 1) sham group (no injury); 2) TBI + vehicle group (0.01 N acetic acid); and 3) TBI + AcSDKP (0.8 mg/kg/day). TBI was induced by controlled cortical impact over the left parietal cortex. AcSDKP or vehicle was administered subcutaneously starting 1 hour postinjury and continuously for 3 days using an osmotic minipump. Sensorimotor function and spatial learning were assessed using a modified Neurological Severity Score and Morris water maze tests, respectively. Some of the animals were euthanized 1 day after injury, and their brains were processed for measurement of fibrin accumulation and neuroinflammation signaling pathways. The remaining animals were euthanized 35 days after injury, and brain sections were processed for measurement of lesion volume, hippocampal cell loss, angiogenesis, neurogenesis, and dendritic spine remodeling. RESULTS Compared with vehicle treatment, AcSDKP treatment initiated 1 hour postinjury significantly improved sensorimotor functional recovery (Days 7-35, p < 0.05) and spatial learning (Days 33-35, p < 0.05), reduced cortical lesion volume, and hippocampal neuronal cell loss, reduced fibrin accumulation and activation of microglia/macrophages, enhanced angiogenesis and neurogenesis, and increased the number of dendritic spines in the injured brain (p < 0.05). AcSDKP treatment also significantly inhibited the transforming growth factor beta 1/nuclear factor-kappa B signaling pathway. CONCLUSIONS AcSDKP treatment initiated 1 hour postinjury provides neuroprotection and neurorestoration after TBI, indicating that this small tetrapeptide has promising therapeutic potential for treatment of TBI. Further investigation of the optimal dose and therapeutic window of AcSDKP treatment for TBI and the associated underlying mechanisms is therefore warranted.	[Zhang, Yanlu; Meng, Yuling; Mahmood, Asim; Xiong, Ye] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael; Zhang, Li] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA		Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Rm 3096,2799 West Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 079612]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079612] Funding Source: NIH RePORTER	This work was partially supported by National Institutes of Health Grant R01 NS 079612 (to Zheng Gang Zhang).	Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Adams RA, 2007, CURR MED CHEM, V14, P2925, DOI 10.2174/092986707782360015; Akassoglou K, 2002, NEURON, V33, P861, DOI 10.1016/S0896-6273(02)00617-7; Azizi M, 1997, HYPERTENSION, V30, P1015, DOI 10.1161/01.HYP.30.5.1015; Azizi M, 1999, HYPERTENSION, V33, P879, DOI 10.1161/01.HYP.33.3.879; Azizi M, 1996, J CLIN INVEST, V97, P839, DOI 10.1172/JCI118484; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Beschorner R, 2007, HISTOL HISTOPATHOL, V22, P515, DOI 10.14670/HH-22.515; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Capilla-Gonzalez V, 2015, ADV EXP MED BIOL, V853, P1, DOI 10.1007/978-3-319-16537-0_1; Castoldi G, 2013, AM J NEPHROL, V37, P65, DOI 10.1159/000346116; Castoldi G, 2010, CLIN SCI, V118, P211, DOI 10.1042/CS20090234; Cavasin Maria A, 2006, Am J Cardiovasc Drugs, V6, P305, DOI 10.2165/00129784-200606050-00003; Centers for Disease Control and Prevention, 2014, C TRAUM BRAIN INJ US; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Christie KJ, 2013, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00070; Cortes-Canteli M, 2012, J ALZHEIMERS DIS, V32, P599, DOI 10.3233/JAD-2012-120820; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dobolyi A, 2012, INT J MOL SCI, V13, P8219, DOI 10.3390/ijms13078219; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gaudron S, 1999, STEM CELLS, V17, P100, DOI 10.1002/stem.170100; Ghashghaei HT, 2007, NAT REV NEUROSCI, V8, P141, DOI 10.1038/nrn2074; GRILLON C, 1990, FEBS LETT, V274, P30, DOI 10.1016/0014-5793(90)81322-F; Harari OA, 2010, ANN NY ACAD SCI, V1207, P32, DOI 10.1111/j.1749-6632.2010.05735.x; Harford-Wright E, 2010, NEUROSCI LETT, V481, P26, DOI 10.1016/j.neulet.2010.06.044; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; HOLNESS CL, 1993, BLOOD, V81, P1607; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Junot C, 1999, J PHARMACOL EXP THER, V289, P1257; Kanasaki K, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00070; Kim DH, 2015, NEUROSCIENCE, V310, P51, DOI 10.1016/j.neuroscience.2015.09.017; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LENFANT M, 1989, P NATL ACAD SCI USA, V86, P779, DOI 10.1073/pnas.86.3.779; Li L, 2012, J CEREBR BLOOD F MET, V32, P2023, DOI 10.1038/jcbfm.2012.106; Li LA, 2011, J NEUROTRAUM, V28, P535, DOI 10.1089/neu.2010.1619; LINZ W, 1986, J CARDIOVASC PHARM, V8, pS91, DOI 10.1097/00005344-198600101-00017; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Liu JM, 2003, BLOOD, V101, P3014, DOI 10.1182/blood-2002-07-2315; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; MONPEZAT JP, 1989, EXP HEMATOL, V17, P1077; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Caoimh R, 2014, J ALZHEIMERS DIS, V40, P595, DOI 10.3233/JAD-131694; Paul J, 2007, J EXP MED, V204, P1999, DOI 10.1084/jem.20070304; Peng HM, 2001, HYPERTENSION, V37, P794, DOI 10.1161/01.HYP.37.2.794; Porritt MJ, 2010, J CEREBR BLOOD F MET, V30, P1520, DOI 10.1038/jcbfm.2010.57; Preston E, 2001, J NEUROTRAUM, V18, P83, DOI 10.1089/089771501750055794; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rotheneichner P, 2013, EPILEPSIA, V54, P40, DOI 10.1111/epi.12274; ROUSSEAU A, 1995, J BIOL CHEM, V270, P3656, DOI 10.1074/jbc.270.8.3656; Ryu JK, 2009, J THROMB HAEMOST, V7, P151, DOI 10.1111/j.1538-7836.2009.03438.x; Schachtrup C, 2007, P NATL ACAD SCI USA, V104, P11814, DOI 10.1073/pnas.0704045104; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Shibuya K, 2005, DIABETES, V54, P838, DOI 10.2337/diabetes.54.3.838; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STIER CT, 1989, HYPERTENSION, V13, P115, DOI 10.1161/01.HYP.13.2.115; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Szmydynger-Chodobska J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079328; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Taupin P, 2006, CURR OPIN MOL THER, V8, P225; Teng H, 2008, J CEREBR BLOOD F MET, V28, P764, DOI 10.1038/sj.jcbfm.9600573; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang DH, 2004, AM J PHYSIOL-HEART C, V287, pH2099, DOI 10.1152/ajpheart.00592.2004; WERNER C, 1991, STROKE, V22, P910, DOI 10.1161/01.STR.22.7.910; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Worou ME, 2015, HYPERTENSION, V66, P816, DOI 10.1161/HYPERTENSIONAHA.115.05970; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054; Zhang L, 2014, STROKE, V45, P1108, DOI 10.1161/STROKEAHA.113.004399; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang YL, 2015, J NEUROSURG, V122, P843, DOI 10.3171/2014.11.JNS14271; Zhang YL, 2013, J NEUROSURG, V118, P1343, DOI 10.3171/2013.3.JNS122061; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579	94	25	28	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2017	126	3					782	795		10.3171/2016.3.JNS152699			14	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	EL9FT	WOS:000394926200012	28245754	Green Accepted			2022-02-06	
J	Wang, CQ; Ye, Y; Chen, F; Han, WC; Sun, JM; Lu, X; Guo, R; Cao, K; Zheng, MJ; Liao, LC				Wang, C. -Q.; Ye, Y.; Chen, F.; Han, W. -C.; Sun, J. -M.; Lu, X.; Guo, R.; Cao, K.; Zheng, M. -J.; Liao, L. -C.			POSTTRAUMATIC ADMINISTRATION OF A SUB-ANESTHETIC DOSE OF KETAMINE EXERTS NEUROPROTECTION VIA ATTENUATING INFLAMMATION AND AUTOPHAGY	NEUROSCIENCE			English	Article						mTOR; autophagy; traumatic brain injury; ketamine	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; UP-REGULATION; MEMORY; RATS; REGENERATION; DEPRESSION; ISCHEMIA; RECEPTOR; RELEASE	As a complex disease, traumatic brain injury (TBI) can result in long-term psychiatric changes and sensorimotor and cognitive impairments. The TBI-induced loss of memory and long-term cognitive dysfunction are related to mechanistic factors including an increased inflammatory response, autophagy, edema, and ischemia. Many published studies have offered evidence for the neuroprotective effects and anti-inflammatory properties of ketamine for TBI patients. Nonetheless, there is a limited understanding of the accurate mechanism that underlies the potential neuroprotective effects of ketamine. Herein, it can be shown that posttraumatic administration of ketamine at a sub anesthetic dose (10 mg/kg ketamine, every 24 h up to 7 days) can prevent the TBI-induced production of IL-6 and TNF-alpha, attenuate deficits of dendrites and spines and exert beneficial effects on memory and behavior. Moreover, studies show that ketamine may activate the mTOR signaling pathway by p-mTOR induction to down-regulate the expression of crucial autophagic proteins such as LC3 and Beclin-1. According to these findings, ameliorating secondary brain injury and anti-inflammatory properties is closely related to the neuroprotection of ketamine, which supports the use of ketamine as a potential therapy for patients with TBI to alleviate functional deficits. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.	[Wang, C. -Q.; Ye, Y.; Chen, F.; Lu, X.; Guo, R.; Liao, L. -C.] Sichuan Univ, Coll Basic & Forens Med, Chengdu 610041, Sichuan, Peoples R China; [Wang, C. -Q.; Han, W. -C.; Sun, J. -M.; Cao, K.; Zheng, M. -J.] Xuzhou Med Coll, Dept Pathol, Xuzhou 221004, Jiangsu, Peoples R China		Liao, LC (corresponding author), Sichuan Univ, Coll Basic & Forens Med, Chengdu 610041, Sichuan, Peoples R China.	linchuanliao@scu.edu.cn			National Natural Sciences Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81373239]	This work was supported by National Natural Sciences Foundation of China (81373239).	Adams SD, 2008, J TRAUMA, V65, P170, DOI 10.1097/TA.0b013e31805824ca; Silva LFA, 2011, J NEUROL SCI, V308, P35, DOI 10.1016/j.jns.2011.06.030; Amini M, 2013, J NEUROSCI, V33, P5773, DOI 10.1523/JNEUROSCI.4247-12.2013; [Anonymous], 2016, GLOBAL HLTH OBSERVAT; [Anonymous], 2016, DOD WORLDWIDE NUMBER; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bhutta AT, 2012, PEDIATR CRIT CARE ME, V13, P328, DOI 10.1097/PCC.0b013e31822f18f9; Bigford GE, 2009, J NEUROTRAUM, V26, P703, DOI 10.1089/neu.2008.0783; Chang ML, 2002, NEUROSCI LETT, V322, P137, DOI 10.1016/S0304-3940(01)02520-4; Chang Y, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/705379; DeClue AE, 2008, AM J VET RES, V69, P228, DOI 10.2460/ajvr.69.2.228; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Duman RS, 2012, SCIENCE, V338, P68, DOI 10.1126/science.1222939; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fletcher PC, 2006, TRENDS COGN SCI, V10, P167, DOI 10.1016/j.tics.2006.02.008; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Harish G, 2015, J NEUROCHEM, V134, P156, DOI 10.1111/jnc.13082; Himmelseher S, 1996, ANESTH ANALG, V83, P505, DOI 10.1097/00000539-199609000-00011; Himmelseher S, 2000, J NEUROSURG ANESTH, V12, P84, DOI 10.1097/00008506-200004000-00003; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Krystal JH, 2013, BIOL PSYCHIAT, V73, P1133, DOI 10.1016/j.biopsych.2013.03.026; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Li NX, 2010, SCIENCE, V329, P959, DOI 10.1126/science.1190287; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lodge D, 2015, BRIT J PHARMACOL, V172, P4254, DOI 10.1111/bph.13222; LUCAS J H, 1990, Journal of Neurotrauma, V7, P229, DOI 10.1089/neu.1990.7.229; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Meyer Kimberly, 2008, J Trauma Nurs, V15, P185, DOI 10.1097/01.JTN.0000343324.55087.de; Morgan CJA, 2006, PSYCHOPHARMACOLOGY, V188, P408, DOI 10.1007/s00213-006-0572-3; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; ROTHMAN SM, 1987, NEUROSCIENCE, V21, P673, DOI 10.1016/0306-4522(87)90028-5; Scheff SW, 2006, NEUROBIOL AGING, V27, P1372, DOI 10.1016/j.neurobiolaging.2005.09.012; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Semchenko V V, 2006, Neurosci Behav Physiol, V36, P613, DOI 10.1007/s11055-006-0065-1; Silva-Gomez AB, 2003, BRAIN RES, V983, P128, DOI 10.1016/S0006-8993(03)03042-7; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yokobori S, 2014, CNS NEUROL DISORD-DR, V13, P606, DOI 10.2174/187152731304140702112805; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang CY, 2002, NEUROSCI LETT, V328, P265, DOI 10.1016/S0304-3940(02)00543-8; Zhao YD, 2013, J NEUROSCI RES, V91, P1165, DOI 10.1002/jnr.23247	46	25	26	4	26	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 20	2017	343						30	38		10.1016/j.neuroscience.2016.11.029			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EJ5PB	WOS:000393269100004	27916727				2022-02-06	
J	Chang, R; Folkerson, LE; Sloan, D; Tomasek, JS; Kitagawa, RS; Choi, HA; Wade, CE; Holcomb, JB				Chang, Ronald; Folkerson, Lindley E.; Sloan, Duncan; Tomasek, Jeffrey S.; Kitagawa, Ryan S.; Choi, H. Alex; Wade, Charles E.; Holcomb, John B.			Early plasma transfusion is associated with improved survival after isolated traumatic brain injury in patients with multifocal intracranial hemorrhage	SURGERY			English	Article							FRESH-FROZEN PLASMA; LARGE ANIMAL-MODEL; DAMAGE CONTROL; RESUSCITATION; MORTALITY; SHOCK; INFLAMMATION; RATIO	Background. Plasma-based resuscitation improves outcomes in trauma patients with hemorrhagic shock, while large-animal and limited clinical data suggest that it also improves outcomes and is neuroprotective in the setting of combined hemorrhage and traumatic brain injury. However; the choice of initial resuscitation fluid, including the role of plasma, is unclear for patients after isolated traumatic brain injury. Methods. We reviewed adult trauma patients admitted from January 2011 to July 2015 with isolated traumatic brain injury. "Early plasma" was defined as transfusion of plasma within 4 hours. Purposeful multiple logistic regression modeling was performed to analyze the relationship of early plasma and inhospital survival. After testing for interaction, subgroup analysis was performed based on the pattern of brain injury on initial head computed tomography: epidural hematoma, intraparenchymal contusion, subarachnoid hemorrhage, subdural hematoma, or multifocal intracranial hemorrhage. Results. Of the 633 isolated traumatic brain injury patients included, 178 (28 %) who received early plasma were injured more severely coagulopathic, hypoperfused, and hypotensive on admission. Survival was similar in the early plasma versus no early plasma groups (78% vs 84%, P = .08). After adjustment for covariates, early plasma was not associated with improved survival (odds ratio 1.18, 95% confidence interval 0.71-1.96). On subgroup analysis, multifocal intracranial hemorrhage was the largest subgroup with 242 patients. Of these, 61 (25 %) received plasma within 4 hours. Within-group logistic regression analysis with adjustment for covariates found that early plasma was associated with improved survival (odds ratio 3.34, 95% confidence interval 1.20-9.35). Conclusion. Although early plasma transfusion was not associated with improved in-hospital survival for all isolated traumatic brain injury patients, early plasma was associated with increased in-hospital survival in those with multifocal intracranial hemorrhage.	[Chang, Ronald; Folkerson, Lindley E.; Sloan, Duncan; Tomasek, Jeffrey S.; Wade, Charles E.; Holcomb, John B.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, 6410 Fannin St Suite 1100, Houston, TX 77030 USA; [Chang, Ronald; Folkerson, Lindley E.; Sloan, Duncan; Tomasek, Jeffrey S.; Wade, Charles E.; Holcomb, John B.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, 6410 Fannin St Suite 1100, Houston, TX 77030 USA; [Kitagawa, Ryan S.; Choi, H. Alex] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA		Chang, R (corresponding author), Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, 6410 Fannin St Suite 1100, Houston, TX 77030 USA.; Chang, R (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Surg, 6410 Fannin St Suite 1100, Houston, TX 77030 USA.	ronald.chang@uth.tmc.edu		chang, ronald/0000-0002-8947-0054; holcomb, john/0000-0001-8312-9157	National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5T32GM-008792]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	R.C. is supported by a T32 fellowship (grant no. 5T32GM-008792) from the National Institute of General Medical Sciences.	Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17; Chang R, 2016, BLOOD, V128, P1043, DOI 10.1182/blood-2016-01-636423; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cotton BA, 2011, ANN SURG, V254, P598, DOI 10.1097/SLA.0b013e318230089e; Cotton BA, 2011, J TRAUMA, V71, P407, DOI 10.1097/TA.0b013e31821e1bf0; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Folkerson LE, 2015, SURGERY, V158, P655, DOI 10.1016/j.surg.2015.02.029; Halaweish I, 2015, J AM COLL SURGEONS, V220, P809, DOI 10.1016/j.jamcollsurg.2015.01.057; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2015, PREHOSP EMERG CARE, V19, P1, DOI 10.3109/10903127.2014.923077; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Hwabejire JO, 2013, J TRAUMA ACUTE CARE, V75, P968, DOI 10.1097/TA.0b013e31829a021a; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Marion DW, 2006, NEUROSURGERY, V58, P655; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Peiniger S, 2011, CRIT CARE, V15, DOI 10.1186/cc10048; Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc; Potter DR, 2015, J TRAUMA ACUTE CARE, V78, pS7, DOI 10.1097/TA.0000000000000630; Prakash R, 2015, CURR OPIN NEUROL, V28, P556, DOI 10.1097/WCO.0000000000000248; Radwan ZA, 2013, JAMA SURG, V148, P170, DOI 10.1001/jamasurgery.2013.414; Ryan CG, 2012, J TRAUMA ACUTE CARE, V73, P1348, DOI 10.1097/TA.0b013e31826fcb30; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	33	25	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	FEB	2017	161	2					538	545		10.1016/j.surg.2016.08.023			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	EJ0MT	WOS:000392904400034	27776795	Green Accepted			2022-02-06	
J	Joseph, B; Azim, A; Haider, AA; Kulvatunyou, N; O'Keeffe, T; Hassan, A; Gries, L; Tran, E; Latifi, R; Rhee, P				Joseph, Bellal; Azim, Asad; Haider, Ansab A.; Kulvatunyou, Narong; O'Keeffe, Terence; Hassan, Ahmed; Gries, Lynn; Tran, Emily; Latifi, Rifat; Rhee, Peter			Bicycle helmets work when it matters the most	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	101st Annual Clinical Congress Scientific Forum of the American-College-of-Surgeons (ACS)	OCT 04-10, 2015	Chicago, IL	Amer Coll Surg		Bicycle; Helmets; Facial fracture; Head injury	SAFETY HELMETS; HEAD-INJURY; FACIAL INJURY; LEGISLATION; PREVENTION; SEVERITY	BACKGROUND: Helmets are known to reduce the incidence of traumatic brain injury (TBI) after bicycle-related accidents. The aim of this study was to assess the association of helmets with severity of TBI and facial fractures after bicycle-related accidents. METHODS: We performed an analysis of the 2012 National Trauma Data Bank abstracted information of all patients with an intracranial hemorrhage after bicycle-related accidents. Regression analysis was also performed. RESULTS: A total of 6,267 patients were included. About 25.1% (n = 1,573) of bicycle riders were helmeted. Overall, 52.4% (n = 3,284) of the patients had severe TBI, and the mortality rate was 2.8% (n = 176). Helmeted bicycle riders had 51% reduced odds of severe TBI (odds ratio [OR].49, 95% confidence interval [CI] .43 to .55, P < .001) and 44% reduced odds of mortality (OR .56, 95% CI .34 to .78, P < .010). Helmet use also reduced the odds of facial fractures by 31% (OR .69, 95% CI .58 to .81, P < .001). CONCLUSION: Bicycle helmet use provides protection against severe TBI, reduces facial fractures, and saves lives even after sustaining an intracranial hemorrhage. (C) 2016 Elsevier Inc. All rights reserved.	[Joseph, Bellal; Azim, Asad; Haider, Ansab A.; Kulvatunyou, Narong; O'Keeffe, Terence; Hassan, Ahmed; Gries, Lynn; Tran, Emily; Latifi, Rifat; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Emergency Surg Crit Care & Burns, Tucson, AZ 85721 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Emergency Surg Crit Care & Burns, Tucson, AZ 85721 USA.	bjoseph@surgery.arizona.edu	Hassan, Ahmed/AAB-7241-2019				Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crompton JG, 2012, ARCH SURG-CHICAGO, V147, P674, DOI 10.1001/archsurg.2012.894; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; Hemmila MR, 2007, SURGERY, V142, P439, DOI 10.1016/j.surg.2007.07.002; Joseph B, 2014, EUR J TRAUMA EMERG S, V40, P729, DOI 10.1007/s00068-014-0453-0; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; MCDERMOTT FT, 1995, ANN ROY COLL SURG, V77, P38; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; Moore L, 2009, J AM COLL SURGEONS, V209, P572, DOI 10.1016/j.jamcollsurg.2009.07.004; Rivara FP, 1998, ANNU REV PUBL HEALTH, V19, P293, DOI 10.1146/annurev.publhealth.19.1.293; Schulman J, 2002, INJ PREV, V8, P47, DOI 10.1136/ip.8.1.47; SPAITE DW, 1991, J TRAUMA, V31, P1510, DOI 10.1097/00005373-199111000-00008; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thompson DC., 1999, COCHRANE DB SYST REV, V308, DOI 10.1002/14651858.CD001855; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101	18	25	26	1	10	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	FEB	2017	213	2					413	417		10.1016/j.amjsurg.2016.05.021			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	EQ3KH	WOS:000397970400034	27596799				2022-02-06	
J	Ramsey, C; Dziura, J; Justice, AC; Altalib, HH; Bathulapalli, H; Burg, M; Decker, S; Driscoll, M; Goulet, J; Haskell, S; Kulas, J; Wang, KH; Mattocks, K; Brandt, C				Ramsey, Christine; Dziura, James; Justice, Amy C.; Altalib, Hamada Hamid; Bathulapalli, Harini; Burg, Matthew; Decker, Suzanne; Driscoll, Mary; Goulet, Joseph; Haskell, Sally; Kulas, Joseph; Wang, Karen H.; Mattocks, Kristen; Brandt, Cynthia			Incidence of Mental Health Diagnoses in Veterans of Operations Iraqi Freedom, Enduring Freedom, and New Dawn, 2001-2014	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; GENDER-DIFFERENCES; AFGHANISTAN VETERANS; US VETERANS; 1ST YEAR; RISK; SERVICE; ONSET; CARE	Objectives. To evaluate gender, age, and race/ethnicity as predictors of incident mental health diagnoses among Operations Iraqi Freedom, Enduring Freedom, and New Dawn veterans. Methods. We used US Veterans Health Administration (VHA) electronic health records from 2001 to 2014 to examine incidence rates and sociodemographic risk factors for mental health diagnoses among 888 142 veterans. Results. Posttraumatic stress disorder (PTSD) was the most frequently diagnosed mental health condition across gender and age groups. Incidence rates for all mental health diagnoses were highest at ages 18 to 29 years and declined thereafter, with the exceptions of major depressive disorder (MDD) in both genders, and PTSD among women. Risk of incident bipolar disorder and MDD diagnoses were greater among women; risk of incident schizophrenia, and alcohol-and drug-use disorders diagnoses were greater in men. Compared with Whites, risk incident PTSD, MDD, and alcohol-use disorder diagnoses were lower at ages 18 to 29 years and higher at ages 45 to 64 years for both Hispanics and African Americans. Conclusions. Differentiating high-risk demographic and gender groups can lead to improved diagnosis and treatment of mental health diagnoses among veterans and other high-risk groups.	[Ramsey, Christine; Justice, Amy C.; Altalib, Hamada Hamid; Bathulapalli, Harini; Burg, Matthew; Decker, Suzanne; Driscoll, Mary; Goulet, Joseph; Haskell, Sally; Kulas, Joseph; Wang, Karen H.; Mattocks, Kristen; Brandt, Cynthia] VA Connecticut Hlth Care Syst, West Haven, CT USA; [Ramsey, Christine; Dziura, James; Justice, Amy C.; Altalib, Hamada Hamid; Bathulapalli, Harini; Burg, Matthew; Decker, Suzanne; Driscoll, Mary; Goulet, Joseph; Haskell, Sally; Kulas, Joseph; Wang, Karen H.; Mattocks, Kristen; Brandt, Cynthia] Yale Univ, Sch Med, New Haven, CT USA		Ramsey, C (corresponding author), 300 George St,Room 780A, New Haven, CT 06511 USA.	christine.ramsey@yale.edu	Altalib, Hamada/B-9656-2018	Altalib, Hamada/0000-0001-7154-1400	VA Health Service Research and Development Project [IIR-12-118]; Veterans AffairsUS Department of Veterans Affairs [I01HX000915] Funding Source: NIH RePORTER	This study was supported by VA Health Service Research and Development Project IIR-12-118 (PI: S. H.).	AKISKAL HS, 1995, ARCH GEN PSYCHIAT, V52, P114; Baker DG, 2009, MIL MED, V174, P773; Blow FC, 2004, SOC PSYCH PSYCH EPID, V39, P841, DOI 10.1007/s00127-004-0824-7; Chen YH, 2011, PSYCHOL MED, V41, P1271, DOI 10.1017/S0033291710001819; Cieslak K, 2016, AM J MED GENET B, V171, P506, DOI 10.1002/ajmg.b.32350; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; Crum-Cianflone NF, 2014, EPIDEMIOL REV, V36, P5, DOI 10.1093/epirev/mxt005; Eaton WW, 1997, ARCH GEN PSYCHIAT, V54, P993; Goldberg JF, 2001, AM J PSYCHIAT, V158, P1265, DOI 10.1176/appi.ajp.158.8.1265; Gray Matt J, 2004, Prehosp Disaster Med, V19, P64; Harpaz-Rotem I, 2014, J NERV MENT DIS, V202, P97, DOI 10.1097/NMD.0000000000000078; Haskell SG, 2011, WOMEN HEALTH ISS, V21, P92, DOI 10.1016/j.whi.2010.08.001; Kessler R C, 1997, Epidemiol Psichiatr Soc, V6, P4; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P768; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kline A, 2010, AM J PUBLIC HEALTH, V100, P276, DOI 10.2105/AJPH.2009.162925; Koo KH, 2015, PSYCHIAT RES, V229, P724, DOI 10.1016/j.psychres.2015.08.013; Koo KH, 2015, PSYCHIAT SERV, V66, P507, DOI 10.1176/appi.ps.201300498; LURIE N, 1992, HOSP COMMUNITY PSYCH, V43, P69; Maguen S, 2012, PSYCHIAT SERV, V63, P1206, DOI 10.1176/appi.ps.201200051; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Martin E.M, 2008, J TRAUMA NURS, V15, P100; Martin Elisabeth Moy, 2008, J Trauma Nurs, V15, P94, DOI 10.1097/01.JTN.0000337149.29549.28; Miller SC, 2015, OCCUP ENVIRON MED, V72, P560, DOI 10.1136/oemed-2014-102646; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Office of Public Health Post-Deployment Health Group Veterans Health Administration Department of Veterans Affairs, 2014, AN VA HLTH CAR UT OP; Office of Public Health Post-Deployment Health Group Veterans Health Administration Department of Veterans Affairs, 2013, AN VA HLTH CAR UT OP; Petersen, 2008, PSYCHOL SERV, V5, P320, DOI [10.1037/a0013719, DOI 10.1037/A0013719]; Prigerson HG, 2001, J NERV MENT DIS, V189, P99, DOI 10.1097/00005053-200102000-00005; Rosen CS, 2011, J NERV MENT DIS, V199, P879, DOI 10.1097/NMD.0b013e3182349ea5; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2010, J TRAUMA STRESS, V23, P5, DOI 10.1002/jts.20493; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; US Department of Veterans Affairs, 2013, INCR VA HLTH CAR US; Yano EM, 2010, J GEN INTERN MED, V25, P56, DOI 10.1007/s11606-009-1116-4	36	25	25	0	15	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	FEB	2017	107	2					329	335		10.2105/AJPH.2016.303574			7	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	EO9XG	WOS:000397040800043	27997229	Green Published			2022-02-06	
J	Herrera, JJ; Bockhorst, K; Kondraganti, S; Stertz, L; Quevedo, J; Narayana, PA				Herrera, Juan J.; Bockhorst, Kurt; Kondraganti, Shakuntala; Stertz, Laura; Quevedo, Joao; Narayana, Ponnada A.			Acute White Matter Tract Damage after Frontal Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; inflammation; mild traumatic brain injury; MRI behavioral assessments	CLOSED-HEAD-INJURY; NECROSIS-FACTOR-ALPHA; RAT SPINAL-CORD; AXONAL INJURY; OUTCOME PREDICTION; IMAGING FINDINGS; BDNF EXPRESSION; MOUSE MODEL; TNF-ALPHA; DIFFUSION	Our understanding of mild traumatic brain injury (mTBI) is still in its infancy and to gain a greater understanding, relevant animal models should replicate many of the features seen in human mTBI. These include changes to diffusion tensor imaging (DTI) parameters, absence of anatomical lesions on conventional neuroimaging, and neurobehavioral deficits. The Maryland closed head TBI model causes anterior-posterior plus sagittal rotational acceleration of the brain, frequently observed with motor vehicle and sports-related TBI injuries. The injury reflects a concussive injury model without skull fracture. The goal of our study was to characterize the acute (72 h) pathophysiological changes occurring following a single mTBI using magnetic resonance imaging (MRI), behavioral assays, and histology. We assessed changes in fractional anisotropy (FA), mean (MD), longitudinal (LD), and radial (RD) diffusivities relative to pre-injury baseline measures. Significant differences were observed in both the longitudinal and radial diffusivities in the fimbria compared with baseline. A significant difference in radial diffusivity was also observed in the splenium of the corpus callosum compared with baseline. The exploratory activity of the mTBI animals was also assessed using computerized activity monitoring. A significant decrease was observed in ambulatory distance, average velocity, stereotypic counts, and vertical counts compared with baseline. Histological examination of the mTBI brain sections indicated a significant decrease in the expression of myelin basic protein in the fimbria, splenium, and internal capsule. Our findings demonstrate the vulnerability of the white matter tracts, specifically the fimbria and splenium, and the ability of DTI to identify changes to the integrity of the white matter tracts following mTBI.	[Herrera, Juan J.; Bockhorst, Kurt; Kondraganti, Shakuntala; Narayana, Ponnada A.] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Dept Diagnost & Intervent Imaging, Houston, TX USA; [Stertz, Laura; Quevedo, Joao] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Dept Psychiat & Behav Sci, Translat Psychiat Program, Houston, TX USA; [Quevedo, Joao] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Dept Psychiat & Behav Sci, Ctr Excellence Mood Disorders, Houston, TX USA		Herrera, JJ (corresponding author), Univ Texas Houston, Med Sch Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin,MSE R102F, Houston, TX 77030 USA.	Juan.Herrera@uth.tmc.edu	Stertz, Laura/AAC-7384-2019; de Quevedo, Joao Luciano/E-5491-2013	Stertz, Laura/0000-0002-1426-6796; de Quevedo, Joao Luciano/0000-0003-3114-6611	Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth); NIH High End Instrumentation Grant [1 S10 RR17205-01]	The Translational Psychiatry Program (USA) is funded by the Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth). The 7T scanner purchase was supported by the NIH High End Instrumentation Grant (1 S10 RR17205-01) awarded to PAN.	Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Cammer W, 2000, BRAIN RES, V864, P213, DOI 10.1016/S0006-8993(00)02178-8; Choy KHC, 2008, HIPPOCAMPUS, V18, P655, DOI 10.1002/hipo.20425; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Council NR, 2011, GUIDE CARE USE LAB A; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M, 2010, TRAUMATIC BRAIN INJU; Gerberding J.L., 2003, C MILD TRAUM BRAIN I; Ghadiri T, 2014, J NEUROSCI METH, V233, P18, DOI 10.1016/j.jneumeth.2014.05.035; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; HAHN KR, 2005, P 13 ANN M ISMRM MIA, P161; Hall J, 2000, NAT NEUROSCI, V3, P533, DOI 10.1038/75698; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; HENDRZAK JA, 1995, LAB INVEST, V72, P619; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Herrera JJ, 2008, J NEUROSCI RES, V86, P443, DOI 10.1002/jnr.21481; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Kita T, 2000, INT J LEGAL MED, V113, P221, DOI 10.1007/s004149900095; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Madi S, 2005, MAGN RESON MED, V53, P118, DOI 10.1002/mrm.20304; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Narayana PA, 2014, PSYCHIAT RES-NEUROIM, V221, P220, DOI 10.1016/j.pscychresns.2014.01.005; Narayana PA, 2009, PSYCHIAT RES-NEUROIM, V171, P242, DOI 10.1016/j.pscychresns.2008.04.004; Pendlebury ST, 1999, STROKE, V30, P956, DOI 10.1161/01.STR.30.5.956; Petraglia Anthony L, 2014, Neurosurgery, V75 Suppl 4, pS34, DOI 10.1227/NEU.0000000000000472; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; TRINCHIERI G, 1994, IMMUNOL TODAY, V15, P460, DOI 10.1016/0167-5699(94)90189-9; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009; Zhou LJ, 2003, J NEUROSCI RES, V74, P221, DOI 10.1002/jnr.10718	61	25	25	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					291	299		10.1089/neu.2016.4407			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800004	27138134	Green Published			2022-02-06	
J	Liu, M; Bachstetter, AD; Cass, WA; Lifshitz, J; Bing, GY				Liu, Mei; Bachstetter, Adam D.; Cass, Wayne A.; Lifshitz, Jonathan; Bing, Guoying			Pioglitazone Attenuates Neuroinflammation and Promotes Dopaminergic Neuronal Survival in the Nigrostriatal System of Rats after Diffuse Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; Parkinson's disease; pioglitazone; substantia nigra	ACTIVATED-RECEPTOR-GAMMA; MITOCHONDRIAL DYSFUNCTION; MOUSE MODEL; PPAR-GAMMA; AGONIST PIOGLITAZONE; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; HEAD TRAUMA; INFLAMMATION; MICROGLIA	Increasing evidence suggests that traumatic brain injury (TBI) may raise the risk of developing late-onset Parkinson's disease (PD). Recently, the peroxisome proliferation-activated receptor gamma (PPAR gamma) agonist pioglitazone has been demonstrated to be neuroprotective in animal models of neurodegeneration. The present study investigates the vulnerability of the nigrostriatal system after TBI, and intervention with pioglitazone treatment. Adult male Sprague-Dawley rats were subjected to sham or moderate midline fluid percussion brain injury (mFPI), followed by an intraperitoneal injection of 10 mg/kg pioglitazone or vehicle beginning 30 min after the injury and subsequently every 24 h for 5 days. Following injury, pro-inflammatory cytokines and chemokine were acutely increased in the striatum and substantia nigra within 6 h. Dopaminergic axonal damage and microglial activation were revealed using immunohistochemistry in the medial fore-brain bundle at 1 day post-injury. Microglial activation identified by Iba1 and OX-6 immunostaining was persistently increased in the substantia nigra pars compacta 7 to 28 days post-injury. Further, brain injury induced significant dopaminergic neuronal loss, which was quantified by tyrosine hydroxylase immunostaining and retrograde fluorescent tracer fluorogold labeling in the nigra at 28 days. Loss of neurons was accompanied by increased extracellular dopamine (DA) turnover in the striatum, indicating enhanced dopaminergic activity in functional compensation after nigrostriatal damage. Strikingly, pioglitazone treatment greatly attenuated microglial activation and improved dopaminergic neuronal survival in the nigrostriatal system, which may promote locomotor recovery. These results suggest that interventions that attenuate secondary inflammation could be a feasible therapeutic treatment to improve outcome after TBI.	[Liu, Mei; Cass, Wayne A.; Bing, Guoying] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, 800 Rose St, Lexington, KY 40536 USA; [Bachstetter, Adam D.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Phoenix Childrens Hosp, BARROW Neurol Inst, Phoenix, AZ USA; [Lifshitz, Jonathan] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ USA; [Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA; [Lifshitz, Jonathan] Arizona State Univ, Interdisciplinary Grad Program Neurosci, Tempe, AZ USA		Bing, GY (corresponding author), Univ Kentucky, Coll Med, Dept Anat & Neurobiol, 800 Rose St, Lexington, KY 40536 USA.	gbing@uky.edu		Bing, Guoying/0000-0003-0609-8152; Bachstetter, Adam/0000-0003-4646-6757	Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) [11-2A]	The authors greatly thank Amanda Lisembee and Andrea Sebastian for technical assistance with mFPI surgery, and Dr. Michael T. Bardo and Emily D. Denehy for providing the locomotor apparatus. Grant sponsor: Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) 11-2A.	Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Breidert T, 2002, J NEUROCHEM, V82, P615, DOI 10.1046/j.1471-4159.2002.00990.x; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Carta AR, 2011, NEUROSCIENCE, V194, P250, DOI 10.1016/j.neuroscience.2011.07.046; Cass WA, 2003, BRAIN RES, V984, P133, DOI 10.1016/S0006-8993(03)03122-6; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; Cheng HC, 2010, ANN NEUROL, V67, P715, DOI 10.1002/ana.21995; Cheng HC, 2010, J NEUROCHEM, V113, P683, DOI 10.1111/j.1471-4159.2010.06632.x; Chinetti-Gbaguidi G, 2011, CIRC RES, V108, P985, DOI 10.1161/CIRCRESAHA.110.233775; Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; FACTOR SA, 1991, MOVEMENT DISORD, V6, P225, DOI 10.1002/mds.870060306; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gash DM, 2008, ANN NEUROL, V63, P184, DOI 10.1002/ana.21288; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Heneka MT, 2001, ANN NEUROL, V49, P276, DOI 10.1002/1531-8249(20010201)49:2<276::AID-ANA53>3.0.CO;2-5; Herrera AJ, 2008, J NEUROCHEM, V105, P750, DOI 10.1111/j.1471-4159.2007.05170.x; Hetzel M, 2003, THORAX, V58, P778, DOI 10.1136/thorax.58.9.778; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Hunter RL, 2007, J NEUROCHEM, V100, P1375, DOI 10.1111/j.1471-4159.2006.04327.x; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Ito K, 2004, EUR J CARDIO-THORAC, V25, P530, DOI 10.1016/j.ejcts.2003.12.017; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Liu M, 2008, J NEUROSCI RES, V86, P2792, DOI 10.1002/jnr.21725; Liu M, 2010, J NEUROCHEM, V112, P773, DOI 10.1111/j.1471-4159.2009.06497.x; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mandrekar-Colucci S, 2012, J NEUROSCI, V32, P10117, DOI 10.1523/JNEUROSCI.5268-11.2012; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Olah M, 2011, CNS NEUROL DISORD-DR, V10, P108, DOI 10.2174/187152711794488575; Patro N, 2010, INDIAN J EXP BIOL, V48, P110; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Perez XA, 2008, J NEUROCHEM, V105, P1861, DOI 10.1111/j.1471-4159.2008.05268.x; Pilipovic K, 2015, PROG NEURO-PSYCHOPH, V59, P8, DOI 10.1016/j.pnpbp.2015.01.003; Pringsheim T, 2014, MOVEMENT DISORD, V29, P1583, DOI 10.1002/mds.25945; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROFFLERTARLOV S, 1971, BRIT J PHARMACOL, V42, P343, DOI 10.1111/j.1476-5381.1971.tb07118.x; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Sadeghian M, 2012, J NEUROIMMUNOL, V246, P69, DOI 10.1016/j.jneuroim.2012.03.010; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sun X, 2012, NEUROBIOL DIS, V45, P601, DOI 10.1016/j.nbd.2011.09.018; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; van Bregt DR, 2012, EXP NEUROL, V234, P8, DOI 10.1016/j.expneurol.2011.12.003; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; YEOMANS JS, 1989, NEUROSCI BIOBEHAV R, V13, P91, DOI 10.1016/S0149-7634(89)80016-8	59	25	25	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					414	422		10.1089/neu.2015.4361			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800017	27142118				2022-02-06	
J	Koning, ME; Scheenen, ME; van der Horn, HJ; Hageman, G; Roks, G; Spikman, JM; van der Naalt, J				de Koning, Myrthe E.; Scheenen, Myrthe E.; van der Horn, Harm J.; Hageman, Gerard; Roks, Gerwin; Spikman, Jacoba M.; van der Naalt, Joukje			Non-Hospitalized Patients with Mild Traumatic Brain Injury: The Forgotten Minority	JOURNAL OF NEUROTRAUMA			English	Article						aftercare; follow-up; mTBI; outcome	GLASGOW OUTCOME SCALE; HEAD-INJURY; EVENT SCALE; TRACK-TBI; IMPACT; VALIDATION; GUIDELINES; COMPLAINTS; SYMPTOMS; DISORDER	Non-hospitalized mild traumatic brain injury (mTBI) patients comprise a substantial part of the trauma population. For these patients, guidelines recommend specialized follow-up only in the case of persistent complaints or problems in returning to previous activities. This study describes injury and outcome characteristics of non-hospitalized mTBI patients, and the possibility of predicting which of the non-hospitalized patients will return to the outpatient neurology clinic. Data from all non-hospitalized mTBI patients (Glasgow Coma Scale [GCS] score 13-15, n = 462) from a prospective follow-up study on mTBI (UPFRONT-study) conducted in three level 1 trauma centers were analyzed. At 2 weeks, and 3 and 6 months after injury, patients completed questionnaires on post-traumatic complaints, depression, anxiety, outpatient follow-up, and resumption of activities. Most patients were male (57%), with a mean age of 40 years (range 16-91 years). Injuries were most often caused by traffic accidents (32%) or falls (39%). Six months after injury, 36% showed incomplete recovery as defined by the Glasgow Outcome Scale - Extended (GOS-E). Twenty-five percent of the non-hospitalized patients returned to the outpatient neurology clinic within 6 months after injury, of which one third had not completely resumed pre-injury activities. Regression analyses showed an increased risk for outpatient follow-up for patients scoring above the cutoff value for anxiety (odds ratio [OR] = 3.0), depression (OR = 3.5), or both (OR = 3.7) 2 weeks after injury. Our findings underline that clinicians and researchers should be aware of recovery for all mTBI patients, preventing their transition into a forgotten minority.	[de Koning, Myrthe E.; van der Horn, Harm J.; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands; [Scheenen, Myrthe E.; Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neuropsychol, Groningen, Netherlands; [Hageman, Gerard] Med Spectrum Twente, Dept Neurol, Enschede, Netherlands; [Roks, Gerwin] St Elizabeth Hosp, Dept Neurol, Tilburg, Netherlands		van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	j.van.der.naalt@umcg.nl		van der Naalt, Joukje/0000-0001-9873-2418; Spikman, Jacoba/0000-0002-6477-0763	Dutch Brain Foundation [PS2012-06]	This study was funded by the Dutch Brain Foundation (Grant no. PS2012-06).	Andriessen TMJC, 2009, BRAIN INJURY, V23, P345, DOI 10.1080/02699050902791414; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall S, 2015, BRAIN INJURY, V29, P688, DOI 10.3109/02699052.2015.1004755; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Patel MB, 2015, J NEUROTRAUM, V32, P984, DOI 10.1089/neu.2014.3652; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Ploeg E, 2004, PSYCHOL ASSESSMENT, V16, P16, DOI 10.1037/1040-3590.16.1.16; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Wohlfarth TD, 2003, PSYCHOL ASSESSMENT, V15, P101, DOI 10.1037/1040-3590.15.1.101; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	25	25	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					257	261		10.1089/neu.2015.4377			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100027	27029852	Green Submitted			2022-02-06	
J	Hu, JQ; Han, H; Cao, P; Yu, WC; Yang, C; Gao, Y; Yuan, W				Hu, Jinquan; Han, Hui; Cao, Peng; Yu, Wenchao; Yang, Chen; Gao, Yang; Yuan, Wen			Resveratrol improves neuron protection and functional recovery through enhancement of autophagy after spinal cord injury in mice	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						Spinal cord injury; resveratrol; apoptosis; autophagy; chloroquine	TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; DORSAL COLUMN; CELL-DEATH; RAT MODEL; DAMAGE; DEGENERATION; APOPTOSIS; RAPAMYCIN; STRESS	Resveratrol (Res), a natural phenolic compound, has been proven to have a wide variety of beneficial health effects. For example, resveratrol has neuroprotective effects in different central nervous system diseases. However, the mechanisms underlying resveratrol neuroprotection in spinal cord injury (SCI) remain unclear. In this study, we showed that resveratrol treatment improved the restoration of locomotor function, and decreased the degeneration of neurons in SCI mice, which was paralleled by a reduction of apoptosis. We further examined autophagy markers via western blot and immunofluorescence. Results showed that the beneficial effects of resveratrol were related to the promotion LC3II and beclin-1 expression. In addition, autophagy suppression with chloroquine (CQ) partially abolished apoptosis inhibition and locomotor functional improvement of Res on SCI, which indicated that the beneficial effect of resveratrol on SCI was through autophagy enhancement. In conclusion, these results illustrated that the neuroprotective effects of resveratrol in SCI are partially through autophagy stimulation, and implied that Res is a promising drug for SCI therapy.	[Hu, Jinquan; Cao, Peng; Yu, Wenchao; Yang, Chen; Gao, Yang; Yuan, Wen] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, 415 Fengyang Rd, Shanghai 200003, Peoples R China; [Han, Hui] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Cardiol, Shanghai 200025, Peoples R China		Gao, Y; Yuan, W (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, 415 Fengyang Rd, Shanghai 200003, Peoples R China.	3011547085@qq.com; wen-yuan2014@126.com			international cooperation program of shanghai science and technology committee [13430721000]	The study was supported by the international cooperation program of shanghai science and technology committee (13430721000).	Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bin Hong Y, 2009, EXP MOL MED, V41, P151, DOI 10.3858/emm.2009.41.3.018; Chen HC, 2012, SPINE, V37, P470, DOI 10.1097/BRS.0b013e318221e859; Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Hou HP, 2014, J NEUROSURG-SPINE, V20, P568, DOI 10.3171/2014.1.SPINE13237; Impellizzeri D, 2012, BIOCHEM PHARMACOL, V83, P1413, DOI 10.1016/j.bcp.2012.02.001; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Kanno H, 2009, NEUROBIOL DIS, V33, P143, DOI 10.1016/j.nbd.2008.09.009; Kesherwani V, 2013, NEUROSCIENCE, V241, P80, DOI 10.1016/j.neuroscience.2013.03.015; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lee DH, 2014, J NEUROSCI, V34, P15347, DOI 10.1523/JNEUROSCI.1935-14.2014; Lin CM, 2015, DRUG DES DEV THER, V9, P4709, DOI 10.2147/DDDT.S86616; Liu CJ, 2011, BRAIN RES, V1374, P100, DOI 10.1016/j.brainres.2010.11.061; Lopez MS, 2015, NEUROCHEM INT, V89, P75, DOI 10.1016/j.neuint.2015.08.009; Sirin BH, 2002, ACTA CARDIOL, V57, P279, DOI 10.2143/AC.57.4.2005427; Tang PF, 2014, MOL NEUROBIOL, V49, P276, DOI 10.1007/s12035-013-8518-3; Terayama R, 2007, NEUROSCIENCE, V148, P175, DOI 10.1016/j.neuroscience.2007.05.037; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wang R, 2014, CELL PHYSIOL BIOCHEM, V34, P854, DOI 10.1159/000366304; Warden P, 2001, EXP NEUROL, V168, P213, DOI 10.1006/exnr.2000.7622; Zhang D, 2017, MOL NEUROBIOL, V54, P3327, DOI 10.1007/s12035-016-9895-1; Zhu SP, 2016, MOL NEUROBIOL, V53, P4375, DOI 10.1007/s12035-015-9372-2	26	25	26	1	2	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2017	9	10					4607	4616					10	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	FL5MU	WOS:000414290700023	29118921				2022-02-06	
J	Martindale, SL; Morissette, SB; Rowland, JA; Dolan, SL				Martindale, Sarah L.; Morissette, Sandra B.; Rowland, Jared A.; Dolan, Sara L.			Sleep Quality Affects Cognitive Functioning in Returning Combat Veterans Beyond Combat Exposure, PTSD, and Mild TBI History	NEUROPSYCHOLOGY			English	Article						neuropsychological tests; veteran; posttraumatic stress disorder; traumatic brain injury; executive function	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHOLOGICAL OUTCOMES; PERFORMANCE VALIDITY; BEHAVIORAL THERAPY; IRAQ-WAR; DEPRIVATION; DEPLOYMENT; DEFICITS; DISTURBANCES	Objective: The purpose of this study was to determine how sleep quality affects cognitive functioning in returning combat veterans after accounting for effects of combat exposure, posttraumatic stress disorder (PTSD), and mild traumatic brain injury (mTBI) history. Method: This was a cross-sectional assessment study evaluating combat exposure, PTSD, mTBI history, sleep quality, and neuropsychological functioning. One hundred and nine eligible male Iraq/Afghanistan combat veterans completed an assessment consisting of a structured clinical interview, neuropsychological battery, and self-report measures. Results: Using partial least squares structural equation modeling, combat experiences and mTBI history were not directly associated with sleep quality. PTSD was directly associated with sleep quality, which contributed to deficits in neuropsychological functioning independently of and in addition to combat experiences, PTSD, and mTBI history. Combat experiences and PTSD were differentially associated with motor speed. Conclusions: Sleep affected cognitive function independently of combat experiences, PTSD, and mTBI history. Sleep quality also contributed to cognitive deficits beyond effects of PTSD. An evaluation of sleep quality may be a useful point of clinical intervention in combat veterans with cognitive complaints. Improving sleep quality could alleviate cognitive complaints, improving veterans' ability to engage in treatment.	[Martindale, Sarah L.; Rowland, Jared A.] WG Bill Hefner Vet Affairs Med Ctr, Mid Atlantic Mental Illness Res Educ & Clin Ctr, 1601 Brenner Ave, Salisbury, NC 28144 USA; [Martindale, Sarah L.; Rowland, Jared A.] WG Bill Hefner Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, 1601 Brenner Ave, Salisbury, NC 28144 USA; [Martindale, Sarah L.] Wake Forest Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC USA; [Morissette, Sandra B.] Univ Texas San Antonio, Dept Psychol, San Antonio, TX 78249 USA; [Rowland, Jared A.] Wake Forest Sch Med, Dept Neurobiol & Anat, Winston Salem, NC USA; [Rowland, Jared A.] Wake Forest Sch Med, Dept Psychiat, Winston Salem, NC USA; [Rowland, Jared A.] Wake Forest Sch Med, Dept Behav Med, Winston Salem, NC USA; [Dolan, Sara L.] Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA		Martindale, SL (corresponding author), WG Bill Hefner Vet Affairs Med Ctr, Mid Atlantic Mental Illness Res Educ & Clin Ctr, 1601 Brenner Ave, Salisbury, NC 28144 USA.; Martindale, SL (corresponding author), WG Bill Hefner Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, 1601 Brenner Ave, Salisbury, NC 28144 USA.	sarah.martindale-supak@va.gov	Rowland, Jared A./AAN-3030-2021; Martindale, Sarah L/O-8553-2018	Rowland, Jared A./0000-0002-3655-3411; Martindale, Sarah L/0000-0002-0059-3454	American Psychological Association; VA VISN 17 Center of Excellence for Research on Returning War Veterans; Psychology and Neuroscience Department at Baylor University; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness, Research, and TreatmentUS Department of Veterans Affairs; W. G. "Bill" Hefner Veterans Affairs Medical Center; VA Mid-Atlantic Mental Illness Research Education and Clinical Center	This research was supported in part by a grant to Sarah L. Martindale from the American Psychological Association, funding from the VA VISN 17 Center of Excellence for Research on Returning War Veterans where the research was partially conducted, and a Research Award from the Psychology and Neuroscience Department at Baylor University, where the research was also partially conducted. This research is also supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness, Research, and Treatment, the W. G. "Bill" Hefner Veterans Affairs Medical Center, and the VA Mid-Atlantic Mental Illness Research Education and Clinical Center. We appreciate the contributions of the veterans who participated in this study. A complete list of publications from this project is available upon request from Sarah L. Martindale at sarah.martindale-supak@va.gov. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Ben-David BM, 2011, J INT NEUROPSYCH SOC, V17, P354, DOI 10.1017/S135561771000175X; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Chin W., 2010, HDB PARTIAL LEAST SQ, P655, DOI DOI 10.1007/978-3-540-32827-8_29; Cohen J., 2013, STAT POWER ANAL BEHA; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-0029-1237117; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Fernandez-Mendoza J, 2010, SLEEP, V33, P459, DOI 10.1093/sleep/33.4.459; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Hair JF, 2011, J MARKET THEORY PRAC, V19, P139, DOI 10.2753/MTP1069-6679190202; Hair JF, 2014, EUR BUS REV, V26, P106, DOI 10.1108/EBR-10-2013-0128; Ho FYY, 2016, CLIN PSYCHOL REV, V43, P90, DOI 10.1016/j.cpr.2015.09.005; Jackson ML, 2011, BRAIN IMAGING BEHAV, V5, P97, DOI 10.1007/s11682-011-9115-6; Jefferson M. L., 2009, MILD TRAUMATIC BRAIN; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kertzman S, 2014, COMPR PSYCHIAT, V55, P1587, DOI 10.1016/j.comppsych.2014.05.004; Kline RB., 2016, PRINCIPLES PRACTICE, V4th edn.; Lucke-Wold BP, 2015, NEUROSCI BIOBEHAV R, V55, P68, DOI 10.1016/j.neubiorev.2015.04.010; Magill RA, 2003, NUTR NEUROSCI, V6, P237, DOI 10.1080/1028415031000120552; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Martin JL, 2011, CHEST, V139, P1514, DOI 10.1378/chest.10-1872; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mohlman J, 2005, BEHAV RES THER, V43, P447, DOI 10.1016/j.brat.2004.03.007; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; Neylan TC, 2006, ANN NY ACAD SCI, V1071, P203, DOI 10.1196/annals.1364.015; Orr N., 2010, CHEST, V138, p704A, DOI [10.1378/chest.10975, DOI 10.1378/CHEST.10975]; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Polley M., 2012, NATL VETERANS SLEEP; Ringle C.M, 2015, SMARTPLS 3; Schwab KA, 2006, NEUROLOGY, V66, pA235; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Thompson DG, 2015, AM J GERIAT PSYCHIAT, V23, P13, DOI 10.1016/j.jagp.2014.02.001; Ulmer CS, 2012, J AGGRESS MALTREAT T, V21, P67, DOI DOI 10.1080/10926771.2012.630339; Vaishnavi S, 2010, PSYCHIAT ANN, V40, P553, DOI 10.3928/00485713-20101018-06; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2010, HANDBOOK OF MEDICAL NEUROPSYCHOLOGY: APPLICATIONS OF COGNITIVE NEUROSCIENCE, P447, DOI 10.1007/978-1-4419-1364-7_24; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Verfaellie M, 2016, J HEAD TRAUMA REHAB, V31, P309, DOI 10.1097/HTR.0000000000000197; Vogt D., 2012, DEPLOYMENT RISK RESI; Waters F, 2011, J INT NEUROPSYCH SOC, V17, P571, DOI 10.1017/S1355617711000610; Wechsler D., 2008, WECHSELER ADULT INTE; West S. G., 1991, MULTIPLE REGRESSION; Wisdom NM, 2014, CLIN NEUROPSYCHOL, V28, P128, DOI 10.1080/13854046.2013.863977; Wrocklage KM, 2016, J INT NEUROPSYCH SOC, V22, P399, DOI 10.1017/S1355617716000059; Wu JC, 2006, NEUROPSYCHOPHARMACOL, V31, P2783, DOI 10.1038/sj.npp.1301166	58	25	25	0	15	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2017	31	1					93	104		10.1037/neu0000312			12	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	EH3WI	WOS:000391702300009	27690479				2022-02-06	
J	Merkel, SF; Razmpour, R; Lutton, EM; Tallarida, CS; Heldt, NA; Cannella, LA; Persidsky, Y; Rawls, SM; Ramirez, SH				Merkel, Steven F.; Razmpour, Roshanak; Lutton, Evan M.; Tallarida, Christopher S.; Heldt, Nathan A.; Cannella, Lee Anne; Persidsky, Yuri; Rawls, Scott M.; Ramirez, Servio H.			Adolescent Traumatic Brain Injury Induces Chronic Mesolimbic Neuroinflammation with Concurrent Enhancement in the Rewarding Effects of Cocaine in Mice during Adulthood	JOURNAL OF NEUROTRAUMA			English	Article						addiction; adolescent; neuroinflammation; psychostimulants; TBI	CONTROLLED CORTICAL IMPACT; SUBSTANCE-ABUSE; TYROSINE-HYDROXYLASE; RAT STRIATUM; EXPRESSION; ADDICTION; INFLAMMATION; GLUTAMATE; SYSTEM; MODEL	Clinical psychiatric disorders of depression, anxiety, and substance abuse are most prevalent after traumatic brain injury (TBI). Pre-clinical research has focused on depression and anxiety post-injury; however, virtually no data exist examining whether the preference for illicit drugs is affected by traumatic injury in the developing adolescent brain. Using the controlled cortical impact (CCI) model of TBI and the conditioned place preference (CPP) assay, we tested the underlying hypothesis that brain injury during adolescence exacerbates the rewarding properties of cocaine in adulthood possibly through an active inflammatory status in the mesolimbic pathway. Six-week old, C57BL/6 mice sustained a single CCI-TBI to the right somatosensory cortex. CPP experiments with cocaine began 2 weeks post-TBI. Animals receiving cocaine displayed significant place preference shifts compared to saline controls. Further, within the cocaine-experienced cohort, moderate CCI-TBI during adolescence significantly increased the preference shift in adulthood when compared to naive controls. Additionally, persistent neuroinflammatory responses were observed in the cortex, nucleus accumbens (NAc), and ventral tegmental area post-CCI-TBI. Significant increases in both astrocytic, glial fibrillary acidic protein, and microglial, ionization basic acid 1, markers were observed in the NAc at the end of CPP testing. Moreover, analysis using focused array gene expression panels identified the upregulation of numerous inflammatory genes in moderate CCI-TBI animals, compared to naive controls, both in the cortex and NAc at 2 weeks post-TBI, before onset of cocaine administration. These results suggest that sustaining moderate TBI during adolescence may augment the rewarding effects of psychostimulants in adulthood, possibly by induction of chronic mesolimbic neuroinflammation.	[Merkel, Steven F.; Razmpour, Roshanak; Lutton, Evan M.; Heldt, Nathan A.; Cannella, Lee Anne; Persidsky, Yuri; Ramirez, Servio H.] Temple Univ, Sch Med, Dept Pathol & Lab Med, 3500 North Broad St, Philadelphia, PA 19140 USA; [Merkel, Steven F.; Tallarida, Christopher S.; Persidsky, Yuri; Rawls, Scott M.] Temple Univ, Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19122 USA; [Ramirez, Servio H.] Temple Univ, Sch Med, Shriners Hosp Pediat Res Ctr, Philadelphia, PA 19122 USA; [Tallarida, Christopher S.; Rawls, Scott M.] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19122 USA		Ramirez, SH (corresponding author), Temple Univ, Sch Med, Dept Pathol & Lab Med, 3500 North Broad St, Philadelphia, PA 19140 USA.	servio@temple.edu		ramirez, servio/0000-0002-4609-5653; Heldt, Nathan/0000-0002-8631-5438	National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32 DA007237, P30 DA013429-16]; NIH/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS086570-01]; Shriners Hospitals for Children [85110-PHI-14]; NIH/National Institute of Mental Health (NIMH) [R01 MH65151]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS043985, R01NS086570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R37AA015913, U01AA023552] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007237, P30DA013429, R01DA040619] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) T32 DA007237 (to S.F.M.) and P30 DA013429-16 (to S.M.R. and S.H.R.), NIH/National Institute of Neurological Disorders and Stroke (NINDS) R01 NS086570-01 (to S.H.R.), The Shriners Hospitals for Children 85110-PHI-14 (to S.H.R.), and NIH/National Institute of Mental Health (NIMH) R01 MH65151 (to Y.P.).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Adler MW, 2005, J LEUKOCYTE BIOL, V78, P1204, DOI 10.1189/jlb.0405222; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Alhilali LM, 2015, RADIOLOGY, V277, P793, DOI 10.1148/radiol.2015142974; Ardelt AA, 2013, EXP NEUROL, V248, P246, DOI 10.1016/j.expneurol.2013.06.017; Blednov YA, 2011, BRAIN BEHAV IMMUN, V25, pS92, DOI 10.1016/j.bbi.2011.01.008; Chen SZ, 2008, P NATL ACAD SCI USA, V105, P19962, DOI 10.1073/pnas.0807758105; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Crews FT, 2011, BRAIN BEHAV IMMUN, V25, pS4, DOI 10.1016/j.bbi.2011.03.003; Cunningham CL, 1999, PSYCHOPHARMACOLOGY, V146, P73, DOI 10.1007/s002130051090; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Edut S, 2014, J MOL NEUROSCI, V54, P684, DOI 10.1007/s12031-014-0399-z; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Faul M, 2010, TRAUMATIC BRAIN INJU; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Hussain ZM, 2012, J NEUROTRAUM, V29, P1785, DOI 10.1089/neu.2011.2286; Hutchinson MR, 2012, J NEUROSCI, V32, P11187, DOI 10.1523/JNEUROSCI.0684-12.2012; Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515; Kerner Berit, 2009, Open Psychiatr J, V3, P1; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lim YW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125130; Lowing JL, 2014, J NEUROTRAUM, V31, P1700, DOI 10.1089/neu.2013.3286; Lynch WJ, 2010, COMPARATIVE MED, V60, P177; Martin BJ, 2011, SYNAPSE, V65, P490, DOI 10.1002/syn.20865; Mayeux JP, 2015, BEHAV BRAIN RES, V279, P22, DOI 10.1016/j.bbr.2014.10.053; Mithal DS, 2013, GLIA, V61, P1288, DOI 10.1002/glia.22515; Motzkin JC, 2014, HUM BRAIN MAPP, V35, P4282, DOI 10.1002/hbm.22474; Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578; Olson-Madden JH, 2010, J HEAD TRAUMA REHAB, V25, P470, DOI 10.1097/HTR.0b013e3181d717a7; Ramesh D, 2015, AM J ADDICTION, V24, P341, DOI 10.1111/ajad.12192; Rau TF, 2012, J TRAUMA ACUTE CARE, V73, pS165, DOI 10.1097/TA.0b013e318260896a; Redell JB, 2003, EXP BIOL MED, V228, P261, DOI 10.1177/153537020322800304; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Shah S, 2012, BRAIN INJURY, V26, P201, DOI 10.3109/02699052.2012.654591; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; Shin SS, 2013, J NEUROTRAUM, V30, P259, DOI 10.1089/neu.2012.2462; Tallarida CS, 2015, DRUG ALCOHOL DEPEN, V149, P145, DOI 10.1016/j.drugalcdep.2015.01.035; Torres LH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136399; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wang XH, 2012, P NATL ACAD SCI USA, V109, P6325, DOI 10.1073/pnas.1200130109; Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8; Weil ZM, 2016, J NEUROTRAUM, V33, P895, DOI 10.1089/neu.2015.3953; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	53	25	25	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					165	181		10.1089/neu.2015.4275			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100019	27026056	Green Published			2022-02-06	
J	Swanson, MW; Weise, KK; Dreer, LE; Johnston, J; Davis, RD; Ferguson, D; Hale, MH; Gould, SJ; Christy, JB; Busettini, C; Lee, SD; Swanson, E				Swanson, Mark W.; Weise, Katherine K.; Dreer, Laura E.; Johnston, James; Davis, Richard D.; Ferguson, Drew; Hale, Matthew Heath; Gould, Sara J.; Christy, Jennifer B.; Busettini, Claudio; Lee, Sarah D.; Swanson, Erin			Academic Difficulty and Vision Symptoms in Children with Concussion	OPTOMETRY AND VISION SCIENCE			English	Article						concussion; school; education; vision; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; POSTCONCUSSION SYNDROME; VISUAL FUNCTION; ADOLESCENTS; MANAGEMENT; IMPAIRMENT; STATEMENT; DIAGNOSIS; ATTENTION	Purpose. Academic difficulty is reported in children with prolonged post-concussive symptoms. Despite growing evidence that vestibular-ocular and vision-specific dysfunction are common in children after concussion, vision is rarely mentioned in return-to-learn protocols. The purpose of this project was to evaluate a cohort of children with prolonged post-concussive symptoms to determine if vision symptoms are associated with those reporting academic difficulty. Methods. Data were obtained from the Children's of Alabama Concussion Clinic REDCap dataset from the period January 2007 to October 2013. From this dataset of 1033 concussion events, a cohort of 276 children aged 5 to 18 years with three or more concussion-related symptoms present for 10 days or more was identified. A cross-sectional cohort study was undertaken to evaluate the association of concussion symptoms, SCAT2 scores, and demographic and concussion severity markers to reported educational difficulty among children with prolonged post-concussive symptoms. Univariate and multivariate logistic regression techniques were used to model the association of reported educational difficulty to self-reported vision abnormalities. Results. Mean age was 13.8 years. Median time since the concussive event was 21 days, with 33% (95/276) reporting their concussion more than 30 days before data collection. Academic difficulty was reported by 29% (79/270) and vision abnormalities in 46% (128/274). After model reduction, vision symptoms (OR 2.17, 95% CI 1.02, 4.62), hearing disturbance (OR 2.39, 95% CI 1.06, 5.36), and concentration difficulty (OR 21.62, 95% CI 9.50, 44.47) remained associated with academic difficulty. For those with symptoms 30 days or more after concussion, only vision (OR 3.15, 95% CI 1.06, 9.38) and concentration difficulty (OR 15.33, 95% CI 4.99, 47.05) remained statistically significant. Conclusions. Vision problems were commonly reported in children with concussions and were independently associated with those reporting academic difficulty. Comprehensive vision assessment should be considered in children reporting academic difficulty and in the development of return-to-learn protocols.	[Swanson, Mark W.; Weise, Katherine K.; Busettini, Claudio; Lee, Sarah D.] Univ Alabama Birmingham, Dept Optometry & Vis Sci, Birmingham, AL USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL USA; [Johnston, James] Univ Alabama Birmingham, Sch Med Pediat Neurosurg, Birmingham, AL USA; [Davis, Richard D.; Swanson, Erin] Univ Alabama Birmingham, Dept Pediat, Div Pediat Rehabil Med, Birmingham, AL USA; [Ferguson, Drew; Hale, Matthew Heath; Gould, Sara J.] Univ Alabama Birmingham, UAB Sports Med, Childrens Alabama, Birmingham, AL USA; [Christy, Jennifer B.] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL USA		Swanson, MW (corresponding author), Sch Optometry, 1716 Univ Blvd, Birmingham, AL 35294 USA.			Gould, Sara/0000-0002-0713-1156; Johnston, James/0000-0001-8564-1808	UAB Department of Optometry; UAB Department of Vision Sciences; UAB Vision Science Research Center's National Institutes of Health [P30 EY003039]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY003039] Funding Source: NIH RePORTER	This study was supported by the UAB Department of Optometry, the UAB Department of Vision Sciences, and the UAB Vision Science Research Center's National Institutes of Health P30 EY003039 core grant.	Alsalaheen BA, 2016, CLIN J SPORT MED, V26, P46, DOI 10.1097/JSM.0000000000000185; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Baker JG, 2015, CLIN PEDIATR, V54, P961, DOI 10.1177/0009922815588820; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Biederman J, 2015, J NERV MENT DIS, V203, P813, DOI 10.1097/NMD.0000000000000375; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Burnham KP., 2002, MODEL SELECTION MULT; Centers for Disease Control and Prevention, 2001, RAT TBI REL EM DEP V; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Ciuffreda KJ, 2014, MIL MED, V179, P1212, DOI 10.7205/MILMED-D-14-00059; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; DeMatteo C, 2015, CLIN PEDIATR, V54, P783, DOI 10.1177/0009922814567305; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kerr ZY, 2015, J ATHL TRAINING, V50, P1174, DOI 10.4085/1062-6050-50.11.11; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Olympia RP, 2016, CLIN J SPORT MED, V26, P115, DOI 10.1097/JSM.0000000000000208; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Purcell L, 2016, CLIN PEDIATR, V55, P452, DOI 10.1177/0009922815589915; Purcell LK, 2014, PAED CHILD HEALT-CAN, V19, P153, DOI 10.1093/pch/19.3.153; Rose SC, 2015, PEDIATR NEUROL, V53, P108, DOI 10.1016/j.pediatrneurol.2015.04.003; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Vargo MM, 2016, PM&R, V8, P241, DOI 10.1016/j.pmrj.2015.07.006; Zhou GW, 2015, OTOLARYNG HEAD NECK, V152, P1133, DOI 10.1177/0194599815576720	37	25	26	3	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	JAN	2017	94	1					60	67		10.1097/OPX.0000000000000977			8	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	EM5ZZ	WOS:000395393900009	27668641	Green Accepted			2022-02-06	
J	Tang, CH; Shan, YD; Hu, YL; Fang, ZJ; Tong, Y; Chen, MD; Wei, XJ; Fu, XJ; Xu, XL				Tang, Chonghui; Shan, Yudong; Hu, Yilan; Fang, Zhanjian; Tong, Yun; Chen, Mengdan; Wei, Xiaojie; Fu, Xiaojun; Xu, Xinlong			FGF2 Attenuates Neural Cell Death via Suppressing Autophagy after Rat Mild Traumatic Brain Injury	STEM CELLS INTERNATIONAL			English	Article							FIBROBLAST-GROWTH-FACTOR; UBIQUITINATED PROTEIN ACCUMULATION; SUBARACHNOID HEMORRHAGE; MITOCHONDRIAL PATHWAY; FUNCTIONAL RECOVERY; CLINICAL-TRIAL; MICE; APOPTOSIS; CONTRIBUTES; NEUROGENESIS	Traumatic brain injury (TBI) can lead to physical and cognitive deficits, which are caused by the secondary injury process. Effective pharmacotherapies for TBI patients are still lacking. Fibroblast growth factor-2 (FGF2) is an important neurotrophic factor that can stimulate neurogenesis and angiogenesis and has been shown to have neuroprotective effects after brain insults. Previous studies indicated that FGF2's neuroprotective effects might be related to its function of regulating autophagy. The present study investigated FGF2's beneficial effects in the early stage of rat mild TBI and the underlying mechanisms. One hundred and forty-four rats were used for creating controlled cortical impact (CCI) models to simulate the pathological damage after TBI. Our results indicated that pretreatment of FGF2 played a neuroprotective role in the early stage of rat mild TBI through alleviating brain edema, reducing neurological deficits, preventing tissue loss, and increasing the number of surviving neurons in injured cortex and the ipsilateral hippocampus. FGF2 could also protect cells from various forms of death such as apoptosis or necrosis through inhibition of autophagy. Finally, autophagy activator rapamycin could abolish the protective effects of FGF2. This study extended our understanding of FGF2's neuroprotective effects and shed lights on the pharmacological therapy after TBI.	[Tang, Chonghui; Shan, Yudong; Hu, Yilan; Fang, Zhanjian; Tong, Yun; Chen, Mengdan; Wei, Xiaojie; Fu, Xiaojun; Xu, Xinlong] Wenzhou Med Univ, Affiliated Cixi Hosp, Dept Neurosurg, 999 Nanerhuandong Rd, Ningbo 315300, Zhejiang, Peoples R China		Xu, XL (corresponding author), Wenzhou Med Univ, Affiliated Cixi Hosp, Dept Neurosurg, 999 Nanerhuandong Rd, Ningbo 315300, Zhejiang, Peoples R China.	xuxinlong2001@126.com			Natural Science Foundation of Ningbo City [2015A610192]; Science and Technology Plan Projects of Cixi City [CN2015022]	This study was supported by the Natural Science Foundation of Ningbo City (2015A610192) and Science and Technology Plan Projects of Cixi City (CN2015022).	Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Feng CC, 2012, INT J PHARMACEUT, V423, P226, DOI 10.1016/j.ijpharm.2011.12.008; Feng Y, 2017, CELL MOL NEUROBIOL, V37, P155, DOI 10.1007/s10571-016-0356-1; Grishchuk Y, 2011, AUTOPHAGY, V7, P1115, DOI 10.4161/auto.7.10.16608; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Huang B, 2012, NEUROBIOL DIS, V46, P204, DOI 10.1016/j.nbd.2012.01.008; Jing CH, 2012, NEUROSCIENCE, V213, P144, DOI 10.1016/j.neuroscience.2012.03.055; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Katsouri L, 2015, NEUROBIOL AGING, V36, P821, DOI 10.1016/j.neurobiolaging.2014.10.004; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lin X, 2011, INT J BIOL SCI, V7, P1114, DOI 10.7150/ijbs.7.1114; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mellergard P, 2010, BRIT J NEUROSURG, V24, P261, DOI 10.3109/02688690903521605; Menon DK, 2015, NAT REV NEUROL, V11, P71, DOI 10.1038/nrneurol.2014.261; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; Ogane K, 2002, NEUROL RES, V24, P365, DOI 10.1179/016164102101200159; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Shetty AK, 2005, GLIA, V51, P173, DOI 10.1002/glia.20187; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Thau-Zuchman O, 2012, J MOL NEUROSCI, V47, P166, DOI 10.1007/s12031-012-9706-8; Wang ZG, 2016, MOL NEUROBIOL, V53, P7298, DOI 10.1007/s12035-015-9583-6; Wang ZG, 2015, SCI REP-UK, V5, DOI 10.1038/srep09287; Wang ZG, 2012, TOXICOL LETT, V212, P137, DOI 10.1016/j.toxlet.2012.05.006; Weickert CS, 2005, NEUROSCIENCE, V131, P219, DOI 10.1016/j.neuroscience.2004.09.070; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152; Woodbury ME, 2014, J NEUROIMMUNE PHARM, V9, P92, DOI 10.1007/s11481-013-9501-5; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Ye LB, 2016, NEUROTHERAPEUTICS, V13, P844, DOI 10.1007/s13311-016-0437-3; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Zhang HY, 2013, MOL NEUROBIOL, V48, P452, DOI 10.1007/s12035-013-8432-8; Zhang J, 2012, AUTOPHAGY, V8, P690, DOI 10.4161/auto.19290; Zhao M., 2015, MOL MED REPORTS, V13	52	25	26	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1687-966X	1687-9678		STEM CELLS INT	Stem Cells Int.		2017	2017								2923182	10.1155/2017/2923182			14	Cell & Tissue Engineering	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	FK0GU	WOS:000413159100001	29181034	Green Submitted, Green Published, gold			2022-02-06	
J	Udy, AA; Jarrett, P; Lassig-Smith, M; Stuart, J; Starr, T; Dunlop, R; Deans, R; Roberts, JA; Senthuran, S; Boots, R; Bisht, K; Bulmer, AC; Lipman, J				Udy, Andrew A.; Jarrett, Paul; Lassig-Smith, Melissa; Stuart, Janine; Starr, Therese; Dunlop, Rachel; Deans, Renae; Roberts, Jason A.; Senthuran, Siva; Boots, Robert; Bisht, Kavita; Bulmer, Andrew C.; Lipman, Jeffrey			Augmented Renal Clearance in Traumatic Brain Injury: A Single-Center Observational Study of Atrial Natriuretic Peptide, Cardiac Output, and Creatinine Clearance	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; clinical management of CNS injury; traumatic brain injury	INADEQUATE ANTIMICROBIAL TREATMENT; CRITICALLY-ILL PATIENTS; INFECTIONS; VANCOMYCIN; ENOXAPARIN; PLASMA; EDEMA	Augmented renal clearance (ARC) is being increasingly described in neurocritical care practice. The mechanisms driving this phenomenon are largely unknown. The aim of this project was therefore to explore changes in renal function, cardiac output (CO), and atrial natriuretic peptide (ANP) concentrations in patientswith isolated traumatic brain injury (TBI). This prospective observational cohort study was conducted in a tertiary-level, university-affiliated intensive care unit (ICU). Patients with normal plasma creatinine concentrations (<120 mu mol/L) at admission and no history of chronic kidney disease, admitted with isolated TBI, were eligible for enrollment. Continuous CO measures were obtained using arterial pulse waveform analysis. Eight-hour urinary creatinine clearances (CLCR) were used to quantify renal function. ANP concentrations in plasma were measured on alternate days. Data were collected from study enrollment until ICU discharge, death, or day 15, which ever came first. Eleven patients, contributing 100 ICU days of physiological data, were enrolled into the study. Most participants were young men, requiring mechanical ventilation. Median ICU length of stay was 9.6 [7.8-13.0] days. Elevated CLCR measures (>150 mL/min) were frequent and appeared to parallel changes in CO. Plasma ANP concentrations were also significantly elevated over the study period (minimum value =243 pg/mL). These data suggest that ARC is likely to complicate the care of TBI patients with normal plasma creatinine concentrations, and may be driven by associated cardiovascular changes and/or elevated plasma ANP concentrations. However, significant additional research is required to further understand these findings.	[Udy, Andrew A.] Alfred, Dept Intens Care & Hyperbar Med, Level 3 East Block,Commercial Rd, Prahran, Vic 3181, Australia; [Udy, Andrew A.] Monash Univ, Alfred Ctr, Sch Publ Hlth & Prevent Med, Fac Med Nursing & Hlth Sci, Prahran, Vic, Australia; [Jarrett, Paul; Lassig-Smith, Melissa; Stuart, Janine; Starr, Therese; Dunlop, Rachel; Deans, Renae; Roberts, Jason A.; Boots, Robert; Lipman, Jeffrey] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Herston, Qld, Australia; Royal Brisbane & Womens Hosp, Dept Pharm, Herston, Qld, Australia; [Roberts, Jason A.; Lipman, Jeffrey] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Herston, Qld, Australia; [Senthuran, Siva] Townsville Hosp, Intens Care Unit, 2nd Floor North Block, Douglas, Qld, Australia; [Bisht, Kavita; Bulmer, Andrew C.] Griffith Univ, Menzies Hlth Inst Queensland, Heart Fdn Res Ctr, Gold Coast, Qld, Australia		Udy, AA (corresponding author), Alfred, Dept Intens Care & Hyperbar Med, Level 3 East Block,Commercial Rd, Prahran, Vic 3181, Australia.	a.udy@alfred.org.au	Roberts, Jason A/F-6272-2010; Bisht, Kavita/AAB-8117-2019; Udy, Andrew/S-1314-2016; Lipman, Jeffrey/G-2211-2010	Roberts, Jason A/0000-0001-6218-435X; Bisht, Kavita/0000-0002-4073-0804; Udy, Andrew/0000-0002-6284-2022; Lipman, Jeffrey/0000-0002-5965-9876	RBWH Research Foundation	This study was funded by a Project Grant provided to A/Prof. Andrew Udy by the RBWH Research Foundation.	Baptista JP, 2012, INT J ANTIMICROB AG, V39, P420, DOI 10.1016/j.ijantimicag.2011.12.011; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Carlier M, 2013, CRIT CARE, V17, DOI 10.1186/cc12705; Clerico A, 1998, J ENDOCRINOL INVEST, V21, P170, DOI 10.1007/BF03347297; CLIFTON G L, 1989, Neurosurgical Review, V12, P465, DOI 10.1007/BF01790692; Cook AM, 2013, NEUROCRIT CARE, V19, P210, DOI 10.1007/s12028-013-9837-y; Dias C, 2015, NEUROCRIT CARE, V22, P192, DOI 10.1007/s12028-014-0045-1; EDWARDS BS, 1988, CIRC RES, V62, P191, DOI 10.1161/01.RES.62.2.191; Fukui S, 2004, J CLIN NEUROSCI, V11, P507, DOI 10.1016/S0967-5868(03)00111-5; Ibrahim EH, 2000, CHEST, V118, P146, DOI 10.1378/chest.118.1.146; Kleindienst Andrea, 2012, Acta Neurochir Suppl, V114, P277, DOI 10.1007/978-3-7091-0956-4_54; Kollef MH, 1999, CHEST, V115, P462, DOI 10.1378/chest.115.2.462; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Lautrette A, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-124; Lonsdale DO, 2013, J NEUROSURG, V118, P297, DOI 10.3171/2012.10.JNS12883; Malinoski D, 2010, J TRAUMA, V68, P874, DOI 10.1097/TA.0b013e3181d32271; MARINGREZ M, 1986, NATURE, V324, P473, DOI 10.1038/324473a0; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; NARUSE S, 1991, STROKE, V22, P61, DOI 10.1161/01.STR.22.1.61; Robinson S, 2010, CRIT CARE, V14, DOI 10.1186/cc8924; TANAKA I, 1984, BIOCHEM BIOPH RES CO, V124, P663, DOI 10.1016/0006-291X(84)91606-1; Udy A, 2010, ANESTH ANALG, V111, P1505, DOI 10.1213/ANE.0b013e3181f7107d; Udy AA, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0657-z; Udy AA, 2013, INTENS CARE MED, V39, P2070, DOI 10.1007/s00134-013-3088-4; Udy AA, 2012, CHEST, V142, P30, DOI 10.1378/chest.11-1671; Udy AA, 2011, NAT REV NEPHROL, V7, P539, DOI 10.1038/nrneph.2011.92; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; YANDLE TG, 1986, LIFE SCI, V38, P1827, DOI 10.1016/0024-3205(86)90137-2	30	25	25	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					137	144		10.1089/neu.2015.4328			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100017	27302851				2022-02-06	
J	Walker, MS; Kaimal, G; Gonzaga, AML; Myers-Coffman, KA; DeGraba, TJ				Walker, Melissa S.; Kaimal, Girija; Gonzaga, Adele M. L.; Myers-Coffman, Katherine A.; DeGraba, Thomas J.			Active-duty military service members' visual representations of PTSD and TBI in masks	INTERNATIONAL JOURNAL OF QUALITATIVE STUDIES ON HEALTH AND WELL-BEING			English	Article						Post-traumatic stress disorder; traumatic brain injury; art therapy; masks; active duty military	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; ART-THERAPY; GROUP-PSYCHOTHERAPY; WAR VETERANS; COMBAT; PERSONNEL; EMOTIONS; COHORT; VIDEO	Active-duty military service members have a significant risk of sustaining physical and psychological trauma resulting in traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD). Within an interdisciplinary treatment approach at the National Intrepid Center of Excellence, service members participated in mask making during art therapy sessions. This study presents an analysis of the mask-making experiences of service members (n = 370) with persistent symptoms from combat and mission-related TBI, PTSD, and other concurrent mood issues. Data sources included mask images and therapist notes collected over a five-year period. The data were coded and analyzed using grounded theory methods. Findings indicated that mask making offered visual representations of the self related to individual personhood, relationships, community, and society. Imagery themes referenced the injury, relational supports/losses, identity transitions/questions, cultural metaphors, existential reflections, and conflicted sense of self. These visual insights provided an increased understanding of the experiences of service members, facilitating their recovery.	[Walker, Melissa S.; DeGraba, Thomas J.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Kaimal, Girija; Gonzaga, Adele M. L.; Myers-Coffman, Katherine A.] Drexel Univ, Coll Nursing & Hlth Profess, Philadelphia, PA 19104 USA		Walker, MS (corresponding author), Natl Intrepid Ctr Excellence, Bldg 51,4860 S Palmer Rd, Bethesda, MD 20889 USA.	melissa.s.walker12.civ@mail.mil		Walker, Melissa/0000-0001-9375-567X	National Endowment for the Arts	This work was supported by the National Endowment for the Arts.	Agberia J. T., 2006, J ASIAN AFR STUD, V41, P249, DOI [10.1177/0021909606063880, DOI 10.1177/0021909606063880]; AKPAN JJ, 1994, AFR ARTS, V27, P48, DOI 10.2307/3337318; Akpan Joseph, 1994, AFR ARTS, V19, P94, DOI DOI 10.2307/3337318; American Art Therapy Association, 2009, US ART THER TREATM V; Andrew E. H., 2014, CROSS CULTURAL COMMU, V10, P211; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; Blakeley K, 2013, POSTTR STRESS DIS ME; Chen D., 2016, THESE POWERFUL MASKS; Coll JE, 2011, SOC WORK HEALTH CARE, V50, P487, DOI 10.1080/00981389.2010.528727; Collie K, 2006, ART THER, V23, P157, DOI 10.1080/07421656.2006.10129335; Defense and Veterans Brain Injury Center, 2016, DOD WORLDW NUMB TBI; Diakparomre A. M., 2010, J ASIAN AFR STUD, V45, P467, DOI [10.1177/0021909610373220, DOI 10.1177/0021909610373220]; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Dursa EK, 2014, J TRAUMA STRESS, V27, P542, DOI 10.1002/jts.21956; Fear NT, 2010, LANCET, V375, P1783, DOI 10.1016/S0140-6736(10)60672-1; Fiet L., 2014, CARIBBEAN Q, V60, P58, DOI [10.1080/00086495.2014.11672526, DOI 10.1080/00086495.2014.11672526]; Frenz M., 2007, THESIS; FRYREAR JL, 1988, ART PSYCHOTHER, V15, P227, DOI 10.1016/0197-4556(88)90007-X; Furuki K, 2011, EURAMERICA, V41, P949; GOLUB D, 1985, ART PSYCHOTHER, V12, P285, DOI 10.1016/0197-4556(85)90041-3; HERMAN JL, 1992, J TRAUMA STRESS, V5, P377, DOI 10.1002/jts.2490050305; Hines-Martin V P, 1993, J Psychosoc Nurs Ment Health Serv, V31, P29; HINZ LD, 1990, ART PSYCHOTHER, V17, P259, DOI 10.1016/0197-4556(90)90009-F; Hogan S., 2001, HEALING ARTS HIST AR; Hyatt KS, 2015, J NURS SCHOLARSHIP, V47, P300, DOI 10.1111/jnu.12143; Jain S, 2012, MIL MED, V177, P1015, DOI 10.7205/MILMED-D-11-00290; Jiachiao L., 2013, CROSS CULTURAL COMMU, V9, P47; Kopytin A, 2013, ART THER, V30, P20, DOI 10.1080/07421656.2013.757758; Kroch R., 2009, THESIS; Lande RG, 2010, ART PSYCHOTHER, V37, P42, DOI 10.1016/j.aip.2009.09.007; Lawrence D., 2012, INVESTIGATE USE ART; Lobban J., 2014, INT J ART THER, V19, P3, DOI [https://doi.org/10.1080/17454832.2012.725547, DOI 10.1080/17454832.2012.725547]; Lobban J., 2016, ART THERAPY MILITARY; Malchiodi CA, 2012, HDB ART THERAPY, P320; Medina V., 2009, COOLABAH, V3, P235; Nanda U, 2010, ENVIRON BEHAV, V42, P376, DOI 10.1177/0013916510361874; North Atlanta Treaty Organization, 2016, NATO AFGHANISTAN; Pachalska M, 2013, ACTA NEUROPSYCHOL, V11, P435; PAOLETTI JT, 1992, ART BULL, V74, P423, DOI 10.2307/3045891; POLLOCK D, 1995, J ROY ANTHROPOL INST, V1, P581, DOI 10.2307/3034576; Reijnen A, 2015, EUR PSYCHIAT, V30, DOI 10.1016/j.eurpsy.2014.05.003; Robles Martinez Angel, 2013, THESIS; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Rubin DC, 2004, APPL COGNITIVE PSYCH, V18, P17, DOI 10.1002/acp.950; Sargent PD, 2013, PSYCHIAT ANN, V43, P181, DOI 10.3928/00485713-20130403-10; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Strauss A., 2008, BASICS QUALITATIVE R, DOI 10.1080/13504620500081384.; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Toblin RL, 2012, J AFFECT DISORDERS, V136, P469, DOI 10.1016/j.jad.2011.10.048; U.S. Government Accountability Office, 2011, VA MENT HLTH NUM VET; van der Kolk B.A., 2014, BODY KEEPS SCORE BRA; Walker MS, 2016, ART PSYCHOTHER, V49, P10, DOI 10.1016/j.aip.2016.05.015; Wall PLH, 2012, J AM PSYCHIAT NURSES, V18, P278, DOI 10.1177/1078390312460578; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zinzow HM, 2013, MIL PSYCHOL, V25, P514, DOI 10.1037/mil0000015; [No title captured]	56	25	25	1	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1748-2623	1748-2631		INT J QUAL STUD HEAL	Int. J. Qual. Stud. Health Well-Being		2017	12								1267317	10.1080/17482631.2016.1267317			12	Public, Environmental & Occupational Health; Nursing; Social Sciences, Biomedical	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Nursing; Biomedical Social Sciences	EN7EY	WOS:000396166100001	28452610	Green Published, gold			2022-02-06	
J	Yang, YQ; Wang, HD; Li, LW; Li, X; Wang, Q; Ding, H; Wang, XL; Ye, ZN; Wu, LY; Zhang, XS; Zhou, ML; Pan, H				Yang, Youqing; Wang, Handong; Li, Liwen; Li, Xiang; Wang, Qiang; Ding, Hui; Wang, Xiaoliang; Ye, Zhennan; Wu, Lingyun; Zhang, Xiangsheng; Zhou, Mengliang; Pan, Hao			Sinomenine Provides Neuroprotection in Model of Traumatic Brain Injury via the Nrf2-ARE Pathway	FRONTIERS IN NEUROSCIENCE			English	Article						traumatic brain injury; nuclear factor erythroid 2-related factor 2; sinomenine; neuroprotection; reactive oxygen species	OXIDATIVE STRESS; GENE-EXPRESSION; ACTIVATION; PROTECTION; APOPTOSIS; INHIBITION; PROTEINS; BALANCE; DISEASE; DAMAGE	The neuroprotective effect of sinomenine (SIN) has been demonstrated in several brain injury models. However, its role and molecular mechanism in traumatic brain injury (TBI) remain unknown. In this study, we investigated the neuroprotective effects of SIN in the weight-drop model of TBI in male ICR mice. Mice were randomly divided into the sham and TBI groups, SIN (10 mg/kg, 30 mg/kg and 50 mg/kg, administered intraperitoneally) or equal volume of vehicle was given at 30 min after TBI. Treatment with 30 mg/kg SIN significantly improved motor performance and alleviated cerebral edema. However, treatment with 10 mg/kg or 50 mg/kg SIN did not exhibit a better outcome. Therefore, we chose 30 mg/kg SIN for our subsequent experiments. SIN significantly increased the expression of Bcl-2 and decreased that of cleaved caspase-3, indicating that SIN is anti-apoptotic. This was confirmed by the observation that SIN-treated animals had fewer apoptotic neurons. Cortical malondialdehyde content, glutathione peroxidase (GPx) activity and superoxide dismutase (SOD) activity were restored in the group that received SIN. Furthermore, Western blot and immunofluorescence experiments showed that SIN enhanced the translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) to the nucleus. SIN administration also significantly upregulated the expression of the downstream factors heme oxygenase 1 and NAD(P)H:quinone oxidoreductase 1 at pre- and post-transcriptional levels. Together, these data demonstrate that SIN exerts a neuroprotective effect in a model of TBI, possibly by activating the Nrf2 antioxidant response element (ARE) pathway.	[Yang, Youqing; Wang, Handong; Ding, Hui; Ye, Zhennan] Southern Med Univ Guangzhou, Clin Med Coll, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Li, Liwen; Li, Xiang; Wang, Qiang; Wang, Xiaoliang; Wu, Lingyun; Zhang, Xiangsheng; Zhou, Mengliang; Pan, Hao] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China		Wang, HD (corresponding author), Southern Med Univ Guangzhou, Clin Med Coll, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81401026]	This study was grant-supported by the National Natural Science Fund of China (grant Nos. 81371357 and 81401026).	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ansari MA, 2006, FREE RADICAL BIO MED, V41, P1694, DOI 10.1016/j.freeradbiomed.2006.09.002; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Cheng Y, 2013, MOL MED REP, V7, P1223, DOI 10.3892/mmr.2013.1302; Cheng Y, 2009, INT IMMUNOPHARMACOL, V9, P894, DOI 10.1016/j.intimp.2009.03.014; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Miller TW, 2009, CHEM REV, V109, P3099, DOI 10.1021/cr8005125; Qian L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-23; Qin T, 2016, TOXICOL APPL PHARM, V304, P1, DOI 10.1016/j.taap.2016.05.009; Radak Z, 2013, ANTIOXID REDOX SIGN, V18, P1208, DOI 10.1089/ars.2011.4498; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; Sun M, 2015, J NEUROTRAUM, V32, P66, DOI 10.1089/neu.2012.2432; Tsai CY, 2013, INT J CARDIOL, V168, P1286, DOI 10.1016/j.ijcard.2012.12.004; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang QX, 2011, INT IMMUNOPHARMACOL, V11, P373, DOI 10.1016/j.intimp.2010.11.018; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu WN, 2011, BRIT J PHARMACOL, V164, P1445, DOI 10.1111/j.1476-5381.2011.01487.x; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Xu M, 2008, PLANTA MED, V74, P1423, DOI 10.1055/s-2008-1081346; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yang Z, 2014, MOL IMMUNOL, V60, P109, DOI 10.1016/j.molimm.2014.03.005; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang Lijuan, 2016, Zhongguo Zhen Jiu, V36, P131; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	41	25	27	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-453X		FRONT NEUROSCI-SWITZ	Front. Neurosci.	DEC 23	2016	10								580	10.3389/fnins.2016.00580			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EF5MK	WOS:000390374100001	28066165	Green Published, gold			2022-02-06	
J	Brooks, BL; Mannix, R; Maxwell, B; Zafonte, R; Berkner, PD; Iverson, GL				Brooks, Brian L.; Mannix, Rebekah; Maxwell, Bruce; Zafonte, Ross; Berkner, Paul D.; Iverson, Grant L.			Multiple Past Concussions in High School Football Players: Are There Differences in Cognitive Functioning and Symptom Reporting?	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						child; adolescent; traumatic brain injury; sports; postconcussion syndrome	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION-LIKE SYMPTOMS; PROFESSIONAL SOCCER PLAYERS; HEAD IMPACT EXPOSURE; BASE-LINE; ELECTROPHYSIOLOGICAL ABNORMALITIES; NEUROPSYCHOLOGICAL PERFORMANCE; NONCLINICAL SAMPLE; SPORT CONCUSSION; 1ST EXPOSURE	Background: There is increasing concern about the possible long-term effects of multiple concussions, particularly on the developing adolescent brain. Whether the effect of multiple concussions is detectable in high school football players has not been well studied, although the public health implications are great in this population. Purpose: To determine if there are measureable differences in cognitive functioning or symptom reporting in high school football players with a history of multiple concussions. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Participants included 5232 male adolescent football players (mean [SD] age, 15.5 1.2 years) who completed baseline testing between 2009 and 2014. On the basis of injury history, athletes were grouped into 0 (n = 4183), 1 (n = 733), 2 (n = 216), 3 (n = 67), or 4 (n = 33) prior concussions. Cognitive functioning was measured by the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) battery, and symptom ratings were obtained from the Post-Concussion Symptom Scale. Results: There were no statistically significant differences between groups (based on the number of reported concussions) regarding cognitive functioning. Athletes with 3 prior concussions reported more symptoms than did athletes with 0 or 1 prior injury. In multivariate analyses, concussion history was independently related to symptom reporting but less so than developmental problems (eg, attention or learning problems) or other health problems (eg, past treatment for psychiatric problems, headaches, or migraines). Conclusion: In the largest study to date, high school football players with multiple past concussions performed the same on cognitive testing as those with no prior concussions. Concussion history was one of several factors that were independently related to symptom reporting.	[Brooks, Brian L.; Mannix, Rebekah; Maxwell, Bruce; Zafonte, Ross; Berkner, Paul D.; Iverson, Grant L.] Colby Coll, Waterville, ME 04901 USA; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Program Brain Injury & Rehabil, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Pediat, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Mannix, Rebekah] Boston Childrens Hosp, Brain Injury Ctr, Div Emergency Med, Boston, MA USA; [Maxwell, Bruce] Colby Coll, Dept Comp Sci, Waterville, ME 04901 USA; [Zafonte, Ross] Harvard Med Sch, Brigham & Womens Hosp, Massachusetts Gen Hosp, Dept Phys Med & Rehabil,Spaulding Rehabil Hosp, Boston, MA USA; [Zafonte, Ross; Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Zafonte, Ross; Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Berkner, Paul D.] Colby Coll, Hlth Serv & Dept Biol, Waterville, ME 04901 USA; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Children, Sport Concuss Program, Boston, MA USA		Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca	Mannix, Rebekah/AAD-8702-2020	Iverson, Grant/0000-0001-7348-9570	Goldfarb Center for Public Affairs and Civic Engagement at Colby College; Bill and Joan Alfond Foundation; Harvard Integrated Program to Protect and Improve the Health of National Football League Players Association Members; Department of Defense of the Harvard Clinical Consortium Post-traumatic Stress Disorder/Traumatic Brain Injury Study Site (INTRuST) [USAMRMC W81XWH-08-2-0159]; ImPACT Applications Inc; Mooney-Reed Charitable Foundation;  [NIH/EKS-NICHD 1 R24 HD065688]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128, R24HD065688] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: This study was funded by the Goldfarb Center for Public Affairs and Civic Engagement at Colby College and the Bill and Joan Alfond Foundation. B.L.B. receives royalties for the sales of a pediatric forensic textbook and pediatric neuropsychological tests; he has previously received support (in-kind test credits) from a different computerized cognitive test publisher. R.Z. was supported in part by the Harvard Integrated Program to Protect and Improve the Health of National Football League Players Association Members. Funding for R.Z. includes the Improving Outcome Measurement for Medical Rehabilitation Clinical Trials (NIH/EKS-NICHD 1 R24 HD065688) and the Department of Defense (USAMRMC W81XWH-08-2-0159) of the Harvard Clinical Consortium Post-traumatic Stress Disorder/Traumatic Brain Injury Study Site (INTRuST); he is also an investigator on the Football Players Health Study at Harvard University. G.L.I. has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to mild traumatic brain injuries (MTBIs) and sport-related concussions at meetings, scientific conferences, and symposiums; he has a clinical practice in forensic neuropsychology involving patients who have sustained MTBIs (including athletes); he has received honoraria for serving on research panels that provide scientific peer reviews of programs; he is a coinvestigator, collaborator, or consultant on grants relating to MTBIs funded by several organizations; and he has received research support from test publishing companies in the past including ImPACT Applications Inc (not in the past 5 years). R.Z. and G.L.I. acknowledge support from the Mooney-Reed Charitable Foundation.	Balasundaram AP, 2013, PHYS THER SPORT, V14, P253, DOI 10.1016/j.ptsp.2013.06.002; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Brooks BL, 2016, APPL NEUROPSYCH-CHIL, V5, P119, DOI 10.1080/21622965.2014.1003066; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Cohen J., 2013, STAT POWER ANAL BEHA; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Connery AK, 2014, NEUROSURGERY, V75, P31, DOI 10.1227/NEU.0000000000000346; Daniel RW, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027872; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Edmed S, 2012, PSYCHIAT RES, V200, P41, DOI 10.1016/j.psychres.2012.05.022; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; ImPACT Applications Inc., 2011, TECHN MAN ONL IMPACT; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckay CD, 2014, J ORTHOP SPORT PHYS, V44, P329, DOI 10.2519/jospt.2014.5053; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Pedhazur, 1997, MULTIPLE REGRESSION; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Silverberg ND, 2016, CLIN J SPORT MED, V26, P226, DOI 10.1097/JSM.0000000000000241; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Tsushima WT, 2016, APPL NEUROPSYCH-CHIL, V5, P9, DOI 10.1080/21622965.2014.902762; Tsushima WT, 2013, APPL NEUROPSYCH-CHIL, V2, P13, DOI 10.1080/09084282.2011.643967; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	78	25	25	0	38	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2016	44	12					3243	3251		10.1177/0363546516655095			9	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	EE8VS	WOS:000389905400029	27474382	Green Accepted			2022-02-06	
J	Clark, JM; Post, A; Hoshizaki, TB; Gilchrist, MD				Clark, J. Michio; Post, Andrew; Hoshizaki, T. Blaine; Gilchrist, Michael D.			Protective Capacity of Ice Hockey Helmets against Different Impact Events	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Ice hockey; Helmet; Concussion; Impact biomechanics; Finite element modeling	INJURY SURVEILLANCE SYSTEM; HEAD IMPACT; INTRACRANIAL-PRESSURE; PROFESSIONAL FOOTBALL; DESCRIPTIVE EPIDEMIOLOGY; ACCIDENT RECONSTRUCTION; ANGULAR ACCELERATION; VIDEO ANALYSIS; BRAIN-INJURY; LEAGUE NHL	In ice hockey, concussions can occur as a result of many different types of impact events, however hockey helmets are certified using a single injury scenario, involving drop tests to a rigid surface. The purpose of this study is to measure the protective capacity of ice hockey helmets for different impact events in ice hockey. A helmeted and unhelmeted Hybrid III headform were impacted simulating falls, elbow, shoulder and puck impacts in ice hockey. Linear and rotational acceleration and maximum principal strain (MPS) were measured. A comparison of helmeted and unhelmeted impacts found significant differences existed in most conditions (p < 0.05), however some shoulder and puck impacts showed no significant difference (p > 0.05). Impacts to the ice hockey helmet tested resulted in acceleration levels below reported ranges of concussion and TBI for falls up to 5 m/s, elbow collisions, and low velocity puck impacts but not for shoulder collisions or high velocity puck impacts and falls. The helmet tested reduced MPS below reported ranges of concussion and TBI for falls up to 5 m/s but not for the other impact events across all velocities and locations. This suggests that the ice hockey helmet tested is unable to reduce engineering parameters below reported ranges of concussion and TBI for impact conditions which do not represent a drop against a rigid surface.	[Clark, J. Michio; Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland; [Clark, J. Michio; Post, Andrew; Hoshizaki, T. Blaine; Gilchrist, Michael D.] Univ Ottawa, Sch Human Kinet, 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada; [Post, Andrew] Childrens Hosp Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada		Clark, JM (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland.; Clark, JM (corresponding author), Univ Ottawa, Sch Human Kinet, 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada.	michio.clark@ucd.ie					Adams J, 1987, P 31 STAPP CAR CRASH, V96, P1355, DOI DOI 10.4271/872197; Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Canadian Standards Association, 2009, Z262109 CAN STAND AS; Coulson NR, 2009, J ASTM INT, V6, P1; Delaney JS, 2014, CLIN J SPORT MED, V24, P233, DOI 10.1097/JSM.0000000000000017; DENG YC, 1989, ACCIDENT ANAL PREV, V21, P85, DOI 10.1016/0001-4575(89)90051-1; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2009, INT J CRASHWORTHINES, V14, P503, DOI 10.1080/13588260902826554; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Fahlstedt M., 2012, 2012 IRCOBI C P INT, P787, DOI DOI 10.1177/1753193412460139; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Gilchrist MD, 2003, KEY ENG MATER, V245-2, P417, DOI 10.4028/www.scientific.net/KEM.245-246.417; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Hardy W. N., 2001, STAPP CAR CRASH J, V51, P17; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Holbourn AHS, 1943, LANCET, V2, P438; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki T Blaine, 2014, Neurosurgery, V75 Suppl 4, pS136, DOI 10.1227/NEU.0000000000000496; Hoshizaki TB, 2004, NEUROSURGERY, V55, P956, DOI 10.1227/01.NEU.0000137275.50246.0B; Hutchison MG, 2015, BRIT J SPORT MED, V49, P552, DOI 10.1136/bjsports-2013-092235; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Karton CM, 2014, AM SOC TEST MATER, V1552, P23, DOI 10.1520/STP155220120175; Kendall M., 2012, INT RES COUNC BIOM I, P430, DOI DOI 10.1016/J.JECP.2012.07.001; Kendall M., 2012, J SPORTS ENG TECHNOL, V0, P1; Kendall M, 2014, AM SOC TEST MATER, V1552, P142, DOI 10.1520/STP155220120150; Kleiven S, 2002, P IRCOBI, P161; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller RT, 1998, P 42 STAPP CAR CRASH; Milne G., 2013, P IRC 13 90 IRCOBI C, V33, P735; Nahum AM, 1977, P 21 STAPP CAR CRASH; Newman J, 2000, P INT RES COUNC BIOM; Nobes KJ, 2003, CAN J APPL PHYSIOL, V28, P1, DOI 10.1139/h03-001; Nusholtz G.S., 1984, 841657 SAE, P41; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ono K., 1980, P 24 STAPP CAR CRASH; Ouckama R., 2014, IRCOBI P, P62; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pearsall D., 1999, SPORTS ENG, V2, P3, DOI [10.1046/j.1460-2687.1999.00018.x, DOI 10.1046/J.1460-2687.1999.00018.X]; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A., 2013, J NEUROSURG, V1-9, P1; Post A., 2015, NEUROSURGERY, V51, P325; Post A, 2012, J SPORTS ENG TECHNOL, P1; Post A., 2013, THESIS; Post A., 2011, COMPUT METHOD BIOMEC, P1; Post A, 2015, ACCIDENT ANAL PREV, V79, P33, DOI 10.1016/j.aap.2015.03.017; Post A, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4028983; Post A, 2015, J MECH BEHAV BIOMED, V41, P325, DOI 10.1016/j.jmbbm.2014.07.034; Post A, 2014, J BIOMECH, V47, P1074, DOI 10.1016/j.jbiomech.2013.12.026; Post A, 2012, TRAUMA, V14, P327, DOI 10.1177/1460408612446573; Post A, 2012, J BIOMECH, V45, P679, DOI 10.1016/j.jbiomech.2011.12.005; Rousseau P, 2014, AM SOC TEST MATER, V1552, P196, DOI 10.1520/STP155220120159; Rousseau P, 2009, P I MECH ENG P-J SPO, V223, P159, DOI 10.1243/17543371JSET36; Rousseau P., 2009, J ASTM INT, V6, P1; Rousseau P., 2014, THESIS; Rousseau P, 2015, SPORT BIOMECH, V14, P57, DOI 10.1080/14763141.2015.1025236; Rowson B., 2015, ANN BIOMED IN PRESS, P1; Roy B., 1975, 5 INT C BIOM INT C B; Ruan J, 1994, THESIS; Seemann M. R., 1986, P 30 STAPP CAR CRASH, V30, P291; Smith TA, 2015, SPORTS ENG, V18, P165, DOI 10.1007/s12283-015-0175-5; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; THOMAS LM, 1966, J NEUROL NEUROSUR PS, V29, P404, DOI 10.1136/jnnp.29.5.404; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Walsh E. S., 2012, ASTM S MECH CONC SPO; Walsh E. S., 2012, J SPORTS ENG, P1; Wayne M., 2014, MECH CONCUSSION SPOR; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R., 1992, P INT IRCOBI C BIOM, P179; Wu T.C., 2003, SPORTS ENG, V6, P31, DOI [10.1007/BF02844158, DOI 10.1007/BF02844158]; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488; Zhou C., 1995, 39 STAPP CAR CRASH C	88	25	25	5	32	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	DEC	2016	44	12					3693	3704		10.1007/s10439-016-1686-3			12	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	EC4MB	WOS:000388103900021	27384941	Green Submitted			2022-02-06	
J	Miszczuk, D; Debski, KJ; Tanila, H; Lukasiuk, K; Pitkanen, A				Miszczuk, Diana; Debski, Konrad J.; Tanila, Heikki; Lukasiuk, Katarzyna; Pitkanen, Asla			Traumatic Brain Injury Increases the Expression of Nos1, A beta Clearance, and Epileptogenesis in APP/PS1 Mouse Model of Alzheimer's Disease	MOLECULAR NEUROBIOLOGY			English	Article						Alzheimer's disease; Beta-amyloid; Epileptogenesis; Nitric oxide synthase 1; Transcriptome; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; NITRIC-OXIDE; POSTTRAUMATIC EPILEPSY; COGNITIVE DEFICITS; APOLIPOPROTEIN-E; TAU; MICE; DEPOSITION; PROTEIN; HYPEREXCITABILITY	To test the hypothesis that an amyloidogenic genetic background predisposes to worsening of post-TBI outcome, we investigated whether traumatic brain injury (TBI) in http://unabridged.merriam-webster.com(APP)/PS1 mice aggravates epileptogenesis and/or enhances somatomotor and cognitive impairment. To elaborate the mechanisms of worsening outcomes, we studied changes in the expression of genes involved in APP processing and Tau pathways in the perilesional cortex, ipsilateral thalamus, and ipsilateral hippocampus 16 weeks post-TBI. Mild (mTBI) or severe TBI (sTBI) was triggered using controlled cortical impact in 3-month-old APP/PS1 mice and wild-type (Wt) littermates. Morris water-maze revealed a genotype effect on spatial learning and memory as APP/PS1-sTBI mice performed more poorly than Wt-sTBI mice (p < 0.05). Epileptogenesis was affected by genotype and TBI as 88 % of APP/PS1-sTBI mice had epilepsy compared to 11 % in Wt-sTBI (genotype effect p < 0.01) or 50 % in APP/PS1-sham groups (TBI effect p < 0.05). The higher the seizure frequency, the higher the cortical expression of Nos1 (r = 0.83, p < 0.001) and Mapk3 (r = 0.67, p < 0.001). Immunohistochemical analysis confirmed increased amount of NOS1 protein in neuronal somata and processes in the perilesional cortex in APP/PS1-sTBI mice compared to APP/PS1-sham (p < 0.05) or Wt-sTBI mice (p < 0.01). Motor impairment correlated (p < 0.001) with the increased cortical expression of genes encoding proteins related to beta-amyloid (A beta) clearance, including Clu (r = 0.83), Abca1 (r = 0.78), A2m (r = 0.76), Apoe (r = 0.70), and Ctsd (r = 0.63). Immunohistochemical analysis revealed a focal reduction in A beta load lateral to lesion core in APP/PS1-sTBI mice compared to APP/PS1-sham mice (p < 0.05). The present study provides the first comprehensive evidence of exacerbated epileptogenesis and its molecular mechanisms in Alzheimer's disease (AD)-related genetic background after TBI.	[Miszczuk, Diana; Debski, Konrad J.; Lukasiuk, Katarzyna] Polish Acad Sci, Nencki Inst Expt Biol, 3 Pasteur St, PL-02093 Warsaw, Poland; [Miszczuk, Diana; Tanila, Heikki; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland		Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uef.fi		Miszczuk, Diana/0000-0001-9798-6088; Lukasiuk, Katarzyna/0000-0002-1582-0920	Academy of Finland grant EuroEPINOMICSAcademy of Finland; Sigrid Juselius FoundationSigrid Juselius Foundation; CIMO (Center for International Mobility); Foundation for Polish Science grant [MPD/2009/4]; National Science Center of PolandNational Science Centre, Poland [2012/05/N/NZ/02500]; Ministry of Science and Higher EducationMinistry of Science and Higher Education, PolandEuropean Commission [DNP/N119/ESF-EuroEPINOMICS/2012]	This study was supported by the Academy of Finland grant EuroEPINOMICS (AP), The Sigrid Juselius Foundation (AP), CIMO (Center for International Mobility) (DM), Foundation for Polish Science grant MPD/2009/4 (KL), National Science Center of Poland grant 2012/05/N/NZ/02500 (DM, KL), and Ministry of Science and Higher Education grant DNP/N119/ESF-EuroEPINOMICS/2012 (KL).	Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bot AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076051; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Devos SL, 2013, J NEUROSCI, V33, P12887, DOI 10.1523/JNEUROSCI.2107-13.2013; Garcia-Alloza M, 2006, NEUROBIOL DIS, V24, P516, DOI 10.1016/j.nbd.2006.08.017; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Holth JK, 2013, J NEUROSCI, V33, P1651, DOI 10.1523/JNEUROSCI.3191-12.2013; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kawai N, 2013, BRAIN INJURY, V27, P1026, DOI 10.3109/02699052.2013.794963; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Minkeviciene R, 2009, J NEUROSCI, V29, P3453, DOI 10.1523/JNEUROSCI.5215-08.2009; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Noebels J, 2011, EPILEPSIA, V52, P39, DOI 10.1111/j.1528-1167.2010.02909.x; Pitkanen A, 2014, EPILEPSY BEHAV, V38, P19, DOI 10.1016/j.yebeh.2014.01.013; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; R Development Core Team,, 2012, R LANG ENV STAT COMP; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Roberson ED, 2011, J NEUROSCI, V31, P700, DOI 10.1523/JNEUROSCI.4152-10.2011; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rogaeva E, 2001, J ALZHEIMERS DIS, V3, P293, DOI 10.3233/JAD-2001-3304; Schellenberg G D, 2000, Curr Psychiatry Rep, V2, P158, DOI 10.1007/s11920-000-0061-z; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shemer I, 2006, EUR J NEUROSCI, V23, P2035, DOI 10.1111/j.1460-9568.2006.04733.x; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209; Valasek MA, 2005, ADV PHYSIOL EDUC, V29, P151, DOI 10.1152/advan.00019.2005; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203	52	25	25	0	22	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	DEC	2016	53	10					7010	7027		10.1007/s12035-015-9578-3			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EC1MQ	WOS:000387870200037	26671618				2022-02-06	
J	Xuan, WJ; Huang, LY; Hamblin, MR				Xuan, Weijun; Huang, Liyi; Hamblin, Michael R.			Repeated transcranial low-level laser therapy for traumatic brain injury in mice: biphasic dose response and long-term treatment outcome	Journal of Biophotonics			English	Article						Traumatic brain injury; controlled cortical impact mouse model; photobiomodulation; LLLT; biphasic dose response; Morris water maze; glial fibrillary acidic protein; reactive gliosis	FIBRILLARY ACIDIC PROTEIN; LIGHT THERAPY; NEUROLOGICAL DEFICITS; CEREBRAL-ISCHEMIA; UNITED-STATES; GFAP; SYNAPTOGENESIS; ACTIVATION; ASTROCYTES; RECOVERY	We previously showed that near-infrared laser photobiomodulation (PBM) (810 nm, CW, 18 J/cm(2), 25 mW/cm(2)) delivered to the mouse daily for 3-days after a controlled cortical impact traumatic brain injury (TBI) gave a significant improvement in neurological/cognitive function. However the same parameters delivered 14X daily gave significantly less benefit. This biphasic dose response intrigued us, and we decided to follow the mice that received 3X or 14X laser treatments out to 56-days post-TBI. We found the 14X group showed worse neurological function than the no-treatment TBI group at 2-weeks, but started to improve steadily during the next 6-weeks, and by 56-days were significantly better than the no-treatment TBI mice, but still worse than the 3X mice. A marker of activated glial cells (GFAP) was significantly increased in the brain regions (compared to both untreated TBI and 3X groups) at 4-weeks in the 14X group, but the GFAP had fallen to low levels in both 3X and 14X groups by 8-weeks. We conclude that an excessive number of laser-treatments delivered to mice can temporarily inhibit the process of brain repair stimulated by tPBM, but then the inhibitory effect ceases, and brain repair can resume. The mechanism may be temporary induction of reactive gliosis. [GRAPHICS] .	[Xuan, Weijun] Guangxi Univ Chinese Med, Dept Otorhinolaryngol Head & Neck Surg, Ruikang Clin Med Coll, Nanning, Peoples R China; [Xuan, Weijun; Huang, Liyi; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Xuan, Weijun; Huang, Liyi; Hamblin, Michael R.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA; [Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA		Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.; Hamblin, MR (corresponding author), Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.; Hamblin, MR (corresponding author), Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.	Hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605	Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9550-13-1-0068]; US Army Medical Research Acquisition Activity [W81XWH-09-1-0514]; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0067]; US NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work was supported by Air Force Office of Scientific Research grant FA9550-13-1-0068, by US Army Medical Research Acquisition Activity grant W81XWH-09-1-0514, and by US Army Medical Research and Materiel Command grant W81XWH-13-2-0067. MRH was supported by US NIH grant R01AI050875. We are grateful to Jie Zhao of the Photopathology Core of Wellman Center for Photomedicine for help with pathology.	Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; Ando T., 2011, PLOS ONE, V6; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Beck H, 2009, ACTA NEUROPATHOL, V117, P481, DOI 10.1007/s00401-009-0483-6; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Calabrese EJ, 2013, ENVIRON POLLUT, V182, P452, DOI 10.1016/j.envpol.2013.07.046; Castano AP, 2007, LASER SURG MED, V39, P543, DOI 10.1002/lsm.20516; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Demidova-Rice TN, 2007, LASER SURG MED, V39, P706, DOI 10.1002/lsm.20549; Dong TT, 2015, J CEREBR BLOOD F MET, V35, P1435, DOI 10.1038/jcbfm.2015.87; Dringen R, 2015, NEUROCHEM RES, V40, P2570, DOI 10.1007/s11064-014-1481-1; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Giacci MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104565; Goldshmit Y, 2014, BRAIN BEHAV, V4, P187, DOI 10.1002/brb3.172; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; Henderson Theodore A, 2015, Adv Mind Body Med, V29, P27; Henderson TA, 2015, NEUROPSYCH DIS TREAT, V11, P2191, DOI 10.2147/NDT.S78182; Huang LJ, 2014, INT J MED SCI, V11, P344, DOI 10.7150/ijms.8140; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Jones OD, 2015, NEUROSCIENCE, V309, P113, DOI 10.1016/j.neuroscience.2015.08.035; Castejon OJ, 2015, FOLIA NEUROPATHOL, V53, P173, DOI 10.5114/fn.2015.54419; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Laskowitz D., 2016, TRANSLATIONAL RES TR; Leo P, 2016, TRANSLATIONAL RES TR; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Messing A, 2003, GLIA, V43, P87, DOI 10.1002/glia.10219; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Morries LD, 2015, NEUROPSYCH DIS TREAT, V11, P2159, DOI 10.2147/NDT.S65809; Naeser MA, 2015, PHOTOMED LASER SURG, V33, P443, DOI 10.1089/pho.2015.3986; Naeser MA, 2014, J NEUROTRAUM, V31, P1008, DOI 10.1089/neu.2013.3244; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Overman JJ, 2012, P NATL ACAD SCI USA, V109, pE2230, DOI 10.1073/pnas.1204386109; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119; Sullivan SM, 2014, J NEUROCHEM, V130, P729, DOI 10.1111/jnc.12754; Taylor CA, 2015, J HEAD TRAUMA REHAB, V30, P150, DOI 10.1097/HTR.0000000000000105; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2015, J BIOPHOTONICS, V8, P502, DOI 10.1002/jbio.201400069; Xuan WJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.108003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Zhang Q, 2014, J CEREBR BLOOD F MET, V34, P1391, DOI 10.1038/jcbfm.2014.95	54	25	28	0	11	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1864-063X	1864-0648		J BIOPHOTONICS	J. Biophotonics	DEC	2016	9	11-12			SI		1263	1272		10.1002/jbio.201500336			10	Biochemical Research Methods; Biophysics; Optics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Optics	EJ0QS	WOS:000392915800015	26990361	Green Accepted			2022-02-06	
J	Licastro, F; Hrelia, S; Porcellini, E; Malaguti, M; Di Stefano, C; Angeloni, C; Carbone, I; Simoncini, L; Piperno, R				Licastro, Federico; Hrelia, Silvana; Porcellini, Elisa; Malaguti, Marco; Di Stefano, Cristina; Angeloni, Cristina; Carbone, Ilaria; Simoncini, Laura; Piperno, Roberto			Peripheral Inflammatory Markers and Antioxidant Response during the Post-Acute and Chronic Phase after Severe Traumatic Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; inflammation; oxidative stress; cytokines plasma levels; follow-up; cognitive outcome	TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; CEREBROSPINAL-FLUID; COGNITIVE DECLINE; DIFFUSION-TENSOR; NEURODEGENERATIVE DISEASES; MICROGLIAL ACTIVATION; LONGITUDINAL CHANGES; NORMATIVE VALUES; HEAD-INJURY	Traumatic brain injury (TBI) is a mechanical insult to the brain caused by external forces and associated with inflammation and oxidative stress. The patients may show different profiles of neurological recovery and a combination of oxidative damage and inflammatory processes can affect their courses. It is known that an overexpression of cytokines can be seen in peripheral blood in the early hours/days after the injury, but little is known about the weeks and months encompassing the post-acute and chronic phases. In addition, no information is available about the antioxidant responses mediated by the major enzymes that regulate reactive oxygen species levels: superoxide dismutase, catalase, peroxidases, and GSH-related enzymes. This study investigates the 6-month trends of inflammatory markers and antioxidant responses in 22 severe TBI patients with prolonged disorders of consciousness, consecutively recruited in a dedicated neurore-habilitation facility. Patients with a high degree of neurological impairment often show an uncertain outcome. In addition, the profiles of plasma activities were related to the neurological recovery after 12 months. Venous peripheral blood samples were taken blindly as soon as clinical signs and laboratory markers confirmed the absence of infections, 3 and 6 months later. The clinical and neuropsychological assessment continued up to 12 months. Nineteen patients completed the follow-up. In the chronic phase, persistent high plasma levels of cytokines can interfere with cognitive functioning and higher post-acute levels of cytokines [ interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, IL1b, IL6] are associated with poorer cognitive recoveries 12 months later. Moreover, higher IFN-gamma, higher TNF-alpha, and lower glutathione peroxidase activity are associated with greater disability. The results add evidence of persistent inflammatory response, provide information about long-term imbalance of antioxidant activity, and suggest that the over-production of cytokines and the alteration of the redox homeostasis in the post-acute phase might adversely affect the neurological and functional recovery. Inflammatory and antioxidant activity markers might offer a feasible way to highlight some of the processes opposing recovery after a severe TBI.	[Licastro, Federico; Porcellini, Elisa; Carbone, Ilaria] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy; [Hrelia, Silvana; Malaguti, Marco; Angeloni, Cristina] Univ Bologna, Dept Life Qual Studies, Rimini, Italy; [Di Stefano, Cristina; Simoncini, Laura; Piperno, Roberto] Maggiore Hosp, Emergency Dept, Neurorehabil Unit, Bologna, Italy		Piperno, R (corresponding author), Maggiore Hosp, Emergency Dept, Neurorehabil Unit, Bologna, Italy.	roberto.piperno@ausl.bologna.it	Simoncini, Laura/AAB-9410-2022; Piperno, Roberto/AAC-3000-2021; Porcellini, Elisa/K-5346-2016	Simoncini, Laura/0000-0002-8853-1791; Piperno, Roberto/0000-0002-2251-9191; Porcellini, Elisa/0000-0003-3991-5294	"Fondazione del Monte di Bologna e Ravenna" (Italy); MIUR-FIRBMinistry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB) [RBAP11HSZS]; "Centro Studi per la Ricerca sul Coma - Amici di Luca ONLUS" of Bologna (Italy)	This work was supported by "Fondazione del Monte di Bologna e Ravenna" (Italy), by MIUR-FIRB (project RBAP11HSZS), and by "Centro Studi per la Ricerca sul Coma - Amici di Luca ONLUS" of Bologna (Italy).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Ayton S, 2014, FREE RADICAL BIO MED, V69, P331, DOI 10.1016/j.freeradbiomed.2014.01.041; Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2; Barone E, 2015, J NEUROSCI RES, V93, P1728, DOI 10.1002/jnr.23627; Basso A, 1987, Funct Neurol, V2, P189; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Block ML, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S8; Bolzani R., 2006, GIORNALE ITALIANO PS, V33, P607, DOI DOI 10.1421/22765; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Burgess P, 1996, BEHAV ASSESSMENT DYS; Caffarra P, 2002, NEUROL SCI, V22, P443, DOI 10.1007/s100720200003; Carlesimo G. A., 1995, Archivio di Psicologia Neurologia e Psichiatria, V56, P471; Chen W, 2014, NEUROCHEM INT, V68, P28, DOI 10.1016/j.neuint.2014.01.015; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; GRANGER CV, 1986, GUIDE USE UNIFORM DA; Hagen C., 1972, LEVELS COGNITIVE FUN; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Jha MK, 2015, EXPERT OPIN THER PAT, V25, P241, DOI 10.1517/13543776.2014.972937; JOHANSSON LH, 1988, ANAL BIOCHEM, V174, P331, DOI 10.1016/0003-2697(88)90554-4; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P151, DOI 10.1016/S0149-7634(96)00005-X; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Laiacona M, 2000, NEUROL SCI, V21, P279, DOI 10.1007/s100720070065; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Licastro F, 2010, CURR PHARM DESIGN, V16, P783, DOI 10.2174/138161210790883543; Licastro F, 2010, NEUROBIOL AGING, V31, P257, DOI 10.1016/j.neurobiolaging.2008.03.019; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lo TYM, 2010, J NEUROTRAUM, V27, P2139, DOI 10.1089/neu.2010.1387; Lo TYM, 2009, J NEUROTRAUM, V26, P1479, DOI [10.1089/neu.2008.0753, 10.1089/neu.2008-0753]; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; Maffei F, 2011, MUTAT RES-FUND MOL M, V714, P88, DOI 10.1016/j.mrfmmm.2011.06.016; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Malaguti M, 2008, INT J SPORT NUTR EXE, V18, P301, DOI 10.1123/ijsnem.18.3.301; Malaguti M, 2009, J APPL PHYSIOL, V107, P1028, DOI 10.1152/japplphysiol.00293.2009; Marsland AL, 2006, PSYCHOSOM MED, V68, P895, DOI 10.1097/01.psy.0000238451.22174.92; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MEASSO G, 1993, DEV NEUROPSYCHOL, V9, P77, DOI 10.1080/87565649109540545; Mooijaart SP, 2013, J INTERN MED, V274, P77, DOI 10.1111/joim.12052; Motori E, 2013, CELL METAB, V18, P844, DOI 10.1016/j.cmet.2013.11.005; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; Orsini A, 2003, WAIS RETERZA ETA NAT; Orsini A, 1997, DISEGNO CON CUBI WAI; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ravaglia G, 2007, NEUROBIOL AGING, V28, P1810, DOI 10.1016/j.neurobiolaging.2006.08.012; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Spinnler H, 1987, STANDARDIZZAZIONE TA; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Sultana R, 2013, FREE RADICAL BIO MED, V62, P157, DOI 10.1016/j.freeradbiomed.2012.09.027; Tai LM, 2015, J NEUROCHEM, V133, P465, DOI 10.1111/jnc.13072; TEASDALE G, 1974, LANCET, V2, P81; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tomaiuolo F, 2012, BRAIN RES BULL, V87, P373, DOI 10.1016/j.brainresbull.2012.01.008; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Valentini L, 2015, CLIN NUTR, V34, P593, DOI 10.1016/j.clnu.2014.09.023; Wiendl H, 2013, NAT REV NEUROL, V9, P125, DOI 10.1038/nrneurol.2013.2; Yang T, 2014, CELL MOL NEUROBIOL, V34, P797, DOI 10.1007/s10571-014-0070-9; Zaghloul N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108168; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zimmermann P, 1994, BATTERIA TEST ESAME	86	25	25	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	NOV 2	2016	7								189	10.3389/fneur.2016.00189			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EA6EG	WOS:000386718000001	27853449	Green Published, gold			2022-02-06	
J	Russell, K; Hutchison, MG; Selci, E; Leiter, J; Chateau, D; Ellis, MJ				Russell, Kelly; Hutchison, Michael G.; Selci, Erin; Leiter, Jeff; Chateau, Daniel; Ellis, Michael J.			Academic Outcomes in High-School Students after a Concussion: A Retrospective Population-Based Analysis	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; 4TH INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; RECOVERY-TIME; SPORT HELD; CHILDREN; MANAGEMENT; SYMPTOMS; ZURICH; IMPACT	Background Many concussion symptoms, such as headaches, vision problems, or difficulty remembering or concentrating may deleteriously affect school functioning. Our objective was to determine if academic performance was lower in the academic calendar year that students sustain a concussion compared to the previous year when they did not sustain a concussion. Methods Using Manitoba Health and Manitoba Education data, we conducted a population-based, controlled before-after study from 2005-2006 to 2010-2011 academic years. Grade 9-12 students with an ICD9/10 code for concussion were matched to non-concussed controls. Overall changes in grade point average (GPA) were compared for the academic year prior to the concussion to the academic year the concussion occurred (or could have occurred among non-concussed matched students). Results Overall, 8240 students (1709 concussed, 6531 non-concussed students) were included. Both concussed and non-concussed students exhibited a lower overall GPA from one year to the next. Having sustained a concussion resulted in a -0.90% (95% CI: -1.88, 0.08) reduction in GPA. Over the same period, non-concussed matched students' GPA reduced by -0.57% (95% CI: -1.32, 0.19). Students who sustained a concussion during high school were just as likely to graduate within four years as their non-concussed peers (ORadj: 0.84; 95% CI: 0.73, 1.02). Conclusions We found that, at a population level, a concussion had minimal long-term effects on academic performance during high school. While academic accommodations and Return-to-Learn programs are an important component of pediatric concussion management, research is needed to identify risk factors for poor academic performance after a concussion and who should receive these programs.	[Russell, Kelly; Selci, Erin] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada; [Russell, Kelly; Selci, Erin; Ellis, Michael J.] Childrens Hosp, Res Inst Manitoba, Winnipeg, MB, Canada; [Russell, Kelly; Leiter, Jeff; Ellis, Michael J.] Canada North Concuss Network, Winnipeg, MB, Canada; [Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON M5S 1A1, Canada; [Leiter, Jeff] Univ Manitoba, Dept Surg, Winnipeg, MB, Canada; [Chateau, Daniel] Univ Manitoba, Manitoba Ctr Hlth Policy, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Sect Neurosurg, Dept Surg, Winnipeg, MB, Canada; [Russell, Kelly] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada		Russell, K (corresponding author), Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada.; Russell, K (corresponding author), Childrens Hosp, Res Inst Manitoba, Winnipeg, MB, Canada.; Russell, K (corresponding author), Canada North Concuss Network, Winnipeg, MB, Canada.; Russell, K (corresponding author), Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada.	krussell@chrim.ca		Russell, Kelly/0000-0002-9159-9201	Manitoba Medical Services Foundation; Winnipeg Foundation; Population Health Research Data Repository [2014011, 2013/2014-56]	This study was funded by the Manitoba Medical Services Foundation (KR) and The Winnipeg Foundation (KR). The funders had no role in the study design, data collection, and analysis, decision to publish, or manuscript preparation.; We thank Mr Mingming (Milton) Hu (MSc in Statistics, Manitoba Center for Health Policy) for conducting the data analysis. He was paid for this work from the aforementioned funders. The authors acknowledge the Manitoba Centre for Health Policy for use of data contained in the Population Health Research Data Repository under project # 2014011 (HIPC# 2013/2014-56). The results and conclusions are those of the authors and no official endorsement by the Manitoba Centre for Health Policy, Manitoba Health, or other data providers is intended or should be inferred. Data used in this study are from the Population Health Research Data Repository housed at the Manitoba Centre for Health Policy, University of Manitoba and were derived from data provided by Manitoba Health and Manitoba Education.	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Chouinard R, 2008, BRIT J EDUC PSYCHOL, V78, P31, DOI 10.1348/000709907X197993; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DeMatteo C, 2015, CLIN PEDIATR, V54, P783, DOI 10.1177/0009922814567305; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ellis MJ, 2015, J NEUROSURG PEDIAT, P1; FARKAS G, 1990, AM EDUC RES J, V27, P807, DOI 10.3102/00028312027004807; Faul M, 2010, TRAUMATIC BRAIN INJU; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hox J., 1998, MULTILEVEL MODELING, P147, DOI DOI 10.1007/978-3-642-72087-1_17; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Manitoba Education, 2015, GRADUATION REQUIREME; Manitoba Government, STUD REC SYST PROF S; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Patel DR, 2010, PEDIATR CLIN N AM, V57, P795, DOI 10.1016/j.pcl.2010.03.002; Purcell LK, 2014, PAED CHILD HEALT-CAN, V19, P153, DOI 10.1093/pch/19.3.153; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; SAS Institute Inc, 1976, SAS VERS 9 3 TS1M0; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Zemek R, 2013, ACAD EMERG MED, V20, P1041, DOI 10.1111/acem.12220	46	25	25	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2016	11	10							e0165116	10.1371/journal.pone.0165116			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DZ9NZ	WOS:000386204500118	27764223	Green Published, gold, Green Submitted			2022-02-06	
J	Drake, A; Donahue, TLH; Stansloski, M; Fox, K; Wheatley, BB; Donahue, SW				Drake, Aaron; Donahue, Tammy L. Haut; Stansloski, Mitchel; Fox, Karen; Wheatley, Benjamin B.; Donahue, Seth W.			Horn and horn core trabecular bone of bighorn sheep rams absorbs impact energy and reduces brain cavity accelerations during high impact ramming of the skull	ACTA BIOMATERIALIA			English	Article						Horn; Trabecular bone; Impact; Concussion; Bioinspired materials	FINITE-ELEMENT-ANALYSIS; MECHANICAL-PROPERTIES; COMPACT-BONE; HEAD IMPACTS; BIOLOGICAL-MATERIALS; BENDING STRENGTH; KERATIN; FOOTBALL; TISSUE; BIOMECHANICS	Bighorn sheep (Ovis canadensis) routinely experience violent impacts to the head as part of intraspecific fighting. Dynamic 3D finite element models of the skull and horns of a male bighorn sheep were developed to gain an understanding of the roles that the horn and bone materials and structure play in absorbing the impact that occurs during ramming. The geometry and volume mesh of the model were derived from CT scan images. The models included the horn, bony horn core, and bone of the skull. The horn core fills a portion of the hollow horn and consists of a thin cortical bone shell filled with foam-like trabecular bone. Two modified models were also created: one with the distal half of the horn length removed to assess the effects of the tapered spiral geometry of the horn, and one with the internal trabecular bone material of the horn core removed. The trabecular bone material stored three times more strain energy during impact than the horn material in the intact model. Removing half of the horn length had the effect of increasing translational accelerations in the brain cavity by 49%. Removing the trabecular bone in the horn core resulted in a 442% increase in rotational accelerations within the brain cavity. These findings support the investigation of novel bioinspired materials and designs that could be used in mitigating brain injuries and in other applications involving high-impact collisions. Statement of Significance Bighorn sheep routinely experience violent impacts to the head and horns without apparent negative consequences to the brain or horns. A portion of the horn is filled with a thin cortical bone shell containing foam-like trabecular bone. We developed novel dynamic finite element models of the skull and horns of bighorn sheep to gain an understanding of the roles that the horn and bone materials play in absorbing the impact that occurs during ramming. The study revealed that both horn and bone materials and the structures made from these materials (i.e., tapered spiral horns and foam-like trabecular bone struts) are important for absorbing impact energy and reducing brain cavity accelerations. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Drake, Aaron; Donahue, Tammy L. Haut; Stansloski, Mitchel; Wheatley, Benjamin B.; Donahue, Seth W.] Colorado State Univ, Dept Mech Engn, 300 West Drake Rd, Ft Collins, CO 80526 USA; [Fox, Karen] Wildlife Res Ctr, Colorado Div Pk & Wildlife, 317 W Prospect Rd, Ft Collins, CO 80525 USA		Donahue, SW (corresponding author), Colorado State Univ, Dept Mech Engn, 300 West Drake Rd, Ft Collins, CO 80526 USA.	seth.donahue@colostate.edu	Wheatley, Benjamin/AAF-7438-2020	Wheatley, Benjamin/0000-0002-9779-485X			Aare M, 2004, INT J CRASHWORTHINES, V9, P15, DOI 10.1533/ijcr.2004.0268; Beckstein JC, 2008, SPINE, V33, pE166, DOI 10.1097/BRS.0b013e318166e001; Bonser RHC, 1996, J ZOOL, V239, P477, DOI 10.1111/j.1469-7998.1996.tb05937.x; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Currey JD, 1999, J EXP BIOL, V202, P2495; Currey JD, 1999, J EXP BIOL, V202, P3285; Doherty AH, 2015, PHYSIOLOGY, V30, P17, DOI 10.1152/physiol.00022.2014; Farke AA, 2008, J EXP BIOL, V211, P3085, DOI 10.1242/jeb.019042; GEIST V, 1974, MOUNTAIN SHEEP STUDY; Gibson LJ, 2005, J BIOMECH, V38, P377, DOI 10.1016/j.jbiomech.2004.09.027; Goff MG, 2015, J BIOMECH, V48, P4142, DOI 10.1016/j.jbiomech.2015.10.023; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hansen U, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2838032; Hutchinson J, 1998, APPL MATH COMPUT, V96, P1, DOI 10.1016/S0096-3003(97)10106-0; JASLOW CR, 1995, J ZOOL, V235, P193; Johnson KL, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026320; KELLER TS, 1990, J ORTHOPAED RES, V8, P592, DOI 10.1002/jor.1100080416; KEYAK JH, 1990, J BIOMED ENG, V12, P389, DOI 10.1016/0141-5425(90)90022-F; KITCHENER A, 1987, J MATER SCI, V22, P1385, DOI 10.1007/BF01233138; KITCHENER A, 1988, J ZOOL, V214, P1, DOI 10.1111/j.1469-7998.1988.tb04983.x; KITCHENER A, 1987, J MATER SCI LETT, V6, P321, DOI 10.1007/BF01729340; KITCHENER A, 1987, J ZOOL, V213, P621, DOI 10.1111/j.1469-7998.1987.tb03730.x; Knowles TPJ, 2011, NAT NANOTECHNOL, V6, P469, DOI [10.1038/nnano.2011.102, 10.1038/NNANO.2011.102]; Lee S, 2011, MAT SCI ENG C-MATER, V31, P730, DOI 10.1016/j.msec.2010.10.017; Maity P, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4003321; Makela T., 1965, LAAKARILEHTI FINLAND, V20, P1869; MARTIN RB, 1993, J BIOMECH, V26, P1047, DOI 10.1016/S0021-9290(05)80004-1; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; MCELHANEY JH, 1966, J APPL PHYSIOL, V21, P1231, DOI 10.1152/jappl.1966.21.4.1231; McKittrick J, 2010, MAT SCI ENG C-MATER, V30, P331, DOI 10.1016/j.msec.2010.01.011; Meyers MA, 2008, PROG MATER SCI, V53, P1, DOI 10.1016/j.pmatsci.2007.05.002; Meyers MA, 2013, SCIENCE, V339, P773, DOI 10.1126/science.1220854; Morgan Elise F., 2005, European Journal of Morphology, V42, P13, DOI 10.1080/09243860500095273; Motherway JA, 2009, J BIOMECH, V42, P2129, DOI 10.1016/j.jbiomech.2009.05.030; MULLER R, 1995, MED ENG PHYS, V17, P126, DOI 10.1016/1350-4533(95)91884-J; Nazarian A, 2007, J BIOMECH, V40, P2573, DOI 10.1016/j.jbiomech.2006.11.022; REILLY DT, 1975, J BIOMECH, V8, P393, DOI 10.1016/0021-9290(75)90075-5; Rho JY, 1998, MED ENG PHYS, V20, P92, DOI 10.1016/S1350-4533(98)00007-1; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Seki Y, 2012, J MECH BEHAV BIOMED, V9, P1, DOI 10.1016/j.jmbbm.2011.08.003; Seref-Ferlengez Z, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.11; Soons J, 2012, J R SOC INTERFACE, V9, P1787, DOI 10.1098/rsif.2011.0910; Taddei F, 2007, MED ENG PHYS, V29, P973, DOI 10.1016/j.medengphy.2006.10.014; Tombolato L, 2010, ACTA BIOMATER, V6, P319, DOI 10.1016/j.actbio.2009.06.033; Trim MW, 2011, ACTA BIOMATER, V7, P1228, DOI 10.1016/j.actbio.2010.11.024; Ulrich D, 1998, J BIOMECH, V31, P1187, DOI 10.1016/S0021-9290(98)00118-3; Wang L. F., 2011, FOREIGN LANGUAGE WOR, V6, P6, DOI DOI 10.1371/J0URNAL.P0NE.0022325	50	25	26	10	69	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	OCT 15	2016	44						41	50		10.1016/j.actbio.2016.08.019			10	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	DZ1JM	WOS:000385594700004	27544811				2022-02-06	
J	Iscan, Z; Nazarova, M; Fedele, T; Blagovechtchenski, E; Nikulin, VV				Iscan, Zafer; Nazarova, Maria; Fedele, Tommaso; Blagovechtchenski, Evgeny; Nikulin, Vadim V.			Pre-stimulus Alpha Oscillations and Inter-subject Variability of Motor Evoked Potentials in Single- and Paired-Pulse TMS Paradigms	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						brain stimulation; variability; paired-pulse; motor evoked potentials; electroencephalography; oscillations	TRANSCRANIAL MAGNETIC STIMULATION; RANGE TEMPORAL CORRELATIONS; TRAUMATIC BRAIN-INJURY; INTRACORTICAL INHIBITION; EEG ALPHA; CORTICAL EXCITABILITY; CORTICOSPINAL EXCITABILITY; ACTIVITY FLUCTUATIONS; ONGOING OSCILLATIONS; BAND OSCILLATIONS	Inter- and intra-subject variability of the motor evoked potentials (MEPs) to TMS is a well-known phenomenon. Although a possible link between this variability and ongoing brain oscillations was demonstrated, the results of the studies are not consistent with each other. Exploring this topic further is important since the modulation of MEPs provides unique possibility to relate oscillatory cortical phenomena to the state of the motor cortex probed with TMS. Given that alpha oscillations were shown to reflect cortical excitability, we hypothesized that their power and variability might explain the modulation of subject-specific MEPs to single- and paired-pulse TMS (spTMS, ppTMS, respectively). Neuronal activity was recorded with multichannel electroencephalogram. We used spTMS and two ppTMS conditions: intracortical facilitation (ICE) and short interval intracortical inhibition (SICI). Spearman correlations were calculated within and across subjects between MEPs and the pre-stimulus power of alpha oscillations in low (8-10 Hz) and high (10-12 Hz) frequency bands. Coefficient of quartile variation was used to measure variability. Across-subject analysis revealed no difference in the pre-stimulus alpha power among the TMS conditions. However, the variability of high-alpha power in spTMS condition was larger than in the SICI condition. In ICF condition pre-stimulus high-alpha power variability correlated positively with MEP amplitude variability. No correlation has been observed between the pre-stimulus alpha power and MEP responses in any of the conditions. Our results show that the variability of the alpha oscillations can be more predictive of TMS effects than the commonly used power of oscillations and we provide further support for the dissociation of high and low-alpha bands in predicting responses produced by the stimulation of the motor cortex.	[Iscan, Zafer; Nazarova, Maria; Fedele, Tommaso; Blagovechtchenski, Evgeny; Nikulin, Vadim V.] Natl Res Univ, Higher Sch Econ, Ctr Cognit & Decis Making, Moscow, Russia; [Nazarova, Maria] Res Ctr Neurol, Moscow, Russia; [Fedele, Tommaso] Univ Zurich, Univ Zurich Hosp, Dept Neurosurg, Zurich, Switzerland; [Blagovechtchenski, Evgeny] St Petersburg State Univ, Inst Translat Biomed, Lab Neurosci & Mol Pharmacol, St Petersburg, Russia; [Nikulin, Vadim V.] Charite Univ Med Berlin, Dept Neurol, Neurophys Grp, Berlin, Germany		Iscan, Z (corresponding author), Natl Res Univ, Higher Sch Econ, Ctr Cognit & Decis Making, Moscow, Russia.	ziscan@hse.ru	Nazarova, Maria A./D-8810-2012; Nikulin, Vadim V/A-6050-2014; Iscan, Zafer/G-8771-2015	Nazarova, Maria A./0000-0001-5347-5948; Nikulin, Vadim V/0000-0001-6082-3859; Iscan, Zafer/0000-0001-9832-6591			Arias P, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00316; Babiloni C, 2014, CLIN NEUROPHYSIOL, V125, P1936, DOI 10.1016/j.clinph.2014.04.021; Beck S, 2009, EUR J NEUROSCI, V29, P1634, DOI 10.1111/j.1460-9568.2009.06710.x; Berger B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/936096; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Bonett DG, 2006, COMPUT STAT DATA AN, V50, P2953, DOI 10.1016/j.csda.2005.05.007; Bosl W, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-18; Brzezicka A, 2017, COGNITION EMOTION, V31, P868, DOI 10.1080/02699931.2016.1170669; Butefisch CM, 2008, NEUROREHAB NEURAL RE, V22, P4, DOI 10.1177/1545968307301769; Butefisch CM, 2005, MOVEMENT DISORD, V20, P545, DOI 10.1002/mds.20367; Cantisani A, 2015, J AFFECT DISORDERS, V188, P167, DOI 10.1016/j.jad.2015.08.018; Casarotto S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010281; Chen R, 1998, J NEUROPHYSIOL, V80, P2870, DOI 10.1152/jn.1998.80.6.2870; Chen R, 2004, EXP BRAIN RES, V154, P1, DOI 10.1007/s00221-003-1684-1; Chouchou F, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00402; Chung YG, 2012, NEURAL NETWORKS, V36, P46, DOI 10.1016/j.neunet.2012.08.006; Churchland MM, 2010, NAT NEUROSCI, V13, P369, DOI 10.1038/nn.2501; Conforto AB, 2012, J HEADACHE PAIN, V13, P29, DOI 10.1007/s10194-011-0379-4; Di Lazzaro V, 2006, J NEUROPHYSIOL, V96, P1765, DOI 10.1152/jn.00360.2006; Di Lazzaro V, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00018; Dugue L, 2011, J NEUROSCI, V31, P11889, DOI 10.1523/JNEUROSCI.1161-11.2011; Ellaway PH, 1998, ELECTROMYOGR MOTOR C, V109, P104, DOI 10.1016/S0924-980X(98)00007-1; Fedele T, 2016, NEUROSCIENCE, V331, P109, DOI 10.1016/j.neuroscience.2016.06.015; Ferreri F, 2011, NEUROIMAGE, V54, P90, DOI 10.1016/j.neuroimage.2010.07.056; Fleming MK, 2012, IEEE T NEUR SYS REH, V20, P617, DOI 10.1109/TNSRE.2012.2202692; da Silva AKF, 2016, ANN NONINVAS ELECTRO, V21, P223, DOI 10.1111/anec.12372; Frenkel-Toledo S, 2013, BRAIN RES, V1509, P43, DOI 10.1016/j.brainres.2013.03.004; Garrett DD, 2013, NEUROSCI BIOBEHAV R, V37, P610, DOI 10.1016/j.neubiorev.2013.02.015; Garrett DD, 2013, CEREB CORTEX, V23, P684, DOI 10.1093/cercor/bhs055; Gharabaghi A, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00122; Giambattistelli F, 2014, HUM BRAIN MAPP, V35, P1740, DOI 10.1002/hbm.22288; Goldsworthy MR, 2016, NEUROSCIENCE, V320, P205, DOI 10.1016/j.neuroscience.2016.02.012; Haegens S, 2011, P NATL ACAD SCI USA, V108, P19377, DOI 10.1073/pnas.1117190108; Hanslmayr S, 2011, BRAIN RES REV, V67, P331, DOI 10.1016/j.brainresrev.2011.04.002; Hebb MO, 2007, J NEUROTRAUM, V24, P579, DOI 10.1089/neu.2006.0146; Hermsen AM, 2016, J NEUROL SCI, V362, P209, DOI 10.1016/j.jns.2016.01.039; Hohlefeld FU, 2012, EUR J NEUROSCI, V36, P2812, DOI 10.1111/j.1460-9568.2012.08198.x; Hyvarinen A, 1999, IEEE T NEURAL NETWOR, V10, P626, DOI 10.1109/72.761722; Julkunen P, 2012, BRAIN STIMUL, V5, P526, DOI 10.1016/j.brs.2011.07.006; Jung NH, 2010, BRAIN STIMUL, V3, P87, DOI 10.1016/j.brs.2009.10.003; Karabanov A, 2016, CURR OPIN NEUROL, V29, P397, DOI 10.1097/WCO.0000000000000342; Keil J, 2014, J NEUROPHYSIOL, V111, P513, DOI 10.1152/jn.00387.2013; Klein-Flugge MC, 2013, J NEUROSCI, V33, P5564, DOI 10.1523/JNEUROSCI.2448-12.2013; Klimesch W, 1998, EVOKED POTENTIAL, V108, P123, DOI 10.1016/S0168-5597(97)00078-6; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Klimesch W, 2012, TRENDS COGN SCI, V16, P606, DOI 10.1016/j.tics.2012.10.007; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Kundu B, 2014, J NEUROPHYSIOL, V112, P1885, DOI 10.1152/jn.00390.2013; Larsson PG, 2005, CLIN NEUROPHYSIOL, V116, P2701, DOI 10.1016/j.clinph.2005.07.019; Linkenkaer-Hansen K, 2007, J NEUROSCI, V27, P13882, DOI 10.1523/JNEUROSCI.3083-07.2007; Lioumis P, 2012, TOP STROKE REHABIL, V19, P182, DOI 10.1310/tsr1902-182; Lioumis P, 2009, HUM BRAIN MAPP, V30, P1387, DOI 10.1002/hbm.20608; Maki H, 2010, CLIN NEUROPHYSIOL, V121, P492, DOI 10.1016/j.clinph.2009.11.078; Maris E, 2007, J NEUROSCI METH, V164, P177, DOI 10.1016/j.jneumeth.2007.03.024; Misic B, 2010, J NEUROPHYSIOL, V104, P2667, DOI 10.1152/jn.00648.2010; Mitchell WK, 2007, J PHYSIOL-LONDON, V583, P567, DOI 10.1113/jphysiol.2007.134031; Mizuno T, 2010, CLIN NEUROPHYSIOL, V121, P1438, DOI 10.1016/j.clinph.2010.03.025; Moore RA, 2008, INT J PSYCHOPHYSIOL, V69, P79, DOI 10.1016/j.ijpsycho.2008.03.003; Nakamura H, 1997, J PHYSIOL-LONDON, V498, P817, DOI 10.1113/jphysiol.1997.sp021905; Nenadovic V, 2008, J NEUROTRAUM, V25, P615, DOI 10.1089/neu.2007.0474; Neuper C, 2006, PROG BRAIN RES, V159, P211, DOI 10.1016/S0079-6123(06)59014-4; Oh BM, 2010, INT J NEUROSCI, V120, P512, DOI 10.3109/00207451003760114; Orth M, 2003, CLIN NEUROPHYSIOL, V114, P2362, DOI 10.1016/S1388-2457(03)00243-8; Palva JM, 2013, P NATL ACAD SCI USA, V110, P3585, DOI 10.1073/pnas.1216855110; Pellicciari MC, 2016, CLIN NEUROPHYSIOL, V127, P621, DOI 10.1016/j.clinph.2015.03.002; Pfurtscheller G, 2000, CLIN NEUROPHYSIOL, V111, P1873, DOI 10.1016/S1388-2457(00)00428-4; Pfurtscheller G, 1997, INT J PSYCHOPHYSIOL, V26, P121, DOI 10.1016/S0167-8760(97)00760-5; Poil SS, 2012, J NEUROSCI, V32, P9817, DOI 10.1523/JNEUROSCI.5990-11.2012; Premoli I, 2014, J NEUROSCI, V34, P5603, DOI 10.1523/JNEUROSCI.5089-13.2014; Ritter P, 2009, HUM BRAIN MAPP, V30, P1168, DOI 10.1002/hbm.20585; Romei V, 2008, CEREB CORTEX, V18, P2010, DOI 10.1093/cercor/bhm229; Romei V, 2010, J NEUROSCI, V30, P8692, DOI 10.1523/JNEUROSCI.0160-10.2010; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Russmann H, 2009, CLIN NEUROPHYSIOL, V120, P1204, DOI 10.1016/j.clinph.2009.04.005; Sadaghiani S, 2009, J NEUROSCI, V29, P13410, DOI 10.1523/JNEUROSCI.2592-09.2009; Samaha J, 2016, J COGNITIVE NEUROSCI, V28, P1090, DOI 10.1162/jocn_a_00955; Sanger TD, 2001, J PHYSIOL-LONDON, V530, P307, DOI 10.1111/j.1469-7793.2001.0307l.x; Sauseng P, 2009, NEUROPSYCHOLOGIA, V47, P284, DOI 10.1016/j.neuropsychologia.2008.07.021; Schlee W, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/436146; Schlogl A, 2007, CLIN NEUROPHYSIOL, V118, P98, DOI 10.1016/j.clinph.2006.09.003; Schulz H, 2014, CEREB CORTEX, V24, P1708, DOI 10.1093/cercor/bht024; Segrave RA, 2011, CLIN EEG NEUROSCI, V42, P45, DOI 10.1177/155005941104200110; Shew WL, 2013, NEUROSCIENTIST, V19, P88, DOI 10.1177/1073858412445487; Smit DJA, 2013, J NEUROSCI, V33, P11212, DOI 10.1523/JNEUROSCI.2816-12.2013; Stagg CJ, 2011, J PHYSIOL-LONDON, V589, P5845, DOI 10.1113/jphysiol.2011.216978; Strube W, 2014, BEHAV BRAIN RES, V264, P17, DOI 10.1016/j.bbr.2014.01.041; Takemi M, 2013, J NEUROPHYSIOL, V110, P1158, DOI 10.1152/jn.01092.2012; Walter A, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00087; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141; Zarkowski P, 2006, CLIN EEG NEUROSCI, V37, P247, DOI 10.1177/155005940603700316; Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028; Zoon HFA, 2013, J CLIN NEUROPHYSIOL, V30, P261, DOI 10.1097/WNP.0b013e3182933d6e; Zrenner C, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00092	94	25	27	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	OCT 7	2016	10								504	10.3389/fnhum.2016.00504			11	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	DZ5FT	WOS:000385888100001	27774060	Green Published, gold			2022-02-06	
J	Fino, PC; Nussbaum, MA; Brolinson, PG				Fino, Peter C.; Nussbaum, Maury A.; Brolinson, Per Gunnar			Decreased high-frequency center-of-pressure complexity in recently concussed asymptomatic athletes	GAIT & POSTURE			English	Article						mTBI; Concussion; Brain injury; Postural stability; Entropy	SPORT-RELATED CONCUSSION; POSTURAL-CONTROL DYNAMICS; TRAUMATIC BRAIN-INJURY; TIME-TO-CONTACT; APPROXIMATE ENTROPY; CEREBRAL CONCUSSION; MULTISCALE ENTROPY; OLDER-ADULTS; INTRACORTICAL INHIBITION; SWAY	Two experiments compared multiple methods of estimating postural stability entropy to address: 1) if postural complexity differences exist between concussed and healthy athletes immediately following return-to-play; 2) which methods best detect such differences; and 3) what is an appropriate interpretation of such differences. First, center of pressure (COP) data were collected from six concussed athletes over the six weeks immediately following their concussion and from 24 healthy athletes. Second, 25 healthy non-athletes performed four quiet standing tasks: normal, co-contracting their lower extremity muscles, performing a cognitive arithmetic task, and voluntarily manipulating their sway. Postural complexity was calculated using approximate, sample, multi-variate sample, and multi-variate composite multi-scale (MV-CompMSE) entropy methods for both high-pass filtered and low-pass filtered COP data. MV-CompMSE of the high-pass filtered COP signal identified the most consistent differences between groups, with concussed athletes exhibiting less complexity over the high frequency COP time series. Among healthy non-athletes, high-pass filtered MV-CompMSE increased only in the co-contraction condition, suggesting the decrease in high frequency MV-CompMSE found in concussed athletes may be due to more relaxed muscles or less complex muscle contractions. This decrease in entropy may associate with reported increases in intra-cortical inhibition. Furthermore, a single-case study suggested high frequency MV-CompMSE may be a useful clinical tool for concussion management. (C) 2016 Elsevier B.V. All rights reserved.	[Fino, Peter C.] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97239 USA; [Fino, Peter C.] Virginia Tech, Dept Mech Engn, Blacksburg, VA USA; [Nussbaum, Maury A.] Virginia Tech, Dept Ind & Syst Engn, Blacksburg, VA USA; [Brolinson, Per Gunnar] Virginia Tech, Dept Sports Med, Blacksburg, VA USA; [Brolinson, Per Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA USA		Fino, PC (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97239 USA.	fino@ohsu.edu; nussbaum@vt.edu; pbrolins@vcom.vt.edu	Nussbaum, Maury A/A-9655-2008	Nussbaum, Maury A/0000-0002-1887-8431; Fino, Peter/0000-0002-8621-3706	National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF) [DGE 0822220]	The authors would like to thank Dr. Thurmon Lockhart for assistance in the initial stages of this work, and Lauren Becker and Brett Griesemer for contributing to data collection. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE 0822220. Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.	ALLUM JHJ, 1984, J NEUROPHYSIOL, V52, P797, DOI 10.1152/jn.1984.52.5.797; Bottaro A, 2005, HUM MOVEMENT SCI, V24, P588, DOI 10.1016/j.humov.2005.07.006; Cantello R, 2007, NEUROSCIENCE, V150, P64, DOI 10.1016/j.neuroscience.2007.08.033; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Costa M, 2007, EPL-EUROPHYS LETT, V77, DOI 10.1209/0295-5075/77/68008; Coxon JP, 2006, J NEUROPHYSIOL, V95, P3371, DOI 10.1152/jn.01334.2005; Dault MC, 2003, COGNITIVE BRAIN RES, V16, P434, DOI 10.1016/S0926-6410(03)00058-2; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Dorman JC, 2015, J SCI MED SPORT, V18, P2, DOI 10.1016/j.jsams.2013.11.010; Duarte M, 2008, EXP BRAIN RES, V191, P265, DOI 10.1007/s00221-008-1521-7; Dubose DF, 2017, MED SCI SPORT EXER, V49, P167, DOI 10.1249/MSS.0000000000001067; EVANS CM, 1983, J PHYSIOL-LONDON, V344, P483, DOI 10.1113/jphysiol.1983.sp014953; Fino P., 2015, ANN BIOMED ENG, P1; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Gow B, 2015, ENTROPY, V17, P7849; Gruber AH, 2011, GAIT POSTURE, V34, P13, DOI 10.1016/j.gaitpost.2011.02.015; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; King L. A., 2013, ARCH PHYS MED REHABI; Kuznetsov N, 2013, ANN BIOMED ENG, V41, P1646, DOI 10.1007/s10439-012-0646-9; Lake DE, 2002, AM J PHYSIOL-REG I, V283, pR789, DOI 10.1152/ajpregu.00069.2002; Liepert J, 1998, EXP BRAIN RES, V118, P421, DOI 10.1007/s002210050296; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Loram ID, 2009, J NEUROPHYSIOL, V102, P460, DOI 10.1152/jn.00007.2009; Loram ID, 2005, J PHYSIOL-LONDON, V564, P281, DOI 10.1113/jphysiol.2004.073437; Loram ID, 2005, J PHYSIOL-LONDON, V564, P295, DOI 10.1113/jphysiol.2004.076307; Manor B, 2010, J APPL PHYSIOL, V109, P1786, DOI 10.1152/japplphysiol.00390.2010; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Mihalik JP, 2014, J SPORT HEALTH SCI, V3, P307, DOI 10.1016/j.jshs.2014.07.005; Miller NR, 2014, BRAIN INJURY, V28, P1270, DOI 10.3109/02699052.2014.915987; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Quatman-Yates CC, 2015, PEDIATR PHYS THER, V27, P316, DOI 10.1097/PEP.0000000000000193; Ramdani S, 2009, MED ENG PHYS, V31, P1023, DOI 10.1016/j.medengphy.2009.06.004; Rehman N., 2009, P ROYAL SOC LOND MAT; Rhea CK, 2015, GAIT POSTURE, V41, P731, DOI 10.1016/j.gaitpost.2015.01.008; Rhea CK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017696; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Roerdink M, 2011, HUM MOVEMENT SCI, V30, P203, DOI 10.1016/j.humov.2010.04.005; Schillings AM, 1999, BRAIN RES, V816, P480, DOI 10.1016/S0006-8993(98)01198-6; Singh NB, 2012, J ELECTROMYOGR KINES, V22, P131, DOI 10.1016/j.jelekin.2011.10.007; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Stins JF, 2009, GAIT POSTURE, V30, P106, DOI 10.1016/j.gaitpost.2009.04.001; Tinazzi M, 2005, NEUROSCI LETT, V378, P55, DOI 10.1016/j.neulet.2004.12.015; Wei Q, 2012, ENTROPY-SWITZ, V14, P2157, DOI 10.3390/e14112157; Winter D. A., 2009, BIOMECHANICS MOTOR C, DOI 10.1002/9780470549148; Wu SD, 2013, ENTROPY-SWITZ, V15, P1069, DOI 10.3390/e15031069; Zatsiorsky VM, 1999, MOTOR CONTROL, V3, P28, DOI 10.1123/mcj.3.1.28; Zhang HB, 2015, J ELECTROMYOGR KINES, V25, P937, DOI 10.1016/j.jelekin.2015.10.011; Zhou DG, 2015, EXP BRAIN RES, V233, P2401, DOI 10.1007/s00221-015-4310-0	57	25	25	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	OCT	2016	50						69	74		10.1016/j.gaitpost.2016.08.026			6	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics; Sport Sciences	EB2LC	WOS:000387192600012	27580081	Bronze			2022-02-06	
J	Tatel, DF; Wade, BSC; Velez, CS; Drennon, AM; Bolzenius, J; Gutman, BA; Thompson, PM; Lewis, JD; Wilde, EA; Bigler, ED; Shenton, ME; Ritter, JL; York, GE				Tatel, David F.; Wade, Benjamin S. C.; Velez, Carmen S.; Drennon, Ann Marie; Bolzenius, Jacob; Gutman, Boris A.; Thompson, Paul M.; Lewis, Jeffrey D.; Wilde, Elisabeth A.; Bigler, Erin D.; Shenton, Martha E.; Ritter, John L.; York, Gerald E.			Volumetric and shape analyses of subcortical structures in United States service members with mild traumatic brain injury	JOURNAL OF NEUROLOGY			English	Article						Mild traumatic brain injury; Military; mTBI; Subcortical structures; Volumetric measures; Shape analyses; Service members	POSTTRAUMATIC-STRESS-DISORDER; TENSOR IMAGING FINDINGS; HIPPOCAMPAL VOLUME; NUCLEUS-ACCUMBENS; CORTICAL THICKNESS; AMYGDALA; MORPHOMETRY; INTEGRITY; VETERANS; ATROPHY	Mild traumatic brain injury (mTBI) is a significant health concern. The majority who sustain mTBI recover, although similar to 20 % continue to experience symptoms that can interfere with quality of life. Accordingly, there is a critical need to improve diagnosis, prognostic accuracy, and monitoring (recovery trajectory over time) of mTBI. Volumetric magnetic resonance imaging (MRI) has been successfully utilized to examine TBI. One promising improvement over standard volumetric approaches is to analyze high-dimensional shape characteristics of brain structures. In this study, subcortical shape and volume in 76 Service Members with mTBI was compared to 59 Service Members with orthopedic injury (OI) and 17 with post-traumatic stress disorder (PTSD) only. FreeSurfer was used to quantify structures from T1-weighted 3 T MRI data. Radial distance (RD) and Jacobian determinant (JD) were defined vertex-wise on parametric mesh-representations of subcortical structures. Linear regression was used to model associations between morphometry (volume and shape), TBI status, and time since injury (TSI) correcting for age, sex, intracranial volume, and level of education. Volumetric data was not significantly different between the groups. JD was significantly increased in the accumbens and caudate and significantly reduced in the thalamus of mTBI participants. Additional significant associations were noted between RD of the amygdala and TSI. Positive trend-level associations between TSI and the amygdala and accumbens were observed, while a negative association was observed for third ventricle. Our findings may aid in the initial diagnosis of mTBI, provide biological targets for functional examination, and elucidate regions that may continue remodeling after injury.	[Tatel, David F.; Velez, Carmen S.; Bolzenius, Jacob] Univ Missouri, Missouri Inst Mental Hlth, 4633 World Pkwy Circle, Berkeley, MO 63134 USA; [Tatel, David F.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wade, Benjamin S. C.; Gutman, Boris A.; Thompson, Paul M.] Univ So Calif, Imaging Genet Ctr, Marina Del Rey, CA USA; [Drennon, Ann Marie] San Antonio Mil Med Ctr, Def & Vet Brain Injury Ctr, San Antonio, TX USA; [Lewis, Jeffrey D.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Sch Med, Bethesda, MD 20814 USA; [Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat & Radiol, Psychiat Neuroimaging Lab, Boston, MA USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA; [Ritter, John L.] Brooke Army Med Ctr, Dept Radiol, San Antonio, TX USA; [York, Gerald E.] Alaska Radiol Associates, TBI Imaging & Res, Anchorage, AK USA		Tatel, DF (corresponding author), Univ Missouri, Missouri Inst Mental Hlth, 4633 World Pkwy Circle, Berkeley, MO 63134 USA.; Tatel, DF (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA.	David.Tate@mimh.edu	Tate, David F/I-3963-2013; Ritter, John/AAG-8899-2020; Shenton, Martha/V-8780-2019; Thompson, Paul M/C-4194-2018	Tate, David F/0000-0003-0213-1920; Thompson, Paul M/0000-0002-4720-8867; Wade, Benjamin/0000-0003-2461-6101	Defense and Veterans Brain Injury Centers; Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0025]; Chronic Effects of Neurotrauma Consortium (CENC) [PT108802-SC104835]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U54 EB020403]; Veterans Administration (VA Merit Grant)US Department of Veterans Affairs; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB020403] Funding Source: NIH RePORTER	The view(s) expressed herein are those of the author and do not reflect the official policy or position of the Defense and Veterans Brain Injury Center, Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, Department of Defense, or the U.S. Government. We gratefully acknowledge the generous time and effort that the Service Members made in supporting this study. We also gratefully acknowledge the clinical effort and expertise of the Brooke Army Medical Center Brain Injury and Rehabilitation Service staff in the identification, recruitment, consenting, and treatment of Service Members who are a part of this study. This work is supported in part by the Defense and Veterans Brain Injury Centers, the Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC; W81XWH-13-2-0025), the Chronic Effects of Neurotrauma Consortium (CENC; PT108802-SC104835), the National Institutes of Health (NIH U54 EB020403), and the Veterans Administration (VA Merit Grant).	Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; [Anonymous], 2016, CLIN PRACT GUID; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Berger-Sweeney J, 2003, NEUROSCI BIOBEHAV R, V27, P401, DOI 10.1016/S0149-7634(03)00070-8; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler E, 2015, NEUROPSYCHOL REV, V25, P224, DOI 10.1007/s11065-015-9290-0; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Brezova V, 2014, NEUROIMAGE-CLIN, V5, P128, DOI 10.1016/j.nicl.2014.03.012; Carlezon WA, 2009, NEUROPHARMACOLOGY, V56, P122, DOI 10.1016/j.neuropharm.2008.06.075; Castro DC, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00090; Chan RCK, 2016, NEUROPSYCHOLOGY, V30, P274, DOI 10.1037/neu0000233; Chen YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048298; Combs HL, 2015, J NEUROTRAUM, V32, P956, DOI 10.1089/neu.2014.3585; Dennis EL, 2016, J NEUROTRAUM, V33, P840, DOI 10.1089/neu.2015.4012; Depue BE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/691505; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Esopenko C, 2015, J NEUROTRAUM, V32, P209, DOI 10.1089/neu.2014.3506; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gooijers J, 2015, NEUROREHABIL NEURAL; Green REA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00067; Gutman Boris A., 2013, Multimodal Brain Image Analysis. Third International Workshop, MBIA 2013. Held in Conjunction with MICCAI 2013. Proceedings: LNCS 8159, P246, DOI 10.1007/978-3-319-02126-3_24; Gutman Boris A, 2015, Proc IEEE Int Symp Biomed Imaging, V2015, P1402, DOI 10.1109/ISBI.2015.7164138; Gutman BA, 2012, 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), P716, DOI 10.1109/ISBI.2012.6235648; Han K, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00231; Haran FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079595; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2014, LANCET PSYCHIAT, V1, P269, DOI 10.1016/S2215-0366(14)70235-4; Hoge CW, 2014, JAMA-J AM MED ASSOC, V312, P1685, DOI 10.1001/jama.2014.6670; Jaramillo CA, 2015, BRAIN IMAGING BEHAV, V9, P445, DOI 10.1007/s11682-015-9402-8; JONES EG, 1976, BRAIN RES, V104, P142, DOI 10.1016/0006-8993(76)90654-5; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Joshi SH, 2016, BIOL PSYCHIAT, V79, P282, DOI 10.1016/j.biopsych.2015.02.029; Karmonik C, 2013, IEEE ENG MED BIO, P1366, DOI 10.1109/EMBC.2013.6609763; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; King JB, 2016, NEUROIMAGE-CLIN, V11, P81, DOI 10.1016/j.nicl.2016.01.003; Kuhn S, 2011, J AFFECT DISORDERS, V134, P315, DOI 10.1016/j.jad.2011.06.003; Leunissen I, 2014, CORTEX, V51, P67, DOI 10.1016/j.cortex.2013.10.009; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lutkenhoff ES, 2013, NEUROIMAGE-CLIN, V3, P396, DOI 10.1016/j.nicl.2013.09.010; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maller JJ, 2014, BEHAV BRAIN RES, V271, P147, DOI 10.1016/j.bbr.2014.05.047; Mathias JL, 2013, BRAIN INJURY, V27, P887, DOI 10.3109/02699052.2013.793398; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Ohman A, 2005, PSYCHONEUROENDOCRINO, V30, P953, DOI 10.1016/j.psyneuen.2005.03.019; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Pezze MA, 2004, PROG NEUROBIOL, V74, P301, DOI 10.1016/j.pneurobio.2004.09.004; Pietrzak RH, 2015, JAMA PSYCHIAT, V72, P396, DOI 10.1001/jamapsychiatry.2014.2470; Prasad MR, 2016, J HEAD TRAUMA REHABI; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Roozendaal B, 2001, J NEUROSCI, V21, P2518, DOI 10.1523/JNEUROSCI.21-07-02518.2001; Sarkar A, 2013, INT J EMERG MULTIDIS, V3, P135; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Tate DF, 2011, J INT NEUROPSYCH SOC, V17, P308, DOI 10.1017/S1355617710001670; Tator CH, 2016, J NEUROSURG, P1; van Rooij SJH, 2015, PSYCHOL MED, V45, P2737, DOI 10.1017/S0033291715000707; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Wade BSC, 2015, NEUROIMAGE-CLIN, V9, P564, DOI 10.1016/j.nicl.2015.10.006; Wang L, 2016, P NATL ACAD SCI USA, V113, P2750, DOI 10.1073/pnas.1514682113; Wilde EA, 2015, BRAIN IMAGING BEHAV, V9, P367, DOI 10.1007/s11682-015-9444-y; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wilke M, 2013, J COGNITIVE NEUROSCI, V25, P1270, DOI 10.1162/jocn_a_00399	74	25	25	2	16	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	OCT	2016	263	10					2065	2079		10.1007/s00415-016-8236-7			15	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DY5WA	WOS:000385173900019	27435967	Green Accepted			2022-02-06	
J	Spencer, NG; Schilling, T; Miralles, F; Eder, C				Spencer, Nicholas G.; Schilling, Tom; Miralles, Francesc; Eder, Claudia			Mechanisms Underlying Interferon-gamma-Induced Priming of Microglial Reactive Oxygen Species Production	PLOS ONE			English	Article							MEDIATED NEUROTOXICITY; SUPEROXIDE-PRODUCTION; ION CHANNELS; K+ CHANNEL; PROTEIN; ACTIVATION; CELLS; NOX2; PHOSPHORYLATION; PROLIFERATION	Microglial priming and enhanced reactivity to secondary insults cause substantial neuronal damage and are hallmarks of brain aging, traumatic brain injury and neurodegenerative diseases. It is, thus, of particular interest to identify mechanisms involved in microglial priming. Here, we demonstrate that priming of microglia with interferon-gamma(IFN gamma) substantially enhanced production of reactive oxygen species (ROS) following stimulation of microglia with ATP. Priming of microglial ROS production was substantially reduced by inhibition of p38 MAPK activity with SB203580, by increases in intracellular glutathione levels with N-Acetyl-L-cysteine, by blockade of NADPH oxidase subunit NOX2 activity with gp91ds-tat or by inhibition of nitric oxide production with L-NAME. Together, our data indicate that priming of microglial ROS production involves reduction of intracellular glutathione levels, upregulation of NADPH oxidase subunit NOX2 and increases in nitric oxide production, and suggest that these simultaneously occurring processes result in enhanced production of neurotoxic peroxynitrite. Furthermore, IFN gamma-induced priming of microglial ROS production was reduced upon blockade of Kir2.1 inward rectifier K+ channels with ML133. Inhibitory effects of ML133 on microglial priming were mediated via regulation of intracellular glutathione levels and nitric oxide production. These data suggest that microglial Kir2.1 channels may represent novel therapeutic targets to inhibit excessive ROS production by primed microglia in brain pathology.	[Spencer, Nicholas G.; Schilling, Tom; Eder, Claudia] St Georges Univ London, Infect & Immun Res Inst, London, England; [Miralles, Francesc] St Georges Univ London, Mol & Clin Sci Res Inst, London, England; [Miralles, Francesc] St Georges Univ London, Inst Med & Biomed Educ, London, England		Eder, C (corresponding author), St Georges Univ London, Infect & Immun Res Inst, London, England.	ceder@sgul.ac.uk		Schilling, Tom/0000-0002-0274-5482; Miralles, Francesc/0000-0003-3069-2725	European Union FP7 grant "TargetBraIn" [279017]	This work was supported by European Union FP7 grant "TargetBraIn" (#279017) to CE.	Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062; BEIS I, 1975, BIOCHEM J, V152, P23, DOI 10.1042/bj1520023; Bhattacharya A, 2016, GLIA, V64, P1772, DOI 10.1002/glia.23001; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; CHAO CC, 1995, J LEUKOCYTE BIOL, V58, P65, DOI 10.1002/jlb.58.1.65; Dale E, 2016, GLIA, V64, P1733, DOI 10.1002/glia.22992; Diebold BA, 2015, ANTIOXID REDOX SIGN, V23, P375, DOI 10.1089/ars.2014.5862; Eder C, 2010, J NEUROIMMUNOL, V224, P51, DOI 10.1016/j.jneuroim.2010.05.008; El-Benna J, 2008, SEMIN IMMUNOPATHOL, V30, P279, DOI 10.1007/s00281-008-0118-3; Franciosi S, 2002, J NEUROSCI RES, V69, P607, DOI 10.1002/jnr.10331; HALLETT MB, 1995, IMMUNOL TODAY, V16, P264, DOI 10.1016/0167-5699(95)80178-2; Haslund-Vinding J, 2017, BRIT J PHARMACOL, V174, P1733, DOI 10.1111/bph.13425; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Klegeris A, 1997, J NEUROSCI RES, V49, P229, DOI 10.1002/(SICI)1097-4547(19970715)49:2<229::AID-JNR11>3.0.CO;2-W; Lam D, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00185; LOWRY OH, 1964, J BIOL CHEM, V239, P18; Mangano EN, 2012, NEUROBIOL AGING, V33, P1411, DOI 10.1016/j.neurobiolaging.2011.02.016; McLarnon JG, 1997, NEUROSCIENCE, V78, P1217, DOI 10.1016/S0306-4522(96)00680-X; McManus RM, 2014, NEUROBIOL AGING, V35, P109, DOI 10.1016/j.neurobiolaging.2013.07.025; Milton RH, 2008, J NEUROSCI, V28, P11488, DOI 10.1523/JNEUROSCI.2431-08.2008; Minogue AM, 2014, NEUROBIOL AGING, V35, P1442, DOI 10.1016/j.neurobiolaging.2013.12.026; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Nayernia Z, 2014, ANTIOXID REDOX SIGN, V20, P2815, DOI 10.1089/ars.2013.5703; Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Park YC, 1996, IMMUNOLOGY, V87, P296, DOI 10.1046/j.1365-2567.1996.456544.x; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Purisai MG, 2007, NEUROBIOL DIS, V25, P392, DOI 10.1016/j.nbd.2006.10.008; Rojo AI, 2014, ANTIOXID REDOX SIGN, V21, P1766, DOI 10.1089/ars.2013.5745; Schilling T, 2015, GLIA, V63, P664, DOI 10.1002/glia.22776; Schilling T, 2014, J CELL SCI, V127, P4561, DOI 10.1242/jcs.151068; Schilling T, 2011, J CELL PHYSIOL, V226, P3295, DOI 10.1002/jcp.22675; Schilling T, 2010, J NEUROIMMUNOL, V225, P190, DOI 10.1016/j.jneuroim.2010.05.024; Schilling T, 2009, J NEUROIMMUNOL, V216, P118, DOI 10.1016/j.jneuroim.2009.07.008; Schmitz M, 2015, NEUROBIOL AGING, V36, P2597, DOI 10.1016/j.neurobiolaging.2015.05.013; Steinert JR, 2010, NEUROSCIENTIST, V16, P435, DOI 10.1177/1073858410366481; Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4; Thomas MP, 2007, J NEUROCHEM, V100, P503, DOI 10.1111/j.1471-4159.2006.04315.x; vanMuiswinkel FL, 1996, J NEUROCHEM, V66, P2468; Vilhardt F, 2002, J BIOL CHEM, V277, P42136, DOI 10.1074/jbc.M200862200; Wu LJ, 2012, NAT NEUROSCI, V15, P565, DOI 10.1038/nn.3059; Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965	46	25	25	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2016	11	9							e0162497	10.1371/journal.pone.0162497			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9IT	WOS:000383254800071	27598576	Green Published, Green Accepted, Green Submitted, gold			2022-02-06	
J	Beamer, M; Tummala, SR; Gullotti, D; Kopil, C; Gorka, S; Abel, T; Bass, CR; Morrison, B; Cohen, AS; Meaney, DF				Beamer, Matthew; Tummala, Shanti R.; Gullotti, David; Kopil, Catherine; Gorka, Samuel; Abel, Ted; Bass, Cameron R. Dale; Morrison, Barclay, III; Cohen, Akiva S.; Meaney, David F.			Primary blast injury causes cognitive impairments and hippocampal circuit alterations	EXPERIMENTAL NEUROLOGY			English	Article						Blast induced traumatic brain injury; Concussion; Blood-brain barrier	TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE RESPONSE; RISK-ASSESSMENT; BARRIER DYSFUNCTION; EXPLOSIVE BLAST; DENTATE GYRUS; SHOCK-WAVES; IN-VITRO; MODEL; RAT	Blast-induced traumatic brain injury (bTBI) and its long term consequences are a major health concern among veterans. Despite recent work enhancing our knowledge about bTBI, very little is known about the contribution of the blast wave alone to the observed sequelae. Herein, we isolated its contribution in a mouse model by constraining the animals' heads during exposure to a shockwave (primary blast). Our results show that exposure to primary blast alone results in changes in hippocampus-dependent behaviors that correspond with electro-physiological changes in area CA1 and are accompanied by reactive gliosis. Specifically, five days after exposure, behavior in an open field and performance in a spatial object recognition (SOR) task were significantly different from sham. Network electrophysiology, also performed five days after injury, demonstrated a significant decrease in excitability and increase in inhibitory tone. Immunohistochemistry for GFAP and Iba1 performed ten days after injury showed a significant increase in staining. Interestingly, a threefold increase in the impulse of the primary blast wave did not exacerbate these measures. However, we observed a significant reduction in the contribution of the NMDA receptors to the field EPSP at the highest blast exposure level. Our results emphasize the need to account for the effects of primary blast loading when studying the sequelae of bTBI. (C) 2016 Published by Elsevier Inc.	[Beamer, Matthew; Tummala, Shanti R.; Gullotti, David; Kopil, Catherine; Gorka, Samuel; Meaney, David F.] Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 South 33rd St, Philadelphia, PA 19104 USA; [Abel, Ted] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Cohen, Akiva S.] Univ Penn, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Cohen, Akiva S.] Childrens Hosp Philadelphia, Div Crit Care Med, Philadelphia, PA 19104 USA; [Bass, Cameron R. Dale] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 South 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Morrison, Barclay/B-7132-2008; Abel, Ted/AAX-2825-2021	Morrison, Barclay/0000-0001-7676-0864; Abel, Ted/0000-0003-2423-4592; Meaney, David/0000-0002-0954-4122	Army Research Office [W911NF-10-1-0526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R37HD059288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088176, R01NS069629, R01NS045975] Funding Source: NIH RePORTER	The authors thank Dr. Brian N. Johnson for his help and assistance over the course of this study. Funding was provided by the Army Research Office through W911NF-10-1-0526.	Alphonse Vanessa D, 2014, Biomed Sci Instrum, V50, P248; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Bandak F A, 2015, Handb Clin Neurol, V127, P89, DOI 10.1016/B978-0-444-52892-6.00006-4; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Center D.a.V.B.1., 2012, DOD WORLDW NUMB TBI; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; de Lanerolle NC, 2014, ANN CLIN TRANSL NEUR, V1, P692, DOI 10.1002/acn3.98; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; De Palma RG., 2015, BRAIN NEUROTRAUMA MO; del Mar N, 2015, EXP NEUROL, V271, P53, DOI 10.1016/j.expneurol.2015.04.023; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; Effgen G. B., 2015, J NEUROTRAUMA; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gullotti DM, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027873; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howard AL, 2007, J NEUROPHYSIOL, V97, P2394, DOI 10.1152/jn.00509.2006; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Hue CD, 2015, J NEUROTRAUMA; Hue CD, 2014, J NEUROTRAUM, V31, P951, DOI 10.1089/neu.2013.3149; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Jean A, 2014, P NATL ACAD SCI USA, V111, P15310, DOI 10.1073/pnas.1415743111; Johnson BN, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00435; Johnstone VPA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063454; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Kovacs SK, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00047; Leonardi AD, 2013, ANN BIOMED ENG, V41, P2488, DOI 10.1007/s10439-013-0850-2; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Ning YL, 2013, J CEREBR BLOOD F MET, V33, P1789, DOI 10.1038/jcbfm.2013.127; Ortinski PI, 2010, NAT NEUROSCI, V13, P584, DOI 10.1038/nn.2535; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Patel TP, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00349; Patel TP, 2014, J NEUROSCI, V34, P4200, DOI 10.1523/JNEUROSCI.4172-13.2014; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sajja VSSS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15075; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Smith DH, 2015, J NEUROTRAUM, V32, P1725, DOI 10.1089/neu.2014.3861; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Vogel E. W., 2015, J NEUROTRAUMA; Wall PLH, 2012, J AM PSYCHIAT NURSES, V18, P278, DOI 10.1177/1078390312460578; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Xie K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064907; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030	70	25	26	1	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2016	283		A				16	28		10.1016/j.expneurol.2016.05.025			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DW0EU	WOS:000383314500002	27246999	Green Accepted			2022-02-06	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Consistency and cost of dual-task gait balance measure in healthy adolescents and young adults	GAIT & POSTURE			English	Article						Gait; Balance; Concussion; Mild traumatic brain injury	ERROR SCORING SYSTEM; CONCUSSION; MANAGEMENT; STABILITY; RECOVERY	Matched control data are commonly used to examine recovery from concussion. Limited data exist, however, examining dual-task gait data consistency collected over time in healthy individuals. The study purposes were to: 1) assess the consistency of single-task and dual-task gait balance control measures, 2) determine the minimal detectable change (MDC) of gait balance control measures, and 3) examine the extent to which age and task complexity affect dual-task walking costs in healthy adolescents and young adults. Twenty-four adolescent (mean age = 15.5 +/- 1.1 years) and 21 young adult (mean age = 21.2 +/- 4.5 years) healthy participants completed 5 testing sessions across a two-month period, which involved analyses of gait balance control and temporal-distance variables during single-task and dual-task walking conditions in a motion analysis laboratory. Cronbach's alpha and MDCs were used to determine the consistency of the gait balance control variables and the smallest amount of change required to distinguish true performance from change due to the performance/measurement variability, respectively. Dual-task costs were evaluated to determine the effect of task complexity and age across time using 3-way ANOVAs. Good to excellent test-retest consistency was found for all single-task and dual-task walking (Cronbach's a range: 0.764-0.970), with a center-of-mass medial-lateral displacement MDC range of 0.835-0.948 cm. Greater frontal plane dual-task costs were observed during more complex secondary tasks (p < 0.001). The results revealed good-excellent consistency across testing sessions for all variables and indicated dual-task costs are affected by task complexity. Thus, healthy controls can be effective comparators when assessing injured subjects. (C) 2016 Elsevier B.V. All rights reserved.	[Howell, David R.] Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA; [Howell, David R.] Boston Childrens Hosp, Div Sports Med, Dept Orthopaed, 319 Longwood Ave, Boston, MA 02115 USA; [Howell, David R.] Boston Childrens Hosp, Brain Injury Ctr, 319 Longwood Ave, Boston, MA 02115 USA; [Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA		Chou, LS (corresponding author), 1240 Univ Oregon, Dept Human Physiol, 122 Esslinger Hall, Eugene, OR 97403 USA.	chou@uoregon.edu		Howell, David/0000-0002-2955-0191; Chou, Li-Shan/0000-0002-2777-7034	Veterans Administration subcontract awards [A4842C8, A4843C]; Translational Research Award from the University of Oregon; Department of Defense-TATRC Award [W81XWH-11-1-0717]; Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology; Peace Health Oregon Region	Funding for the data collection of this work was supported by Veterans Administration subcontract awards [A4842C8 & A4843C], Translational Research Award from the University of Oregon and Peace Health Oregon Region, the Department of Defense-TATRC Award (W81XWH-11-1-0717), and the Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology. The authors would also like to acknowledge Mr. Quinn Peterson, Mr. Michael Kado, Ms. Madison Murray, and Ms. Rachel Klas for their assistance with data collection.	Amin DJ, 2014, J SPORTS SCI, V2, P200, DOI DOI 10.17265/2332-7839/2014.04.005; Buckley T. A., 2015, J SPORT HLTH SCI; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Godde B, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00139; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kim S, 2008, J EDUC MEAS, V45, P179, DOI 10.1111/j.1745-3984.2008.00059.x; Kline P., 2013, HDB PSYCHOL TESTING, P13; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P., 2012, CONS STAT CONC SPORT, p[482013, 554]; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Ries JD, 2009, PHYS THER, V89, P569, DOI 10.2522/ptj.20080258; Ross LM, 2011, J SPORT REHABIL, V20, P296, DOI 10.1123/jsr.20.3.296; SUTHERLAND DH, 1980, J BONE JOINT SURG AM, V62, P336, DOI 10.2106/00004623-198062030-00004; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Winter D. A., 2009, BIOMECHANICS MOTOR C, P86; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	27	25	25	1	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	SEP	2016	49						176	180		10.1016/j.gaitpost.2016.07.008			5	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Orthopedics; Sport Sciences	DY1MF	WOS:000384858400030	27427835	Bronze			2022-02-06	
J	Li, W; Watts, L; Long, J; Zhou, W; Shen, Q; Jiang, Z; Li, YX; Duong, TQ				Li, Wei; Watts, Lora; Long, Justin; Zhou, Wei; Shen, Qiang; Jiang, Zhao; Li, Yunxia; Duong, Timothy Q.			Spatiotemporal changes in blood-brain barrier permeability, cerebral blood flow, T-2 and diffusion following mild traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; BBB permeability; Edema; Diffusion MRI; Dynamic contrast enhanced MRI	QUANTITATIVE PERFUSION; REPERFUSION INJURY; BOLD; GENERATION; RESPONSES; BREAKDOWN; ISCHEMIA; HYPOXIA; MRI; CBF	The blood-brain barrier (BBB) can be impaired following traumatic brain injury (TBI), however the spatiotemporal dynamics of BBB leakage remain incompletely understood. In this study, we evaluated the spatiotemporal evolution of BBB permeability using dynamic contrast-enhanced MRI and measured the volume transfer coefficient, (Kt(rans)), a quantitative measure of contrast agent leakage across the blood and extravascular compartment. Measurements were made in a controlled cortical impact (CCI) model of mild TBI in rats from 1 h to 7 days following TBI. The results were compared with cerebral blood flow, T-2 and diffusion MRI from the same animal. Spatially, K-trans changes were localized to superficial cortical layers within a 1 mm thickness, which was dramatically different from the changes in cerebral blood flow, T-2 and diffusion, which were localized to not only the superficial layers but also to brain regions up to 2.2 mm from the cortical surface. Temporally, K-trans changes peaked at day 3, similar to CBF and ADC changes, but differed from T-2 and FA, whose changes peaked on day 2. The pattern of superficial cortical layer localization of K-trans was consistent with patterns revealed by Evans Blue extravasation. Collectively, these results suggest that BBB disruption, edema formation, blood flow disturbance and diffusion changes are related to different components of the mechanical impact, and may play different roles in determining injury progression and tissue fate processes following TBI. (C) 2016 Elsevier B.V. All rights reserved.	[Li, Wei; Watts, Lora; Long, Justin; Zhou, Wei; Shen, Qiang; Jiang, Zhao; Li, Yunxia; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA; [Li, Wei; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA; [Watts, Lora] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Watts, Lora] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA		Duong, TQ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	duongt@uthscsa.edu	Duong, Tim/AAL-8357-2021; Shen, Qiang/B-8784-2008; Zhou, Wei/AAJ-8509-2020	Duong, Tim/0000-0001-6403-2827; Shen, Qiang/0000-0002-4287-3403; Zhou, Wei/0000-0003-2130-1913; jiang, zhao/0000-0002-8192-9908	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS45879]; TL1 grant; Clinical Translational Science Awards (CTSA) [KL2 TR001118, 8UL1TR000149, TL1TR001119]; Clinical Translational Science Awards [UL1 TR001119]; William & Ella Owens Medical Research Foundation; American Heart AssociationAmerican Heart Association [15SDG26020003]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000149, TL1TR001119, KL2TR001118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045879] Funding Source: NIH RePORTER	This research was funded in part by NIH/NINDS R01 NS45879 (TQD), a TL1 grant (JAL) and KL2 TR001118 (LTW) via the Clinical Translational Science Awards (CTSA, parent grant 8UL1TR000149 and TL1TR001119). This study was supported in part by UL1 TR001119 via the Clinical Translational Science Awards (WL), and a research grant from William & Ella Owens Medical Research Foundation (WL), and a Scientist Development Grant 15SDG26020003 from American Heart Association (WL).	Adelson PD, 1998, ACT NEUR S, V71, P104; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bilston LE, 2011, STUD MECHANOBIOL TIS, V3, P1, DOI 10.1007/978-3-642-13890-4; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Danker JF, 2007, BRAIN RES, V1150, P217, DOI 10.1016/j.brainres.2007.02.082; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Duong TQ, 2007, BRAIN RES, V1135, P186, DOI 10.1016/j.brainres.2006.11.097; Gursoy-Ozdemir Y, 2000, STROKE, V31, P1974, DOI 10.1161/01.STR.31.8.1974; Jiang Z, 2014, NEUROSCI LETT, V566, P298, DOI 10.1016/j.neulet.2014.02.066; Leach MO, 2005, BRIT J CANCER, V92, P1599, DOI 10.1038/sj.bjc.6602550; Li W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114173; Long J. A., 2014, J NEUROTRAUMA; Long JA, 2015, J NEUROTRAUM, V32, P598, DOI 10.1089/neu.2014.3563; Nagaraja TN, 2008, STROKE, V39, P427, DOI 10.1161/STROKEAHA.107.496059; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1265, DOI 10.1038/sj.jcbfm.9600132; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P280, DOI 10.1097/01.WCB.0000110048.43905.E5; Shen Q, 2003, J CEREBR BLOOD F MET, V23, P1479, DOI 10.1097/01.WCB.0000100064.36077.03; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P887, DOI 10.1097/01.WCB.0000124321.60992.87; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sicard K, 2003, J CEREBR BLOOD F MET, V23, P472, DOI 10.1097/01.WCB.0000054755.93668.20; Sicard KM, 2005, NEUROIMAGE, V25, P850, DOI 10.1016/j.neuroimage.2004.12.010; Lawrence KS, 2012, MAGN RESON MED, V67, P1275, DOI 10.1002/mrm.23104; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tofts PS, 2010, SIGNAL, V3, P31; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Wei XE, 2012, J NEUROTRAUM, V29, P2413, DOI 10.1089/neu.2010.1510; Wei XE, 2011, J TRAUMA, V71, P1645, DOI 10.1097/TA.0b013e31823498eb	30	25	26	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 1	2016	1646						53	61		10.1016/j.brainres.2016.05.036			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT9TH	WOS:000381844700006	27208495				2022-02-06	
